PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Andersen, PS; Geisler, C; Buus, S; Mariuzza, RA; Karjalainen, K				Andersen, PS; Geisler, C; Buus, S; Mariuzza, RA; Karjalainen, K			Role of the T cell receptor ligand affinity in T cell activation by bacterial superantigens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-II MOLECULES; MHC CLASS-II; ALANINE SCANNING MUTAGENESIS; STAPHYLOCOCCAL-ENTEROTOXIN-B; COMPLEX CLASS-II; CRYSTAL-STRUCTURE; BETA-CHAIN; 3-DIMENSIONAL STRUCTURE; SIGNAL-TRANSDUCTION; ANTIGEN RECOGNITION	Similar to native peptide/MHC ligands, bacterial superantigens have been found to bind with low affinity to the T cell receptor (TOR). It has been hypothesized that low ligand affinity is required to allow optimal TOR signaling. To test this, we generated variants of Staphylococcus enterotoxin C3 (SEC3) with up to a 150-fold increase in TOR affinity. By stimulating T cells with SEC3 molecules immobilized onto plastic surfaces, we demonstrate that increasing the affinity of the SEC3/TCR interaction caused a proportional increase in the ability of SEC3 to activate T cells. Thus, the potency of the SEC3 variants correlated with enhanced binding without any optimum in the binding range covered by native TCR ligands. Comparable studies using anti-TCR antibodies of known affinity confirmed these observations. By comparing the biological potency of the two sets of ligands, we found a significant correlation between ligand affinity and ligand potency indicating that it is the density of receptor-ligand complexes in the T cell contact area that determines TCR signaling strength.	Univ Copenhagen, Inst Med Microbiol & Immunol, DK-2200 Copenhagen, Denmark; Univ Maryland, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA; Basel Inst Immunol, CH-4005 Basel, Switzerland	University of Copenhagen	Andersen, PS (corresponding author), Univ Copenhagen, Inst Med Microbiol & Immunol, Blegdamsvej 3C, DK-2200 Copenhagen, Denmark.		Buus, Soren/F-5446-2010; Karjalainen, Klaus/A-2206-2011; Geisler, Carsten/A-7056-2012	Geisler, Carsten/0000-0002-8472-0771; Buus, Soren/0000-0001-8363-1999				Acuto O, 2000, ANNU REV IMMUNOL, V18, P165, DOI 10.1146/annurev.immunol.18.1.165; ALAM SM, 1996, NATURE, V381, P161; Andersen PS, 1999, IMMUNITY, V10, P473, DOI 10.1016/S1074-7613(00)80047-3; BENTLEY GA, 1995, SCIENCE, V267, P1984, DOI 10.1126/science.7701320; Boniface JJ, 1998, IMMUNITY, V9, P459, DOI 10.1016/S1074-7613(00)80629-9; Bot A, 1996, J IMMUNOL, V157, P3436; Bunnell SC, 2001, IMMUNITY, V14, P315, DOI 10.1016/S1074-7613(01)00112-1; Churchill HRO, 2000, J EXP MED, V191, P835, DOI 10.1084/jem.191.5.835; Davis MM, 1998, ANNU REV IMMUNOL, V16, P523, DOI 10.1146/annurev.immunol.16.1.523; Davis SJ, 1996, IMMUNOL TODAY, V17, P177, DOI 10.1016/0167-5699(96)80617-7; Ding YH, 1999, IMMUNITY, V11, P45, DOI 10.1016/S1074-7613(00)80080-1; Ding YH, 1998, IMMUNITY, V8, P403, DOI 10.1016/S1074-7613(00)80546-4; ENDRES RO, 1983, J IMMUNOL, V130, P781; Fields BA, 1996, NATURE, V384, P188, DOI 10.1038/384188a0; Frayser M, 1999, PROTEIN EXPRES PURIF, V15, P105, DOI 10.1006/prep.1998.0987; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; Garcia KC, 1998, SCIENCE, V279, P1166, DOI 10.1126/science.279.5354.1166; Garcia KC, 1997, P NATL ACAD SCI USA, V94, P13838, DOI 10.1073/pnas.94.25.13838; Germain RN, 1999, ANNU REV IMMUNOL, V17, P467, DOI 10.1146/annurev.immunol.17.1.467; Harder T, 2000, J CELL BIOL, V151, P199, DOI 10.1083/jcb.151.2.199; HASKINS K, 1983, J EXP MED, V157, P1149, DOI 10.1084/jem.157.4.1149; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; Kim DT, 1996, J IMMUNOL, V156, P2737; KIRBERG J, 1994, J EXP MED, V180, P25, DOI 10.1084/jem.180.1.25; Leder L, 1998, J EXP MED, V187, P823, DOI 10.1084/jem.187.6.823; Li HM, 1999, ANNU REV IMMUNOL, V17, P435, DOI 10.1146/annurev.immunol.17.1.435; Lyons DS, 1996, IMMUNITY, V5, P53, DOI 10.1016/S1074-7613(00)80309-X; MALCHIODI EL, 1995, J EXP MED, V182, P1833, DOI 10.1084/jem.182.6.1833; Manning TC, 1998, IMMUNITY, V8, P413, DOI 10.1016/S1074-7613(00)80547-6; MCCAFFERTY J, 1994, APPL BIOCHEM BIOTECH, V47, P157, DOI 10.1007/BF02787932; MCKEITHAN TW, 1995, P NATL ACAD SCI USA, V92, P5042, DOI 10.1073/pnas.92.11.5042; PAPAGEORGIOU AC, 1995, STRUCTURE, V3, P769, DOI 10.1016/S0969-2126(01)00212-X; Papageorgiou AC, 1998, J MOL BIOL, V277, P61, DOI 10.1006/jmbi.1997.1577; Rabinowitz JD, 1996, P NATL ACAD SCI USA, V93, P1401, DOI 10.1073/pnas.93.4.1401; Reay PA, 2000, J IMMUNOL, V164, P5626, DOI 10.4049/jimmunol.164.11.5626; Redpath S, 1999, J IMMUNOL, V163, P6; Reiser JB, 2000, NAT IMMUNOL, V1, P291, DOI 10.1038/79728; Schodin BA, 1996, IMMUNITY, V5, P137, DOI 10.1016/S1074-7613(00)80490-2; Schuck P, 1997, CURR OPIN BIOTECH, V8, P498, DOI 10.1016/S0958-1669(97)80074-2; SETH A, 1994, NATURE, V369, P324, DOI 10.1038/369324a0; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; Sundberg E, 1999, NAT STRUCT BIOL, V6, P123; Sykulev Y, 1995, P NATL ACAD SCI USA, V92, P11990, DOI 10.1073/pnas.92.26.11990; Valitutti S, 1997, IMMUNOL TODAY, V18, P299, DOI 10.1016/S0167-5699(97)01075-X; VALITUTTI S, 1995, NATURE, V375, P148, DOI 10.1038/375148a0; WALLNY HJ, 1995, EUR J IMMUNOL, V25, P1262, DOI 10.1002/eji.1830250520; Willcox BE, 1999, IMMUNITY, V10, P357, DOI 10.1016/S1074-7613(00)80035-7	47	55	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33452	33457		10.1074/jbc.M103750200	http://dx.doi.org/10.1074/jbc.M103750200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11397806	hybrid			2022-12-25	WOS:000170910200023
J	Shewmaker, F; Maskos, K; Simmerling, C; Landry, SJ				Shewmaker, F; Maskos, K; Simmerling, C; Landry, SJ			The disordered mobile loop of GroES folds into a defined beta-hairpin upon binding GroEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; ESCHERICHIA-COLI GROEL; CRYSTAL-STRUCTURE; NMR-SPECTROSCOPY; CHEMICAL-SHIFT; CHAPERONINS; HYDROLYSIS; MECHANISM; EXCHANGE; DYNAMICS	The GroES mobile loop is a stretch of similar to 16 amino acids that exhibits a high degree of flexible disorder in the free protein. This loop is responsible for the interaction between GroES and GroEL, and it undergoes a folding transition upon binding to GroEL. Results derived from a combination of transferred nuclear Overhauser effect NMR experiments and molecular dynamics simulations indicate that the mobile loop adopts a beta -hairpin structure with a Type I, G1 Bulge turn. This structure is distinct from the conformation of the loop in the cocrystal of GroES with GroEL-ADP but identical to the conformation of the bacteriophage-panned "strongly binding peptide" in the co-crystal with GroEL. Analysis of sequence conservation suggests that sequences of the mobile loop and strongly binding peptide were selected for the ability to adopt this hairpin conformation.	Tulane Univ, Hlth Sci Ctr, Dept Biochem, New Orleans, LA 70112 USA; SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA	Tulane University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Landry, SJ (corresponding author), Tulane Univ, Hlth Sci Ctr, Dept Biochem, 1430 Tulane Ave,Box SL-43, New Orleans, LA 70112 USA.		Landry, Samuel/AAK-5778-2020	Landry, Samuel/0000-0002-4082-0543				BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; Braig K, 1998, CURR OPIN STRUC BIOL, V8, P159, DOI 10.1016/S0959-440X(98)80033-X; Castanie HP, 1997, ANAL BIOCHEM, V254, P150, DOI 10.1006/abio.1997.2423; CLORE GM, 1983, J MAGN RESON, V53, P423, DOI 10.1016/0022-2364(83)90215-9; CLORE GM, 1982, J MAGN RESON, V48, P402, DOI 10.1016/0022-2364(82)90073-7; DAVIS DG, 1985, J AM CHEM SOC, V107, P2821; Dubaquie Y, 1997, P NATL ACAD SCI USA, V94, P9011, DOI 10.1073/pnas.94.17.9011; ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117; Horwich AL, 1999, P NATL ACAD SCI USA, V96, P11033, DOI 10.1073/pnas.96.20.11033; HUTCHINSON EG, 1994, PROTEIN SCI, V3, P2207, DOI 10.1002/pro.5560031206; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; KEPPEL F, 1990, GENE, V86, P19, DOI 10.1016/0378-1119(90)90109-5; KOVALENKO O, 1994, BIOCHEMISTRY-US, V33, P14974, DOI 10.1021/bi00254a004; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; Landry SJ, 1996, P NATL ACAD SCI USA, V93, P11622, DOI 10.1073/pnas.93.21.11622; MACURA S, 1981, J MAGN RESON, V43, P259, DOI 10.1016/0022-2364(81)90037-8; MARION D, 1989, J MAGN RESON, V84, P425, DOI 10.1016/0022-2364(89)90391-0; McEvoy MM, 1998, P NATL ACAD SCI USA, V95, P7333, DOI 10.1073/pnas.95.13.7333; MINOR DL, 1994, NATURE, V367, P660, DOI 10.1038/367660a0; MINOR DL, 1994, NATURE, V371, P264, DOI 10.1038/371264a0; PLATEAU P, 1982, J AM CHEM SOC, V104, P7310, DOI 10.1021/ja00389a067; Ranson NA, 1998, BIOCHEM J, V333, P233, DOI 10.1042/bj3330233; Richardson A, 1999, GENETICS, V152, P1449; Richardson A, 1999, J BIOL CHEM, V274, P52, DOI 10.1074/jbc.274.1.52; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; Rye HS, 1999, CELL, V97, P325, DOI 10.1016/S0092-8674(00)80742-4; Shtilerman M, 1999, SCIENCE, V284, P822, DOI 10.1126/science.284.5415.822; Sigler PB, 1998, ANNU REV BIOCHEM, V67, P581, DOI 10.1146/annurev.biochem.67.1.581; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; Wang JD, 1999, NAT STRUCT BIOL, V6, P597; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944	37	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31257	31264		10.1074/jbc.M102765200	http://dx.doi.org/10.1074/jbc.M102765200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11395498	hybrid			2022-12-25	WOS:000170472900088
J	Norman, JT; Lindahl, GE; Shakib, K; En-Nia, A; Yilmaz, E; Mertens, PR				Norman, JT; Lindahl, GE; Shakib, K; En-Nia, A; Yilmaz, E; Mertens, PR			The Y-box binding protein YB-1 suppresses collagen alpha 1(I) gene transcription via an evolutionarily conserved regulatory element in the proximal promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; C-MYC GENE; GELATINASE-A; CARDIAC FIBROBLASTS; EXPRESSION; ENHANCER; INTRON; ACTIVATION; SEQUENCES; CHK-YB-1B	Appropriate expression of collagen type I, a major component of connective tissue matrices, is dependent on tight transcriptional control and a number of transactivating and repressing factors have been characterized. Here we identify the Y-box binding protein-1 (YB-1) as a novel repressor of the collagen type alpha1(I) (COL1A1) gene. Collagen type I mRNA and protein levels decreased upon overexpression of YB-1 by transfection in NRK fibroblasts. The human, rat, and mouse COL1A1 promoter -220/+115 contains three putative Y-boxes, one of these sites, designated collagen Y-box element (CYE), includes a Y-box. plus an adjacent 3 ' inverted repeat. DNase-I footprinting and Southwestern blotting with fibroblast nuclear extract, demonstrated binding of several nuclear proteins across the CYE, one of which was identified as YB-1. Recombinant YB-1 bound the CYE sequence in gel shift assays with a preference for single-stranded templates. The entire sequence (-88/-48) was required for high affinity binding. Complex formation of endogenous YB-1 with the CYE was established by supershift studies. COL1A1 promoter-reporter constructs were suppressed up to 80% by cotransfection with YB-1 in a variety of cell types. In addition, CYE conferred YB-1 responsiveness on two heterologous promoters further demonstrating the importance of this repressor region. Mung bean nuclease sensitivity analysis suggested that repression is most likely exerted through changes in DNA conformation.	UCL Royal Free & Univ Coll Med Sch, Sir Jules Thorn Inst Clin Sci, Middlesex Hosp, Dept Med, London W1T 3AA, England; Univ Aachen, Dept Nephrol & Immunol, D-52057 Aachen, Germany	University of London; University College London; UCL Medical School; RWTH Aachen University	Mertens, PR (corresponding author), Rhein Westfal TH Aachen, Med Clin 2, Dept Nephrol & Immunol, Paulwelsstr 30, D-52057 Aachen, Germany.	pmertens@post.klinikam.rwth-aachen.de	Mertens, Peter/AAI-7310-2020		PHS HHS [5 RO1 K54602-02] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bian JH, 1997, MOL CELL BIOL, V17, P6330, DOI 10.1128/MCB.17.11.6330; Bornstein P, 1996, MATRIX BIOL, V15, P3, DOI 10.1016/S0945-053X(96)90121-3; Breault DT, 1997, J BIOL CHEM, V272, P31241, DOI 10.1074/jbc.272.50.31241; BUTT RP, 1995, EUR J CELL BIOL, V68, P330; CHEN NN, 1995, P NATL ACAD SCI USA, V92, P1087, DOI 10.1073/pnas.92.4.1087; Chernukhin IV, 2000, J BIOL CHEM, V275, P29915, DOI 10.1074/jbc.M001538200; Clark IM, 1997, BIOCHEM J, V324, P611, DOI 10.1042/bj3240611; Dhalla AK, 1998, BIOCHEM J, V336, P373, DOI 10.1042/bj3360373; Diamond P, 2001, J BIOL CHEM, V276, P7943, DOI 10.1074/jbc.M009836200; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; FRISCH SM, 1990, MOL CELL BIOL, V10, P6524, DOI 10.1128/MCB.10.12.6524; Galera P, 1996, J BIOL CHEM, V271, P21331, DOI 10.1074/jbc.271.35.21331; GRANT CE, 1993, MOL CELL BIOL, V13, P4186, DOI 10.1128/MCB.13.7.4186; Hasegawa T, 1997, J BIOL CHEM, V272, P4915, DOI 10.1074/jbc.272.8.4915; Izumi H, 2001, NUCLEIC ACIDS RES, V29, P1200, DOI 10.1093/nar/29.5.1200; Karsenty G, 1995, Int Rev Immunol, V12, P177, DOI 10.3109/08830189509056711; KARSENTY G, 1990, J BIOL CHEM, V265, P9934; KINNIBURGH AJ, 1994, GENE, V149, P93, DOI 10.1016/0378-1119(94)90416-2; Lee HW, 1998, J MOL CELL CARDIOL, V30, P2495, DOI 10.1006/jmcc.1998.0811; Levens D, 1997, CURR TOP MICROBIOL, V224, P33; MACDONALD GH, 1995, J BIOL CHEM, V270, P3527, DOI 10.1074/jbc.270.8.3527; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; Mertens PR, 1998, J BIOL CHEM, V273, P32957, DOI 10.1074/jbc.273.49.32957; Mertens PR, 1999, J AM SOC NEPHROL, V10, P2480; Mertens PR, 1997, J BIOL CHEM, V272, P22905, DOI 10.1074/jbc.272.36.22905; Michelotti EF, 1997, NATURE, V388, P895, DOI 10.1038/42282; Michelotti GA, 1996, MOL CELL BIOL, V16, P2656, DOI 10.1128/mcb.16.6.2656; NEHLS MC, 1991, MOL CELL BIOL, V11, P4065, DOI 10.1128/MCB.11.8.4065; Orphanides C, 1997, KIDNEY INT, V52, P637, DOI 10.1038/ki.1997.377; PRESTRIDGE DS, 1991, COMPUT APPL BIOSCI, V7, P203; RAVAZZOLO R, 1991, J BIOL CHEM, V266, P7382; Safak M, 1999, J VIROL, V73, P10146, DOI 10.1128/JVI.73.12.10146-10157.1999; Safak R, 1999, MOL CELL BIOL, V19, P2712; Schwartzbauer G, 1998, J BIOL CHEM, V273, P24760, DOI 10.1074/jbc.273.38.24760; Stenina OI, 2000, J CLIN INVEST, V106, P579, DOI 10.1172/JCI9075; Stoddart JH, 2000, J CELL BIOCHEM, V77, P135, DOI 10.1002/(SICI)1097-4644(20000401)77:1<135::AID-JCB14>3.0.CO;2-X; Swamynathan SK, 1997, J VIROL, V71, P2873, DOI 10.1128/JVI.71.4.2873-2880.1997; Swamynathan SK, 2000, BIOCHEM J, V348, P297, DOI 10.1042/0264-6021:3480297; Swamynathan SK, 1998, FASEB J, V12, P515, DOI 10.1096/fasebj.12.7.515; Tomonaga T, 1998, MOL CELL, V1, P759, DOI 10.1016/S1097-2765(00)80075-1; Tomonaga T, 1996, P NATL ACAD SCI USA, V93, P5830, DOI 10.1073/pnas.93.12.5830; Trojanowska M, 1998, J MOL MED, V76, P266, DOI 10.1007/s001090050216; Wada MR, 1998, DEV GROWTH DIFFER, V40, P631; WOLFFE AP, 1992, NEW BIOL, V4, P290; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407	46	61	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29880	29890		10.1074/jbc.M103145200	http://dx.doi.org/10.1074/jbc.M103145200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11395503	hybrid			2022-12-25	WOS:000170558000038
J	Wang, CW; Kim, J; Huang, WP; Abeliovich, H; Stromhaug, PE; Dunn, WA; Klionsky, DJ				Wang, CW; Kim, J; Huang, WP; Abeliovich, H; Stromhaug, PE; Dunn, WA; Klionsky, DJ			Apg2 is a novel protein required for the cytoplasm to vacuole targeting, autophagy, and pexophagy pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; YEAST VACUOLE; PEROXISOME DEGRADATION; CONJUGATION SYSTEM; AMINOPEPTIDASE-I; MACROAUTOPHAGY; TRANSPORT; MUTANTS; COMPLEX; MACHINERY	To survive starvation conditions, eukaryotes have developed an evolutionarily conserved process, termed autophagy, by which the vacuole/lysosome mediates the turnover and recycling of non-essential intracellular material for re-use in critical biosynthetic reactions. Morphological and biochemical studies in Saccharomyces cerevisiae have elucidated the basic steps and mechanisms of the autophagy pathway. Although it is a degradative process, autophagy shows substantial overlap with the biosynthetic cytoplasm to vacuole targeting (Cvt) pathway that delivers resident hydrolases to the vacuole. Recent molecular genetics analyses of mutants defective in autophagy and the Cvt pathway, apg, aut, and cvt, have begun to identify the protein machinery and provide a molecular resolution of the sequestration and import mechanism that are characteristic of these pathways. In this study, we have identified a novel protein, termed Apg2, required for both the Cvt and autophagy pathways as well as the specific degradation of peroxisomes. Apg2 is required for the formation and/or completion of cytosolic, sequestering vesicles that are needed for vacuolar import through both the Cvt pathway and autophagy. Biochemical studies revealed that Apg2 is a peripheral membrane protein. Apg2 localizes to the previously identified perivacuolar compartment that contains Apg9, the only characterized integral membrane protein that, is required for autophagosome/Cvt vesicle formation.	Univ Michigan, Dept Biol, Ann Arbor, MI 48109 USA; Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA	University of Michigan System; University of Michigan; State University System of Florida; University of Florida	Klionsky, DJ (corresponding author), Univ Michigan, Dept Biol, Nat Sci Bldg, Ann Arbor, MI 48109 USA.		Klionsky, Daniel J./ABD-5189-2021	Klionsky, Daniel J./0000-0002-7828-8118; HUANG, WEI-PANG/0000-0001-8410-6555; Wang, Chao-Wen/0000-0002-4073-299X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053396] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM053396, R01 GM053396-11, R01 GM053396-12, GM53396] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abeliovich H, 2000, J CELL BIOL, V151, P1025, DOI 10.1083/jcb.151.5.1025; Baba M, 1997, J CELL BIOL, V139, P1687, DOI 10.1083/jcb.139.7.1687; George MD, 2000, MOL BIOL CELL, V11, P969, DOI 10.1091/mbc.11.3.969; HARDING TM, 1995, J CELL BIOL, V131, P591, DOI 10.1083/jcb.131.3.591; Harding TM, 1996, J BIOL CHEM, V271, P17621, DOI 10.1074/jbc.271.30.17621; HARLOW E, 1999, USING ANTIBODIES LAB, P61; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; Huang WP, 2000, J BIOL CHEM, V275, P5845, DOI 10.1074/jbc.275.8.5845; Hutchins MU, 1999, J CELL SCI, V112, P4079; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Kamada Y, 2000, J CELL BIOL, V150, P1507, DOI 10.1083/jcb.150.6.1507; Kim J, 1999, MOL BIOL CELL, V10, P1337, DOI 10.1091/mbc.10.5.1337; Kim J, 2000, ANNU REV BIOCHEM, V69, P303, DOI 10.1146/annurev.biochem.69.1.303; Kim J, 1997, J CELL BIOL, V137, P609, DOI 10.1083/jcb.137.3.609; Kim J, 2001, J CELL BIOL, V153, P381, DOI 10.1083/jcb.153.2.381; Kim J, 2001, J CELL BIOL, V152, P51, DOI 10.1083/jcb.152.1.51; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; Klionsky DJ, 1997, J MEMBRANE BIOL, V157, P105, DOI 10.1007/s002329900220; KLIONSKY DJ, 1992, J CELL BIOL, V119, P287, DOI 10.1083/jcb.119.2.287; Klionsky DJ, 1998, J BIOL CHEM, V273, P10807, DOI 10.1074/jbc.273.18.10807; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Mizushima N, 1998, J BIOL CHEM, V273, P33889, DOI 10.1074/jbc.273.51.33889; Mizushima N, 1999, EMBO J, V18, P3888, DOI 10.1093/emboj/18.14.3888; Noda T, 2000, J CELL BIOL, V148, P465, DOI 10.1083/jcb.148.3.465; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; Saiz JE, 1999, YEAST, V15, P155, DOI 10.1002/(SICI)1097-0061(19990130)15:2<155::AID-YEA342>3.0.CO;2-U; Scott SV, 2000, J BIOL CHEM, V275, P25840, DOI 10.1074/jbc.M002813200; Scott SV, 1996, P NATL ACAD SCI USA, V93, P12304, DOI 10.1073/pnas.93.22.12304; Scott SV, 1997, J CELL BIOL, V138, P37, DOI 10.1083/jcb.138.1.37; Shintani T, 2001, J BIOL CHEM, V276, P30452, DOI 10.1074/jbc.M102346200; Shintani T, 1999, EMBO J, V18, P5234, DOI 10.1093/emboj/18.19.5234; TEICHERT U, 1989, J BIOL CHEM, V264, P16037; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; TUTTLE DL, 1995, J CELL SCI, V108, P25; Wurmser AE, 1998, EMBO J, V17, P4930, DOI 10.1093/emboj/17.17.4930; Yuan WP, 1999, MOL BIOL CELL, V10, P1353, DOI 10.1091/mbc.10.5.1353	38	117	121	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30442	30451		10.1074/jbc.M102342200	http://dx.doi.org/10.1074/jbc.M102342200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11382760	Green Accepted, Green Submitted, hybrid			2022-12-25	WOS:000170558000110
J	Hubbard, PA; Shen, AL; Paschke, R; Kasper, CB; Kim, JJP				Hubbard, PA; Shen, AL; Paschke, R; Kasper, CB; Kim, JJP			NADPH-cytochrome P450 oxidoreductase - Structural basis for hydride and electron transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENINE-DINUCLEOTIDE PHOSPHATE; REDUCTIVE HALF-REACTION; CRYSTAL-STRUCTURES; NADPH-CYTOCHROME-P-450 OXIDOREDUCTASE; 3-DIMENSIONAL STRUCTURE; P-450 REDUCTASE; BINDING-SITE; CATALYSIS; SYSTEM; NICOTINAMIDE	NADPH-cytochrome P450 oxidoreductase catalyzes transfer of electrons from NADPH, via two flavin cofactors, to various cytochrome P450s. The crystal structure of the rat reductase complexed with NADP(+) has revealed that nicotinamide access to FAD is blocked by an aromatic residue (Trp-677), which stacks against the reface of the isoalloxazine ring of the flavin. To investigate the nature of interactions between the nicotinamide, FAD, and Trp-677 during the catalytic cycle, three mutant proteins were studied by crystallography. The first mutant, W677X, has the last two C-terminal residues, Trp-677 and Ser-678, removed; the second mutant, W677G, retains the C-terminal serine residue. The third mutant has the following three catalytic residues substituted: S457A, C630A, and D675N. In the W677X and W677G structures, the nicotinamide moiety of NADP(+) lies against the FAD isoalloxazine ring with a tilt of similar to 30 degrees between the planes of the two rings. These results, together with the S457A/C630A/D675N structure, allow us to propose a mechanism for hydride transfer regulated by changes in hydrogen bonding and pi-pi interactions between the isoalloxazine ring and either the nicotinamide ring or Trp-677 indole ring. Superimposition of the mutant and wild-type structures shows significant mobility between the two flavin domains of the enzyme. This, together with the high degree of disorder observed in the FMN domain of all three mutant structures, suggests that conformational changes occur during catalysis.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA; Univ Wisconsin, Mcardle Lab Canc Res, Madison, WI 53706 USA	Medical College of Wisconsin; University of Wisconsin System; University of Wisconsin Madison	Kim, JJP (corresponding author), Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA.	jjkim@mcw.edu			NATIONAL CANCER INSTITUTE [P01CA022484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052682] Funding Source: NIH RePORTER; NCI NIH HHS [CA 22484] Funding Source: Medline; NIGMS NIH HHS [GM 52682] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chipot C, 1996, J AM CHEM SOC, V118, P11217, DOI 10.1021/ja961379l; Deng Z, 1999, NAT STRUCT BIOL, V6, P847; Dohr O, 2001, P NATL ACAD SCI USA, V98, P81, DOI 10.1073/pnas.98.1.81; ENOCH HG, 1979, J BIOL CHEM, V254, P8976; GASSNER GT, 1995, FASEB J, V9, P1411, DOI 10.1096/fasebj.9.14.7589982; Gruez A, 2000, J MOL BIOL, V299, P199, DOI 10.1006/jmbi.2000.3748; Gutierrez A, 2000, BIOCHEMISTRY-US, V39, P15990, DOI 10.1021/bi002135n; ILAN Z, 1981, J BIOL CHEM, V256, P66; IYANAGI T, 1981, BIOCHEMISTRY-US, V20, P1722, DOI 10.1021/bi00510a004; IYANAGI T, 1973, BIOCHEMISTRY-US, V12, P2297, DOI 10.1021/bi00736a018; IYANAGI T, 1974, BIOCHEMISTRY-US, V13, P1701, DOI 10.1021/bi00705a023; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; Leclerc D, 1998, P NATL ACAD SCI USA, V95, P3059, DOI 10.1073/pnas.95.6.3059; LI RB, 1995, P NATL ACAD SCI USA, V92, P8846, DOI 10.1073/pnas.92.19.8846; Ludwig ML, 1997, BIOCHEMISTRY-US, V36, P1259, DOI 10.1021/bi962180o; McGaughey GB, 1998, J BIOL CHEM, V273, P15458, DOI 10.1074/jbc.273.25.15458; McPherson A, 1999, CRYSTALLIZATION BIOL, P159; Murataliev MB, 2000, BIOCHEMISTRY-US, V39, P5066, DOI 10.1021/bi992917k; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAI EF, 1988, BIOCHEMISTRY-US, V27, P4465, DOI 10.1021/bi00412a038; Paine MJI, 2000, J BIOL CHEM, V275, P1471, DOI 10.1074/jbc.275.2.1471; PORTER TD, 1986, BIOCHEMISTRY-US, V25, P1682, DOI 10.1021/bi00355a036; SCHACTER BA, 1972, J BIOL CHEM, V247, P3601; SEM DS, 1992, BIOCHEMISTRY-US, V31, P3391, DOI 10.1021/bi00128a013; SEM DS, 1993, BIOCHEMISTRY-US, V32, P11548, DOI 10.1021/bi00094a011; Sevrioukova IF, 1999, P NATL ACAD SCI USA, V96, P1863, DOI 10.1073/pnas.96.5.1863; Shen A.L., 1993, HDB EXPT PHARM, P35; SHEN AL, 1991, J BIOL CHEM, V266, P19976; Shen AL, 1999, J BIOL CHEM, V274, P5391, DOI 10.1074/jbc.274.9.5391; Shen AL, 2000, J BIOL CHEM, V275, P41087, DOI 10.1074/jbc.M008380200; STEHLE T, 1993, EUR J BIOCHEM, V211, P221, DOI 10.1111/j.1432-1033.1993.tb19889.x; Strobel Henry W., 1995, P225; van den Akker F, 1999, ACTA CRYSTALLOGR D, V55, P206, DOI 10.1107/S0907444998007161; VERMILION JL, 1978, J BIOL CHEM, V253, P8812; WAKSMAN G, 1994, J MOL BIOL, V236, P800, DOI 10.1006/jmbi.1994.1190; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; Ziegler GA, 2000, BIOCHEMISTRY-US, V39, P10986, DOI 10.1021/bi000079k	40	182	192	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29163	29170		10.1074/jbc.M101731200	http://dx.doi.org/10.1074/jbc.M101731200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11371558	hybrid			2022-12-25	WOS:000170346000072
J	Iodice, L; Sarnataro, S; Bonatti, S				Iodice, L; Sarnataro, S; Bonatti, S			The carboxyl-terminal valine is required for transport of glycoprotein CD8 alpha from the endoplasmic reticulum to the intermediate compartment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CD8 GLYCOPROTEIN; SINGLE REPORTER PROTEIN; EARLY SECRETORY PATHWAY; AMINO-ACID PERMEASES; LUMINAL ER PROTEINS; TRANSMEMBRANE PROTEINS; CYTOPLASMIC DOMAINS; VIRUS GLYCOPROTEIN; MEMBRANE-PROTEINS; COATED VESICLES	There is evidence that a carboxyl-terminal valine residue is an anterograde transport signal for type I transmembrane proteins. Removal of the signal would either delay glycosylation in the Golgi complex of proteins destined to recycle to the endoplasmic reticulum or determine accumulation in the endoplasmic reticulum of newly synthesized proteins destined for the plasma membrane. We used the human CD8 alpha glycoprotein to investigate the role of the carboxyl-terminal valine in the exocytic pathway. Using immunofluorescence light microscopy, metabolic labeling, and cell fractionation, we demonstrate that removal of the carboxyl-terminal valine residue delays transport of CD8 alpha from the endoplasmic reticulum to the intermediate compartment. Removal of the residue did not affect the other steps of the exocytic pathway or the folding/dimerization and glycosylation processes. Therefore, it is likely that this signal plays a role in the transport of CD8 alpha from the endoplasmic reticulum. to the intermediate compartment either before or during the formation of the transport vesicles that drive the exit the protein from the endoplasmic reticulum.	Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, I-80131 Naples, Italy	University of Naples Federico II	Bonatti, S (corresponding author), Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, Via S Pansini 5, I-80131 Naples, Italy.							BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; BONATTI S, 1989, J BIOL CHEM, V264, P12590; Briley GP, 1997, MOL BIOL CELL, V8, P1619, DOI 10.1091/mbc.8.8.1619; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Erra MC, 1999, CELL BIOL INT, V23, P571, DOI 10.1006/cbir.1999.0420; Fernandez-Larrea J, 1999, MOL CELL, V3, P423, DOI 10.1016/S1097-2765(00)80470-0; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; FUNGLEUNG WP, 1993, EUR J IMMUNOL, V23, P2834, DOI 10.1002/eji.1830231117; Gilstring CF, 1999, MOL BIOL CELL, V10, P3549, DOI 10.1091/mbc.10.11.3549; Grootjans JJ, 1997, P NATL ACAD SCI USA, V94, P13683, DOI 10.1073/pnas.94.25.13683; Herrmann JM, 1999, TRENDS CELL BIOL, V9, P5, DOI 10.1016/S0962-8924(98)01414-7; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; Kappeler F, 1997, J BIOL CHEM, V272, P31801, DOI 10.1074/jbc.272.50.31801; Klumperman J, 2000, CURR OPIN CELL BIOL, V12, P445, DOI 10.1016/S0955-0674(00)00115-0; Kuehn MJ, 1998, NATURE, V391, P187, DOI 10.1038/34438; LJUNGDAHL PO, 1992, CELL, V71, P463, DOI 10.1016/0092-8674(92)90515-E; Lotti LV, 1999, J BIOL CHEM, V274, P10413, DOI 10.1074/jbc.274.15.10413; Ma DK, 2001, SCIENCE, V291, P316, DOI 10.1126/science.291.5502.316; Malide D, 2001, MOL BIOL CELL, V12, P101, DOI 10.1091/mbc.12.1.101; Martinez-Menarguez JA, 1999, CELL, V98, P81, DOI 10.1016/S0092-8674(00)80608-X; Martire G, 1996, J BIOL CHEM, V271, P3541; Marzioch M, 1999, MOL BIOL CELL, V10, P1923, DOI 10.1091/mbc.10.6.1923; Meyer-Franke A, 1998, NEURON, V21, P681, DOI 10.1016/S0896-6273(00)80586-3; MIGLIACCIO G, 1989, EXP CELL RES, V185, P203, DOI 10.1016/0014-4827(89)90049-9; Mottola G, 2000, J BIOL CHEM, V275, P24070, DOI 10.1074/jbc.M910400199; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; Nakamura N, 1998, MOL BIOL CELL, V9, P3493, DOI 10.1091/mbc.9.12.3493; Nishimura N, 1999, J BIOL CHEM, V274, P15937, DOI 10.1074/jbc.274.22.15937; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; Nufer O, 2000, MOL BIOL CELL, V11, p208A; PASCALE MC, 1992, J BIOL CHEM, V267, P9940; PASCALE MC, 1992, J BIOL CHEM, V267, P25196; Pascale MC, 2000, FEBS LETT, V480, P226, DOI 10.1016/S0014-5793(00)01945-1; PELHAM HR, 1995, CURR OPIN CELL BIOL, V7, P539; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; Schneider S, 1999, NAT BIOTECHNOL, V17, P170, DOI 10.1038/6172; Sevier CS, 2000, MOL BIOL CELL, V11, P13, DOI 10.1091/mbc.11.1.13; Springer S, 1999, CELL, V97, P145, DOI 10.1016/S0092-8674(00)80722-9; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; Urena JM, 1999, J CELL SCI, V112, P773; VEILLETTE A, 1992, TRENDS GENET, V8, P61, DOI 10.1016/0168-9525(92)90045-6; VERDE C, 1995, EUR J CELL BIOL, V67, P267	48	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28920	28926		10.1074/jbc.M103558200	http://dx.doi.org/10.1074/jbc.M103558200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11384990	hybrid			2022-12-25	WOS:000170346000039
J	Schuierer, M; Hilger-Eversheim, K; Dobner, T; Bosserhoff, AK; Moser, M; Turner, J; Crossley, M; Buettner, R				Schuierer, M; Hilger-Eversheim, K; Dobner, T; Bosserhoff, AK; Moser, M; Turner, J; Crossley, M; Buettner, R			Induction of AP-2 alpha expression by adenoviral infection involves inactivation of the AP-2rep transcriptional corepressor CtBP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL BINDING-PROTEIN; REGION 1A PROTEINS; GENE-EXPRESSION; GENOMIC STRUCTURE; CELLS; E1A; REPRESSOR; AP-2-BETA; CLONING; DNA	AP-2 transcription factors execute important functions during embryonic development and malignant transformation. Recently, we have isolated a transcriptional repressor of AP-2 alpha expression, the novel Kruppel-related zinc finger protein AP-2rep (KIf12). Here, we show that repression of AP-2 alpha transcription by AP-2rep is dependent on an N-terminal PVDLS motif that interacts specifically with the corepressor CtBP1 both in vivo and in vitro. This interaction motif was previously identified in the C-terminal region of the adenoviral oncoprotein EIA. Infection of both HeLa and PA-1. cells with adenovirus type 5 strongly induced AP-2 alpha mRNA. Consistently, EIA was necessary and sufficient to mediate up-regulation of AP-2 alpha. Transiently transfected wild-type EIA protein activated an AP-2rep sensitive cis-regulatory element of the AP-2 alpha promoter, but E1A protein harboring a mutation in the PVDLS motif failed to activate. In summary, we conclude that the adenoviral oncoprotein EIA activates transcription from the endogenous AP-2 alpha gene, an effect that involves transcriptional derepression of the AP-2 alpha promoter by interaction of E1A with the AP-2rep corepressor CtBP1.	Univ Hosp RWTH Aachen, Inst Pathol, D-52074 Aachen, Germany; Univ Regensburg, Sch Med, Inst Microbiol, D-93042 Regensburg, Germany; Univ Sydney, Dept Biochem, Sydney, NSW 2006, Australia	RWTH Aachen University; RWTH Aachen University Hospital; University of Regensburg; University of Sydney	Buettner, R (corresponding author), Univ Hosp RWTH Aachen, Inst Pathol, Pauwelsstr 30, D-52074 Aachen, Germany.		Crossley, Merlin/D-7888-2011; Bosserhoff, Anja/GNH-4801-2022	Crossley, Merlin/0000-0003-2057-3642; Bosserhoff, Anja/0000-0001-8147-394X				Baskin F, 1997, NEUROSCIENCE, V76, P821; BAUER R, 1994, NUCLEIC ACIDS RES, V22, P1413, DOI 10.1093/nar/22.8.1413; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; BYRNE C, 1994, DEVELOPMENT, V120, P2369; Furusawa T, 1999, MOL CELL BIOL, V19, P8581; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; GretherBeck S, 1997, BIOL CHEM, V378, P1231; HARDY S, 1989, MOL CELL BIOL, V9, P4495, DOI 10.1128/MCB.9.10.4495; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; Hilger-Eversheim K, 2000, GENE, V260, P1, DOI 10.1016/S0378-1119(00)00454-6; Imhof A, 1999, MOL CELL BIOL, V19, P194; KANNAN F, 1994, GENE DEV, V8, P1258, DOI 10.1101/gad.8.11.1258; LIN HJL, 1995, MOL CELL BIOL, V15, P4536; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; Molloy DP, 1998, J BIOL CHEM, V273, P20867, DOI 10.1074/jbc.273.33.20867; Moser M, 1997, GENE DEV, V11, P1938, DOI 10.1101/gad.11.15.1938; Moser M, 1997, DEV DYNAM, V208, P115, DOI 10.1002/(SICI)1097-0177(199701)208:1<115::AID-AJA11>3.0.CO;2-5; MOSER M, 1995, DEVELOPMENT, V121, P2779; OuladAbdelghani M, 1996, EXP CELL RES, V225, P338, DOI 10.1006/excr.1996.0184; Pena P, 1999, MOL ENDOCRINOL, V13, P1402, DOI 10.1210/me.13.8.1402; Roth C, 2000, GENOMICS, V63, P384, DOI 10.1006/geno.1999.6084; Satoda M, 2000, NAT GENET, V25, P42, DOI 10.1038/75578; Schaeper U, 1998, J BIOL CHEM, V273, P8549, DOI 10.1074/jbc.273.15.8549; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; Sewalt RGAB, 1999, MOL CELL BIOL, V19, P777; Sinha S, 2000, MOL CELL BIOL, V20, P2543, DOI 10.1128/MCB.20.7.2543-2555.2000; Sundqvist A, 1998, FEBS LETT, V429, P183, DOI 10.1016/S0014-5793(98)00588-2; Turner BC, 1998, CANCER RES, V58, P5466; Turner J, 1999, INT J BIOCHEM CELL B, V31, P1169, DOI 10.1016/S1357-2725(99)00067-9; West-Mays JA, 1999, DEV BIOL, V206, P46, DOI 10.1006/dbio.1998.9132; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0	34	43	46	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27944	27949		10.1074/jbc.M100070200	http://dx.doi.org/10.1074/jbc.M100070200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11373277	hybrid			2022-12-25	WOS:000170093400028
J	Fadel, MP; Szewczenko-Pawlikowski, M; Leclerc, P; Dziak, E; Symonds, JM; Blaschuk, O; Michalak, M; Opas, M				Fadel, MP; Szewczenko-Pawlikowski, M; Leclerc, P; Dziak, E; Symonds, JM; Blaschuk, O; Michalak, M; Opas, M			Calreticulin affects beta-catenin-associated pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL-ADHESION; PROTEIN-TYROSINE-PHOSPHATASE; RETICULUM CA2+ STORE; ENDOPLASMIC-RETICULUM; GENE-EXPRESSION; SIGNAL-TRANSDUCTION; E-CADHERIN; V-SRC; ENDOTHELIAL-CELLS; N-CADHERIN	Calreticulin, a Ca2+ storage protein and chaperone in the endoplasmic reticulum, also modulates cell adhesiveness. Overexpression of calreticulin correlates with (i) increased cell adhesiveness, (ii) increased expression of N-cadherin and vinculin, and (iii) decreased protein phosphorylation on tyrosine. Among proteins that are dephosphorylated in cells that overexpress calreticulin is beta -catenin, a structural component of cadherin-dependent adhesion complexes, a member of the armadillo family of proteins and a part of the Wnt signaling pathway. We postulate that the changes in cell adhesiveness may be due to calreticulin-mediated effects on a signaling pathway from the endoplasmic reticulum, which impinges on the Wnt signaling pathway via the cadherin/catenin protein system and involves changes in the activity of protein-tyrosine kinases and/or phosphatases.	Univ Toronto, Dept Anat & Cell Biol, Toronto, ON M5S 1A8, Canada; Univ Laval, Dept Obstet & Gynecol, Quebec City, PQ G1L 3L5, Canada; Royal Victoria Hosp, Urol Res Lab, Montreal, PQ H3A 1A1, Canada; Univ Alberta, Dept Biochem, Canadian Inst Hlth, Res Grp Mol Biol Membrane Prot, Edmonton, AB T6G 2H7, Canada	University of Toronto; Laval University; McGill University; Royal Victoria Hospital; University of Alberta	Opas, M (corresponding author), Univ Toronto, Dept Anat & Cell Biol, Med Sci Bldg, Toronto, ON M5S 1A8, Canada.	m.opas@utoronto.ca		Leclerc, Pierre/0000-0003-2053-3958				Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Adams CL, 1998, CURR OPIN CELL BIOL, V10, P572, DOI 10.1016/S0955-0674(98)80031-8; Ayalon O, 1997, J CELL SCI, V110, P547; Balsamo J, 1996, J CELL BIOL, V134, P801, DOI 10.1083/jcb.134.3.801; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; Behrens J, 1999, CANCER METAST REV, V18, P15, DOI 10.1023/A:1006200102166; Brady-Kalnay SM, 1998, J CELL BIOL, V141, P287, DOI 10.1083/jcb.141.1.287; BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977; Braga VMM, 1999, MOL BIOL CELL, V10, P9, DOI 10.1091/mbc.10.1.9; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Burridge K, 1997, TRENDS CELL BIOL, V7, P342, DOI 10.1016/S0962-8924(97)01127-6; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Calautti E, 1998, J CELL BIOL, V141, P1449, DOI 10.1083/jcb.141.6.1449; Chapman R, 1998, ANNU REV CELL DEV BI, V14, P459, DOI 10.1146/annurev.cellbio.14.1.459; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Corbett EF, 2000, J BIOL CHEM, V275, P27177; Corbett EF, 1999, J BIOL CHEM, V274, P6203, DOI 10.1074/jbc.274.10.6203; Corbett EF, 2000, TRENDS BIOCHEM SCI, V25, P307, DOI 10.1016/S0968-0004(00)01588-7; Daniel JM, 1997, BIOESSAYS, V19, P883, DOI 10.1002/bies.950191008; DEFILIPPI P, 1995, EXP CELL RES, V221, P141, DOI 10.1006/excr.1995.1361; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Fadel MP, 1999, J BIOL CHEM, V274, P15085, DOI 10.1074/jbc.274.21.15085; Folsom TD, 1997, GLIA, V20, P348; GEIGER B, 1990, J CELL SCI, V97, P607; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; GUMBINER BM, 1993, J CELL SCI, P155; Hatzfeld M, 1999, INT REV CYTOL, V186, P179; Hazan RB, 1998, J BIOL CHEM, V273, P9078, DOI 10.1074/jbc.273.15.9078; Hazan RB, 1997, J BIOL CHEM, V272, P32448, DOI 10.1074/jbc.272.51.32448; Helenius A, 1997, TRENDS CELL BIOL, V7, P193; Johnson S, 2001, TRENDS CELL BIOL, V11, P122, DOI 10.1016/S0962-8924(01)01926-2; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; Kypta RM, 1996, J CELL BIOL, V134, P1519, DOI 10.1083/jcb.134.6.1519; Lampugnani MG, 1997, J CELL SCI, V110, P2065; LEVITZKI A, 1992, FASEB J, V6, P3275, DOI 10.1096/fasebj.6.14.1426765; Llewellyn DH, 1996, BIOCHEM J, V318, P555, DOI 10.1042/bj3180555; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; MCMILLAN A, 1994, CURR OPIN BIOTECH, V6, P540; Meldolesi J, 1998, TRENDS BIOCHEM SCI, V23, P10, DOI 10.1016/S0968-0004(97)01143-2; MELTON DW, 1984, P NATL ACAD SCI-BIOL, V81, P2147, DOI 10.1073/pnas.81.7.2147; Mery L, 1996, J BIOL CHEM, V271, P9332, DOI 10.1074/jbc.271.16.9332; Michalak M, 1999, BIOCHEM J, V344, P281, DOI 10.1042/0264-6021:3440281; Michalak M, 1996, J BIOL CHEM, V271, P29436, DOI 10.1074/jbc.271.46.29436; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; Nguyen TQ, 1996, MOL IMMUNOL, V33, P379, DOI 10.1016/0161-5890(95)00149-2; OPAS M, 1991, J CELL PHYSIOL, V149, P160, DOI 10.1002/jcp.1041490120; Opas M, 1996, J CELL BIOL, V135, P1913, DOI 10.1083/jcb.135.6.1913; Ozawa M, 1998, J BIOL CHEM, V273, P6166, DOI 10.1074/jbc.273.11.6166; Pahl HL, 1997, TRENDS CELL BIOL, V7, P50, DOI 10.1016/S0962-8924(96)10050-7; Pahl HL, 1997, TRENDS BIOCHEM SCI, V22, P63, DOI 10.1016/S0968-0004(96)10073-6; Papkoff J, 1997, J BIOL CHEM, V272, P4536; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; PRESSMAN BC, 1976, ANNU REV BIOCHEM, V45, P501, DOI 10.1146/annurev.bi.45.070176.002441; Provost E, 1999, CURR OPIN CELL BIOL, V11, P567, DOI 10.1016/S0955-0674(99)00015-0; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; Saito Y, 1999, EMBO J, V18, P6718, DOI 10.1093/emboj/18.23.6718; Strovel ET, 2000, J BIOL CHEM, V275, P2399, DOI 10.1074/jbc.275.4.2399; Takeda H, 1995, J CELL BIOL, V131, P1839, DOI 10.1083/jcb.131.6.1839; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Vleminckx K, 1999, BIOESSAYS, V21, P211, DOI 10.1002/(SICI)1521-1878(199903)21:3<211::AID-BIES5>3.3.CO;2-G; Waser M, 1997, J CELL BIOL, V138, P547, DOI 10.1083/jcb.138.3.547	64	46	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27083	27089		10.1074/jbc.M101676200	http://dx.doi.org/10.1074/jbc.M101676200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11369768	hybrid			2022-12-25	WOS:000169966900048
J	Fukuda, M; Mikoshiba, K				Fukuda, M; Mikoshiba, K			Mechanism of the calcium-dependent multimerization of synaptotagmin VII mediated by its first and second C2 domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-POLYPHOSPHATE BINDING; SQUID GIANT SYNAPSE; CRYSTAL-STRUCTURE; ANTIBODY INJECTION; OLIGOMERIZATION; EXOCYTOSIS; VESICLE; DROSOPHILA; PROTEINS; ISOFORMS	The Ca2+-dependent oligomerization activity of the second C2 (C2B) domain of synaptotagmin I (Syt I) has been hypothesized to regulate neurotransmitter release. We previously showed that the cytoplasmic domains of several other Syt isoforms also show Ca2+ dependent oligomerization activity (Fukuda, M., and Mikoshiba, K. (2000) J. Biol. Chem. 275, 28180-28185), but little is known, about the involvement of their C2 domains in Ca2+-dependent oligomerization, In this study, we, analyzed the Ca2+-dependent oligomerization properties of the first (C2A) and the second C2 (C2B) domains of Syt VII. Unlike Syt I, both C2 domains of Syt VII contribute to Ca2+-dependent homo- and hetero-oligomerization with other isoforms. For instance, the Syt VII C2A domain Ca2+-dependently binds itself and the C2A domain of Syt VI but not its C2B domain, whereas the Syt VII C2B domain Ca2+-dependently binds itself and the C2B domain of Syt II but not its C2A domain. In addition, we showed by gel filtration that a single Syt VII C2 domain is sufficient to form a Ca2+-dependent multimer of very high molecular weight. Because of this "two handed" structure, the Syt VII cytoplasmic domain has been found to show the strongest Ca2+-dependent multimerization activity in the Syt family. We also identified Asn-328 in the C2B domain as a crucial residue for the efficient Ca2+-dependent switch for multimerization by site-directed mutagenesis. Our results suggest that Syt VII is a specific isoform that can cluster different Syt isoforms with two hands in response to Ca2+.	RIKEN, Inst Phys & Chem Res, Brain Sci Inst, Dev Neurobiol Lab, Wako, Saitama 3510198, Japan; Univ Tokyo, Inst Med Sci, Dept Basic Med Sci, Div Mol Neurobiol,Minato Ku, Tokyo 1088639, Japan	RIKEN; University of Tokyo	Fukuda, M (corresponding author), RIKEN, Inst Phys & Chem Res, Brain Sci Inst, Dev Neurobiol Lab, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	mnfukuda@brain.riken.go.jp	Fukuda, MItsunori/I-1511-2015; Mikoshiba, Katsuhiko/N-7943-2015	Fukuda, MItsunori/0000-0002-8620-5853; 				BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; Chapman ER, 1998, J BIOL CHEM, V273, P32966, DOI 10.1074/jbc.273.49.32966; Damer CK, 1996, J NEUROCHEM, V67, P1661; Desai RC, 2000, J CELL BIOL, V150, P1125, DOI 10.1083/jcb.150.5.1125; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; Fukuda M, 2000, BIOCHEM BIOPH RES CO, V276, P626, DOI 10.1006/bbrc.2000.3520; Fukuda M, 2000, FEBS LETT, V482, P269, DOI 10.1016/S0014-5793(00)02064-0; Fukuda M, 2000, J BIOL CHEM, V275, P28180; Fukuda M, 1997, BIOESSAYS, V19, P593, DOI 10.1002/bies.950190710; Fukuda M, 1999, J BIOL CHEM, V274, P31421, DOI 10.1074/jbc.274.44.31421; Fukuda M, 1999, J BIOL CHEM, V274, P31428, DOI 10.1074/jbc.274.44.31428; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; FUKUDA M, 1995, J BIOL CHEM, V270, P26523, DOI 10.1074/jbc.270.44.26523; FUKUDA M, 1995, P NATL ACAD SCI USA, V92, P10708, DOI 10.1073/pnas.92.23.10708; Fukuda M, 2001, BIOCHEM J, V354, P249, DOI 10.1042/0264-6021:3540249; Fukuda M, 2000, P NATL ACAD SCI USA, V97, P14715, DOI 10.1073/pnas.260491197; Fukuda M, 2000, J BIOCHEM, V128, P637, DOI 10.1093/oxfordjournals.jbchem.a022796; Gao ZY, 2000, J BIOL CHEM, V275, P36079, DOI 10.1074/jbc.M004284200; Haucke V, 2000, EMBO J, V19, P6011, DOI 10.1093/emboj/19.22.6011; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; JORGENSEN EM, 1995, NATURE, V378, P196, DOI 10.1038/378196a0; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; Lin RC, 2000, ANNU REV CELL DEV BI, V16, P19, DOI 10.1146/annurev.cellbio.16.1.19; LITTLETON JT, 1995, TRENDS NEUROSCI, V18, P177; LLINAS R, 1994, P NATL ACAD SCI USA, V91, P12990, DOI 10.1073/pnas.91.26.12990; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; Lloyd TE, 2000, NEURON, V26, P45, DOI 10.1016/S0896-6273(00)81136-8; Marqueze B, 2000, BIOCHIMIE, V82, P409, DOI 10.1016/S0300-9084(00)00220-0; Martinez I, 2000, J CELL BIOL, V148, P1141, DOI 10.1083/jcb.148.6.1141; MIKOSHIBA K, 1995, P NATL ACAD SCI USA, V92, P10703, DOI 10.1073/pnas.92.23.10703; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Mizutani A, 1997, BIOCHEM BIOPH RES CO, V240, P128, DOI 10.1006/bbrc.1997.7578; Mochida S, 1997, NEUROSCIENCE, V77, P937; Osborne SL, 1999, J BIOL CHEM, V274, P59, DOI 10.1074/jbc.274.1.59; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; Phillips AM, 2000, J NEUROSCI, V20, P8254, DOI 10.1523/JNEUROSCI.20-22-08254.2000; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; Schiavo G, 1998, BIOCHEM BIOPH RES CO, V248, P1, DOI 10.1006/bbrc.1998.8527; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; Sugita S, 1996, J BIOL CHEM, V271, P1262, DOI 10.1074/jbc.271.3.1262; Sutton RB, 1999, J CELL BIOL, V147, P589, DOI 10.1083/jcb.147.3.589; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; von Poser C, 2000, J BIOL CHEM, V275, P30916, DOI 10.1074/jbc.M005559200; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	45	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27670	27676		10.1074/jbc.M100851200	http://dx.doi.org/10.1074/jbc.M100851200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11373279	hybrid			2022-12-25	WOS:000169966900123
J	Panigone, S; Bergomas, R; Fontanella, E; Prinetti, A; Sandhoff, K; Grabowski, GA; Delia, D				Panigone, S; Bergomas, R; Fontanella, E; Prinetti, A; Sandhoff, K; Grabowski, GA; Delia, D			Up-regulation of prosaposin by the retinoid HPR and the effect on ceramide production and integrin receptors	FASEB JOURNAL			English	Article						fenretinide; retinoic acid; reactive oxygen species; adhesion molecules; c-DNA; differential display	CELL-ADHESION; N-(4-HYDROXYPHENYL) RETINAMIDE; CARCINOMA-CELLS; APOPTOSIS; PROTEIN; GENE; INDUCTION; ACTIVATOR; IDENTIFICATION; NEUROBLASTOMA	N-(4-hydroxyphenyl)retinamide (HPR) is a synthetic retinoid of clinical use in breast cancer chemoprevention. Its in vitro effects on tumor cell lines include growth inhibition and apoptosis and are, to a large extent, independent of the activation of retinoic acid receptors. We have performed a cDNA differential display analysis to identify genes potentially relevant for understanding the mechanism of action of HPR. We report that prosaposin (PSAP), a gene encoding for the common precursor protein of saposins (cofactors involved in the metabolism of various sphingolipids), was significantly up-regulated, both at transcriptional and protein level, in MCF7 and T47D breast cancer cell lines after treatment with HPR, but not with all trans retinoic acid (ATRA). Remarkably, this response was also induced by oxidants, whereas it was abrogated by antioxidants in cells treated with HPR, which implies a direct role of free radicals generated by HPR in prosaposin up-regulation. Stable transfectants of T47D cells overexpressing prosaposin (T47D-PSAP) exhibited morphological changes, reduced proliferation, and impaired attachment to culture plates, which correlated with down-regulation of alpha6, beta1, and beta4 subunits of the integrin family of adhesion receptors. Concordant with a role of prosaposin in ceramide generation, increased amounts of this lipid were found in T47D-PSAP and in HPR-treated T47D cells. Moreover, treatment of T47D with C2-ceramide resulted in the up-regulation of prosaposin and down-regulation of integrin receptors. Altogether, these findings establish a link between prosaposin, ceramide, and integrin receptor regulation. In view of the association between integrin down-regulation and suppression of metastatic capacity, our data raise the possibility that the cancer chemopreventive activity of HPR may rely, at least in part, on its capacity to regulate integrin receptors through prosaposin.	Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; Univ Milan, Sch Med, Dept Med Chem & Biochem, I-20122 Milan, Italy; Gerhard Domagk Strl, Inst Organ Chem & Biochem, D-53121 Bonn, Germany; Childrens Hosp Res Fdn, Div Human Genet, Cincinnati, OH 45229 USA; Childrens Hosp Res Fdn, Program Human Genet, Cincinnati, OH 45229 USA	Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Milan; University of Bonn; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	Delia, D (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Via G Venezian 1, I-20133 Milan, Italy.	delia@istitutotumori.mi.it	Prinetti, Alessandro/R-4206-2017; Sonnino, Sandro/R-4154-2017	Prinetti, Alessandro/0000-0003-0252-2593; Sonnino, Sandro/0000-0001-8180-5908				Alonso DF, 1998, ANTICANCER RES, V18, P4499; Auge N, 1998, J BIOL CHEM, V273, P12893, DOI 10.1074/jbc.273.21.12893; BHATNAGAR R, 1991, BIOCHEM PHARMACOL, V41, P1471, DOI 10.1016/0006-2952(91)90563-K; Bierfreund U, 2000, METHOD ENZYMOL, V311, P255; BOTTINI C, 1993, INT J CANCER, V54, P261, DOI 10.1002/ijc.2910540217; Boudreau J, 1999, BIOCHEM J, V339, P481, DOI 10.1042/0264-6021:3390481; Campana WM, 1999, BBA-GEN SUBJECTS, V1427, P392, DOI 10.1016/S0304-4165(99)00036-7; Campana WM, 1998, FASEB J, V12, P307, DOI 10.1096/fasebj.12.3.307; Chen YR, 1999, MOL PHARMACOL, V56, P1271, DOI 10.1124/mol.56.6.1271; Chigorno V, 1997, EUR J BIOCHEM, V250, P661, DOI 10.1111/j.1432-1033.1997.00661.x; Debernardi S, 1997, GENOMICS, V42, P67, DOI 10.1006/geno.1997.4720; Delia D, 1997, ONCOGENE, V14, P2137, DOI 10.1038/sj.onc.1201050; DELIA D, 1993, CANCER RES, V53, P6036; Delia D, 1997, CARCINOGENESIS, V18, P943, DOI 10.1093/carcin/18.5.943; DELIA D, 1995, BLOOD, V85, P359, DOI 10.1182/blood.V85.2.359.bloodjournal852359; Dowling J, 1996, J CELL BIOL, V134, P559, DOI 10.1083/jcb.134.2.559; Erdreich-Epstein A, 2000, CANCER RES, V60, P712; Fanjul AN, 1996, J BIOL CHEM, V271, P22441, DOI 10.1074/jbc.271.37.22441; Formelli F, 1996, FASEB J, V10, P1014, DOI 10.1096/fasebj.10.9.8801162; Henseler M, 1996, AM J HUM GENET, V58, P65; HIRAIWA M, 1992, P NATL ACAD SCI USA, V89, P11254, DOI 10.1073/pnas.89.23.11254; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Kazmi SMI, 1996, CANCER RES, V56, P1056; Kitareewan S, 1999, ONCOGENE, V18, P5747, DOI 10.1038/sj.onc.1202981; KONDOH K, 1991, BIOCHEM BIOPH RES CO, V181, P286, DOI 10.1016/S0006-291X(05)81415-9; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; Leonova T, 1996, J BIOL CHEM, V271, P17312, DOI 10.1074/jbc.271.29.17312; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; Maurer BJ, 1999, JNCI-J NATL CANCER I, V91, P1138, DOI 10.1093/jnci/91.13.1138; Mauro L, 1999, EXP CELL RES, V252, P439, DOI 10.1006/excr.1999.4639; McCormick DL, 1996, CARCINOGENESIS, V17, P2513, DOI 10.1093/carcin/17.11.2513; Modur V, 1996, J BIOL CHEM, V271, P13094, DOI 10.1074/jbc.271.22.13094; Moon Richard C., 1994, P573; Oridate N, 1997, J NATL CANCER I, V89, P1191, DOI 10.1093/jnci/89.16.1191; PELLEGRINI R, 1992, TUMORI, V78, P1; Piedrafita FJ, 1997, MOL CELL BIOL, V17, P6348, DOI 10.1128/MCB.17.11.6348; Prinetti A, 2000, J BIOL CHEM, V275, P11658, DOI 10.1074/jbc.275.16.11658; RIBONI L, 1992, FEBS LETT, V300, P188, DOI 10.1016/0014-5793(92)80193-K; Sandhoff K, 1997, CLIN CHIM ACTA, V266, P51, DOI 10.1016/S0009-8981(97)00166-6; SHEIKH MS, 1995, CARCINOGENESIS, V16, P2477, DOI 10.1093/carcin/16.10.2477; Sun SY, 1999, MOL PHARMACOL, V55, P403; TOYOKUNI T, 1991, J LABELLED COMPD RAD, V29, P567, DOI 10.1002/jlcr.2580290508; Veronesi U, 1999, J NATL CANCER I, V91, P1847, DOI 10.1093/jnci/91.21.1847; Webber MM, 1999, CLIN EXP METASTAS, V17, P255, DOI 10.1023/A:1006665616932; Zhao Q, 2000, J BIOL CHEM, V275, P24829, DOI 10.1074/jbc.M003497200	46	15	21	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 27	2001	15	6					1475	+		10.1096/fj.00-0531fje	http://dx.doi.org/10.1096/fj.00-0531fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387262				2022-12-25	WOS:000173705800005
J	Awata, H; Huang, CF; Handlogten, ME; Miller, RT				Awata, H; Huang, CF; Handlogten, ME; Miller, RT			Interaction of the calcium-sensing receptor and filamin, a potential scaffolding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BINDING PROTEIN-280; CA2+-SENSING RECEPTOR; SIGNAL-TRANSDUCTION; MEMBRANE DOMAINS; IDENTIFICATION; LOCALIZATION; ORGANIZATION; MUTATIONS; LIGAND; CA2+	In many cases, the biologic responses of cells to extracellular signals and the specificity of the responses cannot be explained solely on the basis of the interactions of known signaling proteins. Recently, scaffolding and adaptor proteins have been identified that organize signaling proteins in cells and that contribute to the nature and specificity of signaling pathways. In an effort to identify proteins that might organize the signaling system(s) activated by the extracellular Ca2+ receptor (CaR), we used a bait construct representing the intracellular C terminus of the human Call and the yeast two hybrid system to screen a human kidney cDNA library. We identified a clone representing the C-terminal 1042 amino acids (aa) of the cytoskeletal protein filamin (ABP-280). Analysis of truncation and deletion constructs of the CaR C terminus and the filamin cDNA clone demonstrated that the CaR and filamin interact via regions containing aa 907-997 of the CaR C terminus and aa 1566-1875 of filamin. Interaction of the two proteins in mammalian REK-293 cells was demonstrated by co-immunoprecipitation and colocalization of them using immunofluorescence microscopy. The functional importance of their interaction was documented by transiently expressing the CaR in M2 melanoma cells that lack filamin, or in A7 melanoma cells that stably express filamin, and demonstrating that the CaR activated ERK only in the presence of filamin. Co-expression of the CaR with a peptide derived from the region of the CaR C terminus that interacts with filamin reduced the ability of the CaR to activate p42ERK in a dose-dependent manner, but did not inhibit the ability of the ETA receptor to activate ERK. The fact that filamin interacts with the CaR and other cell signaling proteins including mitogen-activated protein kinases and small GTPases, indicates that it may act as a scaffolding protein to organize cell signaling systems involving the CaR.	Case Western Reserve Univ, Louis Stokes Vet Affairs Med Ctr, Dept Med, Div Nephrol, Cleveland, OH 44106 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center	Miller, RT (corresponding author), Case Western Reserve Univ, Louis Stokes Vet Affairs Med Ctr, Dept Med, Div Nephrol, 10701 E Blvd, Cleveland, OH 44106 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK041726, R01DK041726] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41726] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Bai M, 1998, J BIOL CHEM, V273, P21267, DOI 10.1074/jbc.273.33.21267; Becker M, 2000, J CELL BIOL, V149, P255, DOI 10.1083/jcb.149.2.255; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; BRASS LF, 1988, J BIOL CHEM, V263, P5348; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; BROWN EM, 1991, PHYSIOL REV, V71, P371, DOI 10.1152/physrev.1991.71.2.371; Brown EM, 1998, ANNU REV MED, V49, P15, DOI 10.1146/annurev.med.49.1.15; BROWN EM, 2001, PHYSIOL REV, V81, P289; Chattopadhyay N, 1997, BIOL CHEM, V378, P759; Cummings CJ, 2000, HUM MOL GENET, V9, P909, DOI 10.1093/hmg/9.6.909; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; Elion EA, 1998, SCIENCE, V281, P1625, DOI 10.1126/science.281.5383.1625; Fox JW, 1998, NEURON, V21, P1315, DOI 10.1016/S0896-6273(00)80651-0; Gama L, 1998, J BIOL CHEM, V273, P29712, DOI 10.1074/jbc.273.45.29712; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Gietz RD, 1997, MOL CELL BIOCHEM, V172, P67, DOI 10.1023/A:1006859319926; Glogauer M, 1998, J BIOL CHEM, V273, P1689, DOI 10.1074/jbc.273.3.1689; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; Hall RA, 1999, J CELL BIOL, V145, P927, DOI 10.1083/jcb.145.5.927; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Handlogten ME, 2001, J BIOL CHEM, V276, P13941, DOI 10.1074/jbc.M007306200; Hastie LE, 1997, FREE RADICAL BIO MED, V22, P955, DOI 10.1016/S0891-5849(96)00482-0; Hofer AM, 2000, NAT CELL BIOL, V2, P392, DOI 10.1038/35017020; James P, 1996, GENETICS, V144, P1425; Kifor O, 1998, J BIOL CHEM, V273, P21708, DOI 10.1074/jbc.273.34.21708; Leonardi A, 2000, J BIOL CHEM, V275, P271, DOI 10.1074/jbc.275.1.271; Li M, 2000, MOL PHARMACOL, V57, P446, DOI 10.1124/mol.57.3.446; Liu GP, 1997, J CELL BIOL, V139, P1719, DOI 10.1083/jcb.139.7.1719; Loo DT, 1998, J BIOL CHEM, V273, P23304, DOI 10.1074/jbc.273.36.23304; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Marti A, 1997, J BIOL CHEM, V272, P2620, DOI 10.1074/jbc.272.5.2620; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Muller M, 1999, EXP CELL RES, V248, P136, DOI 10.1006/excr.1999.4395; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; OHTA Y, 1991, CELL, V67, P275, DOI 10.1016/0092-8674(91)90179-3; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; PATROSSO MC, 1994, GENOMICS, V21, P71, DOI 10.1006/geno.1994.1226; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; POLLAK MR, 1993, CELL, V75, P1297, DOI 10.1016/0092-8674(93)90617-Y; PORTER RM, 1993, J PATHOL, V170, P435, DOI 10.1002/path.1711700406; Ray K, 1997, J BIOL CHEM, V272, P31355, DOI 10.1074/jbc.272.50.31355; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sasaki A, 2001, J BIOL CHEM, V276, P17871, DOI 10.1074/jbc.M008422200; Stahlhut M, 2000, MOL BIOL CELL, V11, P325, DOI 10.1091/mbc.11.1.325; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; Thomas AP, 2000, NAT CELL BIOL, V2, pE126, DOI 10.1038/35017143; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; Zuker CS, 1999, SCIENCE, V283, P650, DOI 10.1126/science.283.5402.650	50	138	142	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34871	34879		10.1074/jbc.M100775200	http://dx.doi.org/10.1074/jbc.M100775200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11390379	hybrid			2022-12-25	WOS:000171024600071
J	Shiina, T; Arai, K; Tanabe, S; Yoshida, N; Haga, T; Nagao, T; Kurose, H				Shiina, T; Arai, K; Tanabe, S; Yoshida, N; Haga, T; Nagao, T; Kurose, H			Clathrin box in G protein-coupled receptor kinase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; BETA-ARRESTIN; ARRESTIN/CLATHRIN INTERACTION; DOWN-REGULATION; SEQUESTRATION; INTERNALIZATION; BINDING; DOMAIN; RESENSITIZATION	beta (1)-Adrenergic receptor (beta (1)AR) shows the resistance to agonist-induced internalization. However, beta (1)AR can internalize as G protein-coupled receptor kinase 2 (GRK2) is fused to its carboxyl terminus. Internalization of the beta (1)AR and GRK2 fusion protein (beta (1)AR/GRK2) is dependent on dynamin but independent of beta -arrestin and phosphorylation. The beta (1)AR/GRK2 fusion protein internalizes via clathrin-coated pits and is found to co-localize with the endosome that contains transferrin. The fusion proteins consisting of beta (1)AR and various portions of GRK2 reveal that the residues 498-502 in the carboxyl-terminal domain of GRK2 are critical to promote internalization of the fusion proteins. This domain contains a consensus sequence of a clathrin-binding motif defined as a clathrin box. In vitro binding assays show that the residues 498-502 of GRK2 bind the amino-terminal domain of clathrin heavy chain to almost the same extent as beta -arrestin1. The mutation of the clathrin box in the carboxyl-terminal domain of GRK2 results in the loss of the ability to promote internalization of the fusion protein. GRK2 activity increases and then decreases as the concentration of clathrin heavy chain increases. Taken together, these results imply that GRK2 contains a functional clathrin box and directly interacts with clathrin to modulate its function.	Univ Tokyo, Lab Pharmacol & Toxicol, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Dept Neurochem, Fac Med, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo; University of Tokyo	Kurose, H (corresponding author), Univ Tokyo, Lab Pharmacol & Toxicol, Grad Sch Pharmaceut Sci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.		Tanabe, Shihori/AAH-6584-2019	Tanabe, Shihori/0000-0003-3706-0616				Barak LS, 1999, J BIOL CHEM, V274, P7565, DOI 10.1074/jbc.274.11.7565; Bohm SK, 1997, BIOCHEM J, V322, P1; Brodsky FM, 1997, TRENDS CELL BIOL, V7, P175, DOI 10.1016/S0962-8924(97)01038-6; Carman CV, 1998, J BIOL CHEM, V273, P20308, DOI 10.1074/jbc.273.32.20308; Carman CV, 1999, J BIOL CHEM, V274, P34483, DOI 10.1074/jbc.274.48.34483; Damke H, 1996, FEBS LETT, V389, P48, DOI 10.1016/0014-5793(96)00517-0; Dell'Angelica EC, 1998, SCIENCE, V280, P431, DOI 10.1126/science.280.5362.431; DUNN KW, 1989, J CELL BIOL, V109, P3303, DOI 10.1083/jcb.109.6.3303; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Furukawa H, 2000, J BIOCHEM-TOKYO, V127, P151, DOI 10.1093/oxfordjournals.jbchem.a022577; Gaidarov I, 2001, MOL CELL, V7, P443, DOI 10.1016/S1097-2765(01)00191-5; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; GREEN SA, 1994, J BIOL CHEM, V269, P26215; Haga K, 1997, BIOCHEMISTRY-US, V36, P1315, DOI 10.1021/bi961613k; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; Kallal L, 1998, J BIOL CHEM, V273, P322, DOI 10.1074/jbc.273.1.322; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; KUROSE H, 1994, J BIOL CHEM, V269, P10093; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; LAW PY, 1984, J BIOL CHEM, V259, P4096; Lee KB, 1998, J BIOL CHEM, V273, P12967, DOI 10.1074/jbc.273.21.12967; Lefkowitz R J, 1998, Adv Pharmacol, V42, P416; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; ROETTGER BF, 1995, J CELL BIOL, V128, P1029, DOI 10.1083/jcb.128.6.1029; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Sato Y, 1996, EUR J PHARMACOL, V315, P363, DOI 10.1016/S0014-2999(96)00648-6; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Shiina T, 2000, J BIOL CHEM, V275, P29082, DOI 10.1074/jbc.M909757199; SUZUKI T, 1992, MOL PHARMACOL, V41, P542; TOUHARA K, 1995, J BIOL CHEM, V270, P17000, DOI 10.1074/jbc.270.28.17000; TSUGA H, 1994, J BIOL CHEM, V269, P32522; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; Vogler O, 1998, J BIOL CHEM, V273, P12155, DOI 10.1074/jbc.273.20.12155; YU SS, 1993, J BIOL CHEM, V268, P337	39	45	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					33019	33026		10.1074/jbc.M100140200	http://dx.doi.org/10.1074/jbc.M100140200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11389137	hybrid			2022-12-25	WOS:000170746000086
J	Huberman, T; Eisenberg-Domovich, Y; Gitlin, G; Kulik, T; Bayer, EA; Wilchek, M; Livnah, O				Huberman, T; Eisenberg-Domovich, Y; Gitlin, G; Kulik, T; Bayer, EA; Wilchek, M; Livnah, O			Chicken avidin exhibits pseudo-catalytic properties - Biochemical, structural, and electrostatic consequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTAVIDIN-BIOTIN COMPLEX; X-RAY-DIFFRACTION; EGG-WHITE AVIDIN; PEPTIDE LIBRARIES; BINDING; TRYPTOPHAN; ANTIBODY; SYSTEM; SITE; TRANSPORT	Avidin and its bacterial analogue streptavidin exhibit similarly high affinities toward the vitamin biotin. The extremely high affinity of these two proteins has been utilized as a powerful tool in many biotechnological applications. Although avidin and streptavidin have similar tertiary and quaternary structures, they differ in many of their properties. Here we show that avidin enhances the alkaline hydrolysis of biotinyl p-nitrophenyl ester, whereas streptavidin protects this reaction even under extreme alkaline conditions (pH > 12). Unlike normal enzymatic catalysis, the hydrolysis reaction proceeds as a single cycle with no turnover because of the extremely high affinity of the protein for one of the reaction products (i.e. free biotin). The three-dimensional crystal structures of avidin (2 Angstrom) and streptavidin (2.4 Angstrom) complexed with the amide analogue, biotinyl p-nitroanilide, as a model for the p-nitrophenyl ester, revealed structural insights into the factors that enhance or protect the hydrolysis reaction. The data demonstrate that several molecular features of avidin are responsible for the enhanced hydrolysis of biotinyl p-nitrophenyl ester. These include the nature of a decisive flexible loop, the presence of an obtrusive arginine 114, and a newly formed critical interaction between lysine III and the nitro group of the substrate. The open conformation of the loop serves to expose the substrate to the solvent, and the arginine shifts the p-nitroanilide moiety toward the interacting lysine, which increases the electron withdrawing characteristics and consequent electrophilicity of the carbonyl group of the substrate. Streptavidin lacked such molecular properties, and analogous interactions with the substrate were consequently absent. The information derived from these structures may provide insight into the action of artificial protein catalysts and the evolution of catalytic sites in general.	Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, Wolfson Ctr Appl Struct Biol, IL-91904 Jerusalem, Israel; Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Hebrew University of Jerusalem; Weizmann Institute of Science	Livnah, O (corresponding author), Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, Wolfson Ctr Appl Struct Biol, IL-91904 Jerusalem, Israel.	oded.livnah@huji.ac.il						[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BAYER EA, 1995, APPL BIOCHEM BIOTECH, V53, P1, DOI 10.1007/BF02783477; Bayer EA, 1996, ELECTROPHORESIS, V17, P1319, DOI 10.1002/elps.1150170808; BAYER EA, 1989, BIOCHEM J, V259, P369, DOI 10.1042/bj2590369; BAYER EA, 1975, FEBS LETT, V60, P309, DOI 10.1016/0014-5793(75)80737-X; BECKER JM, 1971, P NATL ACAD SCI USA, V68, P2604, DOI 10.1073/pnas.68.10.2604; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHILKOTI A, 1995, P NATL ACAD SCI USA, V92, P1754, DOI 10.1073/pnas.92.5.1754; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; Dodson G, 1998, TRENDS BIOCHEM SCI, V23, P347, DOI 10.1016/S0968-0004(98)01254-7; Freitag S, 1998, J MOL BIOL, V279, P211, DOI 10.1006/jmbi.1998.1735; Gigant B, 1997, P NATL ACAD SCI USA, V94, P7857, DOI 10.1073/pnas.94.15.7857; Gissel B, 1995, J Pept Sci, V1, P217, DOI 10.1002/psc.310010402; GREEN NM, 1990, METHOD ENZYMOL, V184, P51; GREEN NM, 1965, BIOCHEM J, V94, P23; HENDRICKSON WA, 1989, P NATL ACAD SCI USA, V86, P2190, DOI 10.1073/pnas.86.7.2190; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JIANG JS, 1994, J MOL BIOL, V243, P100, DOI 10.1006/jmbi.1994.1633; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Katz BA, 1997, J MOL BIOL, V274, P776, DOI 10.1006/jmbi.1997.1444; Laitinen OH, 1999, FEBS LETT, V461, P52, DOI 10.1016/S0014-5793(99)01423-4; LIVNAH O, 1993, P NATL ACAD SCI USA, V90, P5076, DOI 10.1073/pnas.90.11.5076; LIVNAH O, 1993, FEBS LETT, V328, P165, DOI 10.1016/0014-5793(93)80986-5; MCCORMICK D. B., 1970, Methods in Enzymology, V18A, P383, DOI 10.1016/0076-6879(71)18331-0; Miles E W, 1977, Methods Enzymol, V47, P431; MINOR W, 1996, P MACR CRYST COMP SC; Morag E, 1996, BIOCHEM J, V316, P193, DOI 10.1042/bj3160193; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OSTERGAARD S, 1995, FEBS LETT, V362, P306, DOI 10.1016/0014-5793(95)00262-8; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PUGLIESE L, 1993, J MOL BIOL, V231, P698, DOI 10.1006/jmbi.1993.1321; SANO T, 1995, P NATL ACAD SCI USA, V92, P3180, DOI 10.1073/pnas.92.8.3180; Schechter B, 1996, J DRUG TARGET, V4, P171, DOI 10.3109/10611869609015974; SCHULTZ PG, 1995, SCIENCE, V269, P1835, DOI 10.1126/science.7569920; TAKAHASHI K, 1968, J BIOL CHEM, V243, P6171; Thayer MM, 1999, J MOL BIOL, V291, P329, DOI 10.1006/jmbi.1999.2960; WEBER PC, 1989, SCIENCE, V243, P85, DOI 10.1126/science.2911722; Wedemayer GJ, 1997, SCIENCE, V276, P1665, DOI 10.1126/science.276.5319.1665; WILCHEK M, 1967, BIOCHEMISTRY-US, V6, P247, DOI 10.1021/bi00853a038; WILCHEK M, 1988, ANAL BIOCHEM, V171, P1, DOI 10.1016/0003-2697(88)90120-0; WILCHEK M, 1990, METHOD ENZYMOL, V184, P14	42	25	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32031	32039		10.1074/jbc.M102018200	http://dx.doi.org/10.1074/jbc.M102018200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11395489	hybrid			2022-12-25	WOS:000170613500077
J	Krylov, DM; Hurley, JB				Krylov, DM; Hurley, JB			Identification of proximate regions in a complex of retinal guanylyl cyclase 1 and guanylyl cyclase-activating protein-1 by a novel mass spectrometry-based method	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM; DOMAIN; CLONING; EXPRESSION; REGULATOR; AFFINITY; ADENYLYL; MUTANT; GCAP-1; RETGC	A key challenge in studying protein/protein interactions is to accurately identify contact surfaces, i.e. regions of two proteins that are in direct physical contact. Aside from x-ray crystallography and NMR spectroscopy few methods are available that address this problem. Although x-ray crystallography often provides detailed information about contact surfaces, it is limited to situations when a co-crystal of proteins is available. NMR circumvents this requirement but is limited to small protein complexes. Other methods, for instance protection from proteolysis, are less direct and therefore less informative. Here we describe a new method that identifies candidate contact surfaces in protein complexes. The complexes are first stabilized by cross-linking. They are then digested with a protease, and the cross-linked fragments are analyzed by mass spectrometry. We applied this method, referred to as COSUMAS (contact surfaces by mass spectrometry), to two proteins, retinal guanylyl cyclase 1 (RetGC1) and guanylyl cyclase-activating protein-1 (GCAP-1), that regulate cGMP synthesis in photoreceptors. Two regions in GCAP-1 and three in RetGC1 were identified as possible contact sites. The two regions of RetGC1 that are in the vicinities of Cys(741) and Cys(780) map to a kinase homology domain in RetGC1. Their identities as contact sites were independently evaluated by peptide inhibition analysis. Peptides with sequences from these regions block GCAP-1-mediated regulation of guanylyl cyclase at both high and low Ca2+ concentrations. The two regions of GCAP-1 cross-linked to these peptides were in the vicinities of Cys(17) and Cys(105) of GCAP-1. Peptides with sequences derived from these regions inhibit guanylyl cyclase activity directly. These results support a model in which GCAP-1 binds constitutively to RetGC1 and regulates cyclase activity by structural changes caused by the binding or dissociation of Ca2+.	Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle	Hurley, JB (corresponding author), Univ Washington, Dept Biochem, Box 357350, Seattle, WA 98195 USA.				NEI NIH HHS [EY06641] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ames JB, 1999, J BIOL CHEM, V274, P19329, DOI 10.1074/jbc.274.27.19329; CHEN LL, 1991, J BIOL CHEM, V266, P18237; CRABB JW, 1986, BIOCHEMISTRY-US, V25, P4988, DOI 10.1021/bi00366a003; Dizhoor AM, 1998, J BIOL CHEM, V273, P17311, DOI 10.1074/jbc.273.28.17311; DIZHOOR AM, 1995, J BIOL CHEM, V270, P25200, DOI 10.1074/jbc.270.42.25200; DIZHOOR AM, 1994, NEURON, V12, P1345, DOI 10.1016/0896-6273(94)90449-9; Dizhoor AM, 1996, J BIOL CHEM, V271, P19346, DOI 10.1074/jbc.271.32.19346; Duda T, 1996, BIOCHEMISTRY-US, V35, P8478, DOI 10.1021/bi960752z; GORCZYCA WA, 1995, J BIOL CHEM, V270, P22029, DOI 10.1074/jbc.270.37.22029; GORCZYCA WA, 1994, P NATL ACAD SCI USA, V91, P4014, DOI 10.1073/pnas.91.9.4014; HUNT DF, 1986, P NATL ACAD SCI USA, V83, P6233, DOI 10.1073/pnas.83.17.6233; JOHNSON RS, 1987, BIOCHEMISTRY-US, V26, P1209, DOI 10.1021/bi00379a001; Kachi S, 1999, EXP EYE RES, V68, P465, DOI 10.1006/exer.1998.0629; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; Krylov DM, 1999, J BIOL CHEM, V274, P10833, DOI 10.1074/jbc.274.16.10833; Lange C, 1999, FEBS LETT, V460, P27, DOI 10.1016/S0014-5793(99)01312-5; Laura RP, 1996, J BIOL CHEM, V271, P11646, DOI 10.1074/jbc.271.20.11646; Laura RP, 1998, BIOCHEMISTRY-US, V37, P11264, DOI 10.1021/bi9809674; Liu Y, 1997, P NATL ACAD SCI USA, V94, P13414, DOI 10.1073/pnas.94.25.13414; LOWE DG, 1995, P NATL ACAD SCI USA, V92, P5535, DOI 10.1073/pnas.92.12.5535; Olshevskaya EV, 1999, J BIOL CHEM, V274, P10823, DOI 10.1074/jbc.274.16.10823; Rudnicka-Nawrot M, 1998, BIOCHEMISTRY-US, V37, P248, DOI 10.1021/bi972306x; SHYJAN AW, 1992, NEURON, V9, P727, DOI 10.1016/0896-6273(92)90035-C; Sokal I, 1998, MOL CELL, V2, P129, DOI 10.1016/S1097-2765(00)80121-5; Sokal I, 1999, BIOCHEMISTRY-US, V38, P1387, DOI 10.1021/bi982512k; Sokal I, 1999, J BIOL CHEM, V274, P19829, DOI 10.1074/jbc.274.28.19829; THOMAS TC, 1993, P NATL ACAD SCI USA, V90, P10295, DOI 10.1073/pnas.90.21.10295; THOMAS TC, 1993, BIOCHEMISTRY-US, V32, P8626; TOMER KB, 1984, ANAL CHEM, V56, P880, DOI 10.1021/ac00270a006; Tucker CL, 1998, P NATL ACAD SCI USA, V95, P5993, DOI 10.1073/pnas.95.11.5993; Tucker CL, 1997, BIOCHEMISTRY-US, V36, P11995, DOI 10.1021/bi971212k; Wedel BJ, 2001, ANNU REV PHYSIOL, V63, P215, DOI 10.1146/annurev.physiol.63.1.215	32	27	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30648	30654		10.1074/jbc.M104121200	http://dx.doi.org/10.1074/jbc.M104121200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11387342	hybrid			2022-12-25	WOS:000170472900010
J	Ogushi, K; Wada, A; Niidome, T; Mori, N; Oishi, K; Nagatake, T; Takahashi, A; Asakura, H; Makino, S; Hojo, H; Nakahara, Y; Ohsaki, M; Hatakeyama, T; Aoyagi, H; Kurazono, H; Moss, J; Hirayama, T				Ogushi, K; Wada, A; Niidome, T; Mori, N; Oishi, K; Nagatake, T; Takahashi, A; Asakura, H; Makino, S; Hojo, H; Nakahara, Y; Ohsaki, M; Hatakeyama, T; Aoyagi, H; Kurazono, H; Moss, J; Hirayama, T			Salmonella enteritidis FliC (flagella filament protein) induces human beta-defensin-2 mRNA production by Caco-2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PSEUDOMONAS-AERUGINOSA; TYPHI FLAGELLA; BETA-DEFENSINS; EXPRESSION; ACTIVATION; INDUCTION; ALPHA; HBD-1	Antimicrobial peptides are crucial for host defense at mucosal surfaces. Bacterial factors responsible for induction of human beta -defensin-2 (hBD-2) mRNA expression in Caco-2 human carcinoma cells were determined. Salmonella enteritidis, Salmonella typhimurium, Salmonella typhi, Salmonella dublin, and culture supernatants of these strains induced hBD-2 mRNA expression in Caco-2 human carcinoma cells. Using luciferase as a reporter gene for a similar to2.1-kilobase pair hBD-2 promoter, the hBD-2-inducing factor in culture supernatant of S. enteritidis was isolated. The supernatant factor was heat-stable and proteinase-sensitive. After purification by anion exchange and gel filtration chromatography, the hBD-2-inducing factor was identified as a 53-kDa monomeric protein with the amino-terminal sequence AQVINTNSLSLLTQNNLNK, which is identical to that of the flagella filament structural protein (FliC) of S. enteritidis. Consistent with this finding, the 53-kDa protein reacted with anti-FliC antibody, which prevented its induction of hBD-2 mRNA in Caco-2 cells. In agreement, the hBD-2-inducing activity in culture supernatant was completely neutralized by anti-FliC antibody. In gel retardation analyses, FliC increased binding of NF-kappaB (p65 homodimer) to hBD-2 gene promoter sequences. We conclude that S. enteritidis FliC induces hBD-2 expression in Caco-2 cells via NF-kappaB activation and thus plays an important role in up-regulation of the innate immune response.	Nagasaki Univ, Dept Bacteriol, Nagasaki 8528523, Japan; Nagasaki Univ, Dept Prevent Med & AIDS Res, Nagasaki 8528523, Japan; Nagasaki Univ, Inst Trop Med, Dept Internal Med, Nagasaki 8528523, Japan; Nagasaki Univ, Dept Appl Chem, Fac Engn, Nagasaki 8528523, Japan; Univ Tokushima, Sch Med, Dept Nutr, Tokushima 7708503, Japan; Obihiro Univ Agr & Vet Med, Dept Vet Microbiol, Obihiro, Hokkaido 0808555, Japan; Tokai Univ, Dept Ind Chem, Hiratsuka, Kanagawa 2591292, Japan; Okayama Univ, Sch Med, Fac Hlth Sci, Okayama 7008558, Japan; NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA	Nagasaki University; Nagasaki University; Nagasaki University; Nagasaki University; Tokushima University; Obihiro University of Agriculture & Veterinary Medicine; Tokai University; Okayama University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Hirayama, T (corresponding author), Nagasaki Univ, Dept Bacteriol, Sakamoto, Nagasaki 8528523, Japan.	hirayama@net.nagasaki-u.ac.jp	Niidome, Takuro/F-1508-2010	Niidome, Takuro/0000-0002-8070-8708; Hatakeyama, Tomomitsu/0000-0002-9505-1980	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000659, ZIAHL000659] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bals R, 1998, J CLIN INVEST, V102, P874, DOI 10.1172/JCI2410; Baumler AJ, 2000, SCIENCE, V287, P50, DOI 10.1126/science.287.5450.50; BENSCH KW, 1995, FEBS LETT, V368, P331, DOI 10.1016/0014-5793(95)00687-5; Ciacci-Wooline F, 1999, INFECT IMMUN, V67, P5176, DOI 10.1128/IAI.67.10.5176-5185.1999; Ciacci-Woolwine F, 1998, INFECT IMMUN, V66, P1127, DOI 10.1128/IAI.66.3.1127-1134.1998; Eaves-Pyles T, 1999, INFECT IMMUN, V67, P800, DOI 10.1128/IAI.67.2.800-804.1999; Feldman M, 1998, INFECT IMMUN, V66, P43, DOI 10.1128/IAI.66.1.43-51.1998; Gewirtz AT, 2000, J CLIN INVEST, V105, P79, DOI 10.1172/JCI8066; Harder J, 2000, AM J RESP CELL MOL, V22, P714, DOI 10.1165/ajrcmb.22.6.4023; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; HARWIG SSL, 1994, METHOD ENZYMOL, V236, P160; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; IBRAHIM GF, 1985, J CLIN MICROBIOL, V22, P1040, DOI 10.1128/JCM.22.6.1040-1044.1985; JONES DE, 1993, FEBS LETT, V315, P187, DOI 10.1016/0014-5793(93)81160-2; JONES DE, 1992, J BIOL CHEM, V267, P23216; O'Neil DA, 1999, J IMMUNOL, V163, P6718; OHSAKI M, 1998, PEPT SCI, P453; Singh PK, 1998, P NATL ACAD SCI USA, V95, P14961, DOI 10.1073/pnas.95.25.14961; Steiner TS, 2000, J CLIN INVEST, V105, P1769, DOI 10.1172/JCI8892; Svinarich DM, 1997, AM J OBSTET GYNECOL, V176, P470, DOI 10.1016/S0002-9378(97)70517-9; VORDERVISZT F, 1989, J MOL BIOL, V209, P127; Wada A, 1999, BIOCHEM BIOPH RES CO, V263, P770, DOI 10.1006/bbrc.1999.1452; Wada A, 2001, CELL MICROBIOL, V3, P115, DOI 10.1046/j.1462-5822.2001.00096.x; Ward LR, 2000, SCIENCE, V287, P1753, DOI 10.1126/science.287.5459.1753c; Wyant TL, 1999, INFECT IMMUN, V67, P3619, DOI 10.1128/IAI.67.7.3619-3624.1999; Wyant TL, 1999, INFECT IMMUN, V67, P1338, DOI 10.1128/IAI.67.3.1338-1346.1999; Zhao CQ, 1996, FEBS LETT, V396, P319, DOI 10.1016/0014-5793(96)01123-4	27	119	132	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30521	30526		10.1074/jbc.M011618200	http://dx.doi.org/10.1074/jbc.M011618200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11387317	hybrid			2022-12-25	WOS:000170558000120
J	Sasaki, Y; Sugamura, K				Sasaki, Y; Sugamura, K			Involvement of Hgs/Hrs in signaling for cytokine-mediated c-fos induction through interaction with TAK1 and Pak1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; RECEPTOR-BETA-CHAIN; TRANSDUCING ADAPTER MOLECULE; ZINC-FINGER DOMAIN; N-TERMINAL KINASE; I-KAPPA-B; TYROSINE PHOSPHORYLATION; INTERLEUKIN-2 RECEPTOR; ENDOSOMAL LOCALIZATION; IL-2 RECEPTOR	Hgs/Hrs is a tyrosine-phosphorylated FYVE finger protein that is induced by stimulation with various cytokines and growth factors. Here we show that Hgs plays critical roles in the signaling pathway for the interleukin-2. induced activation of the serum-response element and cyclic AMP-response element of the c-fos promoter. We found that Hgs associated physically with transforming growth factor-beta -activated kinase 1 (TAK1) and p21-activated kinase 1 (Pak1), which mediate the activation of c-Jun N-terminal kinase and serum response factor, respectively, leading to transactivation via the serum-response element and cyclic AMP-response element. These results suggest that Hgs is involved in the TAK1-JNK and Pak1-serum response factor pathways for the c-fos induction that is initiated by cytokines.	Tohoku Univ, Grad Sch Med, Dept Microbiol & Immunol, Aoba Ku, Sendai, Miyagi 9808575, Japan; Program Japan Sci & Technol Corp, CREST, Aoba Ku, Sendai, Miyagi 9808575, Japan	Tohoku University; Japan Science & Technology Agency (JST)	Sugamura, K (corresponding author), Tohoku Univ, Grad Sch Med, Dept Microbiol & Immunol, Aoba Ku, Seiryo Machi, Sendai, Miyagi 9858575, Japan.							Amano M, 1998, GENES CELLS, V3, P177, DOI 10.1046/j.1365-2443.1998.00181.x; Asao H, 1997, J BIOL CHEM, V272, P32785, DOI 10.1074/jbc.272.52.32785; ASAO H, 1993, P NATL ACAD SCI USA, V90, P4127, DOI 10.1073/pnas.90.9.4127; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; Burd CG, 1998, MOL CELL, V2, P157, DOI 10.1016/S1097-2765(00)80125-2; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Daniels RH, 1999, TRENDS BIOCHEM SCI, V24, P350, DOI 10.1016/S0968-0004(99)01442-5; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DESCHAMPS J, 1985, SCIENCE, V230, P1174, DOI 10.1126/science.3865371; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Endo K, 2000, FEBS LETT, V477, P55, DOI 10.1016/S0014-5793(00)01760-9; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1992, P NATL ACAD SCI USA, V89, P2022, DOI 10.1073/pnas.89.6.2022; Hayakawa A, 2000, J BIOL CHEM, V275, P29636, DOI 10.1074/jbc.M002696200; Hirai S, 1997, J BIOL CHEM, V272, P15167, DOI 10.1074/jbc.272.24.15167; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Itoh T, 1996, J BIOL CHEM, V271, P7587, DOI 10.1074/jbc.271.13.7587; Kinoshita T, 1997, ONCOGENE, V15, P619, DOI 10.1038/sj.onc.1201234; KOMADA M, 1995, MOL CELL BIOL, V15, P6213; Komada M, 1999, GENE DEV, V13, P1475, DOI 10.1101/gad.13.11.1475; Komada M, 1997, J BIOL CHEM, V272, P20538, DOI 10.1074/jbc.272.33.20538; Ku GM, 2001, EMBO J, V20, P457, DOI 10.1093/emboj/20.3.457; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; Miura S, 2000, MOL CELL BIOL, V20, P9346, DOI 10.1128/MCB.20.24.9346-9355.2000; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Nelson BH, 1998, ADV IMMUNOL, V70, P1, DOI 10.1016/S0065-2776(08)60386-7; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Patki V, 1998, NATURE, V394, P433, DOI 10.1038/28771; POMPO CM, 1995, NATURE, V377, P750; RIDELY AJ, 1992, CELL, V70, P401; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; SUGAMURA K, 1995, ADV IMMUNOL, V59, P225, DOI 10.1016/S0065-2776(08)60632-X; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Takekawa M, 1997, EMBO J, V16, P4973, DOI 10.1093/emboj/16.16.4973; TAKESHITA T, 1992, J IMMUNOL, V148, P2154; Takeshita T, 1997, IMMUNITY, V6, P449, DOI 10.1016/S1074-7613(00)80288-5; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Urbe S, 2000, MOL CELL BIOL, V20, P7685, DOI 10.1128/MCB.20.20.7685-7692.2000; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamaguchi K, 1999, EMBO J, V18, P179, DOI 10.1093/emboj/18.1.179; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	63	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29943	29952		10.1074/jbc.M104230200	http://dx.doi.org/10.1074/jbc.M104230200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11397816	hybrid			2022-12-25	WOS:000170558000046
J	Sreenivas, A; Villa-Garcia, MJ; Henry, SA; Carman, GM				Sreenivas, A; Villa-Garcia, MJ; Henry, SA; Carman, GM			Phosphorylation of the yeast phospholipid synthesis regulatory protein Opi1p by protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR PHO4; SACCHAROMYCES-CEREVISIAE; INO1 GENE; SHUTTLE VECTORS; CELL-SURFACE; BIOSYNTHESIS; INOSITOL; ACTIVATION; IDENTIFICATION; SYNTHASE	Opi1p is a negative regulator of expression of phospholipid-synthesizing enzymes in the yeast Saccharomyces cerevisiae. In this work, we examined the phosphorylation of Opi1p by protein kinase C. Using a purified maltose-binding protein-Opi1p fusion protein as a substrate, protein kinase C activity was time- and dose-dependent, and dependent on the concentrations of Opi1p and ATP. Protein kinase C phosphorylated Opi1p on a serine residue. The Opi1p synthetic peptide GVLKQSCRQK, which contained a protein kinase C sequence motif at Ser(26), was a substrate for protein kinase C. Phosphorylation of a purified S26A mutant maltose-binding protein-Opi1p fusion protein by the kinase was reduced when compared with the wild-type protein. A major phosphopeptide present in purified wild-type Opi1p was absent from the purified S26A mutant protein. In vivo labeling experiments showed that the phosphorylation of Opi1p was physiologically relevant, and that the extent of phosphorylation of the S26A mutant protein was reduced by 50% when compared with the wild-type protein. The physiological consequence of the phosphorylation of Opi1p at Ser(26) was examined by measuring the effect of the S26A mutation on the expression of the phospholipid synthesis gene INO1. The beta -galactosidase activity driven by an INO1-CYC-lacI 'Z reporter gene in opi1 Delta mutant cells expressing the S26A mutant Opi1p was about 50% lower than that of cells expressing the wild-type Opi1p protein. These data supported the conclusion that phosphorylation of Opi1p at Ser(26) mediated the attenuation of the negative regulatory function of Opi1p on the expression of the INO1 gene.	Rutgers State Univ, New Jersey Agr Expt Stn, Cook Coll, Dept Food Sci, New Brunswick, NJ 08901 USA; Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA	Rutgers State University New Brunswick; Cornell University	Carman, GM (corresponding author), Rutgers State Univ, New Jersey Agr Expt Stn, Cook Coll, Dept Food Sci, 65 Dudley Rd, New Brunswick, NJ 08901 USA.	carman@aesop.rutgers.edu	Henry, Susan/K-5464-2014		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM019629, R01GM050679, R01GM019629] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-50679, GM-19629] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACHHAWAT N, 1995, J BIOL CHEM, V270, P25087, DOI 10.1074/jbc.270.42.25087; BELL RM, 1991, J BIOL CHEM, V266, P4661; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Calkhoven CF, 1996, BIOCHEM J, V317, P329, DOI 10.1042/bj3170329; Carman GM, 1999, PROG LIPID RES, V38, P361, DOI 10.1016/S0163-7827(99)00010-7; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; Carman GM, 1996, J BIOL CHEM, V271, P13293, DOI 10.1074/jbc.271.23.13293; CRAVEN GR, 1965, J BIOL CHEM, V240, P2468; CULBERTSON MR, 1975, GENETICS, V80, P23; DONAHUE TF, 1981, J BIOL CHEM, V256, P7077; DOWNES CP, 1990, EUR J BIOCHEM, V193, P1, DOI 10.1111/j.1432-1033.1990.tb19297.x; EXTON JH, 1990, J BIOL CHEM, V265, P1; Graves JA, 2000, GENETICS, V154, P1485; GRAVES JA, 1996, THESIS CARNEGIE MELL; Greenberg ML, 1996, MICROBIOL REV, V60, P1; GREENBERG ML, 1982, GENETICS, V100, P19; HAID A, 1983, METHOD ENZYMOL, V96, P192; Harlow E., 1988, ANTIBODIES LAB MANUA; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; Henry SA, 1998, PROG NUCLEIC ACID RE, V61, P133, DOI 10.1016/S0079-6603(08)60826-0; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HIRSCH JP, 1986, MOL CELL BIOL, V6, P3320, DOI 10.1128/MCB.6.10.3320; Hung W, 1997, EUR J BIOCHEM, V245, P241, DOI 10.1111/j.1432-1033.1997.00241.x; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jiranek V, 1998, MICROBIOL-UK, V144, P2739, DOI 10.1099/00221287-144-10-2739; Kaffman A, 1998, NATURE, V396, P482, DOI 10.1038/24898; KAIBUCHI K, 1985, J BIOL CHEM, V260, P1366; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KLIG LS, 1984, P NATL ACAD SCI-BIOL, V81, P3816, DOI 10.1073/pnas.81.12.3816; KLIG LS, 1985, J BACTERIOL, V162, P1135, DOI 10.1128/JB.162.3.1135-1141.1985; KODAKI T, 1991, J BACTERIOL, V173, P7992, DOI 10.1128/jb.173.24.7992-7995.1991; Komeili A, 1999, SCIENCE, V284, P977, DOI 10.1126/science.284.5416.977; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; Liu C, 2000, J BIOL CHEM, V275, P31972, DOI 10.1074/jbc.M003055200; LOEWY BS, 1984, MOL CELL BIOL, V4, P2479, DOI 10.1128/MCB.4.11.2479; LOPES JM, 1991, NUCLEIC ACIDS RES, V19, P1687, DOI 10.1093/nar/19.7.1687; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MCGEE TP, 1994, J BACTERIOL, V176, P6861, DOI 10.1128/JB.176.22.6861-6868.1994; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OGITA K, 1990, P NATL ACAD SCI USA, V87, P5011, DOI 10.1073/pnas.87.13.5011; PALTAUF F, 1992, MOL CELLULAR BIOL YE, P415; PattonVogt JL, 1997, J BIOL CHEM, V272, P20873, DOI 10.1074/jbc.272.33.20873; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; Rose MD., 1990, METHODS YEAST GENETI; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; ROZENGURT E, 1984, P NATL ACAD SCI-BIOL, V81, P5748, DOI 10.1073/pnas.81.18.5748; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SIKORSKI RS, 1989, GENETICS, V122, P19; SIMON AJ, 1991, P ROY SOC B-BIOL SCI, V243, P165, DOI 10.1098/rspb.1991.0027; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Wagner C, 1999, YEAST, V15, P843, DOI 10.1002/(SICI)1097-0061(199907)15:10A<843::AID-YEA424>3.0.CO;2-M; WHITE MJ, 1991, J BIOL CHEM, V266, P863; Yang WL, 1996, J BIOL CHEM, V271, P11113, DOI 10.1074/jbc.271.19.11113	63	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29915	29923		10.1074/jbc.M105147200	http://dx.doi.org/10.1074/jbc.M105147200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11395523	Green Submitted, hybrid			2022-12-25	WOS:000170558000042
J	Wrenger, C; Luersen, K; Krause, T; Muller, S; Walter, RD				Wrenger, C; Luersen, K; Krause, T; Muller, S; Walter, RD			The Plasmodium falciparum bifunctional ornithine decarboxylase, S-adenosyl-L-methionine decarboxylase, enables a well balanced polyamine synthesis without domain-domain interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSYLMETHIONINE DECARBOXYLASE; DIHYDROFOLATE-REDUCTASE; THYMIDYLATE SYNTHASE; ESCHERICHIA-COLI; ANGSTROM RESOLUTION; PUTRESCINE; SEQUENCES; ANALOGS; DIFLUOROMETHYLORNITHINE; DEGRADATION	In the human malaria parasite Plasmodium falciparum (Pf), polyamines are synthesized by a bifunctional enzyme that possesses both ornithine decarboxylase (ODC) and S-adenosyl-L-methionine decarboxylase (AdoMetDC) activities. The mature enzyme consists of the heterotetrameric N-terminal AdoMetDC and the C-terminal dimeric ODC, which results in the formation of a heterotetrameric complex. For the native bifunctional protein a half-life longer than 2 h was determined, which is in contrast to the extreme short half-life of its mammalian monofunctional counterparts. The biological advantage of the plasmodial bifunctional ODC/ AdoMetDC might be that the control of polyamine synthesis is achieved by only having to regulate the abundance and activity of one protein. An interesting feature in the regulation of the bifunctional protein is that putrescine inhibits PfODC activity similar to 10-fold more efficiently than the mammalian ODC activity, and in contrast to the mammalian AdoMetDC the activity of the PfAdoMetDC domain is not stimulated by the diamine. To analyze post-translational processing, polymerization, and domain-domain interactions, several mutant proteins were generated that have single mutations in either the PfODC or PfAdoMetDC domains. The exchange of amino acids essential for the activity of one domain had no effect on the enzyme activity of the other domain. Even prevention of the post-translational cleavage of the AdoMetDC domain or ODC dimerization and thus the interference with the folding of the protein hardly affected the activity of the partner domain. In addition, inhibition of the activity of the PfODC domain had no effect on the activity of the PfAdoMetDC domain and vice versa. These results demonstrate that no domain-domain interactions occur between the two enzymes of the bifunctional PfODC/AdoMetDC and that both enzymatic activities are operating as independent catalytic sites that do not affect each other.	Bernhard Nocht Inst Trop Med, D-20359 Hamburg, Germany; Univ Dundee, Sch Life Sci, Dundee DD1 5EH, Scotland	Bernhard Nocht Institut fur Tropenmedizin; University of Dundee	Walter, RD (corresponding author), Bernhard Nocht Inst Trop Med, Bernhard Nocht Str 74, D-20359 Hamburg, Germany.	walter@bni.uni-hamburg.de	Wrenger, Carsten/E-4110-2013	Wrenger, Carsten/0000-0001-5987-1749				BITONTI AJ, 1987, EXP PARASITOL, V64, P237, DOI 10.1016/0014-4894(87)90148-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRETON CB, 1990, RES IMMUNOL, V141, P743, DOI 10.1016/0923-2494(90)90005-J; CHRISTOPHERS S. RICKARD, 1939, ANN TROP MED AND PARASITOL, V33, P161; COLEMAN CS, 1994, J BIOL CHEM, V269, P3155; Da'Dara AA, 1998, BIOCHEM J, V336, P545, DOI 10.1042/bj3360545; DEZEURE F, 1989, INT J BIOCHEM, V21, P889, DOI 10.1016/0020-711X(89)90288-7; Ekstrom JL, 1999, STRUCTURE, V7, P583, DOI 10.1016/S0969-2126(99)80074-4; GHODA L, 1990, J BIOL CHEM, V265, P11823; GUATTARI B, 1991, J CHROMATOGR-BIOMED, V567, P254, DOI 10.1016/0378-4347(91)80329-B; HAFNER EW, 1979, J BIOL CHEM, V254, P2419; HAYASHI S, 1989, ORNITHINE DECARBOXYL, P47; HEBY O, 1985, ADV ENZYME REGUL, V24, P103, DOI 10.1016/0065-2571(85)90072-X; INSELBURG J, 1988, AM J TROP MED HYG, V39, P328, DOI 10.4269/ajtmh.1988.39.328; KANAANI J, 1989, J BIOL CHEM, V264, P3194; Kern AD, 1999, STRUCTURE, V7, P567, DOI 10.1016/S0969-2126(99)80073-2; KITANI T, 1983, J BIOL CHEM, V258, P235; Krause T, 2000, BIOCHEM J, V352, P287, DOI 10.1042/0264-6021:3520287; Liang PH, 1998, BIOCHEMISTRY-US, V37, P12195, DOI 10.1021/bi9803168; MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415; MCCANN PP, 1981, MED BIOL, V59, P434; METT H, 1993, CANCER CHEMOTH PHARM, V32, P39, DOI 10.1007/BF00685874; Muller S, 2000, J BIOL CHEM, V275, P8097, DOI 10.1074/jbc.275.11.8097; Muller S, 2001, TRENDS PARASITOL, V17, P242, DOI 10.1016/S1471-4922(01)01908-0; Niemann G, 1996, BIOCHEM J, V317, P135, DOI 10.1042/bj3170135; OSTERMAN A, 1994, BIOCHEMISTRY-US, V33, P13662, DOI 10.1021/bi00250a016; PASVOL G, 1978, ANN TROP MED PARASIT, V72, P87, DOI 10.1080/00034983.1978.11719283; PATCHETT ML, 1988, J CHROMATOGR-BIOMED, V425, P269, DOI 10.1016/0378-4347(88)80031-8; PEGG AE, 1969, J BIOL CHEM, V244, P682; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PEGG AE, 1988, CANCER RES, V48, P759; Pegg AE, 1998, BIOCHEM SOC T, V26, P580, DOI 10.1042/bst0260580; PEGG AE, 1989, ENZYMES AS TARGETS FOR DRUG DESIGN, P157; PORTER CW, 1986, ANTICANCER RES, V6, P525; POULIN R, 1992, J BIOL CHEM, V267, P150; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RUSSELL DH, 1969, MOL PHARMACOL, V5, P253; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shallom S, 1999, J BIOL CHEM, V274, P37781, DOI 10.1074/jbc.274.53.37781; STANEK J, 1993, J MED CHEM, V36, P46, DOI 10.1021/jm00053a007; STANLEY BA, 1989, J BIOL CHEM, V264, P21073; STANLEY BA, 1994, J BIOL CHEM, V269, P7901; Svensson F, 1997, P NATL ACAD SCI USA, V94, P397, DOI 10.1073/pnas.94.2.397; TABOR CW, 1985, MICROBIOL REV, V49, P81, DOI 10.1128/MMBR.49.1.81-99.1985; TABOR H, 1964, PHARMACOL REV, V16, P245; TOBIAS KE, 1993, EUR J BIOCHEM, V218, P245, DOI 10.1111/j.1432-1033.1993.tb18371.x; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; YAYON A, 1983, J PROTOZOOL, V30, P642, DOI 10.1111/j.1550-7408.1983.tb05336.x	48	46	48	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29651	29656		10.1074/jbc.M100578200	http://dx.doi.org/10.1074/jbc.M100578200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11390378	hybrid			2022-12-25	WOS:000170558000009
J	Hay, E; Lemonnier, J; Fromigue, O; Marie, PJ				Hay, E; Lemonnier, J; Fromigue, O; Marie, PJ			Bone morphogenetic protein-2 promotes osteoblast apoptosis through a Smad-independent, protein kinase C-dependent signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; INHIBITS MYOGENIC DIFFERENTIATION; GROWTH-FACTOR-BETA; ALKALINE-PHOSPHATASE; MEDIATED APOPTOSIS; UP-REGULATION; MAP KINASES; ACTIVATION; EXPRESSION; PROLIFERATION	Bone morphogenetic protein-2 (BMP-2), a member of the transforming growth factor-beta (TGF-beta) family, regulates osteoblast differentiation and bone formation. Here we show a novel function of BMP-2 in human osteoblasts and identify a signaling pathway involved in this function. BMP-2 promotes apoptosis in primary human calvaria osteoblasts and in immortalized human neonatal calvaria osteoblasts, as shown by terminal deoxynucleotidyl transferase-mediated nick end labeling analysis. In contrast, TGF-beta2 inhibits apoptosis in human osteoblasts. Studies of the mechanisms of action showed that BMP-2 increases the Bax/Bcl-2 ratio, whereas TG beta -2 has a negative effect. Moreover, BMP-2 increases the release of mitochondrial cytochrome c to the cytosol. Consistent with these results, BMP-2 increases caspase-9 and caspase-3, -6, and -7 activity, and an anti-caspase-9 agent suppresses BMP-2-induced apoptosis. Overexpression of dominant-negative Smad1 effectively blocks BMP-2-induced expression of the osteoblast transcription factor Runx2 but not the activation of caspases or apoptosis induced by BMP-2, indicating that the Smad1 signaling pathway is not involved in the BMP-2-induced apoptosis. The proapoptotic effect of BMP-2 is PKC-dependent, because BMP-2 increases PKC activity, and the selective PKC inhibitor calphostin C blocks the BMP-2-induced increased Bax/Bcl-2, caspase activity, and apoptosis. In contrast, the cAMP-dependent protein kinase A inhibitor H89, the p38 MAPK inhibitor SB203580, and the MEK inhibitor PD-98059 have no effect. The results show that BMP-2 uses a Smad-independent, PKC-dependent pathway to promote apoptosis via a Bax/Bcl-2 and cytochrome c-caspase-9-caspase-3,-6,-7 cascade in human osteoblasts.	Hop Lariboisiere, CNRS, INSERM, U 349,Lab Osteoblast Biol & Pathol, F-75475 Paris 10, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Marie, PJ (corresponding author), Hop Lariboisiere, CNRS, INSERM, U 349,Lab Osteoblast Biol & Pathol, F-75475 Paris 10, France.	pierre.marie@inserm.Irb.ap-hop-paris.fr	Fromigue, Olivia/B-8225-2013	Fromigue, Olivia/0000-0002-3050-6155; Hay, Eric/0000-0002-0131-9983				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Antonsson B, 2000, EXP CELL RES, V256, P50, DOI 10.1006/excr.2000.4839; Aubin Jane E., 1996, P51; Bellido T, 1998, J BIOL CHEM, V273, P21137, DOI 10.1074/jbc.273.33.21137; Bourez RLJH, 1997, J CRANIOFAC SURG, V8, P441, DOI 10.1097/00001665-199711000-00002; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; Buckland RA, 1998, MECH DEVELOP, V71, P143, DOI 10.1016/S0925-4773(98)00008-2; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; CHEN SJ, 1993, BIOCHEMISTRY-US, V32, P1032, DOI 10.1021/bi00055a006; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; Debiais F, 2001, J CELL BIOCHEM, V81, P68, DOI 10.1002/1097-4644(20010401)81:1<68::AID-JCB1024>3.0.CO;2-S; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Ducy P, 1998, CURR OPIN CELL BIOL, V10, P614, DOI 10.1016/S0955-0674(98)80037-9; Ferrari D, 1998, DEV BIOL, V197, P12, DOI 10.1006/dbio.1998.8880; Fromigue O, 1998, J CELL BIOCHEM, V68, P411, DOI 10.1002/(SICI)1097-4644(19980315)68:4<411::AID-JCB2>3.3.CO;2-C; FURTWANGLER JA, 1985, ACTA ANAT, V124, P74; GARCIAMARTINEZ V, 1993, J CELL SCI, V106, P201; GOMEZ J, 1994, EXP CELL RES, V213, P178, DOI 10.1006/excr.1994.1188; HARRIS SE, 1994, J BONE MINER RES, V9, P855; Hay E, 1999, J CELL BIOCHEM, V72, P81, DOI 10.1002/(SICI)1097-4644(19990101)72:1<81::AID-JCB9>3.0.CO;2-N; Hay E, 2000, J CELL PHYSIOL, V183, P117, DOI 10.1002/(SICI)1097-4652(200004)183:1<117::AID-JCP14>3.0.CO;2-#; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hill PA, 1997, ENDOCRINOLOGY, V138, P3849, DOI 10.1210/en.138.9.3849; Iantosca MR, 1999, J NEUROSCI RES, V56, P248; Ishisaki A, 1999, J BIOL CHEM, V274, P13637, DOI 10.1074/jbc.274.19.13637; Israels LG, 1999, STEM CELLS, V17, P306, DOI 10.1002/stem.170306; Jernvall J, 1998, DEVELOPMENT, V125, P161; Jilka RL, 1998, J BONE MINER RES, V13, P793, DOI 10.1359/jbmr.1998.13.5.793; Ju WJ, 2000, J BONE MINER RES, V15, P1889, DOI 10.1359/jbmr.2000.15.10.1889; Kim HJ, 1998, DEVELOPMENT, V125, P1241; Kimura N, 2000, J BIOL CHEM, V275, P17647, DOI 10.1074/jbc.M908622199; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; Lee MH, 1999, J CELL BIOCHEM, V73, P114, DOI 10.1002/(SICI)1097-4644(19990401)73:1<114::AID-JCB13>3.3.CO;2-D; Lee YS, 1997, J CELL PHYSIOL, V170, P153, DOI 10.1002/(SICI)1097-4652(199702)170:2<153::AID-JCP7>3.0.CO;2-N; Lemonnier J, 2001, AM J PATHOL, V158, P1833, DOI 10.1016/S0002-9440(10)64139-9; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Loeffler M, 2000, EXP CELL RES, V256, P19, DOI 10.1006/excr.2000.4833; Lou J, 2000, BIOCHEM BIOPH RES CO, V268, P757, DOI 10.1006/bbrc.2000.2210; LUCAS M, 1995, GEN PHARMACOL, V26, P881, DOI 10.1016/0306-3623(94)00295-X; Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115; Mansukhani A, 2000, J CELL BIOL, V149, P1297, DOI 10.1083/jcb.149.6.1297; Marazzi G, 1997, DEV BIOL, V186, P127, DOI 10.1006/dbio.1997.8576; MARIE PJ, 1998, ADV ORG BIO A-C, V5, P445; MARIE PJ, 1997, J CELL ENG, V2, P92; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Matsuda N, 1998, BIOCHEM BIOPH RES CO, V249, P350, DOI 10.1006/bbrc.1998.9151; Merino R, 1999, ANN NY ACAD SCI, V887, P120, DOI 10.1111/j.1749-6632.1999.tb07927.x; Mohan RR, 1998, INVEST OPHTH VIS SCI, V39, P2626; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nishimura R, 1998, J BIOL CHEM, V273, P1872, DOI 10.1074/jbc.273.4.1872; Ozaki I, 1999, J BIOL CHEM, V274, P5310, DOI 10.1074/jbc.274.9.5310; Palcy S, 1999, BIOCHEM J, V343, P21, DOI 10.1042/0264-6021:3430021; REDDI AH, 1972, P NATL ACAD SCI USA, V69, P1601, DOI 10.1073/pnas.69.6.1601; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; RITKE MK, 1994, MOL PHARMACOL, V46, P605; Rodriguez-Leon J, 1999, NAT CELL BIOL, V1, P125, DOI 10.1038/10098; Sanders JL, 1996, J BONE MINER RES, V11, P1862; Savickiene J, 1999, CELL DEATH DIFFER, V6, P698, DOI 10.1038/sj.cdd.4400541; Schmidt C, 1998, DEV BIOL, V202, P253, DOI 10.1006/dbio.1998.9011; SCHWARTZMAN RA, 1993, ENDOCR REV, V14, P133, DOI 10.1210/er.14.2.133; Schwenger P, 1997, P NATL ACAD SCI USA, V94, P2869, DOI 10.1073/pnas.94.7.2869; Song QB, 1998, DEV BIOL, V196, P119, DOI 10.1006/dbio.1998.8847; Stein GS, 1996, PHYSIOL REV, V76, P593, DOI 10.1152/physrev.1996.76.2.593; Suzuki A, 1999, ENDOCRINOLOGY, V140, P3177, DOI 10.1210/en.140.7.3177; TAMAOKI T, 1990, BIO-TECHNOL, V8, P732, DOI 10.1038/nbt0890-732; Tsuboi M, 1999, J LAB CLIN MED, V134, P222, DOI 10.1016/S0022-2143(99)90201-9; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799; WOZNEY JM, 1992, MOL REPROD DEV, V32, P160, DOI 10.1002/mrd.1080320212; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xiao GZ, 1998, J BIOL CHEM, V273, P32988, DOI 10.1074/jbc.273.49.32988; YAMAGUCHI A, 1991, J CELL BIOL, V113, P681, DOI 10.1083/jcb.113.3.681; YAMAGUCHI A, 1995, SEMIN CELL BIOL, V6, P165, DOI 10.1006/scel.1995.0023; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamaguchi K, 1999, EMBO J, V18, P179, DOI 10.1093/emboj/18.1.179; Yamamoto N, 1997, BIOCHEM BIOPH RES CO, V238, P574, DOI 10.1006/bbrc.1997.7325; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	78	148	154	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29028	29036		10.1074/jbc.M011265200	http://dx.doi.org/10.1074/jbc.M011265200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11395480	hybrid			2022-12-25	WOS:000170346000054
J	Jensen, LE; Whitehead, AS				Jensen, LE; Whitehead, AS			IRAK1b, a novel alternative splice variant of interleukin-1 receptor-associated kinase (IRAK), mediates interleukin-1 signaling and has prolonged stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; IL-1 RECEPTOR; ADAPTER PROTEIN; MESSENGER-RNA; FAMILY; MYD88; ACTIVATION; PATHWAY; CELLS; PHOSPHORYLATION	Interleukin-1 (IL-1) is a pleiotropic cytokine essential for initiation of the immune response to infections and stress. IL-1 interacts with its type I receptor (IEL-M) and triggers a number of intracellular signaling cascades leading to activation of transcription factors, transcriptional up-regulation of target genes, and mRNA stabilization. IL-1RI-associated kinase-1 (IRAK1) is a membrane proximal serine-threonine kinase involved in IL-1 signaling that becomes phosphorylated and progressively degraded in response to IL-1 induction. We have identified a novel variant of IRAK1, which we have named IRAK1b, that arises from the use of an alternative 5 ' -acceptor splice site defined by sequence within exon 12 of IRAK1. IRAK1b mRNA exhibits wide tissue expression and is evolutionarily conserved in both mouse and human. IRAK1b can activate the transcription factor nuclear factor KB and interacts with the IL-1 signaling factors Toll-interacting protein and tumor necrosis factor receptor-associated factor 6. It forms homodimers and heterodimers with the previously described isoform of IRAK1. We show that the IRAK1b protein is kinase-inactive and that, unlike IRAK1, its levels remain constant after IL-1 induction. The presence of an alternative splice variant of IRAK1, which is functionally active and highly stable following IL-1 stimulation, adds further complexity to the control mechanisms that govern IL-1 signaling.	Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Ctr Pharmacogenet, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Jensen, LE (corresponding author), Univ Penn, Dept Pharmacol, 156 Johnson Pavil,3620 Hamilton Walk, Philadelphia, PA 19104 USA.			Jensen, Liselotte/0000-0002-0267-8312				Black DL, 2000, CELL, V103, P367, DOI 10.1016/S0092-8674(00)00128-8; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; Burns K, 2000, NAT CELL BIOL, V2, P346, DOI 10.1038/35014038; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Greene C, 1999, BBA-MOL CELL RES, V1451, P109, DOI 10.1016/S0167-4889(99)00079-8; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; Holtmann H, 2001, J BIOL CHEM, V276, P3508, DOI 10.1074/jbc.M004376200; Jensen LE, 1998, J IMMUNOL METHODS, V215, P45, DOI 10.1016/S0022-1759(98)00085-4; Jensen LE, 2000, J IMMUNOL, V164, P5277, DOI 10.4049/jimmunol.164.10.5277; Knop J, 1999, FEBS LETT, V448, P81, DOI 10.1016/S0014-5793(99)00322-1; Li LW, 2000, J BIOL CHEM, V275, P23340, DOI 10.1074/jbc.M001950200; Li XX, 1999, MOL CELL BIOL, V19, P4643; Li XX, 2001, P NATL ACAD SCI USA, V98, P4461, DOI 10.1073/pnas.071054198; Ling L, 2000, P NATL ACAD SCI USA, V97, P9567, DOI 10.1073/pnas.170279097; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Maschera B, 1999, BIOCHEM J, V339, P227, DOI 10.1042/0264-6021:3390227; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; O'Neill LAJ, 1998, J LEUKOCYTE BIOL, V63, P650, DOI 10.1002/jlb.63.6.650; Sakurai H, 1999, J BIOL CHEM, V274, P10641, DOI 10.1074/jbc.274.15.10641; SHELTON CA, 1993, CELL, V72, P515, DOI 10.1016/0092-8674(93)90071-W; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; SOLOVYEV VV, 1994, NUCLEIC ACIDS RES, V22, P5156, DOI 10.1093/nar/22.24.5156; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Trofimova M, 1996, J BIOL CHEM, V271, P17609, DOI 10.1074/jbc.271.30.17609; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Wesche H, 1999, J BIOL CHEM, V274, P19403, DOI 10.1074/jbc.274.27.19403; Yamin TT, 1997, J BIOL CHEM, V272, P21540, DOI 10.1074/jbc.272.34.21540	31	61	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29037	29044		10.1074/jbc.M103815200	http://dx.doi.org/10.1074/jbc.M103815200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11397809	hybrid			2022-12-25	WOS:000170346000055
J	Kimple, RJ; De Vries, L; Tronchere, H; Behe, CI; Morris, RA; Farquhar, MG; Siderovski, DP				Kimple, RJ; De Vries, L; Tronchere, H; Behe, CI; Morris, RA; Farquhar, MG; Siderovski, DP			RGS12 and RGS14 GoLoco motifs are G alpha(i) interaction sites with guanine nucleotide dissociation inhibitor activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEIN; BETA-GAMMA-SUBUNITS; EXCHANGE FACTOR; INTRINSIC FLUORESCENCE; SIGNALING PATHWAYS; GTPASE ACTIVITY; ALPHA-SUBUNIT; BINDING; DOMAIN; STABILIZATION	The regulators of G-protein signaling (RGS) proteins accelerate the intrinsic guanosine triphosphatase activity of heterotrimeric G-protein a subunits and are thus recognized as key modulators of G-protein-coupled receptor signaling. RGS12 and RGS14 contain not only the hallmark RGS box responsible for GTPase-accelerating activity but also a single G alpha (i/o)-Loco (GoLoco) motif predicted to represent a second G alpha interaction site. Here, we describe functional characterization of the GoLoco motif regions of RGS12 and RGS14. Both regions interact exclusively with G alpha (i1), G alpha (i2), and G alpha (i3) in their GDP-bound forms. In GTP gammaS binding assays, both regions exhibit guanine nucleotide dissociation inhibitor (GDI) activity, inhibiting the rate of exchange of GDP for GTP by G alpha (i1). Both regions also stabilize G alpha (i1) in its GDP-bound form, inhibiting the increase in intrinsic tryptophan fluorescence stimulated by AlF4-. Our results indicate that both RGS12 and RGS14 harbor two distinctly different G alpha interaction sites: a previously recognized N-terminal RGS box possessing G alpha (i). GAP activity and a C-terminal GoLoco region exhibiting G alpha (i) GDI activity. The presence of two, independent G alpha interaction sites suggests that RGS12 and RGS14 participate in a complex coordination of G-protein signaling beyond simple G alpha GAP activity.	Univ N Carolina, Sch Med, Dept Pharmacol, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Ctr Neurosci, Chapel Hill, NC 27599 USA; Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; INSERM, U326, F-31059 Toulouse 3, France	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of California System; University of California San Diego; Institut National de la Sante et de la Recherche Medicale (Inserm)	Siderovski, DP (corresponding author), Univ N Carolina, Sch Med, Dept Pharmacol, Lineberger Comprehens Canc Ctr, CB 7365,Mary Ellen Jones Bldg,Rm 1106, Chapel Hill, NC 27599 USA.		Kimple, Randall/L-6460-2019; Siderovski, David Peter/AAA-9603-2019; TRONCHERE, Helene/M-5631-2014	Kimple, Randall/0000-0001-8336-8000; Siderovski, David Peter/0000-0002-0688-8210; 	NCI NIH HHS [CA58689] Funding Source: Medline; NIDDK NIH HHS [DK07386, DK17780] Funding Source: Medline; NIGMS NIH HHS [GM07040, GM62338] Funding Source: Medline; NIMH NIH HHS [F30 MH064319, F30 MH064319-04] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA058689] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK017780, R37DK017780, T35DK007386] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062338, T32GM007040] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [F30MH064319] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Arshavsky VY, 1998, NEURON, V20, P11, DOI 10.1016/S0896-6273(00)80430-4; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; BRANDT DR, 1985, J BIOL CHEM, V260, P266; Cho H, 2000, MOL PHARMACOL, V58, P569, DOI 10.1124/mol.58.3.569; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; De Vries L, 2000, P NATL ACAD SCI USA, V97, P14364, DOI 10.1073/pnas.97.26.14364; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P752; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lenzen C, 1998, BIOCHEMISTRY-US, V37, P7420, DOI 10.1021/bi972621j; Li Y, 1998, J BIOL CHEM, V273, P16265, DOI 10.1074/jbc.273.26.16265; Luo Y, 1999, J BIOL CHEM, V274, P10685, DOI 10.1074/jbc.274.16.10685; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; McEwen DP, 2001, ANAL BIOCHEM, V291, P109, DOI 10.1006/abio.2001.5011; Natochin M, 2000, J BIOL CHEM, V275, P40981, DOI 10.1074/jbc.M006478200; Peterson YK, 2000, J BIOL CHEM, V275, P33193, DOI 10.1074/jbc.C000509200; PHILLIPS WJ, 1988, J BIOL CHEM, V263, P15498; Ponting CP, 1999, J MOL MED, V77, P695, DOI 10.1007/s001099900054; Schiff ML, 2000, NATURE, V408, P723, DOI 10.1038/35047093; Siderovski DP, 1996, CURR BIOL, V6, P211, DOI 10.1016/S0960-9822(02)00454-2; Siderovski DP, 1999, CRIT REV BIOCHEM MOL, V34, P215, DOI 10.1080/10409239991209273; Siderovski DP, 1999, TRENDS BIOCHEM SCI, V24, P340, DOI 10.1016/S0968-0004(99)01441-3; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Snow BE, 1997, BIOCHEM BIOPH RES CO, V233, P770, DOI 10.1006/bbrc.1997.6537; Snow BE, 1998, P NATL ACAD SCI USA, V95, P13307, DOI 10.1073/pnas.95.22.13307; Snow BE, 1998, J BIOL CHEM, V273, P17749, DOI 10.1074/jbc.273.28.17749; Sondek J, 2001, BIOCHEM PHARMACOL, V61, P1329, DOI 10.1016/S0006-2952(01)00633-5; Takesono A, 1999, J BIOL CHEM, V274, P33202, DOI 10.1074/jbc.274.47.33202; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Traver S, 2000, BIOCHEM J, V350, P19, DOI 10.1042/0264-6021:3500019; Wall MA, 1998, STRUCTURE, V6, P1169, DOI 10.1016/S0969-2126(98)00117-8	38	188	196	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29275	29281		10.1074/jbc.M103208200	http://dx.doi.org/10.1074/jbc.M103208200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11387333	Green Published, hybrid			2022-12-25	WOS:000170346000086
J	Liu, CX; Li, YH; Obermoeller-McCormick, LM; Schwartz, AL; Bu, GJ				Liu, CX; Li, YH; Obermoeller-McCormick, LM; Schwartz, AL; Bu, GJ			The putative tumor suppressor LRP1B, a novel member of the low density lipoprotein (LDL) receptor family, exhibits both overlapping and distinct properties with the LDL receptor-related protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UROKINASE RECEPTOR; BINDING-PROTEIN; CELL-SURFACE; GENE FAMILY; COMPLEXES; CHAPERONE; PATHWAY; SYSTEM; SIGNAL; ROLES	The low density lipoprotein receptor-related protein. deleted in tumor (LRP1B, initially referred to as LRP-DIT) was cloned and characterized as a candidate tumor suppressor. It is a new member of the low density lipoprotein receptor gene family. Its overall domain structure and large size (similar to 600 kDa) are similar to LRP and suggest that it is a multifunctional cell surface receptor. Herein, we characterize a series of ligands for the receptor using cell lines that stably express it as a domain IV minireceptor (mLRP1B4). Ligands of LRP including receptor-associated protein, urokinase plasminogen activator, tissue-type plasminogen activator, and plasminogen activator inhibitor type-1 each demon. strate binding, internalization, and degradation via mLRP1B4. Interestingly, the kinetics of ligand endocytosis is distinctly different from that of LRP, with LRP1B exhibiting a markedly diminished internalization rate. In addition, tissue expression analysis reveals that the LRP1B gene is expressed in brain, thyroid, and salivary gland. These studies thus extend the physiological roles of members of the LDL receptor family.	Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Physiol & Cell Biol, St Louis, MO 63110 USA; St Louis Childrens Hosp, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL)	Bu, GJ (corresponding author), Washington Univ, Sch Med, Dept Pediat, CB 8208,660 S Euclid Ave, St Louis, MO 63110 USA.				NHLBI NIH HHS [HL59150, HL53280] Funding Source: Medline; NIDDK NIH HHS [DK56783] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059150, R01HL053280] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK056783] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; Bacskai BJ, 2000, P NATL ACAD SCI USA, V97, P11551, DOI 10.1073/pnas.200238297; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BU GJ, 1992, J BIOL CHEM, V267, P15595; Bu GJ, 1998, TRENDS CELL BIOL, V8, P272, DOI 10.1016/S0962-8924(98)01283-5; Bu GJ, 1996, J BIOL CHEM, V271, P22218, DOI 10.1074/jbc.271.36.22218; BU GJ, 1993, J BIOL CHEM, V268, P13002; CONESE M, 1995, J CELL BIOL, V131, P1609, DOI 10.1083/jcb.131.6.1609; FITZGERALD DJ, 1995, J CELL BIOL, V129, P1533, DOI 10.1083/jcb.129.6.1533; Goretzki L, 1998, BIOCHEM J, V336, P381, DOI 10.1042/bj3360381; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; Grimme S, 2000, J BIOL CHEM, V275, P33697, DOI 10.1074/jbc.M003789200; HERZ J, 1993, CELL, V73, P428, DOI 10.1016/0092-8674(93)90130-I; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HOLTZMAN DM, 1995, P NATL ACAD SCI USA, V92, P9480, DOI 10.1073/pnas.92.21.9480; Howell BW, 2001, CURR OPIN NEUROBIOL, V11, P74, DOI 10.1016/S0959-4388(00)00176-8; Hussain MM, 1999, ANNU REV NUTR, V19, P141, DOI 10.1146/annurev.nutr.19.1.141; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P21862; Li YH, 2001, MOL CELL BIOL, V21, P1185, DOI 10.1128/MCB.21.4.1185-1195.2001; Li YS, 2000, J BIOL CHEM, V275, P37187, DOI 10.1074/jbc.M000490200; LISITSYN NA, 1995, P NATL ACAD SCI USA, V92, P151, DOI 10.1073/pnas.92.1.151; Liu CX, 2000, GENOMICS, V69, P271, DOI 10.1006/geno.2000.6331; Liu CX, 2000, CANCER RES, V60, P1961; Mignatti P, 2000, ADV CANCER RES, V78, P103; MORTON PA, 1990, J BIOL CHEM, V265, P14093; Narita M, 1997, J NEUROCHEM, V68, P587; Neels JG, 1999, J BIOL CHEM, V274, P31305, DOI 10.1074/jbc.274.44.31305; Nykjaer A, 1997, EMBO J, V16, P2610, DOI 10.1093/emboj/16.10.2610; Nykjaer A, 1999, CELL, V96, P507, DOI 10.1016/S0092-8674(00)80655-8; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; Obermoeller LM, 1997, J BIOL CHEM, V272, P10761; Obermoeller LM, 1998, J BIOL CHEM, V273, P22374, DOI 10.1074/jbc.273.35.22374; Obermoeller-McCormick LM, 2001, J CELL SCI, V114, P899; Stockinger W, 2000, J BIOL CHEM, V275, P25625, DOI 10.1074/jbc.M004119200; Ulery PG, 2000, J CLIN INVEST, V106, P1077, DOI 10.1172/JCI11455; Weaver AM, 1997, J BIOL CHEM, V272, P14372, DOI 10.1074/jbc.272.22.14372; Webb DJ, 2000, J CELL SCI, V113, P123; Willnow TE, 1999, J MOL MED-JMM, V77, P306, DOI 10.1007/s001090050356; Willnow TE, 1996, BIOCHEM J, V313, P71, DOI 10.1042/bj3130071; Zhang JC, 1998, J BIOL CHEM, V273, P32273, DOI 10.1074/jbc.273.48.32273; Zhuo M, 2000, J NEUROSCI, V20, P542, DOI 10.1523/JNEUROSCI.20-02-00542.2000	42	105	115	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28889	28896		10.1074/jbc.M102727200	http://dx.doi.org/10.1074/jbc.M102727200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11384978	hybrid			2022-12-25	WOS:000170346000035
J	Tao, JC; Malbon, CC; Wang, HY				Tao, JC; Malbon, CC; Wang, HY			Insulin stimulates tyrosine phosphorylation and inactivation of protein-tyrosine phosphatase 1B in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEGATIVE REGULATOR; CRYSTAL-STRUCTURE; HUMAN-PLACENTA; ANTISENSE RNA; IN-VIVO; RESISTANCE; RECEPTOR; GROWTH; PURIFICATION; EXPRESSION	Protein-tyrosine phosphatase (PTP) 1B has been implicated in negative regulation of insulin action, although little is known of the ability of insulin to regulate PTP1B itself. The ability of insulin to regulate phosphorylation and activation of PTP1B was probed in vivo. Challenge with insulin in vivo provoked a transient, sharp increase in the phosphotyrosine content of PTP1B in fat and skeletal muscle that peaked within 15 min. Insulin stimulated a decline of 60-70% in PTP1B activity. In mouse adipocytes, the inhibition of PTP1B activity and increased tyrosine phosphorylation of the enzyme were blocked by the insulin receptor tyrosine kinase inhibitor AG1024. Phosphoserine content of PTP1B declined in response to insulin stimulation. Elevation of intracellular cyclic AMP provokes a sharp increase in PTP1B activity and leads to increased phosphorylation of serine residues and decreased tyrosine phosphorylation. Suppression of cyclic AMP levels or inhibition of protein kinase A leads to a sharp decline in PTP1B activity, a decrease in phosphoserine content, and an increase in PTP1B phosphotyrosine content. PTP1B appears to be a critical point for insulin and catecholamine counter-regulation.	SUNY Stony Brook, Med Ctr, Dept Physiol & Biophys, Physiol HSC, Stony Brook, NY 11794 USA; SUNY Stony Brook, Med Ctr, Diabet & Metab Dis Res Program, Stony Brook, NY 11794 USA; SUNY Stony Brook, Med Ctr, Dept Mol Pharmacol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Wang, HY (corresponding author), SUNY Stony Brook, Med Ctr, Dept Physiol & Biophys, Physiol HSC, Stony Brook, NY 11794 USA.		malbon, craig/ABF-3604-2020		NIDDK NIH HHS [DK30111] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030111] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMAD F, 1995, AM J PHYSIOL-ENDOC M, V268, pE932, DOI 10.1152/ajpendo.1995.268.5.E932; AHMAD F, 1995, METABOLISM, V44, P1175, DOI 10.1016/0026-0495(95)90012-8; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; Brautigan David L., 1993, Molecular and Cellular Biochemistry, V127-128, P121, DOI 10.1007/BF01076763; BROWNSHIMER S, 1992, CANCER RES, V52, P478; BROWNSHIMER S, 1990, P NATL ACAD SCI USA, V87, P5148, DOI 10.1073/pnas.87.13.5148; Byon JCH, 1998, MOL CELL BIOCHEM, V182, P101, DOI 10.1023/A:1006868409841; Chen DH, 2000, COMPUT MED IMAG GRAP, V24, P283, DOI 10.1016/S0895-6111(00)00023-9; CICIRELLI MF, 1990, P NATL ACAD SCI USA, V87, P5514, DOI 10.1073/pnas.87.14.5514; Egawa K, 2001, J BIOL CHEM, V276, P10207, DOI 10.1074/jbc.M009489200; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; FLINT AJ, 1993, EMBO J, V12, P1937, DOI 10.1002/j.1460-2075.1993.tb05843.x; HOPPE E, 1994, EUR J BIOCHEM, V223, P1069, DOI 10.1111/j.1432-1033.1994.tb19085.x; Hunter T, 1998, Harvey Lect, V94, P81; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Kennedy BP, 2000, BIOCHEM PHARMACOL, V60, P877, DOI 10.1016/S0006-2952(00)00305-1; Kenner KA, 1996, J BIOL CHEM, V271, P19810, DOI 10.1074/jbc.271.33.19810; KUSARI J, 1994, J CLIN INVEST, V93, P1156, DOI 10.1172/JCI117068; Liu F, 1997, BIOCHEM J, V327, P139, DOI 10.1042/bj3270139; MOXHAM CM, 1993, SCIENCE, V260, P991, DOI 10.1126/science.8493537; Moxham CM, 1996, J BIOL CHEM, V271, P30765, DOI 10.1074/jbc.271.48.30765; Moxham CM, 1996, NATURE, V379, P840, DOI 10.1038/379840a0; MOXHAM CM, 1993, DEV GENET, V14, P266, DOI 10.1002/dvg.1020140404; Pessin JE, 2000, J CLIN INVEST, V106, P165, DOI 10.1172/JCI10582; Sarmiento M, 1998, J BIOL CHEM, V273, P26368, DOI 10.1074/jbc.273.41.26368; SCHIEVELLA AR, 1993, CELL GROWTH DIFFER, V4, P239; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Shifrin VI, 1997, J BIOL CHEM, V272, P2957, DOI 10.1074/jbc.272.5.2957; STADTMAUER L, 1986, J BIOL CHEM, V261, P3402; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; SU XD, 1994, NATURE, V370, P575, DOI 10.1038/370575a0; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1988, J BIOL CHEM, V263, P6722; Van der Sar AM, 1999, INT J DEV BIOL, V43, P785; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; Worm D, 1999, DIABETOLOGIA, V42, P1146	36	61	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29520	29525		10.1074/jbc.M103721200	http://dx.doi.org/10.1074/jbc.M103721200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11395511	hybrid			2022-12-25	WOS:000170346000116
J	Danishpajooh, IO; Gudi, T; Chen, YC; Kharitonov, VG; Sharma, VS; Boss, GR				Danishpajooh, IO; Gudi, T; Chen, YC; Kharitonov, VG; Sharma, VS; Boss, GR			Nitric oxide inhibits methionine synthase activity in vivo and disrupts carbon flow through the folate pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LYMPHOBLASTS; PURINE SYNTHESIS; COBALAMIN; CELLS; INACTIVATION; REDUCTASE; RAT; NO; HOMOCYSTEINE; DEGRADATION	Many of nitric oxide's biological effects are mediated via NO binding to the iron in heme-containing proteins. Cobalamin (vitamin B-12) is structurally similar to heme and is a cofactor for methionine synthase, a key enzyme in folate metabolism, NO inhibits methionine synthase activity in vitro, but data concerning NO binding to cobalamin are controversial. We now show spectroscopically that NO reacts with all three valency states of cobalamin and that NO's inhibition of methionine synthase activity most likely involves its reaction with monovalent cobalamin, By following incorporation of the methyl moiety of [C-14]methyltetrahydrofolic acid into protein, we show that NO inhibits methionine synthase activity in vivo, in cultured mammalian cells. The inhibition of methionine synthase activity disrupted carbon flow through the folate pathway as measured by decreased incorporation of [C-14]formate into methionine, serine, and purine nucleotides, Homocysteine, but not cysteine, attenuated NO's inhibition of purine synthesis, providing further evidence that NO was acting through methionine synthase inhibition. NO's effect was observed both when NO donors were added to cells and when NO was produced physiologically in co-culture experiments. Treating cells with an MO synthase inhibitor increased formate incorporation into methionine, serine, and purines and methyl-tetrahydrofolate incorporation into protein. Thus, physiological concentrations of NO appear to regulate carbon flaw through the folate pathway.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; SkyePharma Inc, San Diego, CA 92121 USA	University of California System; University of California San Diego	Boss, GR (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.			Boss, Gerry/0000-0002-9758-8714	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007233] Funding Source: NIH RePORTER; NIDDK NIH HHS [5T32DK07233-24] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BABIOR BM, 1995, WILLIAMS HEMATOLOGY; BANERJEE RV, 1990, FASEB J, V4, P1450, DOI 10.1096/fasebj.4.5.2407589; Bauer JA, 1998, ANTI-CANCER DRUG, V9, P239, DOI 10.1097/00001813-199803000-00006; BHULLAR RP, 1987, BIOCHEM J, V245, P617, DOI 10.1042/bj2450617; BOSS GR, 1981, J CLIN INVEST, V67, P1659, DOI 10.1172/JCI110202; BOSS GR, 1985, J CLIN INVEST, V76, P213, DOI 10.1172/JCI111948; BOSS GR, 1985, J BIOL CHEM, V260, P6054; BOSS GR, 1984, J CLIN INVEST, V74, P1262, DOI 10.1172/JCI111536; BOSS GR, 1982, J BIOL CHEM, V257, P4242; Brouwer M, 1996, BLOOD, V88, P1857; DEACON R, 1990, BRIT J HAEMATOL, V74, P354, DOI 10.1111/j.1365-2141.1990.tb02595.x; DRUMMOND JT, 1994, BIOCHEMISTRY-US, V33, P3732, DOI 10.1021/bi00178a033; Feinstein DL, 1997, NITRIC OXIDE-BIOL CH, V1, P167, DOI 10.1006/niox.1997.0117; FIRTH RA, 1969, J CHEM SOC A, P381, DOI 10.1039/j19690000381; Fukuyama Y, 1997, BRIT J CANCER, V75, P1125, DOI 10.1038/bjc.1997.194; GIULIDORI P, 1984, J BIOL CHEM, V259, P4205; HALPERN J, 1985, SCIENCE, V227, P869, DOI 10.1126/science.2857503; HERSHFIELD MS, 1977, J BIOL CHEM, V252, P6002; HERSHFIELD MS, 1976, J BIOL CHEM, V251, P7348; Idriss SD, 1999, J BIOL CHEM, V274, P9489, DOI 10.1074/jbc.274.14.9489; Ignarro L., 1995, NITRIC OXIDE BIOCH M; KHARITONOV VG, 1996, METHODS NITRIC OXIDE, P40; Kruszyna H, 1998, J PHARMACOL EXP THER, V285, P665; Leclerc D, 1998, P NATL ACAD SCI USA, V95, P3059, DOI 10.1073/pnas.95.6.3059; LEPOIVRE M, 1992, J BIOL CHEM, V267, P22994; LloydJones DM, 1996, ANNU REV MED, V47, P365; Ludwig ML, 1997, ANNU REV BIOCHEM, V66, P269, DOI 10.1146/annurev.biochem.66.1.269; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; Moro MA, 1996, P NATL ACAD SCI USA, V93, P1480, DOI 10.1073/pnas.93.4.1480; Nicolaou A, 1997, EUR J BIOCHEM, V244, P876, DOI 10.1111/j.1432-1033.1997.00876.x; Nicolaou A, 1996, EUR J CLIN INVEST, V26, P167, DOI 10.1046/j.1365-2362.1996.122254.x; PILZ RB, 1984, J BIOL CHEM, V259, P2927; Pollman MJ, 1996, CIRC RES, V79, P748, DOI 10.1161/01.RES.79.4.748; Qiu WS, 2000, J BIOL CHEM, V275, P31921, DOI 10.1074/jbc.M003327200; ROCHELLE LG, 1995, J PHARMACOL EXP THER, V275, P48; ROSENBLATT DS, 1979, J CLIN INVEST, V63, P1019, DOI 10.1172/JCI109370; ROTHMAN A, 1992, CIRCULATION, V86, P1977, DOI 10.1161/01.CIR.86.6.1977; Scheele JS, 1998, ONCOGENE, V17, P2211, DOI 10.1038/sj.onc.1202137; SCHRAUZER GN, 1971, J AM CHEM SOC, V93, P4060, DOI 10.1021/ja00745a048; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; TRAYLOR TG, 1992, BIOCHEMISTRY-US, V31, P2847, DOI 10.1021/bi00126a001; TRAYLOR TG, 1999, WINTROBES CLIN HEMAT; Welch GN, 1998, NEW ENGL J MED, V338, P1042, DOI 10.1056/NEJM199804093381507	43	83	85	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27296	27303		10.1074/jbc.M104043200	http://dx.doi.org/10.1074/jbc.M104043200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11371572	hybrid			2022-12-25	WOS:000169966900076
J	Buyse, M; Viengchareun, S; Bado, A; Lombes, M				Buyse, M; Viengchareun, S; Bado, A; Lombes, M			Insulin and glucocorticoids differentially regulate leptin transcription and secretion in brown adipocytes	FASEB JOURNAL			English	Article						cell line; uncoupling protein; ob gene; signaling pathway; obesity	OB GENE-EXPRESSION; BINDING-PROTEIN-ALPHA; WHITE ADIPOSE-TISSUE; MOUSE OBESE GENE; UNCOUPLING PROTEIN; MESSENGER-RNA; 3T3-L1 ADIPOCYTES; PLASMA LEPTIN; RAT; PROMOTER	Leptin, the ob gene product, is produced by adipose tissue and is submitted to a complex hormonal and metabolic regulation. Leptin plays a critical role in the balance of body weight. Here we report on secretion and hormonal regulation of leptin by brown adipocytes. Using the recently established T37i cell line, we show that leptin expression and secretion occurred as a function of cell differentiation. In differentiated T37i cells, insulin induced leptin release (similar to0.25 ng/10(6) cells/h) in a concentration-dependent manner (EC50=0.1 nM), and this was totally suppressed by beta3 -adrenergic ligand, thiazolidinedione, cycloheximide, or actinomycin D. Insulin induced a strong, rapid (within 2 h) but transient fivefold increase in leptin mRNA levels. This transcriptional control of ob gene expression by insulin involved both phosphatidylinositol 3-kinase- and MAP kinase-dependent pathways. Glucocorticoids inhibited both insulin-stimulated leptin secretion and ob gene expression without affecting leptin mRNA stability (t(1/2)=3h05). Altogether, our results demonstrate that brown adipocytes express and secrete leptin, whose hormonal regulation clearly differs from that described in white adipose tissue. These findings point to tissue-specific molecular mechanisms and suggest that leptin might exert direct effects on energy homeostasis through an autocrine mechanism.	Univ Paris 07, Inst Federatif Rech Cellules Epitheliales, INSERM, U478, F-75870 Paris 18, France; Univ Paris 07, Inst Federatif Rech Cellules Epitheliales, INSERM, U410, F-75870 Paris 18, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Lombes, M (corresponding author), Univ Paris 07, Inst Federatif Rech Cellules Epitheliales, INSERM, U478, IFR2,16 Rue Henri Huchard, F-75870 Paris 18, France.	mlombes@bichat.inserm.fr	Lombes, Marc/L-5933-2018; BADO, Andre/G-3408-2013; Viengchareun, Say/M-6612-2017; Buyse, Marc/J-4658-2013; Viengchareun, Say/GOV-6812-2022	Lombes, Marc/0000-0003-3189-023X; BADO, Andre/0000-0002-8007-1460; viengchareun, say/0000-0003-4280-3250				Bado A, 1998, NATURE, V394, P790, DOI 10.1038/29547; Barr VA, 1997, ENDOCRINOLOGY, V138, P4463, DOI 10.1210/en.138.10.4463; Bradley RL, 1999, DIABETES, V48, P272, DOI 10.2337/diabetes.48.2.272; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Cinti S, 1997, ENDOCRINOLOGY, V138, P797, DOI 10.1210/en.138.2.797; Coleman RA, 1999, DIABETOLOGIA, V42, P639, DOI 10.1007/s001250051210; Considine RV, 1997, J CELL BIOCHEM, V65, P254, DOI 10.1002/(SICI)1097-4644(199705)65:2<254::AID-JCB10>3.0.CO;2-I; De Vos P, 1998, EUR J BIOCHEM, V253, P619, DOI 10.1046/j.1432-1327.1998.2530619.x; delaBrousse FC, 1996, P NATL ACAD SCI USA, V93, P4096, DOI 10.1073/pnas.93.9.4096; Deng CJ, 1997, ENDOCRINOLOGY, V138, P548, DOI 10.1210/en.138.2.548; Dessolin S, 1997, FASEB J, V11, P382, DOI 10.1096/fasebj.11.5.9141506; DeVos P, 1996, J CLIN INVEST, V98, P1004, DOI 10.1172/JCI118860; Donahoo WT, 1997, J CLIN ENDOCR METAB, V82, P4139, DOI 10.1210/jc.82.12.4139; Elmquist JK, 1998, P NATL ACAD SCI USA, V95, P741, DOI 10.1073/pnas.95.2.741; Fukuda H, 1999, FEBS LETT, V455, P165, DOI 10.1016/S0014-5793(99)00877-7; Gettys TW, 1996, ENDOCRINOLOGY, V137, P4054, DOI 10.1210/en.137.9.4054; Gong DW, 1996, J BIOL CHEM, V271, P3971; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; Hardie LJ, 1996, HORM METAB RES, V28, P685, DOI 10.1055/s-2007-979878; HE YF, 1995, J BIOL CHEM, V270, P28887, DOI 10.1074/jbc.270.48.28887; Hemati N, 1997, J BIOL CHEM, V272, P25913, DOI 10.1074/jbc.272.41.25913; HIMMSHAGEN J, 1995, P SOC EXP BIOL MED, V208, P159, DOI 10.3181/00379727-208-43847A; Hwang CS, 1996, P NATL ACAD SCI USA, V93, P873, DOI 10.1073/pnas.93.2.873; Jain R, 1999, BIOCHEM J, V338, P737, DOI 10.1042/0264-6021:3380737; Jin L, 2000, ENDOCRINOLOGY, V141, P333, DOI 10.1210/en.141.1.333; Kaabache T, 1995, ANAL BIOCHEM, V232, P225, DOI 10.1006/abio.1995.0011; Kallen CB, 1996, P NATL ACAD SCI USA, V93, P5793, DOI 10.1073/pnas.93.12.5793; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Kirchgessner TG, 1997, J CLIN INVEST, V100, P2777, DOI 10.1172/JCI119824; Kosaki A, 1996, DIABETES, V45, P1744, DOI 10.2337/diabetes.45.12.1744; Larsson H, 1996, J CLIN ENDOCR METAB, V81, P4428, DOI 10.1210/jc.81.12.4428; Leroy P, 1996, J BIOL CHEM, V271, P2365, DOI 10.1074/jbc.271.5.2365; MACDOUGALD OA, 1995, P NATL ACAD SCI USA, V92, P9034, DOI 10.1073/pnas.92.20.9034; MACDOUGALD OA, 1994, J BIOL CHEM, V269, P19041; Mason MM, 1998, ENDOCRINOLOGY, V139, P1013, DOI 10.1210/en.139.3.1013; Masuzaki H, 1997, NAT MED, V3, P1029, DOI 10.1038/nm0997-1029; Miller SG, 1996, P NATL ACAD SCI USA, V93, P5507, DOI 10.1073/pnas.93.11.5507; Morash B, 2000, MOL CELL ENDOCRINOL, V165, P97, DOI 10.1016/S0303-7207(00)00259-8; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Penfornis P, 2000, AM J PHYSIOL-ENDOC M, V279, pE386, DOI 10.1152/ajpendo.2000.279.2.E386; Rentsch J, 1996, FEBS LETT, V379, P55, DOI 10.1016/0014-5793(95)01485-3; Reul BA, 1997, BIOCHEM J, V324, P605, DOI 10.1042/bj3240605; Ricci MR, 1999, OBES RES, V7, P233, DOI 10.1002/j.1550-8528.1999.tb00401.x; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; SALADIN R, 1995, NATURE, V377, P527, DOI 10.1038/377527a0; Scarpace PJ, 1998, AM J PHYSIOL-ENDOC M, V275, pE259, DOI 10.1152/ajpendo.1998.275.2.E259; Scarpace PJ, 1997, AM J PHYSIOL-ENDOC M, V273, pE226, DOI 10.1152/ajpendo.1997.273.1.E226; Serradeil-Le Gal C, 2000, FEBS LETT, V475, P150, DOI 10.1016/S0014-5793(00)01649-5; Siegrist-Kaiser CA, 1997, J CLIN INVEST, V100, P2858, DOI 10.1172/JCI119834; Sinha MK, 1996, J CLIN INVEST, V97, P1344, DOI 10.1172/JCI118551; Slieker LJ, 1996, J BIOL CHEM, V271, P5301, DOI 10.1074/jbc.271.10.5301; TRAYHURN P, 1995, FEBS LETT, V368, P488, DOI 10.1016/0014-5793(95)00719-P; Uchida Y, 1999, N-S ARCH PHARMACOL, V360, P691, DOI 10.1007/s002109900134; VIENGCHAREUN S, 2001, IN PRESS AM J PHYSL; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; Wang JL, 1998, NATURE, V393, P684, DOI 10.1038/31474; Webster JC, 1999, TRENDS ENDOCRIN MET, V10, P396, DOI 10.1016/S1043-2760(99)00186-1; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Yoshida T, 1996, EUR J ENDOCRINOL, V135, P619, DOI 10.1530/eje.0.1350619; Zennaro MC, 1998, J CLIN INVEST, V101, P1254, DOI 10.1172/JCI1915; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; Zilberfarb V, 1997, J CELL SCI, V110, P801	63	37	39	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2001	15	8					1357	1366		10.1096/fj.00-0669com	http://dx.doi.org/10.1096/fj.00-0669com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11387233				2022-12-25	WOS:000169261200003
J	Simonitsch, I; Polgar, D; Hajek, M; Duchek, P; Skrzypek, B; Fassl, S; Lamprecht, A; Schmidt, G; Krupitza, G; Cerni, C				Simonitsch, I; Polgar, D; Hajek, M; Duchek, P; Skrzypek, B; Fassl, S; Lamprecht, A; Schmidt, G; Krupitza, G; Cerni, C			The cytoplasmic truncated receptor tyrosine kinase ALK-homodimer immortalizes and cooperates with ras in cellular transformation	FASEB JOURNAL			English	Article						NPM/ALK; NTM/ALK constructs; primary rat embryo cells; immortalization; transformation; tumor formation	ANAPLASTIC LYMPHOMA KINASE; NON-HODGKINS-LYMPHOMA; CHROMOSOMAL TRANSLOCATION; MALIGNANT-TRANSFORMATION; TUMORIGENIC CONVERSION; POSITIVE LYMPHOMA; FUSION PROTEIN; GENE FUSION; NPM-ALK; C-MYC	Anaplastic large-cell lymphomas are highly associated with a chromosomal translocation t(2;5). This condition results in a chimeric protein NPM/ALK (nucleophosmin/anaplastic lymphoma kinase), in which the shuttle protein NPM is fused to the catalytic domain of the tyrosine receptor kinase ALK. Because the oncogenic potential of NPM/ALK is not well understood, we analyzed the effects of NPM/ALK and the specific contribution of ALK in a standardized cell culture system by using primary rat embryo cells (REC) as cellular targets. We demonstrate by several biological parameters that NPM/ALK is an immortalizing oncogene that provides unlimited, yet normal, growth potential to REC and, with cooperation with a c-H-ras oncogene, induces cellular transformation. Targeting NPM/ALK to the nucleus diminishes its oncogenicity, which indicates that the fusion protein exerts its action mainly in the cytoplasm. Expression of the mere catalytic domain of ALK is insufficient with regard to immortalization and transformation. However, reestablishing the potential of ALK to homodimerize by fusing the bacterial dimerization domain of the tetracycline repressor to ALK reenforces the immortalizing function. Collaboration of dimeric ALK with c-H-ras converted primary REC into aggressively growing tumor cell lines. These studies identify ALK as a new member of immortalizing oncoproteins that exerts its function within the cytoplasm.	Univ Vienna, Inst Canc Res, A-1090 Vienna, Austria; Univ Vienna, Inst Clin Pathol, A-1090 Vienna, Austria	University of Vienna; University of Vienna	Cerni, C (corresponding author), Univ Vienna, Inst Canc Res, Borschkegasse 8A, A-1090 Vienna, Austria.	Christa.Cerni@.univie.ac.at		Krupitza, Georg/0000-0003-2949-7906				Amicone L, 1997, EMBO J, V16, P495, DOI 10.1093/emboj/16.3.495; Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Benharroch D, 1998, BLOOD, V91, P2076, DOI 10.1182/blood.V91.6.2076; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Cerni C, 2000, MUTAT RES-REV MUTAT, V462, P31, DOI 10.1016/S1383-5742(99)00091-5; CERNI C, 1995, ONCOGENE, V11, P587; CERNI C, 1990, VIROLOGY, V177, P427, DOI 10.1016/0042-6822(90)90506-M; CERNI C, 1989, P NATL ACAD SCI USA, V86, P3266, DOI 10.1073/pnas.86.9.3266; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; Colleoni GWB, 2000, AM J PATHOL, V156, P781, DOI 10.1016/S0002-9440(10)64945-0; Delsol G, 1997, BLOOD, V89, P1483, DOI 10.1182/blood.V89.5.1483.1483_1483_1490; Drexler HG, 2000, LEUKEMIA, V14, P1533, DOI 10.1038/sj.leu.2401878; FEUERSTEIN N, 1990, BIOCHIM BIOPHYS ACTA, V1087, P127, DOI 10.1016/0167-4781(90)90196-9; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; Garrett TPJ, 1998, NATURE, V394, P395, DOI 10.1038/28668; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; Haas K, 1997, ONCOGENE, V15, P179, DOI 10.1038/sj.onc.1201171; Haas K, 1997, ONCOGENE, V15, P2615, DOI 10.1038/sj.onc.1201434; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hernandez L, 1999, BLOOD, V94, P3265; HINRICHS W, 1994, SCIENCE, V264, P418, DOI 10.1126/science.8153629; Hueber AO, 1998, TRENDS GENET, V14, P364, DOI 10.1016/S0168-9525(98)01520-0; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; KNECHT H, 1993, BRIT J HAEMATOL, V83, P655, DOI 10.1111/j.1365-2141.1993.tb04706.x; Lamant L, 2000, AM J PATHOL, V156, P1711, DOI 10.1016/S0002-9440(10)65042-0; Lamant L, 1999, BLOOD, V93, P3088; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LOPATEGUI JR, 1995, AM J PATHOL, V146, P323; Mason DY, 1998, CANCER RES, V58, P1057; MERZAK A, 1992, ONCOGENE, V7, P2031; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; MOUGNEAU E, 1988, ONCOGENE RES, V2, P177; Ott G, 1998, GENE CHROMOSOME CANC, V22, P114, DOI 10.1002/(SICI)1098-2264(199806)22:2<114::AID-GCC5>3.0.CO;2-#; Pileri SA, 1997, AM J PATHOL, V150, P1207; Pittaluga S, 1997, AM J PATHOL, V151, P343; Popovici C, 1998, P NATL ACAD SCI USA, V95, P5712, DOI 10.1073/pnas.95.10.5712; PORIES SE, 1993, GASTROENTEROLOGY, V104, P1346, DOI 10.1016/0016-5085(93)90343-B; Pospelova TV, 1999, GENE EXPRESSION, V8, P19; Pulford K, 1997, BLOOD, V89, P1394, DOI 10.1182/blood.V89.4.1394; Pulford K, 1999, AM J PATHOL, V154, P1657, DOI 10.1016/S0002-9440(10)65421-1; Sandlund JT, 1996, NEW ENGL J MED, V334, P1238, DOI 10.1056/NEJM199605093341906; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHIOTA M, 1994, ONCOGENE, V9, P1567; Shiota Mami, 1997, Leukemia (Basingstoke), V11, P538; Simonitsch I, 1996, BRIT J HAEMATOL, V92, P866, DOI 10.1046/j.1365-2141.1996.402944.x; Tian QS, 1999, AM J PATHOL, V154, P1643, DOI 10.1016/S0002-9440(10)65419-3; Touriol C, 2000, BLOOD, V95, P3204, DOI 10.1182/blood.V95.10.3204.010k04_3204_3207; Vandel L, 1996, MOL CELL BIOL, V16, P1881; Weisenburger DD, 1996, BLOOD, V87, P3860, DOI 10.1182/blood.V87.9.3860.bloodjournal8793860; ZERLIN M, 1987, ONCOGENE, V1, P19; ZHANG LS, 1995, CANCER RES, V55, P3890	60	17	18	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 27	2001	15	6					1416	+		10.1096/fj.00-0678fje	http://dx.doi.org/10.1096/fj.00-0678fje			32	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387242				2022-12-25	WOS:000173705800026
J	Vohradsky, J				Vohradsky, J			Neural model of the genetic network	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHAGE-LAMBDA; SIMULATION; PROTEIN	Many cell control processes consist of networks of interacting elements that affect the state of each other over time. Such an arrangement resembles the principles of artificial neural networks, in which the state of a particular node depends on the combination of the states of other neurons. The A bacteriophage lysis/lysogeny decision circuit can be represented by such a network. It is used here as a model for testing the validity of a neural approach to the analysis of genetic networks. The model considers multigenic regulation including positive and negative feedback. It is used to simulate the dynamics of the lambda phage regulatory system; the results are compared with experimental observation. The comparison proves that the neural network model describes behavior of the system in full agreement with experiments; moreover, it predicts its function in experimentally inaccessible situations and explains the experimental observations. The application of the principles of neural networks to the cell control system leads to conclusions about the stability and redundancy of genetic networks and the cell functionality. Reverse engineering of the biochemical pathways from proteomics and DNA micro array data using the suggested neural network model is discussed.	Acad Sci Czech Republ, Inst Microbiol, CR-14220 Prague, Czech Republic	Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences	Vohradsky, J (corresponding author), Acad Sci Czech Republ, Inst Microbiol, Videnska 1083, CR-14220 Prague, Czech Republic.	vohr@biomed.cas.cz						Akutsu T, 1999, Pac Symp Biocomput, P17; Bose N.K., 1996, NEURAL NETWORK FUNDA; BOSE NK, 1996, NEURAL NETWORK FUNDA, P323; DAS A, 1992, J BACTERIOL, V174, P6711, DOI 10.1128/JB.174.21.6711-6716.1992; DasGupta B, 1996, NEURAL COMPUT, V8, P805, DOI 10.1162/neco.1996.8.4.805; ECHOLS H, 1983, LAMBDA, V2, P75; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; HERSKOWITZ I, 1980, ANNU REV GENET, V14, P399, DOI 10.1146/annurev.ge.14.120180.002151; HOYT MA, 1982, CELL, V31, P565, DOI 10.1016/0092-8674(82)90312-9; KAUFFMAN SA, 1971, CURR TOP DEV BIOL, V6, P144; KOURILSKY P, 1973, MOL GEN GENET, V122, P183, DOI 10.1007/BF00435190; LEVINE A, 1979, J MOL BIOL, V131, P655, DOI 10.1016/0022-2836(79)90014-7; Liang S, 1998, Pac Symp Biocomput, P18; MARNELLOS G, 1998, PAC S BIOC, V5, P30; MARNELLOS G, 2000, PAC S BIOC, V12, P329; MATSUNO H, 2000, PAC S BIOC, V5, P341; McAdams HH, 2000, CURR BIOL, V10, pR318, DOI 10.1016/S0960-9822(00)00440-1; MCADAMS HH, 1995, SCIENCE, V269, P650, DOI 10.1126/science.7624793; McAdams HH, 1999, TRENDS GENET, V15, P65, DOI 10.1016/S0168-9525(98)01659-X; McAdams HH, 1997, P NATL ACAD SCI USA, V94, P814, DOI 10.1073/pnas.94.3.814; McAdams HH, 1998, ANNU REV BIOPH BIOM, V27, P199, DOI 10.1146/annurev.biophys.27.1.199; Patterson SD, 2000, PHYSIOL GENOMICS, V2, P59, DOI 10.1152/physiolgenomics.2000.2.2.59; PINEDA FJ, 1987, PHYS REV LETT, V59, P2229, DOI 10.1103/PhysRevLett.59.2229; PTASHNE M, 1986, GENETIC SWITCH PHAGE, P54; PTASHNE M, 1986, GENETIC SWITCH PHAGE, P58; Somogyi R, 1996, COMPLEXITY, V1, P45, DOI DOI 10.1002/CPLX.6130010612; SZALLASI Z, 1998, PAC S BIOCOMPUT, V16, P66; THOMAS R, 1973, J THEOR BIOL, V42, P563, DOI 10.1016/0022-5193(73)90247-6; Vohradsky J, 2001, FASEB J, V15, P846, DOI 10.1096/fj.00-0361com; Wen XL, 1998, P NATL ACAD SCI USA, V95, P334, DOI 10.1073/pnas.95.1.334; Wessels L F, 2001, Pac Symp Biocomput, P508; Wuensche A, 1998, Pac Symp Biocomput, P89	33	100	106	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36168	36173		10.1074/jbc.M104391200	http://dx.doi.org/10.1074/jbc.M104391200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11395518	hybrid			2022-12-25	WOS:000171194500018
J	Toney, JH; Hammond, GG; Fitzgerald, PMD; Sharma, N; Balkovec, JM; Rouen, GP; Olson, SH; Hammond, ML; Greenlee, ML; Gao, YD				Toney, JH; Hammond, GG; Fitzgerald, PMD; Sharma, N; Balkovec, JM; Rouen, GP; Olson, SH; Hammond, ML; Greenlee, ML; Gao, YD			Succinic acids as potent inhibitors of plasmid-borne IMP-1 metallo-beta-lactamase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTEROIDES-FRAGILIS; CRYSTAL-STRUCTURE; PSEUDOMONAS-AERUGINOSA; BIPHENYL TETRAZOLES; SERRATIA-MARCESCENS; CARBOXYPEPTIDASE; DERIVATIVES; RESISTANCE; SERIES; L1	IMP-1 metallo-beta -lactamase (class B) is a plasmid-borne zinc metalloenzyme that efficiently hydrolyzes beta -lactam antibiotics, including carbapenems, rendering them ineffective. Because IMP-1 has been found in several clinically important carbapenem-resistant pathogens, there is a need for inhibitors of this enzyme that could protect broad spectrum antibiotics such as imipenem from hydrolysis and thus extend their utility. We have identified a series of 2,3-(S,S)-disubstituted succinic acids that are potent inhibitors of IMP-1. Determination of high resolution crystal structures and molecular modeling of succinic acid inhibitor complexes with IMP-1 has allowed an understanding of the potency, stereochemistry, and structure-activity relationships of these inhibitors.	Merck Res Labs, Dept Biochem, Rahway, NJ 07065 USA; Merck Res Labs, Dept Med Chem, Rahway, NJ 07065 USA; Merck Res Labs, Dept Mol Syst, Rahway, NJ 07065 USA	Merck & Company; Merck & Company; Merck & Company	Toney, JH (corresponding author), Merck Res Labs, Dept Biochem, Rahway, NJ 07065 USA.	jeff_toney@merck.com	ID, IMCACAT/D-5867-2014					AsanteAppiah E, 1997, BIOCHEMISTRY-US, V36, P8710, DOI 10.1021/bi970354b; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Bush K, 1998, CLIN INFECT DIS, V27, pS48, DOI 10.1086/514922; Carfi A, 1998, ACTA CRYSTALLOGR D, V54, P47, DOI 10.1107/S090744499700927X; Carfi A, 1998, ACTA CRYSTALLOGR D, V54, P313, DOI 10.1107/S0907444997010627; CARFI A, 1995, EMBO J, V14, P4914, DOI 10.1002/j.1460-2075.1995.tb00174.x; CHRISTIANSON DW, 1989, ACCOUNTS CHEM RES, V22, P62, DOI 10.1021/ar00158a003; CLISSOLD SP, 1987, DRUGS, V33, P183, DOI 10.2165/00003495-198733030-00001; Concha NO, 1997, PROTEIN SCI, V6, P2671; Concha NO, 1996, STRUCTURE, V4, P823, DOI 10.1016/S0969-2126(96)00089-5; Concha NO, 2000, BIOCHEMISTRY-US, V39, P4288, DOI 10.1021/bi992569m; Cornaglia G, 1999, LANCET, V353, P899, DOI 10.1016/S0140-6736(98)05954-6; Creighton T.E., 1984, PROTEINS STRUCTURE M; Cricco JA, 1999, COORDIN CHEM REV, V190, P519, DOI 10.1016/S0010-8545(99)00113-7; DELENCASTRE H, 1994, J ANTIMICROB CHEMOTH, V33, P7, DOI 10.1093/jac/33.1.7; DIMODUGNO E, 1999, CURR OPIN ANTIINFECT, V1, P26; Feuston BP, 2001, J CHEM INF COMP SCI, V41, P754, DOI 10.1021/ci000464g; Fitzgerald PMD, 1998, BIOCHEMISTRY-US, V37, P6791, DOI 10.1021/bi9730339; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; GILPIN ML, 1995, J ANTIBIOT, V48, P1081, DOI 10.7164/antibiotics.48.1081; Goto M, 1997, BIOL PHARM BULL, V20, P1136, DOI 10.1248/bpb.20.1136; Greenlee ML, 1999, BIOORG MED CHEM LETT, V9, P2549, DOI 10.1016/S0960-894X(99)00425-4; Halgren TA, 1999, J COMPUT CHEM, V20, P730, DOI 10.1002/(SICI)1096-987X(199905)20:7<730::AID-JCC8>3.0.CO;2-T; Hammond GG, 1999, FEMS MICROBIOL LETT, V179, P289, DOI 10.1111/j.1574-6968.1999.tb08740.x; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; Kaminskaia NV, 2000, J AM CHEM SOC, V122, P6411, DOI 10.1021/ja993704l; Koh TH, 1999, LANCET, V353, P2162, DOI 10.1016/S0140-6736(05)75604-X; KROPP H, 1985, REV INFECT DIS, V7, pS389; Laraki N, 1999, ANTIMICROB AGENTS CH, V43, P902, DOI 10.1128/AAC.43.4.902; Lee M, 1999, BIOORGAN MED CHEM, V7, P1755, DOI 10.1016/S0968-0896(99)00110-8; LIPPARD SJ, 1994, PRINCIPLES BIOINORGA, P262; LIVERMORE DM, 1992, ANTIMICROB AGENTS CH, V36, P2046, DOI 10.1128/AAC.36.9.2046; Livermore DM, 1997, J ANTIMICROB CHEMOTH, V39, P673, DOI 10.1093/jac/39.6.673; Livermore DM, 1998, J ANTIMICROB CHEMOTH, V41, P25, DOI 10.1093/jac/41.suppl_4.25; Livermore DM, 2000, CURR OPIN MICROBIOL, V3, P489, DOI 10.1016/S1369-5274(00)00128-4; Miller MD, 1999, J MED CHEM, V42, P1505, DOI 10.1021/jm9806143; Nagano R, 1999, ANTIMICROB AGENTS CH, V43, P2497, DOI 10.1128/AAC.43.10.2497; OSANO E, 1994, ANTIMICROB AGENTS CH, V38, P71, DOI 10.1128/AAC.38.1.71; Page MI, 1998, CHEM COMMUN, P1609, DOI 10.1039/a803578d; Payne DJ, 1997, FEMS MICROBIOL LETT, V157, P171, DOI 10.1016/S0378-1097(97)00472-2; Payne DJ, 1997, ANTIMICROB AGENTS CH, V41, P135, DOI 10.1128/AAC.41.1.135; Payne DJ, 2000, EXPERT OPIN INV DRUG, V9, P247, DOI 10.1517/13543784.9.2.247; Rasmussen BA, 1997, ANTIMICROB AGENTS CH, V41, P223, DOI 10.1128/AAC.41.2.223; Scrofani SDB, 1999, BIOCHEMISTRY-US, V38, P14507, DOI 10.1021/bi990986t; Senda K, 1996, J CLIN MICROBIOL, V34, P2909, DOI 10.1128/JCM.34.12.2909-2913.1996; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Toney JH, 1998, CHEM BIOL, V5, P185, DOI 10.1016/S1074-5521(98)90632-9; Toney JH, 1999, BIOORG MED CHEM LETT, V9, P2741, DOI 10.1016/S0960-894X(99)00458-8; Ullah JH, 1998, J MOL BIOL, V284, P125, DOI 10.1006/jmbi.1998.2148; Walter MW, 1999, BIOORG CHEM, V27, P35, DOI 10.1006/bioo.1998.1111; Walter MW, 1996, BIOORG MED CHEM LETT, V6, P2455, DOI 10.1016/0960-894X(96)00453-2; Wang ZG, 1999, BIOCHEMISTRY-US, V38, P10013, DOI 10.1021/bi990356r; Wang ZG, 1999, CURR OPIN CHEM BIOL, V3, P614, DOI 10.1016/S1367-5931(99)00017-4; WATANABE M, 1991, ANTIMICROB AGENTS CH, V35, P147, DOI 10.1128/AAC.35.1.147; Wong KK, 1998, ADV EXP MED BIOL, V456, P197; Yang KW, 1999, ARCH BIOCHEM BIOPHYS, V368, P1, DOI 10.1006/abbi.1999.1293	57	167	174	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31913	31918		10.1074/jbc.M104742200	http://dx.doi.org/10.1074/jbc.M104742200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11390410	hybrid			2022-12-25	WOS:000170613500062
J	Mornet, E; Stura, E; Lia-Baldini, AS; Stigbrand, T; Menez, A; Le Du, MH				Mornet, E; Stura, E; Lia-Baldini, AS; Stigbrand, T; Menez, A; Le Du, MH			Structural evidence for a functional role of human tissue nonspecific alkaline phosphatase in bone mineralization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFANTILE HYPOPHOSPHATASIA; LETHAL HYPOPHOSPHATASIA; MISSENSE MUTATION; GENE; CALCIUM; LOCALIZATION; MECHANISM	The human tissue nonspecific alkaline phosphatase (TNAP) is found in liver, kidney, and bone. Mutations in the TNAP gene can lead to Hypophosphatasia, a rare inborn disease that is characterized by defective bone mineralization. TNAP is 74% homologous to human placental alkaline phosphatase (PLAP) whose crystal structure has been recently determined at atomic resolution (Le Du, M. H., Stigbrand, T., Taussig, M. J., Menez, A., and Stura, E. A. (2001) J. Biol. Chem, 276,9158-9165). The degree of homology allowed us to build a reliable TNAP model to investigate the relationship between mutations associated with hypophosphatasia and their probable consequences on the activity or the structure of the enzyme. The mutations are clustered within five crucial regions, namely the active site and its vicinity, the active site valley, the homodimer interface, the crown domain, and the metal-binding site. The crown domain and the metal-binding domain are mammalian-specific and were observed for the first time in the PLAP structure. The crown domain contains a collagen binding loop. A synchrotron radiation x-ray fluorescence study confirms that the metal in the metal-binding site is a calcium ion. Several severe mutations in TNAP occur around this calcium site, suggesting that calcium may be of critical importance for the TNAP function. The presence of this extra metal-binding site gives new insights on the controversial role observed for calcium.	CE Saclay, CEA, DIEP, F-91191 Gif Sur Yvette, France; Umea Univ, Dept Immunol, Umea, Sweden; Univ Versailles, Ctr Etud Biol Prenatale, SESEP, F-78000 Versailles, France	CEA; UDICE-French Research Universities; Universite Paris Saclay; Umea University; UDICE-French Research Universities; Universite Paris Saclay	Le Du, MH (corresponding author), CE Saclay, CEA, DIEP, F-91191 Gif Sur Yvette, France.	mhledu@cea.fr	Stura, Enrico A./A-2793-2010	Stura, Enrico A./0000-0001-6718-2118				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAMBYNEK W, 1972, REV MOD PHYS, V44, P716, DOI 10.1103/RevModPhys.44.716; BOSSI M, 1993, J BIOL CHEM, V268, P25409; Cai GM, 1998, J CLIN ENDOCR METAB, V83, P3936, DOI 10.1210/jc.83.11.3936; Callebaut I, 1997, CELL MOL LIFE SCI, V53, P621, DOI 10.1007/s000180050082; COLEMAN JE, 1992, ANNU REV BIOPH BIOM, V21, P441, DOI 10.1146/annurev.biophys.21.1.441; DEBERNARD B, 1986, J CELL BIOL, V103, P1615, DOI 10.1083/jcb.103.4.1615; Fukushi M, 1998, BIOCHEM BIOPH RES CO, V246, P613, DOI 10.1006/bbrc.1998.8674; GENGE BR, 1988, J BIOL CHEM, V263, P18513; Goseki-Sone M, 1998, HUM MUTAT, pS263; GREENBERG CR, 1990, AM J HUM GENET, V46, P286; Harding MM, 2001, ACTA CRYSTALLOGR D, V57, P401, DOI 10.1107/S0907444900019168; Henke B. L., 1982, Atomic Data and Nuclear Data Tables, V27, P1, DOI 10.1016/0092-640X(82)90002-X; HENTHORN PS, 1992, P NATL ACAD SCI USA, V89, P9924, DOI 10.1073/pnas.89.20.9924; HOLYAERTS MF, 1991, BIOCHEM J, V274, P91; Hoylaerts MF, 1997, J BIOL CHEM, V272, P22781, DOI 10.1074/jbc.272.36.22781; Hu JCC, 2000, EUR J ORAL SCI, V108, P189, DOI 10.1034/j.1600-0722.2000.108003189.x; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Le Du MH, 2001, J BIOL CHEM, V276, P9158, DOI 10.1074/jbc.M009250200; Leone FA, 1997, J INORG BIOCHEM, V68, P123, DOI 10.1016/S0162-0134(97)00047-0; MILLAN JL, 1995, CRIT REV CL LAB SCI, V32, P1, DOI 10.3109/10408369509084680; MILLAN JL, 1992, CLIN CHIM ACTA, V209, P123, DOI 10.1016/0009-8981(92)90343-O; MILLAN JL, 1988, ANTICANCER RES, V8, P995; Mochizuki H, 2000, EUR J PEDIATR, V159, P375, DOI 10.1007/s004310051290; Mornet E, 1998, EUR J HUM GENET, V6, P308, DOI 10.1038/sj.ejhg.5200190; ORIMO H, 1994, HUM MOL GENET, V3, P1683, DOI 10.1093/hmg/3.9.1683; Orimo H, 1997, GENOMICS, V42, P364, DOI 10.1006/geno.1997.4733; Ozono K, 1996, J CLIN ENDOCR METAB, V81, P4458, DOI 10.1210/jc.81.12.4458; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sanchez R, 2000, METH MOL B, V143, P97; SCHWARTZ JH, 1961, P NATL ACAD SCI USA, V47, P1996, DOI 10.1073/pnas.47.12.1996; Shibata H, 1998, J BIOCHEM-TOKYO, V123, P968; Shinozaki T, 1996, J RHEUMATOL, V23, P677; Sugimoto N, 1998, J HUM GENET, V43, P160, DOI 10.1007/s100380050061; Taillandier A, 2000, Hum Mutat, V15, P293, DOI 10.1002/(SICI)1098-1004(200003)15:3<293::AID-HUMU11>3.0.CO;2-Q; Taillandier A, 1999, Hum Mutat, V13, P171, DOI 10.1002/(SICI)1098-1004(1999)13:2<171::AID-HUMU16>3.0.CO;2-T; TAILLANDIER A, 2001, IN PRESS HUM MUTAT; WEISS MJ, 1988, P NATL ACAD SCI USA, V85, P7666, DOI 10.1073/pnas.85.20.7666; WHYTE MP, 1994, ENDOCR REV, V15, P439, DOI 10.1210/er.15.4.439; Zurutuza L, 1999, HUM MOL GENET, V8, P1039, DOI 10.1093/hmg/8.6.1039	42	147	168	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31171	31178		10.1074/jbc.M102788200	http://dx.doi.org/10.1074/jbc.M102788200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11395499	hybrid			2022-12-25	WOS:000170472900077
J	De Crescenzo, G; Grothe, S; Zwaagstra, J; Tsang, M; O'Connor-McCourt, MD				De Crescenzo, G; Grothe, S; Zwaagstra, J; Tsang, M; O'Connor-McCourt, MD			Real-time monitoring of the interactions of transforming growth factor-beta (TGF-beta) isoforms with latency-associated protein and the ectodomains of the TGF-beta type II and III receptors reveals different kinetic models and stoichiometries of binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; FACTOR (TGF)-BETA RECEPTOR; LIGAND-BINDING; EXTRACELLULAR DOMAIN; CRYSTAL-STRUCTURE; CONFORMATIONAL CHANGE; COMPLEX; GROWTH-FACTOR-BETA-1; BETAGLYCAN; MEMBRANE	Mature transforming growth factor-beta (TGF-beta) is proteolytically derived from the C terminus of a precursor protein. Latency-associated protein (LAP), the N-terminal remnant of the TGF-beta precursor, is able to bind and neutralize TGF-beta. Mature TGF-beta exerts its activity by binding and complexing members of two subfamilies of receptors, the type I and II receptors. In addition to these signaling receptors, TGF-beta can also interact with an accessory receptor termed the type III receptor. Using a surface plasmon resonance-based biosensor (BIAcore), we determined the mechanisms of interaction of four binding proteins (LAP, the type II and III receptor ectodomains (EDs), and a type II receptor ED/Fc chimera) with three TGF-beta isoforms, and we quantified their related kinetic parameters. Using global fitting based on a numerical integration data analysis method, we demonstrated that LAP and the type II receptor/Fc chimera interacted with the TGF-beta isoforms with a 1:1 stoichiometry. In contrast, the type II ED interactions with TGF-beta were best fit by a kinetic model assuming the presence of two independent binding sites on the ligand molecule. We also showed that the type III ED bound two TGF-beta molecules. Further experiments revealed that LAP was able to block the interactions of TGF-beta with the two EDs, but that the two EDs did not compete or cooperate with each other. Together, these results strongly support the existence of a cell-surface complex consisting of one type III receptor, two TGF-beta molecules, and four type II receptors, prior to the recruitment of the type I receptor for signal transduction. Additionally, our results indicate that the apparent dissociation rate constants are more predictive of the neutralizing potency of these TGF-beta -binding proteins (LAP, the type II and III receptor EDs, and the type II receptor/Fc chimera) than the apparent equilibrium constants.	Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada; R&D Syst, Minneapolis, MN USA	National Research Council Canada	O'Connor-McCourt, MD (corresponding author), Natl Res Council Canada, Biotechnol Res Inst, 6100 RoyalMount Ave, Montreal, PQ H4P 2R2, Canada.							ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Bailly S, 1997, J BIOL CHEM, V272, P16329, DOI 10.1074/jbc.272.26.16329; Blobe GC, 2001, J BIOL CHEM, V276, P24627, DOI 10.1074/jbc.M100188200; BRADLEY JV, 1968, DISTRIBUTION FREE ST, P251; Brown CB, 1999, SCIENCE, V283, P2080, DOI 10.1126/science.283.5410.2080; DAOPIN S, 1992, SCIENCE, V257, P369, DOI 10.1126/science.1631557; De Crescenzo G, 2000, BIOCHEMISTRY-US, V39, P9466, DOI 10.1021/bi992987r; Deng XB, 1999, CELL GROWTH DIFFER, V10, P11; Fisher Robert J., 1994, Current Opinion in Biotechnology, V5, P389, DOI 10.1016/0958-1669(94)90047-7; Fivash M, 1998, CURR OPIN BIOTECH, V9, P97, DOI 10.1016/S0958-1669(98)80091-8; GENTRY LE, 1990, BIOCHEMISTRY-US, V29, P6851, DOI 10.1021/bi00481a014; Gilboa L, 1998, J CELL BIOL, V140, P767, DOI 10.1083/jcb.140.4.767; GREENFIELD C, 1989, EMBO J, V8, P4115, DOI 10.1002/j.1460-2075.1989.tb08596.x; Hinck AP, 1996, BIOCHEMISTRY-US, V35, P8517, DOI 10.1021/bi9604946; Kaname S, 1996, BIOCHEM J, V315, P815, DOI 10.1042/bj3150815; Kirsch T, 2000, NAT STRUCT BIOL, V7, P492; Komesli S, 1998, EUR J BIOCHEM, V254, P505, DOI 10.1046/j.1432-1327.1998.2540505.x; Letourneur O, 1996, BIOCHEM BIOPH RES CO, V224, P709, DOI 10.1006/bbrc.1996.1088; LIN HY, 1995, J BIOL CHEM, V270, P2747, DOI 10.1074/jbc.270.6.2747; LOPEZCASILLAS F, 1994, J CELL BIOL, V124, P557, DOI 10.1083/jcb.124.4.557; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Matsuzaki K, 1996, IN VITRO CELL DEV-AN, V32, P345, DOI 10.1007/BF02722961; McMahon GA, 1996, BIOCHEM J, V313, P343, DOI 10.1042/bj3130343; Mittl PRE, 1996, PROTEIN SCI, V5, P1261, DOI 10.1002/pro.5560050705; MORTON TA, 1995, ANAL BIOCHEM, V227, P176, DOI 10.1006/abio.1995.1268; MOUSTAKAS A, 1993, J BIOL CHEM, V268, P22215; Muller KM, 1998, ANAL BIOCHEM, V261, P149, DOI 10.1006/abio.1998.2725; O'Connor-McCourt M., 1998, QUANTITATIVE ANAL BI, P175; OConnorMcCourt MD, 1995, ANN NY ACAD SCI, V766, P300, DOI 10.1111/j.1749-6632.1995.tb26682.x; OShannessy DJ, 1996, ANAL BIOCHEM, V236, P275, DOI 10.1006/abio.1996.0167; Padgett RW, 1998, BIOESSAYS, V20, P382, DOI 10.1002/(SICI)1521-1878(199805)20:5&lt;382::AID-BIES5&gt;3.0.CO;2-Q; Pepin MC, 1995, FEBS LETT, V377, P368, DOI 10.1016/0014-5793(95)01378-4; PEPIN MC, 1994, P NATL ACAD SCI USA, V91, P6997, DOI 10.1073/pnas.91.15.6997; Philip A, 1999, EUR J BIOCHEM, V261, P618, DOI 10.1046/j.1432-1327.1999.00298.x; PRESS WH, 1986, NUMERICAL RECIPES AR; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; Taniguchi A, 1998, IN VITRO CELL DEV-AN, V34, P232; TSANG MLS, 1995, CYTOKINE, V7, P389, DOI 10.1006/cyto.1995.0054; WAHL SM, 1989, IMMUNOL TODAY, V10, P258, DOI 10.1016/0167-5699(89)90136-9; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Zwaagstra JC, 1999, EXP CELL RES, V252, P352, DOI 10.1006/excr.1999.4640	45	79	86	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29632	29643		10.1074/jbc.M009765200	http://dx.doi.org/10.1074/jbc.M009765200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11382746	hybrid			2022-12-25	WOS:000170558000007
J	Kamura, T; Burian, D; Yan, Q; Schmidt, SL; Lane, WS; Querido, E; Branton, PE; Shilatifard, A; Conaway, RC; Conaway, JW				Kamura, T; Burian, D; Yan, Q; Schmidt, SL; Lane, WS; Querido, E; Branton, PE; Shilatifard, A; Conaway, RC; Conaway, JW			MUF1, a novel Elongin BC-interacting leucine-rich repeat protein that can assemble with Cul5 and Rbx1 to reconstitute a ubiquitin ligase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; RNA-POLYMERASE-II; SOCS-BOX MOTIF; DEPENDENT PROTEOLYSIS; GENE FAMILY; COMPLEX; ELONGATION; BINDING; DOMAIN; SCF	The heterodimeric. Elongin BC complex has been shown to interact in vitro and in mammalian cells with a conserved BC-box motif found in a growing number of proteins including RNA polymerase Il elongation factor Elongin A, SOCS-box proteins, and the von Hippel-Lindau (VHL) tumor suppressor protein. Recently, the VHL-EIongin BC complex was found to interact with a module composed of Cullin family member Cul2 and RING-H2 finger protein Rbx1 to reconstitute a novel E3 ubiquitin ligase that activates ubiquitylation by the E2 ubiquitin-conjugating enzymes Ubc5 and Cdc34. In the context of: the VEL ubiquitin ligase, Elongin BC functions as an adaptor that links the VHL protein to the CuI2/Rbx1 module, raising the possibility that the Elongin BC complex could function as an integral component of a larger family of E3 ubiquitin ligases by linking alternative BC-box proteins to Cullin/Rbx1 modules. In this report, we describe identification and purification from rat liver of a novel leucine-rich repeat-containing BO-box protein, MUF1, which we demonstrate is capable of assembling, with a Cullin/Rbx1 module containing the Cullin family member Cul5 to reconstitute ubiquitin ligase activity. In addition, we show that the additional BC-box, proteins Elongin A, SOCS1, and WSB1 are also capable of assembling with the Cul5/Rbx1. module to reconstitute potential ubiquitin ligases. Taken together, our findings identify MUF1 as a new member of the BO-box family of proteins, and they predict the existence of a larger family of Elongin BC-based E3 ubiquitin ligases.	Oklahoma Med Res Fdn, Howard Hughes Med Inst, Oklahoma City, OK 73104 USA; Oklahoma Med Res Fdn, Program Mol & Cell Biol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA; St Louis Univ, Sch Med, Edward A Doisy Dept Biochem, St Louis, MO 63104 USA; Harvard Univ, Harvard Microchem & Proteom Anal Facil, Cambridge, MA 02138 USA; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3G 1Y6, Canada	Howard Hughes Medical Institute; Oklahoma Medical Research Foundation; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; Saint Louis University; Harvard University; McGill University; McGill University	Conaway, JW (corresponding author), Oklahoma Med Res Fdn, Howard Hughes Med Inst, Oklahoma City, OK 73104 USA.	jlc@stowers-institute.org	Yan, Qin/E-8893-2012	Yan, Qin/0000-0003-4077-453X; Querido, Emmanuelle/0000-0002-8027-3732; Conaway, Joan/0000-0002-2786-0663	NIGMS NIH HHS [R37GM41628] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041628] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Amerik AY, 2000, MOL BIOL CELL, V11, P3365, DOI 10.1091/mbc.11.10.3365; Aso T, 1996, EMBO J, V15, P5557, DOI 10.1002/j.1460-2075.1996.tb00940.x; Burnatowska-Hledin M, 2000, AM J PHYSIOL-CELL PH, V279, pC266, DOI 10.1152/ajpcell.2000.279.1.C266; BURNATOWSKAHLEDIN MA, 1995, AM J PHYSIOL-RENAL, V268, pF1198, DOI 10.1152/ajprenal.1995.268.6.F1198; Chittum HS, 1998, BIOCHEMISTRY-US, V37, P10866, DOI 10.1021/bi981042r; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Conaway RC, 1996, METHOD ENZYMOL, V273, P194; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kamura T, 1999, GENE DEV, V13, P2928, DOI 10.1101/gad.13.22.2928; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kamura T, 2001, J BIOL CHEM, V276, P16528, DOI 10.1074/jbc.M010142200; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; KOBE B, 1995, CURR OPIN STRUC BIOL, V5, P409, DOI 10.1016/0959-440X(95)80105-7; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; Reines D, 1999, CURR OPIN CELL BIOL, V11, P342, DOI 10.1016/S0955-0674(99)80047-7; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071	38	125	142	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29748	29753		10.1074/jbc.M103093200	http://dx.doi.org/10.1074/jbc.M103093200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11384984	hybrid			2022-12-25	WOS:000170558000021
J	Makiniemi, M; Hillukkala, T; Tuusa, J; Reini, K; Vaara, M; Huang, DQ; Pospiech, H; Majuri, I; Westerling, T; Makela, TP; Syvaoja, JE				Makiniemi, M; Hillukkala, T; Tuusa, J; Reini, K; Vaara, M; Huang, DQ; Pospiech, H; Majuri, I; Westerling, T; Makela, TP; Syvaoja, JE			BRCT domain-containing protein TopBP1 functions in DNA replication and damage response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; S-PHASE CHECKPOINT; CELL-CYCLE CHECKPOINT; POLYMERASE-EPSILON; FISSION YEAST; DROSOPHILA-MELANOGASTER; CHROMOSOMAL REPLICATION; CONSERVED DOMAINS; MOLECULAR-CLONING; CATALYTIC SUBUNIT	Topoisomerase II beta -binding protein (TopBP1), a human protein with eight BRCT domains, is similar to Saccharomyces cerevisiae Dpb11 and Schizosaccharomyces pombe Cut5 checkpoint proteins and closely related to Drosophila Mus101. We show that human TopBP1 is required for DNA replication and that it interacts with DNA polymerase epsilon. In S phase TopBP1 colocalizes with Brca1 to foci that do not represent sites of ongoing DNA replication. Inhibition of DNA synthesis leads to relocalization of TopBP1 together with Brca1 to replication forks, suggesting a role in rescue of stalled forks. DNA damage induces formation of distinct TopBP1 foci that colocalize with Brca1 in S phase, but not in Gi phase. We also show that TopBP1 interacts with the checkpoint protein hRad9. Thus, these results implicate TopBP1 in replication and checkpoint functions.	Univ Oulu, Bioctr Oulu, FIN-90014 Oulu, Finland; Univ Oulu, Dept Biochem, FIN-90014 Oulu, Finland; Univ Helsinki, Haartman Inst, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, Diagnost Lab, FIN-00014 Helsinki, Finland; Univ Joensuu, Dept Biol, FIN-80101 Joensuu, Finland	University of Oulu; Finland National Institute for Health & Welfare; University of Oulu; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Eastern Finland	Syvaoja, JE (corresponding author), Univ Oulu, Bioctr Oulu, POB 3000, FIN-90014 Oulu, Finland.	Juhani.Syvaoja@oulu.fi	Pospiech, Helmut/J-8598-2015; makela, tomi/B-3734-2009	makela, tomi/0000-0002-4869-8044; Westerling, Thomas/0000-0001-8537-6493; Reini, Kaarina/0000-0003-1039-8289				ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; ARAKI H, 1995, P NATL ACAD SCI USA, V92, P11791, DOI 10.1073/pnas.92.25.11791; ARAKI H, 1992, EMBO J, V11, P733, DOI 10.1002/j.1460-2075.1992.tb05106.x; Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1223, DOI 10.1093/nar/27.5.1223; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; BOYD JB, 1976, GENETICS, V84, P507; BUDD ME, 1995, MOL CELL BIOL, V15, P2173; BUDD ME, 1993, MOL CELL BIOL, V13, P496, DOI 10.1128/MCB.13.1.496; BURKE JD, 1994, MOL GEN GENET, V242, P169, DOI 10.1007/BF00391010; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Caspari T, 2000, MOL CELL BIOL, V20, P1254, DOI 10.1128/MCB.20.4.1254-1262.2000; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; DUrso G, 1997, P NATL ACAD SCI USA, V94, P12491, DOI 10.1073/pnas.94.23.12491; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; GATTI M, 1983, SCIENCE, V221, P83, DOI 10.1126/science.6407113; HAMATAKE RK, 1990, J BIOL CHEM, V265, P4072; Henderson DS, 1999, METHODS, V18, P377, DOI 10.1006/meth.1999.0797; Holmes AM, 1999, CELL, V96, P415, DOI 10.1016/S0092-8674(00)80554-1; Jokela M, 1998, NUCLEIC ACIDS RES, V26, P730, DOI 10.1093/nar/26.3.730; Kamimura Y, 1998, MOL CELL BIOL, V18, P6102, DOI 10.1128/MCB.18.10.6102; KESTI T, 1993, J BIOL CHEM, V268, P10238; Kesti T, 1999, MOL CELL, V3, P679, DOI 10.1016/S1097-2765(00)80361-5; Kostrub CF, 1998, EMBO J, V17, P2055, DOI 10.1093/emboj/17.7.2055; Krude T, 1997, CELL, V88, P109, DOI 10.1016/S0092-8674(00)81863-2; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Li Y, 1997, J BIOL CHEM, V272, P32337, DOI 10.1074/jbc.272.51.32337; Li Y, 2000, J BIOL CHEM, V275, P23247, DOI 10.1074/jbc.M002548200; Masumoto H, 2000, MOL CELL BIOL, V20, P2809, DOI 10.1128/MCB.20.8.2809-2817.2000; McFarlane RJ, 1997, MOL GEN GENET, V255, P332, DOI 10.1007/s004380050504; Nagase T, 1996, DNA Res, V3, P321, DOI 10.1093/dnares/3.5.321; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; Pospiech H, 1999, NUCLEIC ACIDS RES, V27, P3799, DOI 10.1093/nar/27.19.3799; Rauen M, 2000, J BIOL CHEM, V275, P29767, DOI 10.1074/jbc.M005782200; Saka Y, 1997, GENE DEV, V11, P3387, DOI 10.1101/gad.11.24.3387; SAKA Y, 1993, CELL, V74, P383, DOI 10.1016/0092-8674(93)90428-S; SAKA Y, 1994, EMBO J, V13, P5319, DOI 10.1002/j.1460-2075.1994.tb06866.x; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; SMITH DA, 1985, GENETICS, V110, P647; St Onge RP, 1999, MOL BIOL CELL, V10, P1985; Stoeber K, 1998, EMBO J, V17, P7219, DOI 10.1093/emboj/17.24.7219; TANAKA S, 1982, J BIOL CHEM, V257, P8386; Thelen MP, 1999, CELL, V96, P769, DOI 10.1016/S0092-8674(00)80587-5; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; TUUSA J, 1995, NUCLEIC ACIDS RES, V23, P2178, DOI 10.1093/nar/23.12.2178; UITTO L, 1995, NUCLEIC ACIDS RES, V23, P244, DOI 10.1093/nar/23.2.244; Verkade HM, 1998, MOL GEN GENET, V260, P426, DOI 10.1007/s004380050913; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Volkmer E, 1999, J BIOL CHEM, V274, P567, DOI 10.1074/jbc.274.2.567; Wang H, 1999, P NATL ACAD SCI USA, V96, P3824, DOI 10.1073/pnas.96.7.3824; Wang Y, 2000, GENE DEV, V14, P927; WANG ZG, 1993, MOL CELL BIOL, V13, P1051, DOI 10.1128/MCB.13.2.1051; XU HP, 1990, CELL REGUL, V1, P763, DOI 10.1091/mbc.1.10.763; Yamamoto RR, 2000, GENETICS, V156, P711; Yamane K, 1997, EUR J BIOCHEM, V250, P794, DOI 10.1111/j.1432-1033.1997.00794.x; Yamane K, 1999, ONCOGENE, V18, P5194, DOI 10.1038/sj.onc.1202922; Zlotkin T, 1996, EMBO J, V15, P2298, DOI 10.1002/j.1460-2075.1996.tb00583.x	59	176	180	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30399	30406		10.1074/jbc.M102245200	http://dx.doi.org/10.1074/jbc.M102245200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11395493	hybrid			2022-12-25	WOS:000170558000104
J	Sheridan, AM; Sapirstein, A; Lemieux, N; Martin, BD; Kim, DK; Bonventre, JV				Sheridan, AM; Sapirstein, A; Lemieux, N; Martin, BD; Kim, DK; Bonventre, JV			Nuclear translocation of cytosolic phospholipase A(2) is induced by ATP depletion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ARACHIDONIC-ACID RELEASE; PROXIMAL TUBULAR CELLS; RENAL EPITHELIAL-CELLS; INTRACELLULAR PH; MDCK-CELLS; PHOSPHORYLATION SITES; INDUCED CYTOTOXICITY; MESANGIAL CELLS; CHEMICAL ANOXIA	Phospholipase A(2) (PLA(2)) enzymes may play a role in cellular injury due to ATP depletion. Renal Madin-Darby canine kidney cells were subjected to ATP depletion to assess the effects of cellular energy metabolism on cytosolic PLA(2) (cPLA(2)) regulation. ATP depletion results in a decrease in soluble cPLA2 activity and an increase in membrane-associated activity, which is reversed upon restoration of ATP levels by addition of dextrose. In ATP-depleted cells cPLA(2) mass shifts from cytosol to nuclear fractions. GFP-cPLA(2) is localized at the nuclear membrane of stably transfected ATP-depleted LLC-PK1 cells under conditions where [Ca2+](i) is known to increase. ePLA(2) translocation does not occur if the increase in [Ca2+](i) increase is inhibited. If [Ca2+](i) is allowed to increase when ATP is depleted and the cells are then lysed, cPLA2 remains associated with nuclear fractions even if the homogenate [Ca2+] is markedly reduced. In contrast, ePL(A)2, which becomes associated with the nucleus when [Ca2+], is increased using ionophore, readily dissociates from the nuclear fractions of ATP-replete cells upon reduction of homogenate [Ca2+]. Okadaic acid inhibits the ATP depletion-induced association of cPLA(2) with nuclear fractions. Thus energy deprivation results in [Ca2+]-induced nuclear translocation, which is partially prevented by a phosphatase inhibitor.	Massachusetts Gen Hosp, Med Serv, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Anesthesia Serv, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Dept Med, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Dept Anesthesia, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University	Sheridan, AM (corresponding author), Massachusetts Gen Hosp, Med Serv, 149-4002 13th Str, Charlestown, MA 02129 USA.	asheridan@partners.org			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039773, P01DK038452, K08DK002356, R37DK039773, R56DK054741, R01DK054741] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS010828, P01NS010828] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 54741, DK 39773, DK 38452, DK 02356] Funding Source: Medline; NINDS NIH HHS [NS 10828] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bittova L, 1999, J BIOL CHEM, V274, P9665, DOI 10.1074/jbc.274.14.9665; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; BONVENTRE JV, 1992, J AM SOC NEPHROL, V3, P128; CARDELL M, 1990, NEUROSCI LETT, V119, P228, DOI 10.1016/0304-3940(90)90840-6; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; deCarvalho MGS, 1996, J BIOL CHEM, V271, P6987, DOI 10.1074/jbc.271.12.6987; DOLE VP, 1960, J BIOL CHEM, V235, P2595; Gijon MA, 2000, J BIOL CHEM, V275, P20146, DOI 10.1074/jbc.M908941199; Gijon MA, 1999, J CELL BIOL, V145, P1219, DOI 10.1083/jcb.145.6.1219; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; GRONICH JH, 1990, BIOCHEM J, V271, P37, DOI 10.1042/bj2710037; GRONICH JH, 1988, J BIOL CHEM, V263, P16645; HAJJAR RJ, 1991, J BIOL CHEM, V266, P21589; HAYAKAWA M, 1993, J BIOL CHEM, V268, P11290; Hirabayashi T, 1999, J BIOL CHEM, V274, P5163, DOI 10.1074/jbc.274.8.5163; Jorgensen NK, 1999, J NEUROSCI RES, V56, P358; KIM DK, 1993, BIOCHEM J, V294, P261, DOI 10.1042/bj2940261; Klivenyi P, 1998, J NEUROCHEM, V71, P2634; KOBRYN CE, 1994, AM J PHYSIOL-CELL PH, V267, pC1073, DOI 10.1152/ajpcell.1994.267.4.C1073; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; KRAMER RM, 1995, J BIOL CHEM, V270, P14816, DOI 10.1074/jbc.270.24.14816; KROSHIAN VM, 1994, AM J PHYSIOL, V266, pF21, DOI 10.1152/ajprenal.1994.266.1.F21; Lieberthal W, 1997, J LAB CLIN MED, V129, P260, DOI 10.1016/S0022-2143(97)90148-7; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MCCOY CE, 1988, J CLIN INVEST, V82, P1326, DOI 10.1172/JCI113734; NAKAMURA H, 1991, J CLIN INVEST, V87, P1810, DOI 10.1172/JCI115202; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; Perisic O, 1999, J BIOL CHEM, V274, P14979, DOI 10.1074/jbc.274.21.14979; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; Pickard RT, 1996, J BIOL CHEM, V271, P19225, DOI 10.1074/jbc.271.32.19225; PORTILLA D, 1992, AM J PHYSIOL, V262, pF354, DOI 10.1152/ajprenal.1992.262.3.F354; Qiu ZH, 1998, J BIOL CHEM, V273, P8203, DOI 10.1074/jbc.273.14.8203; QIU ZH, 1993, J BIOL CHEM, V268, P24506; QIU ZH, 1994, J BIOL CHEM, V269, P19480; ROSSOMANDO EF, 1990, METHOD ENZYMOL, V182, P309; Sapirstein A, 1996, J BIOL CHEM, V271, P21505, DOI 10.1074/jbc.271.35.21505; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; SELVAGGIO AM, 1986, AM J PHYSIOL, V251, pC558, DOI 10.1152/ajpcell.1986.251.4.C558; Sheridan AM, 1996, KIDNEY INT, V49, P88, DOI 10.1038/ki.1996.12; Sheridan AM, 2001, MOL CELL BIOL, V21, P4470, DOI 10.1128/MCB.21.14.4470-4481.2001; Sheridan AM, 2000, CURR OPIN NEPHROL HY, V9, P427, DOI 10.1097/00041552-200007000-00015; SHERIDAN AM, 1993, AM J PHYSIOL, V265, pF342, DOI 10.1152/ajprenal.1993.265.3.F342; Tapia R, 1999, NEUROCHEM RES, V24, P1423, DOI 10.1023/A:1022588808260; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; VENKATACHALAM MA, 1988, J CLIN INVEST, V81, P745, DOI 10.1172/JCI113380; VoelkelJohnson C, 1996, J IMMUNOL, V156, P201; XU XX, 1994, J BIOL CHEM, V269, P31693	51	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29899	29905		10.1074/jbc.M103758200	http://dx.doi.org/10.1074/jbc.M103758200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11395512	hybrid			2022-12-25	WOS:000170558000040
J	Vallin, J; Thuret, R; Giacomello, E; Faraldo, MM; Thiery, JP; Broders, F				Vallin, J; Thuret, R; Giacomello, E; Faraldo, MM; Thiery, JP; Broders, F			Cloning and characterization of three Xenopus Slug promoters reveal direct regulation by Lef/beta-catenin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURAL CREST CELLS; GENE-EXPRESSION; SNAIL FAMILY; FACTOR-BETA; INDUCTION; MIGRATION; RNA; IDENTIFICATION; MESENDODERM; SEQUENCES	In amphibians and birds, one of the first steps of neural crest cell (NCC) determination is expression of the transcription factor Slug. This marker has been used to demonstrate that BMP and Writ molecules play a major role in NCC induction. However, it is unknown whether Slug expression is directly or indirectly regulated by these signals. We report here the cloning and characterization of three Xenopus Slug promoters: that of the Xenopus tropicalis slug gene and those of two Xenopus laevis Slug pseudoalleles. Although the three genes encode proteins with almost identical amino acid sequences and are expressed with similar spatiotemporal patterns, their 5'-flanking regions are quite different. A striking difference is a deletion in the X. tropicalis gene located precisely at the transcription initiation site that results in the X.tropicalis promoter being inefficient in X. laevis. Additionally, we identified two regions common to the three promoters that are necessary and sufficient to drive specific expression in NCCs. Interestingly, one of the common regulatory regions presents a functional Lef/beta -catenin-binding site necessary for specific expression. As the Lef.beta -catenin complex is a downstream effector of Wnt signaling, these results suggest that Xenopus Slug is a direct, target of NGC determination signals.	Inst Curie, CNRS, UMR 144, Paris 05, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite	Vallin, J (corresponding author), Inst Curie, CNRS, UMR 144, 26 Rue Ulm, Paris 05, France.		Thiery, Jean Paul/M-9387-2019; Martin-Faraldo, Maria-Luisa/M-5811-2018; Giacomello, Emiliana/E-3080-2018; Thiery, Jean Paul/H-1550-2011	Faraldo, Marisa/0000-0001-9497-1171; Giacomello, Emiliana/0000-0003-3329-6269; Thiery, Jean Paul/0000-0003-0478-5020				Borchers A, 2000, DEV GENES EVOL, V210, P217, DOI 10.1007/s004270050307; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; Carl TF, 1999, DEV BIOL, V213, P101, DOI 10.1006/dbio.1999.9320; Christiansen JH, 2000, CURR OPIN CELL BIOL, V12, P719, DOI 10.1016/S0955-0674(00)00158-7; DESA RO, 1990, MOL BIOL EVOL, V7, P365; ESSEX LJ, 1993, DEV DYNAM, V198, P108, DOI 10.1002/aja.1001980205; Faber J., 1994, NORMAL TABLE XENOPUS, P2; GIESE K, 1991, GENE DEV, V5, P2567, DOI 10.1101/gad.5.12b.2567; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HO L, 1994, MECH DEVELOP, V47, P53, DOI 10.1016/0925-4773(94)90095-7; Ivics Z, 1997, CELL, V91, P501, DOI 10.1016/S0092-8674(00)80436-5; Jiang RL, 1998, BBA-GENE STRUCT EXPR, V1443, P251, DOI 10.1016/S0167-4781(98)00225-5; KLOC M, 1993, SCIENCE, V262, P1712, DOI 10.1126/science.7505061; Labbe E, 2000, P NATL ACAD SCI USA, V97, P8358, DOI 10.1073/pnas.150152697; LaBonne C, 2000, DEV BIOL, V221, P195, DOI 10.1006/dbio.2000.9609; LaBonne C, 1998, DEVELOPMENT, V125, P2403; Le Douarin NM, 1999, NEURAL CREST, V2; Linker C, 2000, DEV BIOL, V224, P215, DOI 10.1006/dbio.2000.9723; Mancilla A, 1996, DEV BIOL, V177, P580, DOI 10.1006/dbio.1996.0187; Marchant L, 1998, DEV BIOL, V198, P319, DOI 10.1006/dbio.1998.8902; Mayor R, 2000, MECH DEVELOP, V97, P47, DOI 10.1016/S0925-4773(00)00412-3; Mayor R, 1997, DEV BIOL, V189, P1, DOI 10.1006/dbio.1997.8634; MAYOR R, 1995, DEVELOPMENT, V121, P767; NIETO MA, 1992, DEVELOPMENT, V116, P227; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; Nishita M, 2000, NATURE, V403, P781, DOI 10.1038/35001602; SaintJeannet JP, 1997, P NATL ACAD SCI USA, V94, P13713, DOI 10.1073/pnas.94.25.13713; SARGENT MG, 1990, DEVELOPMENT, V109, P967; Sefton M, 1998, DEVELOPMENT, V125, P3111; SIVE HL, 2000, EARLY DEV XENOPUS LA; SMITH DE, 1992, DEVELOPMENT, V116, P1038; STALDER J, 1988, J MOL EVOL, V28, P64, DOI 10.1007/BF02143498; Stegmann K, 1999, MUTAT RES-GENOMICS, V406, P63, DOI 10.1016/S1383-5726(99)00002-3; THISSE C, 1995, DEV BIOL, V172, P86, DOI 10.1006/dbio.1995.0007; TSUJIMURA A, 1995, BIOCHEM BIOPH RES CO, V214, P432, DOI 10.1006/bbrc.1995.2305; Vallin J, 1998, MECH DEVELOP, V75, P171, DOI 10.1016/S0925-4773(98)00099-9; Waltzer L, 1999, EMBO J, V18, P1630, DOI 10.1093/emboj/18.6.1630	37	140	145	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30350	30358		10.1074/jbc.M103167200	http://dx.doi.org/10.1074/jbc.M103167200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11402039	Green Published, hybrid			2022-12-25	WOS:000170558000098
J	Hsu, HY; Chiu, SL; Wen, MH; Chen, KY; Hua, KF				Hsu, HY; Chiu, SL; Wen, MH; Chen, KY; Hua, KF			Ligands of macrophage scavenger receptor induce cytokine expression via differential modulation of protein kinase signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; TUMOR-NECROSIS-FACTOR; C-JUN; FACTOR-ALPHA; ATHEROSCLEROTIC LESIONS; CHOLESTEROL DEPOSITION; MOLECULAR-CLONING; ACTIVATION DOMAIN; COMPLEX-FORMATION; GENE-EXPRESSION	Our previous works demonstrated that ligands of macrophage scavenger receptor (MSR) induce protein kinases (PKs) including protein-tyrosine kinase (PTK) and up-regulate urokinase-type plasminogen activator expression (Hsu, H. Y., Hajjar, D. P., Khan, K. M., and Falcone, D. J. (1998) J. Biol. Chem. 273, 1240-1246). To continue to investigate MSR ligand-mediated signal transductions, we focus on ligands, oxidized low density lipoprotein (OxLDL), and fucoidan induction of the cytokines tumor necrosis factor-a (TNF) and interleukin 1 beta (IL-1). In brief, in murine macrophages J774A.1, OxLDL and fucoidan up-regulate TNF production; additionally, fucoidan but not OxLDL induces IL-1 secretion, prointerleukin 1 (proIL-1, precursor of IL-1) protein, and proIL-1 message. Simultaneously, fucoidan stimulates activity of interleukin 1-converting enzyme. We further investigate the molecular mechanism by which ligand binding-induced PK-mediated mitogen-activated protein kinase (MAPK) in regulation of expression of proIL-1 and IL-1. Specifically, fucoidan stimulates activity of p21-activated kinase (PAK) and of the MAPKs extracellular signal-regulated kinase (ERK), c-Jun NH2-terminal kinase (JNK), and p38. Combined with PK inhibitors and genetic mutants of Rac1 and JNK in PK activity assays, Western blotting analyses, and IL-1 enzyme-linked immunosorbent assay, the role of individual PKs in the regulation of proIL-1/IL-1 was extensively dissected. Moreover, tyrosine phosphorylation of pp60Src as well as association between pp60Src and Hsp90 play important roles in fucoidan-induced prolL-1 expression. We are the first to establish two fucoidanmediated signaling pathways: PTK(Src)/Rac1/PAK/JNK and PTK(Src)/Rac1/PAK/p38, but not PTK/phospholipase C-gamma1/PKC/MEK1/ERK, playing critical roles in proIL-1/IL-1 regulation. Our current results indicate and suggest a model for MSR ligands differentially modulating specific PK signal transduction pathways, which regulate atherogenesis-related inflammatory cytokines TNF and IL-1.	Natl Yang Ming Univ, Inst Biotechnol Med, Fac Med Technol, Taipei 112, Taiwan; Natl Hlth Adm, Natl Lab Foods & Drugs, Taipei 115, Taiwan	National Yang Ming Chiao Tung University	Hsu, HY (corresponding author), Natl Yang Ming Univ, Inst Biotechnol Med, Fac Med Technol, 155 Li Nong St, Taipei 112, Taiwan.	hyhsu@ym.edu.tw						ACTON S, 1993, J BIOL CHEM, V268, P3530; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ASHKENAS J, 1993, J LIPID RES, V34, P983; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; Chan ED, 1999, J IMMUNOL, V162, P415; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DOI T, 1993, J BIOL CHEM, V268, P2126; ELKHOURY J, 1994, J BIOL CHEM, V269, P10197; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; FALCONE DJ, 1988, J CELL PHYSIOL, V135, P387, DOI 10.1002/jcp.1041350305; FALCONE DJ, 1991, J BIOL CHEM, V266, P22726; Fong LG, 1999, J BIOL CHEM, V274, P36808, DOI 10.1074/jbc.274.51.36808; Fong LG, 1996, J LIPID RES, V37, P574; FRASER I, 1993, NATURE, V364, P343, DOI 10.1038/364343a0; GENG YJ, 1995, AM J PATHOL, V147, P251; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Goebeler M, 1999, BLOOD, V93, P857, DOI 10.1182/blood.V93.3.857.403k03_857_865; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; HAMILTON TA, 1995, J CLIN INVEST, V95, P2020, DOI 10.1172/JCI117887; HAMPTON RY, 1991, NATURE, V352, P342, DOI 10.1038/352342a0; Hazzalin CA, 1996, CURR BIOL, V6, P1028, DOI 10.1016/S0960-9822(02)00649-8; Hsu HY, 1998, J BIOL CHEM, V273, P1240, DOI 10.1074/jbc.273.2.1240; Hsu HY, 1996, J BIOL CHEM, V271, P7767, DOI 10.1074/jbc.271.13.7767; Hsu HY, 2000, J BIOL CHEM, V275, P41035, DOI 10.1074/jbc.M003464200; Jovinge S, 1996, ARTERIOSCL THROM VAS, V16, P1573, DOI 10.1161/01.ATV.16.12.1573; KAKAR SS, 1994, CANCER LETT, V87, P85, DOI 10.1016/0304-3835(94)90413-8; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Kumar A, 1998, J BIOL CHEM, V273, P15742, DOI 10.1074/jbc.273.25.15742; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Li YS, 1996, MOL CELL BIOL, V16, P5947; Lin JK, 1997, J CELL BIOCHEM, P39; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; Mallat Z, 1997, CIRCULATION, V96, P424; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MATSUMOTO A, 1990, P NATL ACAD SCI USA, V87, P9133, DOI 10.1073/pnas.87.23.9133; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MOULTON KS, 1992, P NATL ACAD SCI USA, V89, P8102, DOI 10.1073/pnas.89.17.8102; NAITO M, 1992, AM J PATHOL, V141, P591; Natoli G, 1997, J BIOL CHEM, V272, P26079, DOI 10.1074/jbc.272.42.26079; OKADA T, 1994, J BIOL CHEM, V269, P3563; OTTNAD E, 1995, P NATL ACAD SCI USA, V92, P1391, DOI 10.1073/pnas.92.5.1391; PALKAMA T, 1991, IMMUNOLOGY, V74, P432; PARTHASARATHY S, 1987, P NATL ACAD SCI USA, V84, P537, DOI 10.1073/pnas.84.2.537; Platt N, 1996, P NATL ACAD SCI USA, V93, P12456, DOI 10.1073/pnas.93.22.12456; Pratt WB, 1997, ANNU REV PHARMACOL, V37, P297, DOI 10.1146/annurev.pharmtox.37.1.297; RESNICK D, 1993, J BIOL CHEM, V268, P3538; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sakaguchi H, 1998, LAB INVEST, V78, P423; Sano H, 1999, MECH AGEING DEV, V107, P333, DOI 10.1016/S0047-6374(99)00011-1; Schreyer SA, 1996, J BIOL CHEM, V271, P26174, DOI 10.1074/jbc.271.42.26174; SPARROW CP, 1989, J BIOL CHEM, V264, P2599; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TIPPING PG, 1993, AM J PATHOL, V142, P1721; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Xu Y, 1999, P NATL ACAD SCI USA, V96, P109, DOI 10.1073/pnas.96.1.109; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZHANG Y, 1993, MOL CELL BIOL, V13, P3831, DOI 10.1128/MCB.13.6.3831	66	146	156	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28719	28730		10.1074/jbc.M011117200	http://dx.doi.org/10.1074/jbc.M011117200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11390374	hybrid			2022-12-25	WOS:000170346000012
J	Ketchum, CJ; Schmidt, WK; Rajendrakumar, GV; Michaelis, S; Maloney, PC				Ketchum, CJ; Schmidt, WK; Rajendrakumar, GV; Michaelis, S; Maloney, PC			The yeast a-factor transporter Ste6p, a member of the ABC superfamily, couples ATP hydrolysis to pheromone export	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; CYSTIC-FIBROSIS GENE; SACCHAROMYCES-CEREVISIAE; MULTIDRUG-RESISTANCE; P-GLYCOPROTEIN; ESCHERICHIA-COLI; MALTOSE TRANSPORT; STIMULATED ATPASE; BINDING PROTEINS; DRUG	ATP-binding cassette (ABC) proteins transport a diverse collection of substrates. It is presumed that these proteins couple ATP hydrolysis to substrate transport, yet ATPase activity has been demonstrated for only a few. To provide direct evidence for such activity in Ste6p, the yeast ABC protein required for the export of a-factor mating pheromone, we established conditions for purification of Ste6p in biochemical quantities from both yeast and Sf9 insect cells. The basal ATPase activity of purified and reconstituted Ste6p (V-max = 18 nmol/ mg/min; K-m for MgATP = 0.2 mm) compares favorably with several other ABC proteins and was inhibited by orthovanadate in a profile diagnostic of ABC transporters (apparent K-I = 12 mum). Modest stimulation (similar to 40%) was observed upon the addition of a-factor either synthetic or in native form. We also used an S-azido[alpha- P-32]ATP binding and vanadate-trapping assay to examine the behavior of wild-type Ste6p and two different double mutants (G392V/G1087V and G509D/G11931)) shown previously to be mating-deficient in vivo. Both mutants displayed a diminished ability to hydrolyze ATP, with the latter uncoupled from pheromone transport. We conclude that Ste6p catalyzes ATP hydrolysis coupled to a-factor transport, which in turn promotes mating.	Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Cell Biol & Anat, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Maloney, PC (corresponding author), Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009995, R01DK058029, P50DK048977] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051508] Funding Source: NIH RePORTER; NIDDK NIH HHS [1 F32 DK09995-01, DK58029, DK48977] Funding Source: Medline; NIGMS NIH HHS [GM51508] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; AMBUDKAR SV, 1986, J BIOL CHEM, V261, P9083; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; Bauer BE, 1999, BBA-BIOMEMBRANES, V1461, P217, DOI 10.1016/S0005-2736(99)00160-1; BERKOWER C, 1991, EMBO J, V10, P3777, DOI 10.1002/j.1460-2075.1991.tb04947.x; BERKOWER C, 1994, MOL BIOL CELL, V5, P1185, DOI 10.1091/mbc.5.11.1185; BERKOWER C, 1996, MEMBRANE PROTEIN TRA, P231; BERKOWER C, 1993, MOL BIOL FUNCTION CA, P130; BISHOP L, 1989, P NATL ACAD SCI USA, V86, P6953, DOI 10.1073/pnas.86.18.6953; BOEKE JD, 1987, METHOD ENZYMOL, V152, P481; CANTLEY LC, 1978, J BIOL CHEM, V253, P7361; DAVIDSON AL, 1990, J BIOL CHEM, V265, P4254; DEAN DA, 1989, P NATL ACAD SCI USA, V86, P9134, DOI 10.1073/pnas.86.23.9134; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; Fann MC, 1998, J BIOL CHEM, V273, P33735, DOI 10.1074/jbc.273.50.33735; Fu DX, 2001, J BIOL CHEM, V276, P8753, DOI 10.1074/jbc.M008417200; GARTNER J, 1992, NAT GENET, V1, P16, DOI 10.1038/ng0492-16; GOODNO CC, 1982, METHOD ENZYMOL, V85, P116; Gottesman MM, 1995, ANNU REV GENET, V29, P607, DOI 10.1146/annurev.ge.29.120195.003135; Hagmann W, 1999, EUR J BIOCHEM, V265, P281, DOI 10.1046/j.1432-1327.1999.00735.x; HIGGINS CF, 1986, NATURE, V323, P448, DOI 10.1038/323448a0; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; HRYCYNA CA, 1991, EMBO J, V10, P1699, DOI 10.1002/j.1460-2075.1991.tb07694.x; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; INESI G, 1985, ANNU REV PHYSIOL, V47, P573, DOI 10.1146/annurev.ph.47.030185.003041; KAPLAN RS, 1985, ANAL BIOCHEM, V150, P97, DOI 10.1016/0003-2697(85)90445-2; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KIOKA N, 1989, BIOCHEM BIOPH RES CO, V162, P224, DOI 10.1016/0006-291X(89)91985-2; Klein I, 1999, BBA-BIOMEMBRANES, V1461, P237, DOI 10.1016/S0005-2736(99)00161-3; Li CH, 1996, J BIOL CHEM, V271, P28463, DOI 10.1074/jbc.271.45.28463; Liu CE, 1997, J BIOL CHEM, V272, P21883, DOI 10.1074/jbc.272.35.21883; Loayza D, 1998, MOL CELL BIOL, V18, P779, DOI 10.1128/MCB.18.2.779; Loayza D, 1998, MOL BIOL CELL, V9, P2767, DOI 10.1091/mbc.9.10.2767; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; Mao QC, 1999, BBA-BIOMEMBRANES, V1461, P69, DOI 10.1016/S0005-2736(99)00150-9; Mao QC, 1997, BBA-BIOMEMBRANES, V1327, P107, DOI 10.1016/S0005-2736(97)00050-3; MARCUS S, 1991, MOL CELL BIOL, V11, P3603, DOI 10.1128/MCB.11.7.3603; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MICHAELIS S, 1988, MOL CELL BIOL, V8, P1309, DOI 10.1128/MCB.8.3.1309; MOSSER J, 1993, NATURE, V361, P726, DOI 10.1038/361726a0; Oldenburg KR, 1997, NUCLEIC ACIDS RES, V25, P451, DOI 10.1093/nar/25.2.451; Rao US, 1998, BIOCHEMISTRY-US, V37, P14981, DOI 10.1021/bi980072r; RIORDAN JR, 1989, SCIENCE, V245, P1066; Romano JD, 1998, MOL BIOL CELL, V9, P2231, DOI 10.1091/mbc.9.8.2231; Sambrook J., 2002, MOL CLONING LAB MANU; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SARKADI B, 1992, J BIOL CHEM, V267, P4854; Schmidt WK, 1998, P NATL ACAD SCI USA, V95, P11175, DOI 10.1073/pnas.95.19.11175; Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269; Urbatsch IL, 1998, BIOCHEMISTRY-US, V37, P4592, DOI 10.1021/bi9728001; URBATSCH IL, 1994, BIOCHEMISTRY-US, V33, P7069, DOI 10.1021/bi00189a008; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x	53	33	34	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29007	29011		10.1074/jbc.M100810200	http://dx.doi.org/10.1074/jbc.M100810200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11389139	hybrid			2022-12-25	WOS:000170346000051
J	Li, LT; Chen, OS; Ward, DM; Kaplan, J				Li, LT; Chen, OS; Ward, DM; Kaplan, J			CCC1 is a transporter that mediates vacuolar iron storage in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; GENE ENCODES; MITOCHONDRIAL; MEMBRANE; OXIDASE; MUTANTS; ACCUMULATION; ENDOCYTOSIS; DISRUPTION; EXPRESSION	The budding yeast Saccharomyces cerevisiae can grow for generations in the absence of exogenous iron, indicating a capacity to store intracellular iron. As cells can accumulate iron by endocytosis we studied iron metabolism in yeast that were defective in endocytosis. We demonstrated that endocytosis-defective yeast (Delta end4) can store iron in the vacuole, indicating a transfer of iron from the cytosol to the vacuole. Using several different criteria we demonstrated that CCC1 encodes a transporter that effects the accumulation of iron and Mn2+ in vacuoles. Overexpression of CCC1, which is localized to the vacuole, lowers cytosolic iron and increases vacuolar iron content. Conversely, deletion of CCC1 results in decreased vacuolar iron content and decreased iron stores, which affect cytosolic iron levels and cell growth. Furthermore Delta ccc1 cells show increased sensitivity to external iron. The sensitivity to iron is exacerbated by ectopic expression of the iron transporter FET4. These results indicate that yeast can store iron in the vacuole and that CCC1 is involved in the transfer of iron from the cytosol to the vacuole.	Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah	Kaplan, J (corresponding author), Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT 84132 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK030534, R01DK030534] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-5238, DK-30534] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMBERG DC, 1995, YEAST, V11, P1275, DOI 10.1002/yea.320111307; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; BODE HP, 1995, EUR J BIOCHEM, V228, P337; Chen OS, 2000, J BIOL CHEM, V275, P7626, DOI 10.1074/jbc.275.11.7626; CONRADT B, 1992, J CELL BIOL, V119, P1469, DOI 10.1083/jcb.119.6.1469; DIX DR, 1994, J BIOL CHEM, V269, P26092; EIDE D, 1992, J BIOL CHEM, V267, P20774; FU DD, 1994, YEAST, V10, P515, DOI 10.1002/yea.320100411; Gitan RS, 1998, J BIOL CHEM, V273, P28617, DOI 10.1074/jbc.273.44.28617; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Lapinskas PJ, 1996, MOL MICROBIOL, V21, P519, DOI 10.1111/j.1365-2958.1996.tb02561.x; Li LT, 1998, J BIOL CHEM, V273, P22181, DOI 10.1074/jbc.273.35.22181; Li LT, 2001, J BIOL CHEM, V276, P5036, DOI 10.1074/jbc.M008969200; Portnoy ME, 2000, MOL CELL BIOL, V20, P7893, DOI 10.1128/MCB.20.21.7893-7902.2000; Radisky D, 1999, J BIOL CHEM, V274, P4481, DOI 10.1074/jbc.274.8.4481; Radisky DC, 1999, J BIOL CHEM, V274, P4497, DOI 10.1074/jbc.274.8.4497; RAGUZZI F, 1988, FEBS LETT, V231, P253, DOI 10.1016/0014-5793(88)80742-7; Sambrook J., 2002, MOL CLONING LAB MANU; SHERMAN F, 1989, METHODS YEAST GENETI; Spizzo T, 1997, MOL GEN GENET, V256, P547; STEVENS TH, 1986, J CELL BIOL, V102, P1551, DOI 10.1083/jcb.102.5.1551; Szczypka MS, 1997, YEAST, V13, P1423, DOI 10.1002/(SICI)1097-0061(199712)13:15<1423::AID-YEA190>3.3.CO;2-3; Urbanowski JL, 1999, J BIOL CHEM, V274, P38061, DOI 10.1074/jbc.274.53.38061; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x	26	253	269	5	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29515	29519		10.1074/jbc.M103944200	http://dx.doi.org/10.1074/jbc.M103944200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11390404	hybrid			2022-12-25	WOS:000170346000115
J	Muir, AI; Chamberlain, L; Elshourbagy, NA; Michalovich, D; Moore, DJ; Calamari, A; Szekeres, PG; Sarau, HM; Chambers, JK; Murdock, P; Steplewski, K; Shabon, U; Miller, JE; Middleton, SE; Darker, JG; Larminie, CGC; Wilson, S; Bergsma, DJ; Emson, P; Faull, R; Philpott, KL; Harrison, DC				Muir, AI; Chamberlain, L; Elshourbagy, NA; Michalovich, D; Moore, DJ; Calamari, A; Szekeres, PG; Sarau, HM; Chambers, JK; Murdock, P; Steplewski, K; Shabon, U; Miller, JE; Middleton, SE; Darker, JG; Larminie, CGC; Wilson, S; Bergsma, DJ; Emson, P; Faull, R; Philpott, KL; Harrison, DC			AXOR12, a novel human G protein-coupled receptor, activated by the peptide KiSS-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE; NEUROPEPTIDES; METASTASIS; IDENTIFICATION; EXPRESSION; CLEAVAGE; GALANIN; FAMILY; BRAIN	A novel human G protein-coupled receptor named AXOR12, exhibiting 81% homology to the rat orphan receptor GPR54, was cloned from a human brain cDNA library. Heterologous expression of AXOR12 in mammalian cells permitted the identification of three surrogate agonist peptides, all with a common C-terminal amidated motif. High potency agonism, indicative of a cognate ligand, was evident from peptides derived from the gene KiSS-1, the expression of which prevents metastasis in melanoma cells. Quantitative reverse transcriptase-polymerase chain reaction was used to study the expression of AXOR12 and KiSS-1 in a variety of tissues. The highest levels of expression of AXOR12 mRNA were observed in brain, pituitary gland, and placenta. The highest levels of KiSS-1 gene expression were observed in placenta and brain. A polyclonal antibody raised to the C. terminus of AXOR12 was generated and used to show localization of the receptor to neurons in the cerebellum, cerebral cortex, and brainstem. The biological significance of these expression patterns and the nature of the putative cognate ligand for AXOR12 are discussed.	GlaxoSmithKline, Dept Neurol, Harlow CM19 5AW, Essex, England; GlaxoSmithKline, Dept Discovery Biol, Harlow CM19 5AW, Essex, England; GlaxoSmithKline, Dept Biotechnol & Genet, Harlow CM19 5AW, Essex, England; GlaxoSmithKline, Dept Discovery Chem, Harlow CM19 5AW, Essex, England; GlaxoSmithKline, Dept Bioinformat, Harlow CM19 5AW, Essex, England; GlaxoSmithKline, Dept Biotechnol & Genet, King Of Prussia, PA 19406 USA; GlaxoSmithKline, Dept Pulm Biol, King Of Prussia, PA 19406 USA; Babraham Inst, Neurobiol Programme, Cambridge CB2 4AT, England; Univ Auckland, Dept Anat & Radiol, Auckland 1, New Zealand	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Auckland	Harrison, DC (corresponding author), GlaxoSmithKline, Dept Neurol, New Frontiers Sci Pk, Harlow CM19 5AW, Essex, England.	David-C-Harrison@gsk.com	Oka, Yoshitaka/C-9670-2010	Oka, Yoshitaka/0000-0002-3482-3051; Faull, Richard/0000-0003-3385-9498; Michalovich, David/0000-0003-4452-5776				Aiyar N, 1999, MOL CELL BIOCHEM, V197, P179, DOI 10.1023/A:1006962221332; Chambers J, 1999, NATURE, V400, P261, DOI 10.1038/22313; Chan WC, 2000, FMOC SOLID PHASE PEP; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Elshourbagy NA, 2000, J BIOL CHEM, V275, P25965, DOI 10.1074/jbc.M004515200; GRAFF D, 1988, FEBS LETT, V239, P137, DOI 10.1016/0014-5793(88)80560-X; GRAFF D, 1988, BRAIN RES, V442, P354, DOI 10.1016/0006-8993(88)91525-9; Hinuma S, 1998, NATURE, V393, P272, DOI 10.1038/30515; Hinuma S, 2000, NAT CELL BIOL, V2, P703, DOI 10.1038/35036326; Johnson EW, 1998, HUM MOL GENET, V7, P63, DOI 10.1093/hmg/7.1.63; Kapfhamer D, 1996, GENOMICS, V35, P533, DOI 10.1006/geno.1996.0394; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee DK, 1999, FEBS LETT, V446, P103, DOI 10.1016/S0014-5793(99)00009-5; Lee JH, 1997, CANCER RES, V57, P2384; Lee JH, 1996, JNCI-J NATL CANCER I, V88, P1731, DOI 10.1093/jnci/88.23.1731; Li C, 1999, BRAIN RES, V848, P26, DOI 10.1016/S0006-8993(99)01972-1; Moore D, 2000, J COMP NEUROL, V421, P374, DOI 10.1002/(SICI)1096-9861(20000605)421:3<374::AID-CNE6>3.0.CO;2-Z; Murray MJ, 1999, SEMIN REPROD ENDOCR, V17, P275, DOI 10.1055/s-2007-1016235; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Nystuen A, 1996, HUM MOL GENET, V5, P525, DOI 10.1093/hmg/5.4.525; Ormandy CJ, 1998, CANCER RES, V58, P1353; Perry SJ, 1997, FEBS LETT, V409, P426, DOI 10.1016/S0014-5793(97)00557-7; PRICE DA, 1977, SCIENCE, V197, P670, DOI 10.1126/science.877582; Sarau HM, 1999, MOL PHARMACOL, V56, P657, DOI 10.1124/mol.56.3.657; Servidei S, 1999, NEUROLOGY, V53, P830, DOI 10.1212/WNL.53.4.830; Seufferlein T, 1996, CANCER RES, V56, P5758; Shepard AR, 1997, NUCLEIC ACIDS RES, V25, P3183, DOI 10.1093/nar/25.15.3183; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; Stadel JM, 1997, TRENDS PHARMACOL SCI, V18, P430, DOI 10.1016/S0165-6147(97)01117-6; Szekeres PG, 2000, J BIOL CHEM, V275, P20247, DOI 10.1074/jbc.C000244200; TRILL JJ, 1995, CURR OPIN BIOTECH, V6, P553, DOI 10.1016/0958-1669(95)80092-1; TRIMMER BA, 1987, J COMP NEUROL, V266, P16, DOI 10.1002/cne.902660103; Wilson S, 1998, BRIT J PHARMACOL, V125, P1387, DOI 10.1038/sj.bjp.0702238; YANG HYT, 1985, P NATL ACAD SCI USA, V82, P7757, DOI 10.1073/pnas.82.22.7757	34	720	771	0	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28969	28975		10.1074/jbc.M102743200	http://dx.doi.org/10.1074/jbc.M102743200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11387329	hybrid			2022-12-25	WOS:000170346000046
J	Stein, U; Jurchott, K; Walther, W; Bergmann, S; Schlag, PM; Royer, HD				Stein, U; Jurchott, K; Walther, W; Bergmann, S; Schlag, PM; Royer, HD			Hyperthermia-induced nuclear translocation of transcription factor YB-1 leads to enhanced expression of multidrug resistance-related ABC transporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOX-BINDING-PROTEIN; HEAT-SHOCK; MDR1 GENE; Y-BOX; P-GLYCOPROTEIN; NF-Y; CARCINOMA CELLS; MRP GENE; ACTIVATION; INVOLVEMENT	Genotoxic stress leads to nuclear translocation of the Y-box transcription factor YB-1 and enhanced expression of the multidrug resistance gene MDR1. Because hyperthermia is used for the treatment of colon cancer in combination with chemoradiotherapy, we investigated the influence of hyperthermia on YB-1 activity and the expression of multidrug resistance-related genes. Here we report that hyperthermia causes YB-1 translocation from the cytoplasm into the nucleus of human colon carcinoma cells HCT15 and HCT116. Nuclear translocation of YB-1 was associated with increased MDR1 and MRP1 gene activity, which is reflected in strong efflux pump activity. However, a combination of hyperthermia and drug treatment effectively reduced cell survival of the HCT15 and HCT116 cells. These results demonstrate that activation of MDR1 and MRP1 gene expression and increased efflux pump activity after hyperthermia were insufficient to cause an increase in drug resistance in colon cancer cell lines. The ability of hyperthermia to abrogate drug resistance in the presence of an increase in functional MDR proteins may provide an explanation for the efficacious results seen in the clinic in colon cancer patients treated with a combination of hyperthermia and chemotherapy.	Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; Humboldt Univ, Charite, D-13122 Berlin, Germany; Univ Dusseldorf, Inst Transplantat Diagnost & Cell Therapy, D-40225 Dusseldorf, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Heinrich Heine University Dusseldorf	Stein, U (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13092 Berlin, Germany.	ustein@mdc-berlin.de	Royer, Hans-dieter/AAH-6293-2019	Walther, Wolfgang/0000-0003-2360-1370; Jurchott, Karsten/0000-0003-1589-0037; Stein, Ulrike/0000-0001-7006-282X				Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; CHAUDHARY PM, 1993, J NATL CANCER I, V85, P632, DOI 10.1093/jnci/85.8.632; CHIN KV, 1990, J BIOL CHEM, V265, P221; Chuman Y, 1996, INT J CANCER, V66, P274, DOI 10.1002/(SICI)1097-0215(19960410)66:2<274::AID-IJC23>3.0.CO;2-B; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322; Dumontet C, 1998, CLIN CANCER RES, V4, P1563; Efferth Thomas, 2001, Current Molecular Medicine (Hilversum), V1, P45, DOI 10.2174/1566524013364194; FINKE J, 1993, BIOTECHNIQUES, V14, P448; Germann UA, 1996, EUR J CANCER, V32A, P927, DOI 10.1016/0959-8049(96)00057-3; GOLDSMITH ME, 1993, J BIOL CHEM, V268, P5856; GRITTI A, 1993, INT J HYPERTHER, V9, P393, DOI 10.3109/02656739309005039; Hever-Szabo A, 1998, ANTICANCER RES, V18, P3045; Hu Z, 2000, J BIOL CHEM, V275, P2979, DOI 10.1074/jbc.275.4.2979; Izquierdo MA, 1996, INT J CANCER, V65, P230; Izumi H, 2001, NUCLEIC ACIDS RES, V29, P1200, DOI 10.1093/nar/29.5.1200; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Kim SH, 1997, CANCER LETT, V115, P9, DOI 10.1016/S0304-3835(97)04725-3; KIOKA N, 1992, FEBS LETT, V301, P37, DOI 10.1016/0014-5793(92)80205-U; KOHNO K, 1989, BIOCHEM BIOPH RES CO, V165, P1415, DOI 10.1016/0006-291X(89)92761-7; Koike K, 1997, FEBS LETT, V417, P390, DOI 10.1016/S0014-5793(97)01296-9; Lee DW, 1996, EUR J CANCER, V32A, P945, DOI 10.1016/0959-8049(96)00046-9; Lee PD, 1996, BRIT J CANCER, V74, P1046, DOI 10.1038/bjc.1996.487; LINN SC, 1995, EUR J CANCER, V31A, P1291, DOI 10.1016/0959-8049(95)00278-Q; Meijer GA, 1999, J CLIN PATHOL, V52, P450, DOI 10.1136/jcp.52.6.450; MIYAZAKI M, 1992, BIOCHEM BIOPH RES CO, V187, P677, DOI 10.1016/0006-291X(92)91248-O; MOSELEY PL, 1994, AM J PHYSIOL, V267, pC425, DOI 10.1152/ajpcell.1994.267.2.C425; Oda Y, 1998, CLIN CANCER RES, V4, P2273; Ohga T, 1998, J BIOL CHEM, V273, P5997, DOI 10.1074/jbc.273.11.5997; Ohga T, 1996, CANCER RES, V56, P4224; Rau B, 1998, ANN SURG, V227, P380, DOI 10.1097/00000658-199803000-00010; ROYER HD, 1991, NUCLEIC ACIDS RES, V19, P2363, DOI 10.1093/nar/19.9.2363; Shibao K, 1999, INT J CANCER, V83, P732; SPITKOVSKY DD, 1992, NUCLEIC ACIDS RES, V20, P797, DOI 10.1093/nar/20.4.797; Stein U, 1996, J CANCER RES CLIN, V122, P275, DOI 10.1007/BF01261403; Stein U, 1997, JNCI-J NATL CANCER I, V89, P807, DOI 10.1093/jnci/89.11.807; Stein U, 1996, JNCI-J NATL CANCER I, V88, P1383, DOI 10.1093/jnci/88.19.1383; Stein U, 1999, INT J CANCER, V80, P5, DOI 10.1002/(SICI)1097-0215(19990105)80:1<5::AID-IJC2>3.3.CO;2-6; Sundseth R, 1997, MOL PHARMACOL, V51, P963, DOI 10.1124/mol.51.6.963; Tanabe M, 1997, J BIOL CHEM, V272, P15389, DOI 10.1074/jbc.272.24.15389; UCHIUMI T, 1993, CELL GROWTH DIFFER, V4, P147; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; YANG JM, 1995, BIOCHEM BIOPH RES CO, V210, P21, DOI 10.1006/bbrc.1995.1622; ZHANG JT, 1995, BIOCHEMISTRY-US, V34, P9159, DOI 10.1021/bi00028a027; ZHU QC, 1994, CANCER RES, V54, P4488	44	111	130	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28562	28569		10.1074/jbc.M100311200	http://dx.doi.org/10.1074/jbc.M100311200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11369762	hybrid			2022-12-25	WOS:000170093400109
J	Yang, J; Duerksen-Hughes, PJ				Yang, J; Duerksen-Hughes, PJ			Activation of a p53-independent, sphingolipid-mediated cytolytic pathway in p53-negative mouse fibroblast cells treated with N-methyl-N-nitro-N-nitrosoguanidine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; CERAMIDE-INDUCED APOPTOSIS; DNA-DAMAGE; PROTEIN-KINASES; SPHINGOMYELIN PATHWAY; SIGNAL-TRANSDUCTION; DEPENDENT PATHWAY; FREE SPHINGOSINE; TERMINAL KINASE; STRESS-RESPONSE	Sphingolipids such as ceramide are important mediators of apoptosis and growth arrest triggered by ligands such as tumor necrosis factor and Fas-L binding to their receptors, When LM (expressing p53) and LME6 (lacking p53) cells were exposed to the genotoxin N-methyl-N-nitro-N-nitrosoguanidine (MNNG), both cell lines underwent cytolysis in a very similar manner, suggesting the presence of a p53-independent apoptotic response to this genotoxic stress. To determine whether sphingolipids such as ceramide might serve as mediators in this system, the responses of these cells to exogenous sphingolipids as well as their changes in endogenous sphingolipid levels after DNA damage were examined. Treatment with exogenous Ca-ceramide and sphingosine led to cell death in both LM and LME6, and treatment of the LME6 cells with MNNG resulted in a transient increase in intracellular ceramide of similar to 50% over a period of 3 h, Finally, treatment with the de novo inhibitor of ceramide synthesis ISP-1 protected LME6 cells from MNNG-triggered cell death. This MNNG-triggered induction of ceramide was not observed in the p53-expressing LM cells, suggesting that it may be down-regulated by p53, Although ceramide-mediated cell death can proceed in the absence of p53, exogenously added C2-ceramide increased the cellular p53 level in LM cells, suggesting that the two pathways do interact.	Loma Linda Univ, Ctr Mol Biol & Gene Therapy, Sch Med, Loma Linda, CA 92354 USA	Loma Linda University	Duerksen-Hughes, PJ (corresponding author), Loma Linda Univ, Ctr Mol Biol & Gene Therapy, Sch Med, 11085 Campus St,105 Mortensen Hall, Loma Linda, CA 92354 USA.	pdhughes@som.llu.edu	Duerksen-Hughes, Penelope/A-3488-2008	Duerksen-Hughes, Penelope/0000-0002-0998-2157				BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; Chiarugi V, 1998, ONCOL RES, V10, P55; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; Coroneos E, 1996, BIOCHEM J, V316, P13, DOI 10.1042/bj3160013; DBAIBO GS, 1995, BIOCHEM J, V310, P453, DOI 10.1042/bj3100453; Dbaibo GS, 1997, BIOCHEM SOC T, V25, P557, DOI 10.1042/bst0250557; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; DBAIBO GS, 1995, P NATL ACAD SCI USA, V92, P1347, DOI 10.1073/pnas.92.5.1347; Dickson RC, 1997, J BIOL CHEM, V272, P30196, DOI 10.1074/jbc.272.48.30196; Duerksen-Hughes PJ, 1999, VIROLOGY, V264, P55, DOI 10.1006/viro.1999.9977; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; FRITSCHE M, 1993, ONCOGENE, V8, P307; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANNUN YA, 1991, METHOD ENZYMOL, V201, P316; Hour TC, 1999, TOXICOL LETT, V110, P191, DOI 10.1016/S0378-4274(99)00158-7; Huang CS, 1997, J BIOL CHEM, V272, P27753, DOI 10.1074/jbc.272.44.27753; Hung WC, 1996, BIOCHEM BIOPH RES CO, V229, P11, DOI 10.1006/bbrc.1996.1750; Jarvis WD, 1997, MOL PHARMACOL, V52, P935, DOI 10.1124/mol.52.6.935; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; Jenkins GM, 1997, J BIOL CHEM, V272, P32566, DOI 10.1074/jbc.272.51.32566; KASTAN MB, 1991, CANCER RES, V51, P6304; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; Kubbutat MHG, 1998, MOL MED TODAY, V4, P250, DOI 10.1016/S1357-4310(98)01260-X; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Mandala SM, 1998, P NATL ACAD SCI USA, V95, P150, DOI 10.1073/pnas.95.1.150; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; Meek DW, 1997, BIOCHEM SOC T, V25, P416, DOI 10.1042/bst0250416; Merrill AH, 1997, TOXICOL APPL PHARM, V142, P208, DOI 10.1006/taap.1996.8029; MERRILL AH, 1988, ANAL BIOCHEM, V171, P373, DOI 10.1016/0003-2697(88)90500-3; Milner J, 1997, PATHOL BIOL, V45, P797; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Nakamura S, 1996, J BIOL CHEM, V271, P1255, DOI 10.1074/jbc.271.3.1255; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; OLIVERA A, 1994, J BIOL CHEM, V269, P17924; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Reunanen N, 1998, J BIOL CHEM, V273, P5137, DOI 10.1074/jbc.273.9.5137; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Skrzypek MS, 1999, J BACTERIOL, V181, P1134, DOI 10.1128/JB.181.4.1134-1140.1999; SMART RC, 1994, CARCINOGENESIS; SMITH ER, 1995, J BIOL CHEM, V270, P18749, DOI 10.1074/jbc.270.32.18749; Spiegel S, 1998, BIOCHEMISTRY-MOSCOW+, V63, P69; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Sweeney EA, 1996, INT J CANCER, V66, P358, DOI 10.1002/(SICI)1097-0215(19960503)66:3<358::AID-IJC16>3.0.CO;2-7; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; Vento R, 1998, MOL CELL BIOCHEM, V185, P7, DOI 10.1023/A:1006836428202; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang XJ, 1997, J RADIAT RES, V38, P179, DOI 10.1269/jrr.38.179; Wells GB, 1998, J BIOL CHEM, V273, P7235, DOI 10.1074/jbc.273.13.7235; Wieder T, 1998, J BIOL CHEM, V273, P11025, DOI 10.1074/jbc.273.18.11025; Wilhelm D, 1997, MOL CELL BIOL, V17, P4792, DOI 10.1128/MCB.17.8.4792; Xia P, 1998, P NATL ACAD SCI USA, V95, P14196, DOI 10.1073/pnas.95.24.14196; Xu J, 1998, J BIOL CHEM, V273, P16521, DOI 10.1074/jbc.273.26.16521; Yang J, 1998, CARCINOGENESIS, V19, P1117, DOI 10.1093/carcin/19.6.1117	61	29	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27129	27135		10.1074/jbc.M100729200	http://dx.doi.org/10.1074/jbc.M100729200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11369765	hybrid			2022-12-25	WOS:000169966900054
J	Zhao, YG; Li, SC; Childs, EE; Kuharsky, DK; Yin, XM				Zhao, YG; Li, SC; Childs, EE; Kuharsky, DK; Yin, XM			Activation of pro-death Bcl-2 family proteins and mitochondria apoptosis pathway in tumor necrosis factor-alpha-induced liver injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; PERMEABILITY TRANSITION PORE; HEPATOCYTE APOPTOSIS; CONFORMATIONAL-CHANGE; INTERACTING PROTEIN; CASPASE ACTIVATION; BAX TRANSLOCATION; FACTOR RECEPTOR; DEFICIENT MICE; ORGAN FAILURE	Tumor-necrosis factor-alpha (TNF alpha)-induced cytotoxicity contributes to the pathogenesis in inflammatory and immune responses. Here, we studied the role of prodeath Bcl-2 family proteins and the mitochondria apoptosis pathway in the development of TNF alpha -induced hepatic injury during endotoxemia, after treating mice with lipopolysaccharide or TNF alpha in the presence of D-galactosamine, Bid was cleaved and translocated to mitochondria in hepatocytes. Independently, Bax was also activated by the death receptor engagement and translocated to mitochondria. However, its subsequent insertion into the mitochondrial membrane depends on Bid. Nevertheless, Bid was required, but fax could be dispensed for the mitochondrial release of cytochrome c from mitochondria, suggesting that Bid could activate additional downstream molecules other than Bax. The lack of this Bid-dependent mitochondria activation and cytochrome c release in the bid-deficient mice was responsible for the significantly delayed effector caspase activation and hepatocyte injury upon endotoxin treatment, culminating in a prolonged survival of the bid-deficient mice. Additional genetic factor(s) could further modify the dependence of TNF alpha toxicity on the mitochondria pathway as the bid-deficient 129/SvJ mice manifested an even higher resistance than the same type of mice in C57BL/6 background. The functional significance of the mitochondria apoptosis pathway was thus elucidated in the TNF alpha -mediated pathogenesis in vivo.	Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Yin, XM (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, 7th Floor,Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	xmyin@pitt.edu			NATIONAL CANCER INSTITUTE [K01CA074885, R01CA083817] Funding Source: NIH RePORTER; NCI NIH HHS [K01 CA74885, R01 CA83817] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ahmad M, 1997, CANCER RES, V57, P615; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BEYAERT R, 1994, FEBS LETT, V340, P9, DOI 10.1016/0014-5793(94)80163-0; Bradham CA, 1998, MOL CELL BIOL, V18, P6353, DOI 10.1128/MCB.18.11.6353; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; CARLSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; FREUDENBERG MA, 1986, INFECT IMMUN, V51, P891, DOI 10.1128/IAI.51.3.891-895.1986; Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335; Goossens V, 1999, BIOFACTORS, V10, P145, DOI 10.1002/biof.5520100210; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Heibein JA, 2000, J EXP MED, V192, P1391, DOI 10.1084/jem.192.10.1391; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Jaeschke H, 1998, J IMMUNOL, V160, P3480; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Khaled AR, 1999, P NATL ACAD SCI USA, V96, P14476, DOI 10.1073/pnas.96.25.14476; Kim TH, 2000, J BIOL CHEM, V275, P39474, DOI 10.1074/jbc.M003370200; Kim YM, 2000, HEPATOLOGY, V32, P770, DOI 10.1053/jhep.2000.18291; Kluck RM, 1999, J CELL BIOL, V147, P809, DOI 10.1083/jcb.147.4.809; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kunstle G, 1999, HEPATOLOGY, V30, P1241, DOI 10.1002/hep.510300517; Kunstle G, 1997, IMMUNOL LETT, V55, P5, DOI 10.1016/S0165-2478(96)02642-9; LARRICK JW, 1990, FASEB J, V4, P3215, DOI 10.1096/fasebj.4.14.2172061; LEIST M, 1994, J IMMUNOL, V153, P1778; LEIST M, 1995, AM J PATHOL, V146, P1220; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MICHIE HR, 1988, NEW ENGL J MED, V318, P1481, DOI 10.1056/NEJM198806093182301; Moore FA, 1996, J TRAUMA, V40, P501, DOI 10.1097/00005373-199604000-00001; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; OLD LJ, 1985, SCIENCE, V230, P630, DOI 10.1126/science.2413547; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; Rouquet N, 1996, CURR BIOL, V6, P1192, DOI 10.1016/S0960-9822(02)70688-X; Ruffolo SC, 2000, CELL DEATH DIFFER, V7, P1101, DOI 10.1038/sj.cdd.4400739; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Schendel SL, 1999, J BIOL CHEM, V274, P21932, DOI 10.1074/jbc.274.31.21932; SCHIRMER WJ, 1989, ARCH SURG-CHICAGO, V124, P445; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; Streetz K, 2000, GASTROENTEROLOGY, V119, P446, DOI 10.1053/gast.2000.9364; Tafani M, 2000, AM J PATHOL, V156, P2111, DOI 10.1016/S0002-9440(10)65082-1; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; TIEGS G, 1989, BIOCHEM PHARMACOL, V38, P627, DOI 10.1016/0006-2952(89)90208-6; TRACEY KJ, 1993, CRIT CARE MED, V21, pS415; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wei MC, 2000, GENE DEV, V14, P2060; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730	62	108	111	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27432	27440		10.1074/jbc.M102465200	http://dx.doi.org/10.1074/jbc.M102465200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11369777	hybrid			2022-12-25	WOS:000169966900093
J	Aprelikova, O; Pace, AJ; Fang, B; Koller, BH; Liu, ET				Aprelikova, O; Pace, AJ; Fang, B; Koller, BH; Liu, ET			BRCA1 is a selective co-activator of 14-3-3 sigma gene transcription in mouse embryonic stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETRACTED ARTICLE. SEE; DNA-DAMAGE RESPONSE; EXPRESSION; PHOSPHORYLATION; ASSOCIATION; FREQUENCY; PROTEIN; REPAIR; CYCLE; LEADS	BRCA1 gene is a tumor suppressor for breast and ovarian cancers with the putative role in DNA repair and transcription. To characterize the role of BRCA1 in transcriptional regulation, we analyzed gene expression profiles of mouse embryonic stem cells deficient in BRCA1 using microarray technology. We found that loss of BRCA1 correlated with decreased expression of several groups of genes including stress response genes, cytoskeleton genes, and genes involved in protein synthesis and degradation. Previous study showed that BRCA1 is a transcriptional co-activator of p53 protein; however the majority of p53 target genes remained at the same expression levels in BRCA1 knockout cells as in the wild type cells, The only p53 target gene downregulated with the loss of BRCA1 was 14-3-3 sigma, a major G(2)/M checkpoint control gene. Similar to cells with decreased 14-3-3 sigma activity, BRCA1-deficient cells were unable to sustain G(2)/M growth arrest after exposure to ionizing radiation. We find that BRCA1 induction of 14-3-3 sigma requires the presence of wild type p53 and can be regulated by a minimal p53 response element.	NCI, Div Clin Sci, Sect Mol Signaling & Oncogenesis, NIH, Bethesda, MD 20892 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Liu, ET (corresponding author), ATC Bldg,Rm 121,8717 Grovemont Cr, Gaithersburg, MD 20878 USA.	apreliko@mail.nih.gov	Liu, Edison/C-4141-2008		NATIONAL CANCER INSTITUTE [R01CA082423] Funding Source: NIH RePORTER; NCI NIH HHS [CA82423] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Cho RJ, 2001, NAT GENET, V27, P48, DOI 10.1038/83751; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Cressman VL, 1999, MOL CELL BIOL, V19, P7061; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Liu QH, 2000, GENE DEV, V14, P1448; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Norton JD, 1998, MOL CELL BIOL, V18, P2371, DOI 10.1128/MCB.18.4.2371; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Relaix F, 2000, P NATL ACAD SCI USA, V97, P2105, DOI 10.1073/pnas.040378897; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Snouwaert JN, 1999, ONCOGENE, V18, P7900, DOI 10.1038/sj.onc.1203334; Somasundaram K, 1999, ONCOGENE, V18, P6605, DOI 10.1038/sj.onc.1203284; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhao RB, 2000, GENE DEV, V14, P981; Zheng L, 2000, MOL CELL, V6, P757, DOI 10.1016/S1097-2765(00)00075-7; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	30	88	91	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25647	25650		10.1074/jbc.C100265200	http://dx.doi.org/10.1074/jbc.C100265200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11384963	hybrid			2022-12-25	WOS:000169823300003
J	Nirodi, C; Hart, J; Dhawan, P; Moon, NS; Nepveu, A; Richmond, A				Nirodi, C; Hart, J; Dhawan, P; Moon, NS; Nepveu, A; Richmond, A			The role of CDP in the negative regulation of CXCL1 gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCAAT DISPLACEMENT PROTEIN; CUT HOMEODOMAIN PROTEIN; HS294T MELANOMA-CELLS; DNA-BINDING DOMAINS; NF-KAPPA-B; ALPHA GENE; MGSA GRO; PROMOTER; TRANSCRIPTION; DROSOPHILA	The CXC chemokine, melanoma growth stimulatory activity/growth-regulated protein, CXCL1 is an important modulator of inflammation, wound healing, angiogenesis, and tumorigenesis, Transcription of CXCL1 is regulated through several cia-acting elements including Spl, NF-kappaB, and an element that lies immediately upstream of the NF-kappaB element, the immediate upstream region (IUR), A transcription element data base search indicated that the IUR element contains a binding site for the transcriptional repressor, human CUT homeodomain protein/CCAAT displacement protein (CDP), It is shown here that in electrophoretic mobility shift assays, complexes obtained with the IUR oligonucleotide probe are supershifted by anti-CDP antibodies and that a CDP polypeptide containing a high affinity DNA binding domain binds to the sequence GGGATCGATC in the IUR element. In Southwestern blot analyses, oligonucleotides containing the wild-type IUR sequence, but not a mutant oligonucleotide with substitutions in the GGGATCGATC sequence, bind a 170-180-kDa protein. Furthermore, overexpression of the CDP protein blocks CXCL1 promoter activity in reporter gene assays, whereas overexpression of an antisense CDP construct leads to a significant increase in CXCL1 promoter activity. Mutations in the IUR element, which map in the putative CUP-binding site, inhibit the binding of CDP to the IUR element and favor increased transcription from the CXCL1 promoter. Based on these results, we propose that transcriptional regulation of the CXCL1 gene is mediated in part by CDP, which could play an important role in inflammatory processes and tumorigenesis.	Dept Vet Affairs, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA; McGill Univ, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada	Vanderbilt University; McGill University	Richmond, A (corresponding author), Dept Vet Affairs, Nashville, TN 37212 USA.		Richmond, Ann/A-3048-2014; /AAB-8315-2020	Moon, Nam-Sung/0000-0002-0455-927X; RICHMOND, ANN/0000-0002-9580-900X	NCI NIH HHS [P30 CA068485, CA 68485, R01 CA056704-08, CA 56704, R01 CA056704-09, R01 CA056704-07] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056704, P30CA068485] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDRES V, 1994, GENE DEV, V8, P245, DOI 10.1101/gad.8.2.245; AUFIERO B, 1994, P NATL ACAD SCI USA, V91, P7757, DOI 10.1073/pnas.91.16.7757; BALENTIEN E, 1991, ONCOGENE, V6, P1115; BLOCHLINGER K, 1988, NATURE, V333, P629, DOI 10.1038/333629a0; Coqueret O, 1996, J BIOL CHEM, V271, P24862, DOI 10.1074/jbc.271.40.24862; Coqueret O, 1998, EMBO J, V17, P4680, DOI 10.1093/emboj/17.16.4680; Devalaraja MN, 1999, CANCER RES, V59, P1372; ENGELAND K, 1995, J BIOL CHEM, V270, P24572, DOI 10.1074/jbc.270.41.24572; FONG CLW, 1994, NUCLEIC ACIDS RES, V22, P1108, DOI 10.1093/nar/22.6.1108; HARADA R, 1995, MOL CELL BIOL, V15, P129, DOI 10.1128/MCB.15.1.129; HARADA R, 1994, J BIOL CHEM, V269, P2062; HOSAKA S, 1994, CLIN EXP IMMUNOL, V97, P451; JAFFE GJ, 1993, INVEST OPHTH VIS SCI, V34, P2776; Johnston LA, 1998, GENETICS, V149, P131; Kim EC, 1997, CELL GROWTH DIFFER, V8, P1329; Li S, 1999, J BIOL CHEM, V274, P7803, DOI 10.1074/jbc.274.12.7803; Li SD, 2000, P NATL ACAD SCI USA, V97, P7166, DOI 10.1073/pnas.130028697; Lievens PMJ, 1997, GENE, V197, P73; LIWEBER M, 1994, J IMMUNOL, V153, P4122; LIWEBER M, 1993, J IMMUNOL, V151, P1371; Lopez S, 1997, J BIOL CHEM, V272, P22788, DOI 10.1074/jbc.272.36.22788; Luan J, 1997, J LEUKOCYTE BIOL, V62, P588, DOI 10.1002/jlb.62.5.588; Ludlow C, 1996, DEV BIOL, V178, P149, DOI 10.1006/dbio.1996.0205; Luo W, 1996, J BIOL CHEM, V271, P18203, DOI 10.1074/jbc.271.30.18203; Mailly F, 1996, MOL CELL BIOL, V16, P5346; MILLER H, 1989, MOL CELL BIOL, V9, P5340, DOI 10.1128/MCB.9.12.5340; Moon NS, 2000, J BIOL CHEM, V275, P31325, DOI 10.1074/jbc.M002912200; Murphy PM, 2000, PHARMACOL REV, V52, P145; NEUFELD EJ, 1992, NAT GENET, V1, P50, DOI 10.1038/ng0492-50; Nirodi C, 2001, J BIOL CHEM, V276, P9366, DOI 10.1074/jbc.M009897200; Nourbakhsh M, 2001, J BIOL CHEM, V276, P4501, DOI 10.1074/jbc.M007532200; Rennekampff HO, 2000, J SURG RES, V93, P41, DOI 10.1006/jsre.2000.5892; ROMANOSPICA V, 1995, J IMMUNOL, V154, P2724; Schug J., 1997, CBILTR19971001V00 U; SHATTUCK RL, 1994, MOL CELL BIOL, V14, P791, DOI 10.1128/MCB.14.1.791; ShattuckBrandt RL, 1997, CANCER RES, V57, P3032; THANOS D, 1993, NUCLEIC ACIDS RES, V21, P6010, DOI 10.1093/nar/21.25.6010; van Gurp MF, 1999, CANCER RES, V59, P5980; Vanden Berghe W, 1999, J BIOL CHEM, V274, P32091, DOI 10.1074/jbc.274.45.32091; vanWijnen AJ, 1997, J CELL BIOCHEM, V66, P512, DOI 10.1002/(SICI)1097-4644(19970915)66:4<512::AID-JCB10>3.0.CO;2-D; Wang ZY, 1999, MOL CELL BIOL, V19, P284; Webster MA, 1998, ONCOGENE, V16, P1963, DOI 10.1038/sj.onc.1201707; Wood LD, 1995, J BIOL CHEM, V270, P30619, DOI 10.1074/jbc.270.51.30619; WOOD LD, 1995, NUCLEIC ACIDS RES, V23, P4210, DOI 10.1093/nar/23.20.4210	44	31	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26122	26131		10.1074/jbc.M102872200	http://dx.doi.org/10.1074/jbc.M102872200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11371564	Green Accepted, hybrid			2022-12-25	WOS:000169823300066
J	Dominguez-Jimenez, C; Yanez-Mo, M; Carreira, A; Tejedor, R; Gonzalez-Amaro, R; Alvarez, V; Sanchez-Madrid, F				Dominguez-Jimenez, C; Yanez-Mo, M; Carreira, A; Tejedor, R; Gonzalez-Amaro, R; Alvarez, V; Sanchez-Madrid, F			Involvement of alpha 3 integrin/tetraspanins complexes in the angiogenic response induced by angiotensin II	FASEB JOURNAL			English	Article						endothelium; lateral junctions; angiogenesis; adhesion molecules; vasoactive peptide	ENDOTHELIAL GROWTH-FACTOR; JUNCTIONAL ADHESION MOLECULE; CELL-ADHESION; STIMULATES ANGIOGENESIS; CLINICAL-APPLICATIONS; INTEGRIN RECEPTOR; BETA-1 INTEGRIN; TNF-ALPHA; IFN-GAMMA; IN-VIVO	The effect of angiotensin II (Ang II) on endothelial cell (EC) function has important potential implications, both under physiological conditions and in the pathogenesis of different cardiovascular diseases. We studied the effect of Ang II on EC junctions and its possible functional consequences. We found that Ang II induced a remarkable change on human umbilical vein endothelial cells (HUVEC) in the distribution of alpha3beta1 integrin and CD151, CD9 tetraspanins on cell membrane, with an important decrease of these molecular complexes at intercellular contacts. However, the morphology of EC, the integrins located at cell-substratum contact areas, the components of adherens and tight-junctions, as well as the barrier functions of EC monolayers, remained unchanged after Ang II exposure. The Ang II effect on alpha3beta 1/tetraspanins complexes was associated with a significant induction of angiotube formation by HUVEC in an in vitro model of capillary formation on Matrigel. The effect of Ang II was mediated through the angiotensin II receptor 1 AT1 receptor and was inhibited with antibodies specific for the alpha3 integrin chain, which indicates the critical role of this integrin in the angiogenic effect of Ang II. These results show that Ang II exerts a direct and very specific effect on EC lateral junctions that is selectively associated with the induction of angiogenesis by this peptide.	Univ Autonoma Madrid, Hosp Univ Princesa, Serv Inmunol, Madrid 28006, Spain; Univ Autonoma Madrid, Hosp Univ Princesa, Serv Nefrol, Madrid 28006, Spain	Autonomous University of Madrid; Hospital de La Princesa; Autonomous University of Madrid; Hospital de La Princesa	Sanchez-Madrid, F (corresponding author), Univ Autonoma Madrid, Hosp Univ Princesa, Serv Inmunol, C Diego de Leon S-N 62, Madrid 28006, Spain.	fsanchez@hlpr.insalud.es	Yáñez-Mó, María/K-8577-2014; Gonzalez-Amaro, Roberto/AAZ-1504-2020; Sanchez-Madrid, Francisco/M-7889-2016; YÃÃez-MÃ, Maria/AAI-4544-2020	Yáñez-Mó, María/0000-0001-7484-2866; Sanchez-Madrid, Francisco/0000-0001-5303-0762; YÃÃez-MÃ, Maria/0000-0001-7484-2866				ARIZA A, 1988, AM J CLIN PATHOL, V90, P437, DOI 10.1093/ajcp/90.4.437; Bader BL, 1998, CELL, V95, P507, DOI 10.1016/S0092-8674(00)81618-9; Bazzoni G, 1999, CURR OPIN CELL BIOL, V11, P573, DOI 10.1016/S0955-0674(99)00023-X; Bazzoni G, 1999, TRENDS CARDIOVAS MED, V9, P147, DOI 10.1016/S1050-1738(99)00022-5; BELL L, 1990, AM J PATHOL, V137, P7; BERDICHEVSKY F, 1994, J CELL SCI, V107, P3557; Berditchevski F, 1999, J CELL BIOL, V146, P477, DOI 10.1083/jcb.146.2.477; Bischoff J, 1997, J CLIN INVEST, V99, P373, DOI 10.1172/JCI119168; Bujan J, 1999, J VASC RES, V36, P106, DOI 10.1159/000025632; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Chua CC, 1998, BBA-MOL CELL RES, V1401, P187, DOI 10.1016/S0167-4889(97)00129-8; DEDHAR S, 1992, J BIOL CHEM, V267, P18908; Dimmeler S, 1997, CIRC RES, V81, P970; Fabre JE, 1999, CIRCULATION, V99, P3043, DOI 10.1161/01.CIR.99.23.3043; FERNANDEZ LA, 1985, J LAB CLIN MED, V105, P141; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; Hodivala-Dilke KM, 1998, J CELL BIOL, V142, P1357, DOI 10.1083/jcb.142.5.1357; JAFFE EA, 1972, CIRCULATION, V46, P211; Kim S, 2000, PHARMACOL REV, V52, P11; Kim S, 2000, AM J PATHOL, V156, P1345, DOI 10.1016/S0002-9440(10)65005-5; Kreidberg JA, 1996, DEVELOPMENT, V122, P3537; Lampugnani MG, 1997, CURR OPIN CELL BIOL, V9, P674, DOI 10.1016/S0955-0674(97)80121-4; leNoble FAC, 1996, J VASC RES, V33, P480, DOI 10.1159/000159187; LENOBLE FAC, 1991, EUR J PHARMACOL, V195, P305, DOI 10.1016/0014-2999(91)90552-2; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; Munzenmaier DH, 1996, HYPERTENSION, V27, P760, DOI 10.1161/01.HYP.27.3.760; Newman PJ, 1997, J CLIN INVEST, V99, P3, DOI 10.1172/JCI119129; Noria S, 1999, CIRC RES, V85, P504, DOI 10.1161/01.RES.85.6.504; Otani A, 1998, CIRC RES, V82, P619, DOI 10.1161/01.RES.82.5.619; Ozaki H, 1999, J IMMUNOL, V163, P553; Penas PF, 2000, J INVEST DERMATOL, V114, P1126, DOI 10.1046/j.1523-1747.2000.00998.x; Pratt RE, 1999, J AM SOC NEPHROL, V10, pS120; Rabiet MJP, 1996, ARTERIOSCL THROM VAS, V16, P488, DOI 10.1161/01.ATV.16.3.488; Rival Y, 1996, J IMMUNOL, V157, P1233; ROMEO G, 1995, EUR J HUM GENET, V3, P1; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Senger DR, 1997, P NATL ACAD SCI USA, V94, P13612, DOI 10.1073/pnas.94.25.13612; Serru V, 1999, BIOCHEM J, V340, P103, DOI 10.1042/0264-6021:3400103; Sincock PM, 1999, J CELL SCI, V112, P833; Stevenson BR, 1998, ANNU REV CELL DEV BI, V14, P89, DOI 10.1146/annurev.cellbio.14.1.89; STOLL M, 1995, J CLIN INVEST, V95, P651, DOI 10.1172/JCI117710; Stoll M, 1995, J HYPERTENS, V13, P1529; Stromblad S, 1996, TRENDS CELL BIOL, V6, P462, DOI 10.1016/0962-8924(96)84942-7; Sugiura T, 1999, J CELL BIOL, V146, P1375, DOI 10.1083/jcb.146.6.1375; TAKADA Y, 1991, J CELL BIOL, V115, P257, DOI 10.1083/jcb.115.1.257; van Rijen HVM, 1998, CYTOKINE, V10, P258, DOI 10.1006/cyto.1997.0287; Volpert OV, 1996, J CLIN INVEST, V98, P671, DOI 10.1172/JCI118838; Williams B, 1998, LANCET, V351, P837, DOI 10.1016/S0140-6736(05)78974-1; Yanez-Mo M, 1998, J CELL BIOL, V141, P791, DOI 10.1083/jcb.141.3.791; Yauch RL, 1998, MOL BIOL CELL, V9, P2751, DOI 10.1091/mbc.9.10.2751	54	15	16	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 27	2001	15	6					1457	+		10.1096/fj.00-0651fje	http://dx.doi.org/10.1096/fj.00-0651fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387256				2022-12-25	WOS:000173705800014
J	Tran, MH; Yamada, K; Olariu, A; Mizuno, M; Ren, XH; Nabeshima, T				Tran, MH; Yamada, K; Olariu, A; Mizuno, M; Ren, XH; Nabeshima, T			Amyloid beta-peptide induces nitric oxide production in rat hippocampus: association with cholinergic dysfunction and amelioration by inducible nitric oxide synthase inhibitors	FASEB JOURNAL			English	Article						amyloid beta-peptide; nitric oxide synthase; Alzheimer's disease; acetylcholine; learning and memory	NECROSIS-FACTOR-ALPHA; ALZHEIMERS-DISEASE; INTERFERON-GAMMA; IN-VIVO; MICROGLIAL CELLS; MEMORY FORMATION; BRAIN; PROTEIN; INDUCTION; PEROXYNITRITE	Amyloid beta-peptide (Abeta) plays a critical role in the development of Alzheimer's disease. However, the molecular mechanisms of Abeta-induced brain damage in vivo remain to be elucidated. Here, we investigated whether overproduction of nitric oxide (NO) catalyzed by inducible NO synthase (iNOS) is involved in Abeta-induced brain dysfunction. Chronic intracerebroventricular infusion of Abeta1-40 induced iNOS mRNA expression in the hippocampus on days 3 and 5 after the infusion. An accumulation of NO metabolites was observed, and the peak correlated with expression of iNOS mRNA. Measurement of NOS activities revealed an increase in Ca2+-independent, but not Ca2+-dependent, activity. Immunohistochemistry identified numerous iNOS-immunoreactive microglia and astrocytes in the dentate gyrus and to a lesser extent in the CA1 subfield of the hippocampus. Daily treatment with the iNOS inhibitor aminoguanidine (AG, 100 mg/kg/day, i.p.) or S-methylisothiourea (10 mg/kg/day, i.p.) during Abeta infusion prevented an impairment of nicotine-evoked acetylcholine release induced by Abeta, whereas the neuronal NOS inhibitor 7-nitroindazole (30 mg/kg/day, i.p.) had no effect. Daily treatment with AG also ameliorated the impairment of spatial learning of Abeta-infused rats in a radial arm maze. Our findings suggest that overproduction of NO catalyzed by iNOS is responsible for Abeta-induced brain dysfunction.	Nagoya Univ, Grad Sch Med, Dept Neuropsychopharmacol & Hosp Pharm, Nagoya, Aichi 4668560, Japan	Nagoya University	Nabeshima, T (corresponding author), Nagoya Univ, Grad Sch Med, Dept Neuropsychopharmacol & Hosp Pharm, Nagoya, Aichi 4668560, Japan.	tnabeshi@med.nagoya-u.ac.jp	Yamada, Kiyofumi/I-7487-2014; Sokabe, Masahiro/I-1565-2012	Yamada, Kiyofumi/0000-0002-5280-5180; 				ADACHI H, 1993, EUR J BIOCHEM, V217, P37, DOI 10.1111/j.1432-1033.1993.tb18215.x; Akama KT, 2000, J BIOL CHEM, V275, P7918, DOI 10.1074/jbc.275.11.7918; Akama KT, 1998, P NATL ACAD SCI USA, V95, P5795, DOI 10.1073/pnas.95.10.5795; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BECKMAN JS, 1994, ANN NY ACAD SCI, V738, P69; BOHME GA, 1993, P NATL ACAD SCI USA, V90, P9191, DOI 10.1073/pnas.90.19.9191; Braak H, 1991, BRAIN PATHOL, V1, P213, DOI 10.1111/j.1750-3639.1991.tb00661.x; COYLE JT, 1983, SCIENCE, V219, P1184, DOI 10.1126/science.6338589; DAWSON TM, 1994, ANN NY ACAD SCI, V738, P76; Dawson VL, 1998, PROG BRAIN RES, V118, P215; Di Stasi AMM, 1999, J NEUROCHEM, V73, P727; Galimberti D, 1999, BIOCHEM BIOPH RES CO, V263, P251, DOI 10.1006/bbrc.1999.1276; GLENNER GG, 1988, CELL, V52, P307, DOI 10.1016/S0092-8674(88)80021-7; GRIFFITHS MJD, 1993, BRIT J PHARMACOL, V110, P963, DOI 10.1111/j.1476-5381.1993.tb13907.x; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Han D, 2000, J NEUROCHEM, V74, P792, DOI 10.1046/j.1471-4159.2000.740792.x; HASEGAWA M, 1993, NEUROSCI LETT, V150, P53, DOI 10.1016/0304-3940(93)90106-U; HEWETT SJ, 1994, NEURON, V13, P487, DOI 10.1016/0896-6273(94)90362-X; IADECOLA C, 1995, AM J PHYSIOL-REG I, V268, pR286, DOI 10.1152/ajpregu.1995.268.1.R286; Itoh A, 1996, J NEUROCHEM, V66, P1113; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kendrick KM, 1997, NATURE, V388, P670, DOI 10.1038/41765; Kitamura Y, 1996, GLIA, V18, P233, DOI 10.1002/(SICI)1098-1136(199611)18:3<233::AID-GLIA7>3.0.CO;2-#; Lee SC, 1999, J NEUROPATH EXP NEUR, V58, P1163, DOI 10.1097/00005072-199911000-00006; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mackenzie GM, 1997, SYNAPSE, V26, P301, DOI 10.1002/(SICI)1098-2396(199707)26:3<301::AID-SYN11>3.0.CO;2-Y; MACKENZIE GM, 1994, NEUROREPORT, V5, P1993, DOI 10.1097/00001756-199410000-00039; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; McGeer PL, 1995, BRAIN RES REV, V21, P195, DOI 10.1016/0165-0173(95)00011-9; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; MERRILL JE, 1993, J IMMUNOL, V151, P2132; Minghetti L, 1997, GLIA, V19, P152, DOI 10.1002/(SICI)1098-1136(199702)19:2<152::AID-GLIA6>3.0.CO;2-2; Nabeshima T, 1997, ALZHEIMER'S DISEASE: BIOLOGY, DIAGNOSIS AND THERAPEUTICS, P623; NITTA A, 1994, NEUROSCI LETT, V170, P63, DOI 10.1016/0304-3940(94)90239-9; Olariu A., 1999, Society for Neuroscience Abstracts, V25, P2118; PARK SK, 1994, BIOCHEM BIOPH RES CO, V201, P762, DOI 10.1006/bbrc.1994.1766; Park SK, 1996, J NEUROCHEM, V67, P1766; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; Smith MA, 1997, J NEUROSCI, V17, P2653; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; SZABO C, 1994, P NATL ACAD SCI USA, V91, P12472, DOI 10.1073/pnas.91.26.12472; Vodovotz Y, 1996, J EXP MED, V184, P1425, DOI 10.1084/jem.184.4.1425; Weldon DT, 1998, J NEUROSCI, V18, P2161; Yamada K, 1996, NEUROSCIENCE, V74, P365, DOI 10.1016/0306-4522(96)00161-3; Yamada K, 1999, EUR J NEUROSCI, V11, P83, DOI 10.1046/j.1460-9568.1999.00408.x; Yamada K, 1999, NEUROSCIENCE, V88, P281, DOI 10.1016/S0306-4522(98)00237-1; YAMADA K, 1995, BRIT J PHARMACOL, V115, P852, DOI 10.1111/j.1476-5381.1995.tb15011.x; Yamada K, 1997, J NEUROCHEM, V68, P1234; YAMADA K, 2000, IN PRESS PHARM THER; Yates SL, 2000, J NEUROCHEM, V74, P1017, DOI 10.1046/j.1471-4159.2000.0741017.x; Zhang FY, 1996, STROKE, V27, P317, DOI 10.1161/01.STR.27.2.317; Zou LB, 1998, NEUROPHARMACOLOGY, V37, P323, DOI 10.1016/S0028-3908(98)00042-2; Zou LB, 1999, NEUROSCIENCE, V92, P819, DOI 10.1016/S0306-4522(99)00029-9	53	88	91	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 27	2001	15	6					1407	+		10.1096/fj.00-0719fje	http://dx.doi.org/10.1096/fj.00-0719fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387239				2022-12-25	WOS:000173705800029
J	Nix, DA; Fradelizi, J; Bockholt, S; Menichi, B; Louvard, D; Friederich, E; Beckerle, MC				Nix, DA; Fradelizi, J; Bockholt, S; Menichi, B; Louvard, D; Friederich, E; Beckerle, MC			Targeting of zyxin to sites of actin membrane interaction and to the nucleus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASODILATOR-STIMULATED PHOSPHOPROTEIN; CYSTEINE-RICH PROTEIN; LIM DOMAIN; LISTERIA-MONOCYTOGENES; FOCAL ADHESION; ALPHA-ACTININ; GENE-EXPRESSION; ENA/VASP FAMILY; CELL-ADHESION; BETA-CATENIN	The localization of proteins to particular intracellular compartments often regulates their functions. Zyxin is a LIM protein found prominently at sites of cell adhesion, faintly in leading lamellipodia, and transiently in cell nuclei. Here we have performed a domain analysis to identify regions in zyxin that are responsible for targeting it to different subcellular locations. The N-terminal proline-rich region of zyxin, which harbors binding sites for alpha -actinin and members of the Ena/VASP family, concentrates in lamellipodial extensions and weakly in focal adhesions. The LIM region of zyxin displays robust targeting to focal adhesions. When overexpressed in cells, the LIM region of zyxin causes displacement of endogenous zyxin from focal adhesions. Upon mislocalization of full-length zyxin, at least one member of the Ena/VASP family is also displaced, and the organization of the actin cytoskeleton is perturbed. Zyxin also has the capacity to shuttle between the nucleus and focal adhesion sites. When nuclear export is inhibited, zyxin accumulates in cell nuclei. The nuclear accumulation of zyxin occurs asynchronously with approximately half of the cells exhibiting nuclear localization of zyxin within 2.3 h of initiating leptomycin B treatment. Our results provide insight into the functions of different zyxin domains.	Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; Inst Curie, Lab Morphogenesis & Cellular Signaling, CNRS, UMR 144, F-75248 Paris, France	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite	Beckerle, MC (corresponding author), Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050877] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM050877, GM50877] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahern-Djamali SM, 1998, MOL BIOL CELL, V9, P2157, DOI 10.1091/mbc.9.8.2157; Aplin AE, 1998, PHARMACOL REV, V50, P197; Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; ASHAR HR, 1995, CELL, V82, P57; Bear JE, 2000, CELL, V101, P717, DOI 10.1016/S0092-8674(00)80884-3; BECKERLE MC, 1986, J CELL BIOL, V103, P1679, DOI 10.1083/jcb.103.5.1679; Beckerle MC, 1998, CELL, V95, P741, DOI 10.1016/S0092-8674(00)81697-9; BENDORI R, 1989, J CELL BIOL, V108, P2383, DOI 10.1083/jcb.108.6.2383; Brown MC, 1996, J CELL BIOL, V135, P1109, DOI 10.1083/jcb.135.4.1109; CARY LA, 1999, FRONT BIOSCI, V4, P102; CRAWFORD AW, 1991, J BIOL CHEM, V266, P5847; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; Drees B, 2000, J BIOL CHEM, V275, P22503, DOI 10.1074/jbc.M001698200; Drees BE, 1999, J CELL BIOL, V147, P1549, DOI 10.1083/jcb.147.7.1549; Fagotto F, 1998, CURR BIOL, V8, P181, DOI 10.1016/S0960-9822(98)70082-X; Fradelizi J, 1999, BIOTECHNIQUES, V26, P484; Geese M, 2000, J CELL SCI, V113, P1415; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; Golsteyn RM, 1997, J CELL SCI, V110, P1893; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Hirota T, 2000, J CELL BIOL, V149, P1073, DOI 10.1083/jcb.149.5.1073; Huttelmaier S, 1998, CURR BIOL, V8, P479, DOI 10.1016/S0960-9822(98)70199-X; Kang F, 1997, BIOCHEMISTRY-US, V36, P8384, DOI 10.1021/bi970065n; Krause M, 2000, J CELL BIOL, V149, P181, DOI 10.1083/jcb.149.1.181; Laurent V, 1999, J CELL BIOL, V144, P1245, DOI 10.1083/jcb.144.6.1245; LIEBL EC, 1992, ONCOGENE, V7, P2417; Louis HA, 1997, J BIOL CHEM, V272, P27484, DOI 10.1074/jbc.272.43.27484; Macalma T, 1996, J BIOL CHEM, V271, P31470, DOI 10.1074/jbc.271.49.31470; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; MCCLURE DB, 1982, GROWTH CELLS HORMONA, P345; MEIGS JB, 1986, J CELL BIOL, V102, P1430, DOI 10.1083/jcb.102.4.1430; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; Nix DA, 1997, J CELL BIOL, V138, P1139, DOI 10.1083/jcb.138.5.1139; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NUCKOLLS GH, 1990, J CELL BIOL, V110, P1635, DOI 10.1083/jcb.110.5.1635; PAINE PL, 1972, EXP CELL RES, V74, P81, DOI 10.1016/0014-4827(72)90483-1; PEREZALVARADO GC, 1994, NAT STRUCT BIOL, V1, P388, DOI 10.1038/nsb0694-388; Petit MMR, 2000, MOL BIOL CELL, V11, P117, DOI 10.1091/mbc.11.1.117; Petit MMR, 1996, GENOMICS, V36, P118, DOI 10.1006/geno.1996.0432; PETROPOULOS CJ, 1991, J VIROL, V65, P3728, DOI 10.1128/JVI.65.7.3728-3737.1991; Purich DL, 1997, BIOCHEM BIOPH RES CO, V231, P686, DOI 10.1006/bbrc.1997.6158; REINHARD M, 1995, P NATL ACAD SCI USA, V92, P7956, DOI 10.1073/pnas.92.17.7956; Reinhard M, 1999, J BIOL CHEM, V274, P13410, DOI 10.1074/jbc.274.19.13410; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; Simcha I, 1998, J CELL BIOL, V141, P1433, DOI 10.1083/jcb.141.6.1433; Small JV, 1998, BBA-MOL CELL RES, V1404, P271, DOI 10.1016/S0167-4889(98)00080-9; Stronach BE, 1996, J CELL BIOL, V134, P1179, DOI 10.1083/jcb.134.5.1179; Thomas SM, 1999, J CELL SCI, V112, P181; Weekes J, 1996, BIOCHEM J, V314, P827, DOI 10.1042/bj3140827; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Yao X, 1999, BIOCHEMISTRY-US, V38, P5701, DOI 10.1021/bi982036y; Yi JS, 1998, GENOMICS, V49, P314, DOI 10.1006/geno.1998.5248; Zeile WL, 1998, P NATL ACAD SCI USA, V95, P13917, DOI 10.1073/pnas.95.23.13917; Zhao MK, 1999, GENE EXPRESSION, V8, P207	57	117	121	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34759	34767		10.1074/jbc.M102820200	http://dx.doi.org/10.1074/jbc.M102820200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11395501	hybrid			2022-12-25	WOS:000171024600057
J	Feng, Y; Huang, HJ; Liao, J; Cohen, SN				Feng, Y; Huang, HJ; Liao, J; Cohen, SN			Escherichia coli poly(A)-binding proteins that interact with components of degradosomes or impede RNA decay mediated by polynucleotide phosphorylase and RNase E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(A) BINDING-PROTEIN; RPSO MESSENGER-RNA; TRANSLATION INITIATION; ANTISENSE RNAI; DEGRADATION; GENE; CSPA; SEQUENCE; POLYADENYLATION; TRANSCRIPTION	The multifunctional ribonuclease RNase E and the 3 ' -exonuclease polynucleotide phosphorylase (PNPase) are major components of an Escherichia coli ribonucleolytic "machine" that has been termed the RNA degradosome. Previous work has shown that poly(A) additions to the 3 ' ends of RNA substrates affect RNA degradation by both of these enzymes. To better understand the mechanism(s) by which poly(A) tails can modulate ribonuclease action, we used selective binding in 1 M salt to identify E. coli proteins that interact at high affinity with poly(A) tracts. We report here that CspE, a member of a family of RNA-binding "cold shock" proteins, and S1, an essential component of the 30 S ribosomal subunit, are poly(A)-binding proteins that interact functionally and physically, respectively, with degradosome ribonucleases. We show that purified CspE impedes poly(A)mediated 3 ' to 5 ' exonucleolytic decay by PNPase by interfering with its digestion through the poly(A) tail and also inhibits both internal cleavage and poly(A) tail removal by RNase E. The ribosomal protein S1, which is known to interact with sequences at the 5 ' ends of mRNA molecules during the initiation of translation, can bind to both RNase E and PNPase, but in contrast to CspE, did not affect the ribonucleolytic actions of these enzymes. Our findings raise the prospect that E. coli proteins that bind to poly(A) tails may link the functions of degradosomes and ribosomes.	Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Program Canc Biol, Stanford, CA 94305 USA; CLONTECH Labs Inc, Palo Alto, CA 94303 USA	Stanford University; Stanford University	Cohen, SN (corresponding author), Stanford Univ, Med Ctr, Dept Genet, Rm M322, Stanford, CA 94305 USA.	ancohen@stanford.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054158] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 54158] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bae WH, 1999, MOL MICROBIOL, V31, P1429, DOI 10.1046/j.1365-2958.1999.01284.x; BERNSTEIN P, 1989, TRENDS BIOCHEM SCI, V14, P373, DOI 10.1016/0968-0004(89)90011-X; BLOBEL G, 1973, P NATL ACAD SCI USA, V70, P924, DOI 10.1073/pnas.70.3.924; Blum E, 1999, J BIOL CHEM, V274, P4009, DOI 10.1074/jbc.274.7.4009; BONI IV, 1991, NUCLEIC ACIDS RES, V19, P155, DOI 10.1093/nar/19.1.155; BOUVET P, 1992, NATURE, V360, P488, DOI 10.1038/360488a0; Caponigro G, 1996, MICROBIOL REV, V60, P233, DOI 10.1128/MMBR.60.1.233-249.1996; Carpousis AJ, 1999, TRENDS GENET, V15, P24, DOI 10.1016/S0168-9525(98)01627-8; CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; Coburn GA, 1998, J MOL BIOL, V279, P1061, DOI 10.1006/jmbi.1998.1842; Coburn GA, 1999, PROG NUCLEIC ACID RE, V62, P55; Cohen SN, 1997, MOL MICROBIOL, V23, P1099, DOI 10.1111/j.1365-2958.1997.tb02593.x; CORMACK RS, 1993, P NATL ACAD SCI USA, V90, P9006, DOI 10.1073/pnas.90.19.9006; Etchegaray JP, 1996, GENES CELLS, V1, P171, DOI 10.1046/j.1365-2443.1996.d01-231.x; Gallie DR, 1998, GENE, V216, P1, DOI 10.1016/S0378-1119(98)00318-7; Hajnsdorf E, 1999, J MOL BIOL, V286, P1033, DOI 10.1006/jmbi.1999.2547; HAJNSDORF E, 1995, P NATL ACAD SCI USA, V92, P3973, DOI 10.1073/pnas.92.9.3973; HAMES BD., 1981, GEL ELECTROPHORESIS, P1; Hanna MM, 1998, J MOL BIOL, V282, P227, DOI 10.1006/jmbi.1998.2005; Huang HJ, 1998, NATURE, V391, P99, DOI 10.1038/34219; Ingle CA, 1996, P NATL ACAD SCI USA, V93, P12926, DOI 10.1073/pnas.93.23.12926; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; Jiang WN, 1997, J BIOL CHEM, V272, P196; Kalapos MP, 1997, BIOCHIMIE, V79, P493, DOI 10.1016/S0300-9084(97)82741-1; Keller W, 1997, CURR OPIN CELL BIOL, V9, P329, DOI 10.1016/S0955-0674(97)80004-X; LANDSMAN D, 1992, NUCLEIC ACIDS RES, V20, P2861, DOI 10.1093/nar/20.11.2861; LINCHAO S, 1994, J BIOL CHEM, V269, P10797; LINCHAO S, 1991, CELL, V65, P1233, DOI 10.1016/0092-8674(91)90018-T; McDowall KJ, 1996, J MOL BIOL, V255, P349, DOI 10.1006/jmbi.1996.0027; MCMURRY LM, 1987, J BACTERIOL, V169, P1321, DOI 10.1128/jb.169.3.1321-1324.1987; Miczak A, 1996, P NATL ACAD SCI USA, V93, P3865, DOI 10.1073/pnas.93.9.3865; OHARA EB, 1995, P NATL ACAD SCI USA, V92, P1807, DOI 10.1073/pnas.92.6.1807; Phadtare S, 1999, MOL MICROBIOL, V33, P1004, DOI 10.1046/j.1365-2958.1999.01541.x; PY B, 1994, MOL MICROBIOL, V14, P717, DOI 10.1111/j.1365-2958.1994.tb01309.x; Py B, 1996, NATURE, V381, P169, DOI 10.1038/381169a0; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; Sarkar N, 1997, ANNU REV BIOCHEM, V66, P173, DOI 10.1146/annurev.biochem.66.1.173; Steege DA, 2000, RNA, V6, P1079, DOI 10.1017/S1355838200001023; SUBRAMANIAN AR, 1983, PROG NUCLEIC ACID RE, V28, P101, DOI 10.1016/S0079-6603(08)60085-9; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; TOMCSANYI T, 1985, J MOL BIOL, V185, P713, DOI 10.1016/0022-2836(85)90056-7; Vanzo NF, 1998, GENE DEV, V12, P2770, DOI 10.1101/gad.12.17.2770; Wahle E, 1999, FEMS MICROBIOL REV, V23, P277, DOI 10.1016/S0168-6445(99)00008-X; Wang ZR, 1999, MOL CELL BIOL, V19, P4552; Wells SE, 1998, MOL CELL, V2, P135, DOI 10.1016/S1097-2765(00)80122-7; WOLFFE AP, 1992, NEW BIOL, V4, P290; XU FF, 1995, NATURE, V374, P180, DOI 10.1038/374180a0; XU FF, 1993, P NATL ACAD SCI USA, V90, P6756, DOI 10.1073/pnas.90.14.6756; YAMANAKA K, 1994, MOL MICROBIOL, V13, P301, DOI 10.1111/j.1365-2958.1994.tb00424.x	50	73	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31651	31656		10.1074/jbc.M102855200	http://dx.doi.org/10.1074/jbc.M102855200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11390393	hybrid			2022-12-25	WOS:000170613500026
J	Maeshima, Y; Yerramalla, UL; Dhanabal, M; Holthaus, KA; Barbashov, S; Kharbanda, S; Reimer, C; Manfredi, M; Dickerson, WM; Kalluri, R				Maeshima, Y; Yerramalla, UL; Dhanabal, M; Holthaus, KA; Barbashov, S; Kharbanda, S; Reimer, C; Manfredi, M; Dickerson, WM; Kalluri, R			Extracellular matrix-derived peptide binds to alpha(v)beta(3) integrin and inhibits angiogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISTINCT ANTITUMOR PROPERTIES; BASEMENT-MEMBRANE COLLAGEN; IV COLLAGEN; ALPHA-3(IV) CHAIN; TUMOR-GROWTH; NONCOLLAGENOUS DOMAINS; MELANOMA-CELLS; IN-VITRO; APOPTOSIS; AUTOANTIBODIES	Angiogenesis is associated with several pathological disorders as well as with normal physiological maintenance. Components of vascular basement membrane are speculated to regulate angiogenesis in both positive and negative manner. Recently, we reported that tumstatin (the NC1 domain of alpha3 chain of type IV collagen) and its deletion mutant tum-5 possess anti-angiogenic activity. In the present study, we confirm that the anti-angiogenic activity of tumstatin and tum-5 is independent of disulfide bond requirement. This property of tum-5 allowed us to use overlapping synthetic peptide strategy to identify peptide sequence(s) which possess anti-angiogenic activity. Among these peptides, only the T3 peptide (69-88 amino acids) and T7 peptide (74-98 amino acids) inhibited proliferation and induced apoptosis specifically in endo. thelial cells. The peptides, similar to tumstatin and the tum-5 domain, bind and function via alpha (v)beta (3) in an RGD-independent manner. Restoration of a disulfide bond be. tween two cysteines within the peptide did not alter the anti-angiogenic activity. Additionally, these studies show that tumstatin peptides can inhibit proliferation of endothelial cells in the presence of vitronectin, fibronectin, and collagen I. Anti-angiogenic effect of the peptides was further confirmed in vivo using a Matrigel plug assay in C57BL/6 mice. Collectively, these experiments suggest that the anti-angiogenic activity of tumstatin is localized to a 25-amino acid region of tumstatin and it is independent of disulfide bond linkage. Structural features and potency of the tumstatin peptide make it highly feasible as a potential anti-cancer drug.	Beth Israel Deaconess Med Ctr, Dept Med, Program Matrix Biol, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Ctr Canc, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; ILEX Oncol Inc, Prod Res & Dev Div, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Kalluri, R (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Program Matrix Biol, RW 514,330 Brookline Ave, Boston, MA 02215 USA.		Peng, Chunwei/F-6788-2010; Kalluri, Raghu/E-2677-2015	Kalluri, Raghu/0000-0002-2190-547X	NIDDK NIH HHS [DK-55001, DK-51711] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051711] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; CHERESH DA, 1987, J BIOL CHEM, V262, P1434; Colorado PC, 2000, CANCER RES, V60, P2520; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P622; Dhanabal M, 1999, BIOCHEM BIOPH RES CO, V258, P345, DOI 10.1006/bbrc.1999.0595; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FOLKMAN J, 1972, ANN SURG, V175, P409, DOI 10.1097/00000658-197203000-00014; Han J, 1997, J BIOL CHEM, V272, P20395, DOI 10.1074/jbc.272.33.20395; HERLYN D, 1990, CANCER RES, V50, P2296; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; KALLURI R, 1991, J BIOL CHEM, V266, P24018; Kalluri R, 1996, J BIOL CHEM, V271, P9062, DOI 10.1074/jbc.271.15.9062; Kalluri R, 2000, CURR OPIN NEPHROL HY, V9, P413, DOI 10.1097/00041552-200007000-00013; Kamphaus GD, 2000, J BIOL CHEM, V275, P1209, DOI 10.1074/jbc.275.2.1209; Madri JA, 1997, TRANSPL IMMUNOL, V5, P179, DOI 10.1016/S0966-3274(97)80035-4; Maeshima Y, 2000, J BIOL CHEM, V275, P23745, DOI 10.1074/jbc.C000186200; Maeshima Y, 2000, J BIOL CHEM, V275, P21340, DOI 10.1074/jbc.M001956200; Maeshima Y, 1998, J CLIN INVEST, V101, P2589, DOI 10.1172/JCI429; Maeshima Y, 2001, J BIOL CHEM, V276, P15240, DOI 10.1074/jbc.M007764200; NEILSON EG, 1993, J BIOL CHEM, V268, P8402; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Pasco S, 2000, J BIOL CHEM, V275, P32999, DOI 10.1074/jbc.M005235200; PAULSSON M, 1992, CRIT REV BIOCHEM MOL, V27, P93; Petitclerc E, 2000, J BIOL CHEM, V275, P8051, DOI 10.1074/jbc.275.11.8051; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Senger DR, 1997, P NATL ACAD SCI USA, V94, P13612, DOI 10.1073/pnas.94.25.13612; Shahan TA, 1999, CANCER RES, V59, P4584; Timpl R, 1996, CURR OPIN CELL BIOL, V8, P618, DOI 10.1016/S0955-0674(96)80102-5; TIMPL R, 1981, EUR J BIOCHEM, V120, P203, DOI 10.1111/j.1432-1033.1981.tb05690.x; TSILIBARY EC, 1990, J CELL BIOL, V111, P1583, DOI 10.1083/jcb.111.4.1583; van Engeland M, 1998, CYTOMETRY, V31, P1, DOI 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R	36	178	213	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31959	31968		10.1074/jbc.M103024200	http://dx.doi.org/10.1074/jbc.M103024200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11399763	hybrid			2022-12-25	WOS:000170613500068
J	Lavigne, M; Polomack, L; Buc, H				Lavigne, M; Polomack, L; Buc, H			Structures of complexes formed by HIV-1 reverse transcriptase at a termination site of DNA synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; STRAND TRANSFER-REACTIONS; RNASE-H; DRUG-RESISTANCE; NUCLEOCAPSID PROTEIN; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURES; POLYPURINE TRACT; KINETIC-ANALYSIS; RIBONUCLEASE-H	This study presents structural parameters associated with termination of human immunodeficiency virus, type 1 (HIV-1) reverse transcriptase (RT) at Ter2, the major termination site located in the center of the HIV-1 genome. DNA footprinting studies of various elongation complexes formed by RT around wild type and mutant Ter2 sites have revealed two major structural transformations of these complexes when the enzyme gets closer to Ter2. First, the interactions between RT and the DNA duplex are less extended, although the global affinity of the enzyme for this duplex is only decreased by 2-fold. Second, there is an atypical positioning of the RT RNase H domain on the DNA duplex. We interpret our data as indicating that the A(n)T(m) motif located upstream of Ter2 prevents a classical positioning of the enzyme on the double-stranded part of the DNA duplex at some precise positions of elongation downstream of this motif. Instead, novel species of binary and/or ternary complexes, characterized by atypical footprints, are formed. The new rate-limiting step of the reaction, characterized in the preceding paper (Lavigne, M., Polomack, L., and Buc, H. (2001) J. BioL Chem. 276,31429-31438), would be a transition leading from these new species to a catalytically competent ternary complex.	Inst Pasteur, Unite Physicochim Macromol Biol, CNRS, URA 1773, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Lavigne, M (corresponding author), Massachusetts Gen Hosp, Dept Mol Biol, Wellman 10,Fruit St, Boston, MA 02114 USA.			LAVIGNE, Marc/0000-0002-3131-2539				Bahar I, 1999, J MOL BIOL, V285, P1023, DOI 10.1006/jmbi.1998.2371; Bebenek K, 1997, NAT STRUCT BIOL, V4, P194, DOI 10.1038/nsb0397-194; Brautigam CA, 1998, CURR OPIN STRUC BIOL, V8, P54, DOI 10.1016/S0959-440X(98)80010-9; Canard B, 1997, P NATL ACAD SCI USA, V94, P11279, DOI 10.1073/pnas.94.21.11279; CHARNEAU P, 1994, J MOL BIOL, V241, P651, DOI 10.1006/jmbi.1994.1542; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DeStefano J, 1998, J BIOL CHEM, V273, P1483, DOI 10.1074/jbc.273.3.1483; Diaz L, 2000, ARCH VIROL, V145, P1117, DOI 10.1007/s007050070113; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Doublie S, 1999, STRUCTURE, V7, pR31, DOI 10.1016/S0969-2126(99)80017-3; Gabbara S, 1999, BIOCHEMISTRY-US, V38, P13070, DOI 10.1021/bi991085n; Gao HQ, 1998, J MOL BIOL, V277, P559, DOI 10.1006/jmbi.1998.1624; Gao HQ, 2000, J MOL BIOL, V300, P403, DOI 10.1006/jmbi.2000.3823; Gotte M, 1998, J BIOL CHEM, V273, P10139, DOI 10.1074/jbc.273.17.10139; Gotte M, 1999, J BIOL CHEM, V274, P11159, DOI 10.1074/jbc.274.16.11159; Gotte M, 1999, ARCH BIOCHEM BIOPHYS, V365, P199, DOI 10.1006/abbi.1999.1209; HERMANN T, 1994, NUCLEIC ACIDS RES, V22, P4625, DOI 10.1093/nar/22.22.4625; HSIEH JC, 1993, J BIOL CHEM, V268, P24607; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Huang HF, 2000, CHEM BIOL, V7, P355, DOI 10.1016/S1074-5521(00)00113-7; Isel C, 1999, EMBO J, V18, P1038, DOI 10.1093/emboj/18.4.1038; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JAGER J, 1994, STRUCTURE, V2, P869, DOI 10.1016/S0969-2126(94)00087-5; Jager Joachim, 1999, Current Opinion in Structural Biology, V9, P21, DOI 10.1016/S0959-440X(99)80004-9; KATI WM, 1992, J BIOL CHEM, V267, P25988; Kim JK, 1997, J BIOL CHEM, V272, P16769, DOI 10.1074/jbc.272.27.16769; Kunkel TA, 1998, NAT STRUCT BIOL, V5, P95, DOI 10.1038/nsb0298-95; Lanchy JM, 1998, J BIOL CHEM, V273, P24425, DOI 10.1074/jbc.273.38.24425; Lanchy JM, 2000, J BIOL CHEM, V275, P12306, DOI 10.1074/jbc.275.16.12306; Larder BA, 1999, NAT STRUCT BIOL, V6, P103, DOI 10.1038/5787; Lavigne M, 1997, J MOL BIOL, V266, P507, DOI 10.1006/jmbi.1996.0805; LAVIGNE M, 1994, EMBO J, V13, P4983, DOI 10.1002/j.1460-2075.1994.tb06825.x; Lavigne M, 2001, J BIOL CHEM, V276, P31429, DOI 10.1074/jbc.M102974200; Lavigne M, 1999, J MOL BIOL, V285, P977, DOI 10.1006/jmbi.1998.2367; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; METZGER W, 1993, P NATL ACAD SCI USA, V90, P5909, DOI 10.1073/pnas.90.13.5909; Negroni M, 2000, P NATL ACAD SCI USA, V97, P6385, DOI 10.1073/pnas.120520497; NEGRONI M, 1995, P NATL ACAD SCI USA, V92, P6971, DOI 10.1073/pnas.92.15.6971; Negroni M, 1999, J MOL BIOL, V286, P15, DOI 10.1006/jmbi.1998.2460; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; Palaniappan C, 1997, J BIOL CHEM, V272, P11157, DOI 10.1074/jbc.272.17.11157; Palaniappan C, 1998, J BIOL CHEM, V273, P3808, DOI 10.1074/jbc.273.7.3808; PALANIAPPAN C, 1995, J BIOL CHEM, V270, P4861, DOI 10.1074/jbc.270.9.4861; Powell MD, 1999, J BIOL CHEM, V274, P19885, DOI 10.1074/jbc.274.28.19885; Powell MD, 1996, J VIROL, V70, P5288, DOI 10.1128/JVI.70.8.5288-5296.1996; Raja A, 1999, BIOCHEMISTRY-US, V38, P5178, DOI 10.1021/bi9828019; Rausch JW, 2000, J BIOL CHEM, V275, P16015, DOI 10.1074/jbc.M909808199; REARDON JE, 1993, J BIOL CHEM, V268, P8743; Ricchetti M, 1996, BIOCHEMISTRY-US, V35, P14970, DOI 10.1021/bi961274v; RITTINGER K, 1995, P NATL ACAD SCI USA, V92, P8046, DOI 10.1073/pnas.92.17.8046; RODGERS DW, 1995, P NATL ACAD SCI USA, V92, P1222, DOI 10.1073/pnas.92.4.1222; Sarafianos SG, 1999, CHEM BIOL, V6, pR137, DOI 10.1016/S1074-5521(99)80071-4; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P12468, DOI 10.1021/bi971218+; Thrall SH, 1998, BIOCHEMISTRY-US, V37, P13349; Tong WJ, 1997, BIOCHEMISTRY-US, V36, P5749, DOI 10.1021/bi962410z; UNGE T, 1990, AIDS RES HUM RETROV, V6, P1297, DOI 10.1089/aid.1990.6.1297; UNGE T, 1994, STRUCTURE, V2, P953, DOI 10.1016/S0969-2126(94)00097-2; Vaccaro JA, 1999, BIOCHEMISTRY-US, V38, P15978, DOI 10.1021/bi990945x; WOHRL BM, 1995, BIOCHEMISTRY-US, V34, P5343; Zennou V, 2000, CELL, V101, P173, DOI 10.1016/S0092-8674(00)80828-4	60	4	4	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31439	31448		10.1074/jbc.M102976200	http://dx.doi.org/10.1074/jbc.M102976200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11402037	hybrid			2022-12-25	WOS:000170472900110
J	Mourey, L; Da Re, S; Pedelacq, JD; Tolstykh, T; Faurie, C; Guillet, V; Stock, JB; Samama, JP				Mourey, L; Da Re, S; Pedelacq, JD; Tolstykh, T; Faurie, C; Guillet, V; Stock, JB; Samama, JP			Crystal structure of the CheA histidine phosphotransfer domain that mediates response regulator phosphorylation in bacterial chemotaxis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; ESCHERICHIA-COLI; KINASE CHEA; KINETIC CHARACTERIZATION; MULTISTEP PHOSPHORELAY; MOLECULAR RECOGNITION; SECONDARY STRUCTURE; 4-HELIX BUNDLE; PROTEIN; ARCB	The x-ray crystal structure of the P1 or H domain of the Salmonella CheA protein has been solved at 2.1-Angstrom resolution. The structure is composed of an up-down up-down four-helix bundle that is typical of histidine phosphotransfer or HPt domains such as Escherichia coli ArcB(C) and Saccharomyces cerevisiae Ypd1. Loop regions and additional structural features distinguish all three proteins. The CheA domain has an additional C-terminal helix that lies over the surface formed by the C and D helices. The phosphoaccepting His-48 is located at a solvent-exposed position in the middle of the B helix where it is surrounded by several residues that are characteristic of other HPt domains. Mutagenesis studies indicate that conserved glutamate and lysine residues that are part of a hydrogen-bond network with His-48 are essential for the ATP-dependent phosphorylation reaction but not for the phosphotransfer reaction with CheY. These results suggest that the CheA-P1 domain may serve as a good model for understanding the general function of HPt domains in complex two-component phosphorelay systems.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; CNRS, Inst Pharmacol & Biol Struct, Grp Cristallog Biol, F-31077 Toulouse, France	Princeton University; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Stock, JB (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.	jstock@princeton.edu; samama@ipbs.fr	Pedelacq, Jean-Denis/C-6053-2011; Da Re, Sandra/F-6383-2011; Mourey, Lionel/B-5662-2009; Guillet, Valérie/C-6058-2011	Da Re, Sandra/0000-0003-3579-9185; Mourey, Lionel/0000-0002-8259-1259; PEDELACQ, Jean-Denis/0000-0002-3202-2517	NIGMS NIH HHS [R01 GM57773] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057773] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Aizawa S, 2000, J BACTERIOL, V182, P1459, DOI 10.1128/JB.182.6.1459-1471.2000; Armitage JP, 1999, ADV MICROB PHYSIOL, V41, P229, DOI 10.1016/S0065-2911(08)60168-X; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bilwes AM, 1999, CELL, V96, P131, DOI 10.1016/S0092-8674(00)80966-6; Boissy G, 1996, STRUCTURE, V4, P1429, DOI 10.1016/S0969-2126(96)00150-5; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHOU KC, 1988, P NATL ACAD SCI USA, V85, P4295, DOI 10.1073/pnas.85.12.4295; CHOU KC, 1992, P NATL ACAD SCI USA, V89, P7315, DOI 10.1073/pnas.89.16.7315; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DUMAS C, 1992, EMBO J, V11, P3203, DOI 10.1002/j.1460-2075.1992.tb05397.x; Dutta R, 1999, MOL MICROBIOL, V34, P633, DOI 10.1046/j.1365-2958.1999.01646.x; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Evans G, 2001, J APPL CRYSTALLOGR, V34, P82, DOI 10.1107/S0021889800014655; Fraser ME, 2000, J MOL BIOL, V299, P1325, DOI 10.1006/jmbi.2000.3807; Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Grebe TW, 1999, ADV MICROB PHYSIOL, V41, P139, DOI 10.1016/S0065-2911(08)60167-8; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; ISHIGE K, 1994, EMBO J, V13, P5195, DOI 10.1002/j.1460-2075.1994.tb06850.x; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; Janiak-Spens F, 2000, MOL MICROBIOL, V37, P136, DOI 10.1046/j.1365-2958.2000.01973.x; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kato M, 1997, CELL, V88, P717, DOI 10.1016/S0092-8674(00)81914-5; Koretke KK, 2000, MOL BIOL EVOL, V17, P1956, DOI 10.1093/oxfordjournals.molbev.a026297; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1987, P CCP4 STUD WEEK SER, P39; Levit M, 1996, J BIOL CHEM, V271, P32057, DOI 10.1074/jbc.271.50.32057; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; Matsubara M, 2000, GENES CELLS, V5, P555, DOI 10.1046/j.1365-2443.2000.00347.x; Matsushika A, 1998, BIOSCI BIOTECH BIOCH, V62, P2236, DOI 10.1271/bbb.62.2236; McEvoy MM, 1998, P NATL ACAD SCI USA, V95, P7333, DOI 10.1073/pnas.95.13.7333; McEvoy MM, 1997, CURR OPIN STRUC BIOL, V7, P793, DOI 10.1016/S0959-440X(97)80148-0; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NINFA AJ, 1988, P NATL ACAD SCI USA, V85, P5492, DOI 10.1073/pnas.85.15.5492; OLMEDO G, 1990, J MOL BIOL, V215, P359, DOI 10.1016/S0022-2836(05)80357-2; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROUSSEL A, 1989, SILICON GRAPHIC GEOM, P71; SANDERS DA, 1989, J BIOL CHEM, V264, P21770; Sasaki S., 1989, Numerical tables of anomalous scattering factors calculated by the Cromer and Liberman's method; Silversmith RE, 1997, BIOCHEMISTRY-US, V36, P14965, DOI 10.1021/bi9715573; Song HK, 1999, J MOL BIOL, V293, P753, DOI 10.1006/jmbi.1999.3215; Sourjik V, 1998, BIOCHEMISTRY-US, V37, P2327, DOI 10.1021/bi972330a; Stewart RC, 2000, BIOCHEMISTRY-US, V39, P13157, DOI 10.1021/bi001100k; Stewart RC, 1997, BIOCHEMISTRY-US, V36, P2030, DOI 10.1021/bi962261k; Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P1, DOI 10.1107/S0108767387099999; Thomason PA, 1999, J BIOL CHEM, V274, P27379, DOI 10.1074/jbc.274.39.27379; Tomomori C, 1999, NAT STRUCT BIOL, V6, P729; Tsuzuki M, 1995, MOL MICROBIOL, V18, P953, DOI 10.1111/j.1365-2958.1995.18050953.x; Varughese KI, 1998, MOL CELL, V2, P485, DOI 10.1016/S1097-2765(00)80148-3; Welch M, 1998, NAT STRUCT BIOL, V5, P25, DOI 10.1038/nsb0198-25; Xu QP, 1999, J MOL BIOL, V292, P1039, DOI 10.1006/jmbi.1999.3143; Zapf J, 2000, STRUCTURE, V8, P851, DOI 10.1016/S0969-2126(00)00174-X; ZHOU HJ, 1995, BIOCHEMISTRY-US, V34, P13858, DOI 10.1021/bi00042a018; Zhou HJ, 1997, BIOCHEMISTRY-US, V36, P699, DOI 10.1021/bi961663p	63	70	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31074	31082		10.1074/jbc.M101943200	http://dx.doi.org/10.1074/jbc.M101943200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11387324	Green Published, hybrid			2022-12-25	WOS:000170472900065
J	Pillai, B; Sampath, V; Sharma, N; Sadhale, P				Pillai, B; Sampath, V; Sharma, N; Sadhale, P			Rpb4, a non-essential subunit of core RNA polymerase II of Saccharomyces cerevisiae is important for activated transcription of a subset of genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; HIGH-TEMPERATURE; YEAST; PROTEIN; PROMOTER; TBP; HOLOENZYME; INVITRO; BINDING; DOMAIN	A major role in the regulation of eukaryotic protein-coding genes is played by the gene-specific transcriptional regulators, which recruit the RNA polymerase II holoenzyme to the specific promoter. Several components of the mediator complex within the holoenzyme also have been shown to affect activation of different subsets of genes. Only recently has it been suggested that besides the largest subunit of RNA polymerase Il, smaller subunits like Rpb3 and Rpb5 may have regulatory roles in expression of specific sets of genes. We report here, the role of Rpb4, a non-essential subunit of core RNA polymerase II, in activation of a subset of genes in Saccharomyces cerevisiae. We have shown below that whereas constitutive transcription is largely unaffected, activation from various promoters tested is severely compromised in the absence of RPB4. This activation defect can be rescued by the overexpression of cognate activators. We have localized the region of Rpb4 involved in activation to the C-terminal 24 amino acids. We have also shown here that transcriptional activation by artificial recruitment of the TATA-binding protein (TBP) to the promoter is also defective in the absence of RPB4. Surprisingly, the overexpression of RPB7 (the interacting partner of Rpb4) does not rescue the activation defect of all the promoters tested, although it rescues the activation defect of the heat shock element-containing promoter and the temperature sensitivity associated with RPB4 deletion. Overall, our results indicate that Rpb4 and Rpb7 play independent roles in transcriptional regulation of genes.	Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Sadhale, P (corresponding author), Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India.		Sadhale, PArag/A-7799-2009	Pillai, Beena/0000-0002-9302-9878				Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Boscheinen O, 1997, MOL GEN GENET, V255, P322, DOI 10.1007/s004380050503; BRENDEL V, 1994, COMPUT CHEM, V18, P251, DOI 10.1016/0097-8485(94)85020-8; CHATTERJEE S, 1995, NATURE, V374, P820, DOI 10.1038/374820a0; CHODER M, 1993, MOL CELL BIOL, V13, P6984, DOI 10.1128/MCB.13.11.6984; Corpet F, 2000, NUCLEIC ACIDS RES, V28, P267, DOI 10.1093/nar/28.1.267; Corpet F, 1999, NUCLEIC ACIDS RES, V27, P263, DOI 10.1093/nar/27.1.263; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; Jensen GJ, 1998, EMBO J, V17, P2353, DOI 10.1017/S1431927600024983; Kabir MA, 2000, MOL GEN GENET, V262, P1113, DOI 10.1007/PL00008654; KLAGES N, 1995, NATURE, V374, P822, DOI 10.1038/374822a0; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; Lee D, 1998, NATURE, V393, P389, DOI 10.1038/30770; LESSER CF, 1993, GENETICS, V133, P851; Li XY, 1999, NATURE, V399, P605, DOI 10.1038/21232; Maillet I, 1999, J BIOL CHEM, V274, P22586, DOI 10.1074/jbc.274.32.22586; McNeil JB, 1998, GENE DEV, V12, P2510, DOI 10.1101/gad.12.16.2510; Miyao T, 1998, P NATL ACAD SCI USA, V95, P15281, DOI 10.1073/pnas.95.26.15281; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Petermann R, 1998, ONCOGENE, V17, P603, DOI 10.1038/sj.onc.1201964; Piruat JI, 1997, GENETICS, V147, P1585; Ranish JA, 1996, CURR OPIN GENET DEV, V6, P151, DOI 10.1016/S0959-437X(96)80044-X; ROSE M, 1983, METHOD ENZYMOL, V101, P167; Rosenheck S, 1998, J BACTERIOL, V180, P6187; RUET A, 1980, J BIOL CHEM, V255, P6450; RUSSNAK R, 1995, MOL CELL BIOL, V15, P1689; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; Schlegel BP, 2000, P NATL ACAD SCI USA, V97, P3148, DOI 10.1073/pnas.070452397; Sharma N, 1999, J GENET, V78, P149, DOI 10.1007/BF02934460; Sheffer A, 1999, MOL CELL BIOL, V19, P2672; SHERMAN F, 1986, LABORATORY COURSE MA, P121; Tan Q, 2000, MOL CELL BIOL, V20, P8124, DOI 10.1128/MCB.20.21.8124-8133.2000; Tan Q, 2000, GENE DEV, V14, P339; THOMPSON CM, 1995, P NATL ACAD SCI USA, V92, P4587, DOI 10.1073/pnas.92.10.4587; VIJAYRAGHAVAN U, 1989, GENE DEV, V3, P1206, DOI 10.1101/gad.3.8.1206; WOYCHIK NA, 1989, MOL CELL BIOL, V9, P2854, DOI 10.1128/MCB.9.7.2854; YOCUM RR, 1984, MOL CELL BIOL, V4, P1985, DOI 10.1128/MCB.4.10.1985	43	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30641	30647		10.1074/jbc.M010952200	http://dx.doi.org/10.1074/jbc.M010952200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11382749	hybrid			2022-12-25	WOS:000170472900009
J	Venning, JD; Rodrigues, DJ; Weston, CJ; Cotton, NPJ; Quirk, PG; Errington, N; Finet, S; White, SA; Jackson, JB				Venning, JD; Rodrigues, DJ; Weston, CJ; Cotton, NPJ; Quirk, PG; Errington, N; Finet, S; White, SA; Jackson, JB			The heterotrimer of the membrane-peripheral components of transhydrogenase and the alternating-site mechanism of proton translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINAMIDE NUCLEOTIDE TRANSHYDROGENASE; ESCHERICHIA-COLI TRANSHYDROGENASE; RHODOSPIRILLUM-RUBRUM; NADP(H)-BINDING COMPONENT; SOLUTION SCATTERING; HYDRIDE TRANSFER; DOMAIN-III; RECOMBINANT; BINDING; ENZYME	Transhydrogenase undergoes conformational changes to couple the redox reaction between NAD(H) and NADP(H) to proton translocation across a membrane. The protein comprises three components: dI, which binds NAD(H); dIII, which binds NADP(H); and dII, which spans the membrane. Experiments using isothermal titration calorimetry, analytical ultracentrifugation, and small angle x-ray scattering show that, as in the crystalline state, a mixture of recombinant dI and dIII from Rhodospirillum rubrum transhydrogenase readily forms a dI(2)dIII(1) heterotrimer in solution, but we could find no evidence for the formation of a dI(2)dIII(2) tetramer using these techniques. The asymmetry of the complex suggests that there is an alternation of conformations at the nucleotide-binding sites during proton translocation by the complete enzyme. The characteristics of nucleotide interaction with the isolated dl and dIII components and with the dI(2)dIII(1) heterotrimer were investigated. (a) The rate of release of NADP(+) from dIII was decreased 5-fold when the component was incorporated into the heterotrimer. (b) The binding affinity of one of the two nucleotide-binding sites for NADH on the dI dimer was decreased about 17-fold in the dI(2)dIII(1), complex; the other binding site was unaffected. These observations lend strong support to the alternating-site mechanism.	Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England; Univ Nottingham, Sch Biosci, Natl Ctr Macromol Hydrodynam, Loughborough LE12 5RD, Leics, England; European Synchrotron Radiat Facil, F-38043 Grenoble, France	University of Birmingham; University of Nottingham; European Synchrotron Radiation Facility (ESRF)	Jackson, JB (corresponding author), Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.		White, Scott/C-6684-2008	White, Scott/0000-0002-0202-6154				ANDERSON WM, 1978, ARCH BIOCHEM BIOPHYS, V187, P180, DOI 10.1016/0003-9861(78)90021-8; Bizouarn T, 1996, EUR J BIOCHEM, V239, P737, DOI 10.1111/j.1432-1033.1996.0737u.x; Bizouarn T, 1996, BBA-BIOENERGETICS, V1273, P4, DOI 10.1016/0005-2728(95)00125-5; Buckley PA, 2000, STRUCTURE, V8, P809, DOI 10.1016/S0969-2126(00)00171-4; Cotton NPJ, 2001, STRUCTURE, V9, P165, DOI 10.1016/S0969-2126(01)00571-8; DIGGLE C, 1995, EUR J BIOCHEM, V232, P315, DOI 10.1111/j.1432-1033.1995.tb20814.x; DIGGLE C, 1995, EUR J BIOCHEM, V228, P719, DOI 10.1111/j.1432-1033.1995.0719m.x; Diggle C, 1996, EUR J BIOCHEM, V241, P162, DOI 10.1111/j.1432-1033.1996.0162t.x; Fjellstrom O, 1997, BIOCHEMISTRY-US, V36, P11331, DOI 10.1021/bi970958f; Guinier A., 1955, SMALL ANGLE SCATTERI; HOEK JB, 1988, BIOCHEM J, V254, P1; HOU C, 1990, BIOCHIM BIOPHYS ACTA, V1018, P61, DOI 10.1016/0005-2728(90)90110-P; Jackson JB, 1999, FEBS LETT, V464, P1, DOI 10.1016/S0014-5793(99)01644-0; Jeeves M, 2000, BBA-BIOENERGETICS, V1459, P248, DOI 10.1016/S0005-2728(00)00159-6; Johansson C, 1999, FEBS LETT, V458, P180, DOI 10.1016/S0014-5793(99)01156-4; Kozin MB, 1997, J APPL CRYSTALLOGR, V30, P811, DOI 10.1107/S0021889897001830; MEJBAUMKATZENELLENBOGEN W, 1959, CLIN CHIM ACTA, V4, P515, DOI 10.1016/0009-8981(59)90158-5; MENDES P, 1993, COMPUT APPL BIOSCI, V9, P563; Meuller J, 1999, J BIOL CHEM, V274, P19072, DOI 10.1074/jbc.274.27.19072; Peake SJ, 1999, BBA-BIOENERGETICS, V1413, P81, DOI 10.1016/S0005-2728(99)00084-5; Peake SJ, 1999, BBA-BIOENERGETICS, V1411, P159, DOI 10.1016/S0005-2728(99)00013-4; PERSSON B, 1987, ARCH BIOCHEM BIOPHYS, V259, P341, DOI 10.1016/0003-9861(87)90500-5; PHELPS DC, 1984, BIOCHEMISTRY-US, V23, P4475, DOI 10.1021/bi00314a037; PHELPS DC, 1985, BIOCHEMISTRY-US, V24, P3503, DOI 10.1021/bi00335a017; Prasad GS, 1999, NAT STRUCT BIOL, V6, P1126; Quirk PG, 1999, FEBS LETT, V446, P127, DOI 10.1016/S0014-5793(99)00198-2; Rodrigues DJ, 2001, EUR J BIOCHEM, V268, P1430, DOI 10.1046/j.1432-1327.2001.02008.x; SAZANOV LA, 1994, FEBS LETT, V344, P109, DOI 10.1016/0014-5793(94)00370-X; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; Svedberg T, 1940, THE ULTRACENTRIFUGE; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; Svergun DI, 1996, ACTA CRYSTALLOGR A, V52, P419, DOI 10.1107/S0108767396000177; Venning JD, 2000, J BIOL CHEM, V275, P19490, DOI 10.1074/jbc.M000577200; Venning JD, 1998, EUR J BIOCHEM, V257, P202, DOI 10.1046/j.1432-1327.1998.2570202.x; Weston CJ, 2001, FEBS LETT, V488, P51, DOI 10.1016/S0014-5793(00)02386-3; White SA, 2000, STRUCT FOLD DES, V8, P1, DOI 10.1016/S0969-2126(00)00075-7; YAMAGUCHI M, 1993, J BIOL CHEM, V268, P17871; YAMAGUCHI M, 1990, BIOCHEMISTRY-US, V29, P4136, DOI 10.1021/bi00469a017; YAMAGUCHI M, 1995, J BIOL CHEM, V270, P28165; Yamaguchi M, 1997, BBA-BIOENERGETICS, V1318, P225, DOI 10.1016/S0005-2728(96)00139-9	40	28	28	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30678	30685		10.1074/jbc.M104429200	http://dx.doi.org/10.1074/jbc.M104429200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11399770	hybrid			2022-12-25	WOS:000170472900014
J	Bell-Parikh, LC; Eipper, BA; Mains, RE				Bell-Parikh, LC; Eipper, BA; Mains, RE			Response of an integral granule membrane protein to changes in pH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-AMIDATING MONOOXYGENASE; PEPTIDE-PROCESSING ENZYME; CYTOSOLIC ROUTING DETERMINANTS; IMMATURE SECRETORY GRANULES; COOH-TERMINAL DOMAIN; ATT-20 CELLS; CHROMOGRANIN-A; PROHORMONE CONVERTASE; NEUROENDOCRINE CELLS; CARBOXYPEPTIDASE-E	A key feature of the regulated secretory pathway in neuroendocrine cells is lumenal pH, which decreases between trans-Golgi network and mature secretory granules. Because peptidylglycine a-amidating monooxygenase, (PA-ML) is one of the few membrane-spanning proteins concentrated. in secretory granules and is a known effector of regulated secretion, we examined its sensitivity to pH. Based on antibody binding experiments, the noncatalytic linker regions between the two enzymatic domains of PAM show pH-dependent conformational changes; these changes occur in the presence or absence of a transmembrane domain. Integral membrane PAM-1 solubilized from rat anterior pituitary or from transfected AtT-20 cells aggregates reversibly at pH 5.5 while retaining enzyme activity. Over 35% of the PAM-1 in anterior pituitary extracts aggregates at pH 5.5, whereas only about 5% aggregates at pH 7.5. PAM-1 recovered from secretory granules and endosomes is highly responsive to low pl-l-induced aggregation, whereas PAM-1 recovered from a light, intracellular recycling compartment is not. Mutagenesis studies indicate that a transmembrane domain is necessary but not sufficient for low pH-induced aggregation and reveal a short lumenal, juxtamembrane segment that also contributes to pH-dependent aggregation. Taken together, these results demonstrate that several properties of membrane PAM serve as indicators of granule pH in neuroendocrine cells.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	Johns Hopkins University	Mains, RE (corresponding author), Univ Connecticut, Ctr Hlth, Dept Neurosci, MC3401,263 Farmington Ave, Farmington, CT 06030 USA.	mains@uchc.edu			NIDDK NIH HHS [DK32949, DK09945, DK32948] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK032948, R01DK032949, R37DK032949, R37DK032948, R56DK032949, R01DK032948] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alam MR, 2001, MOL BIOL CELL, V12, P629, DOI 10.1091/mbc.12.3.629; Alam MR, 1997, J BIOL CHEM, V272, P12667, DOI 10.1074/jbc.272.19.12667; Alam MR, 1996, J BIOL CHEM, V271, P28636, DOI 10.1074/jbc.271.45.28636; Anderson ED, 1997, EMBO J, V16, P1508, DOI 10.1093/emboj/16.7.1508; Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29; BENNETT MK, 1992, J CELL BIOL, V116, P761, DOI 10.1083/jcb.116.3.761; Borza DB, 1998, J BIOL CHEM, V273, P5493, DOI 10.1074/jbc.273.10.5493; Bruzzaniti A, 1999, J BIOL CHEM, V274, P24703, DOI 10.1074/jbc.274.35.24703; Caldwell BD, 1999, J BIOL CHEM, V274, P34646, DOI 10.1074/jbc.274.49.34646; CASEY RP, 1977, BIOCHEMISTRY-US, V16, P972, DOI 10.1021/bi00624a025; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; CHAPMAN RE, 1994, EMBO J, V13, P2305, DOI 10.1002/j.1460-2075.1994.tb06514.x; Ciccotosto GD, 1999, J CELL BIOL, V144, P459, DOI 10.1083/jcb.144.3.459; Colomer V, 1996, J BIOL CHEM, V271, P48, DOI 10.1074/jbc.271.1.48; Cool DR, 1997, CELL, V88, P73, DOI 10.1016/S0092-8674(00)81860-7; Dannies PS, 1999, ENDOCR REV, V20, P3, DOI 10.1210/er.20.1.3; Dittie AS, 1997, EMBO J, V16, P4859, DOI 10.1093/emboj/16.16.4859; Dittie AS, 1999, J CELL SCI, V112, P3955; EIPPER BA, 1995, BIOCHEMISTRY-US, V34, P2857, DOI 10.1021/bi00009a016; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; El Meskini R, 2001, J BIOL CHEM, V276, P3384, DOI 10.1074/jbc.M008062200; HUSTEN EJ, 1994, ARCH BIOCHEM BIOPHYS, V312, P487, DOI 10.1006/abbi.1994.1336; JAMIESON JD, 1971, J CELL BIOL, V48, P503, DOI 10.1083/jcb.48.3.503; JOHNSON RG, 1976, J BIOL CHEM, V251, P2189; Lee MS, 2001, J BIOL CHEM, V276, P715, DOI 10.1074/jbc.M008530200; LINDBERG I, 1995, BIOCHEMISTRY-US, V34, P5486, DOI 10.1021/bi00016a020; Mains RE, 1999, J BIOL CHEM, V274, P2929, DOI 10.1074/jbc.274.5.2929; Mains Richard E., 1999, P363; Martens JR, 2000, J BIOL CHEM, V275, P7443, DOI 10.1074/jbc.275.11.7443; Marx R, 1999, J NEUROSCI, V19, P8300; Meskini RE, 2000, ENDOCRINOLOGY, V141, P3020; Milgram SL, 1996, J BIOL CHEM, V271, P17526, DOI 10.1074/jbc.271.29.17526; MILGRAM SL, 1992, J CELL BIOL, V117, P717, DOI 10.1083/jcb.117.4.717; Milgram SL, 1997, J CELL SCI, V110, P695; MILGRAM SL, 1993, J CELL BIOL, V121, P23, DOI 10.1083/jcb.121.1.23; Muller L, 2000, PROG NUCLEIC ACID RE, V63, P69, DOI 10.1016/S0079-6603(08)60720-5; ORCI L, 1987, CELL, V49, P865, DOI 10.1016/0092-8674(87)90624-6; ORCI L, 1986, J CELL BIOL, V103, P2273, DOI 10.1083/jcb.103.6.2273; ORCI L, 1987, CELL, V51, P1039, DOI 10.1016/0092-8674(87)90590-3; OYARCE AM, 1995, J CELL SCI, V108, P287; Prigge ST, 2000, CELL MOL LIFE SCI, V57, P1236, DOI 10.1007/PL00000763; Ratovitski EA, 1999, J BIOL CHEM, V274, P993, DOI 10.1074/jbc.274.2.993; Rindler MJ, 1998, J BIOL CHEM, V273, P31180, DOI 10.1074/jbc.273.47.31180; SCHMIDT WK, 1995, MOL BIOL CELL, V6, P1271, DOI 10.1091/mbc.6.10.1271; Scougall K, 1998, BIOCHEM J, V334, P531, DOI 10.1042/bj3340531; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; SHENNAN KIJ, 1994, J BIOL CHEM, V269, P18646; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; SONG LX, 1995, J BIOL CHEM, V270, P7963, DOI 10.1074/jbc.270.14.7963; STEINER DF, 1973, NATURE, V243, P528, DOI 10.1038/243528a0; Stoeckelhuber M, 1996, J CELL SCI, V109, P1825; TAUSK FA, 1992, MOL ENDOCRINOL, V6, P2185, DOI 10.1210/me.6.12.2185; Wolins N, 1997, J CELL BIOL, V139, P1735, DOI 10.1083/jcb.139.7.1735; YI Z, 1993, J BIOL CHEM, V268, P5615; YOO SH, 1994, J BIOL CHEM, V269, P12001; YOO SH, 1990, J BIOL CHEM, V265, P14414; Yoo SH, 1996, J BIOL CHEM, V271, P1558; Yoo SH, 1997, FEBS LETT, V406, P259, DOI 10.1016/S0014-5793(97)00276-7; YUN HY, 1993, ARCH BIOCHEM BIOPHYS, V301, P77, DOI 10.1006/abbi.1993.1117; YUN HY, 1995, J BIOL CHEM, V270, P30075; YUN HY, 1995, J BIOL CHEM, V270, P15412, DOI 10.1074/jbc.270.25.15412; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745	62	22	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29854	29863		10.1074/jbc.M103936200	http://dx.doi.org/10.1074/jbc.M103936200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11395514	hybrid			2022-12-25	WOS:000170558000035
J	Ben-Menahem, D; Jablonka-Shariff, A; Hyde, RK; Pixley, MR; Srivastava, S; Berger, P; Boime, I				Ben-Menahem, D; Jablonka-Shariff, A; Hyde, RK; Pixley, MR; Srivastava, S; Berger, P; Boime, I			The position of the alpha and beta subunits in a single chain variant of human chorionic gonadotropin affects the heterodimeric interaction of the subunits and receptor-binding epitopes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLLICLE-STIMULATING-HORMONE; INDIVIDUAL DISULFIDE BONDS; HUMAN CHORIOGONADOTROPIN; GLYCOPROTEIN HORMONES; TERMINAL REGION; EXPRESSION; COMMON; FOLLITROPIN; SEQUENCE; PROTEIN	The glycoprotein hormone family represents a class of heterodimers, which include the placental hormone human chorionic gonadotropin (CG) and the anterior pituitary hormones follitropin, lutropin, and thyrotropin. They are composed of common alpha subunit and a hormone-specific beta subunit. Based on the CG crystal structure, it was suggested that the quaternary subunit interactions are crucial for biological activity. However, recent observations using single chain glycoprotein hormone analogs, where the beta and alpha subunits are linked (NH2-CG beta-alpha; CG beta alpha orientation), implied that the heterodimeric-like quaternary configuration is not a prerequisite for receptor binding/signal transduction. To study the heterodimeric alignment of the two subunit domains in a single chain and its role in the intracellular behavior and biological action of the hormone, a single chain CG variant was constructed in which the carboxyl terminus of a was fused to the CG beta amino terminus (NH2-alpha -CG beta; alpha CG beta orientation). The secretion rate of alpha CG beta from transfected Chinese hamster ovary cells was less than that seen for CG beta alpha. The alpha CG beta tether was not recognized by dimer-specific monoclonal antibodies and did not bind to lutropin/CG receptor. To define if one or both subunit domains were modified in alpha CG beta, it was co-transfected with a monomeric a or CGP gene. In each case, alpha CG beta/alpha and alpha CG beta /CG beta complexes were formed indicating that CG dimer-specific epitopes were established. The alpha CG beta/alpha complex bound to receptor indicating that the beta domain in the alpha CG/beta tether was still functional. In contrast, no significant receptor binding of alpha CG beta /CG beta was observed indicating a major perturbation in the alpha domain. These results suggest that although dimeric-like determinants are present in both alpha CG beta/alpha and alpha CG beta /CG beta complexes, the receptor binding determinants in the alpha domain of the tether are absent. These results show that generating heterodimeric determinants do not necessarily result in a bioactive molecule. Our data also indicate that the determinants for biological activity are distinct from those associated with intracellular behavior.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Austrian Acad Sci, Inst Biomed Aging Res, A-6020 Innsbruck, Austria	Washington University (WUSTL); Austrian Academy of Sciences	Boime, I (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, 660 S Euclin Ave, St Louis, MO 63110 USA.		hyde, kate/S-3235-2019	Ben-Menahem, David/0000-0002-8985-0591				Ben-Menahem D, 1999, BIOCHEMISTRY-US, V38, P15070, DOI 10.1021/bi991510c; BenMenahem D, 1996, TRENDS ENDOCRIN MET, V7, P100, DOI 10.1016/1043-2760(96)88667-X; BenMenahem D, 1997, J BIOL CHEM, V272, P6827, DOI 10.1074/jbc.272.11.6827; BIELINSKA M, 1990, J CELL BIOL, V111, P330; Birken S, 1996, ENDOCRINOLOGY, V137, P1402, DOI 10.1210/en.137.4.1402; BIRKEN S, 1977, J BIOL CHEM, V252, P5386; CHARLESWORTH MC, 1987, J BIOL CHEM, V262, P13409; CHEN F, 1992, MOL ENDOCRINOL, V6, P914, DOI 10.1210/me.6.6.914; Falcon CM, 1999, J BIOL CHEM, V274, P30849, DOI 10.1074/jbc.274.43.30849; FARES FA, 1992, P NATL ACAD SCI USA, V89, P4304, DOI 10.1073/pnas.89.10.4304; Fares FA, 1998, ENDOCRINOLOGY, V139, P2459, DOI 10.1210/en.139.5.2459; FURUHASHI M, 1994, J BIOL CHEM, V269, P25543; FURUHASHI M, 1995, MOL ENDOCRINOL, V9, P54, DOI 10.1210/me.9.1.54; Grossmann M, 1997, J BIOL CHEM, V272, P21312, DOI 10.1074/jbc.272.34.21312; Gupta C. Sen, 2000, Journal of Molecular Endocrinology, V24, P157; Jackson AM, 1999, MOL ENDOCRINOL, V13, P2175, DOI 10.1210/me.13.12.2175; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; Kanda M, 1999, MOL ENDOCRINOL, V13, P1873, DOI 10.1210/me.13.11.1873; KEENE JL, 1989, J BIOL CHEM, V264, P4769; LUSTBADER J, 1987, J BIOL CHEM, V262, P14204; MERZ WE, 1979, EUR J BIOCHEM, V101, P541, DOI 10.1111/j.1432-1033.1979.tb19749.x; NARAYAN P, 1995, MOL ENDOCRINOL, V9, P1720, DOI 10.1210/me.9.12.1720; Narayan P, 2000, ENDOCRINOLOGY, V141, P67, DOI 10.1210/en.141.1.67; PARSONS TF, 1979, J BIOL CHEM, V254, P6010; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; SALESSE R, 1990, MOL CELL ENDOCRINOL, V68, P113, DOI 10.1016/0303-7207(90)90183-9; Sato A, 1997, J BIOL CHEM, V272, P18098, DOI 10.1074/jbc.272.29.18098; Sugahara T, 1996, J BIOL CHEM, V271, P10445, DOI 10.1074/jbc.271.18.10445; SUGAHARA T, 1995, P NATL ACAD SCI USA, V92, P2041, DOI 10.1073/pnas.92.6.2041; SUGANUMA N, 1989, J BIOL CHEM, V264, P19302; WEISS J, 1992, NEW ENGL J MED, V326, P179, DOI 10.1056/NEJM199201163260306; XIA H, 1993, J MOL ENDOCRINOL, V10, P337, DOI 10.1677/jme.0.0100337; YOO JK, 1993, J BIOL CHEM, V268, P13034	33	13	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29871	29879		10.1074/jbc.M104687200	http://dx.doi.org/10.1074/jbc.M104687200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11390409	hybrid			2022-12-25	WOS:000170558000037
J	Gladyshev, VN; Liu, AM; Novoselov, SV; Krysan, K; Sun, QA; Kryukov, VM; Kryukov, GV; Lou, MF				Gladyshev, VN; Liu, AM; Novoselov, SV; Krysan, K; Sun, QA; Kryukov, VM; Kryukov, GV; Lou, MF			Identification and characterization of a new mammalian glutaredoxin (thioltransferase), Grx2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-BLOOD-CELLS; MOLECULAR-CLONING; SWISS-MODEL; THIOREDOXIN; PROTEIN; STRESS; GENE; SELENOCYSTEINE; PURIFICATION; PEROXIDASE	A thiol/disulfide oxidoreductase component of the GSH system, glutaredoxin (Grx), is involved in the reduction of GSH-based mixed disulfides and participates in a variety of cellular redox pathways. A single cytosolic Grx (Grx1) was previously described in mammals. We now report identification and characterization of a second mammalian Grx, designated Grx2. Grx2 exhibited 36% identity with Grx1 and had a disulfide active center containing the Cys-Ser-Tyr-Cys motif. Grx2 was encoded in the, genomes of mammals and birds and expressed in a variety of cell types. The gene for human Grx2 consisted of four exons and three introns, spanned 10 kilobase pairs, and localized to chromosome 1q31.2-31.3. The coding sequence was present in all exons, with the first exon encoding a mitochondrial signal peptide. The mitochondrial leader sequence was also present in mouse and rat Grx2 sequences and was shown to direct either Grx2 or green fluorescent protein to mitochondria. Alternative splicing forms. of mammalian Grx2 mRNAs were identified that differed in sequences upstream of exon 2. To functionally characterize the new protein, human and mouse Grx2 proteins were expressed in Escherichia coli, and the purified proteins were shown to reduce mixed disulfides formed between GSH and S-sulfocysteine, hydroxyethyldisulfide, or cystine. Grx1 and Grx2 were sensitive to inactivation by iodoacetamide and H2O2 and exhibited similar pH dependence of catalytic activity. However, H2O2-inactivated Grx2 could only be reactivated with 5 mM GSH, whereas Grx1 could also be reactivated with dithiothreitol or thioredoxin/thioredoxin reductase. The Grx2 structural model suggested a common reaction mechanism for this class of proteins. The data provide the first example of a mitochondrial Grx and also indicate the occurrence of a second functional Grx in mammals.	Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA; Univ Nebraska, Dept Vet & Biomed Sci, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Lincoln	Gladyshev, VN (corresponding author), Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA.	vgladyshev1@unl.edu	Gladyshev, Vadim N/J-6187-2013; Kryukov, Gregory V/A-9592-2008; Gladyshev, Vadim N/A-9894-2013	Novoselov, Sergey/0000-0003-0104-6492; Kryukov, Gregory/0000-0002-6131-9483; Gladyshev, Vadim/0000-0002-0372-7016				Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Aslund F, 1999, CELL, V96, P751, DOI 10.1016/S0092-8674(00)80584-X; Aslund F, 1999, J BACTERIOL, V181, P1375; Cotgreave IA, 1998, BIOCHEM BIOPH RES CO, V242, P1, DOI 10.1006/bbrc.1997.7812; Esworthy RS, 1997, ARCH BIOCHEM BIOPHYS, V340, P59, DOI 10.1006/abbi.1997.9901; Grant CM, 2000, BBA-GENE STRUCT EXPR, V1490, P33, DOI 10.1016/S0167-4781(99)00234-1; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; KATTI SK, 1995, PROTEIN SCI, V4, P1998, DOI 10.1002/pro.5560041005; Kelner MJ, 2000, BIOCHEM BIOPH RES CO, V269, P366, DOI 10.1006/bbrc.2000.2267; Lee KK, 1998, J BIOL CHEM, V273, P19160, DOI 10.1074/jbc.273.30.19160; Lee SR, 1999, J BIOL CHEM, V274, P4722, DOI 10.1074/jbc.274.8.4722; Lou MF, 2000, J OCUL PHARMACOL TH, V16, P137, DOI 10.1089/jop.2000.16.137; LUNDBERG M, 2001, J BIOL CHEM; MIEYAL JJ, 1991, BIOCHEMISTRY-US, V30, P6088, DOI 10.1021/bi00239a002; MIEYAL JJ, 1991, BIOCHEMISTRY-US, V30, P8883, DOI 10.1021/bi00100a023; Nordstrand K, 2000, J MOL BIOL, V303, P423, DOI 10.1006/jmbi.2000.4145; Pedrajas JR, 2000, J BIOL CHEM, V275, P16296, DOI 10.1074/jbc.275.21.16296; Pedrajas JR, 1999, J BIOL CHEM, V274, P6366, DOI 10.1074/jbc.274.10.6366; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Pfeifer H, 2001, FASEB J, V15, P1236, DOI 10.1096/fj.00-0655fje; QIAO FY, 2000, INVEST OPHTH VIS SCI, V42, P743; Raghavachari N, 1999, EXP EYE RES, V68, P715, DOI 10.1006/exer.1999.0659; Raghavachari N, 1996, EXP EYE RES, V63, P433, DOI 10.1006/exer.1996.0133; Rhee SG, 1999, BIOFACTORS, V10, P207, DOI 10.1002/biof.5520100218; Rodriguez-Manzaneque MT, 1999, MOL CELL BIOL, V19, P8180; SAMBROOC J, 1989, MOL CLONING LAB MANU; Sun CH, 1998, J MOL BIOL, V280, P687, DOI 10.1006/jmbi.1998.1913; Sun QA, 1999, J BIOL CHEM, V274, P24522, DOI 10.1074/jbc.274.35.24522; Ursini F, 1999, SCIENCE, V285, P1393, DOI 10.1126/science.285.5432.1393; Yang YW, 1998, BIOCHEMISTRY-US, V37, P17145, DOI 10.1021/bi9806504	32	183	190	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30374	30380		10.1074/jbc.M100020200	http://dx.doi.org/10.1074/jbc.M100020200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11397793	hybrid, Green Published			2022-12-25	WOS:000170558000101
J	Mullally, JE; Moos, PJ; Edes, K; Fitzpatrick, FA				Mullally, JE; Moos, PJ; Edes, K; Fitzpatrick, FA			Cyclopentenone prostaglandins of the J series inhibit the ubiquitin isopeptidase activity of the proteasome pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; MALIGNANT-MELANOMA CELLS; CROSS-LINKED PROTEIN; P53 TUMOR-SUPPRESSOR; HUMAN GLIOMA-CELLS; MULTICATALYTIC PROTEASE; GROWTH-INHIBITION; OXIDATIVE STRESS; CANCER-CELLS; MUTANT P53	Electrophilic eicosanoids of the J series, with their distinctive cross-conjugated alpha,beta -unsaturated ketone, inactivate genetically wild type tumor suppressor p53 in a manner analogous to prostaglandins of the A series. Like the prostaglandins of the A series, prostaglandins of the J series have a structural determinant (endocyclic cyclopentenone) that confers the ability to impair the conformation, the phosphorylation, and the transcriptional activity of the p53 tumor suppressor with equivalent potency and efficacy. However, J series prostaglandins have a unique structural determinant (exocyclic alpha,beta -unsaturated ketone) that confers unique efficacy as an apoptotic agonist. In seeking to understand how J series prostaglandins cause apoptosis despite their inactivation of p53, we discovered that they inhibit the ubiquitin isopeptidase activity of the proteasome pathway. In this regard, J series prostaglandins were more efficacious inhibitors than representative members of the A, B, or E series prostaglandins. Disruption of the proteasome pathway with proteasome inhibitors can cause apoptosis independently of p53. Therefore, this finding helps reconcile the p53 transcriptional independence of apoptosis caused by Delta 12-prostaglandin J(2). This. discovery represents a novel mechanism for proteasome pathway inhibition in intact cells. Furthermore, it identifies isopeptidases as novel targets for the development of antineoplastic agents.	Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84108 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah	Fitzpatrick, FA (corresponding author), Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84108 USA.			Moos, Philip/0000-0002-8223-442X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026730] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI 26730] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adams J, 1999, CANCER RES, V59, P2615; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARTEK J, 1991, ONCOGENE, V6, P1699; BARTEK J, 1990, ONCOGENE, V5, P893; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; CHARD PS, 1995, NEUROSCIENCE, V65, P1099, DOI 10.1016/0306-4522(94)00548-J; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; Clay CE, 1999, CARCINOGENESIS, V20, P1905, DOI 10.1093/carcin/20.10.1905; Dang LC, 1998, BIOCHEMISTRY-US, V37, P1868, DOI 10.1021/bi9723360; Desterro JMP, 2000, CELL MOL LIFE SCI, V57, P1207, DOI 10.1007/PL00000760; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FITZPATRICK FA, 1983, J BIOL CHEM, V258, P1713; FITZPATRICK FA, 1979, P NATL ACAD SCI USA, V76, P1765, DOI 10.1073/pnas.76.4.1765; FRIGUET B, 1994, ARCH BIOCHEM BIOPHYS, V311, P168, DOI 10.1006/abbi.1994.1222; Friguet B, 1997, FEBS LETT, V405, P21, DOI 10.1016/S0014-5793(97)00148-8; FRIGUET B, 1994, J BIOL CHEM, V269, P21639; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; Glockzin S, 1999, J BIOL CHEM, V274, P19581, DOI 10.1074/jbc.274.28.19581; Hershko A, 2000, NAT MED, V6, P1073, DOI 10.1038/80384; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HONN KV, 1985, BIOCHEM BIOPH RES CO, V129, P34, DOI 10.1016/0006-291X(85)91398-1; HOUGH R, 1986, J BIOL CHEM, V261, P2391; Keller JN, 2000, J CEREBR BLOOD F MET, V20, P1467, DOI 10.1097/00004647-200010000-00008; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kitagawa H, 1999, FEBS LETT, V443, P181, DOI 10.1016/S0014-5793(98)01709-8; LEGROS Y, 1994, ONCOGENE, V9, P3689; Liu H, 1996, J BIOL CHEM, V271, P4805; Ljungman M, 2000, NEOPLASIA, V2, P208, DOI 10.1038/sj.neo.7900073; Lowe Scott W., 1995, Current Opinion in Oncology, V7, P547, DOI 10.1097/00001622-199511000-00013; Meng LH, 1999, CANCER RES, V59, P2798; Moos PJ, 1998, CELL GROWTH DIFFER, V9, P687; Moos PJ, 2000, P NATL ACAD SCI USA, V97, P9215, DOI 10.1073/pnas.160241897; Mueller H, 1996, ANTICANCER RES, V16, P3845; NARUMIYA S, 1987, J PHARMACOL EXP THER, V242, P306; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; NARUMIYA S, 1985, BIOCHEM BIOPH RES CO, V127, P739, DOI 10.1016/S0006-291X(85)80005-X; OConnor PM, 1997, CANCER RES, V57, P4285; Okada K, 1999, J BIOL CHEM, V274, P23787, DOI 10.1074/jbc.274.34.23787; Pich A, 1998, CANCER J - FRANCE, V11, P223; Prives C, 1999, J PATHOL, V187, P112; Rodriguez MS, 2000, MOL CELL BIOL, V20, P8458, DOI 10.1128/MCB.20.22.8458-8467.2000; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Rossi A, 1997, P NATL ACAD SCI USA, V94, P746, DOI 10.1073/pnas.94.2.746; SASAKI H, 1991, GYNECOL ONCOL, V41, P36, DOI 10.1016/0090-8258(91)90251-Y; SCHAEFFER JR, 1996, BIOCHEMISTRY-US, V35, P10886; Shringarpure R, 2000, CELL MOL LIFE SCI, V57, P1802, DOI 10.1007/PL00000660; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; STRINGFELLOW DA, 1979, NATURE, V282, P76, DOI 10.1038/282076a0; Wagenknecht B, 1999, CELL PHYSIOL BIOCHEM, V9, P117, DOI 10.1159/000016308; WANG P, 1995, J BIOL CHEM, V270, P9558, DOI 10.1074/jbc.270.16.9558; Weller M, 1998, CELL TISSUE RES, V292, P435, DOI 10.1007/s004410051072; WILKINSON KD, 1995, BIOCHEMISTRY-US, V34, P14535, DOI 10.1021/bi00044a032; Yin LM, 2000, BIOCHEMISTRY-US, V39, P10001, DOI 10.1021/bi0007019	56	113	114	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30366	30373		10.1074/jbc.M102198200	http://dx.doi.org/10.1074/jbc.M102198200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11390388	hybrid			2022-12-25	WOS:000170558000100
J	Reguenga, C; Oliveira, MEM; Gouveia, AMM; Sa-Miranda, C; Azevedo, JE				Reguenga, C; Oliveira, MEM; Gouveia, AMM; Sa-Miranda, C; Azevedo, JE			Characterization of the mammalian peroxisomal import machinery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE NATIVE ELECTROPHORESIS; MEMBRANE-PROTEIN COMPLEXES; RAT-LIVER PEROXISOMES; PTS1 RECEPTOR PEX5P; TARGETING SIGNAL; SACCHAROMYCES-CEREVISIAE; CELL MUTANT; FUNCTIONAL COMPLEMENTATION; CDNA CLONING; DOCKING	Although many of the proteins involved in the biogenesis of the mammalian peroxisome have already been identified, our knowledge of the architecture of all this machinery is still very limited. In this work we used native gel electrophoresis and sucrose gradient sedimentation analysis in combination with immunoprecipitation experiments to address this issue. After solubilization of rat liver peroxisomes with the mild detergent digitonin, comigration of Pex5p, Pex14p, and a fraction of Pex12p was observed upon native electrophoresis and sucrose gradient sedimentation. The existence of a complex comprising Pex2p, Pex5p, Pex12p, and Pex14p was demonstrated by preparative coimmunoprecipitation experiments using an antibody directed to Pex14p. No stoichiometric amounts of Pex13p were detected in the Pex2p-Pex5p-Pex12p-Pex14p complex, although the presence of a small fraction of Pex13p in this complex could be demonstrated by Western blot analysis. Pex13p is also a component of a high molecular mass complex. Strikingly, partial purification of this Pex13p-containing complex revealed Pex13p as the major (if not the only) component. Taken together, our data indicate that Pex2p, Pex5p, Pex12p, and Pex14p, on one side, and Pex13p, on the other, are subunits of two stable protein complexes that probably interact with each other in the peroxisomal membrane.	Univ Porto, Inst Biol Mol & Celular, P-4150180 Oporto, Portugal; Univ Porto, Inst Ciencias Biomed Abel Salazar, P-4150180 Oporto, Portugal; Inst Genet Med Jacinto Magalhaes, P-4050466 Oporto, Portugal	Universidade do Porto; Universidade do Porto	Azevedo, JE (corresponding author), IBMC UP, Rua Campo Alegre 823, P-4150180 Oporto, Portugal.	Jazevedo@ibmc.up.pt	Gouveia, Alexandra/P-3525-2016; Azevedo, Jorge E/A-4113-2008; sá Miranda, Maria Clara/K-3920-2013	Gouveia, Alexandra/0000-0001-8784-4246; Azevedo, Jorge E/0000-0001-7714-5302; sá Miranda, Maria Clara/0000-0003-0123-5525; Oliveira, Marcia/0000-0003-2437-2004; Reguenga, Carlos/0000-0003-1219-9961				Albertini M, 1997, CELL, V89, P83, DOI 10.1016/S0092-8674(00)80185-3; Bottger G, 2000, MOL BIOL CELL, V11, P3963, DOI 10.1091/mbc.11.11.3963; Chang CC, 1999, J CELL BIOL, V147, P761, DOI 10.1083/jcb.147.4.761; Dodt G, 1996, J CELL BIOL, V135, P1763, DOI 10.1083/jcb.135.6.1763; Fransen M, 1998, P NATL ACAD SCI USA, V95, P8087, DOI 10.1073/pnas.95.14.8087; FRANSEN M, 1995, J BIOL CHEM, V270, P7731, DOI 10.1074/jbc.270.13.7731; Gould SJ, 1996, J CELL BIOL, V135, P85, DOI 10.1083/jcb.135.1.85; Gouveia AMM, 1999, ANAL BIOCHEM, V274, P270, DOI 10.1006/abio.1999.4281; Gouveia AMM, 2000, J BIOL CHEM, V275, P32444, DOI 10.1074/jbc.M004366200; HARTL FU, 1985, ARCH BIOCHEM BIOPHYS, V237, P124, DOI 10.1016/0003-9861(85)90261-9; Hettema EH, 1999, BBA-MOL CELL RES, V1451, P17, DOI 10.1016/S0167-4889(99)00087-7; Huang Y, 2000, BIOCHEM BIOPH RES CO, V270, P717, DOI 10.1006/bbrc.2000.2510; KIMURA C, 1984, J BIOCHEM, V96, P1463, DOI 10.1093/oxfordjournals.jbchem.a134975; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu YF, 1999, AM J HUM GENET, V65, P621, DOI 10.1086/302534; MERRIL CR, 1990, METHOD ENZYMOL, V182, P477; Okumoto K, 2000, J BIOL CHEM, V275, P25700, DOI 10.1074/jbc.M003303200; Okumoto K, 1998, MOL CELL BIOL, V18, P4324, DOI 10.1128/MCB.18.7.4324; Otera H, 2000, J BIOL CHEM, V275, P21703, DOI 10.1074/jbc.M000720200; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; Rehling P, 2000, J BIOL CHEM, V275, P3593, DOI 10.1074/jbc.275.5.3593; Sacksteder KA, 2000, ANNU REV GENET, V34, P623, DOI 10.1146/annurev.genet.34.1.623; Schagger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Shimizu N, 1999, J BIOL CHEM, V274, P12593, DOI 10.1074/jbc.274.18.12593; Subramani S, 2000, ANNU REV BIOCHEM, V69, P399, DOI 10.1146/annurev.biochem.69.1.399; TERLECKY SR, 1995, EMBO J, V14, P3627, DOI 10.1002/j.1460-2075.1995.tb00032.x; TSUKAMOTO T, 1991, NATURE, V350, P77, DOI 10.1038/350077a0; VANDERKLEI IJ, 1995, J BIOL CHEM, V270, P17299; VANDERLEIJ I, 1993, P NATL ACAD SCI USA, V90, P11782, DOI 10.1073/pnas.90.24.11782; Will GK, 1999, MOL CELL BIOL, V19, P2265	32	78	78	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29935	29942		10.1074/jbc.M104114200	http://dx.doi.org/10.1074/jbc.M104114200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11397814	hybrid			2022-12-25	WOS:000170558000045
J	Zhang, J; Kabra, NH; Cado, D; Kang, C; Winoto, A				Zhang, J; Kabra, NH; Cado, D; Kang, C; Winoto, A			FADD-deficient T cells exhibit a disaccord in regulation of the cell cycle machinery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEATH DOMAIN; INHIBITS PROLIFERATION; MEDIATED APOPTOSIS; TRAIL RECEPTOR-2; PROTEIN; FAS; FADD/MORT1; LYMPHOCYTES; PROGRESSION; CASPASE-8	FADD is an adapter protein that was originally isolated as a transducer of apoptotic signals for death domain-containing receptors. However, FADD-deficient mice are embryonic lethal and FADD(-/-) T cells developed from FADD(-/-) embryonic stem cells in the RAG-1(-/-) hosts lack the full potential to proliferate when stimulated through their T-cell receptor complex, suggesting that FADD protein might play a dualistic role in mediating not only cell death signaling but other non-apoptotic cellular pathways as well. Here we show that a substantial number of freshly isolated FADD(-/-) peripheral T cells are cycling but are defective in their co-stimulatory response when stimulated. Analysis of several cell cycle proteins shows normal down-regulation of p27 inhibitor but increased levels of p21, decreased levels of cyclin D2, and constitutive activation of several cyclin-dependent kinases in activated T cells. These data suggest that FADD is involved in the regulation of cell cycle machinery in T lymphocytes.	Univ Calif Berkeley, Dept Mol & Cell Biol, Div Immunol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Canc Res Lab, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley	Winoto, A (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Div Immunol, Berkeley, CA 94720 USA.			Zhang, Jianke/0000-0002-5822-2226	NCI NIH HHS [CA75162] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075162] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; Aravind L, 2001, SCIENCE, V291, P1279, DOI 10.1126/science.291.5507.1279; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; Hueber AO, 2000, J BIOL CHEM, V275, P10453, DOI 10.1074/jbc.275.14.10453; KAHRA NH, 2001, P NATL ACAD SCI USA, V98, P6307; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kuang AA, 2000, J BIOL CHEM, V275, P25065, DOI 10.1074/jbc.C000284200; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; LUCAS JJ, 1995, J IMMUNOL, V154, P6275; Morgan DO, 1996, CURR OPIN CELL BIOL, V8, P767, DOI 10.1016/S0955-0674(96)80076-7; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Newton K, 2000, EMBO J, V19, P931, DOI 10.1093/emboj/19.5.931; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; Newton K, 2001, CURR BIOL, V11, P273, DOI 10.1016/S0960-9822(01)00067-7; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; Nurse P, 2000, CELL, V100, P71, DOI 10.1016/S0092-8674(00)81684-0; Scaffidi C, 2000, J IMMUNOL, V164, P1236, DOI 10.4049/jimmunol.164.3.1236; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Song KM, 2000, J EXP MED, V191, P1095, DOI 10.1084/jem.191.7.1095; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Surh CD, 2000, J EXP MED, V192, pF9, DOI 10.1084/jem.192.4.F9; Tang DM, 1999, J BIOL CHEM, V274, P7245, DOI 10.1074/jbc.274.11.7245; Walsh CM, 1998, IMMUNITY, V8, P439, DOI 10.1016/S1074-7613(00)80549-X; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhang J, 1999, COLD SPRING HARB SYM, V64, P363, DOI 10.1101/sqb.1999.64.363; Zhang J, 1996, MOL CELL BIOL, V16, P2756; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681; Zhou T, 1996, J IMMUNOL, V156, P2661; Zornig M, 1998, CURR BIOL, V8, P467, DOI 10.1016/S0960-9822(98)70182-4	36	78	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29815	29818		10.1074/jbc.M103838200	http://dx.doi.org/10.1074/jbc.M103838200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11390402	hybrid			2022-12-25	WOS:000170558000029
J	Bender, K; Wellner-Kienitz, MC; Inanobe, A; Meyer, T; Kurachi, Y; Pott, L				Bender, K; Wellner-Kienitz, MC; Inanobe, A; Meyer, T; Kurachi, Y; Pott, L			Overexpression of monomeric and multimeric GIRK4 subunits in rat atrial myocytes removes fast desensitization and reduces inward rectification of muscarinic K(+) current (I(K(ACh))) - Evidence for functional homomeric GIRK4 channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-PROTEIN REGULATION; RECTIFYING POTASSIUM CHANNELS; BETA-GAMMA-SUBUNITS; I-KACH; COUPLED RECEPTORS; PLASMA-MEMBRANE; DOWN-REGULATION; M-2 RECEPTORS; ACTIVATION; BINDING	K(+) channels composed of G-protein-coupled inwardly rectifying K(+) channel (GIRK) (Kir3.0) subunits are ex. pressed in cardiac, neuronal, and various endocrine tissues. They are involved in inhibiting excitability and contribute to regulating important physiological functions such as cardiac frequency and secretion of hormones. The functional cardiac (K((ACh))) channel activated by G(i)/G(o)-coupled receptors such as muscarinic M(2) or purinergic A., receptors is supposed to be composed of the subunits GIRK1 and GIRK4 in a heterotetrameric (2:2) fashion. In the present study, we have manipulated the subunit composition of the K(ACh) channels in cultured atrial myocytes from hearts of adult rats by transient transfection of vectors encoding for GIRK1 or GIRK4 subunits or GIRK4 concatemeric constructs and investigated the effects on properties of macroscopic IK(Ach). Transfection with a GIRK1 vector did not cause any measurable effect on properties Of IK(ACh), whereas transfection with a GIRK4 vector resulted in a complete loss in desensitization, a reduction of inward rectification, and a slowing of activation. Transfection of myocytes with a construct encoding for a concatemeric GIRK4(2) subunit had similar effects on desensitization and inward rectification. Following transfection of a tetrameric construct (GIRK4,), these changes in properties Of IK(ACh) were still observed but were less pronounced. Heterologous expression in Chinese hamster ovary cells and human embryonic kidney 293 cells of monomeric, dimeric, and tetrameric GIRK4 resulted in robust currents activated by co-expressed A(1) and M(2) receptors, respectively. These data provide strong evidence that homomeric GIRK4 complexes form functional G(beta gamma) gated ion channels and that kinetic properties of GIRK channels, such as activation rate, desensitization, and inward rectification, depend on subunit composition.	Ruhr Univ Bochum, Inst Physiol, D-4480 Bochum, Germany; Osaka Univ, Grad Sch, Dept Pharmacol 2, Suita, Osaka 5650871, Japan; Osaka Univ, Fac Med, Suita, Osaka 5650871, Japan	Ruhr University Bochum; Osaka University; Osaka University	Pott, L (corresponding author), Ruhr Univ Bochum, Inst Physiol, D-4480 Bochum, Germany.	lutz.pott@ruhr-uni-bochum.de	Pott, Lutz/E-5304-2011	Pott, Lutz/0000-0002-4000-4132				Brandts B, 1997, BRIT J PHARMACOL, V121, P1217, DOI 10.1038/sj.bjp.0701254; Bunemann M, 2000, J BIOL CHEM, V275, P12537, DOI 10.1074/jbc.275.17.12537; Bunemann M, 1996, EMBO J, V15, P5527, DOI 10.1002/j.1460-2075.1996.tb00937.x; Bunemann M, 1999, ANNU REV PHYSIOL, V61, P169, DOI 10.1146/annurev.physiol.61.1.169; Bunemann M, 1997, J PHYSIOL-LONDON, V501, P549, DOI 10.1111/j.1469-7793.1997.549bm.x; BUNEMANN M, 1996, J PHYSIOL-LONDON, V492, P351; Chuang HH, 1998, P NATL ACAD SCI USA, V95, P11727, DOI 10.1073/pnas.95.20.11727; Corey S, 2001, J BIOL CHEM, V276, P11409, DOI 10.1074/jbc.M100058200; Corey S, 1998, J BIOL CHEM, V273, P27499, DOI 10.1074/jbc.273.42.27499; Dascal N, 1997, CELL SIGNAL, V9, P551, DOI 10.1016/S0898-6568(97)00095-8; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P6596, DOI 10.1073/pnas.90.14.6596; Guo DL, 2000, J GEN PHYSIOL, V116, P561, DOI 10.1085/jgp.116.4.561; He C, 1999, J BIOL CHEM, V274, P12517, DOI 10.1074/jbc.274.18.12517; Hedin KE, 1996, NEURON, V16, P423, DOI 10.1016/S0896-6273(00)80060-4; Huang CL, 1997, FEBS LETT, V405, P291, DOI 10.1016/S0014-5793(97)00197-X; Inanobe A, 1999, J NEUROSCI, V19, P1006; Jan LY, 1997, J PHYSIOL-LONDON, V505, P267, DOI 10.1111/j.1469-7793.1997.267bb.x; Jelacic TM, 2000, J BIOL CHEM, V275, P36211, DOI 10.1074/jbc.M007087200; Ji S, 1998, J BIOL CHEM, V273, P1324, DOI 10.1074/jbc.273.3.1324; Karschin A, 1999, NEWS PHYSIOL SCI, V14, P215; Kennedy ME, 1999, J BIOL CHEM, V274, P2571, DOI 10.1074/jbc.274.4.2571; KIM DH, 1993, CIRC RES, V73, P89, DOI 10.1161/01.RES.73.1.89; Kobrinsky E, 2000, NAT CELL BIOL, V2, P507, DOI 10.1038/35019544; Koumi S, 1997, J MEMBRANE BIOL, V157, P71, DOI 10.1007/s002329900217; Krapivinsky G, 1998, J BIOL CHEM, V273, P16946, DOI 10.1074/jbc.273.27.16946; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P29059, DOI 10.1074/jbc.270.49.29059; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; KURACHI Y, 1987, PFLUG ARCH EUR J PHY, V410, P227, DOI 10.1007/BF00580270; Meyer T, 2001, J BIOL CHEM, V276, P5650, DOI 10.1074/jbc.M009179200; Morishige K, 1999, J BIOL CHEM, V274, P7969, DOI 10.1074/jbc.274.12.7969; Oliver D, 2000, EUR J BIOCHEM, V267, P5824, DOI 10.1046/j.1432-1327.2000.01669.x; Shui Z, 1997, J PHYSIOL-LONDON, V505, P77, DOI 10.1111/j.1469-7793.1997.077bc.x; Silverman SK, 1996, J BIOL CHEM, V271, P30524, DOI 10.1074/jbc.271.48.30524; SLESINGER PA, 1995, NEURON, V15, P1145, DOI 10.1016/0896-6273(95)90102-7; TAGLIALATELA M, 1995, EMBO J, V14, P5532, DOI 10.1002/j.1460-2075.1995.tb00240.x; TAKAO K, 1994, NEURON, V13, P747, DOI 10.1016/0896-6273(94)90041-8; Tsao P, 2000, CURR OPIN NEUROBIOL, V10, P365, DOI 10.1016/S0959-4388(00)00096-9; Tucker SJ, 1996, AM J PHYSIOL-HEART C, V271, pH379, DOI 10.1152/ajpheart.1996.271.1.H379; Vivaudou M, 1997, J BIOL CHEM, V272, P31553, DOI 10.1074/jbc.272.50.31553; Wellner-Kienitz MC, 1999, FEBS LETT, V451, P279, DOI 10.1016/S0014-5793(99)00594-3; Wellner-Kienitz MC, 2000, CIRC RES, V86, P643, DOI 10.1161/01.RES.86.6.643; Wickman K, 2000, J NEUROSCI, V20, P5608, DOI 10.1523/JNEUROSCI.20-15-05608.2000; YAMADA M, 1995, J BIOL CHEM, V270, P9289, DOI 10.1074/jbc.270.16.9289; Yamada M, 1998, PHARMACOL REV, V50, P723	45	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28873	28880		10.1074/jbc.M102328200	http://dx.doi.org/10.1074/jbc.M102328200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11384974	hybrid			2022-12-25	WOS:000170346000033
J	Koutsodontis, G; Tentes, I; Papakosta, P; Moustakas, A; Kardassis, D				Koutsodontis, G; Tentes, I; Papakosta, P; Moustakas, A; Kardassis, D			Sp1 plays a critical role in the transcriptional activation of the human cyclin-dependent kinase inhibitor p21(WAF1/Cip1) gene by the p53 tumor suppressor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; CELL-CYCLE; WAF1/CIP1 GENE; P53-INDEPENDENT PATHWAY; FUNCTIONAL INTERACTIONS; SYNERGISTIC ACTIVATION; P53-INDUCED APOPTOSIS; EMBRYONIC-DEVELOPMENT; POTENTIAL MEDIATOR; CARCINOMA-CELLS	In the present study we present evidence for the critical role of Spl in the mechanism of transactivation of the human cell cycle inhibitor p21(WAF1/Cip1) (p21) gene promoter by the tumor suppressor p53 protein. We found that the distal p53-binding site of the p21 promoter acts as an enhancer on the homologous or heterologous promoters in hepatoma HepG2 cells. In transfection experiments, p53 transactivated the p21 promoter in HaCaT cells that express Spl but have a mutated p53 form. In contrast, p53 could not transactivate the p21 promoter in the Drosophila embryo-derived Schneider's SL2 cells that lack endogenous Spl or related factors. Cotransfection of SL2 cells with p53 and Spl resulted in a synergistic transactivation of the p21 promoter. Synergistic transactivation was greatly decreased in SL2 cells and HaCaT cells by mutations in either the p53-binding site or in the -82/-77 Spl-binding site indicating functional cooperation between Spl and p53 in the transactivation of the p21 promoter. Synergistic transactivation was also decreased by mutations in the transactivation domain of p53. Physical interactions between Spl and p53 proteins were established by glutathione S-transferase pull-down and coimmunoprecipitation assays. By using deletion mutants we found that the DNA binding domain of Spl is required for its physical interaction with p53. In conclusion, Spl must play a critical role in regulating important biological processes controlled by p53 via p21 gene activation such as DNA repair, cell growth, differentiation, and apoptosis.	Univ Crete, Sch Med, Dept Basic Sci, GR-71110 Iraklion, Greece; Fdn Res & Technol Hellas, Inst Mol Biol & Biotechnol, GR-71110 Iraklion, Greece; Ludwig Inst Canc Res, S-75124 Uppsala, Sweden; Democritus Univ Thrace, Sch Med, Dept Biochem, GR-68100 Alexandroupolis, Greece	University of Crete; Foundation for Research & Technology - Hellas (FORTH); Ludwig Institute for Cancer Research; Democritus University of Thrace	Kardassis, D (corresponding author), Univ Crete, Sch Med, Dept Basic Sci, GR-71110 Iraklion, Greece.	kardasis@imbb.forth.gr						AKASHI M, 1995, J BIOL CHEM, V270, P19181, DOI 10.1074/jbc.270.32.19181; BERG JM, 1992, P NATL ACAD SCI USA, V89, P11109, DOI 10.1073/pnas.89.23.11109; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Bist A, 2000, BIOCHEMISTRY-US, V39, P1966, DOI 10.1021/bi991721h; Black AR, 1999, J BIOL CHEM, V274, P1207, DOI 10.1074/jbc.274.3.1207; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chen JD, 1996, MOL CELL BIOL, V16, P2445; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Choi J, 1999, CELL MOL LIFE SCI, V55, P38, DOI 10.1007/s000180050268; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DOTTO GP, 2000, BIOCHIM BIOPHYS ACTA, V1471, P43; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Erhardt JA, 1998, J BIOL CHEM, V273, P23517, DOI 10.1074/jbc.273.36.23517; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; GUALBERTO A, 1995, J BIOL CHEM, V270, P19680, DOI 10.1074/jbc.270.34.19680; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; Hirano F, 1998, MOL CELL BIOL, V18, P1266, DOI 10.1128/MCB.18.3.1266; HSU IC, 1993, CARCINOGENESIS, V14, P987, DOI 10.1093/carcin/14.5.987; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; Hunt KK, 1998, CANCER RES, V58, P5656; Jacks T, 1998, SCIENCE, V280, P1035, DOI 10.1126/science.280.5366.1035; Jaiswal AS, 2001, J BIOL CHEM, V276, P18193, DOI 10.1074/jbc.M101298200; JIANG HP, 1994, ONCOGENE, V9, P3397; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; KARDASSIS D, 1992, J BIOL CHEM, V267, P7956; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kolli S, 2001, P NATL ACAD SCI USA, V98, P4646, DOI 10.1073/pnas.081141998; Lange C, 2000, BIOCHEM BIOPH RES CO, V278, P125, DOI 10.1006/bbrc.2000.3782; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; Laronga C, 2000, J BIOL CHEM, V275, P23106, DOI 10.1074/jbc.M905616199; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; Lee SJ, 1998, J BIOL CHEM, V273, P10618, DOI 10.1074/jbc.273.17.10618; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li JM, 1998, NUCLEIC ACIDS RES, V26, P2449, DOI 10.1093/nar/26.10.2449; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Lin SY, 1996, MOL CELL BIOL, V16, P1668; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; MICHIELI P, 1994, CANCER RES, V54, P3391; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Ohlsson C, 1998, ENDOCRINOLOGY, V139, P1101, DOI 10.1210/en.139.3.1101; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Thornborrow EC, 2001, J BIOL CHEM, V276, P15598, DOI 10.1074/jbc.M011643200; Torgeman A, 2001, VIROLOGY, V281, P10, DOI 10.1006/viro.2000.0779; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; Yan GZ, 1997, J NEUROSCI, V17, P6122; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zauberman A, 1997, ONCOGENE, V15, P1705, DOI 10.1038/sj.onc.1201348; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; ZHANG H, 1994, COLD SPRING HARB SYM, V59, P21, DOI 10.1101/SQB.1994.059.01.005; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; Zhang LL, 2000, CANCER RES, V60, P3655; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200; Zhao RB, 2000, GENE DEV, V14, P981	81	141	144	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29116	29125		10.1074/jbc.M104130200	http://dx.doi.org/10.1074/jbc.M104130200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11384995	hybrid			2022-12-25	WOS:000170346000066
J	Leber, R; Silles, E; Sandoval, IV; Mazon, MJ				Leber, R; Silles, E; Sandoval, IV; Mazon, MJ			Yo1082p, a novel CVT protein involved in the selective targeting of aminopeptidase I to the yeast vacuole	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; GENE DELETION; CYTOPLASM; AUTOPHAGY; PATHWAYS; TRANSPORT; MACROAUTOPHAGY; MECHANISM; CELLS	The yeast vacuolar enzyme aminopeptidase I (API) is synthesized in the cytoplasm as a precursor (pAPI). Upon its assembly into dodecamers, pAPI is wrapped by double-membrane saccular structures for its further transport within vesicles that fuse with the vacuolar membrane and release their content in the vacuolar lumen. Targeting of API to the vacuole occurs by two alternative transport routes, the cvt and the autophagy pathways, which although mechanistically similar specifically operate under vegetative growth or nitrogen starvation conditions, respectively. We have studied the role of Yol082p, a protein identified by its ability to interact with API, in the transport of its precursor to the vacuole. We show that Yol082p, interacts with mature API, an interaction that is strengthened by the amino extension of the API protein. Yol082p is required for targeting of pAPI to the vacuole, both under growing and short term nitrogen starvation conditions. Absence of Yol082p does not impede the assembly of pAPI into dodecamers, but precludes the enclosure of pAPI within transport vesicles. Microscopy studies show that during vegetative growth Yol082p is distributed between a cytoplasmic pool and a variable number of 0.13-0.27-mum round, mobile structures, which are no longer observed under conditions of nitrogen starvation, and become larger in cells expressing the inactive Yol082 Delta C32p, or lacking Apg12p. In contrast to the autophagy mutants involved in API transport, a Delta yol082 strain does not lose viability under nitrogen starvation conditions, indicating normal function of the autophagy pathway. The data are consistent with a role of Yol082p in an early step of the API transport, after its assembly into dodecamers. Because Yo1082p fulfills the functional requisites that define the CVT proteins, we propose to name it Cvt19.	Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, E-28029 Madrid, Spain; Univ Autonoma Madrid, Fac Ciencias, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Mazon, MJ (corresponding author), Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, E-28029 Madrid, Spain.		Calpena, María Jesús Mazón/E-9168-2016	Calpena, María Jesús Mazón/0000-0003-4151-4051; Leber, Regina/0000-0001-5306-5834				Abeliovich H, 2000, J CELL BIOL, V151, P1025, DOI 10.1083/jcb.151.5.1025; Adams Alison, 1997, P123; Baba M, 1997, J CELL BIOL, V139, P1687, DOI 10.1083/jcb.139.7.1687; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; George MD, 2000, MOL BIOL CELL, V11, P969, DOI 10.1091/mbc.11.3.969; Harding TM, 1996, J BIOL CHEM, V271, P17621, DOI 10.1074/jbc.271.30.17621; Huang WP, 2000, J BIOL CHEM, V275, P5845, DOI 10.1074/jbc.275.8.5845; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; James P, 1996, GENETICS, V144, P1425; Kim J, 1999, MOL BIOL CELL, V10, P1337, DOI 10.1091/mbc.10.5.1337; Kim J, 2000, ANNU REV BIOCHEM, V69, P303, DOI 10.1146/annurev.biochem.69.1.303; Kim J, 1997, J CELL BIOL, V137, P609, DOI 10.1083/jcb.137.3.609; KLIONSKY DJ, 1992, J CELL BIOL, V119, P287, DOI 10.1083/jcb.119.2.287; Martinez E, 1999, MOL MICROBIOL, V33, P52, DOI 10.1046/j.1365-2958.1999.01446.x; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Niedenthal RK, 1996, YEAST, V12, P773, DOI 10.1002/(SICI)1097-0061(19960630)12:8<773::AID-YEA972>3.3.CO;2-C; Noda T, 2000, J CELL BIOL, V148, P465, DOI 10.1083/jcb.148.3.465; Oda MN, 1996, J CELL BIOL, V132, P999, DOI 10.1083/jcb.132.6.999; Satyanarayana C, 2000, FEBS LETT, V470, P232, DOI 10.1016/S0014-5793(00)01324-7; Scott SV, 2000, J BIOL CHEM, V275, P25840, DOI 10.1074/jbc.M002813200; Scott SV, 1996, P NATL ACAD SCI USA, V93, P12304, DOI 10.1073/pnas.93.22.12304; Scott SV, 1997, J CELL BIOL, V138, P37, DOI 10.1083/jcb.138.1.37; Scott SV, 1995, J CELL BIOL, V131, P1727, DOI 10.1083/jcb.131.6.1727; SEGUIREAL B, 1995, EMBO J, V14, P5476, DOI 10.1002/j.1460-2075.1995.tb00234.x; Silles E, 2000, J BIOL CHEM, V275, P34054, DOI 10.1074/jbc.M003514200; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901	29	59	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29210	29217		10.1074/jbc.M101438200	http://dx.doi.org/10.1074/jbc.M101438200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11382752	hybrid			2022-12-25	WOS:000170346000078
J	Ratnaparkhi, GS; Varadarajan, R				Ratnaparkhi, GS; Varadarajan, R			Osmolytes stabilize ribonuclease S by stabilizing its fragments S protein and S peptide to compact folding-competent states	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VAPOR-PRESSURE OSMOMETRY; THERMODYNAMIC CHARACTERIZATION; PREFERENTIAL HYDRATION; KINETIC MECHANISM; NATIVE-STATE; PACKING; UREA; DENATURATION; RECEPTOR; EXCHANGE	Osmolytes stabilize proteins to thermal and chemical denaturation. We have studied the effects of the osmolytes sarcosine, betaine, trimethylamine-N-oxide, and taurine on the structure and stability of the protein-peptide complex RNase S using x-ray crystallography and titration calorimetry, respectively. The largest degree of stabilization is achieved with 6 M sarcosine, which increases the denaturation temperatures of RNase S and S pro by 24.6 and 17.4 degreesC, respectively, at pH 5 and protects both proteins against tryptic cleavage. Four crystal structures of RNase S in the presence of different osmolytes do not offer any evidence for osmolyte binding to the folded state of the protein or any perturbation in the water structure surrounding the protein. The degree of stabilization in 6 M sarcosine increases with temperature, ranging from -0.52 kcal mol(-1) at 20 degreesC to -5.4 kcal mol(-1) at 60 degreesC. The data support the thesis that osmolytes that stabilize proteins, do so by perturbing unfolded states, which change conformation to a compact, folding competent state in the presence of osmolyte. The increased stabilization thus results from a decrease in conformational entropy of the unfolded state.	Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India; Natl Ctr Biol Sci, Bangalore 560065, Karnataka, India; Jawaharlal Nehru Ctr Adv Sci Res, Chem Biol Unit, Bangalore 560064, Karnataka, India	Indian Institute of Science (IISC) - Bangalore; Tata Institute of Fundamental Research (TIFR); National Centre for Biological Sciences (NCBS); Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR)	Varadarajan, R (corresponding author), Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India.	varadar@mbu.iisc.ernet.in	Ratnaparkhi, Girish/ABC-4128-2020; Ratnaparkhi, Girish S/K-6584-2012	Ratnaparkhi, Girish/0000-0001-7615-3140; Ratnaparkhi, Girish S/0000-0001-7615-3140				ALLENDE JE, 1962, BIOCHEMISTRY-US, V1, P295, DOI 10.1021/bi00908a017; Anjum F, 2000, BBA-PROTEIN STRUCT M, V1476, P75, DOI 10.1016/S0167-4838(99)00215-0; ARAKAWA T, 1990, BIOCHEMISTRY-US, V29, P1924, DOI 10.1021/bi00459a037; ARAKAWA T, 1985, BIOPHYS J, V47, P411, DOI 10.1016/S0006-3495(85)83932-1; Baskakov I, 1998, J BIOL CHEM, V273, P4831, DOI 10.1074/jbc.273.9.4831; Baskakov IV, 1999, J BIOL CHEM, V274, P10693, DOI 10.1074/jbc.274.16.10693; Burton RE, 2000, PROTEIN SCI, V9, P776; Catanzano F, 1996, BIOCHEMISTRY-US, V35, P13378, DOI 10.1021/bi960855h; Chakravarty S, 1999, STRUCT FOLD DES, V7, P723, DOI 10.1016/S0969-2126(99)80097-5; Chakravarty S, 2000, FEBS LETT, V476, P296, DOI 10.1016/S0014-5793(00)01725-7; Chakshusmathi G, 1999, P NATL ACAD SCI USA, V96, P7899, DOI 10.1073/pnas.96.14.7899; CONNELLY PR, 1990, BIOCHEMISTRY-US, V29, P6108, DOI 10.1021/bi00477a031; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; Courtenay ES, 2000, BIOCHEMISTRY-US, V39, P4455, DOI 10.1021/bi992887l; DELPINO IMP, 1995, BIOCHEMISTRY-US, V34, P8621, DOI 10.1021/bi00027a011; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; DOIG AJ, 1991, J MOL BIOL, V217, P389, DOI 10.1016/0022-2836(91)90551-G; Foord RL, 1998, BIOCHEMISTRY-US, V37, P2969, DOI 10.1021/bi9712798; Frye KJ, 1997, PROTEIN SCI, V6, P789; Ganesh C, 1997, BIOCHEMISTRY-US, V36, P5020, DOI 10.1021/bi961967b; Goldberg JM, 1998, BIOCHEMISTRY-US, V37, P2556, DOI 10.1021/bi972403q; Goldberg JM, 1998, BIOCHEMISTRY-US, V37, P2546, DOI 10.1021/bi972402y; Kendrick BS, 1997, P NATL ACAD SCI USA, V94, P11917, DOI 10.1073/pnas.94.22.11917; KIM EE, 1992, BIOCHEMISTRY-US, V31, P12304, DOI 10.1021/bi00164a004; KIM PS, 1984, NATURE, V307, P329, DOI 10.1038/307329a0; Knapp S, 1999, EXTREMOPHILES, V3, P191, DOI 10.1007/s007920050116; Knubovets T, 1999, P NATL ACAD SCI USA, V96, P1262, DOI 10.1073/pnas.96.4.1262; Kurapkat G, 1997, BIOPOLYMERS, V41, P267, DOI 10.1002/(SICI)1097-0282(199703)41:3<267::AID-BIP3>3.0.CO;2-Q; LIN TY, 1994, BIOCHEMISTRY-US, V33, P12695, DOI 10.1021/bi00208a021; LIU YF, 1995, BIOCHEMISTRY-US, V34, P12884, DOI 10.1021/bi00039a051; MANIKEN MW, 1977, ANNU REV BIOPHYS BIO, V6, P301; MITCHINSON C, 1986, Proteins Structure Function and Genetics, V1, P23, DOI 10.1002/prot.340010106; Nadig G, 1996, PROTEIN SCI, V5, P2104, DOI 10.1002/pro.5560051017; OOI T, 1963, BIOCHEMISTRY-US, V2, P432, DOI 10.1021/bi00903a006; Ozer I, 1998, ANAL BIOCHEM, V264, P199, DOI 10.1006/abio.1998.2855; Pattabiraman N, 1995, J MOL RECOGNIT, V8, P334, DOI 10.1002/jmr.300080603; PERSICHETTI RA, 1995, J AM CHEM SOC, V117, P2732, DOI 10.1021/ja00115a008; PFLUMM MN, 1969, J BIOL CHEM, V244, P3973; Qu YX, 1998, P NATL ACAD SCI USA, V95, P9268, DOI 10.1073/pnas.95.16.9268; Ratnaparkhi GS, 1999, PROTEINS, V36, P282, DOI 10.1002/(SICI)1097-0134(19990815)36:3<282::AID-PROT3>3.3.CO;2-6; Ratnaparkhi GS, 2000, BIOCHEMISTRY-US, V39, P12365, DOI 10.1021/bi000775k; Ratnaparkhi GS, 1998, BIOCHEMISTRY-US, V37, P6958, DOI 10.1021/bi972857n; Ratnaparkhi GS, 2000, PROTEIN ENG, V13, P697, DOI 10.1093/protein/13.10.697; RICHARDS FM, 1971, ENZYMES, V4, P647; SANTORO MM, 1992, BIOCHEMISTRY-US, V31, P5278, DOI 10.1021/bi00138a006; THOMSON J, 1994, BIOCHEMISTRY-US, V33, P8587, DOI 10.1021/bi00194a025; Timasheff S N, 1995, Methods Mol Biol, V40, P253; VARADARAJAN R, 1992, BIOCHEMISTRY-US, V31, P1421, DOI 10.1021/bi00120a019; VARADARAJAN R, 1992, BIOCHEMISTRY-US, V31, P12315, DOI 10.1021/bi00164a005; WANG A, 1995, BIOCHEMISTRY-US, V34, P15096, DOI 10.1021/bi00046a016; Xie GF, 1997, PROTEIN SCI, V6, P211; Xie GF, 1997, PROTEIN SCI, V6, P222; YANCEY PH, 1979, BIOCHEM J, V183, P317, DOI 10.1042/bj1830317; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124; Yang DS, 1999, J BIOL CHEM, V274, P32970, DOI 10.1074/jbc.274.46.32970; Zelinski T, 1997, ANGEW CHEM INT EDIT, V36, P722, DOI 10.1002/anie.199707221; Zhang WT, 1996, BIOCHEMISTRY-US, V35, P10506, DOI 10.1021/bi960795f; [No title captured]	58	60	63	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28789	28798		10.1074/jbc.M101906200	http://dx.doi.org/10.1074/jbc.M101906200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11373282	hybrid			2022-12-25	WOS:000170346000021
J	Walter, W; Studitsky, VM				Walter, W; Studitsky, VM			Facilitated transcription through the nucleosome at high ionic strength occurs via a histone octamer transfer mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; ACTIVE TRANSCRIPTION; CHROMATIN TEMPLATES; SWI/SNF COMPLEX; HEAT-SHOCK; IN-VITRO; ELONGATION; SPT5; DNA; INVITRO	The rate of transcription through the nucleosome, the fine structure of the nucleosomal barrier, and the fate of the nucleosome during transcription at different salt concentrations were analyzed using linear 227-base pair mononucleosomal templates containing a uniquely positioned nucleosome core. At lower ionic strength (30 mm NaCl), the nucleosome constitutes a strong barrier for SP6 RNA polymerase. At higher ionic strength (330 mm NaCl), the rates of transcription on nucleosomal and histone-free DNA templates are very similar. At both higher and lower ionic strengths, the complete histone octamer is transferred over the same distance by fundamentally similar mechanisms. The data indicate that even at the rate of transcription characteristic of histone-free DNA, the transfer intermediates can be formed quite efficiently. This suggests possible mechanisms that could facilitate transcription through the nucleosome at physiological ionic strength.	Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Ctr Mol Med & Genet, Detroit, MI 48201 USA	Wayne State University; Wayne State University	Studitsky, VM (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, 540 E Canfield Ave,Rm 5123, Detroit, MI 48201 USA.		Studitsky, Vasily/A-9382-2014		NIGMS NIH HHS [GM58650] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058650] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrulis ED, 2000, GENE DEV, V14, P2635, DOI 10.1101/gad.844200; AUSIO J, 1989, J MOL BIOL, V206, P451, DOI 10.1016/0022-2836(89)90493-2; BASHKIN J, 1993, BIOCHEMISTRY-US, V32, P1895, DOI 10.1021/bi00059a002; Bazett-Jones DP, 1999, MOL CELL BIOL, V19, P1470; Bednar J, 1999, MOL CELL, V4, P377, DOI 10.1016/S1097-2765(00)80339-1; Brown SA, 1996, GENE DEV, V10, P1479, DOI 10.1101/gad.10.12.1479; Chang CH, 1997, J BIOL CHEM, V272, P23427, DOI 10.1074/jbc.272.37.23427; Cho H, 1998, MOL CELL BIOL, V18, P5355, DOI 10.1128/MCB.18.9.5355; Conaway JW, 2000, TRENDS BIOCHEM SCI, V25, P375, DOI 10.1016/S0968-0004(00)01615-7; DING HF, 1994, SCIENCE, V265, P796, DOI 10.1126/science.8047885; FOE VE, 1976, CELL, V9, P131, DOI 10.1016/0092-8674(76)90059-3; Hartzog GA, 1998, GENE DEV, V12, P357, DOI 10.1101/gad.12.3.357; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; JORGENSEN ED, 1991, J BIOL CHEM, V266, P645; KAMAKAKA RT, 1990, EMBO J, V9, P3997, DOI 10.1002/j.1460-2075.1990.tb07621.x; Kaplan CD, 2000, GENE DEV, V14, P2623, DOI 10.1101/gad.831900; LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900; Lorch Y, 1999, CELL, V96, P389, DOI 10.1016/S0092-8674(00)80551-6; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MATHIS DJ, 1978, NUCLEIC ACIDS RES, V5, P3523, DOI 10.1093/nar/5.10.3523; MCKNIGHT SL, 1979, CELL, V17, P551; MEERSSEMAN G, 1992, EMBO J, V11, P2951, DOI 10.1002/j.1460-2075.1992.tb05365.x; OBRIEN T, 1993, MOL CELL BIOL, V13, P3456, DOI 10.1128/MCB.13.6.3456; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; Orphanides G, 2000, NATURE, V407, P471, DOI 10.1038/35035000; PENNINGS S, 1994, P NATL ACAD SCI USA, V91, P10275, DOI 10.1073/pnas.91.22.10275; POSTNIKOV YV, 1991, NUCLEIC ACIDS RES, V19, P717, DOI 10.1093/nar/19.4.717; Protacio RU, 2000, MOL CELL BIOL, V20, P8866, DOI 10.1128/MCB.20.23.8866-8878.2000; Shilatifard A, 1998, FASEB J, V12, P1437, DOI 10.1096/fasebj.12.14.1437; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; STUDITSKY VM, 1995, CELL, V83, P19, DOI 10.1016/0092-8674(95)90230-9; Studitsky VM, 1997, SCIENCE, V278, P1960, DOI 10.1126/science.278.5345.1960; STUDITSKY VM, 1994, CELL, V76, P371, DOI 10.1016/0092-8674(94)90343-3; UCKER DS, 1984, J BIOL CHEM, V259, P7416; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; WASYLYK B, 1979, J MOL BIOL, V128, P411, DOI 10.1016/0022-2836(79)90095-0; WASYLYK B, 1980, EUR J BIOCHEM, V103, P219, DOI 10.1111/j.1432-1033.1980.tb04306.x; WASYLYK B, 1979, EUR J BIOCHEM, V98, P317, DOI 10.1111/j.1432-1033.1979.tb13191.x; Whitehouse I, 1999, NATURE, V400, P784, DOI 10.1038/23506; WILLIAMSON P, 1978, BIOCHEMISTRY-US, V17, P5695, DOI 10.1021/bi00619a015; Wittschieben BO, 1999, MOL CELL, V4, P123, DOI 10.1016/S1097-2765(00)80194-X; Zhou YB, 1998, NATURE, V395, P402, DOI 10.1038/26521	42	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29104	29110		10.1074/jbc.M103704200	http://dx.doi.org/10.1074/jbc.M103704200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11390400	hybrid			2022-12-25	WOS:000170346000064
J	Chen, YA; Scales, SJ; Jagath, JR; Scheller, RH				Chen, YA; Scales, SJ; Jagath, JR; Scheller, RH			A discontinuous SNAP-25 C-terminal coil supports exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-FUSION; SNARE COMPLEX; NEUROTRANSMITTER RELEASE; SYNAPTIC EXOCYTOSIS; ALPHA-SNAP; BOTULINAL NEUROTOXINS; CYTOSOLIC PROTEINS; KINETIC COMPONENTS; NSF; SPECIFICITY	Membrane fusion requires the formation of four-helical bundles comprised of the SNARE proteins syntaxin, vesicle-associated membrane protein (VAMP), and the synaptosomal-associated protein of 25 kDa (SNAP-25). Botulinum. neurotoxin E cleaves the C-terminal coil of SNAP-25, inhibiting exocytosis of norepinephrine from permeabilized PC12 cells. Addition of a 26-mer peptide comprising the C terminus of SNAP-25 that is cleaved by the toxin restores exocytosis, demonstrating that continuity of the SNAP-25 C-terminal helix is not critical for its function. By contrast, vesicle-associated membrane protein peptides could not rescue botulinum neurotoxin D-treated cells, suggesting that helix continuity is critical for VAMP function. Much higher concentrations of the SNAP-25 C-terminal peptide are required for rescuing exocytosis (K-assembly = similar to 460 mum) than for binding to other SNARES in vitro (K-d < 5 <mu>m). Each residue of the peptide was mutated to alanine to assess its functional importance. Whereas most mutants rescue exocytosis with lower efficiency than the wild type peptide, D186A rescues with higher efficiency, and kinetic analysis suggests this is because of higher affinity for the cellular binding site. This is consistent with Asp-186 contributing to negative regulation of the fusion process.	Stanford Univ, Howard Hughes Med Inst, Dept Cellular & Mol Physiol, Sch Med, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University	Scheller, RH (corresponding author), Stanford Univ, Howard Hughes Med Inst, Dept Cellular & Mol Physiol, Sch Med, Stanford, CA 94305 USA.		Junutula, Jagath Reddy/ABD-4753-2020; Scales, Suzie J./H-4507-2019	Junutula, Jagath Reddy/0000-0002-5942-4428; Scales, Suzie J./0000-0003-2544-0283				BINZ T, 1994, J BIOL CHEM, V269, P1617; Bock JB, 1999, P NATL ACAD SCI USA, V96, P12227, DOI 10.1073/pnas.96.22.12227; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; Chen YA, 1999, J BIOL CHEM, V274, P26469, DOI 10.1074/jbc.274.37.26469; Chen YA, 2001, NEURON, V30, P161, DOI 10.1016/S0896-6273(01)00270-7; Fasshauer D, 1998, P NATL ACAD SCI USA, V95, P15781, DOI 10.1073/pnas.95.26.15781; Fasshauer D, 1999, J BIOL CHEM, V274, P15440, DOI 10.1074/jbc.274.22.15440; Fernandez-Chacon R, 2001, NATURE, V410, P41; Fujita Y, 1998, NEURON, V20, P905, DOI 10.1016/S0896-6273(00)80472-9; Gerona RRL, 2000, J BIOL CHEM, V275, P6328, DOI 10.1074/jbc.275.9.6328; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; Hua SY, 1999, NAT NEUROSCI, V2, P1078, DOI 10.1038/16005; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Lin RC, 2000, ANNU REV CELL DEV BI, V16, P19, DOI 10.1146/annurev.cellbio.16.1.19; Lin RC, 1997, NEURON, V19, P1087, DOI 10.1016/S0896-6273(00)80399-2; Littleton JT, 1998, NEURON, V21, P401, DOI 10.1016/S0896-6273(00)80549-8; Lonart G, 2000, J BIOL CHEM, V275, P27703; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; MCMAHON HT, 1995, CELL, V83, P111, DOI 10.1016/0092-8674(95)90239-2; McNew JA, 2000, J CELL BIOL, V150, P105, DOI 10.1083/jcb.150.1.105; McNew JA, 1999, MOL CELL, V4, P415, DOI 10.1016/S1097-2765(00)80343-3; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; Reim K, 2001, CELL, V104, P71, DOI 10.1016/S0092-8674(01)00192-1; Scales SJ, 2000, NEURON, V26, P457, DOI 10.1016/S0896-6273(00)81177-0; Schiavo G, 2000, PHYSIOL REV, V80, P717, DOI 10.1152/physrev.2000.80.2.717; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Weber T, 2000, J CELL BIOL, V149, P1063, DOI 10.1083/jcb.149.5.1063; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Xu T, 1999, CELL, V99, P713, DOI 10.1016/S0092-8674(00)81669-4; Xu T, 1998, NAT NEUROSCI, V1, P192, DOI 10.1038/642; Xu T, 1999, EMBO J, V18, P3293, DOI 10.1093/emboj/18.12.3293; YAMASAKI S, 1994, J BIOL CHEM, V269, P12764; Yang B, 1999, J BIOL CHEM, V274, P5649, DOI 10.1074/jbc.274.9.5649	35	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28503	28508		10.1074/jbc.M103009200	http://dx.doi.org/10.1074/jbc.M103009200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11373287	hybrid			2022-12-25	WOS:000170093400101
J	Allan, AL; Albanese, C; Pestell, RG; LaMarre, J				Allan, AL; Albanese, C; Pestell, RG; LaMarre, J			Activating transcription factor 3 induces DNA synthesis and expression of cyclin D1 in hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER-REGENERATION FACTOR; ELEMENT-BINDING PROTEIN; BREAST-CANCER CELLS; C-JUN; MESSENGER-RNA; GROWTH-FACTOR; HEPATOCELLULAR-CARCINOMA; RETINOBLASTOMA GENE; RAT HEPATOCYTES; DOWN-REGULATION	Activating transcription factor 3 (ATF3) is an early response gene that is induced rapidly during in vivosituations of cellular growth such as liver regeneration. However, neither the physiological function nor the potential target genes of this transcription factor related to cellular proliferation have been identified in the liver or other tissues. We demonstrate here that endogenous ATF3 mRNA expression is rapidly induced up to 4-fold upon mitogenic stimulation of quiescent Hepa 1-6 mouse hepatoma cells. Overexpression of exogenous ATF3 results in a significant, dose-dependent increase in DNA synthesis of up to 140% over control cells. ATF3; transfected cells also display significantly higher rates of [H-3]thymidine incorporation in comparison with nontransfected controls in the presence of serum, Northern blot analysis and co transfection experiments demonstrate that overexpression of ATF3 enhances cyclin D1 mRNA expression and activates the cyclin D1 promoter 2.5-fold when activating protein-1 (AP-1) and cyclic AMP response element (CRE) sites within the promoter are intact. ATF3-mediated promoter activation is reduced to 1.3-fold and 1.6-fold respectively when the AP-1 or CRE sites are mutated, and mutation of both sites simultaneously leads to the complete abrogation of promoter activation. Furthermore, DNA-binding studies demonstrate that ATF3 binds directly to the AP-I site within the cyclin DI promoter. These results indicate that ATF3 expression stimulates hepatocellular proliferation, suggesting that this effect is mediated, at least in part, by the ATF3-dependent activation of cyclin D1 transcription.	Univ Guelph, Dept Biomed Sci, Guelph, ON N1G 2W1, Canada; Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Comprehens Canc Ctr, Div Hormone Depdendent Tumor Biol, Bronx, NY 10461 USA	University of Guelph; Yeshiva University; Albert Einstein College of Medicine	LaMarre, J (corresponding author), Univ Guelph, Dept Biomed Sci, Guelph, ON N1G 2W1, Canada.				NATIONAL CANCER INSTITUTE [R01CA086072, R01CA075503, R01CA070896] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA75503, R01CA86072, R01CA70896] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albanese C, 1999, J BIOL CHEM, V274, P34186, DOI 10.1074/jbc.274.48.34186; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ALBRECHT JH, 1993, AM J PHYSIOL, V265, pG857, DOI 10.1152/ajpgi.1993.265.5.G857; Arnold A, 1995, J INVEST MED, V43, P543; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Barnabas S, 1997, J BIOL CHEM, V272, P20684, DOI 10.1074/jbc.272.33.20684; Beier F, 1999, P NATL ACAD SCI USA, V96, P1433, DOI 10.1073/pnas.96.4.1433; Brown JR, 1998, MOL CELL BIOL, V18, P5609, DOI 10.1128/MCB.18.9.5609; Chen BPC, 1996, MOL CELL BIOL, V16, P1157, DOI 10.1128/mcb.16.3.1157; CHU HM, 1994, MOL ENDOCRINOL, V8, P59, DOI 10.1210/me.8.1.59; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Darlington G J, 1987, Methods Enzymol, V151, P19, DOI 10.1016/S0076-6879(87)51006-0; Della Ragione F, 1999, ADV EXP MED BIOL, V472, P73; Drysdale BE, 1996, MOL IMMUNOL, V33, P989, DOI 10.1016/S0161-5890(96)00043-0; Feitelson MA, 1997, AM J PATHOL, V150, P1141; HABER BA, 1993, J CLIN INVEST, V91, P1319, DOI 10.1172/JCI116332; Hai T, 1999, GENE EXPRESSION, V7, P321; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HERBER B, 1994, ONCOGENE, V9, P1295; HSU JC, 1992, MOL CELL BIOL, V12, P4654, DOI 10.1128/MCB.12.10.4654; HSU JC, 1991, P NATL ACAD SCI USA, V88, P3511, DOI 10.1073/pnas.88.9.3511; Ishiguro T, 1996, CANCER RES, V56, P875; Ishiguro T, 1998, CLIN EXP METASTAS, V16, P179; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; Liao DZ, 1996, CANCER LETT, V100, P215, DOI 10.1016/0304-3835(95)04088-9; Lin SK, 2000, MOL CELL BIOL, V20, P7903, DOI 10.1128/MCB.20.21.7903-7913.2000; LINARDOPOULOS S, 1993, ANTICANCER RES, V13, P257; Loyer P, 1996, J BIOL CHEM, V271, P11484, DOI 10.1074/jbc.271.19.11484; LU XP, 1992, J BIOL CHEM, V267, P2841; LUKAS J, 1994, ONCOGENE, V9, P707; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; Nishida N, 1997, HISTOL HISTOPATHOL, V12, P1019; Palmero I, 1996, CANCER SURV, V27, P351; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Pestell RG, 1999, ENDOCR REV, V20, P501, DOI 10.1210/er.20.4.501; PETERS G, 1994, J CELL SCI S, V18, P89; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; Sambrook J., 2002, MOL CLONING LAB MANU; Scotto C, 1999, MOL CELL BIOL, V19, P7168; STEER CJ, 1995, FASEB J, V9, P1396, DOI 10.1096/fasebj.9.14.7589980; Takeda M, 2000, INVEST OPHTH VIS SCI, V41, P2412; Tarn C, 1999, J BIOL CHEM, V274, P2327, DOI 10.1074/jbc.274.4.2327; Taub R, 1996, FASEB J, V10, P413, DOI 10.1096/fasebj.10.4.8647340; THOMPSON NL, 1986, CANCER RES, V46, P3111; Tsujino H, 2000, MOL CELL NEUROSCI, V15, P170, DOI 10.1006/mcne.1999.0814; Wang ZY, 1996, GENOMICS, V35, P156, DOI 10.1006/geno.1996.0334; Watanabe G, 1996, J BIOL CHEM, V271, P22570, DOI 10.1074/jbc.271.37.22570; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; Weinberg RA, 1996, CYTOKINES MOL THER, V2, P105; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEIR E, 1994, HEPATOLOGY, V20, P955, DOI 10.1002/hep.1840200426; Wolfgang CD, 2000, J BIOL CHEM, V275, P16865, DOI 10.1074/jbc.M909637199; Wolfgang CD, 1997, MOL CELL BIOL, V17, P6700, DOI 10.1128/MCB.17.11.6700; YOSHIZUMI M, 1995, MOL CELL BIOL, V15, P3266; ZHANG YJ, 1993, BIOCHEM BIOPH RES CO, V196, P1010, DOI 10.1006/bbrc.1993.2350	60	94	98	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27272	27280		10.1074/jbc.M103196200	http://dx.doi.org/10.1074/jbc.M103196200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11375399	hybrid			2022-12-25	WOS:000169966900073
J	Ameloot, P; Declercq, W; Fiers, W; Vandenabeele, P; Brouckaert, P				Ameloot, P; Declercq, W; Fiers, W; Vandenabeele, P; Brouckaert, P			Heterotrimers formed by tumor necrosis factors of different species or muteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR TNF-ALPHA; MONOCLONAL-ANTIBODIES; RECEPTOR-BINDING; INTERFERON-GAMMA; MUTANTS; RESOLUTION; GENERATION; MECHANISM; INDUCTION; TOXICITY	Incubation of murine tumor necrosis factor (mTNF) at subnanomolar concentrations results in partial dissociation of the trimers, coinciding with a decrease in bioactivity. Using size-exclusion chromatography, we observed that the conversion of labeled mTNF to monomers is not only prevented by coincubation with an excess of unlabeled mTNF but also with unlabeled human TNF (hTNF). Moreover, after coincubation of mTNF and hTNF four different TNF complexes were revealed by native polyacrylamide gel electrophoresis, viz. homotrimeric mTNF and hTNF, as well as two complexes with an intermediate migration pattern. Analytical gel filtration in combination with native polyacrylamide gel electrophoresis and Western blot immunodetection indicated that these new complexes consisted of heterotrimeric TNF molecules. We conclude that an exchange of monomers takes place during coincubation of two different species of TNF, which results in homotrimeric and heterotrimeric TNF. To assess receptor interaction in vitro, TNF heterotrimeric molecules were used as obtained after incubation of mTNF with labeled hTNF (which only binds to mTNF receptor I) or with labeled mutein mTNF75 (specific for mTNF receptor II). These heterotrimers were retained by both mTNF receptors, which means that the mTNF subunits incorporated in heterotrimeric complexes still can bind to both types of TNF receptor. In addition, the gradual decrease in mTNF bioactivity during preincubation at subnanomolar concentrations was prevented by the presence of mutein mTNF75, which is inactive in an L929 cytotoxicity assay, indicating that heterotrimerization can influence the overall bioactivity.	Flanders Interuniv Inst Biotechnol, Dept Mol Biol, B-9000 Ghent, Belgium; Flanders Interuniv Inst Biotechnol, Unit Mol Pathophysiol & Expt Therapy, B-9000 Ghent, Belgium; Flanders Interuniv Inst Biotechnol, Unit Mol Signaling & Cell Death, B-9000 Ghent, Belgium; Ghent Univ, B-9000 Ghent, Belgium	Ghent University	Brouckaert, P (corresponding author), Flanders Interuniv Inst Biotechnol, Dept Mol Biol, KL Ledeganckst 35, B-9000 Ghent, Belgium.		Vandenabeele, Peter/AAD-5793-2022; Vandenabeele, Peter/C-8597-2009	Vandenabeele, Peter/0000-0002-6669-8822; 				ADERKA D, 1992, J EXP MED, V175, P323, DOI 10.1084/jem.175.2.323; ALZANI R, 1995, BIOCHEMISTRY-US, V34, P6344, DOI 10.1021/bi00019a012; Baeyens KJ, 1999, ACTA CRYSTALLOGR D, V55, P772, DOI 10.1107/S0907444998018435; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BAZZONI F, 1995, P NATL ACAD SCI USA, V92, P5376, DOI 10.1073/pnas.92.12.5376; Beutler B, 1998, BLOOD CELL MOL DIS, V24, P216, DOI 10.1006/bcmd.1998.0187; CORTI A, 1992, BIOCHEM J, V284, P905, DOI 10.1042/bj2840905; DECLERCQ W, 1995, CYTOKINE, V7, P701, DOI 10.1006/cyto.1995.0082; ECK MJ, 1989, J BIOL CHEM, V264, P17595; Fiers W, 1995, BIOL THERAPY CANC, P295; HLODAN R, 1995, EUR J BIOCHEM, V231, P381, DOI 10.1111/j.1432-1033.1995.tb20710.x; LOETSCHER H, 1993, J BIOL CHEM, V268, P26350; LUCAS R, 1990, IMMUNOLOGY, V71, P218; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; SHEEHAN KCF, 1989, J IMMUNOL, V142, P3884; STEVENS HPJD, 1990, TRANSPLANTATION, V50, P856, DOI 10.1097/00007890-199011000-00022; TAKAHASHI N, 1994, CYTOKINE, V6, P235, DOI 10.1016/1043-4666(94)90018-3; Takahashi N, 1995, INT J CANCER, V63, P846, DOI 10.1002/ijc.2910630616; TAVERNIER J, 1990, J MOL BIOL, V211, P493, DOI 10.1016/0022-2836(90)90367-U; VANOSTADE X, 1993, NATURE, V361, P266; VANOSTADE X, 1994, EUR J BIOCHEM, V220, P771; VANOSTADE X, 1991, EMBO J, V10, P827, DOI 10.1002/j.1460-2075.1991.tb08015.x; VANZEE KJ, 1994, J EXP MED, V179, P1185, DOI 10.1084/jem.179.4.1185; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wallach D, 1997, FEBS LETT, V410, P96, DOI 10.1016/S0014-5793(97)00553-X	26	24	32	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27098	27103		10.1074/jbc.M104486200	http://dx.doi.org/10.1074/jbc.M104486200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11371574	hybrid			2022-12-25	WOS:000169966900050
J	Gu, JG; Sumida, Y; Sanzen, N; Sekiguchi, K				Gu, JG; Sumida, Y; Sanzen, N; Sekiguchi, K			Laminin-10/11 and fibronectin differentially regulate integrin-dependent rho and rac activation via p130(Cas)-CrkII-DOCK180 pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; SRC FAMILY KINASES; CELL-MIGRATION; SIGNAL-TRANSDUCTION; ACTIN CYTOSKELETON; ALPHA-5 CHAIN; P120 CATENIN; ALPHA-3-BETA-1; EXPRESSION; MOTILITY	The alpha (5) chain-containing laminin isoforms, laminins-10 and -11 (laminin-10/11), are the major components of the basement membrane, having potent cell-adhesive activity. Ne examined the cell-adhesive and integrin-mediated signaling activities of laminin-10/11 in comparison to fibronectin, the best characterized extracellular adhesive ligand. We found that laminin-10/11 are more active than fibronectin in promoting cell migration and preferentially activate Rac, not Rho, via the p130(Cas)- CrkII-DOCK180 pathway. Cells adhering to fibronectin develop stress fibers and focal contacts, whereas cells adhering to laminin-10/11 do not, consistent with the high cell migration-promoting activity of laminin-10/11. Pull-down assays of GTP-loaded Rac and Rho demonstrated the preferential activation of Rac on laminin-10/11, in contrast to the activation of Rho on fibronectin. Activation of Rac by laminin-10/11 was associated with the phosphorylation of p130(Cas) and an increased formation of a p130(Cas)-CrkII-DOCK180 complex. Cell migration on laminin-10/11 was suppressed by the expression of either a dominant-negative Rac or CrkII mutants defective in p130(Cas) or DOCK180 binding This is the first report demonstrating a distinct activation of Rho family GTPases resulting from adhesion to different extracellular ligands.	Osaka Univ, Inst Prot Res, Div Prot Chem, Osaka 5650871, Japan	Osaka University	Sekiguchi, K (corresponding author), Osaka Univ, Inst Prot Res, Div Prot Chem, 3-2 Yamadaoka, Osaka 5650871, Japan.	sekiguchi@protein.osaka-u.ac.jp	Gu, Jianguo/ABC-9257-2020	Sanzen, Noriko/0000-0001-6518-403X				Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; Aumailley M, 1998, J ANAT, V193, P1, DOI 10.1046/j.1469-7580.1998.19310001.x; Cary LA, 1996, J CELL SCI, V109, P1787; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; Fujiwara H, 2001, J BIOL CHEM, V276, P17550, DOI 10.1074/jbc.M010155200; Fukata Y, 1999, J CELL BIOL, V145, P347, DOI 10.1083/jcb.145.2.347; Fukushima Y, 1998, INT J CANCER, V76, P63, DOI 10.1002/(SICI)1097-0215(19980330)76:1<63::AID-IJC11>3.0.CO;2-H; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hemler ME, 1998, CURR OPIN CELL BIOL, V10, P578, DOI 10.1016/S0955-0674(98)80032-X; Hodivala-Dilke KM, 1998, J CELL BIOL, V142, P1357, DOI 10.1083/jcb.142.5.1357; Honda H, 1999, BIOCHEM BIOPH RES CO, V262, P25, DOI 10.1006/bbrc.1999.1162; Hynes RO, 1996, DEV BIOL, V180, P402, DOI 10.1006/dbio.1996.0314; Kikkawa Y, 1998, J BIOL CHEM, V273, P15854, DOI 10.1074/jbc.273.25.15854; Kikkawa Y, 2000, J CELL SCI, V113, P869; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Koch M, 1999, J CELL BIOL, V145, P605, DOI 10.1083/jcb.145.3.605; Lampe PD, 1998, J CELL BIOL, V143, P1735, DOI 10.1083/jcb.143.6.1735; Manabe R, 1997, J CELL BIOL, V139, P295, DOI 10.1083/jcb.139.1.295; MINER JH, 1995, J BIOL CHEM, V270, P28523, DOI 10.1074/jbc.270.48.28523; Miner JH, 1998, J CELL BIOL, V143, P1713, DOI 10.1083/jcb.143.6.1713; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Sastry SK, 1996, J CELL BIOL, V133, P169, DOI 10.1083/jcb.133.1.169; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Sorokin LM, 1997, DEV BIOL, V189, P285, DOI 10.1006/dbio.1997.8668; Testa JE, 1999, CANCER RES, V59, P3812; Timpl R, 1996, CURR OPIN CELL BIOL, V8, P618, DOI 10.1016/S0955-0674(96)80102-5; vanLeeuwen FN, 1997, J CELL BIOL, V139, P797, DOI 10.1083/jcb.139.3.797; VONDERMARK K, 1989, DIFFERENTIATION, V40, P150, DOI 10.1111/j.1432-0436.1989.tb00823.x; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Wang ZM, 1999, J CELL SCI, V112, P2925; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Wenk MB, 2000, J CELL BIOL, V150, P913, DOI 10.1083/jcb.150.4.913; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; Yanez-Mo M, 1998, J CELL BIOL, V141, P791, DOI 10.1083/jcb.141.3.791; Yauch RL, 1998, MOL BIOL CELL, V9, P2751, DOI 10.1091/mbc.9.10.2751	51	136	145	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27090	27097		10.1074/jbc.M102284200	http://dx.doi.org/10.1074/jbc.M102284200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11369773	hybrid, Green Published			2022-12-25	WOS:000169966900049
J	Tufan, AC; Tuan, RS				Tufan, AC; Tuan, RS			Wnt regulation of limb mesenchymal chondrogenesis is accompanied by altered N-cadherin-related functions	FASEB JOURNAL			English	Article						Wnt-5a; Wnt-7a; limb chondrogenesis; cellular condensation; N-cadherin; beta-catenin; collagen type II	BETA-CATENIN; CELL-ADHESION; TYROSINE PHOSPHORYLATION; IN-VITRO; MICROMASS CULTURES; CARTILAGE DIFFERENTIATION; PATTERN-FORMATION; GENE-EXPRESSION; LECTIN BINDING; MESSENGER-RNA	It has been suggested that Wnt proteins play essential roles in the regulation of limb development and morphogenesis. We have analyzed the effects of RCAS retroviral-mediated misexpression of Wnt-5a and Wnt-7a, two Wnt genes expressed during normal limb development, on chondrogenesis in high-density micromass cultures of chick limb bud mesenchymal cells. Wnt-7a misexpression inhibited chondrogenesis in vitro, whereas Wnt-5a did not. Analysis of cellular condensation and precartilage aggregate formation revealed that the inhibitory effect of Wnt-7a is unlikely to act at the cellular condensation step but, instead, influences the actual chondrogenic differentiation process. During early condensation, N-cadherin expression within the cellular aggregates in Wnt-7a cultures was slightly delayed, whereas Wnt-5a cultures appeared similar to control cultures. With the initiation of differentiation, Wnt-5a and control cultures showed down-regulation of N-cadherin and up-regulation of collagen type II expression, whereas Wnt-7a cultures showed persistent, high levels of N-cadherin expression both at the mRNA and protein levels, up to 72 h, and nearly no collagen type 11 expression. Wnt-7a misexpression was also accompanied by an initial increase in the serine/threonine phosphorylation of beta-catenin and N-cadherin, events known to affect N-cadherin turnover and stabilization of beta-catenin/N-cadherin cell adhesion complex, during chondrogenic differentiation. Writ regulation of limb mesenchymal chondrogenesis is thus likely to involve modulation of N-cadherin expression and function. In addition, Wnt-7a misexpression stimulates the proliferation of limb mesenchymal cells in vitro, possibly contributing to its chondro-inhibitory effect. Finally, the differences between Wnt-5a and Wnt-7a effects suggest functional diversity within the Wnt family.	Thomas Jefferson Univ, Dept Orthopaed Surg, Orthopaed Res Lab, Philadelphia, PA 19107 USA	Jefferson University	Tuan, RS (corresponding author), Thomas Jefferson Univ, Dept Orthopaed Surg, Orthopaed Res Lab, 1015 Walnut St,Room 501, Philadelphia, PA 19107 USA.	Rocky.S.Tuan@mail.tju.edu		Tufan, A. Cevik/0000-0002-5920-0475				AHRENS PB, 1977, DEV BIOL, V60, P69, DOI 10.1016/0012-1606(77)90110-5; ANTONIO JDS, 1986, DEV BIOL, V115, P313, DOI 10.1016/0012-1606(86)90252-6; AULTHOUSE AL, 1987, DEV BIOL, V120, P377, DOI 10.1016/0012-1606(87)90240-5; Austin TW, 1997, BLOOD, V89, P3624, DOI 10.1182/blood.V89.10.3624.3624_3624_3635; Balsamo J, 1996, J CELL BIOL, V134, P801, DOI 10.1083/jcb.134.3.801; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; Bienz M, 1998, CURR OPIN CELL BIOL, V10, P366, DOI 10.1016/S0955-0674(98)80013-6; BOSKEY AL, 1992, BONE MINER, V16, P11, DOI 10.1016/0169-6009(92)90819-Y; Brown JD, 1998, CURR OPIN CELL BIOL, V10, P182, DOI 10.1016/S0955-0674(98)80140-3; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Dale TC, 1998, BIOCHEM J, V329, P209; DEALY CN, 1993, MECH DEVELOP, V43, P175, DOI 10.1016/0925-4773(93)90034-U; DeLise AM, 2000, OSTEOARTHR CARTILAGE, V8, P309, DOI 10.1053/joca.1999.0306; DELISE AM, 2000, DEV BIOL PROTOCOLS, V3, P359; DELISE AM, 2000, DEV BIOL PROTOCOLS, V3, P377; DENKER AE, 1995, DIFFERENTIATION, V59, P25, DOI 10.1046/j.1432-0436.1995.5910025.x; Dierick H, 1999, CURR TOP DEV BIOL, V43, P153, DOI 10.1016/S0070-2153(08)60381-6; FAGOTTO F, 1994, DEVELOPMENT, V120, P3667; FERRARI D, 1994, BIOCHEM BIOPH RES CO, V205, P429, DOI 10.1006/bbrc.1994.2683; Giarre M, 1998, ANN NY ACAD SCI, V857, P43, DOI 10.1111/j.1749-6632.1998.tb10106.x; Gradl D, 1999, MOL CELL BIOL, V19, P5576; Hall BK, 2000, BIOESSAYS, V22, P138, DOI 10.1002/(SICI)1521-1878(200002)22:2<138::AID-BIES5>3.3.CO;2-W; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HAMBURGER V, 1992, DEV DYNAM, V195, P231, DOI 10.1002/dvdy.1001950404; Harlow E., 1988, ANTIBODIES LAB MANUA, P298; Hartmann C, 2000, DEVELOPMENT, V127, P3141; HATTA K, 1986, NATURE, V320, P447, DOI 10.1038/320447a0; HATTA K, 1988, J CELL BIOL, V106, P873, DOI 10.1083/jcb.106.3.873; Hickok NJ, 1998, MICROSC RES TECHNIQ, V43, P174, DOI 10.1002/(SICI)1097-0029(19981015)43:2<174::AID-JEMT9>3.0.CO;2-P; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Johnson RL, 1997, CELL, V90, P979, DOI 10.1016/S0092-8674(00)80364-5; Kawakami Y, 1999, DEV GROWTH DIFFER, V41, P29; Kengaku M, 1997, COLD SPRING HARB SYM, V62, P421; Kengaku M, 1998, SCIENCE, V280, P1274, DOI 10.1126/science.280.5367.1274; Knudson CB, 1999, BIOCHEM SOC T, V27, P142, DOI 10.1042/bst0270142; Kulyk WM, 2000, EXP CELL RES, V255, P327, DOI 10.1006/excr.1999.4784; LANGILLE RM, 1994, MICROSC RES TECHNIQ, V28, P455, DOI 10.1002/jemt.1070280602; Lee MM, 1997, DEV GENET, V20, P224; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; LEV R, 1964, J HISTOCHEM CYTOCHEM, V12, P309, DOI 10.1177/12.4.309; Liu XX, 1999, P NATL ACAD SCI USA, V96, P14383, DOI 10.1073/pnas.96.25.14383; MAINI PK, 1991, INT REV CYTOL, V129, P91; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; Mello MA, 1999, IN VITRO CELL DEV-AN, V35, P262; Meyer RA, 1997, DEV GENET, V21, P290; MILAIRE J, 1991, ANAT EMBRYOL, V184, P479, DOI 10.1007/BF01236054; Molenaar M, 1998, MECH DEVELOP, V75, P151, DOI 10.1016/S0925-4773(98)00085-9; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; Morgan BA, 1996, METHOD CELL BIOL, V51, P185, DOI 10.1016/S0091-679X(08)60629-9; Murray D, 2000, J BIOL CHEM, V275, P3610, DOI 10.1074/jbc.275.5.3610; Niswander L, 1997, CURR OPIN GENET DEV, V7, P530, DOI 10.1016/S0959-437X(97)80082-2; OBERLENDER SA, 1994, CELL ADHES COMMUN, V2, P521, DOI 10.3109/15419069409014216; OBERLENDER SA, 1994, DEVELOPMENT, V120, P177; OLESEN CEM, 1997, RECOMBINANT PROTEIN, P61; OOSTERWEGEL M, 1993, DEVELOPMENT, V118, P439; PARADIES NE, 1993, J NEUROSCI RES, V36, P33, DOI 10.1002/jnr.490360105; PARR BA, 1993, DEVELOPMENT, V119, P247; ROARK EF, 1992, DEVELOPMENT, V114, P973; ROARK EF, 1994, DEV DYNAM, V200, P103, DOI 10.1002/aja.1002000203; Rudnicki JA, 1997, DEV BIOL, V185, P104, DOI 10.1006/dbio.1997.8536; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; Slusarski DC, 1997, NATURE, V390, P410, DOI 10.1038/37138; Slusarski DC, 1997, DEV BIOL, V182, P114, DOI 10.1006/dbio.1996.8463; Stott NS, 1999, J CELL PHYSIOL, V180, P314, DOI 10.1002/(SICI)1097-4652(199909)180:3<314::AID-JCP2>3.3.CO;2-P; Stringa E, 1997, EXP CELL RES, V232, P287, DOI 10.1006/excr.1997.3532; Stringa E, 1996, ANAT EMBRYOL, V194, P427; Takeda H, 1995, J CELL BIOL, V131, P1839, DOI 10.1083/jcb.131.6.1839; Torres MA, 1996, J CELL BIOL, V133, P1123, DOI 10.1083/jcb.133.5.1123; Van den Berg DJ, 1998, BLOOD, V92, P3189, DOI 10.1182/blood.V92.9.3189.421k45_3189_3202; VOLBERG T, 1992, EMBO J, V11, P1733, DOI 10.1002/j.1460-2075.1992.tb05225.x; WIDELITZ RB, 1993, J CELL PHYSIOL, V156, P399, DOI 10.1002/jcp.1041560224; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278; WONG MY, 1993, IN VITRO CELL DEV-AN, V29A, P917; YANG YZ, 1995, CELL, V80, P939, DOI 10.1016/0092-8674(95)90297-X; ZAKANY J, 1993, NATURE, V362, P546, DOI 10.1038/362546a0; ZIMMERMANN B, 1984, HISTOCHEMISTRY, V81, P353, DOI 10.1007/BF00514329	80	67	67	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 27	2001	15	6					1436	+		10.1096/fj.00-0784fje	http://dx.doi.org/10.1096/fj.00-0784fje			31	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387249				2022-12-25	WOS:000173705800019
J	Coe, APF; Askari, JA; Kline, AD; Robinson, MK; Kirby, H; Stephens, PE; Humphries, MJ				Coe, APF; Askari, JA; Kline, AD; Robinson, MK; Kirby, H; Stephens, PE; Humphries, MJ			Generation of a minimal alpha(5)beta(1) integrin-Fc fragment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET GLYCOPROTEIN-IIB; BETA-PROPELLER DOMAIN; DEPENDENT ADHESION SITE; FUNCTION-ASSOCIATED ANTIGEN-1; LIGAND-BINDING REGION; AMINO-ACID-RESIDUES; I-DOMAIN; HUMAN FIBRONECTIN; CELL-ADHESION; CRYSTAL-STRUCTURE	The tertiary structure of the integrin heterodimer is currently unknown, although several predictive models have been generated. Detailed structural studies of integrins have been consistently hampered for several reasons, including the small amounts of purified protein available, the large size and conformational flexibility of integrins, and the presence of transmembrane domains and N-linked glycosylation sites in both receptor subunits. As a first step toward obtaining crystals of an integrin receptor, we have expressed a minimized dimer. By using the Fc dimerization and mammalian cell expression system designed and optimized by Stephens et al. (Stephens, P. E., Ortlepp, S., Perkins, V. C., Robinson, M. K., and Kirby, H. (2000) Cell. Adhes. Commun. 7, 377-390), a series of recombinant soluble human alpha (5)beta (1) integrin truncations have been expressed as Fc fusion proteins. These proteins were examined for their ligand-binding properties and for their expression of anti-integrin antibody epitopes. The shortest functional alpha (5)-subunit truncation contained the N-terminal 613 residues, whereas the shortest beta (1)-subunit was a fragment containing residues 121-455. Each of these minimally truncated integrins displayed the antibody binding characteristics of alpha (5)beta (1) purified from human placenta and bound ligand with the same apparent affinity as the native receptor.	Univ Manchester, Sch Biol Sci, Wellcome Trust, Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England; Celltech Ltd, Slough SL1 4EN, Berks, England	University of Manchester; Celltech Group Ltd	Humphries, MJ (corresponding author), Univ Manchester, Sch Biol Sci, Wellcome Trust, Ctr Cell Matrix Res, 2-205 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.			Humphries, Martin/0000-0002-4331-6967				AOTA S, 1994, J BIOL CHEM, V269, P24756; BAJT ML, 1994, J BIOL CHEM, V269, P20913; Baneres JL, 2000, J BIOL CHEM, V275, P5888, DOI 10.1074/jbc.275.8.5888; BAZZONI G, 1995, J BIOL CHEM, V270, P25570, DOI 10.1074/jbc.270.43.25570; BEBBINGTON C, 1995, DNA CLONING, V4, P85; BENNETT JS, 1993, J BIOL CHEM, V268, P3580; BERMAN PW, 1993, J CELL BIOCHEM, V52, P183, DOI 10.1002/jcb.240520210; Bork P, 1999, TRENDS BIOCHEM SCI, V24, P261, DOI 10.1016/S0968-0004(99)01416-4; BRIESEWITZ R, 1993, MOL BIOL CELL, V4, P593, DOI 10.1091/mbc.4.6.593; Burrows L, 1999, BIOCHEM J, V344, P527, DOI 10.1042/0264-6021:3440527; CALVETE JJ, 1991, BIOCHEM J, V274, P63, DOI 10.1042/bj2740063; CALVETE JJ, 1989, BIOCHEM J, V261, P561, DOI 10.1042/bj2610561; CARRELL NA, 1985, J BIOL CHEM, V260, P1743; Chen J, 1996, CELL ADHES COMMUN, V4, P237, DOI 10.3109/15419069609010769; Clark K, 2000, FEBS LETT, V471, P182, DOI 10.1016/S0014-5793(00)01391-0; COCKETT MI, 1991, NUCLEIC ACIDS RES, V19, P319, DOI 10.1093/nar/19.2.319; Curley GP, 1999, CELL MOL LIFE SCI, V56, P427, DOI 10.1007/s000180050443; DANA N, 1991, P NATL ACAD SCI USA, V88, P3106, DOI 10.1073/pnas.88.8.3106; DANEN EHJ, 1995, J BIOL CHEM, V270, P21612, DOI 10.1074/jbc.270.37.21612; DeMelker AA, 1996, EUR J BIOCHEM, V241, P254; Denda S, 1998, BIOCHEMISTRY-US, V37, P5464, DOI 10.1021/bi9727489; Eble JA, 1998, BIOCHEMISTRY-US, V37, P10945, DOI 10.1021/bi980175+; Edwards CP, 1998, J BIOL CHEM, V273, P28937, DOI 10.1074/jbc.273.44.28937; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; FITZGERALD LA, 1987, BIOCHEMISTRY-US, V26, P8158, DOI 10.1021/bi00399a021; Goodman TG, 1998, J LEUKOCYTE BIOL, V64, P767, DOI 10.1002/jlb.64.6.767; Goodman TG, 1996, J BIOL CHEM, V271, P23729, DOI 10.1074/jbc.271.39.23729; GULINO D, 1995, EUR J BIOCHEM, V227, P108, DOI 10.1111/j.1432-1033.1995.tb20365.x; Henderson WR, 1997, J CLIN INVEST, V100, P3083, DOI 10.1172/JCI119863; Huang CC, 2000, J BIOL CHEM, V275, P21514, DOI 10.1074/jbc.M002286200; HUANG CC, 1995, J BIOL CHEM, V270, P19008, DOI 10.1074/jbc.270.32.19008; Huang CC, 1997, P NATL ACAD SCI USA, V94, P3156, DOI 10.1073/pnas.94.7.3156; Huang CC, 1997, P NATL ACAD SCI USA, V94, P3162, DOI 10.1073/pnas.94.7.3162; Humphries JD, 2000, J BIOL CHEM, V275, P20337, DOI 10.1074/jbc.M000568200; HUMPHRIES MJ, 1986, J CELL BIOL, V103, P2637, DOI 10.1083/jcb.103.6.2637; Humphries MJ, 1998, TRENDS CELL BIOL, V8, P78, DOI 10.1016/S0962-8924(98)80016-0; Humphries MJ, 2000, BIOCHEM SOC T, V28, P311, DOI 10.1042/0300-5127:0280311; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Irie A, 1997, P NATL ACAD SCI USA, V94, P7198, DOI 10.1073/pnas.94.14.7198; IRIE A, 1995, EMBO J, V14, P5550, DOI 10.1002/j.1460-2075.1995.tb00242.x; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; Kamata T, 1999, J BIOL CHEM, V274, P32108, DOI 10.1074/jbc.274.45.32108; KAMATA T, 1995, BIOCHEM J, V305, P945, DOI 10.1042/bj3050945; Krukonis ES, 1998, J BIOL CHEM, V273, P31837, DOI 10.1074/jbc.273.48.31837; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lin ECK, 1997, J BIOL CHEM, V272, P14236, DOI 10.1074/jbc.272.22.14236; Loftus JC, 1996, J BIOL CHEM, V271, P2033, DOI 10.1074/jbc.271.4.2033; Lu CF, 1998, J BIOL CHEM, V273, P15138, DOI 10.1074/jbc.273.24.15138; Mathias P, 1998, J VIROL, V72, P8669, DOI 10.1128/JVI.72.11.8669-8675.1998; McKay BS, 1996, J BIOL CHEM, V271, P30544, DOI 10.1074/jbc.271.48.30544; Mehta RJ, 1998, BIOCHEM J, V330, P861; Mould AP, 2000, J BIOL CHEM, V275, P20324, DOI 10.1074/jbc.M000572200; Mould AP, 1998, J BIOL CHEM, V273, P25664, DOI 10.1074/jbc.273.40.25664; MOULD AP, 1995, J BIOL CHEM, V270, P26270, DOI 10.1074/jbc.270.44.26270; Mould AP, 1996, J BIOL CHEM, V271, P20365, DOI 10.1074/jbc.271.34.20365; Mould AP, 1998, BIOCHEM J, V331, P821, DOI 10.1042/bj3310821; MOULD AP, 1995, FEBS LETT, V363, P118, DOI 10.1016/0014-5793(95)00301-O; MOULD AP, 1997, J BIOL CHEM, V272, P17288; Munoz M, 1997, BIOCHEM J, V327, P727, DOI 10.1042/bj3270727; NERMUT MV, 1988, EMBO J, V7, P4093, DOI 10.1002/j.1460-2075.1988.tb03303.x; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; Oxvig C, 1998, P NATL ACAD SCI USA, V95, P4870, DOI 10.1073/pnas.95.9.4870; PARDI R, 1995, J IMMUNOL, V155, P1252; Peterson JA, 1998, BLOOD, V92, P2053, DOI 10.1182/blood.V92.6.2053.418k14_2053_2063; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PuzonMcLaughlin W, 1996, J BIOL CHEM, V271, P20438, DOI 10.1074/jbc.271.34.20438; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; Redick SD, 2000, J CELL BIOL, V149, P521, DOI 10.1083/jcb.149.2.521; Ridgway JBB, 1996, PROTEIN ENG, V9, P617, DOI 10.1093/protein/9.7.617; SCHIFFER SG, 1995, J BIOL CHEM, V270, P14270, DOI 10.1074/jbc.270.24.14270; Sonnenberg A, 1993, Curr Top Microbiol Immunol, V184, P7; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; Stephens PE, 2000, CELL ADHES COMMUN, V7, P377, DOI 10.3109/15419060009109020; Takada Y, 1997, MATRIX BIOL, V16, P143, DOI 10.1016/S0945-053X(97)90002-0; TAKAHASHI N, 1982, CELL, V29, P671, DOI 10.1016/0092-8674(82)90183-0; Tan SM, 2000, J IMMUNOL, V165, P2574, DOI 10.4049/jimmunol.165.5.2574; Tominaga Y, 1998, J IMMUNOL METHODS, V212, P61, DOI 10.1016/S0022-1759(97)00207-X; Tozer EC, 1996, J BIOL CHEM, V271, P21978, DOI 10.1074/jbc.271.36.21978; Tuckwell DS, 1997, FEBS LETT, V400, P297, DOI 10.1016/S0014-5793(96)01368-3; Wang AZ, 1997, ARTHRITIS RHEUM, V40, P1298, DOI 10.1002/art.1780400715; WEISEL JW, 1992, J BIOL CHEM, V267, P16637; WIPPLER J, 1994, J BIOL CHEM, V269, P8754; YAMADA KM, 1984, J CELL BIOL, V99, P29, DOI 10.1083/jcb.99.1.29; Zhang L, 1997, J BIOL CHEM, V272, P17558, DOI 10.1074/jbc.272.28.17558; Zhang XP, 1999, BIOCHEMISTRY-US, V38, P14424, DOI 10.1021/bi990323b	86	44	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35854	35866		10.1074/jbc.M103639200	http://dx.doi.org/10.1074/jbc.M103639200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11389148	hybrid			2022-12-25	WOS:000171109300085
J	Kim, SH; Goto, M; Akaike, T				Kim, SH; Goto, M; Akaike, T			Specific binding of glucose-derivatized polymers to the asialoglycoprotein receptor of mouse primary hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT HEPATOCYTES; LECTIN; CARBOHYDRATE; RECOGNITION; LIVER; GALACTOSE; ADHESION; EXPRESSION; LIGAND; SUGARS	In this study, we designed a novel amphiphilic poly-(p-N-vinylbenzyl-D-glucuronamide) (PV6Gna) modified at the 6-OH position of glucose for hepatocyte recognition to address the mechanism of the interaction between mouse primary hepatocytes and the PV6Gna. PV6Gna bound to lectins specific for glucose but not galactose as did other glucose-derivatized polymers. However, hepatocyte adhesion onto the PV6Gna surface was inhibited in the presence of galactose and its analogues but not in the presence of glucose and its analogues. We also showed that hepatocyte adhesion to the PV6Gna surface was inhibited dose dependently by asialofetuin (ASF). Interactions between soluble PV6Gna and hepatocytes were inhibited by GalNAc, ASF, and EGTA in flow cytometry analysis using fluorescein isothiocyanate-conjugated PV6Gna. Hepatocyte adhesion to the PV6Gna surface was inhibited more effectively by GalNAc than by methyl beta -D-galactose. In flow cytometry analysis and cell adhesion assay, ASF competed for the inhibition of interaction between PV6Gna and hepatocytes 0.5-4 x 10(5)-fold more effectively than did GalNAc. These results demonstrate involvement of asialoglycoprotein receptors (ASGPRs) in the interaction between PV6Gna and hepatocytes. Furthermore, to clarify the mechanism of the interaction between glycopolymers modified at the 6-OH position of glucose and the hepatocyte, we prepared a gel particle containing 6-O-methacryloyl-D-glucose (PMglc) synthesized by an enzymatic method. ASGPRs could be detected using Western blot analysis following precipitation with PMglc in hepatocyte cell lysate. The precipitation of ASGPRs was inhibited in the presence of galactose, ASF, PV6Gna, and EGTA. The precipitation was inhibited more effectively by GalNAc than by methyl beta -D-galactose. ASGPRs were rarely precipitated by PMglc in the cell lysate that had been treated with ASF-conjugated Sepharose. Taken together, we suggest that mouse primary hepatocytes adhere to the PV6Gna surface mediated by ASGPRs, which specifically interacted with the glycopolymers modified at the C-6 position of glucose.	Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Dept Biomol Engn, Midori Ku, Yokohama, Kanagawa 2268501, Japan; BioQuest Res Ltd, Tokyo 1070062, Japan	Tokyo Institute of Technology	Akaike, T (corresponding author), Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Dept Biomol Engn, Midori Ku, 4259 Nagatsuta, Yokohama, Kanagawa 2268501, Japan.							ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; CHEN XM, 1995, MACROMOLECULES, V28, P6014, DOI 10.1021/ma00122a005; Eto T, 1999, NAT MED, V5, P577, DOI 10.1038/8462; Gordon EJ, 1998, NATURE, V392, P30, DOI 10.1038/32073; Griffith LG, 1998, BIOMATERIALS, V19, P979, DOI 10.1016/S0142-9612(97)00185-3; GUARNACCIA SP, 1982, J BIOL CHEM, V257, P4288; HONG WJ, 1988, HEPATOLOGY, V8, P553, DOI 10.1002/hep.1840080320; ICHIKAWA Y, 1990, J CARBOHYD CHEM, V9, P797; Iobst ST, 1996, J BIOL CHEM, V271, P6686, DOI 10.1074/jbc.271.12.6686; Julyan PJ, 1999, J CONTROL RELEASE, V57, P281, DOI 10.1016/S0168-3659(98)00124-2; KALINOWSKI HO, 1988, CARBON 13 NMR SPECTR, P441; Kim SH, 2000, BIOTECHNOL LETT, V22, P1049, DOI 10.1023/A:1005641928736; KOBAYASHI A, 1992, J BIOMAT SCI-POLYM E, V3, P499, DOI 10.1163/156856292X00466; KOHGO Y, 1993, HYBRIDOMA, V12, P591, DOI 10.1089/hyb.1993.12.591; Kolatkar AR, 1996, J BIOL CHEM, V271, P6679, DOI 10.1074/jbc.271.12.6679; Kolatkar AR, 1998, J BIOL CHEM, V273, P19502, DOI 10.1074/jbc.273.31.19502; LEE RT, 1982, BIOCHEMISTRY-US, V21, P6292, DOI 10.1021/bi00267a039; Lee Y. C., 1994, NEOGLYCOCONJUGATES P; LEE YC, 1992, FASEB J, V6, P3193, DOI 10.1096/fasebj.6.13.1397841; LEE YC, 1983, J BIOL CHEM, V258, P199; Li TL, 1998, J BIOMAT SCI-POLYM E, V9, P327, DOI 10.1080/09205063.1998.9753059; LOGANATHAN D, 1992, ARCH BIOCHEM BIOPHYS, V299, P268, DOI 10.1016/0003-9861(92)90274-Z; MATSUSHITA N, 1994, BIOSCI BIOTECH BIOCH, V58, P1514, DOI 10.1271/bbb.58.1514; MERWIN JR, 1994, BIOCONJUGATE CHEM, V5, P612, DOI 10.1021/bc00030a017; MORELL AG, 1968, J BIOL CHEM, V243, P155; MORITA M, 1995, HEPATOLOGY, V21, P1585, DOI 10.1016/0270-9139(95)90463-8; NAGAKI M, 1995, BIOCHEM BIOPH RES CO, V210, P38, DOI 10.1006/bbrc.1995.1624; OKA JA, 1986, J CELL BIOL, V103, P1055, DOI 10.1083/jcb.103.3.1055; ORA A, 1991, J CELL BIOL, V115, P495; RICE KG, 1990, J BIOL CHEM, V265, P18429; RIVA S, 1988, J AM CHEM SOC, V110, P584, DOI 10.1021/ja00210a045; Sanders WJ, 1999, J BIOL CHEM, V274, P5271, DOI 10.1074/jbc.274.9.5271; SASTRY MVK, 1986, J BIOL CHEM, V261, P1726; SATO Y, 1994, HEPATOLOGY, V19, P1023, DOI 10.1002/hep.1840190430; SCHLEPPERSCHAFER J, 1980, BIOCHEM J, V186, P827, DOI 10.1042/bj1860827; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Sharma V, 1996, J BIOL CHEM, V271, P21209, DOI 10.1074/jbc.271.35.21209; Shibatani S, 1997, BIOTECHNOL LETT, V19, P511; SONNAAR RL, 1978, J BIOL CHEM, V253, P7940; STAHL P, 1980, CELL, V19, P207, DOI 10.1016/0092-8674(80)90402-X; STOCKERT RJ, 1995, PHYSIOL REV, V75, P591, DOI 10.1152/physrev.1995.75.3.591; TAKADA A, 1993, CANCER RES, V53, P354; Taketa K, 1996, ELECTROPHORESIS, V17, P483, DOI 10.1002/elps.1150170309; TIEMEYER M, 1992, J BIOL CHEM, V267, P12252; Wada J, 1997, J CLIN INVEST, V99, P2452, DOI 10.1172/JCI119429; WALL DA, 1980, CELL, V21, P79, DOI 10.1016/0092-8674(80)90116-6; WATANABE T, 1995, CARBOHYD RES, V275, P215, DOI 10.1016/0008-6215(95)00151-I; WEIGEL PH, 1979, J BIOL CHEM, V254, P830; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; WEIS WI, 1996, ANNU REV BIOCHEM, V6, P441; YOSHIMOTO K, 1980, CHEM PHARM BULL, V28, P2065	52	51	62	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35312	35319		10.1074/jbc.M009749200	http://dx.doi.org/10.1074/jbc.M009749200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11390372	hybrid			2022-12-25	WOS:000171109300016
J	Vilardaga, JP; Frank, M; Krasel, C; Dees, C; Nissenson, RA; Lohse, MJ				Vilardaga, JP; Frank, M; Krasel, C; Dees, C; Nissenson, RA; Lohse, MJ			Differential conformational requirements for activation of G proteins and the regulatory proteins arrestin and G protein-coupled receptor kinase in the G protein-coupled receptor for parathyroid hormone (PTH)/PTH-related protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING-PROTEIN; BETA-ARRESTIN; BETA(2)-ADRENERGIC RECEPTOR; TRANSMEMBRANE HELICES; VISUAL ARRESTIN; PHOSPHORYLATION; ENDOCYTOSIS; MUTANTS; INTERNALIZATION; MODEL	After stimulation with agonist, G protein-coupled receptors (GPCRs) activate G proteins and become phosphorylated by G protein-coupled receptor kinases (GRKs), and most of them translocate cytosolic arrestin proteins to the cytoplasmic membrane. Agonist-activated GPCRs are specifically phosphorylated by GRKs and are targeted for endocytosis by arrestin proteins, suggesting a connection between GPCR conformational changes and interaction with GRKs and arrestins. Previously, we showed that by substitution of histidine for residues at the cytoplasmic side of helix 3 (H3) and helix 6 (H6) of the parathyroid hormone (PTH) receptor (PTHR), a zinc metal ion-binding site is engineered that prevents PTH-stimulated G(5) activation (Sheikh, S. P., Vilardaga, J.-P., Baranski, T. J., Lichtarge, O., liri, T., Meng, E. C., Nissenson, R. A., and Bourne, H. R. (1999) J. Biol. Chem. 274,17033-17041). These data suggest that relative movements between H3 and H6 are critical for G. activation. Does this molecular event play a similar role in activation of GRKs and arrestin and in PTHR-mediated G(q) activation? To answer this question, we utilized the two previously described mutant forms of PTHR, H401 and H402, which contain a naturally present histidine residue at position 301 in H3 and a second substituted histidine residue at positions 401 and 402 in H6, respectively. Both mutant receptors showed inhibition of PTH-stimulated inositol phosphate and cAMP generation in the presence of increasing concentrations of Zn(Pi). However, the mutants showed no Zn(Pi)-dependent impairment of phosphorylation by GRK-2. Likewise, the mutants were indistinguishable from wild-type PTHR in the ability to translocate beta-arrestins/green fluorescent protein to the cell membrane and were also not affected by sensitivity to Zn(Il). These results suggest that agonist-mediated phosphorylation and internalization of PTHR require conformational switches of the receptor distinct from the cAMP and inositol phosphate signaling state. Furthermore, PTHR sequestration does not appear to require G protein activation.	Univ Wurzburg, Inst Pharmacol & Toxicol, Dept Pharmacol, D-97078 Wurzburg, Germany; Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94121 USA; Vet Affairs Med Ctr, Endocrine Res Unit, San Francisco, CA 94121 USA	University of Wurzburg; University of California System; University of California San Francisco; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Lohse, MJ (corresponding author), Univ Wurzburg, Inst Pharmacol & Toxicol, Dept Pharmacol, Versbacher Str 9, D-97078 Wurzburg, Germany.	lohse@toxi.uni-wuerzburg.de	Lohse, Martin J/A-7160-2012; Krasel, Cornelius/AAH-7074-2019	Lohse, Martin J/0000-0002-0599-3510; Vilardaga, Jean-Pierre/0000-0002-1217-1435; Krasel, Cornelius/0000-0001-8309-8696	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035323] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BARAK LS, 1995, BIOCHEMISTRY-US, V34, P15407, DOI 10.1021/bi00047a003; BENOVIC JL, 1988, J BIOL CHEM, V263, P3893; BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; CHEUNG AH, 1990, MOL PHARMACOL, V37, P775; Dhanwada KR, 1996, MOL ENDOCRINOL, V10, P544, DOI 10.1210/me.10.5.544; Dicker F, 1999, P NATL ACAD SCI USA, V96, P5476, DOI 10.1073/pnas.96.10.5476; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Ferrari SL, 1999, J BIOL CHEM, V274, P29968, DOI 10.1074/jbc.274.42.29968; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Groarke DA, 1999, J BIOL CHEM, V274, P23263, DOI 10.1074/jbc.274.33.23263; Gurevich VV, 1998, J BIOL CHEM, V273, P15501, DOI 10.1074/jbc.273.25.15501; GUVERICH VV, 1993, J BIOL CHEM, V268, P11628; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; HOESLSHER SR, 1991, ENDOCRINOLOGY, V128, P2837; HUNYADY L, 1994, J BIOL CHEM, V269, P24798; Iiri T, 1998, NATURE, V394, P35, DOI 10.1038/27831; January B, 1997, J BIOL CHEM, V272, P23871, DOI 10.1074/jbc.272.38.23871; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KIM CM, 1993, RECEPTOR, V3, P39; Kovoor A, 1999, J BIOL CHEM, V274, P6831, DOI 10.1074/jbc.274.11.6831; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; LUND KA, 1990, J BIOL CHEM, V265, P15713; Malecz N, 1998, MOL ENDOCRINOL, V12, P1846, DOI 10.1210/me.12.12.1846; Mhaouty-Kodja S, 1999, MOL PHARMACOL, V55, P339, DOI 10.1124/mol.55.2.339; NUSSENZVEIG DR, 1993, MOL ENDOCRINOL, V7, P1105, DOI 10.1210/me.7.9.1105; PEI G, 1994, P NATL ACAD SCI USA, V91, P2699, DOI 10.1073/pnas.91.7.2699; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Pulvermuller A, 2000, J BIOL CHEM, V275, P37679, DOI 10.1074/jbc.M006776200; REN Q, 1993, J BIOL CHEM, V268, P16483; Sheikh SP, 1999, J BIOL CHEM, V274, P17033, DOI 10.1074/jbc.274.24.17033; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; SOHLEMANN P, 1995, EUR J BIOCHEM, V232, P464, DOI 10.1111/j.1432-1033.1995.tb20832.x; SZEKERS PG, 1997, MOL PHARMACOL, V53, P769; Thomas WG, 2000, J BIOL CHEM, V275, P2893, DOI 10.1074/jbc.275.4.2893; Vilardaga JP, 2000, J BONE MINER RES, V15, pS175; Vishnivetskiy SK, 1999, J BIOL CHEM, V274, P11451, DOI 10.1074/jbc.274.17.11451	41	85	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33435	33443		10.1074/jbc.M011495200	http://dx.doi.org/10.1074/jbc.M011495200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11387315	hybrid			2022-12-25	WOS:000170910200021
J	Ford, LP; Zou, Y; Pongracz, K; Gryaznov, S; Shay, JW; Wright, WE				Ford, LP; Zou, Y; Pongracz, K; Gryaznov, S; Shay, JW; Wright, WE			Telomerase can inhibit the recombination-based pathway of telomere maintenance in human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMORTAL HUMAN-CELLS; SACCHAROMYCES-CEREVISIAE; MECHANISM; DNA; YEAST; CHROMOSOMES; ELONGATION; SENESCENCE; RNA	Telomere length can be maintained by telomerase or by a recombination-based pathway. Because individual telomeres in cells using the recombination-based pathway of telomere maintenance appear to periodically become extremely short, cells using this pathway to maintain telomeres may be faced with a continuous state of crisis. We expressed telomerase in a human cell line that uses the recombination-based pathway of telomere maintenance to test whether telomerase would prevent telomeres from becoming critically short and examine the effects that this might have on the recombination-based pathway of telomere maintenance. In these. cells, telomerase maintains the length of the shortest telomeres. In some cases, the long heterogeneous telomeres are completely lost, and the cells now permanently contain short telomeres after only 40 population doublings. This corresponds to a telomere reduction rate of 500 base pairs/population doubling, a rate that is much faster than expected for normal telomere shortening but is consistent with the rapid telomere deletion events observed in cells using the recombination-based. pathway of telomere maintenance (Murnane, J. P., Sabatier, L., Marder, B. A., and Morgan, W. F. (1994) EMBO J. 13, 4953-4962). We also observed reductions in the fraction of cells containing alternative lengthening of telomere-associated promyelocytic leukemia bodies and extrachromosomal telomere repeats; however, no alterations in the rate of sister chromatid exchange were observed. Our results demonstrate that human cells using the recombination-based pathway of telomere maintenance retain factors required for telomerase to maintain telomeres and that once the telomerase-based pathway of telomere length regulation is engaged, recombination-based elongation of telomeres can be functionally inhibited.	Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA; Geron Corp, Menlo Park, CA 94024 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Geron Corporation	Shay, JW (corresponding author), Univ Texas, SW Med Ctr, Dept Cell Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.		Shay, Jerry W/F-7878-2011	Zou, Ying/0000-0003-2787-1917	NATIONAL INSTITUTE ON AGING [R37AG001228, R01AG007992, R01AG001228] Funding Source: NIH RePORTER; NIA NIH HHS [AG01228, AG07992] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLSOPP RC, 1995, EXP CELL RES, V220, P194, DOI 10.1006/excr.1995.1306; Bryan TM, 1997, HUM MOL GENET, V6, P921, DOI 10.1093/hmg/6.6.921; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Colgin LM, 2000, NEOPLASIA, V2, P426, DOI 10.1038/sj.neo.7900112; Ford LP, 2000, MOL CELL BIOL, V20, P9084, DOI 10.1128/MCB.20.23.9084-9091.2000; Fouladi B, 2000, NEOPLASIA, V2, P540, DOI 10.1038/sj.neo.7900107; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; Gryaznov SM, 1999, BBA-GENE STRUCT EXPR, V1489, P131, DOI 10.1016/S0167-4781(99)00151-7; Hande MP, 2001, HUM MOL GENET, V10, P519, DOI 10.1093/hmg/10.5.519; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Herbert BS, 1999, P NATL ACAD SCI USA, V96, P14276, DOI 10.1073/pnas.96.25.14276; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kipling D, 1999, NAT BIOTECHNOL, V17, P313, DOI 10.1038/7827; Le S, 1999, GENETICS, V152, P143; Li BB, 1996, GENE DEV, V10, P1310, DOI 10.1101/gad.10.11.1310; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; MASON JM, 1995, TRENDS GENET, V11, P58, DOI 10.1016/S0168-9525(00)88998-2; McChesney Patricia A., 2000, Molecular Cell Biology Research Communications, V3, P312, DOI 10.1006/mcbr.2000.0229; MURNANE JP, 1994, EMBO J, V13, P4953, DOI 10.1002/j.1460-2075.1994.tb06822.x; NICHOLS WW, 1978, CANCER RES, V38, P960; Niida H, 2000, MOL CELL BIOL, V20, P4115, DOI 10.1128/MCB.20.11.4115-4127.2000; Ogino H, 1998, BIOCHEM BIOPH RES CO, V248, P223, DOI 10.1006/bbrc.1998.8875; Roth CW, 1997, MOL CELL BIOL, V17, P5176, DOI 10.1128/MCB.17.9.5176; Saretzki G, 1999, ONCOGENE, V18, P5148, DOI 10.1038/sj.onc.1202898; Smith CD, 1999, J CELL BIOL, V145, P203, DOI 10.1083/jcb.145.2.203; Teng SC, 2000, MOL CELL, V6, P947, DOI 10.1016/S1097-2765(05)00094-8; Teng SC, 1999, MOL CELL BIOL, V19, P8083; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; Wellinger RJ, 1996, CELL, V85, P423, DOI 10.1016/S0092-8674(00)81120-4; Wright WE, 1999, EXP CELL RES, V251, P492, DOI 10.1006/excr.1999.4602; Yeager TR, 1999, CANCER RES, V59, P4175; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388	34	78	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32198	32203		10.1074/jbc.M104469200	http://dx.doi.org/10.1074/jbc.M104469200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11395519	hybrid			2022-12-25	WOS:000170613500099
J	Morais, F; Kuhn, K; Stewart, DH; Barber, J; Brudvig, GW; Nixon, PJ				Morais, F; Kuhn, K; Stewart, DH; Barber, J; Brudvig, GW; Nixon, PJ			Photosynthetic water oxidation in cytochrome b(559) mutants containing a disrupted heme-binding pocket	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; PHOTOSYSTEM-II COMPLEXES; CYCLIC ELECTRON FLOW; CHLAMYDOMONAS-REINHARDTII; SYNECHOCOCCUS-ELONGATUS; AXIAL LIGANDS; CHLOROPLAST; B-559; PHOTOINHIBITION; POLYPEPTIDE	The role of cytochrome b(559) in photosynthetic oxygen evolution has been investigated in three chloroplast mutants of Chlamydomonas reinhardtii, in which one of the two histidine axial ligands to the heme, provided by the a subunit, has been replaced by the residues methionine, tyrosine, and glutamine. Photosystem two complexes functional for oxygen evolution could be assembled in the methionine and tyrosine mutants up to similar to 15% of wild type levels, whereas no complexes with oxygen evolution activity could be detected in the glutamine mutant. PSII supercomplexes isolated from the tyrosine and methionine mutants were as active as wild type in terms of light-saturated rates of oxygen evolution but in contrast to wild type contained no bound heme despite the presence of the alpha subunit. Oxygen evolution in the tyrosine and methionine mutants was, however, more sensitive to photoinactivation than the WT. Overall, these data establish unambiguously that a redox role for the heme of cytochrome b(559) is not required for photosynthetic oxygen evolution. Instead, our data provide new evidence of a role for cytochrome b(559) in the protection. of the photosystem two complex in vivo.	Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London SW7 2AY, England; Yale Univ, Dept Chem, New Haven, CT 06520 USA	Imperial College London; Yale University	Nixon, PJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London SW7 2AY, England.	p.nixon@ic.ac.uk	Kühn, Kristina/F-4918-2012	Kühn, Kristina/0000-0001-6747-783X; Nixon, Peter/0000-0003-1952-6937	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032715] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32715] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALIZADEH S, 1994, BBA-BIOENERGETICS, V1188, P439, DOI 10.1016/0005-2728(94)90067-1; ALLEN KD, 1994, PLANTA, V194, P42; ANANYEV G, 1994, PHOTOSYNTH RES, V41, P327, DOI 10.1007/BF00019410; Andronis C, 1998, PLANT PHYSIOL, V117, P515, DOI 10.1104/pp.117.2.515; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; ARO EM, 1993, BIOCHIM BIOPHYS ACTA, V1143, P113, DOI 10.1016/0005-2728(93)90134-2; BABCOCK GT, 1985, BIOCHEMISTRY-US, V24, P3638, DOI 10.1021/bi00335a036; BARBER J, 1993, P NATL ACAD SCI USA, V90, P10942, DOI 10.1073/pnas.90.23.10942; BARBER J, 1992, TRENDS BIOCHEM SCI, V17, P61, DOI 10.1016/0968-0004(92)90503-2; BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; BOYNTON JE, 1993, METHOD ENZYMOL, V217, P510; BOYNTON JE, 1988, SCIENCE, V240, P1534, DOI 10.1126/science.2897716; DINER BA, 1980, EUR J BIOCHEM, V110, P521, DOI 10.1111/j.1432-1033.1980.tb04894.x; DINER BA, 1996, OXYGENIC PHOTOSYNTHE, P213; DOLLA A, 1995, BIOCHEM BIOPH RES CO, V211, P742, DOI 10.1006/bbrc.1995.1875; Eshaghi S, 1999, FEBS LETT, V446, P23, DOI 10.1016/S0014-5793(99)00149-0; FALKOWSKI PG, 1986, PLANT PHYSIOL, V81, P310, DOI 10.1104/pp.81.1.310; Fiege R, 1996, FEBS LETT, V387, P33, DOI 10.1016/0014-5793(96)00458-9; GOLDSCHMIDTCLERMONT M, 1991, NUCLEIC ACIDS RES, V19, P4083, DOI 10.1093/nar/19.15.4083; Hankamer B, 1997, ANNU REV PLANT PHYS, V48, P641, DOI 10.1146/annurev.arplant.48.1.641; Hankamer B, 1997, EUR J BIOCHEM, V243, P422, DOI 10.1111/j.1432-1033.1997.0422a.x; Hanley J, 1999, BIOCHEMISTRY-US, V38, P8189, DOI 10.1021/bi990633u; HEBER U, 1979, BIOCHIM BIOPHYS ACTA, V546, P292, DOI 10.1016/0005-2728(79)90047-1; Hippler M, 1998, BBA-BIOENERGETICS, V1367, P1, DOI 10.1016/S0005-2728(98)00136-4; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; JANSSON S, 1994, BBA-BIOENERGETICS, V1184, P1, DOI 10.1016/0005-2728(94)90148-1; KAMMANN M, 1989, NUCLEIC ACIDS RES, V17, P5404, DOI 10.1093/nar/17.13.5404; KOMENDA J, 1995, BIOCHEMISTRY-US, V34, P9625, DOI 10.1021/bi00029a040; KRAUSE GH, 1991, ANNU REV PLANT PHYS, V42, P313, DOI 10.1146/annurev.pp.42.060191.001525; Kruk J, 1999, PHOTOSYNTH RES, V62, P273, DOI 10.1023/A:1006374319191; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; Magnuson A, 1999, BBA-BIOENERGETICS, V1411, P180, DOI 10.1016/S0005-2728(99)00044-4; Matsson M, 2000, BIOCHEMISTRY-US, V39, P8617, DOI 10.1021/bi000271m; Melis A, 1999, TRENDS PLANT SCI, V4, P130, DOI 10.1016/S1360-1385(99)01387-4; MIYAZAKI A, 1989, BIOCHIM BIOPHYS ACTA, V975, P142, DOI 10.1016/S0005-2728(89)80212-9; Morais F, 1998, J BIOL CHEM, V273, P29315, DOI 10.1074/jbc.273.45.29315; Muller B, 1999, PLANT CELL, V11, P2365, DOI 10.1105/tpc.11.12.2365; NANBA O, 1987, P NATL ACAD SCI USA, V84, P109, DOI 10.1073/pnas.84.1.109; Nield J, 2000, J BIOL CHEM, V275, P27940; OHNISHI N, 2000, 9 INT C CELL MOL BIO, P71; PAKRASI HB, 1991, EMBO J, V10, P1619, DOI 10.1002/j.1460-2075.1991.tb07684.x; POULSON M, 1995, BIOCHEMISTRY-US, V34, P10932, DOI 10.1021/bi00034a027; Rova EM, 1996, J BIOL CHEM, V271, P28918, DOI 10.1074/jbc.271.46.28918; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schweitzer RH, 1997, BIOCHEMISTRY-US, V36, P11351, DOI 10.1021/bi9709203; SHAPLEIGH JP, 1992, P NATL ACAD SCI USA, V89, P4786, DOI 10.1073/pnas.89.11.4786; Stewart DH, 1998, BBA-BIOENERGETICS, V1367, P63, DOI 10.1016/S0005-2728(98)00139-X; Stewart DH, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P1113; TAE GS, 1992, BIOCHEMISTRY-US, V31, P4066, DOI 10.1021/bi00131a024; THOMPSON LK, 1988, BIOCHEMISTRY-US, V27, P6653, DOI 10.1021/bi00418a002; Tracewell CA, 2001, BIOCHEMISTRY-US, V40, P193, DOI 10.1021/bi001992o; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589	52	23	25	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31986	31993		10.1074/jbc.M103935200	http://dx.doi.org/10.1074/jbc.M103935200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11390403	hybrid			2022-12-25	WOS:000170613500071
J	Nakagawa, T; Flores-Rozas, H; Kolodner, RD				Nakagawa, T; Flores-Rozas, H; Kolodner, RD			The MER3 helicase involved in meiotic crossing over is stimulated by single-stranded DNA-binding proteins and unwinds DNA in the 3 ' to 5 ' direction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNDROME GENE-PRODUCT; BLOOMS-SYNDROME PROTEIN; SACCHAROMYCES-CEREVISIAE; CHROMOSOME SYNAPSIS; MISMATCH CORRECTION; RAD51 PROTEIN; MUTS HOMOLOG; RECOMBINATION; MEIOSIS; YEAST	The meiosis-specific MER3 protein of Saccharomyces cerevisiae is required for crossing over, which ensures faithful segregation of homologous chromosomes at the first meiotic division. The predicted sequence of the MER3 protein contains the seven motifs characteristic of the DExH-box type of DNA/RNA helicases. The purified MER3 protein is a DNA helicase, which can displace a 50-nucleotide fragment annealed to a single-stranded circular DNA. MER3 was found to have ATPase activity, which was stimulated either by single- or double-stranded DNA. The turnover rate, k(cat), of ATP hydrolysis was similar to 500/min in the presence of either DNA. MER3 was able to efficiently displace relatively long 631-nucleotide fragments from single-stranded circular DNA only in the presence of the S. cerevisiae single-stranded DNA-binding protein, RPA (replication protein A). It appears that RPA inhibits re-annealing of the single-stranded products of the MER3 helicase. The MER3 helicase was found to unwind DNA in the 3 ' to 5 ' direction relative to single-stranded regions in the DNA substrates. Possible roles for the MER3 helicase in meiotic crossing over are discussed.	Univ Calif San Diego, Sch Med, Ludwig Inst Canc Res, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Ctr Canc, Dept Med, La Jolla, CA 92093 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego	Kolodner, RD (corresponding author), Univ Calif San Diego, Sch Med, Ludwig Inst Canc Res, CMME 3080,9500 Gilman Dr, La Jolla, CA 92093 USA.		Nakagawa, Takuro/A-1367-2017	Nakagawa, Takuro/0000-0003-3455-8224	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026017, R37GM026017] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM026017, GM26017, R37 GM026017] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1992, J MOL BIOL, V227, P54, DOI 10.1016/0022-2836(92)90681-9; Bennett RJ, 1999, J MOL BIOL, V289, P235, DOI 10.1006/jmbi.1999.2739; Bennett RJ, 1998, J BIOL CHEM, V273, P9644, DOI 10.1074/jbc.273.16.9644; BISHOP DK, 1994, CELL, V79, P1081, DOI 10.1016/0092-8674(94)90038-8; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; Brosh RM, 2000, J BIOL CHEM, V275, P23500, DOI 10.1074/jbc.M001557200; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; Chua PR, 1998, CELL, V93, P349, DOI 10.1016/S0092-8674(00)81164-2; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Frei C, 2000, GENE DEV, V14, P81; Friedberg E.C., 1995, DNA REPAIR MUTAGENES, P407; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; HEYER WD, 1990, EMBO J, V9, P2321, DOI 10.1002/j.1460-2075.1990.tb07404.x; HOLLINGSWORTH NM, 1995, GENE DEV, V9, P1728, DOI 10.1101/gad.9.14.1728; Hunter N, 1997, GENE DEV, V11, P1573, DOI 10.1101/gad.11.12.1573; JOHNSON AW, 1991, J BIOL CHEM, V266, P14046; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Karow JK, 1999, CURR BIOL, V9, P597, DOI 10.1016/S0960-9822(99)80264-4; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; Kirkpatrick DT, 2000, GENETICS, V156, P1549; Kleckner N, 1996, P NATL ACAD SCI USA, V93, P8167, DOI 10.1073/pnas.93.16.8167; Lee SK, 1999, SCIENCE, V286, P2339, DOI 10.1126/science.286.5448.2339; Li ZF, 1997, P NATL ACAD SCI USA, V94, P11221, DOI 10.1073/pnas.94.21.11221; Liao SR, 2000, GENE DEV, V14, P2570, DOI 10.1101/gad.822400; Lu JA, 1996, NATURE, V383, P678, DOI 10.1038/383678a0; MATSON SW, 1986, J BIOL CHEM, V261, P169; MATSON SW, 1994, BIOESSAYS, V16, P13, DOI 10.1002/bies.950160103; MCENTEE K, 1980, P NATL ACAD SCI-BIOL, V77, P857, DOI 10.1073/pnas.77.2.857; Myung K, 2001, NAT GENET, V27, P113, DOI 10.1038/83673; Nakagawa T, 1997, GENES CELLS, V2, P65, DOI 10.1046/j.1365-2443.1997.d01-283.x; Nakagawa T, 1999, EMBO J, V18, P5714, DOI 10.1093/emboj/18.20.5714; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Roeder GS, 1997, GENE DEV, V11, P2600, DOI 10.1101/gad.11.20.2600; ROSSMACDONALD P, 1994, CELL, V79, P1069, DOI 10.1016/0092-8674(94)90037-X; SCHWACHA A, 1994, CELL, V76, P51, DOI 10.1016/0092-8674(94)90172-4; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Storlazzi A, 1996, P NATL ACAD SCI USA, V93, P9043, DOI 10.1073/pnas.93.17.9043; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; SYM M, 1994, CELL, V79, P283, DOI 10.1016/0092-8674(94)90197-X; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; Tsubouchi H, 2000, MOL BIOL CELL, V11, P2221, DOI 10.1091/mbc.11.7.2221; UMEZU K, 1990, P NATL ACAD SCI USA, V87, P5363, DOI 10.1073/pnas.87.14.5363; Wang TF, 1999, P NATL ACAD SCI USA, V96, P13914, DOI 10.1073/pnas.96.24.13914; Wang WS, 2000, EMBO J, V19, P3428, DOI 10.1093/emboj/19.13.3428; Watt PM, 1996, GENETICS, V144, P935	47	45	47	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31487	31493		10.1074/jbc.M104003200	http://dx.doi.org/10.1074/jbc.M104003200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11376001	Green Accepted, hybrid			2022-12-25	WOS:000170613500004
J	Kaneto, H; Xu, G; Song, KH; Suzuma, K; Bonner-Weir, S; Sharma, A; Weir, GC				Kaneto, H; Xu, G; Song, KH; Suzuma, K; Bonner-Weir, S; Sharma, A; Weir, GC			Activation of the hexosamine pathway leads to deterioration of pancreatic beta-cell function through the induction of oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN GENE-TRANSCRIPTION; O-LINKED GLYCOSYLATION; GLUCOSE TOXICITY; TRANSGENIC MICE; IN-VIVO; GLUTAMINE-FRUCTOSE-6-PHOSPHATE AMIDOTRANSFERASE; SKELETAL-MUSCLE; HOMEOBOX FACTOR; HIT-T15 CELLS; GROWTH-FACTOR	It is known well that activation of the hexosamine pathway causes insulin resistance, but how this activation influences pancreatic beta -cell function remains unclear. In this study, we found that in isolated rat islets adenovirus-mediated overexpression of glutamine:fructose-6-phosphate amidotransferase (GFAT), the first and rate-limiting enzyme of the hexosamine pathway, leads to deterioration of beta -cell function, which is similar to that found in diabetes. Overexpression of GFAT or treatment with glucosamine results in impaired glucose-stimulated insulin secretion and reduction irk the expression levels of several beta -cell specific genes (insulin, GLUT2, and glucokinase). Additionally, the DNA binding activity of PDX-1, an important transcription factor for these three genes, was markedly reduced. These phenomena were not mimicked by the induction of O-linked glycosylation with an inhibitor of O-GlcNAcase, PUG-NAc. It was also found that glucosamine increases hydrogen peroxide levels and that several hexosamine pathway-mediated changes were suppressed by treatment with the antioxidant N-acetyl-L-cysteine. In conclusion, activation of the hexosamine pathway leads to deterioration of beta -cell function through the induction of oxidative stress rather than O-linked glycosylation. Thus, the hexosamine pathway may contribute to the deterioration of beta -cell function found in diabetes.	Joslin Diabet Ctr, Sect Islet Transplantat & Cell Biol, Boston, MA 02215 USA	Harvard University; Joslin Diabetes Center, Inc.	Weir, GC (corresponding author), Joslin Diabet Ctr, Sect Islet Transplantat & Cell Biol, 1 Joslin Pl, Boston, MA 02215 USA.			Bonner-Weir, Susan/0000-0003-4682-0656	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035449] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-35449] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; Akimoto Y, 1999, DIABETES, V48, P2407, DOI 10.2337/diabetes.48.12.2407; Akimoto Y, 2000, DIABETOLOGIA, V43, P1239, DOI 10.1007/s001250051519; Baron AD, 1995, J CLIN INVEST, V96, P2792, DOI 10.1172/JCI118349; BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; BONNERWEIR S, 1983, J CLIN INVEST, V71, P1544, DOI 10.1172/JCI110910; Comer FI, 2000, J BIOL CHEM, V275, P29179, DOI 10.1074/jbc.R000010200; Du XL, 2000, P NATL ACAD SCI USA, V97, P12222, DOI 10.1073/pnas.97.22.12222; Dutta S, 1998, NATURE, V392, P560, DOI 10.1038/33311; Haltiwanger RS, 1998, J BIOL CHEM, V273, P3611, DOI 10.1074/jbc.273.6.3611; Hart GW, 1997, ANNU REV BIOCHEM, V66, P315, DOI 10.1146/annurev.biochem.66.1.315; Hawkins M, 1997, J CLIN INVEST, V99, P2173, DOI 10.1172/JCI119390; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hebert LF, 1996, J CLIN INVEST, V98, P930, DOI 10.1172/JCI118876; Ihara Y, 1999, DIABETES, V48, P927, DOI 10.2337/diabetes.48.4.927; Jonas JC, 1999, J BIOL CHEM, V274, P14112, DOI 10.1074/jbc.274.20.14112; Kaneto H, 1997, J BIOL CHEM, V272, P29137, DOI 10.1074/jbc.272.46.29137; Kaneto H, 1999, DIABETES, V48, P2398, DOI 10.2337/diabetes.48.12.2398; Kaneto H, 1996, BIOCHEM J, V320, P855, DOI 10.1042/bj3200855; KELLY WG, 1993, J BIOL CHEM, V268, P10416; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; Liu K, 2000, P NATL ACAD SCI USA, V97, P2820, DOI 10.1073/pnas.97.6.2820; Maechler P, 1999, J BIOL CHEM, V274, P27905, DOI 10.1074/jbc.274.39.27905; Matsuoka T, 1997, J CLIN INVEST, V99, P144, DOI 10.1172/JCI119126; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; Moloney DJ, 2000, J BIOL CHEM, V275, P9604, DOI 10.1074/jbc.275.13.9604; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; OLSON LK, 1993, J CLIN INVEST, V92, P514, DOI 10.1172/JCI116596; Patti ME, 1999, DIABETES, V48, P1562, DOI 10.2337/diabetes.48.8.1562; SHARMA A, 1995, MOL ENDOCRINOL, V9, P1127, DOI 10.1210/me.9.9.1127; Stoffers DA, 1997, NAT GENET, V17, P138, DOI 10.1038/ng1097-138; SUTTON R, 1986, TRANSPLANTATION, V42, P689, DOI 10.1097/00007890-198612000-00022; Tanaka Y, 1999, P NATL ACAD SCI USA, V96, P10857, DOI 10.1073/pnas.96.19.10857; Tang JP, 2000, DIABETES, V49, P1492, DOI 10.2337/diabetes.49.9.1492; Tiedge M, 1997, DIABETES, V46, P1733, DOI 10.2337/diabetes.46.11.1733; TOKUYAMA Y, 1995, DIABETES, V44, P1447, DOI 10.2337/diabetes.44.12.1447; Veerababu G, 2000, DIABETES, V49, P2070, DOI 10.2337/diabetes.49.12.2070; Waeber G, 1996, MOL ENDOCRINOL, V10, P1327, DOI 10.1210/me.10.11.1327; Watada H, 1996, DIABETES, V45, P1478, DOI 10.2337/diabetes.45.11.1478; Weir GC, 2001, DIABETES, V50, pS154, DOI 10.2337/diabetes.50.2007.S154; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; XIA MH, 1993, DIABETES, V42, P1392, DOI 10.2337/diabetes.42.10.1392; Zangen DH, 1997, DIABETES, V46, P258, DOI 10.2337/diabetes.46.2.258	44	240	255	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31099	31104		10.1074/jbc.M104115200	http://dx.doi.org/10.1074/jbc.M104115200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11390407	hybrid			2022-12-25	WOS:000170472900068
J	Levy, Y; Arbel-Goren, R; Hadari, YR; Eshhar, S; Ronen, D; Elhanany, E; Geiger, B; Zick, Y				Levy, Y; Arbel-Goren, R; Hadari, YR; Eshhar, S; Ronen, D; Elhanany, E; Geiger, B; Zick, Y			Galectin-8 functions as a matricellular modulator of cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; T-CELLS; BINDING; FIBRONECTIN; PROTEINS; LECTIN; DOMAIN; ACTIVATION; EXPRESSION; INTEGRINS	The interaction of cells with the extracellular matrix regulates cell adhesion and motility. Here we demonstrate that different cell types adhere and spread when cultured in serum-free medium on immobilized galectin-8, a mammalian 13-galactoside-binding protein. At maximal doses, galectin-8 is equipotent to fibronectin in promoting cen adhesion and spreading. Cell adhesion to immobilized galectin-8 is mediated by sugar-protein interactions with integrins, and galectin-8 triggers integrin-mediated signaling cascades including Tyr phosphorylation of focal adhesion kinase and paxillin. Cell adhesion is potentiated in the presence of Mn2+, whereas it is interrupted in the presence of soluble galectin-8, integrin beta (1), inhibitory antibodies, EDTA, or thiodigalactoside but not by RGD peptides. Furthermore, cells readily adhere onto immobilized monoclonal galectin-8 antibodies, which are equipotent to integrin antibodies in promoting cell adhesion. Cell adhesion to immobilized galectin-8 is partially inhibited by serum proteins, suggesting that complex formation between immobilized galectin-8 and serum components generates a matrix that is less supportive of cell adhesion. Accordingly, cell motility on immobilized galectin-8 readily takes place in the presence of serum. Truncation of the C-terminal half of galectin-8, including one of its two carbohydrate recognition domains, largely abolishes its ability to modulate cell adhesion, indicating that both carbohydrate recognition domains are required to maintain a functional form of galectin-8. Collectively, our findings implicate galectin-8 as a physiological modulator of cell adhesion. When immobilized, it functions as a matrix protein equipotent to fibronectin in promoting cell adhesion by ligation and clustering of cell surface integrin receptors. In contrast, when present in excess as a soluble ligand, galectin-8 (like fibronectin) forms a complex with integrins that negatively regulates cell adhesion. Because of its dual effects on the adhesive properties of the cells and its association with fibronectin, galectin-8 might be considered a novel type of matricellular protein.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Israel Inst Biol Res, Dept Biochem & Mol Biol, IL-70450 Ness Ziona, Israel	Weizmann Institute of Science	Zick, Y (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	yehiel.zick@weizmann.ac.il	Zick, Yehiel/K-1479-2012					AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; Aplin AE, 1998, PHARMACOL REV, V50, P197; BARONDES SH, 1994, CELL, V76, P597, DOI 10.1016/0092-8674(94)90498-7; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503; CALOF AL, 1994, NEURON, V13, P117, DOI 10.1016/0896-6273(94)90463-4; Camby I, 2001, BRAIN PATHOL, V11, P12; CHIQUETEHRISMANN R, 1995, CURR OPIN CELL BIOL, V7, P715, DOI 10.1016/0955-0674(95)80114-6; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; COOPER DNW, 1991, J CELL BIOL, V115, P1437, DOI 10.1083/jcb.115.5.1437; Eshhar Z, 1985, HYBRIDOMA TECHNOLOGY, P1; FAULL RJ, 1993, J CELL BIOL, V121, P155, DOI 10.1083/jcb.121.1.155; Feizi T, 1999, TRENDS BIOCHEM SCI, V24, P369, DOI 10.1016/S0968-0004(99)01458-9; FENSELAU C, 1997, ANAL CHEM NEWS FEATU, V1, P661; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; Girard JP, 1996, J BIOL CHEM, V271, P4511; Hadari YR, 2000, J CELL SCI, V113, P2385; Hadari YR, 1997, TRENDS GLYCOSCI GLYC, V9, P103, DOI 10.4052/tigg.9.103; HADARI YR, 1995, J BIOL CHEM, V270, P3447, DOI 10.1074/jbc.270.7.3447; Hughes RC, 1999, BBA-GEN SUBJECTS, V1473, P172, DOI 10.1016/S0304-4165(99)00177-4; Hynes RO, 1999, TRENDS CELL BIOL, V9, pM33, DOI 10.1016/S0962-8924(99)01667-0; Jui HY, 1996, BIOCHEMISTRY-US, V35, P14326, DOI 10.1021/bi9613032; Kim JH, 2000, EXP CELL RES, V256, P445, DOI 10.1006/excr.2000.4852; Klapper LN, 1997, ONCOGENE, V14, P2099, DOI 10.1038/sj.onc.1201029; Kuwabara I, 1996, J IMMUNOL, V156, P3939; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIAO DI, 1994, P NATL ACAD SCI USA, V91, P1428, DOI 10.1073/pnas.91.4.1428; Lyman S, 1997, J BIOL CHEM, V272, P22538, DOI 10.1074/jbc.272.36.22538; MAHANTHAPPA NK, 1994, DEVELOPMENT, V120, P1373; MATTHES DJ, 1995, CELL, V81, P631, DOI 10.1016/0092-8674(95)90084-5; Miyamoto S, 1998, ANN NY ACAD SCI, V857, P119, DOI 10.1111/j.1749-6632.1998.tb10112.x; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; MURPHYULLRICH JE, 1991, J CELL BIOL, V115, P1127, DOI 10.1083/jcb.115.4.1127; NEUGEBAUER KM, 1991, NATURE, V350, P68, DOI 10.1038/350068a0; NOSE A, 1994, NEURON, V13, P525, DOI 10.1016/0896-6273(94)90023-X; Paz K, 1999, J BIOL CHEM, V274, P28816, DOI 10.1074/jbc.274.40.28816; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; RAZ A, 1987, CANCER METAST REV, V6, P433, DOI 10.1007/BF00144274; Retta SF, 1999, METH MOL B, V96, P125; SAGE EH, 1991, J BIOL CHEM, V266, P14831; SATO S, 1992, J BIOL CHEM, V267, P6983; SAVAGE B, 1990, J BIOL CHEM, V265, P11766; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schwarzbauer JE, 1999, CURR OPIN CELL BIOL, V11, P622, DOI 10.1016/S0955-0674(99)00017-4; Sharon N, 1995, ESSAYS BIOCHEM, V30, P59; Shih DT, 1997, J CELL SCI, V110, P2619; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; Su ZZ, 1996, P NATL ACAD SCI USA, V93, P7252, DOI 10.1073/pnas.93.14.7252; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; Woods ML, 2000, EUR J IMMUNOL, V30, P38, DOI 10.1002/1521-4141(200001)30:1<38::AID-IMMU38>3.3.CO;2-2; YAMADA KM, 1984, J CELL BIOL, V99, P29, DOI 10.1083/jcb.99.1.29; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; Zamir E, 2000, NAT CELL BIOL, V2, P191, DOI 10.1038/35008607	54	145	152	1	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31285	31295		10.1074/jbc.M100340200	http://dx.doi.org/10.1074/jbc.M100340200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11371555	hybrid			2022-12-25	WOS:000170472900092
J	Tang, CL; Klinman, JP				Tang, CL; Klinman, JP			The catalytic function of bovine lysyl oxidase in the absence of copper	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINE OXIDASE; CROSS-LINKING; COLLAGEN; ELASTIN	Bovine lysyl oxidase (BLO) contains two different co- factors, copper (Kagan, H. M. (1986) in Biology of Fxtra-cellular Matrix (Mecham, R. P., ed) Vol. 1, pp. 321-398, Academic Press, Orlando, FL) and lysine tyrosyl quinone (LTQ) (Wang, S. YL, Mure, M., Medzihradszky, K. F., Burlingame, A. L., Brown, D. E., Dooley, D. M., Smith, A. J., Kagan, H. M., and Klinman, J. P. (1996) Science 273, 1078-1084). By a combination of UV-visible spectroscopy, metal content analysis, and activity measurements, we find that copper-depleted BLO reacts in an irreversible manner with phenylhydrazine, an amine substrate analog, and catalyzes multiple turnovers of the substrate benzylamine. After removal of the majority of enzyme-bound copper, apoBLO exhibits a decrease in the LTQ content, as evidenced by the drop of the 510-520-nm absorbance, suggesting that the copper may play a structural role in stabilizing the LTQ. The remaining intact LTQ in the apoBLO reacted with phenylhydrazine, both in the presence and absence of the chelator, 10 nim 2,2 ' -dipyridyl. When benzylamine was used as the substrate, the apoBLO turned over at a rate of 50-60% of the native BLO (after correction for the residual copper and the change of LTQ content). Copper contamination from the assay buffer was ruled out by comparison of enzyme activity using different apoBLO concentrations. These studies demonstrate that the mature form of lysyl oxidase retains many of its functions in the absence of copper.	Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cellular Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley	Klinman, JP (corresponding author), Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.	klinman@socrates.berkeley.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039296] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 39296] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CRONSHAW AD, 1993, MATRIX, V13, P255, DOI 10.1016/S0934-8832(11)80009-0; GACHERU SN, 1990, J BIOL CHEM, V265, P19022; HARRIS ED, 1974, BIOCHIM BIOPHYS ACTA, V341, P332, DOI 10.1016/0005-2744(74)90226-5; KAGAN HM, 1995, METHOD ENZYMOL, V258, P122; KAGAN HM, 1986, BIOL EXTRACELLULAR M, V1, P321; KUIVANIEMI H, 1982, J CLIN INVEST, V69, P730, DOI 10.1172/JCI110503; Liu GM, 1997, J BIOL CHEM, V272, P32370, DOI 10.1074/jbc.272.51.32370; Mills SA, 2000, J AM CHEM SOC, V122, P9897, DOI 10.1021/ja000325f; PAZ MA, 1991, J BIOL CHEM, V266, P689; PINNELL SR, 1968, P NATL ACAD SCI USA, V61, P708, DOI 10.1073/pnas.61.2.708; SIEGEL RC, 1970, BIOCHEMISTRY-US, V9, P4486, DOI 10.1021/bi00825a004; Su QJ, 1998, BIOCHEMISTRY-US, V37, P12513, DOI 10.1021/bi981103l; TANG SS, 1983, J BIOL CHEM, V258, P4331; Wang SX, 1996, SCIENCE, V273, P1078, DOI 10.1126/science.273.5278.1078; WILLIAMSON PR, 1987, J BIOL CHEM, V262, P8196; WILLIAMSON PR, 1986, J BIOL CHEM, V261, P9477; Zhu ZY, 1998, BBA-BIOENERGETICS, V1364, P297, DOI 10.1016/S0005-2728(98)00035-8	17	37	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30575	30578		10.1074/jbc.C100138200	http://dx.doi.org/10.1074/jbc.C100138200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11395477	hybrid			2022-12-25	WOS:000170472900001
J	Zhao, LC; Shey, M; Farnsworth, M; Dailey, MO				Zhao, LC; Shey, M; Farnsworth, M; Dailey, MO			Regulation of membrane metalloproteolytic cleavage of L-selectin (CD62L) by the epidermal growth factor domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; AMYLOID PRECURSOR PROTEIN; NODE HOMING RECEPTOR; CONVERTING ENZYME SECRETASE; CELL-SURFACE; TNF RECEPTOR; HUMAN NEUTROPHILS; KINASE-C; DISINTEGRIN-METALLOPROTEASE; STRUCTURAL REQUIREMENTS	The adhesion molecule L-selectin is cleaved rapidly from the surface of activated leukocytes by tumor necrosis factor-a converting enzyme, a cell surface metalloprotease, and also undergoes slower constitutive shedding in unactivated cells. The structural features that render it susceptible to shedding are poorly understood. We therefore analyzed the shedding of a series of mutant and chimeric L-selectin molecules. Although murine L-selectin is cleaved at a specific location in the juxtamembrane region 11 amino acids distal to the cell membrane, this cleavage has little sequence specificity. However, proline substitution at the P2 ' or P3 ' position or deletion of the epidermal growth factor (EGF) domain completely blocks the rapid phorbol ester-induced cleavage, but does not affect the slower basal proteolytic shedding. Insertion of the 15-residue membrane-proximal region (MPR) of L-selectin into the heterologous protein B7.2 results in a molecule that undergoes constitutive proteolytic turnover. In contrast, insertion of both the EGF domain and the MPR confers susceptibility to both slow constitutive shedding and the rapid proteolytic cleavage induced by phorbol 12-myristate 13-acetate. These results demonstrate that constitutive and induced L-selectin cleavage are separable processes and that the rapid phorbol ester-induced shedding requires the presence of the EGF domain, a sequence that is remote from the cleavage site.	Univ Iowa, Coll Med, Dept Pathol, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Microbiol, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Interdisciplinary Grad Program, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa	Dailey, MO (corresponding author), Univ Iowa, Coll Med, Dept Pathol, Iowa City, IA 52242 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022730] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-22730] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGER A, 1994, LYMPHOLOGY, V27, P187; Althoff K, 2000, EUR J BIOCHEM, V267, P2624, DOI 10.1046/j.1432-1327.2000.01278.x; ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; Arribas J, 1997, J BIOL CHEM, V272, P17160, DOI 10.1074/jbc.272.27.17160; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Bennett TA, 1996, J IMMUNOL, V156, P3093; Bennett TA, 2000, J IMMUNOL, V164, P4120, DOI 10.4049/jimmunol.164.8.4120; BERG M, 1990, BLOOD, V76, P2381; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; BRAKEBUSCH C, 1994, J BIOL CHEM, V269, P32488; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; CAPPELLUTI E, 1993, BIOCHEMISTRY-US, V32, P551, DOI 10.1021/bi00053a021; Chao CC, 1997, J IMMUNOL, V159, P1686; CHEN AJ, 1995, J EXP MED, V182, P519, DOI 10.1084/jem.182.2.519; CITRON M, 1995, NEURON, V14, P661, DOI 10.1016/0896-6273(95)90323-2; CROWE PD, 1995, J EXP MED, V181, P1205, DOI 10.1084/jem.181.3.1205; DAILEY MO, 1993, LYMPHOCYTE ADHESION, P75; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Dempsey PJ, 1997, J CELL BIOL, V138, P747, DOI 10.1083/jcb.138.4.747; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; Feehan C, 1996, J BIOL CHEM, V271, P7019, DOI 10.1074/jbc.271.12.7019; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; Giblin PA, 1997, J IMMUNOL, V159, P3498; Gopalan PK, 1997, J IMMUNOL, V158, P367; Haass C, 1997, NEURON, V18, P687, DOI 10.1016/S0896-6273(00)80309-8; Hafezi-Moghadam A, 1999, J EXP MED, V189, P939, DOI 10.1084/jem.189.6.939; HATHCOCK KS, 1993, SCIENCE, V262, P905, DOI 10.1126/science.7694361; Herman C, 1998, J IMMUNOL, V160, P2478; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Hwang ST, 1996, J EXP MED, V184, P1343, DOI 10.1084/jem.184.4.1343; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; JUNG TM, 1990, J IMMUNOL, V144, P3130; KAHN J, 1994, J CELL BIOL, V125, P461, DOI 10.1083/jcb.125.2.461; KALDJIAN EP, 1995, J IMMUNOL, V154, P4351; KANSAS GS, 1993, J EXP MED, V177, P833, DOI 10.1084/jem.177.3.833; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Lunn CA, 1997, FEBS LETT, V400, P333, DOI 10.1016/S0014-5793(96)01410-X; Martinez-Pomares L, 1998, J BIOL CHEM, V273, P23376, DOI 10.1074/jbc.273.36.23376; MARUYAMA K, 1991, BIOCHEM BIOPH RES CO, V179, P1670, DOI 10.1016/0006-291X(91)91767-7; Maskos K, 1998, P NATL ACAD SCI USA, V95, P3408, DOI 10.1073/pnas.95.7.3408; McDermott MF, 1999, CELL, V97, P133, DOI 10.1016/S0092-8674(00)80721-7; Middelhoven PJ, 1997, FEBS LETT, V414, P14, DOI 10.1016/S0014-5793(97)00959-9; MIGAKI GI, 1995, J EXP MED, V182, P549, DOI 10.1084/jem.182.2.549; Morrison M, 1980, Methods Enzymol, V70, P214; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; MULLBERG J, 1995, J IMMUNOL, V155, P5198; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; MURAKAWA Y, 1992, J IMMUNOL, V148, P1771; NORMAN DG, 1991, J MOL BIOL, V219, P717, DOI 10.1016/0022-2836(91)90666-T; PANDIELLA A, 1992, J BIOL CHEM, V267, P24028; Parvathy S, 1997, BIOCHEM J, V327, P37, DOI 10.1042/bj3270037; Parvathy S, 1999, BIOCHEMISTRY-US, V38, P9728, DOI 10.1021/bi9906827; Parvathy S, 1998, BIOCHEMISTRY-US, V37, P1680, DOI 10.1021/bi972034y; PEREZ C, 1990, CELL, V63, P251, DOI 10.1016/0092-8674(90)90158-B; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; PIRCHER H, 1989, EMBO J, V8, P719, DOI 10.1002/j.1460-2075.1989.tb03431.x; PORTEU F, 1990, J EXP MED, V172, P599, DOI 10.1084/jem.172.2.599; Preece G, 1996, J BIOL CHEM, V271, P11634, DOI 10.1074/jbc.271.20.11634; Reddy P, 2000, J BIOL CHEM, V275, P14608, DOI 10.1074/jbc.275.19.14608; RETTENMIER CW, 1987, MOL CELL BIOL, V7, P2378, DOI 10.1128/MCB.7.7.2378; Rosendahl MS, 1997, J BIOL CHEM, V272, P24588, DOI 10.1074/jbc.272.39.24588; Rovida E, 2001, J IMMUNOL, V166, P1583, DOI 10.4049/jimmunol.166.3.1583; Sadhukhan R, 1998, P NATL ACAD SCI USA, V95, P138, DOI 10.1073/pnas.95.1.138; SCHLEIFFENBAUM B, 1992, J CELL BIOL, V119, P229, DOI 10.1083/jcb.119.1.229; Schlondorff J, 1999, J CELL SCI, V112, P3603; Schlondorff J, 2001, J BIOL CHEM, V276, P14665, DOI 10.1074/jbc.M010741200; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; SIEGELMAN MH, 1990, CELL, V61, P611, DOI 10.1016/0092-8674(90)90473-R; SIMON SI, 1995, J IMMUNOL, V155, P1502; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; Solomon KA, 1999, J IMMUNOL, V163, P4105; Steeber DA, 1997, J IMMUNOL, V159, P952; WADDELL TK, 1994, J BIOL CHEM, V269, P18485; Walcheck B, 1996, NATURE, V380, P720, DOI 10.1038/380720a0; Werb Z, 1998, SCIENCE, V282, P1279, DOI 10.1126/science.282.5392.1279; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; Yamamoto S, 1999, IMMUNOL TODAY, V20, P278, DOI 10.1016/S0167-5699(99)01464-4; ZHAO LC, 2001, IN PRESS DEV IMMUNOL	83	57	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30631	30640		10.1074/jbc.M103748200	http://dx.doi.org/10.1074/jbc.M103748200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11375402	hybrid			2022-12-25	WOS:000170472900008
J	Hosono, H; Aoki, J; Nagai, Y; Bandoh, K; Ishida, M; Taguchi, R; Arai, H; Inoue, K				Hosono, H; Aoki, J; Nagai, Y; Bandoh, K; Ishida, M; Taguchi, R; Arai, H; Inoue, K			Phosphatidylserine-specific phospholipase A(1) stimulates histamine release from rat peritoneal mast cells through production of 2-acyl-1-lysophosphatidylserine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETORY PHOSPHOLIPASE; ACTIVATED PLATELETS; CONCANAVALIN-A; LYSOPHOSPHATIDYLSERINE; LYSOPHOSPHOLIPIDS; A(2)	Lysophosphatidylserine (1-acyl-24-lso-PS) has been shown to stimulate histamine release from rat peritoneal mast cells (RPMC) triggered by Fc epsilon RI (high affinity receptor for IgE) cross-linking, although the precise mechanism of lyso-PS production has been obscure. In the present study we show that phosphatidylserine-specific. phospholipase A(1), PS-PLA(1), stimulates histamine release from RPMC through production of 2-acyl-1-lyso-PS in the presence of Fc epsilon RI cross-linker. The potency of 2-acyl-1-lyso-PS was almost equal to that of 1-acyl-2-lyso-PS. A catalytically inactive PS-PLA, in which an active serine residue (Ser(166)) was replaced with an alanine residue did not show such activity. sPLA(2)-IIA, another secretory PLA(2) that is capable of producing lyso-PS in vitro, was also a poor histamine inducer against RPMC. PS-PLA(1) significantly stimulated histamine release from crude RPMC, indicating that lyso-PS is mainly derived from cells other than mast cells. In agreement with this phenomenon, the enzyme stimulated the histamine release more efficiently when RPMC were mixed with apoptotic Jurkat cells. Under these conditions, lyso-PS with unsaturated fatty acid was released from the apoptotic cells treated with PS-PLA(1). Finally, heparin, which has affinity for PS-PLA(1) completely blocked. the stimulatory effect of the enzyme. In conclusion, PS-PLA(1) may bind to heparan sulfate proteoglycan, efficiently hydrolyze PS appearing on plasma membranes of apoptotic cells, and stimulate mast cell activation mediated by 2-acyl-1-lyso-PS.	Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; Nagoya City Univ, Fac Pharmaceut Sci, Mizuho Ku, Nagoya, Aichi 4670027, Japan	University of Tokyo; Nagoya City University	Aoki, J (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.			Aoki, Junken/0000-0001-9435-1896				BELLINI F, 1993, FEBS LETT, V316, P1, DOI 10.1016/0014-5793(93)81724-E; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; HARA K, 1994, BIOL PHARM BULL, V17, P1121; HIGASHI S, 1988, J BIOCHEM-TOKYO, V103, P442, DOI 10.1093/oxfordjournals.jbchem.a122289; HORIGOME K, 1987, J BIOCHEM-TOKYO, V101, P625, DOI 10.1093/jb/101.3.625; HORIGOME K, 1986, J BIOCHEM-TOKYO, V100, P571, DOI 10.1093/oxfordjournals.jbchem.a121748; KATAYAMA S, 1978, MICROBIOL IMMUNOL, V22, P89, DOI 10.1111/j.1348-0421.1978.tb00352.x; KOMADA M, 1989, J BIOCHEM-TOKYO, V106, P545, DOI 10.1093/oxfordjournals.jbchem.a122890; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; KUDO I, 1989, DERMATOLOGICA, V179, P72, DOI 10.1159/000248454; Liliom K, 1998, AM J PHYSIOL-CELL PH, V274, pC1065, DOI 10.1152/ajpcell.1998.274.4.C1065; Lourenssen S, 1998, NEUROSCI LETT, V248, P77, DOI 10.1016/S0304-3940(98)00275-4; MARTIN TW, 1978, P NATL ACAD SCI USA, V75, P4997, DOI 10.1073/pnas.75.10.4997; MARTIN TW, 1979, NATURE, V279, P250, DOI 10.1038/279250a0; MIETTO L, 1987, BIOCHIM BIOPHYS ACTA, V930, P145, DOI 10.1016/0167-4889(87)90026-7; Murakami M, 1996, J BIOL CHEM, V271, P30041, DOI 10.1074/jbc.271.47.30041; MURAKAMI M, 1993, J IMMUNOL, V151, P5675; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Nagai Y, 1999, J BIOL CHEM, V274, P11053, DOI 10.1074/jbc.274.16.11053; Sato T, 1997, J BIOL CHEM, V272, P2192; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; SHORE P, 1956, J PHARMACOL EXP THER, V127, P182; SMITH GA, 1979, FEBS LETT, V105, P58, DOI 10.1016/0014-5793(79)80887-X; SUZUKINISHIMURA T, 1991, JPN J PHARMACOL, V57, P79, DOI 10.1254/jjp.57.79; Taguchi R, 2000, J MASS SPECTROM, V35, P953, DOI 10.1002/1096-9888(200008)35:8<953::AID-JMS23>3.0.CO;2-4; TAMORINATORI Y, 1986, J BIOCHEM-TOKYO, V100, P581, DOI 10.1093/oxfordjournals.jbchem.a121749; XU Y, 1995, J CELL PHYSIOL, V163, P441, DOI 10.1002/jcp.1041630303; XU Y, 1995, BIOCHEM J, V309, P933, DOI 10.1042/bj3090933; YOKOYAMA K, 1995, J BIOCHEM-TOKYO, V117, P1280, DOI 10.1093/oxfordjournals.jbchem.a124856	30	63	66	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29664	29670		10.1074/jbc.M104597200	http://dx.doi.org/10.1074/jbc.M104597200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11395520	hybrid			2022-12-25	WOS:000170558000011
J	Jin, YJ; Atkinson, SJ; Marrs, JA; Gallagher, PJ				Jin, YJ; Atkinson, SJ; Marrs, JA; Gallagher, PJ			Myosin II light chain phosphorylation regulates membrane localization and apoptotic signaling of tumor necrosis factor receptor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLGI-DERIVED VESICLES; ESCHERICHIA-COLI; PROTEIN-KINASE; SMOOTH-MUSCLE; DEATH DOMAIN; CELL-DEATH; ACTIVATION; TNF; FADD; CASPASES	Activation of myosin II by myosin light chain kinase (MLCK) produces the force for many cellular processes including muscle contraction, mitosis, migration, and other cellular shape changes. The results of this study show that inhibition or potentiation of myosin II activation via over-expression of a dominant negative or wild type MLCK can delay or accelerate tumor necrosis factor-alpha (TNF)-induced apoptotic cell death in cells. Changes in the activation of caspase-8 that parallel changes in regulatory light chain phosphorylation levels reveal that myosin Il motor activities regulate TNF receptor-1 (TNFR-1) signaling at an early step in the TNF death signaling pathway. Treatment of cells with either ionomycin or endotoxin (lipopolysaccharide) leads to activation of myosin II and increased translocation of TNFR-1 to the plasma membrane independent of TNF signaling. The results of these studies establish a new role for myosin II motor activity in regulating TNFR-1-mediated apoptosis through the translocation of TNFR-1 to or within the plasma membrane.	Indiana Univ, Sch Med, Dept Cellular & Integrav Physiol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Gallagher, PJ (corresponding author), Indiana Univ, Sch Med, Dept Cellular & Integrav Physiol, 635 Barnhill Dr, Indianapolis, IN 46202 USA.	pgallag@iupui.edu			NHLBI NIH HHS [R01 HL054118-03, R01 HL054118, HL54118] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054118] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BALDWIN TJ, 1991, INFECT IMMUN, V59, P1599, DOI 10.1128/IAI.59.5.1599-1604.1991; Barth AIM, 1997, J CELL BIOL, V136, P693, DOI 10.1083/jcb.136.3.693; Boesen-de Cock JGR, 1998, J BIOL CHEM, V273, P7560, DOI 10.1074/jbc.273.13.7560; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Chew TL, 1998, J MUSCLE RES CELL M, V19, P839, DOI 10.1023/A:1005417926585; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; ESSER C, 1995, CYTOMETRY, V21, P382, DOI 10.1002/cyto.990210411; Essler M, 2000, J IMMUNOL, V164, P6543, DOI 10.4049/jimmunol.164.12.6543; GALLAGHER PJ, 1995, J BIOL CHEM, V270, P29090, DOI 10.1074/jbc.270.49.29090; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23936; GAUSH CR, 1966, P SOC EXP BIOL MED, V122, P931; GOECKELER ZM, 1995, J CELL BIOL, V130, P613, DOI 10.1083/jcb.130.3.613; Goeckeler ZM, 2000, J BIOL CHEM, V275, P18366, DOI 10.1074/jbc.M001339200; GUEDDEL DV, 1999, CHEST, V116, pS73S; Heimann K, 1999, J BIOL CHEM, V274, P10743, DOI 10.1074/jbc.274.16.10743; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Ikonen E, 1997, J CELL SCI, V110, P2155; ITOH N, 1993, J BIOL CHEM, V268, P10932; Jones SJ, 1999, J IMMUNOL, V162, P1042; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Kumar S, 1999, TRENDS BIOCHEM SCI, V24, P1, DOI 10.1016/S0968-0004(98)01332-2; Lee N, 1997, P NATL ACAD SCI USA, V94, P13642, DOI 10.1073/pnas.94.25.13642; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; Musch A, 1997, J CELL BIOL, V138, P291, DOI 10.1083/jcb.138.2.291; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Perez D, 1998, J CELL BIOL, V141, P1255, DOI 10.1083/jcb.141.5.1255; PORTOLES MT, 1991, BIOCHIM BIOPHYS ACTA, V1092, P1; SAYEED MM, 1987, AM J PHYSIOL, V253, pR549, DOI 10.1152/ajpregu.1987.253.4.R549; Siegel RM, 1998, J CELL BIOL, V141, P1243, DOI 10.1083/jcb.141.5.1243; SONG SK, 1993, P NATL ACAD SCI USA, V90, P3933, DOI 10.1073/pnas.90.9.3933; Stow JL, 1998, TRENDS CELL BIOL, V8, P138, DOI 10.1016/S0962-8924(98)01238-0; Stow JL, 1998, BBA-MOL CELL RES, V1404, P161, DOI 10.1016/S0167-4889(98)00055-X; Tang DM, 1999, J BIOL CHEM, V274, P7245, DOI 10.1074/jbc.274.11.7245; TARTAGLIA LA, 1992, J BIOL CHEM, V267, P4304; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thornberry NA, 1998, CHEM BIOL, V5, pR97, DOI 10.1016/S1074-5521(98)90615-9; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; Valderrama F, 2000, P NATL ACAD SCI USA, V97, P1560, DOI 10.1073/pnas.97.4.1560; Van Eyk JE, 1998, J BIOL CHEM, V273, P23433, DOI 10.1074/jbc.273.36.23433; WRIGHT SC, 1993, J CELL BIOCHEM, V53, P222, DOI 10.1002/jcb.240530307	48	40	40	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30342	30349		10.1074/jbc.M102404200	http://dx.doi.org/10.1074/jbc.M102404200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11384975	hybrid, Green Accepted, Green Published			2022-12-25	WOS:000170558000097
J	Khandekar, SS; Gentry, DR; Van Aller, GS; Warren, P; Xiang, H; Silverman, C; Doyle, ML; Chambers, PA; Konstantinidis, AK; Brandt, M; Daines, RA; Lonsdale, JT				Khandekar, SS; Gentry, DR; Van Aller, GS; Warren, P; Xiang, H; Silverman, C; Doyle, ML; Chambers, PA; Konstantinidis, AK; Brandt, M; Daines, RA; Lonsdale, JT			Identification, substrate specificity, and inhibition of the Streptococcus pneumoniae beta-ketoacyl-acyl carrier protein synthase III (FabH)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID BIOSYNTHESIS; ESCHERICHIA-COLI K-12; MYCOBACTERIUM-TUBERCULOSIS; CRYSTAL-STRUCTURE; ANTIBIOTIC THIOLACTOMYCIN; ACTIVE-SITE; TARGET; EXPRESSION; CLONING; GENE	In the bacterial type II fatty acid synthase system, beta -ketoacyl-acyl carrier protein (ACP) synthase IH (FabH) catalyzes the condensation of acetyl-CoA with malonyl-ACP. We have identified, expressed, and characterized the Streptococcus pneumoniae homologue of Escherichia coli FabH. S. pneumoniae FabH is similar to 41, 39, and 38% identical in amino acid sequence to Bacillus subtilis, E. coli and Hemophilus influenzae FabH, respectively. The His-Asn-Cys catalytic triad present in other FabH molecules is conserved in S. pneumoniae FabH. The apparent K-m values for acetyl-CoA and malonyl-ACP were determined to be 40.3 and 18.6 muM, respectively. Purified S. pneumoniae FabH preferentially utilized straight short-chain CoA primers. Similar to E. coli FabH, S. pneumoniae FabH was weakly inhibited by thiolactomycin. In contrast, inhibition of S. pneumoniae FabH by the newly developed compound SB418011 was very potent, with an IC50 value of 0.016 muM. SB418011 also inhibited E. coli and H. influenzae FabH with IC50 values of 1.2 and. 0.59 muM, respectively. The availability of purified and characterized S. pneumoniae FabH will greatly aid in structural studies of this class of essential bacterial enzymes and. facilitate the identification of small molecule inhibitors of type II fatty acid synthase with the potential to be novel and potent antibacterial agents active against pathogenic bacteria.	Glaxo SmithKline, Dept Prot Biochem, King Of Prussia, PA 19406 USA; Glaxo SmithKline, Dept Prot Biochem, King Of Prussia, PA 19406 USA; Glaxo SmithKline, Dept Biol Struct, King Of Prussia, PA 19406 USA; Glaxo SmithKline, Dept Bioinformat, King Of Prussia, PA 19406 USA; Glaxo SmithKline, Dept Mechanist Enzymol, King Of Prussia, PA 19406 USA; Glaxo SmithKline, Dept Med Chem, King Of Prussia, PA 19406 USA; Glaxo SmithKline, Dept Microbial Biochem, King Of Prussia, PA 19406 USA	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Khandekar, SS (corresponding author), Glaxo SmithKline, Dept Prot Biochem, 709 Swedeland Rd, King Of Prussia, PA 19406 USA.			Doyle, Michael/0000-0003-4569-6315				BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; Besra GS, 1998, METH MOL B, V101, P91, DOI 10.1385/0-89603-471-2:91; BRICE JL, 1979, J INFECT DIS, V140, P443, DOI 10.1093/infdis/140.4.443; Chirala SS, 1997, P NATL ACAD SCI USA, V94, P5588, DOI 10.1073/pnas.94.11.5588; Choi KH, 2000, J BIOL CHEM, V275, P28201; Choi KH, 2000, J BACTERIOL, V182, P365, DOI 10.1128/JB.182.2.365-370.2000; CLOUGH RC, 1992, J BIOL CHEM, V267, P20992; Cronan JE, 1996, ESCHERICHIA COLI SAL, V1, P612; Davies C, 2000, STRUCTURE, V8, P185, DOI 10.1016/S0969-2126(00)00094-0; Edwards P, 1997, FEBS LETT, V402, P62, DOI 10.1016/S0014-5793(96)01437-8; GARLAND PB, 1964, BIOCHEM J, V92, pC10, DOI 10.1042/bj0920010C; GARWIN JL, 1980, J BIOL CHEM, V255, P1949; Han L, 1998, J BACTERIOL, V180, P4481, DOI 10.1128/JB.180.17.4481-4486.1998; HAYASHI T, 1983, BIOCHEM BIOPH RES CO, V115, P1108, DOI 10.1016/S0006-291X(83)80050-3; Heath RJ, 1996, J BIOL CHEM, V271, P10996, DOI 10.1074/jbc.271.18.10996; Huang WJ, 1998, EMBO J, V17, P1183, DOI 10.1093/emboj/17.5.1183; JACKOWSKI S, 1989, J BIOL CHEM, V264, P7624; JACKOWSKI S, 1987, J BIOL CHEM, V262, P7927; JAYAKUMAR A, 1995, P NATL ACAD SCI USA, V92, P8695, DOI 10.1073/pnas.92.19.8695; KANEDA T, 1991, MICROBIOL REV, V55, P288, DOI 10.1128/MMBR.55.2.288-302.1991; Khandekar SS, 2000, BIOCHEM BIOPH RES CO, V270, P100, DOI 10.1006/bbrc.2000.2380; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; MATHIEU M, 1994, STRUCTURE, V2, P797, DOI 10.1016/S0969-2126(94)00081-6; McMurry LM, 1998, FEMS MICROBIOL LETT, V166, P305, DOI 10.1016/S0378-1097(98)00347-4; Mdluli K, 1998, SCIENCE, V280, P1607, DOI 10.1126/science.280.5369.1607; Moche M, 1999, J BIOL CHEM, V274, P6031, DOI 10.1074/jbc.274.10.6031; Price AC, 2001, J BIOL CHEM, V276, P6551, DOI 10.1074/jbc.M007101200; Qiu XY, 1999, J BIOL CHEM, V274, P36465, DOI 10.1074/jbc.274.51.36465; Qiu XY, 2001, J MOL BIOL, V307, P341, DOI 10.1006/jmbi.2000.4457; Qiu XY, 1999, PROTEIN SCI, V8, P2529, DOI 10.1110/ps.8.11.2529; Rozwarski DA, 1998, SCIENCE, V279, P98, DOI 10.1126/science.279.5347.98; TSAY JT, 1992, J BACTERIOL, V174, P508, DOI 10.1128/jb.174.2.508-513.1992; TSAY JT, 1992, J BIOL CHEM, V267, P6807; VANCE D, 1972, BIOCHEM BIOPH RES CO, V48, P649, DOI 10.1016/0006-291X(72)90397-X; Waller RF, 1998, P NATL ACAD SCI USA, V95, P12352, DOI 10.1073/pnas.95.21.12352; WOODY RW, 1995, METHOD ENZYMOL, V246, P34	36	87	100	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30024	30030		10.1074/jbc.M101769200	http://dx.doi.org/10.1074/jbc.M101769200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11375394	hybrid			2022-12-25	WOS:000170558000056
J	Liu, XB; Ambudkar, IS				Liu, XB; Ambudkar, IS			Characteristics of a store-operated calcium-permeable channel - Sarcoendoplasmic reticulum calcium pump function controls channel gating	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; CA2+ ENTRY; POTENTIAL CHANNELS; CAPACITATIVE CA2+; ACTIVATION; DEPLETION; CELLS; MECHANISM; PROTEIN; INSP(3)	We examined the single channel properties and regulation of store-operated calcium channels (SOCC). In human submandibular gland cells, carbachol (CCh) induced flickery channel activity while thapsigargin (Tg) induced burst-like activity, with relatively lower open probability (NPo) and longer mean open time. Tg- and CCh-activated channels were permeable to Na+ and Ba2+, but not to NTUDG, in the absence of Ca2+. The channels exhibited similar Ca2+, Na2+, and Ba2+ conductances and were inhibited by 2-aminoethoxydiphenylborate, xestospongin C, Gd3+, and La3+. CCh stimulated flickery activity changed to burst-like activity by (i) addition of Tg, (ii) using Na+ instead of Ca2+, (iii) using Ca2+-free bath solution, or (iv) buffering [Ca2+](i) with BAPTA-AM. Buffering [Ca2+](i) induced a 2-fold increase in NPo of Tg-stimulated SOCC. Reducing free [Ca2+] in the endoplasmic reticulum with the divalent cation chelator, N,N,N ' ,N ' -tetrakis(2-pyridylmethyl)ethylenediamine (TPEN), induced burst-like channel activity similar to that seen with CCh + Tg. Thus, SOCC is activated by stimulation of muscarinic receptors, inhibition of the sarcoendoplasmic Ca2+ pump, and lowering [Ca2+] in the internal store. Importantly, SOCC activity depends on [Ca2+](i) and the free [Ca2+] in the internal store. These novel findings reveal that SERCA plays a major role in the gating of SOCC by (i) refilling the internal Ca2+ store(s) and (ii) decreasing the [Ca2+](i)-dependent inhibition.	NIDCR, GTTB, Secretory Physiol Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Ambudkar, IS (corresponding author), NIDCR, GTTB, Secretory Physiol Sect, NIH, Bldg 10,Rm 1N-113, Bethesda, MD 20892 USA.	ambudkar@yoda.nidcr.nih.gov			NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000438] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000438] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ambudkar IS, 2000, CRIT REV ORAL BIOL M, V11, P4, DOI 10.1177/10454411000110010301; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Berridge MJ, 2000, SCIENCE, V287, P1604, DOI 10.1126/science.287.5458.1604; Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; Braun FJ, 2001, J BIOL CHEM, V276, P1063, DOI 10.1074/jbc.M008348200; Broad LM, 1999, J BIOL CHEM, V274, P32881, DOI 10.1074/jbc.274.46.32881; CAMELLO P, 1999, J PHYSIOL-LONDON, V490, P585; Fierro L, 2000, PFLUG ARCH EUR J PHY, V440, P580, DOI 10.1007/s004240050009; FORMINA AF, 2000, J CELL BIOL, V150, P1435; Hofer AM, 1998, J CELL BIOL, V140, P325, DOI 10.1083/jcb.140.2.325; Hofmann T, 2000, J MOL MED, V78, P14, DOI 10.1007/s001090050378; Holda JR, 1998, NEWS PHYSIOL SCI, V13, P157; Hoth M, 2000, P NATL ACAD SCI USA, V97, P10607, DOI 10.1073/pnas.180143997; Kamouchi M, 1999, J PHYSIOL-LONDON, V518, P345, DOI 10.1111/j.1469-7793.1999.0345p.x; Kaznacheyeva E, 2000, J BIOL CHEM, V275, P4561, DOI 10.1074/jbc.275.7.4561; Kerschbaum HH, 1998, J GEN PHYSIOL, V111, P521, DOI 10.1085/jgp.111.4.521; Kerschbaum HH, 1999, SCIENCE, V283, P836, DOI 10.1126/science.283.5403.836; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; Liu XB, 1998, J BIOL CHEM, V273, P33295, DOI 10.1074/jbc.273.50.33295; Liu XB, 1998, AM J PHYSIOL-CELL PH, V275, pC571, DOI 10.1152/ajpcell.1998.275.2.C571; Liu XB, 2000, J BIOL CHEM, V275, P3403, DOI 10.1074/jbc.275.5.3403; Lockwich TP, 2000, J BIOL CHEM, V275, P11934, DOI 10.1074/jbc.275.16.11934; Luo DL, 2001, J BIOL CHEM, V276, P20186, DOI 10.1074/jbc.M100327200; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Ma HT, 2001, J BIOL CHEM, V276, P18888, DOI 10.1074/jbc.M100944200; Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498; Mogami H, 1998, EMBO J, V17, P435, DOI 10.1093/emboj/17.2.435; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Paschen W, 2001, CELL CALCIUM, V29, P1, DOI 10.1054/ceca.2000.0162; Peng JB, 1999, J BIOL CHEM, V274, P22739, DOI 10.1074/jbc.274.32.22739; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Putney JW, 1999, CELL, V99, P5, DOI 10.1016/S0092-8674(00)80056-2; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; Roderick HL, 2000, J CELL BIOL, V149, P1235, DOI 10.1083/jcb.149.6.1235; van Rossum DB, 2000, J BIOL CHEM, V275, P28562, DOI 10.1074/jbc.M003147200; Yue LX, 2001, NATURE, V410, P705, DOI 10.1038/35070596; Zhu X, 1998, NEWS PHYSIOL SCI, V13, P211; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133	39	45	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29891	29898		10.1074/jbc.M103283200	http://dx.doi.org/10.1074/jbc.M103283200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11395504	hybrid			2022-12-25	WOS:000170558000039
J	Lund, AA; Rhoads, DM; Lund, AL; Cerny, RL; Elthon, TE				Lund, AA; Rhoads, DM; Lund, AL; Cerny, RL; Elthon, TE			In vivo modifications of the maize mitochondrial small heat stress protein, HSP22	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZEA-MAYS L; SHOCK-PROTEIN; DIFFERENTIAL DISPLAY; OXIDATIVE STRESS; WATER-STRESS; EXPRESSION; PHOSPHORYLATION; GENES; EMBRYOGENESIS; SEQUENCE	A maize (Zea mays L.) small heat shock protein (HSP), HSP22, was previously shown to accumulate to high levels in mitochondria during, heat stress. Here we have purified native HSP22 and resolved the protein into three peaks using reverse phase high performance liquid chromatography. Mass spectrometry (MS) of the first two peaks revealed the presence of two HSP22 forms in each peak which differed in mass by 80 daltons (Da), indicative of a monophosphorylation. Phosphorylation of HSP22 by [gamma-P-32]ATP was also observed in mitochondria labeled in vitro, but not when purified native HSP22 was similarly used, demonstrating that HSP22 does not autophosphorylate, implicating a kinase involvement hz. vivo. Collisionally induced dissociation tandem MS (CID MS/MS) identified Ser(59) as the phosphorylated residue. We have also observed forms of HSP22 that result from alternative intron splicing. The two HSP22 proteins in the first peak were similar to 57 Da larger than the two HSP22 proteins in the second peak. MS analysis. revealed that the +57-Da forms have an additional Gly residue directly N-terminal of the expected Asp(84) which had been converted to an Asn residue. These results are the first demonstrations of phosphorylation and alternative intron splicing of a plant small RSP.	Univ Nebraska, Sch Biol Sci, Lincoln, NE 68588 USA; Univ Nebraska, Ctr Biotechnol, Lincoln, NE 68588 USA; Univ Nebraska, Nebraska Ctr Mass Spectrometry, Lincoln, NE 68588 USA; Arizona State Univ, Dept Plant Biol, Tempe, AZ 85287 USA	University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Lincoln; Arizona State University; Arizona State University-Tempe	Elthon, TE (corresponding author), Univ Nebraska, Sch Biol Sci, E249 Beadle Ctr, Lincoln, NE 68588 USA.	telthon@biocomp.unl.edu		Lund, Adrian/0000-0002-1267-2926				Almoguera C, 1998, PLANT J, V13, P437, DOI 10.1046/j.1365-313X.1998.00044.x; ANDERSON JV, 1994, PLANT PHYSIOL, V104, P1359, DOI 10.1104/pp.104.4.1359; ATKINSON BG, 1993, DEV GENET, V14, P15, DOI 10.1002/dvg.1020140104; Banzet N, 1998, PLANT J, V13, P519, DOI 10.1046/j.1365-313X.1998.00056.x; Barent RL, 1992, PLANT MOL BIOL REP, V10, P338, DOI 10.1007/BF02668910; Carranco R, 1997, J BIOL CHEM, V272, P27470, DOI 10.1074/jbc.272.43.27470; CASPERS GJ, 1995, J MOL EVOL, V40, P238, DOI 10.1007/BF00163229; Chiesa R, 1997, EXP EYE RES, V65, P223, DOI 10.1006/exer.1997.0324; CLARKE AK, 1994, PHYSIOL PLANTARUM, V92, P118, DOI 10.1111/j.1399-3054.1994.tb06663.x; Clerk A, 1998, BIOCHEM J, V333, P581, DOI 10.1042/bj3330581; Coca MA, 1996, PLANT MOL BIOL, V31, P863, DOI 10.1007/BF00019473; Dong JZ, 1996, PLANTA, V200, P85; Downs CA, 1998, FEBS LETT, V430, P246, DOI 10.1016/S0014-5793(98)00669-3; DUPUIS I, 1990, PLANT PHYSIOL, V94, P665, DOI 10.1104/pp.94.2.665; ELTHON TE, 1986, PLANT PHYSIOL, V82, P1, DOI 10.1104/pp.82.1.1; ENGEL K, 1995, J CELL BIOCHEM, V57, P321, DOI 10.1002/jcb.240570216; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HAYES MK, 1991, PLANT PHYSIOL, V97, P1381, DOI 10.1104/pp.97.4.1381; Helm KW, 1997, PLANT PHYSIOL, V114, P1477, DOI 10.1104/pp.114.4.1477; HOPF N, 1992, PLANT MOL BIOL, V19, P623, DOI 10.1007/BF00026788; Kadyrzhanova DK, 1998, PLANT MOL BIOL, V36, P885, DOI 10.1023/A:1005954909011; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; KNACK G, 1989, NUCLEIC ACIDS RES, V17, P5380, DOI 10.1093/nar/17.13.5380; LaFayette PR, 1996, PLANT MOL BIOL, V30, P159, DOI 10.1007/BF00017810; LARSON E, 1986, ANAL BIOCHEM, V155, P243, DOI 10.1016/0003-2697(86)90432-X; LEE GJ, 1995, J BIOL CHEM, V270, P10432, DOI 10.1074/jbc.270.18.10432; LENNE C, 1995, BIOCHEM J, V311, P805, DOI 10.1042/bj3110805; LENNE C, 1994, PLANT PHYSIOL, V105, P1255, DOI 10.1104/pp.105.4.1255; Leshem YY, 1996, BIOL PLANTARUM, V38, P1, DOI 10.1007/BF02879625; LUETHY MH, 1991, PLANT PHYSIOL, V97, P1317, DOI 10.1104/pp.97.4.1317; LUETHY MH, 1995, J PLANT PHYSIOL, V145, P443, DOI 10.1016/S0176-1617(11)81768-2; Lund AA, 1998, PLANT PHYSIOL, V116, P1097, DOI 10.1104/pp.116.3.1097; LURIE S, 1994, NATO ADV SCI INST SE, V86, P201; Martin JL, 1999, GENE EXPRESSION, V7, P349; MEDYNSKI D, 1992, BIO-TECHNOL, V10, P1002, DOI 10.1038/nbt0992-1002; MEHLEN P, 1993, EUR J BIOCHEM, V215, P277, DOI 10.1111/j.1432-1033.1993.tb18032.x; MING Z, 1993, J BIOL CHEM, V268, P35; NEVEN LG, 1993, PLANT MOL BIOL, V21, P291, DOI 10.1007/BF00019945; NOVER L, 1984, EUR J BIOCHEM, V139, P303, DOI 10.1111/j.1432-1033.1984.tb08008.x; Sabehat A, 1998, PLANT PHYSIOL, V117, P651, DOI 10.1104/pp.117.2.651; SCRUTTON NS, 1992, SCIENCE, V258, P1140, DOI 10.1126/science.1439821; Suzuki TC, 1998, PLANT PHYSIOL, V116, P1151, DOI 10.1104/pp.116.3.1151; Visioli G, 1997, PLANT MOL BIOL, V34, P517, DOI 10.1023/A:1005824314022; Waters ER, 1996, J EXP BOT, V47, P325, DOI 10.1093/jxb/47.3.325; WILLETT DA, 1996, PLANT PHYSIOL, V112, P1399	45	38	45	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29924	29929		10.1074/jbc.M103373200	http://dx.doi.org/10.1074/jbc.M103373200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11397800	hybrid			2022-12-25	WOS:000170558000043
J	Aikawa, T; Segre, GV; Lee, K				Aikawa, T; Segre, GV; Lee, K			Fibroblast growth factor inhibits chondrocytic growth through induction of p21 and subsequent inactivation of cyclin E-Cdk2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA PROTEIN; FACTOR RECEPTOR-3; BONE-DEVELOPMENT; TRANSGENIC MICE; INDIAN HEDGEHOG; DIFFERENTIATION; PROLIFERATION; EXPRESSION; ACTIVATION; ARREST	Fibroblast growth factor (FGF) and its receptor (FGFR) are thought to be negative regulators of chondrocytic growth, as exemplified by achondroplasia and related chondrodysplasias, which are caused by constitutively active mutations in FGFR3. To understand the growth-inhibitory mechanisms of FGF, we analyzed the effects of FGF2 on cell cycle-regulating molecules in chondrocytes. FGF2 dramatically inhibited proliferation of rat chondrosarcoma (RCS) cells and arrested their cell cycle at the G(1) phase. FGF2 increased p21 expression in RCS cells, which assembled with the cyclin E-Cdk2 complexes, although the expression of neither cyclin E nor Cdk2 increased. In addition, the kinase activity of immunoprecipitated cyclin E or Cdk2, assessed with retinoblastoma protein (pRb) as substrate, was dramatically reduced by FGF-2. Moreover, FGF2 shifted pRb to its underphosphorylated, active form in RCS cells. FGF2 not only induced p21 protein expression in proliferating chondrocytes in mouse fetal limbs cultured in vitro but also decreased their proliferation as assessed by the expression of histone H4 mRNA, a marker for cells in S phase. Furthermore, inhibitory effects of FGF2 on chondrocytic proliferation were partially reduced in p21-null limbs, compared with those in wild-type limbs in vitro. Taken together, FGF's growth inhibitory effects of chondrocytes appear to be mediated at least partially through p21 induction and the subsequent inactivation of cyclin E-Cdk2 and activation of pRb.	Harvard Univ, Endocrine Unit, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School	Lee, K (corresponding author), Harvard Univ, Endocrine Unit, Massachusetts Gen Hosp, Sch Med, 50 Blossom St,Wellman 501, Boston, MA 02114 USA.			Aikawa, Tomonao/0000-0001-6906-6874	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053343] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK53343] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Chen L, 1999, J CLIN INVEST, V104, P1517, DOI 10.1172/JCI6690; Colvin JS, 1996, NAT GENET, V12, P390, DOI 10.1038/ng0496-390; Cover CM, 1998, J BIOL CHEM, V273, P3838, DOI 10.1074/jbc.273.7.3838; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Garofalo S, 1999, J BONE MINER RES, V14, P1909, DOI 10.1359/jbmr.1999.14.11.1909; Gius DR, 1999, CANCER RES, V59, P2577; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Iwata T, 2000, HUM MOL GENET, V9, P1603, DOI 10.1093/hmg/9.11.1603; Johnson MR, 1998, ONCOGENE, V16, P2647, DOI 10.1038/sj.onc.1201789; Karp SJ, 2000, DEVELOPMENT, V127, P543; KATO J, 1993, GENE DEV, V7, P331; Lee K, 1996, ENDOCRINOLOGY, V137, P5109, DOI 10.1210/en.137.11.5109; Li CL, 1999, HUM MOL GENET, V8, P35, DOI 10.1093/hmg/8.1.35; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; MUKHOPADHYAY K, 1995, J BIOL CHEM, V270, P27711, DOI 10.1074/jbc.270.46.27711; Naski MC, 1998, DEVELOPMENT, V125, P4977; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Sahni M, 1999, GENE DEV, V13, P1361, DOI 10.1101/gad.13.11.1361; Segev O, 2000, HUM MOL GENET, V9, P249, DOI 10.1093/hmg/9.2.249; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SIERRA F, 1983, NUCLEIC ACIDS RES, V11, P7069, DOI 10.1093/nar/11.20.7069; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; Szebenyi G, 1999, INT REV CYTOL, V185, P45; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Vidal A, 2000, GENE, V247, P1, DOI 10.1016/S0378-1119(00)00092-5; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; Wang HS, 1997, CANCER RES, V57, P1750; Wang YC, 1999, P NATL ACAD SCI USA, V96, P4455, DOI 10.1073/pnas.96.8.4455; Webster MK, 1997, TRENDS GENET, V13, P178, DOI 10.1016/S0168-9525(97)01131-1; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Xu XL, 1999, CELL TISSUE RES, V296, P33, DOI 10.1007/s004410051264	36	84	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29347	29352		10.1074/jbc.M101859200	http://dx.doi.org/10.1074/jbc.M101859200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11384971	hybrid			2022-12-25	WOS:000170346000095
J	Jiang, N; Levavasseur, F; McCright, B; Shoubridge, EA; Hekimi, S				Jiang, N; Levavasseur, F; McCright, B; Shoubridge, EA; Hekimi, S			Mouse CLK-1 is imported into mitochondria by an unusual process that requires a leader sequence but no membrane potential	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; SACCHAROMYCES-CEREVISIAE; PROTEIN IMPORT; GENE CLK-1; LIFE-SPAN; COQ7 GENE; MUTATIONS; RECEPTOR; TIM23; INNER	clk-1 has been identified and characterized in the nematode Caenorhabditis elegans as a gene that affects the rates, regularity, and synchrony of physiological processes. The CLK-1 protein is mitochondrial and is required for ubiquinone biosynthesis in yeast and in worms, but its biochemical function remains unclear. We have studied the expression of murine mclk1 in a variety of tissues, and we find that the pattern of mclk1 m-RNA accumulation closely resembles that of mitochondrial genes involved in oxidative phosphorylation. The pattern of protein accumulation, however, is sharply distinct in some tissues; mCLK1 appears relatively enriched in the gut and depleted in the nervous tissue. We also show that mCLK1 is synthesized as a preprotein that is imported into the mitochondrial matrix, where a leader sequence is cleaved off and the protein becomes loosely associated with the inner membrane. However, in contrast to all known mitochondrial proteins that contain a cleavable pre-sequence, the import of mCLK1 does not require a mitochondrial membrane potential.	McGill Univ, Dept Biol, Montreal, PQ H3A 1B1, Canada; Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada; McGill Univ, Dept Human Genet, Montreal, PQ H3A 2B4, Canada	McGill University; McGill University; McGill University	Hekimi, S (corresponding author), McGill Univ, Dept Biol, 1205 Doctor Penfield Ave, Montreal, PQ H3A 1B1, Canada.							Andersson SGE, 1998, NATURE, V396, P133, DOI 10.1038/24094; Asaumi S, 1999, GENOMICS, V58, P293, DOI 10.1006/geno.1999.5838; Bauer MF, 1996, CELL, V87, P33, DOI 10.1016/S0092-8674(00)81320-3; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Braeckman BP, 1999, CURR BIOL, V9, P493, DOI 10.1016/S0960-9822(99)80216-4; Branicky R, 2000, BIOESSAYS, V22, P48, DOI 10.1002/(SICI)1521-1878(200001)22:1&lt;48::AID-BIES9&gt;3.0.CO;2-F; Casas F, 1999, MOL CELL BIOL, V19, P7913; DIRCKS LK, 1990, MOL CELL BIOL, V10, P4984, DOI 10.1128/MCB.10.9.4984; Donzeau M, 2000, CELL, V101, P401, DOI 10.1016/S0092-8674(00)80850-8; Ewbank JJ, 1997, SCIENCE, V275, P980, DOI 10.1126/science.275.5302.980; Felkai S, 1999, EMBO J, V18, P1783, DOI 10.1093/emboj/18.7.1783; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Gancedo JM, 1998, MICROBIOL MOL BIOL R, V62, P334, DOI 10.1128/MMBR.62.2.334-361.1998; Greenawalt J W, 1974, Methods Enzymol, V31, P310; HEKIMI S, 1995, GENETICS, V141, P1351; Hekimi S, 2000, RES PRO CEL, V29, P81; Hekimi S, 1998, TRENDS GENET, V14, P14, DOI 10.1016/S0168-9525(97)01299-7; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; Jonassen T, 1996, ARCH BIOCHEM BIOPHYS, V330, P285, DOI 10.1006/abbi.1996.0255; Jonassen T, 2001, P NATL ACAD SCI USA, V98, P421, DOI 10.1073/pnas.021337498; Jonassen T, 1998, J BIOL CHEM, V273, P3351, DOI 10.1074/jbc.273.6.3351; Lakowski B, 1996, SCIENCE, V272, P1010, DOI 10.1126/science.272.5264.1010; Marbois BN, 1996, J BIOL CHEM, V271, P2995, DOI 10.1074/jbc.271.6.2995; MARTIN J, 1991, J BIOL CHEM, V266, P18051; Miyadera H, 2001, J BIOL CHEM, V276, P7713, DOI 10.1074/jbc.C000889200; PARSONS DF, 1966, ANN NY ACAD SCI, V137, P643, DOI 10.1111/j.1749-6632.1966.tb50188.x; PFANNER N, 1985, EMBO J, V4, P2819, DOI 10.1002/j.1460-2075.1985.tb04009.x; Proft M, 1995, EMBO J, V14, P6116, DOI 10.1002/j.1460-2075.1995.tb00302.x; RYAN KR, 1995, CELL, V83, P517, DOI 10.1016/0092-8674(95)90089-6; SANYAL A, 1995, J BIOL CHEM, V270, P11970, DOI 10.1074/jbc.270.20.11970; Steenaart NAE, 1997, FEBS LETT, V415, P294, DOI 10.1016/S0014-5793(97)01145-9; WONG A, 1995, GENETICS, V139, P1247	32	31	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29218	29225		10.1074/jbc.M103686200	http://dx.doi.org/10.1074/jbc.M103686200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11387338	hybrid			2022-12-25	WOS:000170346000079
J	Kinoshita, M; Nukada, T; Asano, T; Mori, Y; Akaike, A; Satoh, M; Kaneko, S				Kinoshita, M; Nukada, T; Asano, T; Mori, Y; Akaike, A; Satoh, M; Kaneko, S			Binding of G alpha(o) N terminus is responsible for the voltage-resistant inhibition of alpha(1A)(P/Q-type, Ca(v)2.1) Ca2+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; G-PROTEIN-ALPHA; RAT SYMPATHETIC NEURONS; I-II LOOP; CALCIUM CHANNELS; XENOPUS-OOCYTES; AMINO-TERMINUS; BOVINE BRAIN; DIFFERENTIAL INTERACTIONS; SYNAPTIC TRANSMISSION	G-protein-mediated inhibition of presynaptic voltage-dependent Ca2+ channels is comprised of voltage-dependent and -resistant components. The former is caused by a direct interaction of Ca2+ channel alpha1 subunits with G beta gamma, whereas the latter has not been characterized well. Here, we show that the N terminus of G alpha (o), is critical for the interaction with the C terminus of the alpha (1A) channel subunit, and that the binding induces the voltage-resistant inhibition. An alpha (1A) C-terminal peptide, an antiserum raised against G alpha (o) N terminus, and a G alpha (o) N-terminal peptide all attenuated the voltage-resistant inhibition of alpha (1A) currents. Furthermore, the N terminus of G alpha (o) bound to the C terminus of alpha (1A) in vitro, which was prevented either by the alpha (1A) channel C-terminal or G alpha (o) N-terminal peptide. Although the C-terminal domain of the alpha (1B) channel showed similar ability in the binding with G alpha (o) N terminus, the above mentioned treatments were ineffective in the alpha (1B) channel current. These findings demonstrate that the voltage-resistant inhibition of the P/Q-type, alpha (1A) channel is caused by the interaction between the C-terminal domain of Ca2+ channel alpha (1A) subunit and the N-terminal region of G alpha (o).	Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Neuropharmacol, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Pharmacol, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Mol Pharmacol, Sakyo Ku, Kyoto 6068501, Japan; Tokyo Inst Psychiat, Dept Neurochem, Setagaya Ku, Tokyo 1568585, Japan; Aichi Human Serv Ctr, Inst Dev Res, Dept Biochem, Kasugai, Aichi 4800392, Japan; Okazaki Natl Res Inst, Natl Inst Physiol Sci, Ctr Integrat Biosci, Okazaki, Aichi 4448585, Japan; Okazaki Natl Res Inst, Natl Inst Physiol Sci, Dept Cell Physiol, Okazaki, Aichi 4448585, Japan	Kyoto University; Kyoto University; Kyoto University; Tokyo Institute of Psychiatry; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Okazaki Institute for Integrative Bioscience (OIIB); National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Okazaki Institute for Integrative Bioscience (OIIB)	Kaneko, S (corresponding author), Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Neuropharmacol, Sakyo Ku, Kyoto 6068501, Japan.		Kaneko, Shuji/AAR-1005-2021	Kaneko, Shuji/0000-0001-5152-5809				BEAN BP, 1989, NATURE, V340, P153, DOI 10.1038/340153a0; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; Bourinet E, 1996, P NATL ACAD SCI USA, V93, P1486, DOI 10.1073/pnas.93.4.1486; Brody DL, 2000, J NEUROSCI, V20, P889, DOI 10.1523/JNEUROSCI.20-03-00889.2000; Brody DL, 1997, J PHYSIOL-LONDON, V499, P637, DOI 10.1113/jphysiol.1997.sp021956; Colecraft HM, 2000, J GEN PHYSIOL, V115, P175, DOI 10.1085/jgp.115.2.175; Currie KPM, 1997, J NEUROSCI, V17, P4570; Delmas P, 1999, J PHYSIOL-LONDON, V518, P23, DOI 10.1111/j.1469-7793.1999.0023r.x; Delmas P, 2000, NAT NEUROSCI, V3, P670, DOI 10.1038/76621; DENKER BM, 1992, J BIOL CHEM, V267, P6272; DeWaard M, 1997, NATURE, V385, P446, DOI 10.1038/385446a0; DIVERSEPIERLUISSI M, 1995, NEURON, V14, P191, DOI 10.1016/0896-6273(95)90254-6; DiversePierluissi M, 1997, P NATL ACAD SCI USA, V94, P5417, DOI 10.1073/pnas.94.10.5417; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; Furukawa T, 1998, J BIOL CHEM, V273, P17595, DOI 10.1074/jbc.273.28.17595; Furukawa T, 1998, J BIOL CHEM, V273, P17585, DOI 10.1074/jbc.273.28.17585; GRIECO F, 1992, BIOTECHNIQUES, V13, P856; Hepler JR, 1996, J BIOL CHEM, V271, P496, DOI 10.1074/jbc.271.1.496; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; Iwasaki S, 2000, J NEUROSCI, V20, P59, DOI 10.1523/JNEUROSCI.20-01-00059.2000; Kammermeier PJ, 2000, J NEUROSCI, V20, P5623, DOI 10.1523/JNEUROSCI.20-15-05623.2000; Kaneko S, 1999, JPN J PHARMACOL, V81, P324, DOI 10.1254/jjp.81.324; Kaneko S, 1997, BRIT J PHARMACOL, V121, P806, DOI 10.1038/sj.bjp.0701181; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LUEBKE JI, 1993, NEURON, V11, P895, DOI 10.1016/0896-6273(93)90119-C; MOISES HC, 1994, J NEUROSCI, V14, P3842; Nakamura K, 1996, J BIOCHEM, V120, P996; PADRELL E, 1991, J BIOL CHEM, V266, P9771; Page KM, 1998, J NEUROSCI, V18, P4815; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; Qin N, 1997, P NATL ACAD SCI USA, V94, P8866, DOI 10.1073/pnas.94.16.8866; SCHULTZ AM, 1987, BIOCHEM BIOPH RES CO, V146, P1234, DOI 10.1016/0006-291X(87)90780-7; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; Slep KC, 2001, NATURE, V409, P1071, DOI 10.1038/35059138; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; Sun QQ, 1998, J PHYSIOL-LONDON, V510, P103, DOI 10.1111/j.1469-7793.1998.103bz.x; TAKAO K, 1994, NEURON, V13, P747, DOI 10.1016/0896-6273(94)90041-8; Westenbroek RE, 1998, J NEUROSCI, V18, P6319; Wiley JW, 1997, J NEUROPHYSIOL, V77, P1338, DOI 10.1152/jn.1997.77.3.1338; Zamponi GW, 1997, NATURE, V385, P442, DOI 10.1038/385442a0; Zhang JF, 1996, NEURON, V17, P991, DOI 10.1016/S0896-6273(00)80229-9	43	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28731	28738		10.1074/jbc.M104806200	http://dx.doi.org/10.1074/jbc.M104806200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11395521	hybrid			2022-12-25	WOS:000170346000013
J	Mittelstadt, PR; Ashwell, JD				Mittelstadt, PR; Ashwell, JD			Inhibition of AP-1 by the glucocorticoid-inducible protein GILZ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NUCLEAR RECEPTOR COACTIVATOR; STEROID-HORMONE RECEPTORS; FAS LIGAND EXPRESSION; T-CELL HYBRIDOMA; TRANSCRIPTION FACTORS; DNA-BINDING; NEGATIVE REGULATION; C-JUN; FUNCTIONAL ANTAGONISM	The immunosuppressive effects of glucocorticoids arise largely by inhibition of cytokine gene expression, which has been ascribed to interference between the glucocorticoid receptor and transcription factors such as AP-1 and NF-kappaB as well as by competition for common coactivators. Here we show that glucocorticoid-induced inhibition of interleukin-2 mRNA expression in activated normal T cells required new protein synthesis, suggesting that this phenomenon is secondary to expression of glucocorticoid-regulated genes. One of the most prominent glucocorticoid-induced genes is glucocorticoid-induced leucine zipper (GILZ), which has been reported to inhibit activation-induced up-regulation of Fas ligand (FasL) mRNA. Indeed, transient expression of GILZ in Jurkat T cells blocked induction of a reporter construct driven by the FasL promoter. This could be accounted for by GILZ-mediated inhibition of Egr-2 and Egr-3, NFAT/AP-1-inducible transcription factors that bind a regulatory element in the FasL promoter and up-regulate FasL expression. GILZ also potently inhibited AP-1-driven and IL-2 promoter-driven reporter constructs, and recombinant GILZ specifically interacted with c-Fos and c-Jun in vitro and inhibited the binding of active AP-1 to its target DNA. Whereas homodimerization of GILZ required the presence of its leucine zipper, the interaction with c-Fos and c-Jun occurred through the N-terminal 60-amino acid region of GILZ. Thus, GILZ represents a glucocorticoid-induced gene product that can inhibit a variety of activation-induced events, at least in part by direct interference with AP-1, and is therefore a candidate for a mediator of glucocorticoid-induced immunosuppression.	NCI, Lab Immune Cell Biol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Ashwell, JD (corresponding author), NCI, Lab Immune Cell Biol, NIH, Rm 1B-40,Bdg 10, Bethesda, MD 20892 USA.							AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; Ashwell JD, 2000, ANNU REV IMMUNOL, V18, P309, DOI 10.1146/annurev.immunol.18.1.309; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; BOUMPAS DT, 1993, ANN INTERN MED, V119, P1198, DOI 10.7326/0003-4819-119-12-199312150-00007; CHANDLER VL, 1983, CELL, V33, P489, DOI 10.1016/0092-8674(83)90430-0; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; Collingwood TN, 1999, J MOL ENDOCRINOL, V23, P255, DOI 10.1677/jme.0.0230255; CRISPE IN, 1994, IMMUNITY, V1, P347; D'Adamio F, 1997, IMMUNITY, V7, P803, DOI 10.1016/S1074-7613(00)80398-2; DeBosscher K, 1997, P NATL ACAD SCI USA, V94, P13504, DOI 10.1073/pnas.94.25.13504; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DROUIN J, 1989, MOL CELL BIOL, V9, P5305, DOI 10.1128/MCB.9.12.5305; GILLIS S, 1979, J IMMUNOL, V123, P1624; Glynne R, 2000, NATURE, V403, P672, DOI 10.1038/35001102; Gottlicher M, 1998, J MOL MED-JMM, V76, P480, DOI 10.1007/s001090050242; HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x; HEDRICK SM, 1982, CELL, V30, P141, DOI 10.1016/0092-8674(82)90020-4; Holtz-Heppelmann CJ, 1998, J BIOL CHEM, V273, P4416, DOI 10.1074/jbc.273.8.4416; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KANG SM, 1992, SCIENCE, V257, P1134, DOI 10.1126/science.257.5073.1134; Karin M, 1998, CELL, V93, P487, DOI 10.1016/S0092-8674(00)81177-0; Kester HA, 1999, J BIOL CHEM, V274, P27439, DOI 10.1074/jbc.274.39.27439; Klein-Hitpass L, 1998, J MOL MED, V76, P490, DOI 10.1007/s001090050243; KONIG H, 1992, EMBO J, V11, P2241, DOI 10.1002/j.1460-2075.1992.tb05283.x; KRONKE M, 1985, J EXP MED, V161, P1593, DOI 10.1084/jem.161.6.1593; KUTOH E, 1992, MOL CELL BIOL, V12, P4960, DOI 10.1128/MCB.12.11.4960; Latinis KM, 1997, J BIOL CHEM, V272, P31427, DOI 10.1074/jbc.272.50.31427; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; Li-Weber M, 1999, EUR J IMMUNOL, V29, P3017, DOI 10.1002/(SICI)1521-4141(199909)29:09<3017::AID-IMMU3017>3.0.CO;2-R; LU W, 1995, AIDS, V9, P35, DOI 10.1097/00002030-199501000-00005; Mages HW, 1998, MOL CELL BIOL, V18, P7157, DOI 10.1128/MCB.18.12.7157; Matsui K, 1998, J IMMUNOL, V161, P3469; Mittelstadt PR, 1998, MOL CELL BIOL, V18, P3744, DOI 10.1128/MCB.18.7.3744; MORDACQ JC, 1989, GENE DEV, V3, P760, DOI 10.1101/gad.3.6.760; Nakamura H, 1998, AM J PHYSIOL-LUNG C, V275, pL601, DOI 10.1152/ajplung.1998.275.3.L601; NORTHROP JP, 1992, J EXP MED, V175, P1235, DOI 10.1084/jem.175.5.1235; ONATE SA, 1995, SCIENCE, V270, P1354; ONO S, 1995, IMMUNITY, V2, P639, DOI 10.1016/1074-7613(95)90008-X; PETRAK D, 1994, J IMMUNOL, V153, P2046; PONTA H, 1992, BIOCHIM BIOPHYS ACTA, V1129, P255, DOI 10.1016/0167-4781(92)90501-P; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Rengarajan J, 2000, IMMUNITY, V12, P293, DOI 10.1016/S1074-7613(00)80182-X; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; Serfling E, 2000, BBA-MOL CELL RES, V1498, P1, DOI 10.1016/S0167-4889(00)00082-3; Shan XC, 2000, MOL CELL BIOL, V20, P6945, DOI 10.1128/MCB.20.18.6945-6957.2000; SILLARD R, 1993, EUR J BIOCHEM, V216, P429, DOI 10.1111/j.1432-1033.1993.tb18160.x; STEIN B, 1995, MOL CELL BIOL, V15, P4971; SUSSMAN JJ, 1988, CELL, V52, P85, DOI 10.1016/0092-8674(88)90533-8; VACCA A, 1990, J BIOL CHEM, V265, P8075; WRIGHT APH, 1990, J BIOL CHEM, V265, P14763; YANG YL, 1995, J EXP MED, V181, P1673, DOI 10.1084/jem.181.5.1673; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; Zhang GR, 1997, DNA CELL BIOL, V16, P145, DOI 10.1089/dna.1997.16.145	59	220	235	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29603	29610		10.1074/jbc.M101522200	http://dx.doi.org/10.1074/jbc.M101522200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11397794	hybrid			2022-12-25	WOS:000170346000127
J	Saito, H; Papaconstantinou, J				Saito, H; Papaconstantinou, J			Age-associated differences in cardiovascular inflammatory gene induction during endotoxic stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR-ALPHA; SIGNAL-TRANSDUCTION; HUMAN-FIBROBLASTS; CARDIAC MYOCYTES; TRANSGENIC MICE; SEVERE SEPSIS; NITRIC-OXIDE; INTERLEUKIN-6; IL-6	Upon physiological stress, families of stress response genes are activated as natural defense mechanisms. Here, we show that induction of specific inflammatory genes is significantly dysregulated and altered in the heart of aged (24-26-month-old) versus young (4-month-old) mice experimentally challenged with a bacterial endotoxin, lipopolysaccharide (LPS, 1.5 mg/kg of body mass). Whereas the LPS-mediated induction of cardiac mRNA for tumor necrosis factor a or inducible nitric-oxide synthase showed no age-associated differences, the induction of interleukin-1 beta (IL-1 beta) and intracellular adhesion molecule-1 was modestly extended with aging, and the induction of IL-6 was significantly prolonged with aging. This age-associated phenomenon occurred gradually from 4 to 17 months of age and became more evident after 23 months of age. The age-associated augmentation of the cardiac IL-6 induction was also dramatic at the protein level. Immunohistochemically, the LPS-induced cardiac IL-6 was localized mainly in the microvascular walls. Aged but not young mice showed a high mortality rate during these experiments. These results demonstrate that endotoxin-mediated induction of specific inflammatory genes in cardiovascular tissues is altered with aging, which may be causally related to the increased susceptibility of aged animals to endotoxic stress.	Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Papaconstantinou, J (corresponding author), Univ Texas, Med Branch, Dept Human Biol Chem & Genet, 301 Univ Blvd, Galveston, TX 77555 USA.		Papaconstantinou, John/E-3312-2010		NIA NIH HHS [2-P01-AG10514, P30 AG024832] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P30AG024832, P01AG010514] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AKASHI M, 1990, J CLIN INVEST, V85, P121, DOI 10.1172/JCI114401; AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; BALDWIN KM, 1998, PATHOPHYSIOLOGY BIOL, P1570; BELMIN J, 1995, AM J PHYSIOL-HEART C, V268, pH2288, DOI 10.1152/ajpheart.1995.268.6.H2288; CASTELL JV, 1989, FEBS LETT, V242, P237, DOI 10.1016/0014-5793(89)80476-4; Chorinchath BB, 1996, J IMMUNOL, V156, P1525; DAMAS P, 1992, ANN SURG, V215, P356, DOI 10.1097/00000658-199204000-00009; DeBenedetti F, 1997, J CLIN INVEST, V99, P643, DOI 10.1172/JCI119207; Delpedro AD, 1998, J INTERF CYTOK RES, V18, P429, DOI 10.1089/jir.1998.18.429; FINKEL MS, 1993, AM J CARDIOL, V71, P1231, DOI 10.1016/0002-9149(93)90654-U; FINKEL MS, 1992, SCIENCE, V257, P387, DOI 10.1126/science.1631560; FOSTER KD, 1992, AM J PHYSIOL, V262, pR211, DOI 10.1152/ajpregu.1992.262.2.R211; Fujita J, 1996, EUR SURG RES, V28, P361, DOI 10.1159/000129477; Grocott-Mason RM, 1998, INTENS CARE MED, V24, P286, DOI 10.1007/s001340050570; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Helenius M, 1996, J MOL CELL CARDIOL, V28, P487, DOI 10.1006/jmcc.1996.0045; HIROTA H, 1995, P NATL ACAD SCI USA, V92, P4862, DOI 10.1073/pnas.92.11.4862; Hsieh CC, 1998, MOL BIOL CELL, V9, P1479, DOI 10.1091/mbc.9.6.1479; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Kumar A, 1996, J EXP MED, V183, P949, DOI 10.1084/jem.183.3.949; KUMAR S, 1992, P NATL ACAD SCI USA, V89, P4683, DOI 10.1073/pnas.89.10.4683; LAKATTA EG, 1990, HDB BIOL AGING, P181; LAMY M, 1995, INTENS CARE MED, V21, P250; MANTOVANI A, 1992, FASEB J, V6, P2591, DOI 10.1096/fasebj.6.8.1592209; Miller Richard A., 1996, P355; Papaconstantinou John, 1996, P150; Raber J, 1997, J NEUROSCI, V17, P9473; Saito H, 2000, AM J PHYSIOL-HEART C, V279, pH2241, DOI 10.1152/ajpheart.2000.279.5.H2241; Simpson AJH, 2000, J INFECT DIS, V181, P621, DOI 10.1086/315271; SIRONI M, 1989, J IMMUNOL, V142, P549; SMITH CW, 1991, J CLIN INVEST, V88, P1216, DOI 10.1172/JCI115424; STARNES HF, 1990, J IMMUNOL, V145, P4185; Stengle J, 1994, Crit Care Nurs Clin North Am, V6, P421; Streat SJ, 2000, WORLD J SURG, V24, P655, DOI 10.1007/s002689910107; SUEMATSU S, 1989, P NATL ACAD SCI USA, V86, P7547, DOI 10.1073/pnas.86.19.7547; TANABE O, 1988, J IMMUNOL, V141, P3875; Tateda K, 1996, INFECT IMMUN, V64, P769, DOI 10.1128/IAI.64.3.769-774.1996; THIJS LG, 1995, INTENS CARE MED, V21, P258; Xing Z, 1998, J CLIN INVEST, V101, P311, DOI 10.1172/JCI1368; YAMAUCHITAKIHARA K, 1995, CIRCULATION, V91, P1520, DOI 10.1161/01.CIR.91.5.1520; YOUKER K, 1992, J CLIN INVEST, V89, P602, DOI 10.1172/JCI115626; YUAN L, 1993, EXP CELL RES, V209, P375, DOI 10.1006/excr.1993.1323	42	59	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29307	29312		10.1074/jbc.M103740200	http://dx.doi.org/10.1074/jbc.M103740200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11382779	hybrid			2022-12-25	WOS:000170346000090
J	Samuel, W; Kutty, RK; Nagineni, S; Gordon, JS; Prouty, SM; Chandraratna, RAS; Wiggert, B				Samuel, W; Kutty, RK; Nagineni, S; Gordon, JS; Prouty, SM; Chandraratna, RAS; Wiggert, B			Regulation of stearoyl coenzyme a desaturase expression in human retinal pigment epithelial cells by retinoic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED GENE-EXPRESSION; COA DESATURASE; RECEPTOR-ALPHA; FATTY-ACIDS; DIFFERENTIAL DISPLAY; 3T3-L1 PREADIPOCYTES; X RECEPTOR; HETERODIMERS; LIGAND; LIVER	Stearoyl-CoA desaturase (SCD) is a regulatory enzyme involved in the synthesis of the monounsaturated fatty acids palmitoleate and oleate. The regulation of SCD is of physiological importance because the ratio of saturated fatty acids to unsaturated fatty acids is thought to modulate membrane fluidity. Differential display analysis of retinal pigment epithelial (ARPE-19) cells identified SCD as a gene regulated by retinoic acid. Two SCD transcripts of 3.9 and 5.2 kilobases in size were found to be expressed in these cells by Northern blot analysis. All-trans-retinoic acid (all-trans-RA) increased SCD mRNA expression in a dose- and time-dependent manner; a similar to7-fold increase was observed with 1 mum all-trans-RA at 48 h. SCD m-RNA expression was also increased by 9-cis-retinoic acid (9-cis-RA) as well as 4-(E-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid (TT-NPB), a retinoic acid receptor (RAR)-specific agonist. AGN194301, a RAR alpha -specific antagonist, suppressed the SCD expression induced by all-trans-RA, TTNPB, and 9-cis-RA. These results indicate the involvement of RAR alpha in the induction of SCD expression by retinoic acid. However, AGN194204, a RXR (retinoid X receptor) pan agonist, also increased SCD mRNA expression. This increase was not blocked by AGN194301, suggesting that an RAR-independent mechanism may also be involved. Thus, SCD expression in retinal pigment epithelial cells is regulated by retinoic acid, and the regulation appears to be mediated through RAR and RXR.	NEI, Biochem Sect, Retinal Cell & Mol Biol Lab, NIH, Bethesda, MD 20878 USA; Johnson & Johnson Consumer Prod Inc, Skin Biol Tech Resource Ctr, Skillman, NJ 08558 USA; Allergan Pharmaceut Inc, Retinoid Res, Dept Chem, Irvine, CA 92713 USA; Allergan Pharmaceut Inc, Retinoid Res, Dept Biol, Irvine, CA 92713 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); Johnson & Johnson; Johnson & Johnson USA; AbbVie; Allergan; AbbVie; Allergan	Samuel, W (corresponding author), NEI, LRCMB, NIH, Rm 338,6 Ctr Dr, Bethesda, MD 20892 USA.	william@helix.nih.gov			NATIONAL EYE INSTITUTE [Z01EY000070] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BISSONNETTE RP, 1995, MOL CELL BIOL, V15, P5576; BOK D, 1993, J CELL SCI, P189; BOSSIE MA, 1989, J BACTERIOL, V171, P6409, DOI 10.1128/jb.171.12.6409-6413.1989; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; DAVIS AA, 1995, INVEST OPHTH VIS SCI, V36, P955; deVries JE, 1997, J LIPID RES, V38, P1384; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DORAN TI, 1991, J INVEST DERMATOL, V96, P341, DOI 10.1111/1523-1747.ep12465246; Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020; ENOCH HG, 1976, J BIOL CHEM, V251, P5095; Ershov AV, 2000, J NEUROSCI RES, V60, P328, DOI 10.1002/(SICI)1097-4547(20000501)60:3<328::AID-JNR7>3.0.CO;2-5; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; Gravesen A, 2000, MICROBIOL-UK, V146, P1381, DOI 10.1099/00221287-146-6-1381; HAMEL CP, 1993, J BIOL CHEM, V268, P15751; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; Hovik KE, 1997, BBA-LIPID LIPID MET, V1349, P251, DOI 10.1016/S0005-2760(97)00135-5; KAESTNER KH, 1989, J BIOL CHEM, V264, P14755; KASTURI R, 1982, J BIOL CHEM, V257, P2224; Kurebayashi S, 1997, DIABETES, V46, P2115, DOI 10.2337/diabetes.46.12.2115; Kutty RK, 2001, J BIOL CHEM, V276, P2831, DOI 10.1074/jbc.M007421200; Le XF, 1999, J BIOL CHEM, V274, P21651, DOI 10.1074/jbc.274.31.21651; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LI J, 1994, INT J CANCER, V57, P348, DOI 10.1002/ijc.2910570310; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1994, NUTR REV, V52, P32; Matz M, 1997, NUCLEIC ACIDS RES, V25, P2541, DOI 10.1093/nar/25.12.2541; McCaffery P, 1996, P NATL ACAD SCI USA, V93, P12570, DOI 10.1073/pnas.93.22.12570; Miller CW, 1997, BIOCHEM BIOPH RES CO, V231, P206, DOI 10.1006/bbrc.1997.6070; Nagpal S, 2000, CURR PHARM DESIGN, V6, P919, DOI 10.2174/1381612003400146; NTAMBI JM, 1988, J BIOL CHEM, V263, P17291; Ntambi JM, 1999, J LIPID RES, V40, P1549; NTAMBI JM, 1992, J BIOL CHEM, V267, P10925; PAN DA, 1994, J NUTR, V124, P1555, DOI 10.1093/jn/124.9.1555; PARTHASARATHY S, 1990, P NATL ACAD SCI USA, V87, P3894, DOI 10.1073/pnas.87.10.3894; Rastinejad F, 2001, CURR OPIN STRUC BIOL, V11, P33, DOI 10.1016/S0959-440X(00)00165-2; Standeven AM, 1996, TOXICOL APPL PHARM, V138, P169, DOI 10.1006/taap.1996.0110; STUBBS CD, 1984, BIOCHIM BIOPHYS ACTA, V779, P89, DOI 10.1016/0304-4157(84)90005-4; THIEDE MA, 1986, J BIOL CHEM, V261, P3230; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; Zhang L, 1999, BIOCHEM J, V340, P255, DOI 10.1042/0264-6021:3400255	42	41	42	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28744	28750		10.1074/jbc.M103587200	http://dx.doi.org/10.1074/jbc.M103587200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11397803	hybrid			2022-12-25	WOS:000170346000015
J	Agnihotri, R; Crawford, HC; Haro, H; Matrisian, LM; Havrda, MC; Liaw, L				Agnihotri, R; Crawford, HC; Haro, H; Matrisian, LM; Havrda, MC; Liaw, L			Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELL APOPTOSIS; HERNIATED DISC RESORPTION; MICE LACKING OSTEOPONTIN; GROWTH-FACTOR; IN-VITRO; TUMOR PROGRESSION; THROMBIN-CLEAVAGE; TERMINAL FRAGMENT; DEFICIENT MICE; MIGRATION	Osteopontin (OPN) is a secreted phosphoprotein shown to function in wound healing, inflammation, and tumor progression. Expression of OPN is often co-localized with members of the matrix metalloproteinase (MMP) family. We report that OPN is a novel substrate for two MMPs, MMP-3 (stromelysin-1) and MMP-7 (matrilysin). Three cleavage sites were identified for MMP-3 in human OPN, and two of those sites were also cleaved by MMP-7. These include hydrolysis of the human Gly(166)-Leu(167), Ala(201)-Tyr(202) (MMP-3 only), and Asp(210)-Leu(211) peptide bonds. Only the N-terminal Gly-Leu cleavage site is conserved in rat OPN (Gly(151)-Leu(152)). These sites are distinct from previously reported cleavage sites in OPN for the proteases thrombin or enterokinase. We found evidence for the predicted MMP cleavage fragments of OPN in vitro in tumor cell lines, and in vivo in remodeling tissues such as the postpartum uterus, where OPN and MMPs are co-expressed. Furthermore, cleavage of OPN by MMP-3 or MMP-7 potentiated the function of OPN as an adhesive and migratory stimulus in vitro through cell surface integrins. We predict that interaction of MMPs with OPN at tumor and wound healing sites in vivo may be a mechanism of regulation of OPN bioactivity.	Maine Med Ctr, Res Inst, Ctr Mol Med, Scarborough, ME 04074 USA; Vanderbilt Univ, Dept Canc Biol, Nashville, TN 37232 USA	Maine Medical Center; Vanderbilt University	Liaw, L (corresponding author), Maine Med Ctr, Res Inst, Ctr Mol Med, Scarborough, ME 04074 USA.		Crawford, Howard/A-2874-2008		NATIONAL CANCER INSTITUTE [R01CA060867] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA60867] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexander CM, 1996, J CELL BIOL, V135, P1669, DOI 10.1083/jcb.135.6.1669; Ashkar S, 2000, SCIENCE, V287, P860, DOI 10.1126/science.287.5454.860; Attiga FA, 2000, CANCER RES, V60, P4629; Bayless KJ, 2001, J BIOL CHEM, V276, P13483, DOI 10.1074/jbc.M011392200; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; CHEN YP, 1995, BLOOD, V86, P2606, DOI 10.1182/blood.V86.7.2606.bloodjournal8672606; CRAIG AM, 1988, BIOCHEM BIOPH RES CO, V157, P166, DOI 10.1016/S0006-291X(88)80028-7; Crawford HC, 1998, CANCER RES, V58, P5206; DENHARDT DT, 1995, ANN NY ACAD SCI, V760, P127, DOI 10.1111/j.1749-6632.1995.tb44625.x; DENHARDT DT, 1994, J CELL BIOCHEM, V56, P48, DOI 10.1002/jcb.240560109; FOWLKES JL, 1994, J BIOL CHEM, V269, P25742; GIACHELLI CM, 1995, ANN NY ACAD SCI, V760, P109, DOI 10.1111/j.1749-6632.1995.tb44624.x; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Grant MB, 1998, DIABETES, V47, P1335, DOI 10.2337/diabetes.47.8.1335; Haro H, 2000, J CLIN INVEST, V105, P133, DOI 10.1172/JCI7090; Haro H, 2000, J CLIN INVEST, V105, P143, DOI 10.1172/JCI7091; Imai K, 1997, BIOCHEM J, V322, P809, DOI 10.1042/bj3220809; Ito A, 1996, J BIOL CHEM, V271, P14657, DOI 10.1074/jbc.271.25.14657; Levi E, 1996, P NATL ACAD SCI USA, V93, P7069, DOI 10.1073/pnas.93.14.7069; LIAW L, 1994, CIRC RES, V74, P214, DOI 10.1161/01.RES.74.2.214; Liaw L, 1998, J CLIN INVEST, V101, P1468; McCawley LJ, 2000, MOL MED TODAY, V6, P149, DOI 10.1016/S1357-4310(00)01686-5; Meyer-Siegler K, 2000, CYTOKINE, V12, P914, DOI 10.1006/cyto.2000.0682; Mudgett JS, 1998, ARTHRITIS RHEUM-US, V41, P110, DOI 10.1002/1529-0131(199801)41:1<110::AID-ART14>3.0.CO;2-G; MUKHERJEE BB, 1995, ANN NY ACAD SCI, V760, P201, DOI 10.1111/j.1749-6632.1995.tb44631.x; Nagakawa O, 2000, CANCER LETT, V155, P173, DOI 10.1016/S0304-3835(00)00425-0; Nau GJ, 1999, INFECT IMMUN, V67, P4223, DOI 10.1128/IAI.67.8.4223-4230.1999; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Noiri E, 1999, KIDNEY INT, V56, P74, DOI 10.1046/j.1523-1755.1999.00526.x; O'Regan AW, 1999, J IMMUNOL, V162, P1024; Ohnami S, 1999, CANCER RES, V59, P5565; Ophascharoensuk V, 1999, KIDNEY INT, V56, P571, DOI 10.1046/j.1523-1755.1999.00580.x; Powell WC, 1999, CURR BIOL, V9, P1441, DOI 10.1016/S0960-9822(00)80113-X; Rittling SR, 1999, EXP NEPHROL, V7, P103; Rittling SR, 1998, J BONE MINER RES, V13, P1101, DOI 10.1359/jbmr.1998.13.7.1101; Senger DR, 1996, BBA-MOL CELL RES, V1314, P13, DOI 10.1016/S0167-4889(96)00067-5; SENGER DR, 1994, MOL BIOL CELL, V5, P565, DOI 10.1091/mbc.5.5.565; Senger DR, 1996, AM J PATHOL, V149, P293; Smith LL, 1996, J BIOL CHEM, V271, P28485, DOI 10.1074/jbc.271.45.28485; Sodek J, 2000, CRIT REV ORAL BIOL M, V11, P279, DOI 10.1177/10454411000110030101; Suzuki M, 1997, J BIOL CHEM, V272, P31730, DOI 10.1074/jbc.272.50.31730; Takahashi K, 1998, BIOCHEM MOL BIOL INT, V46, P1081; Uede T, 1997, MICROBIOL IMMUNOL, V41, P641, DOI 10.1111/j.1348-0421.1997.tb01906.x; Weber Georg F., 1996, Cytokine and Growth Factor Reviews, V7, P241, DOI 10.1016/S1359-6101(96)00030-5; WILSON CL, 1995, MOL BIOL CELL, V6, P851, DOI 10.1091/mbc.6.7.851; WRIGHT JH, 1994, MOL CARCINOGEN, V10, P207, DOI 10.1002/mc.2940100405; Yokosaki Y, 1999, J BIOL CHEM, V274, P36328, DOI 10.1074/jbc.274.51.36328; Yoshitake H, 1999, P NATL ACAD SCI USA, V96, P8156, DOI 10.1073/pnas.96.14.8156	48	310	330	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28261	28267		10.1074/jbc.M103608200	http://dx.doi.org/10.1074/jbc.M103608200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11375993	hybrid			2022-12-25	WOS:000170093400070
J	Zhou, J; Hsieh, JT				Zhou, J; Hsieh, JT			The inhibitory role of DOC-2/DAB2 in growth factor receptor-mediated signal cascade - DOC-2/DAB2-mediated inhibition of ERK phosphorylation via binding to Grb2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR GENE; AP-1 ACTIVITY; DOMAIN; CLONING	DOC-2/DAB2 ((d) under bar ifferentially expressed in (o) under bar varian (c) under bar arcinoma-(2) under bar/(d) under bar is (a) under bar(b) under bar led (2) under bar) appears to be a potential tumor suppressor gene with a growth inhibitory effect on several cancer types. Previously, we have shown that DOC2/DAB2 suppresses protein kinase C-induced AP-1 activation, which is modulated by serine 24 phosphorylation in the N terminus of DOC-2/DAB2. However, the functional impact of the C terminus of DOC-2/DAB2, containing three proline-rich domains, has not been explored. In this study, we examined this functional role in modulating signaling mediated by peptide growth factor receptor tyrosine kinase, particularly because it involves the interaction with Grb2. Using sequence-specific peptides, we found that the second proline-rich domain of DOC-2/DAB2 is the key binding site to Grb2 in the presence of growth factors. Such elevated binding interrupts the binding between SOS and Grb2, which consequently suppresses downstream ERK phosphorylation. Reduced ERK phosphorylation was restored when the binding between DOC-2/DAB2 and Grb2 was interrupted by a specific peptide or by increasing the expression of Grb2. Furthermore, the C terminus of the DOC-2/DAB2 construct can inhibit the AP-1 activity elicited by growth factors. We conclude that DOC-2/DAB2, a potent negative regulator, can suppress ERK activation by interrupting the binding between Grb2 and SOS that is elicited by peptide growth factors. This study further illustrates that DOC-2/DAB2 has multiple effects on the RAS-mediated signal cascades active in cancer cells.	Univ Texas, SW Med Ctr, Dept Urol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Hsieh, JT (corresponding author), Univ Texas, SW Med Ctr, Dept Urol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	JT.Hsieh@UTSouthwestern.edu			NCI NIH HHS [CA 59939] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA059939] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Fazili Z, 1999, ONCOGENE, V18, P3104, DOI 10.1038/sj.onc.1202649; Fulop V, 1998, ONCOGENE, V17, P419, DOI 10.1038/sj.onc.1201955; Gutacker C, 1999, BIOCHEM J, V339, P759, DOI 10.1042/0264-6021:3390759; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KHAZAIE K, 1993, CANCER METAST REV, V12, P255, DOI 10.1007/BF00665957; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1994, PROG BIOPHYS MOL BIO, V62, P223, DOI 10.1016/0079-6107(94)90013-2; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; McCarty MF, 1998, MED HYPOTHESES, V50, P511, DOI 10.1016/S0306-9877(98)90273-0; MOK SC, 1994, GYNECOL ONCOL, V52, P247, DOI 10.1006/gyno.1994.1040; Mok SC, 1998, ONCOGENE, V16, P2381, DOI 10.1038/sj.onc.1201769; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; Schwahn DJ, 1998, ONCOGENE, V17, P1173, DOI 10.1038/sj.onc.1202038; Tseng CP, 1999, J BIOL CHEM, V274, P31981, DOI 10.1074/jbc.274.45.31981; Tseng CP, 1998, ENDOCRINOLOGY, V139, P3542, DOI 10.1210/en.139.8.3542; TSOULFAS P, 1993, NEURON, V10, P975, DOI 10.1016/0896-6273(93)90212-A; Ware JL, 1998, CANCER METAST REV, V17, P443, DOI 10.1023/A:1006114527274; XU XX, 1995, J BIOL CHEM, V270, P14184, DOI 10.1074/jbc.270.23.14184; Xu XX, 1998, ONCOGENE, V16, P1561, DOI 10.1038/sj.onc.1201678; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451	24	87	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27793	27798		10.1074/jbc.M102803200	http://dx.doi.org/10.1074/jbc.M102803200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11371563	hybrid			2022-12-25	WOS:000170093400009
J	Furukawa, K; Shirai, H; Azuma, T; Nakamura, H				Furukawa, K; Shirai, H; Azuma, T; Nakamura, H			A role of the third complementarity-determining region in the affinity maturation of an antibody	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOMATIC HYPERMUTATION; JUNCTIONAL DIVERSITY; GERMINAL-CENTERS; N-REGIONS; IMMUNOGLOBULIN; GENERATION; MUTATION; PROGRAM; CDR-H3; FETAL	We recently found that there are two distinct antibody maturation pathways for the immune response of C57BL/6 mice to (4-hydroxy-3-nitrophenyl) acetyl and that a junctional amino acid introduced at a point far in advance of somatic hypermutation determined which pathway of affinity maturation was used. We describe here the structural basis for this aspect of maturation using recently developed H3 rules, which allow for reliable identification of the conformation of the third complementarity-determining region of the heavy chain (CDR-H3) from the primary amino acid sequences only. By the application of these rules, the anti-(4-hydroxy-3-nitrophenyl) acetyl antibodies examined here were classified into two major groups on the basis of their CDR-H3 structure, and these groups were found to be consistent with the maturation pathways. In addition, circular dichroism measurements revealed that the versatile nature-of the antigen binding of the antibodies was significantly influenced by the pathway employed. We postulated in this study that flexibility in the CDR-H3 structure in the antigen-combining site could facilitate efficient antibody maturation supported by a plurality of possible antigen binding modes.	Tokyo Univ Sci, Res Inst Biol Sci, Chiba 2780022, Japan; Tokyo Med & Dent Univ, Med Res Inst, Bunkyo Ku, Tokyo 1138510, Japan; Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England; Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan	Tokyo University of Science; Tokyo Medical & Dental University (TMDU); University of Cambridge; Osaka University	Furukawa, K (corresponding author), Tokyo Univ Sci, Res Inst Biol Sci, 2669 Yamazaki, Chiba 2780022, Japan.	furukama@rs.noda.sut.ac.jp	Furukawa, Koji/L-6909-2018	Furukawa, Koji/0000-0002-5701-2497				ALLEN D, 1988, EMBO J, V7, P1995, DOI 10.1002/j.1460-2075.1988.tb03038.x; Benedict CL, 1999, IMMUNITY, V10, P607, DOI 10.1016/S1074-7613(00)80060-6; BEREK C, 1993, CURR OPIN IMMUNOL, V5, P218, DOI 10.1016/0952-7915(93)90007-F; BOTHWELL ALM, 1981, CELL, V24, P625, DOI 10.1016/0092-8674(81)90089-1; CUMANO A, 1985, EUR J IMMUNOL, V15, P512, DOI 10.1002/eji.1830150517; DESIDERIO SV, 1984, NATURE, V311, P752, DOI 10.1038/311752a0; FEENEY AJ, 1990, J EXP MED, V172, P1377, DOI 10.1084/jem.172.5.1377; FRENCH DL, 1989, SCIENCE, V244, P1152, DOI 10.1126/science.2658060; Furukawa K, 1999, IMMUNITY, V11, P329, DOI 10.1016/S1074-7613(00)80108-9; Joyce GF, 1997, SCIENCE, V276, P1658, DOI 10.1126/science.276.5319.1658; Kelsoe G, 1996, IMMUNITY, V4, P107, DOI 10.1016/S1074-7613(00)80675-5; Kim ST, 1999, PROTEINS, V37, P683, DOI 10.1002/(SICI)1097-0134(19991201)37:4<683::AID-PROT17>3.0.CO;2-D; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LIU YJ, 1992, IMMUNOL TODAY, V13, P17, DOI 10.1016/0167-5699(92)90199-H; MACLENNAN ICM, 1992, IMMUNOL REV, V126, P143, DOI 10.1111/j.1600-065X.1992.tb00635.x; MEEK K, 1990, SCIENCE, V250, P820, DOI 10.1126/science.2237433; MIZUTANI R, 1995, J MOL BIOL, V254, P208, DOI 10.1006/jmbi.1995.0612; MORIKAMI K, 1992, COMPUT CHEM, V16, P243, DOI 10.1016/0097-8485(92)80010-W; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Papavasiliou FN, 2000, NATURE, V408, P216, DOI 10.1038/35041599; Shirai H, 1999, FEBS LETT, V455, P188, DOI 10.1016/S0014-5793(99)00821-2; Shirai H, 1996, FEBS LETT, V399, P1, DOI 10.1016/S0014-5793(96)01252-5; Smith DK, 1997, J MOL BIOL, V274, P530, DOI 10.1006/jmbi.1997.1432; TANIMURA R, 1994, PROTEIN SCI, V3, P2358, DOI 10.1002/pro.5560031220; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; VARGASMADRAZO E, 1995, J MOL BIOL, V254, P497, DOI 10.1006/jmbi.1995.0633; Wedemayer GJ, 1997, SCIENCE, V276, P1665, DOI 10.1126/science.276.5319.1665	28	28	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27622	27628		10.1074/jbc.M102714200	http://dx.doi.org/10.1074/jbc.M102714200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11375987	hybrid			2022-12-25	WOS:000169966900117
J	Claud, EC; Walker, WA				Claud, EC; Walker, WA			Hypothesis: inappropriate colonization of the premature intestine can cause neonatal necrotizing enterocolitis	FASEB JOURNAL			English	Article						necrotizing enterocolitis; prematurity; intestinal inflammation	PLATELET-ACTIVATING-FACTOR; RAT SMALL-INTESTINE; ISCHEMIC BOWEL NECROSIS; BREAST-FED INFANTS; NF-KAPPA-B; BACTERIAL-COLONIZATION; EPITHELIAL-CELLS; HUMAN-MILK; SALMONELLA-TYPHIMURIUM; FACTOR ACETYLHYDROLASE	Neonatal necrotizing enterocolitis (NEC) is a major cause of morbidity in preterm infants. We hypothesize that the intestinal injury in this disease is a consequence of synergy among three of the major risk factors for NEC: prematurity, enteral feeding, and bacterial colonization. Together these factors result in an exaggerated inflammatory response, leading to ischemic bowel necrosis. Human milk may decrease the incidence of NEC by decreasing pathogenic bacterial colonization, promoting growth of nonpathogenic flora, promoting maturation of the intestinal barrier, and ameliorating the proinflammatory response.	Harvard Univ, Massachusetts Gen Hosp, Sch Med,Combined Program Pediat Gastroenterol & N, Dev Gastroenterol Lab, Boston, MA USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Walker, WA (corresponding author), Massachusetts Gen Hosp, Dev Gastroenterol Lab, 149 13th St, Charlestown, MA 02129 USA.	walker@helix.mgh.harvard.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD012437, R01HD031852] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK033506] Funding Source: NIH RePORTER; NICHD NIH HHS [R37-HD12437, R01-HD31852] Funding Source: Medline; NIDDK NIH HHS [P01-DK33506] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AYNSLEYGREEN A, 1990, J PEDIATR-US, V117, pS24, DOI 10.1016/S0022-3476(05)81127-8; BALLANCE WA, 1990, J PEDIATR-US, V117, pS6, DOI 10.1016/S0022-3476(05)81124-2; BARNESS LA, 1994, J NUTR, V124, pS128, DOI 10.1093/jn/124.suppl_1.128S; BEEBY PJ, 1992, ARCH DIS CHILD-FETAL, V67, P432, DOI 10.1136/adc.67.4_Spec_No.432; BENNET R, 1992, ACTA PAEDIATR, V81, P784, DOI 10.1111/j.1651-2227.1992.tb12103.x; Bernt KM, 1999, ACTA PAEDIATR, V88, P27; CAPLAN M, 1990, PROSTAGLANDINS, V39, P705, DOI 10.1016/0090-6980(90)90030-Y; CAPLAN MS, 1993, PEDIATR PATHOL, V13, P357, DOI 10.3109/15513819309048223; CAPLAN MS, 1990, J PEDIATR-US, V117, pS47, DOI 10.1016/S0022-3476(05)81130-8; CAPLAN MS, 1990, J PEDIATR-US, V116, P960, DOI 10.1016/S0022-3476(05)80661-4; CAPLAN MS, 1994, CLIN PERINATOL, V21, P235, DOI 10.1016/S0095-5108(18)30343-9; Caplan MS, 1997, J PEDIATR GASTR NUTR, V24, P296, DOI 10.1097/00005176-199703000-00012; CAPLAN MS, 1992, PEDIATR RES, V31, P428, DOI 10.1203/00006450-199205000-00002; Caplan MS, 2000, J PEDIATR GASTR NUTR, V30, pS18, DOI 10.1097/00005176-200000002-00004; CARBONARO CA, 1988, MICROB PATHOGENESIS, V5, P427, DOI 10.1016/0882-4010(88)90004-6; CHU SHW, 1986, BIOCHIM BIOPHYS ACTA, V883, P496, DOI 10.1016/0304-4165(86)90289-8; CLARK DA, 1990, J PEDIATR-US, V117, pS64, DOI 10.1016/S0022-3476(05)81133-3; CROWLEY P, 1990, BRIT J OBSTET GYNAEC, V97, P11, DOI 10.1111/j.1471-0528.1990.tb01711.x; Dai DW, 2000, J PEDIATR GASTR NUTR, V30, pS23, DOI 10.1097/00005176-200003002-00005; Elewaut D, 1999, J IMMUNOL, V163, P1457; Faix R G, 1994, Adv Pediatr Infect Dis, V9, P1; FURUKAWA M, 1993, PEDIATR RES, V34, P237, DOI 10.1203/00006450-199308000-00027; Fusunyan RD, 1998, PEDIATR RES, V43, P84, DOI 10.1203/00006450-199801000-00013; Gewirtz AT, 2000, J CLIN INVEST, V105, P79, DOI 10.1172/JCI8066; GONZALEZCRUSSI F, 1983, AM J PATHOL, V112, P127; Gronlund MM, 1999, J PEDIATR GASTR NUTR, V28, P19, DOI 10.1097/00005176-199901000-00007; HALAC E, 1990, J PEDIATR-US, V117, P132, DOI 10.1016/S0022-3476(05)72461-6; Harmsen HJM, 2000, J PEDIATR GASTR NUTR, V30, P61, DOI 10.1097/00005176-200001000-00019; HARRIS MC, 1994, J PEDIATR-US, V124, P105, DOI 10.1016/S0022-3476(94)70264-0; Hobbie S, 1997, J IMMUNOL, V159, P5550; HOY C, 1990, ARCH DIS CHILD-FETAL, V65, P1057, DOI 10.1136/adc.65.10_Spec_No.1057; Hoyos A B, 1999, Int J Infect Dis, V3, P197, DOI 10.1016/S1201-9712(99)90024-3; HSUEH W, 1987, FASEB J, V1, P403, DOI 10.1096/fasebj.1.5.3678700; ISRAEL EJ, 1990, GASTROENTEROLOGY, V99, P1333, DOI 10.1016/0016-5085(90)91158-3; KIEN CL, 1990, J PEDIATR-US, V117, pS52, DOI 10.1016/S0022-3476(05)81131-X; Kinugasa T, 2000, GASTROENTEROLOGY, V118, P1001, DOI 10.1016/S0016-5085(00)70351-9; KOSLOSKE A, 1994, ACTA PAEDIATR, V83, P2, DOI 10.1111/j.1651-2227.1994.tb13232.x; LARI AR, 1990, BIOL NEONATE, V58, P73; LODINOVAZADNIKOVA R, 1991, PEDIATR RES, V29, P396, DOI 10.1203/00006450-199104000-00013; LodinovaZadnikova R, 1997, BIOL NEONATE, V71, P224, DOI 10.1159/000244421; LUCAS A, 1990, LANCET, V336, P1519, DOI 10.1016/0140-6736(90)93304-8; MACKENDRICK W, 1993, BIOL NEONATE, V64, P89, DOI 10.1159/000243976; MADARA JL, 1990, AM J PATHOL, V137, P1273; MOYA FR, 1994, J PEDIATR GASTR NUTR, V19, P236, DOI 10.1097/00005176-199408000-00015; MURRAY RD, 1990, J PEDIATR-US, V117, pS59, DOI 10.1016/S0022-3476(05)81132-1; Nanthakumar NN, 2000, P NATL ACAD SCI USA, V97, P6043, DOI 10.1073/pnas.97.11.6043; Neish AS, 2000, SCIENCE, V289, P1560, DOI 10.1126/science.289.5484.1560; NEU J, 1986, PEDIATR RES, V20, P79, DOI 10.1203/00006450-198601000-00022; Newburg DS, 2000, J PEDIATR GASTR NUTR, V30, pS8, DOI 10.1097/00005176-200000002-00003; Orrhage K, 1999, ACTA PAEDIATR, V88, P47; OZAKI CK, 1989, BIOCHIM BIOPHYS ACTA, V991, P243; PANIGRAHI P, 1994, PEDIATR RES, V36, P115, DOI 10.1203/00006450-199407001-00021; Petschow BW, 1999, J MED MICROBIOL, V48, P541, DOI 10.1099/00222615-48-6-541; SANDERSON IR, 1994, J NUTR, V124, pS131, DOI 10.1093/jn/124.suppl_1.131S; SCHIFFRIN EJ, 1993, J PEDIATR GASTR NUTR, V17, P271; Tanaka M, 1996, J NUTR, V126, P424, DOI 10.1093/jn/126.2.424; UDALL JN, 1990, J PEDIATR-US, V117, pS33, DOI 10.1016/S0022-3476(05)81128-X; Walker WA, 1996, TRANSPLANT P, V28, P2438; WALLACE JL, 1987, GASTROENTEROLOGY, V93, P765, DOI 10.1016/0016-5085(87)90438-0; Yeh TF, 1998, PEDIATRICS, V101, part. no., DOI 10.1542/peds.101.5.e7	60	284	336	3	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2001	15	8					1398	1403		10.1096/fj.00-0833hyp	http://dx.doi.org/10.1096/fj.00-0833hyp			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11387237				2022-12-25	WOS:000169261200007
J	Dolznig, H; Boulme, F; Stangl, K; Deiner, EM; Mikulits, W; Beug, H; Mullner, EW				Dolznig, H; Boulme, F; Stangl, K; Deiner, EM; Mikulits, W; Beug, H; Mullner, EW			Establishment of normal, terminally differentiating mouse erythroid progenitors: molecular characterization by cDNA arrays	FASEB JOURNAL			English	Review						erythropoiesis; expression profiling; signal transduction	MAMMARY EPITHELIAL-CELLS; SELF-ORGANIZING MAPS; FACTOR CHOP GADD153; C-SRC ACTIVITY; TRANSCRIPTION FACTOR; GENE-EXPRESSION; HEMATOPOIETIC-CELLS; IN-VITRO; ERYTHROPOIETIN RECEPTOR; GLUCOCORTICOID RECEPTOR	Expression profiling with cDNA arrays is an excellent tool for molecular analysis of complex processes such as terminal erythroid differentiation. The shortcomings of the currently available erythroid in vitro differentiation models, however, severely impaired the usefulness of this approach to study erythropoiesis. Here, we describe a novel, murine erythroid cell system closely corresponding to in vivo erythroid progenitors. Mortal, long-term proliferating erythroid progenitors of fetal liver or immortal strains of p53-deficient erythroblasts were established in culture. Both cell types proliferated in serum-free medium and were strictly dependent on physiologically relevant cytokines and hormones, stably retaining a diploid set of chromosomes. If exposed to physiological differentiation factors (erythropoietin plus insulin), cells synchronously recapitulated the normal in vivo differentiation program to mature terminally into enucleated erythrocytes and expressed stage-specific erythroid transcription factors in the expected temporal order. Using cDNA arrays, we found a large number of genes differentially expressed at time points during differentiation. Already 6 h after differentiation induction, 17% of the expressed genes showed significant alterations in mRNA abundance, increasing to 53% (12% up-regulated, 41% down-regulated genes) by 48 h. Cluster analysis of mRNA expression kinetics during differentiation identified six distinct expression patterns. All genes on the array with a known function in erythropoiesis showed the expected variations in expression. The genes identified also allowed first insights into the sequence of events within the regulatory network responsible for erythroid maturation. In mortal wild-type as well as immortal p53(-/-) erythroblasts, changes in mRNA abundance of several well-regulated gene products was verified at the protein level. Taken together, this novel hematopoietic cell system faithfully executes essential steps of normal erythropoiesis and allows us to dissect and characterize molecular mechanisms involved in erythropoiesis.	Vienna Bioctr, Inst Med Biochem, Div Mol Biol, A-1030 Vienna, Austria; Vienna Bioctr, Inst Mol Pathol, A-1030 Vienna, Austria; Inst Canc Res, A-1090 Vienna, Austria	Vienna Biocenter (VBC); Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Mullner, EW (corresponding author), Vienna Bioctr, Inst Med Biochem, Div Mol Biol, Dr Bohr Gasse 9, A-1030 Vienna, Austria.	em@mol.univie.ac.at	Dolznig, Helmut/L-7005-2015; Mikulits, Wolfgang/AAH-4043-2021	Dolznig, Helmut/0000-0002-6063-3585; Mikulits, Wolfgang/0000-0003-4612-7106				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Alon U, 1999, P NATL ACAD SCI USA, V96, P6745, DOI 10.1073/pnas.96.12.6745; ALTER BP, 1994, ANN NY ACAD SCI, V731, P36, DOI 10.1111/j.1749-6632.1994.tb55746.x; Anderson KP, 2000, BLOOD, V95, P1652, DOI 10.1182/blood.V95.5.1652.005k23_1652_1655; ANDERSON SM, 1985, MOL CELL BIOL, V5, P3369, DOI 10.1128/MCB.5.12.3369; Andrews NC, 1998, INT J BIOCHEM CELL B, V30, P429, DOI 10.1016/S1357-2725(97)00135-0; Athanasiou M, 2000, LEUKEMIA, V14, P439, DOI 10.1038/sj.leu.2401689; Barber DL, 1997, BLOOD, V89, P3166, DOI 10.1182/blood.V89.9.3166; BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; Bauer A, 1999, GENE DEV, V13, P2996, DOI 10.1101/gad.13.22.2996; BAUER A, 2001, IN PRESS HEMATOPOIES; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; Beug H, 1996, CURR TOP MICROBIOL, V211, P29; BEUG H, 1995, METHOD ENZYMOL, V254, P41; Broudy VC, 1996, BLOOD, V88, P75; BROUDY VC, 1991, BLOOD, V77, P2583, DOI 10.1182/blood.V77.12.2583.2583; Carballo E, 2000, BLOOD, V95, P1891, DOI 10.1182/blood.V95.6.1891; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; CONSCIENCE JF, 1982, DIFFERENTIATION, V22, P100, DOI 10.1111/j.1432-0436.1982.tb01232.x; Coutts M, 1999, BLOOD, V93, P3369, DOI 10.1182/blood.V93.10.3369.410k11_3369_3378; Crossley M, 1996, MOL CELL BIOL, V16, P1695; Cui KY, 2000, J BIOL CHEM, V275, P7591, DOI 10.1074/jbc.275.11.7591; DAMEN JE, 1993, BLOOD, V81, P3204; DAMEN JE, 1993, BLOOD, V82, P2296; De Maria R, 1999, BLOOD, V93, P796, DOI 10.1182/blood.V93.3.796.403k23_796_803; DEAN A, 1981, SCIENCE, V212, P459, DOI 10.1126/science.6163216; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; DOLZNIG H, 1995, CELL GROWTH DIFFER, V6, P1341; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONOHUE DM, 1958, J CLIN INVEST, V37, P1571, DOI 10.1172/JCI103750; Duggan DJ, 1999, NAT GENET, V21, P10, DOI 10.1038/4434; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Elefanty AG, 1997, BLOOD, V90, P1435, DOI 10.1182/blood.V90.4.1435.1435_1435_1447; Elwood NJ, 1998, BLOOD, V91, P3756; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Fibach E, 1998, HEMOGLOBIN, V22, P445, DOI 10.3109/03630269809071542; Forsberg EC, 2000, BLOOD, V96, P334, DOI 10.1182/blood.V96.1.334.013k17_334_339; FUERSTENBERG S, 1992, EMBO J, V11, P3355, DOI 10.1002/j.1460-2075.1992.tb05414.x; Gandrillon O, 1999, EMBO J, V18, P2764, DOI 10.1093/emboj/18.10.2764; GRAF T, 1992, CELL, V70, P201, DOI 10.1016/0092-8674(92)90096-U; Grosveld F, 1999, CURR OPIN GENET DEV, V9, P152, DOI 10.1016/S0959-437X(99)80023-9; Gubin AN, 1999, GENOMICS, V59, P168, DOI 10.1006/geno.1999.5855; HAYMAN MJ, 1993, CELL, V74, P157, DOI 10.1016/0092-8674(93)90303-8; Heyer LJ, 1999, GENOME RES, V9, P1106, DOI 10.1101/gr.9.11.1106; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; HOFFMAN R, 1991, HEMATOLOGY BASIC PRI; HROMAS R, 1994, INT J HEMATOL, V59, P257; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Jansen MWJC, 1999, PRENATAL DIAG, V19, P323, DOI 10.1002/(SICI)1097-0223(199904)19:4<323::AID-PD534>3.3.CO;2-1; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; Johannes G, 1999, P NATL ACAD SCI USA, V96, P13118, DOI 10.1073/pnas.96.23.13118; KABAT D, 1975, CELL, V5, P331, DOI 10.1016/0092-8674(75)90109-9; KAHN P, 1984, P NATL ACAD SCI-BIOL, V81, P7122, DOI 10.1073/pnas.81.22.7122; KENNEDY M, 1992, BLOOD, V79, P180; KILLISCH I, 1992, J CELL SCI, V103, P211; Kina T, 2000, BRIT J HAEMATOL, V109, P280, DOI 10.1046/j.1365-2141.2000.02037.x; KLINKEN SP, 1988, P NATL ACAD SCI USA, V85, P8506, DOI 10.1073/pnas.85.22.8506; KOWENZ E, 1987, MODERN TRENDS HUMA 7, V31, P199; LAIRD PW, 1993, NUCLEIC ACIDS RES, V21, P4750, DOI 10.1093/nar/21.20.4750; Lander ES, 1999, NAT GENET, V21, P3, DOI 10.1038/4427; LISTER J, 1995, J BIOL CHEM, V270, P17939, DOI 10.1074/jbc.270.30.17939; LUETHY JD, 1990, J BIOL CHEM, V265, P16521; LUETHY JD, 1992, CANCER RES, V52, P5; MEAGHER RC, 1989, EXP HEMATOL, V17, P374; METZ T, 1995, CELL, V82, P29, DOI 10.1016/0092-8674(95)90049-7; Mikulits W, 1999, BIOTECHNIQUES, V26, P846, DOI 10.2144/99265bm09; Mikulits W, 2000, FASEB J, V14, P1641, DOI 10.1096/fj.14.11.1641; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; Nguyen MT, 1997, NATURE, V390, P78, DOI 10.1038/36342; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; Orkin SH, 1997, ANNU REV GENET, V31, P33, DOI 10.1146/annurev.genet.31.1.33; Oshevski S, 1999, BIOCHEM BIOPH RES CO, V263, P603, DOI 10.1006/bbrc.1999.1425; OZBUN MA, 1993, CANCER RES, V53, P1646; PALMIERI S, 1985, VIROLOGY, V140, P269, DOI 10.1016/0042-6822(85)90365-4; Park CG, 1996, IMMUNITY, V4, P583, DOI 10.1016/S1074-7613(00)80484-7; Pereira R, 1999, ONCOGENE, V18, P1597, DOI 10.1038/sj.onc.1202534; PERKINS AC, 1995, NATURE, V375, P318; Perkins AC, 2000, BLOOD, V95, P1827, DOI 10.1182/blood.V95.5.1827.004k10_1827_1833; Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212; PINCUS SM, 1984, BIOCHEM BIOPH RES CO, V125, P491, DOI 10.1016/0006-291X(84)90567-9; Pollack MA, 2000, WASH QUART, V23, P41, DOI 10.1162/016366000561330; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Rivero JA, 1998, BIOCHEM BIOPH RES CO, V248, P664, DOI 10.1006/bbrc.1998.9041; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SASE S, 1982, BIOCHIM BIOPHYS ACTA, V693, P253, DOI 10.1016/0005-2736(82)90493-X; SAWADA K, 1989, J CLIN INVEST, V83, P1701, DOI 10.1172/JCI114070; SAWADA K, 1988, J CELL PHYSIOL, V137, P337, DOI 10.1002/jcp.1041370218; SAWADA K, 1991, J CELL PHYSIOL, V149, P1, DOI 10.1002/jcp.1041490102; SAWADA K, 1990, J CELL PHYSIOL, V142, P219, DOI 10.1002/jcp.1041420202; SAWADA K, 1987, J CLIN INVEST, V80, P35766; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shigematsu H, 1997, J BIOL CHEM, V272, P14334, DOI 10.1074/jbc.272.22.14334; Sitar G, 1999, CYTOMETRY, V35, P337, DOI 10.1002/(SICI)1097-0320(19990401)35:4<337::AID-CYTO6>3.0.CO;2-U; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Stanley ER, 1997, MOL REPROD DEV, V46, P4, DOI 10.1002/(SICI)1098-2795(199701)46:1<4::AID-MRD2>3.0.CO;2-V; STEINLEIN P, 1995, CURR BIOL, V5, P191, DOI 10.1016/S0960-9822(95)00040-6; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Tamir A, 1999, MOL CELL BIOL, V19, P4452; Taylor GA, 1996, MOL ENDOCRINOL, V10, P140, DOI 10.1210/me.10.2.140; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; Toronen P, 1999, FEBS LETT, V451, P142, DOI 10.1016/S0014-5793(99)00524-4; UDUPA KB, 1988, BRIT J HAEMATOL, V69, P157, DOI 10.1111/j.1365-2141.1988.tb07617.x; UDUPA KB, 1986, BRIT J HAEMATOL, V62, P705, DOI 10.1111/j.1365-2141.1986.tb04094.x; UOSHIMA N, 1995, BRIT J HAEMATOL, V91, P30, DOI 10.1111/j.1365-2141.1995.tb05240.x; von Lindern M, 2000, J BIOL CHEM, V275, P34719, DOI 10.1074/jbc.M007042200; von Lindern M, 1999, BLOOD, V94, P550, DOI 10.1182/blood.V94.2.550.414k39_550_559; Wang RX, 1998, J IMMUNOL, V161, P2201; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; Wessely O, 1999, BIOL CHEM, V380, P187, DOI 10.1515/BC.1999.027; Wessely O, 1997, EMBO J, V16, P267, DOI 10.1093/emboj/16.2.267; White KP, 1999, SCIENCE, V286, P2179, DOI 10.1126/science.286.5447.2179; Wong KS, 1999, ONCOGENE, V18, P5525, DOI 10.1038/sj.onc.1202938; Yamamoto M, 1997, GENES CELLS, V2, P107, DOI 10.1046/j.1365-2443.1997.1080305.x	118	88	91	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 27	2001	15	6					1442	+		10.1096/fj.00-0705fje	http://dx.doi.org/10.1096/fj.00-0705fje			39	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387251				2022-12-25	WOS:000173705800011
J	Li, YP; Schwartz, RJ				Li, YP; Schwartz, RJ			TNF-alpha regulates early differentiation of C2C12 myoblasts in an autocrine fashion	FASEB JOURNAL			English	Article						cytokine; myogenesis; NF-kappa B; SRF; MHCf; alpha-actin	TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; SERUM RESPONSE FACTOR; NITRIC-OXIDE SYNTHASE; C-FOS GENE; SKELETAL-MUSCLE; ACTIN GENE; BINDING-SITE; TRANSCRIPTIONAL REGULATION; MYOGENIC DIFFERENTIATION	Tumor necrosis factor-alpha (TNF-alpha) has long been known to mediate skeletal muscle protein catabolism as a humoral factor. However, recent findings that muscle normally synthesizes TNF-alpha and that strenuous exercise increases circulating TNF-alpha in healthy individuals raised the possibility that this cytokine may also have a physiological role in skeletal muscle. In this study, we observed a basal level of TNF-alpha expression in C2C12 myoblasts that was markedly up-regulated by serum restriction. Serum restriction also increased nuclear factor-kappaB (NF-kappaB) activity, which could be blocked by a TNF-alpha-neutralizing antibody. This antibody also inhibited the expression of a differentiation marker, adult fast myosin heavy chain, during the initial 24 h of serum restriction. Conversely, fast myosin heavy chain expression was stimulated by exogenous TNF-alpha during the same time period, which could be blocked by a dominant negative inhibitor of NF-kappaB activation. TNF-alpha rapidly stimulated the binding activity of serum response factor (SRF), a transcription factor required for myoblast differentiation, and expression of the SRF-dependent skeletal muscle alpha-actin gene. These results demonstrate for the first time that TNT-alpha is an endogenous muscle factor that promotes the early phase of differentiation by stimulating NF-kappaB and SRF activity.	Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cell Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Li, YP (corresponding author), Baylor Coll Med, Dept Med, Suite 520B,1 Baylor Plaza, Houston, TX 77030 USA.	yiping@bcm.tmc.edu						BAINS W, 1984, MOL CELL BIOL, V4, P1449, DOI 10.1128/MCB.4.8.1449; Belaguli NS, 1997, J BIOL CHEM, V272, P18222, DOI 10.1074/jbc.272.29.18222; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; CAMPION DR, 1984, INT REV CYTOL, V87, P225, DOI 10.1016/S0074-7696(08)62444-4; Camus G, 1998, EUR J APPL PHYSIOL O, V79, P62, DOI 10.1007/s004210050474; Chambers R L, 1996, Can J Appl Physiol, V21, P155; Chen CY, 1996, DEV GENET, V19, P119, DOI 10.1002/(SICI)1520-6408(1996)19:2<119::AID-DVG3>3.0.CO;2-C; Croissant JD, 1996, DEV BIOL, V177, P250, DOI 10.1006/dbio.1996.0160; ERNST H, 1991, MOL CELL BIOL, V11, P3735, DOI 10.1128/MCB.11.7.3735; ESPAT NJ, 1994, SURG ONCOL, V3, P255, DOI 10.1016/0960-7404(94)90027-2; Fahey T J 3rd, 1990, Cytokine, V2, P92, DOI 10.1016/1043-4666(90)90002-B; GARCIAMARTINEZ C, 1993, FEBS LETT, V323, P211, DOI 10.1016/0014-5793(93)81341-V; GarciaMartinez C, 1995, BIOCHEM BIOPH RES CO, V217, P839, DOI 10.1006/bbrc.1995.2848; GAUTHIERROUVIERE C, 1991, CELL REGUL, V2, P575, DOI 10.1091/mbc.2.7.575; GILGENKRANTZ H, 1992, J BIOL CHEM, V267, P10823; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Heck S, 1999, J BIOL CHEM, V274, P9828, DOI 10.1074/jbc.274.14.9828; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HU MCT, 1986, MOL CELL BIOL, V6, P15, DOI 10.1128/MCB.6.1.15; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; JOHANSEN FE, 1995, BBA-REV CANCER, V1242, P1, DOI 10.1016/0304-419X(94)00014-S; Kaliman P, 1999, J BIOL CHEM, V274, P17437, DOI 10.1074/jbc.274.25.17437; Kim SS, 1998, FEBS LETT, V433, P47, DOI 10.1016/S0014-5793(98)00883-7; Layne MD, 1999, EXP CELL RES, V249, P177, DOI 10.1006/excr.1999.4465; Lee KH, 1997, BIOCHEM J, V324, P237, DOI 10.1042/bj3240237; Li YP, 1999, ANTIOXID REDOX SIGN, V1, P97, DOI 10.1089/ars.1999.1.1-97; Li YP, 2000, AM J PHYSIOL-REG I, V279, pR1165, DOI 10.1152/ajpregu.2000.279.4.R1165; Li YP, 1998, FASEB J, V12, P871, DOI 10.1096/fasebj.12.10.871; LIN JX, 1987, J BIOL CHEM, V262, P11908; LIU YC, 1990, BIOTECHNIQUES, V9, P558; Llovera M, 1997, BIOCHEM BIOPH RES CO, V230, P238, DOI 10.1006/bbrc.1996.5827; MacLachlan TK, 1998, J CELL BIOCHEM, V71, P461, DOI 10.1002/(SICI)1097-4644(19981215)71:4<461::AID-JCB1>3.0.CO;2-0; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; MILLER SC, 1988, MOL CELL BIOL, V8, P2295, DOI 10.1128/MCB.8.6.2295; MIWA T, 1987, MOL CELL BIOL, V7, P2803, DOI 10.1128/MCB.7.8.2803; Munoz C, 1996, BLOOD, V88, P3482, DOI 10.1182/blood.V88.9.3482.bloodjournal8893482; MUSCAT GEO, 1987, MOL CELL BIOL, V7, P4089, DOI 10.1128/MCB.7.11.4089; NAKASHIMA J, 1995, CANCER RES, V55, P4881; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; Ostrowski K, 1999, J PHYSIOL-LONDON, V515, P287, DOI 10.1111/j.1469-7793.1999.287ad.x; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; Saghizadeh M, 1996, J CLIN INVEST, V97, P1111, DOI 10.1172/JCI118504; SCHULTZ E, 1994, REV PHYSIOL BIOCH P, V123, P213, DOI 10.1007/BFb0030904; SCHUTZE S, 1988, J IMMUNOL, V140, P3000; Sen CK, 1997, BIOCHEM BIOPH RES CO, V237, P645, DOI 10.1006/bbrc.1997.7206; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; Solomon V, 1996, J BIOL CHEM, V271, P26690, DOI 10.1074/jbc.271.43.26690; Soulez M, 1996, MOL CELL BIOL, V16, P6065; SPRIGGS DRD, 1992, TUMOR NECROSIS FACTO; Thaloor D, 1999, AM J PHYSIOL-CELL PH, V277, pC320, DOI 10.1152/ajpcell.1999.277.2.C320; TRACEY KJ, 1989, LANCET, V1, P1122; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VANDROMME M, 1992, J CELL BIOL, V118, P1489, DOI 10.1083/jcb.118.6.1489; VANLINT J, 1992, J BIOL CHEM, V267, P25916; VREUGDENHIL G, 1992, EUR J CLIN INVEST, V22, P488, DOI 10.1111/j.1365-2362.1992.tb01495.x; Yokoyama T, 1997, CIRCULATION, V95, P1247	63	78	83	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 27	2001	15	6					1413	+		10.1096/fj.00-0632fje	http://dx.doi.org/10.1096/fj.00-0632fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387241				2022-12-25	WOS:000173705800027
J	Lindquist, JA; Hammerling, GJ; Trowsdale, J				Lindquist, JA; Hammerling, GJ; Trowsdale, J			ER60/ERp57 forms disulfide-bonded intermediates with MHC class I heavy chain	FASEB JOURNAL			English	Article						antigen presentation; chaperones; disulfide bond formation; endoplasmic reticulum; protein assembly	MAJOR HISTOCOMPATIBILITY COMPLEX; THIOL-DEPENDENT REDUCTASE; LIVER ENDOPLASMIC-RETICULUM; NEWLY SYNTHESIZED PROTEINS; PHOSPHOLIPASE-C-ALPHA; NEGATIVE CELL-LINE; PEPTIDE-BINDING; ER-60 PROTEASE; GLYCOPROTEIN GLUCOSYLTRANSFERASE; ANTIGEN PRESENTATION	We demonstrated previously that ER60/ERp57 is recruited into early folding intermediates in the MHC class I assembly pathway (1). ER60 binding preceded the binding of beta-2-microglobulin and was dependent on the presence of properly trimmed oligosaccharide moieties on the class I heavy chain (HC). Hence, this interaction could not be temporally differentiated from that of calnexin. Here, we show that calnexin is required for the recruitment of ER60 into early folding complexes with the HC and that in the absence of calnexin, ER60 is replaced by another member of the thiol-reductase family, ERp72. We demonstrate that once recruited, ER60 associates covalently with HC via a disulfide bond. The ER60/HC complexes were also found in late assembly complexes, noncovalently bound to the transporter associated with antigen processing and accounted for approximately one-third of the ER60 associated with the transporter associated with antigen processing. These results demonstrate that ER60 assists in the creation of conserved disulfide bonds within the class I HC through the formation of a mixed disulfide intermediate.	Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England; German Canc Res Ctr, Dept Mol Immunol, D-69120 Heidelberg, Germany	University of Cambridge; Helmholtz Association; German Cancer Research Center (DKFZ)	Lindquist, JA (corresponding author), Univ Cambridge, Dept Pathol, Tennis Court Rd, Cambridge CB2 1QP, England.	JL255@mole.bio.cam.ac.uk	Lindquist, Jonathan/AAB-8526-2021	Lindquist, Jonathan/0000-0001-6846-5056				Allen RL, 1999, J IMMUNOL, V162, P5045; Bangia N, 1999, EUR J IMMUNOL, V29, P1858, DOI 10.1002/(SICI)1521-4141(199906)29:06<1858::AID-IMMU1858>3.0.CO;2-C; BARDWELL JCA, 1993, CELL, V74, P769, DOI 10.1016/0092-8674(93)90455-Y; Barnden MJ, 2000, J IMMUNOL, V165, P322, DOI 10.4049/jimmunol.165.1.322; BJORKMAN PJ, 1985, J MOL BIOL, V186, P205, DOI 10.1016/0022-2836(85)90271-2; BUSHKIN Y, 1986, P NATL ACAD SCI USA, V83, P432, DOI 10.1073/pnas.83.2.432; CARRENO BM, 1995, J IMMUNOL, V154, P5173; CELIS JE, 1993, ELECTROPHORESIS, V14, pU1091, DOI 10.1002/elps.11501401178; Coligan JKA, 1991, CURRENT PROTOCOLS IM; Corbett EF, 1999, J BIOL CHEM, V274, P6203, DOI 10.1074/jbc.274.10.6203; Cresswell P, 1999, IMMUNOL RES, V19, P191, DOI 10.1007/BF02786487; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; Edwards JCW, 2000, IMMUNOL TODAY, V21, P256, DOI 10.1016/S0167-5699(00)01625-X; Farmery MR, 2000, J BIOL CHEM, V275, P14933, DOI 10.1074/jbc.275.20.14933; Fremont DH, 1996, SCIENCE, V272, P1001, DOI 10.1126/science.272.5264.1001; GARBI N, 2000, IN PRESS NATURE IMMU; GREENWOOD R, 1994, J IMMUNOL, V153, P5525; Halaby DM, 1999, PROTEIN ENG, V12, P563, DOI 10.1093/protein/12.7.563; HIRANO N, 1995, EUR J BIOCHEM, V234, P336, DOI 10.1111/j.1432-1033.1995.336_c.x; HUBBARD SC, 1979, J BIOL CHEM, V254, P4568; Hughes EA, 1998, CURR BIOL, V8, P709, DOI 10.1016/S0960-9822(98)70278-7; Hughes EA, 1997, P NATL ACAD SCI USA, V94, P1896, DOI 10.1073/pnas.94.5.1896; Huppa JB, 1998, CELL, V92, P145, DOI 10.1016/S0092-8674(00)80907-1; KOOPMANN JO, UNPUB; LAEMLLI VK, 1970, NATURE, V227, P68; Lehner PJ, 1998, IMMUNITY, V8, P221, DOI 10.1016/S1074-7613(00)80474-4; Lewis JW, 1998, EUR J IMMUNOL, V28, P3214, DOI 10.1002/(SICI)1521-4141(199810)28:10<3214::AID-IMMU3214>3.3.CO;2-3; Lewis JW, 1998, CURR BIOL, V8, P717, DOI 10.1016/S0960-9822(98)70280-5; Lindquist JA, 1998, EMBO J, V17, P2186, DOI 10.1093/emboj/17.8.2186; Lobigs M, 2000, EUR J IMMUNOL, V30, P1496, DOI 10.1002/(SICI)1521-4141(200005)30:5<1496::AID-IMMU1496>3.0.CO;2-6; MERRICK BA, 1993, BIOCHEM ARCH, V9, P335; MIYAZAKI JI, 1986, P NATL ACAD SCI USA, V83, P757, DOI 10.1073/pnas.83.3.757; Molinari M, 1999, NATURE, V402, P90, DOI 10.1038/47062; Morrice NA, 1998, CURR BIOL, V8, P713, DOI 10.1016/S0960-9822(98)70279-9; MURTHY MSR, 1994, BIOCHEM J, V304, P31, DOI 10.1042/bj3040031; NEEFJES JJ, 1986, IMMUNOGENETICS, V23, P164, DOI 10.1007/BF00373817; Neisig A, 1996, J IMMUNOL, V156, P3196; NOSSNER E, 1995, J EXP MED, V181, P327, DOI 10.1084/jem.181.1.327; Oliver JD, 1999, MOL BIOL CELL, V10, P2573, DOI 10.1091/mbc.10.8.2573; OTSU M, 1995, J BIOL CHEM, V270, P14958, DOI 10.1074/jbc.270.25.14958; Paz P, 1999, IMMUNITY, V11, P241, DOI 10.1016/S1074-7613(00)80099-0; Reits EAJ, 2000, NATURE, V404, P774, DOI 10.1038/35008103; RIBAUDO RK, 1992, J IMMUNOL, V149, P2935; Rigney E, 1998, J BIOL CHEM, V273, P14200, DOI 10.1074/jbc.273.23.14200; Ritter C, 2000, NAT STRUCT BIOL, V7, P278; ROELSE J, 1994, J EXP MED, V180, P1591, DOI 10.1084/jem.180.5.1591; Sadasivan B, 1996, IMMUNITY, V5, P103, DOI 10.1016/S1074-7613(00)80487-2; Sadasivan BK, 1995, COLD SPRING HARB SYM, V60, P267, DOI 10.1101/SQB.1995.060.01.031; SCHAIFF WT, 1992, J EXP MED, V176, P657, DOI 10.1084/jem.176.3.657; Schoenhals GJ, 1999, EMBO J, V18, P743, DOI 10.1093/emboj/18.3.743; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; SCOTT JE, 1995, J IMMUNOL, V155, P143; SMITH JD, 1995, MOL IMMUNOL, V32, P531, DOI 10.1016/0161-5890(95)00013-5; SNYDER HL, 1994, J EXP MED, V180, P2389, DOI 10.1084/jem.180.6.2389; SOUSA M, 1995, EMBO J, V14, P4196, DOI 10.1002/j.1460-2075.1995.tb00093.x; Spee P, 1999, BIOCHEMISTRY-US, V38, P10559, DOI 10.1021/bi990321r; SRIVASTAVA SP, 1991, J BIOL CHEM, V266, P20337; STAM NJ, 1986, J IMMUNOL, V137, P2299; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; TECTOR M, 1995, J BIOL CHEM, V270, P19638, DOI 10.1074/jbc.270.33.19638; Tector M, 1997, MOL IMMUNOL, V34, P401, DOI 10.1016/S0161-5890(97)00045-X; Tortorella D, 1998, J CELL BIOL, V142, P365, DOI 10.1083/jcb.142.2.365; URADE R, 1992, J BIOL CHEM, V267, P15152; URADE R, 1992, FEBS LETT, V312, P83, DOI 10.1016/0014-5793(92)81415-I; URADE R, 1993, J BIOL CHEM, V268, P22004; Urade R, 1997, J BIOCHEM-TOKYO, V122, P834; WARBURTON RJ, 1994, HUM IMMUNOL, V39, P261, DOI 10.1016/0198-8859(94)90269-0; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; Zapun A, 1998, J BIOL CHEM, V273, P6009, DOI 10.1074/jbc.273.11.6009; Zhang Q, 1998, J IMMUNOL, V160, P831; ZHANG WG, 1992, P NATL ACAD SCI USA, V89, P8403, DOI 10.1073/pnas.89.17.8403	73	62	64	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 27	2001	15	6					1448	+		10.1096/fj.00-0720fje	http://dx.doi.org/10.1096/fj.00-0720fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387253				2022-12-25	WOS:000173705800016
J	Ren, Q; Thony-Meyer, L				Ren, Q; Thony-Meyer, L			Physical interaction of CcmC with heme and the heme chaperone CcmE during cytochrome c maturation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; PARACOCCUS-DENITRIFICANS; MUTATIONAL ANALYSIS; BIOGENESIS; PROTEIN; PATHWAY; PERIPLASM; BACTERIA; CHLOROPLASTS; RECEPTOR	Biogenesis of c-type cytochromes requires the covalent attachment of heme to the apoprotein. In Escherichia coli, this process involves eight membrane proteins encoded by the cemABCDEFGH operon. CcmE binds heme covalently and transfers it to apocytochromes c in the presence of other Cem proteins. CcmC is necessary and sufficient to incorporate heme into CcmE. Here, we report that the CcmC protein directly interacts with heme. We further show that CcmC coimmunoprecipitates with CcmE. CcmC contains two conserved histidines and a signature sequence, the so-called tryptophan-rich motif, which is the only element common to cytochrome c maturation proteins of bacteria, archae, plant mitochondria, and chloroplasts. We report that mutational changes of these motifs affecting the function of CcmC in cytochrome c maturation do not influence heme binding of CcmC. However, the mutants are defective in the CcmC-CcmE interaction, suggesting that these motifs are involved in the formation of a CcmC-CcmE complex. We propose that CcmC, CcmE, and heme interact directly with each other, establishing a periplasmic heme delivery pathway for cytochrome c maturation.	ETH, Inst Mikrobiol, CH-8092 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Thony-Meyer, L (corresponding author), ETH, Inst Mikrobiol, Schmelzbergstr 7, CH-8092 Zurich, Switzerland.		Ren, Qun/A-3532-2016	Ren, Qun/0000-0003-0627-761X				Bracken CS, 1999, J BACTERIOL, V181, P6063, DOI 10.1128/JB.181.19.6063-6072.1999; Cook GM, 2000, MICROBIOL-SGM, V146, P527, DOI 10.1099/00221287-146-2-527; Dickerson R E., 1983, HEMOGLOBIN STRUCTURE, P19; Fabianek RA, 1999, ARCH MICROBIOL, V171, P92, DOI 10.1007/s002030050683; Fabianek RA, 1998, J BACTERIOL, V180, P1947, DOI 10.1128/JB.180.7.1947-1950.1998; Gaballa A, 1998, MOL MICROBIOL, V30, P547, DOI 10.1046/j.1365-2958.1998.01085.x; Gaballa A, 1996, MOL MICROBIOL, V21, P777, DOI 10.1046/j.1365-2958.1996.391399.x; Ghigo JM, 1997, J BACTERIOL, V179, P3572, DOI 10.1128/jb.179.11.3572-3579.1997; Goldman BS, 1998, P NATL ACAD SCI USA, V95, P5003, DOI 10.1073/pnas.95.9.5003; Grove J, 1996, MOL MICROBIOL, V19, P467, DOI 10.1046/j.1365-2958.1996.383914.x; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; IOBBINIVOL C, 1994, FEMS MICROBIOL LETT, V119, P89, DOI 10.1016/0378-1097(94)90397-2; Kranz R, 1998, MOL MICROBIOL, V29, P383, DOI 10.1046/j.1365-2958.1998.00869.x; Letoffe S, 1999, MOL MICROBIOL, V33, P546, DOI 10.1046/j.1365-2958.1999.01499.x; Miller J. H., 1992, LAB MANUAL HDB ESCHE; OHALLORAN TV, 1993, SCIENCE, V261, P715, DOI 10.1126/science.8342038; Page MD, 1997, MICROBIOL-SGM, V143, P563, DOI 10.1099/00221287-143-2-563; Page MD, 1998, TRENDS BIOCHEM SCI, V23, P103, DOI 10.1016/S0968-0004(98)01173-6; PAGE MD, 1990, MOL MICROBIOL, V4, P1181, DOI 10.1111/j.1365-2958.1990.tb00693.x; Page MD, 1999, MICROBIOL-UK, V145, P3047, DOI 10.1099/00221287-145-11-3047; Schulz H, 1998, SCIENCE, V281, P1197, DOI 10.1126/science.281.5380.1197; Schulz H, 1999, P NATL ACAD SCI USA, V96, P6462, DOI 10.1073/pnas.96.11.6462; Schulz H, 2000, MOL MICROBIOL, V37, P1379, DOI 10.1046/j.1365-2958.2000.02083.x; Thony-Meyer L, 2000, BBA-BIOENERGETICS, V1459, P316, DOI 10.1016/S0005-2728(00)00167-5; THONYMEYER L, 1995, J BACTERIOL, V177, P4321; ThonyMeyer L, 1997, MICROBIOL MOL BIOL R, V61, P337; THONYMEYER L, 1994, MOL MICROBIOL, V12, P1, DOI 10.1111/j.1365-2958.1994.tb00988.x; ThonyMeyer L, 1997, EUR J BIOCHEM, V246, P794, DOI 10.1111/j.1432-1033.1997.t01-1-00794.x; ThroneHolst M, 1997, FEBS LETT, V410, P351, DOI 10.1016/S0014-5793(97)00656-X; Xie ZY, 1998, BBA-BIOENERGETICS, V1365, P309, DOI 10.1016/S0005-2728(98)00085-1	30	59	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32591	32596		10.1074/jbc.M103058200	http://dx.doi.org/10.1074/jbc.M103058200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11384983	hybrid			2022-12-25	WOS:000170746000030
J	Hama, T; Maruyama, M; Katoh-Semba, R; Takizawa, M; Iwashima, M; Nara, K				Hama, T; Maruyama, M; Katoh-Semba, R; Takizawa, M; Iwashima, M; Nara, K			Identification and molecular cloning of a novel brain-specific receptor protein that binds to brain injury-derived neurotrophic peptide - Possible role for neuronal survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONOTROPHIC ACTIVITY; MESSENGER-RNA; RAT-BRAIN; LIMBIC SEIZURES; EXPRESSION; DEATH; ANTIBIOTICS; EXTRACTION; SEQUENCE; INCREASE	Brain injury-derived neurotrophic peptide (BIN-P) is a synthetic 13-mer peptide that supports neuronal survival and protects hippocampal neurons in primary cultures from cell death caused by glutamate. We have developed a monoclonal antibody named mAb 6A22 against the 40-kDa BINP-binding protein, p40BBP. mAb 6A22 inhibits binding between BINP and rat brain synaptosomes and abolishes the protective effect of BINP. The antigen of mAb 6A22 should be the BINP-binding protein that mediates the neuroprotective action of BINP. Using an expression cloning approach with mAb 6A22, we isolated a cDNA encoding a novel receptor protein that shows binding activity of BINP. COS7 cells transfected with the cloned cDNA show binding of BIN-P and cell surfaces that are stained by 6A22. The mRNA for p40BBP is specific for the rat brain and is increased after birth. From immunohistochemical studies using mAb 6A22, p40BBP increased after kainic acid treatment in rat hippocampal neurons.	Mitsubishi Kagaku Inst Life Sci, Machida, Tokyo 1948511, Japan; Inst Dev Res, Aichi Human Serv Ctr, Kasugai, Aichi 4800392, Japan; Natl Inst Infect Dis, Dept Immunol, Shinjuku Ku, Tokyo 1628640, Japan	Mitsubishi Kagaku Institute of Life Sciences (MITILS); National Institute of Infectious Diseases (NIID)	Hama, T (corresponding author), Mitsubishi Kagaku Inst Life Sci, 11 Minamiooya, Machida, Tokyo 1948511, Japan.	hama@libra.ls.m-kagaku.co.jp						AEBI R, 1989, ZOOTECNICA INT, V3, P31; ATTWOOD TK, 1994, PROTEIN ENG, V7, P841, DOI 10.1093/protein/7.7.841; Attwood TK, 1999, NUCLEIC ACIDS RES, V27, P220, DOI 10.1093/nar/27.1.220; Bamji SX, 1998, J CELL BIOL, V140, P911, DOI 10.1083/jcb.140.4.911; Barrett GL, 2000, PROG NEUROBIOL, V61, P205, DOI 10.1016/S0301-0082(99)00056-8; BERGER J, 1951, J AM CHEM SOC, V73, P5295, DOI 10.1021/ja01155a084; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.neuro.18.1.223; Casaccia-Bonnefil P, 1999, MICROSC RES TECHNIQ, V45, P217, DOI 10.1002/(SICI)1097-0029(19990515/01)45:4/5<217::AID-JEMT5>3.0.CO;2-5; Casaccia-Bonnefil P, 1998, CELL DEATH DIFFER, V5, P357, DOI 10.1038/sj.cdd.4400377; Dechant G, 1997, CURR OPIN NEUROBIOL, V7, P413, DOI 10.1016/S0959-4388(97)80071-2; FARDE JM, 1993, BIOESSAYS, V20, P137; Friedman WJ, 2000, J NEUROSCI, V20, P6340, DOI 10.1523/JNEUROSCI.20-17-06340.2000; GALL CM, 1989, SCIENCE, V245, P758, DOI 10.1126/science.2549634; Grewal SS, 1999, CURR OPIN NEUROBIOL, V9, P544, DOI 10.1016/S0959-4388(99)00010-0; HAMA T, 1995, J BIOL CHEM, V270, P29067, DOI 10.1074/jbc.270.49.29067; Hama T, 2000, NEUROSCIENCE, V98, P567, DOI 10.1016/S0306-4522(00)00136-6; HEFTI F, 1994, J NEUROBIOL, V25, P1418, DOI 10.1002/neu.480251109; HIGASHIDA H, 1981, BRAIN RES, V214, P287, DOI 10.1016/0006-8993(81)91195-1; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; IP NY, 1993, EUR J NEUROSCI, V5, P25, DOI 10.1111/j.1460-9568.1993.tb00201.x; ISACKSON PJ, 1991, NEURON, V6, P937, DOI 10.1016/0896-6273(91)90234-Q; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; Kato K, 1999, J NEUROCHEM, V73, P229, DOI 10.1046/j.1471-4159.1999.0730229.x; Kihara D, 1998, PROTEIN ENG, V11, P961, DOI 10.1093/protein/11.11.961; MACDERMOT J, 1979, P NATL ACAD SCI USA, V76, P1135, DOI 10.1073/pnas.76.3.1135; Majdan M, 1999, INT J DEV NEUROSCI, V17, P153, DOI 10.1016/S0736-5748(99)00016-7; MANTHORPE M, 1983, BRAIN RES, V267, P47, DOI 10.1016/0006-8993(83)91038-7; Maruyama M, 1999, NEUROSCIENCE, V89, P149, DOI 10.1016/S0306-4522(98)00297-8; NARA K, 1994, P NATL ACAD SCI USA, V91, P7952, DOI 10.1073/pnas.91.17.7952; NIETOSAMPEDRO M, 1982, SCIENCE, V217, P860, DOI 10.1126/science.7100931; NIETOSAMPEDRO M, 1983, J NEUROSCI, V3, P2219; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; REED PW, 1982, POLYETHER ANTIBIOTIC, V1, P185; SAFRAN N, 1993, TOXICOL IN VITRO, V7, P345, DOI 10.1016/0887-2333(93)90026-2; Safran N, 1996, NEUROTOXICOLOGY, V17, P883; Takahashi M, 2000, MOL PSYCHIATR, V5, P293, DOI 10.1038/sj.mp.4000718; TAMATANI T, 1993, EUR J IMMUNOL, V23, P2181, DOI 10.1002/eji.1830230920; TCHELINGERIAN JL, 1993, NEURON, V10, P213, DOI 10.1016/0896-6273(93)90312-F; WALLACE JC, 1992, COMPUT APPL BIOSCI, V8, P249; WATANABE T, 1992, BIOCHIM BIOPHYS ACTA, V1131, P321, DOI 10.1016/0167-4781(92)90033-V; Westley J W, 1977, Adv Appl Microbiol, V22, P177, DOI 10.1016/S0065-2164(08)70163-1; Yoon SO, 1998, J NEUROSCI, V18, P3273	42	7	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31929	31935		10.1074/jbc.M100617200	http://dx.doi.org/10.1074/jbc.M100617200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11399754	hybrid			2022-12-25	WOS:000170613500064
J	Cheng, JJ; Wung, BS; Chao, YJ; Wang, DL				Cheng, JJ; Wung, BS; Chao, YJ; Wang, DL			Sequential activation of protein kinase C (PKC)-alpha and PKC-epsilon contributes to sustained Raf/ERK1/2 activation in endothelial cells under mechanical strain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHESION MOLECULE-1 EXPRESSION; SIGNAL-REGULATED KINASE; EPIDERMAL GROWTH-FACTOR; SHEAR-STRESS; GENE-EXPRESSION; TRANSLOCATION; RAF-1; ALPHA; DIACYLGLYCEROL; TRANSDUCTION	Endothelial cells (ECs) are constantly subjected to hemodynamic forces including cyclic pressure-induced strain. The role of protein kinase C (PKC) in cyclic strain-treated ECs was studied. PKC activities were induced as cyclic strain was initiated. Cyclic strain to ECs caused activation of PKC-alpha and -epsilon. The translocation of PKC-a and -e but not PKC-beta from the cytosolic to membrane fraction was observed. An early transient activation of PKC-a versus a late but sustained activation of PKC-E was shown after the onset of cyclic strain. Consistently, a sequential association of PKC-alpha and -epsilon with the signaling molecule Raf-1 was shown. ECs treated with a PKC inhibitor (calphostin C) abolished the cyclic strain-induced Raf-1 activation. ECs under cyclic strain induced a sustained activation of extracellular signal-regulated protein kinases (ERK1/2), which was inhibited by treating ECs with calphostin C. ECs treated with a specific Ca2+-dependent PKC inhibitor (Go 6976) showed an inhibition in the early phase of ERK1/2 activation but not in the late and sustained phase. ECs transfected with the antisense to PKC-a, the antisense to PKC-epsilon, or the inhibition peptide to PKC-c reduced strain-induced ERK1/2 phosphorylation in a temporal manner. PKC-a mediated mainly the early ERK1/2 activation, whereas PKC-e was involved in the sustained ERK1/2 activation. Strained ECs increased transcriptional activity of Elk1 (an ERK1/2 substrate). ECs transfected with the antisense to each PKC isoform reduced Elk1 and monocyte chemotactic protein-1 promotor activity. Our findings conclude that a sequential activation of PKC isoforin (alpha and epsilon contribute to Raf/ERK1/2 activation, and PKC-epsilon appears to play a key role in endothelial adaptation to hemodynamic environment.	Acad Sinica, Inst Biomed Sci, Div Cardiovasc, Taipei 11529, Taiwan	Academia Sinica - Taiwan	Wang, DL (corresponding author), Acad Sinica, Inst Biomed Sci, Div Cardiovasc, Taipei 11529, Taiwan.	lingwang@ibms.sinica.edu.tw						APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; Bao XP, 1999, ARTERIOSCL THROM VAS, V19, P996, DOI 10.1161/01.ATV.19.4.996; Berk BC, 1999, THROMB HAEMOSTASIS, V82, P810; Berk BC, 1995, J BIOMECH, V28, P1439, DOI 10.1016/0021-9290(95)00092-5; Brodie C, 1999, CELL GROWTH DIFFER, V10, P183; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; Cheng JJ, 1996, HYPERTENSION, V28, P386, DOI 10.1161/01.HYP.28.3.386; Cheng JJ, 1998, HYPERTENSION, V31, P125, DOI 10.1161/01.HYP.31.1.125; Chien S, 1998, HYPERTENSION, V31, P162, DOI 10.1161/01.HYP.31.1.162; Chiu JJ, 1997, ARTERIOSCL THROM VAS, V17, P3570, DOI 10.1161/01.ATV.17.12.3570; DEAN NM, 1994, P NATL ACAD SCI USA, V91, P11762, DOI 10.1073/pnas.91.24.11762; EVANS L, 1997, J PHYSL, V272, pC650; GILBERT JA, 1994, J BIOMECH, V27, P1169, DOI 10.1016/0021-9290(94)90057-4; HA KS, 1993, J BIOL CHEM, V268, P10534; Haller H, 1996, ARTERIOSCL THROM VAS, V16, P678, DOI 10.1161/01.ATV.16.5.678; Hempel A, 1997, CIRC RES, V81, P363, DOI 10.1161/01.RES.81.3.363; Hu YL, 1997, J HISTOCHEM CYTOCHEM, V45, P237, DOI 10.1177/002215549704500209; Ito WD, 1997, CIRC RES, V80, P829; Jalali S, 1998, ARTERIOSCL THROM VAS, V18, P227, DOI 10.1161/01.ATV.18.2.227; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Liang FQ, 2000, HYPERTENSION, V35, P188, DOI 10.1161/01.HYP.35.1.188; Liao DF, 1997, J BIOL CHEM, V272, P6146, DOI 10.1074/jbc.272.10.6146; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; Mills I, 1997, J CELL PHYSIOL, V170, P228, DOI 10.1002/(SICI)1097-4652(199703)170:3<228::AID-JCP2>3.0.CO;2-Q; Morawietz H, 2000, J PHYSIOL-LONDON, V525, P761, DOI 10.1111/j.1469-7793.2000.00761.x; MORITA T, 1994, CIRC RES, V75, P630, DOI 10.1161/01.RES.75.4.630; Neri LM, 1998, J BIOL CHEM, V273, P29738, DOI 10.1074/jbc.273.45.29738; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Rosales OR, 1997, BIOCHEM J, V326, P385, DOI 10.1042/bj3260385; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; Sajan MP, 1999, J BIOL CHEM, V274, P30495, DOI 10.1074/jbc.274.43.30495; Sattler M, 1999, BLOOD, V93, P2928; Schwachtgen JL, 1998, J CLIN INVEST, V101, P2540, DOI 10.1172/JCI1404; SHYY JYJ, 1995, P NATL ACAD SCI USA, V92, P8069, DOI 10.1073/pnas.92.17.8069; Soh JW, 1999, MOL CELL BIOL, V19, P1313; Takahashi M, 1996, J CLIN INVEST, V98, P2623, DOI 10.1172/JCI119083; Takei T, 1997, J CELL BIOCHEM, V67, P327, DOI 10.1002/(SICI)1097-4644(19971201)67:3<327::AID-JCB5>3.0.CO;2-Y; Traub O, 1998, ARTERIOSCL THROM VAS, V18, P677, DOI 10.1161/01.ATV.18.5.677; Traub O, 1997, J BIOL CHEM, V272, P31251, DOI 10.1074/jbc.272.50.31251; Ueffing M, 1997, ONCOGENE, V15, P2921, DOI 10.1038/sj.onc.1201477; WANG DL, 1995, J CELL PHYSIOL, V163, P400, DOI 10.1002/jcp.1041630220; WANG DL, 1995, CIRC RES, V77, P294, DOI 10.1161/01.RES.77.2.294; Ward NE, 1998, J BIOL CHEM, V273, P12558, DOI 10.1074/jbc.273.20.12558; Wung BS, 1996, AM J PHYSIOL-HEART C, V270, pH1462, DOI 10.1152/ajpheart.1996.270.4.H1462; Wung BS, 1997, CIRC RES, V81, P1, DOI 10.1161/01.RES.81.1.1; Wung BS, 1999, CIRC RES, V84, P804; Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006; Yedovitzky M, 1997, J BIOL CHEM, V272, P1417, DOI 10.1074/jbc.272.3.1417; Zou YP, 1998, INT J MOL MED, V1, P827	50	72	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31368	31375		10.1074/jbc.M011317200	http://dx.doi.org/10.1074/jbc.M011317200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11399752	hybrid			2022-12-25	WOS:000170472900101
J	Khatib, AM; Siegfried, G; Prat, A; Luis, J; Chretien, M; Metrakos, P; Seidah, NG				Khatib, AM; Siegfried, G; Prat, A; Luis, J; Chretien, M; Metrakos, P; Seidah, NG			Inhibition of proprotein convertases is associated with loss of growth and tumorigenicity of HT-29 human colon carcinoma cells - Importance of insulin-like growth factor-1 (IGF-1) receptor processing in IGF-1-mediated functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPROTEASE FURIN CONTROLS; HUMAN BREAST-CANCER; FACTOR-I; SECRETORY PATHWAY; MATRIX-METALLOPROTEINASE; STRUCTURAL DETERMINANTS; SIGNAL TRANSDUCTION; ENDOTHELIAL-CELLS; GENE-EXPRESSION; TYROSINE KINASE	Proprotein convertases (PCs) of the subtilisin/kexin family are responsible for the activation of prohormones, protrophic factors, and their receptors. We sought to determine whether loss of PC-mediated activities might affect the malignant phenotypes of cancer cells. Stable transfectants of alpha (1)-antitrypsin Portland (alpha (1)-PDX) cDNA, coding for a potent PC inhibitor, were analyzed in model HT-29 cells (HT-29/PDX) and in other cell lines. Expression of alpha (1)-PDX resulted in a proinsulin-like growth factor-1 receptor (pro-IGF-IR) processing blockade, hence inhibiting the ability of exogenous IGF-1 to induce tyrosine phosphorylation of its beta -subunit and insulin-related substrate-1. Coexpression of IGF-1R with four different PCs or the novel convertase SKI-1 in the furin-defective LoVo-C5 cells demonstrated that pro-IGF-1R (similar to 200 kDa) cleavage into IGF-1R (beta -subunit, similar to 105 kDa) can be achieved by furin and PC5A, but not by PACE4, PC7, or SKI-1. Expression of alpha (1)-PDX resulted in reduction of DNA synthesis and in anchorage-independent growth. Following serum deprivation, the alpha (1)-PDX transfectants exhibited an enhanced apoptotic phenotype and were insensitive to IGF-1-mediated [H-3]thymidine incorporation and protection against apoptosis. These cells showed reduced invasiveness that paralleled decreased mRNA levels of urokinase-type plasminogen activator and its receptor, tissue-type plasminogen activator, and plasminogen activator inhibitor-1. Comparative subcutaneous inoculation of cells in nude mice revealed that animals injected with HT-29/PDX cells exhibited delayed and lower incidence of tumor development as well as reduced tumor size. Immunohistochemical analysis of CD31 antigen expression, a marker of endothelial cells, revealed reduced HT-29/PDX tumor vascularization. These findings indicate that PCs actively contribute to the growth and malignant phenotypes of HT-29 tumors, suggesting that PC inhibition strategies may be a useful adduct to the arsenal of colorectal anticancer gene therapies.	Clin Res Inst Montreal, Biochem Neuroendocrinol Lab, Montreal, PQ H2W 1R7, Canada; Fac Pharm Marseille, Biochim Cellulaire Lab, CNRS UPRESA 6032, F-13385 Marseille 5, France; Ottawa Civic Hosp, Mol Med & Dis Aging Ctr, Loeb Hlth Res Inst, Ottawa, ON K1Y 4K9, Canada; Royal Victoria Hosp, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Surg, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 1A1, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; University of Ottawa; Ottawa Hospital Research Institute; McGill University; Royal Victoria Hospital; McGill University; McGill University	Seidah, NG (corresponding author), Clin Res Inst Montreal, Biochem Neuroendocrinol Lab, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.		KHATIB, Abdel-Majid/A-9948-2015; LUIS, José/M-3071-2013; Siegfried, Géraldine/N-6017-2018; Prat, Annik/S-6757-2018; metrakos, peter/D-3726-2013; Seidah, Nabil/I-3596-2013	KHATIB, Abdel-Majid/0000-0001-6957-0384; Prat, Annik/0000-0002-8007-5277; Seidah, Nabil/0000-0001-6503-9342; siegfried, geraldine/0000-0002-6346-5206; CHRETIEN, Michel/0000-0002-8588-4460				Abrami L, 1998, J BIOL CHEM, V273, P32656, DOI 10.1074/jbc.273.49.32656; Akagi Y, 1998, CANCER RES, V58, P4008; ALARCON C, 1994, BIOCHEM J, V301, P257, DOI 10.1042/bj3010257; ANDERSON ED, 1993, J BIOL CHEM, V268, P24887; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Baserga Renato, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P47; Bassi DE, 2000, MOL CARCINOGEN, V28, P63, DOI 10.1002/1098-2744(200006)28:2<63::AID-MC1>3.3.CO;2-3; Benjannet S, 1997, J BIOL CHEM, V272, P26210, DOI 10.1074/jbc.272.42.26210; Benjannet S, 2001, J BIOL CHEM, V276, P10879, DOI 10.1074/jbc.M009899200; Berthet V, 2000, J BIOL CHEM, V275, P33308, DOI 10.1074/jbc.M004834200; Burfeind P, 1996, P NATL ACAD SCI USA, V93, P7263, DOI 10.1073/pnas.93.14.7263; Campan M, 1996, BIOCHEMISTRY-US, V35, P3797, DOI 10.1021/bi952552d; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; Cheng M, 1997, INT J CANCER, V71, P966, DOI 10.1002/(SICI)1097-0215(19970611)71:6<966::AID-IJC10>3.3.CO;2-A; Cheng M, 2001, J MOL ENDOCRINOL, V26, P95, DOI 10.1677/jme.0.0260095; CHRETIEN M, 1995, P ASSOC AM PHYSICIAN, V107, P47; Cui YZ, 1998, EMBO J, V17, P4735, DOI 10.1093/emboj/17.16.4735; CULOUSCOU JM, 1987, INT J CANCER, V40, P646, DOI 10.1002/ijc.2910400513; Dubois CM, 2001, AM J PATHOL, V158, P305, DOI 10.1016/S0002-9440(10)63970-3; DUBOIS CM, 1995, J BIOL CHEM, V270, P10618, DOI 10.1074/jbc.270.18.10618; Duguay SJ, 1998, J BIOL CHEM, V273, P18443, DOI 10.1074/jbc.273.29.18443; Duguay SJ, 1999, HORM METAB RES, V31, P43, DOI 10.1055/s-2007-978697; Duguay SJ, 1997, J BIOL CHEM, V272, P6663, DOI 10.1074/jbc.272.10.6663; Dunn SE, 2000, MOL CARCINOGEN, V27, P10, DOI 10.1002/(SICI)1098-2744(200001)27:1<10::AID-MC3>3.0.CO;2-Z; Feldser D, 1999, CANCER RES, V59, P3915; GANESH S, 1994, LANCET, V344, P401, DOI 10.1016/S0140-6736(94)91427-3; Gil-Ad I, 1999, GROWTH HORM IGF RES, V9, P458, DOI 10.1054/ghir.1999.0130; Harvey SR, 1999, AM J PATHOL, V155, P1115, DOI 10.1016/S0002-9440(10)65214-5; Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293; Jung YK, 1996, J BIOL CHEM, V271, P5112; Kayo T, 1997, DIABETES, V46, P1296, DOI 10.2337/diabetes.46.8.1296; Kayo T, 1996, J BIOL CHEM, V271, P10731, DOI 10.1074/jbc.271.18.10731; Kimura I, 2000, JPN J PHARMACOL, V83, P47, DOI 10.1254/jjp.83.47; Kinoshita T, 1996, CANCER RES, V56, P2535; Konda Y, 1997, J CLIN INVEST, V99, P1842, DOI 10.1172/JCI119351; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; Kuhn C, 1999, INT J CANCER, V80, P431, DOI 10.1002/(SICI)1097-0215(19990129)80:3<431::AID-IJC16>3.3.CO;2-X; KYRIAZIS AP, 1982, AM J PATHOL, V106, P250; LAHM H, 1994, INT J CANCER, V58, P452, DOI 10.1002/ijc.2910580325; Lebrun P, 1998, J BIOL CHEM, V273, P32244, DOI 10.1074/jbc.273.48.32244; Lehmann M, 1998, ENDOCRINOLOGY, V139, P3763, DOI 10.1210/en.139.9.3763; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; Lissitzky JC, 2000, BIOCHEM J, V346, P133, DOI 10.1042/0264-6021:3460133; LIU B, 1995, INT J CANCER, V63, P276, DOI 10.1002/ijc.2910630222; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; LONG L, 1995, CANCER RES, V55, P1006; Long L, 1998, EXP CELL RES, V238, P116, DOI 10.1006/excr.1997.3814; Lopez-Perez E, 1999, J NEUROCHEM, V73, P2056; Mbikay M, 1997, BRIT J CANCER, V75, P1509, DOI 10.1038/bjc.1997.258; MBIKAY M, 1993, ANN NY ACAD SCI, V680, P13, DOI 10.1111/j.1749-6632.1993.tb19671.x; MCCUE JL, 1991, BRIT J SURG, V78, P921, DOI 10.1002/bjs.1800780808; MIELE C, 1995, J BIOL CHEM, V270, P15844, DOI 10.1074/jbc.270.26.15844; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Parrizas M, 1997, ENDOCRINOLOGY, V138, P1427, DOI 10.1210/en.138.4.1427; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Remacle-Bonnet MM, 2000, CANCER RES, V60, P2007; RODRIGUES CA, 1994, CURR OPIN GENET DEV, V4, P15, DOI 10.1016/0959-437X(94)90086-8; RODRIGUES GA, 1994, ONCOGENE, V9, P2019; Santavicca M, 1996, BIOCHEM J, V315, P953, DOI 10.1042/bj3150953; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; Seidah NG, 1997, CURR OPIN BIOTECH, V8, P602, DOI 10.1016/S0958-1669(97)80036-5; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAKAHASHI S, 1993, BIOCHEM BIOPH RES CO, V195, P1019, DOI 10.1006/bbrc.1993.2146; TRAINER DL, 1988, INT J CANCER, V41, P287, DOI 10.1002/ijc.2910410221; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; VIEAU D, 1994, J CLIN ENDOCR METAB, V79, P1503, DOI 10.1210/jc.79.5.1503; Vollenweider F, 1996, BIOCHEM J, V314, P521, DOI 10.1042/bj3140521; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; WHITE MF, 1997, DIABETOLOGIA, V40, P2; Yana I, 2000, MOL BIOL CELL, V11, P2387, DOI 10.1091/mbc.11.7.2387; Zhong M, 1999, J BIOL CHEM, V274, P33913, DOI 10.1074/jbc.274.48.33913; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745	74	141	147	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30686	30693		10.1074/jbc.M101725200	http://dx.doi.org/10.1074/jbc.M101725200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11402025	hybrid			2022-12-25	WOS:000170472900015
J	Murata, M; Kaji, H; Iida, K; Okimura, Y; Chihara, K				Murata, M; Kaji, H; Iida, K; Okimura, Y; Chihara, K			Dual action of eicosapentaenoic acid in hepatoma cells - Up-regulation of metabolic action of insulin and inhibition of cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3T3-L1 ADIPOCYTES; DIABETES-MELLITUS; GENE-EXPRESSION; DIETARY-FAT; PEPCK GENE; RESISTANCE; LEPTIN; PROTEIN; RATS; LOCALIZATION	Exogenous administration of eicosapentaenoic acid (EPA) improves insulin sensitivity, but its precise mechanism remains unknown. Here we show that EPA stimulates the intracellular insulin signaling pathway in hepatoma cells. Exposure of these cells to EPA caused up-regulation of several insulin-induced activities including tyrosine phosphorylation of insulin receptor substrate-1, insulin receptor substrate-l-associated phosphatidylinositol 3-kinase, and its downstream target Akt kinase activity as well as down-regulation of gluconeogenesis. In contrast, EPA decreased mitogenactivated protein kinase activity and inhibited cell proliferation. These findings raise the possibility that EPA up-regulates metabolic action of insulin and inhibits cell growth in humans.	Kobe Univ, Sch Med, Dept Med, Div 3, Kobe, Hyogo 650017, Japan; Kobe Univ, Sch Med, Dept Basic Allied Med, Kobe, Hyogo 650017, Japan; Coll Nursing Art & Sci, Akashi, Hyogo 6738588, Japan	Kobe University; Kobe University	Murata, M (corresponding author), Kobe Univ, Sch Med, Dept Med, Div 3, 7-5-1 Kusunoki Cho, Kobe, Hyogo 650017, Japan.		Iida, Keiji/ABB-5126-2021	Iida, Keiji/0000-0002-1516-7757				ARAKI E, 1993, DIABETES, V42, P1041, DOI 10.2337/diabetes.42.7.1041; BERRIDGE MV, 1993, ARCH BIOCHEM BIOPHYS, V303, P474, DOI 10.1006/abbi.1993.1311; CARROLL KK, 1986, CANCER, V58, P1818, DOI 10.1002/1097-0142(19861015)58:8+<1818::AID-CNCR2820581406>3.0.CO;2-4; Carroll KK, 1997, CURR OPIN LIPIDOL, V8, P53, DOI 10.1097/00041433-199702000-00011; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; Chen GX, 1996, P NATL ACAD SCI USA, V93, P14795, DOI 10.1073/pnas.93.25.14795; Cohen B, 1996, SCIENCE, V274, P1185, DOI 10.1126/science.274.5290.1185; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; GRANNER D, 1983, NATURE, V305, P549, DOI 10.1038/305549a0; Hawkins M, 1997, J BIOL CHEM, V272, P4889, DOI 10.1074/jbc.272.8.4889; Hawkins M, 1997, J CLIN INVEST, V99, P2173, DOI 10.1172/JCI119390; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Kallen CB, 1996, P NATL ACAD SCI USA, V93, P5793, DOI 10.1073/pnas.93.12.5793; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; Mori Y, 1997, METABOLISM, V46, P1458, DOI 10.1016/S0026-0495(97)90148-7; Murata M, 2000, BIOCHEM BIOPH RES CO, V270, P343, DOI 10.1006/bbrc.2000.2424; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; POPPSNIJDERS C, 1987, DIABETES RES CLIN EX, V4, P141; Rajas F, 2000, DIABETES, V49, P1165, DOI 10.2337/diabetes.49.7.1165; Roden M, 1996, J CLIN INVEST, V97, P2859, DOI 10.1172/JCI118742; Shimomura I, 1999, NATURE, V401, P73, DOI 10.1038/43448; SKOINIK EY, 1993, EMBO J, V12, P1929; STORLIEN LH, 1987, SCIENCE, V237, P885, DOI 10.1126/science.3303333; STORLIEN LH, 1991, DIABETES, V40, P280, DOI 10.2337/diabetes.40.2.280; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; Wang JL, 1998, NATURE, V393, P684, DOI 10.1038/31474; WILLETT WC, 1994, SCIENCE, V264, P532, DOI 10.1126/science.8160011; Willson TM, 1997, CURR OPIN CHEM BIOL, V1, P235, DOI 10.1016/S1367-5931(97)80015-4; XING LP, 1993, MOL ENDOCRINOL, V7, P1484, DOI 10.1210/me.7.11.1484; [No title captured]	32	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31422	31428		10.1074/jbc.M010497200	http://dx.doi.org/10.1074/jbc.M010497200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11390373	hybrid			2022-12-25	WOS:000170472900108
J	Komlosh, A; Momburg, F; Weinschenk, T; Emmerich, N; Schild, H; Nadav, E; Shaked, I; Reiss, Y				Komlosh, A; Momburg, F; Weinschenk, T; Emmerich, N; Schild, H; Nadav, E; Shaked, I; Reiss, Y			A role for a novel luminal endoplasmic reticulum aminopeptidase in final trimming of 26 S proteasome-generated major histocompatability complex class I antigenic peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC-CLASS-I; HISTOCOMPATIBILITY CLASS-I; DISTINCT PROTEOLYTIC PROCESSES; BINDING PEPTIDES; T-CELLS; ORNITHINE DECARBOXYLASE; INHIBITOR LACTACYSTIN; RESTRICTED EPITOPE; PROTEIN SUBSTRATE; SECRETORY PATHWAY	Peptides presented to cytotoxic, T lymphocytes by the class I major histocompatability complex are 8-11 residues long. Although proteasomal activity generates the precise G termini of antigenic epitopes, the mechanism(s) involved in generation of the precise N termini is largely unknown. To investigate the mechanism of N-terminal. peptide processing, we used a cell-free system in which two recombinant ornithine decarboxylase (ODC) constructs, one expressing the native H2-K-b-restricted ovalbumin (ova)-derived epitope SIINFEKL (ODC-ova) and the other expressing the extended epitope LESIINFEKL (ODC-LEova), were targeted to degradation by 26 S proteasomes followed by import into microsomes. We found that the cleavage specificity of the 26 S proteasome was influenced by the N-terminal flank ng amino acids leading to significantly different yields of the final epitope SIINFEKL. Following incubation in the presence of purified 26 S proteasome, ODC-LEova generated largely ESIINFEKL that was efficiently converted to the final epitope SIINFEKL following translocation into microsomes. The conversion of ESIINFEKL to SIINFEKL was strictly dependent on the presence of H2-K-b and was completely inhibited by the metalloaminopeptidase inhibitor 1,10-phenanthroline. Importantly, the converting activity was resistant, to a stringent salt/EDTA wash of the microsomes and was only apparent when transport of TAP, the transporter associated with antigen processing, was facilitated. These results strongly suggest a crucial role for a luminal endoplasmic reticulum-resident metalloaminopeptidase in the N-terminal trimming of major histocompatability complex class I-associated peptides.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel; German Canc Res Ctr, DKFZ, Div Mol Immunol, D-69120 Heidelberg, Germany; Univ Tubingen, Inst Cell Biol, Dept Immunol, D-72076 Tubingen, Germany	Tel Aviv University; Helmholtz Association; German Cancer Research Center (DKFZ); Eberhard Karls University of Tubingen	Reiss, Y (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel.							ANDERSON K, 1991, J EXP MED, V174, P489, DOI 10.1084/jem.174.2.489; Anton LC, 1998, J IMMUNOL, V160, P4859; BACIK I, 1994, J IMMUNOL, V152, P381; Bai AL, 1997, J IMMUNOL, V159, P2139; Ben-Shahar S, 1999, J BIOL CHEM, V274, P21963, DOI 10.1074/jbc.274.31.21963; Benham AM, 1997, J IMMUNOL, V159, P5896; Benham AM, 1998, J IMMUNOL, V161, P83; Beninga J, 1998, J BIOL CHEM, V273, P18734, DOI 10.1074/jbc.273.30.18734; BenShahar S, 1997, J BIOL CHEM, V272, P21060, DOI 10.1074/jbc.272.34.21060; Cerundolo V, 1997, EUR J IMMUNOL, V27, P336, DOI 10.1002/eji.1830270148; Craiu A, 1997, P NATL ACAD SCI USA, V94, P10850, DOI 10.1073/pnas.94.20.10850; EISENLOHR LC, 1992, CELL, V71, P963, DOI 10.1016/0092-8674(92)90392-P; ELLIOTT T, 1995, J EXP MED, V181, P1481, DOI 10.1084/jem.181.4.1481; Emmerich NPN, 2000, J BIOL CHEM, V275, P21140, DOI 10.1074/jbc.M000740200; Geier E, 1999, SCIENCE, V283, P978, DOI 10.1126/science.283.5404.978; Gil-Torregrosa BC, 1998, J EXP MED, V188, P1105, DOI 10.1084/jem.188.6.1105; GRANT EP, 1995, J IMMUNOL, V155, P3750; GRIEM P, 1991, CELL, V65, P633, DOI 10.1016/0092-8674(91)90095-G; HAMMOND SA, 1993, NATURE, V364, P158, DOI 10.1038/364158a0; HARDING CV, 1995, J IMMUNOL, V155, P1767; HENDERSON RA, 1993, P NATL ACAD SCI USA, V90, P10275, DOI 10.1073/pnas.90.21.10275; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; KARTTUNEN J, 1992, P NATL ACAD SCI USA, V89, P6020, DOI 10.1073/pnas.89.13.6020; Kisselev AF, 1999, J BIOL CHEM, V274, P3363, DOI 10.1074/jbc.274.6.3363; Koopmann JO, 2000, IMMUNITY, V13, P117, DOI 10.1016/S1074-7613(00)00013-3; Koopmann JO, 1996, EUR J IMMUNOL, V26, P1720, DOI 10.1002/eji.1830260809; Lauvau G, 1999, J EXP MED, V190, P1227, DOI 10.1084/jem.190.9.1227; Lobigs M, 2000, EUR J IMMUNOL, V30, P1496, DOI 10.1002/(SICI)1521-4141(200005)30:5<1496::AID-IMMU1496>3.0.CO;2-6; Lopez D, 1997, J IMMUNOL, V159, P5769; Lopez D, 2000, J IMMUNOL, V164, P5070, DOI 10.4049/jimmunol.164.10.5070; Luckey CJ, 1998, J IMMUNOL, V161, P112; MICHALEK MT, 1993, NATURE, V363, P552, DOI 10.1038/363552a0; Mo XY, 1999, J IMMUNOL, V163, P5851; Momburg F, 1998, ADV IMMUNOL, V68, P191, DOI 10.1016/S0065-2776(08)60560-X; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; NEEFJES J, 1995, EUR J IMMUNOL, V25, P1133, DOI 10.1002/eji.1830250444; NEISIG A, 1995, J IMMUNOL, V154, P1273; Niedermann G, 1996, P NATL ACAD SCI USA, V93, P8572, DOI 10.1073/pnas.93.16.8572; Niedermann G, 1999, IMMUNOL REV, V172, P29, DOI 10.1111/j.1600-065X.1999.tb01354.x; Nussbaum AK, 1998, P NATL ACAD SCI USA, V95, P12504, DOI 10.1073/pnas.95.21.12504; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; Paz P, 1999, IMMUNITY, V11, P241, DOI 10.1016/S1074-7613(00)80099-0; Perarnau B, 1999, EUR J IMMUNOL, V29, P1243, DOI 10.1002/(SICI)1521-4141(199904)29:04<1243::AID-IMMU1243>3.0.CO;2-A; Porgador A, 1997, IMMUNITY, V6, P715, DOI 10.1016/S1074-7613(00)80447-1; Powers J.C., 1986, PROTEINASE INHIBITOR, P219; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rock KL, 1999, ANNU REV IMMUNOL, V17, P739, DOI 10.1146/annurev.immunol.17.1.739; ROELSE J, 1994, J EXP MED, V180, P1591, DOI 10.1084/jem.180.5.1591; SCHUMACHER TNM, 1994, J EXP MED, V179, P533, DOI 10.1084/jem.179.2.533; SHEPHERD JC, 1993, CELL, V74, P577, DOI 10.1016/0092-8674(93)80058-M; SNYDER HL, 1994, J EXP MED, V180, P2389, DOI 10.1084/jem.180.6.2389; Snyder HL, 1998, EUR J IMMUNOL, V28, P1339; Stoltze L, 2000, NAT IMMUNOL, V1, P413, DOI 10.1038/80852; Stoltze L, 1998, EUR J IMMUNOL, V28, P4029, DOI 10.1002/(SICI)1521-4141(199812)28:12<4029::AID-IMMU4029>3.0.CO;2-N; TOKUNAGA F, 1994, J BIOL CHEM, V269, P17382; TOWNSEND A, 1988, J EXP MED, V168, P1211, DOI 10.1084/jem.168.4.1211; UMEZAWA H, 1982, ANNU REV MICROBIOL, V36, P75, DOI 10.1146/annurev.mi.36.100182.000451; VANENDERT PM, 1995, J EXP MED, V182, P1883, DOI 10.1084/jem.182.6.1883; Verma R, 2000, CELL, V101, P341, DOI 10.1016/S0092-8674(00)80843-0; Vinitsky A, 1997, J IMMUNOL, V159, P554; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Wang Y, 1998, MELANOMA RES, V8, P345, DOI 10.1097/00008390-199808000-00008; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0; Yang B, 1996, J EXP MED, V183, P1545, DOI 10.1084/jem.183.4.1545	66	32	32	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30050	30056		10.1074/jbc.M103177200	http://dx.doi.org/10.1074/jbc.M103177200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11373290	hybrid			2022-12-25	WOS:000170558000060
J	Seet, BT; Barrett, J; Robichaud, J; Shilton, B; Singh, R; McFadden, G				Seet, BT; Barrett, J; Robichaud, J; Shilton, B; Singh, R; McFadden, G			Glycosaminoglycan binding properties of the myxoma virus CC-chemokine inhibitor, M-T1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; HERPES-SIMPLEX VIRUS; T-CELL ADHESION; VACCINIA VIRUS; PROTEIN INTERACTIONS; CHONDROITIN SULFATE; ENDOTHELIAL-CELLS; T1/35KDA FAMILY; RECEPTOR; HOMOLOG	Poxviruses encode a number of secreted virulence factors that function to mitigate or modulate the host immune response. M-T1 is a secreted 43-kDa glycoprotein produced by the myxoma virus, a poxvirus pathogen of rabbits, that binds CC-chemokines with high affinity, blocks binding to their cognate G-protein coupled receptors, and thereby inhibits chemokine-induced leukocyte chemotaxis. The present study indicates that H-TI, but not the related vaccinia virus 35-kDa CC-chemokine-binding protein, can localize to cell surfaces through an interaction with, glycosaminoglycan molecules. In addition to biochemically characterizing the nature of this interaction, we demonstrate that M-TI can also simultaneously interact with CC-chemokines while bound to heparin, suggesting that the binding sites on M-TI for chemokines and heparin are distinct. Furthermore, Using recombinant baculovirus-expressed M-TI truncation and internal deletion mutants, we localize the heparin-binding region of M-TI to the C terminus of the protein, a region that contains a high abundance of basic residues and includes two clusters of basic amino acid residues that. resemble Cardin and Weintraub heparin-binding consensus sequences. The ability of AI-Ti to simultaneously interact with chemokines and glycosaminoglycans may enable M-TI to tether to endothelial. surfaces or extracellular matrix and capture host chemokines that are expressed close to sites of virus infection.	John P Robarts Res Inst, Viral Immunol & Pathogenesis Labs, London, ON N6G 2V4, Canada; Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6A 5C1, Canada; Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	McFadden, G (corresponding author), John P Robarts Res Inst, Viral Immunol & Pathogenesis Labs, 1400 Western Rd,SDRT Rm 133, London, ON N6G 2V4, Canada.		Shilton, Brian H/A-6667-2011					Alcami A, 1998, J IMMUNOL, V160, P624; Ali S, 2000, J BIOL CHEM, V275, P11721, DOI 10.1074/jbc.275.16.11721; BANFIELD BW, 1995, J VIROL, V69, P3290, DOI 10.1128/JVI.69.6.3290-3298.1995; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BOURIN MC, 1993, BIOCHEM J, V289, P313, DOI 10.1042/bj2890313; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUSBY TF, 1995, J BIOL CHEM, V270, P18558, DOI 10.1074/jbc.270.31.18558; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Carfi A, 1999, P NATL ACAD SCI USA, V96, P12379, DOI 10.1073/pnas.96.22.12379; CHRISTOPHER JA, 1998, STRUCTURAL PROPERTIE; Dabbagh K, 2000, J IMMUNOL, V165, P3418, DOI 10.4049/jimmunol.165.6.3418; Damon I, 1998, P NATL ACAD SCI USA, V95, P6403, DOI 10.1073/pnas.95.11.6403; FENNER F, 1965, MYXOMATOSIS; GAO GX, 1995, EMBO J, V14, P2183, DOI 10.1002/j.1460-2075.1995.tb07212.x; Graham KA, 1997, VIROLOGY, V229, P12, DOI 10.1006/viro.1996.8423; GRUENHEID S, 1993, J VIROL, V67, P93, DOI 10.1128/JVI.67.1.93-100.1993; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hileman RE, 1998, BIOESSAYS, V20, P156, DOI 10.1002/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.3.CO;2-#; Hsiao JC, 1999, J VIROL, V73, P8750, DOI 10.1128/JVI.73.10.8750-8761.1999; Hsiao JC, 1998, J VIROL, V72, P8374, DOI 10.1128/JVI.72.10.8374-8379.1998; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim CH, 1999, J LEUKOCYTE BIOL, V65, P6, DOI 10.1002/jlb.65.1.6; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Kuschert GSV, 1999, BIOCHEMISTRY-US, V38, P12959, DOI 10.1021/bi990711d; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lalani AS, 1999, CYTOKINE GROWTH F R, V10, P219, DOI 10.1016/S1359-6101(99)00018-0; Lalani AS, 1999, VIROLOGY, V256, P233, DOI 10.1006/viro.1999.9617; Lalani AS, 1998, VIROLOGY, V250, P173, DOI 10.1006/viro.1998.9340; Lalani AS, 1997, J VIROL, V71, P4356, DOI 10.1128/JVI.71.6.4356-4363.1997; Lin CL, 2000, J VIROL, V74, P3353, DOI 10.1128/JVI.74.7.3353-3365.2000; Liu LY, 2000, J CLIN INVEST, V105, P1613, DOI 10.1172/JCI8934; Lusso P, 2000, VIROLOGY, V273, P228, DOI 10.1006/viro.2000.0443; MANN DM, 1994, J BIOL CHEM, V269, P23661; McFadden G, 1997, BIOCHEM PHARMACOL, V54, P1271, DOI 10.1016/S0006-2952(97)00182-2; Mummery RS, 2000, J IMMUNOL, V165, P5671, DOI 10.4049/jimmunol.165.10.5671; Nash P, 1999, IMMUNOL REV, V168, P103, DOI 10.1111/j.1600-065X.1999.tb01286.x; OPGENORTH A, 1992, J VIROL, V66, P4720, DOI 10.1128/JVI.66.8.4720-4731.1992; PATEL AH, 1990, J GEN VIROL, V71, P2013, DOI 10.1099/0022-1317-71-9-2013; Petersen F, 1998, J IMMUNOL, V161, P4347; Rajarathnam K, 2001, J BIOL CHEM, V276, P4909, DOI 10.1074/jbc.M005085200; REYNOLDS D, 1999, ADV ANIMAL VIROLOGY, P397; RICH RL, 2000, CURR OPIN BIOTECHNOL, V11; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; ROT A, 1993, EUR J IMMUNOL, V23, P303, DOI 10.1002/eji.1830230150; Smith CA, 1997, VIROLOGY, V236, P316, DOI 10.1006/viro.1997.8730; Smith SA, 2000, J VIROL, V74, P5659, DOI 10.1128/JVI.74.12.5659-5666.2000; Smith VP, 2000, J VIROL, V74, P8460, DOI 10.1128/JVI.74.18.8460-8471.2000; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; Tanaka Y, 1996, J EXP MED, V184, P1987, DOI 10.1084/jem.184.5.1987; Tanaka Y, 1998, ARTHRITIS RHEUM-US, V41, P1365, DOI 10.1002/1529-0131(199808)41:8<1365::AID-ART5>3.0.CO;2-W; UPTON C, 1992, SCIENCE, V258, P1369, DOI 10.1126/science.1455233; Ward SG, 1998, BIOCHEM J, V333, P457, DOI 10.1042/bj3330457; Weber KSC, 1999, EUR J IMMUNOL, V29, P700, DOI 10.1002/(SICI)1521-4141(199902)29:02<700::AID-IMMU700>3.0.CO;2-1; WITT DP, 1994, CURR BIOL, V4, P394, DOI 10.1016/S0960-9822(00)00088-9	55	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30504	30513		10.1074/jbc.M011401200	http://dx.doi.org/10.1074/jbc.M011401200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11369757	hybrid			2022-12-25	WOS:000170558000118
J	Camacho, A; Salas, M				Camacho, A; Salas, M			Repression of bacteriophage phi 29 early promoter C2 by viral protein P6 is due to impairment of closed complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBTILIS PHAGE PHI-29; HISTONE-LIKE PROTEIN; RNA-POLYMERASE; ESCHERICHIA-COLI; DNA-REPLICATION; TRANSCRIPTION REGULATION; NUCLEOPROTEIN COMPLEX; INITIATION; SUBUNIT; BINDING	Bacillus subtilis phage phi 29 encodes a very abundant protein, p6, which is a non sequence-specific DNA-binding protein. Protein p6 has the potential to bind cooperatively to the phage genome, forming a nucleoprotein complex in which the DNA adopts a right-handed toroidal conformation winding around a protein core. The formation of this complex at the right end of the phage genome where the early promoter C2 is located affects local topology, which may contribute to the promoter repression, although the underlying molecular mechanism of this repression is not presently known. In this study, we analyzed the effect of the p6 nucleoprotein complex on the formation of transcription complexes at the C2 promoter. The results obtained indicate that the nucleoprotein complex does not occlude promoter C2 to RNA polymerase because both proteins can bind to the same DNA molecule. Protein p6 binds along the fragment including the sequence adjacent to the bound polymerase, altering the structure of the transcriptional complex and affecting specifically the stability of the closed complex. The findings presented might help to answer some of the open questions about the concerted molecular mechanisms of histone-like proteins as transcriptional silencers.	Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Salas, M (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.		Salas, Margarita/J-9873-2014	Salas, Margarita/0000-0001-5939-3441	NIGMS NIH HHS [2R01 GM27242-21] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027242] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adhya S, 1998, COLD SPRING HARB SYM, V63, P1, DOI 10.1101/sqb.1998.63.1; Aki T, 1996, GENES CELLS, V1, P179, DOI 10.1046/j.1365-2443.1996.d01-236.x; BARTHELEMY I, 1989, J VIROL, V63, P460, DOI 10.1128/JVI.63.1.460-462.1989; Buckle M, 1999, J MOL BIOL, V285, P955, DOI 10.1006/jmbi.1998.2391; Camacho A, 2000, J BACTERIOL, V182, P6927, DOI 10.1128/JB.182.24.6927-6932.2000; DERLICA K, 1987, MICROBIOL REV, V51, P301; Elias-Arnanz M, 1999, GENE DEV, V13, P2502, DOI 10.1101/gad.13.19.2502; GUTIERREZ C, 1994, EMBO J, V13, P169; LANZER M, 1988, P NATL ACAD SCI USA, V85, P8973, DOI 10.1073/pnas.85.23.8973; MONSALVE M, 1995, VIROLOGY, V207, P23, DOI 10.1006/viro.1995.1048; PASTRANA R, 1985, NUCLEIC ACIDS RES, V13, P3083, DOI 10.1093/nar/13.9.3083; PRIETO I, 1988, P NATL ACAD SCI USA, V85, P314, DOI 10.1073/pnas.85.2.314; Rine J, 1999, P NATL ACAD SCI USA, V96, P8309, DOI 10.1073/pnas.96.15.8309; Rojo F, 1998, PROG NUCLEIC ACID RE, V60, P29, DOI 10.1016/S0079-6603(08)60888-0; SCHRODER O, 2000, J MOL BIOL, V296, P248; SERRANO M, 1993, J MOL BIOL, V230, P248, DOI 10.1006/jmbi.1993.1140; SERRANO M, 1990, SCIENCE, V248, P1012, DOI 10.1126/science.2111580; SERRANO M, 1989, EMBO J, V8, P1879, DOI 10.1002/j.1460-2075.1989.tb03584.x; SOGO JM, 1979, J MOL BIOL, V127, P411; UEGUCHI C, 1993, EMBO J, V12, P1039, DOI 10.1002/j.1460-2075.1993.tb05745.x	20	14	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28927	28932		10.1074/jbc.M103738200	http://dx.doi.org/10.1074/jbc.M103738200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11384991	hybrid			2022-12-25	WOS:000170346000040
J	Kishi, S; Zhou, XZ; Ziv, Y; Khoo, C; Hill, DE; Shiloh, Y; Lu, KP				Kishi, S; Zhou, XZ; Ziv, Y; Khoo, C; Hill, DE; Shiloh, Y; Lu, KP			Telomeric protein Pin2/TRF1 as an important ATM target in response to double strand DNA breaks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATAXIA-TELANGIECTASIA CELLS; IONIZING-RADIATION; CHROMOSOMAL LOCALIZATION; SACCHAROMYCES-CEREVISIAE; PROLYL ISOMERIZATION; REGULATORY MECHANISM; CYCLE REGULATION; MAMMALIAN-CELLS; DAMAGE RESPONSE; DEFICIENT MICE	ATM mutations are responsible for the genetic disease ataxia-telangiectasia (A-T). ATM encodes a protein kinase that is activated by ionizing radiation-induced double strand DNA breaks. Cells derived from A-T patients show many abnormalities, including accelerated telomere loss and hypersensitivity to ionizing radiation; they enter into mitosis and apoptosis after DNA damage. Pin2 was originally identified as a protein involved in G(2)/M regulation and is almost identical to TRF1, a telomeric protein that negatively regulates telomere elongation. Pin2 and TRF1, probably encoded by the same gene, PIN2/TRF1, are regulated during the cell cycle. Furthermore, up-regulation of Pin2 or TRF1 induces mitotic entry and apoptosis, a phenotype similar to that of A-T cells after DNA damage. These results suggest that ATM may regulate the function of Pin2/TRF1, but their exact relationship remains unknown. Here we show that Pin2/TRF1 coimmunoprecipitated with ATM, and its phosphorylation was increased in an ATM-dependent manner by ionizing DNA damage. Furthermore, activated ATM directly phosphorylated Pin2/TRF1 preferentially on the conserved Ser(219)-Gln site in vitro and in vivo. The biological significance of this phosphorylation is substantiated by functional analyses of the phosphorylation site mutants. Although expression of Pin2 and its mutants has no detectable effect on telomere length in transient transfection, a Pin2 mutant refractory to ATM phosphorylation on Ser(219) potently induces mitotic entry and apoptosis and increases radiation hypersensitivity of A-T cells. In contrast, Pin2 mutants mimicking ATM phosphorylation on Ser(219) completely fail to induce apoptosis and also reduce radiation hypersensitivity of A-T cells. Interestingly, the phenotype of the phosphorylation-mimicking mutants is the same as that which resulted from inhibition of endogenous Pin2/TRF1 in A-T cells by its dominant-negative mutants. These results demonstrate for the first time that ATM interacts with and phosphorylates Pin2/TRF1 and suggest that Pin2/TRF1 may be involved in the cellular response to double strand DNA breaks.	Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Canc Biol Program, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Tel Aviv Univ, Sackler Sch Med, Dept Human Genet & Mol Med, IL-69978 Tel Aviv, Israel; Oncogene Res Prod, Cambridge, MA 02142 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Tel Aviv University; Sackler Faculty of Medicine	Lu, KP (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Canc Biol Program, HIM 1047,330 Brookline Ave, Boston, MA 02215 USA.	klu@Caregroup.Harvard.edu	Hill, David E/B-6617-2011		NIGMS NIH HHS [GM58556, GM56230] Funding Source: Medline; NINDS NIH HHS [NS31763] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056230, R01GM058556] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031763] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; BEAMISH H, 1994, RADIAT RES, V138, pS130, DOI 10.2307/3578780; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Broccoli D, 1997, HUM MOL GENET, V6, P69, DOI 10.1093/hmg/6.1.69; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; Cooper JP, 1997, NATURE, V385, P744, DOI 10.1038/385744a0; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; ELDREDGE ER, 1995, METHOD ENZYMOL, V254, P481; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; Fritz E, 2000, MOL BIOL CELL, V11, P2605, DOI 10.1091/mbc.11.8.2605; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Gilad S, 1996, HUM MOL GENET, V5, P433, DOI 10.1093/hmg/5.4.433; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; Greider CW, 1996, SCI AM, V274, P92, DOI 10.1038/scientificamerican0296-92; Henderson S, 1996, J CELL BIOL, V134, P1, DOI 10.1083/jcb.134.1.1; Hultdin M, 1998, NUCLEIC ACIDS RES, V26, P3651, DOI 10.1093/nar/26.16.3651; Ishibashi T, 1998, P NATL ACAD SCI USA, V95, P4219, DOI 10.1073/pnas.95.8.4219; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kishi S, 2001, ONCOGENE, V20, P1497, DOI 10.1038/sj.onc.1204229; Krauskopf A, 1996, NATURE, V383, P354, DOI 10.1038/383354a0; Lakin ND, 1996, ONCOGENE, V13, P2707; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; Lu K P, 2000, Prog Cell Cycle Res, V4, P83; Lu KP, 1996, NATURE, V380, P544; LU KP, 1995, CELL, V81, P413, DOI 10.1016/0092-8674(95)90394-1; Lu PJ, 1999, NATURE, V399, P784; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Luderus ME, 1996, J CELL BIOL, V135, P867, DOI 10.1083/jcb.135.4.867; Lundblad V, 2000, MUTAT RES-FUND MOL M, V451, P227, DOI 10.1016/S0027-5107(00)00052-X; Marcand S, 1997, SCIENCE, V275, P986, DOI 10.1126/science.275.5302.986; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MCEACHERN MJ, 1995, NATURE, V376, P403, DOI 10.1038/376403a0; Metcalfe JA, 1996, NAT GENET, V13, P350, DOI 10.1038/ng0796-350; Morgan SE, 1997, MOL CELL BIOL, V17, P2020, DOI 10.1128/MCB.17.4.2020; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; PANDITA TK, 1995, CYTOGENET CELL GENET, V71, P86, DOI 10.1159/000134069; PAULES RS, 1995, CANCER RES, V55, P1763; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; RUDOLPH NS, 1989, MUTAT RES, V211, P31, DOI 10.1016/0027-5107(89)90104-8; Rufer N, 1998, NAT BIOTECHNOL, V16, P743, DOI 10.1038/nbt0898-743; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sarkaria JN, 1998, CANCER RES, V58, P4375; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Scherthan H, 1996, J CELL BIOL, V134, P1109, DOI 10.1083/jcb.134.5.1109; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Shen MH, 1997, P NATL ACAD SCI USA, V94, P13618, DOI 10.1073/pnas.94.25.13618; Shen MH, 1998, GENE DEV, V12, P706, DOI 10.1101/gad.12.5.706; Smilenov LB, 1997, ONCOGENE, V15, P2659, DOI 10.1038/sj.onc.1201449; Smilenov LB, 1999, MOL CELL BIOL, V19, P6963; Smilenov LB, 1998, ONCOGENE, V17, P2137, DOI 10.1038/sj.onc.1202138; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Wang JYJ, 1998, CURR OPIN CELL BIOL, V10, P240, DOI 10.1016/S0955-0674(98)80146-4; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Xia SJJ, 1996, MUTAT RES-DNA REPAIR, V364, P1, DOI 10.1016/0921-8777(96)00015-8; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Young AC, 1997, SOMAT CELL MOLEC GEN, V23, P275, DOI 10.1007/BF02674418; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X; ZIV Y, 1989, CANCER RES, V49, P2495; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	78	99	105	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29282	29291		10.1074/jbc.M011534200	http://dx.doi.org/10.1074/jbc.M011534200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11375976	Green Published, hybrid			2022-12-25	WOS:000170346000087
J	Zhou, HJ; Wong, CM; Chen, JH; Qiang, BQ; Yuan, JG; Jin, DY				Zhou, HJ; Wong, CM; Chen, JH; Qiang, BQ; Yuan, JG; Jin, DY			Inhibition of LZIP-mediated transcription through direct interaction with a novel host cell factor-like protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPES-SIMPLEX VIRUS; ACCESSORY FACTOR HCF; HTLV-I TAX; COMPLEX-FORMATION; C1 FACTOR; VP16; FAMILY; ACTIVATION; BINDING; ASSOCIATION	Host cell factor 1 (HCF-1) is a cellular transcriptional coactivator which coordinates the assembly of enhancer complex through direct interactions with viral and cellular trans-activators such as VP16, Oct-1, LZIP, and GA-binding protein. These interactions are mediated by the P-propeller domain comprising the first 380 residues of HCF-1 with six kelch repeats. Here we describe the identification and characterization of a novel HCF-like kelch repeat protein, designated HCLP-1. HCLP-1 is a ubiquitously expressed nuclear protein which is composed almost entirely of a six-bladed P-propeller. HCLP-1 selectively interacts with LZIP but not with VP16. The physical interaction between HCLP-1 and LZIP leads to the repression of the LZIP-dependent transcription. The HCLP-1-binding domain of LZIP maps to residues 109-315, which contain the bZIP DNA-binding motif. Electrophoretic mobility shift assay demonstrates that HCLP-1 indeed interferes with the binding of LZIP to its DNA target. Thus, HCLP-1 serves a transcriptional co-repressor function mediated through its inhibitory interaction with the LZIP transcription factor. Our findings suggest a new mechanism for transcriptional regulation by HCF-like proteins.	Chinese Acad Med Sci, Inst Basic Med Sci, Natl Lab Med Mol Biol, Beijing 100005, Peoples R China; Peking Union, Coll Med, Chinese Natl Human Genome Ctr, Beijing 100005, Peoples R China; Univ Hong Kong, Inst Mol Biol, Hong Kong, Hong Kong, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; University of Hong Kong	Yuan, JG (corresponding author), Chinese Acad Med Sci, Inst Basic Med Sci, Natl Lab Med Mol Biol, Beijing 100005, Peoples R China.		Wong, Chi-Ming/A-7627-2013; Zhou, Houjiang/AFU-3540-2022	Wong, Chi-Ming/0000-0002-0025-7135; 				ABEL T, 1992, GENE DEV, V6, P466, DOI 10.1101/gad.6.3.466; Adams J, 2000, TRENDS CELL BIOL, V10, P17, DOI 10.1016/S0962-8924(99)01673-6; BURBELO PD, 1994, GENE, V139, P241, DOI 10.1016/0378-1119(94)90763-3; Freiman RN, 1997, GENE DEV, V11, P3122, DOI 10.1101/gad.11.23.3122; Goto H, 1997, GENE DEV, V11, P726, DOI 10.1101/gad.11.6.726; Grapes M, 2000, J VIROL, V74, P10112, DOI 10.1128/JVI.74.21.10112-10121.2000; Hughes TA, 1999, J BIOL CHEM, V274, P16437, DOI 10.1074/jbc.274.23.16437; Jin DY, 1997, J BIOL CHEM, V272, P25816, DOI 10.1074/jbc.272.41.25816; Jin DY, 1997, NUCLEIC ACIDS RES, V25, P379, DOI 10.1093/nar/25.2.379; Jin DY, 2000, EMBO J, V19, P729, DOI 10.1093/emboj/19.4.729; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Johnson KM, 1999, J VIROL, V73, P3930, DOI 10.1128/JVI.73.5.3930-3940.1999; KRISTIE TM, 1993, J BIOL CHEM, V268, P6525; Kristie TM, 1999, P NATL ACAD SCI USA, V96, P1229, DOI 10.1073/pnas.96.4.1229; KRISTIE TM, 1995, J BIOL CHEM, V270, P4387, DOI 10.1074/jbc.270.9.4387; La Boissiere S, 1999, EMBO J, V18, P480; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; Liu Y, 1999, MOL CELL BIOL, V19, P909; Lu R, 1997, MOL CELL BIOL, V17, P5117, DOI 10.1128/MCB.17.9.5117; Lu R, 2000, NUCLEIC ACIDS RES, V28, P2446, DOI 10.1093/nar/28.12.2446; Lu R, 1998, J VIROL, V72, P6291, DOI 10.1128/JVI.72.8.6291-6297.1998; Luciano RL, 2000, P NATL ACAD SCI USA, V97, P10757, DOI 10.1073/pnas.190062797; Mahajan SS, 2000, MOL CELL BIOL, V20, P919, DOI 10.1128/MCB.20.3.919-928.2000; Neuveut C, 1997, J BIOMED SCI, V4, P229, DOI 10.1007/BF02253422; Scarr RB, 2000, MOL CELL BIOL, V20, P3568, DOI 10.1128/MCB.20.10.3568-3575.2000; SMOLIK SM, 1992, MOL CELL BIOL, V12, P4123, DOI 10.1128/MCB.12.9.4123; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; Vogel JL, 2000, EMBO J, V19, P683, DOI 10.1093/emboj/19.4.683; Wilson AC, 2000, MOL CELL BIOL, V20, P6721, DOI 10.1128/MCB.20.18.6721-6730.2000; WILSON AC, 1995, GENOMICS, V25, P462, DOI 10.1016/0888-7543(95)80046-O; Wilson AC, 1997, MOL CELL BIOL, V17, P6139, DOI 10.1128/MCB.17.10.6139; WILSON AC, 1993, CELL, V74, P115, DOI 10.1016/0092-8674(93)90299-6; Zhu C, 1997, MOL CELL BIOL, V17, P4957, DOI 10.1128/MCB.17.9.4957	34	15	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28933	28938		10.1074/jbc.M103893200	http://dx.doi.org/10.1074/jbc.M103893200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11384994	hybrid			2022-12-25	WOS:000170346000041
J	Davis, SL; Gurusiddappa, S; McCrea, KW; Perkins, S; Hook, M				Davis, SL; Gurusiddappa, S; McCrea, KW; Perkins, S; Hook, M			SdrG, a fibrinogen-binding bacterial adhesin of the microbial surface components recognizing adhesive matrix molecules subfamily from Staphylococcus epidermidis, targets the thrombin cleavage site in the B beta chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLUMPING FACTOR; ICA LOCUS; AUREUS; PROTEIN; FIBRONECTIN; IDENTIFICATION; PATHOGENESIS; EXPRESSION; RECEPTOR; PLASMA	Staphylococcus epidermidis is an important opportunistic pathogen and is a major cause of foreign body infections. We have characterized the ligand binding activity of SdrG, a fibrinogen-binding microbial surface component recognizing adhesive matrix molecules from S. epidermidis. Western ligand blot analysis showed that a recombinant form of the N-terminal A region of SdrG bound to the native B beta chain of fibrinogen (Fg) and to a recombinant form of the B beta chain expressed in Escherichia coli. By analyzing recombinant truncates and synthetic peptide mimetics of the Fg B beta chain, the binding site for SdrG was localized to residues 6-20 of this polypeptide. Recombinant SdrG bound to a synthetic 25-amino acid peptide (beta1-25) representing the N terminus of the Fg B beta chain with a K-D of 1.4 x 10(-7) M as determined by fluorescence polarization experiments. This was similar to the apparent K-D (0.9 x 10(-7) M) calculated from an enzyme-linked immunosorbent assay where SdrG bound immobilized Fg in a concentration-dependent manner. SdrG could recognize fibrinopeptide B (residues 1-14), but with a substantially lower affinity than that observed for SdrG binding to synthetic peptides beta1-25 and beta6-20. However, SdrG does not bind to thrombin-digested Fg. Thus, SdrG appears to target the thrombin cleavage site in the Fg B beta chain. In fact, SdrG was found to inhibit thrombin-induced fibrinogen clotting by interfering with fibrinopeptide B release.	Univ Texas, Hlth Sci Ctr, Inst Biosci & Technol, Ctr Extracellular Matrix Biol, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Grad Sch Biomed Sci, Houston, TX 77030 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; Texas A&M University System; Texas A&M University College Station	Hook, M (corresponding author), Univ Texas, Hlth Sci Ctr, Inst Biosci & Technol, Ctr Extracellular Matrix Biol, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	mhook@ibt.tamu.edu			NIAID NIH HHS [AI20624] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020624] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Cramton SE, 1999, INFECT IMMUN, V67, P5427, DOI 10.1128/IAI.67.10.5427-5433.1999; Eidhin DN, 1998, MOL MICROBIOL, V30, P245; Entenza JM, 2000, INFECT IMMUN, V68, P5443, DOI 10.1128/IAI.68.9.5443-5446.2000; FARRELL DH, 1992, P NATL ACAD SCI USA, V89, P10729, DOI 10.1073/pnas.89.22.10729; FLOCK JI, 1987, EMBO J, V6, P2351, DOI 10.1002/j.1460-2075.1987.tb02511.x; Foster TJ, 1998, TRENDS MICROBIOL, V6, P484, DOI 10.1016/S0966-842X(98)01400-0; FROMAN G, 1987, J BIOL CHEM, V262, P6564; GALLIANI S, 1994, J LAB CLIN MED, V123, P685; Garrett DO, 1999, INFECT CONT HOSP EP, V20, P167, DOI 10.1086/501605; HAVERKATE F, 1986, THROMB HAEMOSTASIS, V55, P131; Herrick S, 1999, INT J BIOCHEM CELL B, V31, P741, DOI 10.1016/S1357-2725(99)00032-1; KAY AB, 1974, BRIT J HAEMATOL, V27, P669, DOI 10.1111/j.1365-2141.1974.tb06633.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; McCrea KW, 2000, MICROBIOL-SGM, V146, P1535, DOI 10.1099/00221287-146-7-1535; McDevitt D, 1997, EUR J BIOCHEM, V247, P416, DOI 10.1111/j.1432-1033.1997.00416.x; MCDEVITT D, 1995, MOL MICROBIOL, V16, P895, DOI 10.1111/j.1365-2958.1995.tb02316.x; McKenney D, 1998, INFECT IMMUN, V66, P4711, DOI 10.1128/IAI.66.10.4711-4720.1998; Meier PS, 2001, INFECT IMMUN, V69, P657; MOREILLON P, 1995, INFECT IMMUN, V63, P4738, DOI 10.1128/IAI.63.12.4738-4743.1995; Mullin JL, 2000, J BIOL CHEM, V275, P25239, DOI 10.1074/jbc.M004142200; NG AS, 1993, METHOD ENZYMOL, V222, P341; Nilsson M, 1998, INFECT IMMUN, V66, P2666, DOI 10.1128/IAI.66.6.2666-2673.1998; O'Connell DP, 1998, J BIOL CHEM, V273, P6821, DOI 10.1074/jbc.273.12.6821; PATTI JM, 1994, CURR OPIN CELL BIOL, V6, P752, DOI 10.1016/0955-0674(94)90104-X; Pei L, 1999, INFECT IMMUN, V67, P4525, DOI 10.1128/IAI.67.9.4525-4530.1999; RICHARDSON DL, 1976, BRIT J HAEMATOL, V32, P507, DOI 10.1111/j.1365-2141.1976.tb00953.x; SENIOR RM, 1986, J CLIN INVEST, V77, P1014, DOI 10.1172/JCI112353; VAUDAUX P, 1989, J INFECT DIS, V160, P865, DOI 10.1093/infdis/160.5.865; VAUDAUX PE, 1995, INFECT IMMUN, V63, P585, DOI 10.1128/IAI.63.2.585-590.1995; Wann ER, 2000, J BIOL CHEM, V275, P13863, DOI 10.1074/jbc.275.18.13863	30	99	102	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27799	27805		10.1074/jbc.M103873200	http://dx.doi.org/10.1074/jbc.M103873200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11371571	hybrid			2022-12-25	WOS:000170093400010
J	Guertin, DA; McCollum, D				Guertin, DA; McCollum, D			Interaction between the noncatalytic region of Sid1p kinase and Cdc14p is required for full catalytic activity and localization of Sid1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STE20-LIKE PROTEIN-KINASE; FISSION YEAST; CYTOKINESIS; THIAMINE; CLONING; FAMILY; GENE	Sid1p is a group II p21-activated kinase/germinal center kinase family member that is part of a signaling network required for cytokinesis in fission yeast. Germinal center kinases are characterized by well conserved amino-terminal catalytic domains followed by less conserved carboxyl termini. The carboxyl termini among group I germinal center kinases are moderately conserved and thought to be regulatory regions. Little is known about the carboxyl termini of group II family members. Sid1p has been shown to bind the novel protein Cdc14p; however, the functional significance of this interaction is unknown. Here we report that the carboxyl terminus of Sid1p is an essential regulatory region. Our results indicate that this region contains the binding domain for Cdc14p, and this association is required for full Sid1p catalytic activity as well as intracellular localization. Furthermore, overexpression of the carboxyl terminus of Sid1p alone compromises the signaling of cytokinesis. We conclude that Cdc14p positively regulates the Sid1p kinase by binding the noncatalytic carboxyl-terminal region of the protein.	Univ Massachusetts, Sch Med, Dept Mol Genet & Microbiol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	McCollum, D (corresponding author), Univ Massachusetts, Sch Med, Dept Mol Genet & Microbiol, 377 Plantat St, Worcester, MA 01605 USA.				NIGMS NIH HHS [GM58406] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058406] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Balasubramanian MK, 2000, J CELL SCI, V113, P1503; Balasubramanian MK, 1998, GENETICS, V149, P1265; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; Creasy CL, 1996, J BIOL CHEM, V271, P21049, DOI 10.1074/jbc.271.35.21049; Eichinger L, 1998, J BIOL CHEM, V273, P12952, DOI 10.1074/jbc.273.21.12952; FANKHAUSER C, 1993, MOL BIOL CELL, V4, P531, DOI 10.1091/mbc.4.5.531; Guertin DA, 2000, EMBO J, V19, P1803, DOI 10.1093/emboj/19.8.1803; Kyriakis JM, 1999, J BIOL CHEM, V274, P5259, DOI 10.1074/jbc.274.9.5259; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; POMBO CM, 1996, EMBO J, V15, P537; Sawin KE, 2000, CURR BIOL, V10, pR547, DOI 10.1016/S0960-9822(00)00613-8; Schinkmann K, 1997, J BIOL CHEM, V272, P28695, DOI 10.1074/jbc.272.45.28695; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9	13	19	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28185	28189		10.1074/jbc.M103802200	http://dx.doi.org/10.1074/jbc.M103802200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11384993	hybrid			2022-12-25	WOS:000170093400060
J	Ma, H; Fukiage, C; Kim, YH; Duncan, MK; Reed, NA; Shih, M; Azuma, M; Shearer, TR				Ma, H; Fukiage, C; Kim, YH; Duncan, MK; Reed, NA; Shih, M; Azuma, M; Shearer, TR			Characterization and expression of calpain 10 - A novel ubiquitous calpain with nuclear localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-DEPENDENT PROTEASE; ELEGANS SEX DETERMINATION; MESSENGER-RNA; DETERMINATION GENE; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; RAT LENS; IDENTIFICATION; PROTEOLYSIS; ACTIVATION	Calpains are calcium-dependent intracellular nonlysosomal proteases that are believed to hydrolyze specific substrates important in calcium-regulated signaling pathways. Recently, an atypical member of the calpain family, calpain 10, was described, and genetic variation in this gene was associated with an increased risk of type II diabetes mellitus in humans. In the present report, a polyclonal antibody directed against rat calpain 10 was developed. This antibody was used to monitor the expression of calpain 10 protein in tissues from rats, mice, and humans. Calpain 10 protein was found to be present in all tissues examined by Western blotting including the lens, retina, brain, heart, and skeletal muscle. Although some calpain 10 was detectable in the water-soluble protein fraction of these tissues, it was preferentially found in the water-insoluble fraction. In the lens, immunohistochemistry revealed that calpain 10 was predominately located in the cytoplasm of epithelial and newly differentiating lens fibers at the transition zone. However, calpain 10 was found to be associated with the plasma membrane of differentiated lens fiber cells and the sarcolemma of skeletal muscle. In the lens epithelium-derived cell line, alpha TN4-1, the calpain 10 protein was found in a punctate distribution in the cell nucleus as well as the cytoplasm. After the elevation of intracellular calcium levels with ionomycin, calpain 10 protein levels in the nucleus of alpha TN4-1 cells increased markedly, whereas those in the cytoplasm decreased. In the lens, the elevation of intracellular calcium levels after selenite administration resulted in increased levels of calpain 10 RNA within I day and a loss of calpain 10 protein from the lens nucleus coincident with the onset of selenite cataract. In conclusion, calpain 10 seems to be a ubiquitous calpain, the expression level and subcellular distribution of which are dynamically influenced by calcium.	Oregon Hlth & Sci Univ, Dept Oral Mol Biol, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Ophthalmol, Portland, OR 97201 USA; Senju Pharmaceut Co Ltd, Biol Lab, Nishi Ku, Kobe, Hyogo 65122, Japan; Oregon State Univ, Dept Anim Sci, Corvallis, OR 97331 USA; Univ Delaware, Dept Biol Sci, Div Mol Biol & Genet, Newark, DE 19716 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Senju Pharmaceutical Co. Ltd.; Oregon State University; University of Delaware	Shearer, TR (corresponding author), Oregon Hlth & Sci Univ, Dept Oral Mol Biol, 611 SW Campus Dr, Portland, OR 97201 USA.	shearert@ohsu.edu		Kim, Yung Hae/0000-0002-2932-8689; Duncan, Melinda/0000-0003-1570-322X	NEI NIH HHS [EY05786, EY12221] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY012221] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Azuma M, 2000, CURR EYE RES, V21, P710, DOI 10.1076/0271-3683(200009)21:3;1-R;FT710; Baghdiguian S, 1999, NAT MED, V5, P503, DOI 10.1038/8385; Baier LJ, 2000, J CLIN INVEST, V106, pR69, DOI 10.1172/JCI10665; Barnes TM, 1996, EMBO J, V15, P4477, DOI 10.1002/j.1460-2075.1996.tb00825.x; Braun C, 1999, BIOCHEM BIOPH RES CO, V260, P671, DOI 10.1006/bbrc.1999.0948; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; DAVID LL, 1984, INVEST OPHTH VIS SCI, V25, P1275; Dear N, 1997, GENOMICS, V45, P175, DOI 10.1006/geno.1997.4870; DELUCA CI, 1993, BIOCHIM BIOPHYS ACTA, V1216, P81, DOI 10.1016/0167-4781(93)90040-K; EMORI Y, 1986, J BIOL CHEM, V261, P9465; HARDING J, 1991, CATARACT BIOCH EPIDE, P21; Horikawa Y, 2000, NAT GENET, V26, P163, DOI 10.1038/79876; Hosfield CM, 1999, EMBO J, V18, P6880, DOI 10.1093/emboj/18.24.6880; Ma H, 2000, CURR EYE RES, V20, P183, DOI 10.1076/0271-3683(200003)20:3;1-9;FT183; Ma H, 1998, INVEST OPHTH VIS SCI, V39, P454; Ma H, 1997, EXP EYE RES, V64, P437, DOI 10.1006/exer.1996.0229; Ma H, 2000, INVEST OPHTH VIS SCI, V41, P4232; Mugita N, 1997, BIOCHEM BIOPH RES CO, V239, P845, DOI 10.1006/bbrc.1997.7571; *NIH, 1985, DHEW PUBL, V8623; Permutt MA, 2000, J CLIN INVEST, V106, P819, DOI 10.1172/JCI11228; Reed NA, 2001, J IMMUNOL METHODS, V253, P243, DOI 10.1016/S0022-1759(01)00374-X; Shearer T R, 1997, Mol Vis, V3, P8; SHEARER TR, 1992, CURR EYE RES, V11, P357, DOI 10.3109/02713689209001789; Sokol SB, 2000, GENE DEV, V14, P901; SORIMACHI H, 1989, J BIOL CHEM, V264, P20106; SORIMACHI H, 1993, J BIOL CHEM, V268, P19476; Strobl S, 2000, P NATL ACAD SCI USA, V97, P588, DOI 10.1073/pnas.97.2.588; TANAKA Y, 2000, BIOCHEM BIOPH RES CO, V275, P300	28	98	104	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28525	28531		10.1074/jbc.M100603200	http://dx.doi.org/10.1074/jbc.M100603200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11375982	hybrid			2022-12-25	WOS:000170093400104
J	Mazzorana, M; Cogne, S; Goldschmidt, D; Aubert-Foucher, E				Mazzorana, M; Cogne, S; Goldschmidt, D; Aubert-Foucher, E			Collagenous sequence governs the trimeric assembly of collagen XII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACULOVIRUS EXPRESSION SYSTEM; TRIPLE-HELIX; MOLECULAR RECOGNITION; PROLYL 4-HYDROXYLASE; BINDING-PROPERTIES; III PROCOLLAGEN; C-PROPEPTIDE; IN-VITRO; DOMAIN; CHAIN	A minicollagen containing the COLT and NCI domains of chicken collagen XII has been produced in insect cells. Significant amounts of trimers contain a triple-helical domain in which the cysteines are not involved in inter- but in intrachain bonds. In reducing conditions, providing that the triple-helix is maintained, disulfide exchange between intra- and interchain bonding is observed, suggesting that the triple-helix forms first and that in favorable redox conditions interchain bonding occurs to stabilize the molecule. This hypothesis is verified by in vitro reassociation studies performed in the presence of reducing agents, demonstrating that the formation of interchain disulfide bonds is not a prerequisite to the trimeric association and triple-helical folding of the collagen XII molecule. Shortening the COLI domain of minicollagen XII to its five C-terminal GXY triplets results in an absence of trimers. This can be explained by the presence of a collagenous domain that is too short to form a stable triple-helix. In contrast, the presence of five additional C-terminal triplets in COLT allows the formation of triple-helical disulfide-bonded trimers, suggesting that the presence of a triple-helix is essential for the assembly of collagen XII.	Univ Lyon 1, Inst Biol & Chim Prot, CNRS, UMR 5086, F-69367 Lyon 07, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Aubert-Foucher, E (corresponding author), Univ Lyon 1, Inst Biol & Chim Prot, CNRS, UMR 5086, 7 Passage Vercors, F-69367 Lyon 07, France.			MAZZORANA, Marlene/0000-0002-3956-4319				Alvares K, 1999, BIOCHEMISTRY-US, V38, P5401, DOI 10.1021/bi9821824; BACHINGER HP, 1991, INT J BIOL MACROMOL, V13, P152, DOI 10.1016/0141-8130(91)90040-2; BRASS A, 1992, FEBS LETT, V303, P126, DOI 10.1016/0014-5793(92)80503-9; BROWN JC, 1993, J CELL BIOL, V120, P557, DOI 10.1083/jcb.120.2.557; Bulleid NJ, 1997, EMBO J, V16, P6694, DOI 10.1093/emboj/16.22.6694; Bulleid NJ, 1996, BIOCHEM J, V317, P195, DOI 10.1042/bj3170195; Chiquet M, 1996, BIOCHEM CELL BIOL, V74, P737, DOI 10.1139/o96-080; CHOPRA RK, 1982, P NATL ACAD SCI-BIOL, V79, P7180, DOI 10.1073/pnas.79.23.7180; COLIGE A, 1995, J BIOL CHEM, V270, P16724, DOI 10.1074/jbc.270.28.16724; DOEGE KJ, 1986, J BIOL CHEM, V261, P8924; Ehnis T, 1996, EXP CELL RES, V229, P388, DOI 10.1006/excr.1996.0384; ENGEL J, 1991, ANNU REV BIOPHYS BIO, V20, P137, DOI 10.1146/annurev.biophys.20.1.137; FONT B, 1993, J BIOL CHEM, V268, P25015; Font B, 1996, MATRIX BIOL, V15, P341, DOI 10.1016/S0945-053X(96)90137-7; Garrone R, 1997, MICROSC RES TECHNIQ, V38, P407, DOI 10.1002/(SICI)1097-0029(19970815)38:4<407::AID-JEMT8>3.0.CO;2-F; INOUYE K, 1976, BIOCHIM BIOPHYS ACTA, V420, P133, DOI 10.1016/0005-2795(76)90352-4; Kania AM, 1999, J BIOL CHEM, V274, P22053, DOI 10.1074/jbc.274.31.22053; KEENE DR, 1991, J CELL BIOL, V113, P971, DOI 10.1083/jcb.113.4.971; Kivirikko K. I., 1992, POSTTRANSLATIONAL MO, P1; Klein G, 1998, MATRIX BIOL, V16, P307, DOI 10.1016/S0945-053X(98)90002-6; KRIEGIER M, 1990, GENE TRANSFER EXPRES; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lees JF, 1997, EMBO J, V16, P908, DOI 10.1093/emboj/16.5.908; Lesage A, 1996, BIOCHEMISTRY-US, V35, P9647, DOI 10.1021/bi952666p; Lim AL, 1998, J CELL BIOCHEM, V71, P216, DOI 10.1002/(SICI)1097-4644(19981101)71:2<216::AID-JCB7>3.3.CO;2-K; LUNSTRUM GP, 1992, J BIOL CHEM, V267, P20087; MALITSCHEK B, 1991, BIOTECHNIQUES, V11, P177; Mayne R, 1993, CURR OPIN CELL BIOL, V5, P883, DOI 10.1016/0955-0674(93)90039-S; MAZZORANA M, 1993, J BIOL CHEM, V268, P3029; Mazzorana M, 1996, J BIOL CHEM, V271, P29003, DOI 10.1074/jbc.271.46.29003; MAZZORANA M, 1995, MATRIX BIOL, V14, P583, DOI 10.1016/S0945-053X(05)80007-1; McLaughlin SH, 1998, MATRIX BIOL, V16, P369, DOI 10.1016/S0945-053X(98)90010-5; Mechling DE, 1996, J BIOL CHEM, V271, P13781, DOI 10.1074/jbc.271.23.13781; NISHIYAMA T, 1994, J BIOL CHEM, V269, P28193; Niyibizi C, 1995, MATRIX BIOL, V14, P743, DOI 10.1016/S0945-053X(05)80017-4; Persikov AV, 2000, BIOCHEMISTRY-US, V39, P14960, DOI 10.1021/bi001560d; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Ricard-Blum S, 2000, UNCONVENTIONAL COLLA; ROTH W, 1981, INT J PEPT PROT RES, V17, P527; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Shah NK, 1996, BIOCHEMISTRY-US, V35, P10262, DOI 10.1021/bi960046y; SIES H, 1975, EUR J BIOCHEM, V57, P503, DOI 10.1111/j.1432-1033.1975.tb02325.x; SUGRUE SP, 1989, J CELL BIOL, V109, P939, DOI 10.1083/jcb.109.2.939; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; Trachslin J, 1999, EXP CELL RES, V247, P320, DOI 10.1006/excr.1998.4363; VANDERPLAATS GN, 1993, STRUCT OPTIMIZATION, V6, P1, DOI 10.1007/BF01743168; VAUGHAN L, 1988, J CELL BIOL, V106, P991, DOI 10.1083/jcb.106.3.991; VUORI K, 1992, P NATL ACAD SCI USA, V89, P7467, DOI 10.1073/pnas.89.16.7467; Yang W, 1997, J BIOL CHEM, V272, P28837, DOI 10.1074/jbc.272.46.28837; Zafarullah K, 1997, MATRIX BIOL, V16, P201, DOI 10.1016/S0945-053X(97)90009-3	50	17	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27989	27998		10.1074/jbc.M101633200	http://dx.doi.org/10.1074/jbc.M101633200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11375984	hybrid			2022-12-25	WOS:000170093400034
J	Shimizu, A; Persson, C; Heldin, CH; Ostman, A				Shimizu, A; Persson, C; Heldin, CH; Ostman, A			Ligand stimulation reduces platelet-derived growth factor beta-receptor susceptibility to tyrosine dephosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR; PHOSPHATASE LAR; SENSITIVITY; GENERATION; H2O2	Ligand binding to the platelet-derived growth factor (PDGF) beta -receptor leads to increased receptor tyrosine phosphorylation as a consequence of dimerization-induced activation of the intrinsic receptor tyrosine kinase activity. In this study we asked whether ligand-stimulated PDGF -receptor tyrosine phosphorylation, to some extent, also involved reduced susceptibility to tyrosine dephosphorylation. To investigate this possibility we compared the sensitivity of ligand-stimulated and nonstimulated forms of tyrosine-phosphorylated PDGF beta -receptors to dephosphorylation using various preparations containing protein-tyrosine phosphatase activity. Ligand-stimulated or unstimulated tyrosine-phosphorylated receptors were obtained after incubation of cells with pervanadate only or pervanadate, together with PDGF-BB, respectively. Dephosphorylation of receptors immobilized on wheat germ agglutinin-Sepharose, as well as of receptors in intact cell membranes, was investigated under conditions when rephosphorylation did not occur. As compared with unstimulated receptors the ligand-stimulated PDGF beta -receptors showed about 10-fold reduced sensitivity to dephosphorylation by cell membranes, a recombinant form of the catalytic domain of density-enhanced phosphatase-1, or recombinant protein-tyrosine phosphatase 1B. We conclude that ligand-stimulated forms of the PDGF beta -receptor display a reduced susceptibility to dephosphorylation. Our findings suggest a novel mechanism whereby ligand stimulation of PDGF beta -receptor, and possibly other tyrosine kinase receptors, leads to a net increase in receptor tyrosine phosphorylation.	Ludwig Inst Canc Res, S-75124 Uppsala, Sweden	Ludwig Institute for Cancer Research	Ostman, A (corresponding author), Ludwig Inst Canc Res, Box 595, S-75124 Uppsala, Sweden.	arne.ostman@licr.uu.se						Ahmad F, 1997, J BIOL CHEM, V272, P448; Bae YS, 2000, J BIOL CHEM, V275, P10527, DOI 10.1074/jbc.275.14.10527; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Gross S, 1999, J BIOL CHEM, V274, P26378, DOI 10.1074/jbc.274.37.26378; Hansen K, 1996, EMBO J, V15, P5299, DOI 10.1002/j.1460-2075.1996.tb00915.x; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Heldin CH, 1998, BBA-REV CANCER, V1378, pF79, DOI 10.1016/S0304-419X(98)00015-8; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Kokel M, 1998, GENE DEV, V12, P1425, DOI 10.1101/gad.12.10.1425; Kovalenko M, 2000, J BIOL CHEM, V275, P16219, DOI 10.1074/jbc.275.21.16219; KOVALENKO M, 1994, CANCER RES, V54, P6106; Kulas DT, 1996, J BIOL CHEM, V271, P755, DOI 10.1074/jbc.271.2.755; Kulas DT, 1996, J BIOL CHEM, V271, P748, DOI 10.1074/jbc.271.2.748; KULAS DT, 1995, J BIOL CHEM, V270, P2435, DOI 10.1074/jbc.270.6.2435; Ostman A, 2001, TRENDS CELL BIOL, V11, P258, DOI 10.1016/S0962-8924(01)01990-0; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296	22	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27749	27752		10.1074/jbc.C100286200	http://dx.doi.org/10.1074/jbc.C100286200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11390370	hybrid			2022-12-25	WOS:000170093400002
J	Tomura, A; Goto, K; Morinaga, H; Nomura, M; Okabe, T; Yanase, T; Takayanagi, R; Nawata, H				Tomura, A; Goto, K; Morinaga, H; Nomura, M; Okabe, T; Yanase, T; Takayanagi, R; Nawata, H			The subnuclear three-dimensional image analysis of androgen receptor fused to green fluorescence protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROSTATIC-CARCINOMA; ANTIANDROGEN WITHDRAWAL SYNDROME; BINDING DOMAIN; LIVING CELLS; GLUCOCORTICOID RECEPTOR; INSENSITIVITY SYNDROME; NUCLEAR MATRIX; ANTI-ANDROGENS; LNCAP CELLS; LIGAND	To establish the novel approach in order to distinguish the transcriptionally active androgen receptor (AR) from the transcriptionally inactive A-R, we performed the three-dimensional construction of confocal microscopic images of intranuclear AR. This method clearly distinguished the subnuclear localization of transcriptionally active AR tagged with green fluorescent protein (AR-GFP) from the transcriptionally inactive AR-GFP. Transcriptionally active AR-GFP mainly produced 250-400 fluorescence foci in the boundary region between euchromatin and heterochromatin. Although the AR-GFP bound to such antiandrogens as hydroxyflutamide or bicalutamide translocated to the nucleus, they homogeneously spread throughout the nucleus without producing any fluorescence foci. Antiandrogenic environmental disrupting chemicals, such as 1,1-dichloro-2,2-bis (p-chlorophenyl) ethylene, vinclozolin, or nitrofen, also disrupted the intranuclear fluorescence foci. A point mutation (T877A) resulted in the loss of ligand specificity in AR-GFP. Even in this mutant receptor, agonists, such as dihydrotestosterone, hydroxyflutamide, or progesterone, produced the fluorescence foci in the nucleus, whereas the transcriptionally inactive mutant binding bicalutamide was observed to be spread homogeneously in the nucleus. Taken together, our findings suggest that, after nuclear translocation, AR is possibly located in the specific region in the nucleus while demonstrating clustering tightly depending on the agonist-induced transactivation competence.	Kyushu Univ, Grad Sch Med Sci, Dept Internal Med 3,Dept Med & Bioregulatory sci, Higashi Ku, Fukuoka 8128582, Japan; Japan Sci & Technol, CREST, Tsukuba, Ibaraki, Japan	Kyushu University; Japan Science & Technology Agency (JST)	Nawata, H (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Internal Med 3,Dept Med & Bioregulatory sci, Higashi Ku, Maidashi 3-1-1, Fukuoka 8128582, Japan.							Adachi M, 2000, NEW ENGL J MED, V343, P856, DOI 10.1056/NEJM200009213431205; Breul J, 1998, UROLOGE A, V37, P156, DOI 10.1007/s001200050165; Cude KJ, 1999, J MOL MED, V77, P419, DOI 10.1007/s001090050372; Fejes-Toth G, 1998, P NATL ACAD SCI USA, V95, P2973, DOI 10.1073/pnas.95.6.2973; FURR BJA, 1989, HORM RES, V32, P69, DOI 10.1159/000181315; Georget V, 1997, MOL CELL ENDOCRINOL, V129, P17, DOI 10.1016/S0303-7207(97)04034-3; Greer JJ, 2000, PEDIATR PULM, V29, P394, DOI 10.1002/(SICI)1099-0496(200005)29:5<394::AID-PPUL9>3.0.CO;2-2; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Htun H, 1999, MOL BIOL CELL, V10, P471, DOI 10.1091/mbc.10.2.471; Htun H, 1996, P NATL ACAD SCI USA, V93, P4845, DOI 10.1073/pnas.93.10.4845; HURT SSB, 1983, TOXICOLOGY, V29, P1; IMASAKI K, 1994, EUR J ENDOCRINOL, V130, P569, DOI 10.1530/eje.0.1300569; Jenster G, 1999, SEMIN ONCOL, V26, P407; KAIGHN ME, 1979, INVEST UROL, V17, P16; KAUFMANN SH, 1986, J BIOL CHEM, V261, P1962; KELCE WR, 1995, NATURE, V375, P581, DOI 10.1038/375581a0; Kelce WR, 1998, REPROD FERT DEVELOP, V10, P105, DOI 10.1071/R98051; Kelce WR, 1997, J MOL MED, V75, P198, DOI 10.1007/s001090050104; Kemppainen JA, 1996, UROLOGY, V48, P157, DOI 10.1016/S0090-4295(96)00117-3; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; Llopis J, 2000, P NATL ACAD SCI USA, V97, P4363, DOI 10.1073/pnas.97.8.4363; Losada A, 1999, PEDIATR SURG INT, V15, P188, DOI 10.1007/s003830050551; McPhaul MJ, 1999, J STEROID BIOCHEM, V69, P315, DOI 10.1016/S0960-0760(99)00050-3; MICKEY DD, 1977, CANCER RES, V37, P4049; NAKAO R, 1992, J CLIN ENDOCR METAB, V74, P1152, DOI 10.1210/jc.74.5.1152; NERI R, 1972, ENDOCRINOLOGY, V91, P427, DOI 10.1210/endo-91-2-427; OGAWA H, 1995, P NATL ACAD SCI USA, V92, P11899, DOI 10.1073/pnas.92.25.11899; PLYMATE SR, 1991, J STEROID BIOCHEM, V40, P833, DOI 10.1016/0960-0760(91)90309-S; Racz A, 1999, J BIOL CHEM, V274, P19352, DOI 10.1074/jbc.274.27.19352; Remboutsika E, 1999, J CELL SCI, V112, P1671; Scher HI, 1997, EUR UROL, V31, P3; Sohoni P, 1998, J ENDOCRINOL, V158, P327, DOI 10.1677/joe.0.1580327; Stenoien DL, 2000, MOL ENDOCRINOL, V14, P518, DOI 10.1210/me.14.4.518; Tang YT, 1996, MOL CELL BIOL, V16, P1989; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; Tyagi RK, 2000, MOL ENDOCRINOL, V14, P1162, DOI 10.1210/me.14.8.1162; VANSTEENSEL B, 1995, J CELL SCI, V108, P3003; VELDSCHOLTE J, 1992, BIOCHEMISTRY-US, V31, P2393, DOI 10.1021/bi00123a026; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; WONG CI, 1995, J BIOL CHEM, V270, P19998, DOI 10.1074/jbc.270.34.19998; ZHOU ZX, 1994, J BIOL CHEM, V269, P13115	41	116	120	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28395	28401		10.1074/jbc.M101755200	http://dx.doi.org/10.1074/jbc.M101755200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11369770	hybrid			2022-12-25	WOS:000170093400087
J	Grewal, JS; Luttrell, LM; Raymond, JR				Grewal, JS; Luttrell, LM; Raymond, JR			G protein-coupled receptors desensitize and down-regulate epidermal growth factor receptors in renal mesangial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOGENIC SIGNAL TRANSDUCTION; TYROSINE KINASE-ACTIVITY; FLUID-PHASE ENDOCYTOSIS; SMOOTH-MUSCLE CELLS; EGF RECEPTOR; ANGIOTENSIN-II; BETA(2)-ADRENERGIC RECEPTOR; MEDIATED ENDOCYTOSIS; PHOSPHOLIPASE-C; PHORBOL ESTER	Different types of plasma membrane receptors engage in various forms of cross-talk. We used cultures of rat renal mesangial cells to study the regulation of EGF receptors (EGFRs) by various endogenous G protein-coupled receptors (GPCRs). GPCRs (5-hydroxytryptamine(2A) lysophosphatidic acid, angiotensin AT(1), bradykinin B-2) were shown to transactivate EGFRs through a protein kinase C-dependent pathway. This transactivation resulted in the initiation of multiple cellular signals (phosphorylation of the EGFRs and ERK and activation of cAMP-responsive element-binding protein (CREB), NF-kappaB, and E2F), as well as subsequent rapid down-regulation of cell-surface EGFRs and internalization and desensitization of the EGFRs without change in the total cellular complement of EGFRs. Internalization of the EGFRs and the down-regulation of cell-surface receptors in mesangial cells were blocked by pharmacological inhibitors of clathrin-mediated endocytosis and in HEK293 cells by transfection of cDNA constructs that encode dominant negative beta -arrestin-1 or dynamin. Whereas all of the effects of GPCRs on EGFRs were dependent to a great extent on protein kinase C, those initiated by EGF were not. These studies demonstrate that GPCRs can induce multiple signals through protein kinase C-dependent transactivation of EGFRs. Moreover, GPCRs induce profound desensitization of EGFRs by a process associated with the loss of cell-surface EGFRs through clathrin-mediated endocytosis.	Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA; Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC 29401 USA; Ralph H Johnson Vet Affairs Med Ctr, Med Specialty Serv, Charleston, SC 29401 USA; Duke Univ, Med Ctr, Div Endocrinol, Dept Med, Durham, NC 27710 USA; Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Durham, NC 27710 USA	Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; Duke University; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Raymond, JR (corresponding author), Med Univ S Carolina, Dept Med, Div Nephrol, Rm 829,Clin Sci Bldg,171 Ashley Ave, Charleston, SC 29425 USA.	raymondj@musc.edu		Luttrell, Louis/0000-0003-2805-6949	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK055524, R01DK055524, R01DK052448, R56DK052448, R01DK054720] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK52448, DK55524, DK54720] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; Arimura S, 1998, LIFE SCI, V63, P1563, DOI 10.1016/S0024-3205(98)00423-8; Baker VL, 1998, PLACENTA, V19, P475, DOI 10.1016/S0143-4004(98)91040-2; BEGUINOT L, 1985, P NATL ACAD SCI USA, V82, P2774, DOI 10.1073/pnas.82.9.2774; BOWEN S, 1991, J BIOL CHEM, V266, P1162; Carter RE, 1998, J BIOL CHEM, V273, P35000, DOI 10.1074/jbc.273.52.35000; Choudhury GG, 1999, BIOCHEM BIOPH RES CO, V258, P490, DOI 10.1006/bbrc.1999.0599; Dajani OF, 1999, J CELL PHYSIOL, V180, P203, DOI 10.1002/(SICI)1097-4652(199908)180:2<203::AID-JCP8>3.3.CO;2-K; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; DAUKAS G, 1985, J CELL BIOL, V101, P1673, DOI 10.1083/jcb.101.5.1673; DAVIES PJA, 1980, NATURE, V283, P162, DOI 10.1038/283162a0; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Eguchi S, 1999, HYPERTENSION, V33, P201, DOI 10.1161/01.HYP.33.1.201; El-Dahr SS, 1998, AM J PHYSIOL-RENAL, V275, pF343, DOI 10.1152/ajprenal.1998.275.3.F343; ELDAR H, 1990, J BIOL CHEM, V265, P13290; FLOEGE J, 1993, KIDNEY INT, V43, pS47; Gagnon AW, 1998, J BIOL CHEM, V273, P6976, DOI 10.1074/jbc.273.12.6976; Gaits F, 1997, KIDNEY INT, V51, P1022, DOI 10.1038/ki.1997.143; GANZ MB, 1994, AM J PHYSIOL, V266, pF576, DOI 10.1152/ajprenal.1994.266.4.F576; Garnovskaya MN, 1998, BIOCHEM J, V330, P489; Goppelt-Struebe M, 2000, BIOCHEM J, V345, P217, DOI 10.1042/0264-6021:3450217; GRAY GM, 1989, J CELL BIOCHEM, V40, P271, DOI 10.1002/jcb.240400303; Grewal JS, 1996, FEBS LETT, V383, P267, DOI 10.1016/0014-5793(96)00247-5; Grewal JS, 1999, AM J PHYSIOL-RENAL, V276, pF922, DOI 10.1152/ajprenal.1999.276.6.F922; Gulliford T, 1999, CELL SIGNAL, V11, P245, DOI 10.1016/S0898-6568(98)00058-8; HADCOCK JR, 1992, J BIOL CHEM, V267, P26017; HARADA H, 1993, AM J PHYSIOL, V264, pC956, DOI 10.1152/ajpcell.1993.264.4.C956; HAZAN R, 1995, J CELL PHYSIOL, V162, P74, DOI 10.1002/jcp.1041620110; HENIS YI, 1981, EXP CELL RES, V136, P189, DOI 10.1016/0014-4827(81)90050-1; HOFFMAN BL, 1993, J CELL PHYSIOL, V157, P535, DOI 10.1002/jcp.1041570313; HSUAN JJ, 1908, PROG GROWTH FACTOR R, V1, P23; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Jaffa AA, 1997, AM J PHYSIOL-RENAL, V273, pF916, DOI 10.1152/ajprenal.1997.273.6.F916; Jockers R, 1999, J BIOL CHEM, V274, P28900, DOI 10.1074/jbc.274.41.28900; KAJI H, 1988, J BIOL CHEM, V263, P13588; Kallal L, 2000, TRENDS PHARMACOL SCI, V21, P175, DOI 10.1016/S0165-6147(00)01477-2; KAPLOWITZ PB, 1988, J CELL PHYSIOL, V136, P13, DOI 10.1002/jcp.1041360103; Kasho M, 1998, KIDNEY INT, V54, P1083, DOI 10.1046/j.1523-1755.1998.00114.x; Keely SJ, 1998, J BIOL CHEM, V273, P27111, DOI 10.1074/jbc.273.42.27111; KramerGuth A, 1997, AM J PHYSIOL-CELL PH, V273, pC1409, DOI 10.1152/ajpcell.1997.273.4.C1409; Lamm MLG, 1999, ENDOCRINOLOGY, V140, P29, DOI 10.1210/en.140.1.29; LANGGUT W, 1995, FEBS LETT, V372, P173, DOI 10.1016/0014-5793(95)00971-B; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; Lee CSL, 1996, J STEROID BIOCHEM, V58, P267, DOI 10.1016/0960-0760(96)00039-8; Li X, 1998, EMBO J, V17, P2574, DOI 10.1093/emboj/17.9.2574; Liebmann C, 1996, J BIOL CHEM, V271, P31098, DOI 10.1074/jbc.271.49.31098; LUND KA, 1990, J BIOL CHEM, V265, P20517; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; Moriguchi Y, 1999, CIRC RES, V84, P1073, DOI 10.1161/01.RES.84.9.1073; MORRISON P, 1993, J BIOL CHEM, V268, P15536; Morrison P, 1996, J BIOL CHEM, V271, P12891, DOI 10.1074/jbc.271.22.12891; MOSS AL, 1991, J CELL PHYSIOL, V149, P319, DOI 10.1002/jcp.1041490220; Murasawa S, 1998, CIRC RES, V82, P1338, DOI 10.1161/01.RES.82.12.1338; NEBIGIL CG, 1995, AM J PHYSIOL-RENAL, V268, pF122, DOI 10.1152/ajprenal.1995.268.1.F122; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PHONPHOK Y, 1991, FEBS LETT, V281, P188, DOI 10.1016/0014-5793(91)80390-O; Pierce KL, 2000, P NATL ACAD SCI USA, V97, P1489, DOI 10.1073/pnas.97.4.1489; Piiper A, 1997, AM J PHYSIOL-GASTR L, V272, pG1276, DOI 10.1152/ajpgi.1997.272.5.G1276; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; RAMIREZ I, 1995, CELL SIGNAL, V7, P303, DOI 10.1016/0898-6568(95)00001-6; Ranieri E, 1996, KIDNEY INT, V50, P1990, DOI 10.1038/ki.1996.521; ROETTGER BF, 1995, J CELL BIOL, V128, P1029, DOI 10.1083/jcb.128.6.1029; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; RUPPRECHT HD, 1992, AM J PHYSIOL, V263, pF623, DOI 10.1152/ajprenal.1992.263.4.F623; SCHLONDORFF D, 1987, AM J PHYSIOL, V253, pC113, DOI 10.1152/ajpcell.1987.253.1.C113; SEEDORF K, 1995, J BIOL CHEM, V270, P18953, DOI 10.1074/jbc.270.32.18953; SERRERO G, 1995, BIOCHEM BIOPH RES CO, V212, P1125, DOI 10.1006/bbrc.1995.2085; Takata Y, 1996, BBA-MOL CELL RES, V1312, P68, DOI 10.1016/0167-4889(96)00017-1; Takemura T, 1999, J PATHOL, V189, P431; TAKUWA N, 1989, AM J PHYSIOL, V257, pF431, DOI 10.1152/ajprenal.1989.257.3.F431; Tang H, 2000, J BIOL CHEM, V275, P13420, DOI 10.1074/jbc.275.18.13420; Tsai W, 1997, EMBO J, V16, P4597, DOI 10.1093/emboj/16.15.4597; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; VERHEIJDEN GF, 1990, BIOCHEM J, V271, P215, DOI 10.1042/bj2710215; Werbonat Y, 2000, J BIOL CHEM, V275, P21969, DOI 10.1074/jbc.M001736200; Zwick E, 1999, TRENDS PHARMACOL SCI, V20, P408, DOI 10.1016/S0165-6147(99)01373-5	81	48	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27335	27344		10.1074/jbc.M103578200	http://dx.doi.org/10.1074/jbc.M103578200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11371570	hybrid			2022-12-25	WOS:000169966900081
J	Matza, D; Wolstein, O; Dikstein, R; Shachar, I				Matza, D; Wolstein, O; Dikstein, R; Shachar, I			Invariant chain induces B cell maturation by activating a TAF(II)105-NF-kappa B-dependent transcription program	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; HEAT-STABLE ANTIGEN(HI); PHOSPHORYLATION; EXPRESSION; TAF(II)105; PROTEINS; MARROW; MOUSE; GENES; P65	Early stages of B cell development occur in the bone marrow, resulting in formation of immature B cells. From there these immature cells migrate to the spleen where they differentiate to mature cells. This final maturation step is crucial for the B cells to become responsive to antigens and to participate in the immune response. Recently, invariant chain (Ii), a major histocompatibility complex class II chaperone, as well as the transcription factors c-Rel and 65/RelA, were found to play a role in the final antigen-independent differentiation stage of B cells in the spleen. In this study, we investigated a possible link between Ii-dependent B cell maturation and the NF-kappaB pathway, Our studies indicate that Ii-induced B cell maturation involves activation of transcription mediated by the NF-kappaB p65/RelA homodimer and requires the B cell-enriched coactivator TBP-associated factor (II)105.	Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Biol Chem, Martha S Sagon Career Dev Chair, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Biol Chem, Alvin & Gertruder Levine Career Dev Chair Canc Re, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science; Weizmann Institute of Science	Shachar, I (corresponding author), Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel.	shachar@weizmann.ac.il						ALLMAN DM, 1992, J IMMUNOL, V149, P2533; ALLMAN DM, 1993, J IMMUNOL, V151, P4431; Anrather J, 1999, J BIOL CHEM, V274, P13594, DOI 10.1074/jbc.274.19.13594; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bendall HH, 1999, MOL IMMUNOL, V36, P187, DOI 10.1016/S0161-5890(99)00031-0; BOEKEL ET, 1995, INT IMMUNOL, V7, P1013; Dikstein R, 1996, CELL, V87, P137, DOI 10.1016/S0092-8674(00)81330-6; EHLICH A, 1994, CURR BIOL, V4, P573, DOI 10.1016/S0960-9822(00)00129-9; ELLIOTT EA, 1994, J EXP MED, V179, P681, DOI 10.1084/jem.179.2.681; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Grossmann M, 2000, EMBO J, V19, P6351, DOI 10.1093/emboj/19.23.6351; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; Henderson A, 1998, ANNU REV IMMUNOL, V16, P163, DOI 10.1146/annurev.immunol.16.1.163; Kenty G, 1998, J IMMUNOL, V160, P606; Kenty G, 1999, J IMMUNOL, V163, P232; MCMAHON SB, 1995, J IMMUNOL METHODS, V179, P251, DOI 10.1016/0022-1759(94)00292-5; RAJEWSKY K, 1993, IMMUNOL TODAY, V14, P40, DOI 10.1016/0167-5699(93)90324-E; Rolink AG, 1998, EUR J IMMUNOL, V28, P3738, DOI 10.1002/(SICI)1521-4141(199811)28:11<3738::AID-IMMU3738>3.0.CO;2-Q; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHACHAR I, 1995, IMMUNITY, V3, P373, DOI 10.1016/1074-7613(95)90121-3; Shachar I, 1996, SCIENCE, V274, P106, DOI 10.1126/science.274.5284.106; Thomas-Vaslin V, 1989, Int Immunol, V1, P237, DOI 10.1093/intimm/1.3.237; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Yamit-Hezi A, 1998, EMBO J, V17, P5161, DOI 10.1093/emboj/17.17.5161; Yamit-Hezi E, 2000, J BIOL CHEM, V275, P18180, DOI 10.1074/jbc.275.24.18180; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	27	88	91	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27203	27206		10.1074/jbc.M104684200	http://dx.doi.org/10.1074/jbc.M104684200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11371575	hybrid			2022-12-25	WOS:000169966900064
J	Mou, HM; Cote, RH				Mou, HM; Cote, RH			The catalytic and GAF domains of the rod cGMP phosphodiesterase (PDE6) heterodimer are regulated by distinct regions of its inhibitory gamma subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; TRANSDUCIN ALPHA-SUBUNIT; SITE-DIRECTED MUTAGENESIS; DEPENDENT PROTEIN-KINASE; PHOTORECEPTOR G-PROTEIN; BINDING-SITES; OUTER SEGMENTS; RETINAL RODS; NUCLEOTIDE PHOSPHODIESTERASE; TARGET ENZYME	The central effector of visual transduction in retinal rod photoreceptors, cGMP phosphodiesterase (PDE6), is a catalytic heterodimer (alpha beta) to which low molecular weight inhibitory gamma subunits bind to form the nonactivated PDE holoenzyme (alpha beta gamma (2)). Although it is known that gamma binds tightly to alpha beta, the binding affinity for each gamma subunit to alpha beta, the domains on gamma that interact with alpha beta, and the allosteric interactions between gamma and the regulatory and catalytic regions on alpha beta are not well understood. We show here that the gamma subunit binds to two distinct sites on the catalytic alpha beta dimer (K-D1 < 1 pM, K-D2 = 3 pM) when the regulatory GAF domains of bovine rod PDE6 are occupied by cGMP. Binding heterogeneity of <gamma> to alpha beta is absent when cAMP occupies the noncatalytic sites. Two major domains on gamma can interact independently with alpha beta with the N-terminal half of gamma binding with 50-fold greater affinity than its C-terminal, inhibitory region. The N-terminal half of gamma is responsible for the positive cooperativity between gamma and cGMP binding sites on alpha beta but has no effect on catalytic activity. Using synthetic peptides, we identified regions of the amino acid sequence of gamma that bind to alpha beta, restore high affinity cGMP binding to low affinity noncatalytic sites, and retard cGMP exchange with both noncatalytic sites. Subunit heterogeneity, multiple sites of gamma interaction with alpha beta, and positive cooperativity of gamma with the GAF domains are all likely to contribute to precisely controlling the activation and inactivation kinetics of PDE6 during visual transduction in rod photoreceptors.	Univ New Hampshire, Dept Biochem & Mol Biol, Durham, NH 03824 USA	University System Of New Hampshire; University of New Hampshire	Cote, RH (corresponding author), Univ New Hampshire, Dept Biochem & Mol Biol, 46 Coll Rd, Durham, NH 03824 USA.		Cote, Rick H/G-3363-2013	Cote, Rick H/0000-0002-1573-6526	NEI NIH HHS [EY-05798, R01 EY005798] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY005798] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Aravind L, 1997, TRENDS BIOCHEM SCI, V22, P458, DOI 10.1016/S0968-0004(97)01148-1; ARSHAVSKY VY, 1992, J BIOL CHEM, V267, P24501; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; ARTEMYEV NO, 1992, BIOCHEM J, V283, P273, DOI 10.1042/bj2830273; ARTEMYEV NO, 1992, J BIOL CHEM, V267, P25067; Artemyev NO, 1998, METHODS, V14, P93, DOI 10.1006/meth.1997.0568; BENNETT N, 1989, BIOCHEMISTRY-US, V28, P7418, DOI 10.1021/bi00444a040; Berger AL, 1999, BIOCHEMISTRY-US, V38, P1293, DOI 10.1021/bi981683m; Bondarenko VA, 1997, J BIOL CHEM, V272, P15856, DOI 10.1074/jbc.272.25.15856; BOWNDS MD, 1995, BEHAV BRAIN SCI, V18, P415, DOI 10.1017/S0140525X00039170; BROWN RL, 1992, BIOCHEMISTRY-US, V31, P5918, DOI 10.1021/bi00140a031; BRUCKERT F, 1994, BIOCHEMISTRY-US, V33, P12625, DOI 10.1021/bi00208a013; BURNS F, 1992, BIOCHEM J, V283, P487, DOI 10.1042/bj2830487; Calvert PD, 1998, J GEN PHYSIOL, V111, P39, DOI 10.1085/jgp.111.1.39; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CLERC A, 1992, J BIOL CHEM, V267, P6620; Conti M, 2000, MOL ENDOCRINOL, V14, P1317, DOI 10.1210/me.14.9.1317; Corbin JD, 2000, EUR J BIOCHEM, V267, P2760, DOI 10.1046/j.1432-1327.2000.01297.x; COTE RH, 1993, J BIOL CHEM, V268, P17190; Cote RH, 2000, METHOD ENZYMOL, V315, P646; D'Amours MR, 1999, BIOCHEM J, V340, P863, DOI 10.1042/0264-6021:3400863; Dryja TP, 1999, INVEST OPHTH VIS SCI, V40, P1859; GAL A, 1994, NAT GENET, V7, P64, DOI 10.1038/ng0594-64; Granovsky AE, 1998, J BIOL CHEM, V273, P24485, DOI 10.1074/jbc.273.38.24485; Granovsky AE, 1997, J BIOL CHEM, V272, P11686, DOI 10.1074/jbc.272.18.11686; Granovsky AE, 2000, J BIOL CHEM, V275, P41258, DOI 10.1074/jbc.M008094200; HAMILTON SE, 1993, FEBS LETT, V318, P157, DOI 10.1016/0014-5793(93)80012-J; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; Hebert MC, 1998, J BIOL CHEM, V273, P5557, DOI 10.1074/jbc.273.10.5557; Ho YSJ, 2000, EMBO J, V19, P5288, DOI 10.1093/emboj/19.20.5288; LIPKIN VM, 1988, FEBS LETT, V234, P287, DOI 10.1016/0014-5793(88)80100-5; LIPKIN VM, 1993, BIOCHIM BIOPHYS ACTA, V1176, P250, DOI 10.1016/0167-4889(93)90052-Q; Malinski JA, 1996, J BIOL CHEM, V271, P12919, DOI 10.1074/jbc.271.22.12919; MARTINS TJ, 1982, J BIOL CHEM, V257, P1973; Matsuura I, 2000, J BIOL CHEM, V275, P32950, DOI 10.1074/jbc.M000702200; Melia TJ, 2000, J BIOL CHEM, V275, P3535, DOI 10.1074/jbc.275.5.3535; Mou HM, 1999, J BIOL CHEM, V274, P18813, DOI 10.1074/jbc.274.26.18813; Natochin M, 1996, J BIOL CHEM, V271, P19964, DOI 10.1074/jbc.271.33.19964; Norton AW, 2000, J BIOL CHEM, V275, P38611, DOI 10.1074/jbc.M004606200; OTTOBRUC A, 1993, BIOCHEMISTRY-US, V32, P8636, DOI 10.1021/bi00084a035; PFISTER C, 1993, CELL SIGNAL, V5, P235, DOI 10.1016/0898-6568(93)90015-E; PIRIEV NI, 1993, P NATL ACAD SCI USA, V90, P9340, DOI 10.1073/pnas.90.20.9340; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; QIN N, 1994, J BIOL CHEM, V269, P3265; SKIBA NP, 1995, J BIOL CHEM, V270, P13210, DOI 10.1074/jbc.270.22.13210; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; Slep KC, 2001, NATURE, V409, P1071, DOI 10.1038/35059138; SLEPAK VZ, 1995, J BIOL CHEM, V270, P14319, DOI 10.1074/jbc.270.24.14319; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TAKEMOTO DJ, 1992, BIOCHEM J, V281, P637, DOI 10.1042/bj2810637; Tsang SH, 1998, SCIENCE, V282, P117, DOI 10.1126/science.282.5386.117; Tsang SH, 1996, SCIENCE, V272, P1026, DOI 10.1126/science.272.5264.1026; TSUBOI S, 1994, J BIOL CHEM, V269, P15016; WENSEL T G, 1986, Proteins Structure Function and Genetics, V1, P90, DOI 10.1002/prot.340010114; Xu LX, 1998, BIOCHEMISTRY-US, V37, P6205, DOI 10.1021/bi973087i; Xu RX, 2000, SCIENCE, V288, P1822, DOI 10.1126/science.288.5472.1822; YAMAMOTO T, 1983, J BIOL CHEM, V258, P2526; Yamazaki A, 1996, J BIOL CHEM, V271, P32495, DOI 10.1074/jbc.271.51.32495; Yamazaki A, 1996, BIOCHEM BIOPH RES CO, V222, P488, DOI 10.1006/bbrc.1996.0771	59	69	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27527	27534		10.1074/jbc.M103316200	http://dx.doi.org/10.1074/jbc.M103316200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11375400	hybrid			2022-12-25	WOS:000169966900104
J	Tang, L; Ammann, R; Gao, T; Gomer, RH				Tang, L; Ammann, R; Gao, T; Gomer, RH			A cell number-counting factor regulates group size in Dictyostelium by differentially modulating cAMP-induced cAMP and cGMP pulse sizes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-MEDIATED ACTIVATION; SIGNAL-TRANSDUCTION; ADENYLYL-CYCLASE; CYTOSOLIC REGULATOR; GUANINE-NUCLEOTIDES; CHEMOATTRACTANT RECEPTOR; GENE-EXPRESSION; DISCOIDEUM; MUTANTS; CHEMOTAXIS	A secreted counting factor (CF), regulates the size of Dictyostelium discoideum fruiting bodies in part by regulating cell-cell adhesion. Aggregation and the expression of adhesion molecules are mediated by relayed pulses of cAMP. Cells also respond to cAMP with a short cGMP pulse. We find that CF slowly down-regulates the cAMP-induced cGMP pulse by inhibiting guanylyl cyclase activity. A 1-min exposure of cells to purified CF increases the cAMP-induced cAMP pulse. CF does not affect the cAMP receptor or its interaction with its associated G proteins or the translocation of the cytosolic regulator of adenylyl cyclase to the membrane in response to cAMP. Pulsing streaming wild-type cells with a high concentration of cAMP results in the formation of small groups, whereas reducing cAMP pulse size with exogenous cAMP phosphodiesterase during stream formation causes cells to form large groups. Altering the extracellular cAMP pulse size does not phenocopy the effects of CF on the cAMP-induced cGMP pulse size or cell-cell adhesion, indicating that CF does not regulate cGMP pulses and adhesion via CF's effects on cAMP pulses. The results suggest that regulating cell-cell adhesion, the cGMP pulse size, or the cAMP pulse size can control group size and that CF regulates all three of these independently.	Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77005 USA; Rice Univ, Howard Hughes Med Inst, Houston, TX 77005 USA	Rice University; Howard Hughes Medical Institute; Rice University	Gomer, RH (corresponding author), Rice Univ, Dept Biochem & Cell Biol, MS-140,6100 S Main St, Houston, TX 77005 USA.			Gomer, Richard/0000-0003-2361-4307				BONNER JT, 1963, J EMBRYOL EXP MORPH, V11, P571; BONNER JT, 1969, DEV BIOL, V20, P72, DOI 10.1016/0012-1606(69)90005-0; Brazill DT, 1997, FEBS LETT, V404, P100, DOI 10.1016/S0014-5793(97)00104-X; Brazill DT, 1998, J BIOL CHEM, V273, P8161, DOI 10.1074/jbc.273.14.8161; Brock DA, 1996, DEVELOPMENT, V122, P2569; Brock DA, 1999, GENE DEV, V13, P1960, DOI 10.1101/gad.13.15.1960; Chen MY, 1997, GENE DEV, V11, P3218, DOI 10.1101/gad.11.23.3218; Chen MY, 1996, TRENDS GENET, V12, P52, DOI 10.1016/0168-9525(96)81400-4; COUKELL MB, 1984, DEV BIOL, V103, P246, DOI 10.1016/0012-1606(84)90026-5; COUKELL MB, 1986, DEV GENET, V6, P163; Deery WJ, 1999, J BIOL CHEM, V274, P34476, DOI 10.1074/jbc.274.48.34476; FAURE M, 1988, P NATL ACAD SCI USA, V85, P8076, DOI 10.1073/pnas.85.21.8076; FIRTEL RA, 1995, GENE DEV, V9, P1427, DOI 10.1101/gad.9.12.1427; Firtel RA, 2000, CURR OPIN GENET DEV, V10, P421, DOI 10.1016/S0959-437X(00)00107-6; Gerisch G, 1968, Curr Top Dev Biol, V3, P157; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOMER RH, 1991, DEVELOPMENT, V112, P269; Gomer RH, 2001, NAT REV MOL CELL BIO, V2, P48, DOI 10.1038/35048058; HARWOOD AJ, 1992, DEV BIOL, V149, P90, DOI 10.1016/0012-1606(92)90266-J; HOHL HR, 1964, DEV BIOL, V9, P137, DOI 10.1016/0012-1606(64)90018-1; INSALL R, 1994, J CELL BIOL, V126, P1537, DOI 10.1083/jcb.126.6.1537; JAIN R, 1992, GENE DEV, V6, P390, DOI 10.1101/gad.6.3.390; Jin T, 2000, SCIENCE, V287, P1034, DOI 10.1126/science.287.5455.1034; KESBEKE F, 1988, DEV BIOL, V130, P464, DOI 10.1016/0012-1606(88)90342-9; KESBEKE F, 1988, J CELL BIOL, V107, P521, DOI 10.1083/jcb.107.2.521; KLEIN PS, 1988, SCIENCE, V241, P1467, DOI 10.1126/science.3047871; KUMAGAI A, 1989, CELL, V57, P265, DOI 10.1016/0092-8674(89)90964-1; KUWAYAMA H, 1993, J CELL BIOL, V123, P1453, DOI 10.1083/jcb.123.6.1453; Lee S, 1999, MOL BIOL CELL, V10, P2829, DOI 10.1091/mbc.10.9.2829; LILLY P, 1993, GENE DEV, V7, P986, DOI 10.1101/gad.7.6.986; LILLY PJ, 1994, J BIOL CHEM, V269, P14123; Loomis WF., 1975, DICTYOSTELIUM DISCOI; Ma H, 1997, EMBO J, V16, P4317, DOI 10.1093/emboj/16.14.4317; MAEDA R, 1997, FRONTIERS SCI SERIES, V21; Mann SKO, 1997, DEV BIOL, V183, P208, DOI 10.1006/dbio.1996.8499; MEHDY MC, 1985, MOL CELL BIOL, V5, P705, DOI 10.1128/MCB.5.4.705; Meili R, 1999, EMBO J, V18, P2092, DOI 10.1093/emboj/18.8.2092; NEWELL PC, 1992, BIOESSAYS, V14, P473, DOI 10.1002/bies.950140708; NEWELL PC, 1988, J CELL SCI, V89, P123; Parente CA, 1998, CELL, V95, P81, DOI 10.1016/S0092-8674(00)81784-5; PETERS DJM, 1991, DEV GENET, V12, P25, DOI 10.1002/dvg.1020120107; PITT GS, 1992, CELL, V69, P305, DOI 10.1016/0092-8674(92)90411-5; RIEDEL V, 1973, J MOL BIOL, V74, P573, DOI 10.1016/0022-2836(73)90048-X; Roisin-Bouffay C, 2000, MOL CELL, V6, P953, DOI 10.1016/S1097-2765(05)00082-1; ROSS FM, 1981, J GEN MICROBIOL, V127, P339; SHAFFER BM, 1957, Q J MICROSC SCI, V98, P393; SNAARJAGALSKA BE, 1988, J CELL SCI, V91, P287; SNAARJAGALSKA BE, 1994, METHOD ENZYMOL, V237, P387; Spann TP, 1996, P NATL ACAD SCI USA, V93, P5003, DOI 10.1073/pnas.93.10.5003; SUN TJ, 1991, GENE DEV, V5, P572, DOI 10.1101/gad.5.4.572; SUSSMAN RR, 1953, ANN NY ACAD SCI, V56, P949, DOI 10.1111/j.1749-6632.1953.tb30274.x; THADANI V, 1977, EXP CELL RES, V108, P75, DOI 10.1016/S0014-4827(77)80011-6; THEIBERT A, 1986, J BIOL CHEM, V261, P5121; vanHaastert PJM, 1997, FEBS LETT, V410, P25, DOI 10.1016/S0014-5793(97)00416-X; VANHAASTERT PJM, 1989, BIOCHEM J, V258, P577, DOI 10.1042/bj2580577; VANHAASTERT PJM, 1982, MOL CELL ENDOCRINOL, V25, P171, DOI 10.1016/0303-7207(82)90050-8; VANHAASTERT PJM, 1987, EUR J BIOCHEM, V162, P251; VANHAASTERT PJM, 1984, BIOCHEM BIOPH RES CO, V124, P597, DOI 10.1016/0006-291X(84)91596-1; Wang B, 1999, DEV BIOL, V208, P1, DOI 10.1006/dbio.1998.9193; WU L, 1995, DEV BIOL, V171, P149, DOI 10.1006/dbio.1995.1267	60	34	35	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27663	27669		10.1074/jbc.M102205200	http://dx.doi.org/10.1074/jbc.M102205200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11371560	hybrid			2022-12-25	WOS:000169966900122
J	Overmeyer, JH; Wilson, AL; Maltese, WA				Overmeyer, JH; Wilson, AL; Maltese, WA			Membrane targeting of a Rab GTPase that fails to associate with Rab escort protein (REP) or guanine nucleotide dissociation inhibitor (GDI)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY LIPOPROTEIN RECEPTOR; ENDOPLASMIC-RETICULUM; GERANYLGERANYL TRANSFERASE; POSTTRANSLATIONAL MODIFICATION; VESICULAR TRANSPORT; GOLGI COMPARTMENTS; IN-VITRO; BINDING; COMPLEX; FUSION	The targeting of various Rab proteins to different subcellular compartments appears to be determined by variable amino acid sequences located upstream from geranylgeranylated cysteine residues in the C-terminal tail. All nascent Rab proteins are prenylated by geranylgeranyltransferase II, which recognizes the Rab substrate only when it is bound to Rab escort protein (REP), After prenylation, REP remains associated with the modified Rab until it is delivered to the appropriate subcellular membrane. It remains unclear whether docking of the Rab with the correct membrane is solely a function of features contained within the prenylated Rab itself (with REP serving as a "passive" carrier) or whether REP actively participates in the targeting process. To address this issue, we took advantage of a mutation in the alpha2 helix of Rab1B (i.e. Y78D) that abolishes REP and GDI interaction without disrupting nucleotide binding or hydrolysis. These studies demonstrate that replacing the C-terminal GGCC residues of Rab1B(Y78D) with a CLLL motif permits this protein to be prenylated by geranylgeranyltransferase I but not II both in cell-free enzyme assays and in transfected cells. Subcellular fractionation and immunofluorescence studies reveal that the prenylated Rab1B(Y78D)CLLL, which remains deficient in REP and GDI association is, nonetheless, delivered to the Golgi and endoplasmic reticulum (ER) membranes. When the dominant-negative S22N mutation was inserted into Rab1B-CLLL, the resulting monoprenylated construct suppressed ER --> Golgi protein transport. However, when the Y78D mutation was added to the latter construct, its inhibitory effect on protein trafficking was lost despite the fact that it was localized to the ER/Golgi membrane. Therefore, protein interactions mediated by the alpha2 helical domain of Rab1B(S22N) appear to be essential for its functional interaction with components of the ER --> Golgi transport machinery.	Med Coll Ohio, Dept Biochem & Mol Biol, Toledo, OH 43614 USA; Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA	Case Western Reserve University	Maltese, WA (corresponding author), Med Coll Ohio, Dept Biochem & Mol Biol, 3035 Arlington Ave, Toledo, OH 43614 USA.				NATIONAL CANCER INSTITUTE [R01CA034569] Funding Source: NIH RePORTER; NCI NIH HHS [CA34569] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROV K, 1994, EMBO J, V13, P5262, DOI 10.1002/j.1460-2075.1994.tb06860.x; Alexandrov K, 1999, EUR J BIOCHEM, V265, P160, DOI 10.1046/j.1432-1327.1999.00699.x; Allan BB, 2000, SCIENCE, V289, P444, DOI 10.1126/science.289.5478.444; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; ANTONY C, 1992, J CELL SCI, V103, P785; BARBIERI MA, 1994, J BIOL CHEM, V269, P18720; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; CASTELLANO FC, 1995, J RECEPT SIGNAL TR R, V5, P847; CHAVRIER P, 1992, GENE, V112, P261, DOI 10.1016/0378-1119(92)90387-5; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; CUMMINGS RD, 1983, J BIOL CHEM, V258, P5261; Dai Q, 1998, J BIOL CHEM, V273, P15030, DOI 10.1074/jbc.273.24.15030; Danilczyk UG, 2000, J BIOL CHEM, V275, P13089, DOI 10.1074/jbc.275.17.13089; DiracSvejstrup AB, 1997, EMBO J, V16, P465, DOI 10.1093/emboj/16.3.465; Erdman RA, 2000, J BIOL CHEM, V275, P3848, DOI 10.1074/jbc.275.6.3848; JANG GF, 1993, BIOCHEMISTRY-US, V32, P9500, DOI 10.1021/bi00087a031; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; KINSELLA BT, 1991, P NATL ACAD SCI USA, V88, P8934, DOI 10.1073/pnas.88.20.8934; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lupashin VV, 1997, SCIENCE, V276, P1255, DOI 10.1126/science.276.5316.1255; Martinez O, 1998, BBA-MOL CELL RES, V1404, P101, DOI 10.1016/S0167-4889(98)00050-0; Miaczynska M, 1997, J BIOL CHEM, V272, P16972, DOI 10.1074/jbc.272.27.16972; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; MUSHA T, 1992, J BIOL CHEM, V267, P9821; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; NEWMAN CMH, 1992, J BIOL CHEM, V267, P11329; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; NUOFFER C, 1994, J CELL BIOL, V125, P225, DOI 10.1083/jcb.125.2.225; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; OVERMEYER JH, 1992, J BIOL CHEM, V267, P22686; Overmeyer JH, 1998, MOL BIOL CELL, V9, P223, DOI 10.1091/mbc.9.1.223; PFEFFER SR, 1995, J BIOL CHEM, V270, P17057, DOI 10.1074/jbc.270.29.17057; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; PIND SN, 1994, J CELL BIOL, V125, P239, DOI 10.1083/jcb.125.2.239; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; Rothman JE, 1997, SCIENCE, V276, P1212, DOI 10.1126/science.276.5316.1212; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; SARASTE J, 1995, J CELL SCI, V108, P1541; Schalk I, 1996, NATURE, V381, P42, DOI 10.1038/381042a0; Schmidt WK, 1998, P NATL ACAD SCI USA, V95, P11175, DOI 10.1073/pnas.95.19.11175; Seabra MC, 1996, J BIOL CHEM, V271, P14398, DOI 10.1074/jbc.271.24.14398; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; Shen F, 1996, J BIOL CHEM, V271, P3692; SOLDATI T, 1993, MOL BIOL CELL, V4, P425, DOI 10.1091/mbc.4.4.425; STENMARK H, 1994, EMBO J, V13, P575, DOI 10.1002/j.1460-2075.1994.tb06295.x; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; TOLLESHAUG H, 1982, CELL, V30, P715, DOI 10.1016/0092-8674(82)90276-8; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; Vogt A, 1996, ONCOGENE, V13, P1991; WEI C, 1992, ONCOGENE, V7, P467; Wilson AL, 1996, J BIOL CHEM, V271, P10932, DOI 10.1074/jbc.271.18.10932; Wilson AL, 1996, BIOCHEM J, V318, P1007, DOI 10.1042/bj3181007; Wilson AL, 1998, BIOCHEM J, V333, P497, DOI 10.1042/bj3330497; Wu SK, 1998, J BIOL CHEM, V273, P26931, DOI 10.1074/jbc.273.41.26931	60	9	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20379	20386		10.1074/jbc.M101511200	http://dx.doi.org/10.1074/jbc.M101511200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11389151	hybrid			2022-12-25	WOS:000169135100096
J	Horswill, AR; Dudding, AR; Escalante-Semerena, JC				Horswill, AR; Dudding, AR; Escalante-Semerena, JC			Studies of propionate toxicity in Salmonella enterica identify 2-methylcitrate as a potent inhibitor of cell growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CITRATE SYNTHASE REACTION; CHAIN FATTY-ACIDS; ESCHERICHIA-COLI; METHYLCITRATE SYNTHASE; PRP LOCUS; TYPHIMURIUM; TRANSFORMATION; IDENTIFICATION; METABOLISM; MUTANTS	Salmonella enterica serovar Typhimurium LT2 showed increased sensitivity to propionate when the 2-methylcitric acid cycle was blocked. A derivative of a prpC mutant (which lacked 2-methylcitrate synthase activity) resistant to propionate was isolated, and the mutation responsible for the newly acquired resistance to propionate was mapped to the citrate synthase (gltA) gene. These results suggested that citrate synthase activity was the source of the increased sensitivity to propionate observed in the absence of the 2-methylcitric acid cycle. DNA sequencing of the wild-type and mutant gltA alleles revealed that the ATG start codon of the wild-type gene was converted to the rare GTG start codon in the revertant strain. This result suggested that lower levels of this enzyme were present in the mutant. Consistent with this change, cell-free extracts of the propionate-resistant strain contained 12-fold less citrate synthase activity. This was interpreted to mean that, in the wild-type strain, high levels of citrate synthase activity were the source of a toxic metabolite. In vitro experiments performed with homogeneous citrate synthase enzyme indicated that this enzyme was capable of synthesizing 2-methylcitrate from propionyl-CoA and oxaloacetate, This result lent further support to the in vivo data, which suggested that citrate synthase was the source of a toxic metabolite.	Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Escalante-Semerena, JC (corresponding author), Univ Wisconsin, Dept Bacteriol, 1550 Linden Dr, Madison, WI 53706 USA.	jcescala@facstaff.wisc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062203] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM062203, GM62203, GM08349] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARNES EM, 1979, J HYG-CAMBRIDGE, V82, P263, DOI 10.1017/S0022172400025687; BEACH RL, 1977, J BIOL CHEM, V252, P2702; BERKOWIT.D, 1968, J BACTERIOL, V96, P215, DOI 10.1128/JB.96.1.215-220.1968; Blankenhorn D, 1999, J BACTERIOL, V181, P2209, DOI 10.1128/JB.181.7.2209-2216.1999; Bobik TA, 1999, J BACTERIOL, V181, P5967, DOI 10.1128/JB.181.19.5967-5975.1999; BOHNHOFF M, 1962, J INFECT DIS, V111, P117, DOI 10.1093/infdis/111.2.117; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDANGE S, 1977, ACTA CHEM SCAND B, V31, P628, DOI 10.3891/acta.chem.scand.31b-0628; BRANDANGE S, 1984, ACTA CHEM SCAND B, V38, P695, DOI 10.3891/acta.chem.scand.38b-0695; Brock M, 2000, MOL MICROBIOL, V35, P961, DOI 10.1046/j.1365-2958.2000.01737.x; BYRNE BM, 1979, INFECT IMMUN, V23, P559, DOI 10.1128/IAI.23.3.559-563.1979; CHAN RK, 1972, VIROLOGY, V50, P883, DOI 10.1016/0042-6822(72)90442-4; CHANG KH, 1992, BIOCHEMISTRY-US, V31, P5605, DOI 10.1021/bi00139a025; CHEEMADHADLI S, 1975, PEDIATR RES, V9, P905, DOI 10.1203/00006450-197512000-00008; CHERRINGTON CA, 1991, ADV MICROB PHYSIOL, V32, P87; Clark D. P., 1996, ESCHERICHIA COLI SAL, P343; CUMMINGS JH, 1987, GUT, V28, P1221, DOI 10.1136/gut.28.10.1221; DAVIS RW, 1980, MANUAL GENETIC ENG A, P78; DAWSON RMC, 1986, DATA BIOCH RES, P388; EnosBerlage JL, 1997, J BACTERIOL, V179, P3989, DOI 10.1128/jb.179.12.3989-3996.1997; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hammelman TA, 1996, FEMS MICROBIOL LETT, V137, P233; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HARTZ D, 1991, J MOL BIOL, V218, P83, DOI 10.1016/0022-2836(91)90875-7; Hesslinger C, 1998, MOL MICROBIOL, V27, P477, DOI 10.1046/j.1365-2958.1998.00696.x; Hinton A, 1996, J APPL BACTERIOL, V81, P188, DOI 10.1111/j.1365-2672.1996.tb04498.x; Horswill AR, 1999, J BACTERIOL, V181, P5615, DOI 10.1128/JB.181.18.5615-5623.1999; Horswill AR, 1999, MICROBIOL-UK, V145, P1381, DOI 10.1099/13500872-145-6-1381; Horswill AR, 1997, J BACTERIOL, V179, P928, DOI 10.1128/jb.179.3.928-940.1997; HUME ME, 1993, AVIAN DIS, V37, P1051, DOI 10.2307/1591912; INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P; KABARA JJ, 1991, FOOD PRESERVATIVES, P45; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKSHMI TM, 1976, J BACTERIOL, V127, P76, DOI 10.1128/JB.127.1.76-83.1976; LUCK E, 1997, ANTIMICROBIAL FOOD A, P145; Macfarlane GT, 1997, SCAND J GASTROENTERO, V32, P3, DOI 10.1080/00365521.1997.11720708; MAN WJ, 1995, BBA-PROTEIN STRUCT M, V1250, P69, DOI 10.1016/0167-4838(95)00044-U; MARUYAMA K, 1985, J BIOCHEM, V98, P819, DOI 10.1093/oxfordjournals.jbchem.a135340; Matlho G, 1997, AVIAN DIS, V41, P58, DOI 10.2307/1592443; MCHAN F, 1992, AVIAN DIS, V36, P139, DOI 10.2307/1591728; MEYNELL GG, 1963, BRIT J EXP PATHOL, V44, P197; MEYNELL GG, 1963, BRIT J EXP PATHOL, V44, P209; O'Toole GA, 1998, MOL MICROBIOL, V28, P449, DOI 10.1046/j.1365-2958.1998.00797.x; OBRADORS N, 1988, J BACTERIOL, V170, P2159, DOI 10.1128/jb.170.5.2159-2162.1988; PARKER JD, 1991, NUCLEIC ACIDS RES, V19, P3055, DOI 10.1093/nar/19.11.3055; RUSSELL JB, 1992, J APPL BACTERIOL, V73, P363, DOI 10.1111/j.1365-2672.1992.tb04990.x; RYU J, 1990, BIOTECHNIQUES, V8, P43; SALMOND CV, 1984, J GEN MICROBIOL, V130, P2845; SASSE J, 1991, CURRENT PROTOCOLS MO, V1, DOI DOI 10.6.1-10.6.8; SCHMIEGER H, 1973, MOL GEN GENET, V120, P181, DOI 10.1007/BF00267246; SCHMIEGER H, 1971, MOL GEN GENET, V110, P378, DOI 10.1007/BF00438281; Sealy-Lewis HM, 1998, MICROBIOL-UK, V144, P1895, DOI 10.1099/00221287-144-7-1895; SEIDMAN CG, 1997, CURRENT PROTOCOLS MO, V1; SRERE PA, 1963, ACTA CHEM SCAND, V17, P129, DOI 10.3891/acta.chem.scand.17s-0129; TABUCHI T, 1974, AGR BIOL CHEM TOKYO, V38, P1105, DOI 10.1080/00021369.1974.10861293; Textor S, 1997, ARCH MICROBIOL, V168, P428, DOI 10.1007/s002030050518; Thompson JL, 1997, BRIT POULTRY SCI, V38, P59, DOI 10.1080/00071669708417941; TSAI SP, 1989, J GEN MICROBIOL, V135, P2561; VANROOYEN JPG, 1994, J INHERIT METAB DIS, V17, P738, DOI 10.1007/BF00712017; VOYTAS D, 2000, CURRENT PROTOCOLS MO, V1; WAY JC, 1984, GENE, V32, P369, DOI 10.1016/0378-1119(84)90012-X; WEIDMAN SW, 1979, BIOCHEM J, V177, P169, DOI 10.1042/bj1770169	62	71	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19094	19101		10.1074/jbc.m100244200	http://dx.doi.org/10.1074/jbc.m100244200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11376009	hybrid			2022-12-25	WOS:000169091000063
J	Drewett, V; Devitt, A; Saxton, J; Portman, N; Greaney, P; Cheong, N; Alnemri, TF; Alnemri, E; Shaw, PE				Drewett, V; Devitt, A; Saxton, J; Portman, N; Greaney, P; Cheong, N; Alnemri, TF; Alnemri, E; Shaw, PE			Serum response factor cleavage by caspases 3 and 7 linked to apoptosis in human BJAB cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; DNA-BINDING ACTIVITY; C-FOS PROMOTER; TERNARY COMPLEX-FORMATION; NF-KAPPA-B; TRANSCRIPTIONAL ACTIVATION; PHOSPHORYLATION SITES; MEDIATED ACTIVATION; FACTOR ELK-1; EXPRESSION	Apoptosis involves the cessation of cellular processes, the breakdown of intracellular organelles, and, finally, the nonphlogistic clearance of apoptotic cells from the body. Important for these events is a family of proteases, caspases, which are activated by a proteolytic cleavage cascade and drive apoptosis by targeting key proteins within the cell. Here, we demonstrate that serum response factor (SRF), a transcription factor essential for proliferative gene expression, is cleaved by caspases and that this cleavage occurs in proliferating murine fibroblasts and can be induced in the human B-cell line BJAB. We identify the two major sites at which SRF cleavage occurs as Asp(245) and Asp(254), the caspases responsible for the cleavage and generate a mutant of SRF resistant to cleavage in BJAB cells. Investigation of the physiological and functional significance of SRF cleavage reveals that it correlates with the loss of e-fos expression, whereby neither SRF cleavage fragment retains transcriptional activity. Moreover, the expression of a noncleavable SRF in BJAB cells suppresses apoptosis induced by Fas cross-linking. These results suggest that for apoptosis to proceed, the transcriptional events promoting cell survival and proliferation, in which SRF is involved, must first be inactivated.	Univ Nottingham, Queens Med Ctr, Sch Biomed Sci, Nottingham NG7 2UH, England; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	University of Nottingham; Jefferson University	Shaw, PE (corresponding author), Univ Nottingham, Queens Med Ctr, Sch Biomed Sci, Nottingham NG7 2UH, England.		Alnemri, Emad S/B-4526-2010	Devitt, Andrew/0000-0002-4651-6761; Portman, Neil/0000-0003-0248-0258; SHAW, Peter/0000-0002-2598-4283				AMMERER G, 1990, GENE DEV, V4, P299, DOI 10.1101/gad.4.2.299; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Arsenian S, 1998, EMBO J, V17, P6289, DOI 10.1093/emboj/17.21.6289; Belaguli NS, 1999, MOL CELL BIOL, V19, P4582; Bertolotto C, 2000, J BIOL CHEM, V275, P12941, DOI 10.1074/jbc.275.17.12941; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Cotter T.G., 1996, TECHNIQUES APOPTOSIS; Crouch DH, 1996, ONCOGENE, V12, P2689; De Maria R, 1999, NATURE, V401, P489, DOI 10.1038/46809; Drewett V, 2001, NUCLEIC ACIDS RES, V29, P479, DOI 10.1093/nar/29.2.479; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; GauthierRouviere C, 1996, MOL BIOL CELL, V7, P719, DOI 10.1091/mbc.7.5.719; Gervais FG, 1998, J BIOL CHEM, V273, P17102, DOI 10.1074/jbc.273.27.17102; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; Grandgirard D, 1998, EMBO J, V17, P1268, DOI 10.1093/emboj/17.5.1268; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HILL CS, 1994, EMBO J, V13, P5421, DOI 10.1002/j.1460-2075.1994.tb06877.x; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; JANKNECHT R, 1995, IMMUNOBIOLOGY, V193, P137, DOI 10.1016/S0171-2985(11)80536-X; JOHANSEN FE, 1995, BBA-REV CANCER, V1242, P1, DOI 10.1016/0304-419X(94)00014-S; JOLIET V, 1995, NATURE, V373, P632, DOI 10.1038/373632a0; King P, 1998, J BIOL CHEM, V273, P8699, DOI 10.1074/jbc.273.15.8699; Kortenjann M, 1995, CRIT REV ONCOGENESIS, V6, P99; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; MANAK JR, 1991, MOL CELL BIOL, V11, P3652, DOI 10.1128/MCB.11.7.3652; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; MUELLER CGF, 1991, EMBO J, V10, P4219, DOI 10.1002/j.1460-2075.1991.tb05000.x; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; PASSMORE S, 1989, GENE DEV, V3, P921, DOI 10.1101/gad.3.7.921; PELLEGRINI L, 1995, NATURE, V376, P490, DOI 10.1038/376490a0; Ravi R, 1998, CANCER RES, V58, P882; RIVERA V M, 1990, New Biologist, V2, P751; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Savill J, 1998, NATURE, V392, P442, DOI 10.1038/33025; SCHROTER H, 1990, EMBO J, V9, P1123, DOI 10.1002/j.1460-2075.1990.tb08218.x; SCHWARZSOMMER Z, 1990, SCIENCE, V250, P931, DOI 10.1126/science.250.4983.931; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHAW PE, 1989, EMBO J, V8, P2567, DOI 10.1002/j.1460-2075.1989.tb08395.x; SHAW PE, 1994, FOS JUN FAMILIES TRA, P71; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Soulez M, 1996, MOL CELL BIOL, V16, P6065; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srinivasula SM, 1996, J BIOL CHEM, V271, P27099, DOI 10.1074/jbc.271.43.27099; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Townsend KJ, 1999, J BIOL CHEM, V274, P1801, DOI 10.1074/jbc.274.3.1801; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; ZHU H, 1994, J BIOL CHEM, V269, P3489	64	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33444	33451		10.1074/jbc.M103877200	http://dx.doi.org/10.1074/jbc.M103877200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11387340	hybrid, Green Accepted			2022-12-25	WOS:000170910200022
J	Langer, MR; Tanner, KG; Denu, JM				Langer, MR; Tanner, KG; Denu, JM			Mutational analysis of conserved residues in the GCN5 family of histone acetyltransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOME CONDENSATION; TRANSCRIPTIONAL COACTIVATOR; P300/CBP-ASSOCIATED FACTOR; H3 PHOSPHORYLATION; PARTITION ANALYSIS; KINETIC MECHANISM; CRYSTAL-STRUCTURE; COENZYME-A; ACETYLATION; YEAST	GCN5 is a critical transcriptional co-activator and is the defining member of a large superfamily of N-acetyl-transferases. GCN5 catalyzes the transfer of an acetyl group from acetyl-CoA to the epsilon -amino of lysine 14 within the core H3 histone protein. Previous biochemical analyses have indicated a fully ordered kinetic mechanism. Recent structural studies have implicated several conserved residues in catalysis and substrate binding. Here the roles of Glu-173, His-145, and Asp-214 in yeast GCN5 have been evaluated using site-directed mutagenesis, steady state and pre-steady state kinetics, pH analysis, isotope partitioning, and equilibrium binding studies. The results with wild type and E173Q, H145A, and D214A mutants are consistent with chemical catalysis being rate-determining in turnover. All mutants exhibited Kd values (3.5-8.5 mum) for AcCoA that were similar to wild type enzyme, indicating no functional role for these residues in AcCoA binding. The E173Q mutant demonstrated a similar to 500-600-fold decreases in k(cat) and k(cat)/K-m,(H3), consistent with Glu-173 acting as the general base catalyst as proposed previously. No significant effect was observed on substrate binding steps. His-145 was identified as a residue in the peptide binding cleft that must be unprotonated (pK(a) = 5.8) for peptide binding and likely hydrogen-bonds to the Ser-10 hydroxyl of histone H3. His-145 also contributes to lowering the pK(a) value (by 0.8 units) of general base Glu-173 through a water-mediated hydrogen bond to the carboxylate side chain. Analysis of D214A revealed an obligate protein isomerization step that occurs after AcCoA binding and permits efficient peptide binding. Asp-214 is part of a conformationally flexible loop that mediates the isomerization by stabilizing distinct conformers of the protein.	Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA	Oregon Health & Science University	Denu, JM (corresponding author), Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, 3180 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007680] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059785] Funding Source: NIH RePORTER; NIDDK NIH HHS [T32 DK07680] Funding Source: Medline; NIGMS NIH HHS [GM59785] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Cleland W W, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P273; CLELAND WW, 1975, BIOCHEMISTRY-US, V14, P3220, DOI 10.1021/bi00685a029; Clements A, 1999, EMBO J, V18, P3521, DOI 10.1093/emboj/18.13.3521; Grant PA, 1999, J BIOL CHEM, V274, P5895, DOI 10.1074/jbc.274.9.5895; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Kim Y, 2000, ANAL BIOCHEM, V280, P308, DOI 10.1006/abio.2000.4546; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; Krebs JE, 2000, CELL, V102, P587, DOI 10.1016/S0092-8674(00)00081-7; Kuo MH, 2000, MOL CELL, V6, P1309, DOI 10.1016/S1097-2765(00)00129-5; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; Lau OD, 2000, J BIOL CHEM, V275, P21953, DOI 10.1074/jbc.M003219200; Lin YX, 1999, NATURE, V400, P86, DOI 10.1038/21922; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; Mizzen CA, 1998, CELL MOL LIFE SCI, V54, P6, DOI 10.1007/s000180050121; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Rojas JR, 1999, NATURE, V401, P93, DOI 10.1038/43487; Rose I A, 1980, Methods Enzymol, V64, P47; ROSE IA, 1974, J BIOL CHEM, V249, P5163; ROSE IA, 1995, METHOD ENZYMOL, V249, P315; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Schiltz RL, 1999, J BIOL CHEM, V274, P1189, DOI 10.1074/jbc.274.3.1189; Tanner KG, 2000, J BIOL CHEM, V275, P22048, DOI 10.1074/jbc.M002893200; Tanner KG, 2000, BIOCHEMISTRY-US, V39, P11961, DOI 10.1021/bi001272h; Tanner KG, 1999, J BIOL CHEM, V274, P18157, DOI 10.1074/jbc.274.26.18157; Trievel RC, 1999, P NATL ACAD SCI USA, V96, P8931, DOI 10.1073/pnas.96.16.8931; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; Wei Y, 1998, P NATL ACAD SCI USA, V95, P7480, DOI 10.1073/pnas.95.13.7480; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7; Xu WT, 2000, NAT GENET, V26, P229, DOI 10.1038/79973; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zhang WZ, 1998, EMBO J, V17, P3155, DOI 10.1093/emboj/17.11.3155	39	24	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31321	31331		10.1074/jbc.M103839200	http://dx.doi.org/10.1074/jbc.M103839200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11397810	hybrid			2022-12-25	WOS:000170472900096
J	Viscomi, C; Altomare, C; Bucchi, A; Camatini, E; Baruscotti, M; Moroni, A; DiFrancesco, D				Viscomi, C; Altomare, C; Bucchi, A; Camatini, E; Baruscotti, M; Moroni, A; DiFrancesco, D			C terminus-mediated control of voltage and cAMP gating of hyperpolarization-activated cyclic nucleotide-gated channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PACEMAKER CHANNELS; HCN2; FAMILY	The hyperpolarization-activated cyclic nucleotide-gated (RON) family of "pacemaker" channels includes 4 isoforms, the kinetics and cAMP-induced modulation of which differ quantitatively. Because HCN isoforms are highly homologous. in the central region, but diverge more substantially in the N and C termini, we asked whether these latter regions could contribute to the determination of channel properties. To this aim, we analyzed activation/deactivation. kinetics and the response to cAMP of heterologously expressed isoforms mHCN1 and rbHCN4 and verified that mHCN1 has much faster kinetics and lower cAMP sensitivity than rbHCN4. We then constructed rbHCN4 chimeras by replacing either the N or the C terminus, or both, with the analogous domains from mHCN1. We found that: 1) replacement of the N terminus (chimera N1-4) did not substantially modify either the kinetics or cAMP dependence of wildtype channels; 2) replacement of the C terminus, on the contrary, resulted in a chimeric channel (4-Cl), the kinetics of which were strongly accelerated compared with rbHCN4, and that was fully insensitive to cAMP; 3) replacement of both N and C termini led to the same results as replacement of the C terminus alone. These results indicate that the C terminus of rbHCN4 contributes to the regulation of voltage- and cAMP-dependent channel gating, possibly through interaction with other intracellular regions not belonging to the N terminus.	Unita Milano Univ, Dipartimento Fisiol & Biochim Gen, Lab Fisiol Mol & Neurobiol, I-20133 Milan, Italy; Unita Milano Univ, INFM, I-20133 Milan, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Milan	DiFrancesco, D (corresponding author), Unita Milano Univ, Dipartimento Fisiol & Biochim Gen, Lab Fisiol Mol & Neurobiol, Via Celoria 26, I-20133 Milan, Italy.	dario.difrancesco@unimi.it	Bucchi, Annalisa/B-1882-2017; viscomi, Carlo/R-1940-2016; DiFrancesco, Dario/G-8408-2017; moroni, anna/H-2097-2014; BARUSCOTTI, MIRKO/D-7017-2017	Bucchi, Annalisa/0000-0002-5303-4242; DiFrancesco, Dario/0000-0002-7322-1790; moroni, anna/0000-0002-1860-406X; BARUSCOTTI, MIRKO/0000-0002-6155-8388; Viscomi, Carlo/0000-0001-6050-0566; Altomare, Claudia/0000-0001-8743-9080	Telethon [971] Funding Source: Medline	Telethon(Fondazione Telethon)		Accili EA, 1996, PFLUG ARCH EUR J PHY, V431, P757; Altomare C, 2001, J GEN PHYSIOL, V117, P519, DOI 10.1085/jgp.117.6.519; Barbuti A, 1999, J PHYSIOL-LONDON, V520, P737, DOI 10.1111/j.1469-7793.1999.00737.x; Chen J, 2000, J BIOL CHEM, V275, P36465, DOI 10.1074/jbc.M007034200; Clapham DE, 1998, NEURON, V21, P5, DOI 10.1016/S0896-6273(00)80508-5; DIFRANCESCO D, 1986, J PHYSIOL-LONDON, V377, P61, DOI 10.1113/jphysiol.1986.sp016177; DiFrancesco D, 1999, J PHYSIOL-LONDON, V515, P367, DOI 10.1111/j.1469-7793.1999.367ac.x; DIFRANCESCO D, 1993, ANNU REV PHYSIOL, V55, P455, DOI 10.1146/annurev.physiol.55.1.455; DIFRANCESCO D, 1991, NATURE, V351, P145, DOI 10.1038/351145a0; DIFRANCESCO D, 1994, HDB MEMBRANE CHANNEL, P335; Gauss R, 1998, NATURE, V393, P583, DOI 10.1038/31248; Ishii TM, 1999, J BIOL CHEM, V274, P12835, DOI 10.1074/jbc.274.18.12835; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; Kaupp UB, 2001, ANNU REV PHYSIOL, V63, P235, DOI 10.1146/annurev.physiol.63.1.235; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Ludwig A, 1998, NATURE, V393, P587, DOI 10.1038/31255; Ludwig A, 1999, EMBO J, V18, P2323, DOI 10.1093/emboj/18.9.2323; Ludwig A, 1999, CELL PHYSIOL BIOCHEM, V9, P179, DOI 10.1159/000016315; Moosmang S, 2001, EUR J BIOCHEM, V268, P1646, DOI 10.1046/j.1432-1327.2001.02036.x; Moroni A, 2000, PFLUG ARCH EUR J PHY, V439, P618, DOI 10.1007/s004240050985; Pape HC, 1996, ANNU REV PHYSIOL, V58, P299, DOI 10.1146/annurev.ph.58.030196.001503; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Santoro B, 1999, ANN NY ACAD SCI, V868, P741, DOI 10.1111/j.1749-6632.1999.tb11353.x; Santoro B, 1998, CELL, V93, P717, DOI 10.1016/S0092-8674(00)81434-8; Santoro B, 1997, P NATL ACAD SCI USA, V94, P14815, DOI 10.1073/pnas.94.26.14815; Vaca L, 2000, FEBS LETT, V479, P35, DOI 10.1016/S0014-5793(00)01837-8; Vaccari T, 1999, BBA-GENE STRUCT EXPR, V1446, P419, DOI 10.1016/S0167-4781(99)00092-5	27	54	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29930	29934		10.1074/jbc.M103971200	http://dx.doi.org/10.1074/jbc.M103971200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11397812	hybrid			2022-12-25	WOS:000170558000044
J	Loussouarn, G; Pike, LJ; Ashcroft, FM; Makhina, EN; Nichols, CG				Loussouarn, G; Pike, LJ; Ashcroft, FM; Makhina, EN; Nichols, CG			Dynamic sensitivity of ATP-sensitive K+ channels to ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC-B-CELLS; POTASSIUM CHANNELS; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; NUCLEOTIDE SENSITIVITY; SULFONYLUREA RECEPTOR; VENTRICULAR MYOCYTES; KIR6.2 SUBUNIT; HEART-MUSCLE; WORTMANNIN; ADP	ATP and MgADP regulate K-ATP channel activity and hence potentially couple cellular metabolism to membrane electrical activity in various cell types. Using recombinant K-ATP channels that lack sensitivity to MgADP, expressed in COSm6 cells, we demonstrate that similar on-cell activity can be observed with widely varying apparent submembrane [ATP] ([ATP](sub)). Metabolic inhibition leads to a biphasic change in the channel activity; activity first increases, presumably in response to a fast decrease in [ATP](sub), and then declines. The secondary decrease in channel activity reflects a marked increase in ATP sensitivity and is correlated with a fall in polyphosphoinositides (PPIs), including phosphatidylinositol. 4,5-bisphosphate, probed using equilibrium labeling of cells with [H-3]myo-inositol. Both ATP sensitivity and PPIs rapidly recover following removal of metabolic inhibition, and in both cases recovery is blocked by wortmannin. These data are consistent with metabolism having a dual effect on K-ATP channel activity: rapid activation of channels because of relief of ATP inhibition and much slower reduction of channel activity mediated by a fall in PPIs. These two mechanisms constitute a feedback system that will tend to render K-ATP channel activity transiently responsive to a change in [ATP](sub) over a wide range of steady state concentrations.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA; Univ Oxford, Physiol Lab, Oxford OX1 3PT, England	Washington University (WUSTL); Washington University (WUSTL); University of Oxford	Nichols, CG (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.		Loussouarn, Gildas/ABH-6043-2020; Loussouarn, Gildas/D-3590-2015; Nichols, Colin/D-6336-2012	Loussouarn, Gildas/0000-0001-8007-5931; Loussouarn, Gildas/0000-0001-8007-5931; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055282] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK55282] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aharonovitz O, 2000, J CELL BIOL, V150, P213, DOI 10.1083/jcb.150.1.213; Balla T, 1997, J BIOL CHEM, V272, P18358, DOI 10.1074/jbc.272.29.18358; Baukrowitz T, 1998, SCIENCE, V282, P1141, DOI 10.1126/science.282.5391.1141; DEUTSCH N, 1993, J PHYSIOL-LONDON, V465, P163, DOI 10.1113/jphysiol.1993.sp019671; Downing GJ, 1996, BIOCHEMISTRY-US, V35, P3587, DOI 10.1021/bi9517493; DUNNE MJ, 1986, FEBS LETT, V208, P59, DOI 10.1016/0014-5793(86)81532-0; Enkvetchakul D, 2000, BIOPHYS J, V78, P2334, DOI 10.1016/S0006-3495(00)76779-8; Fan Z, 1997, J BIOL CHEM, V272, P5388, DOI 10.1074/jbc.272.9.5388; FINDLAY I, 1991, FEBS LETT, V279, P95, DOI 10.1016/0014-5793(91)80259-6; FINDLAY I, 1988, J MEMBRANE BIOL, V101, P83, DOI 10.1007/BF01872823; Gribble FM, 1997, J PHYSIOL-LONDON, V504, P35, DOI 10.1111/j.1469-7793.1997.00035.x; Gribble FM, 2000, J BIOL CHEM, V275, P30046, DOI 10.1074/jbc.M001010200; GROSS GJ, 1995, BASIC RES CARDIOL, V90, P85, DOI 10.1007/BF00789438; Gross GJ, 1999, CIRC RES, V84, P973, DOI 10.1161/01.RES.84.9.973; Hilgemann DW, 1996, SCIENCE, V273, P956, DOI 10.1126/science.273.5277.956; Jovanovic N, 1999, FASEB J, V13, P923, DOI 10.1096/fasebj.13.8.923; KAKEI M, 1986, FEBS LETT, V208, P63, DOI 10.1016/0014-5793(86)81533-2; Koster JC, 1999, J GEN PHYSIOL, V114, P203, DOI 10.1085/jgp.114.2.203; LEDERER WJ, 1989, J PHYSIOL-LONDON, V419, P193, DOI 10.1113/jphysiol.1989.sp017869; Light PE, 1999, CAN J CARDIOL, V15, P1123; Loussouarn G, 2000, J BIOL CHEM, V275, P1137, DOI 10.1074/jbc.275.2.1137; Miki T, 1999, J MOL ENDOCRINOL, V22, P113, DOI 10.1677/jme.0.0220113; MISLER S, 1986, P NATL ACAD SCI USA, V83, P7119, DOI 10.1073/pnas.83.18.7119; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; NICHOLS CG, 1991, AM J PHYSIOL, V261, pH1675, DOI 10.1152/ajpheart.1991.261.6.H1675; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; PIKE LJ, 1987, J BIOL CHEM, V262, P1644; Shyng SL, 1997, J GEN PHYSIOL, V110, P141, DOI 10.1085/jgp.110.2.141; Shyng SL, 2000, P NATL ACAD SCI USA, V97, P937, DOI 10.1073/pnas.97.2.937; Shyng SL, 1997, J GEN PHYSIOL, V110, P643, DOI 10.1085/jgp.110.6.643; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; Sippel CJ, 1997, J BIOL CHEM, V272, P18290, DOI 10.1074/jbc.272.29.18290; Tanabe K, 1999, J BIOL CHEM, V274, P3931, DOI 10.1074/jbc.274.7.3931; THIERFELDER S, 1994, FEBS LETT, V351, P365, DOI 10.1016/0014-5793(94)00886-8; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Xie LH, 1999, J PHYSIOL-LONDON, V514, P655, DOI 10.1111/j.1469-7793.1999.655ad.x; Xie LH, 1999, P NATL ACAD SCI USA, V96, P15292, DOI 10.1073/pnas.96.26.15292	37	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29098	29103		10.1074/jbc.M102365200	http://dx.doi.org/10.1074/jbc.M102365200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11395495	hybrid			2022-12-25	WOS:000170346000063
J	Lee, S; Park, JB; Kim, JH; Kim, Y; Kim, JH; Shin, KJ; Lee, JS; Ha, SH; Suh, PG; Ryu, SH				Lee, S; Park, JB; Kim, JH; Kim, Y; Kim, JH; Shin, KJ; Lee, JS; Ha, SH; Suh, PG; Ryu, SH			Actin directly interacts with phospholipase D, inhibiting its activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; PROTEIN-KINASE-C; STRESS FIBER FORMATION; PLASMA-MEMBRANE; REGULATED EXOCYTOSIS; DEPENDENT ACTIVATION; PHOSPHATIDIC-ACID; ALPHA-ACTININ; BINDING; CLONING	Mammalian phospholipase D (PLD) plays a key role in several signal transduction pathways and is involved in many diverse functions. To elucidate the complex molecular regulation of PLD, we investigated PLD-binding proteins obtained from rat brain extract. Here we report that a 43-kDa protein in the rat brain, beta -actin, acts as a major PLD2 direct-binding protein as revealed by peptide mass fingerprinting in combination with matrix-assisted laser desorption ionization time-of-flight mass spectrometry. We also determined that the region between amino acids 613 and 723 of PLD2 is required for the direct binding of beta -actin, using bacterially expressed glutathione S-transferase fusion proteins of PLD2 fragments. Intriguingly, purified beta -actin potently inhibited both phosphaticlylinositol-4,5-bisphosphate and oleate-dependent PLD2 activities in a concentration-dependent manner (IC50 = 5 nM). In a previous paper, we reported that alpha -actinin inhibited PLD2 activity in an interaction-dependent and an ADP-ribosylation factor 1 (ARF1)-reversible manner (Park, J. B., Kim, J. H., Kim, Y., Ha, S. H., Kim, J. H., Yoo, J.-S., Du, G., Frohman, M. A., Sub, P.-G., and Ryu, S. H. (2000) J. Biol. Chem. 275, 21295-21301). In vitro binding analyses showed that beta -actin could displace alpha -actinin binding to PLD2, demonstrating independent interaction between cytoskeletal proteins and PLD2. Furthermore, ARF1 could steer the PLD2 activity in a positive direction regardless of the inhibitory effect of beta -actin on PLD2. We also observed that beta -actin regulates PLD1 and PLD2 with similar binding and inhibitory potencies. Immunocytochemical. and co-immunoprecipitation studies demonstrated the in vivo interaction between the two PLD isozymes and actin in cells. Taken together, these results suggest that the regulation of PLD by cytoskeletal proteins, beta -actin and a-actinin, and ARF1 may play an important role in cytoskeleton-related PLD functions.	Pohang Univ Sci & Technol, Div Mol & Life Sci, Pohang 790784, South Korea	Pohang University of Science & Technology (POSTECH)	Kim, Y (corresponding author), Pohang Univ Sci & Technol, Div Mol & Life Sci, Pohang 790784, South Korea.	sungho@postech.ac.kr	Suh, Pann-Ghill/F-3610-2010	Ryu, Sung Ho/0000-0003-0913-3048; Kim, Yong/0000-0002-1387-2962; Kim, Jung Hwan/0000-0001-8548-4435				Banno Y, 1999, J BIOL CHEM, V274, P27385, DOI 10.1074/jbc.274.39.27385; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAY D, 1976, J MOL BIOL, V105, P527, DOI 10.1016/0022-2836(76)90233-3; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Caumont AS, 1998, J BIOL CHEM, V273, P1373, DOI 10.1074/jbc.273.3.1373; Chung JK, 1997, J BIOL CHEM, V272, P15980, DOI 10.1074/jbc.272.25.15980; Colley WC, 1997, BIOCHEM J, V326, P745, DOI 10.1042/bj3260745; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Cross MJ, 1996, CURR BIOL, V6, P588, DOI 10.1016/S0960-9822(02)00545-6; DANNIEL LW, 1999, BIOCHIM BIOPHYS ACTA, V1439, P265; Exton JH, 1999, BBA-MOL CELL BIOL L, V1439, P121, DOI 10.1016/S1388-1981(99)00089-X; Fensome A, 1998, J BIOL CHEM, V273, P13157, DOI 10.1074/jbc.273.21.13157; Frank SR, 1998, MOL BIOL CELL, V9, P3133, DOI 10.1091/mbc.9.11.3133; Frohman MA, 1999, BBA-MOL CELL BIOL L, V1439, P175, DOI 10.1016/S1388-1981(99)00093-1; FROHMAN MA, 1999, BIOCHIM BIOPHYS ACTA, V30, P175; GILSON MK, 1994, SCIENCE, V263, P1276, DOI 10.1126/science.8122110; HA KS, 1994, BIOCHEM J, V303, P55, DOI 10.1042/bj3030055; HA KS, 1993, J CELL BIOL, V123, P1789, DOI 10.1083/jcb.123.6.1789; Han JS, 1998, BIOCHEM MOL BIOL INT, V45, P1089; HAREL M, 1993, P NATL ACAD SCI USA, V90, P9031, DOI 10.1073/pnas.90.19.9031; Hodgkin MN, 1999, BIOCHEM J, V339, P87, DOI 10.1042/0264-6021:3390087; Hodgkin MN, 2000, CURR BIOL, V10, P43, DOI 10.1016/S0960-9822(99)00264-X; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Iyer SS, 1999, J BIOL CHEM, V274, P2350, DOI 10.1074/jbc.274.4.2350; Jenco JM, 1998, BIOCHEMISTRY-US, V37, P4901, DOI 10.1021/bi972776r; JOHN RG, 1992, J BIOL CHEM, V257, P9781; Jones D, 1999, BBA-MOL CELL BIOL L, V1439, P229, DOI 10.1016/S1388-1981(99)00097-9; Kim JH, 1999, FEBS LETT, V454, P42, DOI 10.1016/S0014-5793(99)00745-0; Kim JH, 1998, FEBS LETT, V430, P231, DOI 10.1016/S0014-5793(98)00661-9; Kim JH, 1999, J IMMUNOL, V163, P5462; Kim Y, 1999, BBA-MOL CELL BIOL L, V1436, P319, DOI 10.1016/S0005-2760(98)00120-9; Kim Y, 2000, J BIOL CHEM, V275, P13621, DOI 10.1074/jbc.275.18.13621; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBETH JD, 1995, J BIOL CHEM, V270, P2431, DOI 10.1074/jbc.270.6.2431; LEBART MC, 1990, BIOCHEM BIOPH RES CO, V173, P120, DOI 10.1016/S0006-291X(05)81030-7; Lee C, 2000, J BIOL CHEM, V275, P18751, DOI 10.1074/jbc.M001695200; Lee CH, 1997, J BIOL CHEM, V272, P15986, DOI 10.1074/jbc.272.25.15986; Lee SD, 2000, J NEUROCHEM, V75, P1053, DOI 10.1046/j.1471-4159.2000.0751053.x; Lee TG, 1997, BBA-LIPID LIPID MET, V1347, P199, DOI 10.1016/S0005-2760(97)00083-0; Lopez I, 1998, J BIOL CHEM, V273, P12846, DOI 10.1074/jbc.273.21.12846; Lukowski S, 1996, J BIOL CHEM, V271, P24164, DOI 10.1074/jbc.271.39.24164; Lukowski S, 1998, BIOCHEM BIOPH RES CO, V248, P278, DOI 10.1006/bbrc.1998.8942; MARIECHRISTINE L, 1993, J BIOL CHEM, V268, P5642; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; Min DS, 1998, J BIOL CHEM, V273, P7044, DOI 10.1074/jbc.273.12.7044; Morris AJ, 1996, TRENDS PHARMACOL SCI, V17, P182, DOI 10.1016/0165-6147(96)10016-X; Norman JC, 1998, J CELL BIOL, V143, P1981, DOI 10.1083/jcb.143.7.1981; Olson SC, 1996, CHEM PHYS LIPIDS, V80, P3, DOI 10.1016/0009-3084(96)02541-8; Park JB, 2000, J BIOL CHEM, V275, P21295, DOI 10.1074/jbc.M002463200; Park SK, 1997, J BIOL CHEM, V272, P29263, DOI 10.1074/jbc.272.46.29263; Radhakrishna H, 1996, J CELL BIOL, V134, P935, DOI 10.1083/jcb.134.4.935; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sciorra VA, 1999, EMBO J, V18, P5911, DOI 10.1093/emboj/18.21.5911; Shome K, 1997, CURR BIOL, V7, P387, DOI 10.1016/S0960-9822(06)00186-2; Steed PM, 1996, BIOCHEMISTRY-US, V35, P5229, DOI 10.1021/bi952370j; Sung TC, 1999, J BIOL CHEM, V274, P494, DOI 10.1074/jbc.274.1.494; Sung TC, 1999, J BIOL CHEM, V274, P3659, DOI 10.1074/jbc.274.6.3659	58	97	102	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28252	28260		10.1074/jbc.M008521200	http://dx.doi.org/10.1074/jbc.M008521200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11373276	Green Published, hybrid			2022-12-25	WOS:000170093400069
J	Krogh, BO; Claeboe, CD; Hecht, SM; Shuman, S				Krogh, BO; Claeboe, CD; Hecht, SM; Shuman, S			Effect of 2 '-5 ' phosphodiesters on DNA transesterification by vaccinia topoisomerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXONUCLEASE-III; COVALENT; SITE; PHOSPHOROTHIOATE; MECHANISM; CLEAVAGE; STRAND; ENZYME; IB	Vaccinia topoisomerase forms a covalent DNA-(3'-phosphotyrosyl)-enzyme intermediate at a pentapyrimidine target site 5'-CCCTTp down arrow in duplex DNA. By introducing single 2'-5' phosphodiesters in lieu of a standard 3'-5' phosphodiester linkage, we illuminate the contributions of phosphodiester connectivity to DNA transesterification, We find that the DNA cleavage reaction was slowed by more than six orders of magnitude when a 2'-5' linkage was present at the scissile phosphodiester (CCCTT(2')p down arrow (5).A). Thus, vaccinia topoisomerase is unable to form a DNA-(2'-phosphotyrosyl)-enzyme intermediate. We hypothesize that the altered geometry of the 2'-5' phosphodiester limits the ability of the tyrosine nucleophile tea attain a requisite, presumably apical orientation with respect to the 5'-OH leaving group. A 2'-5' phosphodiester located to the 3' side of the cleavage site (CCCTTp down arrowN(2')p(5),N) reduced the rate of transesterification by a factor of 500, In contrast, 2'-5' phosphodiesters at four other sites in the scissile strand (TpCGCCCTpT down arrow ATpTpC) and five positions in the nonscissile strand (3'-GGGpApApTpApA) had no effect on transesterification rate, The DNAs containing 2'-5' phosphodiesters were protected from digestion by exonuclease III. We found that exonuclease III was consistently arrested at positions 1 and 2 nucleotides prior to the encounter of its active site with the modified 2'-5' phosphodiester and that the 2'-5' linkage itself was poorly hydrolyzed by exonuclease III.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA; Univ Virginia, Dept Chem, Charlottesville, VA 22901 USA; Univ Virginia, Dept Biol, Charlottesville, VA 22901 USA	Memorial Sloan Kettering Cancer Center; University of Virginia; University of Virginia	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.				NATIONAL CANCER INSTITUTE [R01CA078415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046330, R37GM046330] Funding Source: NIH RePORTER; NCI NIH HHS [CA78415] Funding Source: Medline; NIGMS NIH HHS [GM46330] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arslan T, 1998, J BIOL CHEM, V273, P12383, DOI 10.1074/jbc.273.20.12383; Arslan T, 1998, NUCLEOS NUCLEOT NUCL, V17, P515, DOI 10.1080/07328319808005195; Cheng CH, 1998, CELL, V92, P841, DOI 10.1016/S0092-8674(00)81411-7; Cheng CH, 1999, BIOCHEMISTRY-US, V38, P16599, DOI 10.1021/bi992001d; Cheng CH, 1997, J BIOL CHEM, V272, P8263, DOI 10.1074/jbc.272.13.8263; DOUGHERTY JP, 1992, J AM CHEM SOC, V114, P6254, DOI 10.1021/ja00041a058; Krogh BO, 2000, MOL CELL, V5, P1035, DOI 10.1016/S1097-2765(00)80268-3; Krogh BO, 2000, BIOCHEMISTRY-US, V39, P6422, DOI 10.1021/bi000184u; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; Petersen BO, 1997, J BIOL CHEM, V272, P3891, DOI 10.1074/jbc.272.7.3891; Porter KW, 1997, NUCLEIC ACIDS RES, V25, P1611, DOI 10.1093/nar/25.8.1611; PUTNEY SD, 1981, P NATL ACAD SCI-BIOL, V78, P7350, DOI 10.1073/pnas.78.12.7350; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; RIZZO CJ, 1992, TETRAHEDRON LETT, V33, P4129, DOI 10.1016/S0040-4039(00)74670-3; Sekiguchi J, 1996, EMBO J, V15, P3448, DOI 10.1002/j.1460-2075.1996.tb00711.x; SEKIGUCHI J, 1994, J BIOL CHEM, V269, P31731; Sekiguchi J, 1996, J BIOL CHEM, V271, P19436, DOI 10.1074/jbc.271.32.19436; SHUMAN S, 1988, J BIOL CHEM, V263, P16401; Shuman S, 1998, BBA-GENE STRUCT EXPR, V1400, P321, DOI 10.1016/S0167-4781(98)00144-4; SHUMAN S, 1993, J BIOL CHEM, V268, P18943; Stivers JT, 2000, BIOCHEMISTRY-US, V39, P5561, DOI 10.1021/bi992429c; Wittschieben J, 1997, NUCLEIC ACIDS RES, V25, P3001, DOI 10.1093/nar/25.15.3001	22	13	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					20907	20912		10.1074/jbc.M102312200	http://dx.doi.org/10.1074/jbc.M102312200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11399773	hybrid			2022-12-25	WOS:000169297900017
J	Wang, YZ; Guan, J; Wang, HY; Wang, Y; Leeper, D; Iliakis, G				Wang, YZ; Guan, J; Wang, HY; Wang, Y; Leeper, D; Iliakis, G			Regulation of DNA replication after heat shock by replication protein A-nucleolin interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; NUCLEOTIDE EXCISION-REPAIR; SIMIAN VIRUS-40 DNA; BINDING-PROTEIN; MAMMALIAN-CELLS; HELA-CELLS; MACROMOLECULAR-SYNTHESIS; ATAXIA-TELANGIECTASIA; ELEVATED-TEMPERATURES; DAMAGE RESPONSE	Heat shock inhibits replicative DNA synthesis, but the underlying mechanism remains unknown. We investigated mechanistic aspects of this regulation in melanoma cells using a simian virus 40 (SV40)-based in vitro DNA replication assay. Heat shock (44 degreesC) caused a monotonic inhibition of cellular DNA replication following exposures for 5-90 min. SV40 DNA replication activity in extracts of similarly heated cells also decreased after 5-30 min of exposure, but returned to near control levels after 60-90 min of exposure, This transient inhibition of SV40 DNA replication was eliminated by recombinant replication protein A (rRPA), suggesting a regulatory process targeting this key DNA replication factor. SV40 DNA replication inhibition was associated with a transient increase in the interaction between nucleolin and RPA that peaked at 20-30 min. Because binding to nucleolin compromises the ability of RPA to support SV40 DNA replication, we suggest that the observed interaction reflects a mechanism whereby DNA replication is regulated after heat shock. The relevance of this interaction to the regulation of cellular DNA replication is indicated by the transient translocation in heated cells of nucleolin from the nucleolus into the nucleoplasm with kinetics very similar to those of SV40 DNA replication inhibition and of RPA-nucleolin interaction. Because the targeting of RPA by nucleolin in heated cells occurs in an environment that preserves the activity of several essential DNA replication factors, active processes may contribute to DNA replication inhibition to a larger degree than presently thought. RPA-nucleolin interactions may reflect an early step in the regulation of DNA replication, as nucleolin relocalized into the nucleolus 1-2 h after heat exposure but cellular DNA replication remained inhibited for up to 8 h. We propose that the nucleolus functions as a heat sensor that uses nucleolin as a signaling molecule to initiate inhibitory responses equivalent to a checkpoint.	Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, Dept Radiat Oncol,Div Expt Radiat Oncol, Philadelphia, PA 19107 USA	Jefferson University	Iliakis, G (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, Dept Radiat Oncol,Div Expt Radiat Oncol, Philadelphia, PA 19107 USA.				NATIONAL CANCER INSTITUTE [P01CA056690, R01CA056706, P30CA056036] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA56706, P01 CA 56690, P30 CA56036-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APPLEGREN N, 1995, J CELL BIOCHEM, V59, P91, DOI 10.1002/jcb.240590111; BELL J, 1988, MOL CELL BIOL, V8, P91, DOI 10.1128/MCB.8.1.91; BRUSH GS, 1994, P NATL ACAD SCI USA, V91, P12520, DOI 10.1073/pnas.91.26.12520; Cheng XB, 1996, RADIOTHER ONCOL, V39, P43, DOI 10.1016/0167-8140(96)01712-4; CHU GL, 1993, J CELL PHYSIOL, V154, P217, DOI 10.1002/jcp.1041540202; CORRY PM, 1977, RADIOLOGY, V123, P475, DOI 10.1148/123.2.475; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; Daniely Y, 2000, J CELL BIOL, V149, P799, DOI 10.1083/jcb.149.4.799; David-Pfeuty T, 1999, ONCOGENE, V18, P7409, DOI 10.1038/sj.onc.1203103; de Laat WL, 1998, GENE DEV, V12, P2598, DOI 10.1101/gad.12.16.2598; DEWEY WC, 1978, RADIAT RES, V76, P48, DOI 10.2307/3574926; DICKINSON LA, 1995, MOL CELL BIOL, V15, P456, DOI 10.1128/MCB.15.1.456; Dimitrova DS, 1999, J CELL BIOL, V146, P709, DOI 10.1083/jcb.146.4.709; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; ERARD MS, 1988, EUR J BIOCHEM, V175, P525, DOI 10.1111/j.1432-1033.1988.tb14224.x; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; FIRMENICH AA, 1995, MOL CELL BIOL, V15, P1620; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; Ginisty H, 2000, J BIOL CHEM, V275, P18845, DOI 10.1074/jbc.M002350200; Ginisty H, 1999, J CELL SCI, V112, P761; Ginisty H, 1998, EMBO J, V17, P1476, DOI 10.1093/emboj/17.5.1476; Golub EI, 1998, NUCLEIC ACIDS RES, V26, P5388, DOI 10.1093/nar/26.23.5388; Guan J, 2000, NUCLEIC ACIDS RES, V28, P1183, DOI 10.1093/nar/28.5.1183; Hays SL, 1998, MOL CELL BIOL, V18, P4400, DOI 10.1128/MCB.18.7.4400; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HENLE KJ, 1976, RADIOLOGY, V121, P451, DOI 10.1148/121.2.451; HENLE KJ, 1979, CANCER RES, V39, P2665; HIGASHIKUBO R, 1993, RADIAT RES, V134, P193, DOI 10.2307/3578459; Iftode C, 1999, CRIT REV BIOCHEM MOL, V34, P141, DOI 10.1080/10409239991209255; Iliakis G, 1997, SEMIN ONCOL, V24, P602; ILIAKIS GE, 1989, CANCER RES, V49, P1254; JORRITSMA JBM, 1984, RADIAT RES, V98, P198, DOI 10.2307/3576063; Larner JM, 1997, CANCER SURV, V29, P25; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; Liu JS, 2000, J BIOL CHEM, V275, P1391, DOI 10.1074/jbc.275.2.1391; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; LONGHESE MP, 1994, MOL CELL BIOL, V14, P7884, DOI 10.1128/MCB.14.12.7884; Murti KG, 1996, EXP CELL RES, V223, P279, DOI 10.1006/excr.1996.0083; PAN ZQ, 1994, P NATL ACAD SCI USA, V91, P8343, DOI 10.1073/pnas.91.18.8343; Park JS, 1999, J BIOL CHEM, V274, P32520, DOI 10.1074/jbc.274.45.32520; Park MS, 1996, J BIOL CHEM, V271, P18996, DOI 10.1074/jbc.271.31.18996; Roti J.L., 1988, HYPERTHERMIA ONCOLOG, P13; Roti JLR, 1998, CELL STRESS CHAPERON, V3, P245, DOI 10.1379/1466-1268(1998)003<0245:NMAATF>2.3.CO;2; SADIS S, 1988, J CELL PHYSIOL, V135, P377, DOI 10.1002/jcp.1041350304; SMITH J, 1995, MOL CELL BIOL, V15, P1632; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; Tuteja R, 1998, CRIT REV BIOCHEM MOL, V33, P407, DOI 10.1080/10409239891204260; van der Zee J, 2000, LANCET, V355, P1119, DOI 10.1016/S0140-6736(00)02059-6; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; Wang M, 2000, BIOCHEMISTRY-US, V39, P6433, DOI 10.1021/bi000472q; Wang Y, 1998, RADIAT RES, V149, P284, DOI 10.2307/3579962; Wang Y, 1999, J BIOL CHEM, V274, P22060, DOI 10.1074/jbc.274.31.22060; Wang Y, 1997, CANCER RES, V57, P1654; Wang Y, 1999, RADIAT RES, V151, P59, DOI 10.2307/3579747; Wang Y, 1996, RADIAT RES, V145, P408, DOI 10.2307/3579062; WAROCQUI.R, 1969, EUR J BIOCHEM, V10, P362, DOI 10.1111/j.1432-1033.1969.tb00699.x; WARTERS RL, 1983, RADIAT RES, V93, P71, DOI 10.2307/3575945; WARTERS RL, 1990, J CELL PHYSIOL, V142, P365, DOI 10.1002/jcp.1041420220; WARTERS RL, 1984, J CELL PHYSIOL, V118, P153, DOI 10.1002/jcp.1041180207; WARTERS RL, 1988, RADIAT RES, V115, P258, DOI 10.2307/3577162; WARTERS RL, 1985, J CELL PHYSIOL, V124, P481, DOI 10.1002/jcp.1041240318; WARTERS RL, 1987, J CELL PHYSIOL, V133, P144, DOI 10.1002/jcp.1041330118; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; WONG RSL, 1982, RADIAT RES, V92, P370, DOI 10.2307/3576013; WONG RSL, 1988, RADIAT RES, V114, P125, DOI 10.2307/3577150; WONG RSL, 1989, BIOCHIM BIOPHYS ACTA, V1007, P224, DOI 10.1016/0167-4781(89)90043-2; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	74	50	58	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20579	20588		10.1074/jbc.M100874200	http://dx.doi.org/10.1074/jbc.M100874200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11389152	hybrid			2022-12-25	WOS:000169135100122
J	Reyes-Cruz, G; Hu, JX; Goldsmith, PK; Steinbach, PJ; Spiegel, AM				Reyes-Cruz, G; Hu, JX; Goldsmith, PK; Steinbach, PJ; Spiegel, AM			Human Ca2+ receptor extracellular domain - Analysis of function of lobe I loop deletion mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-SENSING RECEPTOR; CELL-SURFACE EXPRESSION; N-LINKED GLYCOSYLATION; SIGNAL-TRANSDUCTION; IDENTIFICATION; DIMERIZATION; MUTATIONS	The G protein-coupled Ca2+ receptor (CaR) possesses an similar to 600-residue extracellular domain involved in ligand binding and receptor activation. Based on an alignment of the amino acid sequence of the CaR with that of bacterial periplasmic-binding proteins, the first similar to 530 residues of the extracellular domain are believed to form a domain resembling a bilobed Venus's flytrap (VFT). Four insertions in the CaR sequence that do not align with those of bacterial periplasmic-binding proteins correspond to four loops within lobe I of the VFT. We constructed a series of deletion mutants of these four loops and tested their ability to form fully processed CaR as well as their ability to be activated by Ca2+. As many as 21 residues (365-385) of loop III could be deleted without impairing receptor expression or activation. Deletion of portions of either loops I (50-59) or IV (438-445) did not impair receptor expression but significantly reduced Ca2+ activation. Deletion of the entire loop II (117-137) abolished receptor expression and function, but the replacement of even a single residue within this deletion mutant led to expression of a monomeric form of the receptor showing increased Ca2+ sensitivity but reduced maximal activation. Our results reveal that certain residues within loops I and IV are dispensable in formation of the VFT domain but are critical for Ca2+ activation of the receptor. In contrast, the residues in loop II are critical for maintaining the inactive state of the CaR. We discuss these results in light of the recently defined crystal structure of the homologous domain of the type 1 metabotropic glutamate receptor.	NIH, CIT, Ctr Mol Modeling, Bethesda, MD 20892 USA; NIDCD, Mol Pathophysiol Sect, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Center for Information Technology (CIT); National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD)	Reyes-Cruz, G (corresponding author), NIH, CIT, Ctr Mol Modeling, Bldg 10,Room 8C101, Bethesda, MD 20892 USA.				CENTER FOR INFORMATION TECHNOLOGY [ZIACT000265, Z01CT000265] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [Z01DC000061] Funding Source: NIH RePORTER	CENTER FOR INFORMATION TECHNOLOGY(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Center for Information Technology (CIT)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Brown EM, 1999, AM J MED, V106, P238, DOI 10.1016/S0002-9343(98)00418-5; Fan GF, 1997, ENDOCRINOLOGY, V138, P1916, DOI 10.1210/en.138.5.1916; Fan GF, 1998, FEBS LETT, V436, P353, DOI 10.1016/S0014-5793(98)01165-X; Goldsmith PK, 1999, J BIOL CHEM, V274, P11303, DOI 10.1074/jbc.274.16.11303; Hendy GN, 2000, HUM MUTAT, V16, P281, DOI 10.1002/1098-1004(200010)16:4<281::AID-HUMU1>3.0.CO;2-A; Hu JX, 2000, J BIOL CHEM, V275, P16382, DOI 10.1074/jbc.M000277200; Jensen AA, 2000, J BIOL CHEM, V275, P29547, DOI 10.1074/jbc.M910023199; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; LEVITT M, 1992, J MOL BIOL, V226, P507, DOI 10.1016/0022-2836(92)90964-L; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; Ray K, 1998, J BIOL CHEM, V273, P34558, DOI 10.1074/jbc.273.51.34558; Ray K, 1999, J BIOL CHEM, V274, P27642, DOI 10.1074/jbc.274.39.27642; Ray K, 1997, J BIOL CHEM, V272, P31355, DOI 10.1074/jbc.272.50.31355; Springer TA, 2000, CELL, V102, P275, DOI 10.1016/S0092-8674(00)00033-7	19	33	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32145	32151		10.1074/jbc.M102977200	http://dx.doi.org/10.1074/jbc.M102977200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11399760	hybrid			2022-12-25	WOS:000170613500092
J	Frang, H; Cockcroft, V; Karskela, T; Scheinin, M; Marjamaki, A				Frang, H; Cockcroft, V; Karskela, T; Scheinin, M; Marjamaki, A			Phenoxybenzamine binding reveals the helical orientation of the third transmembrane domain of adrenergic receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA(2A)-ADRENERGIC RECEPTOR; MEMBRANE-SPANNING SEGMENT; ALPHA-2-ADRENERGIC RECEPTOR; SITE CREVICE; ALPHA(2)-ADRENOCEPTOR SUBTYPES; CONSTITUTIVE ACTIVATION; LIGAND-BINDING; AMINO-ACIDS; CLONING; GENE	Phenoxybenzamine (PB), a classical a-adrenergic antagonist, binds irreversibly to the a-adrenergic receptors (ARs). Amino acid sequence alignments and the predicted helical arrangement of the seven transmembrane (TM) domains suggested an accessible cysteine residue in transmembrane 3 of the alpha (2)-ARs, in position C-3.36 (in subtypes A, B, and C corresponding to amino acid residue numbers 117/96/135, respectively), as a possible site for the PB interaction. Irreversible binding of PB to recombinant human a2-ARs (90 nm, 30 min) reduced the ligand binding capacity of alpha (2A)-, alpha (2B)-, and alpha (2C)-AR by 81, 96, and 77%. When the TM3 cysteine, Cys(117), of alpha (2A)-AR was mutated to valine (alpha (2A)-C117V), the receptor became resistant to PB (inactivation, 10%). The beta (2)-AR contains a valine in this position (V-3.36; position number 117) and a cysteine in the preceding position (Cys(116)) and was not inactivated by PB (10 mum, 30 min) (inactivation 26%). The helical orientation of TM3 was tested by exchanging the amino acids at positions 116 and 117 of the alpha (2A)-AR and beta (2)-AR. The alpha (2A)-F116C/C117V mutant was resistant to PB (inactivation, 7%), whereas beta (2)-V117C was irreversibly inactivated (inactivation, 93%), confirming that position 3.36 is exposed to receptor ligands, and position 3.35 is not exposed in the binding pocket.	Univ Turku, Dept Pharmacol & Clin Pharmacol, FIN-20520 Turku, Finland; Univ Turku, Dept Bio Organ Chem, FIN-20520 Turku, Finland; Orion Pharma, FIN-20101 Turku, Finland	University of Turku; University of Turku; Orion Corporation	Scheinin, M (corresponding author), Univ Turku, Dept Pharmacol & Clin Pharmacol, Kiinamyllynkatu 10, FIN-20520 Turku, Finland.		Karskela, Tuomas/H-2171-2012	Karskela, Tuomas/0000-0001-6352-5283; Scheinin, Mika/0000-0001-7579-9126				Almaula N, 1996, J BIOL CHEM, V271, P14672, DOI 10.1074/jbc.271.25.14672; BALLESTEROS JA, 1995, RECEPTOR MOL BIOL, P366; Cockcroft V, 2000, J NEUROCHEM, V74, P1705, DOI 10.1046/j.1471-4159.2000.0741705.x; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; HALME M, 1995, BBA-MOL CELL RES, V1266, P207, DOI 10.1016/0167-4889(95)90410-I; Hoffman B.B., 1996, PHARMACOL BASIS THER, P199; JAVITCH JA, 1995, NEURON, V14, P825, DOI 10.1016/0896-6273(95)90226-0; Javitch JA, 1997, J BIOL CHEM, V272, P18546, DOI 10.1074/jbc.272.30.18546; JAVITCH JA, 1994, P NATL ACAD SCI USA, V91, P10355, DOI 10.1073/pnas.91.22.10355; Javitch JA, 1996, MOL PHARMACOL, V49, P692; JENKINSON DH, 1996, TXB RECEPTOR PHARM, P3; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; KOBILKA BK, 1995, PHARM COMMUN, V6, P119; LOMASNEY JW, 1991, BIOCHIM BIOPHYS ACTA, V1095, P127, DOI 10.1016/0167-4889(91)90075-9; LOMASNEY JW, 1990, P NATL ACAD SCI USA, V87, P5094, DOI 10.1073/pnas.87.13.5094; Marjamaki A, 1999, J BIOL CHEM, V274, P21867, DOI 10.1074/jbc.274.31.21867; Marjamaki A, 1998, MOL PHARMACOL, V53, P370, DOI 10.1124/mol.53.3.370; MICHEL MC, 1993, MOL PHARMACOL, V44, P1165; Nyronen T, 2001, MOL PHARMACOL, V59, P1343, DOI 10.1124/mol.59.5.1343; PEPPERL JD, 1994, HDB RECEPTORS CHANNE, P45; Perez DM, 1996, MOL PHARMACOL, V49, P112; PHILLIPS D, 1980, HDB EXPT PHARM ADREN, P3; Pohjanoksa K, 1997, EUR J PHARMACOL, V335, P53, DOI 10.1016/S0014-2999(97)01154-0; Porter JE, 1999, J BIOL CHEM, V274, P34535, DOI 10.1074/jbc.274.49.34535; REGAN JW, 1988, P NATL ACAD SCI USA, V85, P6301, DOI 10.1073/pnas.85.17.6301; RUFFOLO RR, 1995, J MED CHEM, V38, P3681, DOI 10.1021/jm00019a001; Salminen T, 1999, J BIOL CHEM, V274, P23405, DOI 10.1074/jbc.274.33.23405; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Scheer A, 1996, EMBO J, V15, P3566, DOI 10.1002/j.1460-2075.1996.tb00726.x; Shulman-Roskes EM, 1998, J MED CHEM, V41, P515, DOI 10.1021/jm9704659; WANG CD, 1991, MOL PHARMACOL, V40, P168	32	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31279	31284		10.1074/jbc.M104167200	http://dx.doi.org/10.1074/jbc.M104167200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11395517	hybrid			2022-12-25	WOS:000170472900091
J	Coulombe, R; Yue, KQ; Ghisla, S; Vrielink, A				Coulombe, R; Yue, KQ; Ghisla, S; Vrielink, A			Oxygen access to the active site of cholesterol oxidase through a narrow channel is gated by an Arg-Glu pair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; CRYSTAL-STRUCTURE; BREVIBACTERIUM-STEROLICUM; BOLL-WEEVIL; SUBSTRATE; BINDING; MECHANISM; FAD	Cholesterol oxidase is a monomeric flavoenzyme that catalyzes the oxidation and isomerization of cholesterol to cholest-4-en-3-one. Two forms of the enzyme are known, one containing the cofactor non-covalently bound to the protein and one in which the cofactor is covalently linked to a histidine residue. The x-ray structure of the enzyme from Brevibacterium sterolicum containing covalently bound FAD has been determined and refined to 1.7-Angstrom resolution. The active site consists of a cavity sealed off from the exterior of the protein. A model for the steroid substrate, cholesterol, can be positioned in the pocket revealing the structural factors that result in different substrate binding affinities between the two known forms of the enzyme. The structure suggests that Glu(475), located at the active site cavity, may act as the base for both the oxidation and the isomerization steps of the catalytic reaction. A water-filled channel extending toward the Ravin moiety, inside the substrate-binding cavity, may act as the entry point for molecular oxygen for the oxidative half-reaction. An arginine and a glutamate residue at the active site, found in two conformations are proposed to control oxygen access to the cavity from the channel. These concerted side chain movements provide an explanation for the biphasic mode of reaction with dioxygen and the ping-pong kinetic mechanism exhibited by the enzyme.	Univ Calif Santa Cruz, Dept Biol, Sinsheimer Lab, Santa Cruz, CA 95064 USA; Univ Calif Santa Cruz, Dept Chem, Sinsheimer Lab, Santa Cruz, CA 95064 USA; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Montreal Joint Ctr Struct Biol, Montreal, PQ H3G 1Y6, Canada; Univ Konstanz, Fachbereich Biol, D-78457 Constance, Germany	University of California System; University of California Santa Cruz; University of California System; University of California Santa Cruz; McGill University; McGill University; University of Konstanz	Vrielink, A (corresponding author), Univ Calif Santa Cruz, Dept Biol, Sinsheimer Lab, 1156 High St, Santa Cruz, CA 95064 USA.	vrielink@biology.ucsc.edu	Vrielink, Alice/D-3652-2013	Vrielink, Alice/0000-0001-8197-3725	NIGMS NIH HHS [GM60535] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BENSON TE, 1995, NAT STRUCT BIOL, V2, P644, DOI 10.1038/nsb0895-644; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CORBIN DR, 1994, APPL ENVIRON MICROB, V60, P4239, DOI 10.1128/AEM.60.12.4239-4244.1994; Corbin DR, 1998, HORTSCIENCE, V33, P614, DOI 10.21273/HORTSCI.33.4.614; Croteau N, 1996, J STRUCT BIOL, V116, P317, DOI 10.1006/jsbi.1996.0047; Dobbek H, 1999, P NATL ACAD SCI USA, V96, P8884, DOI 10.1073/pnas.96.16.8884; Fraaije MW, 1998, TRENDS BIOCHEM SCI, V23, P206, DOI 10.1016/S0968-0004(98)01210-9; Ghoshroy KB, 1997, BIOCHEMISTRY-US, V36, P6133, DOI 10.1021/bi962190p; GREENPLATE JT, 1995, ENTOMOL EXP APPL, V74, P253, DOI 10.1007/BF02381789; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kass IJ, 1998, BIOORG MED CHEM LETT, V8, P2663, DOI 10.1016/S0960-894X(98)00478-8; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LI JY, 1993, BIOCHEMISTRY-US, V32, P11507, DOI 10.1021/bi00094a006; MATHEWS FS, 1991, BIOCHEMISTRY-US, V30, P238, DOI 10.1021/bi00215a034; Mattevi A, 1997, STRUCTURE, V5, P907, DOI 10.1016/S0969-2126(97)00245-1; Mewies M, 1998, PROTEIN SCI, V7, P7, DOI 10.1002/pro.5560070102; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; Pollegioni L, 1999, EUR J BIOCHEM, V264, P140, DOI 10.1046/j.1432-1327.1999.00586.x; PURCELL JP, 1993, BIOCHEM BIOPH RES CO, V196, P1406, DOI 10.1006/bbrc.1993.2409; Riistama S, 1996, BBA-BIOENERGETICS, V1275, P1, DOI 10.1016/0005-2728(96)00040-0; Riistama S, 2000, BIOCHEMISTRY-US, V39, P6365, DOI 10.1021/bi000123w; Sampson NS, 1998, BIOCHEMISTRY-US, V37, P5770, DOI 10.1021/bi973067g; Soulimane T, 2000, EMBO J, V19, P1766, DOI 10.1093/emboj/19.8.1766; Vrielink A, 1994, FLAVINS AND FLAVOPROTEINS 1993, P175; VRIELINK A, 1991, J MOL BIOL, V219, P533, DOI 10.1016/0022-2836(91)90192-9; Yue QK, 1999, BIOCHEMISTRY-US, V38, P4277, DOI 10.1021/bi982497j	32	91	93	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30435	30441		10.1074/jbc.M104103200	http://dx.doi.org/10.1074/jbc.M104103200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11397813	hybrid, Green Submitted			2022-12-25	WOS:000170558000109
J	Erlenbach, I; Kostenis, E; Schmidt, C; Serradeil-Le Gal, C; Raufaste, D; Dumont, ME; Pausch, MH; Wess, J				Erlenbach, I; Kostenis, E; Schmidt, C; Serradeil-Le Gal, C; Raufaste, D; Dumont, ME; Pausch, MH; Wess, J			Single amino acid substitutions and deletions that alter the G protein coupling properties of the V2 vasopressin receptor identified in yeast by receptor random mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; MOLECULAR-BASIS; C5A RECEPTOR; WILD-TYPE; EXPRESSION; BINDING; SELECTIVITY; CLONING; SPECIFICITY; ACTIVATION	To facilitate structure-function relationship studies of the V2 vasopressin receptor, a prototypical G(s)-coupled receptor, we generated V2 receptor-expressing yeast strains (Saccharomyces cerevisiae) that required arginine vasopressin-dependent receptor/G protein coupling for cell growth. V2 receptors heterologously expressed in yeast were unable to productively interact with the endogenous yeast G protein alpha subunit, Gpa1p, or a mutant Gpa1p subunit containing the C-terminal G alpha (q) sequence (Gq5). In contrast, the V2 receptor efficiently coupled to a Gpa1p/G alpha (s) hybrid subunit containing the C-terminal Gas sequence (Gs5), indicating that the V2 receptor retained proper G protein coupling selectivity in yeast. To gain insight into the molecular basis underlying the selectivity of V2 receptor/G protein interactions, we used receptor saturation random mutagenesis to generate a yeast library expressing mutant V2 receptors containing mutations within the second intracellular loop. A subsequent yeast genetic screen of about 30,000 mutant receptors yielded four mutant receptors that, in contrast to the wild-type receptor, showed substantial coupling to Gq5. Functional analysis of these mutant receptors, followed by more detailed site-directed mutagenesis studies, indicated that single amino acid substitutions at position Met(145) in the central portion of the second intracellular loop of the V2 receptor had pronounced effects on receptor/G protein coupling selectivity. We also observed that deletion of single amino acids N-terminal of Met145 led to misfolded receptor proteins, whereas single amino acid deletions C-terminal of Met(145) had no effect on V2 receptor function. These findings highlight the usefulness of combining receptor random mutagenesis and yeast expression technology to study mechanisms governing receptor/G protein coupling selectivity and receptor folding.	NIDDK, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA; Sanofi Synthelabo Rech, Exploratory Res Dept, F-31036 Toulouse, France; Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA; Wyeth Ayerst Res, Dept Neurosci, Princeton, NJ 08543 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Sanofi-Aventis; Sanofi France; University of Rochester; Pfizer	Wess, J (corresponding author), NIDDK, Bioorgan Chem Lab, NIH, Bldg 8A,Rm B1A-05, Bethesda, MD 20892 USA.	jwess@helix.nih.gov			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK032003] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Acharya S, 1997, J BIOL CHEM, V272, P6519, DOI 10.1074/jbc.272.10.6519; ARORA KK, 1995, J BIOL CHEM, V270, P22820, DOI 10.1074/jbc.270.39.22820; Baranski TJ, 1999, J BIOL CHEM, V274, P15757, DOI 10.1074/jbc.274.22.15757; BIRNBAUMER M, 1992, NATURE, V357, P333, DOI 10.1038/357333a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown AJ, 2000, YEAST, V16, P11, DOI 10.1002/(SICI)1097-0061(20000115)16:1<11::AID-YEA502>3.0.CO;2-K; Burbach JPH, 1995, CELL MOL NEUROBIOL, V15, P573, DOI 10.1007/BF02071318; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; Erickson JP, 1998, J BIOL CHEM, V273, P1506, DOI 10.1074/jbc.273.3.1506; Erlenbach I, 1998, J BIOL CHEM, V273, P26549, DOI 10.1074/jbc.273.41.26549; Erlenbach I, 2001, J NEUROCHEM, V77, P1327, DOI 10.1046/j.1471-4159.2001.00344.x; Geva A, 2000, J BIOL CHEM, V275, P35393, DOI 10.1074/jbc.M005602200; GIETZ RD, 1994, MOL GENETICS YEAST P, P124; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; Innamorati G, 1996, MOL PHARMACOL, V50, P467; Kajkowski EM, 1997, J RECEPT SIGNAL TR R, V17, P293, DOI 10.3109/10799899709036610; KING K, 1990, SCIENCE, V250, P121, DOI 10.1126/science.2171146; Kostenis E, 1997, J BIOL CHEM, V272, P23675, DOI 10.1074/jbc.272.38.23675; Kostenis E, 1997, BIOCHEMISTRY-US, V36, P1487, DOI 10.1021/bi962554d; LIU J, 1995, P NATL ACAD SCI USA, V92, P11642, DOI 10.1073/pnas.92.25.11642; Liu J, 1996, J BIOL CHEM, V271, P8772, DOI 10.1074/jbc.271.15.8772; LOLAIT SJ, 1992, NATURE, V357, P336, DOI 10.1038/357336a0; MOREL A, 1992, NATURE, V356, P523, DOI 10.1038/356523a0; MORO O, 1993, J BIOL CHEM, V268, P22273; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NATHANS J, 1983, CELL, V34, P807, DOI 10.1016/0092-8674(83)90537-8; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Pausch Mark H., 1998, P196; Price LA, 1996, MOL PHARMACOL, V50, P829; PRICE LA, 1995, MOL CELL BIOL, V15, P6188; RENSDOMIANO S, 1995, FASEB J, V9, P1059, DOI 10.1096/fasebj.9.11.7649405; ROMANOS MA, 1992, YEAST, V8, P423, DOI 10.1002/yea.320080602; Schoneberg T, 1996, EMBO J, V15, P1283, DOI 10.1002/j.1460-2075.1996.tb00470.x; Serradeil-Le Gal C, 2000, KIDNEY INT, V58, P1613, DOI 10.1046/j.1523-1755.2000.00322.x; SerradeilLeGal C, 1996, J CLIN INVEST, V98, P2729, DOI 10.1172/JCI119098; Smit MJ, 1996, J BIOL CHEM, V271, P7574, DOI 10.1074/jbc.271.13.7574; Sommers CM, 1997, J MOL BIOL, V266, P559, DOI 10.1006/jmbi.1996.0816; SOMMERS CM, 1999, REC BIOCH M, P141; STAPLES RR, 1993, GENETICS, V135, P981; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; Swift S, 2000, J BIOL CHEM, V275, P2627, DOI 10.1074/jbc.275.4.2627; Thibonnier M, 1998, PROG BRAIN RES, V119, P147; WATSON S, 1994, G PROTEIN LINKED REC, P1; Wess J, 1998, PHARMACOL THERAPEUT, V80, P231, DOI 10.1016/S0163-7258(98)00030-8; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; Yun J, 2000, J CLIN INVEST, V106, P1361, DOI 10.1172/JCI9154; Zhu XY, 1998, BIOCHEMISTRY-US, V37, P15773, DOI 10.1021/bi981162z	52	54	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29382	29392		10.1074/jbc.M103203200	http://dx.doi.org/10.1074/jbc.M103203200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11375990	hybrid			2022-12-25	WOS:000170346000100
J	Kadyrov, FA; Drake, JW				Kadyrov, FA; Drake, JW			Conditional coupling of leading-strand and lagging-strand DNA synthesis at bacteriophage T4 replication forks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GP41 FORMS; HELICASE; PROTEIN; POLYMERASE; PURIFICATION; HOLOENZYME; SEQUENCE; COMPLEX	Eight proteins encoded by bacteriophage T4 are required for the replicative synthesis of the leading and lagging strands of T4 DNA. We show here that active T4 replication forks, which catalyze the coordinated synthesis of leading and lagging strands, remain stable in the face of dilution provided that the gp44/62 clamp loader, the gp45 sliding clamp, and the gp32 ssDNA-binding protein are present at sufficient levels after dilution. If any of these accessory proteins is omitted from the dilution mixture, uncoordinated DNA synthesis occurs, and/or large Okazaki fragments are formed. Thus, the accessory proteins must be recruited from solution for each round of initiation of lagging-strand synthesis. A modified bacteriophage T7 DNA polymerase (Sequenase) can replace the T4 DNA polymerase for leading-strand synthesis but not for well coordinated lagging-strand synthesis. Although T4 DNA polymerase has been reported to self-associate, gel-exclusion chromatography displays it as a monomer in solution in the absence of DNA. It forms no stable holoenzyme complex in solution with the accessory proteins or with the gp41-gp61 helicase-primase. Instead, template DNA is required for the assembly of the T4 replication complex, which then catalyzes coordinated synthesis of leading and lagging strands in a conditionally coupled manner.	NIEHS, Lab Mol Genet E3 01, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Kadyrov, FA (corresponding author), NIEHS, Lab Mol Genet E3 01, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES061055, ZIAES061055] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALBERTS BM, 1970, NATURE, V227, P1313, DOI 10.1038/2271313a0; ALBERTS BM, 1982, COLD SPRING HARB SYM, V47, P655, DOI 10.1101/SQB.1983.047.01.077; ALBERTS BM, 1987, PHILOS T ROY SOC B, V317, P395, DOI 10.1098/rstb.1987.0068; BARRY J, 1994, J BIOL CHEM, V269, P33049; Chastain PD, 2000, MOL CELL, V6, P803, DOI 10.1016/S1097-2765(05)00093-6; DEBYSER Z, 1994, CELL, V77, P157, DOI 10.1016/0092-8674(94)90243-7; Delagoutte E, 2001, BIOCHEMISTRY-US, V40, P4459, DOI 10.1021/bi001306l; DONG F, 1995, J BIOL CHEM, V270, P7462, DOI 10.1074/jbc.270.13.7462; Dong F, 1996, J BIOL CHEM, V271, P19625, DOI 10.1074/jbc.271.32.19625; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HUBER HE, 1987, J BIOL CHEM, V262, P16224; Kim S, 1996, J BIOL CHEM, V271, P21406, DOI 10.1074/jbc.271.35.21406; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; Lee J, 1998, MOL CELL, V1, P1001, DOI 10.1016/S1097-2765(00)80100-8; LIU CC, 1980, P NATL ACAD SCI-BIOL, V77, P5698, DOI 10.1073/pnas.77.10.5698; MOSIG G, 1994, MOL BIOL BACTERIOP T, V4, P54; Nossal N.G., 1994, MOL BIOL BACTERIOP T, P43; Nossal NG, 1995, METHOD ENZYMOL, V262, P560; NOSSAL NG, 1992, FASEB J, V6, P871, DOI 10.1096/fasebj.6.3.1310946; NOSSAL NG, 1980, J BIOL CHEM, V255, P2176; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; REDDY MK, 1993, P NATL ACAD SCI USA, V90, P3211, DOI 10.1073/pnas.90.8.3211; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4725; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4732; Salinas F, 2000, P NATL ACAD SCI USA, V97, P7196, DOI 10.1073/pnas.97.13.7196; Schrock RD, 1996, J BIOL CHEM, V271, P16678, DOI 10.1074/jbc.271.28.16678; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; VENKATESAN M, 1982, J BIOL CHEM, V257, P2426; WU CA, 1992, J BIOL CHEM, V267, P4030; WU CA, 1992, J BIOL CHEM, V267, P4064	30	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29559	29566		10.1074/jbc.M101310200	http://dx.doi.org/10.1074/jbc.M101310200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11390383	hybrid			2022-12-25	WOS:000170346000121
J	Torgersen, KM; Vang, T; Abrahamsen, H; Yaqub, S; Horejsi, V; Schraven, B; Rolstad, B; Mustelin, T; Tasken, K				Torgersen, KM; Vang, T; Abrahamsen, H; Yaqub, S; Horejsi, V; Schraven, B; Rolstad, B; Mustelin, T; Tasken, K			Release from tonic inhibition of T cell activation through transient displacement of C-terminal Src kinase (Csk) from lipid rafts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; ANTIGEN-RECEPTOR; SIGNAL-TRANSDUCTION; ADAPTER PROTEIN; PHOSPHATASE PEP; FAMILY KINASES; SH2 DOMAINS; P50(CSK); LYMPHOCYTES; ZAP-70	In resting peripheral T cells, Csk is constitutively present in lipid rafts through an interaction with the Csk SH2-binding protein, PAG, also known as Cbp. Upon triggering of the T cell antigen receptor (TCR), PAG/Cbp is rapidly dephosphorylated leading to dissociation of Csk from lipid rafts. However, tyrosine phosphorylation of PAG/Cbp resumes after 3-5 min, at which time Csk reassociates with the rafts. Cells overexpressing a mutant Csk that lacks the catalytic domain, but displaces endogenous Csk from lipid rafts, have elevated basal levels of TCR-zeta -chain phosphorylation and spontaneous activation of an NFAT-AP1 reporter from the proximal interleukin-2 promoter as well as stronger and more sustained responses to TCR triggering than controls. We suggest that a transient release from Csk-mediated inhibition by displacement of Csk from lipid rafts is important for normal T cell activation.	Univ Oslo, Inst Basic Med Sci, Dept Med Biochem, N-0317 Oslo, Norway; Univ Oslo, Inst Basic Med Sci, Dept Anat, N-0317 Oslo, Norway; Acad Sci Czech Republ, Inst Mol Genet, CR-14220 Prague, Czech Republic; Univ Heidelberg, Immunomodulat Lab, Inst Immunol, D-69120 Heidelberg, Germany; Otto Von Guericke Univ, Inst Immunol, D-39120 Magdeburg, Germany; Burnham Inst, Canc Res Ctr, La Jolla, CA 92037 USA	University of Oslo; University of Oslo; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; Ruprecht Karls University Heidelberg; Otto von Guericke University; Sanford Burnham Prebys Medical Discovery Institute	Tasken, K (corresponding author), Univ Oslo, Inst Basic Med Sci, Dept Med Biochem, POB 1112, N-0317 Oslo, Norway.		Abrahamsen, Hilde/E-5323-2010; Horejsi, Vaclav/G-3113-2014; Yaqub, Sheraz/AAC-3906-2019	Horejsi, Vaclav/0000-0003-4925-0142; Yaqub, Sheraz/0000-0002-5696-2319; Mustelin, Tomas/0000-0001-5912-8840; Tasken, Kjetil/0000-0003-2841-4697	NIAID NIH HHS [AI48032, AI41481, AI40552, AI35603] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040552, R21AI040552, R01AI048032, R01AI041481, R01AI035603] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aandahl EM, 1998, FASEB J, V12, P855, DOI 10.1096/fasebj.12.10.855; Aman MJ, 2000, CURR BIOL, V10, P393, DOI 10.1016/S0960-9822(00)00415-2; Arbet-Engels C, 1999, J BIOL CHEM, V274, P5422, DOI 10.1074/jbc.274.9.5422; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; Brdicka T, 2000, J EXP MED, V191, P1591, DOI 10.1084/jem.191.9.1591; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; Cloutier JF, 1996, EMBO J, V15, P4909, DOI 10.1002/j.1460-2075.1996.tb00871.x; Cloutier JF, 1999, J EXP MED, V189, P111, DOI 10.1084/jem.189.1.111; CLOUTIER JF, 1995, MOL CELL BIOL, V15, P5937; COUTURE C, 1994, P NATL ACAD SCI USA, V91, P5301, DOI 10.1073/pnas.91.12.5301; Gjorloff-Wingren A, 1999, EUR J IMMUNOL, V29, P3845, DOI 10.1002/(SICI)1521-4141(199912)29:12<3845::AID-IMMU3845>3.0.CO;2-U; HATADA MH, 1995, NATURE, V377, P32, DOI 10.1038/377032a0; Holdorf AD, 1999, J EXP MED, V190, P375, DOI 10.1084/jem.190.3.375; HOWELL BW, 1994, MOL CELL BIOL, V14, P5402, DOI 10.1128/MCB.14.8.5402; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; Janes PW, 2000, SEMIN IMMUNOL, V12, P23, DOI 10.1006/smim.2000.0204; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; Kabouridis PS, 1997, EMBO J, V16, P4983, DOI 10.1093/emboj/16.16.4983; Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; MUSTELIN T, 1993, TRENDS BIOCHEM SCI, V18, P215, DOI 10.1016/0968-0004(93)90192-P; MUSTELIN T, 1994, SRC FAMILY TYROSINE, P1; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; OKADA M, 1991, J BIOL CHEM, V266, P24249; Schmedt C, 1998, NATURE, V394, P901, DOI 10.1038/29802; Sheets ED, 1999, CURR OPIN CHEM BIOL, V3, P95, DOI 10.1016/S1367-5931(99)80017-9; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TORGERSEN KM, 2001, IN PRESS CELL SIGNAL; van Leeuwen JEM, 1999, CURR OPIN IMMUNOL, V11, P242, DOI 10.1016/S0952-7915(99)80040-5; Vang T, 1998, BBA-PROTEIN STRUCT M, V1384, P285, DOI 10.1016/S0167-4838(97)00202-1; Vang T, 2001, J EXP MED, V193, P497, DOI 10.1084/jem.193.4.497; WANGE RL, 1993, J BIOL CHEM, V268, P19797; Weber JR, 1998, J EXP MED, V187, P1157, DOI 10.1084/jem.187.7.1157; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	38	129	141	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29313	29318		10.1074/jbc.C100014200	http://dx.doi.org/10.1074/jbc.C100014200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11390365	hybrid			2022-12-25	WOS:000170346000091
J	Hofmann, RM; Pickart, CM				Hofmann, RM; Pickart, CM			In vitro assembly and recognition of Lys-63 polyubiquitin chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-CONJUGATING-ENZYME; POSTREPLICATION REPAIR PATHWAYS; SACCHAROMYCES-CEREVISIAE; DNA-REPAIR; MULTIUBIQUITIN CHAIN; PROTEIN-DEGRADATION; ERROR-PRONE; YEAST RAD6; PROTEASOME; COMPLEX	Polyubiquitin chains assembled through lysine 48 (Lys-48) of ubiquitin act as a signal for substrate proteolysis by 26 S proteasomes, whereas chains assembled through Lys-63 play a mechanistically undefined role in post-replicative DNA repair. We showed previously that the products of the UBC13 and MMS2 genes function in error-free post-replicative DNA repair in the yeast Saccharomyces cerevisiae and form a complex that assembles Lys-63-linked polyubiquitin chains in vitro. Here we confirm that the Mms2.Ubc13 complex functions as a high affinity heterodimer in the chain assembly reaction in vitro and report the results of a kinetic characterization of the polyubiquitin chain assembly reaction. To test whether a Lys-63-linked polyubiquitin chain can signal degradation, we conjugated Lys-63-linked tetra-ubiquitin to a model substrate of 26 S proteasomes. Although the noncanonical chain effectively signaled substrate degradation, the results of new genetic epistasis studies agree with previous genetic data in suggesting that the proteolytic activity of proteasomes is not required for error-free post-replicative repair.	Johns Hopkins Univ, Sch Publ Hlth, Dept Biochem & Mol Biol, Baltimore, MD 21205 USA	Johns Hopkins University	Pickart, CM (corresponding author), Johns Hopkins Univ, Sch Publ Hlth, Dept Biochem & Mol Biol, Rm 8041,615 N Wolfe St, Baltimore, MD 21205 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060372] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM60372] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amerik AY, 1997, EMBO J, V16, P4826; ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; Baboshina OV, 1996, J BIOL CHEM, V271, P2823, DOI 10.1074/jbc.271.5.2823; Bailly V, 1997, MOL CELL BIOL, V17, P4536, DOI 10.1128/MCB.17.8.4536; BAILLY V, 1994, GENE DEV, V8, P811, DOI 10.1101/gad.8.7.811; Broomfield S, 1998, P NATL ACAD SCI USA, V95, P5678, DOI 10.1073/pnas.95.10.5678; Brusky J, 2000, CURR GENET, V37, P168, DOI 10.1007/s002940050515; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN ZJ, 1990, J BIOL CHEM, V265, P21835; COOK WJ, 1994, J MOL BIOL, V236, P601, DOI 10.1006/jmbi.1994.1169; COOK WJ, 1992, J BIOL CHEM, V267, P16467; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Dor Y, 1996, MOL MICROBIOL, V21, P1197, DOI 10.1046/j.1365-2958.1996.671433.x; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; FRASER J, 1991, CURR GENET, V20, P17, DOI 10.1007/BF00312760; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Galan JM, 1996, J BIOL CHEM, V271, P10946, DOI 10.1074/jbc.271.18.10946; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GREGORI L, 1990, J BIOL CHEM, V265, P8354; HAAS AL, 1985, J BIOL CHEM, V260, P2464; Haldeman MT, 1997, BIOCHEMISTRY-US, V36, P10526, DOI 10.1021/bi970750u; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Jelinsky SA, 1999, P NATL ACAD SCI USA, V96, P1486, DOI 10.1073/pnas.96.4.1486; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; JOHNSON RE, 1992, MOL CELL BIOL, V12, P3807, DOI 10.1128/MCB.12.9.3807; Kaiser P, 2000, CELL, V102, P303, DOI 10.1016/S0092-8674(00)00036-2; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; LAM YA, 1997, J BIOL CHEM, V272, P28348; Mastrandrea LD, 1999, J BIOL CHEM, V274, P27299, DOI 10.1074/jbc.274.38.27299; Moore DD, 1995, GLOB MOB SURV; Phillips CL, 2001, ACTA CRYSTALLOGR D, V57, P341, DOI 10.1107/S090744490001800X; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; PICKART CM, 1992, J BIOL CHEM, V267, P14418; PICKART CM, 1988, J BIOL CHEM, V263, P12028; Piotrowski J, 1997, J BIOL CHEM, V272, P23712, DOI 10.1074/jbc.272.38.23712; PRAKASH L, 1981, MOL GEN GENET, V184, P471, DOI 10.1007/BF00352525; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; REYNOLDS P, 1985, P NATL ACAD SCI USA, V82, P168, DOI 10.1073/pnas.82.1.168; RICHTERRUOFF B, 1994, FEBS LETT, V354, P50, DOI 10.1016/0014-5793(94)01085-4; RICHTERRUOFF B, 1992, FEBS LETT, V302, P192, DOI 10.1016/0014-5793(92)80438-M; Russell SJ, 1999, MOL CELL, V3, P687, DOI 10.1016/S1097-2765(01)80001-0; Sancho E, 1998, MOL CELL BIOL, V18, P576, DOI 10.1128/MCB.18.1.576; SCHORK SM, 1994, FEBS LETT, V349, P270, DOI 10.1016/0014-5793(94)00668-7; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; Spence J, 2000, CELL, V102, P67, DOI 10.1016/S0092-8674(00)00011-8; Springael JY, 1998, MOL BIOL CELL, V9, P1253, DOI 10.1091/mbc.9.6.1253; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Ulrich HD, 2000, EMBO J, V19, P3388, DOI 10.1093/emboj/19.13.3388; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6; WILKINSON KD, 1995, BIOCHEMISTRY-US, V34, P14535, DOI 10.1021/bi00044a032; Xiao W, 2000, GENETICS, V155, P1633; Xiao W, 1999, MUTAT RES-DNA REPAIR, V435, P1, DOI 10.1016/S0921-8777(99)00034-8; Yao TT, 2000, J BIOL CHEM, V275, P36862, DOI 10.1074/jbc.M006050200; Yin LM, 2000, BIOCHEMISTRY-US, V39, P10001, DOI 10.1021/bi0007019; You JX, 2001, J BIOL CHEM, V276, P19871, DOI 10.1074/jbc.M100034200; You JX, 1999, BIOTECHNIQUES, V27, P950, DOI 10.2144/99275st01; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	64	202	213	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27936	27943		10.1074/jbc.M103378200	http://dx.doi.org/10.1074/jbc.M103378200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11369780	hybrid			2022-12-25	WOS:000170093400027
J	Cardoso, SM; Santos, S; Swerdlow, RH; Oliveira, CR				Cardoso, SM; Santos, S; Swerdlow, RH; Oliveira, CR			Functional mitochondria are required for amyloid beta-mediated neurotoxicity	FASEB JOURNAL			English	Article						Alzheimer's disease; mitochondria; beta-amyloid; rho 0 cells	COLLAGENASE PERFUSION TECHNIQUE; BROMIDE MTT REDUCTION; ALZHEIMERS-DISEASE; RAT-LIVER; OXIDATIVE STRESS; VASOPRESSIN V1A; PERIVENOUS HEPATOCYTES; ENERGY-METABOLISM; CORTICAL-NEURONS; CYTOSOLIC CA2+	The role of mitochondria. in amyloid betapeptide (Abeta)-induced cytotoxicity is unclear. We therefore exposed NT2 cells, a clonal human teratocarcinoma cell line capable of differentiation into terminal neurons, to Abeta 25-35 or to Abeta 1-42 to evaluate cell viability and altered mitochondrial function. A 24-h incubation of native NT2 cells (rho+ cells) with Abeta 25-35 or with Abeta 1-42 produced a dose-dependent decline in MTT reduction. Abeta 1-42 was shown to be more toxic compared with Abeta 25-35. Abeta 25-35 toxicity was prevented or diminished by a 22-h preincubation with antioxidants (vitamin E, metatonin, and idebenone), as well as by simultaneous incubation with GSH or the nicotinic receptor agonist nicotine. Abeta 25-35 exposure was also associated with (1) inhibition of mitochondrial respiratory chain complexes (I, NADH-ubiquinone oxidoreductase; II/III, succinate-cytochrome c oxidoreductase; and IV, cytochrome c oxidase), (2) ATP depletion, and (3) reduction of the mitochondrial membrane potential. In contrast, NT2 cells rendered incapable of oxidative phosphorylation via depletion of their mitochondrial DNA (rho0 cells) were unaffected by exposure to Abeta 25-35 or Abeta 1-42. These data indicate that Abeta can disrupt mitochondrial function and that such disruption causes oxidative stress. It is further suggested that a functional mitochondrial respiratory chain is required for Abeta toxicity.	Univ Coimbra, Fac Med, Biochem Lab, Ctr Neurosci Coimbra, P-3004504 Coimbra, Portugal; Univ Virginia, Dept Neurol, Charlottesville, VA USA	Universidade de Coimbra; University of Virginia	Oliveira, CR (corresponding author), Univ Coimbra, Fac Med, Biochem Lab, Ctr Neurosci Coimbra, P-3004504 Coimbra, Portugal.	catarina@cnc.cj.uc.pt	Cardoso, Sandra M/L-1962-2013; Cardoso, Sandra/C-9930-2009; Oliveira, Catarina R./F-3685-2010; Cardoso, Sandra M/C-9346-2018	Oliveira, Catarina/0000-0001-6942-4328; Cardoso, Sandra M/0000-0002-2199-0555				AKAIKE A, 1994, BRAIN RES, V644, P181, DOI 10.1016/0006-8993(94)91678-0; Ancellin N, 1998, CELL SIGNAL, V10, P217, DOI 10.1016/S0898-6568(97)00124-1; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BARBERIS C, 1995, NEUROENDOCRINOLOGY, V62, P135, DOI 10.1159/000126998; BEAL MF, 1995, ANN NEUROL, V38, P357, DOI 10.1002/ana.410380304; BEHL C, 1992, BIOCHEM BIOPH RES CO, V186, P944, DOI 10.1016/0006-291X(92)90837-B; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BERTHOUD VM, 1992, AM J PHYSIOL, V263, pG650, DOI 10.1152/ajpgi.1992.263.5.G650; CANTAU B, 1980, J RECEPTOR RES, V1, P137, DOI 10.3109/10799898009044096; COMBETTES L, 1994, BIOCHEM J, V304, P585, DOI 10.1042/bj3040585; COMBETTES L, 1993, CELL CALCIUM, V14, P279, DOI 10.1016/0143-4160(93)90049-C; CURTI D, 1995, NEUROCHEM RES, V20, P1001, DOI 10.1007/BF00995552; DUNN FL, 1973, J CLIN INVEST, V52, P3212, DOI 10.1172/JCI107521; Dupont G, 2000, FASEB J, V14, P279, DOI 10.1096/fasebj.14.2.279; EXTON JH, 1988, HEPATOLOGY, V8, P152, DOI 10.1002/hep.1840080129; FISHMAN JB, 1985, J BIOL CHEM, V260, P2641; FREEMAN BA, 1982, LAB INVEST, V47, P412; GAZIS D, 1978, P SOC EXP BIOL MED, V157, P584; Grazzini E, 1996, ENDOCRINOLOGY, V137, P3906, DOI 10.1210/en.137.9.3906; GUILLON G, 1986, FEBS LETT, V196, P155, DOI 10.1016/0014-5793(86)80232-0; HALLIWELL B, 1985, TRENDS NEUROSCI, V8, P22, DOI 10.1016/0166-2236(85)90010-4; HARDONK MJ, 1992, J LEUKOCYTE BIOL, V52, P296, DOI 10.1002/jlb.52.3.296; Jiang SN, 1999, J BIOL CHEM, V274, P29905, DOI 10.1074/jbc.274.42.29905; JONES GMM, 1992, PSYCHOPHARMACOLOGY, V108, P485, DOI 10.1007/BF02247426; Jungermann K, 2000, HEPATOLOGY, V31, P255, DOI 10.1002/hep.510310201; JUNGERMANN K, 1989, PHYSIOL REV, V69, P708, DOI 10.1152/physrev.1989.69.3.708; Kaabache T, 1995, ANAL BIOCHEM, V232, P225, DOI 10.1006/abio.1995.0011; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KATZMAN R, 1986, NEW ENGL J MED, V314, P964, DOI 10.1056/NEJM198604103141506; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; King T.E., 1967, METHODS ENZYMOL, P216, DOI DOI 10.1016/0076-6879(67)10043-8; KITAMURA T, 1991, HEPATOLOGY, V14, P640, DOI 10.1016/0270-9139(91)90051-V; KrausFriedmann N, 1996, METABOLISM, V45, P389, DOI 10.1016/S0026-0495(96)90296-6; Liu YB, 1997, J NEUROCHEM, V69, P581, DOI 10.1046/j.1471-4159.1997.69020581.x; LOVELL MA, 1995, NEUROLOGY, V45, P1594, DOI 10.1212/WNL.45.8.1594; Mark RJ, 1996, MOL NEUROBIOL, V12, P211, DOI 10.1007/BF02755589; MARK RJ, 1995, J NEUROSCI, V15, P6239; Mark RJ, 1997, J NEUROSCI, V17, P1046; Mark RJ, 1997, BRAIN RES, V756, P205, DOI 10.1016/S0006-8993(97)00196-0; MARTIN EJ, 1994, DRUG DEVELOP RES, V31, P127; Meister A., 1970, METHOD ENZYMOL, V17, P900, DOI 10.1016/0076-6879(71)17304-1; Meyerowitz BE, 1997, J PERS INTERPERS LOS, V2, P49, DOI 10.1080/10811449708414405; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Motoyama K, 1999, AM J PHYSIOL-REG I, V276, pR575, DOI 10.1152/ajpregu.1999.276.2.R575; Munir M, 1995, J NEUROSCI, V15, P7847; NATHANSON MH, 1992, J BIOL CHEM, V267, P23282; Nathanson MH, 1999, GASTROENTEROLOGY, V116, P1176, DOI 10.1016/S0016-5085(99)70021-1; NATHANSON MH, 1995, AM J PHYSIOL-GASTR L, V269, pG167, DOI 10.1152/ajpgi.1995.269.1.G167; NATHANSON MH, 1992, HEPATOLOGY, V15, P107, DOI 10.1002/hep.1840150119; NATHANSON MH, 1996, PROGR LIVER DIS, P1; Newhouse P, 1996, DRUG DEVELOP RES, V38, P278, DOI 10.1002/(SICI)1098-2299(199607/08)38:3/4<278::AID-DDR17>3.0.CO;2-V; NIJLMANS LGJ, 1995, BIOCH BIOPHYS ACT, V1265, P117; Oinonen T, 1998, BIOCHEM J, V329, P17, DOI 10.1042/bj3290017; OSTROWSKI NL, 1993, ENDOCRINOLOGY, V133, P1849, DOI 10.1210/en.133.4.1849; Palmeira CM, 1996, J PHARMACOL TOX MET, V35, P35, DOI 10.1016/1056-8719(95)00131-X; PARKER WD, 1990, NEUROLOGY, V40, P1302, DOI 10.1212/WNL.40.8.1302; Patel S, 1999, NAT CELL BIOL, V1, P467, DOI 10.1038/70249; Pereira C, 1998, NEUROREPORT, V9, P1749, DOI 10.1097/00001756-199806010-00015; Peretti J, 1999, EQUINE ATHLETE, V12, P6; Pierre C., 1994, LIFE SCI, V55, P271; PIKE CJ, 1993, J NEUROSCI, V13, P1676; POEGGELER B, 1993, J PINEAL RES, V14, P151, DOI 10.1111/j.1600-079X.1993.tb00498.x; QUISTORFF B, 1985, BIOCHEM J, V229, P221, DOI 10.1042/bj2290221; Ragan MT, 1987, MITOCHONDRIA PRACTIC, P79; ROBBGASPERS LD, 1995, J BIOL CHEM, V270, P8102, DOI 10.1074/jbc.270.14.8102; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; SAHAKIAN BJ, 1994, DRUG DEVELOP RES, V31, P80, DOI 10.1002/ddr.430310112; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SERRADEILLEGAL C, 1993, J CLIN INVEST, V92, P224, DOI 10.1172/JCI116554; SHEARMAN MS, 1995, J NEUROCHEM, V65, P218, DOI 10.1046/j.1471-4159.1995.65010218.x; Sipma H, 1998, CELL CALCIUM, V23, P11, DOI 10.1016/S0143-4160(98)90070-7; SMITH CD, 1991, P NATL ACAD SCI USA, V88, P10540, DOI 10.1073/pnas.88.23.10540; SMITH MA, 1994, P NATL ACAD SCI USA, V91, P5710, DOI 10.1073/pnas.91.12.5710; Starke DW, 1997, FREE RADICAL BIO MED, V23, P373, DOI 10.1016/S0891-5849(97)00009-9; STOCCHI V, 1985, ANAL BIOCHEM, V146, P118, DOI 10.1016/0003-2697(85)90405-1; Swerdlow RH, 1997, NEUROLOGY, V49, P918, DOI 10.1212/WNL.49.4.918; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; Tordjmann T, 1998, EMBO J, V17, P4695, DOI 10.1093/emboj/17.16.4695; Tordjmann T, 1997, EMBO J, V16, P5398, DOI 10.1093/emboj/16.17.5398; Tordjmann T, 1997, HEPATOLOGY, V26, P1592; Tordjmann T, 1996, GASTROENTEROLOGY, V111, P1343, DOI 10.1053/gast.1996.v111.pm8898649; Valtin H., 1992, HDB PHYSL, P1281; WALLACE DC, 1994, J BIOENERG BIOMEMBR, V26, P241, DOI 10.1007/BF00763096; WATANABE N, 1991, J CELL BIOL, V113, P1069, DOI 10.1083/jcb.113.5.1069; WERTKIN AM, 1993, P NATL ACAD SCI USA, V90, P9513, DOI 10.1073/pnas.90.20.9513; Wharton DC., 1967, METHOD ENZYMOL, P245; WRIGHT SC, 1993, FASEB J, V7, P1045, DOI 10.1096/fasebj.7.11.8370474; YANKNER BA, 1996, NATURE, V382, P685	90	176	186	2	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 27	2001	15	6					1439	+		10.1096/fj.00-0561fje	http://dx.doi.org/10.1096/fj.00-0561fje			34	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387250	Green Submitted			2022-12-25	WOS:000173705800018
J	Serriere, V; Berthon, B; Boucherie, S; Jacquemin, E; Guillon, G; Claret, M; Tordjmann, T				Serriere, V; Berthon, B; Boucherie, S; Jacquemin, E; Guillon, G; Claret, M; Tordjmann, T			Vasopressin receptor distribution in the liver controls calcium wave propagation and bile flow	FASEB JOURNAL			English	Article						intercellular signaling; cellular; heterogeneity; receptor; density; bile flow; vasopressin		Arginine vasopressin elicits elaborate Ca2+ signals in the liver (intercellular Ca2+ waves), the functional implications of which are not understood. Waves propagate across hepatocyte plates following a lobular gradient in V1a vasopressin receptor density. Here, we report that changes in this receptor distribution control Ca2+ wave propagation and bile flow. Although basal circulating vasopressin levels do not play a major role in the regulation of V1a receptor expression, increases in vasopressin. concentration within physiological limits for 24 h can abolish the lobular gradient in V1a receptor, as assessed by spectrofluorimetry, videomicroscopy, binding studies, and RNase protection assays. In animals in which the V1a receptor gradient was abolished, intercellular Ca2+ waves were impaired due to the equalization of Ca2+ responses in the various zones of the lobule. In the isolated perfused liver, the early increase in vasopressin-induced bile flow observed in control rats was much smaller if the V1a receptor density gradient was abolished. These findings suggest that V1a vasopressin receptor distribution controls intercellular Ca2+ wave propagation and bile flow. The control of hormone receptor distribution in a tissue by an agonist may turn the signaling and function of this agonist on or off.	Univ Paris 11, INSERM, U442, Unite Rech, F-91405 Orsay, France; INSERM, U469, Unite Rech, F-34094 Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Tordjmann, T (corresponding author), Univ Paris 11, INSERM, U442, Unite Rech, Bat 443, F-91405 Orsay, France.	thierry.tordjmann@ibaic.u-psud.fr	Tordjmann, Thierry/K-4706-2013						0	22	22	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR 27	2001	15	6					1484	+		10.1096/fj.00-0659fje	http://dx.doi.org/10.1096/fj.00-0659fje			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387265				2022-12-25	WOS:000173705800002
J	Tikhomirov, O; Carpenter, G				Tikhomirov, O; Carpenter, G			Caspase-dependent cleavage of ErbB-2 by geldanamycin and staurosporin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HSP90-BASED CHAPERONE SYSTEM; TYROSINE KINASE-ACTIVITY; CARCINOMA CELL-LINES; HUMAN-BREAST-CANCER; HEAT-SHOCK-PROTEIN; INDUCED APOPTOSIS; AUTOPHOSPHORYLATION SITES; SIGNAL-TRANSDUCTION; DOWN-REGULATION; GENE-PRODUCT	The geldanamycin-induced degradation of ErbB-2 produces a 23-kDa carboxyl-terminal fragment, which has been isolated and subjected to amino-terminal microsequencing. The obtained sequence indicates that the amino terminus of this fragment corresponds to Gly-1126 of ErbB-2. Analysis of the residues immediately before Gly-1126 suggests that cleavage may involve caspase activity. Site-directed mutagenesis of Asp-1125 in ErbB-2 prevents geldanamycin-provoked formation of the 23-kDa fragment, consistent with the requirement of this residue for caspase-dependent cleavage in known substrates. Also, the addition of the pan-caspase inhibitor Z-VAD-FMK blocks formation of the 23-kDa ErbB-2 fragment in cells exposed to geldanamycin. Interestingly, staurosporin and curcumin are also shown to provoke the degradation of ErbB-2 with formation of the 23-kDa carboxyl-terminal fragment. The generation of this fragment by staurosporin or curcumin is likewise blocked by caspase inhibition. Caspase inhibition does not prevent accelerated degradation of the 185-kDa native ErbB-2 in geldanamycin-treated cells but does significantly prevent staurosporin-stimulated metabolic loss of ErbB-2.	Vanderbilt Univ, Dept Biochem, Sch Med, Nashville, TN 37232 USA	Vanderbilt University	Carpenter, G (corresponding author), Vanderbilt Univ, Dept Biochem, Sch Med, Nashville, TN 37232 USA.	grahamcarpenter@mcmail.vanderbilt.edu						Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Andersson M, 2000, INVEST OPHTH VIS SCI, V41, P2623; BLAGOSKLONNY MV, 1995, ONCOGENE, V11, P933; Borg JP, 2000, NAT CELL BIOL, V2, P407, DOI 10.1038/35017038; Chavany C, 1996, J BIOL CHEM, V271, P4974; Chen H, 1999, ANTICANCER RES, V19, P3675; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; Davis MA, 1999, TOXICOL APPL PHARM, V161, P59, DOI 10.1006/taap.1999.8765; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIMARCO E, 1990, MOL CELL BIOL, V11, P3191; HAZAN R, 1990, CELL GROWTH DIFFER, V1, P3; Hong RL, 1999, CLIN CANCER RES, V5, P1884; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Khan SM, 2000, FERTIL STERIL, V74, P359, DOI 10.1016/S0015-0282(00)00633-6; Khar A, 1999, FEBS LETT, V445, P165, DOI 10.1016/S0014-5793(99)00114-3; Klapper LN, 2000, ADV CANCER RES, V77, P25; Kominsky SL, 2000, CANCER RES, V60, P3904; KUMAR R, 1991, MOL CELL BIOL, V11, P979, DOI 10.1128/MCB.11.2.979; Kuo CT, 1996, MATH PROBL ENG, V3, P95, DOI 10.1155/S1024123X97000501; MacKeigan JP, 2000, J BIOL CHEM, V275, P38953, DOI 10.1074/jbc.C000684200; Mandler R, 2000, J NATL CANCER I, V92, P1573, DOI 10.1093/jnci/92.19.1573; Margolin N, 1997, J BIOL CHEM, V272, P7223, DOI 10.1074/jbc.272.11.7223; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; McColl KS, 1998, MOL CELL ENDOCRINOL, V139, P229, DOI 10.1016/S0303-7207(98)00051-3; MILLER P, 1994, CANCER RES, V54, P2724; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; Nicchitta CV, 1998, CURR OPIN IMMUNOL, V10, P103, DOI 10.1016/S0952-7915(98)80039-3; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Nimmanapalli R, 2001, CANCER RES, V61, P1799; Ochel HJ, 1999, MOL GENET METAB, V66, P24, DOI 10.1006/mgme.1998.2774; OMURA S, 1979, J ANTIBIOT, V32, P255, DOI 10.7164/antibiotics.32.255; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Pratt WB, 1997, ANNU REV PHARMACOL, V37, P297, DOI 10.1146/annurev.pharmtox.37.1.297; Pratt WB, 1998, P SOC EXP BIOL MED, V217, P420; Pronk GJ, 1996, SCIENCE, V271, P808, DOI 10.1126/science.271.5250.808; Ramachandran C, 1999, BREAST CANCER RES TR, V54, P269, DOI 10.1023/A:1006170224414; Revillion F, 1998, EUR J CANCER, V34, P791, DOI 10.1016/S0959-8049(97)10157-5; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Roh H, 2000, CANCER RES, V60, P560; Rokhlin OW, 1998, CANCER RES, V58, P5870; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Tikhomirov O, 2000, J BIOL CHEM, V275, P26625, DOI 10.1074/jbc.M003114200; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Xu WP, 2001, J BIOL CHEM, V276, P3702, DOI 10.1074/jbc.M006864200; You XL, 1998, ONCOGENE, V17, P3177, DOI 10.1038/sj.onc.1202246; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	53	43	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33675	33680		10.1074/jbc.M101394200	http://dx.doi.org/10.1074/jbc.M101394200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11402024	hybrid			2022-12-25	WOS:000170910200053
J	Grenard, P; Bates, MK; Aeschlimann, D				Grenard, P; Bates, MK; Aeschlimann, D			Evolution of transglutaminase genes: Identification of a transglutaminase gene cluster on human chromosome 15q15 - Structure of the gene encoding transglutaminase X and a novel gene family member, transglutaminase Z	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-COAGULATION FACTOR; PROSTATE-SPECIFIC TRANSGLUTAMINASE; HUMAN ERYTHROCYTE PROTEIN-4.2; MURINE PALLID MUTATION; AMINO-ACID-SEQUENCE; TISSUE TRANSGLUTAMINASE; FACTOR-XIII; KERATINOCYTE TRANSGLUTAMINASE; CROSS-LINKING; TRANSCRIPTION FACTORS	We isolated and characterized the gene encoding human transglutaminase (TG)(X) (TGM5) and mapped it to the 15q15.2 region of chromosome 15 by fluorescence in situ hybridization. The gene consists of 13 exons separated by 12 introns and spans about 35 kilobases. Further sequence analysis and mapping showed that this locus contained three transglutaminase genes arranged in tandem: EPB42 (band 4.2 protein), TGM5, and a novel gene (TGM7). A full-length cDNA for the novel transglutaminase (TG(Z)) was obtained by anchored polymerase chain reaction. The deduced amino acid sequence encoded a protein with 710 amino acids and a molecular mass of 80 kDa. Northern blotting showed that the three genes are differentially expressed in human tissues. Band 4.2 protein expression was associated with hematopoiesis, whereas TG(X) and TG(Z) showed widespread expression in different tissues. Interestingly, the chromosomal segment containing the human TGM5, TGM7, and EPB42 genes and the segment containing the genes encoding TG(C),TG(E), and another novel gene (TGM6) on chromosome 20q11 are in mouse all found on distal chromosome 2 as determined by radiation hybrid mapping. This finding suggests that in evolution these six genes arose from local duplication of a single gene and subsequent redistribution to two distinct chromosomes in the human genome.	Univ Wales Coll Cardiff, Connect Tissue Biol Labs, Sch Biosci, Cardiff CF10 3US, S Glam, Wales; Univ Wisconsin, Div Orthoped Surg, Madison, WI 53792 USA	Cardiff University; University of Wisconsin System; University of Wisconsin Madison	Aeschlimann, D (corresponding author), Univ Wales Coll Cardiff, Connect Tissue Biol Labs, Sch Biosci, Museums Ave, Cardiff CF10 3US, S Glam, Wales.			Aeschlimann, Daniel/0000-0003-0930-7706				Aeschlimann D, 1998, J BIOL CHEM, V273, P3452, DOI 10.1074/jbc.273.6.3452; Aeschlimann D, 2000, CONNECT TISSUE RES, V41, P1, DOI 10.3109/03008200009005638; AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; Akimov SS, 2000, J CELL BIOL, V148, P825, DOI 10.1083/jcb.148.4.825; Ausubel FM, 1991, CURRENT PROTOCOLS MO, V1; BEBBINGTON CR, 1987, DNA CLONING PRACTICA, V3, P184; BERGET SM, 1984, NATURE, V309, P179, DOI 10.1038/309179a0; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BOARD PG, 1993, BLOOD REV, V7, P229, DOI 10.1016/0268-960X(93)90010-2; BOARD PG, 1988, CYTOGENET CELL GENET, V48, P25, DOI 10.1159/000132580; CHIANNILKULCHAI N, 1995, HUM MOL GENET, V4, P717, DOI 10.1093/hmg/4.4.717; Corbett SA, 1997, J BIOL CHEM, V272, P24999, DOI 10.1074/jbc.272.40.24999; De Laurenzi V, 2001, MOL CELL BIOL, V21, P148, DOI 10.1128/MCB.21.1.148-155.2001; Dubbink HJ, 1998, GENOMICS, V51, P434, DOI 10.1006/geno.1998.5393; Dubbink HJ, 1996, BIOCHEM J, V315, P901, DOI 10.1042/bj3150901; Eckert RL, 1997, J INVEST DERMATOL, V109, P501, DOI 10.1111/1523-1747.ep12336477; Eppig JT, 1996, CURR OPIN GENET DEV, V6, P723, DOI 10.1016/S0959-437X(96)80027-X; Folk J E, 1977, Adv Protein Chem, V31, P1, DOI 10.1016/S0065-3233(08)60217-X; Fraij BM, 1997, BBA-GENE STRUCT EXPR, V1354, P65, DOI 10.1016/S0167-4781(97)00132-2; Gaudry CA, 1999, J BIOL CHEM, V274, P30707, DOI 10.1074/jbc.274.43.30707; GENTILE V, 1995, GENOMICS, V27, P219, DOI 10.1006/geno.1995.1032; GENTILE V, 1994, GENOMICS, V20, P295, DOI 10.1006/geno.1994.1170; GENTILE V, 1991, J BIOL CHEM, V266, P478; Gibson TJ, 2000, BIOCHEM SOC T, V28, P259, DOI 10.1042/bst0280259; GRANT FJ, 1994, BIOCHEM BIOPH RES CO, V203, P1117, DOI 10.1006/bbrc.1994.2298; GRUNDMANN U, 1986, P NATL ACAD SCI USA, V83, P8024, DOI 10.1073/pnas.83.21.8024; Gwynn B, 1997, GENOMICS, V42, P532, DOI 10.1006/geno.1997.4764; ICHINOSE A, 1988, P NATL ACAD SCI USA, V85, P5829, DOI 10.1073/pnas.85.16.5829; KELLER EB, 1984, P NATL ACAD SCI-BIOL, V81, P7417, DOI 10.1073/pnas.81.23.7417; Kim H. T., 2000, P 6 INT C TRANSGL TR, P16; KIM HC, 1991, J BIOL CHEM, V266, P536; KIM IG, 1993, J BIOL CHEM, V268, P12682; KIM IG, 1992, J BIOL CHEM, V267, P7710; KIM IG, 1994, J INVEST DERMATOL, V103, P137, DOI 10.1111/1523-1747.ep12392470; KORSGREN C, 1991, P NATL ACAD SCI USA, V88, P4840, DOI 10.1073/pnas.88.11.4840; KORSGREN C, 1990, P NATL ACAD SCI USA, V87, P613, DOI 10.1073/pnas.87.2.613; KORSGREN C, 1994, GENOMICS, V21, P478, DOI 10.1006/geno.1994.1304; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Lee JH, 1996, J BIOL CHEM, V271, P4561; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; LU S, 1995, J BIOL CHEM, V270, P9748, DOI 10.1074/jbc.270.17.9748; McCarthy LC, 1997, GENOME RES, V7, P1153, DOI 10.1101/gr.7.12.1153; MCLAUCHLAN J, 1985, NUCLEIC ACIDS RES, V13, P1347, DOI 10.1093/nar/13.4.1347; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAJFELD V, 1992, AM J HUM GENET, V50, P71; Nanda N, 1999, ARCH BIOCHEM BIOPHYS, V366, P151, DOI 10.1006/abbi.1999.1189; Nemes Z, 1999, EXP MOL MED, V31, P5, DOI 10.1038/emm.1999.2; Noguchi K, 2001, J BIOL CHEM, V276, P12055, DOI 10.1074/jbc.M009862200; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; PEDERSEN LC, 1994, PROTEIN SCI, V3, P1131, DOI 10.1002/pro.5560030720; PHILLIPS MA, 1990, P NATL ACAD SCI USA, V87, P9333, DOI 10.1073/pnas.87.23.9333; PHILLIPS MA, 1992, J BIOL CHEM, V267, P2282; POLAKOWSKA RR, 1992, P NATL ACAD SCI USA, V89, P4476, DOI 10.1073/pnas.89.10.4476; Rossi A, 1998, J INVEST DERMATOL, V110, P34, DOI 10.1046/j.1523-1747.1998.00071.x; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; Spring J, 1997, FEBS LETT, V400, P2, DOI 10.1016/S0014-5793(96)01351-8; SUNG LPA, 1992, BLOOD, V79, P2763; TAKAHASHI N, 1986, P NATL ACAD SCI USA, V83, P8019, DOI 10.1073/pnas.83.21.8019; WHITE RA, 1992, NAT GENET, V2, P80, DOI 10.1038/ng0992-80; YEE VC, 1994, P NATL ACAD SCI USA, V91, P7296, DOI 10.1073/pnas.91.15.7296; Yee Vivien C., 1996, Seminars in Thrombosis and Hemostasis, V22, P377, DOI 10.1055/s-2007-999035	62	163	171	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					33066	33078		10.1074/jbc.M102553200	http://dx.doi.org/10.1074/jbc.M102553200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11390390	hybrid			2022-12-25	WOS:000170746000092
J	Siegmund, D; Mauri, D; Peters, N; Juo, P; Thome, M; Reichwein, M; Blenis, J; Scheurich, P; Tschopp, J; Wajant, H				Siegmund, D; Mauri, D; Peters, N; Juo, P; Thome, M; Reichwein, M; Blenis, J; Scheurich, P; Tschopp, J; Wajant, H			Fas-associated death domain protein (FADD) and caspase-8 mediate up-regulation of c-Fos by Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) via a FLICE inhibitory protein (FLIP)-regulated pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL PROLIFERATION; NF-KAPPA-B; LYMPHOPROLIFERATIVE SYNDROME; ACTIVATION; MICE; LYMPHOCYTES; FIBROBLASTS; FADD/MORT1; KINASE; CYTOTOXICITY	Fas, a death domain-containing member of the tumor necrosis factor receptor family and its ligand FasL have been predominantly studied with respect to their capability to induce cell death. However, a few studies indicate a proliferation-inducing signaling activity of these molecules too. We describe here a novel signaling pathway of FasL and the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) that triggers transcriptional activation of the proto-oncogene c-fos, a typical target gene of mitogenic pathways. FasL- and TRAIL-mediated up-regulation of c-Fos was completely dependent on the presence of Fas-associated death domain protein (FADD) and caspase-8, but caspase activity seemed to be dispensable as a pan inhibitor of caspases had no inhibitory effect. Upon overexpression of the long splice form of cellular FADD-like interleukin-1-converting enzyme (FLICE) inhibitory protein (cFLIP) in Jurkat cells, FasL- and TRAIL-induced up-regulation of c-Fos was almost completely blocked. The short splice form of FLIP, however, showed a rather stimulatory effect on c-Fos induction. Together these data demonstrate the existence of a death receptor-induced, FADD- and caspase-8-dependent pathway leading to c-Fos induction that is inhibited by the long splice form FLIP-L.	Univ Stuttgart, Inst Cell Biol & Immunol, D-70569 Stuttgart, Germany; Apotech Biochem Ltd, CH-1066 Epalinges, Switzerland; Univ Calif Berkeley, Dept Mol & Cellular Biol, Berkeley, CA 94720 USA; Univ Lausanne, Inst Biochem, CH-1066 Epalinges, Switzerland; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	University of Stuttgart; University of California System; University of California Berkeley; University of Lausanne; Harvard University; Harvard Medical School	Wajant, H (corresponding author), Univ Stuttgart, Inst Cell Biol & Immunol, Allmandring 31, D-70569 Stuttgart, Germany.		Juo, Peter/CJY-3695-2022; Thome, Margot/F-8167-2011; Wajant, Harald/A-3020-2017	Juo, Peter/0000-0002-3039-2266; Thome, Margot/0000-0002-5656-2139; Wajant, Harald/0000-0002-2005-3949				AGGARWAL BB, 1995, FEBS LETT, P3645; Alam A, 1999, J EXP MED, V190, P1879, DOI 10.1084/jem.190.12.1879; ALDERSON MR, 1995, J EXP MED, V181, P71, DOI 10.1084/jem.181.1.71; ALDERSON MR, 1993, J EXP MED, V178, P2231, DOI 10.1084/jem.178.6.2231; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; Berberich I, 1996, EMBO J, V15, P92, DOI 10.1002/j.1460-2075.1996.tb00337.x; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; Chaudhary PM, 1999, J BIOL CHEM, V274, P19211, DOI 10.1074/jbc.274.27.19211; Desbarats J, 1999, P NATL ACAD SCI USA, V96, P8104, DOI 10.1073/pnas.96.14.8104; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; Freiberg RA, 1997, J INVEST DERMATOL, V108, P215, DOI 10.1111/1523-1747.ep12334273; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Han DKM, 1997, P NATL ACAD SCI USA, V94, P11333, DOI 10.1073/pnas.94.21.11333; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Hu WH, 2000, J BIOL CHEM, V275, P10838, DOI 10.1074/jbc.275.15.10838; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; JANKNECHT R, 1995, IMMUNOBIOLOGY, V193, P137, DOI 10.1016/S0171-2985(11)80536-X; Jelaska A, 1998, J CELL PHYSIOL, V175, P19, DOI 10.1002/(SICI)1097-4652(199804)175:1<19::AID-JCP3>3.0.CO;2-F; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; Juo P, 1999, CELL GROWTH DIFFER, V10, P797; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; Kataoka T, 2000, CURR BIOL, V10, P640, DOI 10.1016/S0960-9822(00)00512-1; Kawahara A, 1998, J CELL BIOL, V143, P1353, DOI 10.1083/jcb.143.5.1353; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Kuang AA, 2000, J BIOL CHEM, V275, P25065, DOI 10.1074/jbc.C000284200; Kurasawa K, 2000, J ALLERGY CLIN IMMUN, V106, pS19, DOI 10.1067/mai.2000.106773; Lin Y, 2000, MOL CELL BIOL, V20, P6638, DOI 10.1128/MCB.20.18.6638-6645.2000; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; Mariani SM, 1998, EUR J IMMUNOL, V28, P1492, DOI 10.1002/(SICI)1521-4141(199805)28:05<1492::AID-IMMU1492>3.0.CO;2-X; Muhlenbeck F, 1998, J BIOL CHEM, V273, P33091, DOI 10.1074/jbc.273.49.33091; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; Ponton A, 1996, J BIOL CHEM, V271, P8991, DOI 10.1074/jbc.271.15.8991; Rasper DM, 1998, CELL DEATH DIFFER, V5, P271, DOI 10.1038/sj.cdd.4400370; Rescigno M, 2000, J EXP MED, V192, P1661, DOI 10.1084/jem.192.11.1661; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Wajant H, 2000, J BIOL CHEM, V275, P24357, DOI 10.1074/jbc.M000811200; Walsh CM, 1998, IMMUNITY, V8, P439, DOI 10.1016/S1074-7613(00)80549-X; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; Wu JG, 1996, J CLIN INVEST, V98, P1107, DOI 10.1172/JCI118892; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681; Zornig M, 1998, CURR BIOL, V8, P467, DOI 10.1016/S0960-9822(98)70182-4	55	58	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32585	32590		10.1074/jbc.M100444200	http://dx.doi.org/10.1074/jbc.M100444200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11384965	hybrid			2022-12-25	WOS:000170746000029
J	Bell, JK; Yennawar, HP; Wright, SK; Thompson, JR; Viola, RE; Banaszak, LJ				Bell, JK; Yennawar, HP; Wright, SK; Thompson, JR; Viola, RE; Banaszak, LJ			Structural analyses of a malate dehydrogenase with a variable active site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; MOLECULAR-REPLACEMENT; SUBSTRATE-SPECIFICITY; TERNARY COMPLEX; RESOLUTION; CRYSTALLOGRAPHY; REFINEMENT; CITRATE; MODEL	Malate dehydrogenase specifically oxidizes malate to oxaloacetate. The specificity arises from three arginines in the active site pocket that coordinate the carboxyl groups of the substrate and stabilize the newly forming hydroxyl/keto group during catalysis. Here, the role of Arg-153 in distinguishing substrate specificity is examined by the mutant R153C. The x-ray structure of the NAD binary complex at 2.1 Angstrom reveals two sulfate ions bound in the closed form of the active site. The sulfate that occupies the substrate binding site has been translated similar to2 Angstrom toward the opening of the active site cavity. Its new location suggests that the low catalytic turnover observed in the R153C mutant may be due to misalignment of the hydroxyl or ketone group of the substrate with the appropriate catalytic residues. In the NAD-pyruvate ternary complex, the monocarboxylic inhibitor is bound in the open conformation of the active site. The pyruvate is coordinated not by the active site arginines, but through weak hydrogen bonds to the amide backbone. Energy minimized molecular models of unnatural analogues of R153C (Wright, S. K., and Viola, R. E. (2001) J. Biol Chem. 276, 31151-31155) reveal that the regenerated amino and amido side chains can form favorable hydrogen-bonding interactions with the substrate, although a return to native enzymatic activity is not observed. The low activity of the modified R153C enzymes suggests that precise positioning of the guanidino side chain is essential for optimal orientation of the substrate.	Univ Toledo, Dept Chem, Toledo, OH 43606 USA; Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA; Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; Univ Toledo, Dept Chem, Toledo, OH 43606 USA	University System of Ohio; University of Toledo; University of Minnesota System; University of Minnesota Twin Cities; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University System of Ohio; University of Toledo	Viola, RE (corresponding author), Univ Toledo, Dept Chem, 2801 W Bancroft St, Toledo, OH 43606 USA.		Viola, Ronald/C-5904-2011	Yennawar, Hemant P./0000-0003-2869-1109				BIRKTOFT JJ, 1989, BIOCHEMISTRY-US, V28, P6065, DOI 10.1021/bi00440a051; BIRKTOFT JJ, 1983, J BIOL CHEM, V258, P472; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CASTELLANO EE, 1992, J APPL CRYSTALLOGR, V25, P281, DOI 10.1107/S0021889891012773; Chapman ADM, 1999, J MOL BIOL, V285, P703, DOI 10.1006/jmbi.1998.2357; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; HALL MD, 1991, J MOL BIOL, V220, P551, DOI 10.1016/0022-2836(91)90099-R; HALL MD, 1993, J MOL BIOL, V232, P213, DOI 10.1006/jmbi.1993.1377; HALL MD, 1992, J MOL BIOL, V226, P867, DOI 10.1016/0022-2836(92)90637-Y; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS DJ, 1992, BIOCHEM BIOPH RES CO, V189, P1057, DOI 10.1016/0006-291X(92)92311-K; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rodriguez R, 1998, BIOINFORMATICS, V14, P523, DOI 10.1093/bioinformatics/14.6.523; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WILKS HM, 1988, SCIENCE, V242, P1541, DOI 10.1126/science.3201242; Wright SK, 2000, J BIOL CHEM, V275, P31689, DOI 10.1074/jbc.M003652200; Wright SK, 2001, J BIOL CHEM, V276, P31151, DOI 10.1074/jbc.M100892200	21	23	24	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31156	31162		10.1074/jbc.M100902200	http://dx.doi.org/10.1074/jbc.M100902200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11389141	hybrid			2022-12-25	WOS:000170472900075
J	Hsu, LS; Chen, GD; Lee, LS; Chi, CW; Cheng, JF; Chen, JY				Hsu, LS; Chen, GD; Lee, LS; Chi, CW; Cheng, JF; Chen, JY			Human Ca2+/calmodulin-dependent protein kinase kinase beta gene encodes multiple isoforms that display distinct kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADULT-RAT BRAIN; MOLECULAR-CLONING; 2 ISOFORMS; MESSENGER-RNAS; CALMODULIN; ACTIVATION; CASCADE; EXPRESSION; CALCIUM; LOCALIZATION	Ca+2/calmodulin-dependent protein kinases (CaMKs) are activated upon binding of Ca+2/calmodulin. To gain maximal activity, CaMK I and CaMK TV can be further phosphorylated by an upstream kinase, CaMK kinase (CaMKK). We previously isolated cDNA clones encoding human CaMKK beta isoforms that are heterogeneous in their 3 ' -sequences (Hsu, L.-S., Tsou, A.-P., Chi, C.-W,, Lee, C.-H., and Chen, J.-Y. (1998) J. Biomed. Sci. 5,141-149). In the present study, we examined the genomic organization and transcription of the human CaMKK beta gene. The human CaMKK beta locus spans more than 40 kilobase pairs and maps to chromosome 12q24.2. It is organized into 18 exons and 17 introns that are flanked by typical splice donor and acceptor sequences. Two major species of transcripts, namely the beta1 (5.6 kilobase pairs) and beta2 (2.9 kilobase pairs), are generated through differential usage of polyadenylation sites located in the last and penultimate exons. Additional forms of CaMKK beta transcripts were also identified that resulted from alternative splicing of the internal exons 14 and/or 16. These isoforms display differential expression patterns in human tissues and tumor-derived cell lines. They also exhibit a distinct ability to undergo autophosphorylation and to phosphorylate the downstream kinases CaMK I and CaMK IV. The differential expression of CaMKK beta isoforms with distinct activity further suggests the complexity of the regulation of the CaMKK/CaMK cascade and an important role for CaMKK in the action of Ca+2- mediated cellular responses.	Acad Sinica, Inst Biomed Sci, Taipei, Taiwan; Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan; Inst Neurol, Taipei, Taiwan; Vet Gen Hosp, Med Res & Educ Dept, Taipei, Taiwan; Natl Yang Ming Univ, Taipei 112, Taiwan; Lawrence Berkeley Lab, Genome Sci Dept, Berkeley, CA 94720 USA	Academia Sinica - Taiwan; National Defense Medical Center; National Yang Ming Chiao Tung University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	Chen, JY (corresponding author), Acad Sinica, Inst Biomed Sci, Taipei, Taiwan.			Cheng, Jan-Fang/0000-0001-7315-7613				ACHESON NH, 1984, MOL CELL BIOL, V4, P722, DOI 10.1128/MCB.4.4.722; AMARA SG, 1982, NATURE, V298, P240, DOI 10.1038/298240a0; AMARA SG, 1984, MOL CELL BIOL, V4, P2151, DOI 10.1128/MCB.4.10.2151; Anderson KA, 1998, J BIOL CHEM, V273, P31880, DOI 10.1074/jbc.273.48.31880; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; CHEN JY, 1993, ONCOGENE, V8, P2159; CRENSHAW EB, 1987, CELL, V49, P389, DOI 10.1016/0092-8674(87)90291-1; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; Edelman AM, 1996, J BIOL CHEM, V271, P10806, DOI 10.1074/jbc.271.18.10806; EdwaldsGilbert G, 1997, NUCLEIC ACIDS RES, V25, P2547, DOI 10.1093/nar/25.13.2547; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; Eto K, 1999, J BIOL CHEM, V274, P22556, DOI 10.1074/jbc.274.32.22556; GuptaRoy B, 1996, J BIOL CHEM, V271, P19846, DOI 10.1074/jbc.271.33.19846; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; Heist EK, 1998, CELL CALCIUM, V23, P103; Hsu LS, 1998, J BIOMED SCI, V5, P141, DOI 10.1007/BF02258368; Kitani T, 1997, J BIOCHEM-TOKYO, V122, P243; LEE JSC, 1994, J BIOL CHEM, V269, P2158; Loseth OP, 2000, BRAIN RES, V869, P137, DOI 10.1016/S0006-8993(00)02359-3; Means AR, 2000, MOL ENDOCRINOL, V14, P4, DOI 10.1210/me.14.1.4; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; Naito Y, 1997, J BIOL CHEM, V272, P32704, DOI 10.1074/jbc.272.51.32704; OHSAKO S, 1993, J BIOL CHEM, V268, P2052; OKUNO S, 1994, J BIOCHEM, V116, P923, DOI 10.1093/oxfordjournals.jbchem.a124617; Osawa M, 1999, NAT STRUCT BIOL, V6, P819; Park IK, 1995, J BIOL CHEM, V270, P30464, DOI 10.1074/jbc.270.51.30464; Sakagami H, 1998, MOL BRAIN RES, V54, P311, DOI 10.1016/S0169-328X(97)00362-8; Sakagami H, 2000, EUR J NEUROSCI, V12, P89, DOI 10.1046/j.1460-9568.2000.00883.x; Sambrook J., 2002, MOL CLONING LAB MANU; Santella L, 1998, BIOCHEM BIOPH RES CO, V244, P317, DOI 10.1006/bbrc.1998.8086; SCHULMAN H, 1993, NEUROCHEM RES, V18, P65, DOI 10.1007/BF00966924; Schulman H, 1993, CURR OPIN CELL BIOL, V5, P247, DOI 10.1016/0955-0674(93)90111-3; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; Soderling TR, 1999, TRENDS BIOCHEM SCI, V24, P232, DOI 10.1016/S0968-0004(99)01383-3; SUGITA R, 1994, BIOCHEM BIOPH RES CO, V203, P694, DOI 10.1006/bbrc.1994.2238; Sun PQ, 1996, J BIOL CHEM, V271, P3066, DOI 10.1074/jbc.271.6.3066; Tokumitsu H, 1999, J BIOL CHEM, V274, P15803, DOI 10.1074/jbc.274.22.15803; Tokumitsu H, 1997, BIOCHEMISTRY-US, V36, P12823, DOI 10.1021/bi971348i; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; Tombes RM, 1999, BBA-MOL CELL RES, V1452, P1, DOI 10.1016/S0167-4889(99)00113-5; Tombes RM, 1997, BBA-MOL CELL RES, V1355, P281, DOI 10.1016/S0167-4889(96)00141-3; Uemura A, 1998, BIOCHEM BIOPH RES CO, V249, P355, DOI 10.1006/bbrc.1998.9154; URQUIDI V, 1995, FEBS LETT, V358, P23, DOI 10.1016/0014-5793(94)01381-A; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; Zeng WR, 2000, GENE, V241, P75, DOI 10.1016/S0378-1119(99)00465-5	47	34	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31113	31123		10.1074/jbc.M011720200	http://dx.doi.org/10.1074/jbc.M011720200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11395482	hybrid			2022-12-25	WOS:000170472900070
J	Bhattacharyya, AM; Horowitz, PM				Bhattacharyya, AM; Horowitz, PM			The aggregation state of rhodanese during folding influences the ability of GroEL to assist reactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLORIDE-DENATURED RHODANESE; ATP HYDROLYSIS; PROTEIN; ASSOCIATION; DETERGENT; SHOW	The in vitro folding of rhodanese involves a competition between formation of properly folded enzyme and off-pathway inactive species. Co-solvents like glycerol or low temperature, e.g. refolding at 10 degreesC, successfully retard the off-pathway formation of large inactive aggregates, but the process does not yield 100% active enzyme. These data suggest that mis-folded species are formed from early folding intermediates. GroEL can capture early folding intermediates, and it loses the ability to capture and reactivate rhodanese if the enzyme is allowed first to spontaneously fold for longer times before it is presented to GroEL, a process that leads to the formation of unproductive intermediates. In addition, GroEL cannot reverse large aggregates once they are formed, but it could capture some folding intermediates and activate them, even though they are not capable of forming active enzyme if left to spontaneous refolding. The interaction between GroEL and rhodanese substantially but not completely inhibits intra-protein inactivation, which is responsible for incomplete activation during unassisted refolding. Thus, GroEL not only decreases aggregation, but it gives the highest reactivation of any method of assistance. The results are interpreted using a previously suggested model based on studies of the spontaneous folding of rhodanese (Gorovits, B. M., McGee, W. A., and Horowitz, P. M. (1998) Biochim Biophys. Acta 1382, 120-128 and Panda, M., Gorovits, B. M., and Horowitz, P. M. (2000) J. BioL Chem 275, 63-70).	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Horowitz, PM (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.				NIGMS NIH HHS [GM 5177] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baldwin RL, 1996, FOLD DES, V1, pR1, DOI 10.1016/S1359-0278(96)00003-X; Bhattacharyya AM, 2000, J BIOL CHEM, V275, P14860, DOI 10.1074/jbc.275.20.14860; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; CHRUNYK BA, 1990, BIOCHEMISTRY-US, V29, P2149, DOI 10.1021/bi00460a027; Clark AC, 1996, BIOCHEMISTRY-US, V35, P5893, DOI 10.1021/bi953051v; Ellis R J, 1990, Semin Cell Biol, V1, P1; FISCHER G, 1990, BIOCHEMISTRY-US, V29, P2205, DOI 10.1021/bi00461a001; Gorovits BM, 1998, BBA-PROTEIN STRUCT M, V1382, P120, DOI 10.1016/S0167-4838(97)00158-1; HAGIHARA Y, 1998, MOL CHAPERONES LIFE, P1; HOROWITZ PM, 1989, J BIOL CHEM, V264, P3311; HOROWITZ PM, 1993, J BIOL CHEM, V268, P2500; HOROWITZ PM, 1990, J BIOL CHEM, V265, P2576; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; Jaenicke Rainer, 1997, V50, P1; Klibanov AM, 1997, TRENDS BIOTECHNOL, V15, P97, DOI 10.1016/S0167-7799(97)01013-5; MENDOZA JA, 1991, J BIOL CHEM, V266, P13587; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MENDOZA JA, 1991, J BIOL CHEM, V266, P16973; MILLER DM, 1991, J BIOL CHEM, V266, P4686; MITRAKI A, 1989, BIO-TECHNOL, V7, P690, DOI 10.1038/nbt0789-690; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; Panda M, 2000, J BIOL CHEM, V275, P63, DOI 10.1074/jbc.275.1.63; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; Shibatani T, 1999, J BIOL CHEM, V274, P33795, DOI 10.1074/jbc.274.47.33795; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SORBO BH, 1953, ACTA CHEM SCAND, V7, P1129, DOI 10.3891/acta.chem.scand.07-1129; STANIFORTH RA, 1994, FEBS LETT, V344, P129, DOI 10.1016/0014-5793(94)00348-3; TANDON S, 1989, J BIOL CHEM, V264, P9859; TANDON S, 1986, J BIOL CHEM, V261, P5615; TANDON S, 1987, J BIOL CHEM, V262, P4486; Timasheff S N, 1995, Methods Mol Biol, V40, P253; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003	33	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28739	28743		10.1074/jbc.M102500200	http://dx.doi.org/10.1074/jbc.M102500200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11397797	hybrid			2022-12-25	WOS:000170346000014
J	Hilairet, S; Foord, SM; Marshall, FH; Bouvier, M				Hilairet, S; Foord, SM; Marshall, FH; Bouvier, M			Protein-protein interaction and not glycosylation determines the binding selectivity of heterodimers between the calcitonin receptor-like receptor and the receptor activity-modifying proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-RELATED PEPTIDE; AMYLIN RECEPTOR; LIGAND-BINDING; CELLS; RAMPS; IDENTIFICATION; TERMINUS; PRODUCT; VECTOR; STATE	The receptor activity-modifying proteins (RAMPs) and the calcitonin receptor-like receptor (CRLR) are both required to generate adrenomedullin (AM) and calcitonin gene-related peptide (CGRP) receptors. A mature, fully glycosylated, form of CRLR was associated with I-125-CGRP binding, upon co-expression of RAMP1 and CRLR. In contrast, RAMP2 and -3 promoted the expression of smaller, core-glycosylated, CRLR forms, which were linked to AM receptor pharmacology. Since core glycosylation is classically a trademark of immature proteins, we tested the hypothesis that the core-glycosylated CRLR forms the AM receptor. Although significant amounts of core-glycosylated CRLR were produced upon co-expression with RAMP2 or -3, crosslinking experiments revealed that I-125-AM only bound to the fully glycosylated forms. Similarly, I-125-CGRP selectively recognized the mature CRLR species upon co-expression with RAMP1, indicating that the glycosylation does not determine ligand-binding selectivity. Our results also show that the three RAMPs lie close to the peptide binding pocket within the CRLR-RAMP heterodimers, since I-125-AM and I-125-CGRP were incorporated in RAMP2, -3, and -1, respectively. Cross-linking also stabilized the peptide-CRLR-RAMP ternary complexes, with the expected ligand selectivity, indicating that the fully processed heterodimers represent the functional receptors. Overall, the data indicate that direct protein-protein interactions dictate the pharmacological properties of the CRLR-RAMP complexes.	Univ Montreal, Fac Med, Dept Biochim, Montreal, PQ H3C 3J7, Canada; Glaxo Wellcome Med Res Ctr, Receptor Syst Unit, Stevenage SG1 2NY, Herts, England	Universite de Montreal; GlaxoSmithKline	Bouvier, M (corresponding author), Univ Montreal, Fac Med, Dept Biochim, POB 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.		Marshall, Fiona/AAZ-9626-2020; Bouvier, Michel/H-2758-2014	Bouvier, Michel/0000-0003-1128-0100; Marshall, Fiona/0000-0002-8681-005X				Aldecoa A, 2000, FEBS LETT, V471, P156, DOI 10.1016/S0014-5793(00)01387-9; Buhlmann N, 1999, ENDOCRINOLOGY, V140, P2883, DOI 10.1210/en.140.6.2883; Christopoulos G, 1999, MOL PHARMACOL, V56, P235, DOI 10.1124/mol.56.1.235; Foord SM, 1999, TRENDS PHARMACOL SCI, V20, P184, DOI 10.1016/S0165-6147(99)01347-4; Foord SM, 1999, BIOCHEM SOC T, V27, P535, DOI 10.1042/bst0270535; Fraser NJ, 1999, MOL PHARMACOL, V55, P1054, DOI 10.1124/mol.55.6.1054; KURODA K, 1990, VIROLOGY, V174, P418, DOI 10.1016/0042-6822(90)90095-9; Kuwasako K, 2000, J BIOL CHEM, V275, P29602, DOI 10.1074/jbc.M004534200; Leuthauser K, 2000, BIOCHEM J, V351, P347, DOI 10.1042/0264-6021:3510347; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; MELLON P, 1981, CELL, V27, P279, DOI 10.1016/0092-8674(81)90411-6; Muff R, 1998, FEBS LETT, V441, P366, DOI 10.1016/S0014-5793(98)01587-7; Muff R, 1999, ENDOCRINOLOGY, V140, P2924, DOI 10.1210/en.140.6.2924; Owji AA, 1996, J NEUROCHEM, V67, P2172; Petaja-Repo UE, 2000, J BIOL CHEM, V275, P13727, DOI 10.1074/jbc.275.18.13727; Sexton PM, 2001, CELL SIGNAL, V13, P73, DOI 10.1016/S0898-6568(00)00143-1; Zumpe ET, 2000, BIOCHEM BIOPH RES CO, V267, P368, DOI 10.1006/bbrc.1999.1943	17	115	120	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29575	29581		10.1074/jbc.M102722200	http://dx.doi.org/10.1074/jbc.M102722200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11387328	hybrid			2022-12-25	WOS:000170346000123
J	Li, RH; Wong, N; Jabali, MD; Johnson, P				Li, RH; Wong, N; Jabali, MD; Johnson, P			CD44-initiated cell spreading induces Pyk2 phosphorylation, is mediated by Src family kinases, and is negatively regulated by CD45	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE; LIPID RAFTS; MONOCLONAL-ANTIBODIES; CYTOPLASMIC DOMAIN; MURINE MACROPHAGES; MEMBRANE DOMAINS; ANTIGEN RECEPTOR; T-LYMPHOCYTES; ADHESION; ACTIVATION	CD44 is a cell adhesion molecule implicated in leukocyte adhesion and migration, co-stimulation of T cells, and tumor metastasis. CD45 is a leukocyte-specific protein tyrosine phosphatase that dephosphorylates the Src family kinases, Lek and Fyn, in T cells. Positive regulation of Lek by CD45 is required for its effective participation in T cell receptor signaling events. Here, immobilized CD44 antibody induced a distinctive cell spreading in CD45(-), but not CD45(+), T cells, and this correlated with the induction of tyrosine-phosphorylated proteins. Two focal adhesion family kinases, Pyk2 and, to a lesser extent, FAK were inducibly phosphorylated, as was a potential substrate, Cas. CD44-mediated cell spreading and induced tyrosine phosphorylation were prevented by the Src family kinase inhibitor, PP2. Furthermore, 2-fold more Lek associated with CD44 in the low density sucrose fraction from CD45- T cells compared with CD45(+) T cells, suggesting that CD45 may regulate the association of Lek with CD44 in this fraction. Therefore, in CD45- T cells, CD44 signaling is mediated by Src family kinases, and this leads to Pyk2 phosphorylation, cytoskeletal changes, and cell spreading. This implicates CD45 in the negative regulation of Src family kinase-mediated CD44 signaling leading to T cell spreading.	Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Johnson, P (corresponding author), Univ British Columbia, Dept Microbiol & Immunol, 6174 Univ Blvd, Vancouver, BC V6T 1Z3, Canada.		Johnson, Pauline/G-9659-2019; Wong, Nelson/S-5526-2016	Johnson, Pauline/0000-0001-7367-4653; Wong, Nelson/0000-0002-7003-6020				Alexander DR, 2000, SEMIN IMMUNOL, V12, P349, DOI 10.1006/smim.2000.0218; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; Ashwell JD, 1999, IMMUNOL TODAY, V20, P412, DOI 10.1016/S0167-5699(99)01505-4; Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; BELITSOS PC, 1990, J IMMUNOL, V144, P1661; Berg NN, 1997, J IMMUNOL, V159, P1753; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Calderwood DA, 2000, J BIOL CHEM, V275, P22607, DOI 10.1074/jbc.R900037199; CAMP RL, 1993, J EXP MED, V178, P497, DOI 10.1084/jem.178.2.497; DeGrendele HC, 1997, SCIENCE, V278, P672, DOI 10.1126/science.278.5338.672; Fujisaki T, 1999, CANCER RES, V59, P4427; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HodgeDufour J, 1997, J IMMUNOL, V159, P2492; Horejsi V, 1999, IMMUNOL TODAY, V20, P356, DOI 10.1016/S0167-5699(99)01489-9; HOREJSI V, 1994, BRAZ J MED BIOL RES, V27, P255; HUET S, 1989, J IMMUNOL, V143, P798; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; HYMAN R, 1981, IMMUNOGENETICS, V12, P511, DOI 10.1007/BF01561692; Ilangumaran S, 2000, IMMUNOL TODAY, V21, P2, DOI 10.1016/S0167-5699(99)01494-2; Ilangumaran S, 1998, BLOOD, V91, P3901; Janes PW, 2000, SEMIN IMMUNOL, V12, P23, DOI 10.1006/smim.2000.0204; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; Johnson P, 2000, BIOCHEM PHARMACOL, V59, P455, DOI 10.1016/S0006-2952(99)00266-X; Kawakami N, 1999, J IMMUNOL, V163, P3211; KELLEHER D, 1995, J LEUKOCYTE BIOL, V58, P539, DOI 10.1002/jlb.58.5.539; Kim JH, 2000, EXP CELL RES, V256, P445, DOI 10.1006/excr.2000.4852; KOOPMAN G, 1990, J IMMUNOL, V145, P3589; Lee JY, 2000, CURR OPIN CELL BIOL, V12, P581, DOI 10.1016/S0955-0674(00)00135-6; LESLEY J, 1985, CELL IMMUNOL, V91, P397, DOI 10.1016/0008-8749(85)90237-0; LESLEY J, 1992, J EXP MED, V175, P257, DOI 10.1084/jem.175.1.257; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; McKee CM, 1997, J BIOL CHEM, V272, P8013, DOI 10.1074/jbc.272.12.8013; MIYAKE K, 1990, J EXP MED, V171, P477, DOI 10.1084/jem.171.2.477; Ng DHW, 1997, BIOCHEM J, V327, P867; Ng DHW, 1996, J BIOL CHEM, V271, P1295, DOI 10.1074/jbc.271.3.1295; Noble PW, 1996, J EXP MED, V183, P2373, DOI 10.1084/jem.183.5.2373; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PERSCHL A, 1995, J CELL SCI, V108, P1033; Roach T, 1997, CURR BIOL, V7, P408, DOI 10.1016/S0960-9822(06)00188-6; Rodgers W, 1996, J CELL BIOL, V135, P1515, DOI 10.1083/jcb.135.6.1515; SantosArgumedo L, 1997, IMMUNOLOGY, V90, P147, DOI 10.1046/j.1365-2567.1997.00126.x; Shenoi H, 1999, J IMMUNOL, V162, P7120; Siegelman MH, 1999, J LEUKOCYTE BIOL, V66, P315, DOI 10.1002/jlb.66.2.315; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; Taher TEI, 1996, J BIOL CHEM, V271, P2863, DOI 10.1074/jbc.271.5.2863; Thomas ML, 1999, IMMUNOL TODAY, V20, P406, DOI 10.1016/S0167-5699(99)01506-6; TROWBRIDGE IS, 1982, IMMUNOGENETICS, V15, P299, DOI 10.1007/BF00364338; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T	52	44	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28767	28773		10.1074/jbc.M100158200	http://dx.doi.org/10.1074/jbc.M100158200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11369760	hybrid			2022-12-25	WOS:000170346000018
J	Wells, CD; Gutowski, S; Bollag, G; Sternweis, PC				Wells, CD; Gutowski, S; Bollag, G; Sternweis, PC			Identification of potential mechanisms for regulation of p115 RhoGEF through analysis of endogenous and mutant forms of the exchange factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILY GTPASES; LYSOPHOSPHATIDIC ACID; SIGNAL-TRANSDUCTION; ACTIN CYTOSKELETON; CRYSTAL-STRUCTURE; HOMOLOGY DOMAIN; ALPHA-SUBUNIT; PROTEIN; ACTIVATION; G-ALPHA(13)	Rho GTPases play a fundamental role in numerous cellular processes that are initiated by extracellular stimuli including agonists that work through G protein-coupled receptors. A direct pathway for such regulation was elucidated by the identification of p115 RhoGEF, an exchange factor for RhoA that is activated through its RGS domain by G alpha (13). Endogenous p115 RhoGEF was found mainly in the cytosol of serum-starved cells but partially localized to membranes in cells stimulated with lysophosphatidic acid. Overexpressed p115 RhoGEF was equally distributed between membranes and cytosol; either the RGS or pleckstrin homology domain was sufficient for this partial targeting to membranes. Removal of the pleckstrin homology domain dramatically reduced the in vitro rate of p115 RhoGEF exchange activity. Deletion of amino acids 252-288 in the linker region between the RGS domain and the Dbl homology domain or of the last 150 C-terminal amino acids resulted in non-additive reduction of in vitro exchange activity. In contrast, p115 RhoGEF pieces lacking this extended C terminus were over 5-fold more active than the full-length exchange factor in vivo. These results suggest that p115 RhoGEF is inhibited in the cellular milieu through modification or interaction of inhibitory factors with its C terminus. Endogenous p115 RhoGEF that was immunoprecipitated from cells stimulated with lysophosphatidic acid or sphingosine 1-phosphate was more active than when the enzyme was immunoprecipitated from untreated cells. This indicates an additional and potentially novel long lived mechanism for regulation of p115 RhoGEF by G protein-coupled receptors.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Onyx Pharmaceut, Richmond, CA 94806 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Sternweis, PC (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031954, T32GM007062] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31954, GM07062] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; Bhattacharyya R, 2000, J BIOL CHEM, V275, P14992, DOI 10.1074/jbc.M000415200; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Frost JA, 2000, J BIOL CHEM, V275, P19693, DOI 10.1074/jbc.M909860199; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Lenzen C, 1998, BIOCHEMISTRY-US, V37, P7420, DOI 10.1021/bi972621j; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; Malcolm KC, 1996, J BIOL CHEM, V271, P13135, DOI 10.1074/jbc.271.22.13135; Mao JH, 1998, P NATL ACAD SCI USA, V95, P12973, DOI 10.1073/pnas.95.22.12973; Meredith JE, 1996, ENDOCR REV, V17, P207, DOI 10.1210/er.17.3.207; Michaely PA, 1999, J BIOL CHEM, V274, P21430, DOI 10.1074/jbc.274.30.21430; NOBES C, 1994, CURR OPIN GENET DEV, V4, P77, DOI 10.1016/0959-437X(94)90094-9; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; Ren XD, 2000, METHOD ENZYMOL, V325, P264; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Sambrook J., 2002, MOL CLONING LAB MANU; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SINGER WD, 1994, J BIOL CHEM, V269, P19796; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Treisman R, 1998, COLD SPRING HARB SYM, V63, P643, DOI 10.1101/sqb.1998.63.643; VAN AL, 1997, GENE DEV, V11, P2295; van Horck FPG, 2001, J BIOL CHEM, V276, P4948, DOI 10.1074/jbc.M003839200; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	42	64	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28897	28905		10.1074/jbc.M102913200	http://dx.doi.org/10.1074/jbc.M102913200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11384980	hybrid			2022-12-25	WOS:000170346000036
J	Callahan, NA; Xiong, LW; Caughey, B				Callahan, NA; Xiong, LW; Caughey, B			Reversibility of scrapie-associated prion protein aggregation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREUTZFELDT-JAKOB-DISEASE; BETA-AMYLOID PROTOFIBRILS; CELL-FREE FORMATION; ALZHEIMERS-DISEASE; RESISTANT STATE; INFRARED-SPECTROSCOPY; FIBRILS SAF; PRP 27-30; CONVERSION; FORM	During the course of the transmissible spongiform encephalopathy diseases, a protease-resistant ordered aggregate of scrapie prion protein (PrPSc) accumulates in affected animals. From mechanistic and therapeutic points of view, it is relevant to determine the extent to which PrPSc formation and aggregation are reversible. PrPSc solubilized with 5 M guanidine hydrochloride (GdnHCl) was unfolded to a predominantly random coil conformation. Upon dilution of GdnHCl, PrP refolded into a conformation that was high in a-helix as measured by CD spectroscopy, similar to the normal cellular isoform. of PrP (PrPC). This provided evidence that PrPSc can be induced to revert to a PrPC-like conformation with a strong denaturant. To examine the reversibility of PrPSc formation and aggregation under more physiological conditions, PrPSc aggregates were washed and resuspended in buffers lacking GdnHCl and monitored over time for the appearance of soluble PrP. No dissociation of PrP from the PrPSc aggregates was detected in aqueous buffers at pH 6 and 7.5. The effective solubility of PrP was <0.7 nM. Treatment of PrPSc with proteinase K (PK) before the analysis did not enhance the dissociation of PrP from the PrPSc aggregates. Treatment with 2.5 M GdnHCl, which partially and reversibly unfolds PrPSc, caused only limited dissociation of PrP from the aggregates. The PrP that dissociated from the aggregates over time was entirely PK-sensitive, like PrPC, whereas all of the aggregated PrP was partially PK-resistant. PrP also dissociated from aggregates of protease-resistant PrP generated in a cell-free conversion reaction, but only if treated with GdnHCl. Overall, the results suggest that PrP aggregation is not appreciably reversible under physiological conditions' but dissociation and refolding can be enhanced by treatments with GdnHCl.	NIAID, Rocky Mt Labs, NIH, Hamilton, MT 59840 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Caughey, B (corresponding author), NIAID, Rocky Mt Labs, NIH, Hamilton, MT 59840 USA.	beaughey@niaid.nih.gov			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000580, Z01AI000580] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDREU JM, 1986, METHOD ENZYMOL, V130, P47; BARRY RA, 1985, J IMMUNOL, V135, P603; BODE L, 1985, J GEN VIROL, V66, P2471, DOI 10.1099/0022-1317-66-11-2471; BOLTON DC, 1987, ARCH BIOCHEM BIOPHYS, V258, P579, DOI 10.1016/0003-9861(87)90380-8; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; Brandner S, 1996, NATURE, V379, P339, DOI 10.1038/379339a0; BROWN DR, 1994, NEUROREPORT, V5, P2057, DOI 10.1097/00001756-199410270-00017; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; Caughey B, 1997, J VIROL, V71, P4107, DOI 10.1128/JVI.71.5.4107-4110.1997; Caughey B, 1999, METHOD ENZYMOL, V309, P122; Caughey B, 1995, CHEM BIOL, V2, P807, DOI 10.1016/1074-5521(95)90087-X; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; COME JH, 1993, P NATL ACAD SCI USA, V90, P5959, DOI 10.1073/pnas.90.13.5959; Cooper JA, 2000, CURR OPIN CELL BIOL, V12, P97, DOI 10.1016/S0955-0674(99)00062-9; DebBurman SK, 1997, P NATL ACAD SCI USA, V94, P13938, DOI 10.1073/pnas.94.25.13938; DIRINGER H, 1983, NATURE, V306, P476, DOI 10.1038/306476a0; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; Esler WP, 2000, BIOCHEMISTRY-US, V39, P6288, DOI 10.1021/bi992933h; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; GADJUSEK DC, 1988, J NEUROIMMUNOL, V20, P95; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; Harper JD, 1999, BIOCHEMISTRY-US, V38, P8972, DOI 10.1021/bi9904149; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; Harper JD, 1997, CHEM BIOL, V4, P119, DOI 10.1016/S1074-5521(97)90255-6; Hill AF, 1999, J GEN VIROL, V80, P11, DOI 10.1099/0022-1317-80-1-11; Hope J, 1996, NEURODEGENERATION, V5, P1, DOI 10.1006/neur.1996.0001; HOPE J, 1986, EMBO J, V5, P2591, DOI 10.1002/j.1460-2075.1986.tb04539.x; Horiuchi M, 1999, EMBO J, V18, P3193, DOI 10.1093/emboj/18.12.3193; James TL, 1997, P NATL ACAD SCI USA, V94, P10086, DOI 10.1073/pnas.94.19.10086; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Kocisko DA, 1996, BIOCHEMISTRY-US, V35, P13434, DOI 10.1021/bi9610562; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; KORN ED, 1982, PHYSIOL REV, V62, P672, DOI 10.1152/physrev.1982.62.2.672; LANSBURY PT, 1995, CHEM BIOL, V2, P1, DOI 10.1016/1074-5521(95)90074-8; MAGGIO JE, 1992, P NATL ACAD SCI USA, V89, P5462, DOI 10.1073/pnas.89.12.5462; Masel J, 1999, BIOPHYS CHEM, V77, P139, DOI 10.1016/S0301-4622(99)00016-2; MCKINLEY MP, 1991, J VIROL, V65, P1340, DOI 10.1128/JVI.65.3.1340-1351.1991; MCKINLEY MP, 1991, LAB INVEST, V65, P622; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; MULLER WEG, 1993, EUR J PHARM-MOLEC PH, V246, P261, DOI 10.1016/0922-4106(93)90040-G; NGUYEN JT, 1995, J MOL BIOL, V252, P412, DOI 10.1006/jmbi.1995.0507; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PRIOLA SA, 1995, J BIOL CHEM, V270, P3299, DOI 10.1074/jbc.270.7.3299; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; RUBENSTEIN R, 1996, BOVINE SPONGIFORM EN, P232; SAFAR J, 1993, J BIOL CHEM, V268, P20276; Seshadri S, 1999, METHOD ENZYMOL, V309, P559; SKLAVIADIS TK, 1989, J VIROL, V63, P1212, DOI 10.1128/JVI.63.3.1212-1222.1989; SOMERVILLE RA, 1989, J GEN VIROL, V70, P25, DOI 10.1099/0022-1317-70-1-25; Soto C, 2000, LANCET, V355, P192, DOI 10.1016/S0140-6736(99)11419-3; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; Supattapone S, 2001, J VIROL, V75, P3453, DOI 10.1128/JVI.75.7.3453-3461.2001; TOBACMAN LS, 1983, J BIOL CHEM, V258, P3207; Torii Hajime, 1996, P1; Wong C, 2001, EMBO J, V20, P377, DOI 10.1093/emboj/20.3.377	60	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28022	28028		10.1074/jbc.M103629200	http://dx.doi.org/10.1074/jbc.M103629200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11375994	hybrid			2022-12-25	WOS:000170093400038
J	Voskoboinik, I; Mar, J; Strausak, D; Camakaris, J				Voskoboinik, I; Mar, J; Strausak, D; Camakaris, J			The regulation of catalytic activity of the menkes copper-translocating P-type ATPase - Role of high affinity copper-binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILSON-DISEASE PROTEIN; HAMSTER OVARY CELLS; CANDIDATE GENE; CALCIUM-PUMP; SACCHAROMYCES-CEREVISIAE; SARCOPLASMIC-RETICULUM; FUNCTIONAL EXPRESSION; TRANSPORTING ATPASE; PLASMA-MEMBRANE; DOMAINS	The Menkes protein is a transmembrane copper translocating P-type ATPase. Mutations in the Menkes gene that affect the function of the Menkes protein may cause Menkes disease in humans, which is associated with severe systemic copper deficiency. The catalytic mechanism of the Menkes protein, including the formation of transient acylphosphate, is poorly understood. We transfected and overexpressed wild-type and targeted mutant Menkes protein in yeast and investigated its transient acyl phosphorylation. We demonstrated that the Menkes protein is transiently phosphorylated by ATP in a copper-specific and copper-dependent manner and appears to undergo conformational changes in accordance with the classical P-type ATPase model. Our data suggest that the catalytic cycle of the Menkes protein begins with the binding of copper to high affinity binding sites in the transmembrane channel, followed by ATP binding and transient phosphorylation. We propose that. putative copper-binding sites at the N-terminal domain of the Menkes protein are important as sensors of low concentrations of copper but are not essential for the overall catalytic activity.	Univ Melbourne, Dept Genet, Parkville, Vic 3010, Australia; Deakin Univ, Sch Biol & Chem Sci, Ctr Cellular & Mol Biol, Burwood 3125, Australia	University of Melbourne; Deakin University	Camakaris, J (corresponding author), Univ Melbourne, Dept Genet, Parkville, Vic 3010, Australia.	j.camakaris@unimelb.edu.au		Voskoboinik, Ilia/0000-0002-6410-009X				[Anonymous], 1995, METABOLIC BASIS INHE; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Camakaris J, 1999, BIOCHEM BIOPH RES CO, V261, P225, DOI 10.1006/bbrc.1999.1073; CAMAKARIS J, 1995, HUM MOL GENET, V4, P2117, DOI 10.1093/hmg/4.11.2117; CARAFOLI E, 1991, PHYSIOL REV, V71, P129, DOI 10.1152/physrev.1991.71.1.129; CHELLY J, 1993, NAT GENET, V3, P14, DOI 10.1038/ng0193-14; Daly SE, 1996, J BIOL CHEM, V271, P23683, DOI 10.1074/jbc.271.39.23683; DiDonato M, 1997, J BIOL CHEM, V272, P33279, DOI 10.1074/jbc.272.52.33279; Forbes JR, 1998, AM J HUM GENET, V63, P1663, DOI 10.1086/302163; Goodyer ID, 1999, HUM MOL GENET, V8, P1473, DOI 10.1093/hmg/8.8.1473; Huffman DL, 2000, J BIOL CHEM, V275, P18611, DOI 10.1074/jbc.C000172200; Hung IH, 1997, J BIOL CHEM, V272, P21461, DOI 10.1074/jbc.272.34.21461; Iida M, 1998, FEBS LETT, V428, P281, DOI 10.1016/S0014-5793(98)00546-8; La Fontaine S, 1998, HUM MOL GENET, V7, P1293, DOI 10.1093/hmg/7.8.1293; LINDER MC, 1991, BIOCH ELEMENTS, P331; Lutsenko S, 1997, J BIOL CHEM, V272, P18939, DOI 10.1074/jbc.272.30.18939; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MERCER JFB, 1993, NAT GENET, V3, P20, DOI 10.1038/ng0193-20; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; MOLLMAN JE, 1980, J BIOL CHEM, V255, P569; ONEAL SG, 1979, BIOCHEM BIOPH RES CO, V89, P845, DOI 10.1016/0006-291X(79)91855-2; Payne AS, 1998, J BIOL CHEM, V273, P3765, DOI 10.1074/jbc.273.6.3765; PAYNTER JA, 1994, FEBS LETT, V351, P186, DOI 10.1016/0014-5793(94)00868-X; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; Pena MMO, 1999, J NUTR, V129, P1251, DOI 10.1093/jn/129.7.1251; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; Petris MJ, 2000, HUM MOL GENET, V9, P2845, DOI 10.1093/hmg/9.19.2845; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Rensing C, 1999, J BACTERIOL, V181, P5891, DOI 10.1128/JB.181.19.5891-5897.1999; SARKADI B, 1986, J BIOL CHEM, V261, P9552; SOLIOZ M, 1994, FEBS LETT, V346, P44, DOI 10.1016/0014-5793(94)00316-5; Solioz M, 1997, FEBS LETT, V412, P165, DOI 10.1016/S0014-5793(97)00770-9; Strausak D, 1999, J BIOL CHEM, V274, P11170, DOI 10.1074/jbc.274.16.11170; Theophilos MB, 1996, HUM MOL GENET, V5, P1619, DOI 10.1093/hmg/5.10.1619; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; Voskoboinik I, 2001, BIOCHEM BIOPH RES CO, V281, P966, DOI 10.1006/bbrc.2001.4445; Voskoboinik I, 1998, FEBS LETT, V435, P178, DOI 10.1016/S0014-5793(98)01059-X; Voskoboinik N, 1999, J BIOL CHEM, V274, P22008, DOI 10.1074/jbc.274.31.22008; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; Wei Y, 1999, BIOCHEMISTRY-US, V38, P14534, DOI 10.1021/bi9911233; Wernimont AK, 2000, NAT STRUCT BIOL, V7, P766; Wunderli-Ye H, 2001, BIOCHEM BIOPH RES CO, V280, P713, DOI 10.1006/bbrc.2000.4176; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632	46	103	104	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28620	28627		10.1074/jbc.M103532200	http://dx.doi.org/10.1074/jbc.M103532200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11373292	hybrid			2022-12-25	WOS:000170093400116
J	Yan, B; Calderwood, DA; Yaspan, B; Ginsberg, MH				Yan, B; Calderwood, DA; Yaspan, B; Ginsberg, MH			Calpain cleavage promotes talin binding to the beta(3) integrin cytoplasmic domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; VINCULIN-BINDING; FOCAL ADHESIONS; CELL-ADHESION; ACTIN; ACTIVATION; SITES; ALPHA(IIB)BETA(3); IDENTIFICATION; EQUILIBRIUM	Talin links integrin beta cytoplasmic domains to the actin cytoskeleton and is involved in the clustering and activation of these receptors. To understand how talin recognizes integrin beta cytoplasmic domains, we configured surface plasmon resonance methodology to measure the interaction of talin with the beta (3) integrin cytoplasmic domain. Here we report that the N-terminal similar to 47-kDa talin head domain (talin-H) has a 6-fold higher binding affinity than intact talin for the beta (3) tail. The affinity difference is mainly due to a difference in k(on). Calpain cleavage of intact talin released talin-H and resulted in a 16-fold increase in apparent K-alpha and a 100-fold increase in apparent k(on). The increase in talin binding after cleavage was greater than predicted for stoichiometric liberation of free talin-H. This additional increase in binding was due to cooperative binding of talin-H and talin rod domain to the beta (3) tail. Talin resembles ERM (ezrin, radixin, moesin) proteins in possessing an N-terminal FERM (band four-point-one, ezrin, radixin, moesin) domain. These data show that the talin FERM domain, like that in the ERM proteins, is masked in the intact molecule. Furthermore, they suggest that talin cleavage by calpain may contribute to the effects of the protease on the clustering and activation of integrins.	Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Ginsberg, MH (corresponding author), Scripps Res Inst, Dept Vasc Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	ginsberg@scripps.edu	Calderwood, David A/AAC-6954-2019	Calderwood, David A/0000-0002-0791-4142; Yaspan, Brian/0000-0002-3787-2510	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057900, P01HL048728, P01HL031950] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR027214, R37AR027214] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 31950, HL 57900, HL 48728] Funding Source: Medline; NIAMS NIH HHS [AR 27214] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Azam M, 2001, MOL CELL BIOL, V21, P2213, DOI 10.1128/MCB.21.6.2213-2220.2001; BECKERLE MC, 1987, CELL, V51, P569, DOI 10.1016/0092-8674(87)90126-7; Belkin AM, 1997, J CELL BIOL, V139, P1583, DOI 10.1083/jcb.139.6.1583; Bennett JS, 1999, J BIOL CHEM, V274, P25301, DOI 10.1074/jbc.274.36.25301; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; Bialkowska K, 2000, J CELL BIOL, V151, P685, DOI 10.1083/jcb.151.3.685; Bretscher A, 1999, CURR OPIN CELL BIOL, V11, P109, DOI 10.1016/S0955-0674(99)80013-1; Bretscher A, 2000, ANNU REV CELL DEV BI, V16, P113, DOI 10.1146/annurev.cellbio.16.1.113; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; Calderwood DA, 2000, J BIOL CHEM, V275, P22607, DOI 10.1074/jbc.R900037199; Croce K, 1999, J BIOL CHEM, V274, P36321, DOI 10.1074/jbc.274.51.36321; DU XP, 1995, J BIOL CHEM, V270, P26146, DOI 10.1074/jbc.270.44.26146; ELEMER GS, 1994, J BIOL CHEM, V269, P3159; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; Goldmann WH, 2000, BIOCHEM BIOPH RES CO, V271, P553, DOI 10.1006/bbrc.2000.2653; Hato T, 1998, J CELL BIOL, V141, P1685, DOI 10.1083/jcb.141.7.1685; Hemmings L, 1996, J CELL SCI, V109, P2715; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Isenberg G, 1998, FEBS LETT, V426, P165, DOI 10.1016/S0014-5793(98)00336-6; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KAUFMANN S, 1991, FEBS LETT, V284, P187, DOI 10.1016/0014-5793(91)80681-R; Knezevic I, 1996, J BIOL CHEM, V271, P16416, DOI 10.1074/jbc.271.27.16416; MARGUERIE GA, 1979, J BIOL CHEM, V254, P5357; Martel V, 2001, J BIOL CHEM, V276, P21217, DOI 10.1074/jbc.M102373200; McCann RO, 1998, MOL BIOL CELL, V9, p138A; OHALLORAN T, 1985, NATURE, V317, P449, DOI 10.1038/317449a0; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; OTTO JJ, 1983, J CELL BIOL, V97, P1283, DOI 10.1083/jcb.97.4.1283; Patil S, 1999, J BIOL CHEM, V274, P28575, DOI 10.1074/jbc.274.40.28575; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; Priddle H, 1998, J CELL BIOL, V142, P1121, DOI 10.1083/jcb.142.4.1121; REES DJG, 1990, NATURE, V347, P685, DOI 10.1038/347685a0; Sampath R, 1998, J BIOL CHEM, V273, P33588, DOI 10.1074/jbc.273.50.33588; Schuck P, 1997, ANNU REV BIOPH BIOM, V26, P541, DOI 10.1146/annurev.biophys.26.1.541; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; Yan B, 2000, J BIOL CHEM, V275, P7249, DOI 10.1074/jbc.275.10.7249; Yauch RL, 1997, J EXP MED, V186, P1347, DOI 10.1084/jem.186.8.1347	41	182	185	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28164	28170		10.1074/jbc.M104161200	http://dx.doi.org/10.1074/jbc.M104161200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11382782	hybrid			2022-12-25	WOS:000170093400057
J	Fantz, DA; Jacobs, D; Glossip, D; Kornfeld, K				Fantz, DA; Jacobs, D; Glossip, D; Kornfeld, K			Docking sites on substrate proteins direct extracellular signal-regulated kinase to phosphorylate specific residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY INTERACTION; COMPLEX FACTOR ELK-1; ERK MAP KINASE; INTERACTION MOTIF; IN-VIVO; PTP-SL; ACTIVATION; DOMAIN; BINDING; TRANSCRIPTION	Mitogen-activated protein (MAP) kinases such as extracellular signal-regulated kinase (ERK) are important signaling proteins that phosphorylate (S/T)P sites in many different protein substrates, ERK binding to substrate proteins is mediated by docking sites including the FXFP motif and the D-domain, We characterized the sequence of amino acids that can constitute the FXFP motif using peptide and protein substrates, Substitutions of the phenylalanines at positions 1 and 3 had significant effects, indicating that these phenylalanines provide substantial binding affinity, whereas substitutions of the residues at positions 2 and 4 had less effect. The FXFP and D-domain docking sites were analyzed in a variety of positions and arrangements in the proteins ELK-1 and KSR-1, Our results indicate that the FXFP and D-domain docking sites form a flexible, modular system that has two functions. First, the affinity of a substrate for ERK can be regulated by the number, type, position, and arrangement of docking sites. Second, in substrates with multiple potential phosphorylation sites, docking sites can direct phosphorylation of specific (SPT)P residues. In particular, the FQFP motif of ELK-1 is necessary and sufficient to direct phosphorylation of serine 383, whereas the D-domain directs phosphorylation of other (SPT)P sites in ELK-1.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL)	Kornfeld, K (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, Box 8103,660 S Euclid Ave, St Louis, MO 63110 USA.							ALESSI DR, 1995, METHOD ENZYMOL, V255, P279; Bardwell L, 1996, TRENDS BIOCHEM SCI, V21, P373, DOI 10.1016/S0968-0004(96)30032-7; Bardwell L, 1996, MOL CELL BIOL, V16, P3637; Blackwood EM, 1998, SCIENCE, V281, P60, DOI 10.1126/science.281.5373.60; Cacace AM, 1999, MOL CELL BIOL, V19, P229; Cruzalegui FH, 1999, ONCOGENE, V18, P7948, DOI 10.1038/sj.onc.1203362; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Dillon N, 2000, BIOESSAYS, V22, P657, DOI 10.1002/1521-1878(200007)22:7<657::AID-BIES8>3.3.CO;2-U; Drewett V, 2000, J BIOL CHEM, V275, P1757, DOI 10.1074/jbc.275.3.1757; Ferrell JE, 1996, CURR TOP DEV BIOL, V33, P1, DOI 10.1016/S0070-2153(08)60336-1; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; Galanis A, 2001, J BIOL CHEM, V276, P965, DOI 10.1074/jbc.M007697200; Gavin AC, 1999, CURR BIOL, V9, P281, DOI 10.1016/S0960-9822(99)80120-1; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Jacobs D, 1998, GENETICS, V149, P1809; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Johnson TR, 2000, J BIOL CHEM, V275, P31755, DOI 10.1074/jbc.M004182200; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; KORNFELD K, 1995, CELL, V83, P903, DOI 10.1016/0092-8674(95)90206-6; MacKenzie SJ, 2000, J BIOL CHEM, V275, P16609, DOI 10.1074/jbc.275.22.16609; Madhani HD, 1998, TRENDS GENET, V14, P151, DOI 10.1016/S0168-9525(98)01425-5; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Nichols A, 2000, J BIOL CHEM, V275, P24613, DOI 10.1074/jbc.M001515200; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; ROBERSON MS, 1995, MOL CELL BIOL, V15, P3531; Sambrook J., 2002, MOL CLONING LAB MANU; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V19, P459; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; Tanoue T, 2001, EMBO J, V20, P466, DOI 10.1093/emboj/20.3.466; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TRIESMAN R, 1994, CURR OPIN GENET DEV, V4, P96; Volle DJ, 1999, BIOCHEMISTRY-US, V38, P5130, DOI 10.1021/bi983050d; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Xu BE, 1999, J BIOL CHEM, V274, P34029, DOI 10.1074/jbc.274.48.34029; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; Yu W, 1998, CURR BIOL, V8, P56, DOI 10.1016/S0960-9822(98)70020-X; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; Zuniga A, 1999, J BIOL CHEM, V274, P21900, DOI 10.1074/jbc.274.31.21900	49	151	157	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27256	27265		10.1074/jbc.M102512200	http://dx.doi.org/10.1074/jbc.M102512200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11371562	hybrid			2022-12-25	WOS:000169966900071
J	Way, JM; Gorgun, CZ; Tong, Q; Uysal, KT; Brown, KK; Harrington, WW; Oliver, WR; Willson, TM; Kliewer, SA; Hotamisligil, GS				Way, JM; Gorgun, CZ; Tong, Q; Uysal, KT; Brown, KK; Harrington, WW; Oliver, WR; Willson, TM; Kliewer, SA; Hotamisligil, GS			Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor gamma agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIDIABETIC THIAZOLIDINEDIONE; INSULIN-RESISTANCE	Elevated levels of the hormone resistin, which is secreted by fat cells, are proposed to cause insulin resistance and to serve as a link between obesity and type 2 diabetes, In this report we show that resistin expression is significantly decreased in the white adipose tissue of several different models of obesity including the ob/ob, db/db, tub/tub, and KKA(Y) mice compared with their lean counterparts. Furthermore, in response to several different classes of antidiabetic peroxisome proliferator-activated receptor gamma agonists, adipose tissue resistin expression is increased in both ob/ob mice and Zucker diabetic fatty rats. These data demonstrate that experimental obesity in rodents is associated with severely defective resistin expression, and decreases in resistin expression are not required for the antidiabetic actions of peroxisome proliferator-activated receptor gamma agonists.	Harvard Univ, Sch Publ Hlth, Div Biol Sci, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; GlaxoSmithKline Res & Dev, Res Triangle Pk, NC 27709 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; GlaxoSmithKline	Hotamisligil, GS (corresponding author), Harvard Univ, Sch Publ Hlth, Div Biol Sci, 665 Huntington Ave, Boston, MA 02115 USA.		feinstein, doug/M-9414-2019		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052539] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK52539] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Boden G, 1997, DIABETES, V46, P3, DOI 10.2337/diabetes.46.1.3; Brown KK, 1999, DIABETES, V48, P1415, DOI 10.2337/diabetes.48.7.1415; Hotamisligil GS, 1999, J INTERN MED, V245, P621, DOI 10.1046/j.1365-2796.1999.00490.x; Kim KH, 2001, J BIOL CHEM, V276, P11252, DOI 10.1074/jbc.C100028200; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Reginato MJ, 1998, J BIOL CHEM, V273, P32679, DOI 10.1074/jbc.273.49.32679; Saltiel AR, 2001, CELL, V104, P517, DOI 10.1016/S0092-8674(01)00239-2; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Tong Q, 2000, SCIENCE, V290, P134, DOI 10.1126/science.290.5489.134; Way JM, 2001, ENDOCRINOLOGY, V142, P1269, DOI 10.1210/en.142.3.1269	12	362	390	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25651	25653		10.1074/jbc.C100189200	http://dx.doi.org/10.1074/jbc.C100189200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11373275	hybrid			2022-12-25	WOS:000169823300004
J	Nickenig, G; Michaelsen, F; Muller, C; Vogel, T; Strehlow, K; Bohm, M				Nickenig, G; Michaelsen, F; Muller, C; Vogel, T; Strehlow, K; Bohm, M			Post-transcriptional regulation of the AT1 receptor mRNA: identification and functional characterization of the mRNA binding motif	FASEB JOURNAL			English	Article						angiotensin II; vascular smooth muscle cells; mRNA binding protein; mRNA stability; RNA turnover	NITRIC-OXIDE SYNTHASE; NUCLEAR RIBONUCLEOPROTEIN-PARTICLES; AGONIST-INDUCED DESTABILIZATION; ANGIOTENSIN-II; UP-REGULATION; GENE-EXPRESSION; AT(1) RECEPTOR; UNTRANSLATED REGION; IN-VITRO; PROTEIN	The expression of the angiotensin AT1 receptor is regulated predominately via post-transcriptional mechanisms. Angiotensin II reduces the AT1 receptor mRNA half-life from approximately 6 to 2 h, as assessed by experiments under transcriptional blockade and by in vitro mRNA decay assays in vascular smooth muscle cells (VSMC). UV light-treated mRNA-protein cross-link assays revealed that the AT1 receptor mRNA interacts with at least six polysomal proteins at its T-end. Multiple mutational studies demonstrated that several binding proteins associated with the AT1 receptor mRNA at bases 2175-2195. Stimulation of VSMC with angiotensin 11 significantly enhanced the binding of 50 and 60 kDa proteins to the 3'-untranslated region of the AT1 receptor mRNA. Transfection decoy assays with AT1 receptor mRNA transcript bases 1864-2213, 2175-2213, and 2175-2195 led to a significantly increased basal expression of AT1 receptor mRNA and inhibited angiotensin II-induced AT1 receptor mRNA down-regulation. In vitro decay assays revealed that competition of binding of polysomal proteins to bases 2175-2195 stabilizes the AT1 receptor mRNA. Polysomal proteins thus bind to the 3'-untranslated region of the AT1 receptor mRNA at the nucleotide sequence 2175-2195. This protein-mRNA interaction is decisively involved in the destabilization of the AT 1 receptor mRNA by angiotensin II.	Univ Saarland, Klin & Poliklin Innere Med 3, D-66421 Homburg, Germany	Saarland University	Nickenig, G (corresponding author), Univ Saarland, Klin & Poliklin Innere Med 3, D-66421 Homburg, Germany.	nickenig@med-in.uni-sb.de	Böhm, Michael/C-3638-2011					BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; BOHJANEN PR, 1992, J BIOL CHEM, V267, P6302; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BRAWERMAN G, 1989, CELL, V57, P9, DOI 10.1016/0092-8674(89)90166-9; BRAWERMAN G, 1987, CELL, V48, P5, DOI 10.1016/0092-8674(87)90346-1; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; CHAMLEYCAMPBELL J, 1979, PHYSIOL REV, V59, P1, DOI 10.1152/physrev.1979.59.1.1; CHEN CYA, 1994, MOL CELL BIOL, V14, P8471, DOI 10.1128/MCB.14.12.8471; CHEN CYA, 1994, MOL CELL BIOL, V14, P416, DOI 10.1128/MCB.14.1.416; CLEVELAND DW, 1988, TRENDS BIOCHEM SCI, V13, P339, DOI 10.1016/0968-0004(88)90103-X; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cellbio.2.1.459; GRIENDLING KK, 1993, CIRCULATION, V87, P1816, DOI 10.1161/01.CIR.87.6.1816; HADCOCK JR, 1989, J BIOL CHEM, V264, P19928; HARGROVE JL, 1989, FASEB J, V3, P2360, DOI 10.1096/fasebj.3.12.2676679; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; LASSEGUE B, 1995, MOL PHARMACOL, V48, P601; Laufs U, 1998, CIRCULATION, V97, P1129, DOI 10.1161/01.CIR.97.12.1129; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; Linscheid P, 1998, BIOCHEM BIOPH RES CO, V243, P137, DOI 10.1006/bbrc.1998.8072; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; Myer VE, 1997, EMBO J, V16, P2130, DOI 10.1093/emboj/16.8.2130; NATHAN C, 1994, J BIOL CHEM, V269, P13725; Nickenig G, 1997, CIRCULATION, V95, P473; Nickenig G, 1998, CIRCULATION, V98, P2453, DOI 10.1161/01.CIR.98.22.2453; Nickenig G, 1997, AM J PHYSIOL-HEART C, V272, pH2701, DOI 10.1152/ajpheart.1997.272.6.H2701; NICKENIG G, 1994, MOL PHARMACOL, V46, P653; Nickenig G, 1996, MOL PHARMACOL, V50, P743; Nickenig G, 1999, CIRCULATION, V100, P2131, DOI 10.1161/01.CIR.100.21.2131; Nickenig G, 1998, CIRCULATION, V97, P2197, DOI 10.1161/01.CIR.97.22.2197; Pande A, 1996, J BIOL CHEM, V271, P8493, DOI 10.1074/jbc.271.14.8493; PEACH MJ, 1977, PHYSIOL REV, V57, P313, DOI 10.1152/physrev.1977.57.2.313; PELTZ S W, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P99; PORT JD, 1992, J BIOL CHEM, V267, P24103; RAGHOW R, 1987, J CLIN INVEST, V79, P1285, DOI 10.1172/JCI112950; ROSS J, 1987, J BIOL CHEM, V262, P9374; ROSS J, 1988, MOL BIOL MED, V5, P1; ROSS R, 1970, J CELL BIOL, V47, pA175; SCHIFFRIN EL, 1984, AM J PHYSIOL, V246, pH608, DOI 10.1152/ajpheart.1984.246.4.H608; Searles CD, 1999, CIRC RES, V85, P588, DOI 10.1161/01.RES.85.7.588; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; STEITZ JA, 1982, COLD SPRING HARB SYM, V47, P893, DOI 10.1101/SQB.1983.047.01.103; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; Tholanikunnel BG, 1997, J BIOL CHEM, V272, P11471; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; WILUSZ J, 1990, MOL CELL BIOL, V10, P6397, DOI 10.1128/MCB.10.12.6397	46	17	18	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 27	2001	15	6					1490	+		10.1096/fj.00-0842fje	http://dx.doi.org/10.1096/fj.00-0842fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387267				2022-12-25	WOS:000173705800012
J	Rahmouni, S; Aandahl, EM; Trebak, M; Boniver, J; Tasken, K; Moutschen, M				Rahmouni, S; Aandahl, EM; Trebak, M; Boniver, J; Tasken, K; Moutschen, M			Increased cAMP levels and protein kinase (PKA) type I activation in CD4(+) T cells and B cells contribute to the retrovirus-induced immunodeficiency of mice (MAIDS). A useful in vivo model for drug testing in PKA type I-induced immunodeficiency	FASEB JOURNAL			English	Article						immunodeficiency diseases; cellular proliferation; signal transduction; second messengers; protein kinases/phosphatases	BLOOD MONONUCLEAR-CELLS; MURINE AIDS; LYMPHOCYTE SUBSET; LACKING THY-1; MESSENGER-RNA; HUMAN CD7; RI-ALPHA; RECEPTOR; EXPRESSION; ANTIGEN	Murine AIDS (MAIDS) is characterized by a lymphoproliferative disease and a profound anergy, which involves mostly CD4(+) T cells. To better define the mechanisms responsible for anergy, we measured cAMP concentrations in the different lymphocyte subsets of the infected mice. CD4(+) T cells and B cells displayed a dramatic 10- to 30-fold increase of cAMP. cAMP was also significantly increased in CD8(+) T cells, although to a far lesser extent. The unusual CD4(+) CD90(-) T cells, typical of MAIDS, were characterized by a much higher cAMP level than their CD90(+) counterparts. T cells of the infected mice were much more sensitive to inhibition by the cAMP analogue 8-CPT-cAMP, which confirmed increased in vivo exposure to cAMP. In accordance with the increased cAMP levels, PKA type I was constitutively activated and its C subunit was translocated to the nucleus. Finally, the profound T-cell anergy associated with MAIDS could be reversed by treating T cells with a PKA type I-selective antagonist ex vivo. MAIDS could constitute a suitable model for the study of new pharmacological agents aimed at reversing the immunosuppressive effects of cAMP previously shown to be involved in several pathological states, including HIV infection and common variable immunodeficiency.	Univ Liege, Dept Pathol, Liege, Belgium; Univ Oslo, Inst Med Biochem, Oslo, Norway	University of Liege; University of Oslo	Moutschen, M (corresponding author), CHU Liege, Dept Pathol 1, B-35, B-4000 Liege, Belgium.	mmoutschen@chu.ulg.ac.be	Trebak, Mohamed/E-7405-2014	Aandahl, Einar Martin/0000-0002-0115-8382; Tasken, Kjetil/0000-0003-2841-4697				Aandahl EM, 1998, FASEB J, V12, P855, DOI 10.1096/fasebj.12.10.855; ANDERSSON KB, 1994, FEBS LETT, V337, P71, DOI 10.1016/0014-5793(94)80632-2; Andrews C, 1997, J IMMUNOL, V159, P2132; Arakawa T, 1996, J BIOL CHEM, V271, P29569, DOI 10.1074/jbc.271.47.29569; Aukrust P, 1999, J IMMUNOL, V162, P1178; Autran B, 1999, IMMUNOL LETT, V66, P207, DOI 10.1016/S0165-2478(98)00159-X; AZIZ DC, 1989, NATURE, V338, P505, DOI 10.1038/338505a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAYEUX SJ, 1993, BONE MARROW TRANSPL, V11, P483; CERNY A, 1990, EUR J IMMUNOL, V20, P1577, DOI 10.1002/eji.1830200725; CHATTOPADHYAY SK, 1989, P NATL ACAD SCI USA, V86, P3862, DOI 10.1073/pnas.86.10.3862; Chun TW, 1999, P NATL ACAD SCI USA, V96, P10958, DOI 10.1073/pnas.96.20.10958; Chun TW, 1998, P NATL ACAD SCI USA, V95, P8869, DOI 10.1073/pnas.95.15.8869; COBB CE, 1988, METHOD ENZYMOL, V159, P202; De Leval L, 1998, J VIROL, V72, P5285, DOI 10.1128/JVI.72.6.5285-5290.1998; De Leval L, 1999, IMMUNOLOGY, V98, P630, DOI 10.1046/j.1365-2567.1999.00900.x; Dupraz P, 1997, J VIROL, V71, P2615, DOI 10.1128/JVI.71.4.2615-2620.1997; Dybul M, 2000, J IMMUNOL, V165, P1685, DOI 10.4049/jimmunol.165.3.1685; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; GIESE NA, 1994, J VIROL, V68, P5819, DOI 10.1128/JVI.68.9.5819-5824.1994; Green KA, 1996, J VIROL, V70, P2569, DOI 10.1128/JVI.70.4.2569-2575.1996; HARRIMAN GR, 1990, J IMMUNOL, V145, P2406; HOLMES KL, 1990, EUR J IMMUNOL, V20, P2783, DOI 10.1002/eji.1830201237; INGRAHAM HA, 1986, J IMMUNOL, V136, P1482; JOLICOEUR P, 1991, FASEB J, V5, P2398, DOI 10.1096/fasebj.5.10.2065888; Kalams SA, 1999, J VIROL, V73, P6715, DOI 10.1128/JVI.73.8.6715-6720.1999; Kalams SA, 1998, J EXP MED, V188, P2199, DOI 10.1084/jem.188.12.2199; KAMMER GM, 1988, IMMUNOL TODAY, V9, P222, DOI 10.1016/0167-5699(88)91220-0; KEMP BE, 1976, P NATL ACAD SCI USA, V73, P1038, DOI 10.1073/pnas.73.4.1038; KNUDSEN JH, 1995, SCAND J CLIN LAB INV, V55, P9, DOI 10.3109/00365519509075373; Kolenko V, 1999, BLOOD, V93, P2308, DOI 10.1182/blood.V93.7.2308.407k16_2308_2318; KUKEL S, 1994, CLIN EXP IMMUNOL, V98, P163; LANDMANN R, 1992, EUR J CLIN INVEST, V22, P30; Leblond V, 1997, TRANSPLANTATION, V64, P1453, DOI 10.1097/00007890-199711270-00014; Lee DM, 1996, IMMUNOGENETICS, V44, P108; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LEGAC E, 1992, BLOOD, V79, P1746; LEGRAND E, 1981, LEUKEMIA RES, V5, P223, DOI 10.1016/0145-2126(81)90107-7; Lombardi MS, 1999, FASEB J, V13, P715, DOI 10.1096/fasebj.13.6.715; Masuda A, 1996, CLIN IMMUNOL IMMUNOP, V81, P253, DOI 10.1006/clin.1996.0186; Meroni L, 1999, AIDS, V13, P621, DOI 10.1097/00002030-199904010-00012; MORSE HC, 1989, J IMMUNOL, V143, P844; MOUTSCHEN MP, 1994, SCAND J IMMUNOL, V39, P216, DOI 10.1111/j.1365-3083.1994.tb03363.x; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; Pitcher CJ, 1999, NAT MED, V5, P518, DOI 10.1038/8400; Pontesilli O, 1999, J INFECT DIS, V180, P76, DOI 10.1086/314837; RICHARDSON JM, 1990, J BIOL CHEM, V265, P13635; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SCHANBERG LE, 1991, P NATL ACAD SCI USA, V88, P603, DOI 10.1073/pnas.88.2.603; SELVEY LA, 1995, J IMMUNOL, V154, P171; SIMARD C, 1994, J VIROL, V68, P1903, DOI 10.1128/JVI.68.3.1903-1912.1994; Simard C, 1997, J VIROL, V71, P3013, DOI 10.1128/JVI.71.4.3013-3022.1997; Skalhegg Bjorn S., 1997, Frontiers in Bioscience (online), V2, pD331; Skalhegg BS, 1998, J CELL PHYSIOL, V177, P85, DOI 10.1002/(SICI)1097-4652(199810)177:1<85::AID-JCP9>3.3.CO;2-#; Smith J P, 1998, Dev Immunol, V6, P285, DOI 10.1155/1998/38923; STEINBERG RA, 1981, J BIOL CHEM, V256, P1356; SUNDERPLASSMANN R, 1991, CELL IMMUNOL, V138, P289, DOI 10.1016/0008-8749(91)90154-4; SVETIC A, 1991, J IMMUNOL, V147, P2391; TASKEN K, 1993, J BIOL CHEM, V268, P23483; TASKEN K, 1993, J BIOL CHEM, V268, P21276; Valentine FT, 1998, AIDS RES HUM RETROV, V14, pS161; Wajeman-Chao SA, 1998, J IMMUNOL, V161, P4825; Yu P, 1999, EUR J IMMUNOL, V29, P615, DOI 10.1002/(SICI)1521-4141(199902)29:02<615::AID-IMMU615>3.0.CO;2-I; Zheng B, 1996, J EXP MED, V184, P1083, DOI 10.1084/jem.184.3.1083	65	19	21	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 27	2001	15	6					1466	+		10.1096/fj.00-0813fje	http://dx.doi.org/10.1096/fj.00-0813fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387259				2022-12-25	WOS:000173705800008
J	McAllister-Lucas, LM; Inohara, N; Lucas, PC; Ruland, J; Benito, A; Li, QT; Chen, S; Chen, FF; Yamaoka, S; Verma, IM; Mak, TW; Nunez, G				McAllister-Lucas, LM; Inohara, N; Lucas, PC; Ruland, J; Benito, A; Li, QT; Chen, S; Chen, FF; Yamaoka, S; Verma, IM; Mak, TW; Nunez, G			Bimp1, a MAGUK family member linking protein kinase C activation to Bcl10-mediated NF-kappa B induction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASPASE RECRUITMENT DOMAIN; LYMPHOID-TISSUE; CELL LYMPHOMA; SIGNALING PATHWAYS; MALT LYMPHOMA; GENE; THETA; T(11-18)(Q21-Q21); COSTIMULATION; APOPTOSIS	Bcl10 and MALT1, products of distinct chromosomal translocations in mucosa-associated lymphoid tissue lymphoma, cooperate in activating NF-kappaB Mice lacking Bcl10 demonstrate severe immunodeficiency associated with failure of lymphocytes to activate nuclear factor kappaB (NF-kappaB) in response to antigen receptor stimulation and protein kinase C activation. We characterize Bimp1, a new signaling protein that binds Bcl10 and activates NF-kappaB. Bimp1-mediated NF-kappaB activation requires Bcl10 and I kappaB kinases, indicating that Bimp1 acts upstream of these mediators. Bimp1, Bcl10, and MALT1 form a ternary complex, with Bcl10 bridging the Bimp1/ MALT1 interaction. A dominant negative Bimp1 mutant inhibits NF-kappaB activation by anti-CD3 ligation, phorbol ester, and protein kinase C expression. These results suggest that Bimp1 links surface receptor stimulation and protein kinase C activation to Bcl10/MALT1, thus leading to NF-kappaB induction.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Pediat & Commun Dis, Ann Arbor, MI 48109 USA; Univ Toronto, Amgen Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 2C1, Canada; Salk Inst Biol Studies, Genet Lab, La Jolla, CA 92037 USA; Tokyo Med & Dent Univ, Sch Med, Dept Microbiol, Bunkyo Ku, Tokyo 1138519, Japan	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; Salk Institute; Tokyo Medical & Dental University (TMDU)	Nunez, G (corresponding author), Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA.		Ruland, Jürgen/Q-6680-2018; Nuñez, Gabriel/A-7160-2014	Ruland, Jürgen/0000-0002-8381-3597; Lucas, Peter/0000-0003-4880-7172	NATIONAL CANCER INSTITUTE [F32CA088470, R01CA084064] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007622] Funding Source: NIH RePORTER; NCI NIH HHS [CA84064, F23-CA88470-01] Funding Source: Medline; NHLBI NIH HHS [T32-HL07622] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akagi T, 1999, ONCOGENE, V18, P5785, DOI 10.1038/sj.onc.1203018; Bertin J, 2001, J BIOL CHEM, V276, P11877, DOI 10.1074/jbc.M010512200; Bertin J, 2000, J BIOL CHEM, V275, P41082, DOI 10.1074/jbc.C000726200; Chen CC, 2000, J IMMUNOL, V165, P2719, DOI 10.4049/jimmunol.165.5.2719; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; Costanzo A, 1999, J BIOL CHEM, V274, P20127, DOI 10.1074/jbc.274.29.20127; Coudronniere N, 2000, P NATL ACAD SCI USA, V97, P3394, DOI 10.1073/pnas.060028097; Dierlamm J, 1999, BLOOD, V93, P3601, DOI 10.1182/blood.V93.11.3601; Dimitratos SD, 1999, BIOESSAYS, V21, P912, DOI 10.1002/(SICI)1521-1878(199911)21:11<912::AID-BIES3>3.0.CO;2-Z; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Inohara N, 2000, J BIOL CHEM, V275, P27823; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Koseki T, 1999, J BIOL CHEM, V274, P9955, DOI 10.1074/jbc.274.15.9955; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Leitges M, 1996, SCIENCE, V273, P788, DOI 10.1126/science.273.5276.788; Li QT, 2000, GENE DEV, V14, P1729; Li RCX, 2000, AM J PHYSIOL-HEART C, V279, pH1679, DOI 10.1152/ajpheart.2000.279.4.H1679; Lin X, 2000, MOL CELL BIOL, V20, P2933, DOI 10.1128/MCB.20.8.2933-2940.2000; Lucas PC, 2001, J BIOL CHEM, V276, P19012, DOI 10.1074/jbc.M009984200; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Morgan JA, 1999, CANCER RES, V59, P6205; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Qin HX, 1999, NATURE, V399, P549, DOI 10.1038/21124; Ruland J, 2001, CELL, V104, P33, DOI 10.1016/S0092-8674(01)00189-1; Shimada T, 1999, INT IMMUNOL, V11, P1357, DOI 10.1093/intimm/11.8.1357; Srinivasula SM, 1999, J BIOL CHEM, V274, P17946, DOI 10.1074/jbc.274.25.17946; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; Thome M, 1999, J BIOL CHEM, V274, P9962, DOI 10.1074/jbc.274.15.9962; Tojima Y, 2000, NATURE, V404, P778, DOI 10.1038/35008109; Tokoyoda K, 2000, J BIOL CHEM, V275, P11728, DOI 10.1074/jbc.275.16.11728; Uren AG, 2000, MOL CELL, V6, P961, DOI 10.1016/S1097-2765(05)00086-9; Vertegaal ACO, 2000, CELL SIGNAL, V12, P759, DOI 10.1016/S0898-6568(00)00133-9; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yan MH, 1999, J BIOL CHEM, V274, P10287, DOI 10.1074/jbc.274.15.10287; Zhang QG, 1999, NAT GENET, V22, P63, DOI 10.1038/8767; Zucca E, 2000, BLOOD, V96, P410	42	154	162	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30589	30597		10.1074/jbc.M103824200	http://dx.doi.org/10.1074/jbc.M103824200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11387339	hybrid			2022-12-25	WOS:000170472900003
J	Yan, WH; Nehrke, K; Choi, J; Barber, DL				Yan, WH; Nehrke, K; Choi, J; Barber, DL			The Nck-interacting kinase (NIK) phosphorylates the Na+-H+ exchanger NHE1 and regulates NHE1 activation by platelet-derived growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2/SH3 ADAPTER PROTEIN; STE20-RELATED KINASE; SIGNAL-TRANSDUCTION; CYTOPLASMIC DOMAIN; MAMMALIAN-CELLS; ISOFORM-1 NHE1; ANTIPORTER; MISSHAPEN; CASCADE; STE20	NIK, a recently identified Nck-interacting kinase, acts upstream of the MEK kinase MEKK1 to activate the c-Jun N-terminal kinase JNK. We now show that NIK binds to and divergently activates the plasma membrane Na+-H+ exchanger NHE1 In a genetic screen, NHE1 interacted with NIK at a site N-terminal (amino acids 407-502) to the Nck-binding domain, and this site is critical for its association with NHE1 in vivo. NIK also phosphorylates NHE1; however, the phosphorylation sites, which are distal to amino acid 638, are distinct from the NIK-binding site on NHE1 (amino acids 538-638). Expression of wild-type, but not a kinase-inactive, NIK in fibroblasts increased NHE1 phosphorylation and activity. The kinase domain of NIK, however, was not sufficient for this response in vivo. Full phosphorylation and activation of NHE1 required both the kinase and the NHE1-binding domains of NIK, suggesting that the NHE1-binding site functions as a targeting signal. The functional significance of an interaction between NIK and NHE1 was confirmed by the ability of a kinase-inactive NIK to selectively inhibit activation of NHE1 by platelet-derived growth factor but not by thrombin. Moreover, although NIK activates JNK through a mechanism dependent on MEKK1, it phosphorylated and activated NHE1 independently of MEKK1. These findings indicate that NIK acts downstream of platelet-derived growth factor receptors to phosphorylate and activate NHE1 divergently of its activation of JNK.	Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; Univ Rochester, Ctr Oral Biold, Rochester, NY 14642 USA; Univ Calif San Francisco, Dept Stomatol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of Rochester; University of California System; University of California San Francisco	Barber, DL (corresponding author), Univ Calif San Francisco, Dept Stomatol, Box 0512,513 Parnassus ave, San Francisco, CA 94143 USA.	barber@itsa.ucsf.edu		Nehrke, Keith/0000-0001-9697-726X	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE008921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE008921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040259, R29DK040259] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047413] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE08921] Funding Source: Medline; NIDDK NIH HHS [DK40259] Funding Source: Medline; NIGMS NIH HHS [GM47413] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Avruch J, 1998, MOL CELL BIOCHEM, V182, P31, DOI 10.1023/A:1006823109415; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Becker E, 2000, MOL CELL BIOL, V20, P1537, DOI 10.1128/MCB.20.5.1537-1545.2000; BERTRAND B, 1994, J BIOL CHEM, V269, P13703; Bianchini L, 1997, J BIOL CHEM, V272, P271; BORON WF, 1976, J GEN PHYSIOL, V67, P91, DOI 10.1085/jgp.67.1.91; CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; CHOU MM, 1995, J BIOL CHEM, V270, P7359, DOI 10.1074/jbc.270.13.7359; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; Denker SP, 2000, MOL CELL, V6, P1425, DOI 10.1016/S1097-2765(00)00139-8; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; GOSS GG, 1994, J BIOL CHEM, V269, P8741; GRINSTEIN S, 1992, J BIOL CHEM, V267, P23823; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; HU QJ, 1995, MOL CELL BIOL, V15, P1169; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; Lin X, 1996, P NATL ACAD SCI USA, V93, P12631, DOI 10.1073/pnas.93.22.12631; Liu HZ, 1999, CURR BIOL, V9, P101, DOI 10.1016/S0960-9822(99)80023-2; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; McCarty JH, 1998, BIOESSAYS, V20, P913, DOI 10.1002/(SICI)1521-1878(199811)20:11<913::AID-BIES6>3.0.CO;2-T; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; Paricio N, 1999, EMBO J, V18, P4669, DOI 10.1093/emboj/18.17.4669; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; Ruan WJ, 1999, NEURON, V24, P595, DOI 10.1016/S0896-6273(00)81115-0; SARDET C, 1991, J BIOL CHEM, V266, P19166; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Su YC, 1998, GENE DEV, V12, P2371, DOI 10.1101/gad.12.15.2371; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Takahashi E, 1999, J BIOL CHEM, V274, P20206, DOI 10.1074/jbc.274.29.20206; Takahashi K, 1998, ONCOGENE, V16, P3279, DOI 10.1038/sj.onc.1201874; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; Tominaga T, 1998, EMBO J, V17, P4712, DOI 10.1093/emboj/17.16.4712; Tominaga T, 1998, MOL BIOL CELL, V9, P2287, DOI 10.1091/mbc.9.8.2287; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P13710; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P5583; WINKEL GK, 1993, J BIOL CHEM, V268, P3396	46	86	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31349	31356		10.1074/jbc.M102679200	http://dx.doi.org/10.1074/jbc.M102679200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11369779	hybrid			2022-12-25	WOS:000170472900099
J	Henion, TR; Zhou, DP; Wolfer, DP; Jungalwala, FB; Hennet, T				Henion, TR; Zhou, DP; Wolfer, DP; Jungalwala, FB; Hennet, T			Cloning of a mouse beta 1,3 N-acetylglucosaminyltransferase GlcNAc(beta 1,3)Gal(beta 1,4)Glc-ceramide synthase gene encoding the key regulator of lacto-series glycolipid biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVOUS-SYSTEM; GLYCOSPHINGOLIPID BIOSYNTHESIS; CARBOHYDRATE ANTIGENS; EXPRESSION CLONING; HUMAN-LEUKOCYTES; UDP-GALACTOSE; CELL-LINES; BETA-1,3-GALACTOSYLTRANSFERASE; DIFFERENTIATION; CEREBELLUM	The distinction between the different classes of glycolipids is conditioned by the action of specific core transferases. The entry point for lacto-series glycolipids is catalyzed by the beta1,3 N-acetylglucosaminyltransferase GlcNAc(beta1,3)Gal(beta1,4)Glc-ceramide (Lc3) synthase enzyme. The Lc3 synthase activity has been shown to be regulated during development, especially during brain morphogenesis. Here, we report the molecular cloning of a mouse gene encoding an Lc3 synthase enzyme. The mouse cDNA included an open reading frame of 1131 base pairs encoding a protein of 376 amino acids. The Lc3 synthase protein shared several structural motifs previously identified in the members of the beta1,3 glycosyltransferase superfamily. The Lc3 synthase enzyme efficiently utilized the lactosyl ceramide glycolipid acceptor. The identity of the reaction products of Lc3 synthase-transfected CHOP2/1 cells was confirmed by thin-layer chromatography immunostaining using antibodies TE-8 and 1B2 that recognize Lc3 and Gal(beta1,4)GlcNAc(beta1,3)Gal(beta1,4)Glc-ceramide (nLc4) structures, respectively. In addition to the initiating activity for lacto-chain synthesis, the Lc3 synthase could extend the terminal N-acetyllactosamine unit of nLc4 and also had a broad specificity for gangliosides GA1, GM1, and GD1b to generate neolacto-ganglio hybrid structures. The mouse Lc3 synthase gene was mainly expressed during embryonic development. In situ hybridization analysis revealed that that the Lc3 synthase was expressed in most tissues at embryonic day 11 with elevated expression in the developing central nervous system. Postnatally, the expression was restricted to splenic B-cells, the placenta, and cerebellar Purkinje cells where it colocalized with HNK-1 reactivity. These data support a key role for the Lc3 synthase in regulating neolacto-series glycolipid synthesis during embryonic development.	Univ Zurich, Inst Physiol, CH-8057 Zurich, Switzerland; Univ Zurich, Inst Anat, CH-8057 Zurich, Switzerland; Univ Massachusetts, Sch Med, Eunice Kennedy Shriver Ctr Mental Retardat Inc, Waltham, MA 02452 USA	University of Zurich; University of Zurich; University of Massachusetts System	Hennet, T (corresponding author), Univ Zurich, Inst Physiol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.		zhou, dapeng/GXG-9715-2022; Wolfer, David P/B-3293-2016; Zhou, Dapeng/A-6446-2019	Wolfer, David P/0000-0002-5957-1401; Zhou, Dapeng/0000-0003-1347-3811	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD005515] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024405] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 05515] Funding Source: Medline; NINDS NIH HHS [NS 24405] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANGSTROM J, 1994, P NATL ACAD SCI USA, V91, P11859, DOI 10.1073/pnas.91.25.11859; BHAT S, 1991, P NATL ACAD SCI USA, V88, P7131, DOI 10.1073/pnas.88.16.7131; Chou DKH, 1996, GLYCOCONJUGATE J, V13, P295, DOI 10.1007/BF00731504; Chou DKH, 1996, J BIOL CHEM, V271, P28868, DOI 10.1074/jbc.271.46.28868; CHOU DKH, 1993, J BIOL CHEM, V268, P21727; Chou DKH, 1998, J BIOL CHEM, V273, P8508, DOI 10.1074/jbc.273.14.8508; CHOU DKH, 1986, J BIOL CHEM, V261, P1717; CUMMINGS L, 1993, BIOCHEM BIOPH RES CO, V195, P814, DOI 10.1006/bbrc.1993.2118; EPAND RM, 1995, BIOCHEMISTRY-US, V34, P1084, DOI 10.1021/bi00003a045; FELDINGHABERMANN B, 1990, BIOCHEMISTRY-US, V29, P6314, DOI 10.1021/bi00478a028; FENDERSON BA, 1990, BIOESSAYS, V12, P173, DOI 10.1002/bies.950120406; HENDRICKS SP, 1990, J BIOL CHEM, V265, P17621; Hennet T, 1998, J BIOL CHEM, V273, P58, DOI 10.1074/jbc.273.1.58; HOLMES EH, 1987, J BIOL CHEM, V262, P15649; HU J, 1994, GLYCOBIOLOGY, V4, P251; KOJIMA N, 1994, J BIOL CHEM, V269, P30451; LINDBERG AA, 1987, J BIOL CHEM, V262, P1779; MACHER BA, 1982, MOL CELL BIOCHEM, V47, P81; Miura R, 1999, J BIOL CHEM, V274, P11431, DOI 10.1074/jbc.274.16.11431; Miyazaki H, 1997, J BIOL CHEM, V272, P24794, DOI 10.1074/jbc.272.40.24794; NAKAMURA M, 1992, J BIOL CHEM, V267, P23507; NOHARA K, 1994, BIOCHEMISTRY-US, V33, P4661, DOI 10.1021/bi00181a601; NOJIRI H, 1986, P NATL ACAD SCI USA, V83, P782, DOI 10.1073/pnas.83.3.782; NORDQUIST DT, 1988, J NEUROSCI, V8, P4780; NORIHISA Y, 1994, J IMMUNOL, V152, P485; Ogiso M, 1997, GLYCOBIOLOGY, V7, P605, DOI 10.1093/glycob/7.5.605; Okajima T, 2000, J BIOL CHEM, V275, P40498, DOI 10.1074/jbc.M006902200; Sheikh KA, 1999, P NATL ACAD SCI USA, V96, P7532, DOI 10.1073/pnas.96.13.7532; Shiraishi N, 2001, J BIOL CHEM, V276, P3498, DOI 10.1074/jbc.M004800200; SINGHAL A, 1990, BIOESSAYS, V12, P223, DOI 10.1002/bies.950120506; STULTS CLM, 1993, ARCH BIOCHEM BIOPHYS, V303, P125, DOI 10.1006/abbi.1993.1263; Togayachi A, 2001, J BIOL CHEM, V276, P22032, DOI 10.1074/jbc.M011369200; TOLE S, 1995, J NEUROSCI, V15, P957; YAMAMOTO M, 1985, P NATL ACAD SCI USA, V82, P3045, DOI 10.1073/pnas.82.9.3045; Zhou DP, 2000, P NATL ACAD SCI USA, V97, P11673; Zhou DP, 1999, EUR J BIOCHEM, V263, P571, DOI 10.1046/j.1432-1327.1999.00541.x; Zhou DP, 2000, J BIOL CHEM, V275, P22631, DOI 10.1074/jbc.C000263200; Zhou DP, 1999, P NATL ACAD SCI USA, V96, P406, DOI 10.1073/pnas.96.2.406	38	45	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30261	30269		10.1074/jbc.M102979200	http://dx.doi.org/10.1074/jbc.M102979200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11384981	hybrid			2022-12-25	WOS:000170558000087
J	Ito, K; Jazrawi, E; Cosio, BJ; Barnes, PJ; Adcock, IM				Ito, K; Jazrawi, E; Cosio, BJ; Barnes, PJ; Adcock, IM			p65-activated histone acetyltransferase activity is repressed by glucocorticoids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TRANSCRIPTION FACTOR ACCESS; CREB-BINDING-PROTEIN; DNA-BINDING; RECEPTOR; ACETYLATION; GENE; ACTIVATION; EXPRESSION; TRANSACTIVATION	Glucocorticoids acting through their specific receptor can either enhance or repress gene transcription. Dexamethasone represses interleukin-1 beta -stimulated histone acetylation and granulocyte-macrophage colony-stimulating factor expression through a combination of direct inhibition of p65-associated histone acetyltransferase CHAT) activity and by recruiting histone deacetylase 2 (HDAC2) to the p65-HAT complex. Here we show that mifepristone, a glucocorticoid receptor partial agonist, has no ability to induce gene expression but represses interleukin-1 beta -stimulated histone acetylation and granulocyte-macrophage colony-stimulating factor release by 50% maximally. Mifepristone was able to inhibit p65-associated HAT activity to the same extent as dexamethasone but failed to inhibit the natural promoter to an equal extent clue to an inability to recruit HDAC2 to the p65-associated HAT complex. These data suggest that the maximal repressive actions of glucocorticoids require recruitment of HDAC2 to a p65-HAT complex. These data also suggest that pharmacological manipulation of specific histone acetylation status is a potentially useful approach for the treatment of inflammatory diseases.	Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Sch Med, London SW3 6LY, England	Imperial College London	Adcock, IM (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Sch Med, Dovehouse St, London SW3 6LY, England.	ian.adcock@ic.ac.uk	G.Cosio, Borja/P-4963-2017; Ito, Kazuhiro/AAF-5994-2019; Adcock, Ian/L-3217-2019	G.Cosio, Borja/0000-0002-6388-8209; Adcock, Ian/0000-0003-2101-8843; Barnes, Peter/0000-0002-5122-4018				Adcock IM, 1999, BRIT J PHARMACOL, V127, P1003, DOI 10.1038/sj.bjp.0702613; Adkins KK, 1998, AM J PHYSIOL-LUNG C, V275, pL372, DOI 10.1152/ajplung.1998.275.2.L372; BARNES PJ, 1995, NEW ENGL J MED, V332, P868, DOI 10.1056/NEJM199503303321307; Barnes PJ, 1998, EUR RESPIR J, V12, P221, DOI 10.1183/09031936.98.12010221; Beato M, 1996, J MOL MED, V74, P711, DOI 10.1007/s001090050076; Beato M, 1997, NUCLEIC ACIDS RES, V25, P3559, DOI 10.1093/nar/25.18.3559; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; De B.K., 1997, P NATL ACAD SCI USA, V94, P13504; De Bosscher K, 2000, P NATL ACAD SCI USA, V97, P3919, DOI 10.1073/pnas.97.8.3919; FLOWER RJ, 1994, TRENDS PHARMACOL SCI, V15, P71, DOI 10.1016/0165-6147(94)90281-X; Hecht A, 1999, METHOD ENZYMOL, V304, P399; Heck S, 1997, EMBO J, V16, P4698, DOI 10.1093/emboj/16.15.4698; HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x; Ikeda A, 2000, BIOCHEM BIOPH RES CO, V272, P375, DOI 10.1006/bbrc.2000.2786; Imhof A, 1998, CURR BIOL, V8, pR422, DOI 10.1016/S0960-9822(98)70268-4; Ito K, 2000, MOL CELL BIOL, V20, P6891, DOI 10.1128/MCB.20.18.6891-6903.2000; Karin M, 1998, CELL, V93, P487, DOI 10.1016/S0092-8674(00)81177-0; Kolle D, 1998, METHODS, V15, P323, DOI 10.1006/meth.1998.0636; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; Levine SJ, 1996, AM J RESP CELL MOL, V15, P245, DOI 10.1165/ajrcmb.15.2.8703481; McKay LI, 2000, MOL ENDOCRINOL, V14, P1222, DOI 10.1210/me.14.8.1222; Nightingale KP, 1998, EMBO J, V17, P2865, DOI 10.1093/emboj/17.10.2865; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PERRY M, 1982, J BIOL CHEM, V257, P7336; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952; SALLENAVE JM, 1994, AM J RESP CELL MOL, V11, P733, DOI 10.1165/ajrcmb.11.6.7946401; Sheppard KA, 1998, J BIOL CHEM, V273, P29291, DOI 10.1074/jbc.273.45.29291; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; TURNER BM, 1989, FEBS LETT, V253, P141, DOI 10.1016/0014-5793(89)80947-0; Ura K, 1997, EMBO J, V16, P2096, DOI 10.1093/emboj/16.8.2096; Vanden Berghe W, 1999, J BIOL CHEM, V274, P32091, DOI 10.1074/jbc.274.45.32091; Vayssiere BM, 1997, MOL ENDOCRINOL, V11, P1245, DOI 10.1210/me.11.9.1245; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; WORKMAN JL, 1993, TRENDS BIOCHEM SCI, V18, P90, DOI 10.1016/0968-0004(93)90160-O; Wright LC, 1998, AM J PHYSIOL-LUNG C, V275, pL694, DOI 10.1152/ajplung.1998.275.4.L694; WU RS, 1986, CRIT REV BIOCHEM MOL, V20, P201, DOI 10.3109/10409238609083735; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	40	105	114	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30208	30215		10.1074/jbc.M103604200	http://dx.doi.org/10.1074/jbc.M103604200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11395507	hybrid			2022-12-25	WOS:000170558000081
J	Maturana, A; Arnaudeau, S; Ryser, S; Banfi, B; Hossle, JP; Schlegel, W; Krause, KH; Demaurex, N				Maturana, A; Arnaudeau, S; Ryser, S; Banfi, B; Hossle, JP; Schlegel, W; Krause, KH; Demaurex, N			Heme histidine ligands within gp91(phox) modulate proton conduction by the phagocyte NADPH oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; RESPIRATORY BURST OXIDASE; H+ CHANNEL; HUMAN-NEUTROPHILS; FLAVOCYTOCHROME B(558); CYTOCHROME B(558); ELECTRON-TRANSFER; INTRACELLULAR PH; ARACHIDONATE; ACTIVATION	The membrane subunit of the phagocyte NADPH oxidase, gp91(phox), possesses a H+ channel motif formed by membrane-spanning histidines postulated to coordinate the two heme groups forming the redox center of the flavocytochrome. To study the role of heme-binding histidines on proton conduction, we stably expressed the gp91(phox) cytochrome in human embryonic kidney 293 cells and measured proton currents with the patch clamp technique. Similar to its shorter homologue, NADPH oxidase homologue 1, which is predicted not to bind heme, gp91(phox) generated voltage-activated, pH-dependent, H+-selective currents that were reversibly blocked by Zn2+. The gp91(phox) currents, however, activated faster, deactivated more slowly, and were markedly affected by the inhibition of heme synthesis. Upon heme removal, the currents had larger amplitude, activated faster and at lower voltages, and became sensitive to the histidine reagent diethylpyrocarbonate. Mutation of the His-115 residue to leucine abolished both the gp91(phox) characteristic 558-nm absorbance peak and voltage-activated currents, indicating that His-115 is involved in both heme ligation and proton conduction. These results indicate that the gp91(phox) proton channel is activated upon release of heme from its His-115 ligand. During activation of the oxidase complex, changes in heme coordination within the cytochrome might increase the mobility of histidine ligands, thereby coupling electron and proton transport.	Univ Geneva, Med Ctr, Dept Physiol, CH-1211 Geneva 4, Switzerland; Univ Geneva, Fdn Rech Med, CH-1211 Geneva, Switzerland; Geneva Sch Med, Dept Geriatr, Biol Aging Lab, CH-1225 Geneva, Switzerland; Univ Zurich, Childrens Hosp, Div Immunol & Hematol, CH-8032 Zurich, Switzerland	University of Geneva; University of Geneva; University of Geneva; University Children's Hospital Zurich; University of Zurich	Demaurex, N (corresponding author), Univ Geneva, Med Ctr, Dept Physiol, 1 Michel Servet, CH-1211 Geneva 4, Switzerland.		Krause, Karl-Heinz/E-8030-2011	Krause, Karl-Heinz/0000-0002-9033-6768; Demaurex, Nicolas/0000-0002-9933-6772; Banfi, Botond/0000-0001-9273-1318				Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Banfi B, 1999, J EXP MED, V190, P183, DOI 10.1084/jem.190.2.183; Banfi B, 2000, SCIENCE, V287, P138, DOI 10.1126/science.287.5450.138; Batot G, 1998, BBA-MOL BASIS DIS, V1406, P188, DOI 10.1016/S0925-4439(98)00004-0; BOKOCH GM, 1994, CURR OPIN IMMUNOL, V6, P98, DOI 10.1016/0952-7915(94)90040-X; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; Cherny VV, 1999, J GEN PHYSIOL, V114, P819, DOI 10.1085/jgp.114.6.819; CLARK RA, 1990, HOSP PRACT, V25, P51; CROSS AR, 1991, BIOCHIM BIOPHYS ACTA, V1057, P281, DOI 10.1016/S0005-2728(05)80140-9; DeCoursey TE, 2000, P NATL ACAD SCI USA, V97, P6885, DOI 10.1073/pnas.100047297; DECOURSEY TE, 1993, BIOPHYS J, V65, P1590, DOI 10.1016/S0006-3495(93)81198-6; DeCoursey TE, 1998, FRONT BIOSCI, V3, P477; DeLeo FR, 2000, J BIOL CHEM, V275, P13986, DOI 10.1074/jbc.275.18.13986; DEMAUREX N, 1993, J PHYSIOL-LONDON, V466, P329; Demaurex N, 1996, J CELL BIOL, V133, P1391, DOI 10.1083/jcb.133.6.1391; Doussiere J, 1996, BIOCHEMISTRY-US, V35, P13400, DOI 10.1021/bi960916b; Doussiere J, 1999, BIOCHEMISTRY-US, V38, P16394, DOI 10.1021/bi991502w; EBERT PS, 1979, BIOCHEM BIOPH RES CO, V88, P1382, DOI 10.1016/0006-291X(79)91133-1; ELLIS JA, 1989, BIOCHEM J, V262, P575, DOI 10.1042/bj2620575; Henderson LM, 1999, J GEN PHYSIOL, V114, P771, DOI 10.1085/jgp.114.6.771; HENDERSON LM, 1987, BIOCHEM J, V246, P325, DOI 10.1042/bj2460325; HENDERSON LM, 1992, BIOCHEM J, V283, P171, DOI 10.1042/bj2830171; HENDERSON LM, 1988, BIOCHEM J, V255, P285; HENDERSON LM, 1995, J BIOL CHEM, V270, P5909, DOI 10.1074/jbc.270.11.5909; Henderson LM, 1998, J BIOL CHEM, V273, P33216, DOI 10.1074/jbc.273.50.33216; Henderson LM, 1996, BBA-BIOENERGETICS, V1273, P87, DOI 10.1016/0005-2728(95)00140-9; Henderson LM, 1997, BIOCHEM J, V325, P701, DOI 10.1042/bj3250701; Lowenthal A, 1999, J BIOL CHEM, V274, P21603, DOI 10.1074/jbc.274.31.21603; NAGLE JF, 1978, P NATL ACAD SCI USA, V75, P298, DOI 10.1073/pnas.75.1.298; NANDA A, 1994, J CLIN INVEST, V93, P1770, DOI 10.1172/JCI117162; NUSSE O, 1990, J EXP MED, V171, P775, DOI 10.1084/jem.171.3.775; Schneider SD, 1997, GENE THER, V4, P524, DOI 10.1038/sj.gt.3300432; Segal AW, 1997, ANN NY ACAD SCI, V832, P215, DOI 10.1111/j.1749-6632.1997.tb46249.x; Starace DM, 1997, NEURON, V19, P1319, DOI 10.1016/S0896-6273(00)80422-5; Verhoeven AJ, 1997, ANN NY ACAD SCI, V832, P85, DOI 10.1111/j.1749-6632.1997.tb46239.x; VERHOEVEN AJ, 1989, BLOOD, V73, P1686; Yu LX, 1999, J BIOL CHEM, V274, P4364, DOI 10.1074/jbc.274.7.4364; Yu LX, 1997, J BIOL CHEM, V272, P27288, DOI 10.1074/jbc.272.43.27288; Yu LX, 1998, P NATL ACAD SCI USA, V95, P7993, DOI 10.1073/pnas.95.14.7993	39	54	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30277	30284		10.1074/jbc.M010438200	http://dx.doi.org/10.1074/jbc.M010438200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11389135	hybrid, Green Published			2022-12-25	WOS:000170558000089
J	Ohtsuka, T; Sakamoto, M; Guillemot, F; Kageyama, R				Ohtsuka, T; Sakamoto, M; Guillemot, F; Kageyama, R			Roles of the basic helix-loop-helix genes Hes1 and Hes5 in expansion of neural stem cells of the developing brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; NEURONAL DIFFERENTIATION; NEGATIVE REGULATOR; MAMMALIAN HAIRY; ACHAETE-SCUTE; NOTCH; NEUROGENESIS; EXPRESSION; GENERATION; ENHANCER	Neural stem cells, which differentiate into neurons and glia, are present in the ventricular zone of the embryonal brain. The precise mechanism by which neural stem cells are maintained during embryogenesis remains to be determined. Here, we found that transient misexpression of the basic helix-loop-helix genes Hes1 and Hes5 keeps embryonal telencephalic cells undifferentiated although they have been shown to induce gliogenesis in the retina. These telencephalic cells later differentiate into neurons and astroglia when Hes expression is down-regulated, suggesting that Hes1- and Hes5- expressing cells are maintained as neural stem cells during embryogenesis. Conversely, in the absence of Hes1 and Hes5, neural stem cells are not properly maintained, generating fewer and smaller neurospheres than the wild type. These results indicate that Hes1 and Hes5 play an important role in the maintenance of neural stem cells but not in gliogenesis in the embryonal telencephalon.	Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan; Univ Strasbourg 1, Coll France, Ctr Univ Strasbourg, CNRS,INSERM Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	Kyoto University; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Kageyama, R (corresponding author), Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan.		Guillemot, Francois/AAV-1482-2021					AKAZAWA C, 1992, J BIOL CHEM, V267, P21879; Allen T, 1999, CELL MOL BIOL, V45, P687; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Cai L, 2000, DEVELOPMENT, V127, P3021; Castella P, 2000, MOL CELL BIOL, V20, P6170, DOI 10.1128/MCB.20.16.6170-6183.2000; Castella P, 1999, J NEUROSCI RES, V56, P229, DOI 10.1002/(SICI)1097-4547(19990501)56:3<229::AID-JNR2>3.0.CO;2-Z; Cau E, 2000, DEVELOPMENT, V127, P2323; Chen H, 1997, P NATL ACAD SCI USA, V94, P5355, DOI 10.1073/pnas.94.10.5355; Chiasson BJ, 1999, J NEUROSCI, V19, P4462; delaPompa J, 1997, DEVELOPMENT, V124, P1139; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; DORSKY RI, 1995, NEURON, V14, P487, DOI 10.1016/0896-6273(95)90305-4; Funahashi J, 1999, DEV GROWTH DIFFER, V41, P59; Furukawa T, 2000, NEURON, V26, P383, DOI 10.1016/S0896-6273(00)81171-X; Gaiano N, 2000, NEURON, V26, P395, DOI 10.1016/S0896-6273(00)81172-1; Hatakeyama J, 2001, DEVELOPMENT, V128, P1313; Hirata H, 2000, J BIOL CHEM, V275, P19083, DOI 10.1074/jbc.M001075200; Hojo M, 2000, DEVELOPMENT, V127, P2515; ISHIBASHI M, 1994, EMBO J, V13, P1799, DOI 10.1002/j.1460-2075.1994.tb06448.x; Ishibashi M, 1995, GENE DEV, V9, P3136, DOI 10.1101/gad.9.24.3136; Jacobson M., 1991, DEV NEUROBIOLOGY; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; Kageyama R, 1997, CURR OPIN GENET DEV, V7, P659, DOI 10.1016/S0959-437X(97)80014-7; Lobe CG, 1997, MECH DEVELOP, V62, P227, DOI 10.1016/S0925-4773(97)00665-5; Malatesta P, 2000, DEVELOPMENT, V127, P5253; Morrison SJ, 2000, CELL, V101, P499, DOI 10.1016/S0092-8674(00)80860-0; Nakamura Y, 2000, J NEUROSCI, V20, P283, DOI 10.1523/JNEUROSCI.20-01-00283.2000; Nieto M, 2001, NEURON, V29, P401, DOI 10.1016/S0896-6273(01)00214-8; Noctor SC, 2001, NATURE, V409, P714, DOI 10.1038/35055553; NYE JS, 1994, DEVELOPMENT, V120, P2421; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; Qian XM, 2000, NEURON, V28, P69, DOI 10.1016/S0896-6273(00)00086-6; RAKIC P, 1971, BRAIN RES, V33, P471, DOI 10.1016/0006-8993(71)90119-3; Reynolds BA, 1996, DEV BIOL, V175, P1, DOI 10.1006/dbio.1996.0090; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; Strom A, 1997, GENE DEV, V11, P3168, DOI 10.1101/gad.11.23.3168; Sun Y, 2001, CELL, V104, P365, DOI 10.1016/S0092-8674(01)00224-0; Tanigaki K, 2001, NEURON, V29, P45, DOI 10.1016/S0896-6273(01)00179-9; Tomita K, 2000, EMBO J, V19, P5460, DOI 10.1093/emboj/19.20.5460; Tomita K, 1996, NEURON, V16, P723, DOI 10.1016/S0896-6273(00)80093-8; Wang SL, 1998, NEURON, V21, P63, DOI 10.1016/S0896-6273(00)80515-2; Zheng JL, 2000, DEVELOPMENT, V127, P4551	43	327	338	2	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30467	30474		10.1074/jbc.M102420200	http://dx.doi.org/10.1074/jbc.M102420200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11399758	hybrid			2022-12-25	WOS:000170558000113
J	Scarselli, M; Novi, F; Schallmach, E; Ling, RW; Baragli, A; Colzi, A; Griffon, N; Corsini, GU; Sokoloff, P; Levenson, R; Vogel, Z; Maggio, R				Scarselli, M; Novi, F; Schallmach, E; Ling, RW; Baragli, A; Colzi, A; Griffon, N; Corsini, GU; Sokoloff, P; Levenson, R; Vogel, Z; Maggio, R			D-2/D-3 dopamine receptor heterodimers exhibit unique functional properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; ADENYLYL-CYCLASE; D-3 RECEPTOR; LINKED RECEPTORS; RAT-BRAIN; EXPRESSION; DIMERS; COEXPRESSION; FRAGMENTS; CELLS	Evidence for heterodimerization has recently been provided for dopamine D-1 and adenosine A(1) receptors as well as for dopamine D-2 and somatostatin SSTR5 receptors. In this paper, we have studied the possibility that D2 and Da receptors interact functionally by forming receptor heterodimers. Initially, we split the two receptors at the level of the third cytoplasmic loop into two fragments. The first, containing transmembrane domains (TM) I to V and the N-terminal part of the third cytoplasmic loop, was named D-2trunk or D-3trunk, and the second, containing the C-terminal part of the third cytoplasmic loop, TAM and TMVII, and the C-terminal tail, was named D-2tail or D-3tail. Then we defined the pharmacological profiles of the homologous (D-2trunk/ D-2tail and D-3trunk/D-3tail) as well as of the heterologous (D-2trunk/D-3tail and D-3trunk/D-2tail) cotransfected receptor fragments. The pharmacological profile of the cross-cotransfected fragments was different from that of the native D-2 or D-3 receptors. In most cases, the D-3trunk/D-2tail was the one with the highest affinity for most agonists and antagonists. Moreover, we observed that all of these receptor fragments reduced the expression of the wild type dopamine D-2, and D-3 receptors, suggesting that D-2 and D-3 receptors can form complexes with these fragments and that these complexes bind [H-3]nemonapride less efficiently or are not correctly targeted to the membrane. In a second set of experiments, we tested the ability of the split and the wild type receptors to inhibit adenylyl cyclase (AC) types V and VI. All of the native and split receptors inhibited AC-V and AC-VI, with the exception of D-3, which was unable to inhibit AC-VI. We therefore studied the ability of D2 and D3 to interact functionally with one another to inhibit AC-VI. We found that with D-2 alone, R-(+)-7-hydroxydypropylaminotetralin hydrobromide inhibited AC-VI with an IC50 of 2.05 +/- 0.15 nM, while in the presence of D2 and D3 it inhibited AC-Vr with an IC50 of 0.083 +/- 0.011 nM. Similar results were obtained with a chimeric cyclase made from AC-V and AC-VI. Coimmunoprecipitation experiments indicate that D-2 and D-3 receptors are capable of physical interaction.	Univ Pisa, Dept Neurosci, I-56100 Pisa, Italy; Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; Penn State Univ, Milton S Hershey Med Ctr, Sch Med, Dept Pharmacol, Hershey, PA 17033 USA; Penn State Univ, Milton S Hershey Med Ctr, Sch Med, Grad Program Neurosci, Hershey, PA 17033 USA; Eli Lilly Italia & Co, I-50019 Sesto Fiorentino, Italy; Ctr Paul Broca, INSERM, Unite Neurobiol & Pharmacol, F-75014 Paris, France	University of Pisa; Weizmann Institute of Science; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Eli Lilly; Institut National de la Sante et de la Recherche Medicale (Inserm)	Maggio, R (corresponding author), Univ Pisa, Dept Neurosci, Via Roma 55, I-56100 Pisa, Italy.		maggio, Roberto/Q-2032-2015	Maggio, Roberto/0000-0003-4436-2356; Levenson, Robert/0000-0002-0936-8421; Scarselli, Marco/0000-0001-5087-3182				AvidorReiss T, 1997, J BIOL CHEM, V272, P5040, DOI 10.1074/jbc.272.8.5040; AVIDORREISS T, 1995, J BIOL CHEM, V270, P29732; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DALTOSO R, 1989, EMBO J, V8, P4025, DOI 10.1002/j.1460-2075.1989.tb08585.x; Filteau F, 1999, FEBS LETT, V447, P251, DOI 10.1016/S0014-5793(99)00290-2; FISHBURN CS, 1993, J BIOL CHEM, V268, P5872; George SR, 1998, J BIOL CHEM, V273, P30244, DOI 10.1074/jbc.273.46.30244; Gines S, 2000, P NATL ACAD SCI USA, V97, P8606, DOI 10.1073/pnas.150241097; GIROS B, 1989, NATURE, V342, P923, DOI 10.1038/342923a0; Gouldson PR, 1998, PROTEIN ENG, V11, P1181, DOI 10.1093/protein/11.12.1181; Gouldson PR, 1997, J MED CHEM, V40, P3871, DOI 10.1021/jm960647n; Gudermann T, 1997, ANNU REV NEUROSCI, V20, P399, DOI 10.1146/annurev.neuro.20.1.399; Gurevich EV, 1999, NEUROPSYCHOPHARMACOL, V20, P60, DOI 10.1016/S0893-133X(98)00066-9; Hall DA, 1997, BRIT J PHARMACOL, V121, P731, DOI 10.1038/sj.bjp.0701196; Hebert TE, 1998, BIOCHEM CELL BIOL, V76, P1, DOI 10.1139/bcb-76-1-1; Karpa KD, 2000, MOL PHARMACOL, V58, P677, DOI 10.1124/mol.58.4.677; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; Lachowicz JE, 1997, BIOCHEM BIOPH RES CO, V237, P394, DOI 10.1006/bbrc.1997.7146; Lee SP, 2000, MOL PHARMACOL, V58, P120, DOI 10.1124/mol.58.1.120; LeMoine C, 1996, NEUROSCIENCE, V73, P131, DOI 10.1016/0306-4522(96)00029-2; LEVESQUE D, 1992, P NATL ACAD SCI USA, V89, P8155, DOI 10.1073/pnas.89.17.8155; Maggio R, 1999, J PHARMACOL EXP THER, V291, P251; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; MAGGIO R, 1993, FEBS LETT, V319, P195, DOI 10.1016/0014-5793(93)80066-4; MCELROY JF, 1994, PHARMACOL BIOCHEM BE, V48, P531, DOI 10.1016/0091-3057(94)90565-7; Millan MJ, 2000, J PHARMACOL EXP THER, V293, P1063; MONSMA FJ, 1989, NATURE, V342, P926, DOI 10.1038/342926a0; Ng GYK, 1996, BIOCHEM BIOPH RES CO, V227, P200, DOI 10.1006/bbrc.1996.1489; Nielsen SM, 1998, EUR J BIOCHEM, V251, P217, DOI 10.1046/j.1432-1327.1998.2510217.x; Nimchinsky EA, 1997, J BIOL CHEM, V272, P29229, DOI 10.1074/jbc.272.46.29229; RIDGE KD, 1995, P NATL ACAD SCI USA, V92, P3204, DOI 10.1073/pnas.92.8.3204; Robinson SW, 1997, MOL PHARMACOL, V52, P508, DOI 10.1124/mol.52.3.508; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; Scarselli M, 2000, EUR J PHARMACOL, V397, P291, DOI 10.1016/S0014-2999(00)00272-7; Schoneberg T, 1996, EMBO J, V15, P1283, DOI 10.1002/j.1460-2075.1996.tb00470.x; SOKOLOFF P, 1995, TRENDS PHARMACOL SCI, V16, P270, DOI 10.1016/S0165-6147(00)89044-6; Varga EV, 1998, EUR J PHARMACOL, V348, pR1, DOI 10.1016/S0014-2999(98)00258-1; Zawarynski P, 1998, FEBS LETT, V441, P383, DOI 10.1016/S0014-5793(98)01588-9; Zhu XY, 1998, BIOCHEMISTRY-US, V37, P15773, DOI 10.1021/bi981162z	39	175	177	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30308	30314		10.1074/jbc.M102297200	http://dx.doi.org/10.1074/jbc.M102297200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11373283	hybrid			2022-12-25	WOS:000170558000093
J	Simon, E; Clotet, J; Calero, F; Ramos, J; Arino, J				Simon, E; Clotet, J; Calero, F; Ramos, J; Arino, J			A screening for high copy suppressors of the sit4 hal3 synthetically lethal phenotype reveals a role for the yeast Nha1 antiporter in cell cycle regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY K+ TRANSPORTER; SACCHAROMYCES-CEREVISIAE; PROTEIN PHOSPHATASE; SALT-TOLERANCE; NA+/H+-ANTIPORTER; FISSION YEAST; ZYGOSACCHAROMYCES-ROUXII; POTASSIUM TRANSPORTER; FUNCTIONAL EXPRESSION; ESCHERICHIA-COLI	A screening for multicopy suppressors of the G(1)/S blockage of a conditional sit4 hal3 mutant yielded the NHA1 gene, encoding a Na+, K+/H+ antiporter, composed of a transmembrane domain and a large carboxyl-terminal tail, which has been related to cation detoxification processes. Expression of either the powerful Saccharomyces cerevisiae, Ena-1 Na+/H+-ATPase or the Schizosaccharomyces pombe Sod2 Na+/H+ antiporter, although increasing tolerance to sodium, was unable to mimic the Nha1 function in the cell cycle. Mutation of the conserved Asp residues Asp(266)-Asp(267) selectively abolished Na+ efflux without modifying K+ efflux and did not affect the capacity of Nha1 to relieve the G(1) blockage. Mutagenesis analysis revealed that the region near the carboxyl-terminal end of Nha1 comprising residues 800 - 948 is dispensable for sodium detoxification. but necessary for transport of K+ cations. Therefore, this portion of the protein contains structural elements that selectively modulate Nha1 antiporter functions. This region is also required for Nha1 to function in the cell cycle. However,. expression of the closely related Cnh1 antiporter from Candida albicans, which also contains a long carboxyl-terminal extension, although allowing efficient K+ transport does not relieve cell cycle blockage. This indicates that although the determinants for Nha1-mediated regulation of potassium transport and the cell cycle map very closely in the protein, most probably the function of Nha1 on cell cycle is independent of its ability to extrude potassium cations.	Univ Autonoma Barcelona, Fac Vet, Dept Bioquim & Biol Mol, Bellaterra 08193, Barcelona, Spain; Univ Int Catalunya, Fac Ciencies Salut, Dept Bioquim, Barcelona 08190, Spain; Escuela Tecn Super Ingn Agron & Montes, Dept Microbiol, Cordoba 14080, Spain	Autonomous University of Barcelona; Universitat Internacional de Catalunya (UIC)	Arino, J (corresponding author), Univ Autonoma Barcelona, Fac Vet, Dept Bioquim & Biol Mol, Ed V, Bellaterra 08193, Barcelona, Spain.		Clotet, Josep/ABC-8727-2020; Clotet, Josep/AAF-2618-2019; Arino, Joaquin/D-3756-2011; Ramos, Jose/K-4307-2014; Zhang, Ning/F-1387-2014	Clotet, Josep/0000-0001-5462-8598; Arino, Joaquin/0000-0002-6774-2987; Ramos, Jose/0000-0002-9797-1561; Arino Carmona, Joaquin/0000-0002-0390-4270				Adams A, 1997, METHODS YEAST GENETI; Aloy P, 1997, COMPUT APPL BIOSCI, V13, P231; ARNDT KT, 1989, CELL, V56, P527, DOI 10.1016/0092-8674(89)90576-X; Banuelos MA, 1998, MICROBIOL-UK, V144, P2749, DOI 10.1099/00221287-144-10-2749; BANUELOS MA, 1995, EMBO J, V14, P3021, DOI 10.1002/j.1460-2075.1995.tb07304.x; Bastians H, 1996, J CELL SCI, V109, P2865; Belli G, 1998, YEAST, V14, P1127, DOI 10.1002/(SICI)1097-0061(19980915)14:12<1127::AID-YEA300>3.0.CO;2-#; Benito B, 1997, BBA-BIOMEMBRANES, V1328, P214, DOI 10.1016/S0005-2736(97)00098-9; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; Calero F, 2000, J BACTERIOL, V182, P394, DOI 10.1128/JB.182.2.394-399.2000; Cedano J, 1997, J MOL BIOL, V266, P594, DOI 10.1006/jmbi.1996.0804; Clotet J, 1999, MOL CELL BIOL, V19, P2408; CORMAK B, 1997, CURRENT PROTOCOLS MO; Counillon L, 2000, J BIOL CHEM, V275, P1, DOI 10.1074/jbc.275.1.1; de Nadal E, 1999, J BACTERIOL, V181, P6456, DOI 10.1128/JB.181.20.6456-6462.1999; de Nadal E, 1998, P NATL ACAD SCI USA, V95, P7357, DOI 10.1073/pnas.95.13.7357; Diatloff E, 1998, FEBS LETT, V432, P31, DOI 10.1016/S0014-5793(98)00833-3; Dibrov P, 1998, FEBS LETT, V424, P1, DOI 10.1016/S0014-5793(98)00119-7; Dibrov P, 1998, BIOCHEMISTRY-US, V37, P8282, DOI 10.1021/bi9801457; DICOMO CJ, 1995, GENETICS, V139, P95; Espinosa-Ruiz A, 1999, PLANT J, V20, P529, DOI 10.1046/j.1365-313X.1999.00626.x; FERNANDEZSARABIA MJ, 1992, GENE DEV, V6, P2417, DOI 10.1101/gad.6.12a.2417; FERRANDO A, 1995, MOL CELL BIOL, V15, P5470; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Gillies R. J., 1982, INTRACELLULAR PH ITS, P341; Hahnenberger KM, 1996, P NATL ACAD SCI USA, V93, P5031, DOI 10.1073/pnas.93.10.5031; Iwaki T, 1998, YEAST, V14, P1167, DOI 10.1002/(SICI)1097-0061(19980930)14:13<1167::AID-YEA318>3.0.CO;2-5; JIA ZP, 1992, EMBO J, V11, P1631, DOI 10.1002/j.1460-2075.1992.tb05209.x; Lorenz MC, 1998, EMBO J, V17, P1236, DOI 10.1093/emboj/17.5.1236; MANN DJ, 1993, EMBO J, V12, P4833, DOI 10.1002/j.1460-2075.1993.tb06173.x; Mulet JM, 1999, MOL CELL BIOL, V19, P3328; POSAS F, 1995, J BIOL CHEM, V270, P13036, DOI 10.1074/jbc.270.22.13036; Prior C, 1996, FEBS LETT, V387, P89, DOI 10.1016/0014-5793(96)00470-X; Ramirez J, 1998, J BACTERIOL, V180, P5860; Rodriguez-Navarro A, 2000, BBA-REV BIOMEMBRANES, V1469, P1, DOI 10.1016/S0304-4157(99)00013-1; Rubio F, 1999, J BIOL CHEM, V274, P6839, DOI 10.1074/jbc.274.11.6839; SAMBROOK J, 1989, MOL CLONING LAB MANU, P145; SHIMANUKI M, 1993, MOL BIOL CELL, V4, P303, DOI 10.1091/mbc.4.3.303; Soong TW, 2000, MICROBIOL-UK, V146, P1035, DOI 10.1099/00221287-146-5-1035; SUTTON A, 1991, COLD SPRING HARB SYM, V56, P75; SUTTON A, 1991, MOL CELL BIOL, V11, P2133, DOI 10.1128/MCB.11.4.2133; Sychrova H, 1999, FEMS MICROBIOL LETT, V171, P167, DOI 10.1111/j.1574-6968.1999.tb13428.x; WATANABE Y, 1995, YEAST, V11, P829, DOI 10.1002/yea.320110905	43	44	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29740	29747		10.1074/jbc.M101992200	http://dx.doi.org/10.1074/jbc.M101992200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11382758	hybrid			2022-12-25	WOS:000170558000020
J	Song, L; Dentler, WL				Song, L; Dentler, WL			Flagellar protein dynamics in Chlamydomonas	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE CAPPING STRUCTURES; INTRAFLAGELLAR TRANSPORT IFT; LEFT-RIGHT ASYMMETRY; DYNEIN LIGHT-CHAIN; CYTOPLASMIC DYNEIN; KINESIN-II; CHEMOSENSORY NEURONS; TUBULIN SYNTHESIS; CILIARY; GENE	Cilia and flagella appear to be stable, terminal, microtubule-containing organelles, but they also elongate and shorten in response to a variety of signals. To understand mechanisms that regulate flagellar dynamics, Chlamydomonas cells with nongrowing flagella were labeled with S-35, and flagella and basal body components were examined for labeled polypeptides. Maximal incorporation of label into the flagella occurred within 3 h. Twenty percent of the flagellar polypeptides were exchanged. These included tubulins, dyneins, and 80 other axonemal and membrane plus matrix polypeptides. The most stable flagellar structure is the PF-ribbon, which comprises part of the wall of each doublet microtubule and is composed of tubulin and three other polypeptides. Most 35S was incorporated into the high molecular weight ribbon polypeptide, rib240, and little, if any, S-35 is incorporated into PF-ribbon-associated tubulin. Both wild-type (9 + 2) and 9 + 0 flagella, which lack central microtubules, exhibited nearly identical exchange patterns, so labeling is not due to turnover of relatively labile central microtubules. To determine if flagellar length is balanced by protein exchange, 35S incorporation into disassembling flagella was examined, as was exchange in flagella in which microtubule assembly was blocked by colchicine. Incorporation of S-35-Iabeled polypeptides was found to occur into flagellar axonemes during wavelength-dependent shortening in pf78 and in fla-10 cells induced to shorten flagella by incubation at 33 degreesC. Colchicine blocked tubulin addition but did not affect the exchange of the other exchangeable polypeptides; nor did it induce any change in flagellar length. Basal bodies also incorporated newly synthesized proteins. These data reveal that Chlamydomonas flagella are dynamic structures that incorporate new protein both during steady state and as flagella shorten and that protein exchange does not, alone, explain length regulation.	Univ Kansas, Dept Mol Biosci, Lawrence, KS 66045 USA	University of Kansas	Dentler, WL (corresponding author), Univ Kansas, Dept Mol Biosci, Lawrence, KS 66045 USA.	wdent@ukans.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032556] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Afzelius BA, 1999, INT J DEV BIOL, V43, P283; Asleson CM, 1998, GENETICS, V148, P693; BLOODGOOD RA, 1984, EXP CELL RES, V150, P488, DOI 10.1016/0014-4827(84)90594-9; BLOODGOOD RA, 1974, CYTOBIOS, V9, P143; Brown JM, 1999, MOL BIOL CELL, V10, P3081, DOI 10.1091/mbc.10.10.3081; Cleveland DW, 1989, CURR OPIN CELL BIOL, V1, P10, DOI 10.1016/S0955-0674(89)80030-4; Cole DG, 1998, J CELL BIOL, V141, P993, DOI 10.1083/jcb.141.4.993; DENTLER WL, 1987, INT REV CYTOL, P391; DENTLER WL, 1980, J CELL SCI, V42, P207; DENTLER WL, 1992, J CELL BIOL, V117, P1289, DOI 10.1083/jcb.117.6.1289; DENTLER WL, 1982, CELL MOTIL CYTOSKEL, V2, P549, DOI 10.1002/cm.970020605; DRENCKHAHN D, 1993, METHOD CELL BIOL, V37, P7, DOI 10.1016/S0091-679X(08)60242-3; GONZALEZSANTANDER R, 1976, ACTA ANAT, V95, P368, DOI 10.1159/000144626; GOROVSKY MA, 1970, ANAL BIOCHEM, V35, P359, DOI 10.1016/0003-2697(70)90196-X; GOULD RR, 1975, J CELL BIOL, V65, P65, DOI 10.1083/jcb.65.1.65; Harris EH, 1989, CHLAMYDOMONAS SOURCE, P25, DOI [DOI 10.1016/B978-0-12-326880-8.50007-9, DOI 10.1126/SCIENCE.246.4936.1503-A]; JOHNSON KA, 1992, J CELL BIOL, V119, P1605, DOI 10.1083/jcb.119.6.1605; KING SM, 1995, METHOD CELL BIOL, V47, P9, DOI 10.1016/S0091-679X(08)60783-9; KOZMINSKI KG, 1995, J CELL BIOL, V131, P1517, DOI 10.1083/jcb.131.6.1517; KOZMINSKI KG, 1993, P NATL ACAD SCI USA, V90, P5519, DOI 10.1073/pnas.90.12.5519; LEFEBVRE PA, 1986, ANNU REV CELL BIOL, V2, P517, DOI 10.1146/annurev.cb.02.110186.002505; LEFEBVRE PA, 1978, J CELL BIOL, V78, P8, DOI 10.1083/jcb.78.1.8; Margolis RL, 1998, BIOESSAYS, V20, P830, DOI 10.1002/(SICI)1521-1878(199810)20:10<830::AID-BIES8>3.0.CO;2-N; Marshall W, 1998, MOL BIOL CELL, V9, p278A; Marshall WF, 2000, MOL BIOL CELL, V11, p368A; Marszalek JR, 1999, P NATL ACAD SCI USA, V96, P5043, DOI 10.1073/pnas.96.9.5043; Morris RL, 1997, J CELL BIOL, V138, P1009, DOI 10.1083/jcb.138.5.1009; Murcia NS, 2000, DEVELOPMENT, V127, P2347; NAKAMURA S, 1987, CELL STRUCT FUNCT, V12, P369, DOI 10.1247/csf.12.369; NAKAO T, 1984, AM J ANAT, V170, P55, DOI 10.1002/aja.1001700105; NELSEN EM, 1975, EXP CELL RES, V94, P152, DOI 10.1016/0014-4827(75)90542-X; Nonaka S, 1998, CELL, V95, P829, DOI 10.1016/S0092-8674(00)81705-5; Norrander JM, 2000, MOL BIOL CELL, V11, P201, DOI 10.1091/mbc.11.1.201; Orozco JT, 1999, NATURE, V398, P674, DOI 10.1038/19448; Ostrowski LE, 1999, AM J RESP CELL MOL, V20, P675, DOI 10.1165/ajrcmb.20.4.3496; Pazour GJ, 1999, J CELL BIOL, V144, P473, DOI 10.1083/jcb.144.3.473; Pazour GJ, 1998, J CELL BIOL, V141, P979, DOI 10.1083/jcb.141.4.979; Piperno G, 1996, J CELL BIOL, V133, P371, DOI 10.1083/jcb.133.2.371; Piperno G, 1998, J CELL BIOL, V143, P1591, DOI 10.1083/jcb.143.6.1591; Porter ME, 1999, MOL BIOL CELL, V10, P693, DOI 10.1091/mbc.10.3.693; PORTMAN RW, 1987, J CELL SCI, V87, P85; REMILLARD SP, 1982, J CELL BIOL, V93, P615, DOI 10.1083/jcb.93.3.615; RIEDERERHENDERSON MA, 1979, DEV BIOL, V70, P500, DOI 10.1016/0012-1606(79)90041-1; ROSENBAU.JL, 1969, J CELL BIOL, V41, P600, DOI 10.1083/jcb.41.2.600; ROSENBAUM JL, 1967, J CELL BIOL, V34, P345, DOI 10.1083/jcb.34.1.345; SHAKIR MA, 1993, NEUROREPORT, V4, P891, DOI 10.1097/00001756-199307000-00013; Signor D, 1999, J CELL BIOL, V147, P519, DOI 10.1083/jcb.147.3.519; Smith EF, 1997, CELL MOTIL CYTOSKEL, V38, P1; SNELL WJ, 1986, METHOD ENZYMOL, V134, P252; STEPHENS RE, 1994, J EXP ZOOL, V269, P106, DOI 10.1002/jez.1402690204; STEPHENS RE, 1994, J CELL SCI, V107, P683; Stephens RE, 2000, CELL MOTIL CYTOSKEL, V47, P130, DOI 10.1002/1097-0169(200010)47:2<130::AID-CM4>3.0.CO;2-0; Stephens RE, 1997, MOL BIOL CELL, V8, P2187, DOI 10.1091/mbc.8.11.2187; STEPHENS RE, 1995, METHOD CELL BIOL, V47, P361, DOI 10.1016/S0091-679X(08)60830-4; SULIK K, 1994, DEV DYNAM, V201, P260, DOI 10.1002/aja.1002010309; TABISH M, 1995, J MOL BIOL, V247, P377, DOI 10.1006/jmbi.1994.0146; Tai AW, 1999, CELL, V97, P877, DOI 10.1016/S0092-8674(00)80800-4; Takeda S, 1999, J CELL BIOL, V145, P825, DOI 10.1083/jcb.145.4.825; Tuxhorn J, 1998, CELL MOTIL CYTOSKEL, V40, P133, DOI 10.1016/j.semcdb.2008.07.005; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; WALTHER Z, 1994, J CELL BIOL, V126, P175, DOI 10.1083/jcb.126.1.175; Wilson NF, 2000, MOL BIOL CELL, V11, p368A; WITMAN GB, 1972, J CELL BIOL, V54, P507, DOI 10.1083/jcb.54.3.507; WITMAN GB, 1975, ANN NY ACAD SCI, V253, P178, DOI 10.1111/j.1749-6632.1975.tb19199.x	64	64	65	0	19	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29754	29763		10.1074/jbc.M103184200	http://dx.doi.org/10.1074/jbc.M103184200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11384985	hybrid			2022-12-25	WOS:000170558000022
J	Okamoto, T; Akaike, T; Sawa, T; Miyamoto, Y; van der Vliet, A; Maeda, H				Okamoto, T; Akaike, T; Sawa, T; Miyamoto, Y; van der Vliet, A; Maeda, H			Activation of matrix metalloproteinases by peroxynitrite-induced protein S-glutathiolation via disulfide S-oxide formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; TYROSINE NITRATION; RESPIRATORY-TRACT; CYSTEINE SWITCH; URIC-ACID; OXIDATION; COLLAGENASE; SUPEROXIDE; THIOLS; EXPRESSION	Oxidative stress may cause tissue injury through activation of the precursors of matrix metalloproteinase (proMMPs). In this study, we observed glutathione (GSH)-dependent proMMP activation induced by peroxynitrite, a potent oxidizing agent formed during inflammatory processes. Peroxynitrite strongly activated all three types of purified human proMMPs (proMMP-1, -8, and -9) in the presence of similar concentrations of GSH. Of the potential reaction products between peroxynitrite and GSH, only S-nitroglutathione (GSNO(2)) caused proMMP activation. Extensive S-glutathiolation of the proMMP protein occurred during activation of proMMP by peroxynitrite and GSH, as shown by radiolabeling studies with [S-35]GSH or [H-3]GSH. Evidence of appreciable S-glutathiolation persisted even after dithiothreitol and protein-denaturing treatment, however, suggesting that some S-glutathiolation did not occur through formation of simple mixed disulfide. Matrix-assisted laser-desorption ionization-time-of-flight mass spectrometry indicated that not only peroxynitrite plus GSH but also synthetic GSNO(2) produced dithiothreitol-resistant S-glutathiolation of the synthetic peptide PRCGVPD, which is a well conserved Cys-containing sequence of the propeptide autoinhibitory domain of proMMPs. PRCGVPD S-glutathiolation is presumed to be formed through glutathione disulfide S-oxide (GS(O)SR), based on the m/z 1064. Our results illustrate a unique mechanism of oxidative proMMP activation and oxidative tissue injury during inflammation.	Kumamoto Univ, Sch Med, Dept Microbiol, Kumamoto 8600811, Japan; Univ Calif Davis, Sch Med, Dept Internal Med, Div Pulm Crit Care Med, Davis, CA 95616 USA	Kumamoto University; University of California System; University of California Davis	Akaike, T (corresponding author), Kumamoto Univ, Sch Med, Dept Microbiol, Kumamoto 8600811, Japan.							Akaike T, 2000, FREE RADICAL RES, V33, P461, DOI 10.1080/10715760000301001; Balazy M, 1998, J BIOL CHEM, V273, P32009, DOI 10.1074/jbc.273.48.32009; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; CAMERON DR, 1995, CAN J CHEM, V73, P1627, DOI 10.1139/v95-202; CANTIN AM, 1989, AM REV RESPIR DIS, V139, P370, DOI 10.1164/ajrccm/139.2.370; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Coddington JW, 1999, J AM CHEM SOC, V121, P2438, DOI 10.1021/ja982887t; Cotgreave IA, 1998, BIOCHEM BIOPH RES CO, V242, P1, DOI 10.1006/bbrc.1997.7812; Davis DA, 1996, BIOCHEMISTRY-US, V35, P2482, DOI 10.1021/bi951525k; Frears ER, 1996, FEBS LETT, V381, P21, DOI 10.1016/0014-5793(96)00065-8; Goldstein S, 2000, J BIOL CHEM, V275, P3031, DOI 10.1074/jbc.275.5.3031; Grant G A, 1992, Matrix Suppl, V1, P217; Griffith OW, 1999, FREE RADICAL BIO MED, V27, P922, DOI 10.1016/S0891-5849(99)00176-8; Hogg N, 1996, FEBS LETT, V382, P223, DOI 10.1016/0014-5793(96)00086-5; Ischiropoulos H, 1998, ARCH BIOCHEM BIOPHYS, V356, P1, DOI 10.1006/abbi.1998.0755; Karoui H, 1996, J BIOL CHEM, V271, P6000, DOI 10.1074/jbc.271.11.6000; Li JF, 2001, J BIOL CHEM, V276, P3098, DOI 10.1074/jbc.M008260200; MAINARDI CL, 1985, ANN NY ACAD SCI, V460, P345, DOI 10.1111/j.1749-6632.1985.tb51181.x; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MEISTER A, 1994, CANCER RES, V54, pS1969; Miyamoto Y, 2000, BIOCHEM BIOPH RES CO, V267, P918, DOI 10.1006/bbrc.1999.2046; NAGASE H, 1990, BIOCHEMISTRY-US, V29, P5783, DOI 10.1021/bi00476a020; Okamoto T, 1997, ARCH BIOCHEM BIOPHYS, V342, P261, DOI 10.1006/abbi.1997.0127; Okamoto T, 1997, J BIOL CHEM, V272, P6059, DOI 10.1074/jbc.272.9.6059; PACHT ER, 1991, CHEST, V100, P1397, DOI 10.1378/chest.100.5.1397; RADI R, 1991, J BIOL CHEM, V266, P4244; Rahman I, 2000, FREE RADICAL BIO MED, V28, P1405, DOI 10.1016/S0891-5849(00)00215-X; Reddy S, 2000, BIOCHEM J, V347, P821, DOI 10.1042/0264-6021:3470821; Reiter CD, 2000, J BIOL CHEM, V275, P32460, DOI 10.1074/jbc.M910433199; RIES C, 1995, BIOL CHEM H-S, V376, P345; SALO T, 1991, J BIOL CHEM, V266, P11436; SALO T, 1994, LAB INVEST, V70, P176; Sawa T, 2000, J BIOL CHEM, V275, P32467, DOI 10.1074/jbc.M910169199; Sies H, 1999, FREE RADICAL BIO MED, V27, P916, DOI 10.1016/S0891-5849(99)00177-X; Sies H, 1997, J BIOL CHEM, V272, P27812, DOI 10.1074/jbc.272.44.27812; Silvester JA, 1998, FREE RADICAL BIO MED, V24, P754, DOI 10.1016/S0891-5849(97)00327-4; Skinner KA, 1998, J BIOL CHEM, V273, P24491, DOI 10.1074/jbc.273.38.24491; SORSA T, 1994, ANN NY ACAD SCI, V732, P112, DOI 10.1111/j.1749-6632.1994.tb24729.x; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; Squadrito GL, 2000, ARCH BIOCHEM BIOPHYS, V376, P333, DOI 10.1006/abbi.2000.1721; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; Suga M, 2000, AM J RESP CRIT CARE, V162, P1949, DOI 10.1164/ajrccm.162.5.9906096; THOMAS JA, 1995, ARCH BIOCHEM BIOPHYS, V319, P1, DOI 10.1006/abbi.1995.1261; TSCHESCHE H, 1981, EUR J BIOCHEM, V120, P183, DOI 10.1111/j.1432-1033.1981.tb05687.x; van der Vliet A, 1999, AM J PHYSIOL-LUNG C, V276, pL289, DOI 10.1152/ajplung.1999.276.2.L289; van der Vliet A, 1998, J BIOL CHEM, V273, P30255, DOI 10.1074/jbc.273.46.30255; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; Viner RI, 1999, BIOCHEMISTRY-US, V38, P12408, DOI 10.1021/bi9909445; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WEISS SJ, 1985, SCIENCE, V227, P747, DOI 10.1126/science.2982211; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; Wu J, 2001, JPN J CANCER RES, V92, P439, DOI 10.1111/j.1349-7006.2001.tb01114.x; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	54	349	356	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29596	29602		10.1074/jbc.M102417200	http://dx.doi.org/10.1074/jbc.M102417200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11395496	hybrid			2022-12-25	WOS:000170346000126
J	Soriano, S; Lu, DC; Chandra, S; Pietrzik, CU; Koo, EH				Soriano, S; Lu, DC; Chandra, S; Pietrzik, CU; Koo, EH			The amyloidogenic pathway of amyloid precursor protein (APP) is independent of its cleavage by caspases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA PEPTIDE FORMATION; ALZHEIMERS-DISEASE; APOPTOSIS; DOMAIN; INVOLVEMENT; ENDOCYTOSIS; SECRETION; FRAGMENT; NEURONS; CELLS	Amyloid beta -protein (A beta) is the main constituent of senile plaques in Alzheimer's disease and is derived by proteolysis from the amyloid precursor protein (APP). Generation and secretion of both A beta 40 and A beta 42 isoforms depend largely on internalization of APP and occurs mainly in the endocytic pathway. Evidence has also been presented (Gervais, F. G., Xu, D., Robertson, G. S., Vaillancourt, J. P., Zhu, Y., Huang, J., LeBlanc, A., Smith, D., Rigby, M., Shearman, M. S., Clarke, E. E., Zheng, H., Van der Ploeg, L. H. T., Ruffolo, S. C., Thornberry, N. A., Xanthoudakis, S., Zamboni, R. J., Roy, S., and Nicholson, D. W. (1999) Cell, 97, 395-406) that caspase cleavage of APP at its cytosolic tail affects its processing such that it is redirected to a more amyloidogenic pathway, resulting in enhanced A beta generation. However, caspase cleavage of APP,also results in loss of its endocytosis signal (YENP), an event that would predict a decline in internalization and a concomitant decrease, not an increase, in A beta generation. In the present work, we examined whether caspase cleavage of APP is relevant to amyloidogenesis. We found that 1) caspase cleavage of APP results in reduced internalization and, accordingly, a decline in A beta secretion; 2) masking of the caspase site in APP did not affect A beta levels and, 3) caspase activation in cells by serum withdrawal did not increase A beta secretion. Thus, caspase cleavage of APP is unlikely to play a direct role in amyloidogenesis.	Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Soriano, S (corresponding author), Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA.				NIA NIH HHS [AG12376, AG05131] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG012376] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Barnes NY, 1998, J NEUROSCI, V18, P5869; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; Desdouits F, 1996, J BIOL CHEM, V271, P24670, DOI 10.1074/jbc.271.40.24670; Galli C, 1998, P NATL ACAD SCI USA, V95, P1247, DOI 10.1073/pnas.95.3.1247; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; HAASS C, 1993, J BIOL CHEM, V268, P3021; Koo EH, 1996, J CELL SCI, V109, P991; KOO EH, 1994, J BIOL CHEM, V269, P17386; LeBlanc A, 1995, J NEUROSCI, V15, P7837; LeBlanc A, 1999, J BIOL CHEM, V274, P23426, DOI 10.1074/jbc.274.33.23426; LEBLANC AC, 1994, BIOCHEM BIOPH RES CO, V204, P1371, DOI 10.1006/bbrc.1994.2615; Lee JP, 2000, J NEUROSCI RES, V60, P565, DOI 10.1002/(SICI)1097-4547(20000515)60:4<565::AID-JNR16>3.0.CO;2-I; Lu DC, 2000, NAT MED, V6, P397, DOI 10.1038/74656; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; Passer Brent, 2000, Journal of Alzheimer's Disease, V2, P289; Pellegrini L, 1999, J BIOL CHEM, V274, P21011, DOI 10.1074/jbc.274.30.21011; Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Tanzi RE, 1999, NAT NEUROSCI, V2, P585, DOI 10.1038/10133; Weidemann A, 1999, J BIOL CHEM, V274, P5823, DOI 10.1074/jbc.274.9.5823	20	55	55	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29045	29050		10.1074/jbc.M102456200	http://dx.doi.org/10.1074/jbc.M102456200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11397796	hybrid			2022-12-25	WOS:000170346000056
J	Wang, GF; Nikovits, W; Bao, ZZ; Stockdale, FE				Wang, GF; Nikovits, W; Bao, ZZ; Stockdale, FE			Irx4 forms an inhibitory complex with the vitamin D and retinoic X receptors to regulate cardiac chamber-specific slow MyHC3 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN HEAVY-CHAIN; NATRIURETIC-FACTOR GENE; HEART TUBE; SKELETAL-MUSCLE; ANTEROPOSTERIOR POLARITY; TRANSGENIC MICE; PROTEIN; NKX2-5; ACID; DNA	The slow myosin heavy chain 3 gene (slow MyHC3) is restricted in its expression to the atrial chambers of the heart. Understanding its regulation provides a basis for determination of the mechanisms controlling chamber-specific gene expression in heart development. The observed chamber distribution results from repression of slow MyHC3 gene expression in the ventricles. A binding site, the vitamin D response element (VDRE), for a heterodimer of vitamin D receptor (VDR) and retinoic X receptor alpha (RXR alpha) within the slow MyHC3 promoter mediates chamber-specific expression of the gene. Irx4, an Iroquois family homeobox gene whose expression is restricted to the ventricular chambers at all stages of development, inhibits AMHC1, the chick homolog of quail slow MyHC3, gene expression within developing ventricles. Repression of the slow MyHC3 gene in ventricular cardiomyocytes by Irx4 requires the VDRE. Unlike VDR and RXR alpha, Irx4 does not bind directly to the VDRE. Instead two-hybrid and co-immunoprecipitation assays show that Irx4 interacts with the RXR alpha component of the VDR/RXR alpha heterodimer and that the amino terminus of the Irx4 protein is required for its inhibitory action. These observations indicate that the mechanism of atrial chamber-specific expression requires the formation of an inhibitory protein complex composed of VDR, RXR alpha, and Irx4 that binds at the VDRE inhibiting slow MyHC3 expression in the ventricles.	Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA; Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01605 USA	Stanford University; University of Massachusetts System; University of Massachusetts Worcester	Stockdale, FE (corresponding author), Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA.	mlfes@stanford.edu						Bao ZZ, 1999, SCIENCE, V283, P1161, DOI 10.1126/science.283.5405.1161; BISAHA JG, 1991, DEV BIOL, V148, P355, DOI 10.1016/0012-1606(91)90343-2; Bruneau BG, 1999, DEV BIOL, V211, P100, DOI 10.1006/dbio.1999.9298; Bruneau BG, 2000, DEV BIOL, V217, P266, DOI 10.1006/dbio.1999.9548; Bruneau BG, 2001, MOL CELL BIOL, V21, P1730, DOI 10.1128/MCB.21.5.1730-1736.2001; CHEN CY, 1995, J BIOL CHEM, V270, P15628, DOI 10.1074/jbc.270.26.15628; Durocher D, 1996, MOL CELL BIOL, V16, P4648, DOI 10.1128/mcb.16.9.4648; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; ELION EA, 1999, CURRENT PROTOCOLS MO, V4; EVANS D, 1988, DEV BIOL, V127, P376, DOI 10.1016/0012-1606(88)90324-7; Fishman MC, 1997, DEVELOPMENT, V124, P2099; GomezSkarmeta JL, 1996, CELL, V85, P95, DOI 10.1016/S0092-8674(00)81085-5; IZUMO S, 1986, SCIENCE, V231, P597, DOI 10.1126/science.3945800; KELLY R, 1995, J CELL BIOL, V129, P383, DOI 10.1083/jcb.129.2.383; KUBALAK SW, 1994, J BIOL CHEM, V269, P16961; LEE KJ, 1994, MOL CELL BIOL, V14, P1220, DOI 10.1128/MCB.14.2.1220; Lee Y, 1998, MOL CELL BIOL, V18, P3120, DOI 10.1128/MCB.18.6.3120; Lee Y, 2000, CIRC RES, V86, P932, DOI 10.1161/01.RES.86.9.932; Li XL, 1999, EMBO J, V18, P198, DOI 10.1093/emboj/18.1.198; Liberatore CM, 2000, DEV BIOL, V223, P169, DOI 10.1006/dbio.2000.9748; Lin NUT, 1996, J CLIN ENDOCR METAB, V81, P2564, DOI 10.1210/jc.81.7.2564; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; MAHDAVI V, 1984, P NATL ACAD SCI-BIOL, V81, P2626, DOI 10.1073/pnas.81.9.2626; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Morin S, 2000, EMBO J, V19, P2046, DOI 10.1093/emboj/19.9.2046; Nikovits W, 1996, J BIOL CHEM, V271, P17047, DOI 10.1074/jbc.271.29.17047; Oana S, 1998, BIOL CELL, V90, P605; OBRIEN TX, 1993, P NATL ACAD SCI USA, V90, P5157, DOI 10.1073/pnas.90.11.5157; Passner JM, 1999, NATURE, V397, P714, DOI 10.1038/17833; Piper DE, 1999, CELL, V96, P587, DOI 10.1016/S0092-8674(00)80662-5; STAINIER DYR, 1992, DEV BIOL, V153, P91, DOI 10.1016/0012-1606(92)90094-W; SUBRAMANIAM A, 1993, J BIOL CHEM, V268, P4331; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; Tanaka M, 1999, DEVELOPMENT, V126, P1269; Thomas T, 1998, DEV BIOL, V196, P228, DOI 10.1006/dbio.1998.8849; Wang GF, 1998, MOL CELL BIOL, V18, P6023, DOI 10.1128/MCB.18.10.6023; Wang GF, 1996, J BIOL CHEM, V271, P19836, DOI 10.1074/jbc.271.33.19836; WANG GF, 1999, HEART DEV, P357; Xavier-Neto J, 1999, DEVELOPMENT, V126, P2677; Yelon D, 1999, DEV BIOL, V214, P23, DOI 10.1006/dbio.1999.9406; Yu Y, 1997, NATURE, V385, P552, DOI 10.1038/385552a0; YUTZEY KE, 1995, CIRC RES, V77, P216, DOI 10.1161/01.RES.77.2.216; YUTZEY KE, 1994, DEVELOPMENT, V120, P871; ZELLER R, 1987, GENE DEV, V1, P693, DOI 10.1101/gad.1.7.693; Zou YM, 1997, DEVELOPMENT, V124, P793; ZOU YM, 1995, MOL CELL BIOL, V15, P2972	47	54	56	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28835	28841		10.1074/jbc.M103716200	http://dx.doi.org/10.1074/jbc.M103716200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11382777	hybrid			2022-12-25	WOS:000170346000028
J	Kusanagi, K; Kawabata, M; Mishima, HK; Miyazono, K				Kusanagi, K; Kawabata, M; Mishima, HK; Miyazono, K			alpha-Helix 2 in the amino-terminal mad homology 1 domain is responsible for specific DNA binding of Smad3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; TUMOR SUPPRESSORS SMAD2; MH1 DOMAIN; PROMOTER; PROTEINS; TRANSCRIPTION; MUTATIONS; ELEMENT; ACTIVATION; RECEPTORS	Smads, signal transducers of the transforming growth factor-beta (TGF-beta) superfamily proteins, directly bind to DNA and regulate transcription of target genes. Smad3 binds to CAGA box, whereas Smad1 and Smad5 preferentially bind to GC-rich sequences. The beta -hairpin loop in the amino-terminal Mad homology 1 (MH1) domain is the direct DNA-binding site of Smad3; however, the amino acid sequences of the beta -hairpin loop of Smad3 and Smad1/5 are identical, suggesting that other regions may be responsible for the differential DNA binding of Smad3 and Smad1/5. To identify regions other than the beta -hairpin loop responsible for specific DNA binding of Smad3, we generated chimeras containing various regions of Smad3 and Smad1. Luciferase assays using a TGF-beta -responsive reporter (CAGA)(9)-MLP-Luc and gel-mobility shift assays using 3xCAGA as a probe revealed that alpha -helix 2 (H2) in the amino-terminal part of the MH1 domain plays an important role in specific DNA binding and transcriptional activation of Smad3. Luciferase assays using natural TGF-beta -responsive reporters also revealed the functional importance of H2 in the Smad3 AMI domain in direct DNA binding. Smad3 thus binds to DNA directly through the beta -hairpin loop, and H2 supports specific DNA binding of Smad3.	Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Toshima Ku, Tokyo 1708455, Japan; Hiroshima Univ, Sch Med, Dept Ophthalmol, Minami Ku, Hiroshima 7348551, Japan; Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Bunkyo Ku, Tokyo 1130033, Japan	Japanese Foundation for Cancer Research; Hiroshima University; University of Tokyo	Miyazono, K (corresponding author), Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Toshima Ku, 1-37-1 Kami Ikebukuro, Tokyo 1708455, Japan.	miyazono-ind@umin.ac.jp						ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Chacko BM, 2001, NAT STRUCT BIOL, V8, P248, DOI 10.1038/84995; Daluiski A, 2001, NAT GENET, V27, P84, DOI 10.1038/83810; Das P, 1999, GENES CELLS, V4, P123, DOI 10.1046/j.1365-2443.1999.00244.x; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dennler S, 1999, ONCOGENE, V18, P1643, DOI 10.1038/sj.onc.1202729; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Goldman LA, 1996, BIOTECHNIQUES, V21, P1013; Gouedard L, 2000, J BIOL CHEM, V275, P27973; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Ishida W, 2000, J BIOL CHEM, V275, P6075, DOI 10.1074/jbc.275.9.6075; Jones JB, 2000, NUCLEIC ACIDS RES, V28, P2363, DOI 10.1093/nar/28.12.2363; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kaestner KH, 2000, GENE DEV, V14, P142; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Kirkpatrick H, 2001, J BIOL CHEM, V276, P18216, DOI 10.1074/jbc.M101365200; Kurisaki A, 2001, MOL BIOL CELL, V12, P1079, DOI 10.1091/mbc.12.4.1079; Kusanagi K, 2000, MOL BIOL CELL, V11, P555, DOI 10.1091/mbc.11.2.555; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Lo RS, 1998, EMBO J, V17, P996, DOI 10.1093/emboj/17.4.996; Marquez RM, 2001, GENETICS, V157, P1639; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Miyazono K, 2001, J CELL PHYSIOL, V187, P265, DOI 10.1002/jcp.1080; Moren A, 2000, ONCOGENE, V19, P4396, DOI 10.1038/sj.onc.1203798; Nagarajan RP, 2000, BIOCHEM J, V350, P253, DOI 10.1042/0264-6021:3500253; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; Reddi AH, 1998, NAT BIOTECHNOL, V16, P247, DOI 10.1038/nbt0398-247; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Tang SJ, 1998, DEVELOPMENT, V125, P1877; Wu JW, 2001, J BIOL CHEM, V276, P20688, DOI 10.1074/jbc.M100174200; Xiao Z, 2000, P NATL ACAD SCI USA, V97, P7853, DOI 10.1073/pnas.97.14.7853; Xu J, 2000, P NATL ACAD SCI USA, V97, P4820, DOI 10.1073/pnas.97.9.4820; Xu X, 1998, GENE DEV, V12, P2354, DOI 10.1101/gad.12.15.2354; Yagi K, 1999, J BIOL CHEM, V274, P703, DOI 10.1074/jbc.274.2.703; Yakmovych I, 2001, FASEB J, V15, P553; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	45	19	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28155	28163		10.1074/jbc.M103371200	http://dx.doi.org/10.1074/jbc.M103371200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11382774	hybrid			2022-12-25	WOS:000170093400056
J	Morisco, C; Seta, K; Hardt, SE; Lee, Y; Vatner, SF; Sadoshima, J				Morisco, C; Seta, K; Hardt, SE; Lee, Y; Vatner, SF; Sadoshima, J			Glycogen synthase kinase 3 beta regulates GATA4 in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-4; HEAVY-CHAIN GENE; NUCLEAR EXPORT; PROTEIN-KINASE; ALPHA(1)-ADRENERGIC AGONIST; MOLECULAR CHARACTERIZATION; RESPONSIVE TRANSCRIPTION; COVALENT MODIFICATION; IN-VITRO; HYPERTROPHY	Inactivation of glycogen synthase kinase 3 beta (GSK3 beta) is critical for transcription of atrial natriuretic factor (ANF) by beta -adrenergic receptors in cardiac myocytes. We examined the mechanism by which GSK3 beta regulates ANF transcription. Stimulation of beta -adrenergic receptors induced nuclear accumulation of GATA4, whereas beta -adrenergic ANF transcription was suppressed by dominant negative GATA4, suggesting that GATA4 plays an important role in beta -adrenergic ANF transcription. Interestingly, GATA4-mediated transcription was markedly attenuated by GSK3 beta. GSK3 beta physically associates with GATA4 and phosphorylates GATA4 in vitro. Overexpression of GSK3 beta suppressed both basal and beta -adrenergic increases in nuclear expression of GATA4, whereas inhibition of GSK3 beta by LiCl caused nuclear accumulation of GATA4, suggesting that GSK3 beta negatively regulates nuclear expression of GATA4. The nuclear exportin Crm1 reduced nuclear expression of GATA4, and the reduction was enhanced by GSK3 beta but not by kinase-inactive GSK3 beta. Leptomycin B, an inhibitor for Crm1, increased basal nuclear GATA4 and suppressed GSK3 beta -induced decreases in nuclear GATA4. These results suggest that GSK3 beta negatively regulates nuclear expression of GATA4 by stimulating Crm1-dependent nuclear export. Inhibition of GSK3 beta by beta -adrenergic stimulation abrogates GSK3 beta -induced nuclear export of GATA4, causing nuclear accumulation of GATA4, which may represent an important signaling mechanism mediating cardiac hypertrophy.	Univ Med & Dent New Jersey, New Jersey Med Sch, Inst Cardiovasc Res, Newark, NJ 07103 USA; Hackensack Univ, Med Ctr, Hackensack, NJ 07601 USA; Univ Wisconsin, Sch Med, Dept Anat, Madison, WI 53706 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Hackensack University Medical Center; University of Wisconsin System; University of Wisconsin Madison	Sadoshima, J (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Inst Cardiovasc Res, 185 S Orange Ave,MSB,Rm I-574, Newark, NJ 07103 USA.	sadoshju@umdnj.edu		Sadoshima, Junichi/0000-0003-3724-4132; MORISCO, Carmine/0000-0002-2158-6317				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Aoki H, 2000, BIOCHEM J, V347, P275, DOI 10.1042/0264-6021:3470275; Aoki H, 1998, CIRC RES, V82, P666, DOI 10.1161/01.RES.82.6.666; ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Charron F, 1999, MOL CELL BIOL, V19, P4355; Cheng GM, 1999, J BIOL CHEM, V274, P12819, DOI 10.1074/jbc.274.18.12819; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; CROSSLEY M, 1994, J BIOL CHEM, V269, P16589; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; FIOL CJ, 1987, J BIOL CHEM, V262, P14042; FIOL CJ, 1994, J BIOL CHEM, V269, P32187; Ginger RS, 2000, EMBO J, V19, P5483, DOI 10.1093/emboj/19.20.5483; GREPIN C, 1994, MOL CELL BIOL, V14, P3115, DOI 10.1128/MCB.14.5.3115; Haq S, 2000, J CELL BIOL, V151, P117, DOI 10.1083/jcb.151.1.117; Hasegawa K, 1997, CIRCULATION, V96, P3943; Herzig TC, 1997, P NATL ACAD SCI USA, V94, P7543, DOI 10.1073/pnas.94.14.7543; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; Hunter JJ, 1999, NEW ENGL J MED, V341, P1276, DOI 10.1056/NEJM199910213411706; IP HS, 1994, MOL CELL BIOL, V14, P7517, DOI 10.1128/MCB.14.11.7517; ITO H, 1991, CIRC RES, V69, P209, DOI 10.1161/01.RES.69.1.209; IWAKI K, 1990, J BIOL CHEM, V265, P13809; KARIYA K, 1994, J BIOL CHEM, V269, P3775; KELLEY C, 1993, DEVELOPMENT, V118, P817; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Kumagai A, 1999, GENE DEV, V13, P1067, DOI 10.1101/gad.13.9.1067; Kunisada K, 1998, CIRCULATION, V98, P346, DOI 10.1161/01.CIR.98.4.346; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; Lee Y, 1998, MOL CELL BIOL, V18, P3120, DOI 10.1128/MCB.18.6.3120; Lien CL, 1999, DEVELOPMENT, V126, P75; Lu JR, 1999, MOL CELL BIOL, V19, P4495; Malhotra R, 1999, CIRC RES, V85, P137, DOI 10.1161/01.RES.85.2.137; Mann DL, 1999, CIRCULATION, V100, P999, DOI 10.1161/01.CIR.100.9.999; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Molkentin JD, 1997, CIRCULATION, V96, P3833; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P4947, DOI 10.1128/MCB.14.7.4947; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Morimoto T, 1999, J BIOL CHEM, V274, P12811, DOI 10.1074/jbc.274.18.12811; Morimoto T, 2000, J BIOL CHEM, V275, P13721, DOI 10.1074/jbc.275.18.13721; Morin S, 2000, EMBO J, V19, P2046, DOI 10.1093/emboj/19.9.2046; Morisco C, 2000, J BIOL CHEM, V275, P14466, DOI 10.1074/jbc.275.19.14466; Morisco C, 2001, J MOL CELL CARDIOL, V33, P561, DOI 10.1006/jmcc.2000.1332; Morrisey EE, 1997, J BIOL CHEM, V272, P8515, DOI 10.1074/jbc.272.13.8515; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; Olson EN, 1999, CIRC RES, V84, P623, DOI 10.1161/01.RES.84.6.623; Reecy JM, 1999, DEVELOPMENT, V126, P839; Sadoshima J, 1997, ANNU REV PHYSIOL, V59, P551, DOI 10.1146/annurev.physiol.59.1.551; SADOSHIMA J, 1992, J BIOL CHEM, V267, P10551; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shiojima I, 1999, J BIOL CHEM, V274, P8231, DOI 10.1074/jbc.274.12.8231; SPRENKLE AB, 1995, CIRC RES, V77, P1060, DOI 10.1161/01.RES.77.6.1060; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Sugden PH, 1999, CIRC RES, V84, P633, DOI 10.1161/01.RES.84.6.633; Svensson EC, 1999, P NATL ACAD SCI USA, V96, P956, DOI 10.1073/pnas.96.3.956; Takeda K, 2000, HUM MOL GENET, V9, P125, DOI 10.1093/hmg/9.1.125; TOWATARI M, 1995, J BIOL CHEM, V270, P4101, DOI 10.1074/jbc.270.8.4101; Ullman KS, 1997, CELL, V90, P967, DOI 10.1016/S0092-8674(00)80361-X; Xia Y, 2000, J BIOL CHEM, V275, P1855, DOI 10.1074/jbc.275.3.1855	66	174	183	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28586	28597		10.1074/jbc.M103166200	http://dx.doi.org/10.1074/jbc.M103166200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11382772	hybrid			2022-12-25	WOS:000170093400112
J	Norris, RA; Kern, MJ				Norris, RA; Kern, MJ			The identification of Prx1 transcription regulatory domains provides a mechanism for unequal compensation by the Prx1 and Prx2 loci	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; SERUM RESPONSE FACTOR; DNA-BINDING ACTIVITY; HOMEOBOX GENE; HOMEODOMAIN PROTEIN; DROSOPHILA; EXPRESSION; ACTIVATION; HOX; SKELETOGENESIS	Transcription regulatory domains of the Prx1a and Prx1b homeoproteins were analyzed in transient transfection assays using artificial promoters as well as an established downstream target promoter (tenascin-c), Activation and repression domains were detected in their common amino end. In the carboxyl end of Prx1a an activation domain and an inhibition/masking region (OAR domain) were detected. The Prx1b isoform, generated by alternative splicing, does not contain these carboxyl activation or inhibition domains. Instead, the data demonstrate that the carboxyl tail of Prx1b contains a potent repressor region. This difference in the carboxyl tail accounts for a 45-fold difference observed in transcription regulatory activity between Prx1a and Prx1b, The data also support the likelihood that this difference between Prx1a and Prx1b is higher in the presence of still undetermined cofactors, DNA binding affinities of Prx1a, Prx1b, and a series of truncation mutants were also examined. The carboxyl tail of Prx1a, which inhibited transcription activation in the transfection assays, also inhibited DNA binding, These differences in biochemical function between Prx1a and Prx1b, as well as the recently described activities of Prx2, provide a mechanism for the unequal compensation between the Prx1 and Prx2 loci.	Med Univ S Carolina, Dept Anat & Cell Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Kern, MJ (corresponding author), Med Univ S Carolina, Dept Anat & Cell Biol, 171 Ashley Ave, Charleston, SC 29425 USA.				NHLBI NIH HHS [HL-56596] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056596] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amendt BA, 1999, MOL CELL BIOL, V19, P7001; ANANTHAN J, 1993, MOL CELL BIOL, V13, P1599, DOI 10.1128/MCB.13.3.1599; Bergwerff M, 2000, VIRCHOWS ARCH, V436, P12, DOI 10.1007/PL00008193; Catron KM, 1996, MECH DEVELOP, V55, P185, DOI 10.1016/0925-4773(96)00503-5; CATRON KM, 1995, MOL CELL BIOL, V15, P861; CSERJESI P, 1992, DEVELOPMENT, V115, P1087; DEJONG R, 1993, NUCLEIC ACIDS RES, V21, P4711, DOI 10.1093/nar/21.20.4711; Dorfler P, 1996, EMBO J, V15, P1971, DOI 10.1002/j.1460-2075.1996.tb00548.x; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; FITZPATRICK VD, 1992, NATURE, V356, P610, DOI 10.1038/356610a0; Galliot B, 1999, DEV GENES EVOL, V209, P186, DOI 10.1007/s004270050243; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GRUENEBERG DA, 1995, MOL CELL BIOL, V15, P3318; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; Grueneberg DA, 1997, GENE DEV, V11, P2482, DOI 10.1101/gad.11.19.2482; Guichet A, 1997, NATURE, V385, P548, DOI 10.1038/385548a0; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; JAYARAMAN PS, 1994, EMBO J, V13, P2192, DOI 10.1002/j.1460-2075.1994.tb06496.x; Jones FS, 2000, DEV DYNAM, V218, P235, DOI 10.1002/(SICI)1097-0177(200006)218:2<235::AID-DVDY2>3.3.CO;2-7; Kataoka K, 2001, J BIOL CHEM, V276, P819, DOI 10.1074/jbc.M007643200; KERN MJ, 1992, NUCLEIC ACIDS RES, V20, P5189, DOI 10.1093/nar/20.19.5189; KERN MJ, 1994, GENOMICS, V19, P334, DOI 10.1006/geno.1994.1066; KONGSUWAN K, 1988, EMBO J, V7, P2131, DOI 10.1002/j.1460-2075.1988.tb03052.x; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; KURATANI S, 1994, DEV BIOL, V161, P357, DOI 10.1006/dbio.1994.1037; LEUSSINK B, 1995, MECH DEVELOP, V52, P51, DOI 10.1016/0925-4773(95)00389-I; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; Lu MF, 1999, DEV BIOL, V205, P145, DOI 10.1006/dbio.1998.9116; Lu MF, 1999, DEVELOPMENT, V126, P495; Lu Q, 1996, MOL CELL BIOL, V16, P1632; MADDEN SL, 1993, ONCOGENE, V8, P1713; MARTIN JF, 1995, GENE DEV, V9, P1237, DOI 10.1101/gad.9.10.1237; NOHNO T, 1993, DEV BIOL, V158, P254, DOI 10.1006/dbio.1993.1184; Norris RA, 2000, MAMM GENOME, V11, P1000, DOI 10.1007/s003350010193; Okubo Y, 1999, BIOCHEM BIOPH RES CO, V262, P739, DOI 10.1006/bbrc.1999.1281; OPSTELTEN DJE, 1991, MECH DEVELOP, V34, P29, DOI 10.1016/0925-4773(91)90089-O; Pai SR, 1997, ANTICANCER RES, V17, P3265; Peltenburg LTC, 1997, DEVELOPMENT, V124, P1089; PHELAN ML, 1995, MOL CELL BIOL, V15, P3989; Qu SM, 1999, DEVELOPMENT, V126, P359; SIMEONE A, 1994, NEURON, V13, P83, DOI 10.1016/0896-6273(94)90461-8; ten Berge D, 1998, DEVELOPMENT, V125, P3831; Yu Y, 1997, NATURE, V385, P552, DOI 10.1038/385552a0; ZAPPAVIGNA V, 1994, GENE DEV, V8, P732, DOI 10.1101/gad.8.6.732	45	51	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26829	26837		10.1074/jbc.M100239200	http://dx.doi.org/10.1074/jbc.M100239200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11373278	hybrid			2022-12-25	WOS:000169966900015
J	Tan, I; Ng, CH; Lim, L; Leung, T				Tan, I; Ng, CH; Lim, L; Leung, T			Phosphorylation of a novel myosin binding subunit of protein phosphatase 1 reveals a conserved mechanism in the regulation of actin cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-ASSOCIATED KINASE; CDC42-BINDING KINASE; FOCAL ADHESIONS; MUSCLE; SITE; ALPHA; ASSOCIATION; FILAMENTS; GTPASES; REORGANIZATION	The myotonic dystrophy kinase-related kinases RhoA binding kinase and myotonic dystrophy kinase-related Cdc42 binding kinase (MRCK) are effecters of RhoA and Cdc42, respectively, for actin reorganization, Using substrate screening in various tissues, we uncovered two major substrates, p130 and p85, for MRCK alpha -kinase, p130 is identified as myosin binding subunit p130, whereas p85 is a novel related protein. p85 contains N-terminal ankyrin repeats, an a-helical C terminus with leucine repeats, and a centrally located conserved motif with the MRCK alpha -kinase phosphorylation site. Like MBS130, p85 is specifically associated with protein phosphatase 1 delta (PP1 delta), and this requires the N terminus, including the ankyrin repeats. This association is required for the regulation of both the catalytic activities and the assembly of actin cytoskeleton, The N terminus, in association with PP1 delta, is essential for actin depolymerization, whereas the C terminus antagonizes this action. The C-terminal effects consist of two independent events that involved both the conserved phosphorylation inhibitory motif and the a-helical leucine repeats. The former was able to interact with PP1 delta only in the phosphorylated state and result in inactivation of PP1 delta activity, This provides further evidence that phosphorylation of a myosin binding subunit protein by specific kinases confers conformational changes in a highly conserved region that plays an essential role in the regulation of its catalytic subunit activities.	Glaxo IMCB Grp, Inst Mol & Cell Biol, Singapore 117609, Singapore; UCL, Neurol Inst, London WC1N 1PJ, England	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); GlaxoSmithKline; University of London; University College London	Leung, T (corresponding author), Glaxo IMCB Grp, Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.	mcbthoml@imcb.nus.edu.sg		Ng, Chong Han/0000-0003-2926-9831				Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Chen XQ, 1999, J BIOL CHEM, V274, P19901, DOI 10.1074/jbc.274.28.19901; CHEN YH, 1994, FEBS LETT, V356, P51, DOI 10.1016/0014-5793(94)01231-8; Dutheil N, 2000, P NATL ACAD SCI USA, V97, P4862, DOI 10.1073/pnas.080079397; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Feng JH, 1999, J BIOL CHEM, V274, P37385, DOI 10.1074/jbc.274.52.37385; Fukata Y, 1998, J CELL BIOL, V141, P409, DOI 10.1083/jcb.141.2.409; Goto H, 1998, J BIOL CHEM, V273, P11728, DOI 10.1074/jbc.273.19.11728; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hartshorne DJ, 1999, MOL CELL BIOCHEM, V190, P79, DOI 10.1023/A:1006917032557; Ichikawa K, 1996, BIOCHEMISTRY-US, V35, P6313, DOI 10.1021/bi960208q; Inada H, 1999, J BIOL CHEM, V274, P34932, DOI 10.1074/jbc.274.49.34932; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Johnson D, 1997, EUR J BIOCHEM, V244, P931, DOI 10.1111/j.1432-1033.1997.00931.x; Kawano Y, 1999, J CELL BIOL, V147, P1023, DOI 10.1083/jcb.147.5.1023; Kimura K, 1998, J BIOL CHEM, V273, P5542, DOI 10.1074/jbc.273.10.5542; Kosako H, 1999, ONCOGENE, V18, P2783, DOI 10.1038/sj.onc.1202633; KOTIN RM, 1992, EMBO J, V11, P5071, DOI 10.1002/j.1460-2075.1992.tb05614.x; Kureishi Y, 1997, J BIOL CHEM, V272, P12257, DOI 10.1074/jbc.272.19.12257; Leung T, 1996, MOL CELL BIOL, V16, P5313; Leung T, 1998, MOL CELL BIOL, V18, P130, DOI 10.1128/MCB.18.1.130; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Moorhead G, 1998, FEBS LETT, V438, P141, DOI 10.1016/S0014-5793(98)01276-9; Recchia A, 1999, P NATL ACAD SCI USA, V96, P2615, DOI 10.1073/pnas.96.6.2615; SHIMIZU H, 1994, J BIOL CHEM, V269, P30407; Sin WC, 1998, MOL CELL BIOL, V18, P6325, DOI 10.1128/MCB.18.11.6325; Surks HK, 1999, SCIENCE, V286, P1583, DOI 10.1126/science.286.5444.1583; Totsukawa G, 1999, J CELL BIOL, V144, P735, DOI 10.1083/jcb.144.4.735; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	32	119	130	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21209	21216		10.1074/jbc.M102615200	http://dx.doi.org/10.1074/jbc.M102615200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11399775	hybrid			2022-12-25	WOS:000169297900056
J	Ciciarello, M; Mangiacasale, R; Casenghi, M; Limongi, MZ; D'Angelo, M; Soddu, S; Lavia, P; Cundari, E				Ciciarello, M; Mangiacasale, R; Casenghi, M; Limongi, MZ; D'Angelo, M; Soddu, S; Lavia, P; Cundari, E			p53 displacement from centrosomes and p53-mediated G(1) arrest following transient inhibition of the mitotic spindle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CHECKPOINT; MICROTUBULE NUCLEATION; VERTEBRATE CELLS; MAMMALIAN-CELLS; ANIMAL-CELLS; DNA-DAMAGE; APOPTOSIS; INSTABILITY; DUPLICATION; NOCODAZOLE	Growing evidence indicates a central role for p53 in mediating cell cycle arrest in response to mitotic spindle defects so as to prevent rereplication in cells in which the mitotic division has failed. Here we report that a transient inhibition of spindle assembly induced by nocodazole, a tubulin-depolymerizing drug, triggers a stable activation of p53, which can transduce a cell cycle inhibitory signal even when the spindle-damaging agent is removed and the spindle is allowed to reassemble. Cells transiently exposed to nocodazole continue to express high levels of p53 and p21 in the cell cycle that follows the transient exposure to nocodazole and become arrested in G,, regardless of whether they carry a diploid or polyploid genome after mitotic exit. We also show that p53 normally associates with centrosomes in mitotic cells, whereas nocodazole disrupts this association. Together these results suggest that the induction of spindle damage, albeit transient, interferes with the subcellular localization of p53 at specific mitotic locations, which in turn dictates cell cycle arrest in the offspring of such defective mitoses.	Univ Rome La Sapienza, Dept Genet & Mol Biol, CNR, Ctr Evolutionary Genet, I-00185 Rome, Italy; Regina Elena Canc Inst, Mol Oncogenesis Lab, I-00158 Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome	Cundari, E (corresponding author), Univ Rome La Sapienza, Dept Genet & Mol Biol, CNR, Ctr Evolutionary Genet, Via Apuli 4, I-00185 Rome, Italy.		Soddu, Silvia/K-2467-2018; Lavia, Patrizia/AAL-3982-2021; Ciciarello, Marilena/AAA-7950-2022; Soddu, Silvia/ABH-6774-2020; Lavia, Patrizia/J-5793-2019; Ciciarello, Marilena/A-4401-2015	Soddu, Silvia/0000-0001-8526-0044; Ciciarello, Marilena/0000-0002-4744-507X; Soddu, Silvia/0000-0001-8526-0044; Lavia, Patrizia/0000-0003-3310-6701; 				Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; Battistoni A, 1997, J CELL SCI, V110, P2345; Bobinnec Y, 1998, J CELL BIOL, V143, P1575, DOI 10.1083/jcb.143.6.1575; BROWN CR, 1994, J CELL PHYSIOL, V160, P47, DOI 10.1002/jcp.1041600107; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Casenghi M, 1999, EXP CELL RES, V250, P339, DOI 10.1006/excr.1999.4554; Chiba S, 2000, EXP CELL RES, V258, P310, DOI 10.1006/excr.2000.4916; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; Di Fiore B, 1999, J BIOL CHEM, V274, P10339, DOI 10.1074/jbc.274.15.10339; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; Giannakakou P, 2000, NAT CELL BIOL, V2, P709, DOI 10.1038/35036335; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HEAD J, 1985, J BIOL CHEM, V260, P1060; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; HOEBEKE J, 1976, BIOCHEM BIOPH RES CO, V69, P319, DOI 10.1016/0006-291X(76)90524-6; JORDAN MA, 1992, J CELL SCI, V102, P401; Kirsch-Volders M, 1998, MUTAGENESIS, V13, P321, DOI 10.1093/mutage/13.4.321; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; Meek DW, 2000, PATHOL BIOL, V48, P246; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Merdes A, 2000, J CELL BIOL, V149, P851, DOI 10.1083/jcb.149.4.851; Merdes A, 1997, J CELL BIOL, V138, P953, DOI 10.1083/jcb.138.5.953; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; Morris VB, 2000, EXP CELL RES, V256, P122, DOI 10.1006/excr.2000.4800; Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Paoletti A, 1996, J CELL SCI, V109, P3089; Piel M, 2000, J CELL BIOL, V149, P317, DOI 10.1083/jcb.149.2.317; Pietenpol JA, 1996, P NATL ACAD SCI USA, V93, P8390, DOI 10.1073/pnas.93.16.8390; Pihan GA, 1999, SEMIN CANCER BIOL, V9, P289, DOI 10.1006/scbi.1999.0131; Rieder CL, 1998, TRENDS CELL BIOL, V8, P310, DOI 10.1016/S0962-8924(98)01299-9; Sablina AA, 1998, J CELL SCI, V111, P977; Schiebel E, 2000, CURR OPIN CELL BIOL, V12, P113, DOI 10.1016/S0955-0674(99)00064-2; Sorger PK, 1997, CURR OPIN CELL BIOL, V9, P807, DOI 10.1016/S0955-0674(97)80081-6; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Stewart ZA, 2001, ONCOGENE, V20, P113, DOI 10.1038/sj.onc.1204060; Tarapore P, 2000, CANCER INVEST, V18, P148, DOI 10.3109/07357900009038246; Tassin AM, 1999, BIOL CELL, V91, P343, DOI 10.1016/S0248-4900(99)80095-1; Verdoodt B, 1999, MUTAGENESIS, V14, P513, DOI 10.1093/mutage/14.5.513; Vessey CJ, 2000, PROG NUCLEIC ACID RE, V63, P189, DOI 10.1016/S0079-6603(08)60723-0; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; Zimmerman W, 1999, CURR OPIN CELL BIOL, V11, P122, DOI 10.1016/S0955-0674(99)80015-5	50	106	110	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19205	19213		10.1074/jbc.M009528200	http://dx.doi.org/10.1074/jbc.M009528200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11376010	hybrid			2022-12-25	WOS:000169091000077
J	Patallo, EP; Blanco, G; Fischer, C; Brana, AF; Rohr, J; Mendez, C; Salas, JA				Patallo, EP; Blanco, G; Fischer, C; Brana, AF; Rohr, J; Mendez, C; Salas, JA			Deoxysugar methylation during biosynthesis of the antitumor polyketide elloramycin by Streptomyces olivaceus - Characterization of three methyltransferase genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECT FERMENTATIVE PRODUCTION; SUBSTRATE-SPECIFICITY; O-METHYLTRANSFERASE; METABOLIC PRODUCTS; SEQUENCE-ANALYSIS; ESCHERICHIA-COLI; DRUG MITHRAMYCIN; IDENTIFICATION; FRADIAE; TYLOSIN	The anthracycline-like polyketide drug elloramycin is produced by Streptomyces olivaceus Tu2353. Elloramycin has antibacterial activity against Gram-positive bacteria and also exhibits antitumor activity. From a cosmid clone (cos16F4) containing part of the elloramycin biosynthesis gene cluster, three genes (elmMI, elmMII, and elmMIII) have been cloned. Sequence analysis and data base comparison showed that their deduced products resembled S-adenosylmethionine-dependent O-methyltransferases. The genes were individually expressed in Streptomyces albus and also coexpressed with genes involved in the biosynthesis of L-rhamnose, tbe 6-deoxysugar attached to the elloramycin aglycon, The resulting recombinant strains were used to biotransform three different elloramycin-type compounds: L-rhamnosyl-tetracenomycin C, L-olivosyl-tetracenomycin C, and L-oleandrosyl-tetracenomycin, which differ in their 2'-, 3'-, and 4'-substituents of the sugar moieties, When only the three methyltransferase-encoding genes elmMI elmMII, and elmMIII were individually expressed in S. albus, the methylating activity of the three methyltransferases was also assayed in vitro using various externally added glycosylated substrates, From the combined results of all of these experiments, it is proposed that methyltransferases ElmMI, ElmMII, and ElmMIII are involved in the biosynthesis of the permethylated L-rhamnose moiety of elloramycin, ElmMI, ElmMII, and ElmMIII are responsible for the consecutive methylation of the hydroxy groups at the 2'-, 3'-, and 4'-position, respectively, after the sugar moiety has been attached to the aglycon.	Med Univ S Carolina, Dept Pharmaceut Sci, Charleston, SC 29425 USA; Univ Oviedo, Dept Biol Func, E-33006 Oviedo, Spain; Univ Oviedo, Inst Univ Oncol Principado Asturias, E-33006 Oviedo, Spain	Medical University of South Carolina; University of Oviedo; University of Oviedo; Instituto Universitario de Oncologia de Asturias	Rohr, J (corresponding author), Med Univ S Carolina, Dept Pharmaceut Sci, 171 Ashley Ave, Charleston, SC 29425 USA.		Patallo, Eugenio P./AAT-7342-2021; Brana, Alfredo/M-1836-2014; Rohr, Jurgen/G-5375-2014; Mendez-Fernandez, Carmen/ABE-5745-2020; Fernandez-Brana, Alfredo/O-1488-2019; Blanco, Gloria/K-5850-2014	Brana, Alfredo/0000-0002-3277-9085; Rohr, Jurgen/0000-0001-6447-5951; Mendez-Fernandez, Carmen/0000-0003-2729-841X; Fernandez-Brana, Alfredo/0000-0002-3277-9085; Blanco-Blanco, Maria Gloria/0000-0002-6388-4929; Perez Patallo, Eugenio/0000-0003-1857-8022				Aguirrezabalaga I, 2000, ANTIMICROB AGENTS CH, V44, P1266, DOI 10.1128/AAC.44.5.1266-1275.2000; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARISAWA A, 1994, APPL ENVIRON MICROB, V60, P2657, DOI 10.1128/AEM.60.7.2657-2660.1994; Arisawa A, 1996, J ANTIBIOT, V49, P349, DOI 10.7164/antibiotics.49.349; Bate N, 1999, J IND MICROBIOL BIOT, V23, P118, DOI 10.1038/sj.jim.2900707; Blanco G, 2001, CHEM BIOL, V8, P253, DOI 10.1016/S1074-5521(01)00010-2; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CHATER KF, 1980, J GEN MICROBIOL, V116, P323; DECKER H, 1995, GENE, V166, P121, DOI 10.1016/0378-1119(95)00573-7; Decker H, 1996, FEMS MICROBIOL LETT, V141, P195, DOI 10.1016/0378-1097(96)00221-2; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRAUTZ H, 1985, J ANTIBIOT, V38, P1291, DOI 10.7164/antibiotics.38.1291; EPP JK, 1989, GENE, V85, P293, DOI 10.1016/0378-1119(89)90421-6; Fernandez E, 1998, J BACTERIOL, V180, P4929; FIEDLER HP, 1986, J ANTIBIOT, V39, P856, DOI 10.7164/antibiotics.39.856; Fouces R, 1999, MICROBIOL-UK, V145, P855, DOI 10.1099/13500872-145-4-855; Hopwood D. A., 1985, GENETIC MANIPULATION; INOUYE M, 1994, GENE, V141, P121; KAGAN RM, 1994, ARCH BIOCHEM BIOPHYS, V310, P417, DOI 10.1006/abbi.1994.1187; KIRST HA, 1991, TETRAHEDRON LETT, V32, P4839, DOI 10.1016/S0040-4039(00)93474-9; KREUZMAN AJ, 1988, J BIOL CHEM, V263, P15626; LIU HW, 1994, ANNU REV MICROBIOL, V48, P223, DOI 10.1146/annurev.micro.48.1.223; Lozano MJF, 2000, J BIOL CHEM, V275, P3065, DOI 10.1074/jbc.275.5.3065; Olano C, 1998, MOL GEN GENET, V259, P299, DOI 10.1007/s004380050816; PAULUS TJ, 1990, J BACTERIOL, V172, P2541, DOI 10.1128/jb.172.5.2541-2546.1990; PIEPERSBERG W, 1994, CRIT REV BIOTECHNOL, V14, P251, DOI 10.3109/07388554409079835; Rodriguez L, 2000, J MOL MICROB BIOTECH, V2, P271; ROHR J, 1990, J ANTIBIOT, V43, P1169, DOI 10.7164/antibiotics.43.1169; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULMAN MD, 1990, J BIOL CHEM, V265, P16965; SENO ET, 1981, ANTIMICROB AGENTS CH, V20, P370, DOI 10.1128/AAC.20.3.370; Steffensky M, 2000, ANTIMICROB AGENTS CH, V44, P1214, DOI 10.1128/AAC.44.5.1214-1222.2000; Trefzer A, 1999, NAT PROD REP, V16, P283, DOI 10.1039/a804431g; Wohlert SE, 1998, J AM CHEM SOC, V120, P10596, DOI 10.1021/ja981687e; Ylihonko K, 1996, MOL GEN GENET, V251, P113	36	48	53	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					18765	18774		10.1074/jbc.M101225200	http://dx.doi.org/10.1074/jbc.M101225200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11376004	hybrid			2022-12-25	WOS:000169091000018
J	Ido, Y; Chang, K; Woolsey, TA; Williamson, JR				Ido, Y; Chang, K; Woolsey, TA; Williamson, JR			NADH: sensor of blood flow need in brain, muscle, and other tissues	FASEB JOURNAL			English	Article						diabetes; glycolysis; NAD; nitric oxide; redox; superoxide; whisker barrels; work	VASCULAR SMOOTH-MUSCLE; OXIDE SYNTHASE INHIBITION; ENDOTHELIAL GROWTH-FACTOR; ELEVATED GLUCOSE-LEVELS; HUMAN SKELETAL-MUSCLE; REACTIVE OXYGEN; NITRIC-OXIDE; IN-VITRO; SOMATOSENSORY STIMULATION; OXIDATIVE-METABOLISM	The sensor for blood-flow need with neural activity and exercise is not known. We tested the hypothesis that accumulation of electrons in cytosolic free nicotinamide adenine dinucleotide (NAD) activates redox signaling pathways to augment blood flow. NAD is the primary carrier of electrons from glucose and lactate for ATP synthesis. Because increased glycolysis transfers electrons from glucose to NAD(+) faster than they are used for mitochondrial ATP synthesis, electrons accumulate in cytosolic NADH. Because cytosolic NADH and intra- and extracellular lactate/pyravate (L/P) ratios are all in near-equilibrium, NADH can be increased or decreased by i.v. lactate or pyruvate. Here, we report that elevated plasma L/P in normal rats increases blood flow in numerous resting tissues and augments blood flow increases in activated somatosensory (barrel) cortex and contracting skeletal muscle. Increased flows are largely prevented by injection of pyruvate (to lower L/P), a superoxide dismutase mimic (to block vascular effects of superoxide), or an inhibitor of nitric oxide synthase (to block (NO)-N-. vasodilation). Electrons carried by NADH, in addition to fueling ATP synthesis, also fuel redox signaling pathways to augment blood flow in resting and working tissues. These novel findings are fundamental to understanding blood-flow physiology and pathology.	Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Neurol & Neurol Surg, St Louis, MO 63110 USA; Boston Univ, Med Ctr Hosp, Diabet & Metab Unit, Boston, MA 02215 USA	Washington University (WUSTL); Washington University (WUSTL); Boston University	Williamson, JR (corresponding author), Washington Univ, Sch Med, Dept Pathol, Box 8118,660 S Euclid Ave, St Louis, MO 63110 USA.	jrw@PATHOLOGY.WUSTL.edu		Ido, Yasuo/0000-0002-3036-9971				ANDERSEN BJ, 1992, BRAIN RES, V585, P190, DOI 10.1016/0006-8993(92)91206-T; Barron JT, 1999, MOL CELL BIOCHEM, V194, P283, DOI 10.1023/A:1006928516648; Barron JT, 1997, J MOL CELL CARDIOL, V29, P2225, DOI 10.1006/jmcc.1997.0461; Berry GT, 1998, METABOLISM, V47, P1423, DOI 10.1016/S0026-0495(98)90317-1; Boero JA, 1999, J APPL PHYSIOL, V86, P1211, DOI 10.1152/jappl.1999.86.4.1211; BROOKS GA, 1986, FASEB J, V45, P2924; CARR DB, 1984, J CLIN PSYCHIAT, V45, P323; Chang K, 1997, AM J PHYSIOL-ENDOC M, V273, pE164, DOI 10.1152/ajpendo.1997.273.1.E164; Cholet N, 1997, J CEREBR BLOOD F MET, V17, P1191, DOI 10.1097/00004647-199711000-00008; Chua CC, 1998, FREE RADICAL BIO MED, V25, P891, DOI 10.1016/S0891-5849(98)00115-4; COGGAN AR, 1992, J APPL PHYSIOL, V72, P1780, DOI 10.1152/jappl.1992.72.5.1780; Demestre M, 1997, J PHYSIOL-LONDON, V499, P825, DOI 10.1113/jphysiol.1997.sp021971; Dowling JL, 1996, J NEUROSCI METH, V66, P113, DOI 10.1016/0165-0270(96)00007-6; DUFFY TE, 1972, J NEUROCHEM, V19, P959, DOI 10.1111/j.1471-4159.1972.tb01417.x; FOX PT, 1988, SCIENCE, V241, P462, DOI 10.1126/science.3260686; FOX PT, 1986, P NATL ACAD SCI USA, V83, P1140, DOI 10.1073/pnas.83.4.1140; Gustafsson T, 1999, AM J PHYSIOL-HEART C, V276, pH679, DOI 10.1152/ajpheart.1999.276.2.H679; Hansen PA, 1997, AM J PHYSIOL-ENDOC M, V273, pE28, DOI 10.1152/ajpendo.1997.273.1.E28; HARDY MM, 1994, J BIOL CHEM, V269, P18535; Hickner RC, 1997, AM J PHYSIOL-HEART C, V273, pH405, DOI 10.1152/ajpheart.1997.273.1.H405; HOGAN MC, 1995, MED SCI SPORT EXER, V27, P371; Huang PL, 1998, PROG BRAIN RES, V118, P13; Hyder F, 1996, P NATL ACAD SCI USA, V93, P7612, DOI 10.1073/pnas.93.15.7612; IKEBUCHI Y, 1991, J BIOL CHEM, V266, P13233; IMRE G, 1964, Br J Ophthalmol, V48, P75, DOI 10.1136/bjo.48.2.75; ISAACS KR, 1992, J CEREBR BLOOD F MET, V12, P110, DOI 10.1038/jcbfm.1992.14; Katz A, 1990, Exerc Sport Sci Rev, V18, P1; KILGORE KS, 1994, J MOL CELL CARDIOL, V26, P995, DOI 10.1006/jmcc.1994.1120; KOBAYASHI K, 1979, CIRC RES, V44, P166, DOI 10.1161/01.RES.44.2.166; Kuroki M, 1996, J CLIN INVEST, V98, P1667, DOI 10.1172/JCI118962; LADECOLA C, 1993, TRENDS NEUROSCI, V16, P206; Lash JM, 1996, P SOC EXP BIOL MED, V211, P218; LAUGHLIN MR, 1994, J MOL CELL CARDIOL, V26, P1525, DOI 10.1006/jmcc.1994.1173; LAUGHLIN MR, 1993, AM J PHYSIOL, V264, pH2068, DOI 10.1152/ajpheart.1993.264.6.H2068; LEAR JL, 1991, J CEREBR BLOOD F MET, V11, P576, DOI 10.1038/jcbfm.1991.106; Lindauer U, 1996, NEUROSCI LETT, V216, P207, DOI 10.1016/S0304-3940(96)13044-5; Magistretti PJ, 1999, PHILOS T R SOC B, V354, P1155, DOI 10.1098/rstb.1999.0471; MCGILVERY RM, 1983, BIOCH FUNCTIONAL APP, P484; McKinnon W, 1996, J PHYSIOL-LONDON, V490, P783, DOI 10.1113/jphysiol.1996.sp021186; Parolin ML, 2000, AM J PHYSIOL-ENDOC M, V278, pE522, DOI 10.1152/ajpendo.2000.278.3.E522; POOLE RC, 1993, AM J PHYSIOL, V264, P761; Powers WJ, 1996, AM J PHYSIOL-HEART C, V270, pH554, DOI 10.1152/ajpheart.1996.270.2.H554; Reid MB, 1996, NEWS PHYSIOL SCI, V11, P114, DOI 10.1152/physiologyonline.1996.11.3.114; REIMAN EM, 1989, ARCH GEN PSYCHIAT, V46, P493; Roca J, 1998, J APPL PHYSIOL, V85, P1142, DOI 10.1152/jappl.1998.85.3.1142; ROWELL LB, 1986, AM J PHYSIOL, V251, P1038; SHOLTZ TD, 1995, AM J PHYSIOL, V268, pH82; Siesjo B K, 1979, Adv Neurol, V26, P267; Stainsby W N, 1990, Exerc Sport Sci Rev, V18, P29; STROMINGER RN, 1987, J NEUROSCI METH, V22, P113, DOI 10.1016/0165-0270(87)90004-5; STRYER L, 1995, BIOCHEMISTRY-US, P548; SULLIVAN MJ, 1994, J APPL PHYSIOL, V77, P2194, DOI 10.1152/jappl.1994.77.5.2194; Tilton RG, 1997, J CLIN INVEST, V99, P2192, DOI 10.1172/JCI119392; UEKI M, 1988, J CEREBR BLOOD F MET, V8, P486, DOI 10.1038/jcbfm.1988.89; VANDENENDEN MK, 1995, INVEST OPHTH VIS SCI, V36, P1675; VEECH RL, 1986, AM J CLIN NUTR, V44, P519, DOI 10.1093/ajcn/44.4.519; VIGUIE CA, 1993, J APPL PHYSIOL, V75, P566, DOI 10.1152/jappl.1993.75.2.566; Volk T, 1997, MOL CELL BIOCHEM, V171, P11, DOI 10.1023/A:1006886215193; Wagner AD, 1998, SCIENCE, V281, P1188, DOI 10.1126/science.281.5380.1188; WEI EP, 1985, AM J PHYSIOL, V248, P157; WEISS J, 1985, J CLIN INVEST, V75, P436, DOI 10.1172/JCI111718; Williams B, 1997, DIABETES, V46, P1497, DOI 10.2337/diabetes.46.9.1497; WILLIAMSON DH, 1967, BIOCHEM J, V103, P514, DOI 10.1042/bj1030514; WILLIAMSON JR, 1993, DIABETES, V42, P801, DOI 10.2337/diabetes.42.6.801; Willmitzer L, 1999, CURR OPIN BIOTECH, V10, P161, DOI 10.1016/S0958-1669(99)80028-7; Wojtaszewski JFP, 1998, BBA-GEN SUBJECTS, V1380, P396, DOI 10.1016/S0304-4165(98)00011-7; Wolin Michael S., 1996, Microcirculation (Philadelphia), V3, P1, DOI 10.3109/10739689609146778	67	54	58	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 27	2001	15	6					1419	+		10.1096/fj.00-0652fje	http://dx.doi.org/10.1096/fj.00-0652fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387243				2022-12-25	WOS:000173705800025
J	Thomas, CJ; Surolia, N; Surolia, A				Thomas, CJ; Surolia, N; Surolia, A			Kinetic and thermodynamic analysis of the interactions of 23-residue peptides with endotoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; GRAM-NEGATIVE BACTERIA; HOST-DEFENSE PEPTIDES; POLYMYXIN-B; ANTIMICROBIAL PEPTIDES; ESCHERICHIA-COLI; PSEUDOMONAS-AERUGINOSA; OUTER-MEMBRANE; LIPID-A; SALMONELLA-TYPHIMURIUM	Many naturally occurring peptides exhibit lipopolysaccharide binding properties. In this work we describe the endotoxin binding properties of a series of 23-residue peptides based on the sequence corresponding to the antisense strand of the magainin gene. Biochemical and biophysical characterization of these peptides reveals that they have the tendency to perturb both the inner and outer membranes of test pathogens. Structurally these peptides are amphiphilic and adopt helical conformations in membranes. Three of the seven peptides tested have high affinities for endotoxin that approach the values shown by polymyxin B, a cyclic cationic acylated decapeptide, which is used clinically in treating extreme cases of sepsis. The kinetic parameters obtained using stopped-flow methods and BIA-core (TM) analysis, when considered in conjunction with the isothermal titration calorimetry-derived thermodynamic parameters, allow us to highlight the key structural features essential for lipopolysaccharide (LPS) recognition by these peptides. The studies stress the role of ionic forces in the initial recognition of LPS. The fortification of the strength of these ionic charges increases affinity for LPS, whereas the hydrophobic residues involved in interactions are more amenable to disruptions in contiguity. Peptides that improve these features further are expected to perform better as endotoxin-neutralizing agents.	Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India; Jawaharlal Nehru Ctr Adv Sci & Res Jakkur, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore; Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR)	Surolia, A (corresponding author), Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India.		SUROLIA, AVADESHA/C-5442-2009					Bechinger B, 1999, BBA-BIOMEMBRANES, V1462, P157, DOI 10.1016/S0005-2736(99)00205-9; Bechinger B, 1997, J MEMBRANE BIOL, V156, P197, DOI 10.1007/s002329900201; BERKOWITZ BA, 1990, BIOCHEM PHARMACOL, V39, P625, DOI 10.1016/0006-2952(90)90138-B; Boman HG, 2000, IMMUNOL REV, V173, P5, DOI 10.1034/j.1600-065X.2000.917301.x; BOMAN HG, 1993, INFECT IMMUN, V61, P2978, DOI 10.1128/IAI.61.7.2978-2984.1993; Brandenburg K, 1997, BBA-BIOMEMBRANES, V1329, P183, DOI 10.1016/S0005-2736(97)00109-0; Chaby R, 1999, DRUG DISCOV TODAY, V4, P209, DOI 10.1016/S1359-6446(99)01336-7; Chen HM, 1997, BBA-GEN SUBJECTS, V1336, P171, DOI 10.1016/S0304-4165(97)00024-X; CHRISTENSEN B, 1988, P NATL ACAD SCI USA, V85, P5072, DOI 10.1073/pnas.85.14.5072; Datta AK, 1999, INDIAN J BIOCHEM BIO, V36, P55; Evans ME, 1999, ANN PHARMACOTHER, V33, P960, DOI 10.1345/aph.18426; FINK PF, 1990, SEPSIS SYNDROME HDB, P619; Frecer V, 2000, EUR J BIOCHEM, V267, P837, DOI 10.1046/j.1432-1327.2000.01069.x; GALANOS C, 1977, INT REV BIOCH BIOCH, V14, P239; HANCOCK REW, 1981, ANTIMICROB AGENTS CH, V19, P777, DOI 10.1128/AAC.19.5.777; IWANAGA S, 1993, CURR OPIN IMMUNOL, V5, P74, DOI 10.1016/0952-7915(93)90084-6; JUAN TSC, 1995, J BIOL CHEM, V270, P17237, DOI 10.1074/jbc.270.29.17237; Kato N, 2000, MOL MICROBIOL, V36, P796, DOI 10.1046/j.1365-2958.2000.01893.x; KIRKLAND TN, 1993, J BIOL CHEM, V268, P24818; LIEVE L, 1974, ANN NY ACAD SCI, V235, P109; Lockey TD, 1996, EUR J BIOCHEM, V236, P263, DOI 10.1111/j.1432-1033.1996.00263.x; LOH B, 1984, ANTIMICROB AGENTS CH, V26, P546, DOI 10.1128/AAC.26.4.546; MALOY WL, 1995, BIOPOLYMERS, V37, P105, DOI 10.1002/bip.360370206; MOORE RA, 1986, ANTIMICROB AGENTS CH, V29, P496, DOI 10.1128/AAC.29.3.496; Morrison D C, 1981, Contemp Top Mol Immunol, V8, P187; Oren Z, 1998, BIOPOLYMERS, V47, P451; PATHAK N, 1995, PROTEINS, V22, P182, DOI 10.1002/prot.340220210; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; RIETSCHEL ET, 1992, SCI AM, V267, P26; SANDERSON KE, 1974, CAN J MICROBIOL, V20, P1135, DOI 10.1139/m74-176; SCHINDLER PRG, 1975, ANTIMICROB AGENTS CH, V8, P95, DOI 10.1128/AAC.8.1.95; Srimal S, 1996, BIOCHEM J, V315, P679, DOI 10.1042/bj3150679; Thomas CJ, 1999, J BIOL CHEM, V274, P29624, DOI 10.1074/jbc.274.42.29624; Thomas CJ, 1998, J AM CHEM SOC, V120, P12428, DOI 10.1021/ja981777j; Thomas CJ, 1999, FEBS LETT, V445, P420, DOI 10.1016/S0014-5793(99)00150-7; TONOMURA B, 1978, ANAL BIOCHEM, V84, P370, DOI 10.1016/0003-2697(78)90054-4; Wong PMC, 2000, SCAND J IMMUNOL, V51, P123; YIN ET, 1972, BIOCHIM BIOPHYS ACTA, V261, P284; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449; ZASLOFF M, 1988, P NATL ACAD SCI USA, V85, P910, DOI 10.1073/pnas.85.3.910; ZEIGLER EJ, 1991, NEW ENGL J MED, V324, P429	41	24	24	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 21	2001	276	38					35701	35706		10.1074/jbc.M011319200	http://dx.doi.org/10.1074/jbc.M011319200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	474LU	11384964	hybrid			2022-12-25	WOS:000171109300066
J	Henry, RA; Tews, B; Li, XL; Scott, MJ				Henry, RA; Tews, B; Li, XL; Scott, MJ			Recruitment of the male-specific lethal (MSL) dosage compensation complex to an autosomally integrated roX chromatin entry site correlates with an increased expression of an adjacent reporter gene in male Drosophila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-CHROMOSOME; HISTONE H4; PROTEIN; RNAS; TRANSCRIPTION; MELANOGASTER; ASSOCIATION; BOUNDARIES; ENCODES; ASSAY	Drosophila dosage compensate (equalize X-linked gene products) by doubling the transcription of most X-linked genes in males. The MSL (male-specific lethal) ribonucleoprotein complex consisting of at least five proteins and two non-coding RNAs (roX1 and roX2) is essential for this transcription response. Recently it has been shown that the X-linked roX1 and roX2 genes each contain at least one chromatin entry site for the MSL complex. In this study we show that insertion of either roX1 or roX2 DNA sequences, upstream of an insulated lacZ reporter gene controlled with the constitutive armadillo promoter (arm-lacZ), results in a significant elevation of expression of lacZ in males. However, full compensation, that is a precise doubling of lacZ expression in males relative to females, was only observed in some lines carrying autosomal insertions of either roX1-arm-lacZ or roX2-arm-lacZ transgenes. Furthermore, we found that a 419-base pair fragment of roX1 that contains an MSL binding site was sufficient to cause a modest elevation of expression of lacZ in males, but this response was significantly less than obtained with a full-length roX1 cDNA. This is the first direct demonstration that insertion of an MSL chromatin entry site on an autosome results in elevated expression in males of genes near the entry site.	Massey Univ, Inst Mol BioSci, Palmerston North 5320, New Zealand	Massey University	Scott, MJ (corresponding author), Massey Univ, Inst Mol BioSci, Private Bag 11222, Palmerston North 5320, New Zealand.		Scott, Maxwell J/J-1935-2015	Scott, Maxwell J/0000-0001-6536-4735; Kirk, Rebecca/0000-0001-8487-8088; Tews, Birke Andrea/0000-0002-8647-0497				Akhtar A, 2000, MOL CELL, V5, P367, DOI 10.1016/S1097-2765(00)80431-1; Amrein H, 1997, CELL, V88, P459, DOI 10.1016/S0092-8674(00)81886-3; BASHAW GJ, 1995, DEVELOPMENT, V121, P3245; BELOTE JM, 1980, NATURE, V285, P573, DOI 10.1038/285573a0; BONE JR, 1994, GENE DEV, V8, P96, DOI 10.1101/gad.8.1.96; Fitzsimons HL, 1999, GENETICA, V105, P215, DOI 10.1023/A:1003801402153; Franke A, 1999, MOL CELL, V4, P117, DOI 10.1016/S1097-2765(00)80193-8; Jin Y, 2000, J CELL BIOL, V149, P1005, DOI 10.1083/jcb.149.5.1005; Kageyama Y, 2001, EMBO J, V20, P2236, DOI 10.1093/emboj/20.9.2236; Kelley RL, 1999, CELL, V98, P513, DOI 10.1016/S0092-8674(00)81979-0; KELLEY RL, 1995, CELL, V81, P867, DOI 10.1016/0092-8674(95)90007-1; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KELLUM R, 1992, MOL CELL BIOL, V12, P2424, DOI 10.1128/MCB.12.5.2424; Lee CG, 1997, EMBO J, V16, P2671, DOI 10.1093/emboj/16.10.2671; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; LUCCHESI JC, 1987, ADV GENET, V24, P371, DOI 10.1016/S0065-2660(08)60013-9; Lucchesi JC, 1998, CURR OPIN GENET DEV, V8, P179, DOI 10.1016/S0959-437X(98)80139-1; Lyman LM, 1997, GENETICS, V147, P1743; Meller VH, 2000, CURR BIOL, V10, P136, DOI 10.1016/S0960-9822(00)00311-0; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Smith ER, 2000, MOL CELL BIOL, V20, P312, DOI 10.1128/MCB.20.1.312-318.2000; Smith J.A., 2000, CURRENT PROTOCOLS MO; Stuckenholz C, 1999, TRENDS GENET, V15, P454, DOI 10.1016/S0168-9525(99)01855-7; XIAO H, 1989, MOL CELL BIOL, V9, P1746, DOI 10.1128/MCB.9.4.1746; ZHOU SB, 1995, EMBO J, V14, P2884, DOI 10.1002/j.1460-2075.1995.tb07288.x	25	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31953	31958		10.1074/jbc.M103008200	http://dx.doi.org/10.1074/jbc.M103008200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11402038	hybrid			2022-12-25	WOS:000170613500067
J	Qiu, X; Hong, HP; MacKenzie, SL				Qiu, X; Hong, HP; MacKenzie, SL			Identification of a Delta 4 fatty acid desaturase from Thraustochytrium sp involved in the biosynthesis of docosahexanoic acid by heterologous expression in Saccharomyces cerevisiae and Brassica juncea	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-LINOLENIC ACID; CAENORHABDITIS-ELEGANS; MORTIERELLA-ALPINA; 4,7,10,13,16,19-DOCOSAHEXAENOIC ACID; 4,7,10,13,16-DOCOSAPENTAENOIC ACID; DOCOSAPENTAENOIC 22/5N-6; ARACHIDONIC-ACID; 22/6N-3 ACIDS; RAT-LIVER; CLONING	The existence of Delta4 fatty acid desaturation in the biosynthesis of docosahexanoic acid (DHA) has been questioned over the years. In this report we describe the identification from Thraustochytrium sp. of two cDNAs, Fad4 and Fad5, coding for Delta4 and Delta5 fatty acid desaturases, respectively. The Delta4 desaturase, when expressed in Saccharomyces cerevisiae, introduced a double bond at position 4 of 22:5(n-3) and 22:4(n-6) resulting in the production of DHA and docosapentanoic acid. The enzyme, when expressed in Brassica juncea under the control of a constitutive promoter, desaturated the exogenously supplied substrate 22:5(n-3), resulting in the production of DHA in vegetative tissues. These results support the notion that DHA can be synthesized via Delta4 desaturation and suggest the possibility that DHA can be produced in oilseed crops on a large scale.	Bioriginal Food & Sci Corp, Dept Res & Dev, Saskatoon, SK S7J 0R1, Canada; Natl Res Council Canada, Inst Plant Biotechnol, Saskatoon, SK S7N 0W9, Canada	National Research Council Canada	Qiu, X (corresponding author), Bioriginal Food & Sci Corp, Dept Res & Dev, Saskatoon, SK S7J 0R1, Canada.	xqiu@pbi.nrc.ca						Beaudoin F, 2000, P NATL ACAD SCI USA, V97, P6421, DOI 10.1073/pnas.110140197; Cho HP, 1999, J BIOL CHEM, V274, P471, DOI 10.1074/jbc.274.1.471; Cho HP, 1999, J BIOL CHEM, V274, P37335, DOI 10.1074/jbc.274.52.37335; Crawford MA, 1997, AM J CLIN NUTR, V66, P1032, DOI 10.1093/ajcn/66.4.1032S; Girke T, 1998, PLANT J, V15, P39, DOI 10.1046/j.1365-313X.1998.00178.x; Giusto NM, 2000, PROG LIPID RES, V39, P315, DOI 10.1016/S0163-7827(00)00009-6; Gurr M., 1992, Lipid Technology, V4, P141; HORROBIN DF, 1992, PROG LIPID RES, V31, P163, DOI 10.1016/0163-7827(92)90008-7; Horrocks LA, 1999, PHARMACOL RES, V40, P211, DOI 10.1006/phrs.1999.0495; Huang YS, 1999, LIPIDS, V34, P649, DOI 10.1007/s11745-999-0410-8; Infante JP, 1997, MOL CELL BIOCHEM, V168, P101, DOI 10.1023/A:1006895209833; Infante JP, 2000, FEBS LETT, V468, P1, DOI 10.1016/S0014-5793(00)01083-8; Infante JP, 1998, FEBS LETT, V431, P1, DOI 10.1016/S0014-5793(98)00720-0; Innis SM, 1999, LIPIDS, V34, P139, DOI 10.1007/s11745-999-0348-x; Knutzon DS, 1998, J BIOL CHEM, V273, P29360, DOI 10.1074/jbc.273.45.29360; Leonard AE, 2000, BIOCHEM J, V350, P765, DOI 10.1042/0264-6021:3500765; Leonard AE, 2000, BIOCHEM J, V347, P719, DOI 10.1042/0264-6021:3470719; Lewis TE, 1999, MAR BIOTECHNOL, V1, P580, DOI 10.1007/PL00011813; Luthria DL, 1996, J BIOL CHEM, V271, P16020, DOI 10.1074/jbc.271.27.16020; MARTINEZ M, 1992, J PEDIATR-US, V120, pS129, DOI 10.1016/S0022-3476(05)81247-8; Michaelson LV, 1998, FEBS LETT, V439, P215, DOI 10.1016/S0014-5793(98)01385-4; Michaelson LV, 1998, J BIOL CHEM, V273, P19055, DOI 10.1074/jbc.273.30.19055; Mohammed BS, 1997, BIOCHEM J, V326, P425, DOI 10.1042/bj3260425; MOHAMMED BS, 1995, ARCH BIOCHEM BIOPHYS, V317, P179, DOI 10.1006/abbi.1995.1151; Napier JA, 1999, TRENDS PLANT SCI, V4, P2, DOI 10.1016/S1360-1385(98)01357-0; Napier JA, 1998, BIOCHEM J, V330, P611; Parker-Barnes JM, 2000, P NATL ACAD SCI USA, V97, P8284, DOI 10.1073/pnas.97.15.8284; Qiu X, 2001, PLANT PHYSIOL, V125, P847, DOI 10.1104/pp.125.2.847; Qiu X., 1994, Plant Molecular Biology Reporter, V12, P209, DOI 10.1007/BF02668743; RADKE SE, 1992, PLANT CELL REP, V11, P499, DOI 10.1007/BF00236265; Saito T, 2000, EUR J BIOCHEM, V267, P1813, DOI 10.1046/j.1432-1327.2000.01180.x; Sakuradani E, 1999, GENE, V238, P445, DOI 10.1016/S0378-1119(99)00359-5; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sayanova O, 1997, P NATL ACAD SCI USA, V94, P4211, DOI 10.1073/pnas.94.8.4211; Spector AA, 1999, LIPIDS, V34, pS1, DOI 10.1007/BF02562220; Sperling P, 2000, EUR J BIOCHEM, V267, P3801, DOI 10.1046/j.1432-1327.2000.01418.x; Sperling P, 1998, J BIOL CHEM, V273, P28590, DOI 10.1074/jbc.273.44.28590; Sprecher H, 1995, J LIPID RES, V36, P2471; Sprecher H, 1996, NUTRITION, V12, pS5; Sprecher H, 1999, LIPIDS, V34, pS153, DOI 10.1007/BF02562271; Sprecher H, 2000, BBA-MOL CELL BIOL L, V1486, P219, DOI 10.1016/S1388-1981(00)00077-9; VOSS A, 1991, J BIOL CHEM, V266, P19995; Wallis JG, 1999, ARCH BIOCHEM BIOPHYS, V365, P307, DOI 10.1006/abbi.1999.1167; Watts JL, 1999, ARCH BIOCHEM BIOPHYS, V362, P175, DOI 10.1006/abbi.1998.1024; Weete JD, 1997, LIPIDS, V32, P839, DOI 10.1007/s11745-997-0107-z	45	172	237	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31561	31566		10.1074/jbc.M102971200	http://dx.doi.org/10.1074/jbc.M102971200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11397798	hybrid			2022-12-25	WOS:000170613500014
J	Kirschenbaum, F; Hsu, SC; Cordell, B; McCarthy, JV				Kirschenbaum, F; Hsu, SC; Cordell, B; McCarthy, JV			Glycogen synthase kinase-3 beta regulates presenilin 1 C-terminal fragment levels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISEASE-ASSOCIATED PRESENILIN-1; PROTEOLYTIC FRAGMENTS; IN-VIVO; PROTEIN; APOPTOSIS; PHOSPHORYLATION; DEGRADATION; EXPRESSION; COMPLEX; DEFICIENCY	The majority of familial Alzheimer's disease cases have been attributed to mutations in the presenilin 1 (PSI) gene. PSI is synthesized as an inactive holoprotein that undergoes endoproteolytic processing to generate a functional N- and C-terminal heterodimer (NTF and CTF, respectively). We identified a single residue in PSI, Ser(397), which regulates the CTF levels in a population of dimer that has a rapid turnover. This residue is part of a highly conserved glycogen synthase kinase-3 beta (GSK-3 beta) consensus phosphorylation site within the loop domain of PSI. Site-directed mutagenesis at the Ser(397) position increased levels of PSI CTF but not NTF or holoprotein. Similar increases in only CTF levels were seen when cells expressing wild type PSI were treated with lithium chloride, an inhibitor of GSK-3 beta. Both wild type and PSI S397A CTF displayed a biphasic turnover, reflecting rapidly degraded and stable populations. Rapid turnover was delayed for mutant PSI S397A, causing increased CTF. These data demonstrate that PSI NTF-CTF endoproteolytic fragments are generated in excess, that phosphorylation at Ser(397) by GSK-3 beta regulates the discard of excess CTF, and that the disposal of surplus NTF is mediated by an independent mechanism. Overall, the results indicate that production of active NTF-CTF dimer is more complex than limited endoproteolysis of PSI holoprotein and instead involves additional regulatory events.	Scios Inc, Sunnyvale, CA 94085 USA	Scios	Cordell, B (corresponding author), Scios Inc, 820 W Maude Ave, Sunnyvale, CA 94085 USA.	cordell@sciosinc.com	mccarthy, justin/AAG-7550-2019	mccarthy, justin/0000-0002-2667-7365				Baumann K, 1997, NEUROBIOL AGING, V18, P181, DOI 10.1016/S0197-4580(97)00004-3; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Cruts M, 1998, HUM MUTAT, V11, P183, DOI 10.1002/(SICI)1098-1004(1998)11:3<183::AID-HUMU1>3.3.CO;2-M; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Dong LQ, 1999, J BIOL CHEM, V274, P8117, DOI 10.1074/jbc.274.12.8117; FIOL CJ, 1990, J BIOL CHEM, V265, P6061; Herreman A, 1999, P NATL ACAD SCI USA, V96, P11872, DOI 10.1073/pnas.96.21.11872; Honda T, 1999, J NEUROCHEM, V72, P255, DOI 10.1046/j.1471-4159.1999.0720255.x; Kim TW, 1997, J BIOL CHEM, V272, P11006; Kirschenbaum F, 2001, J BIOL CHEM, V276, P7366, DOI 10.1074/jbc.M004697200; Levesque G, 1999, J NEUROCHEM, V72, P999, DOI 10.1046/j.1471-4159.1999.0720999.x; Mah AL, 2000, J CELL BIOL, V151, P847, DOI 10.1083/jcb.151.4.847; Marambaud P, 1998, MOL MED, V4, P147, DOI 10.1007/BF03401912; Mattson MP, 1998, J NEUROCHEM, V70, P1; Mercken M, 1996, FEBS LETT, V389, P297, DOI 10.1016/0014-5793(96)00608-4; Murayama M, 1998, FEBS LETT, V433, P73, DOI 10.1016/S0014-5793(98)00886-2; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Ratovitski T, 1997, J BIOL CHEM, V272, P24536, DOI 10.1074/jbc.272.39.24536; Saura CA, 1999, J BIOL CHEM, V274, P13818, DOI 10.1074/jbc.274.20.13818; Seeger M, 1997, P NATL ACAD SCI USA, V94, P5090, DOI 10.1073/pnas.94.10.5090; Steiner H, 1998, J BIOL CHEM, V273, P32322, DOI 10.1074/jbc.273.48.32322; Takashima A, 1998, P NATL ACAD SCI USA, V95, P9637, DOI 10.1073/pnas.95.16.9637; Tesco G, 1998, J BIOL CHEM, V273, P33909, DOI 10.1074/jbc.273.51.33909; Thinakaran G, 1999, J CLIN INVEST, V104, P1321, DOI 10.1172/JCI8728; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Vezina J, 1999, NEUROSCI LETT, V263, P65, DOI 10.1016/S0304-3940(99)00097-X; Vito P, 1996, J BIOL CHEM, V271, P31025, DOI 10.1074/jbc.271.49.31025; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; Walter J, 1998, BIOCHEMISTRY-US, V37, P5961, DOI 10.1021/bi971763a; Walter J, 1997, P NATL ACAD SCI USA, V94, P5349, DOI 10.1073/pnas.94.10.5349; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Yu G, 2000, J BIOL CHEM, V275, P27348; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; Zhang JM, 1998, J BIOL CHEM, V273, P12436, DOI 10.1074/jbc.273.20.12436; Zhou JH, 1997, NEUROREPORT, V8, P1489, DOI 10.1097/00001756-199704140-00033	37	89	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30701	30707		10.1074/jbc.M102849200	http://dx.doi.org/10.1074/jbc.M102849200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11402035	hybrid			2022-12-25	WOS:000170472900017
J	Lai, ZH; Ferry, KV; Diamond, MA; Wee, KE; Kim, YB; Ma, JH; Yang, T; Benfield, PA; Copeland, RA; Auger, KR				Lai, ZH; Ferry, KV; Diamond, MA; Wee, KE; Kim, YB; Ma, JH; Yang, T; Benfield, PA; Copeland, RA; Auger, KR			Human mdm2 mediates multiple mono-ubiquitination of p53 by a mechanism requiring enzyme isomerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RING-FINGER DOMAIN; NUCLEAR EXPORT; PROTEIN LIGASE; SELF-UBIQUITINATION; DNA-DAMAGE; DEGRADATION; E3; SIGNAL; ONCOPROTEIN; PROTEASOME	The mdm2 gene product is an important regulator of p53 function and stability. mdm2 is an E3 ubiquitin ligase for p53 and the RING finger domain of mdm2 is critical for ligase activity. Ubiquitin (Uh) conjugation is a general targeting modification and poly-ubiquitin chains specifically target proteins to the proteasome for degradation. In this report, we show that the multistep cascade of mdm2-mediated p53 ubiquitination can be reduced to three purified recombinant proteins: ubiquitin-conjugated E2, mdm2, and p53. This simplification allows enzymatic analysis of the isolated ligase reaction. The simplified reaction recapitulates the ubiquitination of p53 observed with individual components and the p53-Ub((n)) is qualitatively similar to p53-Ub((n)), detected in lactacystin-treated cells. Surprisingly, we find that p53 is modified with multiple mono-ubiquitin moieties as opposed to a poly-ubiquitin chain. Finally, kinetic analysis indicates the transfer reaction proceeds either through a modified Ping Pong mechanism involving requisite enzyme isomerization steps, or through a Rapid Equilibrium Random Bi Bi mechanism involving very large anti-cooperative interactions between the two substrate binding pockets on the enzyme, mediated through allosteric changes in enzyme structure.	Dupont Merck Pharmaceut Co, Canc Res, Glenolden, PA 19036 USA; Dupont Merck Pharmaceut Co, Chem Enzymol, Wilmington, DE 19880 USA	DuPont; DuPont	Copeland, RA (corresponding author), Dupont Merck Pharmaceut Co, Canc Res, Glenolden, PA 19036 USA.							Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; Dubiel W, 1999, CURR BIOL, V9, pR554, DOI 10.1016/S0960-9822(99)80353-4; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; HAAS AL, 1982, J BIOL CHEM, V257, P2543; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kaiser P, 2000, CELL, V102, P303, DOI 10.1016/S0092-8674(00)00036-2; Kao WH, 2000, J VIROL, V74, P6408, DOI 10.1128/JVI.74.14.6408-6417.2000; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kumar S, 1997, J BIOL CHEM, V272, P13548, DOI 10.1074/jbc.272.21.13548; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Nakamura S, 2000, MOL CELL BIOL, V20, P9391, DOI 10.1128/MCB.20.24.9391-9398.2000; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Pham AD, 2000, SCIENCE, V289, P2357, DOI 10.1126/science.289.5488.2357; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; Piotrowski J, 1997, J BIOL CHEM, V272, P23712, DOI 10.1074/jbc.272.38.23712; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Robzyk K, 2000, SCIENCE, V287, P501, DOI 10.1126/science.287.5452.501; Rodriguez MS, 2000, MOL CELL BIOL, V20, P8458, DOI 10.1128/MCB.20.22.8458-8467.2000; ROLFE M, 1995, P NATL ACAD SCI USA, V92, P3264, DOI 10.1073/pnas.92.8.3264; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Segel I.H., 1975, ENZYME KINETICS; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Strack P, 2000, ONCOGENE, V19, P3529, DOI 10.1038/sj.onc.1203647; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Tyers M, 1999, SCIENCE, V284, P601, DOI 10.1126/science.284.5414.601; Wee KE, 2000, J PROTEIN CHEM, V19, P489, DOI 10.1023/A:1026501515450; Wu K, 2000, MOL CELL BIOL, V20, P1382, DOI 10.1128/MCB.20.4.1382-1393.2000; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	47	129	131	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31357	31367		10.1074/jbc.M011517200	http://dx.doi.org/10.1074/jbc.M011517200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11397792	hybrid			2022-12-25	WOS:000170472900100
J	Cunto-Amesty, G; Dam, TK; Luo, P; Monzavi-Karbassi, B; Brewer, CF; Van Cott, TC; Kieber-Emmons, T				Cunto-Amesty, G; Dam, TK; Luo, P; Monzavi-Karbassi, B; Brewer, CF; Van Cott, TC; Kieber-Emmons, T			Directing the immune response to carbohydrate antigens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; DIOCLEA-GRANDIFLORA LECTIN; CONCANAVALIN-A; HTLV-III; CAPSULAR POLYSACCHARIDE; MONOCLONAL-ANTIBODY; CONJUGATE VACCINES; FUNCTIONAL MIMICRY; PEPTIDE MIMOTOPES; STRUCTURAL BASIS	Peptide mimetics may substitute for carbohydrate antigens in vaccine design applications. At present, the structural and immunological aspects of antigenic, mimicry, which translate into immunologic mimicry, as well as the functional correlates of each, are unknown. In contrast to screening peptide display libraries, we demonstrate the feasibility of a structure-assisted vaccine design approach to identify functional mimeotopes. By using concanavalin A (ConA), as a recognition template, peptide mimetics reactive with ConA were identified. Designed peptides were observed to compete with synthetic carbohydrate probes for ConA binding, as demonstrated by enzyme-linked immunosorbent assay and isothermal titration calorimetry (ITC) analysis' ITC measurements indicate that a multivalent form of one particular mimetic binds to ConA with.. ar affinity as does trimannoside. Splenocytes from mimeotope-immunized mice display a peptide-specific cellular response,, confirming a T-cell-dependent nature for the mimetic. As ConA binds to the Envelope protein of the human immunodeficiency virus, type I (HIV-1), we observed that mimeotope-induced serum also binds to HIV-1-infected cells, as assessed by flow cytometry, and could neutralize T-cell line adapted HIV-1 isolates in vitro, albeit at low titers. These studies emphasize that mimicry is based more upon functional rather than structural determinants that regulate mimeotope-induced T-dependent antibody responses to polysaccharide and emphasize that rational approaches can be employed to develop further vaccine candidates.	Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Albert Einstein Coll Med, Dept Mol Pharmacol & Microbiol & Immunol, Bronx, NY 10461 USA; Henry M Jackson Fdn, Rockville, MD 20850 USA	University of Pennsylvania; Yeshiva University; Albert Einstein College of Medicine; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc	Kieber-Emmons, T (corresponding author), Univ Penn, Dept Pathol & Lab Med, Rm 205,John Morgan Bldg,36th & Hamilton Walk, Philadelphia, PA 19104 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI044412] Funding Source: NIH RePORTER; NIAID NIH HHS [AI44412] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARENDRUP M, 1993, J GEN VIROL, V74, P855, DOI 10.1099/0022-1317-74-5-855; ARTHUR LO, 1992, SCIENCE, V258, P1935, DOI 10.1126/science.1470916; BALZARINI J, 1991, ANTIMICROB AGENTS CH, V35, P410, DOI 10.1128/AAC.35.3.410; BHATTACHARYYA L, 1990, BIOCHEMISTRY-US, V29, P7523, DOI 10.1021/bi00484a022; BOHM HJ, 1992, J COMPUT AID MOL DES, V6, P593, DOI 10.1007/BF00126217; CHESEBRO B, 1988, J VIROL, V62, P3779, DOI 10.1128/JVI.62.10.3779-3788.1988; CUNTOARNESTY G, 2001, VACCINE, V19, P2861; Dam TK, 1998, J BIOL CHEM, V273, P32826, DOI 10.1074/jbc.273.49.32826; Dam TK, 2000, J BIOL CHEM, V275, P14223, DOI 10.1074/jbc.275.19.14223; Fleuridor R, 2001, J IMMUNOL, V166, P1087, DOI 10.4049/jimmunol.166.2.1087; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; GATTEGNO L, 1992, AIDS RES HUM RETROV, V8, P27, DOI 10.1089/aid.1992.8.27; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5; Goldblatt D, 1998, J MED MICROBIOL, V47, P563, DOI 10.1099/00222615-47-7-563; Gupta D, 1997, J BIOL CHEM, V272, P6388, DOI 10.1074/jbc.272.10.6388; HAERTLE T, 1988, J BIOL CHEM, V263, P5870; Hansen JES, 1996, ARCH VIROL, V141, P291, DOI 10.1007/BF01718400; HARADA S, 1985, SCIENCE, V229, P563, DOI 10.1126/science.2992081; Harris SL, 1997, P NATL ACAD SCI USA, V94, P2454, DOI 10.1073/pnas.94.6.2454; Hruby VJ, 2000, CURR MED CHEM, V7, P945, DOI 10.2174/0929867003374499; Jain D, 2000, BIOCHEM BIOPH RES CO, V272, P843, DOI 10.1006/bbrc.2000.2871; JOHNSON VA, 1990, TECHNIQUES HIV RES, P71; Kaur KJ, 1997, J BIOL CHEM, V272, P5539, DOI 10.1074/jbc.272.9.5539; Kieber-Emmons T, 2000, J IMMUNOL, V165, P623, DOI 10.4049/jimmunol.165.2.623; Kieber-Emmons T, 1999, J BIOL CHEM, V274, P9648, DOI 10.1074/jbc.274.14.9648; Kieber-Emmons T, 1999, NAT BIOTECHNOL, V17, P660, DOI 10.1038/10870; KNELLER DG, 1990, J MOL BIOL, V214, P171, DOI 10.1016/0022-2836(90)90154-E; Kudryashov V, 2001, P NATL ACAD SCI USA, V98, P3264, DOI 10.1073/pnas.051623598; Lin CL, 2000, J EXP MED, V192, P587, DOI 10.1084/jem.192.4.587; LIN CM, 1994, J BIOL CHEM, V269, P2805; Lo-Man R, 2001, J IMMUNOL, V166, P2849, DOI 10.4049/jimmunol.166.4.2849; LOPALCO L, 1993, EUR J IMMUNOL, V23, P2016, DOI 10.1002/eji.1830230844; Luo P, 1998, MOL IMMUNOL, V35, P865, DOI 10.1016/S0161-5890(98)00067-4; Luo P, 2000, J BIOL CHEM, V275, P16146, DOI 10.1074/jbc.M909121199; Mbemba E, 1996, AIDS RES HUM RETROV, V12, P47, DOI 10.1089/aid.1996.12.47; McCool TL, 1999, INFECT IMMUN, V67, P4862, DOI 10.1128/IAI.67.9.4862-4869.1999; Moe GR, 1999, FEMS IMMUNOL MED MIC, V26, P209; MOND JJ, 1995, ANNU REV IMMUNOL, V13, P655, DOI 10.1146/annurev.iy.13.040195.003255; Moothoo DN, 1998, GLYCOBIOLOGY, V8, P173, DOI 10.1093/glycob/8.2.173; MULLER WEG, 1991, J ACQ IMMUN DEF SYND, V4, P694; MULLER WEG, 1990, AIDS, V4, P159, DOI 10.1097/00002030-199002000-00010; Murali R, 1997, J MOL RECOGNIT, V10, P269, DOI 10.1002/(SICI)1099-1352(199711/12)10:6<269::AID-JMR370>3.0.CO;2-9; Murthy MRN, 1997, BIOPHYS CHEM, V68, P33, DOI 10.1016/S0301-4622(97)00005-7; Naismith JH, 1996, J BIOL CHEM, V271, P972, DOI 10.1074/jbc.271.2.972; O I, 2000, BIOCHEM BIOPH RES CO, V268, P106, DOI 10.1006/bbrc.1999.2061; Park BW, 2000, NAT BIOTECHNOL, V18, P194, DOI 10.1038/72651; PINCUS SH, 1989, J IMMUNOL, V142, P3070; Pinilla C, 1998, J MOL BIOL, V283, P1013, DOI 10.1006/jmbi.1998.2137; POPOVIC M, 1984, LANCET, V2, P1472; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; ROBBINS JB, 1990, J INFECT DIS, V161, P821, DOI 10.1093/infdis/161.5.821; ROBINSON WE, 1987, AIDS RES HUM RETROV, V3, P265, DOI 10.1089/aid.1987.3.265; Saifuddin M, 2000, J GEN VIROL, V81, P949, DOI 10.1099/0022-1317-81-4-949; SALTER RD, 1985, IMMUNOGENETICS, V21, P235, DOI 10.1007/BF00375376; SCHNEERSON R, 1980, J EXP MED, V152, P361, DOI 10.1084/jem.152.2.361; SHAW GM, 1984, SCIENCE, V226, P1165, DOI 10.1126/science.6095449; SMITH SD, 1984, CANCER RES, V44, P5657; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; STEIN KE, 1992, J INFECT DIS, V165, P549; Vos Q, 2000, IMMUNOL REV, V176, P154; WESTERINK MAJ, 1995, P NATL ACAD SCI USA, V92, P4021, DOI 10.1073/pnas.92.9.4021; Zhu XG, 2000, BIOCHEMISTRY-US, V39, P11194, DOI 10.1021/bi000432m; Zou W, 1999, J IMMUNOL, V163, P820	65	38	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30490	30498		10.1074/jbc.M103257200	http://dx.doi.org/10.1074/jbc.M103257200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11384987	hybrid			2022-12-25	WOS:000170558000116
J	Matassa, AA; Carpenters, L; Biden, TJ; Humphries, MJ; Reyland, ME				Matassa, AA; Carpenters, L; Biden, TJ; Humphries, MJ; Reyland, ME			PKC delta is required for mitochondrial-dependent apoptosis in salivary epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C-DELTA; MEMBRANE POTENTIAL LOSS; PROTEIN-KINASE; PROTEOLYTIC ACTIVATION; CLEAVAGE; RELEASE; DEATH; TRANSLOCATION; PATHWAYS; PHOSPHORYLATION	We report here that the novel protein kinase C isoform, PKC delta, is required at or prior to the level of the mitochondria for apoptosis induced by a diverse group of cell toxins. We have used adenoviral expression of a kinase-dead (KD) mutant of PKC delta to explore the requirement for PKC delta in the mitochondrial-dependent apoptotic pathway. Expression of PKC delta KD, but not PKC delta KD, in salivary epithelial cells resulted in a dose-dependent inhibition of apoptosis induced by etoposide, UV-irradiation, brefeldin A, and paclitaxel. DNA fragmentation was blocked up to 71% in parotid C5 cells infected with the PKC delta KD adenovirus, whereas caspase-3 activity was inhibited up to 65%. The activation of caspase-9-like proteases by all agents was also inhibited in parotid C5 cells expressing PKC delta KD. The ability of PKC delta KD to block the loss of mitochondrial membrane potential was similarly determined. Expression of PKC delta KD blocked the decrease in mitochondrial membrane potential observed in cells treated with etoposide, UV, brefeldin A, or paclitaxel in a dose-dependent manner. In contrast to the protective function of PKC delta KD, expression of PKC delta WT resulted in a potent induction of apoptosis, which could be inhibited by coinfection with PKC delta KD. These results suggest that PKC delta is a common intermediate in mitochondrial-dependent apoptosis in salivary epithelial cells.	Univ Colorado, Hlth Sci Ctr, Dept Basic Sci & Oral Res, Sch Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Cell & Struct Biol, Sch Med, Denver, CO 80262 USA; Garvan Inst Med Res, Darlinghurst, NSW 2010, Australia	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Garvan Institute of Medical Research	Reyland, ME (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Basic Sci & Oral Res, Sch Med, 4200 E 9th Ave,Box C286, Denver, CO 80262 USA.	mary.reyland@UCHSC.edu	Biden, Trevor/AAW-2829-2021	Biden, Trevor/0000-0001-5211-0234	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE012798] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE12798] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Anderson SM, 1999, CELL DEATH DIFFER, V6, P454, DOI 10.1038/sj.cdd.4400507; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; Carpenter L, 2001, J BIOL CHEM, V276, P5368, DOI 10.1074/jbc.M010036200; Cross T, 2000, ONCOGENE, V19, P2331, DOI 10.1038/sj.onc.1203555; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; DONALDSON KL, 1994, CELL GROWTH DIFFER, V5, P1041; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Endo K, 2000, J BIOL CHEM, V275, P18476, DOI 10.1074/jbc.M002266200; Frasch SC, 1998, J BIOL CHEM, V273, P8389, DOI 10.1074/jbc.273.14.8389; Frutos S, 1999, J BIOL CHEM, V274, P10765, DOI 10.1074/jbc.274.16.10765; Fujii T, 2000, J BIOL CHEM, V275, P7574, DOI 10.1074/jbc.275.11.7574; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; GRAHAM FL, 1995, MOL BIOTECHNOL, V3, P207, DOI 10.1007/BF02789331; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Heiskanen KM, 1999, J BIOL CHEM, V274, P5654, DOI 10.1074/jbc.274.9.5654; Johnson BW, 2000, J BIOL CHEM, V275, P31546, DOI 10.1074/jbc.M001363200; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; Keenan C, 1997, FEBS LETT, V415, P101, DOI 10.1016/S0014-5793(97)01104-6; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1999, BLOOD, V94, P291, DOI 10.1182/blood.V94.1.291.413k10_291_301; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Koya RC, 2000, J BIOL CHEM, V275, P15343, DOI 10.1074/jbc.275.20.15343; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Li LW, 1999, MOL CELL BIOL, V19, P8547; LI WQ, 1995, J BIOL CHEM, V270, P8311, DOI 10.1074/jbc.270.14.8311; Majumder PK, 2000, J BIOL CHEM, V275, P21793, DOI 10.1074/jbc.C000048200; McGregor WG, 1999, J INVEST DERM SYMP P, V4, P1, DOI 10.1038/sj.jidsp.5640172; Nevins JR, 1997, METHOD ENZYMOL, V283, P205; Powell CT, 1996, CELL GROWTH DIFFER, V7, P419; Quissell DO, 1998, IN VITRO CELL DEV-AN, V34, P58; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Reyland ME, 2000, CELL DEATH DIFFER, V7, P1200, DOI 10.1038/sj.cdd.4400744; Robertson JD, 2000, J BIOL CHEM, V275, P32438, DOI 10.1074/jbc.C000518200; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; SCHAACK J, 1995, J VIROL, V69, P3920, DOI 10.1128/JVI.69.6.3920-3923.1995; Scheel-Toellner D, 1999, EUR J IMMUNOL, V29, P2603, DOI 10.1002/(SICI)1521-4141(199908)29:08<2603::AID-IMMU2603>3.0.CO;2-L; Schwarz T, 1998, J PHOTOCH PHOTOBIO B, V44, P91, DOI 10.1016/S1011-1344(98)00126-2; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; Smith L, 2000, J BIOL CHEM, V275, P40620, DOI 10.1074/jbc.M908517199; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; TORII S, 1995, J BIOL CHEM, V270, P11574, DOI 10.1074/jbc.270.19.11574; Utz PJ, 2000, CELL DEATH DIFFER, V7, P589, DOI 10.1038/sj.cdd.4400696; Whelan RDH, 1998, ONCOGENE, V16, P1939, DOI 10.1038/sj.onc.1201725; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; YANG L, 1985, CANCER RES, V45, P5872; Zhao X, 1997, J BIOL CHEM, V272, P22751, DOI 10.1074/jbc.272.36.22751	51	113	116	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29719	29728		10.1074/jbc.M100273200	http://dx.doi.org/10.1074/jbc.M100273200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11369761	hybrid			2022-12-25	WOS:000170558000018
J	Rodriguez, C; Huang, LJS; Son, JK; McKee, A; Xiao, Z; Lodish, HF				Rodriguez, C; Huang, LJS; Son, JK; McKee, A; Xiao, Z; Lodish, HF			Functional cloning of the proto-oncogene brain factor-1 (BF-1) as a smad-binding antagonist of transforming growth factor-beta signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATOR INHIBITOR-1 GENE; TGF-BETA; TRANSCRIPTION FACTORS; RECEPTOR COMPLEX; QIN PROTEIN; EXPRESSION; RESPONSES; SPECIFICITY; ONCOPROTEIN; REPRESSOR	Using the plasminogen activator inhibitor (PAI) promoter to drive the expression of a reporter gene (mouse CD2), we devised a system to clone negative regulators of the transforming growth factor-beta (TGF-beta) signaling pathway. We infected a TGF-beta -responsive cell line (MvLu1) with a retroviral cDNA library, selecting by fluorescence-activated cell sorter single cells displaying low PAI promoter activity in response to TGF-beta. Using this strategy we cloned the proto-oncogene brain factor-1 (BF-1). BF-1 represses the PAI promoter in part by associating with both unphosphorylated Smad3 (in the cytoplasm) and phosphorylated Smad3 (in the nucleus), thus preventing its binding to DNA BF-1 also associates with Smad1, -2, and -4, the Smad MH2 domain binds to BF-1, and the C-terminal segment of BF-1 is uniquely and solely required for binding to Smads. Further, BF-1 represses another TGF-beta -induced promoter (p15), it upregulates a TGF-beta -repressed promoter (Cyclin A), and it reverses the growth arrest caused by TGF-beta. Our results suggest that BF-1 is a general inhibitor of TGF-beta signaling and as such may play a key role during brain development.	Whitehead Inst Biomed Res, Cambridge Ctr 9, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Lodish, HF (corresponding author), Whitehead Inst Biomed Res, Cambridge Ctr 9, Cambridge, MA 02142 USA.			rodriguez, carlos/0000-0001-9593-8680	NCI NIH HHS [CA63260] Funding Source: Medline; NHLBI NIH HHS [5F32HL10048-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063260] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL010048] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Amoroso SR, 1998, P NATL ACAD SCI USA, V95, P189, DOI 10.1073/pnas.95.1.189; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Bergelson S, 1998, J BIOL CHEM, V273, P2396, DOI 10.1074/jbc.273.4.2396; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; Chang HW, 1996, ONCOGENE, V13, P441; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; DeCoteau JF, 1997, P NATL ACAD SCI USA, V94, P5877, DOI 10.1073/pnas.94.11.5877; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Dou CL, 2000, MOL CELL BIOL, V20, P6201, DOI 10.1128/MCB.20.17.6201-6211.2000; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; HemmatiBrivanlou A, 1997, CELL, V88, P13, DOI 10.1016/S0092-8674(00)81853-X; Hua XX, 1999, P NATL ACAD SCI USA, V96, P13130, DOI 10.1073/pnas.96.23.13130; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Huang LJS, 1999, J CELL BIOL, V145, P951, DOI 10.1083/jcb.145.5.951; KITAMURA T, 1995, P NATL ACAD SCI USA, V92, P9146, DOI 10.1073/pnas.92.20.9146; Knaus PI, 1996, MOL CELL BIOL, V16, P3480; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; Li J, 1997, P NATL ACAD SCI USA, V94, P10885, DOI 10.1073/pnas.94.20.10885; LI J, 1995, CANCER RES, V55, P5540; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Mahony D, 1998, MECH DEVELOP, V75, P95, DOI 10.1016/S0925-4773(98)00092-6; MASSAGUE J, 1995, CURR OPIN GENET DEV, V5, P91, DOI 10.1016/S0959-437X(95)90059-4; Moses HL, 1996, CURR OPIN GENET DEV, V6, P581, DOI 10.1016/S0959-437X(96)80087-6; Onishi M, 1996, EXP HEMATOL, V24, P324; Pepper Michael S., 1997, Cytokine and Growth Factor Reviews, V8, P21, DOI 10.1016/S1359-6101(96)00048-2; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; Rodriguez C, 1998, BIOTECHNIQUES, V24, P750, DOI 10.2144/98245bm11; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; TAO W, 1992, NEURON, V8, P957, DOI 10.1016/0896-6273(92)90210-5; TEN DP, 2000, TRENDS BIOCHEM SCI, V25, P64; Watanabe M, 1999, CELL MOL BIOL, V45, P537; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; XUAN SH, 1995, NEURON, V14, P1141, DOI 10.1016/0896-6273(95)90262-7; Yang YL, 1999, NAT GENET, V21, P216, DOI 10.1038/6005	45	43	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30224	30230		10.1074/jbc.M102759200	http://dx.doi.org/10.1074/jbc.M102759200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11387330	hybrid			2022-12-25	WOS:000170558000083
J	Rundlof, AK; Carlsten, M; Arner, ESJ				Rundlof, AK; Carlsten, M; Arner, ESJ			The core promoter of human thioredoxin reductase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELENOCYSTEINE INSERTION-SEQUENCE; MESSENGER-RNA STABILITY; MAMMALIAN THIOREDOXIN; TRANSCRIPTION FACTORS; MOLECULAR-CLONING; REDOX REGULATION; GENE-EXPRESSION; GROWTH-FACTOR; SELENOPROTEIN; CELLS	The selenoprotein thioredoxin reductase 1 (TrxR1) carries many vital antioxidant and redox regulatory functions, Its mRNA levels are known to be post-transcriptionally modulated via AUUUA motifs (AU-rich elements (AREs)), but the promoter yet remains unknown. Here we. have cloned and determined the sequence of a 0.8-kilobase pair human genomic. fragment containing the proximal promoter for TrxR1, which has transcriptional. activity in several different cell types. The core promoter (-115 to +167) had an increased GC content and lacked TATA or CCAAT boxes. It contained a POU motif binding the Oct-1 transcription factor and two sites binding Sp1 and Sp3, which were identified with electrophoretic mobility shift assays using crude nuclear extracts of A549 cells. The TrxR1 promoter fulfills the typical criteria of a housekeeping gene. To our knowledge this is the first housekeeping-type promoter characterized for a gene with post-transcriptional regulation via ARE motifs generally possessed by transiently expressed proto-oncogenes, nuclear transcription factors, or cytokines and influencing mRNA stability in response to diverse exogenous factors. Expression of TrxR1 as an ARE-regulated housekeeping gene agrees with a role for the enzyme to maintain a balance between intracellular signaling via reactive oxygen species and protection of cells from excessive oxidative damage.	Karolinska Inst, Dept Med Biochem & Biophys, Nobel Inst Biochem, SE-17177 Stockholm, Sweden	Karolinska Institutet	Arner, ESJ (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Nobel Inst Biochem, SE-17177 Stockholm, Sweden.		Arnér, Elias/K-6737-2019; Arnér, Elias S.J./J-5832-2012; Carlsten, Mattias/AAH-7001-2019	Arnér, Elias/0000-0002-4807-6114; Arnér, Elias S.J./0000-0002-4807-6114; Carlsten, Mattias/0000-0001-9815-0012				Allen RG, 2000, FREE RADICAL BIO MED, V28, P463, DOI 10.1016/S0891-5849(99)00242-7; Anema SM, 1999, BIOCHEM J, V342, P111, DOI 10.1042/0264-6021:3420111; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Arner ESJ, 1996, BIOCHEM BIOPH RES CO, V225, P268, DOI 10.1006/bbrc.1996.1165; Bakheet T, 2001, NUCLEIC ACIDS RES, V29, P246, DOI 10.1093/nar/29.1.246; Becker K, 2000, EUR J BIOCHEM, V267, P6118, DOI 10.1046/j.1432-1327.2000.01703.x; Berggren M, 1996, ANTICANCER RES, V16, P3459; Bertini R, 1999, J EXP MED, V189, P1783, DOI 10.1084/jem.189.11.1783; BJORNSTEDT M, 1995, J BIOL CHEM, V270, P11761, DOI 10.1074/jbc.270.20.11761; Chae HZ, 1999, METHOD ENZYMOL, V300, P219; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Du XL, 2000, P NATL ACAD SCI USA, V97, P12222, DOI 10.1073/pnas.97.22.12222; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Fujiwara N, 1999, BIOCHEM J, V340, P439, DOI 10.1042/0264-6021:3400439; Gasdaska JR, 1996, GENOMICS, V37, P257, DOI 10.1006/geno.1996.0554; Gasdaska JR, 1999, J BIOL CHEM, V274, P25379, DOI 10.1074/jbc.274.36.25379; GASDASKA PY, 1995, FEBS LETT, V373, P5, DOI 10.1016/0014-5793(95)01003-W; Ghosh R, 1999, NUCLEIC ACIDS RES, V27, P3213, DOI 10.1093/nar/27.15.3213; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; Gunther M, 2000, MOL CELL BIOCHEM, V210, P131, DOI 10.1023/A:1007177623283; HOLMGREN A, 1980, P NATL ACAD SCI-BIOL, V77, P5149, DOI 10.1073/pnas.77.9.5149; HOLMGREN A, 1977, J BIOL CHEM, V252, P4600; Howie AF, 1998, J CLIN ENDOCR METAB, V83, P2052, DOI 10.1210/jc.83.6.2052; Jensen DE, 1997, J CELL BIOCHEM, V67, P24, DOI 10.1002/(SICI)1097-4644(19971001)67:1<24::AID-JCB3>3.0.CO;2-Y; Kawai H, 2000, GENE, V242, P321, DOI 10.1016/S0378-1119(99)00498-9; Koishi R, 1997, J BIOL CHEM, V272, P2570; KUMAR S, 1992, EUR J BIOCHEM, V207, P435, DOI 10.1111/j.1432-1033.1992.tb17068.x; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; LAURENT TC, 1964, J BIOL CHEM, V239, P3436; Lee SR, 1999, J BIOL CHEM, V274, P4722, DOI 10.1074/jbc.274.8.4722; Lescure A, 1999, J BIOL CHEM, V274, P38147, DOI 10.1074/jbc.274.53.38147; Lickteig K, 1996, MOL REPROD DEV, V44, P146, DOI 10.1002/(SICI)1098-2795(199606)44:2<146::AID-MRD2>3.0.CO;2-N; Miranda-Vizuete A, 1999, EUR J BIOCHEM, V261, P405, DOI 10.1046/j.1432-1327.1999.00286.x; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; Pages G, 2000, J BIOL CHEM, V275, P26484, DOI 10.1074/jbc.M002104200; Pesce M, 1999, CELLS TISSUES ORGANS, V165, P144, DOI 10.1159/000016694; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; ROZELL B, 1985, EUR J CELL BIOL, V38, P79; Rundlof AK, 2000, BIOCHEM J, V347, P661, DOI 10.1042/0264-6021:3470661; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Scherf M, 2000, J MOL BIOL, V297, P599, DOI 10.1006/jmbi.2000.3589; Schutze N, 1998, BIOFACTORS, V7, P299, DOI 10.1002/biof.5520070402; Schutze N, 1999, BIOFACTORS, V10, P329, DOI 10.1002/biof.5520100403; Soderberg A, 2000, CANCER RES, V60, P2281; Strom AC, 1996, NUCLEIC ACIDS RES, V24, P1981, DOI 10.1093/nar/24.11.1981; Sun QA, 1999, J BIOL CHEM, V274, P24522, DOI 10.1074/jbc.274.35.24522; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; SWICK AG, 1989, NUCLEIC ACIDS RES, V17, P9291, DOI 10.1093/nar/17.22.9291; Tamura T, 1996, P NATL ACAD SCI USA, V93, P1006, DOI 10.1073/pnas.93.3.1006; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; WAKASUGI N, 1990, P NATL ACAD SCI USA, V87, P8282, DOI 10.1073/pnas.87.21.8282; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Wu XS, 1996, MOL CELL BIOL, V16, P1035; Zhang P, 1997, J BIOL CHEM, V272, P30615, DOI 10.1074/jbc.272.49.30615; Zhon LW, 1998, J BIOL CHEM, V273, P8581, DOI 10.1074/jbc.273.15.8581; Zhong LW, 2000, P NATL ACAD SCI USA, V97, P5854, DOI 10.1073/pnas.100114897; Zhong LW, 2000, J BIOL CHEM, V275, P18121, DOI 10.1074/jbc.M000690200	60	74	76	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30542	30551		10.1074/jbc.M101452200	http://dx.doi.org/10.1074/jbc.M101452200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11375392	hybrid			2022-12-25	WOS:000170558000123
J	Ananthanarayanan, M; Balasubramanian, N; Makishima, M; Mangelsdorf, DJ; Suchy, FJ				Ananthanarayanan, M; Balasubramanian, N; Makishima, M; Mangelsdorf, DJ; Suchy, FJ			Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; NUCLEAR RECEPTOR; PHOSPHOINOSITIDE 3-KINASE; P-GLYCOPROTEIN; APICAL DOMAIN; PROTEIN GENE; SISTER GENE; TRANSPORT; EXPRESSION; IDENTIFICATION	The bile salt excretory pump (BSEP, ABCb11) is critical for ATP-dependent transport of bile acids across the hepatocyte canalicular membrane and for generation of bile acid-dependent bile secretion. Recent studies have demonstrated that the expression of this transporter is sensitive to the flux of bile acids through the hepatocyte, possibly at the level of transcription of the BSEP gene. To determine the mechanisms underlying the regulation of BSEP by bile acids, the promoter of the BSEP gene was cloned. The sequence of the promoter contained an inverted repeat (IR)-1 element (5 ' -GGGACA T TGATCCT-3 ') at base pairs -63/-50 consisting of two nuclear receptor half-sites organized as an inverted repeat and separated by a single nucleotide. This IR-1 element has been shown in several recent studies to serve as a binding site for the farnesoid X receptor (FXR), a nuclear receptor for bile acids. FXR activity requires heterodimerization with RXR alpha, and when bound by bile acids, the complex effectively regulates the transcription of several genes involved in bile acid homeostasis. Gel mobility shift assays demonstrated specific binding of FXR/RXR alpha heterodimers to the IR-1 element in the BSEP promoter. In HepG2 cells, co-transfection of FXR and RXRa is required to attain full transactivation of the BSEP promoter by bile acids. Two FXR transactivation-deficient mutants (an AF-2 deletion and a W469A point mutant) failed to transactivate, indicating that the effect of bile acids is FXR-dependent. Further, mutational analysis confirms that the FXR/RXRa heterodimer activates transcription through the IR-1 site in the human BSEP promoter. These results demonstrate a mechanism by which bile acids transcriptionally regulate the activity of the bile salt excretory pump, a critical component involved in the enterohepatic circulation of bile acids.	Mt Sinai Med Ctr, Dept Pediat, Lab Dev & Mol Hepatol, New York, NY 10029 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	Icahn School of Medicine at Mount Sinai; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Ananthanarayanan, M (corresponding author), Mt Sinai Med Ctr, Dept Pediat, Lab Dev & Mol Hepatol, 1 Gustave L Levy Pl, New York, NY 10029 USA.	meena_ananth@mssm.edu		Mangelsdorf, David/0000-0002-4355-0796	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD020632, R01HD020632] Funding Source: NIH RePORTER; NICHD NIH HHS [HD20632] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARRESE M, 2000, GASTROENTEROLOGY, V118, pA33; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BALASUBRAMANIAN N, 2001, FASEB J, V15, P762; BOYER JL, 1995, GASTROENTEROLOGY, V109, P1600, DOI 10.1016/0016-5085(95)90649-5; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Chawla A, 2000, CELL, V103, P1, DOI 10.1016/S0092-8674(00)00097-0; Chiang JYL, 2000, J BIOL CHEM, V275, P10918, DOI 10.1074/jbc.275.15.10918; Childs S, 1998, CANCER RES, V58, P4160; CHILDS S, 1995, CANCER RES, V55, P2029; Denson LJ, 2000, HEPATOLOGY, V32, p297A; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; FICKERT P, 2000, GASTROENTEROLOGY, V118, pA33; Gartung C, 1996, GASTROENTEROLOGY, V110, P199, DOI 10.1053/gast.1996.v110.pm8536857; Gatmaitan ZC, 1997, AM J PHYSIOL-GASTR L, V272, pG1041, DOI 10.1152/ajpgi.1997.272.5.G1041; Gerloff T, 1998, J BIOL CHEM, V273, P10046, DOI 10.1074/jbc.273.16.10046; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Green RM, 1996, GASTROENTEROLOGY, V111, P193, DOI 10.1053/gast.1996.v111.pm8698199; Grober J, 1999, J BIOL CHEM, V274, P29749, DOI 10.1074/jbc.274.42.29749; HAGENBUCH B, 1991, P NATL ACAD SCI USA, V88, P10629, DOI 10.1073/pnas.88.23.10629; JAVITT NB, 1989, J BIOL CHEM, V264, P10384; KADONAGA JT, 1980, TRENDS BIOCHEM SCI, V11, P20; Kipp H, 2000, J BIOL CHEM, V275, P15917, DOI 10.1074/jbc.M909875199; Kullak-Ublick GA, 2000, SEMIN LIVER DIS, V20, P273, DOI 10.1055/s-2000-9426; Laffitte BA, 2000, J BIOL CHEM, V275, P10638, DOI 10.1074/jbc.275.14.10638; Lee JM, 2000, GASTROENTEROLOGY, V118, P163, DOI 10.1016/S0016-5085(00)70425-2; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Misra S, 1999, P NATL ACAD SCI USA, V96, P5814, DOI 10.1073/pnas.96.10.5814; Misra S, 1998, J BIOL CHEM, V273, P26638, DOI 10.1074/jbc.273.41.26638; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Moseley RH, 1996, AM J PHYSIOL-GASTR L, V271, pG137, DOI 10.1152/ajpgi.1996.271.1.G137; Muller M, 2000, SEMIN LIVER DIS, V20, P323, DOI 10.1055/s-2000-9387; NATHANSON MH, 1991, HEPATOLOGY, V14, P551, DOI 10.1002/hep.1840140324; NISHIDA T, 1991, P NATL ACAD SCI USA, V88, P6590, DOI 10.1073/pnas.88.15.6590; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; STIEGER B, 1992, BIOCHEM J, V284, P67, DOI 10.1042/bj2840067; Strautnieks SS, 1998, NAT GENET, V20, P233, DOI 10.1038/3034; Thompson R, 2000, SEMIN LIVER DIS, V20, P365, DOI 10.1055/s-2000-9384; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; Urizar NL, 2000, J BIOL CHEM, V275, P39313, DOI 10.1074/jbc.M007998200; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; ZHANG L, 2000, J BIOL CHEM, V276, P2663	45	597	634	5	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28857	28865		10.1074/jbc.M011610200	http://dx.doi.org/10.1074/jbc.M011610200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11387316	hybrid			2022-12-25	WOS:000170346000031
J	Jun, CD; Carman, CV; Redick, SD; Shimaoka, M; Erickson, HP; Springer, TA				Jun, CD; Carman, CV; Redick, SD; Shimaoka, M; Erickson, HP; Springer, TA			Ultrastructure and function of dimeric, soluble intercellular adhesion molecule-1 (ICAM-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTION-ASSOCIATED ANTIGEN-1; SURFACE-PLASMON RESONANCE; ELECTRON-MICROSCOPY; MASS-TRANSPORT; LIGAND-BINDING; COILED-COILS; RHINOVIRUS; RECEPTOR; DOMAINS; LFA-1	Previous studies have demonstrated dimerization of intercellular adhesion molecule-1 (ICAM-1) on the cell surface and suggested a role for immunoglobulin superfamily domain 5 and/or the transmembrane domain in mediating such dimerization. Crystallization studies suggest that domain I may also mediate dimerization. ICAM-1 binds through domain 1 to the I domain of the integrin alpha (L)beta (2) (lymphocyte function-associated antigen 1). Soluble C-terminally dimerized ICAM-1 was made by replacing the transmembrane and cytoplasmic domains with an a-helical coiled coil. Electron microscopy revealed C-terminal dimers that were straight, slightly bent, and sometimes U-shaped. A small number of apparently closed ring-like dimers and W-shaped tetramers were found. To capture ICAM-1 dimerized at the crystallographically defined dimer interface in domain 1, cysteines were introduced into this interface. Several of these mutations resulted in the formation of soluble disulfide-bonded ICAM-1 dimers (domain 1 dimers). Combining a domain I cysteine mutation with the C-terminal dimers (domain 1/C-terminal dimers) resulted in significant amounts of both closed ring-like dimers and W-shaped tetramers. Surface plasmon resonance studies showed that all of the dimeric forms of ICAM-1 (domain 1, C-terminal, and domain 1/C-terminal dimers) bound similarly to the integrin alpha (L)beta (2) I domain, with affinities similar to1.5-3-fold greater than that of monomeric ICAM-1. These studies demonstrate that ICAM-1 can form at least three different topologies and that dimerization at domain 1 does not interfere with binding in domain I to alpha (L)beta (2).	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Anesthesia, Boston, MA 02115 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; Duke University	Springer, TA (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 200 Longwood Ave, Boston, MA 02115 USA.		Carman, Christopher V./AAX-8995-2020; Carman, Christopher/L-8108-2016	Carman, Christopher V./0000-0001-7358-2548; Carman, Christopher/0000-0001-7358-2548				Bella J, 1998, P NATL ACAD SCI USA, V95, P4140, DOI 10.1073/pnas.95.8.4140; CARRELL NA, 1989, J BIOL CHEM, V264, P551; CASASNOVAS JM, 1994, J VIROL, V68, P5882, DOI 10.1128/JVI.68.9.5882-5889.1994; CASASNOVAS JM, 1995, J BIOL CHEM, V270, P13216, DOI 10.1074/jbc.270.22.13216; Casasnovas JM, 1998, P NATL ACAD SCI USA, V95, P4134, DOI 10.1073/pnas.95.8.4134; de Mol NJ, 2000, ANAL BIOCHEM, V279, P61, DOI 10.1006/abio.1999.4464; DEFOUGEROLLES AR, 1994, J EXP MED, V179, P619, DOI 10.1084/jem.179.2.619; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; DUSTIN ML, 1999, GUIDEBOOK EXTRACELLU, P228; FOWLER WE, 1979, J MOL BIOL, V134, P241, DOI 10.1016/0022-2836(79)90034-2; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HAZES B, 1988, PROTEIN ENG, V2, P119, DOI 10.1093/protein/2.2.119; Janin J, 1997, NAT STRUCT BIOL, V4, P973, DOI 10.1038/nsb1297-973; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KIRCHHAUSEN T, 1993, J LEUKOCYTE BIOL, V53, P342, DOI 10.1002/jlb.53.3.342; Labadia ME, 1998, J IMMUNOL, V161, P836; LEVITT M, 1992, J MOL BIOL, V226, P507, DOI 10.1016/0022-2836(92)90964-L; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2387, DOI 10.1073/pnas.041606398; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2393, DOI 10.1073/pnas.041618598; MAIO M, 1989, J IMMUNOL, V143, P181; MARLIN SD, 1990, NATURE, V344, P70, DOI 10.1038/344070a0; MILLER J, 1995, J EXP MED, V182, P1231, DOI 10.1084/jem.182.5.1231; Oxvig C, 1999, P NATL ACAD SCI USA, V96, P2215, DOI 10.1073/pnas.96.5.2215; Parkos CA, 1996, MOL MED, V2, P489, DOI 10.1007/BF03401908; REILLY PL, 1995, J IMMUNOL, V155, P529; ROTHLEIN R, 1991, J IMMUNOL, V147, P3788; ROTHLEIN R, 1988, J IMMUNOL, V141, P1665; ROTHLEIN R, 1986, J EXP MED, V163, P1132, DOI 10.1084/jem.163.5.1132; Schuck P, 1996, BIOPHYS J, V70, P1230, DOI 10.1016/S0006-3495(96)79681-9; Schurmann G, 2001, MOL BIOL CELL, V12, P1765, DOI 10.1091/mbc.12.6.1765; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; Shimaoka M, 2001, P NATL ACAD SCI USA, V98, P6009, DOI 10.1073/pnas.101130498; STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; Stewart M, 1996, J CELL BIOCHEM, V61, P554, DOI 10.1002/(SICI)1097-4644(19960616)61:4<554::AID-JCB8>3.0.CO;2-N; Takagi J, 2001, NAT STRUCT BIOL, V8, P412, DOI 10.1038/87569; Wagschal K, 1999, J MOL BIOL, V285, P785, DOI 10.1006/jmbi.1998.2284; Wang JH, 1998, IMMUNOL REV, V163, P197, DOI 10.1111/j.1600-065X.1998.tb01198.x	38	56	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29019	29027		10.1074/jbc.M103394200	http://dx.doi.org/10.1074/jbc.M103394200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11390397	hybrid			2022-12-25	WOS:000170346000053
J	Xu, FP; Zhao, RX; Peng, YD; Guerrah, A; Zhao, ZZJ				Xu, FP; Zhao, RX; Peng, YD; Guerrah, A; Zhao, ZZJ			Association of tyrosine phosphatase SHP-2 with F-actin at low cell densities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; INTEGRIN-MEDIATED ADHESION; SRC-FAMILY KINASES; DOMINANT-NEGATIVE MUTANT; TUMOR-SUPPRESSOR PTEN; SUBSTRATUM ADHESION; INTERACTING PROTEIN; IN-VIVO; PTP-MU; GROWTH	SHP-2 is an intracellular SH2 domain-containing protein-tyrosine phosphatase with an essential role in cell signaling. Here we demonstrate that localization of SHP-2 is regulated by cell density in a cell adhesion-dependent manner. When cells were plated at low densities, SHP-2 was distributed in Triton X-100-insoluble fractions, whereas it was totally soluble when cells were plated at high densities or when low density cells approached confluency. In all cases, the total protein level of SHP-2 was not changed. Fluorescent cell staining revealed that SHP-2 was co-localized with actin stress fibers to the cell peripheral at low cell densities but was diffused in the entire cytoplasm at high cell densities. Transient transfection of cells with truncated forms of SHP-2 demonstrated that the catalytic domain of the enzyme was responsible for the density-regulated distribution of SHP-2, but the catalytic activity was not required. An in vitro co-sedimentation study demonstrated direct binding of full-length and SH2 domain-truncated forms of SHP-2 to F-actin. The data indicate that SHP-2 is regulated by cell density and that it may have a role in assembling and disassembling of the actin network.	Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Dept Med Hematol Oncol, Nashville, TN 37232 USA	Vanderbilt University	Zhao, ZZJ (corresponding author), 547,PRB,2220 Pierce Ave, Nashville, TN 37232 USA.				NATIONAL CANCER INSTITUTE [R01CA075218, P30CA068485] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057393] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015555, T32DK007186] Funding Source: NIH RePORTER; NCI NIH HHS [CA-68485, CA75218] Funding Source: Medline; NHLBI NIH HHS [HL-57393] Funding Source: Medline; NIDDK NIH HHS [DK-15555, T32-DK07186] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; Arregui CO, 1998, J CELL BIOL, V143, P861, DOI 10.1083/jcb.143.3.861; BARNEA G, 1994, J BIOL CHEM, V269, P14349; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; BENNETT PA, 1993, J CELL SCI, V106, P891; Brady-Kalnay SM, 1998, J CELL BIOL, V141, P287, DOI 10.1083/jcb.141.1.287; BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977; Choquet D, 1997, CELL, V88, P39, DOI 10.1016/S0092-8674(00)81856-5; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DEFILIPPI P, 1995, EXP CELL RES, V221, P141, DOI 10.1006/excr.1995.1361; Feng GS, 1999, EXP CELL RES, V253, P47, DOI 10.1006/excr.1999.4668; Flinn HM, 1996, J CELL SCI, V109, P1133; Fuchs M, 1996, J BIOL CHEM, V271, P16712, DOI 10.1074/jbc.271.28.16712; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; GEBBINK MFBG, 1995, J CELL BIOL, V131, P251, DOI 10.1083/jcb.131.1.251; Hakak Y, 2000, ONCOGENE, V19, P3164, DOI 10.1038/sj.onc.1203655; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Harder KW, 1998, J BIOL CHEM, V273, P31890, DOI 10.1074/jbc.273.48.31890; HOWARD PK, 1993, SCIENCE, V259, P241, DOI 10.1126/science.7678470; HOWARD PK, 1992, CELL, V71, P637, DOI 10.1016/0092-8674(92)90597-6; Huang C, 1997, J BIOL CHEM, V272, P19248, DOI 10.1074/jbc.272.31.19248; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; Inagaki K, 2000, ONCOGENE, V19, P75, DOI 10.1038/sj.onc.1203204; Jackson DE, 1997, J BIOL CHEM, V272, P6986, DOI 10.1074/jbc.272.11.6986; Kadlec L, 1997, P NATL ACAD SCI USA, V94, P12390, DOI 10.1073/pnas.94.23.12390; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Kodama A, 2000, MOL BIOL CELL, V11, P2565, DOI 10.1091/mbc.11.8.2565; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; Manes S, 1999, MOL CELL BIOL, V19, P3125; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; Ogata M, 1999, J BIOL CHEM, V274, P12905, DOI 10.1074/jbc.274.18.12905; Oh ES, 1999, MOL CELL BIOL, V19, P3205; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; PALLEN CJ, 1991, P NATL ACAD SCI USA, V88, P6996, DOI 10.1073/pnas.88.16.6996; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; Qi JH, 1999, J BIOL CHEM, V274, P14455, DOI 10.1074/jbc.274.20.14455; Qu CK, 2000, CELL RES, V10, P279, DOI 10.1038/sj.cr.7290055; Retta SF, 1996, EXP CELL RES, V229, P307, DOI 10.1006/excr.1996.0376; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; Roach T, 1997, CURR BIOL, V7, P408, DOI 10.1016/S0960-9822(06)00188-6; Roach TIA, 1998, CURR BIOL, V8, P1035, DOI 10.1016/S0960-9822(07)00426-5; Sabe H, 1997, ONCOGENE, V14, P1779, DOI 10.1038/sj.onc.1201022; Sagawa K, 1997, J BIOL CHEM, V272, P31086, DOI 10.1074/jbc.272.49.31086; Salgia R, 1997, J CLIN INVEST, V100, P46, DOI 10.1172/JCI119520; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; Stein-Gerlach M, 1998, INT J BIOCHEM CELL B, V30, P559, DOI 10.1016/S1357-2725(98)00002-8; Streuli M, 1996, CURR OPIN CELL BIOL, V8, P182, DOI 10.1016/S0955-0674(96)80064-0; Su J, 1999, CURR BIOL, V9, P505, DOI 10.1016/S0960-9822(99)80234-6; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tamura M, 1999, CANCER RES, V59, P442; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; VAN AL, 1997, GENE DEV, V11, P2295; Wang BL, 1997, J BIOL CHEM, V272, P17542, DOI 10.1074/jbc.272.28.17542; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; Weng LP, 1999, GENES CELLS, V4, P185, DOI 10.1046/j.1365-2443.1999.00251.x; Xu FP, 2001, EXP CELL RES, V262, P49, DOI 10.1006/excr.2000.5075; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Zhao RX, 2000, J BIOL CHEM, V275, P5453, DOI 10.1074/jbc.275.8.5453; Zhao RX, 1999, BIOCHEM J, V338, P35, DOI 10.1042/0264-6021:3380035; ZHAO ZZ, 1994, J BIOL CHEM, V269, P8780; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765	66	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29479	29484		10.1074/jbc.M104428200	http://dx.doi.org/10.1074/jbc.M104428200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11382784	hybrid			2022-12-25	WOS:000170346000110
J	Furumura, M; Potter, SB; Toyofuku, K; Matsunaga, J; Muller, J; Hearing, VJ				Furumura, M; Potter, SB; Toyofuku, K; Matsunaga, J; Muller, J; Hearing, VJ			Involvement of ITF2 in the transcriptional regulation of melanogenic genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGOUTI-RELATED PROTEIN; MELANOCYTE-SPECIFIC TRANSCRIPTION; WAARDENBURG SYNDROME; IN-VITRO; SIGNAL PROTEIN; MELANOCORTIN RECEPTORS; TYROSINASE GENE; SPLICE VARIANT; CYCLIC-AMP; E-BOX	In response to agouti signal protein, melanocytes switch from producing eumelanin to pheomelanin concomitant with the down-regulation of melanogenic gene transcription. We previously reported that a ubiquitous basic helix-loop-helix transcription factor, known as ITF2, is up-regulated during this switch, and we now report that treatment of melanocytes with melanocyte-stimulating hormone down-regulates expression of ITF2. To more fully characterize the involvement of ITF2 in regulating melanogenic gene transcription, ITF2 sense or antisense constructs were introduced into melan-a melanocytes. Gene and protein expression analyses and luciferase reporter assays using promoters from melanogenic genes showed that up-regulation of ITF2 suppressed melanogenic gene expression as well as the expression of Mitf, a melanocyte-specific transcription factor. In addition, stable ITF2 sense transfectants had significant reductions in pigmentation and a less dendritic phenotype compared with mock transfectants. In contrast, ITF2 antisense-transfected melanocytes were more pigmented and more dendritic. These results demonstrate that up-regulation of ITF2 during the pheomelanin switch is functionally significant and reveal that differential expression of a ubiquitous basic helix-loop-helix transcription factor can modulate expression of melanogenic genes and the differentiation of melanocytes.	NCI, Pigment Cell Biol Sect, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; US FDA, Div Virol, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Food & Drug Administration (FDA)	Hearing, VJ (corresponding author), NCI, Pigment Cell Biol Sect, Cell Biol Lab, NIH, Bldg 37,Rm 1B25, Bethesda, MD 20892 USA.							ABDELMALEK Z, 1995, P NATL ACAD SCI USA, V92, P1789, DOI 10.1073/pnas.92.5.1789; ABDELMALEK Z, 1992, J CELL PHYSIOL, V150, P416, DOI 10.1002/jcp.1041500226; Aberdam E, 1998, J BIOL CHEM, V273, P19560, DOI 10.1074/jbc.273.31.19560; AROCA P, 1993, J BIOL CHEM, V268, P25650; Atchley WR, 1997, P NATL ACAD SCI USA, V94, P5172, DOI 10.1073/pnas.94.10.5172; Barsh GS, 1996, TRENDS GENET, V12, P299, DOI 10.1016/0168-9525(96)10031-7; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; BENTLEY NJ, 1994, MOL CELL BIOL, V14, P7997; Bertolotto C, 1996, J CELL BIOL, V134, P747, DOI 10.1083/jcb.134.3.747; Bertolotto C, 1998, MOL CELL BIOL, V18, P694, DOI 10.1128/MCB.18.2.694; Bertolotto C, 1998, J CELL BIOL, V142, P827, DOI 10.1083/jcb.142.3.827; Busca R, 2000, PIGM CELL RES, V13, P60, DOI 10.1034/j.1600-0749.2000.130203.x; Chen BB, 1997, J BIOL CHEM, V272, P2459, DOI 10.1074/jbc.272.4.2459; Cone RD, 1996, RECENT PROG HORM RES, V51, P287; Dinulescu DM, 2000, J BIOL CHEM, V275, P6695, DOI 10.1074/jbc.275.10.6695; Furumura M, 1998, P NATL ACAD SCI USA, V95, P7374, DOI 10.1073/pnas.95.13.7374; He L, 2001, NAT GENET, V27, P40, DOI 10.1038/83741; Hearing VJ, 2000, PIGM CELL RES, V13, P23, DOI 10.1034/j.1600-0749.13.s8.7.x; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; HUNT G, 1995, PIGM CELL RES, V8, P202, DOI 10.1111/j.1600-0749.1995.tb00664.x; JACKSON IJ, 1993, NATURE, V362, P587, DOI 10.1038/362587a0; JIMENEZ M, 1991, J BIOL CHEM, V266, P1147; KOBAYASHI T, 1994, J BIOL CHEM, V269, P29198; KOBAYASHI T, 1995, J CELL SCI, V108, P2301; Lamoreux ML, 1995, PIGM CELL RES, V8, P263, DOI 10.1111/j.1600-0749.1995.tb00673.x; Lee M, 2000, J BIOL CHEM, V275, P37978, DOI 10.1074/jbc.M003816200; Liu Y, 1998, J BIOL CHEM, V273, P19269, DOI 10.1074/jbc.273.30.19269; Matsunaga N, 2000, BIOCHEM BIOPH RES CO, V270, P176, DOI 10.1006/bbrc.2000.2409; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; Nobukuni Y, 1996, AM J HUM GENET, V59, P76; Ollmann MM, 1999, J BIOL CHEM, V274, P15837, DOI 10.1074/jbc.274.22.15837; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; Ollmann MM, 1998, GENE DEV, V12, P316, DOI 10.1101/gad.12.3.316; Opdecamp K, 1997, DEVELOPMENT, V124, P2377; OZEKI H, 1995, J INVEST DERMATOL, V105, P361, DOI 10.1111/1523-1747.ep12320792; Price ER, 1998, J BIOL CHEM, V273, P33042, DOI 10.1074/jbc.273.49.33042; Price ER, 1998, J BIOL CHEM, V273, P17983, DOI 10.1074/jbc.273.29.17983; Prota G., 1992, MELANINS MELANOGENES; Sakai C, 1997, EMBO J, V16, P3544, DOI 10.1093/emboj/16.12.3544; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SIRACUSA LD, 1994, TRENDS GENET, V10, P423, DOI 10.1016/0168-9525(94)90112-0; Skerjanc IS, 1996, J BIOL CHEM, V271, P3555, DOI 10.1074/jbc.271.7.3555; Suzuki I, 1997, J INVEST DERMATOL, V108, P838, DOI 10.1111/1523-1747.ep12292572; Tachibana M, 1996, NAT GENET, V14, P50, DOI 10.1038/ng0996-50; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; TSUKAMOTO K, 1992, EMBO J, V11, P519, DOI 10.1002/j.1460-2075.1992.tb05082.x; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; Watanabe A, 1998, NAT GENET, V18, P283, DOI 10.1038/ng0398-283; Yang YK, 1999, J BIOL CHEM, V274, P14100, DOI 10.1074/jbc.274.20.14100; YASUMOTO KI, 1994, MOL CELL BIOL, V14, P8058, DOI 10.1128/MCB.14.12.8058; YAVUZER U, 1995, ONCOGENE, V10, P123; YOON SO, 1994, J BIOL CHEM, V269, P18453	53	35	37	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28147	28154		10.1074/jbc.M101626200	http://dx.doi.org/10.1074/jbc.M101626200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11382753	hybrid			2022-12-25	WOS:000170093400055
J	Nagai, T; Osaki, T; Kawabata, S				Nagai, T; Osaki, T; Kawabata, S			Functional conversion of hemocyanin to phenoloxidase by horseshoe crab antimicrobial peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRO-PHENOL-OXIDASE; TACHYPLEUS-TRIDENTATUS; BOMBYX-MORI; ARTHROPOD HEMOCYANIN; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; CATECHOL OXIDASE; CDNA CLONING; INSECT; PROTEIN	Arthropod hemocyanins and phenoloxidases serve different physiological functions as oxygen transporters and enzymes involved in defense reactions, respectively. However, they are equipped with a structurally similar oxygen-binding center, We have shown that the clotting enzyme of the horseshoe crab, Tachypleus tridentatus, functionally converts hemocyanin to phenoloxidase by forming a complex without proteolytic cleavage (Nagai, T., and Kawabata, S, (2000) J. Biol, Chem. 275, 35297-35301), Here we show that chitin-binding antimicrobial peptides of the horseshoe crab induce the intrinsic phenoloxidase activity of hemocyanin, Tachyplesin, a major Tachypleus antimicrobial peptide with an amphiphilic structure, converted the hemocyanin to phenoloxidase, Surface plasmon resonance analysis revealed the specific interaction of tachyplesin with hemocyanin at Kd = 3.4 x 10(-6) M. The chemical modification of Trp or Tyr in tachyplesin, but not Lys or Arg, dramatically reduced the affinity to hemocyanin, suggesting that the binding site is located in the hydrophobic face of tachyplesin. Hemocyanin has no affinity with chitin, but it significantly binds to tachyplesin-coated chitin, leading to the expression of phenoloxidase activity. The chitin coated with antimicrobial peptides may serve as a scaffold for the binding of hemocyanin, and the resulting phenoloxidase activity appears to function as a trigger of exoskeleton wound healing.	Kyushu Univ, Dept Biol, Fukuoka 8128581, Japan; Kyushu Univ, Dept Mol Biol, Grad Sch Med Sci, Fukuoka 8128582, Japan	Kyushu University; Kyushu University	Kawabata, S (corresponding author), Kyushu Univ, Dept Biol, Fukuoka 8128581, Japan.	skawascb@mbox.nc.kyushu-u.ac.jp		Osaki, Tsukasa/0000-0002-9487-3253				Asano T, 2001, J BIOL CHEM, V276, P11100, DOI 10.1074/jbc.M008426200; Asano T, 2001, J BIOL CHEM, V276, P11113, DOI 10.1074/jbc.M008425200; Ashida M., 1990, P239; ASHIDA M, 1995, P NATL ACAD SCI USA, V92, P10698, DOI 10.1073/pnas.92.23.10698; Ashida Masaaki, 1998, P135; ASPAN A, 1995, P NATL ACAD SCI USA, V92, P939, DOI 10.1073/pnas.92.4.939; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burmester T, 1996, J MOL EVOL, V42, P713, DOI 10.1007/BF02338804; CUATRECASAS P, 1968, J BIOL CHEM, V243, P4787; Daquinag AC, 1999, BIOCHEMISTRY-US, V38, P2179, DOI 10.1021/bi9819834; DAQUINAG AC, 1995, P NATL ACAD SCI USA, V92, P2964, DOI 10.1073/pnas.92.7.2964; Decker H, 1998, J BIOL CHEM, V273, P25889, DOI 10.1074/jbc.273.40.25889; Decker H, 2000, J EXP BIOL, V203, P1777; Eicken C, 1999, CURR OPIN STRUC BIOL, V9, P677, DOI 10.1016/S0959-440X(99)00029-9; FUJIMOTO K, 1995, P NATL ACAD SCI USA, V92, P7769, DOI 10.1073/pnas.92.17.7769; HAZES B, 1993, PROTEIN SCI, V2, P597; Higashi S, 1999, J BIOL CHEM, V274, P10497, DOI 10.1074/jbc.274.15.10497; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; HOPKINS TL, 1992, ANNU REV ENTOMOL, V37, P273, DOI 10.1146/annurev.en.37.010192.001421; Iwanaga S, 1998, J BIOCHEM, V123, P1; Jiang HB, 1998, P NATL ACAD SCI USA, V95, P12220, DOI 10.1073/pnas.95.21.12220; Kawabata S, 1999, DEV COMP IMMUNOL, V23, P391, DOI 10.1016/S0145-305X(99)00019-1; Kawabata S, 1996, J BIOCHEM-TOKYO, V120, P1253; Kawabata Shun-ichiro, 1996, P255; KAWABATA T, 1995, P NATL ACAD SCI USA, V92, P7774, DOI 10.1073/pnas.92.17.7774; KAWANO K, 1990, J BIOL CHEM, V265, P15365; KIM JI, 1995, J MOL BIOL, V250, P659, DOI 10.1006/jmbi.1995.0406; Klabunde T, 1998, NAT STRUCT BIOL, V5, P1084, DOI 10.1038/4193; Lee SY, 1998, EUR J BIOCHEM, V257, P615, DOI 10.1046/j.1432-1327.1998.2570615.x; LINZEN B, 1985, SCIENCE, V229, P519, DOI 10.1126/science.4023698; MAGNUS KA, 1994, PROTEINS, V19, P302, DOI 10.1002/prot.340190405; Nagai T, 2000, J BIOL CHEM, V275, P29264, DOI 10.1074/jbc.M002556200; NAKAMURA T, 1988, J BIOL CHEM, V263, P16709; Nellaiappan K, 1996, COMP BIOCHEM PHYS B, V113, P163, DOI 10.1016/0305-0491(95)02047-0; Okino N, 1995, J BIOL CHEM, V270, P31008, DOI 10.1074/jbc.270.52.31008; Omecinsky DO, 1996, BIOCHEMISTRY-US, V35, P2836, DOI 10.1021/bi952605r; Osaki T, 1999, J BIOL CHEM, V274, P26172, DOI 10.1074/jbc.274.37.26172; PATTHY L, 1975, J BIOL CHEM, V250, P565; RZEPECKI LM, 1989, ANAL BIOCHEM, V179, P375, DOI 10.1016/0003-2697(89)90148-6; SAITO T, 1995, J BIOCHEM-TOKYO, V117, P1131, DOI 10.1093/oxfordjournals.jbchem.a124818; SAITO T, 1995, J BIOL CHEM, V270, P14493, DOI 10.1074/jbc.270.24.14493; Salvato B, 1998, BIOCHEMISTRY-US, V37, P14065, DOI 10.1021/bi980879j; Satoh D, 1999, J BIOL CHEM, V274, P7441, DOI 10.1074/jbc.274.11.7441; SHECHTER Y, 1972, BIOCHEMISTRY-US, V11, P653, DOI 10.1021/bi00754a030; SHIGENAGA T, 1993, J BIOCHEM-TOKYO, V114, P307, DOI 10.1093/oxfordjournals.jbchem.a124173; Soderhall K, 1998, CURR OPIN IMMUNOL, V10, P23, DOI 10.1016/S0952-7915(98)80026-5; Solomon EI, 1996, CHEM REV, V96, P2563, DOI 10.1021/cr950046o; STONE KL, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P31; Suetake T, 2000, J BIOL CHEM, V275, P17929, DOI 10.1074/jbc.C000184200; SUGITA H, 1979, DEV BIOL, V73, P183, DOI 10.1016/0012-1606(79)90062-9; Sugumaran M, 1998, ADV INSECT PHYSIOL, V27, P229, DOI 10.1016/S0065-2806(08)60014-4; Sugumaran Manickam, 1993, P317; TAKAGI T, 1980, J BIOCHEM, V87, P1785, DOI 10.1093/oxfordjournals.jbchem.a132923; TELFER WH, 1991, ANNU REV ENTOMOL, V36, P205, DOI 10.1146/annurev.en.36.010191.001225; Terwilliger NB, 1999, P NATL ACAD SCI USA, V96, P2013, DOI 10.1073/pnas.96.5.2013; Terwilliger NB, 1999, AM ZOOL, V39, P589; TSUKAMOTO T, 1992, BIOCHEM BIOPH RES CO, V184, P86, DOI 10.1016/0006-291X(92)91161-I; vanHolde KE, 1995, ADV PROTEIN CHEM, V47, P1, DOI 10.1016/S0065-3233(08)60545-8; WINDER AJ, 1991, EUR J BIOCHEM, V198, P317, DOI 10.1111/j.1432-1033.1991.tb16018.x; Zlateva T, 1996, FEBS LETT, V384, P251, DOI 10.1016/0014-5793(96)00326-2	60	158	173	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27166	27170		10.1074/jbc.M102596200	http://dx.doi.org/10.1074/jbc.M102596200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11375396	hybrid			2022-12-25	WOS:000169966900059
J	Mangoni, ML; Miele, R; Renda, TG; Barra, D; Simmaco, M				Mangoni, ML; Miele, R; Renda, TG; Barra, D; Simmaco, M			The synthesis of antimicrobial peptides in the skin of Rana esculenta is stimulated by microorganisms	FASEB JOURNAL			English	Article						amphibian skin glands; innate immunity; glucocorticoid; Amphibia	AMPHIBIAN SKIN; MOLECULAR-CLONING; EPITHELIAL-CELLS; INNATE IMMUNITY; KAPPA-B; GENE; ANTIBIOTICS; EXPRESSION; DROSOPHILA; INDUCTION	Secretions of amphibian skin glands contain numerous antimicrobial peptides that play a crucial role in the defense against microorganisms. The location of these glands on the surface of the animal makes them a useful model for in vivo studies of the relationships between the innate immune system and the natural flora. Here, we present the results of a study showing that in Rana esculenta the total antimicrobial activity of skin secretion is modulated by the presence of the natural flora. Frogs kept in a sterile environment do not produce antimicrobial peptides. This finding represents the first in vivo demonstration of the induction of defense peptides in a vertebrate. We also present data on the morphological changes in skin glands of animals kept in sterile conditions or treated with glucocorticoids. Cells from glands regenerated under normal conditions, but not those from "sterile" frogs, contain kappaB-binding activity in the cytoplasm.	Univ Roma La Sapienza, Dipartimento Sci Biochim A Rossi Fanelli, I-00185 Rome, Italy; Univ Roma La Sapienza, CNR, Ctr Biol Mol, I-00185 Rome, Italy; Univ Roma La Sapienza, Ist Anat Umana, I-00185 Rome, Italy	Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; Sapienza University Rome	Barra, D (corresponding author), Univ Roma La Sapienza, Dipartimento Sci Biochim, Piazzale Aldo Moro 5, I-00185 Rome, Italy.	donatella.barra@uniroma1.it	Simmaco, Maurizio/AAC-2870-2019; Barra, Donatella/D-1236-2011	Simmaco, Maurizio/0000-0003-4164-1472; Miele, Rossella/0000-0001-9577-3177; Mangoni, Maria Luisa/0000-0002-5991-5868				Ayabe T, 2000, NAT IMMUNOL, V1, P113, DOI 10.1038/77783; Barra D, 1998, FEBS LETT, V430, P130, DOI 10.1016/S0014-5793(98)00494-3; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; DIAMOND G, 1993, P NATL ACAD SCI USA, V90, P4596, DOI 10.1073/pnas.90.10.4596; Diamond G, 2000, INFECT IMMUN, V68, P113, DOI 10.1128/IAI.68.1.113-119.2000; ENGSTROM Y, 1993, J MOL BIOL, V232, P327, DOI 10.1006/jmbi.1993.1392; Hancock REW, 2000, TRENDS MICROBIOL, V8, P402, DOI 10.1016/S0966-842X(00)01823-0; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; Hoffmann JA, 1997, TRENDS CELL BIOL, V7, P309, DOI 10.1016/S0962-8924(97)01087-8; HULTMARK D, 1983, EMBO J, V2, P571, DOI 10.1002/j.1460-2075.1983.tb01465.x; Lemaitre B, 1997, P NATL ACAD SCI USA, V94, P14614, DOI 10.1073/pnas.94.26.14614; LI CY, 1987, J HISTOCHEM CYTOCHEM, V35, P1457, DOI 10.1177/35.12.2824601; Matutte B, 2000, FEBS LETT, V483, P135, DOI 10.1016/S0014-5793(00)02102-5; Miele R, 1998, FEBS LETT, V431, P23, DOI 10.1016/S0014-5793(98)00718-2; Miele R, 2001, EUR J BIOCHEM, V268, P443, DOI 10.1046/j.1432-1327.2001.01908.x; Ponti D, 1999, EUR J BIOCHEM, V263, P921, DOI 10.1046/j.1432-1327.1999.00597.x; SCHONWETTER BS, 1995, SCIENCE, V267, P1645, DOI 10.1126/science.7886453; Simmaco M, 1997, FEBS LETT, V416, P273, DOI 10.1016/S0014-5793(97)01216-7; Simmaco M, 1998, SCAND J IMMUNOL, V48, P357; SIMMACO M, 1994, J BIOL CHEM, V269, P11956; Simmaco M, 1998, BIOPOLYMERS, V47, P435, DOI 10.1002/(SICI)1097-0282(1998)47:6<435::AID-BIP3>3.3.CO;2-#; Stolzenberg ED, 1997, P NATL ACAD SCI USA, V94, P8686, DOI 10.1073/pnas.94.16.8686	22	74	77	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR 27	2001	15	6					1431	+		10.1096/fj.00-0695fje	http://dx.doi.org/10.1096/fj.00-0695fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387247				2022-12-25	WOS:000173705800021
J	Menoret, A; Li, ZH; Niswonger, ML; Altmeyer, A; Srivastava, PK				Menoret, A; Li, ZH; Niswonger, ML; Altmeyer, A; Srivastava, PK			An endoplasmic reticulum protein implicated in chaperoning peptides to major histocompatibility of class I is an aminopeptidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; MOLECULAR CHAPERONE; BINDING; TAP; GLYCOPROTEIN; RECEPTORS; COMPLEXES; ANTIGENS; MEMBRANE; ABUNDANT	gp96, an abundant peptide-binding chaperone of the lumen of the endoplasmic reticulum. and an acceptor of peptides transported into the endoplasmic reticulum through transporter associated with antigen processing, is shown to be an aminopeptidase. gp96 can trim an amino-terminal extended 19-mer precursor of the K-b-binding VSV8 epitope for recognition by the cognate cytotoxic T lymphocyte clone. These observations support a role for gp96 in the amino-terminal trimming of extended peptides in the endoplasmic reticulum.	Univ Connecticut, Sch Med, Ctr Immunotherapy Canc & Infect Dis MC1601, Farmington, CT 06030 USA; Antigen Inc, Woburn, MA 01801 USA; Cornell Univ, New York, NY 10021 USA	University of Connecticut; Agenus Inc; Cornell University	Srivastava, PK (corresponding author), Univ Connecticut, Sch Med, Ctr Immunotherapy Canc & Infect Dis MC1601, Farmington, CT 06030 USA.	srivastava@nso2.uchc.edu			NCI NIH HHS [CA-64394, CA-44786] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064394, R01CA044786, R29CA044786] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arnold D, 1997, J EXP MED, V186, P461, DOI 10.1084/jem.186.3.461; Arnold-Schild D, 2000, CANCER RES, V60, P4175; Craiu A, 1997, P NATL ACAD SCI USA, V94, P10850, DOI 10.1073/pnas.94.20.10850; Csermely P, 1998, PHARMACOL THERAPEUT, V79, P129, DOI 10.1016/S0163-7258(98)00013-8; DAVID F, 1993, J BIOL CHEM, V268, P17247; EDWARDS DP, 1984, BIOCHEMISTRY-US, V23, P4427, DOI 10.1021/bi00314a029; ELLIOTT T, 1995, J EXP MED, V181, P1481, DOI 10.1084/jem.181.4.1481; Goldstein LA, 1997, BBA-MOL BASIS DIS, V1361, P11, DOI 10.1016/S0925-4439(97)00032-X; Guthapfel R, 1996, J BIOL CHEM, V271, P2663, DOI 10.1074/jbc.271.5.2663; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; KOCH G, 1986, J CELL SCI, V86, P217; Lammert E, 1997, EUR J IMMUNOL, V27, P923, DOI 10.1002/eji.1830270418; Lauvau G, 1999, J EXP MED, V190, P1227, DOI 10.1084/jem.190.9.1227; MAKI RG, 1993, SOMAT CELL MOLEC GEN, V19, P73, DOI 10.1007/BF01233956; MAZZARELLA RA, 1987, J BIOL CHEM, V262, P8875; MELNICK J, 1995, IMMUNOL TODAY, V16, P243, DOI 10.1016/0167-5699(95)80167-7; MENORET A, 1995, J IMMUNOL, V155, P740; Ortmann B, 1997, SCIENCE, V277, P1306, DOI 10.1126/science.277.5330.1306; Powis SJ, 1996, IMMUNITY, V4, P159, DOI 10.1016/S1074-7613(00)80680-9; RAMMENSEE HG, 1993, CURR OPIN IMMUNOL, V5, P35, DOI 10.1016/0952-7915(93)90078-7; ROELSE J, 1994, J EXP MED, V180, P1591, DOI 10.1084/jem.180.5.1591; SACHS L, 1982, BIOCHIM BIOPHYS ACTA, V706, P229, DOI 10.1016/0167-4838(82)90491-5; SNYDER HL, 1994, J EXP MED, V180, P2389, DOI 10.1084/jem.180.6.2389; Snyder HL, 1998, EUR J IMMUNOL, V28, P1339; Srivastava PK, 1998, IMMUNITY, V8, P657, DOI 10.1016/S1074-7613(00)80570-1; SRIVASTAVA PK, 1986, P NATL ACAD SCI USA, V83, P3407, DOI 10.1073/pnas.83.10.3407; Srivastava PK, 1997, METHODS, V12, P165, DOI 10.1006/meth.1997.0464; SRIVASTAVA PK, 1991, CURR TOP MICROBIOL, V167, P109; SUTO R, 1995, SCIENCE, V269, P1585, DOI 10.1126/science.7545313; Townsend A, 1993, Semin Cell Biol, V4, P53, DOI 10.1006/scel.1993.1007; Trudel J, 1998, ELECTROPHORESIS, V19, P1788, DOI 10.1002/elps.1150191041; van Dijl JM, 1998, P NATL ACAD SCI USA, V95, P10584, DOI 10.1073/pnas.95.18.10584; VANBLEEK GM, 1991, P NATL ACAD SCI USA, V88, P11032, DOI 10.1073/pnas.88.24.11032	33	43	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33313	33318		10.1074/jbc.M103383200	http://dx.doi.org/10.1074/jbc.M103383200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11397801	hybrid			2022-12-25	WOS:000170910200006
J	Beerens, N; Groot, F; Berkhout, B				Beerens, N; Groot, F; Berkhout, B			Initiation of HIV-1 reverse transcription is regulated by a primer activation signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LONG TERMINAL REPEAT; RNA SECONDARY STRUCTURE; BINDING-SITE; EFFICIENT INITIATION; SEQUENCE ELEMENTS; TYPE-1 PARTICLES; DNA-SYNTHESIS; LEADER RNA; RICH LOOP	Reverse transcription of the human immunodeficiency virus type 1 (HIV-1) RNA genome appears to be strictly regulated at the level of initiation. The primer binding site (PBS), at which the tRNA(3)(LYS) molecule anneals and reverse transcription is initiated, is present in a highly structured region of the untranslated leader RNA. Detailed mutational analysis of the U5 leader stem identified a sequence motif in the U5 region that is critical for activation of the PBS-bound tRNA(3)(Lys) primer. This U5 motif, termed the primer activation signal Lys (PAS), may interact with the T psiC arm of the tRNA(3)(Lys) primer, similar to the additional interaction proposed for the genome of Rous sarcoma virus and its tRNA(Trp) primer. This suggests that reverse transcription is regulated by a common mechanism in all retroviruses. In HIV-1, the PAS is masked through base pairing in the U5 leader stem. This provides a mechanism for positive and negative regulation of reverse transcription. Based on structure probing of the mutant and wild-type RNAs, an RNA secondary structure model is proposed that juxtaposes the critical PAS and PBS motifs.	Univ Amsterdam, Acad Med Ctr, Dept Human Retrovirol, NL-1100 DE Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	Berkhout, B (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Human Retrovirol, POB 22700, NL-1100 DE Amsterdam, Netherlands.							AIYAR A, 1992, J VIROL, V66, P2464, DOI 10.1128/JVI.66.4.2464-2472.1992; ARTS EJ, 1994, J GEN VIROL, V75, P1605, DOI 10.1099/0022-1317-75-7-1605; Arts EJ, 1996, J BIOL CHEM, V271, P9054, DOI 10.1074/jbc.271.15.9054; Arts EJ, 1996, P NATL ACAD SCI USA, V93, P10063, DOI 10.1073/pnas.93.19.10063; Back NKT, 1996, EMBO J, V15, P4040, DOI 10.1002/j.1460-2075.1996.tb00777.x; BAUDIN F, 1993, J MOL BIOL, V229, P382, DOI 10.1006/jmbi.1993.1041; Beerens N, 2000, NUCLEIC ACIDS RES, V28, P4130, DOI 10.1093/nar/28.21.4130; Beerens N, 2000, J VIROL, V74, P2227, DOI 10.1128/JVI.74.5.2227-2238.2000; Berkhout B, 1997, NUCLEIC ACIDS RES, V25, P4013, DOI 10.1093/nar/25.20.4013; BERKHOUT B, 1993, NUCLEIC ACIDS RES, V21, P1171, DOI 10.1093/nar/21.5.1171; Berkhout B, 1996, PROG NUCLEIC ACID RE, V54, P1, DOI 10.1016/S0079-6603(08)60359-1; Berkhout B, 2000, RNA, V6, P282, DOI 10.1017/S1355838200991684; COBRINIK D, 1988, J VIROL, V62, P3622, DOI 10.1128/JVI.62.10.3622-3630.1988; COBRINIK D, 1991, J VIROL, V65, P3864, DOI 10.1128/JVI.65.7.3864-3872.1991; CORDELL B, 1979, J BIOL CHEM, V254, P1866; Damgaard CK, 1998, NUCLEIC ACIDS RES, V26, P3667, DOI 10.1093/nar/26.16.3667; Das AT, 1997, J VIROL, V71, P2346, DOI 10.1128/JVI.71.3.2346-2356.1997; Dhellin O, 1997, EMBO J, V16, P6590, DOI 10.1093/emboj/16.21.6590; El Kharroubi A, 1998, MOL CELL BIOL, V18, P2535, DOI 10.1128/MCB.18.5.2535; Esposito D, 1998, EMBO J, V17, P5832, DOI 10.1093/emboj/17.19.5832; Essink BBO, 1996, J MOL BIOL, V264, P243, DOI 10.1006/jmbi.1996.0638; Huang Y, 1998, J VIROL, V72, P3907, DOI 10.1128/JVI.72.5.3907-3915.1998; Huang Y, 1997, J VIROL, V71, P726, DOI 10.1128/JVI.71.1.726-728.1997; Huthoff H, 2001, RNA, V7, P143, DOI 10.1017/S1355838201001881; Isel C, 1998, NUCLEIC ACIDS RES, V26, P1198, DOI 10.1093/nar/26.5.1198; Isel C, 1999, EMBO J, V18, P1038, DOI 10.1093/emboj/18.4.1038; ISEL C, 1995, J MOL BIOL, V247, P236, DOI 10.1006/jmbi.1994.0136; KLAVER B, 1994, J VIROL, V68, P3830, DOI 10.1128/JVI.68.6.3830-3840.1994; Lenz C, 1997, J VIROL, V71, P2757, DOI 10.1128/JVI.71.4.2757-2764.1997; Liang C, 1997, J MOL BIOL, V272, P167, DOI 10.1006/jmbi.1997.1239; Liang C, 1998, J BIOL CHEM, V273, P21309, DOI 10.1074/jbc.273.33.21309; Liang C, 2000, J VIROL, V74, P6251, DOI 10.1128/JVI.74.14.6251-6261.2000; Liang C, 1997, J VIROL, V71, P5750, DOI 10.1128/JVI.71.8.5750-5757.1997; LORI F, 1992, J VIROL, V66, P5067, DOI 10.1128/JVI.66.8.5067-5074.1992; MARQUET R, 1995, BIOCHIMIE, V77, P113, DOI 10.1016/0300-9084(96)88114-4; Masuda T, 1998, J VIROL, V72, P8396, DOI 10.1128/JVI.72.10.8396-8402.1998; Miller JT, 1997, J VIROL, V71, P7648, DOI 10.1128/JVI.71.10.7648-7656.1997; Morris S, 1999, J VIROL, V73, P6307, DOI 10.1128/JVI.73.8.6307-6318.1999; Rein A, 1998, TRENDS BIOCHEM SCI, V23, P297, DOI 10.1016/S0968-0004(98)01256-0; RIZVI TA, 1993, J VIROL, V67, P2681, DOI 10.1128/JVI.67.5.2681-2688.1993; Telesnitsky A., 1997, P121; TRONO D, 1992, J VIROL, V66, P4893, DOI 10.1128/JVI.66.8.4893-4900.1992; VanLint C, 1997, J VIROL, V71, P6113, DOI 10.1128/JVI.71.8.6113-6127.1997; VICENZI E, 1994, J VIROL, V68, P7879, DOI 10.1128/JVI.68.12.7879-7890.1994; Wakefield JK, 1996, VIROLOGY, V220, P290, DOI 10.1006/viro.1996.0317; Wakefield JK, 1996, J VIROL, V70, P966, DOI 10.1128/JVI.70.2.966-975.1996	46	106	106	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31247	31256		10.1074/jbc.M102441200	http://dx.doi.org/10.1074/jbc.M102441200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11384976	hybrid			2022-12-25	WOS:000170472900087
J	Bartl, FJ; Ritter, E; Hofmann, KP				Bartl, FJ; Ritter, E; Hofmann, KP			Signaling states of rhodopsin - Absorption of light in active metarhodopsin II generates an all-trans-retinal bound inactive state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FTIR SPECTROSCOPY; VISUAL EXCITATION; BOVINE RHODOPSIN; PROTEIN; BACTERIORHODOPSIN; ACTIVATION; PIGMENTS; PEPTIDES; BINDING; MECHANISM	Absorption of light in rhodopsin leads through 11-cis- and all-trans-retinal isomerization, proton transfers, and structural changes to the active G-protein binding meta-II state. When meta-II is photolysed by blue light absorption, the activating pathway is apparently reverted, and rhodopsin is photoregenerated. However, the product formed, a P subspecies with A(max) = 500 nm (P-500), is different from the ground state based on the following observations: (i) the ground state fingerprint of 11-cis-retinal does not appear in the infrared spectra, although the proton transfers and structural changes are reverted; (ii) extraction of the retinal from P-500 does not yield the expected stoichiometric amount of 11-cis-retinal but predominantly yields all-trans-retinal; (iii) the infrared spectrum of P-500 is similar to the classical meta-III intermediate, which arises from meta-II by thermal decay; and (iv) both P-500 and meta-III can be photoconverted to meta-II with the same changes in the infrared spectrum and without a significant change in the isomerization state of the extracted chromophore. The data indicate the presence of a "second switch" between active and inactive conformations that operates by photolysis but without isomerization around the C-11-C-12 double bond. This emphasizes the exclusivity of the ground state, which is only accessible by the metabolic regeneration with 11-cis-retinal.	Humboldt Univ, Med Fak Charite, Inst Med Phys & Biophys, D-10098 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Bartl, FJ (corresponding author), Humboldt Univ, Med Fak Charite, Inst Med Phys & Biophys, Schumann Str 20-21, D-10098 Berlin, Germany.							Aharoni A, 2000, J BIOL CHEM, V275, P21010, DOI 10.1074/jbc.M001208200; ARNIS S, 1995, BIOCHEMISTRY-US, V34, P9333, DOI 10.1021/bi00029a008; Bartl F, 2000, FEBS LETT, V473, P259, DOI 10.1016/S0014-5793(00)01544-1; Borhan B, 2000, SCIENCE, V288, P2209, DOI 10.1126/science.288.5474.2209; COOPER A, 1976, BIOCHEMISTRY-US, V15, P2970, DOI 10.1021/bi00659a006; COOPER A, 1979, NATURE, V282, P531, DOI 10.1038/282531a0; DEGRIP WJ, 2000, MOL MECH VISUAL TRAN, P1, DOI DOI 10.1016/S1383-8121(00)80004-4; DeLange F, 1998, BIOCHEMISTRY-US, V37, P1411, DOI 10.1021/bi972397y; Ernst OP, 2000, J BIOL CHEM, V275, P1937, DOI 10.1074/jbc.275.3.1937; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Grimm C, 2000, INVEST OPHTH VIS SCI, V41, P3984; GROENENDIJK GWT, 1979, ANAL BIOCHEM, V99, P304, DOI 10.1016/S0003-2697(79)80011-1; Haupts U, 1999, ANNU REV BIOPH BIOM, V28, P367, DOI 10.1146/annurev.biophys.28.1.367; Heberle J, 2000, BIOPHYS CHEM, V85, P229, DOI 10.1016/S0301-4622(99)00154-4; HOFMANN KP, 2000, MOL MECH VISUAL TRAN, P99; JAGER F, 1994, BIOCHEMISTRY-US, V33, P7389; Jager S, 1996, BIOCHEMISTRY-US, V35, P2901, DOI 10.1021/bi9524068; Jang GF, 2001, J BIOL CHEM, V276, P26148, DOI 10.1074/jbc.M102212200; KIBELBEK J, 1991, BIOCHEMISTRY-US, V30, P6761, DOI 10.1021/bi00241a019; KLINGER AL, 1992, BIOPHYS J, V63, P1244, DOI 10.1016/S0006-3495(92)81700-9; LANDERS GM, 1988, J CHROMATOGR, V438, P383, DOI 10.1016/S0021-9673(00)90269-3; LIU RSH, 1988, J AM CHEM SOC, V110, P8617, DOI 10.1021/ja00234a007; MATTHEWS RG, 1963, J GEN PHYSIOL, V47, P215, DOI 10.1085/jgp.47.2.215; Meyer CK, 2000, J BIOL CHEM, V275, P19713, DOI 10.1074/jbc.M000603200; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Palczewski K, 1999, BIOCHEMISTRY-US, V38, P12012, DOI 10.1021/bi990504d; PAULSEN R, 1983, NATURE, V302, P417, DOI 10.1038/302417a0; Pulvermuller A, 2000, J BIOL CHEM, V275, P37679, DOI 10.1074/jbc.M006776200; ROTHSCHILD KJ, 1987, BIOPHYS J, V51, P345, DOI 10.1016/S0006-3495(87)83341-6; Rousso I, 1997, P NATL ACAD SCI USA, V94, P7937, DOI 10.1073/pnas.94.15.7937; Sachs K, 2000, J BIOL CHEM, V275, P6189, DOI 10.1074/jbc.275.9.6189; Sakmar TP, 1998, PROG NUCLEIC ACID RE, V59, P1; SCHERRER P, 1989, BIOCHEMISTRY-US, V28, P829, DOI 10.1021/bi00428a063; Siebert F, 1995, ISRAEL J CHEM, V35, P309; WILLIAMS TP, 1968, VISION RES, V8, P1457, DOI 10.1016/0042-6989(68)90120-X; YOSHIZAWA T, 1963, NATURE, V197, P1279, DOI 10.1038/1971279a0	37	41	41	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30161	30166		10.1074/jbc.M101506200	http://dx.doi.org/10.1074/jbc.M101506200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11384968	hybrid			2022-12-25	WOS:000170558000075
J	Allen, NPC; Huang, L; Burlingame, A; Rexach, M				Allen, NPC; Huang, L; Burlingame, A; Rexach, M			Proteomic analysis of nucleoporin interacting proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PORE COMPLEX; GTPASE-ACTIVATING PROTEIN; MESSENGER-RNA EXPORT; IN-VIVO; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; BINDING-PROTEINS; RAN GTPASE; TRANSPORT; YEAST	The Saccharomyces cerevisiae nuclear pore complex is a supramolecular assembly of 30 nucleoporins that cooperatively facilitate nucleocytoplasmic transport. Thirteen nucleoporins that contain FG peptide repeats (FG Nups) are proposed to function as stepping stones in karyopherin-mediated transport pathways. Here, protein interactions that occur at individual FG Nups were sampled using immobilized nucleoporins and yeast extracts. We find that many proteins bind to FG Nups in highly reproducible patterns. Among 135 proteins identified by mass spectrometry, most were karyopherins and nucleoporins. The PSFG nucleoporin Nup42p and the GLFG nucleoporins Nup49p, Nup57p, Nup100p, and Nup116p exhibited generic interactions with karyopherins; each bound 6-10 different karyopherin betas, including importins as well as exportins. Unexpectedly, the same Nups also captured the hexameric Nup84p complex and Nup2p. In contrast, the FXFG nucleoporins Nup1p, Nup2p, and Nup60p were more selective and captured mostly the Kap95p . Kap60p heterodimer. When the concentration of Gsp1p-GTP was elevated in the extracts to mimic the nucleoplasmic environment, the patterns of interacting proteins changed; exportins exhibited enhanced binding to FG Nups, and importins exhibited reduced binding. The results demonstrate a global role for Gsp1p-GTP on karyopherin-nucleoporin interactions and provide a rudimentary map of the routes that karyopherins take as they cross the nuclear pore complex.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, Mass Spectrometry Facil, San Francisco, CA 94143 USA	Stanford University; University of California System; University of California San Francisco	Rexach, M (corresponding author), Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA.		Huang, Lan/C-3618-2011					Aitchison JD, 1996, SCIENCE, V274, P624, DOI 10.1126/science.274.5287.624; BARLOWE C, 1995, FEBS LETT, V369, P93, DOI 10.1016/0014-5793(95)00618-J; Bayliss R, 2000, CELL, V102, P99, DOI 10.1016/S0092-8674(00)00014-3; Ben-Efraim I, 2001, J CELL BIOL, V152, P411, DOI 10.1083/jcb.152.2.411; Delphin C, 1997, MOL BIOL CELL, V8, P2379, DOI 10.1091/mbc.8.12.2379; Fahrenkrog B, 1998, J CELL BIOL, V143, P577, DOI 10.1083/jcb.143.3.577; Feng WQ, 1999, J CELL SCI, V112, P339; Floer M, 1999, J BIOL CHEM, V274, P16279, DOI 10.1074/jbc.274.23.16279; Floer M, 1997, J BIOL CHEM, V272, P19538, DOI 10.1074/jbc.272.31.19538; Gagny B, 2000, J CELL SCI, V113, P3309; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gorlich D, 1997, J CELL BIOL, V138, P65, DOI 10.1083/jcb.138.1.65; Gray NK, 2000, EMBO J, V19, P4723, DOI 10.1093/emboj/19.17.4723; Hood JK, 2000, J CELL SCI, V113, P1471; Kaffman A, 1998, NATURE, V396, P482, DOI 10.1038/24898; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Nanduri J, 1999, J BIOL CHEM, V274, P33785, DOI 10.1074/jbc.274.47.33785; Nehrbass U, 1996, SCIENCE, V272, P120, DOI 10.1126/science.272.5258.120; Peng RW, 2000, J BIOL CHEM, V275, P11521, DOI 10.1074/jbc.275.15.11521; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Ryan KJ, 2000, CURR OPIN CELL BIOL, V12, P361, DOI 10.1016/S0955-0674(00)00101-0; Schlaich NL, 1997, MOL BIOL CELL, V8, P33, DOI 10.1091/mbc.8.1.33; Seedorf M, 1999, MOL CELL BIOL, V19, P1547; Segref A, 1997, EMBO J, V16, P3256, DOI 10.1093/emboj/16.11.3256; Shulga N, 1996, J CELL BIOL, V135, P329, DOI 10.1083/jcb.135.2.329; Siniossoglou S, 1996, CELL, V84, P265, DOI 10.1016/S0092-8674(00)80981-2; Siniossoglou S, 2000, J CELL BIOL, V149, P41, DOI 10.1083/jcb.149.1.41; Solsbacher J, 2000, MOL CELL BIOL, V20, P8468, DOI 10.1128/MCB.20.22.8468-8479.2000; Stage-Zimmermann T, 2000, MOL BIOL CELL, V11, P3777, DOI 10.1091/mbc.11.11.3777; Strasser K, 2000, J CELL BIOL, V150, P695, DOI 10.1083/jcb.150.4.695; Strawn LA, 2001, J BIOL CHEM, V276, P6445, DOI 10.1074/jbc.M008311200; Talcott B, 1999, TRENDS CELL BIOL, V9, P312, DOI 10.1016/S0962-8924(99)01608-6; TARUN SZ, 1995, GENE DEV, V9, P2997, DOI 10.1101/gad.9.23.2997; Wozniak RW, 1998, TRENDS CELL BIOL, V8, P184, DOI 10.1016/S0962-8924(98)01248-3; Yoshida K, 2001, J CELL BIOL, V152, P729, DOI 10.1083/jcb.152.4.729; YOSHIHISA T, 1993, SCIENCE, V259, P1466, DOI 10.1126/science.8451644	39	146	157	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29268	29274		10.1074/jbc.M102629200	http://dx.doi.org/10.1074/jbc.M102629200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11387327	hybrid			2022-12-25	WOS:000170346000085
J	Jourd'heuil, D; Jourd'heuil, FL; Kutchukian, PS; Musah, RA; Wink, DA; Grisham, MB				Jourd'heuil, D; Jourd'heuil, FL; Kutchukian, PS; Musah, RA; Wink, DA; Grisham, MB			Reaction of superoxide and nitric oxide with peroxynitrite - Implications for peroxynitrite-mediated oxidation reactions in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE-RADICAL FORMATION; TYROSINE NITRATION; SIMULTANEOUS GENERATION; CHEMISTRY; (NO)-N-CENTER-DOT	Peroxynitrite (ONOO-/ONOOH), the product of the diffusion-limited reaction of nitric oxide ((NO)-N-.) with superoxide (O-2(radical anion)), has been implicated as an important mediator of tissue injury during conditions associated with enhanced (NO)-N-. and O-2(radical anion) production. Although several groups of investigators have demonstrated substantial oxidizing and cytotoxic activities of chemically synthesized peroxynitrite, others have proposed that the relative rates of (NO)-N-. and production may be critical in determining the reactivity of peroxynitrite formed in situ (Miles, A. M., Bohle, D. S., Glassbrenner, P. A., Hansert, B., Wink, D. A., and Grisham, At B. (1996) J. Biol. Chem. 271, 40-47). In the present study, we examined the mechanisms by which excess O-2(radical anion) or (NO)-N-. production 2 inhibits peroxynitrite-mediated oxidation reactions. Peroxynitrite was generated in situ by the co-addition of a chemical source of (NO)-N-., spermineNONOate, and an enzymatic source of O-2(radical anion), xanthine oxidase, with either hypoxanthine or lumazine as a substrate. We found that the oxidation of the model compound dihydrorhodamine by peroxynitrite occurred via the free radical intermediates OH and NO2, formed during the spontaneous decomposition of peroxynitrite and not via direct reaction with peroxynitrite. The inhibitory effect of excess O-2(radical anion) on the oxidation of dihydrorhodamine could not be ascribed to the accumulation of the peroxynitrite scavenger urate produced from the oxidation of hypoxanthine by xanthine oxidase. A biphasic oxidation profile was also observed upon oxidation of NADH by the simultaneous generation of (NO)-N-. and O-2(radical anion). Conversely, the oxidation of glutathione, which 2 occurs via direct reaction with peroxynitrite, was not affected by excess production of (NO)-N-.. We conclude that the oxidative processes initiated by the free radical intermediates formed from the decomposition of peroxynitrite, are inhibited by excess production of (NO)-N-. or O-2(radical anion), whereas oxidative pathways involving a direct reaction with peroxynitrite are not altered. The physiological implications of these findings are discussed.	Albany Med Coll, Ctr Cardiovasc Sci, Albany, NY 12208 USA; SUNY Albany, Dept Chem, Albany, NY 12222 USA; NCI, Tumor Biol Sect, Radiat Biol Branch, Bethesda, MD 20892 USA; Louisiana State Univ, Med Ctr, Dept Mol & Cellular Physiol, Shreveport, LA 71130 USA	Albany Medical College; State University of New York (SUNY) System; State University of New York (SUNY) Albany; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Jourd'heuil, D (corresponding author), Albany Med Coll, Ctr Cardiovasc Sci, 47 New Scotland Ave,MC8, Albany, NY 12208 USA.	jourdhd@mail.amc.edu	Kutchukian, Peter/A-9826-2016	Kutchukian, Peter/0000-0002-5684-1971; Azad, Mahan/0000-0002-8633-3513; Jourd'heuil, David/0000-0002-6555-5061; Wink, David/0000-0002-5652-7480				BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Coddington JW, 1999, J AM CHEM SOC, V121, P2438, DOI 10.1021/ja982887t; Fukuto JM, 1997, ACCOUNTS CHEM RES, V30, P149, DOI 10.1021/ar960010y; Goldstein S, 2000, CHEM RES TOXICOL, V13, P736, DOI 10.1021/tx000099n; Goldstein S, 2000, J BIOL CHEM, V275, P3031, DOI 10.1074/jbc.275.5.3031; Grisham MB, 1999, AM J PHYSIOL-GASTR L, V276, pG315, DOI 10.1152/ajpgi.1999.276.2.G315; Hodges GR, 2000, CHEM RES TOXICOL, V13, P1287, DOI 10.1021/tx0001272; Ischiropoulos H, 1998, ARCH BIOCHEM BIOPHYS, V356, P1, DOI 10.1006/abbi.1998.0755; Jourd'heuil D, 1999, ARCH BIOCHEM BIOPHYS, V365, P92, DOI 10.1006/abbi.1999.1143; Kirsch M, 2000, J BIOL CHEM, V275, P16702, DOI 10.1074/jbc.M909228199; KOOY NW, 1994, FREE RADICAL BIO MED, V16, P149, DOI 10.1016/0891-5849(94)90138-4; LYMAR SV, 1995, J AM CHEM SOC, V117, P8867, DOI 10.1021/ja00139a027; Lymar SV, 1998, INORG CHEM, V37, P294, DOI 10.1021/ic970946i; Merenyi G, 1998, CHEM RES TOXICOL, V11, P243, DOI 10.1021/tx980026s; Miles AM, 1996, J BIOL CHEM, V271, P40, DOI 10.1074/jbc.271.1.40; NAGANO T, 1985, Journal of Free Radicals in Biology and Medicine, V1, P39, DOI 10.1016/0748-5514(85)90027-3; Pfeiffer S, 1997, J BIOL CHEM, V272, P3465, DOI 10.1074/jbc.272.6.3465; Pfeiffer S, 1998, J BIOL CHEM, V273, P27280, DOI 10.1074/jbc.273.42.27280; RADI R, 1991, J BIOL CHEM, V266, P4244; Reiter CD, 2000, J BIOL CHEM, V275, P32460, DOI 10.1074/jbc.M910433199; Richeson CE, 1998, J AM CHEM SOC, V120, P7211, DOI 10.1021/ja980871x; ROSS AB, 1998, NDRL NIST SOLUTION K; Rota C, 1999, FREE RADICAL BIO MED, V27, P873, DOI 10.1016/S0891-5849(99)00137-9; RUBBO H, 1994, J BIOL CHEM, V269, P26066; Sawa T, 2000, J BIOL CHEM, V275, P32467, DOI 10.1074/jbc.M910169199; Wink DA, 1997, J BIOL CHEM, V272, P11147	27	191	195	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28799	28805		10.1074/jbc.M102341200	http://dx.doi.org/10.1074/jbc.M102341200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11373284	hybrid			2022-12-25	WOS:000170346000022
J	Saha, D; Datta, PK; Beauchamp, RD				Saha, D; Datta, PK; Beauchamp, RD			Oncogenic Ras represses transforming growth factor-beta/Smad signaling by degrading tumor suppressor Smad4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; FACTOR-BETA; COLORECTAL-CANCER; EXPRESSION; PATHWAY; DPC4; GENE; DEGRADATION; INHIBITION; TGF-BETA-1	The loss of growth-inhibitory responses to transforming growth factor-beta (TGF-beta) is a frequent consequence of malignant transformation. Smad2, Smad3, and Smad4 proteins are important mediators of the antiproliferative responses to TGF-beta and may become inactivated in some human cancers. Epithelial cells harboring oncogenic Ras mutations often exhibit a loss of TGF-beta antiproliferative responses. To further investigate the effect of oncogenic Ras in TGF-beta signaling, we used an isopropyl-1-thio-beta -D-galactopyranoside-inducible expression system to express Ha-Ras (Val-12) in intestinal epithelial cells. Induction of Ha-Ras(Val-12) caused a decrease in the level of Smad4 expression, inhibited TGF-beta -induced complex formation between Smad2/Smad3 and Smad4, blocked Smad4 nuclear translocation, inhibited the TGF-beta -mediated decrease in [H-3]thymidine incorporation, and repressed TGF-beta -activated transcriptional responses. The withdrawal of isopropyl-1-thio-beta -D-galactopyranoside or the addition of an inhibitor of the ubiquitin-proteasome pathway restored the Smad4 level and TGF-beta -induced Smad complex formation. Forced expression of Smad4 resulted in partial recovery of the TGF-beta -mediated growth inhibition and transcriptional responses in the presence of oncogenic Ras. Further, PD98059, a specific inhibitor of the MEK/ERF/mitogenactivated protein kinase pathway prevented the Ras-induced decrease in Smad4 expression and complex formation. Our results suggest a novel mechanism by which oncogenic Ras represses TGF-beta signaling by mitogen-activated protein kinase-dependent down-regulation of Smad4, thereby subverting the tumor suppressor function of TGF-beta.	Vanderbilt Univ, Ctr Med, Dept Surg, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Ctr Med, Dept Cell Biol, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Beauchamp, RD (corresponding author), Vanderbilt Univ, Ctr Med, Dept Surg, Vanderbilt Ingram Canc Ctr, D5230 MCN,21st Ave S, Nashville, TN 37232 USA.			Beauchamp, Robert Daniel/0000-0002-8446-4114	NATIONAL CANCER INSTITUTE [P01CA077839, R01CA069457, P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK010138, R01DK052334] Funding Source: NIH RePORTER; NCI NIH HHS [CA77839, CA69457, CA68485] Funding Source: Medline; NIDDK NIH HHS [F32 DK10138, DK52334] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Calonge MJ, 1999, J BIOL CHEM, V274, P33637, DOI 10.1074/jbc.274.47.33637; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FILMUS J, 1992, ONCOGENE, V7, P521; Grady WM, 1999, CANCER RES, V59, P320; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hata A, 1998, MOL MED TODAY, V4, P257, DOI 10.1016/S1357-4310(98)01247-7; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; Iglesias M, 2000, ONCOGENE, V19, P4134, DOI 10.1038/sj.onc.1203764; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Ko TC, 1998, ONCOGENE, V16, P3445, DOI 10.1038/sj.onc.1201902; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; RIGGINS GJ, 1997, CANCER RES, V57, P4221; Shao JY, 2000, J BIOL CHEM, V275, P22916, DOI 10.1074/jbc.M002235200; Sheng HM, 2000, J BIOL CHEM, V275, P6628, DOI 10.1074/jbc.275.9.6628; Takaku K, 1999, CANCER RES, V59, P6113; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Winesett MP, 1996, CARCINOGENESIS, V17, P989, DOI 10.1093/carcin/17.5.989; Xu J, 2000, P NATL ACAD SCI USA, V97, P4820, DOI 10.1073/pnas.97.9.4820; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	30	96	111	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29531	29537		10.1074/jbc.M100069200	http://dx.doi.org/10.1074/jbc.M100069200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11371552	hybrid			2022-12-25	WOS:000170346000118
J	Kremer, L; Nampoothiri, KM; Lesjean, S; Dover, LG; Graham, S; Betts, J; Brennan, PJ; Minnikin, DE; Locht, C; Besra, GS				Kremer, L; Nampoothiri, KM; Lesjean, S; Dover, LG; Graham, S; Betts, J; Brennan, PJ; Minnikin, DE; Locht, C; Besra, GS			Biochemical characterization of acyl carrier protein (AcpM) and malonyl-CoA : AcpM transacylase (mtFabD), two major components of Mycobacterium tuberculosis fatty acid synthase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; POLYKETIDE SYNTHASE; CELL-WALL; STREPTOMYCES-GLAUCESCENS; LIPID BIOSYNTHESIS; CRYSTAL-STRUCTURE; FABD GENE; PURIFICATION; RHIZOBIUM	Malonyl coenzyme A (CoA)-acyl carrier protein (ACP) transacylase (MCAT) is an essential enzyme in the biosynthesis of fatty acids in all bacteria, including Mycobacterium tuberculosis. MCAT catalyzes the transacylation of malonate from malonyl-CoA to activated holo-ACP, to generate malonyl-ACP, which is an elongation substrate in fatty acid biosynthesis. To clarify the roles of the mycobacterial acyl carrier protein (AcpM) and MCAT in fatty acid and mycolic acid biosynthesis, we have cloned, expressed, and purified acpM and mtfabD (malonyl-COA: AcpM transacylase) from M. tuberculosis. According to the culture conditions used, AcpM was produced in Escherichia coli in two or three different forms: apo-AcpM, holo-AcpM, and palmitoylated-AcpM, as revealed by electrospray mass spectrometry. The mtfabD gene encoding a putative MCAT was used to complement a thermosensitive E. coli fabD mutant. Expression and purification of mtFabD resulted in an active enzyme displaying strong MCAT activity in vitro. Enzymatic studies using different ACP substrates established that holo-AcpM constitutes the preferred substrate for mtFabD. In order to provide further insight into the structure-function relationship of mtFabD, different mutant proteins were generated. All mutations (Q9A, R116A, H194A, Q243A, S91T, and S91A) completely abrogated MCAT activity in vitro, thus underlining the importance of these residues in transacylation. The generation and characterization of the AcpM forms and mtFabD opens the way for further studies relating to fatty acid and mycolic acid biosynthesis to be explored in M. tuberculosis. Since a specific type of FabD is found in mycobacterial species, it represents an attractive new drug target waiting to be exploited.	Univ Newcastle Upon Tyne, Dept Microbiol & Immunol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Inst Pasteur, INSERM, U447, F-59019 Lille, France; GlaxoSmithKine Res & Dev, Stevenage SG1 2NY, Herts, England; Colorado State Univ, Dept Microbiol, Ft Collins, CO 80523 USA; Univ Newcastle Upon Tyne, Dept Chem, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	Newcastle University - UK; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; GlaxoSmithKline; Colorado State University; Newcastle University - UK	Besra, GS (corresponding author), Univ Newcastle Upon Tyne, Dept Microbiol & Immunol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.		Dover, Lynn George/Q-6778-2019; Dover, Lynn G/F-3021-2010; Kremer, Laurent/M-4935-2017; Locht, Camille/L-3516-2018; Nampoothiri, K.Madhavan/J-4727-2017	Dover, Lynn George/0000-0002-4776-2665; Dover, Lynn G/0000-0002-4776-2665; Kremer, Laurent/0000-0002-6604-4458; Nampoothiri, K.Madhavan/0000-0003-4151-0974; Besra, Gurdyal/0000-0002-5605-0395	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI038087] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-38087] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; BRENNER S, 1988, NATURE, V334, P528, DOI 10.1038/334528a0; Brozek KA, 1996, J BIOL CHEM, V271, P32126, DOI 10.1074/jbc.271.50.32119; Choi KH, 2000, J BIOL CHEM, V275, P28201; Cole ST, 2001, NATURE, V409, P1007, DOI 10.1038/35059006; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Cox JS, 1999, NATURE, V402, P79, DOI 10.1038/47042; DEBELLE F, 1986, NUCLEIC ACIDS RES, V14, P7453, DOI 10.1093/nar/14.18.7453; DESSEN A, 1995, SCIENCE, V267, P1638, DOI 10.1126/science.7886450; Dreier J, 1999, J BIOL CHEM, V274, P25108, DOI 10.1074/jbc.274.35.25108; Epple G, 1998, J BACTERIOL, V180, P4950, DOI 10.1128/JB.180.18.4950-4954.1998; GEIGER O, 1991, J BACTERIOL, V173, P2872, DOI 10.1128/JB.173.9.2872-2878.1991; George KM, 1999, SCIENCE, V283, P854, DOI 10.1126/science.283.5403.854; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; Kolattukudy PE, 1997, MOL MICROBIOL, V24, P263, DOI 10.1046/j.1365-2958.1997.3361705.x; Kremer L, 2000, J BIOL CHEM, V275, P16857, DOI 10.1074/jbc.M000569200; Kremer L, 2000, MOLECULAR GENETICS OF MYCOBACTERIA, P173; Kutchma AJ, 1999, J BACTERIOL, V181, P5498, DOI 10.1128/JB.181.17.5498-5504.1999; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU J, 1995, P NATL ACAD SCI USA, V92, P11254, DOI 10.1073/pnas.92.24.11254; MAGNUSON K, 1992, FEBS LETT, V299, P262, DOI 10.1016/0014-5793(92)80128-4; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; McAllister KA, 2000, J BIOL CHEM, V275, P30864, DOI 10.1074/jbc.M004475200; Mdluli K, 1998, SCIENCE, V280, P1607, DOI 10.1126/science.280.5369.1607; MINNIKIN DE, 1982, BIOL MYCOBACTERIA, V1, P95; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Morbidoni HR, 1996, J BACTERIOL, V178, P4794, DOI 10.1128/jb.178.16.4794-4800.1996; NIKAIDO H, 1993, MOL MICROBIOL, V8, P1025, DOI 10.1111/j.1365-2958.1993.tb01647.x; PRESCOTT DJ, 1972, ADV ENZYMOL RAMB, V36, P269; QUEMARD A, 1995, BIOCHEMISTRY-US, V34, P8235, DOI 10.1021/bi00026a004; RAWLINGS M, 1992, J BIOL CHEM, V267, P5751; REVILL WP, 1995, J BACTERIOL, V177, P3946, DOI 10.1128/jb.177.14.3946-3952.1995; Sambrook J., 2002, MOL CLONING LAB MANU; SERRE L, 1995, J BIOL CHEM, V270, P12961, DOI 10.1074/jbc.270.22.12961; SHEN B, 1992, J BACTERIOL, V174, P3818, DOI 10.1128/JB.174.11.3818-3821.1992; Slayden RA, 2000, MOL MICROBIOL, V38, P514, DOI 10.1046/j.1365-2958.2000.02145.x; SUMMERS RG, 1995, BIOCHEMISTRY-US, V34, P9389, DOI 10.1021/bi00029a015; VERWOERT IIGS, 1994, FEBS LETT, V348, P311, DOI 10.1016/0014-5793(94)00630-X; VERWOERT IIGS, 1992, J BACTERIOL, V174, P2851, DOI 10.1128/JB.174.9.2851-2857.1992; Wilson W, 1999, P NATL ACAD SCI USA, V96, P12833, DOI 10.1073/pnas.96.22.12833; Yuan Y, 1998, J BIOL CHEM, V273, P21282, DOI 10.1074/jbc.273.33.21282; Zhou P, 1999, CHEM BIOL, V6, P577, DOI 10.1016/S1074-5521(99)80090-8	43	102	108	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27967	27974		10.1074/jbc.M103687200	http://dx.doi.org/10.1074/jbc.M103687200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11373295	hybrid			2022-12-25	WOS:000170093400031
J	Whitehead, JP; Molero, JC; Clark, S; Martin, S; Meneilly, G; James, DE				Whitehead, JP; Molero, JC; Clark, S; Martin, S; Meneilly, G; James, DE			The role of Ca2+ in insulin-stimulated glucose transport in 3T3-L1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC FREE CALCIUM; ISOLATED SKELETAL-MUSCLE; GLUT4 TRANSLOCATION; PHOSPHATIDYLINOSITOL 3-KINASE; GLUCOSE-TRANSPORTER-4 TRANSLOCATION; 3T3L1 ADIPOCYTES; HEXOSE-TRANSPORT; RAT ADIPOCYTES; KINASE-B; FUSION	We have examined the requirement for Ca2+ in the signaling and trafficking pathways involved in insulin-stimulated glucose uptake in 3T3-LI adipocytes. Chelation of intracellular Ca2+, using 1,2-bis (o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid tetra (acetoxymethyl) ester (BAPTA-AM), resulted in >95% inhibition of insulin-stimulated glucose uptake. The calmodulin antagonist, W13, inhibited insulin-stimulated glucose uptake by 60%. Both BAPTA-AM and W13 inhibited Akt phosphorylation by 70-75%. However, analysis of insulin-dose response curves indicated that this inhibition was not sufficient to explain the effects of BAPTA-AM and W13 on glucose uptake. BAPTA-AM inhibited insulin-stimulated translocation of GLUT4 by 50%, as determined by plasma membrane lawn assay and subcellular fractionation. In contrast, the insulin-stimulated appearance of HA-tagged GLUT4 at the cell surface, as measured by surface binding, was blocked by BAPTA/AM.. While the ionophores A23187 or ionomycin prevented the inhibition of Akt phosphorylation and GLUT4 translocation by BAPTA-AM, they did not overcome the inhibition of glucose transport. Moreover, glucose uptake of cells pretreated with insulin followed by rapid cooling to 4 degreesC, to promote cell surface expression of GLUT4 and prevent subsequent endocytosis, was inhibited specifically by BAPTA-AM. This indicates that inhibition of glucose uptake by BAPTA-AM is independent of both trafficking and signal transduction. These data indicate that Ca2+ is involved in at least two different steps of the insulin-dependent recruitment of GLUT4 to the plasma membrane. One involves the translocation step. The second involves the fusion of GLUT4 vesicles with the plasma membrane. These data are consistent with the hypothesis that Ca2+/cahnodulin plays a fundamental role in eukaryotic vesicle docking and fusion. Finally, BAPTA-AM may inhibit the activity of the facilitative transporters by binding directly to the transporter itself.	Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia; Univ Queensland, Dept Physiol & Pharmacol, St Lucia, Qld 4072, Australia	University of Queensland; University of Queensland	Whitehead, JP (corresponding author), Univ Queensland, Inst Mol Biosci, Ritchie Res Bldg,Res Rd, St Lucia, Qld 4072, Australia.		Clark, Sharon/B-8057-2009; Martin, Sally/A-7150-2010; Whitehead, Jonathan/F-5022-2014	Martin, Sally/0000-0001-9294-5404; Whitehead, Jonathan/0000-0003-3978-3148; James, David/0000-0001-5946-5257				Benzeroual K, 2000, BBA-MOL CELL RES, V1495, P14, DOI 10.1016/S0167-4889(99)00147-0; Brozinick JT, 1999, BIOCHEM J, V339, P533, DOI 10.1042/0264-6021:3390533; Bruton JD, 1999, P NATL ACAD SCI USA, V96, P3281, DOI 10.1073/pnas.96.6.3281; CARTEE GD, 1992, AM J PHYSIOL, V263, pR70, DOI 10.1152/ajpregu.1992.263.1.R70; Chen D, 1997, J BIOL CHEM, V272, P27401, DOI 10.1074/jbc.272.43.27401; CHEUNG JY, 1987, AM J PHYSIOL, V252, pC163, DOI 10.1152/ajpcell.1987.252.2.C163; Clark SF, 1998, J CELL BIOL, V140, P1211, DOI 10.1083/jcb.140.5.1211; Clark SF, 2000, J BIOL CHEM, V275, P3819, DOI 10.1074/jbc.275.6.3819; DRAZNIN B, 1987, J BIOL CHEM, V262, P14385; Garza LA, 2000, J BIOL CHEM, V275, P2560, DOI 10.1074/jbc.275.4.2560; GRIFFIN JF, 1982, P NATL ACAD SCI-BIOL, V79, P3759, DOI 10.1073/pnas.79.12.3759; Guilherme A, 1998, J BIOL CHEM, V273, P33119, DOI 10.1074/jbc.273.50.33119; Hill MM, 1999, MOL CELL BIOL, V19, P7771; Holroyd C, 1999, MOL BIOL CELL, V10, P3035, DOI 10.1091/mbc.10.9.3035; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; Joyal JL, 1997, J BIOL CHEM, V272, P28183, DOI 10.1074/jbc.272.45.28183; KELLY KL, 1989, J BIOL CHEM, V264, P12754; Khayat ZA, 1998, AM J PHYSIOL-CELL PH, V275, pC1487, DOI 10.1152/ajpcell.1998.275.6.C1487; Khayat ZA, 2000, J CELL SCI, V113, P279; Khil LY, 1997, BIOCHEM PHARMACOL, V54, P97, DOI 10.1016/S0006-2952(97)00145-7; KLIP A, 1984, AM J PHYSIOL, V247, pE297, DOI 10.1152/ajpendo.1984.247.3.E297; KLIP A, 1987, J BIOL CHEM, V262, P9141; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; LEE AD, 1995, AM J PHYSIOL-REG I, V268, pR997, DOI 10.1152/ajpregu.1995.268.4.R997; Mayer A, 1999, CURR OPIN CELL BIOL, V11, P447, DOI 10.1016/S0955-0674(99)80064-7; Munshi HG, 1996, BIOCHEMISTRY-US, V35, P15883, DOI 10.1021/bi962107y; Oatey PB, 1999, BIOCHEM J, V344, P511, DOI 10.1042/0264-6021:3440511; PERSHADSINGH HA, 1987, P NATL ACAD SCI USA, V84, P1025, DOI 10.1073/pnas.84.4.1025; Peters C, 2001, NATURE, V409, P581, DOI 10.1038/35054500; Peters C, 1998, NATURE, V396, P575, DOI 10.1038/25133; PIPER RC, 1992, J CELL BIOL, V117, P729, DOI 10.1083/jcb.117.4.729; PIPER RC, 1991, AM J PHYSIOL, V260, P570; Porat A, 2000, J BIOL CHEM, V275, P29233, DOI 10.1074/jbc.M005316200; Pryor PR, 2000, J CELL BIOL, V149, P1053, DOI 10.1083/jcb.149.5.1053; Rea S, 1997, DIABETES, V46, P1667, DOI 10.2337/diabetes.46.11.1667; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; SHASHKIN P, 1995, J BIOL CHEM, V270, P25613, DOI 10.1074/jbc.270.43.25613; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Shewan AM, 2000, BIOCHEM J, V350, P99, DOI 10.1042/0264-6021:3500099; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; Wang QH, 1998, FEBS LETT, V427, P193, DOI 10.1016/S0014-5793(98)00423-2; Wang QH, 1999, MOL CELL BIOL, V19, P4008; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Yang CM, 2000, MOL ENDOCRINOL, V14, P317, DOI 10.1210/me.14.2.317	44	121	123	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27816	27824		10.1074/jbc.M011590200	http://dx.doi.org/10.1074/jbc.M011590200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11375387	Green Submitted			2022-12-25	WOS:000170093400012
J	Kim, JW; Joe, CO; Choi, EJ				Kim, JW; Joe, CO; Choi, EJ			Role of receptor-interacting protein in tumor necrosis factor-alpha-dependent MEKK1 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; DOMAIN KINASE RIP; SIGNALING COMPLEX DISC; INDUCED CELL-DEATH; TNF RECEPTOR; INDUCED APOPTOSIS; TERMINAL KINASE; IKK ACTIVATION; JNK; PHOSPHORYLATION	Receptor-interacting protein (RIP), a death domain serine/threonine kinase, has been Shown to play a critical role in tumor necrosis factor-alpha (TNF-alpha)-induced activation of the nuclear factor-kappaB signaling pathway. We demonstrate here that ectopically expressed RIP induces I-kappaB kinase-beta (IKK beta) activation in intact cells and that RIP-induced IKK beta activation can be blocked by a kinase-inactive form of MEKK1, MEKK1(K1253M). Interestingly, RIP physically associated with MEKK1 both in vitro and in vivo. RIP phosphorylated MEKK1 at Ser-957 and Ser-994. Our data also indicate that RIP induced the stimulation of MEKK1 but not MEKK1 (S957A/S994A) in transfected cells. Furthermore, overexpressed MEKK1 (S957A/S994A) inhibited the RIP-induced activation of both IKK beta and nuclear factor-kappaB. We also demonstrated that the TNF-alpha -induced MEKK1 activation was defective in RIP-deficient Jurkat cells. Taken together, our results suggest that RIP phosphorylates and activates MEKK1 and that RIP is involved in TNF-alpha -induced MEKK1 activation.	Korea Univ, Natl Creat Res Instiat Ctr Cell Death, Grad Sch Biotechnol, Seoul 156701, South Korea; Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea	Korea University; Korea Advanced Institute of Science & Technology (KAIST)	Choi, EJ (corresponding author), Korea Univ, Natl Creat Res Instiat Ctr Cell Death, Grad Sch Biotechnol, Seoul 156701, South Korea.	cojoe@mail.kaist.ac.kr; ejchoi@mail.korea.ac.kr	KIM, JIN WOO/C-1655-2011; Joe, Cheol O/C-1917-2011	KIM, JIN WOO/0000-0003-0767-1918; 				Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; CHAPLIN DD, 1980, J IMMUNOL, V124, P2390; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; Grimm S, 1996, P NATL ACAD SCI USA, V93, P10923, DOI 10.1073/pnas.93.20.10923; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Izumi KM, 1999, MOL CELL BIOL, V19, P5759; Karin M, 1998, CANCER J SCI AM, V4, pS92; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kim JW, 2000, ONCOGENE, V19, P4491, DOI 10.1038/sj.onc.1203796; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Lin Y, 2000, MOL CELL BIOL, V20, P6638, DOI 10.1128/MCB.20.18.6638-6645.2000; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Minamino T, 1999, P NATL ACAD SCI USA, V96, P15127, DOI 10.1073/pnas.96.26.15127; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Navas TA, 1999, J BIOL CHEM, V274, P33684, DOI 10.1074/jbc.274.47.33684; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Ozes ON, 1999, NATURE, V401, P82; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Pimentel-Muinos FX, 1999, IMMUNITY, V11, P783, DOI 10.1016/S1074-7613(00)80152-1; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Varfolomeev EE, 1996, J EXP MED, V183, P1271, DOI 10.1084/jem.183.3.1271; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	50	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27064	27070		10.1074/jbc.M009364200	http://dx.doi.org/10.1074/jbc.M009364200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11369754	hybrid			2022-12-25	WOS:000169966900045
J	Speigelman, VS; Stavropoulos, P; Latres, E; Pagano, M; Ronai, Z; Slaga, TJ; Fuchs, SY				Speigelman, VS; Stavropoulos, P; Latres, E; Pagano, M; Ronai, Z; Slaga, TJ; Fuchs, SY			Induction of beta-transducin repeat-containing protein by JNK signaling and its role in the activation of NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-BOX PROTEINS; INTERLEUKIN-2 MESSENGER-RNA; JUN NH2-TERMINAL KINASE; UBIQUITIN LIGASE; C-JUN; DEPENDENT DEGRADATION; ALPHA UBIQUITINATION; CELL-DEATH; TNF-ALPHA; IN-VITRO	Activation of Jun N-kinase (JNK) and NF-kappaB transcription factor are the hallmarks of cellular response to stress. Phosphorylation of NF-kappaB inhibitor (I kappaB) by respective stress-inducible kinases (IKK) is:a key event in NF-kappaB activation. beta -TrCP F-box protein mediates ubiquitination of phosphorylated I kappaB via recruitment of SCFbeta -TrCP-Roc1 E3 ubiquitin Ligase complex. Subsequent proteasome-dependent degradation of I kappaB results in activation of the NF-kappaB pathway, We found that a variety of cellular stress stimuli induce an increase in the steady state levels of beta -TrCP mRNA and protein levels in human cells. Activation of stress-activated protein kinases JNK (and, to a lesser extent, p38) by forced expression of constitutively active mutants of JNKK2 and MKK6 (but not MEK1 or IKK beta) also leads to accumulation of beta -TrCP. Transcription of the beta -TrCP gene is not required for JNK-mediated induction of beta -TrCP. A synergistic effect of stimulation of IKK and JNK on the transcriptional activity of NF-kappaB was observed. The mechanisms of beta -TrCP induction via stress and its role in NF-kappaB activation are discussed.	Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA; AMC Canc Res Ctr, Lakewood, CO 80214 USA; CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA; NYU, Dept Pathol, New York, NY 10016 USA	University of Pennsylvania; AMC Cancer Research Center; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; New York University	Fuchs, SY (corresponding author), Univ Penn, Sch Vet Med, Dept Anim Biol, 3800 Spruce St,Rm 161E VET, Philadelphia, PA 19104 USA.	sfuks@vet.upenn.edu		pagano, michele/0000-0003-3210-2442; Spiegelman, Vladimir S/0000-0003-4847-155X; RONAI, ZEEV/0000-0002-3859-0400	NCI NIH HHS [CA 92900, CA 76262] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092900] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Alpert D, 2000, J BIOL CHEM, V275, P10925, DOI 10.1074/jbc.275.15.10925; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; Cenciarelli C, 1999, CURR BIOL, V9, P1177, DOI 10.1016/S0960-9822(00)80020-2; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; Chen CY, 2000, GENE DEV, V14, P1236; Chirillo P, 1996, J VIROL, V70, P641, DOI 10.1128/JVI.70.1.641-646.1996; Das KC, 2001, J BIOL CHEM, V276, P4662, DOI 10.1074/jbc.M006206200; Davis RJ, 1999, BIOCHEM SOC SYMP, P1; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Diao JY, 2001, J BIOL CHEM, V276, P8328, DOI 10.1074/jbc.M006026200; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Fuchs SY, 1999, ONCOGENE, V18, P2039, DOI 10.1038/sj.onc.1202760; Hatakeyama S, 1999, P NATL ACAD SCI USA, V96, P3859, DOI 10.1073/pnas.96.7.3859; Hattori K, 1999, J BIOL CHEM, V274, P29641, DOI 10.1074/jbc.274.42.29641; Jaaro H, 1997, P NATL ACAD SCI USA, V94, P3742, DOI 10.1073/pnas.94.8.3742; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kasibhatla S, 1999, MOL CELL BIOL, V19, P2021; KEKULE AS, 1992, ARCH VIROL, P63; Kroll M, 1999, J BIOL CHEM, V274, P7941, DOI 10.1074/jbc.274.12.7941; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Leonardi A, 2000, P NATL ACAD SCI USA, V97, P10494, DOI 10.1073/pnas.190245697; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Mazars A, 2000, ONCOGENE, V19, P1277, DOI 10.1038/sj.onc.1203420; Ming XF, 1998, EMBO J, V17, P6039, DOI 10.1093/emboj/17.20.6039; Mitchell P, 2000, CURR OPIN GENET DEV, V10, P193, DOI 10.1016/S0959-437X(00)00063-0; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Moriguchi T, 1996, J BIOL CHEM, V271, P26981, DOI 10.1074/jbc.271.43.26981; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; Pages G, 2000, J BIOL CHEM, V275, P26484, DOI 10.1074/jbc.M002104200; Potapova O, 2000, MOL CELL BIOL, V20, P1713, DOI 10.1128/MCB.20.5.1713-1722.2000; Ronai Z, 1999, ONCOGENE, V18, P6084, DOI 10.1038/sj.onc.1203175; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Schwenger P, 1998, MOL CELL BIOL, V18, P78, DOI 10.1128/MCB.18.1.78; Shi CS, 1999, J IMMUNOL, V163, P3279; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Spiegelman VS, 2000, MOL CELL, V5, P877, DOI 10.1016/S1097-2765(00)80327-5; Stein B, 1996, J BIOL CHEM, V271, P11427, DOI 10.1074/jbc.271.19.11427; Suzuki H, 2000, J BIOL CHEM, V275, P2877, DOI 10.1074/jbc.275.4.2877; Suzuki H, 1999, BIOCHEM BIOPH RES CO, V256, P127, DOI 10.1006/bbrc.1999.0289; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Weil R, 1999, MOL CELL BIOL, V19, P6345; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Winston JT, 1999, CURR BIOL, V9, P1180, DOI 10.1016/S0960-9822(00)80021-4; XU SC, 1995, P NATL ACAD SCI USA, V92, P6808, DOI 10.1073/pnas.92.15.6808; Yaron A, 1997, EMBO J, V16, P6486, DOI 10.1093/emboj/16.21.6486; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zwacka RM, 2000, J GENE MED, V2, P334, DOI 10.1002/1521-2254(200009/10)2:5<334::AID-JGM129>3.0.CO;2-Q	60	60	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27152	27158		10.1074/jbc.M100031200	http://dx.doi.org/10.1074/jbc.M100031200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11375388	hybrid			2022-12-25	WOS:000169966900057
J	Wyckoff, MH; Chambliss, KL; Mineo, C; Yuhanna, IS; Mendelsohn, ME; Mumby, SM; Shaul, PW				Wyckoff, MH; Chambliss, KL; Mineo, C; Yuhanna, IS; Mendelsohn, ME; Mumby, SM; Shaul, PW			Plasma membrane estrogen receptors are coupled to endothelial nitric-oxide synthase through G alpha(i)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-ALPHA-SUBUNITS; PHOSPHOLIPASE-C; ACTIVATION; CELLS; MOBILIZATION; SUBFAMILY; ESTRADIOL; HORMONES; CALCIUM; BETA	Estrogen causes rapid endothelial nitric oxide (NO) production because of the activation of plasma membrane-associated estrogen receptors (ER) coupled to endothelial NO synthase (eNOS). In the present study, we determined the role of G proteins in eNOS activation by estrogen. Estradiol-17 beta (E-2, 10(-8) M) and acetylcholine (10(-5) hr) caused comparable increases in NOS activity (15 min) in intact endothelial cells that were fully blocked by pertussis toxin (Ptox). In addition, exogenous guanosine 5'-O-(2- thiodiphosphate) inhibited E-2-mediated eNOS stimulation in isolated endothelial plasma membranes, and Ptox prevented enzyme activation by E-2 in COS-7 cells expressing ER alpha and eNOS. Coimmunoprecipitation studies of plasma membranes from COS-7 cells transfected with ER alpha and specific G alpha proteins demonstrated E-2-stimulated interaction between ER alpha and G alpha (i) but not between ER alpha and either G alpha (q) or G alpha (s); the observed ER alpha -G alpha (i) interaction was blocked by the ER antagonist ICI 182,780 and by Ptox, E-2-stimulated ER alpha -G alpha (i) interaction was also demonstrable in endothelial cell plasma membranes. Cotransfection of G alpha (i) into COS-7 cells expressing ER alpha and eNOS yielded a 3-fold increase in E-2-mediated eNOS stimulation, whereas cotransfection with a protein regulator of G protein signaling, RGS4, inhibited the E-2 response. These findings indicate that eNOS stimulation by E-2 requires plasma membrane ER alpha coupling to G alpha (i) and that activated G alpha (i) mediates the requisite downstream signaling events. Thus, novel G protein coupling enables a subpopulation of ER alpha to initiate signal transduction at the cell surface. Similar mechanisms may underly the nongenomic actions of other steroid hormones.	Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; New England Med Ctr, Mol Cardiol Res Inst, Boston, MA 02111 USA; Tufts Univ, Sch Med, Boston, MA 02111 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Tufts Medical Center; Tufts University	Shaul, PW (corresponding author), Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75390 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD030276] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059953, R01HL053546, R01HL058888, R01HL056069] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL59953, HL58888, HL53546, HL56069] Funding Source: Medline; NICHD NIH HHS [HD30276] Funding Source: Medline; NIGMS NIH HHS [GM50515] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Benten WPM, 1999, MOL BIOL CELL, V10, P3113, DOI 10.1091/mbc.10.10.3113; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Blair A, 1999, J BIOL CHEM, V274, P32512, DOI 10.1074/jbc.274.45.32512; CALDWELL JD, 1995, BRAIN RES, V693, P225, DOI 10.1016/0006-8993(95)00727-8; CARSONJURICA MA, 1990, ENDOCR REV, V11, P201, DOI 10.1210/edrv-11-2-201; CARTY DJ, 1994, METHOD ENZYMOL, V237, P63; CaulinGlaser T, 1997, CIRC RES, V81, P885; Chen Y Z, 1999, Mol Cell Biol Res Commun, V2, P145, DOI 10.1006/mcbr.1999.0163; Chen Z, 1999, J CLIN INVEST, V103, P401, DOI 10.1172/JCI5347; GILMAN AG, 1995, BIOSCIENCE REP, V15, P65, DOI 10.1007/BF01200143; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; Kelly MJ, 1999, STEROIDS, V64, P64, DOI 10.1016/S0039-128X(98)00095-6; LantinHermoso RL, 1997, AM J PHYSIOL-LUNG C, V273, pL119, DOI 10.1152/ajplung.1997.273.1.L119; LeMellay V, 1997, J BIOL CHEM, V272, P11902, DOI 10.1074/jbc.272.18.11902; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LIU J, 1995, P NATL ACAD SCI USA, V92, P11642, DOI 10.1073/pnas.92.25.11642; Machelon V, 1996, J CELL BIOCHEM, V61, P619, DOI 10.1002/(SICI)1097-4644(19960616)61:4<619::AID-JCB16>3.0.CO;2-A; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Morelli S, 1996, MOL CELL ENDOCRINOL, V122, P207, DOI 10.1016/0303-7207(96)03886-5; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; PAPPAS TC, 1995, ENDOCRINE, V3, P743, DOI 10.1007/BF03000207; Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307; Watters JJ, 1997, ENDOCRINOLOGY, V138, P4030, DOI 10.1210/en.138.9.4030; Wehling M, 1997, ANNU REV PHYSIOL, V59, P365, DOI 10.1146/annurev.physiol.59.1.365; Wess J, 1998, PHARMACOL THERAPEUT, V80, P231, DOI 10.1016/S0163-7258(98)00030-8	26	244	256	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27071	27076		10.1074/jbc.M100312200	http://dx.doi.org/10.1074/jbc.M100312200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11369763	hybrid			2022-12-25	WOS:000169966900046
J	Hill, MM; Andjelkovic, M; Brazil, DP; Ferrari, S; Fabbro, D; Hemmings, BA				Hill, MM; Andjelkovic, M; Brazil, DP; Ferrari, S; Fabbro, D; Hemmings, BA			Insulin-stimulated protein kinase B phosphorylation on Ser-473 is independent of its activity and occurs through a staurosporine-insensitive kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN-LINKED KINASE; 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN-KINASE-1; ACTIVATION; CELLS; MECHANISM; GROWTH; PDK1; SITE; APOPTOSIS; INHIBITOR	Full activation of protein kinase B (PKB, also called Akt) requires phosphorylation on two regulatory sites, Thr-308 in the activation loop and Ser-473 in the hydrophobic C-terminal regulatory domain (numbering for PKB alpha /Akt-1), Although 3 ' -phosphoinositide-dependent protein kinase 1 (PDK1) has now been identified as the Thr-308 kinase, the mechanism of the Ser-473 phosphorylation remains controversial. As a step to further characterize the Ser-473 kinase, we examined the effects of a range of protein kinase inhibitors on the activation and phosphorylation of PKB. We found that staurosporine, a broad-specificity kinase inhibitor and inducer of cell apoptosis, attenuated PKB activation exclusively through the inhibition of Thr-308 phosphorylation, with Ser-473 phosphorylation unaffected. The increase in Thr-308 phosphorylation because of overexpression of PDK1 was also inhibited by staurosporine, We further show that staurosporine (CGP 39360) potently inhibited PDK1 activity in vitro with an IC50 of similar to0.22 muM. These data indicate that agonist-induced phosphorylation of Ser-473 of PKB is independent of PDK1 or PKB activity and occurs through a distinct Ser-473 kinase that is not inhibited by staurosporine, Moreover, our results suggest that inhibition of PKB signaling is involved in the proapoptotic action of staurosporine.	Friedrich Miescher Inst, CH-4058 Basel, Switzerland; Novartis Pharma AG, Dept Oncol, CH-4057 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research; Novartis	Hemmings, BA (corresponding author), Friedrich Miescher Inst, Maulbeerstr 66, CH-4058 Basel, Switzerland.		Hill, Michelle Mei Chih/G-4417-2010; Ferrari, Stefano/I-7357-2016	Hill, Michelle Mei Chih/0000-0003-1134-0951; Ferrari, Stefano/0000-0002-6607-215X; Brazil, Derek/0000-0003-1375-1076				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1999, MOL CELL BIOL, V19, P5061; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Begemann M, 1998, ANTICANCER RES, V18, P3139; Begemann M, 1998, ANTICANCER RES, V18, P2275; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Fabbro D, 2000, ANTI-CANCER DRUG DES, V15, P17; Fabbro D, 1999, PROTEIN EXPRES PURIF, V17, P83, DOI 10.1006/prep.1999.1102; Flynn P, 2000, CURR BIOL, V10, P1439, DOI 10.1016/S0960-9822(00)00801-0; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; Geiges D, 1997, BIOCHEM PHARMACOL, V53, P865, DOI 10.1016/S0006-2952(96)00885-4; HILL MM, 2001, IN PRESS METHODS ENZ, V345; Jensen CJ, 1999, J BIOL CHEM, V274, P27168, DOI 10.1074/jbc.274.38.27168; Lynch DK, 1999, ONCOGENE, V18, P8024, DOI 10.1038/sj.onc.1203258; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Shao RG, 1997, EXP CELL RES, V234, P388, DOI 10.1006/excr.1997.3650; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Toledo LM, 1999, CURR MED CHEM, V6, P775; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3	25	113	123	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25643	25646		10.1074/jbc.C100174200	http://dx.doi.org/10.1074/jbc.C100174200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11373274	hybrid, Green Accepted			2022-12-25	WOS:000169823300002
J	Yang, HL; Reinherz, EL				Yang, HL; Reinherz, EL			Dynamic recruitment of human CD2 into lipid rafts - Linkage to T cell signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE-T; CYTOPLASMIC DOMAIN; MEMBRANE DOMAINS; TYROSINE KINASE; ERYTHROPOIETIN RECEPTOR; BIOLOGICAL-MEMBRANES; ANTIGEN RECOGNITION; PLASMA-MEMBRANE; N-GLYCANS; ACTIVATION	CD2 mediates T cell adhesion via its ectodomain and signal transduction utilizing its 117-amino acid cytoplasmic tail. Here we show that a significant fraction of human CD2 molecules is inducibly recruited into lipid rafts upon CD2 cross-linking by a specific pair of mitogenic anti-CD2 monoclonal antibodies (anti-T11(2), + anti-T11(3)) or during cellular conjugate formation by CD58, the physiologic ligand expressed on antigen-presenting cells. Translocation to lipid microdomains is independent of the T cell receptor (TCR) and, unlike inducible TCR-raft association, requires no tyrosine phosphorylation. Structural integrity of rafts is necessary for CDS stimulated elevation of intracellular free calcium and tyrosine phosphorylation of cellular substrates, Whereas murine CD2 contains two membrane-proximal intracellular cysteines, partitioning CD2 into cholesterol-rich lipid rafts constitutively, human CD2 has no cytoplasmic cysteines. Mapping studies using CD2 point mutation, deletion, and chimeric molecules suggest that conformational change in the CD2 ectodomain participates in inducible raft association and excludes the membrane-proximal N-linked glycans, the transmembrane segment, and the CD2 cytoplasmic region (residues 8-117) as necessary for translocation. Translocation of CD2 into lipid rafts may reorganize the membrane into an activation-ready state prior to TCR engagement by a peptide associated with a major histocompatibility complex molecule, accounting for synergistic T cell stimulation by CD2 and the TCR.	Dana Farber Canc Inst, Immunobiol Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Reinherz, EL (corresponding author), Dana Farber Canc Inst, Immunobiol Lab, 44 Binney St, Boston, MA 02115 USA.	ellis_reinherz@dfci.harvard.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021226] Funding Source: NIH RePORTER; NIAID NIH HHS [AI21226] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aman MJ, 2000, CURR BIOL, V10, P393, DOI 10.1016/S0960-9822(00)00415-2; ARULANANDAM AR, 1993, LEUCOCYTE TYPING 5, V1, P349; ARULANANDAM ARN, 1994, J EXP MED, V180, P1861, DOI 10.1084/jem.180.5.1861; ARULANANDAM ARN, 1993, J EXP MED, V177, P1439, DOI 10.1084/jem.177.5.1439; Bachmann MF, 1999, J EXP MED, V190, P1383, DOI 10.1084/jem.190.10.1383; Bell GM, 1996, J EXP MED, V183, P169, DOI 10.1084/jem.183.1.169; Benting JH, 1999, J CELL BIOL, V146, P313, DOI 10.1083/jcb.146.2.313; BIERER BE, 1989, ANNU REV IMMUNOL, V7, P579, DOI 10.1146/annurev.immunol.7.1.579; BOUSSIOTIS VA, 1994, J EXP MED, V180, P1665, DOI 10.1084/jem.180.5.1665; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Brown DA, 1997, BIOCHEM BIOPH RES CO, V240, P1, DOI 10.1006/bbrc.1997.7575; Cebecauer M, 1998, BIOCHEM BIOPH RES CO, V243, P706, DOI 10.1006/bbrc.1998.8149; CHANG HC, 1989, J EXP MED, V169, P2073, DOI 10.1084/jem.169.6.2073; CHANG HC, 1990, J EXP MED, V172, P351, DOI 10.1084/jem.172.1.351; Cheng PC, 1999, J EXP MED, V190, P1549, DOI 10.1084/jem.190.11.1549; CLAYTON LK, 1987, EUR J IMMUNOL, V17, P1367, DOI 10.1002/eji.1830170922; Costello PS, 1999, P NATL ACAD SCI USA, V96, P3035, DOI 10.1073/pnas.96.6.3035; Davis MM, 1998, ANNU REV IMMUNOL, V16, P523, DOI 10.1146/annurev.immunol.16.1.523; Davis SJ, 1998, IMMUNOL REV, V163, P217, DOI 10.1111/j.1600-065X.1998.tb01199.x; Deans JP, 1998, J BIOL CHEM, V273, P344, DOI 10.1074/jbc.273.1.344; Dustin ML, 1997, J BIOL CHEM, V272, P30889, DOI 10.1074/jbc.272.49.30889; Dustin ML, 1998, CELL, V94, P667, DOI 10.1016/S0092-8674(00)81608-6; Field KA, 1997, J BIOL CHEM, V272, P4276, DOI 10.1074/jbc.272.7.4276; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960-9822(98)70224-6; FUJIMOTO T, 1993, J CELL BIOL, V120, P1147, DOI 10.1083/jcb.120.5.1147; Fukai I, 2000, EUR J IMMUNOL, V30, P3507, DOI 10.1002/1521-4141(2000012)30:12<3507::AID-IMMU3507>3.0.CO;2-O; Gollob JA, 1996, J IMMUNOL, V157, P1886; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Green JM, 2000, J IMMUNOL, V164, P3591, DOI 10.4049/jimmunol.164.7.3591; HAHN WC, 1993, J EXP MED, V178, P1831, DOI 10.1084/jem.178.5.1831; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; HE Q, 1988, CELL, V54, P979, DOI 10.1016/0092-8674(88)90112-2; Holsinger LJ, 1998, CURR BIOL, V8, P563, DOI 10.1016/S0960-9822(98)70225-8; Horejsi V, 1999, IMMUNOL TODAY, V20, P356, DOI 10.1016/S0167-5699(99)01489-9; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; Kabouridis PS, 1997, EMBO J, V16, P4983, DOI 10.1093/emboj/16.16.4983; King PD, 1996, INT IMMUNOL, V8, P1707, DOI 10.1093/intimm/8.11.1707; Kivens WJ, 1998, MOL CELL BIOL, V18, P5291, DOI 10.1128/MCB.18.9.5291; KLEIN U, 1995, BIOCHEMISTRY-US, V34, P13784, DOI 10.1021/bi00042a009; KOYASU S, 1990, P NATL ACAD SCI USA, V87, P2603, DOI 10.1073/pnas.87.7.2603; Langlet C, 2000, CURR OPIN IMMUNOL, V12, P250, DOI 10.1016/S0952-7915(00)00084-4; Lanzavecchia A, 1999, CELL, V96, P1, DOI 10.1016/S0092-8674(00)80952-6; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; Li J, 1998, EMBO J, V17, P7320, DOI 10.1093/emboj/17.24.7320; Li J, 1996, J MOL BIOL, V263, P209, DOI 10.1006/jmbi.1996.0570; Lin HM, 1998, J BIOL CHEM, V273, P19914, DOI 10.1074/jbc.273.31.19914; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; MEUER SC, 1984, CELL, V36, P897, DOI 10.1016/0092-8674(84)90039-4; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; MOINGEON P, 1989, NATURE, V339, P312, DOI 10.1038/339312a0; MOINGEON P, 1989, IMMUNOL REV, V111, P111, DOI 10.1111/j.1600-065X.1989.tb00544.x; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; Nishizawa K, 1998, P NATL ACAD SCI USA, V95, P14897, DOI 10.1073/pnas.95.25.14897; Pike LJ, 1996, J BIOL CHEM, V271, P26453, DOI 10.1074/jbc.271.43.26453; RECNY MA, 1992, J BIOL CHEM, V267, P22428; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; SELVARAJ P, 1987, NATURE, V326, P400, DOI 10.1038/326400a0; SILICIANO RF, 1985, NATURE, V317, P428, DOI 10.1038/317428a0; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Stauffer TP, 1997, J CELL BIOL, V139, P1447, DOI 10.1083/jcb.139.6.1447; TAVERNOR AS, 1994, EUR J BIOCHEM, V219, P969, DOI 10.1111/j.1432-1033.1994.tb18579.x; VALITUTTI S, 1995, NATURE, V375, P148, DOI 10.1038/375148a0; van der Merwe PA, 2000, SEMIN IMMUNOL, V12, P5, DOI 10.1006/smim.2000.0203; van't Hof W, 1999, J CELL BIOL, V145, P377, DOI 10.1083/jcb.145.2.377; Viola A, 1999, SCIENCE, V283, P680, DOI 10.1126/science.283.5402.680; Wang J, 1999, CELL, V97, P791, DOI 10.1016/S0092-8674(00)80790-4; Xavier R, 1999, CURR OPIN IMMUNOL, V11, P265, DOI 10.1016/S0952-7915(99)80043-0; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; YANG SY, 1986, J IMMUNOL, V137, P1097; Yashiro-Ohtani Y, 2000, J IMMUNOL, V164, P1251, DOI 10.4049/jimmunol.164.3.1251; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	80	45	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					18775	18785		10.1074/jbc.M009852200	http://dx.doi.org/10.1074/jbc.M009852200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11376005	hybrid			2022-12-25	WOS:000169091000019
J	Parenti, A; Morbidelli, L; Ledda, F; Granger, HJ; Ziche, M				Parenti, A; Morbidelli, L; Ledda, F; Granger, HJ; Ziche, M			The bradykinin/B1 receptor promotes angiogenesis by up-regulation of endogenous FGF-2 in endothelium via the nitric oxide synthase pathway	FASEB JOURNAL			English	Article						neovascularization; kinins; endothelial cells; angiogenic factor expression; receptor signaling	FIBROBLAST GROWTH-FACTOR; B-1 RECEPTORS; IN-VIVO; CELL-PROLIFERATION; DNA-SYNTHESIS; B2 RECEPTORS; KININS; EXPRESSION; MECHANISM; RAT	Bradykinin (BK) mediates inflammation and contributes to angiogenesis. We assessed the mechanisms for BK contribution to angiogenesis. Nanomolar concentrations of BK induced angiogenesis in rabbit corneas in absence of inflammation. The effect was dose-dependent and mediated by the B1 receptor. B2 receptor stimulation failed to directly promote vascular growth unless inflammation was induced. Anti-fibroblast growth factor-2 (FGF-2) antibody blocked the effect of BK or 131 receptor agonist. In postcapillary venular endothelial cells (CVEC), B2 receptor activation induced inositol phosphate turnover and calcium transients, whereas the B1 receptor was coupled to nitric oxide synthase (NOS) up-regulation and activation and cGMP increase. Differential RT-PCR and Western blot analysis revealed FGF-2 up-regulation in cells exposed to BK or to the selective B1 agonist, whereas the B2 agonist was without effect. Consistently, BK and the B1 but not the B2 agonist exerted a proliferative effect on CVEC, which was prevented by anti-FGF-2 antibody and by NOS inhibition. These results demonstrate that BK is angiogenic despite its proinflammatory activity and that the B1 receptor is involved. The B 1 receptor is coupled to NOS activation and FGF-2 up-regulation, events not shared by the B2 receptor activation.	Univ Siena, Inst Pharmacol Sci, I-53100 Siena, Italy; Univ Florence, Dept Pharmacol, I-50139 Florence, Italy; Texas A&M Univ, Syst Hlth Sci Ctr, Dept Physiol, College Stn, TX USA; Texas A&M Univ, Syst Hlth Sci Ctr, Microcirculat Res Inst, College Stn, TX USA	University of Siena; University of Florence; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Ziche, M (corresponding author), Univ Siena, Inst Pharmacol Sci, Via S Piccolomini 170, I-53100 Siena, Italy.	ziche@unisi.it	Morbidelli, Lucia/K-4053-2016; Morbidelli, Lucia/AAC-7858-2020	Morbidelli, Lucia/0000-0001-8148-7049; Parenti, Astrid/0000-0002-7980-6853				Ahluwalia A, 1999, TRENDS PHARMACOL SCI, V20, P100, DOI 10.1016/S0165-6147(99)01321-8; Ambs S, 1998, NAT MED, V4, P1371, DOI 10.1038/3957; Bastian S, 1998, BIOCHEM BIOPH RES CO, V253, P750, DOI 10.1006/bbrc.1998.9848; Bouchard JF, 1998, BRIT J PHARMACOL, V123, P413, DOI 10.1038/sj.bjp.0701619; Braun C, 1997, J CARDIOVASC PHARM, V30, P446, DOI 10.1097/00005344-199710000-00007; CAMBRIDGE H, 1995, BRIT J PHARMACOL, V115, P641, DOI 10.1111/j.1476-5381.1995.tb14980.x; Cuevas P, 1997, Eur J Med Res, V2, P282; Dixon BS, 1997, AM J PHYSIOL-CELL PH, V273, pC7, DOI 10.1152/ajpcell.1997.273.1.C7; DORLEANSJUSTE P, 1989, BRIT J PHARMACOL, V96, P920, DOI 10.1111/j.1476-5381.1989.tb11903.x; FARHY RD, 1993, CIRC RES, V72, P1202, DOI 10.1161/01.RES.72.6.1202; Frimm CD, 1996, J MOL CELL CARDIOL, V28, P1279; Gobeil F, 1996, HYPERTENSION, V28, P833, DOI 10.1161/01.HYP.28.5.833; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gualandris A, 1996, CELL GROWTH DIFFER, V7, P147; HALL JM, 1992, PHARMACOL THERAPEUT, V56, P131, DOI 10.1016/0163-7258(92)90016-S; He P, 1998, AM J PHYSIOL-HEART C, V274, pH1865, DOI 10.1152/ajpheart.1998.274.6.H1865; HU DE, 1993, BRIT J PHARMACOL, V109, P14, DOI 10.1111/j.1476-5381.1993.tb13525.x; Kay EP, 1998, CURR EYE RES, V17, P286, DOI 10.1076/ceyr.17.3.286.5212; KOSTYK SK, 1995, AM J PHYSIOL-HEART C, V269, pH1583, DOI 10.1152/ajpheart.1995.269.5.H1583; LEIBOVICH SJ, 1994, P NATL ACAD SCI USA, V91, P4190, DOI 10.1073/pnas.91.10.4190; Marceau F, 1998, PHARMACOL REV, V50, P357; Matoba S, 1999, CIRCULATION, V99, P817, DOI 10.1161/01.CIR.99.6.817; Morbidelli L, 1998, BRIT J PHARMACOL, V124, P1286, DOI 10.1038/sj.bjp.0701943; Pan HL, 2000, AM J PHYSIOL-HEART C, V279, pH116; Parenti A, 1998, J BIOL CHEM, V273, P4220, DOI 10.1074/jbc.273.7.4220; PATEL KV, 1992, CANCER RES, V52, P334; REGOLI D, 1994, LIFE SCI, V55, P735, DOI 10.1016/0024-3205(94)00557-5; Safi J, 1997, J MOL CELL CARDIOL, V29, P2311, DOI 10.1006/jmcc.1997.0459; SCHELLING ME, 1988, AM J PHYSIOL, V254, pH1211, DOI 10.1152/ajpheart.1988.254.6.H1211; SCHLEMPER V, 1994, BRIT J PHARMACOL, V111, P83, DOI 10.1111/j.1476-5381.1994.tb14027.x; Schumacher B, 1998, CIRCULATION, V97, P645, DOI 10.1161/01.CIR.97.7.645; Sellke FW, 1996, AM J PHYSIOL-HEART C, V271, pH713, DOI 10.1152/ajpheart.1996.271.2.H713; Su JB, 2000, CIRCULATION, V101, P1848, DOI 10.1161/01.CIR.101.15.1848; SUNG CP, 1988, J PHARMACOL EXP THER, V247, P8; Tabata H, 1997, CARDIOVASC RES, V35, P470, DOI 10.1016/S0008-6363(97)00152-1; TODA N, 1987, EUR J PHARMACOL, V135, P321, DOI 10.1016/0014-2999(87)90681-9; Tsutsui M, 2000, AM J PHYSIOL-HEART C, V278, pH367, DOI 10.1152/ajpheart.2000.278.2.H367; Ueno H, 1997, ARTERIOSCL THROM VAS, V17, P2453, DOI 10.1161/01.ATV.17.11.2453; Wahl M, 1996, IMMUNOPHARMACOLOGY, V33, P257, DOI 10.1016/0162-3109(96)00068-9; Wohlfart P, 1997, J PHARMACOL EXP THER, V280, P1109; ZICHE M, 1993, AM J PHYSIOL, V265, pH569, DOI 10.1152/ajpheart.1993.265.2.H569; Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451; Ziche M, 1997, CIRC RES, V80, P845, DOI 10.1161/01.res.80.6.845; ZICHE M, 1994, J CLIN INVEST, V94, P2036, DOI 10.1172/JCI117557; Ziche M, 1996, NEUROPEPTIDES, V30, P345, DOI 10.1016/S0143-4179(96)90023-2; ZICHE M, 1993, BIOCHEM BIOPH RES CO, V192, P1198, DOI 10.1006/bbrc.1993.1543	46	127	141	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 27	2001	15	6					1487	+		10.1096/fj.00-0503fje	http://dx.doi.org/10.1096/fj.00-0503fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387266				2022-12-25	WOS:000173705800001
J	Ruponen, M; Ronkko, S; Honkakoski, P; Pelkonen, J; Tammi, M; Urtti, A				Ruponen, M; Ronkko, S; Honkakoski, P; Pelkonen, J; Tammi, M; Urtti, A			Extracellular glycosaminoglycans modify cellular trafficking of lipoplexes and polyplexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED GENE-TRANSFER; SMOOTH-MUSCLE CELLS; DELIVERY SYSTEMS; MAMMALIAN-CELLS; DNA COMPLEXES; IN-VIVO; PROTEOGLYCANS; HYALURONAN; EXPRESSION; HEPARIN	It has been shown that extracellular glycosaminoglycans (GAGs) limit the gene transfer by cationic lipids and polymers. The purpose of this study was to clarify how interactions with anionic GAGS (hyaluronic acid and heparan sulfate) modify the cellular uptake and distribution of lipoplexes and polyplexes. Experiments on cellular DNA uptake and GFP reporter gene expression showed that decreased gene expression can rarely be explained by lower cellular uptake. In most cases, the cellular uptake is not changed by GAG binding to the lipoplexes or polyplexes. Reporter gene expression is decreased or blocked by heparan sulfate, but it is increased by hyaluronic acid; this suggests that intracellular factors are involved. Confocal microscopy experiments demonstrated that extracellular heparan sulfate and hyaluronic acid are taken into cells both with free and DNA-associated carriers. We conclude that extracellular GAGs may alter both the cellular uptake and the intracellular behavior of the DNA complexes.	Univ Kuopio, Dept Pharmaceut, FIN-70211 Kuopio, Finland; Univ Kuopio, Dept Clin Microbiol, FIN-70211 Kuopio, Finland; Univ Kuopio, Dept Anat, FIN-70211 Kuopio, Finland; Kuopio Univ Hosp, Dept Pediat, FIN-70211 Kuopio, Finland	University of Eastern Finland; University of Eastern Finland; University of Eastern Finland; Kuopio University Hospital	Ruponen, M (corresponding author), Univ Kuopio, Dept Pharmaceut, POB 1627, FIN-70211 Kuopio, Finland.		Honkakoski, Paavo/AAJ-1278-2020	Honkakoski, Paavo/0000-0002-4332-3577				ARSCOTT PG, 1990, BIOPOLYMERS, V30, P619, DOI 10.1002/bip.360300514; Barzu T, 1996, J CELL PHYSIOL, V167, P8, DOI 10.1002/(SICI)1097-4652(199604)167:1<8::AID-JCP2>3.0.CO;2-T; BEHR JP, 1986, TETRAHEDRON LETT, V27, P5861, DOI 10.1016/S0040-4039(00)85347-2; BEHR JP, 1989, P NATL ACAD SCI USA, V86, P6982, DOI 10.1073/pnas.86.18.6982; Belting M, 1999, J BIOL CHEM, V274, P19375, DOI 10.1074/jbc.274.27.19375; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Calabro A, 2000, GLYCOBIOLOGY, V10, P273, DOI 10.1093/glycob/10.3.273; CASTELLOT JJ, 1985, J CELL PHYSIOL, V124, P13, DOI 10.1002/jcp.1041240104; DEBALDER AN, 1975, CARBOHYD RES, V44, P251; Evanko SP, 1999, J HISTOCHEM CYTOCHEM, V47, P1331, DOI 10.1177/002215549904701013; Felgner PL, 1997, HUM GENE THER, V8, P511, DOI 10.1089/hum.1997.8.5-511; FELGNER PL, 1989, NATURE, V337, P387, DOI 10.1038/337387a0; GUSTAFSSON J, 1995, BBA-BIOMEMBRANES, V1235, P305, DOI 10.1016/0005-2736(95)80018-B; HAENSLER J, 1993, BIOCONJUGATE CHEM, V4, P372, DOI 10.1021/bc00023a012; HICKMAN MA, 1994, HUM GENE THER, V5, P1477, DOI 10.1089/hum.1994.5.12-1477; Koltover I, 1998, SCIENCE, V281, P78, DOI 10.1126/science.281.5373.78; Ledley FD, 1996, PHARM RES-DORDR, V13, P1595, DOI 10.1023/A:1016420102549; Lesley J, 2000, J BIOL CHEM, V275, P26967; LEVENTIS R, 1990, BIOCHIM BIOPHYS ACTA, V1023, P124, DOI 10.1016/0005-2736(90)90017-I; LINDAHL U, 1973, J BIOL CHEM, V248, P7234; Lukacs GL, 2000, J BIOL CHEM, V275, P1625, DOI 10.1074/jbc.275.3.1625; MCGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365; MEYER KB, 1995, GENE THER, V2, P450; Mislick KA, 1996, P NATL ACAD SCI USA, V93, P12349, DOI 10.1073/pnas.93.22.12349; Mosser DD, 1997, BIOTECHNIQUES, V22, P150, DOI 10.2144/97221rr02; Mounkes LC, 1998, J BIOL CHEM, V273, P26164, DOI 10.1074/jbc.273.40.26164; NAGASAWA K, 1978, BIOCHIM BIOPHYS ACTA, V544, P430, DOI 10.1016/0304-4165(78)90110-1; Pollard H, 1998, J BIOL CHEM, V273, P7507, DOI 10.1074/jbc.273.13.7507; Ruponen M, 1999, BBA-BIOMEMBRANES, V1415, P331, DOI 10.1016/S0005-2736(98)00199-0; STERNBERG B, 1994, FEBS LETT, V356, P361, DOI 10.1016/0014-5793(94)01315-2; Tang MX, 1997, GENE THER, V4, P823, DOI 10.1038/sj.gt.3300454; WAGNER E, 1991, P NATL ACAD SCI USA, V88, P4255, DOI 10.1073/pnas.88.10.4255; WIGHT TN, 1991, CELL BIOL EXTRACELLU, P45, DOI DOI 10.1007/978-1-4615-3770-0_3; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; Xu YH, 1999, BIOPHYS J, V77, P341, DOI 10.1016/S0006-3495(99)76894-3; ZABNER J, 1995, J BIOL CHEM, V270, P18997, DOI 10.1074/jbc.270.32.18997	36	178	182	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33875	33880		10.1074/jbc.M011553200	http://dx.doi.org/10.1074/jbc.M011553200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11390375	hybrid			2022-12-25	WOS:000170910200080
J	Franzetti, B; Schoehn, G; Ebel, C; Gagnon, J; Ruigrok, RWH; Zaccai, G				Franzetti, B; Schoehn, G; Ebel, C; Gagnon, J; Ruigrok, RWH; Zaccai, G			Characterization of a novel complex from halophilic archaebacteria, which displays chaperone-like activities in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALATE-DEHYDROGENASE; ESCHERICHIA-COLI; SEDIMENTATION ANALYSIS; THERMAL-DENATURATION; MOLECULAR CHAPERONES; HALOFERAX-VOLCANII; ATP HYDROLYSIS; CENTRAL CAVITY; PROTEIN; GROEL	We isolated a protein, P45, from the extreme halophilic archaeon Haloarcula marismortui, which displays molecular chaperone activities in vitro. P45 is a weak ATPase that assembles into a large ring-shaped oligomeric complex comprising about 10 subunits. The protein shows no significant homology to any known protein. P45 forms complexes with halophilic malate dehydrogenase during its salt-dependent denaturation/renaturation and decreases the rate of deactivation of the enzyme in an ATP-dependent manner. Compared with other halophilic proteins, the P45 complex appears to be much less dependent on salt for its various activities or stability. In vivo experiments showed that P45 accumulates when cells are exposed to a low salt environment. We suggest, therefore, that P45 could protect halophilic proteins against denaturation under conditions of cellular hyposaline stress.	Univ Grenoble 1, CEA, CNRS, Inst Biol Struct,Lab Biophys Mol, F-38027 Grenoble 1, France; Univ Grenoble 1, CEA, CNRS, Inst Biol Struct,Lab Enzymol Mol, F-38027 Grenoble, France; EMBL, EMBL Grenoble Outstn, F-38042 Grenoble 9, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); European Molecular Biology Laboratory (EMBL)	Franzetti, B (corresponding author), Univ Grenoble 1, CEA, CNRS, Inst Biol Struct,Lab Biophys Mol, 41 Rue J Horowitz, F-38027 Grenoble 1, France.		Gagnon, Jean/C-3136-2008	Gagnon, Jean/0000-0002-0177-824X; Ebel, Christine/0000-0002-6912-500X; Schoehn, Guy/0000-0002-1459-3201				BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; Behlke J, 1997, BIOCHEMISTRY-US, V36, P5149, DOI 10.1021/bi962755h; BONNETE F, 1994, J MOL BIOL, V244, P436, DOI 10.1006/jmbi.1994.1741; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown JR, 1997, MICROBIOL MOL BIOL R, V61, P456, DOI 10.1128/.61.4.456-502.1997; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Cannac-Caffrey V, 1998, BIOCHIMIE, V80, P1003, DOI 10.1016/S0300-9084(99)80005-4; CENDRIN F, 1993, BIOCHEMISTRY-US, V32, P4308, DOI 10.1021/bi00067a020; Ebel C, 1999, BIOCHEMISTRY-US, V38, P9039, DOI 10.1021/bi9900774; EBEL C, 1992, J MOL BIOL, V223, P361, DOI 10.1016/0022-2836(92)90737-5; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; Ellis R. John, 1999, Current Opinion in Structural Biology, V9, P102, DOI 10.1016/S0959-440X(99)80013-X; Ellis RJ, 2000, TRENDS BIOCHEM SCI, V25, P210, DOI 10.1016/S0968-0004(00)01576-0; Franzetti B, 1997, J BACTERIOL, V179, P1180, DOI 10.1128/jb.179.4.1180-1185.1997; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GINZBURG M, 1970, Journal of General Physiology, V55, P187, DOI 10.1085/jgp.55.2.187; GUAGLIARDI A, 1994, PROTEIN SCI, V3, P1436, DOI 10.1002/pro.5560030910; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HARTMAN DJ, 1993, P NATL ACAD SCI USA, V90, P2276, DOI 10.1073/pnas.90.6.2276; Houry WA, 1999, NATURE, V402, P147, DOI 10.1038/45977; Klumpp M, 1998, FEBS LETT, V430, P73, DOI 10.1016/S0014-5793(98)00541-9; Klumpp M, 1997, CELL, V91, P263, DOI 10.1016/S0092-8674(00)80408-0; Kuo YP, 1997, J BACTERIOL, V179, P6318, DOI 10.1128/jb.179.20.6318-6324.1997; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; Leroux MR, 2000, CURR BIOL, V10, pR260, DOI 10.1016/S0960-9822(00)00432-2; Macario AJL, 1999, MICROBIOL MOL BIOL R, V63, P923, DOI 10.1128/MMBR.63.4.923-967.1999; Madern D, 2000, EXTREMOPHILES, V4, P91, DOI 10.1007/s007920050142; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; MEVARECH M, 1977, BIOCHEMISTRY-US, V16, P3781, DOI 10.1021/bi00636a009; Mevarech M, 2000, BIOPHYS CHEM, V86, P155, DOI 10.1016/S0301-4622(00)00126-5; Mojica FJM, 1997, J BACTERIOL, V179, P5471, DOI 10.1128/jb.179.17.5471-5481.1997; NH WV, 2000, P NATL ACAD SCI USA, V97, P12176; Oesterhelt D, 1974, Methods Enzymol, V31, P667; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; Ranson NA, 1998, BIOCHEM J, V333, P233, DOI 10.1042/bj3330233; Rohrwild M, 1997, NAT STRUCT BIOL, V4, P133, DOI 10.1038/nsb0297-133; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Schuck P, 1999, BIOPHYS J, V76, P2288, DOI 10.1016/S0006-3495(99)77384-4; Schuck P, 1998, BIOPHYS J, V75, P1503, DOI 10.1016/S0006-3495(98)74069-X; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; Tokunaga M, 1997, FEMS MICROBIOL LETT, V152, P321, DOI 10.1111/j.1574-6968.1997.tb10446.x; TRENT JD, 1991, NATURE, V354, P490, DOI 10.1038/354490a0; van den Berg B, 1999, EMBO J, V18, P6927, DOI 10.1093/emboj/18.24.6927; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; Wilson HL, 2000, J BACTERIOL, V182, P1680, DOI 10.1128/JB.182.6.1680-1692.2000; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; ZACCAI G, 1989, J MOL BIOL, V208, P491, DOI 10.1016/0022-2836(89)90512-3; ZACCAI G, 1986, J MOL BIOL, V192, P155, DOI 10.1016/0022-2836(86)90471-7; Zwickl P, 1999, J BIOL CHEM, V274, P26008, DOI 10.1074/jbc.274.37.26008	57	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29906	29914		10.1074/jbc.M102098200	http://dx.doi.org/10.1074/jbc.M102098200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11395490	hybrid			2022-12-25	WOS:000170558000041
J	Li, BQ; Lee, MYW				Li, BQ; Lee, MYW			Transcriptional regulation of the human DNA polymerase delta catalytic subunit gene POLD1 by p53 tumor suppressor and Sp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; CELL-NUCLEAR-ANTIGEN; SACCHAROMYCES-CEREVISIAE; DOWN-REGULATION; G1 CHECKPOINT; IN-VITRO; EXPRESSION; BINDING; REPLICATION; PROTEIN	The DNA polymerase delta catalytic subunit gene (POLD1) was studied as a transcriptional target of p53. Northern blotting showed that a significantly decreased steady-state level of POLD1 mRNA was associated with increased wild-type p53 expression in cells treated with methyl methanesulfonate. When ectopic wild-type p53 expression was induced to a physiologically relevant level in "tet-off" cultured cells in which p53 expression was tightly regulated by tetracycline, it was found that POLD1 steady-state mRNA was repressed by about 65%. Transient cotransfection experiments using a POLD1 promoter luciferase reporter construct showed that: (i) POLD1 promoter activity was inhibited by transfected wild-type p53 plasmid to a maximum of about 86%; (ii) p53 mediated a large part of the transcriptional repression through a sequence-specific interaction with a site identified as the P4 site of the POLD1 promoter; (iii) tumor-derived p53 mutations in the p53 DNA-binding domain completely abolished the p53 transrepression activity. Moreover, transfection assays demonstrated that p53 was able to repress Sp1-stimulated POLD1 promoter activity and that this repression was largely due to the loss of the sequence-specific interaction between Sp1 protein and the P4 Spl-binding site, which overlaps the P4 p53-binding site. Finally, gel shift assays suggested that p53 competes with Sp1 protein for binding to the P4 sequence of the POLD1 promoter.	New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA	New York Medical College	Lee, MYW (corresponding author), New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031973] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 31973] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; Bargonetti J, 1997, CELL MOL BIOL, V43, P935; BARTEK J, 1990, ONCOGENE, V5, P893; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; BUDD ME, 1995, MOL CELL BIOL, V15, P2173; Carr AM, 2000, SCIENCE, V287, P1765, DOI 10.1126/science.287.5459.1765; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DELPHIN C, 1994, EUR J BIOCHEM, V223, P683, DOI 10.1111/j.1432-1033.1994.tb19041.x; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Dominguez O, 2000, EMBO J, V19, P1731, DOI 10.1093/emboj/19.7.1731; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gopalkrishnan RV, 1998, J BIOL CHEM, V273, P10972, DOI 10.1074/jbc.273.18.10972; GUALBERTO A, 1995, J BIOL CHEM, V270, P19680, DOI 10.1074/jbc.270.34.19680; Halas A, 1997, CURR GENET, V31, P292, DOI 10.1007/s002940050208; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; HAO HL, 1992, CHROMOSOMA, V102, pS121, DOI 10.1007/BF02451795; Holmes AM, 1999, CELL, V96, P415, DOI 10.1016/S0092-8674(00)80554-1; JACKSON P, 1994, BIOCHEM BIOPH RES CO, V203, P133, DOI 10.1006/bbrc.1994.2159; Kanaya T, 2000, CLIN CANCER RES, V6, P1239; Kannan K, 2000, FEBS LETT, V470, P77, DOI 10.1016/S0014-5793(00)01291-6; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lee KC, 1999, MOL CELL BIOL, V19, P1279; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; Liu L, 2000, J BIOL CHEM, V275, P18739, DOI 10.1074/jbc.M001217200; Longley MJ, 1997, J BIOL CHEM, V272, P10917; MACLEOD MC, 1993, NUCLEIC ACIDS RES, V21, P1439, DOI 10.1093/nar/21.6.1439; MOORE AL, 1994, CELL GROWTH DIFFER, V5, P485; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; Ohlsson C, 1998, ENDOCRINOLOGY, V139, P1101, DOI 10.1210/en.139.3.1101; PERREM K, 1995, ONCOGENE, V11, P1299; Sandri MI, 1996, NUCLEIC ACIDS RES, V24, P4464, DOI 10.1093/nar/24.22.4464; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Subbaramaiah K, 1999, J BIOL CHEM, V274, P10911, DOI 10.1074/jbc.274.16.10911; WAGA S, 1994, J BIOL CHEM, V269, P10923; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; Wang QJ, 1998, CANCER RES, V58, P5762; Wang QJ, 1997, MOL CELL BIOL, V17, P389, DOI 10.1128/MCB.17.1.389; Woodgate R, 1999, GENE DEV, V13, P2191, DOI 10.1101/gad.13.17.2191; Yamabe Y, 1998, MOL CELL BIOL, V18, P6191, DOI 10.1128/MCB.18.11.6191; YAMAGUCHI M, 1994, EUR J BIOCHEM, V221, P227, DOI 10.1111/j.1432-1033.1994.tb18733.x; YANG CL, 1992, NUCLEIC ACIDS RES, V20, P735, DOI 10.1093/nar/20.4.735; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; ZENG XR, 1994, J BIOL CHEM, V269, P24027; ZENG XR, 1994, J BIOL CHEM, V269, P13748; Zhan QM, 1998, MOL CELL BIOL, V18, P2768, DOI 10.1128/MCB.18.5.2768; Zhang LL, 2000, CANCER RES, V60, P3655; Zhao LY, 1997, J BIOL CHEM, V272, P4869, DOI 10.1074/jbc.272.8.4869; Zhao RB, 2000, GENE DEV, V14, P981; Zuo SJ, 2000, J BIOL CHEM, V275, P5153, DOI 10.1074/jbc.275.7.5153	57	57	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29729	29739		10.1074/jbc.M101167200	http://dx.doi.org/10.1074/jbc.M101167200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11375983	hybrid			2022-12-25	WOS:000170558000019
J	Zentner, MD; Lin, HH; Deng, HT; Kim, KJ; Shih, HM; Ann, DK				Zentner, MD; Lin, HH; Deng, HT; Kim, KJ; Shih, HM; Ann, DK			Requirement for high mobility group protein HMGI-C interaction with STAT3 inhibitor PIAS3 in repression of a-subunit of epithelial Na+ channel (alpha-ENaC) transcription by Ras activation in salivary epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP CHROMOSOMAL-PROTEINS; IFN-BETA GENE; NEOPLASTIC TRANSFORMATION; GLUCOCORTICOID HORMONE; THYROID CELLS; GROWTH-FACTOR; EXPRESSION; KINASE; LUNG; INDUCTION	Previously, we have demonstrated that oxidative stress or Ras/ERK activation leads to the transcriptional repression of alpha -subunit of epithelial Na+ channel (ENaC in lung and salivary epithelial cells. Here, we further investigated the coordinated molecular mechanisms by which alpha -ENaC expression is regulated. Using both stable and transient transfection assays, we demonstrate that the overexpression of high mobility group protein I-C (HMGI-C), a Ras/ERK-inducible HMG-I family member, represses glucocorticoid receptor (GR)/dexamethasone (Dex)-stimulated alpha -ENaC/reporter activity in salivary epithelial cells. Northern analyses further confirm that the expression of endogenous a-ENaC gene in salivary Pa-4 cells is suppressed by an ectopic HMGI-C overexpression. Through yeast two-hybrid screening and co-immunoprecipitation assays from eukaryotic cells, we also discovered the interaction between HMGI-C and PIAS3 (protein inhibitor of activated STAT3 (signal transducer and activator of transcription 3)). A low level of ectopically expressed PIAS3 cooperatively inhibits GR/Dex-dependent alpha -ENaC transcription in the presence of HMGI-C. Reciprocally, HMGI-C expression also coordinately enhances PIAS3-mediated repression of STAT3-dependent transactivation. Moreover, overexpression of antisense HMGI-C construct is capable of reversing the repression mediated by Ras V12 on GR- and STAT3-dependent transcriptional activation. Together, our results demonstrate that Ras/ERK-mediated induction of HMGI-C is required to effectively repress GR/Dex-stimulated transcription of alpha -ENaC gene and STAT3-mediated transactivation. These findings delineate a network of inhibitory signaling pathways that converge on HMGI-C.PIAS3 complex, causally associating Ras/ERK activation with the repression of both GR and STAT3 signaling pathways in salivary epithelial cells.	Univ So Calif, Will Rogers Inst, Pulm Res Ctr, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90033 USA; Univ So Calif, Will Rogers Inst, Pulm Res Ctr, Dept Med, Los Angeles, CA 90033 USA; Univ So Calif, Will Rogers Inst, Pulm Res Ctr, Dept Physiol & Biophys, Los Angeles, CA 90033 USA; Univ So Calif, Will Rogers Inst, Pulm Res Ctr, Dept Biomed Engn, Los Angeles, CA 90033 USA; Univ So Calif, Ctr Craniofacial Mol Biol, Los Angeles, CA 90033 USA; Natl Hlth Res Inst, Div Mol & Genom Med, Taipei 11529, Taiwan	University of Southern California; University of Southern California; University of Southern California; University of Southern California; University of Southern California; National Health Research Institutes - Taiwan	Ann, DK (corresponding author), Univ So Calif, Sch Pharm, PSC 210B,1985 Zonal Ave, Los Angeles, CA 90033 USA.	ann@hsc.usc.edu	Shih, Hsiu-Ming/S-7023-2018		NHLBI NIH HHS [HL64365, HL38658] Funding Source: Medline; NIDCR NIH HHS [DE07211, DE10742] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064365, R01HL038658] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE010742] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [T32DE007211] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Anand A, 2000, NAT GENET, V24, P377, DOI 10.1038/74207; BARTEL P, 1997, YEAST 2 HYDRID SYSTE; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Bustin M, 1999, MOL CELL BIOL, V19, P5237; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; Cella N, 1998, MOL CELL BIOL, V18, P1783, DOI 10.1128/MCB.18.4.1783; CHAMPIGNY G, 1994, EMBO J, V13, P2177, DOI 10.1002/j.1460-2075.1994.tb06494.x; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; GIANCOTTI V, 1987, EMBO J, V6, P1981, DOI 10.1002/j.1460-2075.1987.tb02461.x; Himes SR, 2000, J IMMUNOL, V164, P3157, DOI 10.4049/jimmunol.164.6.3157; Jui HY, 2000, J BIOL CHEM, V275, P41124, DOI 10.1074/jbc.M007772200; Ke SA, 1999, PROG BIOPHYS MOL BIO, V71, P405, DOI 10.1016/S0079-6107(98)00051-0; Kotaja N, 2000, MOL ENDOCRINOL, V14, P1986, DOI 10.1210/me.14.12.1986; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LI D, 1997, THESIS U SO CALIFORN; Li DX, 1997, J BIOL CHEM, V272, P25062, DOI 10.1074/jbc.272.40.25062; Lin HH, 1999, J BIOL CHEM, V274, P21544, DOI 10.1074/jbc.274.31.21544; Lin HH, 1996, J BIOL CHEM, V271, P27637, DOI 10.1074/jbc.271.44.27637; Quissell DO, 1998, IN VITRO CELL DEV-AN, V34, P58; Reeves R, 2001, MOL CELL BIOL, V21, P575, DOI 10.1128/MCB.21.2.575-594.2001; REEVES R, 1990, J BIOL CHEM, V265, P8573; Sayegh R, 1999, J BIOL CHEM, V274, P12431, DOI 10.1074/jbc.274.18.12431; Stewart PM, 1999, LANCET, V353, P1341, DOI 10.1016/S0140-6736(98)06102-9; Stokes JB, 1998, AM J PHYSIOL-CELL PH, V274, pC1699, DOI 10.1152/ajpcell.1998.274.6.C1699; Tallini G, 1999, ADV ANAT PATHOL, V6, P237, DOI 10.1097/00125480-199909000-00001; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Vallone D, 1997, EMBO J, V16, P5310, DOI 10.1093/emboj/16.17.5310; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Volk KA, 1995, J CLIN INVEST, V96, P2748, DOI 10.1172/JCI118344; Wang HC, 2000, J BIOL CHEM, V275, P8600, DOI 10.1074/jbc.275.12.8600; Wen X, 1999, J BIOL CHEM, V274, P38204, DOI 10.1074/jbc.274.53.38204; Zentner MD, 1998, J BIOL CHEM, V273, P30770, DOI 10.1074/jbc.273.46.30770; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0	39	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29805	29814		10.1074/jbc.M103153200	http://dx.doi.org/10.1074/jbc.M103153200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11390395	hybrid			2022-12-25	WOS:000170558000028
J	Blouin, C; Wallace, CJA				Blouin, C; Wallace, CJA			Protein matrix and dielectric effect in cytochrome c	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST ISO-1-CYTOCHROME-C; CONFORMATION CHANGE; FERRICYTOCHROME-C; WATER MOLECULE; RESOLUTION; HEME; TYROSINE-67; REFINEMENT; STABILITY	The effect of the protein matrix on the standard potential of a buried redox center has been investigated by using a selection of mutants and chemical derivatives in Saccharomyces cerevisiae cytochrome c isoform 1. Assuming only local structural perturbation and no alteration of the iron-ligation chemistry, DeltaE(m)(0,) can be regarded as a measure of the difference in polypeptide solvation of the heme charge, which reflects the dielectric properties of the protein. The evaluation of an apparent dielectric constant (U-exp/U-theo) yields variable, and sometimes even negative, values if U-exp = DeltaG(0)redox. However, some consistent result are observed if U-exp = DeltaH(0)redox with a measured epsilon (Delta Delta Hredox) = 19 +/- 6. The variability is thus attributed to an entropic factor (epsilon (Delta Delta Sredox)) that is investigated using a series of substitutions of Asn(52) and/or Tyr(67). In double mutants Y67F/N521 Y67F/ N52V, where most of the hydrogen bond network in the heme crevice is eliminated, DeltaS(redox). compares to the wild type. This indicates that a fully consistent hydrogen bond network has a similar polarizability as an apolar matrix. We therefore argue that the variability in net dielectric susceptibility arises from conformational polarizability, a factor that is not a function of atomic properties and coordinates and is therefore hard to predict using conventional physical relationships.	Dalhousie Univ, Dept Biochem & Mol Biol, Halifax, NS B3H 4H7, Canada	Dalhousie University	Blouin, C (corresponding author), Dalhousie Univ, Dept Biochem & Mol Biol, Halifax, NS B3H 4H7, Canada.			Blouin, Christian/0000-0002-4434-4142				Banci L, 1999, J BIOL INORG CHEM, V4, P21, DOI 10.1007/s007750050285; BERGHUIS AM, 1994, J MOL BIOL, V235, P1326, DOI 10.1006/jmbi.1994.1086; BERGHUIS AM, 1992, J MOL BIOL, V223, P959, DOI 10.1016/0022-2836(92)90255-I; BERGHUIS AM, 1994, J MOL BIOL, V236, P786, DOI 10.1006/jmbi.1994.1189; CHURG AK, 1986, BIOCHEMISTRY-US, V25, P1675, DOI 10.1021/bi00355a035; Edholm O, 2000, BIOCHEM BIOPH RES CO, V268, P683, DOI 10.1006/bbrc.2000.2201; Hill T.L., 1986, INTRO STAT THERMODYN; KOSHY TI, 1994, BIOCHEM J, V299, P347, DOI 10.1042/bj2990347; Lett CM, 1996, J BIOL CHEM, V271, P29088, DOI 10.1074/jbc.271.46.29088; LINSKEOCONNELL LI, 1995, BIOCHEMISTRY-US, V34, P7094, DOI 10.1021/bi00021a022; LOUIE GV, 1990, J MOL BIOL, V214, P527, DOI 10.1016/0022-2836(90)90197-T; MOORE GR, 1983, FEBS LETT, V161, P171, DOI 10.1016/0014-5793(83)81001-1; MOORE GR, 1980, BIOCHIM BIOPHYS ACTA, V590, P261, DOI 10.1016/0005-2728(80)90030-4; Qi PXR, 1996, BIOCHEMISTRY-US, V35, P12275, DOI 10.1021/bi961042w; REES DC, 1980, J MOL BIOL, V141, P323, DOI 10.1016/0022-2836(80)90184-9; SCHEJTER A, 1994, BIOCHEM J, V302, P95, DOI 10.1042/bj3020095; Schroeder HR, 1997, BIOCHEM CELL BIOL, V75, P191, DOI 10.1139/bcb-75-3-191; Sharp K, 2001, PROTEIN SCI, V10, P661, DOI 10.1110/ps.37801; SIMONSON T, 1995, P NATL ACAD SCI USA, V92, P1082, DOI 10.1073/pnas.92.4.1082; SIMONSON T, 1991, BIOPHYS J, V59, P670, DOI 10.1016/S0006-3495(91)82282-2; SOBER HA, 1970, HDB BIOCH, pJ41; Springs SL, 2000, BIOCHEMISTRY-US, V39, P6075, DOI 10.1021/bi0001675; TAKANO T, 1981, J MOL BIOL, V153, P95, DOI 10.1016/0022-2836(81)90529-5; TAKANO T, 1981, J MOL BIOL, V153, P79, DOI 10.1016/0022-2836(81)90528-3; WALLACE CJA, 1986, BIOPOLYMERS, V25, P2121, DOI 10.1002/bip.360251107; Woods AC, 1996, J BIOL CHEM, V271, P32008, DOI 10.1074/jbc.271.50.32008	26	17	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28814	28818		10.1074/jbc.M103348200	http://dx.doi.org/10.1074/jbc.M103348200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11375991	hybrid			2022-12-25	WOS:000170346000024
J	Gomez, I; Oltean, DI; Gill, SS; Bravo, A; Soberon, M				Gomez, I; Oltean, DI; Gill, SS; Bravo, A; Soberon, M			Mapping the epitope in cadherin-like receptors involved in Bacillus thuringiensis Cry1A toxin interaction using phage display	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; CRYIA(C) DELTA-ENDOTOXIN; BY-PASSING IMMUNIZATION; AMINOPEPTIDASE-N; MANDUCA-SEXTA; INSECTICIDAL TOXIN; CRYSTAL-STRUCTURE; HUMAN-ANTIBODIES; BINDING-PROTEIN; BOMBYX-MORI	In susceptible lepidopteran insects, aminopeptidase N and cadherin-like proteins are the putative receptors for Bacillus thuringiensis (Bt) toxins. Using phage display, we identified a key epitope that is involved in toxin-receptor interaction. Three different scFv molecules that bind Cry1Ab toxin were obtained, and these scFv proteins have different amino acid sequences in the complementary determinant region 3 (CDR3). Binding analysis of these scFv molecules to different members of the Cry1A toxin family and to Escherichia coli clones expressing different Cry1A toxin domains showed that the three selected scFv molecules recognized only domain 11. Heterologous binding competition of Cry1Ab toxin to midgut membrane vesicles from susceptible Manduca sexta larvae using the selected scFv molecules showed that scFv73 competed with Cry1Ab binding to the receptor. The calculated binding affinities (Kd) of scFv73 to Cry1Aa, Cry1Ab, and Cry1Ac toxins are in the range of 20-51 nm. Sequence analysis showed this scFv73 molecule has a CDR3 significantly homologous to a region present in the cadherin-like protein from M. sexta (Bt-R-1), Bombyx mori (Bt-R-175), and Lymantria dispar. We demonstrated that peptides of 8 amino acids corresponding to the CDR3 from scFv73 or to the corresponding regions of Bt-R-1 or Bt-R-175 are also able to compete with the binding of Cry1Ab and Cry1Aa toxins to the Bt-R-1 or Bt-R-175 receptors. Finally, we showed that synthetic peptides homologous to Bt-R-1 and scFv73 CDR3 and the scFv73 antibody decreased the in vivo toxicity of Cry1Ab to M. sexta larvae. These results show that we have identified the amino acid region of Bt-Ri and Bt-R-175 involved in Cry1A toxin interaction.	Univ Nacl Autonoma Mexico, Dept Mol Microbiol, Inst Biotecnol, Cuernavaca 62250, Morelos, Mexico; Univ Calif Riverside, Dept Neurosci & Cell Biol, Riverside, CA 92521 USA	Universidad Nacional Autonoma de Mexico; University of California System; University of California Riverside	Soberon, M (corresponding author), Univ Nacl Autonoma Mexico, Dept Mol Microbiol, Inst Biotecnol, Apdo Postal 510-3, Cuernavaca 62250, Morelos, Mexico.	mario@ibt.unam.mx	de la Parra, Maria Alejandra Bravo/R-6740-2017	Bravo, Alejandra/0000-0002-7573-7475				Aranda E, 1996, J INVERTEBR PATHOL, V68, P203, DOI 10.1006/jipa.1996.0087; ARANTES O, 1991, GENE, V108, P115, DOI 10.1016/0378-1119(91)90495-W; BELFIORE CJ, 1994, BIOCHEM BIOPH RES CO, V200, P359, DOI 10.1006/bbrc.1994.1456; BRAVO A, 1992, J INVERTEBR PATHOL, V60, P237, DOI 10.1016/0022-2011(92)90004-N; Burton SL, 1999, J MOL BIOL, V287, P1011, DOI 10.1006/jmbi.1999.2649; CORTESE R, 1994, TRENDS BIOTECHNOL, V12, P262, DOI 10.1016/0167-7799(94)90137-6; Dean DH, 1996, GENE, V179, P111, DOI 10.1016/S0378-1119(96)00442-8; DELEO FR, 1995, P NATL ACAD SCI USA, V92, P7110, DOI 10.1073/pnas.92.15.7110; Demangel C, 2000, EUR J BIOCHEM, V267, P2345, DOI 10.1046/j.1432-1327.2000.01244.x; Denolf P, 1997, EUR J BIOCHEM, V248, P748, DOI 10.1111/j.1432-1033.1997.t01-1-00748.x; Flores H, 1997, FEBS LETT, V414, P313, DOI 10.1016/S0014-5793(97)01015-6; GARCZYNSKI SF, 1995, INSECT BIOCHEM MOLEC, V25, P409, DOI 10.1016/0965-1748(94)00072-7; GARCZYNSKI SF, 1991, APPL ENVIRON MICROB, V57, P2816, DOI 10.1128/AEM.57.10.2816-2820.1991; GILL SS, 1995, J BIOL CHEM, V270, P27277, DOI 10.1074/jbc.270.45.27277; GROCHULSKI P, 1995, J MOL BIOL, V254, P447, DOI 10.1006/jmbi.1995.0630; HOFMANN C, 1988, P NATL ACAD SCI USA, V85, P7844, DOI 10.1073/pnas.85.21.7844; HOOGENBOOM HR, 1992, J MOL BIOL, V227, P381, DOI 10.1016/0022-2836(92)90894-P; IHARA H, 1993, BIOSCI BIOTECH BIOCH, V57, P200, DOI 10.1271/bbb.57.200; Jenkins JL, 2000, J BIOL CHEM, V275, P14423, DOI 10.1074/jbc.275.19.14423; Keeton TP, 1997, APPL ENVIRON MICROB, V63, P3419, DOI 10.1128/AEM.63.9.3419-3425.1997; KNIGHT PJK, 1994, MOL MICROBIOL, V11, P429, DOI 10.1111/j.1365-2958.1994.tb00324.x; KNOWLES BH, 1991, P ROY SOC B-BIOL SCI, V245, P31, DOI 10.1098/rspb.1991.0084; Lee MK, 1996, APPL ENVIRON MICROB, V62, P2845, DOI 10.1128/AEM.62.8.2845-2849.1996; LERECLUS D, 1989, FEMS MICROBIOL LETT, V60, P211, DOI 10.1016/0378-1097(89)90511-9; LI JD, 1991, NATURE, V353, P815, DOI 10.1038/353815a0; LORENCE A, 1995, FEBS LETT, V360, P217, DOI 10.1016/0014-5793(95)00092-N; Low NM, 1996, J MOL BIOL, V260, P359, DOI 10.1006/jmbi.1996.0406; Luo K, 1997, APPL ENVIRON MICROB, V63, P1024, DOI 10.1128/AEM.63.3.1024-1027.1997; LUZZAGO A, 1993, GENE, V128, P51, DOI 10.1016/0378-1119(93)90152-S; MARKS JD, 1991, J MOL BIOL, V222, P581, DOI 10.1016/0022-2836(91)90498-U; MASSON L, 1995, J BIOL CHEM, V270, P20309, DOI 10.1074/jbc.270.35.20309; Myszyka DG, 1999, J MOL RECOGNIT, V12, P279, DOI 10.1002/(SICI)1099-1352(199909/10)12:5<279::AID-JMR473>3.0.CO;2-3; Nagamatsu Y, 1998, BIOSCI BIOTECH BIOCH, V62, P718, DOI 10.1271/bbb.62.718; Nagamatsu Y, 1999, FEBS LETT, V460, P385, DOI 10.1016/S0014-5793(99)01327-7; Nakanishi K, 1999, BBA-PROTEIN STRUCT M, V1432, P57, DOI 10.1016/S0167-4838(99)00086-2; NISSIM A, 1994, EMBO J, V13, P692, DOI 10.1002/j.1460-2075.1994.tb06308.x; Oltean DI, 1999, APPL ENVIRON MICROB, V65, P4760; Pietrantonio P. V., 1996, P345; Schnepf E, 1998, MICROBIOL MOL BIOL R, V62, P775, DOI 10.1128/MMBR.62.3.775-806.1998; SCHWARTZ JL, 1993, J MEMBRANE BIOL, V132, P53, DOI 10.1007/BF00233051; Soberon M, 2000, FEMS MICROBIOL LETT, V191, P221, DOI 10.1016/S0378-1097(00)00394-3; Szardenings M, 1997, J BIOL CHEM, V272, P27943, DOI 10.1074/jbc.272.44.27943; THOMAS WE, 1983, J CELL SCI, V60, P181; VADLAMUDI RK, 1995, J BIOL CHEM, V270, P5490, DOI 10.1074/jbc.270.10.5490; Valaitis AP, 1995, INSECT BIOCHEM MOLEC, V25, P1143, DOI 10.1016/0965-1748(95)00050-X; WOLFERSBERGER M, 1987, COMP BIOCHEM PHYS A, V86, P301, DOI 10.1016/0300-9629(87)90334-3; Yaoi K, 1997, EUR J BIOCHEM, V246, P652, DOI 10.1111/j.1432-1033.1997.t01-1-00652.x	47	88	110	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28906	28912		10.1074/jbc.M103007200	http://dx.doi.org/10.1074/jbc.M103007200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11384982	hybrid			2022-12-25	WOS:000170346000037
J	Singla, SI; Hudmon, A; Goldberg, JM; Smith, JL; Schulman, H				Singla, SI; Hudmon, A; Goldberg, JM; Smith, JL; Schulman, H			Molecular characterization of calmodulin trapping by calcium/calmodulin-dependent protein kinase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAM-KINASE; TRANSITION-STATE; CA2+; AUTOPHOSPHORYLATION; ALPHA; DISSOCIATION; RECOGNITION; ACTIVATION; PHOSPHORYLATION; CA2+-CALMODULIN	Autophosphorylation of alpha -Ca2+/calmodulin-dependent protein kinase II (CaM kinase II) at Thr(286) results in cal. modulin (CaM) trapping, a > 10,000-fold decrease in the dissociation rate of CaM from the enzyme. Here we present the first site-directed mutagenesis study on the dissociation of the high affinity complex between CaM and full-length CaM kinase IEL We measured dissociation kinetics of CaM and CaM kinase II proteins by using a fluorescently modified CaM that is sensitive to binding to target proteins. In low [Ca2+], the phosphorylated mutant kinase F293A and the CaM mutant E120A/M124A exhibited deficient trapping compared with wild-type. In high [Ca2+], the CaM mutations E120A, M124A, and E120A/M124A and the CaM kinase II mutations F293A, F293E, N294A, N294P, and R297E increased dissociation rate constants by factors ranging from 2.3 to 116. We have also identified residues in CaM and CaM kinase II that interact in the trapped state by mutant cycle-based analysis, which suggests that interactions between Phe(293) in the kinase and Glu(120) and Met(124) in CaM specifically stabilize the trapped CaM-CaM kinase II complex. Our studies farther show that Phe(293) and Asn(294) in CaM kinase II play dual roles, because they likely destabilize the low affinity state of CaM complexed to unphosphorylated kinase but stabilize the trapped state of CaM bound to phosphorylated kinase.	Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA; Boston Biomed Res Inst, Watertown, MA 02472 USA	Stanford University; Boston Biomedical Research Institute	Schulman, H (corresponding author), Stanford Univ, Sch Med, Dept Neurobiol, 299 Campus Dr, Stanford, CA 94305 USA.	schulman@cmgm.stanford.edu			NIGMS NIH HHS [GM40600] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040600] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEACH ME, 1995, CELL, V81, P905, DOI 10.1016/0092-8674(95)90010-1; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; Brown SE, 1997, J BIOL CHEM, V272, P3389, DOI 10.1074/jbc.272.6.3389; CARTER PJ, 1984, CELL, V38, P835, DOI 10.1016/0092-8674(84)90278-2; Chin D, 1997, J BIOL CHEM, V272, P31235, DOI 10.1074/jbc.272.50.31235; Chin D, 2000, CRC METH SIG TRANS, P297; Chin D, 1996, J BIOL CHEM, V271, P30465, DOI 10.1074/jbc.271.48.30465; COLBRAN RJ, 1993, J BIOL CHEM, V268, P7163; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; CRUZALEGUI FH, 1992, P NATL ACAD SCI USA, V89, P12127, DOI 10.1073/pnas.89.24.12127; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; FINN BE, 1995, STRUCTURE, V3, P7, DOI 10.1016/S0969-2126(01)00130-7; Giese KP, 1998, SCIENCE, V279, P870, DOI 10.1126/science.279.5352.870; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; Goldberg JM, 1999, P NATL ACAD SCI USA, V96, P2019, DOI 10.1073/pnas.96.5.2019; HANSON PI, 1994, NEURON, V12, P943, DOI 10.1016/0896-6273(94)90306-9; HANSON PI, 1992, J BIOL CHEM, V267, P17216; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; KENNEDY MB, 1990, COLD SH Q B, V55, P101; Kolodziej SJ, 2000, J BIOL CHEM, V275, P14354, DOI 10.1074/jbc.275.19.14354; Lockless SW, 1999, SCIENCE, V286, P295, DOI 10.1126/science.286.5438.295; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MILLA ME, 1995, BIOCHEMISTRY-US, V34, P13914, DOI 10.1021/bi00042a024; MUKHERJI S, 1994, J BIOL CHEM, V269, P13744; OHYA Y, 1987, EUR J BIOCHEM, V168, P13, DOI 10.1111/j.1432-1033.1987.tb13380.x; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; Peersen OB, 1997, PROTEIN SCI, V6, P794; Persechini A, 1996, J BIOL CHEM, V271, P62, DOI 10.1074/jbc.271.1.62; Persechini A, 1999, J BIOL CHEM, V274, P6827, DOI 10.1074/jbc.274.11.6827; Putkey JA, 1996, J BIOL CHEM, V271, P29619, DOI 10.1074/jbc.271.47.29619; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; Rich RC, 1998, J BIOL CHEM, V273, P28424, DOI 10.1074/jbc.273.43.28424; Schulman H, 1999, CALCIUM AS A CELLULAR REGULATOR, P311; Shen K, 2000, NAT NEUROSCI, V3, P881, DOI 10.1038/78783; Soderling TR, 2000, TRENDS NEUROSCI, V23, P75, DOI 10.1016/S0166-2236(99)01490-3; Sosnick TR, 1996, PROTEINS, V24, P427; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Teruel MN, 2000, CURR BIOL, V10, P86, DOI 10.1016/S0960-9822(00)00295-5; VALLANO ML, 1989, J NEUROSCI METH, V30, P1, DOI 10.1016/0165-0270(89)90067-8; Waxham MN, 1998, J BIOL CHEM, V273, P17579, DOI 10.1074/jbc.273.28.17579; Xavier KA, 1999, PROTEIN ENG, V12, P79, DOI 10.1093/protein/12.1.79; Yang EY, 1999, J BIOL CHEM, V274, P26199, DOI 10.1074/jbc.274.37.26199	45	63	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29353	29360		10.1074/jbc.M101744200	http://dx.doi.org/10.1074/jbc.M101744200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11384969	hybrid			2022-12-25	WOS:000170346000096
J	Ashida, H; Anderson, K; Nakayama, J; Maskos, K; Chou, CW; Cole, RB; Li, SC; Li, YT				Ashida, H; Anderson, K; Nakayama, J; Maskos, K; Chou, CW; Cole, RB; Li, SC; Li, YT			A novel endo-beta-galactosidase from Clostridium perfringens that liberates the disaccharide GlcNAc alpha 1 -> 4Gal from glycans specifically expressed in the gastric gland mucous cell-type mucin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED N-ACETYLGLUCOSAMINE; FLAVOBACTERIUM-KERATOLYTICUS; ESCHERICHIA-FREUNDII; MONOCLONAL-ANTIBODY; H-1-NMR SPECTRA; SPECTROSCOPY; PURIFICATION; CLONING; DIFFERENTIATION; RESOLUTION	We found that commercially available sialidases prepared from Clostridium perfringens ATCC10543 were contaminated with an endoglycosidase capable of releasing the disaccharide GlcNAc alpha1->4Gal from glycans expressed in the gastric gland mucous cell-type mucin. We have isolated this enzyme in electrophoretically homogeneous form from the culture supernatant of this organism by ammonium sulfate precipitation followed by affinity chromatography using a Sephacryl S-200 HR column. The enzyme was specifically retained by and eluted from the column with methyl-alpha -Glc. By spectroscopy, the structure of the disaccharide released from porcine gastric mucin by this enzyme was established to be GlcNAc alpha1-->4Gal. The specificity of this enzyme as an endo-beta -galactosidase was established by analyzing the liberation of GlcNAc alpha1-->4Gal from GlcNAc alpha1--->4Gal beta1-->4GlcNAc beta1-->6(GlcNAc alpha1-->4Gal beta1-3)GalNAc-ol by mass spectrometry. Because this novel endo-beta -galactosidase specifically releases the GlcNAc alpha1-->4Gal moiety from porcine gastric mucin, we propose to call this enzyme a GlcNAc alpha1-->4Gal-releasing endo-beta -galactosidase (Endo-beta -Gal(GnGa)). Endo-beta -Gal(GnGa) was found to remove the GlcNAc alpha1-->4Gal epitope expressed in gastric adenocarcinoma AGS cells transfected with alpha1,4-N-acetylglucosaminyltransferase cDNA. Endo-beta -Gal(GnGa) should become useful for studying the structure and function of glycoconjugates containing the terminal GlcNAc alpha1-->4Gal epitope.	Tulane Univ, Hlth Sci Ctr, Sch Med, Dept Biochem, New Orleans, LA 70112 USA; Shinshu Univ, Grad Sch Med, Inst Organ Transplants Reconstruct Med & Tissue E, Matsumoto, Nagano 3908621, Japan; Tulane Univ, Coordinated Instrumentat Facil, New Orleans, LA 70118 USA; Univ New Orleans, Dept Chem, New Orleans, LA 70148 USA	Tulane University; Shinshu University; Tulane University; University of Louisiana System; University of New Orleans	Li, YT (corresponding author), Tulane Univ, Hlth Sci Ctr, Sch Med, Dept Biochem, SL43,1430 Tulane Ave, New Orleans, LA 70112 USA.		Ashida, Hisashi/HCI-0293-2022	Ashida, Hisashi/0000-0001-5844-4075	NINDS NIH HHS [NS 09626] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS009626] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anderson K, 2000, ANAL BIOCHEM, V287, P337, DOI 10.1006/abio.2000.4829; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1985, J MAGN RESON, V63, P207, DOI 10.1016/0022-2364(85)90171-4; BORRIELLO SP, 1995, CLIN INFECT DIS, V20, pS242, DOI 10.1093/clinids/20.Supplement_2.S242; BOX A, 1986, J AM CHEM SOC, V108, P2093; CASSIDY JT, 1965, J BIOL CHEM, V240, P3501; DAVIS DG, 1985, J AM CHEM SOC, V107, P2820, DOI 10.1021/ja00295a052; FUKUDA MN, 1976, J BIOL CHEM, V251, P6218; HATHEWAY CL, 1990, CLIN MICROBIOL REV, V3, P66, DOI 10.1128/CMR.3.1.66-98.1990; Honda T, 1998, AM J CLIN PATHOL, V109, P423; Ishihara K, 1996, BIOCHEM J, V318, P409, DOI 10.1042/bj3180409; Ishii K, 1998, VIRCHOWS ARCH, V432, P315, DOI 10.1007/s004280050172; Jung E, 1998, EUR J BIOCHEM, V253, P517, DOI 10.1046/j.1432-1327.1998.2530517.x; KATSUYAMA T, 1978, J HISTOCHEM CYTOCHEM, V26, P233, DOI 10.1177/26.4.351046; KITAMIKADO M, 1981, J BIOL CHEM, V256, P3906; KOCHETKOV NK, 1976, EUR J BIOCHEM, V67, P129, DOI 10.1111/j.1432-1033.1976.tb10641.x; Leng L, 1998, GENE, V222, P187, DOI 10.1016/S0378-1119(98)00496-X; LI SC, 1970, J BIOL CHEM, V245, P5153; Li Y.-T., 1972, METHOD ENZYMOL, V28, P702; LLOYD KO, 1969, J IMMUNOL, V102, P1354; MOORE GL, 1969, ANAL BIOCHEM, V32, P122, DOI 10.1016/0003-2697(69)90111-0; NAKAGAWA H, 1971, B JPN SOC SCI FISH, V37, P919; NAKAGAWA H, 1980, J BIOL CHEM, V255, P5955; Nakamura N, 1998, J HISTOCHEM CYTOCHEM, V46, P793, DOI 10.1177/002215549804600702; Nakayama J, 1999, P NATL ACAD SCI USA, V96, P8991, DOI 10.1073/pnas.96.16.8991; NIILO L, 1980, CAN VET J, V21, P141; NORWOOD TJ, 1990, J MAGN RESON, V87, P488, DOI 10.1016/0022-2364(90)90306-T; Ogawa H, 2000, J BIOL CHEM, V275, P19368, DOI 10.1074/jbc.M001888200; Ota H, 1998, HISTOCHEM CELL BIOL, V110, P113, DOI 10.1007/s004180050272; Previato JO, 1998, J BIOL CHEM, V273, P14982, DOI 10.1074/jbc.273.24.14982; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; ROOD JI, 1991, MICROBIOL REV, V55, P621, DOI 10.1128/MMBR.55.4.621-648.1991; SCUDDER P, 1983, BIOCHEM J, V213, P485, DOI 10.1042/bj2130485; SHAKA AJ, 1983, J MAGN RESON, V51, P169, DOI 10.1016/0022-2364(83)90117-8; SMITH LDS, 1979, REV INFECT DIS, V1, P254; Sterne M, 1981, Br Vet J, V137, P443; SUMMERS MF, 1986, J AM CHEM SOC, V108, P4285, DOI 10.1021/ja00275a008; TAKASAKI S, 1976, J BIOL CHEM, V251, P3603; VANHALBEEK H, 1983, BIOCHIM BIOPHYS ACTA, V747, P107, DOI 10.1016/0167-4838(83)90128-0	39	17	19	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28226	28232		10.1074/jbc.M103589200	http://dx.doi.org/10.1074/jbc.M103589200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11382776	hybrid			2022-12-25	WOS:000170093400066
J	Tatsuki, M; Mori, H				Tatsuki, M; Mori, H			Phosphorylation of tomato 1-aminocyclopropane-1-carboxylic acid synthase, LE-ACS2, at the C-terminal region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ETHYLENE BIOSYNTHESIS; MESSENGER-RNA; KEY ENZYME; INDUCTION; ELICITOR; PROTEIN; CLONING; PLANTS; CELLS; METHIONINE	1-Aminocyclopropane-1-carboxylic acid synthase is a key enzyme in the ethylene biosynthesis pathway. Recent studies raise the possibility that 1-aminocyclopropane-1-carboxylic acid synthase (ACS) is regulated not only transcriptionally but also post-translationally. To elucidate post-translational ACS regulation, we analyzed the modification of LE-ACS2 protein, a wound-inducible isozyme in the ACS family, in tomato fruit (Lycopersicon esculentum L.) using an anti-LE-ACS2 antibody. We detected phosphorylated LE-ACS2 at 55-kDa using immunoprecipitation from an extract of wounded fruit fed with [P-32]inorganic phosphate. Analysis of LE-ACS2 phosphoamino acids indicated that serine residue(s) were phosphorylated. In vitro phosphorylation analyses using site-directed mutagenesis of recombinant LE-ACS2 as a substrate demonstrate that serine 460 located at the C-terminal region of ACS is phosphorylated. During tomato ripening stages, expression of both LE-ACS2 and LE-ACS4 mRNA increased. LE-ACS4, however, was not phosphorylated in vitro. These results suggest that ACS isozymes have different post-translational regulatory mechanisms, such as phosphorylation.	Nagoya Univ, Grad Sch Bioagr Sci, Chikusa Ku, Aichi 4648601, Japan	Nagoya University	Mori, H (corresponding author), Nagoya Univ, Grad Sch Bioagr Sci, Chikusa Ku, Furo Cho, Aichi 4648601, Japan.	morihito@agr.nagoya-u.ac.jp						Abeles F, 1992, ETHYLENE PLANT BIOL; ADAMS DO, 1979, P NATL ACAD SCI USA, V76, P170, DOI 10.1073/pnas.76.1.170; Capitani G, 1999, J MOL BIOL, V294, P745, DOI 10.1006/jmbi.1999.3255; CHAPPELL J, 1984, PLANTA, V161, P475, DOI 10.1007/BF00394581; EDELMAN L, 1990, PLANTA, V182, P635, DOI 10.1007/BF02341042; FELIX G, 1991, PLANT PHYSIOL, V97, P19, DOI 10.1104/pp.97.1.19; Hardie D. G., 1996, V39, P3; ICHIHARA Y, 1993, GENE, V130, P153, DOI 10.1016/0378-1119(93)90361-6; Im KH, 2000, PLANT PHYSIOL, V123, P463, DOI 10.1104/pp.123.2.463; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KENDE H, 1993, ANNU REV PLANT PHYS, V44, P283, DOI 10.1146/annurev.pp.44.060193.001435; KING MM, 1983, J BIOL CHEM, V258, P9925; Li N, 1996, FEBS LETT, V378, P286, DOI 10.1016/0014-5793(95)01464-0; LI N, 1994, J BIOL CHEM, V269, P6908; LIZADA MCC, 1979, ANAL BIOCHEM, V100, P140, DOI 10.1016/0003-2697(79)90123-4; NAKAJIMA N, 1988, PLANT CELL PHYSIOL, V29, P989; Oetiker JH, 1997, PLANT MOL BIOL, V34, P275, DOI 10.1023/A:1005800511372; OLSON DC, 1995, J BIOL CHEM, V270, P14056, DOI 10.1074/jbc.270.23.14056; Sambrook J, 2001, MOL CLONING LAB MANU; SATO T, 1991, J BIOL CHEM, V266, P3752; SATO T, 1989, P NATL ACAD SCI USA, V86, P6621, DOI 10.1073/pnas.86.17.6621; SATOH S, 1989, PLANT PHYSIOL, V91, P1036, DOI 10.1104/pp.91.3.1036; SPANU P, 1994, PLANT PHYSIOL, V106, P529, DOI 10.1104/pp.106.2.529; Tatsuki M, 1999, PLANT CELL PHYSIOL, V40, P709, DOI 10.1093/oxfordjournals.pcp.a029597; Tuomainen J, 1997, PLANT J, V12, P1151, DOI 10.1046/j.1365-313X.1997.12051151.x; Vaitukaitis J L, 1981, Methods Enzymol, V73, P46; VAN DER STRAETEN D, 1990, P NATL ACAD SCI USA, V87, P4859, DOI 10.1073/pnas.87.12.4859; Vogel JP, 1998, P NATL ACAD SCI USA, V95, P4766, DOI 10.1073/pnas.95.8.4766; Woeste KE, 1999, PLANT PHYSIOL, V119, P521, DOI 10.1104/pp.119.2.521; YOSHII H, 1981, PLANT CELL PHYSIOL, V22, P369; ZAREMBINSKI TI, 1994, PLANT MOL BIOL, V26, P1579, DOI 10.1007/BF00016491	31	118	127	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28051	28057		10.1074/jbc.M101543200	http://dx.doi.org/10.1074/jbc.M101543200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11375393	hybrid			2022-12-25	WOS:000170093400042
J	Wiederschain, D; Gu, JJ; Yuan, ZM				Wiederschain, D; Gu, JJ; Yuan, ZM			Evidence for a distinct inhibitory factor in the regulation of p53 functional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; APOPTOTIC RESPONSE; MUTANT P53; IDENTIFICATION; ACTIVATION; PROTEIN; PEPTIDE; DOMAINS; GROWTH; REGION	Under normal conditions, tumor suppressor protein p53 exists in the cell in its latent form and is unable to function as a transcription factor. The allosteric model of p53 regulation postulates that the extreme portion of p53 carboxyl terminus (aa 364-393) binds to the core domain of the protein, thereby abrogating specific DNA binding in that region. In this study we propose an alternative mechanism of p53 functional regulation, which involves a separate molecule acting in trans to inhibit p53 transcriptional activity. Through the use of chimeric proteins of p53, p63 gamma and p73 beta, we show that the extreme COOH-terminal domain of p53 exerts a powerful and specific inhibitory effect on the p73- and p63-driven expression of a reporter gene. Moreover, fusion of p53 extreme COOH terminus to a completely unrelated transcriptional activator Gal4-VP16 also results in significant inhibition of transactivation. activity. Since p73, p63, or Gal4-VP16 cannot associate with any part of the p53 molecule, we conclude that p53(aa 364-393) represses transcriptional activity of chimeric proteins and p53 itself through the binding of external negative modulator(s) in that region and not by the allosteric mechanism of regulation. In accordance with the "distinct inhibitor" hypothesis, the activity of wild type p53 is substantially increased by overexpression of chimeric proteins bearing p53(aa 364-393), which might be due to the competitive removal of trancriptional inhibitor(s). Our findings provide the basis for the identification of such negative modulators of p53 transcriptional activity.	Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA; Harvard Univ, Grad Sch Arts & Sci, Program Biol Sci Publ Hlth, Cambridge, MA 02138 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University	Yuan, ZM (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Bldg 1,Rm 209,665 Huntington Ave, Boston, MA 02115 USA.	zyuan@hsph.harvard.edu						Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Davison TS, 1999, J BIOL CHEM, V274, P18709, DOI 10.1074/jbc.274.26.18709; Farmer G, 1996, NUCLEIC ACIDS RES, V24, P4281, DOI 10.1093/nar/24.21.4281; Gu JJ, 2000, MOL CELL BIOL, V20, P1243, DOI 10.1128/MCB.20.4.1243-1253.2000; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kubbutat MHG, 1998, MOL MED TODAY, V4, P250, DOI 10.1016/S1357-4310(98)01260-X; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; Muller-Tiemann BF, 1998, P NATL ACAD SCI USA, V95, P6079, DOI 10.1073/pnas.95.11.6079; Selivanova G, 1999, MOL CELL BIOL, V19, P3395; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zotchev SB, 2000, NUCLEIC ACIDS RES, V28, P4005, DOI 10.1093/nar/28.20.4005	22	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27999	28005		10.1074/jbc.M102400200	http://dx.doi.org/10.1074/jbc.M102400200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11382762	hybrid			2022-12-25	WOS:000170093400035
J	Zhang, CX; Reiter, C; Eiserich, JP; Boersma, B; Parks, DA; Beckman, JS; Barnes, S; Kirk, M; Baldus, S; Darley-Usmar, VM; White, CR				Zhang, CX; Reiter, C; Eiserich, JP; Boersma, B; Parks, DA; Beckman, JS; Barnes, S; Kirk, M; Baldus, S; Darley-Usmar, VM; White, CR			L-arginine chlorination products inhibit endothelial nitric oxide production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUTROPHILS EMPLOY; ALPHA-AMINO-ACIDS; ISCHEMIA-REPERFUSION; DEPENDENT RELAXATION; REACTIVE ALDEHYDES; MYELOPEROXIDASE; MECHANISMS; INJURY; INFLAMMATION; DYSFUNCTION	The myeloperoxidase-derived oxidant hypochlorous acid (HOCl) is thought to contribute to endothelial dysfunction, but the mechanisms underlying this inhibitory effect are unknown. The present study tested the hypothesis that HOCl and L-arginine (L-Arg) react to form novel compounds that adversely affect endothelial function by inhibiting nitric oxide (NO) formation. Using spectrophotometric techniques, we found that HOCl and L-Arg react rapidly (k = 7.1 x 10(5) M-1 s(-1)) to form two major products that were identified by mass spectrometry as monochlorinated and dichlorinated adducts of L-Arg. Pretreatment of bovine aortic endothelial cells with the chlorinated L-Arg metabolites (Cl-L-Arg) inhibited the A23187-induced formation of the NO metabolites nitrate (NO3-) and nitrite (NO2-) in a concentration-dependent manner. Preincubation of rat aortic ring segments with Cl-L-Arg resulted in concentration-dependent inhibition of acetylcholine-induced relaxation, In contrast, blood vessels relaxed normally to the endothelium-independent vasodilator sodium nitroprusside, In vivo administration of Cl-L-Arg to anesthetized rats increased carotid artery vascular resistance. A greater than 10-fold excess of L-Arg was required to reverse the inhibitory effects of Cl-L-Arg in vivo and in vitro. Reaction of HOCl with D-arginine (D-Arg) did not result in the formation of inhibitory products. These results suggest that HOCl reacts with L-Arg to form chlorinated products that act as nitric-oxide synthase inhibitors.	Univ Alabama, Ctr Free Rad Biol, Birmingham, AL 35294 USA; Univ Alabama, Dept Med, Vasc Biol & Hypertens Program, Birmingham, AL 35294 USA; Univ Alabama, Dept Anesthesiol, Birmingham, AL 35294 USA; Univ Alabama, Dept Pharmacol & Toxicol, Birmingham, AL 35294 USA; Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA; Univ Alabama, Ctr Comprehens Canc, Mass Spectrometry Shared Facil, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	White, CR (corresponding author), Univ Alabama, Ctr Free Rad Biol, Zeigler Res Bldg,Rm 1046, Birmingham, AL 35294 USA.		Boersma, Brenda/A-9270-2009; zhang, xiang chun/HCH-7063-2022	Boersma, Brenda/0000-0002-8992-2735; zhang, xiang chun/0000-0001-8303-6495; Darley-Usmar, Victor/0000-0001-8921-7086	NCI NIH HHS [P30 CA13148] Funding Source: Medline; NCRR NIH HHS [S10RR06487] Funding Source: Medline; NHLBI NIH HHS [HL-03812, HL-54815] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013148] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR006487] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL054815] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Boger RH, 1998, CIRCULATION, V98, P1842, DOI 10.1161/01.CIR.98.18.1842; Cameron EM, 1998, SHOCK, V9, P184, DOI 10.1097/00024382-199803000-00005; Campbell B, 2000, BRIT J PHARMACOL, V129, P71, DOI 10.1038/sj.bjp.0703010; Conner EM, 1996, NUTRITION, V12, P274, DOI 10.1016/S0899-9007(96)00000-8; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; FLISS H, 1988, MOL CELL BIOCHEM, V84, P177, DOI 10.1007/BF00421053; FOLKES LK, 1995, ARCH BIOCHEM BIOPHYS, V323, P120, DOI 10.1006/abbi.1995.0017; Friese RS, 1996, J SURG RES, V63, P23, DOI 10.1006/jsre.1996.0216; Fullerton DA, 1996, AM J PHYSIOL-LUNG C, V271, pL326, DOI 10.1152/ajplung.1996.271.2.L326; Granger DN, 1999, MICROCIRCULATION, V6, P167; Grisham MB, 1998, FREE RADICAL BIO MED, V25, P404, DOI 10.1016/S0891-5849(98)00094-X; Hayward R, 1998, AM J PHYSIOL-HEART C, V275, pH23, DOI 10.1152/ajpheart.1998.275.1.H23; Hazen SL, 1998, BIOCHEMISTRY-US, V37, P6864, DOI 10.1021/bi972449j; Hazen SL, 1997, FREE RADICAL BIO MED, V23, P909, DOI 10.1016/S0891-5849(97)00084-1; Hazen SL, 1998, J BIOL CHEM, V273, P4997, DOI 10.1074/jbc.273.9.4997; Heinecke JW, 1999, J LAB CLIN MED, V133, P321, DOI 10.1016/S0022-2143(99)90061-6; HOBBS AJ, 1999, HAEMODYNAMIC EFFECTS, P52; Huang YI, 1998, J LEUKOCYTE BIOL, V64, P322, DOI 10.1002/jlb.64.3.322; Ito A, 1999, CIRCULATION, V99, P3092, DOI 10.1161/01.CIR.99.24.3092; Jorge PAR, 1997, EXP TOXICOL PATHOL, V49, P147; LEIPERT B, 1992, AM J PHYSIOL, V262, pH1676, DOI 10.1152/ajpheart.1992.262.6.H1676; Marcinkiewicz J, 1997, IMMUNOPHARMACOLOGY, V37, P35, DOI 10.1016/S0162-3109(96)00168-3; McKenna R, 1996, SHOCK, V6, P106, DOI 10.1097/00024382-199608000-00005; Miyazaki H, 1999, CIRCULATION, V99, P1141, DOI 10.1161/01.CIR.99.9.1141; Nauseef WM, 1998, J MOL MED-JMM, V76, P661, DOI 10.1007/s001090050265; REES DD, 1990, BRIT J PHARMACOL, V101, P746, DOI 10.1111/j.1476-5381.1990.tb14151.x; SCHRAUFSTATTER IU, 1990, J CLIN INVEST, V85, P554, DOI 10.1172/JCI114472; Shabani F, 1998, FREE RADICAL RES, V28, P115, DOI 10.3109/10715769809065797; Thomas E L, 1986, Methods Enzymol, V132, P569; Vinten-Johansen J, 1999, ANN NY ACAD SCI, V874, P354, DOI 10.1111/j.1749-6632.1999.tb09251.x; Wang P, 1999, CRIT CARE MED, V27, P959, DOI 10.1097/00003246-199905000-00035; Whiteman M, 1999, BRIT J PHARMACOL, V126, P1646, DOI 10.1038/sj.bjp.0702465; Whitman SC, 1999, ARTERIOSCL THROM VAS, V19, P1238, DOI 10.1161/01.ATV.19.5.1238; WONG JM, 1995, NITRIC OXIDE BIOCH M, P155	34	70	75	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27159	27165		10.1074/jbc.M100191200	http://dx.doi.org/10.1074/jbc.M100191200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11375389	hybrid			2022-12-25	WOS:000169966900058
J	Fukushima, K; Hara-Kuge, S; Ideo, H; Yamashita, K				Fukushima, K; Hara-Kuge, S; Ideo, H; Yamashita, K			Carbohydrate recognition site of interleukin-2 in relation to cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BETA-CHAIN; SIGNAL-TRANSDUCTION; POSSIBLE INVOLVEMENT; 3RD COMPONENT; ALPHA-CHAIN; BINDING; COMPLEX; AFFINITY; IL-2; SPECIFICITY	Interleukin-2 (IL-2) is a cytokine with important roles in the immune system. IL-2 initially binds a high mannose-type glycan and a specific peptide sequence of the IL-2 receptor a-subunit and sequentially forms a high affinity complex of IL-2 . IL-2 receptor alpha-, beta-, and gamma -subunits. This formation induces cellular signaling and cell proliferation (Fukushima, K., and Yamashita, IL (2001) J. Biol Chem. 276, 7351-7356). To determine the carbohydrate-binding site of IL-2, we prepared wild-type and point-mutated S-35-IL-2 by an in vitro transcription and translation method. We found that wild-type 35S-IL-2 tends to form a dimer spontaneously, and the dimeric form has both carbohydrate recognition activity and cell proliferation activity. Moreover, substitution of Asn-26 in IL-2 with Gln or Asp conserved the dimeric form and affected the carbohydrate recognition activities in correspondence with the cell proliferation activities, suggesting that Asn-26 in IL-2 is involved in the carbohydrate recognition site. These results suggest that the carbohydrate recognition of IL-2 dimer triggers formation of high affinity complex (IL-2-IL-2R alpha, -beta, -gamma)(2), and the hetero-octamer stimulates IL-2-dependent T-cell proliferation by intensifying cellular signaling.	Sasaki Inst, Dept Biochem, Chiyoda Ku, Tokyo 1010062, Japan; Japan Sci & Technol Corp, CREST, Chiyoda Ku, Tokyo 1010062, Japan	Japan Science & Technology Agency (JST)	Yamashita, K (corresponding author), Sasaki Inst, Dept Biochem, Chiyoda Ku, 2-2 Kanda Surugadai, Tokyo 1010062, Japan.							ANDERSON DM, 1995, J BIOL CHEM, V270, P29862; ARIMA N, 1992, J EXP MED, V176, P1265, DOI 10.1084/jem.176.5.1265; Aritomi M, 1999, NATURE, V401, P713, DOI 10.1038/44394; ASAO H, 1994, FEBS LETT, V351, P201, DOI 10.1016/0014-5793(94)00831-0; BAMBOROUGH P, 1994, STRUCTURE LONDON, V2, P677; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BRANDHUBER BJ, 1987, J BIOL CHEM, V262, P12306; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; EZEKOWITZ RAB, 1988, J EXP MED, V167, P1034, DOI 10.1084/jem.167.3.1034; Fukushima K, 2001, J BIOL CHEM, V276, P7351, DOI 10.1074/jbc.M008781200; Gaffen SL, 1996, J BIOL CHEM, V271, P21381, DOI 10.1074/jbc.271.35.21381; Hara-Kuge S, 1999, GLYCOBIOLOGY, V9, P833, DOI 10.1093/glycob/9.8.833; IMLER JL, 1992, EMBO J, V11, P2047, DOI 10.1002/j.1460-2075.1992.tb05262.x; ITO S, 1977, J BIOCHEM, V81, P1621, DOI 10.1093/oxfordjournals.jbchem.a131621; Iwasaki W, 1997, EMBO J, V16, P6936, DOI 10.1093/emboj/16.23.6936; LAMBERT G, 1989, J BIOL CHEM, V264, P12730; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LIANG CJ, 1980, J BIOCHEM-TOKYO, V88, P51; MIKAELIAN I, 1992, NUCLEIC ACIDS RES, V20, P376, DOI 10.1093/nar/20.2.376; Moreau JL, 1995, MOL IMMUNOL, V32, P1047, DOI 10.1016/0161-5890(95)00084-4; Nelson BH, 1998, ADV IMMUNOL, V70, P1, DOI 10.1016/S0065-2776(08)60386-7; SAUVE K, 1991, P NATL ACAD SCI USA, V88, P4636, DOI 10.1073/pnas.88.11.4636; SHERBLOM AP, 1989, J IMMUNOL, V143, P939; SHIMUZU A, 1985, NUCLEIC ACIDS RES, V13, P1505, DOI 10.1093/nar/13.5.1505; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; TAI T, 1975, J BIOL CHEM, V250, P8569; TAKASAKI S, 1982, METHOD ENZYMOL, V83, P263; TAKESHITA T, 1992, J IMMUNOL, V148, P2154; TANIGUCHI T, 1983, NATURE, V302, P305, DOI 10.1038/302305a0; TSUJI T, 1987, BIOCHEMISTRY-US, V26, P3129, DOI 10.1021/bi00385a028; VOSS SD, 1993, P NATL ACAD SCI USA, V90, P2428, DOI 10.1073/pnas.90.6.2428; Ward LD, 1996, J BIOL CHEM, V271, P20138, DOI 10.1074/jbc.271.33.20138; YAMASHITA K, 1983, J BIOL CHEM, V258, P1098; YAYON A, 1991, CELL, V64, P844; ZURAWSKI SM, 1990, EMBO J, V9, P3899, DOI 10.1002/j.1460-2075.1990.tb07610.x	36	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31202	31208		10.1074/jbc.M102789200	http://dx.doi.org/10.1074/jbc.M102789200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11390392	hybrid			2022-12-25	WOS:000170472900081
J	Honda, A; Endo, A; Mizumoto, K; Ishihama, A				Honda, A; Endo, A; Mizumoto, K; Ishihama, A			Differential roles of viral RNA and cRNA in functional modulation of the influenza virus RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; BINDING-SITE; SUBUNIT CONSTITUTE; MOLECULAR ANATOMY; INFECTED-CELLS; GENOME RNA; 3 SUBUNITS; IN-VITRO; POLYADENYLATION; TRANSCRIPTION	The RNA-dependent RNA polymerase of influenza virus is composed of three viral P proteins (PB1, PB2, and PA) and involved in both transcription and replication of the RNA genome. For the molecular anatomy of this multifunctional enzyme, we have established a simultaneous expression of three P proteins in cultured insect cells using recombinant baculoviruses. For purification of P protein complexes, the PA protein was expressed as a fusion with a histidine tag added at its N terminus. By using affinity chromatography, a complex consisting of the three P proteins was isolated from nuclear extracts of virus-infected cells. The affinity-purified 3P complex showed the activities of capped RNA binding, capped RNA cleavage, viral model RNA binding, model RNA-directed RNA synthesis, and polyadenylation of newly synthesized RNA. We conclude that a functional form of the viral RNA polymerase with the catalytic specificity of transcriptase is formed in recombinant baculovirus-infected insect cells. Using the viral RNA-free 3P complex, we found that the capped RNA cleavage takes place in the presence of vRNA but not of cRNA, indicating that the vRNA functions as a regulatory factor for the specificity control of viral RNA polymerase as well as a template for transcription. The structural elements of RNA directing the expression of RNA polymerase functions were analyzed using variant forms of the model RNA templates.	Natl Inst Genet, Dept Mol Genet, Shizuoka 4118540, Japan; Japan Sci & Technol Corp, Kawaguchi, Saitama 3320012, Japan; Daiichi Pharmaceut Co Ltd, Exploratory Res Labs, Tokyo 1340081, Japan; Kitasato Univ, Fac Pharmaceut Sci, Minato Ku, Tokyo 1088641, Japan	Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Japan Science & Technology Agency (JST); Daiichi Sankyo Company Limited; Kitasato University	Honda, A (corresponding author), Natl Inst Genet, Dept Mol Genet, Shizuoka 4118540, Japan.							BEATON AR, 1981, NUCLEIC ACIDS RES, V9, P4423, DOI 10.1093/nar/9.17.4423; BOULOY M, 1978, P NATL ACAD SCI USA, V75, P4886, DOI 10.1073/pnas.75.10.4886; Cai JS, 1997, J BIOL CHEM, V272, P18974, DOI 10.1074/jbc.272.30.18974; CIANCI C, 1995, J VIROL, V69, P3995, DOI 10.1128/JVI.69.7.3995-3999.1995; FODOR E, 1993, J GEN VIROL, V74, P1327, DOI 10.1099/0022-1317-74-7-1327; Galarza JM, 1996, J VIROL, V70, P2360, DOI 10.1128/JVI.70.4.2360-2368.1996; Gonzalez S, 1999, EMBO J, V18, P3767, DOI 10.1093/emboj/18.13.3767; HAGEN M, 1994, J VIROL, V68, P1509, DOI 10.1128/JVI.68.3.1509-1515.1994; HAY AJ, 1982, VIROLOGY, V116, P517, DOI 10.1016/0042-6822(82)90144-1; HERZ C, 1981, CELL, V26, P391, DOI 10.1016/0092-8674(81)90208-7; Honda A, 1999, GENES CELLS, V4, P475, DOI 10.1046/j.1365-2443.1999.00275.x; Honda A, 1998, VIRUS RES, V55, P199, DOI 10.1016/S0168-1702(98)00048-3; Honda A, 1997, BIOL CHEM, V378, P483; HONDA A, 1990, J BIOCHEM-TOKYO, V107, P624, DOI 10.1093/oxfordjournals.jbchem.a123097; HONDA A, 1987, J BIOCHEM-TOKYO, V102, P1241, DOI 10.1093/oxfordjournals.jbchem.a122163; HORISBERGER MA, 1980, VIROLOGY, V107, P302, DOI 10.1016/0042-6822(80)90296-2; HSU MT, 1987, P NATL ACAD SCI USA, V84, P8140, DOI 10.1073/pnas.84.22.8140; Hwang JS, 2000, J VIROL, V74, P4074, DOI 10.1128/JVI.74.9.4074-4084.2000; Ishihama A, 1996, BIOCHIMIE, V78, P1097, DOI 10.1016/S0300-9084(97)86735-1; ISHIHAMA A, 1986, J BIOL CHEM, V261, P417; ITO N, 1987, J BIOL CHEM, V262, P1989; JACKSON DA, 1982, NATURE, V296, P366, DOI 10.1038/296366a0; KATO A, 1985, VIRUS RES, V3, P115; KAWAKAMI K, 1985, J BIOCHEM-TOKYO, V97, P655, DOI 10.1093/oxfordjournals.jbchem.a135101; KAWAKAMI K, 1983, NUCLEIC ACIDS RES, V11, P3637, DOI 10.1093/nar/11.11.3637; KAWAKAMI K, 1981, J BIOCH, V89, P18751; Kimura M, 2000, NUCLEIC ACIDS RES, V28, P952, DOI 10.1093/nar/28.4.952; KOBAYASHI M, 1992, VIRUS RES, V22, P235, DOI 10.1016/0168-1702(92)90055-E; KRUG RM, 1989, INFLUENZA VIRUSES, P89; Li ML, 1998, EMBO J, V17, P5844, DOI 10.1093/emboj/17.19.5844; LUO GX, 1991, J VIROL, V65, P2861, DOI 10.1128/JVI.65.6.2861-2867.1991; MAHY BWJ, 1981, REPLICATION NEGATIVE, P379; NAITO S, 1976, J BIOL CHEM, V251, P4307; PALESE P, 1983, GENETICS INFLUENZA V; PARVIN JD, 1989, J VIROL, V63, P5142, DOI 10.1128/JVI.63.12.5142-5152.1989; PLOTCH SJ, 1981, CELL, V23, P847, DOI 10.1016/0092-8674(81)90449-9; Pritlove DC, 1998, J VIROL, V72, P1280, DOI 10.1128/JVI.72.2.1280-1286.1998; ROBERTSON JS, 1981, J VIROL, V38, P157, DOI 10.1128/JVI.38.1.157-163.1981; Roy P, 1997, GENE, V190, P119, DOI 10.1016/S0378-1119(96)00619-1; SCHOLTISSEK C, 1978, ARCH VIROL, V58, P323, DOI 10.1007/BF01317824; SEONG BL, 1992, J GEN VIROL, V73, P3115, DOI 10.1099/0022-1317-73-12-3115; SEONG BL, 1992, J BIOCHEM-TOKYO, V111, P496, DOI 10.1093/oxfordjournals.jbchem.a123786; SHAW MW, 1984, VIRUS RES, V1, P455, DOI 10.1016/0168-1702(84)90003-0; SZEWCZYK B, 1988, P NATL ACAD SCI USA, V85, P7907, DOI 10.1073/pnas.85.21.7907; Toyoda T, 1996, J GEN VIROL, V77, P2149, DOI 10.1099/0022-1317-77-9-2149; Zuker M., 1999, V70, P11	46	27	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31179	31185		10.1074/jbc.M102856200	http://dx.doi.org/10.1074/jbc.M102856200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11373286	hybrid			2022-12-25	WOS:000170472900078
J	Vaisman, A; Tissier, A; Frank, EG; Goodman, MF; Woodgate, R				Vaisman, A; Tissier, A; Frank, EG; Goodman, MF; Woodgate, R			Human DNA polymerase iota promiscuous mismatch extension	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XERODERMA-PIGMENTOSUM; GENE ENCODES; THYMINE DIMER; FIDELITY; BYPASS; REPLICATION; ETA; MUTAGENESIS; PROTEIN; MISINSERTION	Human DNA polymerase iota is a low-fidelity template copier that preferentially catalyzes the incorporation of the wobble base G, rather than the Watson-Crick base A, opposite template T (Tissier, A., McDonald, CF. P., Frank, E. G., and Woodgate, R. (2000) Genes Dev. 14, 1642-1650; Johnson, R. E., Washington, M. T., Haracska, L., Prakash, S., and Prakash, L. (2000) Nature 406, 10151019; Zhang, Y., Yuan, F., Wu, X., and Wang, Z. (2000) Mol. Cell. Biol. 20,7099-7108). Here, we report on its ability to extend all 12 possible mispairs and 4 correct pairs in different sequence contexts. Extension from both matched and mismatched primer termini is generally most efficient and accurate when A is the next template base. In contrast, extension occurs less efficiently and accurately when T is the target template base. A striking exception occurs during extension of a G:T mispair, where the enzyme switches specificity, "preferring" to make a correct A.T base pair immediately downstream from an originally favored G:T mispair. Polymerase L generates a variety of single and tandem mispairs with high frequency, implying that it may act as a strong mutator when copying undamaged DNA templates in vivo. Even so, its limited ability to catalyze extension from a relatively stable primer/template containing a "buried" mismatch suggests that polymerase iota -catalyzed errors are confined to short template regions.	NICHHD, Sect DNA Replicat Repair & Mutagenesis, NIH, Bethesda, MD 20892 USA; Univ So Calif, Dept Sci Biol, Hedco Mol Biol Labs, Los Angeles, CA 90089 USA; Univ So Calif, Dept Chem, Hedco Mol Biol Labs, Los Angeles, CA 90089 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Southern California; University of Southern California	Woodgate, R (corresponding author), NICHHD, Sect DNA Replicat Repair & Mutagenesis, NIH, Bldg 6,Rm 1A13,9000 Rockville Pike, Bethesda, MD 20892 USA.	woodgate@helix.nih.gov	Tissier, Agnes/I-4850-2018; Vaisman, Alexandra/C-3766-2013	Vaisman, Alexandra/0000-0002-2521-1467; TISSIER, Agnes/0000-0002-5676-8719; Woodgate, Roger/0000-0001-5581-4616	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001500] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001500] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021422, R37GM021422] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM21422, GM2554] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aoufouchi S, 2000, NUCLEIC ACIDS RES, V28, P3684, DOI 10.1093/nar/28.18.3684; Bebenek K, 2001, SCIENCE, V291, P2156, DOI 10.1126/science.1058386; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; Burgers PMJ, 1998, CHROMOSOMA, V107, P218, DOI 10.1007/s004120050300; Creighton S, 1995, METHOD ENZYMOL, V262, P232; CREIGHTON S, 1995, J BIOL CHEM, V270, P4759, DOI 10.1074/jbc.270.9.4759; Dominguez O, 2000, EMBO J, V19, P1731, DOI 10.1093/emboj/19.7.1731; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; Frank EG, 2001, EMBO J, V20, P2914, DOI 10.1093/emboj/20.11.2914; Garcia-Diaz M, 2000, J MOL BIOL, V301, P851, DOI 10.1006/jmbi.2000.4005; Gerlach VL, 2001, J BIOL CHEM, V276, P92, DOI 10.1074/jbc.M004413200; Goodman MF, 2000, NAT REV MOL CELL BIO, V1, P101, DOI 10.1038/35040051; ITO J, 1991, NUCLEIC ACIDS RES, V19, P4045, DOI 10.1093/nar/19.15.4045; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Johnson RE, 2000, P NATL ACAD SCI USA, V97, P3838, DOI 10.1073/pnas.97.8.3838; Johnson RE, 2000, J BIOL CHEM, V275, P7447, DOI 10.1074/jbc.275.11.7447; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; Lawrence CW, 2000, COLD SPRING HARB SYM, V65, P61, DOI 10.1101/sqb.2000.65.61; Maor-Shoshani A, 2000, P NATL ACAD SCI USA, V97, P565, DOI 10.1073/pnas.97.2.565; Masutani C, 2000, EMBO J, V19, P3100, DOI 10.1093/emboj/19.12.3100; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Masutani C, 1999, EMBO J, V18, P3491, DOI 10.1093/emboj/18.12.3491; McDonald JP, 1999, GENOMICS, V60, P20, DOI 10.1006/geno.1999.5906; McDonald JP, 2001, PHILOS T R SOC B, V356, P53, DOI 10.1098/rstb.2000.0748; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; Nelson JR, 1996, NATURE, V382, P729, DOI 10.1038/382729a0; Ohashi E, 2000, GENE DEV, V14, P1589; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; Pham P, 2001, NATURE, V409, P366, DOI 10.1038/35053116; Poltoratsky V, 2000, J EXP MED, V192, pF27, DOI 10.1084/jem.192.10.F27; Reuven NB, 2001, J BIOL CHEM, V276, P5511, DOI 10.1074/jbc.M006828200; Reuven NB, 1999, J BIOL CHEM, V274, P31763, DOI 10.1074/jbc.274.45.31763; Sharief FS, 1999, GENOMICS, V59, P90, DOI 10.1006/geno.1999.5843; Spencer J, 1999, J IMMUNOL, V162, P6596; Tang MJ, 1999, P NATL ACAD SCI USA, V96, P8919, DOI 10.1073/pnas.96.16.8919; Tang MJ, 1998, P NATL ACAD SCI USA, V95, P9755, DOI 10.1073/pnas.95.17.9755; Tissier A, 2000, GENE DEV, V14, P1642; Tissier A, 2000, EMBO J, V19, P5259, DOI 10.1093/emboj/19.19.5259; Tissier A, 2001, BIOCHEM SOC T, V29, P183, DOI 10.1042/0300-5127:0290183; Wagner J, 1999, MOL CELL, V4, P281, DOI 10.1016/S1097-2765(00)80376-7; Washington MT, 2001, J BIOL CHEM, V276, P2263, DOI 10.1074/jbc.M009049200; Winter DB, 1998, IMMUNOL REV, V162, P89, DOI 10.1111/j.1600-065X.1998.tb01432.x; Zhang YB, 2000, MOL CELL BIOL, V20, P7099, DOI 10.1128/MCB.20.19.7099-7108.2000; Zhang YB, 2001, NUCLEIC ACIDS RES, V29, P928, DOI 10.1093/nar/29.4.928	47	49	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30615	30622		10.1074/jbc.M102694200	http://dx.doi.org/10.1074/jbc.M102694200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11402031	hybrid			2022-12-25	WOS:000170472900006
J	Sartori, AA; Schar, P; Fitz-Gibbon, S; Miller, JH; Jiricny, J				Sartori, AA; Schar, P; Fitz-Gibbon, S; Miller, JH; Jiricny, J			Biochemical characterization of uracil processing activities in the hyperthermophilic archaeon Pyrobaculum aerophilum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYMINE DNA GLYCOSYLASE; BASE-EXCISION-REPAIR; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; DEAMINATION; IDENTIFICATION; RECOGNITION; EXPRESSION; INHIBITOR; RESIDUES	Deamination of cytosine to uracil and 5-methyleytosine to thymine represents a major mutagenic threat particularly at high temperatures. In double-stranded DNA, these spontaneous hydrolytic reactions give rise to G-U and G-T mispairs, respectively, that must be restored to G-C pairs prior to the next round of DNA replication; if left unrepaired, 50% of progeny DNA would acquire G.C --> A.T transition mutations. The genome of the hyperthermophilic archaeon Pyrobaculum aerophilum has been recently shown to encode a protein, Pa-MIG, a member of the endonuclease III family, capable of processing both G-U and G-T mispairs. We now show that this latter activity is undetectable in crude extracts of P. aerophilum. However, uracil residues in G-U mispairs, in A-U pairs, and in single-stranded DNA were efficiently removed in these extracts. These activities were assigned to a similar to 22-kDa polypeptide named Pa-UDG (P. aerophilum uracil-DNA glycosylase). The recombinant Pa-UDG protein is highly thermostable and displays a considerable degree of homology to the recently described uracil-DNA glycosylases from Archaeoglobus fulgidus and Thermotoga maritima. Interestingly, neither Pa-MIG nor Pa-UDG was inhibited by UGI, a generic inhibitor of the UNG family of uracil glycosylases. Yet a small fraction of the total uracil processing activity present in crude extracts of P. aerophilum was inhibited by this peptide. This implies that the hyperthermophilic archaeon possesses at least a three-pronged defense against the mutagenic threat of hydrolytic deamination of cytosines in its genomic DNA.	Univ Zurich, Inst Med Radiobiol, CH-8008 Zurich, Switzerland; Paul Scherrer Inst, CH-8008 Zurich, Switzerland; Univ Calif Los Angeles, Dept Microbiol & Mol Genet, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of Zurich; Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Jiricny, J (corresponding author), Univ Zurich, Inst Med Radiobiol, August Forel Str 7, CH-8008 Zurich, Switzerland.	jiricny@imr.unizh.ch	Sartori, Alessandro/AAK-7840-2021; Schär, Primo/G-5967-2012	Sartori, Alessandro/0000-0003-2770-0333; Schär, Primo/0000-0003-1843-6147				Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1223, DOI 10.1093/nar/27.5.1223; Aravind L, 2000, GENOME BIOL, V1, P1, DOI DOI 10.1186/GB-2000-1-4-RESEARCH0007; Barrett TE, 1999, EMBO J, V18, P6599, DOI 10.1093/emboj/18.23.6599; Barrett TE, 1998, CELL, V92, P117, DOI 10.1016/S0092-8674(00)80904-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Dennis PP, 1997, CELL, V89, P1007, DOI 10.1016/S0092-8674(00)80288-3; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DODSON ML, 1994, J BIOL CHEM, V269, P32709; FitzGibbon S, 1997, EXTREMOPHILES, V1, P36, DOI 10.1007/s007920050013; Gallinari P, 1996, NATURE, V383, P735, DOI 10.1038/383735a0; Hardeland U, 2000, J BIOL CHEM, V275, P33449, DOI 10.1074/jbc.M005095200; Haushalter KA, 1999, CURR BIOL, V9, P174, DOI 10.1016/S0960-9822(99)80087-6; Hendrich B, 1999, NATURE, V401, P301, DOI 10.1038/45843; Horst JP, 1996, EMBO J, V15, P5459, DOI 10.1002/j.1460-2075.1996.tb00929.x; HUDEPOHL U, 1990, P NATL ACAD SCI USA, V87, P5851, DOI 10.1073/pnas.87.15.5851; Jacobs KL, 1997, J BACTERIOL, V179, P3298, DOI 10.1128/jb.179.10.3298-3303.1997; Kavli B, 1996, EMBO J, V15, P3442, DOI 10.1002/j.1460-2075.1996.tb00710.x; Koulis A, 1996, FEMS MICROBIOL LETT, V143, P267; Krokan HE, 1997, BIOCHEM J, V325, P1; LINDAHL T, 1974, BIOCHEMISTRY-US, V13, P3405, DOI 10.1021/bi00713a035; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; NEDDERMANN P, 1994, P NATL ACAD SCI USA, V91, P1642, DOI 10.1073/pnas.91.5.1642; Neddermann P, 1996, J BIOL CHEM, V271, P12767, DOI 10.1074/jbc.271.22.12767; Pearl LH, 2000, MUTAT RES-DNA REPAIR, V460, P165, DOI 10.1016/S0921-8777(00)00025-2; ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P5519, DOI 10.1093/nar/19.20.5519; Sambrook J, 1989, MOL CLONING LAB MANU, V3; Sandigursky M, 1999, CURR BIOL, V9, P531, DOI 10.1016/S0960-9822(99)80237-1; Sandigursky M, 2000, J BIOL CHEM, V275, P19146, DOI 10.1074/jbc.M001995200; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; VOLKL P, 1993, APPL ENVIRON MICROB, V59, P2918; WANG Z, 1989, J BIOL CHEM, V264, P1163; WANG ZG, 1991, GENE, V99, P31; Waters TR, 1999, J BIOL CHEM, V274, P67, DOI 10.1074/jbc.274.1.67; WIEBAUER K, 1989, NATURE, V339, P234, DOI 10.1038/339234a0; Yang HJ, 2000, J BACTERIOL, V182, P1272, DOI 10.1128/JB.182.5.1272-1279.2000	36	50	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29979	29986		10.1074/jbc.M102985200	http://dx.doi.org/10.1074/jbc.M102985200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11399761	hybrid, Green Accepted			2022-12-25	WOS:000170558000050
J	Scrittori, L; Hans, F; Angelov, D; Charra, M; Prigent, C; Dimitrov, S				Scrittori, L; Hans, F; Angelov, D; Charra, M; Prigent, C; Dimitrov, S			pEg2 aurora-A kinase, histone H3 phosphorylation, and chromosome assembly in Xenopus egg extract	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY GENE INDUCTION; CELL-CYCLE; ASPERGILLUS-NIDULANS; CHROMATIN DISRUPTION; LINKER HISTONES; CONDENSATION; H1; MITOSIS; SPINDLE; PROTEIN	In eukaryotes cell division is accompanied by phosphorylation of histone H3 at serine 10. In this work we have studied the kinase activity responsible for this histone H3 modification by using cell-free extracts prepared from Xenopus eggs. We have found that the Xenopus aurora-A kinase pEg2, immunoprecipitated from the extract, is able to phosphorylate specifically histone H3 at serine 10. The enzyme is incorporated into chromatin during in vitro chromosome assembly, and the, kinetics of this incorporation parallels that of histone H3 phosphorylation. Recombinant pEg2 phosphorylates efficiently histone H3 at serine 10 in reconstituted nucleosomes and in sperm nuclei decondensed in heated extracts. These data identify pEg2 as a good candidate for mitotic histone H3 kinase. However, immunodepletion of pEg2 does not interfere with the chromosome assembly properties of the extract nor with the pattern of H3 phosphorylation, suggesting the existence of multiple kinases involved in this H3 modification in Xenopus eggs. This hypothesis is supported by in gel activity assay experiments using extracts from Saccharomyces cerevisiae.	Inst Albert Bonniot, INSERM U309, Lab Biol Mol & Cellulaire Differenciat, F-38706 La Tronche, France; Univ Rennes 1, Fac Med, CNRS UPR41, Grp Cycle Cellulaire, F-35043 Rennes, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); Universite de Rennes	Dimitrov, S (corresponding author), Inst Albert Bonniot, INSERM U309, Lab Biol Mol & Cellulaire Differenciat, Domaine Merci, F-38706 La Tronche, France.		Angelov, Dimitar/K-2004-2017; dimitrov, stefan/M-7697-2013	Angelov, Dimitar/0000-0002-5511-6647; dimitrov, stefan/0000-0002-1326-3630				Adams RR, 2000, CURR BIOL, V10, P1075, DOI 10.1016/S0960-9822(00)00673-4; Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; ALLIS CD, 1981, BIOCHEMISTRY-US, V20, P3828, DOI 10.1021/bi00516a025; Barra JL, 2000, MOL CELL BIOL, V20, P61, DOI 10.1128/MCB.20.1.61-69.2000; Berger SL, 1999, CURR OPIN CELL BIOL, V11, P336, DOI 10.1016/S0955-0674(99)80046-5; BRADBURY EM, 1973, EUR J BIOCHEM, V33, P131, DOI 10.1111/j.1432-1033.1973.tb02664.x; BRADBURY EM, 1992, BIOESSAYS, V14, P9; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; CHAN CSM, 1993, GENETICS, V135, P677; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; DASSO M, 1994, P NATL ACAD SCI USA, V91, P12477, DOI 10.1073/pnas.91.26.12477; de la Barre AE, 1999, METH MOL B, V119, P219; de la Barre AE, 2000, EMBO J, V19, P379, DOI 10.1093/emboj/19.3.379; De Souza CPC, 2000, CELL, V102, P293, DOI 10.1016/S0092-8674(00)00035-0; DIMITROV S, 1994, J CELL BIOL, V126, P591, DOI 10.1083/jcb.126.3.591; Dimitrov S, 1996, EMBO J, V15, P5897, DOI 10.1002/j.1460-2075.1996.tb00976.x; EARNSHAW WC, 1991, CHROMOSOMA, V100, P139, DOI 10.1007/BF00337241; Giet R, 1999, J CELL SCI, V112, P3591; Goto H, 1999, J BIOL CHEM, V274, P25543, DOI 10.1074/jbc.274.36.25543; GUO XW, 1995, EMBO J, V14, P976, DOI 10.1002/j.1460-2075.1995.tb07078.x; GURLEY LR, 1978, EUR J BIOCHEM, V84, P1, DOI 10.1111/j.1432-1033.1978.tb12135.x; Hans F, 2001, ONCOGENE, V20, P3021, DOI 10.1038/sj.onc.1204326; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Hirano T, 2000, ANNU REV BIOCHEM, V69, P115, DOI 10.1146/annurev.biochem.69.1.115; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; Hsu JY, 2000, CELL, V102, P279, DOI 10.1016/S0092-8674(00)00034-9; HUNTER T, 1997, TRENDS BIOCHEM SCI, V22, P11; Kaszas E, 2000, J CELL SCI, V113, P3217; Kimura K, 1998, SCIENCE, V282, P487, DOI 10.1126/science.282.5388.487; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Luger K, 1997, J MOL BIOL, V272, P301, DOI 10.1006/jmbi.1997.1235; Mendez R, 2000, NATURE, V404, P302, DOI 10.1038/35005126; MIRZABEKOV AD, 1990, J MOL BIOL, V211, P479, DOI 10.1016/0022-2836(90)90366-T; Mutskov V, 1998, MOL CELL BIOL, V18, P6293, DOI 10.1128/MCB.18.11.6293; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; OHSUMI K, 1993, SCIENCE, V262, P2033, DOI 10.1126/science.8266099; PERRY M, 1982, J BIOL CHEM, V257, P7336; PHILPOTT A, 1991, CELL, V65, P569, DOI 10.1016/0092-8674(91)90089-H; Ramon A, 2000, MOL MICROBIOL, V35, P223, DOI 10.1046/j.1365-2958.2000.01702.x; Rhee K, 1997, DEVELOPMENT, V124, P2167; Roghi C, 1998, J CELL SCI, V111, P557; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; SHEN XT, 1995, CELL, V82, P47, DOI 10.1016/0092-8674(95)90051-9; SHIBATA K, 1990, EUR J BIOCHEM, V192, P87, DOI 10.1111/j.1432-1033.1990.tb19199.x; Speliotes EK, 2000, MOL CELL, V6, P211, DOI 10.1016/S1097-2765(00)00023-X; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Thomson S, 1999, SEMIN CELL DEV BIOL, V10, P205, DOI 10.1006/scdb.1999.0302; Van Hooser A, 1998, J CELL SCI, V111, P3497; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Wolffe AP, 1999, NUCLEIC ACIDS RES, V27, P711, DOI 10.1093/nar/27.3.711	52	52	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30002	30010		10.1074/jbc.M102701200	http://dx.doi.org/10.1074/jbc.M102701200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11402032	hybrid			2022-12-25	WOS:000170558000053
J	Weisiger, RA; Ostrow, JD; Koehler, RK; Webster, CC; Mukerjee, P; Pascolo, L; Tiribelli, C				Weisiger, RA; Ostrow, JD; Koehler, RK; Webster, CC; Mukerjee, P; Pascolo, L; Tiribelli, C			Affinity of human serum albumin for bilirubin varies with albumin concentration and buffer composition - Results of a novel ultrafiltration method	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID-BINDING; UNCONJUGATED BILIRUBIN; ALPHA-FETOPROTEIN; PROTEIN; LIVER; CONFORMATION; CONSTANTS; PARTITION; TRANSPORT; PALMITATE	Albumin binding is a crucial determinant of bilirubin clearance in health and bilirubin toxicity in certain disease states. However, prior attempts to measure the affinity of albumin for bilirubin have yielded highly variable results, reflecting both differing conditions and the confounding influence of impurities. We therefore have devised a method based on serial ultrafiltration that successively removes impurities in [C-14]bilirubin until a stable binding affinity is achieved, and then we used it to assess the effect of albumin concentration and buffer composition on binding. The apparent binding affinity of human serum albumin for [C-14]bilirubin was strongly dependent on assay conditions, falling from (5.09 +/- 0.24) X 10(7) liters/mol at lower albumin concentrations (15 muM) to (0.54 +/- 0.05) X 10(7) liters/mol at higher albumin concentrations (300 mum). To determine whether radioactive impurities were responsible for this change, we estimated impurities in the stock bilirubin using a novel modeling approach and found them to be 0.11-0.13%. Formation of new impurities during the study and their affinity for albumin were also estimated. After correction for impurities, the binding affinity remained heavily dependent on the albumin concentration (range (5.37 +/- 0.26) X 10(7) liters/mol to (0.65 +/- 0.03) X 10(7) liters/ mol). Affinities decreased by about half in the presence of chloride (50 mm). Thus, the affinity of human albumin for bilirubin is not constant, but varies with both albumin concentration and buffer composition. Binding may be considerably less avid at physiological albumin concentrations than previously believed.	Univ Calif San Francisco, Med Ctr, Ctr Liver, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Amsterdam, Acad Med Ctr, Dept Gastroenterol & Hepatol, NL-1105 AZ Amsterdam, Netherlands; Vet Affairs Lakeside Med Ctr, Div Gastroenterol & Hepatol, Chicago, IL 60611 USA; Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA; Univ Trieste, Dipartimento Biochim Biofis Chim Macromol, Ctr Studi Fegato, I-34127 Trieste, Italy	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Amsterdam; Academic Medical Center Amsterdam; University of Wisconsin System; University of Wisconsin Madison; University of Trieste	Weisiger, RA (corresponding author), Univ Calif San Francisco, Med Ctr, Ctr Liver, 513 Parnassus Ave,S-357,Box 0538, San Francisco, CA 94143 USA.		Pascolo, Lorella/AAB-5207-2020; mukerjee, pasupati/A-7163-2012; Tiribelli, Claudio/A-4716-2014	Pascolo, Lorella/0000-0003-1044-7263; Tiribelli, Claudio/0000-0001-6596-7595	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032898] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-32898] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHLFORS CE, 1986, J PEDIATR-US, V108, P295, DOI 10.1016/S0022-3476(86)81008-3; Ahlfors CE, 2000, ANAL BIOCHEM, V279, P130, DOI 10.1006/abio.2000.4485; AHLFORS GE, 1981, CLIN CHEM, V27, P692; BLANCKAERT N, 1986, BILE PIGMENTS JAUNDI, P31; BOOBIS SW, 1979, BIOCHEM PHARMACOL, V28, P751, DOI 10.1016/0006-2952(79)90354-X; BOWMER CJ, 1978, BIOCHEM PHARMACOL, V27, P937, DOI 10.1016/0006-2952(78)90421-5; BRODERSEN R, 1979, Critical Reviews in Clinical Laboratory Sciences, V11, P305; Brodersen R, 1982, BILIRUBIN, P75; BRUNKHORST WK, 1965, ARCH BIOCHEM BIOPHYS, V111, P54, DOI 10.1016/0003-9861(65)90321-8; BURCZYNSKI FJ, 1993, AM J PHYSIOL, V265, pG555, DOI 10.1152/ajpgi.1993.265.3.G555; CAMERON IL, 1990, BIOCHEM CELL BIOL, V68, P894, DOI 10.1139/o90-132; CLEGG LS, 1984, J PHARM PHARMACOL, V36, P776, DOI 10.1111/j.2042-7158.1984.tb04873.x; COSTANTINO HR, 1995, BIO-TECHNOL, V13, P493, DOI 10.1038/nbt0595-493; DWYER JD, 1993, BIOPHYS J, V65, P1810, DOI 10.1016/S0006-3495(93)81235-9; EBBESEN F, 1983, ACTA PAEDIATR SCAND, V72, P665, DOI 10.1111/j.1651-2227.1983.tb09791.x; FENERTY CA, 1989, J NEUROCHEM, V53, P416, DOI 10.1111/j.1471-4159.1989.tb07350.x; Gourley G R, 1997, Adv Pediatr, V44, P173; JORI G, 1988, INT J PEPT PROT RES, V31, P17; KNOBLOCH E, 1991, J CHROMATOGR-BIOMED, V566, P89, DOI 10.1016/0378-4347(91)80113-Q; KOREN R, 1982, BIOCHIM BIOPHYS ACTA, V703, P42, DOI 10.1016/0167-4838(82)90008-5; KRAGHHANSEN U, 1990, DAN MED BULL, V37, P57; KULLAKUBLICK GA, 1995, GASTROENTEROLOGY, V109, P1274, DOI 10.1016/0016-5085(95)90588-X; LAMOLA AA, 1983, EUR J BIOCHEM, V132, P165, DOI 10.1111/j.1432-1033.1983.tb07342.x; Luxon BA, 2000, BBA-MOL CELL BIOL L, V1487, P309, DOI 10.1016/S1388-1981(00)00104-9; MCDONAGH AF, 1972, BIOCHEM J, V129, P797, DOI 10.1042/bj1290797; MCDONAGH AF, 1980, SCIENCE, V208, P145, DOI 10.1126/science.7361112; MICHAELSSON M, 1961, SCAND J CLIN INVEST, V13, P1; MIZEJEWSKI GJ, 1982, CLIN CHEM, V28, P1207; MUELLER UW, 1981, BIOCHEM PHARMACOL, V30, P727, DOI 10.1016/0006-2952(81)90158-1; Nozaki S, 1999, MOL CELL BIOCHEM, V192, P129, DOI 10.1023/A:1006816702425; OSTROW JD, 1994, J LIPID RES, V35, P1715; OSTROW JD, 1961, J CLIN INVEST, V40, P1442, DOI 10.1172/JCI104375; OSTROW JD, 1970, GASTROENTEROLOGY, V58, P15; OSTROW JD, 1972, SEMIN HEMATOL, V9, P113; OSTROW JD, 1963, J CLIN INVEST, V42, P1286, DOI 10.1172/JCI104813; Pascolo L, 1996, BIOCHEM J, V316, P999, DOI 10.1042/bj3160999; PEDERSEN JB, 1990, BIOCHEM PHARMACOL, V39, P1138, DOI 10.1016/0006-2952(90)90296-W; PETERS T, 1985, ADV PROTEIN CHEM, V37, P161, DOI 10.1016/S0065-3233(08)60065-0; POND SM, 1994, AM J PHYSIOL-GASTR L, V267, pG656, DOI 10.1152/ajpgi.1994.267.4.G656; RAY A, 1966, BIOCHEMISTRY-US, V5, P2606, DOI 10.1021/bi00872a019; REED RG, 1977, J BIOL CHEM, V252, P7483; SCATCHARD G, 1946, J AM CHEM SOC, V68, P2610, DOI 10.1021/ja01216a055; SHEN D, 1974, J PHARM SCI-US, V63, P1698, DOI 10.1002/jps.2600631106; SIMPSON RB, 1974, J LIPID RES, V15, P415; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPECTOR AA, 1971, BIOCHEMISTRY-US, V10, P3229; THOMPSON JM, 1973, BRIT J PHARMACOL, V47, P133, DOI 10.1111/j.1476-5381.1973.tb08166.x; TIRIBELLI C, 1990, BIOCHIM BIOPHYS ACTA, V1031, P261, DOI 10.1016/0304-4157(90)90012-2; VERSEE V, 1979, BIOCHEM J, V179, P705, DOI 10.1042/bj1790705; Weisiger Richard A., 1993, P171; Wennberg RP, 2000, CELL MOL NEUROBIOL, V20, P97, DOI 10.1023/A:1006900111744; WILTING J, 1980, J BIOL CHEM, V255, P3032; WILTING J, 1980, BIOCHIM BIOPHYS ACTA, V626, P291, DOI 10.1016/0005-2795(80)90123-3; WISSE E, 1985, HEPATOLOGY, V5, P683, DOI 10.1002/hep.1840050427; ZINI R, 1981, J CHROMATOGR, V216, P191, DOI 10.1016/S0021-9673(00)82347-X	55	95	103	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29953	29960		10.1074/jbc.M104628200	http://dx.doi.org/10.1074/jbc.M104628200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11397817	hybrid			2022-12-25	WOS:000170558000047
J	Brown, CL; Coffey, RJ; Dempsey, PJ				Brown, CL; Coffey, RJ; Dempsey, PJ			The proamphiregulin cytoplasmic domain is required for basolateral sorting, but is not essential for constitutive or stimulus-induced processing in polarized Madin-Darby canine kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; FACTOR EGF RECEPTOR; TGF-ALPHA PRECURSOR; HEPARIN-BINDING; EPITHELIAL-CELLS; PHORBOL-ESTER; PROTGF-ALPHA; METALLOPROTEINASE CLEAVAGE; AUTOCRINE REGULATION; ECTODOMAIN CLEAVAGE	In this study, the role of the amphiregulin precursor (pro-AR) cytoplasmic domain in the basolateral. sorting and cell-surface processing of pro-AR in polarized epithelial cells has been investigated using Madin-Darby canine kidney cells stably expressing various human pro-AR forms. Our results demonstrate that newly synthesized wild-type pro-AR (50 kDa) is delivered directly to the basolateral membrane domain with > 95% efficiency, where it is sequentially cleaved within the ectodomain to release several soluble amphiregulin (AR) forms. Analyses of a pro-AR cytoplasmic domain truncation mutant (ARTL27) and two pro-AR secretory mutants (ARsec184 and ARsec190) indicated that the pro-AR cytoplasmic domain is not required for efficient delivery to the plasma membrane, but does contain essential basolateral sorting information. We show that the pro-AR cytoplasmic domain truncation mutant (ARTL27) is not sorted in polarized Madin-Darby canine kidney cells, with similar to 65% of the newly synthesized protein delivered to the apical cell surface. Under base-line conditions, ARTL27 was preferentially cleaved from the basolateral surface with 4-fold greater efficiency compared with cleavage from the apical membrane domain. However, ARTL27 ectodomain cleavage could be stimulated equivalently from either membrane domain by a variety of different stimuli. The metalloprotease inhibitor BB-94 could inhibit both base-line and stimulus-induced ectodomain cleavage of wild-type pro-AR and ARTL27. These results indicate that the pro-AR cytoplasmic domain is required for basolateral sorting, but is not essential for ectodomain processing. Preferential constitutive cleavage of ARTL27 from the basolateral cell surface also suggests that the metalloprotease activity involved in base-line and stimulus-induced ARTL27 ectodomain cleavage may be regulated differently in the apical and basolateral membrane domains of polarized epithelial cells.	Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Cell Biol, Nashville, TN 37232 USA; Vet Affairs Med Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Coffey, RJ (corresponding author), Vanderbilt Univ, Ctr Med, Dept Med, CC-2201 Med Ctr N, Nashville, TN 37232 USA.	coffeyrj@ctrvax.vanderbilt.edu			NCI NIH HHS [CA46413] Funding Source: Medline; NHLBI NIH HHS [5 T32 HL-07751] Funding Source: Medline; NIAMS NIH HHS [5P30 AR41943-05] Funding Source: Medline; NIDDK NIH HHS [DK20593] Funding Source: Medline; PHS HHS [CS68485] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046413] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007751] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR041943] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aroeti B, 1998, BBA-REV BIOMEMBRANES, V1376, P57, DOI 10.1016/S0304-4157(98)00005-7; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Baselga J, 1996, J BIOL CHEM, V271, P3279, DOI 10.1074/jbc.271.6.3279; BLASBAND AJ, 1990, ONCOGENE, V5, P1213; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; BOSENBERG MW, 1993, J CELL BIOL, V122, P95, DOI 10.1083/jcb.122.1.95; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; Briley GP, 1997, MOL BIOL CELL, V8, P1619, DOI 10.1091/mbc.8.8.1619; Brown CL, 1998, J BIOL CHEM, V273, P17258, DOI 10.1074/jbc.273.27.17258; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; COOK PW, 1991, MOL CELL BIOL, V11, P2547, DOI 10.1128/MCB.11.5.2547; Cook PW, 1999, J INVEST DERMATOL, V113, P860, DOI 10.1046/j.1523-1747.1999.00753.x; Cook PW, 1997, J CLIN INVEST, V100, P2286, DOI 10.1172/JCI119766; Damstrup L, 1999, BRIT J CANCER, V80, P1012, DOI 10.1038/sj.bjc.6690456; DAVIES B, 1993, CANCER RES, V53, P2087; DEMPSEY PJ, 1994, J BIOL CHEM, V269, P16878; Dempsey PJ, 1997, J CELL BIOL, V138, P747, DOI 10.1083/jcb.138.4.747; Dethlefsen SM, 1998, J CELL BIOCHEM, V69, P143, DOI 10.1002/(SICI)1097-4644(19980501)69:2<143::AID-JCB5>3.0.CO;2-S; Diaz-Rodriguez E, 2000, BIOCHEM J, V346, P359, DOI 10.1042/0264-6021:3460359; Dong JY, 2000, J BIOL CHEM, V275, P557, DOI 10.1074/jbc.275.1.557; Dong JY, 1999, P NATL ACAD SCI USA, V96, P6235, DOI 10.1073/pnas.96.11.6235; Eldering JA, 1997, EUR J BIOCHEM, V247, P920, DOI 10.1111/j.1432-1033.1997.00920.x; Fan HZ, 1999, EMBO J, V18, P6962, DOI 10.1093/emboj/18.24.6962; Fernandez-Larrea J, 1999, MOL CELL, V3, P423, DOI 10.1016/S1097-2765(00)80470-0; Folsch H, 1999, CELL, V99, P189, DOI 10.1016/S0092-8674(00)81650-5; Gechtman Z, 1999, J BIOL CHEM, V274, P28828, DOI 10.1074/jbc.274.40.28828; GOISHI K, 1995, MOL BIOL CELL, V6, P967, DOI 10.1091/mbc.6.8.967; Han B, 1999, J BIOL CHEM, V274, P26407, DOI 10.1074/jbc.274.37.26407; HIGASHIYAMA S, 1995, J CELL BIOL, V128, P929, DOI 10.1083/jcb.128.5.929; Hobert ME, 1997, J BIOL CHEM, V272, P32901, DOI 10.1074/jbc.272.52.32901; Inui S, 1997, J CELL PHYSIOL, V171, P291, DOI 10.1002/(SICI)1097-4652(199706)171:3<291::AID-JCP7>3.0.CO;2-J; Iwamoto R, 1999, J BIOL CHEM, V274, P25906, DOI 10.1074/jbc.274.36.25906; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Kahn J, 1998, CELL, V92, P809, DOI 10.1016/S0092-8674(00)81408-7; Kalmes A, 2000, CIRC RES, V87, P92, DOI 10.1161/01.RES.87.2.92; Kuo A, 2000, EMBO J, V19, P6427, DOI 10.1093/emboj/19.23.6427; LANZREIN M, 1995, BIOCHEM J, V310, P285, DOI 10.1042/bj3100285; LEE DC, 1995, PHARMACOL REV, V47, P51; Liu XF, 1998, J BIOL CHEM, V273, P34335, DOI 10.1074/jbc.273.51.34335; Lottaz D, 1999, EUR J BIOCHEM, V259, P496, DOI 10.1046/j.1432-1327.1999.00071.x; MartinezLacaci I, 1996, J CELL PHYSIOL, V169, P497, DOI 10.1002/(SICI)1097-4652(199612)169:3<497::AID-JCP10>3.0.CO;2-3; Merlos-Suarez A, 1999, BIOCHEM SOC T, V27, P243, DOI 10.1042/bst0270243; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; Mostov KE, 2000, CURR OPIN CELL BIOL, V12, P483, DOI 10.1016/S0955-0674(00)00120-4; PANDIELLA A, 1991, J BIOL CHEM, V266, P5769; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; PIEPKORN M, 1995, J INVEST DERMATOL, V105, P802, DOI 10.1111/1523-1747.ep12326567; Piepkorn M, 1998, J INVEST DERMATOL, V111, P715, DOI 10.1046/j.1523-1747.1998.00390.x; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; RAAB G, 1994, BIOCHEM BIOPH RES CO, V204, P592, DOI 10.1006/bbrc.1994.2500; Shi W, 2000, J CELL BIOL, V148, P591, DOI 10.1083/jcb.148.3.591; SHUM L, 1994, J CELL BIOL, V125, P903, DOI 10.1083/jcb.125.4.903; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; Suzuki M, 1997, J BIOL CHEM, V272, P31730, DOI 10.1074/jbc.272.50.31730; THORNE BA, 1994, MOL CELL BIOL, V14, P1635, DOI 10.1128/MCB.14.3.1635; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; Tokumaru S, 2000, J CELL BIOL, V151, P209, DOI 10.1083/jcb.151.2.209; Urena JM, 1999, J CELL SCI, V112, P773; VASSAR R, 1991, CELL, V64, P365, DOI 10.1016/0092-8674(91)90645-F; Vecchi M, 1998, J BIOL CHEM, V273, P20589, DOI 10.1074/jbc.273.32.20589; Wiley HS, 1998, J CELL BIOL, V143, P1317, DOI 10.1083/jcb.143.5.1317; Wong L, 1999, J BIOL CHEM, V274, P8900, DOI 10.1074/jbc.274.13.8900; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3	65	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29538	29549		10.1074/jbc.M102114200	http://dx.doi.org/10.1074/jbc.M102114200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11382759	hybrid			2022-12-25	WOS:000170346000119
J	Chen, PL; Hutter, D; Yang, XL; Gorospe, M; Davis, RJ; Liu, YS				Chen, PL; Hutter, D; Yang, XL; Gorospe, M; Davis, RJ; Liu, YS			Discordance between the binding affinity of mitogen-activated protein kinase subfamily members for MAP kinase phosphatase-2 and their ability to activate the phosphatase catalytically	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; DUAL-SPECIFICITY PHOSPHATASES; TYROSINE-PHOSPHATASE; CRYSTAL-STRUCTURE; IN-VIVO; HEAT-SHOCK; C-JUN; STRESS; DOMAIN; EXPRESSION	MKP-2 is a member of the mitogen-activated protein (MAP) kinase phosphatase family which has been suggested to play an important role in the feedback control of MAP kinase-mediated gene expression. Although MKP-2 preferentially inactivates extracellular signal-regulated kinase (ERK) and c-Jun NH2-terminal kinase (JNK) MAP kinase subfamilies, the mechanisms underlying its own regulation remain unclear. In this report, we have examined the MKP-2 interaction with and catalytic activation by distinct MAP kinase subfamilies. We found that the catalytic activity of MKP-2 was enhanced dramatically by ERK and JNK but was affected only minimally by p38. By contrast, p38 and ERK bound MKP-2 with comparably strong affinities, whereas JNK and MKP-2 interacted very weakly. Through site-directed mutagenesis, we defined the ERK/p38-binding site as a cluster of arginine residues in the NH2-terminal domain of MKP-2. Mutation of the basic motif abrogated its interaction with both ERK and p38 and severely compromised the catalytic activation of MKP-2 by these kinases. Unexpectedly, such mutations had little effect on JNK-triggered catalytic activation. Both in vitro and in vivo, wild type MKP-2 effectively inactivated ERK2 whereas MKP-2 mutants incapable of binding to ERK/p38 did not. Finally, in addition to its role as a docking site for ERK and p38, the MKP-2 basic motif plays a role in regulating its nuclear localization. Our studies provided a mechanistic explanation for the substrate preference of MKP-2 and suggest that catalytic activation of MKP-2 upon binding to its substrates is crucial for its function.	NIA, Mol & Cellular Biol Lab, NIH, Baltimore, MD 21224 USA; Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Program Mol Med,Dept BIochem & Mol Biol, Worcester, MA 01605 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester	Liu, YS (corresponding author), NIA, Mol & Cellular Biol Lab, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.		Liu, Yusen/E-3527-2011	Liu, Yusen/0000-0002-0994-0109	NATIONAL INSTITUTE ON AGING [Z01AG000511, Z01AG000510, ZIAAG000511] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALESSI DR, 1993, ONCOGENE, V8, P2015; ALESSI DR, 1995, METHOD ENZYMOL, V255, P279; Ben-Levy R, 1998, CURR BIOL, V8, P1049, DOI 10.1016/S0960-9822(98)70442-7; Butch ER, 1996, J BIOL CHEM, V271, P4230; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; Chen W, 1998, MOL CELL BIOL, V18, P5178, DOI 10.1128/MCB.18.9.5178; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dowd S, 1998, J CELL SCI, V111, P3389; Eckstein JW, 1996, PROTEIN SCI, V5, P5; Fauman EB, 1998, CELL, V93, P617, DOI 10.1016/S0092-8674(00)81190-3; Fjeld CC, 2000, J BIOL CHEM, V275, P6749, DOI 10.1074/jbc.275.10.6749; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hirsch DD, 1997, J BIOL CHEM, V272, P4568, DOI 10.1074/jbc.272.7.4568; Hutter D, 2000, BIOCHEM J, V352, P155, DOI 10.1042/0264-6021:3520155; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; Johnson TR, 2000, J BIOL CHEM, V275, P31755, DOI 10.1074/jbc.M004182200; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; Liu YS, 1996, FREE RADICAL BIO MED, V21, P771, DOI 10.1016/0891-5849(96)00176-1; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; Nichols A, 2000, J BIOL CHEM, V275, P24613, DOI 10.1074/jbc.M001515200; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Puri PL, 2000, GENE DEV, V14, P574; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; RON D, 1992, BIOTECHNIQUES, V13, P866; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Saxena M, 1999, NAT CELL BIOL, V1, P305, DOI 10.1038/13024; Slack DN, 2001, J BIOL CHEM, V276, P16491, DOI 10.1074/jbc.M010966200; Stewart AE, 1999, NAT STRUCT BIOL, V6, P174; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Tanoue T, 1999, J BIOL CHEM, V274, P19949, DOI 10.1074/jbc.274.28.19949; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; WALKER J, 1993, MOL BIOCHEM PARASIT, V61, P255, DOI 10.1016/0166-6851(93)90071-5; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yuvaniyama J, 1996, SCIENCE, V272, P1328, DOI 10.1126/science.272.5266.1328; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0	53	91	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29440	29449		10.1074/jbc.M103463200	http://dx.doi.org/10.1074/jbc.M103463200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11387337	hybrid			2022-12-25	WOS:000170346000106
J	Conkright, MD; Wani, MA; Lingrel, JB				Conkright, MD; Wani, MA; Lingrel, JB			Lung Kruppel-like factor contains an autoinhibitory domain that regulates its transcriptional activation by binding WWP1, an E3 ubiquitin ligase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEIN; NF-KAPPA-B; PROTEASOME PATHWAY; IN-VIVO; C-FOS; IDENTIFICATION; DEGRADATION; SYSTEM; CELLS; CLONING	Lung Kruppel-like factor (LKLF/Kruppel-like factor 2), a member of the Kruppel-like factor family of transcription factors, is expressed predominately in the lungs, with low levels of expression in other organs such as heart, spleen, skeletal muscle, and testis. LKLF is essential during pulmonary development and single-positive T-cell development and is indispensable during mouse embryogenesis. In this study, we performed a series of experiments to define the activation domain of LKLF as a means to further advance the understanding of the molecular mechanisms underlying transcriptional regulation by this transcription factor. Using deletion analysis, it is shown that LKLF contains a transcriptional activation domain as well as a strong autoinhibitory subdomain. The inhibitory subdomain is able to independently suppress transcriptional activation of other strong activators such as viral protein 16, VP16. This occurs either when the inhibitory domain is fused directly to VP16 or when the inhibitory domain is independently bound to DNA by GAL4 DNA-binding domain independent of the VP16 activator. Overexpression of the LKLF autoinhibitory domain alone potentiates transactivation by wild type LKLF, suggesting that the inhibitory domain binds a cofactor that prevents LKLF from transactivating. A yeast-two hybrid screen identified WWP1, an E3 ubiquitin ligase that binds specifically to the LKLF inhibitory domain but not to other transcription factors. In mammalian cells, WWP1 functions as a cofactor by binding LKLF and suppressing transactivation. These data demonstrate that LKLF contains multiple domains that either potentiate or inhibit the ability of this factor to function as an activator of transcription; moreover, regulation of LKLF transactivation is attenuated by an E3 ubiquitin ligase, WWP1.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Lingrel, JB (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007752, R01HL057281] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 57281, 5-T32 HL07752] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON KP, 1995, MOL CELL BIOL, V15, P5957; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; Chen XY, 1996, EMBO J, V15, P5888, DOI 10.1002/j.1460-2075.1996.tb00975.x; CIECHANOVER A, 1991, PROG CLIN BIOL RES, V366, P37; Conkright MD, 1999, NUCLEIC ACIDS RES, V27, P1263, DOI 10.1093/nar/27.5.1263; Crossley M, 1996, MOL CELL BIOL, V16, P1695; DEGEIMAN TTH, 2000, NUCLEIC ACIDS RES, V28, P1106; Goetz TL, 2000, MOL CELL BIOL, V20, P81, DOI 10.1128/MCB.20.1.81-90.2000; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Huang K, 2000, GENE, V252, P137, DOI 10.1016/S0378-1119(00)00216-X; James P, 1996, GENETICS, V144, P1425; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; Kaiser P, 2000, CELL, V102, P303, DOI 10.1016/S0092-8674(00)00036-2; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kuo CT, 1997, GENE DEV, V11, P2996, DOI 10.1101/gad.11.22.2996; Kuo CT, 1997, SCIENCE, V278, P788; Kuo CT, 1997, SCIENCE, V277, P1986, DOI 10.1126/science.277.5334.1986; Li XY, 1996, GENE DEV, V10, P517, DOI 10.1101/gad.10.5.517; Matsumoto N, 1998, J BIOL CHEM, V273, P28229, DOI 10.1074/jbc.273.43.28229; Nawaz Z, 1999, MOL CELL BIOL, V19, P1182; NIRMALA PB, 1995, BIOCHEM BIOPH RES CO, V213, P24, DOI 10.1006/bbrc.1995.2093; ORIAN A, 1995, J BIOL CHEM, V270, P21707, DOI 10.1074/jbc.270.37.21707; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Pirozzi G, 1997, J BIOL CHEM, V272, P14611, DOI 10.1074/jbc.272.23.14611; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Shields JM, 1997, J BIOL CHEM, V272, P18504, DOI 10.1074/jbc.272.29.18504; STANCOVSKI I, 1995, MOL CELL BIOL, V15, P7106; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; Turner J, 1999, TRENDS BIOCHEM SCI, V24, P236, DOI 10.1016/S0968-0004(99)01406-1; Wani MA, 1998, TRANSGENIC RES, V7, P229, DOI 10.1023/A:1008809809843; Wani MA, 1999, J BIOL CHEM, V274, P21180, DOI 10.1074/jbc.274.30.21180; Wani MA, 1999, GENOMICS, V60, P78, DOI 10.1006/geno.1999.5888; Weissman AM, 1997, IMMUNOL TODAY, V18, P189, DOI 10.1016/S0167-5699(97)84666-X; Yet SF, 1998, J BIOL CHEM, V273, P1026, DOI 10.1074/jbc.273.2.1026; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974	43	55	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29299	29306		10.1074/jbc.M103670200	http://dx.doi.org/10.1074/jbc.M103670200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11375995	hybrid			2022-12-25	WOS:000170346000089
J	Izaguirre, G; Aguirre, L; Hu, YP; Lee, HY; Schlaepfer, DD; Aneskievich, BJ; Haimovich, B				Izaguirre, G; Aguirre, L; Hu, YP; Lee, HY; Schlaepfer, DD; Aneskievich, BJ; Haimovich, B			The cytoskeletal/non-muscle isoform of alpha-actinin is phosphorylated on its actin-binding domain by the focal adhesion kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; MECHANICAL-PROPERTIES; STRESS FIBERS; CROSS-LINKING; ACTIVATED PLATELETS; CELL-MIGRATION; C-SRC; ALPHA-ACTININ-1; IDENTIFICATION; PURIFICATION	alpha -Actinin is tyrosine-phosphorylated in activated human platelets (Izaguirre, G., Aguirre, L., Ji, P., Aneskievich, B., and Haimovich, B. (1999) J. Biol. Chem. 274, 37012-37020). Analysis of platelet RNA by reverse transcription-polymerase chain reaction revealed that a-actinin expressed in platelets is identical to the cytoskeletal/non-muscle isoform. A construct of this isoform containing a His(6) tag at the amino terminus was generated. Robust tyrosine phosphorylation of the recombinant protein was detected in cells treated with the tyrosine phosphatase inhibitor vanadate. The tyrosine phosphorylation site was localized to the amino-terminal domain by proteolytic digestion. A recombinant a-actinin protein containing a Tyr --> Phe mutation at position 12 (Y12F) was no longer phosphorylated when expressed in vanadate-treated cells, indicating that tyrosine 12 is the site of phosphorylation. The wild type recombinant protein was not phosphorylated in cells lacking the focal adhesion kinase (FAR). Re-expression of FAK in these cells restored alpha -actinin phosphorylation. Purified wild type alpha -actinin, but not the Y12F mutant, was phosphorylated in vitro by wild type as well as a Phe-397 mutant of FAK. In contrast, no phosphorylation was detected in the presence of a kinase-dead FAK. Tyrosine phosphorylation reduced the amount of a-actinin that cosedimented with actin filaments. These results establish that alpha -actinin is a direct substrate for FAK and suggest that alpha -actinin mediates FAK-dependent signals that could impact the physical properties of the cytoskeleton.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Surg, New Brunswick, NJ 08903 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, New Brunswick, NJ 08903 USA; Univ Connecticut, Dept Pharmaceut Sci, Storrs, CT 06269 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Connecticut; Scripps Research Institute	Haimovich, B (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Surg, CINJ Rm 2050,195 Little Albany St, New Brunswick, NJ 08903 USA.			Aguirre, Lina/0000-0003-0711-314X	NCI NIH HHS [R29 CA75240] Funding Source: Medline; NHLBI NIH HHS [HL-541044] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA075240] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Banuelos S, 1998, STRUCTURE, V6, P1419, DOI 10.1016/S0969-2126(98)00141-5; Bauer K, 2000, BLOOD, V96, P4236; BEGGS AH, 1992, J BIOL CHEM, V267, P9281; CARPEN O, 1992, J CELL BIOL, V118, P1223, DOI 10.1083/jcb.118.5.1223; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; Christerson LB, 1999, CELL MOTIL CYTOSKEL, V43, P186, DOI 10.1002/(SICI)1097-0169(1999)43:3<186::AID-CM2>3.0.CO;2-1; CRAWFORD AW, 1991, J BIOL CHEM, V266, P5847; DAVISON MD, 1989, INT J BIOL MACROMOL, V11, P81, DOI 10.1016/0141-8130(89)90047-0; DEARRUDA MV, 1990, J CELL BIOL, V111, P1069, DOI 10.1083/jcb.111.3.1069; Egerton M, 1996, BIOCHEM BIOPH RES CO, V224, P666, DOI 10.1006/bbrc.1996.1082; Fukami K, 1996, J BIOL CHEM, V271, P2646, DOI 10.1074/jbc.271.5.2646; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; Goldsmith SC, 1997, NAT STRUCT BIOL, V4, P708, DOI 10.1038/nsb0997-708; Greenwood JA, 2000, J CELL BIOL, V150, P627, DOI 10.1083/jcb.150.3.627; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; Haimovich B, 1996, BLOOD, V87, P152, DOI 10.1182/blood.V87.1.152.bloodjournal871152; Hammell RL, 1996, J BIOL CHEM, V271, P4236; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Harbeck B, 2000, J BIOL CHEM, V275, P30817, DOI 10.1074/jbc.M005066200; Heiska L, 1996, J BIOL CHEM, V271, P26214, DOI 10.1074/jbc.271.42.26214; HEMMINGS L, 1992, J CELL BIOL, V116, P1369, DOI 10.1083/jcb.116.6.1369; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; Ilic D, 1997, J CELL SCI, V110, P401; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; IMAMURA M, 1992, J BIOL CHEM, V267, P25927; Izaguirre G, 1999, J BIOL CHEM, V274, P37012, DOI 10.1074/jbc.274.52.37012; Johnson RP, 2000, J BIOL CHEM, V275, P95, DOI 10.1074/jbc.275.1.95; Keep NH, 1999, J MOL BIOL, V285, P1257, DOI 10.1006/jmbi.1998.2406; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; LANDON F, 1985, EUR J BIOCHEM, V153, P231, DOI 10.1111/j.1432-1033.1985.tb09291.x; LAZARIDES E, 1975, CELL, V6, P289, DOI 10.1016/0092-8674(75)90180-4; Leinweber BD, 1999, BIOCHEM J, V344, P117, DOI 10.1042/0264-6021:3440117; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MATSUDAIRA P, 1991, TRENDS BIOCHEM SCI, V16, P87, DOI 10.1016/0968-0004(91)90039-X; MILLAKE DB, 1989, NUCLEIC ACIDS RES, V17, P6725, DOI 10.1093/nar/17.16.6725; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; Mukai H, 1997, J BIOL CHEM, V272, P4740, DOI 10.1074/jbc.272.8.4740; Nieset JE, 1997, J CELL SCI, V110, P1013; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; Parast MM, 2000, J CELL BIOL, V150, P643, DOI 10.1083/jcb.150.3.643; Pinna LA, 1996, BBA-MOL CELL RES, V1314, P191, DOI 10.1016/S0167-4889(96)00083-3; Puius YA, 1998, CURR OPIN CELL BIOL, V10, P23, DOI 10.1016/S0955-0674(98)80083-5; Ren XD, 2000, J CELL SCI, V113, P3673; ROSENBERG S, 1981, J BIOL CHEM, V256, P2986; Sampath R, 1998, J BIOL CHEM, V273, P33588, DOI 10.1074/jbc.273.50.33588; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SHIBASAKI F, 1994, BIOCHEM J, V302, P551, DOI 10.1042/bj3020551; Sieg DJ, 1999, J CELL SCI, V112, P2677; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; TANIGUCHI T, 1993, J BIOL CHEM, V268, P2277; Vallenius T, 2000, J BIOL CHEM, V275, P11100, DOI 10.1074/jbc.275.15.11100; WACHSSTOCK DH, 1987, BIOCHEM BIOPH RES CO, V146, P554, DOI 10.1016/0006-291X(87)90564-X; WACHSSTOCK DH, 1994, BIOPHYS J, V66, P801, DOI 10.1016/S0006-3495(94)80856-2; WACHSSTOCK DH, 1993, BIOPHYS J, V65, P205, DOI 10.1016/S0006-3495(93)81059-2; WAITES GT, 1992, J BIOL CHEM, V267, P6263; Weyrich AS, 1998, P NATL ACAD SCI USA, V95, P5556, DOI 10.1073/pnas.95.10.5556; WITKE W, 1993, J CELL BIOL, V121, P599, DOI 10.1083/jcb.121.3.599; Xu JY, 1998, J BIOL CHEM, V273, P9570, DOI 10.1074/jbc.273.16.9570; YOUSSOUFIAN H, 1990, AM J HUM GENET, V47, P62	65	116	119	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28676	28685		10.1074/jbc.M101678200	http://dx.doi.org/10.1074/jbc.M101678200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11369769	hybrid			2022-12-25	WOS:000170346000007
J	Miller, GJ; Ball, EH				Miller, GJ; Ball, EH			Conformational change in the vinculin C-terminal depends on a critical histidine residue (His-906)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRAMOLECULAR ASSOCIATION; ACIDIC PHOSPHOLIPIDS; BINDING-SITE; TAIL DOMAIN; ADHERENS JUNCTIONS; FOCAL ADHESIONS; TALIN-BINDING; ACTIN-BINDING; HEAD; PURIFICATION	A phospholipid-controlled interaction between the N-terminal and C-terminal domains of vinculin is thought to be a major mechanism that regulates binding activities of the protein. To probe the mechanisms underlying these interactions we used chemical modification and site-directed mutagenesis directed at histidine residues. Diethylpyrocarbonate (DEPC) modification of the C-terminal, but not the N-terminal, domain greatly decreased affinity of the N-terminal-C-terminal binding, implicating histidine residues in the C-terminal. Mutation of either or both C-terminal histidines (at positions 906 and 1026), however, did not affect N-C binding at neutral pH. The H906A mutation did prevent DEPC effects and also prevented the normal decrease in binding affinity for the N-terminal at lower pH. We found that the wild type C-terminal domain, but not the H906A mutant, underwent a conformational change at pH 6.5, reflected in an altered circular dichroism spectrum and apparent oligomerization. Phospholipid also induced conformational changes in the wild type C-terminal domain but not in the H906A mutant, even though the mutant protein did bind to the phospholipid. Finally, the sensitivity of the N-C interaction to phospholipid was much reduced by the H906A mutation. These results show that H906 plays a key role in the conformational dynamics of the C-terminal domain and thus the regulation of vinculin.	Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada	Western University (University of Western Ontario)	Ball, EH (corresponding author), Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada.	ehball@uwo.ca		Ball, Eric/0000-0003-2542-9156				ALMOG R, 1990, ANAL BIOCHEM, V188, P237, DOI 10.1016/0003-2697(90)90559-R; Bakolitsa C, 1999, CELL, V99, P603, DOI 10.1016/S0092-8674(00)81549-4; BALL EH, 1986, J CELL BIOL, V103, P641, DOI 10.1083/jcb.103.2.641; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Clement-Collin V, 1999, EUR J BIOCHEM, V264, P358, DOI 10.1046/j.1432-1327.1999.00608.x; Critchley DR, 2000, CURR OPIN CELL BIOL, V12, P133, DOI 10.1016/S0955-0674(99)00067-8; GEIGER B, 1985, J CELL BIOL, V101, P1523, DOI 10.1083/jcb.101.4.1523; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; Goldmann WH, 1996, J MUSCLE RES CELL M, V17, P1, DOI 10.1007/BF00140319; GROESCH ME, 1990, CELL MOTIL CYTOSKEL, V15, P41, DOI 10.1002/cm.970150107; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Huttelmaier S, 1998, CURR BIOL, V8, P479, DOI 10.1016/S0960-9822(98)70199-X; Jockusch BM, 1996, TRENDS CELL BIOL, V6, P311, DOI 10.1016/0962-8924(96)10022-2; Johnson RP, 1998, BIOCHEMISTRY-US, V37, P10211, DOI 10.1021/bi9727242; Johnson RP, 2000, J BIOL CHEM, V275, P95, DOI 10.1074/jbc.275.1.95; JOHNSON RP, 1995, NATURE, V373, P261, DOI 10.1038/373261a0; JOHNSON RP, 1995, BIOCHEM BIOPH RES CO, V210, P159, DOI 10.1006/bbrc.1995.1641; JOHNSON RP, 1994, J BIOL CHEM, V269, P12611; JUDD RC, 1990, METHOD ENZYMOL, V182, P613; KROEMKER M, 1994, FEBS LETT, V355, P259, DOI 10.1016/0014-5793(94)01216-4; Miles E W, 1977, Methods Enzymol, V47, P431; Miller GJ, 2001, J BIOL CHEM, V276, P11729, DOI 10.1074/jbc.M008646200; OTTO JJ, 1990, CELL MOTIL CYTOSKEL, V16, P1, DOI 10.1002/cm.970160102; Rai SS, 1998, J BIOL CHEM, V273, P31131, DOI 10.1074/jbc.273.47.31131; Rudiger M, 1998, BIOESSAYS, V20, P733; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHLESSINGER J, 1983, CELL MOTIL CYTOSKEL, V3, P399, DOI 10.1002/cm.970030508; Steinmetz MO, 1998, EMBO J, V17, P1883, DOI 10.1093/emboj/17.7.1883; TEMPEL M, 1995, BIOPHYS J, V69, P228, DOI 10.1016/S0006-3495(95)79894-0; VANDERGOOT FG, 1991, NATURE, V354, P408, DOI 10.1038/354408a0; Weekes J, 1996, BIOCHEM J, V314, P827, DOI 10.1042/bj3140827; Xu WM, 1998, DEVELOPMENT, V125, P327	35	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28829	28834		10.1074/jbc.M102561200	http://dx.doi.org/10.1074/jbc.M102561200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11382765	hybrid			2022-12-25	WOS:000170346000027
J	Mitchell, DA; Fadden, AJ; Drickamer, K				Mitchell, DA; Fadden, AJ; Drickamer, K			A novel mechanism of carbohydrate recognition by the C-type lectins DC-SIGN and DC-SIGNR - Subunit organization and binding to multivalent ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; OLIGOSACCHARIDE; EXPRESSION; RECEPTOR; DOMAINS	DC-SIGN and DC-SIGNR are cell-surface receptors that mediate cell-cell interactions within the immune system by binding to intercellular adhesion molecule-3. The receptor polypeptides share 77% amino acid sequence identity and are type 11 transmembrane proteins. The extracellular domain of each comprises seven 23-residue tandem repeats and a C-terminal C-type carbohydrate-recognition domain (CRD). Cross-linking, equilibrium ultracentrifugation, and circular dichroism studies of soluble recombinant fragments of DC-SIGN and DC-SIGNR have been used to show that the extracellular domain of each receptor is a tetramer stabilized by an a-helical stalk. Both DC-SIGN and DC-SIGNR bind ligands bearing mannose and related sugars through the CRDs. The CRDs of DC-SIGN and DC-SIGNR bind Man(9)GIcNAc(2) oligosaccharide 130- and 17-fold more tightly than mannose, and affinity for a glycopeptide bearing two such oligosaccharides is increased by a further factor of 5- to 25-fold. These results indicate that the CRDs contain extended or secondary oligosaccharide binding sites that accommodate mammalian-type glycan structures. When the CRDs are clustered in the tetrameric extracellular domain, their arrangement provides a means of amplifying specificity for multiple glycans on host molecules targeted by DC-SIGN and DC-SIGNR, Binding to clustered oligosaccharides may also explain the interaction of these receptors with the gp120 envelope protein of human immunodeficiency virus-1, which contributes to virus infection.	Univ Oxford, Dept Biochem, Inst Glycobiol, Oxford OX1 3QU, England	University of Oxford	Drickamer, K (corresponding author), Univ Oxford, Dept Biochem, Inst Glycobiol, S Parks Rd, Oxford OX1 3QU, England.	kd@glycob.ox.ac.uk	Mitchell, Daniel A/A-6580-2009	Mitchell, Daniel A/0000-0003-0936-6212				ASHFORD D, 1987, EUR J BIOCHEM, V166, P311, DOI 10.1111/j.1432-1033.1987.tb13516.x; Bashirova AA, 2001, J EXP MED, V193, P671, DOI 10.1084/jem.193.6.671; CHILDS RA, 1990, J BIOL CHEM, V265, P20770; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; CURTIS BM, 1992, P NATL ACAD SCI USA, V89, P8356, DOI 10.1073/pnas.89.17.8356; DRICKAMER K, 1992, NATURE, V360, P183, DOI 10.1038/360183a0; DUNCAN RJS, 1983, ANAL BIOCHEM, V132, P68, DOI 10.1016/0003-2697(83)90426-8; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; Funatsu O, 2001, EUR J BIOCHEM, V268, P1020, DOI 10.1046/j.1432-1327.2001.01960.x; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5; GORDON JA, 1972, FEBS LETT, V24, P193, DOI 10.1016/0014-5793(72)80765-8; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; Hirs C. H. W., 1967, METHOD ENZYMOL, V11, P325; HUDGIN RL, 1974, J BIOL CHEM, V249, P5536; Iobst ST, 1996, J BIOL CHEM, V271, P6686, DOI 10.1074/jbc.271.12.6686; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langone J J, 1980, Methods Enzymol, V70, P221; LEE RT, 1991, J BIOL CHEM, V266, P4810; LEE RT, 1992, ARCH BIOCHEM BIOPHYS, V299, P129, DOI 10.1016/0003-9861(92)90254-T; LEE YC, 1983, J BIOL CHEM, V258, P199; Maniatis T., 1982, MOL CLONING LAB MANU; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; MIZUOCHI T, 1989, J BIOL CHEM, V264, P13834; Ng KKS, 1996, J BIOL CHEM, V271, P663, DOI 10.1074/jbc.271.2.663; Pohlmann S, 2001, P NATL ACAD SCI USA, V98, P2670, DOI 10.1073/pnas.051631398; Segrest J P, 1971, Biochem Biophys Res Commun, V44, P390; Soilleux EJ, 2000, J IMMUNOL, V165, P2937, DOI 10.4049/jimmunol.165.6.2937; STAROS JV, 1982, BIOCHEMISTRY-US, V21, P3950, DOI 10.1021/bi00260a008; Stetefeld J, 2000, NAT STRUCT BIOL, V7, P772, DOI 10.1038/79006; Wallis R, 1997, BIOCHEM J, V325, P391, DOI 10.1042/bj3250391; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x	34	417	449	3	47	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28939	28945		10.1074/jbc.M104565200	http://dx.doi.org/10.1074/jbc.M104565200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11384997	hybrid			2022-12-25	WOS:000170346000042
J	Raghavan, SC; Kirsch, IR; Lieber, MR				Raghavan, SC; Kirsch, IR; Lieber, MR			Analysis of the V(D)J recombination efficiency at lymphoid chromosomal translocation breakpoints	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; T-CELL RECEPTOR; DEVELOPMENTAL-STAGE; LOCUS; GENE; DELTA; METHYLATION; T(10-14); CLUSTER; REGION	Chromosomal translocations and deletions are among the major events that initiate neoplasia. For lymphoid chromosomal translocations, misrecognition by the RAG (recombination activating gene) complex of V(D)J recombination is one contributing factor that has long been proposed. The chromosomal translocations involving LMO2 (t(11;14)(p13;q11)), Ttg-1 (t(11;14)(p15;q11)), and Hox11 (t(10;14)(q24;q11)) are among the clearest examples in which it appears that a D or J segment has synapsed with an adventitious heptamer/nonamer at a gene outside of one of the antigen receptor loci. The interstitial deletion at 1p32 involving SIL (SCL-interrupting locus)/SCL (stem cell leukemia) is a case involving two non-V(D)J sites that have been suggested to be V(D)J recombination mistakes. Here we have used our human extrachromosomal substrate assay to formally test the hypothesis that these regions are V(D)J recombination misrecognition sites and, more importantly, to quantify their efficiency as V(D)J recombination targets within the cell. We find that the LMO2 fragile site functions as a 12-signal at an efficiency that is only 27-fold lower than that of a consensus 12-signal. The Ttg-1 site functions as a 23-signal at an efficiency 530-fold lower than that of a consensus 23-signal. Hox11 failed to undergo recombination as a 12. or 23-signal and was at least 20,000-fold less efficient than consensus signals. SIL has been predicted to function as a 12-signal and SCL as a 23-signal. However, we find that SH, actually functions as a 23-signal. These results provide a formal demonstration that certain chromosomal fragile sites can serve as RAG complex targets, and they determine whether these sites function as 12- versus 23-signals. These results quantify one of the three major factors that determine the frequency of these translocations in T-cell acute lymphocytic leukemia.	Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90089 USA; Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA; Univ So Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90089 USA; Univ So Calif, Keck Sch Med, Dept Biol Sci, Norris Comprehens Canc Ctr, Los Angeles, CA 90089 USA; NCI, Med Branch, NIH, Bethesda, MD 20889 USA; NCI, Dept Genet, NIH, Bethesda, MD 20889 USA	University of Southern California; University of Southern California; University of Southern California; University of Southern California; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lieber, MR (corresponding author), Univ So Calif, Keck Sch Med, Dept Pathol, Rm 5428,1441 Eastlake Ave, Los Angeles, CA 90089 USA.	lieber@usc.edu		Lieber, Michael/0000-0001-8809-0909; Lieber, Michael/0000-0003-3700-6345				AKIRA S, 1987, SCIENCE, V238, P1134, DOI 10.1126/science.3120312; APLAN PD, 1992, BLOOD, V79, P1327; Aplan PD, 1997, EMBO J, V16, P2408, DOI 10.1093/emboj/16.9.2408; APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; BASH RO, 1993, BLOOD, V81, P2110; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; BOEHM T, 1989, EMBO J, V8, P2621, DOI 10.1002/j.1460-2075.1989.tb08402.x; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; BOEHM T, 1988, EMBO J, V7, P2011, DOI 10.1002/j.1460-2075.1988.tb03040.x; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; CHENG JT, 1990, J EXP MED, V171, P489, DOI 10.1084/jem.171.2.489; CROCE CM, 1987, CELL, V49, P155, DOI 10.1016/0092-8674(87)90552-6; ENGLER P, 1993, MOL CELL BIOL, V13, P571, DOI 10.1128/MCB.13.1.571; FORONI L, 1990, GENE CHROMOSOME CANC, V1, P301, DOI 10.1002/gcc.2870010407; Fugmann SD, 2000, ANNU REV IMMUNOL, V18, P495, DOI 10.1146/annurev.immunol.18.1.495; GARCIA IS, 1991, ONCOGENE, V6, P577; GAUSS GH, 1993, MOL CELL BIOL, V13, P3900, DOI 10.1128/MCB.13.7.3900; Gauss GH, 1996, MOL CELL BIOL, V16, P258; GAUSS GH, 1992, NUCLEIC ACIDS RES, V20, P6739, DOI 10.1093/nar/20.24.6739; Gauss GH, 1998, EUR J IMMUNOL, V28, P351, DOI 10.1002/(SICI)1521-4141(199801)28:01<351::AID-IMMU351>3.0.CO;2-#; Gellert M, 1997, ADV IMMUNOL, V64, P39, DOI 10.1016/S0065-2776(08)60886-X; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HECHT F, 1984, SCIENCE, V226, P1445, DOI 10.1126/science.6438800; HESSE JE, 1989, GENE DEV, V3, P1053, DOI 10.1101/gad.3.7.1053; HESSE JE, 1987, CELL, V49, P775, DOI 10.1016/0092-8674(87)90615-5; Hsieh CL, 2000, CURR OPIN GENET DEV, V10, P224, DOI 10.1016/S0959-437X(00)00064-2; HSIEH CL, 1992, EMBO J, V11, P315, DOI 10.1002/j.1460-2075.1992.tb05054.x; HURWITZ R, 1979, INT J CANCER, V23, P174, DOI 10.1002/ijc.2910230206; KAGAN J, 1989, P NATL ACAD SCI USA, V86, P4161, DOI 10.1073/pnas.86.11.4161; KAGAN J, 1987, P NATL ACAD SCI USA, V84, P4543, DOI 10.1073/pnas.84.13.4543; LARSON RC, 1994, ONCOGENE, V9, P3675; Lewis SM, 1997, MOL CELL BIOL, V17, P3125, DOI 10.1128/MCB.17.6.3125; LEWIS SM, 1991, EMBO J, V10, P3631, DOI 10.1002/j.1460-2075.1991.tb04929.x; Lieber MR, 1998, AM J PATHOL, V153, P1323, DOI 10.1016/S0002-9440(10)65716-1; LIEBER MR, 1988, P NATL ACAD SCI USA, V85, P8588, DOI 10.1073/pnas.85.22.8588; LIEBER MR, 1987, GENE DEV, V1, P751, DOI 10.1101/gad.1.8.751; Lieber MR, 1999, GENES CELLS, V4, P77, DOI 10.1046/j.1365-2443.1999.00245.x; Lieber MR., 1993, CAUSES CONSEQUENCES, P239; LU M, 1990, GENE CHROMOSOME CANC, V2, P217, DOI 10.1002/gcc.2870020309; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; RABBITTS TH, 1993, CAUSES CONSEQUENCES, P393; RAMSDEN DA, 1991, P NATL ACAD SCI USA, V88, P10721, DOI 10.1073/pnas.88.23.10721; ROSENFELD C, 1977, NATURE, V267, P841, DOI 10.1038/267841a0; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; WILLIAMS DL, 1984, CELL, V36, P101, DOI 10.1016/0092-8674(84)90078-3; YOFFE G, 1989, BLOOD, V74, P374; Yu KF, 2000, MOL CELL BIOL, V20, P7914, DOI 10.1128/MCB.20.21.7914-7921.2000; ZUTTER M, 1990, P NATL ACAD SCI USA, V87, P3161, DOI 10.1073/pnas.87.8.3161	49	100	103	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29126	29133		10.1074/jbc.M103797200	http://dx.doi.org/10.1074/jbc.M103797200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11390401	hybrid			2022-12-25	WOS:000170346000067
J	Pellicena, P; Miller, WT				Pellicena, P; Miller, WT			Processive phosphorylation of p130Cas by Src depends on SH3-polyproline interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED TYROSINE PHOSPHORYLATION; PROTEIN-PROTEIN INTERACTIONS; V-SRC; DUAL PHOSPHORYLATION; HOMOLOGY DOMAINS; SH3 DOMAINS; KINASE HCK; C-SRC; P130(CAS); SPECIFICITY	Many in vivo substrates of Src family tyrosine kinases possess sequences conforming to Src homology 2 and 3 (SH2 and SH3) domain-binding motifs. One such substrate is p130Cas, a protein that is hyperphosphorylated in v-Src transformed cells. Cas contains a substrate domain consisting of 15 potential tyrosine phosphorylation sites, C- and N-terminal polyproline regions fitting the consensus sequence for SH3 domain ligands, and a YDYV motif that binds the Src SH2 domain when phosphorylated. In an effort to understand the mechanisms of processive phosphorylation, we have explored the regions of Cas necessary for interaction with Src using the yeast two-hybrid system. Mutations in the SH2 domain-binding region of Cas or the Src SH2 domain have little effect in Cas-Src complex formation or phosphorylation. However, disruption of the C-terminal polyproline region of Cas completely abolishes interaction between the two proteins and results in impaired phosphorylation of Cas. Kinetic analyses using purified proteins indicated that multisite phosphorylation of Cas by Src follows a processive rather than a distributive mechanism. Furthermore, the kinetic studies show that there are two properties of the polyproline region of Cas that are important in enhancing substrate phosphorylation. First, the C-terminal polyproline serves to activate Src kinases through the process of SH3 domain displacement. Second, this region aids in anchoring the kinase to Cas to facilitate processive phosphorylation of the substrate domain. The two processes combine to ensure phosphorylation of Cas with high efficiency.	SUNY Stony Brook, Sch Med, Dept Physiol & Biophys, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Miller, WT (corresponding author), SUNY Stony Brook, Sch Med, Dept Physiol & Biophys, Basic Sci Tower,T-6, Stony Brook, NY 11794 USA.	miller@physiology.pnb.sunysb.edu			NATIONAL CANCER INSTITUTE [R01CA058530, R29CA058530] Funding Source: NIH RePORTER; NCI NIH HHS [CA58530] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Astier A, 1997, J BIOL CHEM, V272, P228; BARKER SC, 1995, BIOCHEMISTRY-US, V34, P14843, DOI 10.1021/bi00045a027; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Burack WR, 1997, BIOCHEMISTRY-US, V36, P5929, DOI 10.1021/bi970535d; Burnham MR, 2000, MOL CELL BIOL, V20, P5865, DOI 10.1128/MCB.20.16.5865-5878.2000; Burnham MR, 1996, ONCOGENE, V12, P2467; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DUYSTER J, 1995, P NATL ACAD SCI USA, V92, P1555, DOI 10.1073/pnas.92.5.1555; Ferrell JE, 1997, J BIOL CHEM, V272, P19008, DOI 10.1074/jbc.272.30.19008; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; GARCIA P, 1993, J BIOL CHEM, V268, P25146; Guappone AC, 1997, MOL CELL BIOCHEM, V175, P243, DOI 10.1023/A:1006840104666; Keegan K, 1996, ONCOGENE, V12, P1537; Lewis LA, 1997, J IMMUNOL, V159, P2292; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Nakamoto T, 1997, MOL CELL BIOL, V17, P3884, DOI 10.1128/MCB.17.7.3884; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; Nakamura I, 1998, J BIOL CHEM, V273, P11144, DOI 10.1074/jbc.273.18.11144; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; Ojaniemi M, 1997, J BIOL CHEM, V272, P25993, DOI 10.1074/jbc.272.41.25993; Pellicena P, 1998, J BIOL CHEM, V273, P15325, DOI 10.1074/jbc.273.25.15325; Petruzzelli L, 1996, J BIOL CHEM, V271, P7796, DOI 10.1074/jbc.271.13.7796; Sakai R, 1997, ONCOGENE, V14, P1419, DOI 10.1038/sj.onc.1200954; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Scott MP, 2000, BIOCHEMISTRY-US, V39, P14531, DOI 10.1021/bi001850u; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Tachibana K, 1997, J BIOL CHEM, V272, P29083, DOI 10.1074/jbc.272.46.29083; Tian MX, 1997, MOL BIOL CELL, V8, P1183, DOI 10.1091/mbc.8.7.1183; TILL JH, 1994, J BIOL CHEM, V269, P7423; WU JZ, 1994, BIOCHEMISTRY-US, V33, P14825, DOI 10.1021/bi00253a022; Xu B, 1996, MOL CELL BIOCHEM, V158, P57; Yokoyama N, 1999, FEBS LETT, V456, P403, DOI 10.1016/S0014-5793(99)00992-8; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	38	102	102	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28190	28196		10.1074/jbc.M100055200	http://dx.doi.org/10.1074/jbc.M100055200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11389136	hybrid			2022-12-25	WOS:000170093400061
J	Wei, RR; Richardson, JP				Wei, RR; Richardson, JP			Identification of an RNA-binding site in the ATP binding domain of Escherichia coli Rho by H2O2/Fe-EDTA cleavage protection studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION TERMINATION FACTOR; PROTEIN-RHO; MICROCOCCUS-LUTEUS; CRYSTAL-STRUCTURE; MESSENGER-RNA; SEQUENCES; RECOGNITION; POLYMERASE; COMPLEXES; AFFINITY	Transcription factor Rho is a ring-shaped, homohexameric protein that causes transcript termination through actions on nascent RNAs that are coupled to ATP hydrolysis. The Rho polypeptide has a distinct RNA binding domain of known structure as well as an ATP binding domain for which a structure has been proposed based on homology modeling. Treatment of Rho with H2O2 in the presence of Fe-EDTA caused single-cut cleavage at a number of points that coincide with solvent-exposed loops in both the known and predicted structures, thereby providing support for the validity of the tertiary and quaternary structural models of Rho. The binding of ATP caused one distinct change in the cleavage pattern, a strong protection at a cleavage point in the P-loop of the ATP binding domain. Binding of RNA and single-stranded DNA (poly(dC)) caused strong protection at several accessible parts of the oligosaccharide/oligonucleotide binding (OB) fold in the RNA binding domain. RNA molecules but not DNA molecules also caused a strong, ATP-dependent protection at a cleavage site in the predicted Q-loop of the ATP binding domain. These results suggest that Rho has two distinct binding sites for RNA. Besides the site composed of multiples of the RNA binding domain, to which single-stranded DNA as well as RNA can bind, it has a separate, RNA-specific site on the Q-loop in the ATP binding main. In the proposed quaternary structure of Rho, the Q-loops from the six subunits form the upper entrance to the hole in the ring-shaped hexamer through which the nascent transcript is translocated by actions coupled to ATP hydrolyses.	Indiana Univ, Dept Chem, Bloomington, IN 47405 USA; Indiana Univ, Dept Biol, Bloomington, IN 47405 USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington	Richardson, JP (corresponding author), Indiana Univ, Dept Chem, 800 E Kirkwood Ave, Bloomington, IN 47405 USA.	richardj@indiana.edu			NIGMS NIH HHS [GM 56095] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Allison TJ, 1998, NAT STRUCT BIOL, V5, P352, DOI 10.1038/nsb0598-352; BEAR DG, 1988, J MOL BIOL, V199, P623, DOI 10.1016/0022-2836(88)90306-3; BERNOWITZ M, 1986, METHOD ENZYMOL, V30, P133; Bogden CE, 1999, MOL CELL, V3, P487, DOI 10.1016/S1097-2765(00)80476-1; Briercheck DM, 1996, J BIOMOL NMR, V8, P429; Briercheck DM, 1998, NAT STRUCT BIOL, V5, P393, DOI 10.1038/nsb0598-393; Burgess BR, 2001, J BIOL CHEM, V276, P4182, DOI 10.1074/jbc.M007066200; DOLAN JW, 1990, J BIOL CHEM, V265, P5747; DOMBROSKI AJ, 1988, J BIOL CHEM, V263, P18810; FAUS I, 1989, BIOCHEMISTRY-US, V28, P3510, DOI 10.1021/bi00434a054; GALLUPPI GR, 1980, J MOL BIOL, V138, P513, DOI 10.1016/S0022-2836(80)80016-7; Gan E, 1999, BIOCHEMISTRY-US, V38, P16882, DOI 10.1021/bi991559i; GEISELMANN J, 1993, P NATL ACAD SCI USA, V90, P7754, DOI 10.1073/pnas.90.16.7754; GEISELMANN J, 1992, PROTEIN SCI, V1, P850, DOI 10.1002/pro.5560010703; GOGOL EP, 1991, J MOL BIOL, V221, P1127, DOI 10.1016/0022-2836(91)80116-C; Gulick AM, 1997, BIOCHEMISTRY-US, V36, P11619, DOI 10.1021/bi9712596; HEYDUK E, 1994, BIOCHEMISTRY-US, V33, P9643, DOI 10.1021/bi00198a033; Heyduk T, 1996, P NATL ACAD SCI USA, V93, P10162, DOI 10.1073/pnas.93.19.10162; Loizos N, 1999, J BIOL CHEM, V274, P23378, DOI 10.1074/jbc.274.33.23378; Martinez A, 1996, J MOL BIOL, V257, P909, DOI 10.1006/jmbi.1996.0211; MCSWIGGEN JA, 1988, J MOL BIOL, V199, P609, DOI 10.1016/0022-2836(88)90305-1; MIWA Y, 1995, J MOL BIOL, V254, P815, DOI 10.1006/jmbi.1995.0658; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Nowatzke W, 1996, METHOD ENZYMOL, V274, P353; Nowatzke WL, 1996, J BIOL CHEM, V271, P742, DOI 10.1074/jbc.271.2.742; O IS, 1994, J BIOL CHEM, V269, P5009; ODA T, 1972, J MOL BIOL, V71, P799; OPPERMAN T, 1994, J BACTERIOL, V176, P5033, DOI 10.1128/jb.176.16.5033-5043.1994; PINKHAM JL, 1983, NUCLEIC ACIDS RES, V11, P3531, DOI 10.1093/nar/11.11.3531; PLATIS IE, 1993, BIOCHEMISTRY-US, V32, P12761, DOI 10.1021/bi00210a027; PLATT T, 1994, MOL MICROBIOL, V11, P983, DOI 10.1111/j.1365-2958.1994.tb00376.x; Raghunathan S, 2000, NAT STRUCT BIOL, V7, P648, DOI 10.1038/77943; RANA TM, 1991, P NATL ACAD SCI USA, V88, P10578, DOI 10.1073/pnas.88.23.10578; Richardson J. P., 1996, ESCHERICHIA COLI SAL, P822; RICHARDSON JP, 1982, J BIOL CHEM, V257, P5760; Richardson JP, 1996, J BIOL CHEM, V271, P1251, DOI 10.1074/jbc.271.3.1251; RICHARDSON JP, 1990, BIOCHIM BIOPHYS ACTA, V1048, P127, DOI 10.1016/0167-4781(90)90048-7; Sawaya MR, 1999, CELL, V99, P167, DOI 10.1016/S0092-8674(00)81648-7; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Stitt BL, 1998, J BIOL CHEM, V273, P26477, DOI 10.1074/jbc.273.41.26477; STITT BL, 1988, J BIOL CHEM, V263, P11130; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; WOOD TC, 1999, THESIS U VIRGINIA; YOUNT RG, 1971, BIOCHEMISTRY-US, V10, P2484, DOI 10.1021/bi00789a009; Yu X, 2000, J MOL BIOL, V299, P1279, DOI 10.1006/jmbi.2000.3810	47	49	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28380	28387		10.1074/jbc.M102444200	http://dx.doi.org/10.1074/jbc.M102444200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11369775	hybrid			2022-12-25	WOS:000170093400085
J	Xiao, R; Solovyov, A; Gilbert, HF; Holmgren, A; Lundstrom-Ljung, J				Xiao, R; Solovyov, A; Gilbert, HF; Holmgren, A; Lundstrom-Ljung, J			Combinations of protein-disulfide isomerase domains show that there is little correlation between isomerase activity and wild-type growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOREDOXIN-LIKE DOMAINS; ENDOPLASMIC-RETICULUM; ESCHERICHIA-COLI; BOND FORMATION; SACCHAROMYCES-CEREVISIAE; RIBONUCLEASE-A; SITE CYSTEINE; REDUCTASE; CHAPERONE; CATALYSIS	Protein-disulfide isomerase (PDI) has five domains: a, b, b', a' and c, all of which except c have a thioredoxin fold. A single catalytic domain (a or a') is effective in catalyzing oxidation of a reduced protein but not isomerization of disulfides (Darby, N. J., and Creighton, T. E. (1995) Biochemistry 34, 11725-11735). To examine the structural basis for this oxidase and isomerase activity of PDI, shuffled domain mutants were generated using a method that should be generally applicable to multidomain proteins. Domains a and a' along with constructs ab, aa', aba', ab'a' display low disulfide isomerase activity, but all show significant reactivity with mammalian thioredoxin reductase, suggesting that the structure is not seriously compromised. The only domain order that retains significant isomerase activity has the b' domain coupled to the N terminus of the a' domain. This b'a'c has 38% of the isomerase activity of wild-type PDI, equivalent to the activity of full-length PDI with one of the active sites inactivated by mutation (Walker, K. W., Lyles, M. M., and Gilbert, H. F. (1996) Biochemistry 35, 1972-1980). Individual a and a' domains, despite their very low isomerase activities in vitro, support wild-type growth of a pdi1 Delta Saccharomyces cerevisiae strain yeast. Thus, most of the PDI structure is dispensable for its essential function in yeast, and high-level isomerase activity appears not required for viability or rapid growth.	Karolinska Inst, Dept Med Biochem & Biophys, Med Nobel Inst Biochem, S-17177 Stockholm, Sweden; Baylor Coll Med, Verna & Marrs McLean Dept Biochem, Houston, TX 77030 USA	Karolinska Institutet; Baylor College of Medicine	Lundstrom-Ljung, J (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Med Nobel Inst Biochem, S-17177 Stockholm, Sweden.				NIGMS NIH HHS [GM-40379] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040379] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arner ESJ, 1999, J MOL BIOL, V292, P1003, DOI 10.1006/jmbi.1999.3085; Chivers PT, 1996, EMBO J, V15, P2659, DOI 10.1002/j.1460-2075.1996.tb00626.x; CREIGHTON TE, 1995, TRENDS BIOTECHNOL, V13, P18, DOI 10.1016/S0167-7799(00)88896-4; Cuozzo JW, 1999, NAT CELL BIOL, V1, P130, DOI 10.1038/11047; DARBY NJ, 1995, BIOCHEMISTRY-US, V34, P11725, DOI 10.1021/bi00037a009; Darby NJ, 1998, J MOL BIOL, V276, P239, DOI 10.1006/jmbi.1997.1504; Darby NJ, 1995, BIOCHEMISTRY-US, V34, P16770, DOI 10.1021/bi00051a027; Darby NJ, 1996, BIOCHEMISTRY-US, V35, P10517, DOI 10.1021/bi960763s; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FARQUHAR R, 1991, GENE, V108, P81, DOI 10.1016/0378-1119(91)90490-3; Ferrari DM, 1999, BIOCHEM J, V339, P1, DOI 10.1042/0264-6021:3390001; Frand AR, 1999, MOL CELL, V4, P469, DOI 10.1016/S1097-2765(00)80198-7; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; Gilbert HF, 1997, J BIOL CHEM, V272, P29399, DOI 10.1074/jbc.272.47.29399; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Holst B, 1997, J CELL BIOL, V138, P1229, DOI 10.1083/jcb.138.6.1229; Kemmink J, 1996, BIOCHEMISTRY-US, V35, P7684, DOI 10.1021/bi960335m; Kemmink J, 1997, CURR BIOL, V7, P239, DOI 10.1016/S0960-9822(06)00119-9; Klappa P, 1998, EMBO J, V17, P927, DOI 10.1093/emboj/17.4.927; Koivunen P, 1999, EMBO J, V18, P65, DOI 10.1093/emboj/18.1.65; KRAUSE G, 1991, J BIOL CHEM, V266, P9494; LABOISSIERE MCA, 1995, J BIOL CHEM, V270, P28006; Laboissiere MCA, 1997, BIOL CHEM, V378, P431; LUNDSTROM J, 1990, J BIOL CHEM, V265, P9114; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P619, DOI 10.1021/bi00217a005; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; Puig A, 1997, J BIOL CHEM, V272, P32988, DOI 10.1074/jbc.272.52.32988; SIKORSKI RS, 1989, GENETICS, V122, P19; Sun XX, 2000, BBA-PROTEIN STRUCT M, V1481, P45, DOI 10.1016/S0167-4838(00)00122-9; VUORI K, 1992, J BIOL CHEM, V267, P7211; Walker KW, 1996, BIOCHEMISTRY-US, V35, P1972, DOI 10.1021/bi952157n; ZAPUN A, 1992, PROTEINS, V14, P10, DOI 10.1002/prot.340140104	34	22	25	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27975	27980		10.1074/jbc.M104203200	http://dx.doi.org/10.1074/jbc.M104203200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11375405	hybrid			2022-12-25	WOS:000170093400032
J	Ponce, ML; Nomizu, M; Kleinman, HK				Ponce, ML; Nomizu, M; Kleinman, HK			An angiogenic laminin site and its antagonist bind through the alpha v beta 3 and alpha 5 beta 1 integrins	FASEB JOURNAL			English	Article						angiogenesis; laminin-1; bFGF; endothelium; peptides	HUMAN-ENDOTHELIAL CELLS; TUMOR-GROWTH; SYNTHETIC PEPTIDES; ADHESION MOLECULE; ALPHA-1 CHAIN; GAMMA-1 CHAIN; IDENTIFICATION; ALPHA(V)BETA(3); RECEPTORS; PROTEIN	Angiogenesis is important for wound healing, tumor growth, and metastasis. Endothelial cells differentiate into capillary-like structures on a laminin-1-rich matrix (Matrigel). We previously identified 20 angiogenic sites on laminin-1 (alpha1 beta1 gamma1) by screening 559 overlapping synthetic peptides. C16, the most potent gamma1 chain peptide, blocked laminin-1-mediated adhesion and was the only gamma1 chain peptide to block attachment to both collagen I and fibronectin. This suggested that C16 was acting via a receptor common to these substrates. We demonstrated that C16 is angiogenic in vivo. Affinity chromatography identified the integrins alpha5 beta1 and alphav beta3 as surface receptors. Blocking antibodies confirmed the role of these receptors in C16 adhesion. C16 does not contain an RGD sequence and, as expected, an RGD-containing peptide did not block C16 adhesion nor did C16 act via MAP kinase phosphorylation. Furthermore, we identified a C16 scrambled sequence, C16S, which antagonizes the angiogenic activity of bFGF and of C16 by binding to the same receptors. Because the laminin gamma1 chain is ubiquitous in most tissues, C16 is likely an important functional site. Since the biological activity of C16 is blocked by a scrambled peptide, C16S may serve as an anti-angiogenic therapeutic agent.	NIDCR, CDBRB, NIH, Bethesda, MD 20892 USA; Hokkaido Univ, Grad Sch Environm Earth Sci, Sapporo, Hokkaido 060, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Hokkaido University	Kleinman, HK (corresponding author), NIDCR, CDBRB, NIH, Bldg 30,Room 433,30 Convent Dr, Bethesda, MD 20892 USA.	hkleinman@dir.nidcr.nih.gov						BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; Eliceiri BP, 2000, CANCER J, V6, pS245; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; GRAF J, 1987, CELL, V48, P989, DOI 10.1016/0092-8674(87)90707-0; GRANT DS, 1992, J CELL PHYSIOL, V153, P614, DOI 10.1002/jcp.1041530324; Hauzenberger D, 1999, EUR J IMMUNOL, V29, P1435, DOI 10.1002/(SICI)1521-4141(199905)29:05<1435::AID-IMMU1435>3.0.CO;2-N; Hoffman MP, 1998, J BIOL CHEM, V273, P28633, DOI 10.1074/jbc.273.44.28633; HORTON MA, 1994, BONE, V15, P639, DOI 10.1016/8756-3282(94)90312-3; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KIBBEY MC, 1992, J NATL CANCER I, V84, P1633, DOI 10.1093/jnci/84.21.1633; KIBBEY MC, 1993, P NATL ACAD SCI USA, V90, P10150, DOI 10.1073/pnas.90.21.10150; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; Malinda KM, 1999, FASEB J, V13, P53, DOI 10.1096/fasebj.13.1.53; Miner JH, 1997, J CELL BIOL, V137, P685, DOI 10.1083/jcb.137.3.685; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Montgomery AMP, 1996, J CELL BIOL, V132, P475, DOI 10.1083/jcb.132.3.475; Nath D, 1999, J CELL SCI, V112, P579; Newham P, 1996, MOL MED TODAY, V2, P304, DOI 10.1016/1357-4310(96)10021-6; NICOSIA RF, 1990, LAB INVEST, V63, P115; Nomizu M, 1997, J BIOL CHEM, V272, P32198, DOI 10.1074/jbc.272.51.32198; Nomizu M, 1998, J BIOL CHEM, V273, P32491, DOI 10.1074/jbc.273.49.32491; NOMIZU M, 1995, J BIOL CHEM, V270, P20583, DOI 10.1074/jbc.270.35.20583; O'Reilly MS, 1999, SCIENCE, V285, P1926, DOI 10.1126/science.285.5435.1926; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OREILLY MS, 1997, CELL, V88, P276; Petitclerc E, 2000, J BIOL CHEM, V275, P8051, DOI 10.1074/jbc.275.11.8051; PFAFF M, 1994, CELL ADHES COMMUN, V2, P491, DOI 10.3109/15419069409014213; Pike SE, 1999, BLOOD, V94, P2461, DOI 10.1182/blood.V94.7.2461.419a26_2461_2468; Ponce ML, 1999, CIRC RES, V84, P688, DOI 10.1161/01.RES.84.6.688; Ruppert M, 1995, J CELL BIOL, V131, P1881, DOI 10.1083/jcb.131.6.1881; TIMPL R, 1994, MATRIX BIOL, V14, P275, DOI 10.1016/0945-053X(94)90192-9; TIMPL R, 1979, J BIOL CHEM, V254, P9933	36	71	75	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2001	15	8					1389	1397		10.1096/fj.00-0736com	http://dx.doi.org/10.1096/fj.00-0736com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11387236				2022-12-25	WOS:000169261200006
J	Oshima, Y; Puri, RK				Oshima, Y; Puri, RK			A novel interleukin-13 (IL-13) antagonist that blocks the biological activity of human IL-13 in immune and nonimmune cells	FASEB JOURNAL			English	Article						pleiotropic cytokine; inflammatory disease	HIGH-AFFINITY INTERLEUKIN-4; CHIMERIC PROTEIN; CARCINOMA-CELLS; PSEUDOMONAS EXOTOXIN; RECEPTOR-BINDING; PROLIFERATIVE ACTIVITY; SIGNAL-TRANSDUCTION; ATOPIC-DERMATITIS; SARCOMA-CELLS; TUMOR-CELLS	The pleiotropic cytokine interleukin-13 (IL-13) plays a major role in the pathogenesis of inflammatory diseases, including allergic rhinitis, atopic dermatitis, allergic asthma, and malignancies. Therefore, specific inhibitors of IL-13 may have important clinical applications. We have previously produced a super agonist of IL-13 (termed IL-13R112D) by single amino acid substitution changing Arg to Asp at position 112. In an effort to create a cell-selective IL-13 agonist, we performed a second mutation in the IL-13R112D molecule substituting Lys for Glu at position 13. Unexpectedly, rather than an agonist, this novel double mutein (IL-13 DM, termed IL-13E13KR112D, turned out to be an IL-13 antagonist. It competes for I-125-IL-13 binding sites as effectively as wtIL-13. Designation of IL-13E13KR112D as an IL-13 antagonist is supported further by a second assay involving a fusion protein consisting of the bacterial cytotoxic molecule PE38QQR as well as wtIL-13 (IL-13-PE38QQR or IL-13 cytotoxin). IL-13E13KR112D neutralizes the cytotoxic activity of IL-13 cytotoxin exhibited in U251 and PM-RCC cancer cell lines. In addition, IL-13E13KR112D inhibits the proliferative activity of wtIL-13 in TF-1 and L1236 hematopoietic cell lines, neutralizes wtIL-13 induced inhibition of CD14 expression on primary monocytes, and prevents wtIL-13 induced activation of signal transducer and activator of transcription (STAT-6) protein in KSY-1 and THP-1 cell lines. Thus, IL-13E13KR112D may be a useful agent for the study of interaction between IL-13 and its cognate receptors and may contribute to the development of new treatments for inflammatory diseases, even malignancies, in which IL-13 plays a central role.	US FDA, Lab Mol Tumor Biol, Div Cellular & Gene Therapies, Ctr Biol Evaluat & Res,NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; US Food & Drug Administration (FDA)	Puri, RK (corresponding author), US FDA, Lab Mol Tumor Biol, Div Cellular & Gene Therapies, Ctr Biol Evaluat & Res,NIH, 29 Lincoln Dr,NIH Bldg 29B,Room 2NN10, Bethesda, MD 20892 USA.	puri@cber.fda.gov	Oshima, Yasuo/AGN-3291-2022	Oshima, Yasuo/0000-0002-6236-6986				Akdis M, 1997, J IMMUNOL, V159, P4611; ALTMANN SW, 1995, J BIOL CHEM, V270, P2233, DOI 10.1074/jbc.270.5.2233; Aman MJ, 1996, J BIOL CHEM, V271, P29265, DOI 10.1074/jbc.271.46.29265; Caput D, 1996, J BIOL CHEM, V271, P16921, DOI 10.1074/jbc.271.28.16921; Chiaramonte MG, 1999, J CLIN INVEST, V104, P777, DOI 10.1172/JCI7325; COSENTINO G, 1995, J IMMUNOL, V155, P3145; Debinski W, 1998, NAT BIOTECHNOL, V16, P449, DOI 10.1038/nbt0598-449; Debinski W, 1995, CLIN CANCER RES, V1, P1253; Debinski W, 1996, J BIOL CHEM, V271, P22428, DOI 10.1074/jbc.271.37.22428; DEBINSKI W, 1995, J BIOL CHEM, V270, P16775, DOI 10.1074/jbc.270.28.16775; Donaldson DD, 1998, J IMMUNOL, V161, P2317; Fricker J, 1999, MOL MED TODAY, V5, P463, DOI 10.1016/S1357-4310(99)01586-5; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hage T, 1999, CELL, V97, P271, DOI 10.1016/S0092-8674(00)80736-9; Harding PA, 1996, J BIOL CHEM, V271, P6708, DOI 10.1074/jbc.271.12.6708; HERCUS TR, 1994, P NATL ACAD SCI USA, V91, P5838, DOI 10.1073/pnas.91.13.5838; HON FSD, 1994, J EXP MED, V180, P2395; Hudson KR, 1996, J BIOL CHEM, V271, P11971, DOI 10.1074/jbc.271.20.11971; Husain SR, 1999, NAT MED, V5, P817, DOI 10.1038/10541; Husain SR, 2000, BLOOD, V95, P3506, DOI 10.1182/blood.V95.11.3506.011k47_3506_3513; Husain SR, 1997, CLIN CANCER RES, V3, P151; Kapp U, 1999, J EXP MED, V189, P1939, DOI 10.1084/jem.189.12.1939; Katagiri K, 1997, CLIN EXP IMMUNOL, V108, P289, DOI 10.1046/j.1365-2249.1997.d01-1015.x; Kawakami K, 2000, HUM GENE THER, V11, P1829, DOI 10.1089/10430340050129459; Kim YS, 1998, J IMMUNOL, V160, P5742; KREITMAN RJ, 1995, CYTOKINE, V7, P311, DOI 10.1006/cyto.1995.0039; KRUSE N, 1992, EMBO J, V11, P3237, DOI 10.1002/j.1460-2075.1992.tb05401.x; KRUSE N, 1993, EMBO J, V12, P5121, DOI 10.1002/j.1460-2075.1993.tb06207.x; KRUSE N, 1991, FEBS LETT, V286, P58, DOI 10.1016/0014-5793(91)80939-Z; LELAND P, 1995, ONCOL RES, V7, P227; LEMM JD, 1998, ANNU REV IMMUNOL, V16, P569; Livnah O, 1998, NAT STRUCT BIOL, V5, P993, DOI 10.1038/2965; Maini A, 1997, J UROLOGY, V158, P948, DOI 10.1016/S0022-5347(01)64369-6; MARUYAMA K, 1994, J BIOL CHEM, V269, P5976; Matthews DJ, 2000, J IMMUNOL, V164, P1458, DOI 10.4049/jimmunol.164.3.1458; MCKENZIE ANJ, 1993, P NATL ACAD SCI USA, V90, P3735, DOI 10.1073/pnas.90.8.3735; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; Murad AM, 1997, CLIN DRUG INVEST, V13, P90, DOI 10.2165/00044011-199713020-00005; Murata T, 1998, INT J MOL MED, V1, P551; Murata T, 1997, INT J CANCER, V70, P230, DOI 10.1002/(SICI)1097-0215(19970117)70:2<230::AID-IJC15>3.0.CO;2-M; Murata T, 1996, J IMMUNOL, V156, P2972; Murata T, 1998, BLOOD, V91, P3884; Muthukumaran G, 1997, J BIOL CHEM, V272, P4993, DOI 10.1074/jbc.272.8.4993; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; OBIRI NI, 1993, J CLIN INVEST, V91, P88, DOI 10.1172/JCI116205; OBIRI NI, 1995, J BIOL CHEM, V270, P8797, DOI 10.1074/jbc.270.15.8797; Obiri NI, 1997, J IMMUNOL, V158, P756; Obiri NI, 1996, CLIN CANCER RES, V2, P1743; OHASHI H, 1994, P NATL ACAD SCI USA, V91, P158, DOI 10.1073/pnas.91.1.158; Oshima Y, 2000, J BIOL CHEM, V275, P14375, DOI 10.1074/jbc.275.19.14375; PAWANKAR RU, 1995, AM J RESP CRIT CARE, V152, P2059, DOI 10.1164/ajrccm.152.6.8520776; Pettit DK, 1997, J BIOL CHEM, V272, P2312; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; PURI RK, 1991, CANCER RES, V51, P3011; Puri RK, 1996, BLOOD, V87, P4333, DOI 10.1182/blood.V87.10.4333.bloodjournal87104333; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Skinnider BF, 2001, BLOOD, V97, P250, DOI 10.1182/blood.V97.1.250; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; TAVERNIER J, 1995, P NATL ACAD SCI USA, V92, P5194, DOI 10.1073/pnas.92.11.5194; TONY HP, 1994, EUR J BIOCHEM, V225, P659, DOI 10.1111/j.1432-1033.1994.00659.x; Wang YH, 1997, P NATL ACAD SCI USA, V94, P1657, DOI 10.1073/pnas.94.5.1657; Watowich SS, 1996, ANNU REV CELL DEV BI, V12, P91, DOI 10.1146/annurev.cellbio.12.1.91; WEIGEL U, 1989, EUR J BIOCHEM, V180, P295, DOI 10.1111/j.1432-1033.1989.tb14647.x; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	66	6	6	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 27	2001	15	6					1469	+		10.1096/fj.00-0711fje	http://dx.doi.org/10.1096/fj.00-0711fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387260				2022-12-25	WOS:000173705800007
J	Percherancier, Y; Planchenault, T; Valenzuela-Fernandez, A; Virelizier, JL; Arenzana-Seisdedos, F; Bachelerie, F				Percherancier, Y; Planchenault, T; Valenzuela-Fernandez, A; Virelizier, JL; Arenzana-Seisdedos, F; Bachelerie, F			Palmitoylation-dependent control of degradation, life span, and membrane expression of the CCR5 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; PROTEIN-COUPLED RECEPTORS; MANNOSE 6-PHOSPHATE RECEPTOR; HIV-1 CORECEPTOR ACTIVITY; CHEMOKINE RECEPTORS; CYTOPLASMIC TAIL; CYSTEINE RESIDUES; POSTTRANSLATIONAL MODIFICATION; SIGNAL-TRANSDUCTION; ADENOSINE RECEPTOR	We have shown that the chemokine and HIV receptor CCR5 is palmitoylated on a cluster of cysteine residues located at the boundary between the seventh transmembrane region and the cytoplasmic tail. Single or combined substitutions of the three cysteines (Cys-321, Cys-323, and Cys-324) or incubation of wild-type CCR5-transfected cells with the palmitic acid analog 2-bromopalmitate prevented palmitoylation of the receptor. Moreover, failure of CCR5 to be palmitoylated resulted in both accumulation in intracellular stores and a profound decrease of membrane expression of the receptor. Upon metabolic labeling, kinetic experiments showed that the half-life of palmitoylation-deficient CCR5 is profoundly decreased. Bafilomycin A1, but not a specific proteasome inhibitor, prevented early degradation of palmitoylation-deficient CCR5 and promoted its accumulation in lysosomal compartments. Although membrane expression of the CCR5 mutant was diminished, the molecules reaching the membrane were still able to interact efficiently with the chemokine ligand MIP1 beta and remained able to function as BW co-receptors. Thus we conclude that palmitoylation controls CCR5 expression through regulation of the life span of this receptor.	Inst Pasteur, Unite Immunol Virale, F-75724 Paris 15, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Bachelerie, F (corresponding author), Inst Pasteur, Unite Immunol Virale, 25-28 Rue Dr Roux, F-75724 Paris 15, France.	fbachele@pasteur.fr	Arenzana-Seisdedos, Fernando/E-5835-2016; BACHELERIE, FRANCOISE/F-8823-2013; Valenzuela-Fernández, Agustín/B-6219-2014; Valenzuela-Fernández, Agustín/P-1638-2019	BACHELERIE, FRANCOISE/0000-0002-0399-3277; Valenzuela-Fernández, Agustín/0000-0002-2585-8703; Valenzuela-Fernández, Agustín/0000-0002-2585-8703; percherancier, yann/0000-0002-2410-5806				Alfano M, 2000, J VIROL, V74, P8767, DOI 10.1128/JVI.74.18.8767-8770.2000; Alfano M, 1999, J EXP MED, V190, P597, DOI 10.1084/jem.190.5.597; Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Alkhatib G, 1997, VIROLOGY, V234, P340, DOI 10.1006/viro.1997.8673; Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139; AnsariLari MA, 1997, NAT GENET, V16, P221, DOI 10.1038/ng0797-221; Aramori I, 1997, EMBO J, V16, P4606, DOI 10.1093/emboj/16.15.4606; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Blagosklonny MV, 1999, ONCOGENE, V18, P6460, DOI 10.1038/sj.onc.1203068; Blanpain C, 1999, BLOOD, V94, P1899; Blanpain C, 2001, J BIOL CHEM, V276, P23795, DOI 10.1074/jbc.M100583200; BOUVIER M, 1995, BIOCHEM SOC T, V23, P577, DOI 10.1042/bst0230577; Breuer P, 1998, J BIOL CHEM, V273, P33254, DOI 10.1074/jbc.273.50.33254; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; CRISE B, 1992, J BIOL CHEM, V267, P13593; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; DRAGIC T, 1993, J VIROL, V67, P2355, DOI 10.1128/JVI.67.4.2355-2359.1993; Drose S, 1997, J EXP BIOL, V200, P1; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; Farzan M, 1997, J BIOL CHEM, V272, P6854, DOI 10.1074/jbc.272.11.6854; Gao ZH, 1999, BIOCHEM J, V342, P387, DOI 10.1042/0264-6021:3420387; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; Gosling J, 1997, P NATL ACAD SCI USA, V94, P5061, DOI 10.1073/pnas.94.10.5061; Guntermann C, 1999, BIOCHEM BIOPH RES CO, V256, P429, DOI 10.1006/bbrc.1999.0333; Hall RA, 1999, J CELL BIOL, V145, P927, DOI 10.1083/jcb.145.5.927; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Hayashi MK, 1997, ARCH BIOCHEM BIOPHYS, V340, P376, DOI 10.1006/abbi.1997.9906; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Horstmeyer A, 1996, J BIOL CHEM, V271, P20811, DOI 10.1074/jbc.271.34.20811; JENSEN AA, 1995, J NEUROCHEM, V65, P1325, DOI 10.1046/j.1471-4159.1995.65031325.x; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; JING SQ, 1990, J BIOL CHEM, V265, P11555; KARNIK SS, 1993, P NATL ACAD SCI USA, V90, P40, DOI 10.1073/pnas.90.1.40; KAWATE N, 1994, J BIOL CHEM, V269, P30651; Littman DR, 1998, CELL, V93, P677, DOI 10.1016/S0092-8674(00)81429-4; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Loisel TP, 1996, BIOCHEMISTRY-US, V35, P15923, DOI 10.1021/bi9611321; Margolis LB, 1998, J CLIN INVEST, V101, P1876, DOI 10.1172/JCI2015; MERRITT EA, 1994, PROTEIN SCI, V3, P166; Mirzabekov T, 1999, J BIOL CHEM, V274, P28745, DOI 10.1074/jbc.274.40.28745; MOENCH SJ, 1994, BIOCHEMISTRY-US, V33, P5791, DOI 10.1021/bi00185a017; Moffett S, 2001, J NEUROCHEM, V76, P269, DOI 10.1046/j.1471-4159.2001.00005.x; Moore JP, 1997, SCIENCE, V276, P51, DOI 10.1126/science.276.5309.51; Morello JP, 1996, BIOCHEM CELL BIOL, V74, P449, DOI 10.1139/o96-049; Moser B, 2001, NAT IMMUNOL, V2, P123, DOI 10.1038/84219; Mumby SM, 1997, CURR OPIN CELL BIOL, V9, P148, DOI 10.1016/S0955-0674(97)80056-7; Murphy PM, 2001, NAT IMMUNOL, V2, P116, DOI 10.1038/84214; OBRIEN PJ, 1984, J BIOL CHEM, V259, P5054; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; Okamoto Y, 1997, J BIOL CHEM, V272, P21589, DOI 10.1074/jbc.272.34.21589; OVCHINNIKOV YA, 1988, FEBS LETT, V230, P1, DOI 10.1016/0014-5793(88)80628-8; Palmer TM, 2000, MOL PHARMACOL, V57, P539, DOI 10.1124/mol.57.3.539; Paoletti F, 1997, J CELL PHYSIOL, V172, P63, DOI 10.1002/(SICI)1097-4652(199707)172:1<63::AID-JCP7>3.3.CO;2-F; Petaja-Repo UE, 2000, J BIOL CHEM, V275, P13727, DOI 10.1074/jbc.275.18.13727; Petaja-Repo UE, 2001, J BIOL CHEM, V276, P4416, DOI 10.1074/jbc.M007151200; PLANELLES V, 1995, J VIROL, V69, P5883, DOI 10.1128/JVI.69.9.5883-5889.1995; Quillent C, 1998, LANCET, V351, P14, DOI 10.1016/S0140-6736(97)09185-X; Renard P, 2000, J BIOL CHEM, V275, P15193, DOI 10.1074/jbc.275.20.15193; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROHRER J, 1995, J CELL BIOL, V130, P1297, DOI 10.1083/jcb.130.6.1297; Rucker J, 1996, CELL, V87, P437, DOI 10.1016/S0092-8674(00)81364-1; Sadeghi HM, 1997, MOL PHARMACOL, V52, P21, DOI 10.1124/mol.52.1.21; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Schweizer A, 1996, J CELL BIOL, V132, P577, DOI 10.1083/jcb.132.4.577; Segerer S, 1999, KIDNEY INT, V56, P52, DOI 10.1046/j.1523-1755.1999.00544.x; Shioda T, 2001, J VIROL, V75, P3462, DOI 10.1128/JVI.75.7.3462-3468.2001; Signoret N, 1997, J CELL BIOL, V139, P651, DOI 10.1083/jcb.139.3.651; Tanaka K, 1998, ENDOCRINOLOGY, V139, P803, DOI 10.1210/en.139.2.803; Thelen M, 2001, NAT IMMUNOL, V2, P129, DOI 10.1038/84224; van de Loo JWHP, 2000, BIOCHEM J, V352, P827, DOI 10.1042/0264-6021:3520827; VINITSKY A, 1992, BIOCHEMISTRY-US, V31, P9421, DOI 10.1021/bi00154a014; Webb Y, 2000, J BIOL CHEM, V275, P261, DOI 10.1074/jbc.275.1.261; Wu LJ, 1997, J EXP MED, V186, P1373, DOI 10.1084/jem.186.8.1373; Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707; ZHU HY, 1995, MOL ENDOCRINOL, V9, P141, DOI 10.1210/me.9.2.141	79	120	123	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31936	31944		10.1074/jbc.M104013200	http://dx.doi.org/10.1074/jbc.M104013200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11390405	hybrid			2022-12-25	WOS:000170613500065
J	Lee-Kwon, W; Johns, DC; Cha, BY; Cavet, M; Park, J; Tsichlis, P; Donowitz, M				Lee-Kwon, W; Johns, DC; Cha, BY; Cavet, M; Park, J; Tsichlis, P; Donowitz, M			Constitutively active phosphatidylinositol 3-kinase and AKT are sufficient to stimulate the epithelial Na+/H+ exchanger 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE B; C-TERMINAL DOMAINS; GROWTH-FACTOR; PHOSPHOINOSITIDE 3-KINASE; GLUT4 TRANSLOCATION; GLUCOSE-TRANSPORT; LIPID PRODUCTS; INSULIN STIMULATION; ADENOVIRUS VECTORS; 3T3-L1 ADIPOCYTES	Phosphatidylinositol 3-kinase (PI 3-kinase) is a cytoplasmic signaling molecule that is recruited to activated growth factor receptors and has been shown to be involved in regulation of stimulated exocytosis and endocytosis. One of the downstream signaling molecules activated by PI 3-kinase is the protein kinase Akt. Previous studies have indicated that PI 3-kinase is necessary for basal Na+/H+ exchanger 3 (NHE3) transport and for fibroblast growth factor-stimulated NHE3 activity in PS120 fibroblasts. However, it is not known whether activation of PI 3-kinase is sufficient to stimulate NHE3 activity or whether Akt is involved in this PI 3-kinase effect. We used an adenoviral infection system to test the possibility that activation of PI 3-kinase or Akt alone is sufficient to stimulate NHE3 activity. This hypothesis was investigated in PS120 fibroblasts stably expressing NHE3 after somatic gene transfer using a replication-deficient recombinant adenovirus containing constitutively active catalytic subunit of PI 3-kinase or constitutively active Akt. The adenovirus construct used was engineered with an upstream ecdysone promoter to allow time-regulated expression. Adenoviral infection was nearly 100% at 48 h after infection. Forty-eight hours after infection (24 It after activation of the ecdysone promoter), PI 3-kinase and Akt amount and activity were increased. Increases in both PI 3-kinase activity and Akt activity stimulated NHE3 transport. In addition, a membrane-permeant synthetic 10-mer peptide that binds polyphosphoinositides and increases PI 3-kinase activity similarly enhanced NHE3 transport activity and also increased the percentage of NHE3 on the plasma membrane. The magnitudes of stimulation of NHE3 by constitutively active PI 3-kinase, PI 3-kinase peptide, and constitutively active Akt were similar to each other. These results demonstrate that activation of PI 3-kinase or Akt is sufficient to stimulate NHE3 transport activity in PS120/NHE3 cells.	Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Thomas Jefferson Univ, Dept Microbiol, Kimmel Canc Inst, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Philadelphia, PA 19107 USA; Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Jefferson University; Jefferson University; Johns Hopkins University	Donowitz, M (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, 725 Rutland Ave, Baltimore, MD 21205 USA.	mdonowit@jhmi.edu			NIDDK NIH HHS [R01 DK26523] Funding Source: Medline; PHS HHS [P01 44484] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026523] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akhter S, 2000, BIOCHEMISTRY-US, V39, P1990, DOI 10.1021/bi991739s; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; DONOWITZ M, 1994, AM J PHYSIOL, V266, pG647, DOI 10.1152/ajpgi.1994.266.4.G647; Donowitz M, 2001, CURR TOP MEMBR, V50, P437; Foster LJ, 2000, AM J PHYSIOL-CELL PH, V279, pC877, DOI 10.1152/ajpcell.2000.279.4.C877; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Frevert EU, 1998, J BIOL CHEM, V273, P25480, DOI 10.1074/jbc.273.39.25480; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; Guilherme A, 1998, J BIOL CHEM, V273, P33119, DOI 10.1074/jbc.273.50.33119; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Hausdorff SF, 1999, J BIOL CHEM, V274, P24677, DOI 10.1074/jbc.274.35.24677; Hoogerwerf WA, 1996, AM J PHYSIOL-GASTR L, V270, pG29, DOI 10.1152/ajpgi.1996.270.1.G29; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Hubner S, 1998, EUR J BIOCHEM, V258, P846, DOI 10.1046/j.1432-1327.1998.2580846.x; ISAKOFF SJ, 1995, P NATL ACAD SCI USA, V92, P10247, DOI 10.1073/pnas.92.22.10247; Janecki AJ, 2000, J HISTOCHEM CYTOCHEM, V48, P1479, DOI 10.1177/002215540004801105; Janecki AJ, 2000, J BIOL CHEM, V275, P8133, DOI 10.1074/jbc.275.11.8133; Janecki AJ, 1998, J BIOL CHEM, V273, P8790, DOI 10.1074/jbc.273.15.8790; Janmey PA, 1999, CHEM PHYS LIPIDS, V101, P93, DOI 10.1016/S0009-3084(99)00058-4; Jiang T, 1998, J BIOL CHEM, V273, P11017, DOI 10.1074/jbc.273.18.11017; Johns DC, 1999, J NEUROSCI, V19, P1691; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khurana S, 1996, J BIOL CHEM, V271, P9919, DOI 10.1074/jbc.271.17.9919; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; KLIPPEL A, 1994, MOL CELL BIOL, V14, P2675, DOI 10.1128/MCB.14.4.2675; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; Krasilnikov MA, 2000, BIOCHEMISTRY-MOSCOW+, V65, P59; Kurashima K, 1998, J BIOL CHEM, V273, P20828, DOI 10.1074/jbc.273.33.20828; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Lee-Kwon W, 1998, BIOCHEMISTRY-US, V37, P15747, DOI 10.1021/bi9805947; Lee-Kwon W, 1998, EXP CELL RES, V241, P458, DOI 10.1006/excr.1998.4087; LEVINE SA, 1995, J BIOL CHEM, V270, P13716, DOI 10.1074/jbc.270.23.13716; LEVINE SA, 1993, J BIOL CHEM, V268, P25527; Misra S, 1999, P NATL ACAD SCI USA, V96, P5814, DOI 10.1073/pnas.96.10.5814; Mittereder N, 1996, J VIROL, V70, P7498, DOI 10.1128/JVI.70.11.7498-7509.1996; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Noel J, 1996, J CELL SCI, V109, P929; PALMER RH, 1995, J BIOL CHEM, V270, P22412, DOI 10.1074/jbc.270.38.22412; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Sharma PM, 1998, J BIOL CHEM, V273, P18528, DOI 10.1074/jbc.273.29.18528; Tanti JF, 1996, J BIOL CHEM, V271, P25227, DOI 10.1074/jbc.271.41.25227; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TSE CM, 1993, P NATL ACAD SCI USA, V90, P9110, DOI 10.1073/pnas.90.19.9110; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; Valverde AM, 1999, BIOCHEM J, V337, P397, DOI 10.1042/0264-6021:3370397; Wang LH, 1999, J BIOL CHEM, V274, P19246, DOI 10.1074/jbc.274.27.19246; Wang QH, 1999, MOL CELL BIOL, V19, P4008	54	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31296	31304		10.1074/jbc.M103900200	http://dx.doi.org/10.1074/jbc.M103900200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11375999	hybrid			2022-12-25	WOS:000170472900093
J	Egloff, AM; Desiderio, S				Egloff, AM; Desiderio, S			Identification of phosphorylation sites for Bruton's tyrosine kinase within the transcriptional regulator BAP/TFII-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED AGAMMAGLOBULINEMIA; B-CELL MATURATION; C-FOS PROMOTER; TFII-I; IMMUNODEFICIENT MICE; BINDING PROTEIN; FAMILY KINASES; TEC KINASE; SRC FAMILY; ACTIVATION	Bruton's tyrosine kinase (Btk), a member of the Tee family of cytosolic kinases, is essential for B cell development and function. BAP/TFII-I, a protein implicated in transcriptional regulation, is associated with Btk in B cells and is transiently phosphorylated on tyrosine following B cell receptor engagement. BAP/TFII-I is a substrate for Btk in vitro and is hyperphosphorylated on tyrosine upon coexpression with Btk in mammalian cells. In an effort to understand the physiologic consequences of BAP/TFII-I tyrosine phospholylation following B cell receptor stimulation, site-directed mutagenesis and phosphopeptide mapping were used to locate the predominant sites of BAP/TFII-I phosphorylation by Btk in vitro. These residues, Tyr(248), Tyr(357), and Tyr(462), were also found to be the major sites for Btk-dependent phosphorylation of BAP/TFII-I in vivo. Residues Tyr(357) and Tyr(462) are contained within the loop regions of adjacent helix-loop-helix-like repeats within BAP/TFII-L Mutation of either Tyr(248), Tyr(357), or Tyr(462) to phenylalanine reduced transcription from a c-fos promoter relative to wild-type BAP/TFII-I in transfected COS-7 cells, consistent with the interpretation that phosphorylation at these sites contributes to transcriptional activation. Phosphorylation of BAP/TFII-I by Btk may link engagement of receptors such as surface immunoglobulin to modulation of gene expression.	Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University	Desiderio, S (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, 725 N Wolfe St, Baltimore, MD 21205 USA.				NCI NIH HHS [CA16519] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA016519] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baba Y, 1999, BLOOD, V93, P2003, DOI 10.1182/blood.V93.6.2003.406k13_2003_2012; Bence K, 1997, NATURE, V389, P296, DOI 10.1038/38520; Cheriyath V, 2000, J BIOL CHEM, V275, P26300, DOI 10.1074/jbc.M002980200; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; Grueneberg DA, 1997, GENE DEV, V11, P2482, DOI 10.1101/gad.11.19.2482; HAIRE RN, 1994, HUM MOL GENET, V3, P897, DOI 10.1093/hmg/3.6.897; HARDY RR, 1983, NATURE, V306, P270, DOI 10.1038/306270a0; HAYAKAWA K, 1986, EUR J IMMUNOL, V16, P450, DOI 10.1002/eji.1830160423; HU Q, 1995, J BIOL CHEM, V270, P1928, DOI 10.1074/jbc.270.4.1928; HUNTER T, 1991, METHOD ENZYMOL, V210, P110; JONES DH, 1992, BIOTECHNIQUES, V12, P528; KAWAKAMI Y, 1994, MOL CELL BIOL, V14, P5108, DOI 10.1128/MCB.14.8.5108; Khan WN, 1997, INT IMMUNOL, V9, P395, DOI 10.1093/intimm/9.3.395; Kim DW, 1998, MOL CELL BIOL, V18, P3310, DOI 10.1128/MCB.18.6.3310; Kim DW, 2000, MOL CELL BIOL, V20, P1140, DOI 10.1128/MCB.20.4.1140-1148.2000; KOIKE M, 1995, INT IMMUNOL, V7, P21, DOI 10.1093/intimm/7.1.21; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; LANGHANSRAJASEKARAN SA, 1995, P NATL ACAD SCI USA, V92, P8601, DOI 10.1073/pnas.92.19.8601; MANO H, 1993, ONCOGENE, V8, P417; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; Novina CD, 1998, J BIOL CHEM, V273, P33443, DOI 10.1074/jbc.273.50.33443; Novina CD, 1999, MOL CELL BIOL, V19, P5014; PABORSKY LR, 1990, PROTEIN ENG, V3, P547, DOI 10.1093/protein/3.6.547; PEARL ER, 1978, J IMMUNOL, V120, P1169; PERLMUTTER RM, 1979, J EXP MED, V149, P993, DOI 10.1084/jem.149.4.993; Rawlings DJ, 1999, CLIN IMMUNOL, V91, P243, DOI 10.1006/clim.1999.4732; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Roy AL, 1997, EMBO J, V16, P7091, DOI 10.1093/emboj/16.23.7091; SANTOSARGUMEDO L, 1995, INT IMMUNOL, V7, P163, DOI 10.1093/intimm/7.2.163; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; SCHER I, 1982, ADV IMMUNOL, V33, P1, DOI 10.1016/S0065-2776(08)60834-2; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; VIHINEN M, 1994, FEBS LETT, V350, P263, DOI 10.1016/0014-5793(94)00783-7; WEST MHP, 1984, ELECTROPHORESIS, V5, P133, DOI 10.1002/elps.1150050302; Yang WY, 1997, P NATL ACAD SCI USA, V94, P604, DOI 10.1073/pnas.94.2.604; YANG WY, 1995, J BIOL CHEM, V270, P20832, DOI 10.1074/jbc.270.35.20832; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175	44	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27806	27815		10.1074/jbc.M103692200	http://dx.doi.org/10.1074/jbc.M103692200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11373296	hybrid			2022-12-25	WOS:000170093400011
J	Kawaguchi, T; Veech, RL; Uyeda, K				Kawaguchi, T; Veech, RL; Uyeda, K			Regulation of energy metabolism in macrophages during hypoxia - Roles of fructose 2,6-bisphosphate and ribose 1,5-bisphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; RAT-LIVER; KINETIC-PROPERTIES; PHOSPHOLIPASE-C; PATHWAY; ACTIVATION; 6-PHOSPHOFRUCTO-2-KINASE/FRUCTOSE-2,6-BISPHOSPHATASE; PHOSPHOFRUCTOKINASES; HEPATOCYTES; GLYCOLYSIS	Macrophages can adapt to the absence of oxygen by switching to anaerobic glycolysis. In this study, we investigated (a) the roles of fructose 2,6-bisphosphate (Fru-2,6-P-2) and ribose 1,5-bisphosphate (Rib-1,5-P-2), Potent activators of phosphofructokinase, (b) the enzymes responsible for the synthesis of Rib-1,5-P-2, and (c) the mechanisms of regulation of these enzymes in H36.12j macrophages during the initial phase of hypoxia. Within I min after initiating hypoxia, glycolysis was activated through activation of phosphofructokinase. Over the same period, Fru-2,6-P-2 decreased 50% and recovered completely upon reoxygenation. Similar changes in cAMP levels were observed. In contrast, the Rib-1,5-P-2 concentration rapidly increased to a maximum level of 8.0 +/- 0.9 nmol/g cell 30 s after hypoxia. Thus, Rib-1,5-P-2 was the major factor increasing the rate of glycolysis during the initial phase of hypoxia. Moreover, we found that Rib-1,5-P-2 was synthesized by two steps: the ribose-phosphate pyrophosphokinase (5-phosphoribosyl-1-pyrophosphate synthetase; PRPP synthetase) reaction (EC 2.7.6.1) catalyzing the reaction, Rib-5-P + ATP --> PRPP + AMP and a new enzyme, "PRPP pyrophosphatase" catalyzing the reaction, PRPP --> Rib-1,5-P-2 + P-i. Both PRPP synthetase and PRPP pyrophosphatase were significantly activated 30 s after hypoxia. Pretreatment with 1-octadecyl-2-methyl-rac-glycero-3-phosphocholine and calphostin C prevented the activation of ribose PRPP synthetase and PRPP pyrophosphatase as well as increase in Rib-1,5-P-2 and activation of phosphofructokinase 30 s after hypoxia. These data suggest that the activation of the above enzymes was mediated by protein kinase C acting via activation of phosphatidylinositol specific phospholipase C in the macrophages during hypoxia.	Dallas Vet Affairs Med Ctr, Dept Biochem, Dallas, TX 75216 USA; Univ Texas, SW Med Ctr Dallas, Dept Biochem, Dallas, TX 75223 USA; NIAAA, Rockville, MD 20852 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	Uyeda, K (corresponding author), Dallas Vet Affairs Med Ctr, Dept Biochem, 4500 S Lancaster Rd, Dallas, TX 75216 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016194] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK16194] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Beitner-Johnson D, 1998, BIOCHEM BIOPH RES CO, V242, P61, DOI 10.1006/bbrc.1997.7907; BLACKMORE PF, 1982, FEBS LETT, V142, P255, DOI 10.1016/0014-5793(82)80147-6; Derevianko A, 1996, J SURG RES, V62, P32, DOI 10.1006/jsre.1996.0169; FEDOROV S, 1992, J BIOL CHEM, V267, P20826; GUHA SK, 1986, ARCH BIOCHEM BIOPHYS, V250, P513, DOI 10.1016/0003-9861(86)90756-3; HUE L, 1982, BIOCHEM J, V206, P359, DOI 10.1042/bj2060359; ISHIKAWA E, 1990, J BIOL CHEM, V265, P18875; Kato H, 2000, BRAIN PATHOL, V10, P137; KIM YA, 1992, AM J PHYSIOL, V262, pE344, DOI 10.1152/ajpendo.1992.262.3.E344; KING MT, 1990, ANAL BIOCHEM, V187, P179, DOI 10.1016/0003-2697(90)90438-F; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KORNBERG A, 1955, J BIOL CHEM, V215, P389; Lewis JS, 1999, J LEUKOCYTE BIOL, V66, P889, DOI 10.1002/jlb.66.6.889; NISHIMURA M, 1994, J BIOL CHEM, V269, P26100; OGUSHI S, 1990, J BIOL CHEM, V265, P10943; Okamura N, 1998, BIOSCI BIOTECH BIOCH, V62, P2039, DOI 10.1271/bbb.62.2039; POWIS G, 1992, CANCER RES, V52, P2835; RACKER E, 1974, METHOD ENZYMAT AN, V2, P1342; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; ROSE IA, 1974, BIOCHEM BIOPH RES CO, V59, P1333, DOI 10.1016/0006-291X(74)90460-4; Sakai A, 1996, J BIOCHEM-TOKYO, V119, P506; Sakakibara R, 1997, J BIOCHEM-TOKYO, V122, P122; SAKAKIBARA R, 1984, J BIOL CHEM, V259, P41; Sakakibara R, 1999, BIOCHEM BIOPH RES CO, V257, P177, DOI 10.1006/bbrc.1999.0429; Simakajornboon N, 2000, NEUROSCI LETT, V278, P17, DOI 10.1016/S0304-3940(99)00887-3; Tarantini F, 1998, J BIOL CHEM, V273, P22209, DOI 10.1074/jbc.273.35.22209; UYEDA K, 1981, J BIOL CHEM, V256, P8394; UYEDA K, 1991, STUDY ENZYMES, V2, P445; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V129, P191; VINCENT MF, 1982, BIOCHEM J, V202, P117, DOI 10.1042/bj2020117; Weissmann N, 1999, AM J PHYSIOL-LUNG C, V276, pL90, DOI 10.1152/ajplung.1999.276.1.L90	31	55	60	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28554	28561		10.1074/jbc.M101396200	http://dx.doi.org/10.1074/jbc.M101396200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11373280	hybrid			2022-12-25	WOS:000170093400108
J	Reuther, GW; Lambert, QT; Booden, MA; Wennerberg, K; Becknell, B; Marcucci, G; Sondek, J; Caligiuri, MA; Der, CJ				Reuther, GW; Lambert, QT; Booden, MA; Wennerberg, K; Becknell, B; Marcucci, G; Sondek, J; Caligiuri, MA; Der, CJ			Leukemia-associated Rho guanine nucleotide exchange factor, a Dbl family protein found mutated in leukemia, causes transformation by activation of RhoA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; HETEROTRIMERIC G-PROTEINS; STRESS FIBER FORMATION; GTP-BINDING PROTEINS; RAS TRANSFORMATION; SIGNAL-TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION; STRUCTURAL SIMILARITIES; DEPENDENT ACTIVATION; EXPRESSION CLONING	Leukemia-associated Rho guanine nucleotide exchange factor (LARG) was originally identified as a fusion partner with mixed-lineage leukemia in a patient with acute myeloid leukemia. LARG possesses a tandem Dbl homology and pleckstrin homology domain structure and, consequently, may function as an activator of Rho GTPases. In this study, we demonstrate that LARG is a functional Dbl protein. Expression of LARG in cells caused activation of the serum response factor, a known downstream target of Rho-mediated signaling pathways. Transient overexpression of LARG did not activate the extracellular signal-regulated kinase or c-Jun NH2-terminal kinase mitogen-activated protein kinase cascade, suggesting LARG is not an activator of Ras, Rac, or Cdc42, We performed in vitro exchange assays where the isolated Dbl homology (DH) or DH/pleckstrin homology domains of LARG functioned as a strong activator of RhoA, but exhibited no activity toward Rad or Cdc42. We found that LARG could complex with RhoA, but not Rac or Cdc42, in vitro, and that expression of LARG caused an increase in the levels of the activated GTP-bound form of RhoA, but not Rad or Cdc42, in vivo. Thus, we conclude that LARG is a RhoA-specific guanine nucleotide exchange factor. Finally, like activated RhoA, we determined that LARG cooperated with activated Raf-1 to transform NIH3T3 cells. These data demonstrate that LARG is the first functional Dbl protein mutated in cancer and indicate LARG-mediated activation of RhoA may play a role in the development of human leukemias.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA; Ohio State Univ, Coll Med & Publ Hlth, Div Hematol & Oncol, Dept Internal Med, Columbus, OH 43210 USA; Ohio State Univ, Coll Med & Publ Hlth, Div Human Canc Genet, Columbus, OH 43210 USA; Ohio State Univ, Coll Med & Publ Hlth, Dept Mol Virol Immunol & Med Genet, Ctr Comprehens Canc, Columbus, OH 43210 USA	University of North Carolina; University of North Carolina Chapel Hill; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Reuther, GW (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, CB 7295, Chapel Hill, NC 27599 USA.	greuther@med.unc.edu	Reuther, Gary/AFR-2892-2022; Wennerberg, Krister/AFM-0539-2022; Wennerberg, Krister/AAH-2919-2022	Wennerberg, Krister/0000-0002-1352-4220; Wennerberg, Krister/0000-0002-1352-4220; Sondek, John/0000-0002-1127-8310; Der, Channing/0000-0002-7751-2747	NATIONAL CANCER INSTITUTE [R01CA042978, K08CA090469, R01CA063071, R01CA055008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057391] Funding Source: NIH RePORTER; NCI NIH HHS [CA63071, CA42978, KO8-CA90469, CA55008] Funding Source: Medline; NIGMS NIH HHS [R01-GM57391] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; Abe R, 1999, J BIOL CHEM, V274, P30410, DOI 10.1074/jbc.274.43.30410; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Borkhardt A, 2000, P NATL ACAD SCI USA, V97, P9168, DOI 10.1073/pnas.150079597; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHEN SY, 1994, ONCOGENE, V9, P2691; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Davis RJ, 1999, BIOCHEM SOC SYMP, P1; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; GRAZIANI G, 1989, ONCOGENE, V4, P823; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HART M, 1995, METHOD ENZYMOL, V255, P129; HART MJ, 1994, J BIOL CHEM, V269, P62; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HAUSER CA, 1995, METHOD ENZYMOL, V255, P412; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; JOHANSEN FE, 1995, BBA-REV CANCER, V1242, P1, DOI 10.1016/0304-419X(94)00014-S; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Knaus UG, 1998, INT J BIOCHEM CELL B, V30, P857, DOI 10.1016/S1357-2725(98)00059-4; Kourlas PJ, 2000, P NATL ACAD SCI USA, V97, P2145, DOI 10.1073/pnas.040569197; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; Liu BP, 2000, MOL CELL BIOL, V20, P7160, DOI 10.1128/MCB.20.19.7160-7169.2000; Manser E, 1999, Prog Mol Subcell Biol, V22, P115; Mao JH, 1998, P NATL ACAD SCI USA, V95, P12973, DOI 10.1073/pnas.95.22.12973; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; Murphy GA, 1999, ONCOGENE, V18, P3831, DOI 10.1038/sj.onc.1202758; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Reid T, 1999, J BIOL CHEM, V274, P33587, DOI 10.1074/jbc.274.47.33587; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ren XD, 2000, METHOD ENZYMOL, V325, P264; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Rumenapp U, 1999, FEBS LETT, V459, P313, DOI 10.1016/S0014-5793(99)01270-3; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; Siderovski DP, 1999, CRIT REV BIOCHEM MOL, V34, P215, DOI 10.1080/10409239991209273; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Solski PA, 2000, METHOD ENZYMOL, V325, P425; Sterpetti P, 1999, MOL CELL BIOL, V19, P1334; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; vanLeeuwen FN, 1995, ONCOGENE, V11, P2215; Westwick JK, 1998, J BIOL CHEM, V273, P16739, DOI 10.1074/jbc.273.27.16739; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Zheng Y, 1996, J BIOL CHEM, V271, P33169, DOI 10.1074/jbc.271.52.33169; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	73	101	105	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27145	27151		10.1074/jbc.M103565200	http://dx.doi.org/10.1074/jbc.M103565200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11373293	hybrid			2022-12-25	WOS:000169966900056
J	White, P; Burton, KA; Fowden, AL; Dauncey, MJ				White, P; Burton, KA; Fowden, AL; Dauncey, MJ			Developmental expression analysis of thyroid hormone receptor isoforms reveals new insights into their essential functions in cardiac and skeletal muscles	FASEB JOURNAL			English	Article						cardiac and skeletal muscle; myosin; prenatal and postnatal development; TR	POSTNATAL-DEVELOPMENT; BINDING CAPACITY; PORCINE SKELETAL; GENE-EXPRESSION; ENERGY-BALANCE; BETA; GROWTH; ACID; MICE; RAT	Nuclear thyroid hormone (TH) receptors (TR) play a critical role in mediating the diverse actions of TH in development, differentiation, and metabolism of most tissues, but the role of TR isoforms in muscle development and function is unclear. Therefore, we have undertaken a comprehensive expression analysis of TR alpha 1, TR beta 1, TR beta 2 (TH binding), and TR alpha 2 (non-TH binding) in functionally distinct porcine muscles during prenatal and postnatal development. Use of a novel and highly sensitive RNase protection assay revealed striking muscle-specific developmental profiles of all four TR isoform mRNAs in cardiac, longissimus, soleus, rhomboideus, and diaphragm. Distribution of TR isoforms varied markedly between muscles; TR alpha expression was considerably greater than TR beta and there were significant differences in the ratios TR alpha 1:TR alpha 2, and TR beta1:TR beta 2. Together with immunohistochemistry of myosin heavy chain isoforms and data on myogenesis and maturation of the TH axis, these findings provide new evidence that highlights central roles for 1) TR alpha isoforms in fetal myogenesis, 2) the ratio TR alpha 1: TR alpha 2 in determining cardiac and skeletal muscle phenotype and function; 3) TR beta in maintaining a basal level of cellular response to TH throughout development and a specific maturational function around birth. These findings suggest that events disrupting normal developmental profiles of TR isoforms may impair optimal function of cardiac and skeletal muscles.	Babraham Inst, Dev Genet Programme, Cambridge CB2 4AT, England; Univ Cambridge, Dept Physiol, Cambridge CB2 3EG, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Cambridge	Dauncey, MJ (corresponding author), Babraham Inst, Dev Genet Programme, Bldg 540,Babraham Hall, Cambridge CB2 4AT, England.	dauncey@bbsrc.ac.uk	White, Peter/E-4301-2011	White, Peter/0000-0002-5218-5903				Bakker O, 1998, BIOCHEM BIOPH RES CO, V242, P492, DOI 10.1006/bbrc.1997.7992; BERTHON D, 1993, J DEV PHYSIOL, V19, P253; Brown K, 1999, CRIT REV EUKAR GENE, V9, P203, DOI 10.1615/CritRevEukarGeneExpr.v9.i3-4.50; Chatterjee VKK, 1997, HORM RES, V48, P43, DOI 10.1159/000191312; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANFORTH E, 1989, ANNU REV NUTR, V9, P201, DOI 10.1146/annurev.nu.09.070189.001221; Dauncey MJ, 1996, P NUTR SOC, V55, P543, DOI 10.1079/PNS19960047; DAUNCEY MJ, 1990, P NUTR SOC, V49, P203, DOI 10.1079/PNS19900024; Dauncey MJ, 2001, P NUTR SOC, V60, P63, DOI 10.1079/PNS200071; DAUNCEY MJ, 1995, THERMOCHIM ACTA, V250, P305, DOI 10.1016/0040-6031(94)01967-L; Dauncey MJ, 1996, ACTA PHYSIOL SCAND, V156, P313, DOI 10.1046/j.1365-201X.1996.188000.x; Drvota V, 1998, BIOCHEM BIOPH RES CO, V242, P593, DOI 10.1006/bbrc.1997.8013; DUCHAMP C, 1994, AM J PHYSIOL-ENDOC M, V267, pE687, DOI 10.1152/ajpendo.1994.267.5.E687; ErcanFang S, 1996, ENDOCRINOLOGY, V137, P3228, DOI 10.1210/en.137.8.3228; Fisher D A, 1976, Recent Prog Horm Res, V33, P59; Fisher Delbert A., 1996, P974; Forrest D, 1996, EMBO J, V15, P3006, DOI 10.1002/j.1460-2075.1996.tb00664.x; FOWDEN AL, 1995, REPROD FERT DEVELOP, V7, P351, DOI 10.1071/RD9950351; Fraichard A, 1997, EMBO J, V16, P4412, DOI 10.1093/emboj/16.14.4412; Gauthier K, 1999, EMBO J, V18, P623, DOI 10.1093/emboj/18.3.623; Harrison AP, 1997, REPROD FERT DEVELOP, V9, P731, DOI 10.1071/R97026; HODIN RA, 1989, SCIENCE, V244, P76, DOI 10.1126/science.2539642; IZUMO S, 1986, SCIENCE, V231, P597, DOI 10.1126/science.3945800; Johansson C, 1999, AM J PHYSIOL-HEART C, V276, pH2006, DOI 10.1152/ajpheart.1999.276.6.H2006; Johansson C, 2000, AM J PHYSIOL-REG I, V278, pR598, DOI 10.1152/ajpregu.2000.278.3.R598; Katsumata M, 1999, FASEB J, V13, P1405, DOI 10.1096/fasebj.13.11.1405; Katsumata M, 2000, J NUTR, V130, P2482, DOI 10.1093/jn/130.10.2482; Laudet V, 1997, J MOL ENDOCRINOL, V19, P207, DOI 10.1677/jme.0.0190207; LEFAUCHEUR L, 1995, DEV DYNAM, V203, P27, DOI 10.1002/aja.1002030104; MOROVAT A, 1995, J ENDOCRINOL, V144, P233, DOI 10.1677/joe.0.1440233; MUSCAT GEO, 1995, BIOESSAYS, V17, P211, DOI 10.1002/bies.950170307; OPPENHEIMER JH, 1987, ENDOCR REV, V8, P288, DOI 10.1210/edrv-8-3-288; POLK D, 1989, AM J PHYSIOL, V256, pE543, DOI 10.1152/ajpendo.1989.256.4.E543; RODD C, 1992, ENDOCRINOLOGY, V131, P2559, DOI 10.1210/en.131.6.2559; SCHIAFFINO S, 1994, J APPL PHYSIOL, V77, P493, DOI 10.1152/jappl.1994.77.2.493; STRAIT KA, 1990, J BIOL CHEM, V265, P10514; Tumbleson ME, 1996, ADV SWINE BIOMEDICAL; White P, 1999, J MOL ENDOCRINOL, V23, P241, DOI 10.1677/jme.0.0230241; White P, 2000, BRIT J NUTR, V84, P185; WHITE P, 1998, LIFE SCI NEWS, V0001, P00023; Yu FS, 2000, AM J PHYSIOL-REG I, V278, pR1545, DOI 10.1152/ajpregu.2000.278.6.R1545; Zhang JS, 2000, ANNU REV PHYSIOL, V62, P439, DOI 10.1146/annurev.physiol.62.1.439	42	34	36	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2001	15	8					1367	1376		10.1096/fj.00-0725com	http://dx.doi.org/10.1096/fj.00-0725com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11387234				2022-12-25	WOS:000169261200004
J	Lefer, DJ; Scalia, R; Jones, SP; Sharp, BR; Hoffmeyer, MR; Farvid, AR; Gibson, MF; Lefer, AM				Lefer, DJ; Scalia, R; Jones, SP; Sharp, BR; Hoffmeyer, MR; Farvid, AR; Gibson, MF; Lefer, AM			HMG-CoA reductase inhibition protects the diabetic myocardium from ischemia-reperfusion injury	FASEB JOURNAL			English	Article						nitric oxide; endothelium; infarct; heart; leukocytes	NITRIC-OXIDE SYNTHASE; ENDOTHELIAL CELL-INTERACTIONS; CORONARY-ARTERY DISEASE; MONOCLONAL-ANTIBODY; MELLITUS; ADHESION; CHOLESTEROL; SIMVASTATIN; INFARCTION; PRAVASTATIN	HMG-CoA reductase inhibitors (statins) exert beneficial effects independently of reducing blood cholesterol levels. We tested the hypothesis that statin therapy could reduce injury in the diabetic heart following myocardial ischemia (MI) and reperfusion (R) by increasing the bioavailability of nitric oxide (NO). The db/db diabetic mouse exhibits obesity, hyperinsulinemia, hyperglycemia, and endothelial dysfunction similar to Type II diabetes in humans. Diabetic mice received daily injections of simvastatin (0.5 mg/kg) or vehicle for 5 days before MI-R. Simvastatin did not reduce serum cholesterol levels (105 +/- 2 mg/dl vs. 103 3 mg/dl). However, simvastatin increased eNOS mRNA levels in diabetic hearts (n=7) by 97 +/- 31% (P<0.05) compared with vehicle (n=7). Simvastatin also significantly augmented (P<0.05) vascular NO production compared with vehicle (16.0 +/- 1.6 vs. 8.9 +/- 1.5 nmol/g). Diabetic (n=12) and nondiabetic (n=10) mice were subjected to 30 min of MI and 2 h of R. Simvastatin treatment (n=11) in diabetic mice reduced (P<0.02) myocardial necrosis from 62.6 +/- 3.3 % to 37.0 +/- 6.4%. Neutrophil infiltration in the I-R myocardium was attenuated by 62% (P<0.01) in simvastatin-treated mice. Intravital microscopy demonstrated reduced leukocyte-endothelial cell interactions in simvastatin-treated diabetic mice. Thus, simvastatin attenuates injury in the diabetic myocardium by enhanced NO production without reducing cholesterol levels.	Louisiana State Univ, Hlth Sci Ctr, Dept Cellular & Mol Physiol, Shreveport, LA 71130 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Surg, Shreveport, LA 71130 USA; Thomas Jefferson Univ, Dept Physiol, Philadelphia, PA 19107 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Jefferson University	Lefer, AM (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Cellular & Mol Physiol, 1501 Kings Highway, Shreveport, LA 71130 USA.	dlefer@lsuhsc.edu	Lefer, David/A-6372-2012; Jones, Steven P./D-5092-2009	Jones, Steven P./0000-0001-5376-8089; Scalia, Rosario/0000-0002-1829-943X; Lefer, David/0000-0003-2293-7278				ABBOTT RD, 1988, JAMA-J AM MED ASSOC, V260, P3456, DOI 10.1001/jama.260.23.3456; Endres M, 1998, P NATL ACAD SCI USA, V95, P8880, DOI 10.1073/pnas.95.15.8880; ENTMAN ML, 1993, CIRCULATION, V88, P800, DOI 10.1161/01.CIR.88.2.800; GARCIA MJ, 1974, DIABETES, V23, P105, DOI 10.2337/diab.23.2.105; Goldberg RB, 1998, CIRCULATION, V98, P2513, DOI 10.1161/01.CIR.98.23.2513; Guo JP, 1996, J APPL PHYSIOL, V81, P774, DOI 10.1152/jappl.1996.81.2.774; Haffner SM, 1998, NEW ENGL J MED, V339, P229, DOI 10.1056/NEJM199807233390404; HOGAN M, 1992, J CLIN INVEST, V90, P1110, DOI 10.1172/JCI115928; Jones SP, 1999, AM J PHYSIOL-HEART C, V277, pH763, DOI 10.1152/ajpheart.1999.277.2.H763; Jones SP, 1999, AM J PHYSIOL-HEART C, V276, pH1567, DOI 10.1152/ajpheart.1999.276.5.H1567; Kaesemeyer WH, 1999, J AM COLL CARDIOL, V33, P234, DOI 10.1016/S0735-1097(98)00514-2; Kawachi S, 2000, BIOCHEM BIOPH RES CO, V276, P851, DOI 10.1006/bbrc.2000.3559; Kimura M, 1997, ARTERIOSCL THROM VAS, V17, P1521, DOI 10.1161/01.ATV.17.8.1521; KRAEMER R, 1991, CARDIOVASC RES, V25, P172, DOI 10.1093/cvr/25.2.172; Laufs U, 1998, J BIOL CHEM, V273, P24266, DOI 10.1074/jbc.273.37.24266; Laufs U, 1997, J BIOL CHEM, V272, P31725, DOI 10.1074/jbc.272.50.31725; Laufs U, 1998, CIRCULATION, V97, P1129, DOI 10.1161/01.CIR.97.12.1129; Lefer AM, 1999, CIRCULATION, V100, P178, DOI 10.1161/01.CIR.100.2.178; Lefer DJ, 1999, AM J PHYSIOL-HEART C, V276, pH1943, DOI 10.1152/ajpheart.1999.276.6.H1943; Lekakis J, 1997, CARDIOVASC RES, V34, P164, DOI 10.1016/S0008-6363(97)00015-1; MA XL, 1992, CIRCULATION, V86, P937, DOI 10.1161/01.CIR.86.3.937; MA XL, 1991, J CLIN INVEST, V88, P1237, DOI 10.1172/JCI115427; Massy ZA, 1996, LANCET, V347, P102, DOI 10.1016/S0140-6736(96)90217-2; MAYHAN WG, 1989, AM J PHYSIOL, V256, pH621, DOI 10.1152/ajpheart.1989.256.3.H621; MAZZONE A, 1993, CIRCULATION, V88, P358, DOI 10.1161/01.CIR.88.2.358; ODriscoll G, 1997, CIRCULATION, V95, P1126, DOI 10.1161/01.cir.95.5.1126; OHRVALL M, 1995, METABOLISM, V44, P212, DOI 10.1016/0026-0495(95)90267-8; PEDERSEN TR, 1994, LANCET, V344, P1383; Pieper GM, 1997, CARDIOVASC RES, V34, P145, DOI 10.1016/S0008-6363(96)00237-4; PIEWPER GM, 1988, AM J PHYSIOL, V255, pH825; Pruefer D, 1999, ARTERIOSCL THROM VAS, V19, P2894, DOI 10.1161/01.ATV.19.12.2894; RASKIN P, 1995, AM J MED, V99, P362, DOI 10.1016/S0002-9343(99)80182-X; SIMPSON PJ, 1988, J CLIN INVEST, V81, P624, DOI 10.1172/JCI113364; TREASURE CB, 1995, NEW ENGL J MED, V332, P481, DOI 10.1056/NEJM199502233320801; ZUANETTI G, 1993, J AM COLL CARDIOL, V22, P1788, DOI 10.1016/0735-1097(93)90758-S	36	82	85	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 27	2001	15	6					1454	+		10.1096/fj.00-0819fje	http://dx.doi.org/10.1096/fj.00-0819fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387255				2022-12-25	WOS:000173705800010
J	Eubank, DW; Duplus, E; Williams, SC; Forest, C; Beale, EG				Eubank, DW; Duplus, E; Williams, SC; Forest, C; Beale, EG			Peroxisome proliferator-activated receptor gamma and chicken ovalbumin upstream promoter transcription factor II negatively regulate the phosphoenolpyruvate carboxykinase promoter via a common element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID RESPONSE ELEMENT; RETINOID-X-RECEPTOR; FACTOR COUP-TF; PPAR-GAMMA; GENE-TRANSCRIPTION; GTP GENE; ADIPOCYTE DIFFERENTIATION; TERMINAL DIFFERENTIATION; GLUCOCORTICOID RESPONSE; INSULIN-RESISTANCE	A heterodimer of peroxisome proliferator-activated receptor gamma (PPAR gamma) and retinoid X receptor (RXR) is required for adipocyte differentiation. The gene encoding cytosolic phosphoenolpyruvate carboxykinase (PEPCK) is a PPAR gamma /RXR target gene in adipose tissue. Of the two PPAR gamma response elements, gAF1/PCK1 and PCK2, only PCK2 is required for PEPCK expression and responsiveness to the PPAR gamma agonist, rosiglitazone, in adipose tissue even though both elements bind PPAR gamma /RXR in vitro. In contrast, gAF1/PCK1 is essential for glucocorticoid inhibition of PPAR gamma -induced PEPCK gene expression in adipocytes. We report that chicken ovalbumin upstream promoter transcription factor II (COUP-TFII) is the predominant nuclear receptor bound to gAF1/PCK1 in preadipocytes. COUP-TFII declines during adipogenesis in reciprocal fashion to PPAR gamma. In transiently transfected fibroblasts COUP-TFII acts at gAF1/PCK1 to inhibit PPAR gamma /RXR activation via PCK2. In contrast COUP-TFs are transcriptional activators of PEPCK in hepatocytes. PPAR gamma /RXR occupies gAF1/PCK1 in adipocytes, and mutation of gAF1/PCK1 enhances PEPCK promoter transactivation by PPAR gamma /RXR in fibroblasts, suggesting that this element is also a negative PPAR gamma response element. These results indicate that gAF1/PCK1 is a pleiotropic element through which COUP-TFII inhibits premature PEPCK expression, and perhaps adipogenesis in general, and PPAR gamma /RXR uses this same element in adipocytes to participate in PEPCK modulation by glucocorticoids.	Texas Tech Univ, Hlth Sci Ctr, Dept Cell Biol & Biochem, Lubbock, TX 79430 USA; CNRS, INSERM, Unit 530, F-92190 Meudon, France	Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Beale, EG (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Dept Cell Biol & Biochem, Stop 6540, Lubbock, TX 79430 USA.		Beale, Elmus/GNM-8181-2022; DUPLUS, Eric/F-2969-2013	DUPLUS, Eric/0000-0003-1954-4836; Forest, Claude/0000-0003-3401-8148; Beale, Elmus/0000-0002-7758-0600	NICHD NIH HHS [T32-HD07271] Funding Source: Medline; NIGMS NIH HHS [GM39895] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007271] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM039895, R01GM039895] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAES M, 1995, BIOCHEM BIOPH RES CO, V215, P338, DOI 10.1006/bbrc.1995.2471; BALLARD FJ, 1967, J BIOL CHEM, V242, P2746; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Barroso I, 1999, NATURE, V402, P880, DOI 10.1038/47254; BEALE EG, 1985, J BIOL CHEM, V260, P748; BEALE EG, 1992, FASEB J, V6, P330; Brodie AE, 1996, BIOCHEM BIOPH RES CO, V228, P655, DOI 10.1006/bbrc.1996.1713; Chinetti G, 1998, J BIOL CHEM, V273, P25573, DOI 10.1074/jbc.273.40.25573; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Croniger C, 1998, J BIOL CHEM, V273, P31629, DOI 10.1074/jbc.273.48.31629; Demetri GD, 1999, P NATL ACAD SCI USA, V96, P3951, DOI 10.1073/pnas.96.7.3951; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Devine JH, 1999, J BIOL CHEM, V274, P13604, DOI 10.1074/jbc.274.19.13604; Duplus E, 2000, J BIOL CHEM, V275, P30749, DOI 10.1074/jbc.R000015200; Forest C, 1997, PROSTAG LEUKOTR ESS, V57, P47, DOI 10.1016/S0952-3278(97)90492-0; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FRANCKHAUSER S, 1995, BIOCHEM J, V305, P65, DOI 10.1042/bj3050065; FranckhauserVogel S, 1997, MOL CELL ENDOCRINOL, V127, P171, DOI 10.1016/S0303-7207(96)04006-3; FROST SC, 1985, J BIOL CHEM, V260, P2646; Glorian M, 1998, J CELL BIOCHEM, V68, P298, DOI 10.1002/(SICI)1097-4644(19980301)68:3<298::AID-JCB2>3.0.CO;2-P; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; HALL RK, 1992, MOL CELL BIOL, V12, P5527, DOI 10.1128/MCB.12.12.5527; HALL RK, 1995, P NATL ACAD SCI USA, V92, P412, DOI 10.1073/pnas.92.2.412; HANSON RW, 1973, AM J CLIN NUTR, V26, P55, DOI 10.1093/ajcn/26.1.55; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; Hollenberg AN, 1997, J BIOL CHEM, V272, P5283, DOI 10.1074/jbc.272.8.5283; Ijpenberg A, 1997, J BIOL CHEM, V272, P20108, DOI 10.1074/jbc.272.32.20108; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; JugeAubry C, 1997, J BIOL CHEM, V272, P25252, DOI 10.1074/jbc.272.40.25252; Kalhan SC, 2001, J BIOL CHEM, V276, P12928, DOI 10.1074/jbc.M006186200; KIEBACK DG, 1993, GYNECOL ONCOL, V51, P167, DOI 10.1006/gyno.1993.1266; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; LUCAS PC, 1991, P NATL ACAD SCI USA, V88, P2184, DOI 10.1073/pnas.88.6.2184; LUCAS PC, 1991, MOL CELL BIOL, V11, P5164, DOI 10.1128/MCB.11.10.5164; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Marcus SL, 1996, MOL CELL ENDOCRINOL, V120, P31, DOI 10.1016/0303-7207(96)03813-0; MIYATA KS, 1993, J BIOL CHEM, V268, P19169; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; NECHUSHTAN H, 1987, NUCLEIC ACIDS RES, V15, P6405, DOI 10.1093/nar/15.16.6405; PATEL YM, 1994, J BIOL CHEM, V269, P5619; Ristow M, 1998, NEW ENGL J MED, V339, P953, DOI 10.1056/NEJM199810013391403; Robinson CE, 1999, ENDOCRINOLOGY, V140, P1586, DOI 10.1210/en.140.4.1586; Rodriguez JC, 1997, BIOCHEM J, V326, P587, DOI 10.1042/bj3260587; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Sarraf P, 1999, MOL CELL, V3, P799, DOI 10.1016/S1097-2765(01)80012-5; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; She P, 2000, MOL CELL BIOL, V20, P6508, DOI 10.1128/MCB.20.17.6508-6517.2000; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; Spiegelman BM, 1998, CELL, V93, P153, DOI 10.1016/S0092-8674(00)81567-6; Sugiyama T, 1998, MOL ENDOCRINOL, V12, P1487, DOI 10.1210/me.12.10.1487; Sugiyama T, 2000, J BIOL CHEM, V275, P3446, DOI 10.1074/jbc.275.5.3446; Tilghman SM, 1976, GLUCONEOGENESIS ITS, P47; Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237; TONTONOZ P, 1995, MOL CELL BIOL, V15, P351, DOI 10.1128/MCB.15.1.351; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Wendling O, 1999, P NATL ACAD SCI USA, V96, P547, DOI 10.1073/pnas.96.2.547; Williams CP, 1999, MOL CELL ENDOCRINOL, V148, P67, DOI 10.1016/S0303-7207(98)00234-2	63	36	37	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30561	30569		10.1074/jbc.M103019200	http://dx.doi.org/10.1074/jbc.M103019200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11399762	hybrid			2022-12-25	WOS:000170558000125
J	Ikebe, M; Komatsu, S; Woodhead, JL; Mabuchi, K; Ikebe, R; Saito, J; Craig, R; Higashihara, M				Ikebe, M; Komatsu, S; Woodhead, JL; Mabuchi, K; Ikebe, R; Saito, J; Craig, R; Higashihara, M			The tip of the coiled-coil rod determines the filament formation of smooth muscle and nonmuscle myosin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN GENE; AMINO-ACID-SEQUENCES; LIGHT-CHAIN; UNCONVENTIONAL MYOSINS; DICTYOSTELIUM MYOSIN; ESCHERICHIA-COLI; IONIC-STRENGTH; DNA-SEQUENCE; REGION; EXPRESSION	Myosin II self-assembles to form thick filaments that are attributed to its long coiled-coil tail domain. The present study has determined a region critical for filament formation of vertebrate smooth muscle and nonmuscle myosin IL A monoclonal antibody recognizing the 28 residues from the C-terminal end of the coiled-coil domain of smooth muscle myosin II completely inhibited filament formation, whereas other antibodies recognizing other parts of the coiled-coil did not. To determine the importance of this region in the filament assembly in vivo, green fluorescent protein (GFP)-tagged smooth muscle myosin was expressed in COS-7 cells, and the filamentous localization of the GFP signal was monitored by fluorescence microscopy. Wild type GFP-tagged smooth muscle myosin colocalized with F-actin during interphase and was also recruited into the contractile ring during cytokinesis. Myosin with the nonhelical tail piece deleted showed similar behavior, whereas deletion of the 28 residues at the C-terminal end of the coiled-coil domain abolished this localization. Deletion of the corresponding region of GFP-tagged nonmuscle myosin IIA also abolished this localization. We conclude that the C-terminal end of the coiled-coil domain, but not the nonhelical tail piece, of myosin II is critical for myosin filament formation both in vitro and in vivo.	Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; Boston Biomed Res Inst, Watertown, MA 02472 USA; Kitasato Univ, Sch Med, Dept Internal Med, Sagamihara, Kanagawa 2288555, Japan	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Boston Biomedical Research Institute; Kitasato University	Ikebe, M (corresponding author), Univ Massachusetts, Sch Med, Dept Physiol, 55 Lake Ave N, Worcester, MA 01655 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056218, R01HL062468] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041653, P01AR041637] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56218, HL62468] Funding Source: Medline; NIAMS NIH HHS [AR41637, AR41653, R01 AR041653] Funding Source: Medline; PHS HHS [MG55834] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ATKINSON SJ, 1991, J CELL SCI, V99, P823; Baker JP, 1997, J MOL BIOL, V272, P523, DOI 10.1006/jmbi.1997.1232; Cohen C, 1998, J STRUCT BIOL, V122, P180, DOI 10.1006/jsbi.1998.3983; CRAIG R, 1977, J CELL BIOL, V75, P990, DOI 10.1083/jcb.75.3.990; CROSS RA, 1986, FEBS LETT, V200, P355, DOI 10.1016/0014-5793(86)81168-1; CROSS RA, 1984, EUR J BIOCHEM, V145, P305, DOI 10.1111/j.1432-1033.1984.tb08553.x; CROSS RA, 1984, FEBS LETT, V176, P197, DOI 10.1016/0014-5793(84)80940-0; CROSS RA, 1991, EMBO J, V10, P747, DOI 10.1002/j.1460-2075.1991.tb08006.x; DELOZANNE A, 1987, J CELL BIOL, V105, P2999, DOI 10.1083/jcb.105.6.2999; Ford HL, 1997, BIOCHEMISTRY-US, V36, P16321, DOI 10.1021/bi971182l; Higashihara M, 1989, J BIOL CHEM, V264, P5218; Hodge T, 2000, J CELL SCI, V113, P3353; HODGE TP, 1992, J CELL BIOL, V118, P1085, DOI 10.1083/jcb.118.5.1085; HOPE PE, 1996, J CELL BIOL, V135, P371; IKEBE M, 1991, J BIOL CHEM, V266, P7030; IKEBE M, 1994, J BIOL CHEM, V269, P28173; IKEBE M, 1985, J BIOL CHEM, V260, P3146; KELLERMAN KA, 1992, J CELL BIOL, V119, P823, DOI 10.1083/jcb.119.4.823; KING L, 1995, BIOCHEM J, V312, P511, DOI 10.1042/bj3120511; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE RJ, 1994, J CELL SCI, V107, P2875; MABUCHI K, 1990, J STRUCT BIOL, V103, P249, DOI 10.1016/1047-8477(90)90043-C; MABUCHI K, 1991, J STRUCT BIOL, V107, P22, DOI 10.1016/1047-8477(91)90027-T; MCLACHLAN AD, 1983, J MOL BIOL, V164, P605, DOI 10.1016/0022-2836(83)90053-0; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; NYITRAY L, 1983, J BIOL CHEM, V258, P3213; ONISHI H, 1982, J BIOCHEM-TOKYO, V92, P871, DOI 10.1093/oxfordjournals.jbchem.a134001; PAGH K, 1984, EMBO J, V3, P3271, DOI 10.1002/j.1460-2075.1984.tb02289.x; PARRY DAD, 1981, J MOL BIOL, V153, P459, DOI 10.1016/0022-2836(81)90290-4; PARRY DAD, 1979, FIBROUS PROTEINS SCI, V1, P393; PHILLIPS CL, 1995, J MUSCLE RES CELL M, V16, P379, DOI 10.1007/BF00114503; SCHOLEY JM, 1980, NATURE, V287, P233, DOI 10.1038/287233a0; Sellers J. R., 1999, MYOSINS; SHOHET RV, 1989, P NATL ACAD SCI USA, V86, P7726, DOI 10.1073/pnas.86.20.7726; SINARD JH, 1990, J CELL BIOL, V111, P2417, DOI 10.1083/jcb.111.6.2417; Sohn RL, 1997, J MOL BIOL, V266, P317, DOI 10.1006/jmbi.1996.0790; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STREHLER EE, 1986, J MOL BIOL, V190, P291, DOI 10.1016/0022-2836(86)90003-3; SUZUKI H, 1978, J BIOCHEM, V84, P1529, DOI 10.1093/oxfordjournals.jbchem.a132278; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Titus MA, 1997, TRENDS CELL BIOL, V7, P119, DOI 10.1016/S0962-8924(97)01019-2; TRYBUS KM, 1984, J BIOL CHEM, V259, P8564; VISTROM KL, 1993, CELL MOTIL CYTOSKEL, V26, P192; WARRICK HM, 1986, P NATL ACAD SCI USA, V83, P9433, DOI 10.1073/pnas.83.24.9433; Xu JQ, 1996, J CELL BIOL, V134, P53, DOI 10.1083/jcb.134.1.53; YANAGISAWA M, 1987, J MOL BIOL, V198, P143, DOI 10.1016/0022-2836(87)90302-0; YANO K, 1993, BIOCHEMISTRY-US, V32, P12054, DOI 10.1021/bi00096a016	47	50	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30293	30300		10.1074/jbc.M101969200	http://dx.doi.org/10.1074/jbc.M101969200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11395487	hybrid			2022-12-25	WOS:000170558000091
J	Poon, KKH; Chu, JCL; Wong, SL				Poon, KKH; Chu, JCL; Wong, SL			Roles of glucitol in the GutR-mediated transcription activation process in Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER-BINDING PROTEIN; BIOTIN HOLOENZYME SYNTHETASE; COLI MALTOSE SYSTEM; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; ATP-BINDING; PSEUDOMONAS-PUTIDA; TERMINAL DOMAIN; GTP-HYDROLYSIS; DNA-BINDING	GutR is a 95-kDa glucitol-dependent transcription activator that mediates the expression of the Bacillus subtilis glucitol operon. Glucitol allows GutR to bind tightly to its binding site located upstream of the gut promoter. In this study, a second functional role of glucitol is identified. Glucitol induces GutR to change its conformation and triggers GutR to bind ATP efficiently. After sequential binding of glucitol and ATP to GutR, GutR adopts a new conformation by forming a compact structure that is resistant to trypsin digestion. Under this condition, the ATP.glucitiol.GutR complex can dissociate slowly from the gutR-binding site (t(1/2) = 274 min). Interestingly, if ATP in the ATP.glucitiol.GutR complex is replaced by ADP, GutR adopts another conformation and can dissociate from the gutR-binding site even faster (t(1/2) = 82 min). In all these GutR-DNA binding studies in the presence of different ligands (glucitol, ATP, or ADP), only the off-rate is affected. The vital role of ATP in the GutR-mediated transcription activation process is reflected by the poor transcription from the gut promoter with GutR(D285A) which has a mutation in the motif B of the putative ATP-binding site. A working model for this transcription activation process is presented.	Univ Calgary, Dept Biol Sci, Div Cellular Mol & Microbial Biol, Calgary, AB T2N 1N4, Canada	University of Calgary	Wong, SL (corresponding author), Univ Calgary, Dept Biol Sci, Div Cellular Mol & Microbial Biol, Calgary, AB T2N 1N4, Canada.							BARKER DF, 1981, J MOL BIOL, V146, P451, DOI 10.1016/0022-2836(81)90042-5; Boos W, 2000, TRENDS GENET, V16, P404, DOI 10.1016/S0168-9525(00)02086-2; Boos W, 1998, MICROBIOL MOL BIOL R, V62, P204, DOI 10.1128/MMBR.62.1.204-229.1998; Bowman WC, 1998, GENE DEV, V12, P1884, DOI 10.1101/gad.12.12.1884; BUONCRISTIANI MR, 1986, GENE, V44, P255, DOI 10.1016/0378-1119(86)90189-7; CHALUMEAU H, 1978, J BACTERIOL, V134, P921; Chapman A G, 1977, Adv Microb Physiol, V15, P253, DOI 10.1016/S0065-2911(08)60318-5; DELOBBE A, 1975, EUR J BIOCHEM, V51, P503; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; GAY P, 1983, J BACTERIOL, V153, P1133, DOI 10.1128/JB.153.3.1133-1137.1983; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; MARQUES S, 1993, MOL MICROBIOL, V9, P923, DOI 10.1111/j.1365-2958.1993.tb01222.x; Mizushima T, 1998, J BIOL CHEM, V273, P20847, DOI 10.1074/jbc.273.33.20847; Neri D, 1996, TRENDS BIOTECHNOL, V14, P465, DOI 10.1016/S0167-7799(96)10067-6; NG K, 1992, J BIOL CHEM, V267, P24989; OSHANNESSY DJ, 1994, METHOD ENZYMOL, V240, P323; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Peng HL, 1997, J BACTERIOL, V179, P1497, DOI 10.1128/jb.179.5.1497-1504.1997; PEREZMARTIN J, 1995, P NATL ACAD SCI USA, V92, P9392, DOI 10.1073/pnas.92.20.9392; PerezMartin J, 1996, J MOL BIOL, V258, P575, DOI 10.1006/jmbi.1996.0270; Poon KKH, 2001, J BIOL CHEM, V276, P9620, DOI 10.1074/jbc.M009864200; RICHET E, 1989, EMBO J, V8, P981, DOI 10.1002/j.1460-2075.1989.tb03461.x; Rombel I, 1999, J BACTERIOL, V181, P4628, DOI 10.1128/JB.181.15.4628-4638.1999; Sato K, 1996, J BIOL CHEM, V271, P17439, DOI 10.1074/jbc.271.29.17439; Schweins T, 1997, J MOL BIOL, V266, P847, DOI 10.1006/jmbi.1996.0814; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEDEL A, 1995, GENE DEV, V9, P2042, DOI 10.1101/gad.9.16.2042; WILSON KP, 1992, P NATL ACAD SCI USA, V89, P9257, DOI 10.1073/pnas.89.19.9257; WU XC, 1990, J BIOL CHEM, V265, P6845; YE RQ, 1994, J BACTERIOL, V176, P3314, DOI 10.1128/jb.176.11.3314-3320.1994; YE RQ, 1994, J BACTERIOL, V176, P3321, DOI 10.1128/jb.176.11.3321-3327.1994; Zhong XT, 1998, J BACTERIOL, V180, P1347, DOI 10.1128/JB.180.6.1347-1353.1998	33	11	11	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29819	29825		10.1074/jbc.M100905200	http://dx.doi.org/10.1074/jbc.M100905200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11390381	hybrid			2022-12-25	WOS:000170558000030
J	Kim, BY; Kramer, H; Yamamoto, A; Kominami, E; Kohsaka, S; Akazawa, C				Kim, BY; Kramer, H; Yamamoto, A; Kominami, E; Kohsaka, S; Akazawa, C			Molecular characterization of mammalian homologues of class CVPS proteins that interact with syntaxin-7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LATE ENDOSOME-LYSOSOME; VACUOLAR BIOGENESIS; SACCHAROMYCES-CEREVISIAE; VESICLE TRAFFICKING; DEEP-ORANGE; YEAST; MUTANTS; COMPLEX; FUSION; GENE	Vesicle-mediated protein sorting plays an important role in segregation of intracellular molecules into distinct organelles. Extensive genetic studies using yeast have identified more than 40 vacuolar protein sorting (VPS) genes involved in vesicle transport to vacuoles. However, their mammalian counterparts are not fully elucidated. In this study, we identified two human homologues of yeast Class C VPS genes, human VPS11 (hVPS11) and human VPS18 (hVPS18). We also characterized the subcellular localization and interactions of the protein products not only from these genes but also from the other mammalian Class C VPS homologue genes, hVPS16 and rVPS33a. The protein products of hVPS11 (hVps11) and hVPS18 (hVps18) were ubiquitously expressed in peripheral tissues, suggesting that they have a fundamental role in cellular function. Indirect immunofluoreseence microscopy revealed that the mammalian Class C Vps proteins are predominantly associated with late endosomes/lysosomes. Immunoprecipitation and gel filtration studies showed that the mammalian Class C Vps proteins constitute a large hetero-oligomeric complex that interacts with syntaxin-7. These results indicate that like their yeast counterparts, mammalian Class C Vps proteins mediate vesicle trafficking steps in the endosome/lysosome pathway.	NCNP, Natl Inst Neurosci, Dept Neurochem, Tokyo 1878502, Japan; Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dallas, TX 75235 USA; Kansai Med Univ, Dept Physiol, Osaka 5708506, Japan; Juntendo Univ, Sch Med, Dept Biochem, Bunkyo Ku, Tokyo 1138421, Japan	National Center for Neurology & Psychiatry - Japan; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Kansai Medical University; Juntendo University	Akazawa, C (corresponding author), NCNP, Natl Inst Neurosci, Dept Neurochem, Tokyo 1878502, Japan.	akazawa@ncnp.go.jp	Kominami, Eiki/D-3802-2009	Kramer, Helmut/0000-0002-1167-2676	NATIONAL EYE INSTITUTE [R01EY010199] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY010199, EY 10199] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AKAZAWA C, 1994, J COMP NEUROL, V347, P150, DOI 10.1002/cne.903470112; BANKAITIS VA, 1986, P NATL ACAD SCI USA, V83, P9075, DOI 10.1073/pnas.83.23.9075; BANTA LM, 1988, J CELL BIOL, V107, P1369, DOI 10.1083/jcb.107.4.1369; CARLSSON SR, 1988, J BIOL CHEM, V263, P18911; Darsow T, 1997, J CELL BIOL, V138, P517, DOI 10.1083/jcb.138.3.517; DULIC V, 1989, EMBO J, V8, P1349, DOI 10.1002/j.1460-2075.1989.tb03515.x; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; Hay JC, 1996, J BIOL CHEM, V271, P5671, DOI 10.1074/jbc.271.10.5671; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; HOPKINS CR, 1983, CELL, V35, P321, DOI 10.1016/0092-8674(83)90235-0; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Mullock BM, 2000, MOL BIOL CELL, V11, P3137, DOI 10.1091/mbc.11.9.3137; Nakamura N, 2000, J BIOL CHEM, V275, P6523, DOI 10.1074/jbc.275.9.6523; Patki V, 1998, NATURE, V394, P433, DOI 10.1038/28771; PRESTON RA, 1991, MOL CELL BIOL, V11, P5801, DOI 10.1128/MCB.11.12.5801; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; Rieder SE, 1997, MOL BIOL CELL, V8, P2307, DOI 10.1091/mbc.8.11.2307; ROBINSON JS, 1991, MOL CELL BIOL, V11, P5813, DOI 10.1128/MCB.11.12.5813; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; ROTHMAN JH, 1986, CELL, V47, P1041, DOI 10.1016/0092-8674(86)90819-6; Sato TK, 2000, MOL CELL, V6, P661, DOI 10.1016/S1097-2765(00)00064-2; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Seals DF, 2000, P NATL ACAD SCI USA, V97, P9402, DOI 10.1073/pnas.97.17.9402; Sevrioukov EA, 1999, MOL CELL, V4, P479, DOI 10.1016/S1097-2765(00)80199-9; Shestopal SA, 1997, MOL GEN GENET, V253, P642; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Smith CJ, 1999, TRENDS CELL BIOL, V9, P335, DOI 10.1016/S0962-8924(99)01631-1; Stenmark H, 1999, J CELL SCI, V112, P4175; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; WADA Y, 1992, J BIOL CHEM, V267, P18665; Wang H, 1997, GENE, V199, P39, DOI 10.1016/S0378-1119(97)00343-0; Ward DM, 2000, MOL BIOL CELL, V11, P2327, DOI 10.1091/mbc.11.7.2327; Weimbs T, 1997, P NATL ACAD SCI USA, V94, P3046, DOI 10.1073/pnas.94.7.3046; Wong SH, 1998, J BIOL CHEM, V273, P375, DOI 10.1074/jbc.273.1.375; WOOLFORD CA, 1990, GENETICS, V125, P739; Wurmser AE, 2000, J CELL BIOL, V151, P551, DOI 10.1083/jcb.151.3.551; Ybe JA, 1999, NATURE, V399, P371, DOI 10.1038/20708	42	67	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29393	29402		10.1074/jbc.M101778200	http://dx.doi.org/10.1074/jbc.M101778200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11382755	hybrid			2022-12-25	WOS:000170346000101
J	Lin, J; Weiss, A				Lin, J; Weiss, A			Identification of the minimal tyrosine residues required for linker for activation of T cell function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADAPTER PROTEIN SLP-76; ANTIGEN RECEPTOR; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE C-GAMMA-1; SH3 DOMAIN; LAT; PLC-GAMMA-1; KINASES; TCR; RAS	The linker for activation of T cells (LAT) is essential for signaling through the T cell receptor (TOR). Following TCR stimulation, LAT becomes tyrosine-phosphorylated, creating docking sites for other signaling proteins such as phospholipase C-gamma (1) (PLC-gamma (1)), Grb2, and Gads. In this study, we have attempted to identify the critical tyrosine residues in LAT that mediate TCR activation-induced mobilization of intracellular Ca2+ and activation of the MAP kinase Erk2. By using the LAT-deficient Jurkat derivative, J.CaM2, stable cell lines were established expressing various tyrosine mutants of LAT. We show that three spe. cific tyrosine residues (Tyr(132), Tyr(171), and Tyr(191)) are necessary and sufficient to achieve a Ca2+ flux following TOR stimulation. These tyrosine residues function by reconstituting PLC-gamma (1) phosphorylation and recruitment to LAT. However, these same tyrosines can only partially reconstitute Erk activation. Full reconstitution of Erk requires two additional tyrosine residues (Tyr(110) and Tyr(226)), both of which have the Grb2-binding motif YXN. This reconstitution of Erk activation requires that the critical tyrosine residues be on the same molecule of LAT, suggesting that a single LAT molecule nucleates multiple protein-protein interactions required for optimal signal transduction.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, Biomed Sci Grad Program, Howard Hughes Med Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Weiss, A (corresponding author), Univ Calif San Francisco, Dept Med, 3rd & Parnassus Ave, San Francisco, CA 94143 USA.							Boerth NJ, 2000, J EXP MED, V192, P1047, DOI 10.1084/jem.192.7.1047; Bunnell SC, 2000, J BIOL CHEM, V275, P2219, DOI 10.1074/jbc.275.3.2219; Ching KA, 2000, J IMMUNOL, V165, P256, DOI 10.4049/jimmunol.165.1.256; Clements JL, 1998, SCIENCE, V281, P416, DOI 10.1126/science.281.5375.416; DeBell KE, 1999, MOL CELL BIOL, V19, P7388; Dower NA, 2000, NAT IMMUNOL, V1, P317, DOI 10.1038/79766; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; Ebinu JO, 2000, BLOOD, V95, P3199; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Genot E, 2000, CURR OPIN IMMUNOL, V12, P289, DOI 10.1016/S0952-7915(00)00089-3; GOLDSMITH MA, 1988, P NATL ACAD SCI USA, V85, P8613, DOI 10.1073/pnas.85.22.8613; Ishiai M, 2000, J EXP MED, V192, P847, DOI 10.1084/jem.192.6.847; Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; Kim MJ, 2000, BIOCHEMISTRY-US, V39, P8674, DOI 10.1021/bi992558t; LIAO F, 1993, BIOCHEM BIOPH RES CO, V191, P1028, DOI 10.1006/bbrc.1993.1320; Lin J, 1999, J BIOL CHEM, V274, P28861, DOI 10.1074/jbc.274.41.28861; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; Musci MA, 1997, J BIOL CHEM, V272, P11674, DOI 10.1074/jbc.272.18.11674; Pivniouk V, 1998, CELL, V94, P229, DOI 10.1016/S0092-8674(00)81422-1; Scholler JK, 2000, EUR J IMMUNOL, V30, P2378, DOI 10.1002/1521-4141(2000)30:8<2378::AID-IMMU2378>3.0.CO;2-E; Sekiya F, 1999, CHEM PHYS LIPIDS, V98, P3, DOI 10.1016/S0009-3084(99)00013-4; Shan XC, 1999, J BIOL CHEM, V274, P29323, DOI 10.1074/jbc.274.41.29323; Shapiro VS, 1996, J EXP MED, V184, P1663, DOI 10.1084/jem.184.5.1663; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Su YW, 1999, EUR J IMMUNOL, V29, P3702, DOI 10.1002/(SICI)1521-4141(199911)29:11<3702::AID-IMMU3702>3.0.CO;2-R; TAKATA M, 1995, J EXP MED, V182, P907, DOI 10.1084/jem.182.4.907; Tomlinson MG, 2000, IMMUNOL TODAY, V21, P584, DOI 10.1016/S0167-5699(00)01716-3; Tuosto L, 1996, J EXP MED, V184, P1161, DOI 10.1084/jem.184.3.1161; van Oers NSC, 1999, SEMIN IMMUNOL, V11, P227, DOI 10.1006/smim.1999.0179; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; Yablonski D, 2001, MOL CELL BIOL, V21, P4208, DOI 10.1128/MCB.21.13.4208-4218.2001; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; Yoder J, 2001, SCIENCE, V291, P1987, DOI 10.1126/science.1057176; Zhang WG, 2000, J BIOL CHEM, V275, P23355, DOI 10.1074/jbc.M000404200; Zhang WG, 1999, IMMUNITY, V10, P323, DOI 10.1016/S1074-7613(00)80032-1; Zhang WG, 1999, INT IMMUNOL, V11, P943, DOI 10.1093/intimm/11.6.943; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	43	141	146	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29588	29595		10.1074/jbc.M102221200	http://dx.doi.org/10.1074/jbc.M102221200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11395491	hybrid			2022-12-25	WOS:000170346000125
J	Siebers, B; Brinkmann, H; Dorr, C; Tjaden, B; Lilie, H; van der Oost, J; Verhees, CH				Siebers, B; Brinkmann, H; Dorr, C; Tjaden, B; Lilie, H; van der Oost, J; Verhees, CH			Archaeal fructose-1,6-bisphosphate aldolases constitute a new family of archaeal type class I aldolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; ENTNER-DOUDOROFF-PATHWAY; PYROCOCCUS-FURIOSUS; THERMOPROTEUS-TENAX; ESCHERICHIA-COLI; DEPENDENT PHOSPHOFRUCTOKINASE; THERMOPLASMA-ACIDOPHILUM; SULFOLOBUS-SOLFATARICUS; SUGAR FERMENTATION; EUGLENA-GRACILIS	Fructose-1,6-bisphosphate (FBP) aldolase activity has been detected previously in several Archaea. However, no obvious orthologs of the bacterial and eucaryal Class I and II FBP aldolases have yet been identified in sequenced archaeal genomes. Based on a recently described novel type of bacterial aldolase, we report on the identification and molecular characterization of the first archaeal FBP aldolases. We have analyzed the FBP aldolases of two hyperthermophilic Archaea, the facultatively heterotrophic Crenarchaeon Thermoproteus tenax and the obligately heterotrophic Euryarchaeon Pyrococcus furiosus. For enzymatic studies the fba genes of T. tenax and P. furiosus were expressed in Escherichia coli. The recombinant FBP aldolases show preferred substrate specificity for FBP in the catabolic direction and exhibit metal-independent Class I FBP aldolase activity via a Schiff-base mechanism. Transcript analyses reveal that the expression of both archaeal genes is induced during sugar fermentation. Remarkably, the fbp gene of T. tenax is co-transcribed with the pfp gene that codes for the reversible PPi-dependent phosphofructokinase. As revealed by phylogenetic analyses, orthologs of the T. tenax and P. furiosus enzyme appear to be present in almost all sequenced archaeal genomes, as well as in some bacterial genomes, strongly suggesting that this new enzyme family represents the typical archaeal FBP aldolase. Because this new family shows no significant sequence similarity to classical Class I and II enzymes, a new name is propose, archaeal type Class I FBP aldolases (FBP aldolase lass IA).	Univ Essen Gesamthsch, FB 9, Dept Microbiol, D-45117 Essen, Germany; Univ Konstanz, Dept Biol, Inst Evolut Biol, D-78547 Constance, Germany; Univ Halle Wittenberg, Dept Biochem & Biotechnol, Inst Biotechnol, D-06120 Halle Saale, Saale, Germany; Univ Wageningen & Res Ctr, Microbiol Lab, NL-6703 CT Wageningen, Netherlands	University of Duisburg Essen; University of Konstanz; Martin Luther University Halle Wittenberg; Wageningen University & Research	Siebers, B (corresponding author), Univ Essen Gesamthsch, FB 9, Dept Microbiol, Univ Str 5, D-45117 Essen, Germany.		van+der+Oost, John/Y-2548-2019	Siebers, Bettina/0000-0002-9905-541X				ADACHI J, 1996, MOLPHY VERSION 2 3; ALEFOUNDER PR, 1989, BIOCHEM J, V257, P529, DOI 10.1042/bj2570529; Bell SD, 2001, CURR OPIN MICROBIOL, V4, P208, DOI 10.1016/S1369-5274(00)00190-9; Blom NS, 1996, NAT STRUCT BIOL, V3, P856, DOI 10.1038/nsb1096-856; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunner NA, 1998, J BIOL CHEM, V273, P6149, DOI 10.1074/jbc.273.11.6149; Brunner NA, 2001, EXTREMOPHILES, V5, P101, DOI 10.1007/s007920100181; BUDGEN N, 1986, FEBS LETT, V196, P207, DOI 10.1016/0014-5793(86)80247-2; Choi KH, 1999, BIOCHEMISTRY-US, V38, P12655, DOI 10.1021/bi9828371; Condo I, 1999, MOL MICROBIOL, V34, P377, DOI 10.1046/j.1365-2958.1999.01615.x; Copley RR, 2000, J MOL BIOL, V303, P627, DOI 10.1006/jmbi.2000.4152; DHAR NM, 1986, FEMS MICROBIOL LETT, V35, P177, DOI 10.1016/0378-1097(86)90087-X; FIALA G, 1986, ARCH MICROBIOL, V145, P56, DOI 10.1007/BF00413027; FISCHER F, 1983, NATURE, V301, P511, DOI 10.1038/301511a0; FOTHERGILLGILMORE LA, 1993, PROG BIOPHYS MOL BIO, V59, P105, DOI 10.1016/0079-6107(93)90001-Z; FUCHS G, 1983, ARCH MICROBIOL, V136, P160, DOI 10.1007/BF00404793; Galperin MY, 2000, FEMS MICROBIOL LETT, V183, P259, DOI 10.1016/S0378-1097(99)00612-6; GIBSON JL, 1991, J BIOL CHEM, V266, P14646; GROSS W, 1994, PLANT PHYSIOL, V105, P1393, DOI 10.1104/pp.105.4.1393; Henze K, 1998, GENE, V222, P163, DOI 10.1016/S0378-1119(98)00499-5; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; KENGEN SWM, 1994, J BIOL CHEM, V269, P17537; KENGEN SWM, 1993, EUR J BIOCHEM, V213, P305, DOI 10.1111/j.1432-1033.1993.tb17763.x; Kengen SWM, 1995, J BIOL CHEM, V270, P30453, DOI 10.1074/jbc.270.51.30453; KRISHNAN G, 1991, EUR J BIOCHEM, V195, P343, DOI 10.1111/j.1432-1033.1991.tb15712.x; Lang D, 2000, SCIENCE, V289, P1546, DOI 10.1126/science.289.5484.1546; LEBHERZ HG, 1969, BIOCHEMISTRY-US, V8, P109, DOI 10.1021/bi00829a016; MARSH JJ, 1992, TRENDS BIOCHEM SCI, V17, P110, DOI 10.1016/0968-0004(92)90247-7; MUKUND S, 1995, J BIOL CHEM, V270, P8389, DOI 10.1074/jbc.270.15.8389; PELZERREITH B, 1994, PLANT PHYSIOL, V106, P1137, DOI 10.1104/pp.106.3.1137; PHILIPPE H, 1993, NUCLEIC ACIDS RES, V21, P5264, DOI 10.1093/nar/21.22.5264; Plaumann M, 1997, CURR GENET, V31, P430, DOI 10.1007/s002940050226; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Ruepp A, 2000, NATURE, V407, P508, DOI 10.1038/35035069; RUTTER WJ, 1964, FED PROC, V23, P1248; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAFER T, 1992, ARCH MICROBIOL, V158, P188, DOI 10.1007/BF00290815; Schramm A, 2000, J BACTERIOL, V182, P2001, DOI 10.1128/JB.182.7.2001-2009.2000; Siebers B, 1997, ARCH MICROBIOL, V168, P120, DOI 10.1007/s002030050477; SIEBERS B, 1993, FEMS MICROBIOL LETT, V111, P1; Siebers B, 1998, J BACTERIOL, V180, P2137, DOI 10.1128/JB.180.8.2137-2143.1998; Soppa J, 1999, MOL MICROBIOL, V31, P1589, DOI 10.1046/j.1365-2958.1999.01274.x; Soppa J, 1999, MOL MICROBIOL, V31, P1295, DOI 10.1046/j.1365-2958.1999.01273.x; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; Strimmer K, 1996, MOL BIOL EVOL, V13, P964, DOI 10.1093/oxfordjournals.molbev.a025664; SWOFFORD DL, 1999, PAUP VERSION 4; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Thomson GJ, 1998, BIOCHEM J, V331, P437, DOI 10.1042/bj3310437; Tolstrup N, 2000, EXTREMOPHILES, V4, P175, DOI 10.1007/s007920070032; Tuininga JE, 1999, J BIOL CHEM, V274, P21023, DOI 10.1074/jbc.274.30.21023; van der Oost J, 1998, J BIOL CHEM, V273, P28149, DOI 10.1074/jbc.273.43.28149; van der Oost J, 1998, Adv Biochem Eng Biotechnol, V61, P87; vandenBergh ERE, 1996, J BACTERIOL, V178, P888, DOI 10.1128/jb.178.3.888-893.1996; Ward DE, 2000, J BACTERIOL, V182, P2559, DOI 10.1128/JB.182.9.2559-2566.2000; WITKE C, 1993, J BACTERIOL, V175, P7495, DOI 10.1128/JB.175.22.7495-7499.1993; YU JP, 1994, J BACTERIOL, V176, P325, DOI 10.1128/JB.176.2.325-332.1994; ZILLIG W, 1981, ZBL BAKT MIK HYG I C, V2, P205, DOI 10.1016/S0721-9571(81)80001-4	59	86	91	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28710	28718		10.1074/jbc.M103447200	http://dx.doi.org/10.1074/jbc.M103447200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11387336	hybrid			2022-12-25	WOS:000170346000011
J	Tous, C; Vega-Palas, MA; Vioque, A				Tous, C; Vega-Palas, MA; Vioque, A			Conditional expression of RNase P in the cyanobacterium Synechocystis sp PCC6803 allows detection of precursor RNAs - Insight in the in vivo maturation pathway of transfer and other stable RNAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RIBONUCLEASE-P; GENE; SEQUENCE; PCC-6803; PROTEIN; SUBUNIT; SUBSTRATE; MOLECULE; CLONING	We have constructed a strain (CTI) that expresses RNase P conditionally with the aim to analyze the in vivo tRNA processing pathway and the biological role that RNase P plays in Synechocystis 6803. In this strain, the rnpB gene, coding for the RNA subunit of RNase P, has been placed under the control of the petJ gene promoter (P-petJ), which is repressed by copper, cell growth, and accumulation of RNase P RNA is inhibited in CT1 after the addition of copper, indicating that the regulation by copper is maintained in the chimerical P-petJ rnpB gene and that RNase P is essential for growth in Synechocystis. We have analyzed several RNAs by Northern blot and primer extension in CT1. Upon addition of copper to the culture medium, precursors of the mature tRNAs are detected. Furthermore, our results indicate that there is a preferred order in the action of RNase P when it processes a dimeric tRNA precursor. The precursors detected are 3 ' -processed, indicating that 3 ' processing can occur before 5 ' processing by RNase P. The size of the precursors suggests that the terminal CCA sequence is already present before RNase P processing. We have also analyzed other potential RNase P substrates, such as the precursors of tmRNA and 4.5 S RNA. In both cases, accumulation of larger than mature size RNAs is observed after transferring the cells to a copper-containing medium.	Univ Seville, CSIC, Inst Bioquim Vegetal & Fotosintesis, Seville 41092, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC - Instituto de Bioquimica Vegetal y Fotosintesis (IBVF)	Vioque, A (corresponding author), Univ Seville, CSIC, Inst Bioquim Vegetal & Fotosintesis, C Amer Vespucio S-N, Seville 41092, Spain.	vioque@cica.es	tous, cristina/X-5472-2019; Vioque, Agustín/K-1809-2014; Palas, Miguel Angel Vega/K-6424-2014	tous, cristina/0000-0002-3590-1904; Vioque, Agustín/0000-0002-3975-7348; Palas, Miguel Angel Vega/0000-0003-1841-540X				ALTMAN S, 1971, NATURE-NEW BIOL, V233, P35, DOI 10.1038/newbio233035a0; Altman S., 1999, RNA WORLD, P351; BANTA AB, 1992, NUCLEIC ACIDS RES, V20, P911, DOI 10.1093/nar/20.4.911; BOTHWELL ALM, 1976, J BIOL CHEM, V251, P7709; Buikema WJ, 2001, P NATL ACAD SCI USA, V98, P2729, DOI 10.1073/pnas.051624898; CAI YP, 1990, J BACTERIOL, V172, P3138, DOI 10.1128/jb.172.6.3138-3145.1990; Deutscher MP, 2001, PROG NUCLEIC ACID RE, V66, P67; Deutscher Murray P., 1995, P51; ELHAI J, 1988, GENE, V68, P119, DOI 10.1016/0378-1119(88)90605-1; Frank DN, 1998, ANNU REV BIOCHEM, V67, P153, DOI 10.1146/annurev.biochem.67.1.153; Garcia-Dominguez M, 1997, PLANT MOL BIOL, V35, P723, DOI 10.1023/A:1005846626187; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HARTMANN RK, 1995, P NATL ACAD SCI USA, V92, P5822, DOI 10.1073/pnas.92.13.5822; Kaneko T, 1997, PLANT CELL PHYSIOL, V38, P1171, DOI 10.1093/oxfordjournals.pcp.a029103; Kaneko T, 1996, DNA Res, V3, P109; KOMINE Y, 1994, P NATL ACAD SCI USA, V91, P9223, DOI 10.1073/pnas.91.20.9223; Li ZW, 1996, CELL, V86, P503, DOI 10.1016/S0092-8674(00)80123-3; MacKinney G, 1941, J BIOL CHEM, V140, P315; Pascual A, 1999, P NATL ACAD SCI USA, V96, P6672, DOI 10.1073/pnas.96.12.6672; Pascual A, 1996, EUR J BIOCHEM, V241, P17, DOI 10.1111/j.1432-1033.1996.0017t.x; REYES JC, 1994, J BACTERIOL, V176, P1260, DOI 10.1128/jb.176.5.1260-1267.1994; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHEDL P, 1973, P NATL ACAD SCI USA, V70, P2091, DOI 10.1073/pnas.70.7.2091; SCHMIDT FJ, 1978, J BIOL CHEM, V253, P4730; VIOQUE A, 1992, NUCLEIC ACIDS RES, V20, P6331, DOI 10.1093/nar/20.23.6331; WAUGH DS, 1990, J BACTERIOL, V172, P6316, DOI 10.1128/jb.172.11.6316-6322.1990; ZHANG L, 1992, J BIOL CHEM, V267, P19054	28	28	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29059	29066		10.1074/jbc.M103418200	http://dx.doi.org/10.1074/jbc.M103418200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11384989	hybrid, Green Published			2022-12-25	WOS:000170346000058
J	van Rossum, GSAT; Klooster, R; van den Bosch, H; Verkleij, AJ; Boonstra, J				van Rossum, GSAT; Klooster, R; van den Bosch, H; Verkleij, AJ; Boonstra, J			Phosphorylation of p42/44(MAPK) by various signal transduction pathways activates cytosolic phospholipase A(2) to variable degrees	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GROWTH-FACTOR RECEPTOR; ARACHIDONIC-ACID METABOLISM; SMOOTH-MUSCLE; INDEPENDENT PATHWAYS; DEPENDENT ACTIVATION; MAP KINASE; RELEASE; ALPHA; STIMULATION	Arachidonic acid has been implicated to play a role in physiological and pathophysiological processes and is selectively released by the 85-kDa cytosolic phospholipase A(2) (cPLA(2)). The activity of cPLA(2) is regulated by calcium, translocating the enzyme to its substrate, and by phosphorylation by a mitogen-activated protein kinase (MAPK) family member and a MAPK-activated protein kinase. In this study, the signal transduction pathways in growth factor-induced phosphorylation of p42/44(MAPK) and cPLA(2) activation were investigated in Her14 fibroblasts. p42/44MAPK in response to epidermal growth factor was not only phosphorylated via the Raf-MEK pathway but mainly through protein kinase C (PKC) or a related or unrelated kinase in which the phosphorylated p42/ 44(MAPK) corresponded with cPLA(2) activity. Serum-induced phosphorylation of p42/44(MAPK) also corresponded with cPLA(2) activity but is predominantly mediated via Raf-MEK and partly through PKC or a related or un elated kinase. In contrast, activation of PKC by phorbol. ester did not result in increased cPLA2 activity, while p42/44(MAPK) is phosphorylated, mainly via Raf-MEK and through MEM Moreover, p42/44(MAPK) phosphorylation is present in quiescent and proliferating cells, and p42/ 44(MAPK) is entirely phosphorylated via Raf-MEK, but it only corresponds to cPLA(2) activity in the former cells. Collectively, these data show that p42/44(MAPK) in proliferating, quiescent, and stimulated cells is phosphorylated by various signal transduction pathways, suggesting the activation of different populations of p42/44(MAPK) and cPLA(2).	Univ Utrecht, Dept Mol Cell Biol, NL-3584 CH Utrecht, Netherlands; Univ Utrecht, Inst Biomembranes, Ctr Biomembranes & Lipid Enzymol, NL-3584 CH Utrecht, Netherlands	Utrecht University; Utrecht University	van Rossum, GSAT (corresponding author), Univ Utrecht, Dept Mol Cell Biol, Padualaan 8, NL-3584 CH Utrecht, Netherlands.	G.S.A.T.vanRossum@bio.uu.nl						Adomeit A, 1999, MOL CELL BIOL, V19, P5289; AKIMOTO K, 1994, J BIOL CHEM, V269, P12677; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Atsumi G, 1998, J BIOL CHEM, V273, P13870, DOI 10.1074/jbc.273.22.13870; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BAASS PC, 1995, TRENDS CELL BIOL, V5, P465, DOI 10.1016/S0962-8924(00)89116-3; Bayburt T, 1997, BIOCHEMISTRY-US, V36, P3216, DOI 10.1021/bi961659d; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; Berra E, 1998, J BIOL CHEM, V273, P10792, DOI 10.1074/jbc.273.17.10792; Bokemeyer D, 1996, KIDNEY INT, V49, P1187, DOI 10.1038/ki.1996.172; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; BONVENTRE JV, 1990, J BIOL CHEM, V265, P4934; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P4449, DOI 10.1074/jbc.273.8.4449; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bunt G, 1997, J CELL SCI, V110, P2449; Bunt G, 2000, BIOCHEMISTRY-US, V39, P7847, DOI 10.1021/bi992725p; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Burke JR, 1999, ARCH BIOCHEM BIOPHYS, V365, P239, DOI 10.1006/abbi.1999.1151; Cifone MG, 1997, J IMMUNOL, V159, P309; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; Conway AM, 1999, BIOCHEM J, V337, P171, DOI 10.1042/0264-6021:3370171; COULDWELL WT, 1994, FEBS LETT, V345, P43, DOI 10.1016/0014-5793(94)00415-3; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; DOORNBOS RP, 2000, THESIS UTRECHT U, P67; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Grammer TC, 1997, ONCOGENE, V14, P1635, DOI 10.1038/sj.onc.1201000; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; HAYSTEAD TAJ, 1992, FEBS LETT, V306, P17, DOI 10.1016/0014-5793(92)80828-5; Hefner Y, 2000, J BIOL CHEM, V275, P37542, DOI 10.1074/jbc.M003395200; Heller A, 1998, DRUGS, V55, P487, DOI 10.2165/00003495-199855040-00001; Hernandez M, 1999, J NEUROCHEM, V73, P1641, DOI 10.1046/j.1471-4159.1999.0731641.x; Hirabayashi T, 2000, BBA-MOL CELL BIOL L, V1488, P124, DOI 10.1016/S1388-1981(00)00115-3; Husain S, 1998, BBA-LIPID LIPID MET, V1392, P127, DOI 10.1016/S0005-2760(98)00011-3; HUWILER A, 1992, FEBS LETT, V300, P259, DOI 10.1016/0014-5793(92)80858-E; HUWILER A, 1993, EXP NEPHROL, V1, P19; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Korystov YN, 1998, FEBS LETT, V431, P224, DOI 10.1016/S0014-5793(98)00757-1; Kramer HK, 1999, J NEUROCHEM, V72, P594, DOI 10.1046/j.1471-4159.1999.0720594.x; KRAMER RM, 1993, J BIOL CHEM, V268, P26796; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; LAI WH, 1989, J CELL BIOL, V109, P2751, DOI 10.1083/jcb.109.6.2751; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; NEWBY AC, 1995, BRIT J PHARMACOL, V114, P1652, DOI 10.1111/j.1476-5381.1995.tb14953.x; Piomelli D, 1993, CURR OPIN CELL BIOL, V5, P274, DOI 10.1016/0955-0674(93)90116-8; Pol A, 1998, FEBS LETT, V441, P34, DOI 10.1016/S0014-5793(98)01517-8; QIU ZH, 1993, J BIOL CHEM, V268, P24506; QIU ZH, 1994, J BIOL CHEM, V269, P19480; Romanelli A, 1997, METABOLISM, V46, P548, DOI 10.1016/S0026-0495(97)90193-1; SA G, 1995, J BIOL CHEM, V270, P2360, DOI 10.1074/jbc.270.5.2360; Schalkwijk CG, 1996, BIOCHEM J, V313, P91, DOI 10.1042/bj3130091; SCHALKWIJK CG, 1995, EUR J BIOCHEM, V231, P593, DOI 10.1111/j.1432-1033.1995.tb20737.x; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SOZERI O, 1992, ONCOGENE, V7, P2259; SPAARGAREN M, 1992, BIOCHEM J, V287, P37, DOI 10.1042/bj2870037; van Rossum GSAT, 1999, LIPIDS, V34, pS65, DOI 10.1007/BF02562230; VANDENBOSCH H, 1974, BIOCHIM BIOPHYS ACTA, V348, P197, DOI 10.1016/0005-2760(74)90231-8; vanDijk MCM, 1997, BIOCHEM J, V323, P693, DOI 10.1042/bj3230693; WADA I, 1992, J CELL BIOL, V116, P321, DOI 10.1083/jcb.116.2.321; WENZELSEIFERT K, 1994, BIOCHEM BIOPH RES CO, V200, P1536, DOI 10.1006/bbrc.1994.1625; WIJKANDER J, 1992, BIOCHEM BIOPH RES CO, V184, P118, DOI 10.1016/0006-291X(92)91166-N; Wissing D, 1997, P NATL ACAD SCI USA, V94, P5073, DOI 10.1073/pnas.94.10.5073; WITMER MR, 1995, ARCH BIOCHEM BIOPHYS, V318, P430, DOI 10.1006/abbi.1995.1251	69	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28976	28983		10.1074/jbc.M101361200	http://dx.doi.org/10.1074/jbc.M101361200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11390384	hybrid			2022-12-25	WOS:000170346000047
J	Zhang, LJ; Lawrence, R; Schwartz, JJ; Bai, XM; Wei, G; Esko, JD; Rosenberg, RD				Zhang, LJ; Lawrence, R; Schwartz, JJ; Bai, XM; Wei, G; Esko, JD; Rosenberg, RD			The effect of precursor structures on the action of glucosaminyl 3-O-sulfotransferase-1 and the biosynthesis of anticoagulant heparan sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-DEACETYLASE/N-SULFOTRANSFERASE; EMBRYONAL CARCINOMA-CELLS; HAMSTER OVARY CELLS; MOLECULAR-CLONING; ANTITHROMBIN-III; CDNA CLONING; PROTEOGLYCANS; EXPRESSION; BINDING; ACID	To understand how 2-O-sulfation of uronic acid residues influences the biosynthesis of anticoagulant heparan sulfate, the cDNA encoding glucosaminyl 3-O-sulfotransferase-1 (3-OST-1) was introduced into wild-type Chinese hamster ovary cells and mutant pgsF-17 cells, which are defective in 2-O-sulfation. 3-OST-1-transduced cells gained the ability to bind to antithrombin. Structural analysis of the heparan sulfate chains showed that 3-OST-1 generates sequences containing GlcUA-GlcN(SO3)3(SO3) and GlcUA-GlcN(SO3)3(SO3)6(SO.) in both wild-type and mutant cells. In addition, IdoUA-GIcN(SO3)3(SO3) and IdoUA-GIcN(SO3)3(SO3)6(SO3) accumulate in the mutant chain. These disaccharides were also observed by tagging [6-H-3]GIcN-labeled pgsF-17 heparan sulfate in vitro with [S-35]PAPs and purified 3-OST-1. Heparan sulfate derived from the transduced mutant also had similar to2-fold higher affinity for antithrombin than heparan sulfate derived from the transduced wildtype cells, and it inactivated factor Xa more efficiently. This study demonstrates for the first time that (i) 3-O-sulfation by 3-OST-1 can occur independently of the 2-O-sulfation of uronic acids, (ii) 2-0-sulfation usually occurs before 3-O-sulfation, (iii) 2-0-sulfation blocks the action of 3-OST-1 at glucosamine residues located to the reducing side of IdoUA units, and (iv) that alternative antithrombin-binding structures can be made in the absence of 2-0-sulfation.	MIT, Dept Biol, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, BIDMC, Dept Med, Boston, MA 02215 USA; Univ Calif San Diego, Dept Cellular & Mol Med, Glycobiol Res & Training Ctr, La Jolla, CA 92093 USA	Massachusetts Institute of Technology (MIT); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of California System; University of California San Diego	Rosenberg, RD (corresponding author), MIT, Dept Biol, Bldg 68-480,77 Massachusetts Ave, Cambridge, MA 02139 USA.				NHLBI NIH HHS [5R01-HL58479, 5P01-HL41484] Funding Source: Medline; NIGMS NIH HHS [R37-GM33063] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM033063] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aikawa J, 1999, J BIOL CHEM, V274, P2690, DOI 10.1074/jbc.274.5.2690; Aikawa J, 2001, J BIOL CHEM, V276, P5876, DOI 10.1074/jbc.M009606200; ATHA DH, 1985, BIOCHEMISTRY-US, V24, P6723, DOI 10.1021/bi00344a063; ATHA DH, 1984, P NATL ACAD SCI-BIOL, V81, P1030, DOI 10.1073/pnas.81.4.1030; ATHA DH, 1987, BIOCHEMISTRY-US, V26, P6454, DOI 10.1021/bi00394a024; Bai XM, 1997, J BIOL CHEM, V272, P23172, DOI 10.1074/jbc.272.37.23172; Bai XM, 1996, J BIOL CHEM, V271, P17711, DOI 10.1074/jbc.271.30.17711; BAME KJ, 1991, J BIOL CHEM, V266, P10287; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; DULBECCO R, 1954, J EXP MED, V99, P167, DOI 10.1084/jem.99.2.167; EDGE ASB, 1990, J BIOL CHEM, V265, P15874; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; Fersht AR, 1985, ENZYME STRUCTURES ME; FIELDSBERRY SC, 1992, P NATL ACAD SCI USA, V89, P693, DOI 10.1073/pnas.89.2.693; Habuchi H, 1998, J BIOL CHEM, V273, P9208, DOI 10.1074/jbc.273.15.9208; Habuchi H, 2000, J BIOL CHEM, V275, P2859, DOI 10.1074/jbc.275.4.2859; HABUCHI H, 1995, J BIOL CHEM, V270, P4172, DOI 10.1074/jbc.270.8.4172; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; HAWLEY RG, 1994, GENE THER, V1, P136; Lander AD, 2000, J CELL BIOL, V148, P227, DOI 10.1083/jcb.148.2.227; Lindqvist C, 1999, SKANDINAVISTIK, V29, P1; Liu J, 1996, J BIOL CHEM, V271, P27072, DOI 10.1074/jbc.271.43.27072; Liu JA, 1999, J BIOL CHEM, V274, P38155, DOI 10.1074/jbc.274.53.38155; Liu JA, 1999, J BIOL CHEM, V274, P5185, DOI 10.1074/jbc.274.8.5185; LOGANATHAN D, 1990, BIOCHEMISTRY-US, V29, P4362, DOI 10.1021/bi00470a015; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; PERUCHO M, 1980, CELL, V22, P309, DOI 10.1016/0092-8674(80)90178-6; Petitou M, 1992, Fortschr Chem Org Naturst, V60, P143; Rosenberg RD, 1997, J CLIN INVEST, V100, pS67; Rostand KS, 1997, INFECT IMMUN, V65, P1; Selleck SB, 2000, TRENDS GENET, V16, P206, DOI 10.1016/S0168-9525(00)01997-1; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; Shworak NW, 1997, J BIOL CHEM, V272, P28008, DOI 10.1074/jbc.272.44.28008; Shworak NW, 1999, J BIOL CHEM, V274, P5170, DOI 10.1074/jbc.274.8.5170; Shworak NW, 1996, J BIOL CHEM, V271, P27063, DOI 10.1074/jbc.271.43.27063; WITT DP, 1994, CURR BIOL, V4, P394, DOI 10.1016/S0960-9822(00)00088-9; ZHANG LJ, 1994, J BIOL CHEM, V269, P19295; Zhang LJ, 1999, J BIOL CHEM, V274, P5681, DOI 10.1074/jbc.274.9.5681; Zhang LJ, 1998, J BIOL CHEM, V273, P27998, DOI 10.1074/jbc.273.43.27998	41	53	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28806	28813		10.1074/jbc.M100204200	http://dx.doi.org/10.1074/jbc.M100204200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11375390	hybrid			2022-12-25	WOS:000170346000023
J	Zhang, Y; Dimtchev, A; Dritschilo, A; Jung, M				Zhang, Y; Dimtchev, A; Dritschilo, A; Jung, M			Ionizing radiation-induced apoptosis in ataxia-telangiectasia fibroblasts - Roles of caspase-9 and cellular inhibitor of apoptosis protein-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 FAMILY PROTEINS; CYTOCHROME-C; POLY(ADP-RIBOSE) POLYMERASE; CYSTEINE PROTEASES; DEATH PROTEASES; MITOCHONDRIA; ATM; ACTIVATION; REQUIREMENT; INDUCTION	Ionizing radiation (IR) has been shown to induce apoptosis to a greater extent in a fibroblast cell line AT5BIVA derived from an individual with ataxia-telangiectasia (AT) than in control fibroblasts. However, the signaling pathway that underlies IR-induced apoptosis in AT cells has remained unknown. The mechanism of apoptosis in response to gamma -irradiation has now been examined in three AT fibroblast lines (AT3BIVA, AT4BIVA, and AT5BIVA) derived from different individuals with AT. The apoptotic indexes of these cell lines at 72 h after irradiation were 12, 31, and 35%, respectively, compared with a value of 2.3% for control fibroblasts. Immunoblot analysis and fluorometric assays revealed that the extents of IR-induced activation of caspase-3 and caspase-9 were markedly greater in AT4BrVA and AT5BIVA cells than in AT3BIVA and control cells. Furthermore, the basal abundance of the apoptotic inhibitor, a cellular inhibitor of apoptosis proteins (c-IAP-1), was markedly reduced in AT4BIVA and AT5BIVA cells compared with that in AT3BIVA and control cells. The overexpression of either caspase-9 mutant forms or recombinant c-IAP-1 in AT5BIVA cells inhibited the IR-induced activation of caspases-3 and 9 and reduced the apoptotic index of the irradiated cells. These results indicate that the extent of IR-induced apoptosis in different AT cell lines is inversely related to the abundance of c-IAP-1 and directly related to the extent of activation of caspases-3 and 9.	Georgetown Univ, Sch Med, Vincent T Lombardi Canc Res Ctr, Dept Radiat Med,Div Radiat Res,Med Ctr, Washington, DC 20007 USA; Georgetown Univ, Sch Med, Vincent T Lombardi Canc Res Ctr, Dept Microbiol,Div Radiat Res, Washington, DC 20007 USA	Georgetown University; Georgetown University	Jung, M (corresponding author), Georgetown Univ, Sch Med, Vincent T Lombardi Canc Res Ctr, Dept Radiat Med,Div Radiat Res,Med Ctr, Res Bldg,Rm E211A,3970 Reservoir Rd NW, Washington, DC 20007 USA.				NCI NIH HHS [CA74175, CA68023, CA45408] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045408, P01CA074175] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alnemri ES, 1997, J CELL BIOCHEM, V64, P33, DOI 10.1002/(SICI)1097-4644(199701)64:1<33::AID-JCB6>3.0.CO;2-0; Amarante-Mendes GP, 1998, ONCOGENE, V16, P1383, DOI 10.1038/sj.onc.1201664; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Barlow C, 1997, NAT GENET, V17, P453, DOI 10.1038/ng1297-453; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; Golstein P, 1997, SCIENCE, V275, P1081, DOI 10.1126/science.275.5303.1081; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Han ZY, 1998, CELL DEATH DIFFER, V5, P469, DOI 10.1038/sj.cdd.4400367; HERMANN S, 1995, SCIENCE, V267, P1445; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; Hetts SW, 1998, JAMA-J AM MED ASSOC, V279, P300, DOI 10.1001/jama.279.4.300; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Jung M, 1998, RADIAT RES, V149, P596, DOI 10.2307/3579906; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MEYN MS, 1995, CANCER RES, V55, P5991; MEYN MS, 1994, INT J RADIAT BIOL, V66, P141; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Nicholson DW, 1996, NAT BIOTECHNOL, V14, P297, DOI 10.1038/nbt0396-297; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Reed JC, 1998, BBA-BIOENERGETICS, V1366, P127, DOI 10.1016/S0005-2728(98)00108-X; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; SHAFMAN TD, 1995, CANCER RES, V55, P3242; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srinivasula SM, 1999, CANCER RES, V59, P999; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Takao N, 2000, FEBS LETT, V472, P133, DOI 10.1016/S0014-5793(00)01422-8; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Tsujimoto Y, 1998, GENES CELLS, V3, P697, DOI 10.1046/j.1365-2443.1998.00223.x; Wallach D, 1997, FEBS LETT, V410, P96, DOI 10.1016/S0014-5793(97)00553-X; Watters D, 1999, J BIOL CHEM, V274, P34277, DOI 10.1074/jbc.274.48.34277; Westphal CH, 1997, NAT GENET, V16, P397, DOI 10.1038/ng0897-397; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	48	19	21	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28842	28848		10.1074/jbc.M010525200	http://dx.doi.org/10.1074/jbc.M010525200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11382748	hybrid			2022-12-25	WOS:000170346000029
J	Col, E; Caron, C; Seigneurin-Berny, D; Gracia, J; Favier, A; Khochbin, S				Col, E; Caron, C; Seigneurin-Berny, D; Gracia, J; Favier, A; Khochbin, S			The histone acetyltransferase, hGCN5, interacts with and acetylates the HIV transactivator, Tat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREB-BINDING-PROTEIN; TRANSCRIPTIONAL ACTIVITY; COACTIVATORS P300; FAMILY MEMBERS; DNA-DAMAGE; IN-VIVO; BROMODOMAIN; GCN5; ACTIVATION; P/CAF	Factor acetyltransferase activity associated with several histone acetyltransferases plays a key role in the control of transcription. Here we report that hGCN5, a well known histone acetyltransferase, specifically interacts with and acetylates the human immunodeficiency virus type 1 (HIV-1) transactivator protein, Tat. The interaction between Tat and hGCN5 is direct and involves the acetyltransferase and the bromodomain regions of hGCN5, as well as a limited region of Tat encompassing the cysteine-rich domain of the protein. Tat lysines 50 and 51, target of acetylation by p300/CBP, were also found to be acetylated by hGCN5. The acetylation of these two lysines by p300/CBP has been recently shown to stimulate Tat transcriptional activity and accordingly, we have found that hGCN5 can considerably enhance Tat-dependent transcription of the HIV-1 long terminal repeat. These data highlight the importance of the acetylation of lysines 50 and 51 in the function of Tat, since different histone acetyltransferases involved in distinct signaling pathways, GCN5 and p300/CBP, converge to acetylate Tat on the same site.	Fac Med, Inst Albert Bonniot, INSERM, U309,Lab Biol Mol & Cellulaire Differenciat, F-38706 La Tronche, France; Fac Pharm, Lab Biol Stress Oxydant, F-38700 La Tronche, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA)	Khochbin, S (corresponding author), Fac Med, Inst Albert Bonniot, INSERM, U309,Lab Biol Mol & Cellulaire Differenciat, Domaine Merci, F-38706 La Tronche, France.		Khochbin, Saadi/M-8090-2013; SEIGNEURIN-BERNY, Daphne/C-8412-2017	Khochbin, Saadi/0000-0002-0455-0857; SEIGNEURIN-BERNY, Daphne/0000-0002-7436-9885				Bannister AJ, 2000, CURR BIOL, V10, P467, DOI 10.1016/S0960-9822(00)00445-0; Benkirane M, 1998, J BIOL CHEM, V273, P24898, DOI 10.1074/jbc.273.38.24898; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Candau R, 1996, MOL CELL BIOL, V16, P593; Creaven M, 1999, BIOCHEMISTRY-US, V38, P8826, DOI 10.1021/bi9907274; Currie RA, 1998, J BIOL CHEM, V273, P1430, DOI 10.1074/jbc.273.3.1430; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hansen JC, 1998, BIOCHEMISTRY-US, V37, P17637, DOI 10.1021/bi982409v; Herrera JE, 1999, MOL CELL BIOL, V19, P3466; Hotttiger MO, 1998, J VIROL, V72, P8252, DOI 10.1128/JVI.72.10.8252-8256.1998; Huang SM, 2000, EMBO J, V19, P6792, DOI 10.1093/emboj/19.24.6792; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; Jeanmougin F, 1997, TRENDS BIOCHEM SCI, V22, P151, DOI 10.1016/S0968-0004(97)01042-6; Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; Karn J, 1999, J MOL BIOL, V293, P235, DOI 10.1006/jmbi.1999.3060; Kiernan RE, 1999, EMBO J, V18, P6106, DOI 10.1093/emboj/18.21.6106; Kuo CH, 1996, IEEE SIGNAL PROC LET, V3, P269, DOI 10.1109/97.536598; Liu L, 1999, MOL CELL BIOL, V19, P1202; Luger K, 1998, CURR OPIN GENET DEV, V8, P140, DOI 10.1016/S0959-437X(98)80134-2; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887; Marzio G, 1998, P NATL ACAD SCI USA, V95, P13519, DOI 10.1073/pnas.95.23.13519; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Ott M, 1999, CURR BIOL, V9, P1489, DOI 10.1016/S0960-9822(00)80120-7; Owen DJ, 2000, EMBO J, V19, P6141, DOI 10.1093/emboj/19.22.6141; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Schiltz RL, 1999, J BIOL CHEM, V274, P1189, DOI 10.1074/jbc.274.3.1189; Smith ER, 1998, NUCLEIC ACIDS RES, V26, P2948, DOI 10.1093/nar/26.12.2948; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Syntichaki P, 2000, NATURE, V404, P414, DOI 10.1038/35006136; Tomita A, 2000, ONCOGENE, V19, P444, DOI 10.1038/sj.onc.1203329; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; VESCHAMBRE P, 1995, J MOL BIOL, V250, P169, DOI 10.1006/jmbi.1995.0368; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Weissman JD, 1998, P NATL ACAD SCI USA, V95, P11601, DOI 10.1073/pnas.95.20.11601; Winston F, 1999, NAT STRUCT BIOL, V6, P601, DOI 10.1038/10640; Wolffe AP, 1999, NUCLEIC ACIDS RES, V27, P711, DOI 10.1093/nar/27.3.711; Xu WT, 1998, MOL CELL BIOL, V18, P5659, DOI 10.1128/MCB.18.10.5659; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zhang QH, 2000, P NATL ACAD SCI USA, V97, P14323, DOI 10.1073/pnas.011283598; Zhou Q, 1998, EMBO J, V17, P3681, DOI 10.1093/emboj/17.13.3681	44	120	125	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28179	28184		10.1074/jbc.M101385200	http://dx.doi.org/10.1074/jbc.M101385200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11384967	hybrid			2022-12-25	WOS:000170093400059
J	Fatyol, K; Szalay, AA				Fatyol, K; Szalay, AA			The p14(ARF) tumor suppressor protein facilitates nucleolar sequestration of hypoxia-inducible factor-1 alpha (HIF-1 alpha) and inhibits HIF-1-mediated transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR 1-ALPHA HIF-1-ALPHA; ENDOTHELIAL GROWTH-FACTOR; P53; MDM2; EXPRESSION; P19(ARF); PATHWAY; HIF-1; CELL; LOCALIZATION	Oncogenic alterations can influence tumor cell survival partly by affecting the activity of the hypoxia-inducible factor-1 (HIF-1) transcription factor. The a subunit of HIF-1 was found to be frequently overexpressed in advanced tumors, which was proposed to help the adaptation of tumor cells to hypoxia. Here we show that an important tumor suppressor protein, p14(ARF) (alternative reading frame product of the INK4A locus) can directly inhibit the transcriptional activity of HIF-1 by sequestering its alpha subunit into the nucleolus. The interaction requires neither p53 nor HDM2. This is one of the first reports that describe the interaction of p14(ARF) with a protein besides HDM2, which may define a p53-independent tumor suppressor activity for p14(ARF).	Loma Linda Univ, Dept Biochem, Loma Linda, CA 92350 USA	Loma Linda University	Fatyol, K (corresponding author), Loma Linda Univ, Dept Biochem, Loma Linda, CA 92350 USA.							Blagosklonny MV, 1998, J BIOL CHEM, V273, P11995, DOI 10.1074/jbc.273.20.11995; Brown JM, 2000, MOL MED TODAY, V6, P157, DOI 10.1016/S1357-4310(00)01677-4; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ishii N, 1999, BRAIN PATHOL, V9, P469, DOI 10.1111/j.1750-3639.1999.tb00536.x; Jiang BH, 1997, CANCER RES, V57, P5328; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kung AL, 2000, NAT MED, V6, P1335, DOI 10.1038/82146; Lohrum MAE, 2000, NAT CELL BIOL, V2, P179, DOI 10.1038/35004057; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mazure NM, 1996, CANCER RES, V56, P3436; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Ravi R, 2000, GENE DEV, V14, P34; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Sambrook J., 2002, MOL CLONING LAB MANU; Semenza GL, 2000, CRIT REV BIOCHEM MOL, V35, P71, DOI 10.1080/10409230091169186; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sutter CH, 2000, P NATL ACAD SCI USA, V97, P4748, DOI 10.1073/pnas.080072497; Visintin R, 2000, CURR OPIN CELL BIOL, V12, P372, DOI 10.1016/S0955-0674(00)00102-2; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Zhong H, 1998, CANCER RES, V58, P5280; Zhong H, 1999, CANCER RES, V59, P5830; Zundel W, 2000, GENE DEV, V14, P391	35	94	104	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28421	28429		10.1074/jbc.M102847200	http://dx.doi.org/10.1074/jbc.M102847200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11382768	hybrid			2022-12-25	WOS:000170093400090
J	Keren, T; Roth, IG; Henis, YI				Keren, T; Roth, IG; Henis, YI			Internalization-competent influenza hemagglutinin mutants form complexes with clathrin-deficient multivalent AP-2 oligomers in live cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; FACTOR-BETA RECEPTORS; COATED PIT FORMATION; VIRUS HEMAGGLUTININ; SORTING SIGNALS; PLASMA-MEMBRANE; CYTOPLASMIC DOMAIN; VESICLE FORMATION; APPENDAGE DOMAIN; TYROSINE	Most membrane proteins are endocytosed through clathrin-coated pits via AP-2 adaptor complexes. However, little is known about the interaction of internalization signals with AP-2 in live cells in the absence of clathrin lattices. To investigate this issue, we employed cells cotransfected with pairs of antigenically distinct influenza hemagglutinin (HA) mutants containing different internalization signals of the YXXZ family. To enable studies on the possible association of the naturally trimeric HAs into higher order complexes via binding to AP-2, we exploited the inability of HAs from different influenza strains to form mutual trimers. Thus, we coexpressed HA pairs from different strains (Japan and X:31) bearing similar cytoplasmic tails mutated to include internalization signals. Using antibody-mediated immunofluorescence co-patching on live cells, we demonstrate that internalization-competent HA mutants form higher order complexes and that this clustering depends on the strength of the internalization signal. The clustering persisted in cells treated with hypertonic medium to disperse the clathrin lattices, as validated by co-immunoprecipitation experiments. The clustering of HAs bearing strong internalization signals appears to be mediated via binding to AP-2, as indicated by (i) the coprecipitation of alpha -adaptin with these HAs, even in hypertonically treated cells; (ii) the co-localization (after hypertonic treatment) of AP-2 with antibody-mediated patches of these mutants; and (iii) the dispersal of the higher order HA complexes following chlorpromazine treatment, which removes AP-2 from the plasma membrane. These results suggest that even in the absence of clathrin lattices, AP-2 exists in multivalent complexes capable of simultaneously binding several internalization signals from the same family.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA	Tel Aviv University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Henis, YI (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel.	henis@post.tau.ac.il		Henis, Yoav/0000-0002-1408-3877; Roth, Michael/0000-0002-9056-332X	NIGMS NIH HHS [GM37547] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037547] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; BOULAY F, 1988, J CELL BIOL, V106, P629, DOI 10.1083/jcb.106.3.629; Bremnes T, 1998, J BIOL CHEM, V273, P8638, DOI 10.1074/jbc.273.15.8638; Brown CM, 1999, BIOCHEMISTRY-US, V38, P15166, DOI 10.1021/bi991170v; CHIN DJ, 1989, P NATL ACAD SCI USA, V86, P9289, DOI 10.1073/pnas.86.23.9289; DANIELS RS, 1983, J GEN VIROL, V64, P1657, DOI 10.1099/0022-1317-64-8-1657; Fire E, 1997, J BIOL CHEM, V272, P29538, DOI 10.1074/jbc.272.47.29538; FIRE E, 1995, J BIOL CHEM, V270, P21075, DOI 10.1074/jbc.270.36.21075; FIRE E, 1991, J CELL BIOL, V115, P1585, DOI 10.1083/jcb.115.6.1585; GETHING MJ, 1980, NATURE, V287, P301, DOI 10.1038/287301a0; Gilboa L, 1998, J CELL BIOL, V140, P767, DOI 10.1083/jcb.140.4.767; Gilboa L, 2000, MOL BIOL CELL, V11, P1023, DOI 10.1091/mbc.11.3.1023; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; Kibbey RG, 1998, J CELL BIOL, V142, P59, DOI 10.1083/jcb.142.1.59; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; LAZAROVITS J, 1988, CELL, V53, P743, DOI 10.1016/0092-8674(88)90092-X; Lewis CM, 2000, TRAFFIC, V1, P282, DOI 10.1034/j.1600-0854.2000.010310.x; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; Musacchio A, 1999, MOL CELL, V3, P761, DOI 10.1016/S1097-2765(01)80008-3; NAIM HY, 1994, METHOD CELL BIOL, V43, P113; NAIM HY, 1993, J VIROL, V67, P4831, DOI 10.1128/JVI.67.8.4831-4841.1993; NAIM HY, 1994, J BIOL CHEM, V269, P3928; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Owen DJ, 2000, EMBO J, V19, P4216, DOI 10.1093/emboj/19.16.4216; Owen DJ, 1999, CELL, V97, P805, DOI 10.1016/S0092-8674(00)80791-6; Owen DJ, 2001, TRAFFIC, V2, P105, DOI 10.1034/j.1600-0854.2001.020205.x; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; Rapoport I, 1997, EMBO J, V16, P2240, DOI 10.1093/emboj/16.9.2240; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; Rodionov DG, 1998, J BIOL CHEM, V273, P6005, DOI 10.1074/jbc.273.11.6005; ROTH MG, 1986, J CELL BIOL, V102, P1271, DOI 10.1083/jcb.102.4.1271; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SANDOVAL IV, 1994, J BIOL CHEM, V269, P6622; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Scheiffele P, 1997, EMBO J, V16, P5501, DOI 10.1093/emboj/16.18.5501; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; SEAMAN MNJ, 1993, J CELL BIOL, V123, P1093, DOI 10.1083/jcb.123.5.1093; SKIBBENS JE, 1989, J CELL BIOL, V108, P821, DOI 10.1083/jcb.108.3.821; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; Sorkin A, 1996, J BIOL CHEM, V271, P13377, DOI 10.1074/jbc.271.23.13377; SUBTIL A, 1994, J CELL SCI, V107, P3461; THOMAS DC, 1994, J BIOL CHEM, V269, P15732; Traub LM, 1999, P NATL ACAD SCI USA, V96, P8907, DOI 10.1073/pnas.96.16.8907; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; Tugizov S, 1999, J VIROL, V73, P8677, DOI 10.1128/JVI.73.10.8677-8688.1999; von Poser C, 2000, J BIOL CHEM, V275, P30916, DOI 10.1074/jbc.M005559200; WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107; Wells RG, 1999, J BIOL CHEM, V274, P5716, DOI 10.1074/jbc.274.9.5716; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1; Zwart DE, 1996, J BIOL CHEM, V271, P907, DOI 10.1074/jbc.271.2.907	58	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28356	28363		10.1074/jbc.M102235200	http://dx.doi.org/10.1074/jbc.M102235200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11369772	hybrid			2022-12-25	WOS:000170093400082
J	Mariner, DJ; Anastasiadis, P; Keilhack, H; Bohmer, FD; Wang, J; Reynolds, AB				Mariner, DJ; Anastasiadis, P; Keilhack, H; Bohmer, FD; Wang, J; Reynolds, AB			Identification of Src phosphorylation sites in the catenin p120(ctn)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; GROWTH-FACTOR RECEPTOR; CELL-CELL ADHESION; E-CADHERIN; ALPHA-CATENIN; P120 CATENIN; BETA-CATENIN; SIGNAL-TRANSDUCTION; ENDOTHELIAL-CELLS; CARCINOMA-CELLS	p120-catenin (p120(ctn)) interacts with the cytoplasmic tail of cadherins and is thought to regulate cadherin clustering during formation of adherens junctions. Several observations suggest that p120 can both positively and negatively regulate cadherin adhesiveness depending on signals that so far remain unidentified. Although p120 tyrosine phosphorylation is a leading candidate, the role of this modification in normal and Src-transformed cells remains unknown. Here, as a first step toward pinpointing this role, we have employed two-dimensional tryptic mapping to directly identify the major sites of Src-induced p120 phosphorylation. Eight sites were identified by direct mutation of candidate tyrosines to phenylalanine and elimination of the accompanying spots on the two-dimensional maps. Identical sites were observed in vitro and in vivo, strongly suggesting that the physiologically important sites have been correctly identified. Changing all of these sites to phenylalanine resulted in a p120 mutant, p120-8F, that could not be efficiently phosphorylated by Src and failed to interact with SHP-1, a tyrosine phosphatase shown previously to interact selectively with tyrosine-phosphorylated p120 in cells stimulated with epidermal growth factor. Using selected tyrosine to phenylalanine p120 mutants as dominant negative reagents, it may now be possible to selectively block events postulated to be dependent on p120 tyrosine phosphorylation.	Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA; Univ Jena, Fac Med, Res Unit Mol Cell Biol, D-07747 Jena, Germany	Vanderbilt University; Friedrich Schiller University of Jena	Reynolds, AB (corresponding author), Vanderbilt Univ, Sch Med, Dept Canc Biol, 1161 21st Ave S,MCN C-2310, Nashville, TN 37232 USA.	al.reynolds@mcmail.vanderbilt.edu			NATIONAL CANCER INSTITUTE [R29CA055724, R01CA055724] Funding Source: NIH RePORTER; NCI NIH HHS [CA69485, CA55724] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anastasiadis PZ, 2000, J CELL SCI, V113, P1319; Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; Aono S, 1999, J CELL BIOL, V145, P551, DOI 10.1083/jcb.145.3.551; Balsamo J, 1996, J CELL BIOL, V134, P801, DOI 10.1083/jcb.134.3.801; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977; Calautti E, 1998, J CELL BIOL, V141, P1449, DOI 10.1083/jcb.141.6.1449; Cozzolino M, 2000, J CELL SCI, V113, P1601; DANIEL JM, 1995, MOL CELL BIOL, V15, P4819; Daniel JM, 1997, BIOESSAYS, V19, P883, DOI 10.1002/bies.950191008; DOWNING JR, 1991, ONCOGENE, V6, P607; Fuchs M, 1996, J BIOL CHEM, V271, P16712, DOI 10.1074/jbc.271.28.16712; Grosheva I, 2001, J CELL SCI, V114, P695; HERRENKNECHT K, 1991, P NATL ACAD SCI USA, V88, P9156, DOI 10.1073/pnas.88.20.9156; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; Keilhack H, 1998, J BIOL CHEM, V273, P24839, DOI 10.1074/jbc.273.38.24839; Keilhack H, 2000, J BIOL CHEM, V275, P26376, DOI 10.1074/jbc.M001315200; KIM L, 1995, MOL CELL BIOL, V15, P4553; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; Kypta RM, 1996, J CELL BIOL, V134, P1519, DOI 10.1083/jcb.134.6.1519; Lampugnani MG, 1997, J CELL SCI, V110, P2065; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Nieset JE, 1997, J CELL SCI, V110, P1013; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; Ohkubo T, 1999, J BIOL CHEM, V274, P21409, DOI 10.1074/jbc.274.30.21409; Owens DW, 2000, MOL BIOL CELL, V11, P51, DOI 10.1091/mbc.11.1.51; Ozawa M, 2001, J CELL SCI, V114, P503; Papkoff J, 1997, J BIOL CHEM, V272, P4536; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; REYNOLDS AB, 1992, ONCOGENE, V7, P2439; RIMM DL, 1994, BIOCHEM BIOPH RES CO, V203, P1691, DOI 10.1006/bbrc.1994.2381; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; Skoudy A, 1996, BIOCHEM J, V317, P279, DOI 10.1042/bj3170279; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; STAPPERT J, 1994, CELL ADHES COMMUN, V2, P319, DOI 10.3109/15419069409014207; Takeda H, 1995, J CELL BIOL, V131, P1839, DOI 10.1083/jcb.131.6.1839; Tamir I, 2000, CURR OPIN IMMUNOL, V12, P307, DOI 10.1016/S0952-7915(00)00092-3; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; Ukropec JA, 2000, J BIOL CHEM, V275, P5983, DOI 10.1074/jbc.275.8.5983; Van Der Geer P., 1993, PROTEIN PHOSPHORYLAT, P31; Yap AS, 1998, J CELL BIOL, V141, P779, DOI 10.1083/jcb.141.3.779	47	116	119	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28006	28013		10.1074/jbc.M102443200	http://dx.doi.org/10.1074/jbc.M102443200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11382764	hybrid			2022-12-25	WOS:000170093400036
J	Sorensen, CE; Novak, I				Sorensen, CE; Novak, I			Visualization of ATP release in pancreatic acini in response to cholinergic stimulus - Use of fluorescent probes and confocal microscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETORY GRANULES; FIREFLY LUCIFERASE; EXTRACELLULAR ATP; EPITHELIAL-CELLS; CONDUCTANCE; MECHANISM; CHANNELS; MEMBRANE; DUCTS	The energy providing substrate ATP can be released from various cells and act extracellularly to regulate the same cells or neighboring cells. However, the pathway for ATP release and the eliciting physiological stimulus are unclear. Recently, we showed that ATP activates P2X and P2Y purinergic receptors on pancreatic ducts. Thus, it was relevant to ask whether the upstream acini could be the source of releasable ATP and what the stimulus might be. We used freshly prepared rat pancreatic acini and applied conventional luminescence measurements of luciferin/luciferase reaction. As a new application of this reaction in confocal microscopy, we monitored luciferin fluorescence as a sign of ATP release by single acini. In addition we used quinacrine to mark ATP stores, which were similar to those marked with fluorescent ATP, 2 '-(or-3 ')-O-(N-methylanthraniloyl) adenosine 5 ' -triphosphate, but only partially overlapping with those marked by aeridine orange and LysoTracker Red. In functional studies we show that native pancreatic acini release ATP in response to various stimuli but most importantly to cholinergic stimulation, a very likely physiological stimulus in this epithelium. In a close vicinity of acini we detect about 9 mum ATP after cholinergic stimulation. Thus, ATP is poised as the paracrine mediator between pancreatic acini and ducts.	Univ Copenhagen, August Krogh Inst, DK-2100 Copenhagen O, Denmark	University of Copenhagen	Novak, I (corresponding author), Univ Copenhagen, August Krogh Inst, Univ Pk 13, DK-2100 Copenhagen O, Denmark.		Novak, Ivana/M-2791-2014	Novak, Ivana/0000-0002-8917-8010; Soerensen, Christiane/0000-0001-6814-1166				ARVAN P, 1984, J BIOL CHEM, V259, P3567; Beigi R, 1999, AM J PHYSIOL-CELL PH, V276, pC267, DOI 10.1152/ajpcell.1999.276.1.C267; Belan PV, 1996, J BIOL CHEM, V271, P7615, DOI 10.1074/jbc.271.13.7615; BOKVIST K, 1995, EMBO J, V14, P50, DOI 10.1002/j.1460-2075.1995.tb06974.x; CHEY WY, 1979, J PHYSIOL-LONDON, V293, P435, DOI 10.1113/jphysiol.1979.sp012898; DELISLE RC, 1987, AM J PHYSIOL, V253, pG711, DOI 10.1152/ajpgi.1987.253.6.G711; Fields RD, 2000, TRENDS NEUROSCI, V23, P625, DOI 10.1016/S0166-2236(00)01674-X; Ford SR, 1996, J BIOLUM CHEMILUM, V11, P149, DOI 10.1002/(SICI)1099-1271(199605)11:3<149::AID-BIO411>3.0.CO;2-Q; Grygorczyk R, 1997, AM J PHYSIOL-CELL PH, V272, pC1058; Gualix J, 1999, J NEUROCHEM, V73, P1098, DOI 10.1046/j.1471-4159.1999.0731098.x; HAMLYN JM, 1983, BIOCHEM J, V214, P59, DOI 10.1042/bj2140059; Hazama A, 1998, PFLUG ARCH EUR J PHY, V437, P31, DOI 10.1007/s004240050742; Hede SE, 1999, J BIOL CHEM, V274, P31784, DOI 10.1074/jbc.274.45.31784; Ishiguro H, 1999, J PHYSIOL-LONDON, V519, P551, DOI 10.1111/j.1469-7793.1999.0551m.x; Konig J, 1999, HEPATOLOGY, V29, P1156, DOI 10.1002/hep.510290404; LEITNER JW, 1975, ENDOCRINOLOGY, V96, P662; NIEDERAU C, 1986, GASTROENTEROLOGY, V91, P1433, DOI 10.1016/0016-5085(86)90197-6; NOVAK I, 1995, CELL PHYSIOL BIOCHEM, V5, P344, DOI 10.1159/000154770; NOVAK I, 2000, DRUG DEVELOP RES, V50, P112; OLSON L, 1976, CELL TISSUE RES, V171, P407; ORCI L, 1987, NATURE, V326, P77, DOI 10.1038/326077a0; Park HS, 1998, AM J PHYSIOL-GASTR L, V274, pG413, DOI 10.1152/ajpgi.1998.274.2.G413; Roman RM, 1999, AM J PHYSIOL-GASTR L, V276, pG1391, DOI 10.1152/ajpgi.1999.276.6.G1391; Saito H, 1996, J BIOL CHEM, V271, P20719, DOI 10.1074/jbc.271.34.20719; Schneider SW, 1999, P NATL ACAD SCI USA, V96, P12180, DOI 10.1073/pnas.96.21.12180; Schreiber R, 1999, J BIOL CHEM, V274, P11811, DOI 10.1074/jbc.274.17.11811; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; Sevigny J, 1998, AM J PHYSIOL-GASTR L, V275, pG473, DOI 10.1152/ajpgi.1998.275.3.G473; Taylor AL, 1998, AM J PHYSIOL-CELL PH, V275, pC1391, DOI 10.1152/ajpcell.1998.275.5.C1391; Wang Y, 1996, P NATL ACAD SCI USA, V93, P12020, DOI 10.1073/pnas.93.21.12020; Watt WC, 1998, J BIOL CHEM, V273, P14053, DOI 10.1074/jbc.273.22.14053; WHITE PN, 1995, HEARING RES, V90, P97, DOI 10.1016/0378-5955(95)00151-1; WHITE TD, 1987, J NEUROCHEM, V49, P1266, DOI 10.1111/j.1471-4159.1987.tb10019.x	33	148	151	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32925	32932		10.1074/jbc.M103313200	http://dx.doi.org/10.1074/jbc.M103313200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11387334	hybrid			2022-12-25	WOS:000170746000074
J	Wang, XW; Tseng, A; Ellis, NA; Spillare, EA; Linke, SP; Robles, AI; Seker, H; Yang, Q; Hu, P; Beresten, S; Bemmels, NA; Garfield, S; Harris, CC				Wang, XW; Tseng, A; Ellis, NA; Spillare, EA; Linke, SP; Robles, AI; Seker, H; Yang, Q; Hu, P; Beresten, S; Bemmels, NA; Garfield, S; Harris, CC			Functional interaction of p53 and BLM DNA helicase in apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOM-SYNDROME CELLS; WERNERS-SYNDROME GENES; SYNDROME PROTEIN; P53-MEDIATED APOPTOSIS; PREMATURE SENESCENCE; GENOMIC INSTABILITY; IONIZING-RADIATION; NUCLEAR-STRUCTURE; ONCOGENIC RAS; CYCLE	The Bloom syndrome (BS) protein, BLM, is a member of the RecQ DNA helicase family that also includes the Werner syndrome protein, WRN. Inherited mutations in these proteins are associated with cancer predisposition of these patients. We recently discovered that cells from Werner syndrome patients displayed a deficiency in p53-mediated apoptosis and WRN binds to p53. Here, we report that analogous to WRN, BLM also binds to p53 in vivo and in vitro, and the C-terminal domain of p53 is responsible for the interaction. p53-mediated apoptosis is defective in BS fibroblasts and can be rescued by expression of the normal BLM gene. Moreover, lymphoblastoid cell lines (LCLs) derived from BS donors are resistant to both gamma -radiation and doxorubicin-induced cell killing, and sensitivity can be restored by the stable expression of normal BLM. In contrast, BS cells have a normal Fas-mediated apoptosis, and in response to DNA damage normal accumulation of p53, normal induction of p53 responsive genes, and normal G(1)-S and G(2)-M Cell cycle arrest. BLM localizes to nuclear foci referred to as PAM nuclear bodies (NBs). Cells from Li-Fraumeni syndrome patients carrying p53 germline mutations and LCLs lacking a functional p53 have a decreased accumulation of BLM in NBs, whereas isogenic lines with functional p53 exhibit normal accumulation. Certain BLM mutants (C1055S or Delta 133-237) that have a reduced ability to localize to the NBs when expressed in normal cells can impair the localization of wild type BLM to NBs and block p53-mediated apoptosis, suggesting a dominant-negative effect. Taken together, our results indicate both a novel mechanism of p53 function by which p53 mediates nuclear trafficking of BLM to NBs and the cooperation of p53 and BLM to induce apoptosis.	NCI, LHC, NIH, Ctr Canc Res, Bethesda, MD 20892 USA; Mem Sloan Kettering Canc Ctr, Lab Canc Susceptibil, Dept Human Genet, New York, NY 10021 USA; NCI, Expt Carcinogenesis Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Memorial Sloan Kettering Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Harris, CC (corresponding author), NCI, LHC, NIH, Ctr Canc Res, Bldg 37,Rm 2C05,MSC4255, Bethesda, MD 20892 USA.	curtis_harris@nih.gov	Wang, Xin Wei/B-6162-2009	Wang, Xin Wei/0000-0001-9735-606X; Robles, Ana/0000-0001-5019-4374; Linke, Steven/0000-0001-8584-4947	NCI NIH HHS [R01 CA085867, R01 CA085867-01A2] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085867] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ababou M, 2000, ONCOGENE, V19, P5955, DOI 10.1038/sj.onc.1204003; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Bahr A, 1998, ONCOGENE, V17, P2565, DOI 10.1038/sj.onc.1202389; Bischof O, 2001, J CELL BIOL, V153, P367, DOI 10.1083/jcb.153.2.367; Blander G, 1999, J BIOL CHEM, V274, P29463, DOI 10.1074/jbc.274.41.29463; Collister M, 1998, CARCINOGENESIS, V19, P2115, DOI 10.1093/carcin/19.12.2115; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; DOUCAS V, 1996, BIOCHIM BIOPHYS ACTA, V1288, P25; Dutertre S, 2000, ONCOGENE, V19, P2731, DOI 10.1038/sj.onc.1203595; Ellis NA, 1998, AM J HUM GENET, V63, P1685, DOI 10.1086/302167; Ellis NA, 1997, CURR OPIN GENET DEV, V7, P354, DOI 10.1016/S0959-437X(97)80149-9; Ellis NA, 1999, AM J HUM GENET, V65, P1368, DOI 10.1086/302616; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Ferbeyre G, 2000, GENE DEV, V14, P2015; German J, 1996, CLIN GENET, V49, P223; German J, 1997, CANCER GENET CYTOGEN, V93, P100, DOI 10.1016/S0165-4608(96)00336-6; Gharibyan V, 1999, MOL CARCINOGEN, V26, P261, DOI 10.1002/(SICI)1098-2744(199912)26:4<261::AID-MC5>3.0.CO;2-A; Hodges M, 1998, AM J HUM GENET, V63, P297, DOI 10.1086/301991; Hu P, 2001, HUM MOL GENET, V10, P1287, DOI 10.1093/hmg/10.12.1287; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Jayaraman L, 1999, CELL MOL LIFE SCI, V55, P76, DOI 10.1007/s000180050271; Karow JK, 1999, CURR BIOL, V9, P597, DOI 10.1016/S0960-9822(99)80264-4; Karow JK, 2000, CURR OPIN GENET DEV, V10, P32, DOI 10.1016/S0959-437X(99)00039-8; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; Kawabe T, 2000, ONCOGENE, V19, P4764, DOI 10.1038/sj.onc.1203841; Kitao S, 1999, NAT GENET, V22, P82, DOI 10.1038/8788; Lain S, 1999, EXP CELL RES, V248, P457, DOI 10.1006/excr.1999.4433; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LITTLE JB, 1995, J BIOL CHEM, V270, P11033, DOI 10.1074/jbc.270.19.11033; Liu JH, 2001, CELL, V104, P353, DOI 10.1016/S0092-8674(01)00223-9; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Marciniak RA, 1998, P NATL ACAD SCI USA, V95, P6887, DOI 10.1073/pnas.95.12.6887; Neff NF, 1999, MOL BIOL CELL, V10, P665, DOI 10.1091/mbc.10.3.665; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Robles AI, 1999, ONCOGENE, V18, P4681, DOI 10.1038/sj.onc.1202862; Schwartz D, 1998, SEMIN CANCER BIOL, V8, P325, DOI 10.1006/scbi.1998.0095; Spillare EA, 1999, GENE DEV, V13, P1355, DOI 10.1101/gad.13.11.1355; Sun H, 1998, J BIOL CHEM, V273, P27587, DOI 10.1074/jbc.273.42.27587; vanLaar T, 1995, BIOCHEM BIOPH RES CO, V217, P769, DOI 10.1006/bbrc.1995.2839; VANLAAR T, 1994, ONCOGENE, V9, P981; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; Wang Y, 2000, GENE DEV, V14, P927; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Watt PM, 1996, CURR BIOL, V6, P265, DOI 10.1016/S0960-9822(02)00474-8; Watt PM, 1996, GENETICS, V144, P935; Yamagata K, 1998, P NATL ACAD SCI USA, V95, P8733, DOI 10.1073/pnas.95.15.8733; Yankiwski V, 2000, P NATL ACAD SCI USA, V97, P5214, DOI 10.1073/pnas.090525897; Zong S, 1999, ONCOGENE, V18, P7941, DOI 10.1038/sj.onc.1203367	52	122	127	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32948	32955		10.1074/jbc.M103298200	http://dx.doi.org/10.1074/jbc.M103298200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11399766	hybrid			2022-12-25	WOS:000170746000077
J	Inoue, S; Inoue, Y				Inoue, S; Inoue, Y			Developmental profile of neural cell adhesion molecule glycoforms with a varying degree of polymerization of polysialic acid chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANION-EXCHANGE CHROMATOGRAPHY; PERFORMANCE LIQUID-CHROMATOGRAPHY; ESCHERICHIA-COLI K1; RAT SPINAL-CORD; N-CAM; ADULT-RAT; SIALIC-ACID; EMBRYONIC FORM; GROUP-B; NCAM EXPRESSION	More precise information on the degree of polymerization (DP) of polysialie acid (polySia) chains expressed on neural cell adhesion molecule (NCAM) and its developmental stage-dependent variation are considered important in understanding the mechanism of regulated polysialylation and fine-tuning of NCAM-mediated cell adhesion by polySia. In this paper, first we performed a kinetic study of acid-catalyzed hydrolysis of polySia and report our findings that (a) in (--> 8Neu5Ac alpha2 -->)(n)--> 8Neu5Ac alpha2 --> 3Gal beta1 -->R, the proximal Neu5Ac residue alpha2 -->3 linked to Gal is cleaved about 2.5-4 times faster than the alpha2 -->8 linkages and (b) in contrary to general belief that alpha2 -->8 linkages in polySia are extremely labile, the kinetic consideration showed that they are not so unstable, and every ketosidic bond is hydrolyzed at the same rate. These findings are the basis of our strategy for DP analysis of polySia on NCAM. Second, using the recently developed method that provides base-line resolution of oligo/polySia from DP 2 to > 80 with detection thresholds of 1.4 fmol per resolved peak, we have determined the DP of polySia chains expressed in embryonic chicken brains at different developmental stages. Our results support the presence of numerous NCAM glycoforms differing in DPs of oligo/polySia chains and a delicate change in their distribution during development.	Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan	Academia Sinica - Taiwan	Inoue, Y (corresponding author), Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan.							Abrous DN, 1997, BRAIN RES, V744, P285, DOI 10.1016/S0006-8993(96)01115-8; Allan DW, 1998, J COMP NEUROL, V391, P275, DOI 10.1002/(SICI)1096-9861(19980216)391:3<275::AID-CNE1>3.0.CO;2-Z; Angata K, 1998, J BIOL CHEM, V273, P28524, DOI 10.1074/jbc.273.43.28524; Angata K, 1997, J BIOL CHEM, V272, P7182, DOI 10.1074/jbc.272.11.7182; ASHWELL G, 1994, ANAL BIOCHEM, V222, P495, DOI 10.1006/abio.1994.1523; BARTSCH U, 1990, J NEUROCYTOL, V19, P550, DOI 10.1007/BF01257243; BERARDI M, 1995, CELL TISSUE RES, V280, P463, DOI 10.1007/s004410050375; BONFANTI L, 1992, NEUROSCIENCE, V49, P419, DOI 10.1016/0306-4522(92)90107-D; Bruses JL, 1998, J CELL BIOL, V140, P1177, DOI 10.1083/jcb.140.5.1177; Butler AK, 1997, J COMP NEUROL, V389, P289, DOI 10.1002/(SICI)1096-9861(19971215)389:2<289::AID-CNE8>3.0.CO;2-Y; Bystricky S, 1997, BIOPHYS CHEM, V63, P147, DOI 10.1016/S0301-4622(96)02242-9; Cheng MC, 1998, ANAL BIOCHEM, V260, P154, DOI 10.1006/abio.1998.2701; Chuck ET, 1997, DEV DYNAM, V209, P182, DOI 10.1002/(SICI)1097-0177(199706)209:2<182::AID-AJA4>3.3.CO;2-T; CUNNINGHAM BA, 1983, P NATL ACAD SCI-BIOL, V80, P3116, DOI 10.1073/pnas.80.10.3116; Dey PM, 1997, NEUROTOXICOLOGY, V18, P633; DUBOIS C, 1995, J IMMUNOL METHODS, V181, P125, DOI 10.1016/0022-1759(94)00336-U; FigarellaBranger D, 1996, J CLIN ONCOL, V14, P2066, DOI 10.1200/JCO.1996.14.7.2066; FRIEDLANDER DR, 1985, J CELL BIOL, V101, P412, DOI 10.1083/jcb.101.2.412; FROST G, 1991, NEUROPATH APPL NEURO, V17, P207, DOI 10.1111/j.1365-2990.1991.tb00716.x; Gerety M, 1997, ANAT REC, V247, P71; GLASS JD, 1994, NEUROENDOCRINOLOGY, V60, P87; GRIFFITH CM, 1991, ANAT EMBRYOL, V183, P205; HALLENBECK PC, 1987, ANAL BIOCHEM, V161, P181, DOI 10.1016/0003-2697(87)90670-1; HARA S, 1987, ANAL BIOCHEM, V164, P138, DOI 10.1016/0003-2697(87)90377-0; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; HOFFMAN S, 1984, P NATL ACAD SCI-BIOL, V81, P6881, DOI 10.1073/pnas.81.21.6881; HUSMANN M, 1989, EUR J IMMUNOL, V19, P1761, DOI 10.1002/eji.1830190935; Inoue S, 2000, J BIOL CHEM, V275, P29968, DOI 10.1074/jbc.M004150200; INOUE S, 2001, IN PRESS BIOCH, P83; JOOSTEN EAJ, 1994, DEV BRAIN RES, V78, P226, DOI 10.1016/0165-3806(94)90030-2; KABAT EA, 1988, J EXP MED, V168, P699, DOI 10.1084/jem.168.2.699; Kakehi K, 1999, ANAL CHEM, V71, P1592, DOI 10.1021/ac981248y; KITAJIMA K, 1992, ANAL BIOCHEM, V205, P244, DOI 10.1016/0003-2697(92)90430-F; KITAZUME S, 1994, J BIOL CHEM, V269, P22712; KITAZUME S, 1992, ANAL BIOCHEM, V202, P25, DOI 10.1016/0003-2697(92)90200-Q; Kojima N, 1996, J BIOL CHEM, V271, P19457, DOI 10.1074/jbc.271.32.19457; Kudo M, 1998, GLYCOBIOLOGY, V8, P771, DOI 10.1093/glycob/8.8.771; Kudo M, 1996, J BIOL CHEM, V271, P32667, DOI 10.1074/jbc.271.51.32667; LASALLE GL, 1991, CR ACAD SCI III-VIE, V312, P43; LIFELY MR, 1986, CARBOHYD RES, V156, P123, DOI 10.1016/S0008-6215(00)90104-6; Lin SL, 1999, GLYCOBIOLOGY, V9, P807, DOI 10.1093/glycob/9.8.807; Lin SL, 2000, CARBOHYD RES, V329, P447, DOI 10.1016/S0008-6215(00)00177-4; LIVINGSTON BD, 1988, J BIOL CHEM, V263, P9443; MANZI AE, 1994, J BIOL CHEM, V269, P23617; MIRAGALL F, 1990, J NEUROCYTOL, V19, P899, DOI 10.1007/BF01186818; MIRAGALL F, 1988, DEV BIOL, V129, P516, DOI 10.1016/0012-1606(88)90397-1; Muhlenhoff M, 1996, CURR BIOL, V6, P1188, DOI 10.1016/S0960-9822(02)70687-8; MULLER D, 1994, NEUROSCIENCE, V61, P441, DOI 10.1016/0306-4522(94)90424-3; NADANO D, 1986, J BIOL CHEM, V261, P1550; Nishiyama I, 1996, ANAT EMBRYOL, V194, P419; NOMOTO H, 1982, ARCH BIOCHEM BIOPHYS, V218, P335, DOI 10.1016/0003-9861(82)90352-6; Nothias F, 1997, EUR J NEUROSCI, V9, P1553, DOI 10.1111/j.1460-9568.1997.tb01513.x; OUMESMAR BN, 1995, EUR J NEUROSCI, V7, P480, DOI 10.1111/j.1460-9568.1995.tb00344.x; PERERA AD, 1993, ENDOCRINOLOGY, V133, P2729, DOI 10.1210/en.133.6.2729; ROHR TE, 1980, J BIOL CHEM, V255, P2332; ROTH J, 1989, VERH DEUT G, V73, P372; ROUGON G, 1986, J CELL BIOL, V103, P2429, DOI 10.1083/jcb.103.6.2429; SATO C, 1993, J BIOL CHEM, V268, P23675; Sato C, 1999, ANAL BIOCHEM, V266, P102, DOI 10.1006/abio.1998.2921; SCHLOSSHAUER B, 1984, NATURE, V310, P141, DOI 10.1038/310141a0; SEKI T, 1991, NEUROSCI RES, V12, P503, DOI 10.1016/S0168-0102(09)80003-5; SEKI T, 1991, ANAT EMBRYOL, V184, P395, DOI 10.1007/BF00957900; SEKI T, 1993, DEV BRAIN RES, V73, P141, DOI 10.1016/0165-3806(93)90056-G; Seki T, 1998, J NEUROSCI, V18, P3757; SUNSHINE J, 1987, P NATL ACAD SCI USA, V84, P5986, DOI 10.1073/pnas.84.16.5986; THEODOSIS DT, 1991, P NATL ACAD SCI USA, V88, P5494, DOI 10.1073/pnas.88.13.5494; Wood GK, 1997, MOL BRAIN RES, V51, P69, DOI 10.1016/S0169-328X(97)00209-X; Zhang Y, 1999, J BIOL CHEM, V274, P6183, DOI 10.1074/jbc.274.10.6183; Zhang Y, 1997, ANAL BIOCHEM, V250, P245, DOI 10.1006/abio.1997.2225; ZHANG Y, 1995, J COMP NEUROL, V361, P193, DOI 10.1002/cne.903610202	70	43	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31863	31870		10.1074/jbc.M103336200	http://dx.doi.org/10.1074/jbc.M103336200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11371567	hybrid			2022-12-25	WOS:000170613500055
J	Zheng, LX; Schickling, O; Peter, ME; Lenardo, MJ				Zheng, LX; Schickling, O; Peter, ME; Lenardo, MJ			The death effector domain-associated factor plays distinct regulatory roles in the nucleus and cytoplasm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR YY1; CELL-DEATH; CONTAINING PROTEIN; SIGNALING COMPLEX; CD95 FAS/APO-1; APOPTOSIS; FADD; FAS; INTERACTS; RECEPTOR	Homophilic interactions of death effector domains (DEDs) are crucial for the signaling pathways of death receptor-mediated apoptosis. The machinery that regulates proper oligomerization and autoactivation of procaspase-8 and/or procaspase-10 during T lymphocyte activation determines whether the cells will undergo caspase-mediated apoptosis or proliferation. We screened a yeast two-hybrid library by using the DEDs contained in the prodomains of procaspase-8 and procaspase-10 and isolated a DED-associated factor (DEDAF) that interacts with several DED-containing proteins but does not itself contain a DED. DEDAF is highly conserved between human and mouse (98% amino acid identity) and is homologous to a nuclear regulatory protein YAF-2. DEDAF is expressed at the highest levels in lymphoid tissues and placenta. DEDAF interacts with FADD, procaspase-8, and procaspase-10 in the cytosol as well as with the DED-containing DNA-binding protein (DEDD) in the nucleus. At the cell membrane, DEDAF augmented the formation of CD95-FADD-caspase-8 complexes and enhanced death receptor- as well as DED-mediated apoptosis. In the nucleus, DEDAF caused the DEDD protein to relocalize from subnuclear structures to a diffuse distribution in the nucleoplasm. Our data therefore suggest that DEDAF may be involved in the regulation of both cytoplasmic and nuclear events of apoptosis.	NIAID, Immunol Lab, NIH, Bethesda, MD 20892 USA; Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60637 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Chicago	Lenardo, MJ (corresponding author), NIAID, Immunol Lab, NIH, Bldg 10, Bethesda, MD 20892 USA.			Peter, Marcus Ernst/0000-0003-3216-036X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000717, Z01AI000769, ZIAAI000769, ZIAAI000718, Z01AI000717, Z01AI000718] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Eberstadt M, 1998, NATURE, V392, P941, DOI 10.1038/31972; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Fesik SW, 2000, CELL, V103, P273, DOI 10.1016/S0092-8674(00)00119-7; Garcia E, 1999, EMBO J, V18, P3404, DOI 10.1093/emboj/18.12.3404; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; Hofmann K, 1999, CELL MOL LIFE SCI, V55, P1113, DOI 10.1007/s000180050361; ITOH N, 1993, J BIOL CHEM, V268, P10932; Kalenik JL, 1997, NUCLEIC ACIDS RES, V25, P843, DOI 10.1093/nar/25.4.843; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Lee SW, 2000, MOL MICROBIOL, V35, P1540, DOI 10.1046/j.1365-2958.2000.01824.x; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Siegel RM, 1998, J CELL BIOL, V141, P1243, DOI 10.1083/jcb.141.5.1243; Stegh AH, 1998, EMBO J, V17, P5974, DOI 10.1093/emboj/17.20.5974; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5	24	65	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31945	31952		10.1074/jbc.M102799200	http://dx.doi.org/10.1074/jbc.M102799200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11395500	hybrid			2022-12-25	WOS:000170613500066
J	Yang, JP; Tang, HL; Reddy, TR; Wong-Staal, F				Yang, JP; Tang, HL; Reddy, TR; Wong-Staal, F			Mapping the functional domains of HAP95, a protein that binds RNA helicase A and activates the constitutive transport element of type D retroviruses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NUCLEAR EXPORT; POSTTRANSCRIPTIONAL REGULATION; TAP; SIGNAL; CRM1; IDENTIFICATION; PURIFICATION; REPLICATION; CONTAINS	The complex retroviruses such as human immunodeficiency virus, type 1, employ a virally encoded protein, Rev, to mediate the nuclear export of unspliced and partially spliced mRNA. In contrast, the simian type D retroviruses act through a cis-acting constitutive transport element (CTE) that presumably interacts directly with cellular export proteins. We first reported that RNA helicase A (RHA) is a shuttle protein that binds to functional CTE in vitro and in vivo. Recently, we isolated a novel protein, HAP95, that specifically binds to the nuclear transport domain of RHA and up-regulates CTE-mediated gene expression. Here, using truncation and deletion mutations, we mapped the domains of HAP95 that are important for RHA binding, transactivation of CTE, and nuclear cytoplasmic shuttling. We report evidence for a novel nuclear export signal in HAP95 and showed that the domains involved in RHA binding and nuclear localization are required for CTE activation. Finally, we showed that HAP95 synergizes significantly with RHA on CTE-mediated reporter gene expression and promotes nuclear export of unspliced mRNA in transfected cells. Taken together, these data support the proposal that HAP95 specifically facilitates CTE-mediated gene expression by directly binding to RHA.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Wong-Staal, F (corresponding author), Univ Calif San Diego, Dept Biol, Stein Clin Res Bldg, La Jolla, CA 92093 USA.	fwongstaal@ucsd.edu	Tang, Hengli/F-2085-2014		NIAID NIH HHS [P30AI 36214] Funding Source: Medline; NIGMS NIH HHS [GM056089] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036214] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Braun IC, 1999, EMBO J, V18, P1953, DOI 10.1093/emboj/18.7.1953; BRAY M, 1994, P NATL ACAD SCI USA, V91, P1256, DOI 10.1073/pnas.91.4.1256; COGHLAN VM, 1994, J BIOL CHEM, V269, P7658; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gruter P, 1998, MOL CELL, V1, P649, DOI 10.1016/S1097-2765(00)80065-9; Hope TJ, 1999, ARCH BIOCHEM BIOPHYS, V365, P186, DOI 10.1006/abbi.1999.1207; Kang YB, 1999, GENE DEV, V13, P1126, DOI 10.1101/gad.13.9.1126; Katahira J, 1999, EMBO J, V18, P2593, DOI 10.1093/emboj/18.9.2593; Li JZ, 1999, P NATL ACAD SCI USA, V96, P709, DOI 10.1073/pnas.96.2.709; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; MICHAEL WM, 1995, CELL, V83, P415; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Pollard VW, 1998, ANNU REV MICROBIOL, V52, P491, DOI 10.1146/annurev.micro.52.1.491; Reddy TR, 2000, ONCOGENE, V19, P3570, DOI 10.1038/sj.onc.1203676; Reddy TR, 1999, NAT MED, V5, P635, DOI 10.1038/9479; Tang H, 1999, MOL CELL BIOL, V19, P3540; Tang HL, 1997, VIROLOGY, V228, P333, DOI 10.1006/viro.1996.8407; Tang HL, 1997, SCIENCE, V276, P1412, DOI 10.1126/science.276.5317.1412; Westberg C, 2000, J BIOL CHEM, V275, P21396, DOI 10.1074/jbc.M909887199; Yang JP, 1999, J BIOL CHEM, V274, P15662, DOI 10.1074/jbc.274.22.15662; ZHANG SS, 1991, J BIOL CHEM, V266, P20483	23	23	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30694	30700		10.1074/jbc.M102809200	http://dx.doi.org/10.1074/jbc.M102809200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11402034	hybrid			2022-12-25	WOS:000170472900016
J	Zhao, DZ; Letterman, J; Schreiber, BM				Zhao, DZ; Letterman, J; Schreiber, BM			beta-migrating very low density lipoprotein (beta VLDL) activates smooth muscle cell mitogen-activated protein (MAP) kinase via G protein-coupled receptor-mediated transactivation of the epidermal growth factor (EGF) receptor - Effect of map kinase activation on beta VLDL plus EGF-induced cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOPHOSPHATIDIC ACID; TYROSINE KINASE; ANGIOTENSIN-II; CYCLIN D1; C-FOS; NEURONAL DIFFERENTIATION; NEOINTIMA FORMATION; PORCINE CORONARY; DOWN-REGULATION; GENE-TRANSFER	This study examined the premise that the atherogenic lipoprotein, beta -migrating very low density lipoprotein (beta VLDL), might activate the mitogen-activated protein (MAP) kinases ERK1/ERK2, thereby contributing to the induction of smooth muscle cell proliferation in atherosclerosis. The data show that beta VLDL activates rabbit smooth muscle cell ERK1/ERK2. Interestingly, ERK1/ ERK2 activation is mediated by G protein-coupled receptors that transactivate the epidermal growth factor (EGF) receptor.,beta VLDL-induced MAP kinase activation depends on Ras and Src activity as well as protein kinase C. The inhibition of lysosomal degradation of beta VLDL has no effect on ERK1/ERK2 activation. The contribution of beta VLDL-induced activation of ERK1/ERK2 to smooth muscle cell proliferation was also explored. beta VLDL induces expression of egr-1 and c-fos mRNA. Despite its ability to stimulate early gene expression, beta VLDL alone is unable to inspire quiescent cells into S phase. When added in conjunction with EGF, however, stimulation of [H-3]thymidine incorporation into DNA and an increase in histone gene expression are observed. Moreover, beta VLDL plus EGF synergistically induce cyclin D1 expression and down-regulate p27(KIP1) expression. The addition of either,beta VLDL or EGF stimulates a robust activation of ERK1/ ERK2, but the addition of both agents simultaneously sustains the activation for a longer time period. Inhibition of MAP kinase kinase, pertussis toxin-sensitive G proteins, the EGF receptor, or protein kinase C blocks beta VLDL plus EGF-induced proliferation, demonstrating that activation of the beta VLDL-induced signaling pathway results in smooth muscle cell proliferation.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University	Schreiber, BM (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St, Boston, MA 02118 USA.	schreibe@biochem.bumc.bu.edu		Schreiber, Barbara/0000-0001-8560-4249	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL013262] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG009006] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-13262] Funding Source: Medline; NIA NIH HHS [AG-9006] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Auge N, 1998, J BIOL CHEM, V273, P12893, DOI 10.1074/jbc.273.21.12893; Balagopalakrishna C, 1997, MOL CELL BIOCHEM, V170, P85, DOI 10.1023/A:1006840927835; Balmanno K, 1999, ONCOGENE, V18, P3085, DOI 10.1038/sj.onc.1202647; BOONSTRA J, 1995, CELL BIOL INT, V19, P413, DOI 10.1006/cbir.1995.1086; Bornfeldt KE, 1997, J CLIN INVEST, V100, P875, DOI 10.1172/JCI119603; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Chatterjee S, 1997, GLYCOBIOLOGY, V7, P703, DOI 10.1093/glycob/7.5.703; CHATTERJEE S, 1992, MOL CELL BIOCHEM, V111, P143; Chen DH, 1997, J CLIN INVEST, V99, P2334, DOI 10.1172/JCI119414; CHEN JK, 1986, J CELL PHYSIOL, V129, P207, DOI 10.1002/jcp.1041290212; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; Cook SJ, 1999, MOL CELL BIOL, V19, P330; Cook SJ, 1996, BIOCHEM J, V320, P237, DOI 10.1042/bj3200237; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Cunnick JM, 1998, J BIOL CHEM, V273, P14468, DOI 10.1074/jbc.273.23.14468; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Deigner HP, 1996, FEBS LETT, V385, P149, DOI 10.1016/0014-5793(96)00371-7; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Eguchi S, 1996, J BIOL CHEM, V271, P14169, DOI 10.1074/jbc.271.24.14169; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FLESS GM, 1982, ATHEROSCLEROSIS, V41, P171, DOI 10.1016/0021-9150(82)90183-6; Force T, 1998, HYPERTENSION, V31, P152, DOI 10.1161/01.HYP.31.1.152; Gallo R, 1999, CIRCULATION, V99, P2164, DOI 10.1161/01.CIR.99.16.2164; GOLDSTEIN JL, 1980, J BIOL CHEM, V255, P1839; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HEASLEY LE, 1992, MOL BIOL CELL, V3, P545, DOI 10.1091/mbc.3.5.545; HEERY JM, 1995, J CLIN INVEST, V96, P2322, DOI 10.1172/JCI118288; HERBER B, 1994, ONCOGENE, V9, P1295; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; Horiuchi A, 1999, MOL HUM REPROD, V5, P139, DOI 10.1093/molehr/5.2.139; Iaccarino G, 1999, P NATL ACAD SCI USA, V96, P3945, DOI 10.1073/pnas.96.7.3945; Inagami T, 1999, J AM SOC NEPHROL, V10, pS57; Indolfi C, 1997, BASIC RES CARDIOL, V92, P378, DOI 10.1007/BF00796211; IZUMI H, 1994, EXP CELL RES, V214, P654, DOI 10.1006/excr.1994.1303; KAMANNA VS, 1999, KIDNEY INT S, V71, P70; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Koyama H, 1998, CIRC RES, V82, P713, DOI 10.1161/01.RES.82.6.713; Kranenburg O, 1997, EMBO J, V16, P3097, DOI 10.1093/emboj/16.11.3097; Kusuhara M, 1997, ARTERIOSCL THROM VAS, V17, P141, DOI 10.1161/01.ATV.17.1.141; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laufs U, 1999, J BIOL CHEM, V274, P21926, DOI 10.1074/jbc.274.31.21926; Lavoie J N, 1996, Prog Cell Cycle Res, V2, P49; LIBBY P, 1985, J CELL PHYSIOL, V124, P1, DOI 10.1002/jcp.1041240102; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Matsumura T, 1997, ARTERIOSCL THROM VAS, V17, P3013, DOI 10.1161/01.ATV.17.11.3013; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NATARAJAN V, 1995, J LIPID RES, V36, P2005; Paulus W, 1996, J VIROL, V70, P62, DOI 10.1128/JVI.70.1.62-67.1996; Pyles JM, 1997, CIRC RES, V81, P904; RESINK TJ, 1995, J VASC RES, V32, P328, DOI 10.1159/000159107; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sachinidis A, 1997, MOL PHARMACOL, V52, P389, DOI 10.1124/mol.52.3.389; SACHINIDIS A, 1993, BIOCHEM BIOPH RES CO, V192, P794, DOI 10.1006/bbrc.1993.1484; SACHINIDIS A, 1990, HYPERTENSION, V15, P704, DOI 10.1161/01.HYP.15.6.704; Sakai T, 1999, J BIOL CHEM, V274, P15480, DOI 10.1074/jbc.274.22.15480; SCHREIBER BM, 1988, ATHEROSCLEROSIS, V69, P69, DOI 10.1016/0021-9150(88)90290-0; SCHREIBER BM, 1992, ATHEROSCLEROSIS, V95, P201, DOI 10.1016/0021-9150(92)90023-A; SCHREIBER BM, 1994, J LIPID RES, V35, P1177; SCOTTBURDEN T, 1989, J BIOL CHEM, V264, P12582; Servant MJ, 2000, J CELL BIOL, V148, P543, DOI 10.1083/jcb.148.3.543; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Takahashi E, 1998, ACTA PHYSIOL SCAND, V164, P611, DOI 10.1111/j.1365-201X.1998.tb10705.x; Takahashi T, 1997, J BIOL CHEM, V272, P16018, DOI 10.1074/jbc.272.25.16018; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; Tsai W, 1997, EMBO J, V16, P4597, DOI 10.1093/emboj/16.15.4597; WEISGRABER KH, 1990, ANN NY ACAD SCI, V598, P37, DOI 10.1111/j.1749-6632.1990.tb42274.x; YOSHIDA Y, 1984, EXP MOL PATHOL, V41, P258, DOI 10.1016/0014-4800(84)90042-X; Zou YZ, 1998, CIRC RES, V82, P337, DOI 10.1161/01.RES.82.3.337	73	28	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30579	30588		10.1074/jbc.M103761200	http://dx.doi.org/10.1074/jbc.M103761200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11375998	hybrid			2022-12-25	WOS:000170472900002
J	Breitinger, HG; Villmann, C; Becker, K; Becker, CM				Breitinger, HG; Villmann, C; Becker, K; Becker, CM			Opposing effects of molecular volume and charge at the hyperekplexia site alpha 1 (P250) govern glycine receptor activation and desensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID	Allelic variants of the glycine receptor al subunit gene GLRA1 underlie the human neurological disorder hyperekplexia. Among these, the subunit variant alpha1(P250T) is characterized by an amino acid substitution within the cytoplasmic TM1-2 loop. To identify structural elements at position alpha1(250) that govern receptor function, homomeric mutant receptor channels were subjected to electrophysiological analysis after recombinant expression in HEK293 cells. Wild-type alpha1(P250) channels were nondesensitizing with an ECO for glycine of 8 muM, whereas bulky hydrophobic side chains of the channel variants alpha1(P250V/I/L/F) showed rapid desensitization (tau (desens), 50-250 ms) and EC50 values of 400-1800 mum. Small side chains (P250G/A/S) gave rise to wild-type-like channels. Effects of volume were counteracted by charge: alpha1(P250E/R) were nondesensitizing; EC50 was similar to 70 muM. The mutants alpha1(P250C/Y) displayed intermediate channel properties (EC50, 42/70 muM,4 tau (desens), 3300/2800 ms, respectively). The isotropic forces volume and hydropathy were sufficient to account for the observed effects of residue alpha1(250) on receptor function. Indeed, channel behavior was best predicted by a combined hydropathy/volume index describing the hydrophobic surface of individual amino acids. These observations characterize the short intracellular TM1-2 loop as a regulatory domain for channel activation and a crucial mediator of glycine receptor desensitization.	Univ Erlangen Nurnberg, Emil Fischer Zentrum, Inst Biochem, D-91054 Erlangen, Germany	University of Erlangen Nuremberg	Becker, CM (corresponding author), Univ Erlangen Nurnberg, Emil Fischer Zentrum, Inst Biochem, Fahrstr 17, D-91054 Erlangen, Germany.	cmb@biochem.uni-erlangen.de	Breitinger, Hans-Georg/ABD-3247-2021	Breitinger, Hans-Georg/0000-0003-0111-3528				Becker C. M., 1995, NEUROSCIENTIST, V1, P130; BECKER CM, 1998, FRONT NEUROBIOL, V3, P93; Becker K, 2000, CHANNELOPATHIES - COMMON MECHANISMS IN AURA, ARRHYTHMIA AND ALKALOSIS, P199, DOI 10.1016/B978-044450489-0/50010-0; Breitinger HG, 1998, CURR PHARM DESIGN, V4, P315; Breitinger HG, 2001, NEUROSCIENTIST, V7, P95, DOI 10.1177/107385840100700204; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; HESS GP, 1993, BIOCHEMISTRY-US, V32, P989, DOI 10.1021/bi00055a001; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Kling C, 1997, NEUROSCIENCE, V78, P411, DOI 10.1016/S0306-4522(96)00567-2; KRISHTAL OA, 1980, NEUROSCIENCE, V5, P2325, DOI 10.1016/0306-4522(80)90149-9; Lewis TM, 1999, ANN NY ACAD SCI, V868, P681, DOI 10.1111/j.1749-6632.1999.tb11345.x; LEWIS TM, 1998, J PHYSIOL-LONDON, V15, P25; Lynch JW, 1997, EMBO J, V16, P110, DOI 10.1093/emboj/16.1.110; Nikolic Z, 1998, J BIOL CHEM, V273, P19708, DOI 10.1074/jbc.273.31.19708; Saul B, 1999, J NEUROSCI, V19, P869; SONTHEIMER H, 1989, NEURON, V2, P1491, DOI 10.1016/0896-6273(89)90195-5; UDGAONKAR JB, 1987, P NATL ACAD SCI USA, V84, P8758, DOI 10.1073/pnas.84.24.8758; Wick MJ, 1998, P NATL ACAD SCI USA, V95, P6504, DOI 10.1073/pnas.95.11.6504; Yamakura T, 1999, J BIOL CHEM, V274, P23006, DOI 10.1074/jbc.274.33.23006; Ye Q, 1998, J BIOL CHEM, V273, P3314, DOI 10.1074/jbc.273.6.3314; Zamyatnin A A, 1972, Prog Biophys Mol Biol, V24, P107, DOI 10.1016/0079-6107(72)90005-3	21	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29657	29663		10.1074/jbc.M100446200	http://dx.doi.org/10.1074/jbc.M100446200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11395484	hybrid			2022-12-25	WOS:000170558000010
J	Jin, TG; Satoh, T; Liao, YH; Song, CH; Gao, XL; Kariya, K; Hu, CD; Kataoka, T				Jin, TG; Satoh, T; Liao, YH; Song, CH; Gao, XL; Kariya, K; Hu, CD; Kataoka, T			Role of the CDC25 homology domain of phospholipase C epsilon in amplification of Rap1-dependent signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-EXCHANGE FACTOR; RAS-DEPENDENT ACTIVATION; NERVE GROWTH-FACTOR; PHOSPHOINOSITIDE 3-KINASE; KINASE ACTIVATION; ADENYLYL-CYCLASE; STRUCTURAL BASIS; GOLGI-COMPLEX; RAP1 GTPASE; MAP KINASE	Phospholipase CE (PLC epsilon) is a novel class of phosphoinositide-specific PLC characterized by possession of CDC25 homology and Ras/Rap1-associating domains. We and others have shown that human PLC epsilon is translocated from the cytoplasm to the plasma membrane and activated by direct association with Ras at its Ras/Rap1associating domain. In addition, translocation to the perinuclear region was induced upon association with Rap1-GTP. However, the function of the CDC25 homology domain remains to be clarified. Here we show that the CDC25 homology domain of PLC epsilon functions as a guanine nucleotide exchange factor for Rap1 but not for any other Ras family GTPases examined including Rap2 and Ha-Ras. Consistent with this, coexpression of full. length PLC epsilon or its N-terminal fragment carrying the CDC25 homology domain causes an increase of the intracellular level of Rap1-GTP. Concurrently, stimulation of the downstream kinases B-Raf and extracellular signal. regulated kinase is observed, whereas the intracellular level of Ras-GTP and Raf-1 kinase activity are unaffected. In wild-type Rap1-overexpressing cells, epidermal growth factor induces translocation of PLC epsilon to the perinuclear compartments such as the Golgi apparatus, which is sustained for at least 20 min. In contrast, PLC epsilon lacking the CDC25 domain translocates to the perinuclear compartments only transiently. Further, the formation of Rapl-GTP upon epidermal growth factor stimulation exhibits a prolonged time course in cells expressing full-length PLCe compared with those expressing PLC epsilon lacking the CDC25 homology domain. These results suggest a pivotal role of the CDC25 homology domain in amplifying Rap1-dependent signal transduction, including the activation of PLC epsilon itself, at specific subcellular locations such as the Golgi apparatus.	Kobe Univ, Grad Sch Med, Dept Mol & Cellular Biol, Div Mol Biol,Chuo Ku, Kobe, Hyogo 6500017, Japan; Univ Ryukyus, Sch Med, Dept Biochem 2, Okinawa 9030215, Japan	Kobe University; University of the Ryukyus	Kataoka, T (corresponding author), Kobe Univ, Grad Sch Med, Dept Mol & Cellular Biol, Div Mol Biol,Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	kataoka@kobe-u.ac.jp	song, chunhua/K-7882-2016; Satoh, Takaya/K-2628-2014; song, chunhua/K-7882-2016	song, chunhua/0000-0001-7563-0339; song, chunhua/0000-0002-4081-2543				BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; de Rooij J, 1999, J BIOL CHEM, V274, P38125, DOI 10.1074/jbc.274.53.38125; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Hu CD, 1997, J BIOL CHEM, V272, P11702, DOI 10.1074/jbc.272.18.11702; Hu CD, 1995, J BIOL CHEM, V270, P30274, DOI 10.1074/jbc.270.51.30274; Huang L, 1997, NAT STRUCT BIOL, V4, P609, DOI 10.1038/nsb0897-609; Huang L, 1998, NAT STRUCT BIOL, V5, P422, DOI 10.1038/nsb0698-422; Ichiba T, 1999, FEBS LETT, V457, P85, DOI 10.1016/S0014-5793(99)01012-1; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; Kelley GG, 2001, EMBO J, V20, P743, DOI 10.1093/emboj/20.4.743; Kiyono M, 1999, P NATL ACAD SCI USA, V96, P4826, DOI 10.1073/pnas.96.9.4826; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; Liao YH, 1999, J BIOL CHEM, V274, P37815, DOI 10.1074/jbc.274.53.37815; Lopez I, 2001, J BIOL CHEM, V276, P2758, DOI 10.1074/jbc.M008119200; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Matsubara K, 1999, ONCOGENE, V18, P1303, DOI 10.1038/sj.onc.1202425; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NODA M, 1993, BIOCHIM BIOPHYS ACTA, V1155, P97, DOI 10.1016/0304-419X(93)90024-7; Ohba Y, 2000, MOL CELL BIOL, V20, P6074, DOI 10.1128/MCB.20.16.6074-6083.2000; Ohtsuka T, 1999, BIOCHEM BIOPH RES CO, V265, P38, DOI 10.1006/bbrc.1999.1619; Okada T, 1999, MOL CELL BIOL, V19, P6057; Pacold ME, 2000, CELL, V103, P931, DOI 10.1016/S0092-8674(00)00196-3; Pham N, 2000, CURR BIOL, V10, P555, DOI 10.1016/S0960-9822(00)00473-5; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8; Rebhun JF, 2000, J BIOL CHEM, V275, P34901, DOI 10.1074/jbc.M005327200; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; Roth MG, 1999, TRENDS CELL BIOL, V9, P174, DOI 10.1016/S0962-8924(99)01535-4; Schmidt A, 2001, MOL CELL BIOL, V21, P438, DOI 10.1128/MCB.21.2.438-448.2001; Shibatohge M, 1998, J BIOL CHEM, V273, P6218, DOI 10.1074/jbc.273.11.6218; Shima F, 2000, MOL CELL BIOL, V20, P26, DOI 10.1128/MCB.20.1.26-33.2000; Song C, 2001, J BIOL CHEM, V276, P2752, DOI 10.1074/jbc.M008324200; Tsukamoto N, 1999, J BIOL CHEM, V274, P18463, DOI 10.1074/jbc.274.26.18463; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Walker EH, 1999, NATURE, V402, P313, DOI 10.1038/46319; Wang QMJ, 1999, J BIOL CHEM, V274, P37233, DOI 10.1074/jbc.274.52.37233; Wienecke R, 1996, ONCOGENE, V13, P913; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; York RD, 2000, MOL CELL BIOL, V20, P8069, DOI 10.1128/MCB.20.21.8069-8083.2000; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451	46	105	115	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30301	30307		10.1074/jbc.M103530200	http://dx.doi.org/10.1074/jbc.M103530200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11395506	hybrid			2022-12-25	WOS:000170558000092
J	Lee, CH; Chung, JH				Lee, CH; Chung, JH			The hCds1 (Chk2)-FHA domain is essential for a chain of phosphorylation events on hCds1 that is induced by ionizing radiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; DEPENDENT PROTEIN-KINASE; FHA DOMAIN; CATALYTIC SUBUNIT; CRYSTAL-STRUCTURE; HUMAN CDC25C; ATM PROTEIN; CHK2; LINKAGE; CDS1	hCds1 (Chk2) (1-4) is an evolutionarily conserved kinase that functions in DNA damage response and cell cycle checkpoint. The Cds1 family of kinases are activated by a family of large phosphatidylinositol 3-kinase-like kinases. In humans, ataxia telangiectasia-mutated (ATM) (5) and ataxia-telangiectasia and Rad3-related (6) kinases activate hCds1 by phosphorylating Thr(68) (7-9). hCds1 and Cds1-related kinases contain the FHA (fork. head-associated) domain (10), which appears to be important for integrating the DNA damage signal. It is not known how ATM phosphorylation activates hCds1 function and whether the phosphorylation is linked to the FHA. Here, we demonstrate that the hCds1-FHA domain is essential for Thr(68) phosphorylation. Thr(68) phosphorylation, in turn, is required for ionizing radiation-induced autophosphorylation of two amino acid residues in hCds1, Thr(383) and Thr(387). These two amino acid residues, located in the activation loop of hCds1, are conserved in hCds1-related kinases and are essential for hCds1 activity. Thus, the hCds1-FRA domain mediates a chain of phosphorylation events on hCds1, which includes phosphorylation by ATM and hCds1 autophosphorylation, in response to DNA damage.	NHLBI, Lab Biochem Genet, NIH, Bethesda, MD 20892 USA; Yonsei Univ, Coll Med, Dept Pathol, Brain Korea Projects Med Sci 21, Seoul 120752, South Korea	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Yonsei University; Yonsei University Health System	Chung, JH (corresponding author), NHLBI, Lab Biochem Genet, NIH, Bldg 10-7D13,10 Ctr Dr, Bethesda, MD 20892 USA.							Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chehab NH, 2000, GENE DEV, V14, P278; Chen P, 2000, CELL, V100, P681, DOI 10.1016/S0092-8674(00)80704-7; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Durocher D, 1999, MOL CELL, V4, P387, DOI 10.1016/S1097-2765(00)80340-8; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; HOFMANN K, 1995, TRENDS BIOCHEM SCI, V20, P347, DOI 10.1016/S0968-0004(00)89072-6; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; O'Neill T, 2000, J BIOL CHEM, V275, P22719, DOI 10.1074/jbc.M001002200; OGG S, 1994, J BIOL CHEM, V269, P30461; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108; Shieh SY, 2000, GENE DEV, V14, P289; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Wu XL, 2001, J BIOL CHEM, V276, P2971, DOI 10.1074/jbc.M009727200; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	33	125	130	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30537	30541		10.1074/jbc.M104414200	http://dx.doi.org/10.1074/jbc.M104414200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11390408	hybrid			2022-12-25	WOS:000170558000122
J	Lu, M; Holliday, LS; Zhang, L; Dunn, WA; Gluck, SL				Lu, M; Holliday, LS; Zhang, L; Dunn, WA; Gluck, SL			Interaction between aldolase and vacuolar H+ -ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE-MARROW CULTURES; MAMMALIAN KIDNEY; BOVINE KIDNEY; B2 SUBUNIT; F-ACTIN; BINDING; COMPLEX; CELLS; SITE; PURIFICATION	Vacuolar H+-ATPases (V-ATPases) are essential for acidification of intracellular compartments and for proton secretion from the plasma membrane in kidney epithelial cells and osteoclasts. The cellular proteins that regulate V-ATPases remain largely unknown. A screen for proteins that bind the V-ATPase E subunit using the yeast two-hybrid assay identified the cDNA clone coded for al. dolase, an enzyme of the glycolytic pathway. The interaction between E subunit and aldolase was confirmed in vitro by precipitation assays using E subunit-glutathione S-transferase chimeric fusion proteins and metabolically labeled aldolase. Aldolase was isolated associated with intact V-ATPase from bovine kidney microsomes and osteoclast-containing mouse marrow cultures in co-immunoprecipitation studies performed using an anti-E subunit monoclonal antibody. The interaction was not affected by incubation with aldolase substrates or products. In immunocytochemical assays, aldolase was found to colocalize with V-ATPase in the renal proximal tubule. In osteoclasts, the aldolase-V-ATPase complex appeared to undergo a subcellular redistribution from perinuclear compartments to the ruffled membranes following activation of resorption. In yeast cells deficient in aldolase, the peripheral V-1 domain of V-ATPase was found to dissociate from the integral membrane V-0 domain, indicating direct coupling of glycolysis to the proton pump. The direct binding interaction between V-ATPase and aldolase may be a new mechanism for the regulation of the V-ATPase and may underlie the proximal tubule acidification defect in hereditary fructose intolerance.	Univ Florida, Coll Med, Dept Med, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Lu, M (corresponding author), Univ Florida, Coll Med, Dept Med, Campus Box 100224,Rm CG-98 SW Archer Rd, Gainesville, FL 32610 USA.	luming@medicine.ufl.edu	Holliday, Lexie/GYQ-4972-2022	Holliday, Lexie/0000-0002-0844-1965	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054362, R01DK038848] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK54362, DK38848] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ali M, 1998, J MED GENET, V35, P353, DOI 10.1136/jmg.35.5.353; ARNOLD H, 1970, EUR J BIOCHEM, V15, P360, DOI 10.1111/j.1432-1033.1970.tb01016.x; Breton S, 2000, J BIOL CHEM, V275, P18219, DOI 10.1074/jbc.M909857199; BROOKS SPJ, 1991, J THEOR BIOL, V149, P361, DOI 10.1016/S0022-5193(05)80311-X; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; GLUCK S, 1987, J BIOL CHEM, V262, P15780; Gluck SL, 1998, ACTA PHYSIOL SCAND, V163, P203; Gluck SL, 1996, ANNU REV PHYSIOL, V58, P427, DOI 10.1146/annurev.physiol.58.1.427; GOLDSTEIN DJ, 1992, EMBO J, V11, P4851, DOI 10.1002/j.1460-2075.1992.tb05591.x; Heiner CR, 1998, GENOME RES, V8, P557, DOI 10.1101/gr.8.5.557; HEMKEN P, 1992, J BIOL CHEM, V267, P9948; HIRSCH S, 1988, P NATL ACAD SCI USA, V85, P3004, DOI 10.1073/pnas.85.9.3004; HOLLIDAY LS, 1995, J BIOL CHEM, V270, P18983, DOI 10.1074/jbc.270.32.18983; Holliday LS, 1997, J BIOL CHEM, V272, P22053, DOI 10.1074/jbc.272.35.22053; Holliday LS, 2000, J BIOL CHEM, V275, P32331, DOI 10.1074/jbc.M004795200; Jager D, 1996, J EXP BIOL, V199, P1019; James P, 1996, GENETICS, V144, P1425; KOPPITZ B, 1986, EUR J BIOCHEM, V161, P421, DOI 10.1111/j.1432-1033.1986.tb10462.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee BS, 1999, J BIOL CHEM, V274, P29164, DOI 10.1074/jbc.274.41.29164; LEE BS, 1995, J BIOL CHEM, V270, P7320, DOI 10.1074/jbc.270.13.7320; Lee BS, 1997, J BIOL CHEM, V272, P174; Lee BS, 1999, J BONE MINER RES, V14, P2127, DOI 10.1359/jbmr.1999.14.12.2127; Lenk SE, 1999, J CELL PHYSIOL, V178, P17, DOI 10.1002/(SICI)1097-4652(199901)178:1<17::AID-JCP3>3.0.CO;2-R; LOBO Z, 1984, J BACTERIOL, V160, P222, DOI 10.1128/JB.160.1.222-226.1984; Lu XB, 1998, IMMUNITY, V8, P647, DOI 10.1016/S1074-7613(00)80569-5; MILLER H, 1987, METHOD ENZYMOL, V152, P145; MORRIS RC, 1968, J CLIN INVEST, V47, P1389, DOI 10.1172/JCI105830; NELSON N, 1992, BIOCHIM BIOPHYS ACTA, V1100, P109; PAGLIARO L, 1988, J CELL BIOL, V107, P981, DOI 10.1083/jcb.107.3.981; PARKHOUSE WS, 1992, CAN J PHYSIOL PHARM, V70, P150, DOI 10.1139/y92-022; Parra KJ, 1998, MOL CELL BIOL, V18, P7064, DOI 10.1128/MCB.18.12.7064; Pollard J W, 1994, Methods Mol Biol, V32, P67; RICHARDSON RMA, 1979, METABOLISM, V28, P1133, DOI 10.1016/0026-0495(79)90152-5; ROTTMANN WH, 1987, BIOCHIMIE, V69, P137, DOI 10.1016/0300-9084(87)90246-X; Salvatore F, 1986, Horiz Biochem Biophys, V8, P611; Seol JH, 2001, NAT CELL BIOL, V3, P384, DOI 10.1038/35070067; Skinner MA, 1999, J BIOL CHEM, V274, P23119, DOI 10.1074/jbc.274.33.23119; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; THIELECZEK R, 1989, J BIOL CHEM, V264, P7349; WACHSMUTH ED, 1975, HISTOCHEMISTRY, V45, P143, DOI 10.1007/BF00495158; Wang J, 1997, EXP CELL RES, V237, P445, DOI 10.1006/excr.1997.3811; Wang JA, 1996, J BIOL CHEM, V271, P6861, DOI 10.1074/jbc.271.12.6861; WEISS TL, 1981, BIOCHIM BIOPHYS ACTA, V661, P221, DOI 10.1016/0005-2744(81)90007-3; Wieczorek H, 1999, BIOESSAYS, V21, P637, DOI 10.1002/(SICI)1521-1878(199908)21:8<637::AID-BIES3>3.3.CO;2-N; Wu K, 1997, P NATL ACAD SCI USA, V94, P13273, DOI 10.1073/pnas.94.24.13273; Xu T, 1999, J BIOL CHEM, V274, P28909, DOI 10.1074/jbc.274.41.28909; YURKO MA, 1987, J BIOL CHEM, V262, P15770; ZHANG K, 1992, J BIOL CHEM, V267, P14539; ZHANG K, 1992, J BIOL CHEM, V267, P9701	50	142	145	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30407	30413		10.1074/jbc.M008768200	http://dx.doi.org/10.1074/jbc.M008768200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11399750	hybrid			2022-12-25	WOS:000170558000105
J	Pajor, AM				Pajor, AM			Conformationally sensitive residues in transmembrane domain 9 of the Na+/dicarboxylate co-transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-DICARBOXYLATE COTRANSPORTER; FUNCTIONAL-CHARACTERIZATION; ACETYLCHOLINE-RECEPTOR; CYSTEINE; SUBSTRATE; NADC-1; ACCESSIBILITY; CHANNEL; PROTEIN; CATION	The Na+/dicarboxylate co-transporter, NaDC-1, couples the transport of sodium and Krebs cycle intermediates, such as succinate and citrate. Previous studies identified two functionally important amino acids, Glu-475 and Cys-476, located in transmembrane domain (TMD) 9 of NaDC-1. In the present study, each amino acid in TMD-9 was mutated to cysteine, one at a time, and the accessibility of the membrane-impermeant reagent [2-(trimethylammonium)ethyl]methanethiosulfonate (MTSET) to the replacement cysteines was determined. Cysteine substitution was tolerated at all but five of the sites: the A461C mutant was not present at the plasma membrane, whereas the F473C, T474C, E475C, and N479C mutants were inactive proteins located on the plasma membrane. Cysteine substitution of four residues found near the extracellular surface of TMD-9 (Ser-478, Ala-480, Ala-481, and Thr-482) resulted in proteins that were sensitive to inhibition by MTSET. The accessibility of MTSET to the four substituted cysteines was highest in the presence of the transported cations, sodium or lithium, and low in choline. The four mutants also exhibited substrate protection of MTSET accessibility. The MTSET accessibility to S478C, A481C, and A480C was independent of voltage. In contrast, T482C was more accessible to MTSET in choline buffer at negative holding potentials, but there was no effect of voltage in sodium buffer. In conclusion, TMD-9 may be involved in transducing conformational changes between the cation-binding sites and the substrate-binding site in NaDC-1, and it may also form part of the translocation pathway through the transporter.	Univ Texas, Med Branch, Dept Physiol & Biophys, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Pajor, AM (corresponding author), Univ Texas, Med Branch, Dept Physiol & Biophys, Galveston, TX 77555 USA.				NIDDK NIH HHS [DK46269, DK02429] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046269, K02DK002429] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; Danielson MA, 1997, J BIOL CHEM, V272, P32878, DOI 10.1074/jbc.272.52.32878; Frillingos S, 1997, PROTEIN SCI, V6, P438; Golovanevsky V, 1999, J BIOL CHEM, V274, P23020, DOI 10.1074/jbc.274.33.23020; Griffith DA, 1999, BIOCHEMISTRY-US, V38, P7524, DOI 10.1021/bi990076b; Horn R, 1998, METHOD ENZYMOL, V293, P145; Kaback HR, 1999, ACCOUNTS CHEM RES, V32, P805, DOI 10.1021/ar970256i; Kahn ES, 1999, BIOCHEMISTRY-US, V38, P6151, DOI 10.1021/bi9827722; Karlin A, 1998, METHOD ENZYMOL, V293, P123; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Loo DDF, 1998, P NATL ACAD SCI USA, V95, P7789, DOI 10.1073/pnas.95.13.7789; Pajor AM, 2000, AM J PHYSIOL-RENAL, V279, pF482, DOI 10.1152/ajprenal.2000.279.3.F482; Pajor AM, 1998, J BIOL CHEM, V273, P18923, DOI 10.1074/jbc.273.30.18923; Pajor AM, 1999, BIOCHEM J, V344, P205, DOI 10.1042/0264-6021:3440205; Pajor AM, 1998, BBA-BIOMEMBRANES, V1370, P98, DOI 10.1016/S0005-2736(97)00249-6; Pajor AM, 2000, J MEMBRANE BIOL, V175, P1, DOI 10.1007/s002320001049; Pajor AM, 1998, BIOCHEM J, V331, P257, DOI 10.1042/bj3310257; Pajor AM, 1996, AM J PHYSIOL-RENAL, V271, pF1093, DOI 10.1152/ajprenal.1996.271.5.F1093; Pajor AM, 1996, AM J PHYSIOL-CELL PH, V271, pC1808, DOI 10.1152/ajpcell.1996.271.6.C1808; PAJOR AM, 1995, J BIOL CHEM, V270, P5779, DOI 10.1074/jbc.270.11.5779; Pajor AM, 1999, ANNU REV PHYSIOL, V61, P663, DOI 10.1146/annurev.physiol.61.1.663; Pascual JM, 1998, J GEN PHYSIOL, V111, P717, DOI 10.1085/jgp.111.6.717; WRIGHT EM, 1982, P NATL ACAD SCI-BIOL, V79, P7514, DOI 10.1073/pnas.79.23.7514; WRIGHT SH, 1983, J BIOL CHEM, V258, P5456; YAO CX, 2000, AM J PHYSIOL-RENAL, V274, pF54; Zhang FF, 2001, BBA-BIOMEMBRANES, V1511, P80, DOI 10.1016/S0005-2736(00)00385-0	26	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29961	29968		10.1074/jbc.M011387200	http://dx.doi.org/10.1074/jbc.M011387200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11399753	hybrid			2022-12-25	WOS:000170558000048
J	Ramjaun, AR; Angers, A; Legendre-Guillemin, V; Tong, XK; McPherson, PS				Ramjaun, AR; Angers, A; Legendre-Guillemin, V; Tong, XK; McPherson, PS			Endophilin regulates JNK activation through its interaction with the germinal center kinase-like kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE ENDOCYTOSIS; DOMAIN-CONTAINING PROTEINS; SH3 DOMAIN; BINDING PARTNERS; NERVOUS-SYSTEM; RAT-BRAIN; FAMILY; AMPHIPHYSIN; IDENTIFICATION; SYNAPTOJANIN	The endophilin family of proteins function in clathrin-mediated endocytosis. Here, we have identified and cloned the rat germinal center kinase-like kinase (rGLK), a member of the GCK (germinal center kinase) family of e-Jun N-terminal kinase (JNK) activating enzymes, as a novel endophilin I-binding partner. The interaction occurs both in vitro and in cells and is mediated by the Src homology 3 domain of endophilin I and a region of rGLK containing the endophilin consensus-binding sequence PPRPPPPR. Overlay analysis of rat brain extracts demonstrates that endophilin I is a major Src homology 3 domain-binding partner for rGLK. Overexpression of full-length endophilin I activates rGLK-mediated JNK activation, whereas N- and C-terminal fragments of endophilin I block JNK activation. Thus, endophilin I appears to have a novel function in JNK activation.	McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada	McGill University	McPherson, PS (corresponding author), McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada.		Angers, Annie/P-1217-2018	Angers, Annie/0000-0003-0131-256X				Adams A, 2000, J BIOL CHEM, V275, P27414; Anafi M, 1997, J BIOL CHEM, V272, P27804, DOI 10.1074/jbc.272.44.27804; Cestra G, 1999, J BIOL CHEM, V274, P32001, DOI 10.1074/jbc.274.45.32001; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; deHeuvel E, 1997, J BIOL CHEM, V272, P8710, DOI 10.1074/jbc.272.13.8710; Diener K, 1997, P NATL ACAD SCI USA, V94, P9687, DOI 10.1073/pnas.94.18.9687; Fish KN, 2000, J CELL BIOL, V150, P145, DOI 10.1083/jcb.150.1.145; Gad H, 2000, NEURON, V27, P301, DOI 10.1016/S0896-6273(00)00038-6; Giachino C, 1997, GENOMICS, V41, P427, DOI 10.1006/geno.1997.4645; Howard L, 1999, J BIOL CHEM, V274, P31693, DOI 10.1074/jbc.274.44.31693; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Kyriakis JM, 1999, J BIOL CHEM, V274, P5259, DOI 10.1074/jbc.274.9.5259; Leprince C, 1997, J BIOL CHEM, V272, P15101, DOI 10.1074/jbc.272.24.15101; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; McPherson PS, 1999, CELL SIGNAL, V11, P229, DOI 10.1016/S0898-6568(98)00059-X; McPherson PS, 2001, TRAFFIC, V2, P375, DOI 10.1034/j.1600-0854.2001.002006375.x; Micheva KD, 1997, J BIOL CHEM, V272, P27239, DOI 10.1074/jbc.272.43.27239; Micheva KD, 1997, FEBS LETT, V414, P308, DOI 10.1016/S0014-5793(97)01016-8; Mielke K, 2000, PROG NEUROBIOL, V61, P45, DOI 10.1016/S0301-0082(99)00042-8; Ramjaun AR, 1997, J BIOL CHEM, V272, P16700, DOI 10.1074/jbc.272.26.16700; Rasmussen RK, 1998, BIOCHEM J, V335, P119, DOI 10.1042/bj3350119; Ren MD, 1996, P NATL ACAD SCI USA, V93, P5151, DOI 10.1073/pnas.93.10.5151; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; Ringstad N, 1999, NEURON, V24, P143, DOI 10.1016/S0896-6273(00)80828-4; Schmidt A, 1999, NATURE, V401, P133, DOI 10.1038/43613; Simpson F, 1999, NAT CELL BIOL, V1, P119, DOI 10.1038/10091; SNUTCH TP, 1990, P NATL ACAD SCI USA, V87, P3391, DOI 10.1073/pnas.87.9.3391; So CW, 1997, P NATL ACAD SCI USA, V94, P2563, DOI 10.1073/pnas.94.6.2563; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; Tang YT, 1999, P NATL ACAD SCI USA, V96, P12559, DOI 10.1073/pnas.96.22.12559; Tong XK, 2000, J BIOL CHEM, V275, P29894, DOI 10.1074/jbc.M004096200; Tong XK, 2000, EMBO J, V19, P1263, DOI 10.1093/emboj/19.6.1263; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681	35	41	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28913	28919		10.1074/jbc.M103198200	http://dx.doi.org/10.1074/jbc.M103198200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11384986	hybrid, Green Accepted			2022-12-25	WOS:000170346000038
J	Westbroek, I; van der Plas, A; de Rooij, KE; Klein-Nulend, J; Nijweide, PJ				Westbroek, I; van der Plas, A; de Rooij, KE; Klein-Nulend, J; Nijweide, PJ			Expression of serotonin receptors in bone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; HUMAN 5-HYDROXYTRYPTAMINE(2B) RECEPTOR; MESSENGER-RNA EXPRESSION; OSTEOBLAST-LIKE CELLS; 5-HT2B RECEPTOR; NITRIC-OXIDE; POSTMENOPAUSAL WOMEN; SIGNAL-TRANSDUCTION; SMOOTH-MUSCLE; BW 723C86	The 5-hydroxytryptamine (5-HT) receptors 5-HT(2A), 5-HT(2B), and 5-HT(2C) belong to a subfamily of serotonin receptors. Amino acid and mRNA sequences of these receptors have been published for several species including man. The 5-HT(2) receptors have been reported to act on nervous, muscle, and endothelial tissues. Here we report the presence of 5-HT(2B) receptor in fetal chicken bone cells. 5-HT(2B) receptor mRNA expression was demonstrated in osteocytes, osteoblasts, and periosteal fibroblasts, a population containing osteoblast precursor cells. Pharmacological studies using several agonists and antagonists showed that occupancy of the 5-HT2. receptor stimulates the proliferation of periosteal fibroblasts. Activity of the 5-HT(2A) receptor could however not be excluded. mRNA for both receptors was shown to be equally present in adult mouse osteoblasts. Osteocytes, which showed the highest expression of 5-HT(2B) receptor mRNA in chicken, and to a lesser extent osteoblasts, are considered to be mechanosensor cells involved in the adaptation of bone to its mechanical usage. Nitric oxide is one of the signaling molecules that is released upon mechanical stimulation of osteocytes and osteoblasts. The serotonin analog alpha -methyl-5-HT, which preferentially binds to 5-HT2 receptors, decreased nitric oxide release by mechanically stimulated mouse osteoblasts. These results demonstrate that serotonin is involved in bone metabolism and its mechanoregulation.	Leiden Univ, Med Ctr, Dept Mol Cell Biol, NL-2333 AL Leiden, Netherlands; Free Univ Amsterdam, Acad Ctr Dent Amsterdam, Dept Oral Cell Biol, NL-1081 BT Amsterdam, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Academic Center for Dentistry Amsterdam; Vrije Universiteit Amsterdam	Nijweide, PJ (corresponding author), Leiden Univ, Med Ctr, Dept Mol Cell Biol, Wassenaarseweg 72, NL-2333 AL Leiden, Netherlands.	P.J.Nijweide@LUMC.NL						Ajubi NE, 1996, BIOCHEM BIOPH RES CO, V225, P62, DOI 10.1006/bbrc.1996.1131; Aubin JE, 1998, BIOCHEM CELL BIOL, V76, P899, DOI 10.1139/bcb-76-6-899; BAXTER G, 1995, TRENDS PHARMACOL SCI, V16, P105, DOI 10.1016/S0165-6147(00)88991-9; BECKSTEAD JH, 1994, J HISTOCHEM CYTOCHEM, V42, P1127, DOI 10.1177/42.8.8027531; Berendsen HHG, 2000, MATURITAS, V36, P155, DOI 10.1016/S0378-5122(00)00151-1; BESSEY OA, 1946, J BIOL CHEM, V164, P321; Blum I, 1996, ISRAEL J MED SCI, V32, P1158; BONHAUS DW, 1995, BRIT J PHARMACOL, V115, P622, DOI 10.1111/j.1476-5381.1995.tb14977.x; Borman RA, 1997, ANN NY ACAD SCI, V812, P222, DOI 10.1111/j.1749-6632.1997.tb48182.x; Burger EH, 1999, FASEB J, V13, pS101, DOI 10.1096/fasebj.13.9001.s101; Choi DS, 1995, BEHAV BRAIN RES, V73, P253; Choi DS, 1996, FEBS LETT, V391, P45, DOI 10.1016/0014-5793(96)00695-3; CHOPRA RK, 1992, MOL CELL BIOCHEM, V117, P127; Chow JWM, 1998, J BONE MINER RES, V13, P1039, DOI 10.1359/jbmr.1998.13.6.1039; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Duxon MS, 1997, NEUROPHARMACOLOGY, V36, P601, DOI 10.1016/S0028-3908(97)00042-7; Duxon MS, 1997, NEUROSCIENCE, V76, P323, DOI 10.1016/S0306-4522(96)00480-0; ELLIS ES, 1995, BRIT J PHARMACOL, V114, P400, DOI 10.1111/j.1476-5381.1995.tb13240.x; Fanburg BL, 1997, AM J PHYSIOL-LUNG C, V272, pL795, DOI 10.1152/ajplung.1997.272.5.L795; FANBURG BL, 1997, AM J PHYSIOL, V272, pF795; FORBES IT, 1995, J MED CHEM, V38, P2524, DOI 10.1021/jm00014a004; Forwood MR, 1996, J BONE MINER RES, V11, P1688; FROST HM, 1987, ANAT RECORD, V219, P1, DOI 10.1002/ar.1092190104; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; FUTO J, 1992, LIFE SCI, V50, P1165, DOI 10.1016/0024-3205(92)90459-3; Glusa E, 1996, BRIT J PHARMACOL, V119, P330, DOI 10.1111/j.1476-5381.1996.tb15990.x; GODA SK, 1995, NUCLEIC ACIDS RES, V23, P3357, DOI 10.1093/nar/23.16.3357; GONZALES GF, 1993, MATURITAS, V17, P23, DOI 10.1016/0378-5122(93)90120-7; GOODSHIP AE, 1979, J BONE JOINT SURG AM, V61, P539, DOI 10.2106/00004623-197961040-00008; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GUICHENEY P, 1988, EUR J CLIN INVEST, V18, P297, DOI 10.1111/j.1365-2362.1988.tb01262.x; HAGENAARS CE, 1989, BONE MINER, V6, P179, DOI 10.1016/0169-6009(89)90049-4; HARMS G, 1986, HISTOCHEMISTRY, V85, P139, DOI 10.1007/BF00491761; HARRIS SA, 1996, PRINCIPLES BONE BIOL, P6507; HOHMANN EL, 1983, ENDOCRINOLOGY, V112, P1233, DOI 10.1210/endo-112-4-1233; HOYER D, 1994, PHARMACOL REV, V46, P157; ISMAIEL AM, 1990, J MED CHEM, V33, P755, DOI 10.1021/jm00164a046; Kennett GA, 1998, NEUROPHARMACOLOGY, V37, P1603, DOI 10.1016/S0028-3908(98)00115-4; Kennett GA, 1997, NEUROPHARMACOLOGY, V36, P233, DOI 10.1016/S0028-3908(96)00171-2; Klein-Nulend J, 1998, BIOCHEM BIOPH RES CO, V250, P108, DOI 10.1006/bbrc.1998.9270; KleinNulend J, 1995, BIOCHEM BIOPH RES CO, V217, P640, DOI 10.1006/bbrc.1995.2822; KLEINNULEND J, 1995, FASEB J, V9, P441, DOI 10.1096/fasebj.9.5.7896017; KleinNulend J, 1997, J BONE MINER RES, V12, P45, DOI 10.1359/jbmr.1997.12.1.45; Konttinen YT, 1996, ACTA ORTHOP SCAND, V67, P632, DOI 10.3109/17453679608997772; KURSAR JD, 1994, MOL PHARMACOL, V46, P227; Lauder JM, 2000, INT J DEV NEUROSCI, V18, P653, DOI 10.1016/S0736-5748(00)00032-0; Launay JM, 1996, J BIOL CHEM, V271, P3141, DOI 10.1074/jbc.271.6.3141; LEAN JM, 1995, AM J PHYSIOL-ENDOC M, V268, pE318, DOI 10.1152/ajpendo.1995.268.2.E318; Lerner Ulf H., 1996, P581; LOSCALZO J, 1995, NEW ENGL J MED, V333, P251, DOI 10.1056/NEJM199507273330410; Mason DJ, 1997, BONE, V20, P199, DOI 10.1016/S8756-3282(96)00386-9; Nebigil CG, 2000, P NATL ACAD SCI USA, V97, P2591, DOI 10.1073/pnas.050282397; Nijweide P. J., 1996, P115; NIJWEIDE PJ, 1975, P K NED AKAD C BIOL, V78, P410; NIJWEIDE PJ, 1986, HISTOCHEMISTRY, V84, P342, DOI 10.1007/BF00482961; Pakala R, 1997, CIRCULATION, V96, P2280; PAKALA R, 1994, CIRCULATION, V90, P1919, DOI 10.1161/01.CIR.90.4.1919; Patton AJ, 1998, BONE, V22, P645, DOI 10.1016/S8756-3282(98)00061-1; Porter RHP, 1999, BRIT J PHARMACOL, V128, P13, DOI 10.1038/sj.bjp.0702751; Saucier C, 1998, BIOCHEM PHARMACOL, V56, P1347, DOI 10.1016/S0006-2952(98)00244-5; SCHEVEN BAA, 1986, NATURE, V321, P79, DOI 10.1038/321079a0; Schirrmacher K, 1998, BONE, V23, P521, DOI 10.1016/S8756-3282(98)00142-2; SINGERSAM J, 1990, NUCLEIC ACIDS RES, V18, P1255, DOI 10.1093/nar/18.5.1255; SKERRY TM, 1989, J BONE MINER RES, V4, P783, DOI 10.1002/jbmr.5650040519; Sterck JGH, 1996, J BONE MINER RES, V11, P367; STROEBEL M, 1994, J BIOL CHEM, V269, P22952; SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66; ULLMER C, 1995, FEBS LETT, V370, P215, DOI 10.1016/0014-5793(95)00828-W; VANDERPLAS A, 1985, BIOCHEM BIOPH RES CO, V129, P918, DOI 10.1016/0006-291X(85)91979-5; VANDERPLAS A, 1992, J BONE MINER RES, V7, P389; VANDERPLAS A, 1994, J BONE MINER RES, V9, P1697; Wainscott DB, 1996, J PHARMACOL EXP THER, V276, P720; Winding B, 1997, EXP PHYSIOL, V82, P871, DOI 10.1113/expphysiol.1997.sp004070	73	156	167	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28961	28968		10.1074/jbc.M101824200	http://dx.doi.org/10.1074/jbc.M101824200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11387323	hybrid			2022-12-25	WOS:000170346000045
J	Bhagwat, M; Nossal, NG				Bhagwat, M; Nossal, NG			Bacteriophage T4 RNase H removes both RNA primers and adjacent DNA from the 5 ' end of lagging strand fragments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; OKAZAKI FRAGMENT; REPLICATION FORK; SACCHAROMYCES-CEREVISIAE; POLYMERASE HOLOENZYME; SLIDING CLAMPS; PROTEINS; 5'-EXONUCLEASE; ENDONUCLEASE; HELICASE	Bacteriophage T4 RNase H belongs to a family of prokaryotic and eukaryotic nucleases that remove RNA primers from lagging strand fragments during DNA replication. Each enzyme has a flap endonuclease activity, cutting at or near the junction between single- and double-stranded DNA, and a 5'- to 3-exonuclease, degrading both RNA-DNA and DNA-DNA duplexes. On model substrates for lagging strand synthesis, T4 RNase H functions as an exonuclease removing short oligonucleotides, rather than as an endonuclease removing longer flaps created by the advancing polymerase. The combined length of the DNA oligonucleotides released from each fragment ranges from 3 to 30 nucleotides, which corresponds to one round of processive degradation by T4 RNase H with 32 single-stranded DNA-binding protein present. Approximately 30 nucleotides are removed from each fragment during coupled leading and lagging strand synthesis with the complete T4 replication system. We conclude that the presence of 32 protein on the single-stranded DNA between lagging strand fragments guarantees that the nuclease will degrade processively, removing adjacent DNA as well as the RNA primers, and that the difference in the relative rates of synthesis and hydrolysis ensures that there is usually only a single round of degradation during each lagging strand cycle.	NIDDKD, Mol & Cellular Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Nossal, NG (corresponding author), NIDDKD, Mol & Cellular Biol Lab, NIH, Bldg 8,Rm 2A19, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK057801] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bae SH, 2000, J BIOL CHEM, V275, P38022, DOI 10.1074/jbc.M006513200; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; Bhagwat M, 1997, J BIOL CHEM, V272, P28523, DOI 10.1074/jbc.272.45.28523; BUDD ME, 1995, J BIOL CHEM, V270, P26766, DOI 10.1074/jbc.270.45.26766; Ceska TA, 1996, NATURE, V382, P90, DOI 10.1038/382090a0; Chastain PD, 2000, MOL CELL, V6, P803, DOI 10.1016/S1097-2765(05)00093-6; FREY MW, 1993, P NATL ACAD SCI USA, V90, P2579, DOI 10.1073/pnas.90.7.2579; FUNNELL BE, 1986, J BIOL CHEM, V261, P5616; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; HACKER KJ, 1994, J BIOL CHEM, V269, P24221; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; HINTON DM, 1987, J BIOL CHEM, V262, P10873; Hobbs LJ, 1996, J BACTERIOL, V178, P6772, DOI 10.1128/jb.178.23.6772-6777.1996; HOLLINGSWORTH HC, 1991, J BIOL CHEM, V266, P1888; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; KITANI T, 1985, J MOL BIOL, V184, P45, DOI 10.1016/0022-2836(85)90042-7; Kornberg A., 1992, DNA REPLICATION; Kreuzer KN, 2000, TRENDS BIOCHEM SCI, V25, P165, DOI 10.1016/S0968-0004(00)01559-0; Lee KH, 2000, NUCLEIC ACIDS RES, V28, P2873, DOI 10.1093/nar/28.15.2873; LIU CC, 1980, P NATL ACAD SCI-BIOL, V77, P5698, DOI 10.1073/pnas.77.10.5698; LYAMICHEV V, 1993, SCIENCE, V260, P778, DOI 10.1126/science.7683443; Mosig G, 1998, ANNU REV GENET, V32, P379, DOI 10.1146/annurev.genet.32.1.379; Mueser TC, 1996, CELL, V85, P1101, DOI 10.1016/S0092-8674(00)81310-0; MURANTE RS, 1994, J BIOL CHEM, V269, P1191; Nossal N.G., 1994, MOL BIOL BACTERIOP T, P43; Nossal NG, 1995, METHOD ENZYMOL, V262, P560; NOSSAL NG, 1980, J BIOL CHEM, V255, P2176; OGAWA T, 1984, MOL GEN GENET, V193, P231, DOI 10.1007/BF00330673; Park K, 1998, J BIOL CHEM, V273, P5260, DOI 10.1074/jbc.273.9.5260; Qiu JZ, 1999, MOL CELL BIOL, V19, P8361, DOI 10.1128/mcb.19.12.8361; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; RICHARDSON RW, 1990, UCLA SYM BI, V127, P247; Salinas F, 2000, P NATL ACAD SCI USA, V97, P7196, DOI 10.1073/pnas.97.13.7196; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; Soumillion P, 1998, BIOCHEMISTRY-US, V37, P1819, DOI 10.1021/bi972526a; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; TURCHI JJ, 1993, J BIOL CHEM, V268, P15136; VENKATESAN M, 1982, J BIOL CHEM, V257, P2426; WAGA S, 1994, J BIOL CHEM, V269, P10923; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Xu Y, 2000, J BIOL CHEM, V275, P20949, DOI 10.1074/jbc.M909135199; Yao N, 1996, GENES CELLS, V1, P101, DOI 10.1046/j.1365-2443.1996.07007.x	42	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28516	28524		10.1074/jbc.M103914200	http://dx.doi.org/10.1074/jbc.M103914200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11376000	hybrid			2022-12-25	WOS:000170093400103
J	Perez-Canadillas, JM; Zaballos, A; Gutierrez, J; Varona, R; Roncal, F; Albar, JP; Marquez, G; Bruix, M				Perez-Canadillas, JM; Zaballos, A; Gutierrez, J; Varona, R; Roncal, F; Albar, JP; Marquez, G; Bruix, M			NMR solution structure of murine CCL20/MIP-3 alpha, a chemokine that specifically chemoattracts immature dendritic cells and lymphocytes through its highly specific interaction with the beta-chemokine receptor CCR6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CC-CHEMOKINE; 3-DIMENSIONAL STRUCTURE; CRYSTAL-STRUCTURE; SPECTROSCOPY; ACTIVATION; DYNAMICS; DISTINCT; INTERLEUKIN-8; LOCALIZATION; ASSIGNMENTS	CCL20/MIP-3 alpha is a beta -chemokine expressed in the thymus, skin, and intestinal epithelial cells that exclusively binds and activates the CCR6 receptor in both mice and humans. The strict receptor binding specificity of CCL20 is exceptional; other chemokines and their receptors bind promiscuously with multiple partners. Toward determining the structural basis for the selective receptor specificity of CCL20, we have determined its three-dimensional structure by H-1 NMR spectroscopy. CCL20 exhibits the same monomeric structure previously described for other chemokines: a three-stranded beta -sheet and an overlying alpha -helix. The CCL20 receptor selectivity could arise from the rigid conformation of the N-terminal DCCL motif as well as the groove between the N-loop and the beta (2)-beta (3) hairpin, which is significantly narrower in CCL20 than in other chemokines. Similar structural features are seen in human beta -defensin 2, a small nonchemokine polypeptide reported to selectively bind and activate CCR6, which stresses their importance for the specific binding of both CCL20 and beta -defensin 2 to CCR6. CCL20's structure will be useful to design tools aimed to modulate its important biological functions.	CSIC, Inst Estructura Mat, E-28006 Madrid, Spain; Ctr Nacl Biotecnol, Dept Inmunol & Oncol, Madrid 28040, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Estructura de la Materia (IEM); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Bruix, M (corresponding author), CSIC, Inst Estructura Mat, Serrano 119, E-28006 Madrid, Spain.	marta@malika.iem.csic.es	Perez-Canadillas, Jose M/J-5748-2013; Bruix, Marta/H-4161-2011; Zaballos, Ángel/O-2853-2015; Pérez-Cañadillas, Jose Manuel/AAN-1864-2020	Perez-Canadillas, Jose M/0000-0002-8266-5502; Bruix, Marta/0000-0002-0096-3558; Zaballos, Angel/0000-0002-7555-5815				ArenzanaSeisdedos F, 1996, NATURE, V383, P400, DOI 10.1038/383400a0; AUE WP, 1976, J CHEM PHYS, V64, P2229, DOI 10.1063/1.432450; Baba M, 1997, J BIOL CHEM, V272, P14893, DOI 10.1074/jbc.272.23.14893; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Carramolino L, 1999, J LEUKOCYTE BIOL, V66, P837, DOI 10.1002/jlb.66.5.837; CHUNG C, 1995, BIOCHEMISTRY-US, V34, P5329; CLARKLEWIS I, 1995, J LEUKOCYTE BIOL, V57, P703, DOI 10.1002/jlb.57.5.703; ClarkLewis I, 1997, METHOD ENZYMOL, V287, P233; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P1689, DOI 10.1021/bi00459a004; CLORE GM, 1991, J MOL BIOL, V217, P611, DOI 10.1016/0022-2836(91)90518-B; Cook DN, 2000, IMMUNITY, V12, P495, DOI 10.1016/S1074-7613(00)80201-0; COVELL DG, 1994, PROTEIN SCI, V3, P2064, DOI 10.1002/pro.5560031119; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; Crump MP, 1998, J BIOL CHEM, V273, P22471, DOI 10.1074/jbc.273.35.22471; Dealwis C, 1998, P NATL ACAD SCI USA, V95, P6941, DOI 10.1073/pnas.95.12.6941; Dieu MC, 1998, J EXP MED, V188, P373, DOI 10.1084/jem.188.2.373; FAIRBROTHER WJ, 1994, J MOL BIOL, V242, P252, DOI 10.1006/jmbi.1994.1577; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Handel TM, 1996, BIOCHEMISTRY-US, V35, P6569, DOI 10.1021/bi9602270; HANZAWA H, 1994, FEBS LETT, V354, P207, DOI 10.1016/0014-5793(94)01081-1; Hoover DM, 2000, J BIOL CHEM, V275, P32911, DOI 10.1074/jbc.M006098200; Iwasaki A, 2000, J EXP MED, V191, P1381, DOI 10.1084/jem.191.8.1381; Keizer DW, 2000, BIOCHEMISTRY-US, V39, P6053, DOI 10.1021/bi000089l; KIM KS, 1994, J BIOL CHEM, V269, P32909; Kim KS, 1996, FEBS LETT, V395, P277, DOI 10.1016/0014-5793(96)01024-1; KING DS, 1990, INT J PEPT PROT RES, V36, P255; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRAULIS PJ, 1994, BIOCHEMISTRY-US, V33, P3515, DOI 10.1021/bi00178a008; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Liao F, 1999, J IMMUNOL, V162, P186; LODI PJ, 1994, SCIENCE, V263, P1762, DOI 10.1126/science.8134838; Lubkowski J, 1997, NAT STRUCT BIOL, V4, P64, DOI 10.1038/nsb0197-64; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; MALKOWSKI MG, 1995, J BIOL CHEM, V270, P7077, DOI 10.1074/jbc.270.13.7077; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; Mayer KL, 2000, BIOCHEMISTRY-US, V39, P8382, DOI 10.1021/bi000523j; Meunier S, 1997, BIOCHEMISTRY-US, V36, P4412, DOI 10.1021/bi9627929; Minton A.P., 1994, MODERN ANAL ULTRACEN, P81; Mizoue LS, 1999, BIOCHEMISTRY-US, V38, P1402, DOI 10.1021/bi9820614; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Murphy PM, 2000, PHARMACOL REV, V52, P145; Pakianathan DR, 1997, BIOCHEMISTRY-US, V36, P9642, DOI 10.1021/bi970593z; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; RAJARATHNAM K, 1995, BIOCHEMISTRY-US, V34, P12983, DOI 10.1021/bi00040a008; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; Schutyser E, 2000, J IMMUNOL, V165, P4470, DOI 10.4049/jimmunol.165.8.4470; Shao WP, 1998, BIOCHEMISTRY-US, V37, P8303, DOI 10.1021/bi980112r; Skelton NJ, 1999, STRUCTURE, V7, P157, DOI 10.1016/S0969-2126(99)80022-7; SKELTON NJ, 1995, BIOCHEMISTRY-US, V34, P5329, DOI 10.1021/bi00016a004; STCHARLES R, 1989, J BIOL CHEM, V264, P2092; Stone MJ, 2000, CHEMOKINES IN ALLERGIC DISEASE, P67; Tanaka Y, 1999, EUR J IMMUNOL, V29, P633, DOI 10.1002/(SICI)1521-4141(199902)29:02<633::AID-IMMU633>3.0.CO;2-I; van Gunsteren W. F., 1987, GRONINGEN MOL SIMULA; Varona R, 1998, FEBS LETT, V440, P188, DOI 10.1016/S0014-5793(98)01450-1; Varona R, 2001, J CLIN INVEST, V107, pR37, DOI 10.1172/JCI11297; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	63	68	74	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28372	28379		10.1074/jbc.M103121200	http://dx.doi.org/10.1074/jbc.M103121200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11373289	Green Published, hybrid			2022-12-25	WOS:000170093400084
J	Thiriot, DS; Ruoho, AE				Thiriot, DS; Ruoho, AE			Mutagenesis and derivatization of human vesicle monoamine transporter 2 (VMAT2) cysteines identifies transporter domains involved in tetrabenazine binding and substrate transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METAL-TETRACYCLINE/H+ ANTIPORTER; VESICULAR AMINE TRANSPORTER; SCANNING MUTAGENESIS; TRANSMEMBRANE DOMAIN; RESIDUES CONTRIBUTE; LIGAND RECOGNITION; KNOCKOUT MICE; ACETYLCHOLINE; SENSITIVITY; AMPHETAMINE	The vesicle monoamine transporter (VMAT2) concentrates monoamine neurotransmitter into synaptic vesicles. Photoaffinity labeling, chimera analysis, and mutagenesis have identified functionally important amino acids and provided some information regarding structure and ligand binding sites. To extend these studies, we engineered functional human VMAT2 constructs with reduced numbers of cysteines. Subsets of cysteines were discovered, which restore function to an inactive cysteine-less human VMAT2. Replacement of three transmembrane (TM) cysteines together (net removal/replacement of three atoms) significantly enhanced monoamine transport. Cysteine modification studies involving single and combination cysteine mutants with methanethiosulfonate ethylamine revealed that [H-3]dihydrotetrabenazine binding is >90% inhibited by modification of two sets of cysteines, The primary target (responsible for similar to 80% of inhibition) is Cys(439) in TM 11. The secondary target (responsible for similar to 20% of inhibition) is one or more of the four non-TM cysteines, [H-3]Dihydrotetrabenazine protects against modification of Cys(439) by a 10,000-fold molar excess of methanethiosulfonate ethylamine, demonstrating that Cys(439) is either at the tetrabenazine binding site, or conformationally linked to tetrabenazine binding. Supporting a direct effect, the position of tetrabenazine-protectable Cys439 is consistent with previous mutagenesis, chimera, and photoaffinity labeling data, demonstrating involvement of TM 10-12 in a tetrabenazine binding domain.	Univ Wisconsin, Sch Med, Dept Pharmacol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Ruoho, AE (corresponding author), Univ Wisconsin, Sch Med, Dept Pharmacol, 1300 Univ Ave, Madison, WI 53706 USA.	aeruoho@facstaff.wisc.edu			NINDS NIH HHS [R01NS33650] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033650] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Chen JG, 1997, J BIOL CHEM, V272, P28321, DOI 10.1074/jbc.272.45.28321; Duerr JS, 1999, J NEUROSCI, V19, P72, DOI 10.1523/JNEUROSCI.19-01-00072.1999; Eiden LE, 2000, FASEB J, V14, P2396, DOI 10.1096/fj.00-0817rev; Erickson J D, 1998, Adv Pharmacol, V42, P227; ERICKSON JD, 1992, P NATL ACAD SCI USA, V89, P10993, DOI 10.1073/pnas.89.22.10993; Erickson JD, 2000, FASEB J, V14, P2450, DOI 10.1096/fj.00-0206rev; Ferrer JV, 1998, P NATL ACAD SCI USA, V95, P9238, DOI 10.1073/pnas.95.16.9238; Finn JP, 1998, J BIOL CHEM, V273, P3943, DOI 10.1074/jbc.273.7.3943; Finn JP, 1997, J BIOL CHEM, V272, P16301, DOI 10.1074/jbc.272.26.16301; Fon EA, 1997, NEURON, V19, P1271, DOI 10.1016/S0896-6273(00)80418-3; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; Itokawa K, 1999, MOL BRAIN RES, V71, P354, DOI 10.1016/S0169-328X(99)00194-1; Javitch JA, 1998, METHOD ENZYMOL, V296, P331; Keller JE, 2000, J NEUROCHEM, V74, P1739, DOI 10.1046/j.1471-4159.2000.0741739.x; Kimura-Someya T, 2000, J BIOL CHEM, V275, P18692, DOI 10.1074/jbc.M000354200; Kubo Y, 2000, J BIOL CHEM, V275, P5270, DOI 10.1074/jbc.275.8.5270; LIMBIRD LE, 1996, CELL SURFACE RECEPTO, P70; Liu YJ, 1997, ANNU REV NEUROSCI, V20, P125; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; Loo TW, 1999, BBA-BIOMEMBRANES, V1461, P315, DOI 10.1016/S0005-2736(99)00165-0; MARTIN TFJ, 1989, METHOD ENZYMOL, V168, P225; MERICKEL A, 1995, J BIOL CHEM, V270, P25798, DOI 10.1074/jbc.270.43.25798; Merickel A, 1997, J BIOL CHEM, V272, P5403, DOI 10.1074/jbc.272.9.5403; Parsons SM, 2000, FASEB J, V14, P2423, DOI 10.1096/fj.00-0203rev; Peter D, 1996, J BIOL CHEM, V271, P2979, DOI 10.1074/jbc.271.6.2979; SCHERMAN D, 1988, MOL PHARMACOL, V33, P72; Sievert MK, 1998, BIOCHEM J, V330, P959; Sievert MK, 1997, J BIOL CHEM, V272, P26049, DOI 10.1074/jbc.272.41.26049; SteinerMordoch S, 1996, J BIOL CHEM, V271, P13048, DOI 10.1074/jbc.271.22.13048; STERNBACH Y, 1990, J BIOL CHEM, V265, P3961; SURRATT CK, 1993, FEBS LETT, V318, P325, DOI 10.1016/0014-5793(93)80539-7; Takahashi N, 1997, MOL BRAIN RES, V49, P7, DOI 10.1016/S0169-328X(97)00116-2; Takahashi N, 1997, P NATL ACAD SCI USA, V94, P9938, DOI 10.1073/pnas.94.18.9938; Tan PK, 1998, J BIOL CHEM, V273, P17351, DOI 10.1074/jbc.273.28.17351; Wang YM, 1997, NEURON, V19, P1285, DOI 10.1016/S0896-6273(00)80419-5; Yelin R, 1998, J NEUROCHEM, V71, P2518	36	22	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27304	27315		10.1074/jbc.M103947200	http://dx.doi.org/10.1074/jbc.M103947200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11375404	hybrid			2022-12-25	WOS:000169966900077
J	Tulin, EE; Onoda, N; Maeda, M; Hasegawa, M; Nosaka, T; Nomura, H; Asano, S; Kitamura, T				Tulin, EE; Onoda, N; Maeda, M; Hasegawa, M; Nosaka, T; Nomura, H; Asano, S; Kitamura, T			A novel secreted form of immune suppressor factor with high homology to vacuolar ATPases identified by a forward genetic approach of functional screening based on cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; MARROW STROMAL CELLS; BONE-MARROW; EXPRESSION; MURINE; CDNA; APOPTOSIS; RECEPTOR; MOLECULE; SUBUNIT	In the search for stromal-derived growth factors, we have identified a novel secreted short form of immune suppressor factor (ISF) using a combination of a genetic approach and retrovirus-mediated functional screening. This protein, which we termed ShIF, was isolated based on its ability to support proliferation of a mutant clone S21, which was established from Ba/F3 cells that are usually interleukin 3-dependent but became dependent on a stroma cell line ST2 after chemical mutagenesis. ISF, a membrane protein harboring six transmembrane domains, was reported to have immunosuppressive functions. The coding region of ShIF started from the third transmembrane domain of ISF. Biochemical analysis demonstrated that ShIF was expressed in both the secreted and membrane-bound forms of 27-kDa protein, which was supposed to have an internal ATG present in the third transmembrane domain of ISF as a start codon, In addition to the full-length form of ISF, a major protein with a molecular size of 27 kDa was also expressed through the proteolytic process of ISF, ShIF resembles this naturally occurring short form of ISF (sISF). Deletion analysis of the major domains of ISF cDNA revealed that ShIF is an active functional domain of ISF with a capability to support proliferation of S21 cells. Enforced expression of ShIF in MS10 cells, bone marrow stroma cells that do not express endogenous ShIF or ISF, conferred on the cells an ability to support the growth of S21 cells as well as bone marrow cells. Interestingly, ShIF shows a high sequence homology to the C-terminal part of a 95-kDa yeast vacuolar H (+)-ATPase subunit, Vph1p (39%), and a 116-kDa proton pump (VPP1) (54%) of the rat and bovine synaptic vesicle. Therefore, it is possible that ShIF also acts as a proton pump and somehow prevents the cells from undergoing apoptosis.	Univ Tokyo, Div Hematopoiet Factors, Inst Med Sci, Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Div Mol Therapy,Adv Clin Res Ctr, Inst Med Sci, Minato Ku, Tokyo 1088639, Japan; Chugai Res Inst Mol Med, Ibaraki, Osaka 3004101, Japan	University of Tokyo; University of Tokyo	Kitamura, T (corresponding author), Univ Tokyo, Div Hematopoiet Factors, Inst Med Sci, Minato Ku, Tokyo 1088639, Japan.		Kitamura, Toshio/AAA-2071-2021					DORSHKIND K, 1990, ANNU REV IMMUNOL, V8, P111, DOI 10.1146/annurev.iy.08.040190.000551; Gottlieb RA, 1996, J CLIN INVEST, V97, P2391, DOI 10.1172/JCI118683; HARTWELL LH, 1991, GENETICS, V129, P975; KAISHO T, 1992, J IMMUNOL, V149, P4088; KINCADE PW, 1989, ANNU REV IMMUNOL, V7, P111, DOI 10.1146/annurev.iy.07.040189.000551; Kitamura T, 1998, INT J HEMATOL, V67, P351; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; KITAMURA T, 1995, P NATL ACAD SCI USA, V92, P9146, DOI 10.1073/pnas.92.20.9146; LEE CK, 1990, MOL IMMUNOL, V27, P1137; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; Metzstein MM, 1998, TRENDS GENET, V14, P410, DOI 10.1016/S0168-9525(98)01573-X; MIYAJIMA A, 1986, EMBO J, V5, P1193, DOI 10.1002/j.1460-2075.1986.tb04346.x; MIYAKE K, 1991, J CELL BIOL, V114, P557, DOI 10.1083/jcb.114.3.557; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; Onishi M, 1996, BLOOD, V88, P1399, DOI 10.1182/blood.V88.4.1399.bloodjournal8841399; Onishi M, 1996, EXP HEMATOL, V24, P324; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PERIN MS, 1991, J BIOL CHEM, V266, P3877; RAJOTTE D, 1992, J BIOL CHEM, V267, P9980	19	10	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27519	27526		10.1074/jbc.M101781200	http://dx.doi.org/10.1074/jbc.M101781200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11375395	hybrid			2022-12-25	WOS:000169966900103
J	Berry, D; Kwan, CP; Shriver, Z; Venkataraman, G; Sasisekharan, R				Berry, D; Kwan, CP; Shriver, Z; Venkataraman, G; Sasisekharan, R			Distinct heparan sulfate glycosaminoglycans are responsible for mediating fibroblast growth factor-2 biological activity through different fibroblast growth factor receptors	FASEB JOURNAL			English	Article						heparin; smooth muscle cells; BaF3	SMOOTH-MUSCLE CELLS; ENZYMATIC DEGRADATION; FACTOR-BINDING; PROTEOGLYCANS; ACTIVATION; BFGF; OLIGOSACCHARIDES; MITOGENESIS; SPECIFICITY; INHIBITION	Fibroblast growth factor (FGF) signaling is involved in many important biological processes such as smooth muscle cell (SMC) proliferation, a key event leading to atherosclerosis. It is well known that heparin/heparan sulfate-like glycosaminoglycans (HLGAGs), found ubiquitously on the cell surface and in the extracellular matrix, modulate FGF signaling by interacting with both FGF and FGF receptor (FGFR). To study the modulatory effect of SMC-derived HLGAGs on FGF2 signaling, we employed a panel of HLGAG-degrading enzymes, or heparinases, to depolymerize cell surface HLGAGs isolated from SMCs and assayed their abilities to modulate FGF2 activity on engineered cell lines expressing defined FGFR isoforms. Our findings indicate that FGF2-mediated proliferation is dependent on the composition of the SMC-derived HLGAG fragments as well as the type of FGFR isoform expressed. We postulate that the chemical composition and sequence of HLGAGs dictate the specificity of interactions between FGF2 and a given FGFR.	MIT, Harvard MIT Div Hlth Sci & Technol, Cambridge, MA 02139 USA; MIT, Div Bioengn & Environm Hlth, Cambridge, MA 02139 USA; MIT, Ctr Biomed Engn, Cambridge, MA 02139 USA	Harvard University; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Sasisekharan, R (corresponding author), MIT, Harvard MIT Div Hlth Sci & Technol, 77 Massachusetts Ave,Bldg 16-561, Cambridge, MA 02139 USA.	rams@mit.edu		KWAN, CHI-PONG/0000-0002-7654-0826				Bjornsson S, 1998, ANAL BIOCHEM, V256, P229, DOI 10.1006/abio.1997.2494; Brickman YG, 1998, J BIOL CHEM, V273, P4350, DOI 10.1074/jbc.273.8.4350; CASTELLOT JJ, 1985, J CELL PHYSIOL, V124, P21, DOI 10.1002/jcp.1041240105; Conrad H. E., 1998, HEPARIN BINDING PROT; Davis JC, 1999, BIOCHEM J, V341, P613, DOI 10.1042/0264-6021:3410613; Dowd CJ, 1999, J BIOL CHEM, V274, P5236, DOI 10.1074/jbc.274.8.5236; Duteil S, 1999, RAPID COMMUN MASS SP, V13, P1889, DOI 10.1002/(SICI)1097-0231(19991015)13:19<1889::AID-RCM719>3.0.CO;2-#; ERNST S, 1995, CRIT REV BIOCHEM MOL, V30, P387, DOI 10.3109/10409239509083490; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Forsten KE, 1997, J CELL PHYSIOL, V172, P209, DOI 10.1002/(SICI)1097-4652(199708)172:2<209::AID-JCP8>3.0.CO;2-S; FRITZE LMS, 1985, J CELL BIOL, V100, P1041, DOI 10.1083/jcb.100.4.1041; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; Godavarti R, 1996, BIOCHEM BIOPH RES CO, V229, P770, DOI 10.1006/bbrc.1996.1879; Guimond SE, 1999, CURR BIOL, V9, P1343, DOI 10.1016/S0960-9822(00)80060-3; GUYTON JR, 1980, CIRC RES, V46, P625, DOI 10.1161/01.RES.46.5.625; HAHNENBERGER R, 1993, GLYCOBIOLOGY, V3, P567, DOI 10.1093/glycob/3.6.567; Han RO, 1997, AM J PHYSIOL-HEART C, V273, pH2586, DOI 10.1152/ajpheart.1997.273.6.H2586; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KLAGSBRUN M, 1989, ARTERIOSCLEROSIS, V9, P269, DOI 10.1161/01.ATV.9.3.269; LIN X, 1999, HEPARAN SULFATE PROT; Lundin L, 2000, J BIOL CHEM, V275, P24653, DOI 10.1074/jbc.M908930199; MAJACK RA, 1984, J CELL PHYSIOL, V118, P253, DOI 10.1002/jcp.1041180306; Natke B, 1999, Angiogenesis, V3, P249, DOI 10.1023/A:1009008824246; NUGENT MA, 1993, CIRC RES, V73, P1051, DOI 10.1161/01.RES.73.6.1051; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; ORNITZ DM, 1995, SCIENCE, V268, P432, DOI 10.1126/science.7536345; Padera R, 1999, FASEB J, V13, P1677, DOI 10.1096/fasebj.13.13.1677; Park YM, 1999, BIOCHEM J, V344, P723, DOI 10.1042/0264-6021:3440723; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; Plotnikov AN, 2000, CELL, V101, P413, DOI 10.1016/S0092-8674(00)80851-X; Pye DA, 1998, J BIOL CHEM, V273, P22936, DOI 10.1074/jbc.273.36.22936; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Rhomberg AJ, 1998, P NATL ACAD SCI USA, V95, P4176, DOI 10.1073/pnas.95.8.4176; ROGHANI M, 1992, J BIOL CHEM, V267, P22156; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sasisekharan R, 1997, Angiogenesis, V1, P45, DOI 10.1023/A:1018318914258; SOMMER A, 1989, J CELL PHYSIOL, V138, P215, DOI 10.1002/jcp.1041380129; Sperinde GV, 1998, BIOCHEMISTRY-US, V37, P13153, DOI 10.1021/bi980600z; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; Stauber DJ, 2000, P NATL ACAD SCI USA, V97, P49, DOI 10.1073/pnas.97.1.49; Tumova S, 2000, INT J BIOCHEM CELL B, V32, P269, DOI 10.1016/S1357-2725(99)00116-8; VANNECK JW, 1995, BBA-GENE STRUCT EXPR, V1261, P210, DOI 10.1016/0167-4781(94)00247-Z; Venkataraman G, 1999, P NATL ACAD SCI USA, V96, P1892, DOI 10.1073/pnas.96.5.1892; Venkataraman G, 1999, SCIENCE, V286, P537, DOI 10.1126/science.286.5439.537; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	50	13	13	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 27	2001	15	6					1422	+		10.1096/fj.00-0661fje	http://dx.doi.org/10.1096/fj.00-0661fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387244				2022-12-25	WOS:000173705800024
J	Cicala, C; Morello, S; Santagada, V; Caliendo, G; Sorrentino, L; Cirino, G				Cicala, C; Morello, S; Santagada, V; Caliendo, G; Sorrentino, L; Cirino, G			Pharmacological dissection of vascular effects caused by activation of protease-activated receptor 1 and 2 in anesthetized rats	FASEB JOURNAL			English	Article						nitric oxide; hypertension; blood pressure	THROMBIN-RECEPTOR; SMOOTH-MUSCLE; RECEPTOR-2-ACTIVATING PEPTIDES; ENDOTHELIAL-CELLS; MOLECULAR-CLONING; IN-VIVO; PAR-2; CONTRACTILE; RESPONSES; DISTINCT	To clarify the role of protease-activated receptor 1 and 2 (PAR-1 and PAR-2) in controlling blood pressure, we evaluated changes in blood pressure induced by a peptide that activates the receptor PAR-1 (PAR-1AP, SFLLRNPND) and a peptide that activates the receptor PAR-2 (PAR-2AP, SLIGRL) in naive and ganglion-blocked anesthetized rats. The role of nitric oxide on the effects observed was also investigated. Intravenous injection of PAR-1AP induced a biphasic change in mean arterial blood pressure (MABP) characterized by hypotension followed by hypertension, the latter was enhanced strongly by ganglion-blockade. After L-NAME infusion in ganglion-blocked rats, hypertension induced by PAR-1AP was still increased, which returned to control value after L-arginine infusion. L-NAME did not inhibit PAR-1AP-induced hypotension. Intravenous injection of PAR-2AP induced a biphasic change in MABP, characterized by hypotension followed by a hypertensive phase that reached the maximum value in 5-6 min. Hypertension was abolished by ganglion-blockade and was restored by an infusion of L-NAME. This effect was reverted by L-arginine. L-NAME reduced the duration of hypotension induced by PAR-2AP. In conclusion, we define that PAR-1 mainly mediates hypertension, whereas PAR-2 mainly is responsible for hypotension. Furthermore, we give evidence for a hypertensive effect of PAR-2AP linked to a reflex mechanism that is modulated by nitric oxide.	Univ Naples Federico II, Dipartimento Farmacol Sperimentale, I-80131 Naples, Italy; Univ Naples Federico II, Dipartimento Chim Farmaceut, I-80131 Naples, Italy	University of Naples Federico II; University of Naples Federico II	Cicala, C (corresponding author), Univ Naples Federico II, Dipartimento Farmacol Sperimentale, Via Domenico Montesano 49, I-80131 Naples, Italy.	cicala@unina.it	Morello, Silvana/E-9328-2012; cicala, carla/AAK-3831-2020	Morello, Silvana/0000-0002-6541-0997; cicala, carla/0000-0002-8977-8251; Caliendo, Giuseppe/0000-0002-5098-6045; Cirino, Giuseppe/0000-0003-3954-4083				ALANI B, 1995, CAN J PHYSIOL PHARM, V73, P1203, DOI 10.1139/y95-172; ANTONACCIO MJ, 1993, J PHARMACOL EXP THER, V266, P125; Capers Q, 1997, CIRC RES, V80, P838; Cheung WM, 1998, CAN J PHYSIOL PHARM, V76, P16, DOI 10.1139/cjpp-76-1-16; Chintala MS, 1998, EUR J PHARMACOL, V349, P237, DOI 10.1016/S0014-2999(98)00200-3; Cicala C, 1999, CIRCULATION, V99, P2590, DOI 10.1161/01.CIR.99.19.2590; D'Andrea MR, 1998, J HISTOCHEM CYTOCHEM, V46, P157; DEITCHMAN D, 1980, J PHARMACOL METHOD, V3, P311, DOI 10.1016/0160-5402(80)90073-X; DENNINGTON PM, 1994, CLIN EXP PHARMACOL P, V21, P349, DOI 10.1111/j.1440-1681.1994.tb02527.x; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; Emilsson K, 1997, J VASC RES, V34, P267, DOI 10.1159/000159233; Fox MT, 1997, FEBS LETT, V417, P267, DOI 10.1016/S0014-5793(97)01298-2; Glusa E, 1996, SEMIN THROMB HEMOST, V22, P261, DOI 10.1055/s-2007-999017; Hamilton JR, 2000, BRIT J PHARMACOL, V130, P181, DOI 10.1038/sj.bjp.0703146; Hollenberg MD, 1996, MOL PHARMACOL, V49, P229; Hwa JJ, 1996, CIRC RES, V78, P581, DOI 10.1161/01.RES.78.4.581; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; Komuro T, 1997, BRIT J PHARMACOL, V120, P851, DOI 10.1038/sj.bjp.0701003; LANIYONU AA, 1995, BRIT J PHARMACOL, V114, P1680, DOI 10.1111/j.1476-5381.1995.tb14957.x; Moffatt JD, 1998, BRIT J PHARMACOL, V125, P591, DOI 10.1038/sj.bjp.0702157; Molino M, 1998, ARTERIOSCL THROM VAS, V18, P825, DOI 10.1161/01.ATV.18.5.825; Molino M, 1997, J BIOL CHEM, V272, P4043, DOI 10.1074/jbc.272.7.4043; MURAMATSU I, 1992, CAN J PHYSIOL PHARM, V70, P996, DOI 10.1139/y92-137; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; NYSTEDT S, 1996, J BIOL CHEM, V21, P14010; ROY S, 1997, P W PHARMACOL SOC, V40, P50; Roy SS, 1998, BRIT J PHARMACOL, V123, P1434, DOI 10.1038/sj.bjp.0701726; Saifeddine M, 1996, BRIT J PHARMACOL, V118, P521, DOI 10.1111/j.1476-5381.1996.tb15433.x; Saifeddine M, 1998, BRIT J PHARMACOL, V125, P1445, DOI 10.1038/sj.bjp.0702213; SIMONET S, 1992, EUR J PHARMACOL, V216, P135, DOI 10.1016/0014-2999(92)90222-P; TESFAMARIAM B, 1994, CIRC RES, V74, P930, DOI 10.1161/01.RES.74.5.930; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642	33	21	21	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR 27	2001	15	6					1433	+		10.1096/fj.00-0633fje	http://dx.doi.org/10.1096/fj.00-0633fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387248				2022-12-25	WOS:000173705800020
J	Frangogiannis, NG; Mendoza, LH; Lewallen, M; Michael, LH; Smith, CW; Entman, ML				Frangogiannis, NG; Mendoza, LH; Lewallen, M; Michael, LH; Smith, CW; Entman, ML			Induction and suppression of interferon-inducible protein (IP)-10 in reperfused myocardial infarcts may regulate angiogenesis	FASEB JOURNAL			English	Article						endothelium; IP-10; TGF-beta; infarction; angiogenesis	ENDOTHELIAL GROWTH-FACTOR; TRANSFORMING GROWTH-FACTOR-BETA-1; MICROVASCULAR HYPERPERMEABILITY; CHEMOKINE EXPRESSION; IN-VITRO; ISCHEMIA; CELLS; BETA; INHIBITION; ALPHA	Regulation of angiogenesis is dependent on the net biological balance between expression of angiogenic and angiostatic molecules in the injured tissue. Using a canine model of myocardial ischemia/reperfusion, we demonstrated that expression of the angiostatic chemokine interferon-inducible protein (IP-10) peaked at 1-3 h of reperfusion and virtually disappeared by 24 h of reperfusion. IP-10 mRNA and protein were localized in the venular endothelium during early reperfusion of ischemic myocardial segments and were not detected after 24 h. Endothelial cell proliferation was first noted after 24 h of reperfusion, and alphav beta3 expressing neovessels were seen after 72-120 h of reperfusion, suggesting that neovascularization began only when IP-10 expression was markedly reduced. Isolated canine venular endothelial cells expressed high levels of IP-10 and IL-8 mRNA upon stimulation with tumor necrosis factor (TNF) -alpha and endotoxin. Transforming growth factor (TGF) -beta, but not interleukin (IL) -10, decreased TNF-alpha-mediated IP-10 expression in canine endothelial cells. In contrast, TNF-alpha-mediated IL-8 induction was not affected by incubation with IL-10 or TGF-beta. Induction of angiostatic factors, such as IP-10, in the first hours following injury may be important in inhibiting premature neovessel formation, until the appropriate supportive matrix is present. IP-10 down-regulation by active TGF-beta may mediate the onset of neovascularization by allowing unopposed VEGF- and IL-8-mediated angiogenic activity.	Baylor Coll Med, Methodist Hosp, Dept Med, Cardiovasc Sci Sect, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Sect Leukocyte Biol, DeBakey Heart Ctr, Houston, TX 77030 USA	Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; Methodist DeBakey Heart & Vascular Center	Frangogiannis, NG (corresponding author), Baylor Coll Med, Dept Med, Cardiovasc Sci Sect, 1 Baylor Plaza,M-S F-602, Houston, TX 77030 USA.	ngf@bcm.tmc.edu		Frangogiannis, Nikolaos/0000-0002-8186-5131				ANGIOLILLO AL, 1995, J EXP MED, V182, P155, DOI 10.1084/jem.182.1.155; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; BAIRD A, 1986, BIOCHEM BIOPH RES CO, V138, P476, DOI 10.1016/0006-291X(86)90305-0; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Beck L, 1997, FASEB J, V11, P365, DOI 10.1096/fasebj.11.5.9141503; Becker LC, 1999, AM J PHYSIOL-HEART C, V277, pH243, DOI 10.1152/ajpheart.1999.277.1.H243; Birdsall HH, 1997, CIRCULATION, V95, P684, DOI 10.1161/01.CIR.95.3.684; BONINI JA, 1991, BIOTECHNIQUES, V11, P708; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; Buschmann I, 2000, J PATHOL, V190, P338, DOI 10.1002/(SICI)1096-9896(200002)190:3<338::AID-PATH594>3.0.CO;2-7; Carmeliet P, 1999, NAT MED, V5, P495, DOI 10.1038/8379; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Clark RAF, 1996, AM J PATHOL, V148, P1407; CLEUTJENS JPM, 1995, AM J PATHOL, V147, P325; Davis S, 1999, CURR TOP MICROBIOL, V237, P173; DiPietro LA, 1996, AM J PATHOL, V148, P1851; Dvorak HF, 1999, CURR TOP MICROBIOL, V237, P97; DVORAK HF, 1995, AM J PATHOL, V146, P1029; ENTMAN ML, 1994, CARDIOVASC RES, V28, P1301, DOI 10.1093/cvr/28.9.1301; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; Folkman J, 1983, Symp Fundam Cancer Res, V36, P201; FORD JW, 1981, IN VITRO CELL DEV B, V17, P44, DOI 10.1007/BF02618029; Frangogiannis NG, 1999, HISTOCHEM J, V31, P221, DOI 10.1023/A:1003541332070; Frangogiannis NG, 1998, CIRCULATION, V98, P699, DOI 10.1161/01.CIR.98.7.699; Frangogiannis NG, 1998, CIRCULATION, V98, P687, DOI 10.1161/01.CIR.98.7.687; Frangogiannis NG, 1998, J MOL CELL CARDIOL, V30, P2567, DOI 10.1006/jmcc.1998.0829; Frangogiannis NG, 2000, J IMMUNOL, V165, P2798, DOI 10.4049/jimmunol.165.5.2798; Frangogiannis NG, 2000, CELL TISSUE RES, V302, P365, DOI 10.1007/s004410000274; GRANT DS, 1994, PATHOL RES PRACT, V190, P854; HASHIMOTO E, 1994, AM J PHYSIOL-HEART C, V267, pH1948; HERSKOWITZ A, 1995, AM J PATHOL, V146, P419; Heymans S, 1999, NAT MED, V5, P1135, DOI 10.1038/13459; Ito S, 1999, BLOOD, V93, P1456, DOI 10.1182/blood.V93.5.1456; Keane M P, 1999, Chem Immunol, V72, P86, DOI 10.1159/000058728; Keane MP, 1999, J IMMUNOL, V163, P5686; Keane MP, 1998, P ASSOC AM PHYSICIAN, V110, P288; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; Kopydlowski KM, 1999, J IMMUNOL, V163, P1537; KUKIELKA GL, 1995, J CLIN INVEST, V95, P89, DOI 10.1172/JCI117680; KUNKEL SL, 1995, AGENT ACTION SUPPL, V46, P11; Lee SH, 2000, NEW ENGL J MED, V342, P626, DOI 10.1056/NEJM200003023420904; LEFER AM, 1993, P NATL ACAD SCI USA, V90, P1018, DOI 10.1073/pnas.90.3.1018; LEFER AM, 1990, SCIENCE, V249, P61, DOI 10.1126/science.2164258; Li J, 1996, AM J PHYSIOL-HEART C, V270, pH1803, DOI 10.1152/ajpheart.1996.270.5.H1803; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; LUSTER AD, 1987, J EXP MED, V166, P1084, DOI 10.1084/jem.166.4.1084; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Oh JW, 1999, J NEUROVIROL, V5, P82, DOI 10.3109/13550289909029749; Papapetropoulos A, 1999, LAB INVEST, V79, P213; PEPPER MS, 1993, EXP CELL RES, V204, P356, DOI 10.1006/excr.1993.1043; PHAN SH, 1992, J IMMUNOL, V149, P103; PLOUET J, 1989, J CELL PHYSIOL, V141, P392, DOI 10.1002/jcp.1041410221; RICHARD V, 1995, CIRCULATION, V92, P1891, DOI 10.1161/01.CIR.92.7.1891; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Salcedo R, 2000, FASEB J, V14, P2055, DOI 10.1096/fj.99-0963com; SCHAPER W, 1991, BASIC RES CARDIOL, V86, P51; Simonini A, 2000, CIRCULATION, V101, P1519, DOI 10.1161/01.CIR.101.13.1519; STAVRI GT, 1995, CIRCULATION, V92, P11, DOI 10.1161/01.CIR.92.1.11; STRIETER RM, 1995, J LEUKOCYTE BIOL, V57, P752, DOI 10.1002/jlb.57.5.752; STRIETER RM, 1995, BIOCHEM BIOPH RES CO, V210, P51, DOI 10.1006/bbrc.1995.1626; STRIETER RM, 1995, J BIOL CHEM, V270, P27348, DOI 10.1074/jbc.270.45.27348; Sun Y, 2000, CARDIOVASC RES, V46, P250, DOI 10.1016/S0008-6363(00)00032-8; Sun YO, 1998, J MOL CELL CARDIOL, V30, P1559, DOI 10.1006/jmcc.1998.0721; Tebo JM, 1998, BLOOD, V92, P4742, DOI 10.1182/blood.V92.12.4742.424k26_4742_4749; Thompson NL, 1988, GROWTH FACTORS, V1, P91, DOI 10.3109/08977198809000251; VANGURI P, 1990, J BIOL CHEM, V265, P15049; Veikkola T, 1999, SEMIN CANCER BIOL, V9, P211, DOI 10.1006/scbi.1998.0091; WUNSCH M, 1991, J MOL CELL CARDIOL, V23, P1051, DOI 10.1016/0022-2828(91)91640-D	72	84	96	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 27	2001	15	6					1428	+		10.1096/fj.00-0745fje	http://dx.doi.org/10.1096/fj.00-0745fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387246	Bronze			2022-12-25	WOS:000173705800022
J	Chai, ZL; Sarcevic, B; Mawson, A; Toh, BH				Chai, ZL; Sarcevic, B; Mawson, A; Toh, BH			SET-related cell division autoantigen-1 (CDA1) arrests cell growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASE-2; PROTEIN PHOSPHATASE 2A; SRC HOMOLOGY-3 DOMAINS; AUG INITIATOR CODON; SH3 DOMAINS; MOLECULAR CHARACTERIZATION; MYELOID LEUKEMOGENESIS; EUKARYOTIC RIBOSOMES; HUMAN AUTOANTIBODIES; LUPUS-ERYTHEMATOSUS	We used an autoimmune serum from a patient with discoid lupus erythematosus to clone a cDNA of 2808 base pairs. Its open reading frame of 2079 base pairs encodes a predicted polypeptide of 693 amino acids named CDA1 (cell division autoantigen-1). CDA1 has a predicted molecular mass of 79,430 Daltons and a pl of 4.26. The size of the cDNA is consistent with its estimated mRNA size. CDA1 comprises an N-terminal proline-rich domain, a central basic domain, and a C-terminal bipartite acidic domain. It has four putative nuclear localization signals and potential sites for phosphorylation by cAMP and cGMP-dependent kinases, protein kinase C, thymidine kinase, casein kinase II, and cyclin-dependent kinases (CDKs). CDA1 is phosphorylated in HeLa cells and by cyclin D1/CDK4, cyclin A/CDK2, and cyclin B/CDK1 in vitro. Its basic and acidic domains contain regions homologous to almost the entire human leukemia-associated SET protein. The same basic region is also homologous to nucleosome assembly proteins, testis TSPY protein, and an uncharacterized brain protein. CDA1 is present in the nuclear fraction of HeLa cells and localizes to the nucleus and nucleolus in HeLa cells transfected with CDA1 or its N terminus containing all four nuclear localization signals. Its acidic C terminus localizes mainly to the cytoplasm. CDA1 levels are low in serum-starved cells, increasing dramatically with serum stimulation. Expression of the CDA1 transgene, but not its N terminus, arrests HeLa cell growth, colony numbers, cell density, and bromodeoxyuridine uptake in a dose-dependent manner. The ability of CDA1 to arrest cell growth is abolished by mutation of the two CDK consensus phosphorylation sites. We propose that CDA1 is a negative regulator of cell growth and that its activity is regulated by its expression level and phosphorylation.	Monash Univ, Sch Med, Dept Pathol & Immunol, Prahran, Vic 3181, Australia; St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia	Monash University; Garvan Institute of Medical Research; St Vincents Hospital Sydney	Toh, BH (corresponding author), Monash Univ, Sch Med, Dept Pathol & Immunol, Prahran, Vic 3181, Australia.	Ban-Hock.Toh@med.monash.edu.au	CHAI, ZHONGLIN/X-1342-2019; Chai, Zhonglin/E-7482-2010	CHAI, ZHONGLIN/0000-0001-8182-8579; Sarcevic, Boris/0000-0002-8063-1050				ADACHI Y, 1994, J BIOL CHEM, V269, P2258; Adler HT, 1997, J BIOL CHEM, V272, P28407, DOI 10.1074/jbc.272.45.28407; ALDERUCCIO F, 1991, J EXP MED, V173, P941, DOI 10.1084/jem.173.4.941; ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; Altman R, 1997, J CELL BIOL, V138, P119, DOI 10.1083/jcb.138.1.119; CALLEN JP, 1982, ARCH DERMATOL, V118, P412, DOI 10.1001/archderm.118.6.412; Campbell DH, 1999, CANCER RES, V59, P5376; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; DOLBEARE F, 1983, P NATL ACAD SCI-BIOL, V80, P5573, DOI 10.1073/pnas.80.18.5573; Erlich R, 1996, J BIOL CHEM, V271, P8328, DOI 10.1074/jbc.271.14.8328; Estanyol JM, 1999, J BIOL CHEM, V274, P33161, DOI 10.1074/jbc.274.46.33161; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; Gitlits VM, 1997, IMMUNOLOGY, V92, P362, DOI 10.1046/j.1365-2567.1997.00355.x; Gitlits VM, 2000, J INVEST MED, V48, P172; Holmes JK, 1996, J BIOL CHEM, V271, P25240, DOI 10.1074/jbc.271.41.25240; KELLOGG DR, 1995, J CELL BIOL, V130, P661, DOI 10.1083/jcb.130.3.661; KELLOGG DR, 1995, J CELL BIOL, V130, P675, DOI 10.1083/jcb.130.3.675; KOOY J, 1992, J BIOL CHEM, V267, P20255; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; MORTON CJ, 1994, CURR BIOL, V4, P615, DOI 10.1016/S0960-9822(00)00134-2; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; NAGATA K, 1995, P NATL ACAD SCI USA, V92, P4279, DOI 10.1073/pnas.92.10.4279; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; RICKLES RJ, 1995, P NATL ACAD SCI USA, V92, P10909, DOI 10.1073/pnas.92.24.10909; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; ROBSON B, 1976, J MOL BIOL, V107, P327, DOI 10.1016/S0022-2836(76)80008-3; Rodriguez P, 2000, J MOL BIOL, V298, P225, DOI 10.1006/jmbi.2000.3674; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sarcevic B, 1997, J BIOL CHEM, V272, P33327, DOI 10.1074/jbc.272.52.33327; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Spector D. L., 1998, CELLS LAB MANUAL; TAN EM, 1989, ADV IMMUNOL, V44, P93, DOI 10.1016/S0065-2776(08)60641-0; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; Toh BH, 1997, NEW ENGL J MED, V337, P1441, DOI 10.1056/NEJM199711133372007; TOH BH, 1990, P NATL ACAD SCI USA, V87, P6418, DOI 10.1073/pnas.87.16.6418; Ueki N, 1998, NAT BIOTECHNOL, V16, P1338, DOI 10.1038/4315; VONLINDERN M, 1992, BAILLIERE CLIN HAEM, V5, P857, DOI 10.1016/S0950-3536(11)80049-1; VONLINDERN M, 1992, MOL CELL BIOL, V12, P3346, DOI 10.1128/MCB.12.8.3346; XIE WQ, 1991, BIOTECHNIQUES, V11, P324; Yam CH, 2000, J BIOL CHEM, V275, P3158, DOI 10.1074/jbc.275.5.3158	56	65	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33665	33674		10.1074/jbc.M007681200	http://dx.doi.org/10.1074/jbc.M007681200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11395479	hybrid			2022-12-25	WOS:000170910200052
J	Miao, DS; Tong, XK; Chan, GK; Panda, D; McPherson, PS; Goltzman, D				Miao, DS; Tong, XK; Chan, GK; Panda, D; McPherson, PS; Goltzman, D			Parathyroid hormone-related peptide stimulates oesteogenic cell proliferation through protein kinase C activation of the Ras/mitogen-activated protein kinase signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE FILAMENT PROTEINS; INCREASED BONE-FORMATION; COUPLED RECEPTORS; FUNCTIONAL-PROPERTIES; HUMAN-TISSUES; MARROW; RAS; RATS; PTHRP; OSTEOPOROSIS	We investigated the mechanisms of parathyroid hormone-related peptide (PTUrP)-mediated effects on osteogenic cells in primary rat bone marrow cell (BMC) cultures. We first demonstrated by reverse transcriptase-polymerase chain reaction and immunocytochemistry that BMCs express the type I parathyroid hormone/PTHrP receptor. Treatment with. PTHrP increased osteogenic cell proliferation as determined by [H-3]thymidine and bromodeoxyuridine incorporation and augmented osteogenic colonies. Immunocytochemistry and Western blotting revealed no direct effect on expression of the osteoblast markers, type I collagen, bone sialoprotein, and osteocalcin, indicating that PTHrP did not directly stimulate differentiation in this system. PTHrP increased mitogen-activated protein kinase (MAPK) activity in BMC and MAPK activity, and PTHrP-induced osteogenic cell proliferation could be blocked by the MEK inhibitor PD-098059. PTHrP also increased Ras activity in BMC. Although wortmannin and HS, inhibitors of phosphoinositol 3-kinase and protein kinase A, respectively, did not block PTHrP-stimulated Ras or MAPK activity, chelerythrin chloride, a known protein kinase C inhibitor, did block these PTHrP actions as well as PTHrP-induced osteogenic cell proliferation. These results demonstrate that PTHrP Stimulates osteogenic cell proliferation in rat marrow mesenchymal progenitor cells through protein kinase C-dependent activation of the Ras and ALA-PK signaling pathway.	McGill Univ, Ctr Hlth, Calcium Res Lab, Montreal, PQ H3A 1A1, Canada; McGill Univ, Ctr Hlth, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Ctr Hlth, Dept Neurol & Neurosurg, Montreal, PQ H3A 1A1, Canada	McGill University; McGill University; McGill University	Goltzman, D (corresponding author), Royal Victoria Hosp, Dept Med, Calcium Res Lab, H4-67,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.			Miao, Dengshun/0000-0002-2682-3502				ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; ALTMANNSBERGER M, 1981, LAB INVEST, V45, P427; Amizuka N, 1996, DEV BIOL, V175, P166, DOI 10.1006/dbio.1996.0104; AUBIN JE, 1995, BONE, V17, P77; BERESFORD JN, 1989, CLIN ORTHOP RELAT R, P270; BIANCO P, 1991, CALCIFIED TISSUE INT, V49, P421, DOI 10.1007/BF02555854; Boarder MR, 1998, TRENDS PHARMACOL SCI, V19, P99, DOI 10.1016/S0165-6147(98)01170-5; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; Cole JA, 1999, ENDOCRINOLOGY, V140, P5771, DOI 10.1210/en.140.12.5771; Conget PA, 1999, J CELL PHYSIOL, V181, P67, DOI 10.1002/(SICI)1097-4652(199910)181:1<67::AID-JCP7>3.0.CO;2-C; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Eguchi S, 1996, J BIOL CHEM, V271, P14169, DOI 10.1074/jbc.271.24.14169; Erben RG, 1997, ENDOCRINOLOGY, V138, P4629, DOI 10.1210/en.138.11.4629; EverhartCaye M, 1996, J CLIN ENDOCR METAB, V81, P199, DOI 10.1210/jc.81.1.199; FRAHER LJ, 1995, AM J RESP CELL MOL, V12, P669, DOI 10.1165/ajrcmb.12.6.7766430; FRIEDENSTEIN AJ, 1987, CELL TISSUE KINET, V20, P263, DOI 10.1111/j.1365-2184.1987.tb01309.x; Goltzman D, 1999, J BONE MINER RES, V14, P173, DOI 10.1359/jbmr.1999.14.2.173; GOWN AM, 1982, J CELL BIOL, V95, P414, DOI 10.1083/jcb.95.2.414; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; Henry JG, 1997, J CLIN ENDOCR METAB, V82, P900, DOI 10.1210/jc.82.3.900; HOCK JM, 1989, ENDOCRINOLOGY, V125, P2022, DOI 10.1210/endo-125-4-2022; Huang HM, 2000, BLOOD, V96, P1764, DOI 10.1182/blood.V96.5.1764.h8001764_1764_1771; Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KARAPLIS AC, 1999, PTHRP MOL MICE MEN, P397; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LEAFFER D, 1995, ENDOCRINOLOGY, V136, P3624, DOI 10.1210/en.136.8.3624; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; MALAVAL L, 1994, J CELL PHYSIOL, V158, P555, DOI 10.1002/jcp.1041580322; Mannstadt M, 1999, AM J PHYSIOL-RENAL, V277, pF665, DOI 10.1152/ajprenal.1999.277.5.F665; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; Miao DS, 2001, ENDOCRINOLOGY, V142, P926, DOI 10.1210/en.142.2.926; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; Morley P, 1999, CURR MED CHEM, V6, P1095; NISHIDA S, 1994, BONE, V15, P717, DOI 10.1016/8756-3282(94)90322-0; Plotkin H, 1998, J CLIN ENDOCR METAB, V83, P2786, DOI 10.1210/jc.83.8.2786; Reeve J, 1996, J BONE MINER RES, V11, P440; Sato H, 2000, ONCOGENE, V19, P2904, DOI 10.1038/sj.onc.1203615; STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424; Stewart AF, 2000, J BONE MINER RES, V15, P1517, DOI 10.1359/jbmr.2000.15.8.1517; STEWART AF, 1982, J CLIN ENDOCR METAB, V55, P219, DOI 10.1210/jcem-55-2-219; Stewart AF, 1996, BONE, V19, P303, DOI 10.1016/S8756-3282(96)00221-9; Sugden PH, 1997, CELL SIGNAL, V9, P337, DOI 10.1016/S0898-6568(96)00191-X; Swarthout JT, 2001, J BIOL CHEM, V276, P7586, DOI 10.1074/jbc.M007400200; Tong XK, 2000, J BIOL CHEM, V275, P29894, DOI 10.1074/jbc.M004096200; Tong XK, 2000, EMBO J, V19, P1263, DOI 10.1093/emboj/19.6.1263; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; Verheijen MHG, 1997, J BIOL CHEM, V272, P3423, DOI 10.1074/jbc.272.6.3423; Vickery BH, 1996, J BONE MINER RES, V11, P1943; Waters SB, 1996, J BIOL CHEM, V271, P18224, DOI 10.1074/jbc.271.30.18224; Weinreb M, 1997, BONE, V20, P521, DOI 10.1016/S8756-3282(97)00033-1; WEIR EC, 1992, CALCIFIED TISSUE INT, V51, P30, DOI 10.1007/BF00296214	56	95	104	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32204	32213		10.1074/jbc.M101084200	http://dx.doi.org/10.1074/jbc.M101084200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11402023	hybrid			2022-12-25	WOS:000170613500100
J	Hwang, J; Inouye, M				Hwang, J; Inouye, M			An essential GTPase, Der, containing double GTP-binding domains from Escherichia coli and Thermotoga maritima	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE; PROTEIN; DNA; RECOMBINATION; ELONGATION; FRAGMENTS; SEQUENCE; HOMOLOG; MOTIF	A gene encoding a putative GTPase containing two tandemly repeated GTP-binding domains from a hyperthermophilic bacterium, Thermotoga maritima, was cloned and expressed in Escherichia coli. The gene (TM1446) termed der is highly conserved in Eubacteria including E. coli. The purified der product (Tm-Der) has GTPase activity but no ATPase activity. GTP, GDP, and dGTP but not GMP, ATP, CTP, and UTP compete for GTP binding to Tm-Der. An optimal condition for the GTPase assay was determined to be pH 7.5 in 400 mm KCI and 5 mM MgCl2 at 70 degreesC, where K-m, V-max, and k(cat) values were determined to be 110 mum, 3.46 mum/min, and 0.87 min(-1), respectively. A der deletion strain of E. coli was constructed by replacing the der gene (originally annotated yfgK) with a kanamycin resistance gene. The deletion strain was found to form colonies only if the cells harbored a plasmid containing der, indicating that der is essential for E. coli growth.	Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Inouye, M (corresponding author), Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes Lane, Piscataway, NJ 08854 USA.							AHNN J, 1986, P NATL ACAD SCI USA, V83, P8849, DOI 10.1073/pnas.83.23.8849; ARMSTRONG KA, 1984, J MOL BIOL, V175, P331, DOI 10.1016/0022-2836(84)90352-8; BELFIELD GP, 1995, J MOL EVOL, V41, P376, DOI 10.1007/BF01215185; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Cabedo H, 1999, EMBO J, V18, P7063, DOI 10.1093/emboj/18.24.7063; Chen X, 1999, P NATL ACAD SCI USA, V96, P8396, DOI 10.1073/pnas.96.15.8396; Farmery M, 1998, BBA-PROTEIN STRUCT M, V1385, P61, DOI 10.1016/S0167-4838(98)00045-4; HIRAGA S, 1989, J BACTERIOL, V171, P1496, DOI 10.1128/jb.171.3.1496-1505.1989; JASIN M, 1984, J BACTERIOL, V159, P783, DOI 10.1128/JB.159.2.783-786.1984; Kawabata S, 2000, ORAL MICROBIOL IMMUN, V15, P58, DOI 10.1034/j.1399-302x.2000.150110.x; KAZIRO Y, 1978, BIOCHIM BIOPHYS ACTA, V505, P95, DOI 10.1016/0304-4173(78)90009-5; Kjeldgaard M, 1996, FASEB J, V10, P1347, DOI 10.1096/fasebj.10.12.8903506; Lu Q, 1996, P NATL ACAD SCI USA, V93, P5720, DOI 10.1073/pnas.93.12.5720; MARCH PE, 1988, ONCOGENE, V2, P539; Mehr IJ, 2000, GENETICS, V154, P523; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; Mittenhuber G, 2001, J MOL MICROB BIOTECH, V3, P21; Nelson KE, 1999, NATURE, V399, P323, DOI 10.1038/20601; STAHL FW, 1986, GENETICS, V113, P215; Yamanaka K, 2000, J BACTERIOL, V182, P7078, DOI 10.1128/JB.182.24.7078-7082.2000	21	55	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31415	31421		10.1074/jbc.M104455200	http://dx.doi.org/10.1074/jbc.M104455200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11387344	hybrid			2022-12-25	WOS:000170472900107
J	Drissi, R; Zindy, F; Roussel, MF; Cleveland, JL				Drissi, R; Zindy, F; Roussel, MF; Cleveland, JL			c-Myc-mediated regulation of telomerase activity is disabled in immortalized cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE TELOMERASE; CYCLE; P53; TRANSCRIPTION; FIBROBLASTS; EXPRESSION; APOPTOSIS; GENES; IDENTIFICATION; INDUCTION	Myc overexpression is a hallmark of human cancer and promotes transformation by facilitating immortalization. This function has been linked to the ability of c-Myc to induce the expression of the catalytic subunit of telomerase, telomerase reverse transcriptase (TERT), as ectopic expression of TERT immortalizes some primary human cell types. c-Myc up-regulates telomerase activity in primary mouse embryonic fibroblasts (MEFs) and myeloid cells. Paradoxically, Myc overexpression also triggers the ARF-p53 apoptotic program, which is activated when MEFs undergo replicative crises following culture ex vivo. The rare immortal variants that arise from these cultures generally suffer mutations in p53 or delete Ink4a/ARF, and Myc greatly increases the frequency of these events. Alternative reading frame (ARF)- and p53-null MEFs have increased telomerase activity, as do variant immortal clones that bypass replicative crisis. Similarly, immortal murine NIH-3T3 fibroblasts and myeloid 32D.3 and FDC-P1.2 cells do not express ARF and have robust telomerase activity. However Myc overexpression in these immortal cells results ever, I in remarkably discordant regulation of TERT and telomerase activity. Furthermore, in MEFs and 32D.3 cells TERT expression and telomerase activity are regulated independently of endogenous c-Myc. Thus, the regulation of TERT and telomerase activity is complex and is also regulated by factors other than Myc, ARF, or p53.	St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38105 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital	Cleveland, JL (corresponding author), St Jude Childrens Res Hosp, Dept Biochem, 332 N Lauderdale St, Memphis, TN 38105 USA.	john.cleveland@stjude.org	Roussel, Martine F/F-1469-2016	Roussel, Martine F/0000-0002-1740-8139				Artandi SE, 2000, CURR OPIN GENET DEV, V10, P39, DOI 10.1016/S0959-437X(99)00047-7; ASKEW DS, 1991, ONCOGENE, V6, P1915; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Blasco Maria A., 1999, Genes and Development, V13, P2353, DOI 10.1101/gad.13.18.2353; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Brun C, 1997, TRENDS CELL BIOL, V7, P317, DOI 10.1016/S0962-8924(97)01092-1; Campisi Judith, 1996, P121; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Dexter T M, 1976, Methods Cell Biol, V14, P387, DOI 10.1016/S0091-679X(08)60498-7; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EISCHEN CM, 1999, GENES DEB, V20, P2658; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANG G, 1995, TELOMERE PROTEINS; Fu WM, 1999, J BIOL CHEM, V274, P7264, DOI 10.1074/jbc.274.11.7264; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; Guo QM, 2000, CANCER RES, V60, P5922; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; Holt SE, 1997, P NATL ACAD SCI USA, V94, P10687, DOI 10.1073/pnas.94.20.10687; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.immunol.4.1.317; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Mandal M, 1997, J BIOL CHEM, V272, P14183, DOI 10.1074/jbc.272.22.14183; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nip J, 2001, ONCOGENE, V20, P910, DOI 10.1038/sj.onc.1204171; Packham G, 1997, ONCOGENE, V15, P1219, DOI 10.1038/sj.onc.1201273; Packham G, 1998, GENE DEV, V12, P2475, DOI 10.1101/gad.12.16.2475; Palmero I, 1996, CANCER SURV, V27, P351; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; QUELLE DE, 1995, CELL, V83, P993; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; SHAY JW, 1989, EXP CELL RES, V184, P109, DOI 10.1016/0014-4827(89)90369-8; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; TAVTIGIAN SV, 1994, MOL BIOL CELL, V5, P375, DOI 10.1091/mbc.5.3.375; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; VALTIERI M, 1987, J IMMUNOL, V138, P3829; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	59	26	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29994	30001		10.1074/jbc.M101899200	http://dx.doi.org/10.1074/jbc.M101899200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11402027	hybrid			2022-12-25	WOS:000170558000052
J	Boskovic, DS; Bajzar, LS; Nesheim, ME				Boskovic, DS; Bajzar, LS; Nesheim, ME			Channeling during prothrombin activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-VA; FACTOR-XA; CATALYZED ACTIVATION; MEIZOTHROMBIN; INTERMEDIATE; SUBSTRATE; BINDING; COMPLEX; THROMBOMODULIN; SPECIFICITY	The plasma zymogen prothrombin (II) is converted to the clotting enzyme thrombin (IIa) by two prothrombinase-catalyzed proteolytic cleavages. Thus, two intermediates, meizothrombin (mIIa) and prethrombin-2 (P2), are possible on the reaction pathway. Measurements of the time courses of II, mIIa, P2, and IIa suggested a channeling phenomenon, whereby a portion of the Il is converted directly to IIa without free mlIa and P2 as obligatory intermediates. Evidence for this was that the maximum rate of IIa formation preceded the maximum in the level of either intermediate. In addition, analysis of the data according to a model that included two parallel pathways through mIIa and P2 indicated that about 40% of the II consumed did not yield free mlIa or P2. Further studies were carried out in which II was continuously infused in a reactor at a constant rate. Under these conditions II, mIIa, and P2 reached constant steady-state levels, and IIa was produced at a constant rate, equal to that of II infusion. During the steady state, traces of II, mIIa, and P2 were introduced as radiolabels. Time courses of isotope consumption were first order, thus allowing the rates of consumption of II, mIIa, and P2 to be calculated. Under these conditions the rate of II consumption equaled the rate of IIa formation. Rates of consumption of the free intermediates, however, were only 22 (mlIa) and 15% (P2), respectively, of the rate of thrombin formation. Thus, both the time course experiments and the steady-state experiments indicate that an appreciable fraction of II is channeled directly to IIa without proceeding through the free intermediates mIIa and P2.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Med, Kingston, ON K7L 3N6, Canada; Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; Hamilton Civ Hosp, Res Ctr, Hamilton, ON L8V 1C3, Canada	Queens University - Canada; Queens University - Canada; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; McMaster University	Nesheim, ME (corresponding author), Queens Univ, Dept Biochem, Botterell Hall,Rm A212, Kingston, ON K7L 3N6, Canada.		Boskovic, Danilo/D-4670-2012	Boskovic, Danilo/0000-0001-6919-3726				Anderson PJ, 2000, J BIOL CHEM, V275, P16435, DOI 10.1074/jbc.M001255200; BAJAJ SP, 1973, J BIOL CHEM, V248, P7729; Boskovic DS, 2000, J BIOL CHEM, V275, P38561, DOI 10.1074/jbc.M006637200; BOSKOVIC DS, 1990, J BIOL CHEM, V265, P10497; BOSKOVIC DS, 1989, THESIS QUEENS U KING; Cote HCF, 1997, J BIOL CHEM, V272, P6194, DOI 10.1074/jbc.272.10.6194; DAVIE EW, 1964, SCIENCE, V145, P1310, DOI 10.1126/science.145.3638.1310; ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164; Fenton J W 2nd, 1981, Ann N Y Acad Sci, V370, P468, DOI 10.1111/j.1749-6632.1981.tb29757.x; HIBBARD LS, 1982, BIOCHEMISTRY-US, V21, P2285, DOI 10.1021/bi00539a003; KANE WH, 1980, J BIOL CHEM, V255, P1170; Kassell B., 1970, METHOD ENZYMOL, V19, P853; Kornberg A, 1992, DNA REPLICATION, P471; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P8977; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3708; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; KURACHI K, 1977, BIOCHEMISTRY-US, V16, P5831, DOI 10.1021/bi00645a030; MACFARLANE RG, 1964, NATURE, V202, P498, DOI 10.1038/202498a0; Mann K G, 1976, Methods Enzymol, V45, P123; MANN KG, 1990, BLOOD, V76, P1; MANN KG, 1987, TRENDS BIOCHEM SCI, V12, P229, DOI 10.1016/0968-0004(87)90115-0; MANN KG, 1992, ARCH PATHOL LAB MED, V116, P1330; MANN KG, 1974, THROMB DIATH HAEMO, V57, P179; MANN KG, 1986, BLOOD COAGULATION, P15; Morris DP, 1995, J BIOL CHEM, V270, P30491, DOI 10.1074/jbc.270.51.30491; NESHEIM ME, 1981, METHOD ENZYMOL, V80, P249; NESHEIM ME, 1984, SURV SYN PATHOL RES, V3, P219; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; ROSING J, 1988, THROMB HAEMOSTASIS, V60, P355; ROSING J, 1986, J BIOL CHEM, V261, P4224; ROSING J, 1980, J BIOL CHEM, V255, P274; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Wolberg AS, 1997, BIOCHEMISTRY-US, V36, P4074, DOI 10.1021/bi962274y	33	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28686	28693		10.1074/jbc.M101813200	http://dx.doi.org/10.1074/jbc.M101813200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11384970	hybrid			2022-12-25	WOS:000170346000008
J	Rebrin, I; Geha, RM; Chen, K; Shih, JC				Rebrin, I; Geha, RM; Chen, K; Shih, JC			Effects of carboxyl-terminal truncations on the activity and solubility of human monoamine oxidase B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; OUTER-MEMBRANE; BOUND FAD; LIVER; PROTEINS; BEHAVIOR; CLONING; GENES; YEAST; CELLS	Monoamine oxidase is an outer mitochondrial membrane protein that catalyzes the deamination of a number of neurotransmitters and dietary amines. To determine the roles of the carboxyl-terminal amino acids on the activity and solubility of human monoamine oxidase (MAO B), 10 sequential mutants were made with stop codons at amino acid positions 511, 504, 498, 492, 486, 481, 476, 467, 417, and 397, respectively. All truncated mutants were expressed in Sf21 insect cells using baculovirus, and the enzyme kinetic parameters were determined. Truncations at amino acid positions 511, 504, and 498 slightly decreased MAO B catalytic activity and had no significant changes on deprenyl inhibition. Further deletions up to amino acid 417 decreased the specific activity 10-100-fold without significant changes of the K-m for phenylethylamine or dopamine or the IC50 for deprenyl and clorgyline. The truncation mutant C397, which lacks covalently attached FAD, was inactive. Progressive carboxylterminal truncations up to position 481 were correlated with increased solubility of MAO B mutants. 47% of the activity of the truncated C481 was found in the 105,000 x g supernatant in the absence of detergent. However, further truncated mutants, C476, C467, and C417, remained associated with the membrane fraction. In contrast to crude homogenate, the water-soluble C481 mutant was rapidly inactivated at 4 degreesC and 37 degreesC, which indicates that the membrane environment is required for the stability of MAO B. Expression of the green fluorescent protein-MAO B C481 fusion protein revealed that this mutant was located in the cytoplasm, whereas its counterpart in MAO A, truncated mutant C490, was located on the mitochondria. These results suggest that the carboxyl-terminal amino acid residues 417-520 of MAO B are not directly involved in the active site but are required for maintaining the appropriate conformation and interaction with the outer mitochondrial membrane. The different solubilities of the various carboxyl-terminal truncation mutants indicate that the interaction of MAO B with mitochondrial membrane is not simply anchoring through the carboxyl. terminal hydrophobic tail. Further, our results suggest that the carboxyl-terminal of MAO A and B plays different roles in mitochondrial attachment.	Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90089 USA; Univ So Calif, Sch Med, Dept Cell & Neurobiol, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California	Shih, JC (corresponding author), Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, 1985 Zonal Ave, Los Angeles, CA 90089 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH037020, R37MH039085, K05MH000796] Funding Source: NIH RePORTER; NIMH NIH HHS [R01 MH37020, R37 MH039085, K05 MH00796, R37 MH39085] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BACH AWJ, 1988, P NATL ACAD SCI USA, V85, P4934, DOI 10.1073/pnas.85.13.4934; Binda C, 1999, STRUCTURE, V7, P265, DOI 10.1016/S0969-2126(99)80037-9; Chen K, 1996, J NEUROCHEM, V66, P797; CHEN K, 1994, MOL PHARMACOL, V46, P1226; GOTTOWIK J, 1993, FEBS LETT, V317, P152, DOI 10.1016/0014-5793(93)81512-X; GREENAWALT JW, 1970, J CELL BIOL, V46, P173, DOI 10.1083/jcb.46.1.173; GRIMSBY J, 1991, P NATL ACAD SCI USA, V88, P3637, DOI 10.1073/pnas.88.9.3637; Hirashiki I, 1995, BIOCHEM MOL BIOL INT, V37, P39; Hiro I, 1996, J BIOCHEM-TOKYO, V120, P759; JOHNSTON JP, 1968, BIOCHEM PHARMACOL, V17, P1285, DOI 10.1016/0006-2952(68)90066-X; Knoll J, 1972, Adv Biochem Psychopharmacol, V5, P393; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAN NC, 1989, J NEUROCHEM, V52, P1652, DOI 10.1111/j.1471-4159.1989.tb09223.x; Lu G, 1996, PROTEIN EXPRES PURIF, V7, P315, DOI 10.1006/prep.1996.0045; MITOMA J, 1992, J BIOCHEM-TOKYO, V111, P20, DOI 10.1093/oxfordjournals.jbchem.a123712; NGUYEN M, 1993, J BIOL CHEM, V268, P2565; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Shih JC, 1999, AM J HUM GENET, V65, P593, DOI 10.1086/302562; Shih JC, 1999, ANNU REV NEUROSCI, V22, P197, DOI 10.1146/annurev.neuro.22.1.197; Shiloff BA, 1996, EUR J BIOCHEM, V242, P41, DOI 10.1111/j.1432-1033.1996.0041r.x; SHORE GC, 1995, EUR J BIOCHEM, V227, P9, DOI 10.1111/j.1432-1033.1995.tb20354.x; URBAN P, 1991, FEBS LETT, V286, P142, DOI 10.1016/0014-5793(91)80960-B; WALKER WH, 1971, EUR J BIOCHEM, V24, P328, DOI 10.1111/j.1432-1033.1971.tb19690.x; WEYLER W, 1994, J NEURAL TRANSM-SUPP, P3; WEYLER W, 1990, BIOCHEM BIOPH RES CO, V173, P1205, DOI 10.1016/S0006-291X(05)80914-3; Wouters J, 1998, PROTEINS, V32, P97; WU HF, 1993, MOL PHARMACOL, V43, P888	27	46	50	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29499	29506		10.1074/jbc.M100431200	http://dx.doi.org/10.1074/jbc.M100431200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11371556	hybrid			2022-12-25	WOS:000170346000113
J	Hilber, K; Sandtner, W; Kudlacek, O; Glaaser, IW; Weisz, E; Kyle, JW; French, RJ; Fozzard, HA; Dudley, SC; Todt, H				Hilber, K; Sandtner, W; Kudlacek, O; Glaaser, IW; Weisz, E; Kyle, JW; French, RJ; Fozzard, HA; Dudley, SC; Todt, H			The selectivity filter of the voltage-gated sodium channel is involved in channel activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MU-CONOTOXIN-GIIIA; TRANSMEMBRANE SEGMENT IVS6; POST-REPOLARIZATION BLOCK; ULTRA-SLOW INACTIVATION; EPICARDIAL BORDER ZONE; NA+-CHANNEL; CYSTEINE MUTAGENESIS; PERIODIC PARALYSIS; LIDOCAINE BLOCK; K+-CHANNEL	Amino acids located in the outer vestibule of the voltage-gated Na+ channel determine the permeation properties of the channel. Recently, residues lining the outer pore have also been implicated in channel gating. The domain (D) IV P-loop residue alanine 1529 forms a part of the putative selectivity filter of the adult rat skeletal muscle (mu1) Na+ channel. Here we report that replacement of alanine 1529 by aspartic acid enhances entry to an ultraslow inactivated state. Ultra-slow inactivation is characterized by recovery time constants on the order of similar to 100 s from prolonged depolarizations and by the fact that entry to this state can be reduced by binding to the pore of a mutant p-conotoxin GIIIA, suggesting that ultra-slow inactivation may reflect a structural rearrangement of the outer vestibule. The voltage dependence of ultra-slow inactivation in DIV-A1529D is U-shaped, with a local maximum near -60 mV, whereas activation is maximal only above -20 mV. Furthermore, a train of brief depolarizations produces more ultra-slow inactivation than a single maintained depolarization of the same duration. These data suggest that ultra-slow inactivation emanates from "partially activated" closed states and that the P-loop in DIV may undergo a conformational change during channel activation, which is accentuated by DIV-A1529D.	Univ Vienna, Inst Pharmacol, A-1090 Vienna, Austria; Emory Univ, Div Cardiol, Atlanta, GA 30033 USA; Atlanta Vet Adm Hosp, Decatur, GA 30033 USA; Univ Calgary, Dept Physiol & Biophys, Calgary, AB T2N 4N1, Canada; Univ Chicago, Cardiac Electrophysiol Lab, Chicago, IL 60637 USA	University of Vienna; Emory University; University of Calgary; University of Chicago	Todt, H (corresponding author), Univ Vienna, Inst Pharmacol, Wahringer Str 13A, A-1090 Vienna, Austria.	hannes.todt@univie.ac.at	Dudley, Samuel C/A-7085-2009; Dudley, Samuel/AAR-7950-2021	Dudley, Samuel/0000-0001-5843-5961; Kudlacek, Oliver/0000-0002-3086-8551; Hilber, Karlheinz/0000-0002-3033-0874	NHLBI NIH HHS [HL-P01-20592, HL64828] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020592, R01HL064828] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALDRICH RW, 1979, J PHYSIOL-LONDON, V291, P507, DOI 10.1113/jphysiol.1979.sp012828; ALDRICH RW, 1981, BIOPHYS J, V36, P519, DOI 10.1016/S0006-3495(81)84750-9; BECKER S, 1992, BIOCHEMISTRY-US, V31, P8229, DOI 10.1021/bi00150a016; Benitah JP, 1997, BIOPHYS J, V73, P603, DOI 10.1016/S0006-3495(97)78096-2; Bertoli A, 1996, EXP BRAIN RES, V110, P401; BULATKO AK, 1995, J PHYSIOL-LONDON, V484, P307, DOI 10.1113/jphysiol.1995.sp020666; CANNON SC, 1993, PFLUG ARCH EUR J PHY, V423, P155, DOI 10.1007/BF00374974; CANNON SC, 1993, NEURON, V10, P317, DOI 10.1016/0896-6273(93)90321-H; Cannon SC, 1996, TRENDS NEUROSCI, V19, P3, DOI 10.1016/0166-2236(96)81859-5; Cha A, 1999, NEURON, V22, P73, DOI 10.1016/S0896-6273(00)80680-7; Chahine M, 1998, BIOPHYS J, V75, P236, DOI 10.1016/S0006-3495(98)77510-1; CHANDLER WK, 1970, J PHYSIOL-LONDON, V211, P653, DOI 10.1113/jphysiol.1970.sp009298; Chang SY, 1996, BIOPHYS J, V70, P2581, DOI 10.1016/S0006-3495(96)79829-6; Chiamvimonvat N, 1996, NEURON, V16, P1037, DOI 10.1016/S0896-6273(00)80127-0; Chiamvimonvat N, 1996, J PHYSIOL-LONDON, V491, P51, DOI 10.1113/jphysiol.1996.sp021195; CREIGHTON TE, 1993, PROTEINS STRUCTURES, P7; Cummins TR, 1996, BIOPHYS J, V71, P227, DOI 10.1016/S0006-3495(96)79219-6; DECOURSEY TE, 1984, NATURE, V307, P465, DOI 10.1038/307465a0; DECOURSEY TE, 1990, J GEN PHYSIOL, V95, P617, DOI 10.1085/jgp.95.4.617; del Camino D, 2000, NATURE, V403, P321, DOI 10.1038/35002099; Dudley SC, 2000, J GEN PHYSIOL, V116, P679, DOI 10.1085/jgp.116.5.679; ECKERT R, 1984, PROG BIOPHYS MOL BIO, V44, P215, DOI 10.1016/0079-6107(84)90009-9; Favre I, 1996, BIOPHYS J, V71, P3110, DOI 10.1016/S0006-3495(96)79505-X; Featherstone DE, 1996, BIOPHYS J, V71, P3098, DOI 10.1016/S0006-3495(96)79504-8; Fleidervish IA, 1996, J PHYSIOL-LONDON, V493, P83, DOI 10.1113/jphysiol.1996.sp021366; FOX JM, 1976, BIOCHIM BIOPHYS ACTA, V426, P232, DOI 10.1016/0005-2736(76)90334-5; Fozzard HA, 1996, PHYSIOL REV, V76, P887, DOI 10.1152/physrev.1996.76.3.887; French R J, 1999, Methods Enzymol, V294, P575; French RJ, 1996, NEURON, V16, P407, DOI 10.1016/S0896-6273(00)80058-6; French RJ, 1997, SER CENT ES, P67; Hanck DA, 2000, PFLUG ARCH EUR J PHY, V439, P814, DOI 10.1007/s004240051009; Hayward LJ, 1997, BIOPHYS J, V72, P1204, DOI 10.1016/S0006-3495(97)78768-X; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; Hille B., 1992, IONIC CHANNELS EXCIT; Holmgren M, 1998, NEURON, V21, P617, DOI 10.1016/S0896-6273(00)80571-1; Horn R, 2000, J GEN PHYSIOL, V116, P461, DOI 10.1085/jgp.116.3.461; ISOM LL, 1992, SCIENCE, V256, P839, DOI 10.1126/science.1375395; Jones LP, 1999, BIOPHYS J, V76, P2530, DOI 10.1016/S0006-3495(99)77407-2; Kambouris NG, 1998, J PHYSIOL-LONDON, V512, P693, DOI 10.1111/j.1469-7793.1998.693bd.x; KHODOROV BI, 1985, PROG BIOPHYS MOL BIO, V45, P57, DOI 10.1016/0079-6107(85)90005-7; Klemic KG, 1998, BIOPHYS J, V74, P1779, DOI 10.1016/S0006-3495(98)77888-9; Linford NJ, 1998, P NATL ACAD SCI USA, V95, P13947, DOI 10.1073/pnas.95.23.13947; Lipkind GM, 2000, BIOCHEMISTRY-US, V39, P8161, DOI 10.1021/bi000486w; LIPKIND GM, 1994, BIOPHYS J, V66, P1, DOI 10.1016/S0006-3495(94)80746-5; MAKIELSKI JC, 1993, BIOPHYS J, V65, P790, DOI 10.1016/S0006-3495(93)81102-0; MAROM S, 1993, RECEPTOR CHANNEL, V1, P81; Mathes C, 1997, J GEN PHYSIOL, V109, P435, DOI 10.1085/jgp.109.4.435; MATTESON DR, 1984, NATURE, V307, P468, DOI 10.1038/307468a0; MCPHEE JC, 1994, P NATL ACAD SCI USA, V91, P12346, DOI 10.1073/pnas.91.25.12346; MCPHEE JC, 1995, J BIOL CHEM, V270, P12025, DOI 10.1074/jbc.270.20.12025; Mitrovic N, 2000, J GEN PHYSIOL, V115, P707, DOI 10.1085/jgp.115.6.707; NEHER E, 1971, PFLUG ARCH EUR J PHY, V322, P35, DOI 10.1007/BF00586662; Nuss HB, 1996, J PHYSIOL-LONDON, V494, P411, DOI 10.1113/jphysiol.1996.sp021502; Nuss HB, 1995, J GEN PHYSIOL, V106, P1171, DOI 10.1085/jgp.106.6.1171; Nuss HB, 2000, BIOPHYS J, V78, P200, DOI 10.1016/S0006-3495(00)76585-4; Nuss HB, 1995, J GEN PHYSIOL, V106, P1193, DOI 10.1085/jgp.106.6.1193; Ong BH, 2000, J GEN PHYSIOL, V116, P653, DOI 10.1085/jgp.116.5.653; Patil PG, 1998, NEURON, V20, P1027, DOI 10.1016/S0896-6273(00)80483-3; PATTON DE, 1992, P NATL ACAD SCI USA, V89, P10905, DOI 10.1073/pnas.89.22.10905; PATTON DE, 1994, J BIOL CHEM, V269, P17649; PerezGarcia MT, 1997, BIOPHYS J, V72, P989, DOI 10.1016/S0006-3495(97)78751-4; PerezGarcia MT, 1996, P NATL ACAD SCI USA, V93, P300, DOI 10.1073/pnas.93.1.300; Perozo E, 1999, SCIENCE, V285, P73, DOI 10.1126/science.285.5424.73; Pu JL, 1998, CIRC RES, V83, P431, DOI 10.1161/01.RES.83.4.431; Pu JL, 1997, CIRC RES, V81, P110, DOI 10.1161/01.RES.81.1.110; QUATTROCKI EA, 1994, NEURON, V12, P73, DOI 10.1016/0896-6273(94)90153-8; RUFF RL, 1987, J PHYSIOL-LONDON, V383, P339; SATIN J, 1994, BIOPHYS J, V66, P1353, DOI 10.1016/S0006-3495(94)80926-9; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; Sunami A, 2000, P NATL ACAD SCI USA, V97, P2326, DOI 10.1073/pnas.030438797; Sunami A, 1997, P NATL ACAD SCI USA, V94, P14126, DOI 10.1073/pnas.94.25.14126; Todt H, 2000, BIOPHYS J, V78, p83A; Todt H, 1999, BIOPHYS J, V76, P1335, DOI 10.1016/S0006-3495(99)77296-6; Tsushima RG, 1997, J GEN PHYSIOL, V109, P463, DOI 10.1085/jgp.109.4.463; Tsushima RG, 1997, J GEN PHYSIOL, V110, P59, DOI 10.1085/jgp.110.1.59; UKOMADU C, 1992, NEURON, V8, P663, DOI 10.1016/0896-6273(92)90088-U; Vedantham V, 1999, J GEN PHYSIOL, V113, P7, DOI 10.1085/jgp.113.1.7; Vedantham V, 2000, BIOPHYS J, V78, P2943, DOI 10.1016/S0006-3495(00)76834-2; WANG GK, 1992, J GEN PHYSIOL, V99, P1, DOI 10.1085/jgp.99.1.1; Wang SY, 1996, PFLUG ARCH EUR J PHY, V432, P692, DOI 10.1007/s004240050187; Wang SY, 1999, BIOPHYS J, V76, P3141, DOI 10.1016/S0006-3495(99)77465-5; WEST JW, 1992, P NATL ACAD SCI USA, V89, P10910, DOI 10.1073/pnas.89.22.10910; Wright SN, 1998, MOL PHARMACOL, V54, P733; ZHOU JY, 1991, NEURON, V7, P775, DOI 10.1016/0896-6273(91)90280-D	84	45	46	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27831	27839		10.1074/jbc.M101933200	http://dx.doi.org/10.1074/jbc.M101933200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11382756	hybrid			2022-12-25	WOS:000170093400014
J	Leslie, EM; Ito, K; Upadhyaya, P; Hecht, SS; Deeley, RG; Cole, SPC				Leslie, EM; Ito, K; Upadhyaya, P; Hecht, SS; Deeley, RG; Cole, SPC			Transport of the beta-O-glucuronide conjugate of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) by the multidrug resistance protein 1 (MRP1) - Requirement for glutathione or a non-sulfur-containing analog	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUNG CARCINOGEN; EXPORT PUMP; MONOCLONAL-ANTIBODIES; SUBSTRATE-SPECIFICITY; VINCRISTINE TRANSPORT; REDUCED GLUTATHIONE; LEUKOTRIENE C-4; CDNA CLONING; CELL-LINES; GENE	Nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and its metabolite 4-(methylnitrosamino)-1(3-pyridyl)-1-butanol (NNAL) play a crucial role in the induction of lung cancer, and NNAL-O-glucuronide formation and elimination are important steps in detoxification of these compounds. In the present study, we investigated the ATP-binding cassette (ABC) protein, MRP1 (ABCC1), as a candidate transporter responsible for NNAL-O-glucuronide export. MRP1 mediates the active transport of numerous GSH-, sulfate-, and glucuronide-conjugated organic anions and can transport certain xenobiotics by a mechanism that may involve co-transport with GSH. Using membrane vesicles prepared from transfected cells, we found that MRP1 transports [H-3]NNAL-O-glucuronide but is dependent on the presence of GSH (K-m 39 muM, V-max 48 pmol mg(-1) min(-1)). We also found that the sulfur atom in GSH was dispensable because transport was supported by the GSH analog, gamma -glutamyl-alpha -aminobutyryl-glycine. Despite stimulation of NNAL-O-glueuronide transport by GSH, there was no detectable reciprocal stimulation of [H-3]GSH transport. Moreover, whereas the MRP1 substrates leukotriene C-4 (LTC4) and 17 beta -estradiol 17 beta-(D-glucuronide) (E(2)17 betaG) inhibited GSH-dependent uptake of [H-3]NNAL-O-glucuronide, only [H-3]LTC4 transport was inhibited by NNAL-O-glucuronide (+GSH) and the kinetics of inhibition were complex. A mutant form of MRP1, which transports LTC4 but not E(2)17 betaG, also did not transport NNAL-O-glucuronide suggesting a commonality in the binding elements for these two glucuronidated substrates, despite their lack of reciprocal transport inhibition. Finally, the related MRP2 transported NNAL-O-glucuronide with higher efficiency than MRP1 and unexpectedly, GSH inhibited rather than stimulated uptake. These studies provide further insight into the complex interactions of the MRP-related proteins with GSH and their conjugated organic anion substrates, and extend the range of xenotoxins transported by MRP1 and MRP2 to include metabolites of known carcinogens involved in the etiology of lung and other cancers.	Queens Univ, Canc Res Labs, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Pharmacol & Toxicol, Kingston, ON K7L 3N6, Canada; Univ Minnesota, Ctr Canc, Minneapolis, MN 55455 USA	Queens University - Canada; Queens University - Canada; University of Minnesota System; University of Minnesota Twin Cities	Cole, SPC (corresponding author), Queens Univ, Canc Res Labs, Rm 328,Botterell Hall, Kingston, ON K7L 3N6, Canada.		Cole, Susan P.C./I-6389-2017; Deeley, Roger/J-4828-2012	Cole, Susan P.C./0000-0001-6571-6884; Hecht, Stephen/0000-0001-7228-1356; Leslie, Elaine/0000-0003-1825-348X				Bakos E, 2000, MOL PHARMACOL, V57, P760, DOI 10.1124/mol.57.4.760; Borst P, 1999, BBA-BIOMEMBRANES, V1461, P347, DOI 10.1016/S0005-2736(99)00167-4; Buchler M, 1996, J BIOL CHEM, V271, P15091; Carmella SG, 1999, CANCER RES, V59, P3602; COLE SPC, 1994, CANCER RES, V54, P5902; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Evers R, 1997, FEBS LETT, V419, P112, DOI 10.1016/S0014-5793(97)01442-7; Flens MJ, 1996, AM J PATHOL, V148, P1237; GRANT CE, 1994, CANCER RES, V54, P357; Hecht SS, 2000, P NATL ACAD SCI USA, V97, P12493, DOI 10.1073/pnas.220207697; Hecht SS, 1998, CHEM RES TOXICOL, V11, P559, DOI 10.1021/tx980005y; HECHT SS, 1980, CANCER RES, V40, P4144; Hecht SS, 2000, CARCINOGENESIS, V21, P850, DOI 10.1093/carcin/21.4.850; Hecht SS, 1999, JNCI-J NATL CANCER I, V91, P1194, DOI 10.1093/jnci/91.14.1194; Heijn M, 1997, BBA-BIOMEMBRANES, V1326, P12, DOI 10.1016/S0005-2736(97)00003-5; Hipfner DR, 1999, J BIOL CHEM, V274, P15420, DOI 10.1074/jbc.274.22.15420; Hipfner DR, 1996, CANCER RES, V56, P3307; HIPFNER DR, 1994, CANCER RES, V54, P5788; Hipfner DR, 1999, BBA-BIOMEMBRANES, V1461, P359, DOI 10.1016/S0005-2736(99)00168-6; Hirohashi T, 1998, MOL PHARMACOL, V53, P1068; Hirohashi T, 1999, J BIOL CHEM, V274, P15181, DOI 10.1074/jbc.274.21.15181; Ito K, 2001, J BIOL CHEM, V276, P15616, DOI 10.1074/jbc.M011246200; Jedlitschky G, 1996, CANCER RES, V56, P988; Kiuchi Y, 1998, FEBS LETT, V433, P149, DOI 10.1016/S0014-5793(98)00899-0; Konig J, 1999, HEPATOLOGY, V29, P1156, DOI 10.1002/hep.510290404; Konig J, 1999, BBA-BIOMEMBRANES, V1461, P377, DOI 10.1016/S0005-2736(99)00169-8; Kool M, 1997, CANCER RES, V57, P3537; LESLIE EM, 2001, IN PRESS TOXICOLOGY; Li LQ, 2000, MOL PHARMACOL, V58, P335, DOI 10.1124/mol.58.2.335; Liu GS, 2001, J BIOL CHEM, V276, P8648, DOI 10.1074/jbc.M009690200; Loe DW, 2000, BIOCHEM BIOPH RES CO, V275, P795, DOI 10.1006/bbrc.2000.3384; Loe DW, 2000, J PHARMACOL EXP THER, V293, P530; Loe DW, 1997, MOL PHARMACOL, V51, P1034, DOI 10.1124/mol.51.6.1034; Loe DW, 1996, J BIOL CHEM, V271, P9683, DOI 10.1074/jbc.271.16.9683; Loe DW, 1998, CANCER RES, V58, P5130; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; Mao QC, 2000, J BIOL CHEM, V275, P34166, DOI 10.1074/jbc.M004584200; Maser E, 1996, EUR J BIOCHEM, V238, P484, DOI 10.1111/j.1432-1033.1996.0484z.x; Meger M, 1999, DRUG METAB DISPOS, V27, P471; Meiser H, 2000, Eur J Med Res, V5, P241; MURPHY SE, 1995, CHEM RES TOXICOL, V8, P772, DOI 10.1021/tx00047a018; Murphy SE, 1997, CHEM-BIOL INTERACT, V103, P153, DOI 10.1016/S0009-2797(96)03756-8; Ogawa K, 2000, AM J PHYSIOL-GASTR L, V278, pG438, DOI 10.1152/ajpgi.2000.278.3.G438; Ortiz DF, 1999, AM J PHYSIOL-GASTR L, V276, pG1493, DOI 10.1152/ajpgi.1999.276.6.G1493; Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126; Qian YM, 2001, J BIOL CHEM, V276, P6404, DOI 10.1074/jbc.M008251200; Rappa G, 1997, CANCER RES, V57, P5232; Ren Q, 2000, DRUG METAB DISPOS, V28, P1352; Renes J, 2000, BIOCHEM J, V350, P555, DOI 10.1042/0264-6021:3500555; Sakamoto H, 1999, CANCER LETT, V135, P113; Schaub TP, 1999, J AM SOC NEPHROL, V10, P1159; Staretz ME, 1997, CARCINOGENESIS, V18, P1715, DOI 10.1093/carcin/18.9.1715; Stockel B, 2000, EUR J BIOCHEM, V267, P1347, DOI 10.1046/j.1432-1327.2000.01106.x; Stride BD, 1999, J BIOL CHEM, V274, P22877, DOI 10.1074/jbc.274.32.22877; Su T, 2000, CANCER RES, V60, P5074; Suzuki H, 1998, SEMIN LIVER DIS, V18, P359, DOI 10.1055/s-2007-1007170; Upadhyaya P, 1999, CARCINOGENESIS, V20, P1577, DOI 10.1093/carcin/20.8.1577; Vazquez-Laslop N, 2000, BIOCHEM SOC T, V28, P517, DOI 10.1042/0300-5127:0280517; VERSANTVOORT CHM, 1995, BRIT J CANCER, V72, P82, DOI 10.1038/bjc.1995.281; WALEY SG, 1956, BIOCHEM J, V64, P715, DOI 10.1042/bj0640715; WIENCH K, 1992, CARCINOGENESIS, V13, P867, DOI 10.1093/carcin/13.5.867; Wijnholds J, 2000, J CLIN INVEST, V105, P279, DOI 10.1172/JCI8267; Wijnholds J, 1997, NAT MED, V3, P1275, DOI 10.1038/nm1197-1275; Wijnholds J, 1998, J EXP MED, V188, P797, DOI 10.1084/jem.188.5.797; ZAMAN GJR, 1995, P NATL ACAD SCI USA, V92, P7690, DOI 10.1073/pnas.92.17.7690; Zeng H, 2000, CANCER RES, V60, P4779; Zhang DW, 2001, J BIOL CHEM, V276, P13231, DOI 10.1074/jbc.M010008200; Zheleznova EE, 2000, TRENDS BIOCHEM SCI, V25, P39, DOI 10.1016/S0968-0004(99)01514-5	68	142	152	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27846	27854		10.1074/jbc.M102453200	http://dx.doi.org/10.1074/jbc.M102453200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11375986	hybrid			2022-12-25	WOS:000170093400016
J	Pei, Y; Hausmann, S; Ho, CK; Schwer, B; Shuman, S				Pei, Y; Hausmann, S; Ho, CK; Schwer, B; Shuman, S			The length, phosphorylation state, and primary structure of the RNA polymerase II carboxyl-terminal domain dictate interactions with mRNA capping enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHIZOSACCHAROMYCES-POMBE; LARGEST SUBUNIT; GUANYLYLTRANSFERASE; TRIPHOSPHATASE; CTD; ASSOCIATION; COMPLEX; COMPONENT; SEQUENCE; BINDING	The carboxyl-terminal domain (CTD) of elongating RNA polymerase Il serves as a landing pad for macromolecular assemblies that regulate mRNA synthesis and processing. The capping apparatus is the first of the assemblies to act on the nascent pre-mRNA and the one for which binding of the catalytic components is most clearly dependent on CTD phosphorylation. The present study highlights a distinctive strategy of cap targeting in fission yeast whereby the triphosphatase (Pct1) and guanylyltransferase (Peel) enzymes of the capping apparatus do not interact physically with each other (as they do in budding yeast and metazoans), but instead bind independently to the phosphorylated CTD. In vivo interactions of Pct1 and Pce1 with the CTD in a two-hybrid assay require 12 and 14 tandem repeats of the CTD heptapeptide, respectively. Pct1 and Pce1 bind in vitro to synthetic CTD peptides containing phosphoserine uniquely at position 5 or doubly at positions 2 and 5 of each of four tandem YSPTSPS repeats, but they bind weakly (Pce1) or not at all (Pct1) to a peptide containing phosphoserine at position 2. These results illustrate how remodeling of the CTD phosphorylation array might influence the recruitment and dissociation of the capping enzymes during elongation. But how does the CTD structure itself dictate interactions with the RNA processing enzymes independent of the phosphorylation state? Using CTD-Ser5 phosphopeptides containing alanine substitutions at other positions of the heptad, we define essential roles for Tyr-1 and Pro-3 (but not Thr-4 or Pro-6) in the binding of Schizosaccharomyces pombe guanylyltransferase. Tyr-l is also essential for binding and allosteric activation of mammalian guanylyltransferase by CTD Ser5-PO4, whereas alanine mutations of Pro-3 and Pro-6 reduce the affinity for the allosteric CTD-binding site. These are the first structure-activity relationships deduced for an effector function of the phosphorylated CTD.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.	s.shuman@ski.mskcc.org	Pei, Yi/D-8998-2011; Ho, KIong/GPP-6051-2022	Pei, Yi/0000-0002-3466-760X; 	NIGMS NIH HHS [GM52470] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052470] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AZUMA Y, 1991, NUCLEIC ACIDS RES, V19, P461, DOI 10.1093/nar/19.3.461; BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; Cho EJ, 1998, GENE DEV, V12, P3482, DOI 10.1101/gad.12.22.3482; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; Cooper JP, 1997, NATURE, V385, P744, DOI 10.1038/385744a0; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; Gebara MM, 1997, J CELL BIOCHEM, V64, P390; Hirose Y, 2000, GENE DEV, V14, P1415; Ho CK, 1999, NUCLEIC ACIDS RES, V27, P4671, DOI 10.1093/nar/27.24.4671; Ho CK, 1998, MOL CELL BIOL, V18, P5189, DOI 10.1128/MCB.18.9.5189; Ho CK, 1998, J BIOL CHEM, V273, P9577, DOI 10.1074/jbc.273.16.9577; Ho CK, 2000, J VIROL, V74, P5486, DOI 10.1128/JVI.74.12.5486-5494.2000; Ho CK, 1999, MOL CELL, V3, P405, DOI 10.1016/S1097-2765(00)80468-2; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Lehman K, 1999, J BIOL CHEM, V274, P22668, DOI 10.1074/jbc.274.32.22668; Lima CD, 1999, CELL, V99, P533, DOI 10.1016/S0092-8674(00)81541-X; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; Patturajan M, 1998, J BIOL CHEM, V273, P4689, DOI 10.1074/jbc.273.8.4689; Pei Y, 2001, NUCLEIC ACIDS RES, V29, P387, DOI 10.1093/nar/29.2.387; Rickert P, 1999, ONCOGENE, V18, P1093, DOI 10.1038/sj.onc.1202399; Schroeder SC, 2000, GENE DEV, V14, P2435, DOI 10.1101/gad.836300; Schwer B, 2001, J BIOL CHEM, V276, P1857, DOI 10.1074/jbc.M006072200; Shuman S, 2001, PROG NUCLEIC ACID RE, V66, P1; SHUMAN S, 1994, P NATL ACAD SCI USA, V91, P12046, DOI 10.1073/pnas.91.25.12046; Stiller JW, 2000, YEAST, V16, P57, DOI 10.1002/(SICI)1097-0061(20000115)16:1<57::AID-YEA509>3.0.CO;2-E; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; Wen YX, 1999, GENE DEV, V13, P1774, DOI 10.1101/gad.13.14.1774; WEST ML, 1995, GENETICS, V140, P1223; Yamada-Okabe T, 1998, FEBS LETT, V435, P49, DOI 10.1016/S0014-5793(98)01037-0; YamadaOkabe T, 1996, MICROBIOL-UK, V142, P2515, DOI 10.1099/00221287-142-9-2515; Yue ZY, 1997, P NATL ACAD SCI USA, V94, P12898, DOI 10.1073/pnas.94.24.12898; Yuryev A, 1996, GENETICS, V143, P661; Zhou MS, 2000, MOL CELL BIOL, V20, P5077, DOI 10.1128/MCB.20.14.5077-5086.2000	34	59	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28075	28082		10.1074/jbc.M102170200	http://dx.doi.org/10.1074/jbc.M102170200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11387325	hybrid			2022-12-25	WOS:000170093400045
J	Blom, AM; Kask, L; Dahlback, B				Blom, AM; Kask, L; Dahlback, B			Structural requirements for the complement regulatory activities of C4BP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN C4B-BINDING PROTEIN; HUMAN FACTOR-H; HUMAN C4-BINDING PROTEIN; CHARGED AMINO-ACIDS; I COFACTOR FUNCTION; ALPHA-CHAIN; LIGAND-BINDING; C3B/C4B RECEPTOR; C3B INACTIVATOR; SITES	C4b-binding protein (C4BP) is a regulator of the classical complement pathway C3 convertase (C4bC2a complex). It is a disulfide-linked polymer of seven cr-chains and a unique beta -chain; the alpha- and beta -chains are composed of eight and three complement control protein (CCP) domains, respectively. To elucidate the importance of the polymeric nature of C4BP and the structural requirements for the interaction between C4b and the alpha -chain, 19 recombinant C4BP variants were created. Six truncated monomeric variants, nine polymeric variants in which individual CCPs were deleted, and finally, four variants in which double alanine residues were introduced between CCPs were functionally characterized. The smallest truncated C4BP variant still active in regulating fluid phase C4b comprised CCPI-3, The monomeric variants were less efficient than polymeric C4BP in degrading C4b on cell surfaces. All three N-terminal CCP domains contributed to the binding of C4b and mere important for full functional activity; CCP2 and CCPS were the most important. The spatial arrangements of the first CCPs were found to be important, as introduction of alanine residues between CCPs 1 and 2, CCPs 2 and 3, and CCPs 3 and 4 resulted in functional impairment. The results presented here elucidate the structural requirements of individual CCPs of C4BP, as well as their spatial arrangements within and between subunits for expression of full functional activity.	Univ Lund, Malmo Univ Hosp, Wallenberg Lab, Dept Clin Chem, S-20502 Malmo, Sweden	Lund University; Skane University Hospital	Blom, AM (corresponding author), Univ Lund, Malmo Univ Hosp, Wallenberg Lab, Dept Clin Chem, S-20502 Malmo, Sweden.		Blom, Anna/AFS-7369-2022; Blom, Anna/B-9607-2009	Blom, Anna/0000-0002-1348-1734; Kask, Lena/0000-0002-4380-4354; Dahlback, Bjorn/0000-0003-1546-0328				Accardo P, 1996, J IMMUNOL, V157, P4935; ADAMS EM, 1991, J IMMUNOL, V147, P3005; ALSENZ J, 1984, BIOCHEM J, V224, P389, DOI 10.1042/bj2240389; ANDERSSON M, 1991, EUR J CLIN PHARMACOL, V40, P261, DOI 10.1007/BF00315206; Berggard K, 1997, INFECT IMMUN, V65, P3638; Blom AM, 2000, MOL IMMUNOL, V37, P445, DOI 10.1016/S0161-5890(00)00059-6; Blom AM, 2000, J IMMUNOL, V164, P5328, DOI 10.4049/jimmunol.164.10.5328; Blom AM, 1999, J BIOL CHEM, V274, P19237, DOI 10.1074/jbc.274.27.19237; Brodbeck WG, 1996, J IMMUNOL, V156, P2528; CHUNG LP, 1985, BIOSCIENCE REP, V5, P855, DOI 10.1007/BF01119897; CROSSLEY LG, 1980, BIOCHEM J, V191, P173, DOI 10.1042/bj1910173; DAHLBACK B, 1983, BIOCHEM J, V209, P857, DOI 10.1042/bj2090857; DAHLBACK B, 1984, J BIOL CHEM, V259, P1631; DAHLBACK B, 1983, BIOCHEM J, V209, P847, DOI 10.1042/bj2090847; DAHLBACK B, 1983, P NATL ACAD SCI-BIOL, V80, P3461, DOI 10.1073/pnas.80.11.3461; FUJITA T, 1985, J IMMUNOL, V134, P3320; FUJITA T, 1983, J EXP MED, V157, P1239, DOI 10.1084/jem.157.4.1239; GIGLI I, 1976, BIOCHEM J, V157, P541, DOI 10.1042/bj1570541; GIGLI I, 1979, P NATL ACAD SCI USA, V76, P6596, DOI 10.1073/pnas.76.12.6596; Goodfellow RM, 2000, CLIN EXP IMMUNOL, V119, P210, DOI 10.1046/j.1365-2249.2000.01129.x; GORDON DL, 1995, J IMMUNOL, V155, P348; Hardig Y, 1997, BIOCHEM J, V323, P469; HESSING M, 1993, FEBS LETT, V317, P228, DOI 10.1016/0014-5793(93)81281-4; HILLARP A, 1988, J BIOL CHEM, V263, P12759; Hourcade D, 2000, IMMUNOPHARMACOLOGY, V49, P103, DOI 10.1016/S0162-3109(00)80296-9; IWATA K, 1995, J BIOL CHEM, V270, P15148, DOI 10.1074/jbc.270.25.15148; Jokiranta TS, 2000, J BIOL CHEM, V275, P27657; KLICKSTEIN LB, 1988, J EXP MED, V168, P1699, DOI 10.1084/jem.168.5.1699; KRISTENSEN T, 1987, BIOCHEMISTRY-US, V26, P4668, DOI 10.1021/bi00389a012; KRYCH M, 1991, P NATL ACAD SCI USA, V88, P4353, DOI 10.1073/pnas.88.10.4353; Krych M, 1998, J BIOL CHEM, V273, P8623, DOI 10.1074/jbc.273.15.8623; KRYCH M, 1994, J BIOL CHEM, V269, P13273; Kuhn S, 1996, EUR J IMMUNOL, V26, P2383, DOI 10.1002/eji.1830261017; KUHN S, 1995, J IMMUNOL, V155, P5663; Linton SM, 1999, MOL IMMUNOL, V36, P905, DOI 10.1016/S0161-5890(99)00113-3; Mikata S, 1998, MOL IMMUNOL, V35, P537, DOI 10.1016/S0161-5890(98)00046-7; NAGASAWA S, 1982, J BIOCHEM-TOKYO, V92, P1329, DOI 10.1093/oxfordjournals.jbchem.a134052; NORMAN DG, 1991, J MOL BIOL, V219, P717, DOI 10.1016/0022-2836(91)90666-T; OGATA RT, 1993, J IMMUNOL, V150, P2273; Ram S, 2001, J EXP MED, V193, P281, DOI 10.1084/jem.193.3.281; SAHU A, 1993, MOL IMMUNOL, V30, P679, DOI 10.1016/0161-5890(93)90079-Q; SCHARFSTEIN J, 1978, J EXP MED, V148, P207, DOI 10.1084/jem.148.1.207; Villoutreix BO, 1998, PROTEINS, V31, P391, DOI 10.1002/(SICI)1097-0134(19980601)31:4<391::AID-PROT6>3.0.CO;2-L; ZICCARDI RJ, 1984, J BIOL CHEM, V259, P3674	44	107	109	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27136	27144		10.1074/jbc.M102445200	http://dx.doi.org/10.1074/jbc.M102445200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11369776	hybrid			2022-12-25	WOS:000169966900055
J	Boxrud, PD; Verhamme, IMA; Fay, WP; Bock, PE				Boxrud, PD; Verhamme, IMA; Fay, WP; Bock, PE			Streptokinase triggers conformational activation of plasminogen through specific interactions of the amino-terminal sequence and stabilizes the active zymogen conformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; CATALYTIC DOMAIN; BOVINE TRYPSINOGEN; ACID-SEQUENCE; SITE; MECHANISM; PEPTIDES; BINDING; COMPLEX; TRANSITION	Cleavage of Arg(561)-Val(562) in plasminogen (Pg) generates plasmin (Pm) through a classical activation mechanism triggered by an insertion of the new amino terminus into a binding pocket in the Pg catalytic domain. Streptokinase (SK) circumvents this process and activates Pg through a unique nonproteolytic mechanism postulated to be initiated by the intrusion of IIe(1) of SK in place of Val(562). This hypothesis was evaluated in equilibrium binding and kinetic studies of Pg activation with an SK mutant lacking IIe(1) (SK2-414). SK2-414 retained the affinity of native SK for fluorescein-labeled [Lys]Pg and [Lys]Pm but induced no detectable conformational activation of Pg. The activity of SK2-414 was partially restored by the peptides SK1-2, Sg(1-5), SK1-10, and SK1-15, whereas Pg(562-569) peptides were much less effective. Active site-specific fluorescence labeling demonstrated directly that the active catalytic site was formed on the Pg zymogen by the combination of SK1-10 and Sk(2-414), whereas sequence-scrambled SK1-10 was inactive. The characterization of SK1-10 containing single Ala substitutions demonstrated the sequence specificity of the interaction. SK1-10 did not restore activity to the further truncated mutant SK55-414, which was correlated with the loss of binding affinity of SK55-414 for labeled [Lys]Pm but not for [Lys]Pg. The studies support a mechanism for conformational activation in which the insertion of II1 of SK into the Pg amino-terminal binding cleft occurs through sequence-specific interactions of the first 10 SK residues. This event and the preferentially higher affinity of SK2-414 for the activated proteinase domain of Pm are thought to function cooperatively to trigger the conformational change and stabilize the active zymogen conformation.	Vanderbilt Univ, Sch Med, Dept Pathol, Med Ctr N C3321A, Nashville, TN 37232 USA; Vet Affairs Hosp, Med Serv, Ann Arbor, MI 48109 USA	Vanderbilt University	Bock, PE (corresponding author), Vanderbilt Univ, Sch Med, Dept Pathol, Med Ctr N C3321A, Nashville, TN 37232 USA.				NHLBI NIH HHS [HL-56181, HL-10082] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056181, F32HL010082] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALKJAERSIG N, 1959, J BIOL CHEM, V234, P832; BOCK PE, 1993, METHOD ENZYMOL, V222, P478; Bock PE, 1996, J BIOL CHEM, V271, P1072, DOI 10.1074/jbc.271.2.1072; BODE W, 1976, FEBS LETT, V68, P231, DOI 10.1016/0014-5793(76)80443-7; BODE W, 1979, J MOL BIOL, V127, P357, DOI 10.1016/0022-2836(79)90227-4; Boxrud PD, 2000, J BIOL CHEM, V275, P14579, DOI 10.1074/jbc.275.19.14579; Boxrud PD, 2000, BIOCHEMISTRY-US, V39, P13974, DOI 10.1021/bi000594i; CASTELLINO FJ, 1981, METHOD ENZYMOL, V80, P365; DAVIDSON DJ, 1990, BIOCHEMISTRY-US, V29, P3585, DOI 10.1021/bi00466a023; Fay WP, 1998, THROMB HAEMOSTASIS, V79, P985; FREER ST, 1970, BIOCHEMISTRY-US, V9, P1997, DOI 10.1021/bi00811a022; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; JACKSON KW, 1982, BIOCHEMISTRY-US, V21, P6620, DOI 10.1021/bi00269a001; KERR MA, 1976, BIOCHEMISTRY-US, V15, P5566, DOI 10.1021/bi00670a022; Khan AR, 1998, PROTEIN SCI, V7, P815; KOSOW DP, 1975, BIOCHEMISTRY-US, V20, P4459; MCCLINTOCK DK, 1971, BIOCHEM BIOPH RES CO, V43, P694, DOI 10.1016/0006-291X(71)90670-X; NIEUWENHUIZEN W, 1989, THROMB HAEMOSTASIS, V61, P208; Peisach E, 1999, BIOCHEMISTRY-US, V38, P11180, DOI 10.1021/bi991130r; PONTING CP, 1992, BLOOD COAGUL FIBRIN, V3, P605, DOI 10.1097/00001721-199210000-00012; REDDY KNN, 1972, J BIOL CHEM, V247, P1683; REED GL, 1995, BIOCHEMISTRY-US, V34, P10266, DOI 10.1021/bi00032a021; TAYLOR FB, 1968, BIOCHEMISTRY-US, V7, P232, DOI 10.1021/bi00841a028; Wang SG, 1999, BIOCHEMISTRY-US, V38, P5232, DOI 10.1021/bi981915h; Wang SG, 2000, EUR J BIOCHEM, V267, P3994, DOI 10.1046/j.1432-1327.2000.01434.x; Wang XQ, 1998, SCIENCE, V281, P1662, DOI 10.1126/science.281.5383.1662; Wang XQ, 2000, J MOL BIOL, V295, P903, DOI 10.1006/jmbi.1999.3397; WOHL RC, 1980, J BIOL CHEM, V255, P2005; YOUNG KC, 1995, J BIOL CHEM, V270, P29601, DOI 10.1074/jbc.270.49.29601	30	38	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26084	26089		10.1074/jbc.M101966200	http://dx.doi.org/10.1074/jbc.M101966200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11369771	hybrid			2022-12-25	WOS:000169823300061
J	Beck, MA; Nelson, HK; Shi, Q; Van Dael, P; Schiffrin, EJ; Blum, S; Barclay, D; Levander, OA				Beck, MA; Nelson, HK; Shi, Q; Van Dael, P; Schiffrin, EJ; Blum, S; Barclay, D; Levander, OA			Selenium deficiency increases the pathology of an influenza virus infection	FASEB JOURNAL			English	Article						oxidative stress; cytokine; chemokine	NF-KAPPA-B; T-CELLS; COXSACKIEVIRUS B3; HUMAN ENTEROVIRUS; GENE-EXPRESSION; VIRAL-INFECTION; KESHAN-DISEASE; A VIRUS; MICE; THIOREDOXIN	Selenium (Se) deficiency has previously been shown to induce myocarditis in mice infected with a benign strain of coxsackievirus. To determine if Se deficiency would also intensify an infection with influenza virus, Se-deficient and Se-adequate mice were infected with a mild strain of influenza, influenza A/Bangkok/1/79 (H3N2). Infected Se-deficient mice developed much more severe interstitial pneumonitis than did Se-adequate mice. This increase in pathology was associated with significant alterations in mRNA levels for cytokines and chemokines involved in pro-inflammatory responses. These results demonstrate that adequate nutrition is required for protection against viral infection and suggest that nutritional deprivation may be one of many factors that increase the susceptibility of individuals to influenza infection.	Univ N Carolina, Dept Pediat, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Nutr, Chapel Hill, NC 27599 USA; Nestle Res Ctr, Dept Nutr, CH-1000 Lausanne, Switzerland; ARS, USDA, Beltsville Human Nutr Res Ctr, Beltsville, MD 20705 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Nestle SA; United States Department of Agriculture (USDA)	Beck, MA (corresponding author), Univ N Carolina, Dept Pediat, 535 Burnett Womack,CB 7220, Chapel Hill, NC 27599 USA.	melinda_beck@unc.edu						Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Allan CB, 1999, ANNU REV NUTR, V19, P1, DOI 10.1146/annurev.nutr.19.1.1; ALLEN W, 1990, J IMMUNOL, V144, P3980; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Baum MK, 1998, NUTR REV, V56, pS135; BECK MA, 1994, J INFECT DIS, V170, P351, DOI 10.1093/infdis/170.2.351; BECK MA, 1995, NAT MED, V1, P433, DOI 10.1038/nm0595-433; BECK MA, 1994, J MED VIROL, V43, P166, DOI 10.1002/jmv.1890430213; Bender B S, 1992, Semin Respir Infect, V7, P38; BENDER BS, 1992, J EXP MED, V175, P1143, DOI 10.1084/jem.175.4.1143; Bernstein E, 1999, VACCINE, V17, P82, DOI 10.1016/S0264-410X(98)00117-0; Burk RF, 1999, BIOESSAYS, V21, P231, DOI 10.1002/(SICI)1521-1878(199903)21:3<231::AID-BIES7>3.3.CO;2-4; Campa A, 1999, J ACQ IMMUN DEF SYND, V20, P508, DOI 10.1097/00042560-199904150-00015; *CDCP, 2000, MMWR-MORBID MORTAL W, V49, P113; Chakraborti S, 1998, CELL SIGNAL, V10, P675, DOI 10.1016/S0898-6568(98)00014-X; CLEMENTS ML, 1986, J CLIN MICROBIOL, V24, P157, DOI 10.1128/JCM.24.1.157-160.1986; COOK DN, 1995, SCIENCE, V269, P1583, DOI 10.1126/science.7667639; COUCH RB, 1983, ANNU REV MICROBIOL, V37, P529, DOI 10.1146/annurev.mi.37.100183.002525; DAS KC, 2000, J BIOL CHEM     1103; DHUR A, 1990, COMP BIOCHEM PHYS C, V96, P271, DOI 10.1016/0742-8413(90)90007-V; DOWDLE WR, 1975, INFLUENZA VIRUSES IN, P243; EICHELBERGER M, 1991, J EXP MED, V174, P875, DOI 10.1084/jem.174.4.875; EICHELBERGER MC, 1991, J GEN VIROL, V72, P1695, DOI 10.1099/0022-1317-72-7-1695; Flory E, 2000, J BIOL CHEM, V275, P8307, DOI 10.1074/jbc.275.12.8307; GU BQ, 1983, CHINESE MED J-PEKING, V96, P251; Harbige Laurence S., 1996, Nutrition and Health (Bicester), V10, P285; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; HENNET T, 1992, J IMMUNOL, V149, P932; Hill KE, 1997, BIOCHEM BIOPH RES CO, V234, P293, DOI 10.1006/bbrc.1997.6618; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1979, J BIOL CHEM, V254, P9113; Knobil K, 1998, AM J PHYSIOL-LUNG C, V274, pL134, DOI 10.1152/ajplung.1998.274.1.L134; Kukreja Rajni, 1998, Indian Journal of Experimental Biology, V36, P203; Levander OA, 1997, BIOL TRACE ELEM RES, V56, P5, DOI 10.1007/BF02778980; LIGHTMAN S, 1987, IMMUNOLOGY, V62, P139; Matsukura S, 1998, AM J RESP CELL MOL, V18, P255, DOI 10.1165/ajrcmb.18.2.2822; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; PAHL HL, 1995, J VIROL, V69, P1480, DOI 10.1128/JVI.69.3.1480-1484.1995; Palmer DF, 1975, IMMUNOLOGY SERIES US; Schwarz KB, 1996, FREE RADICAL BIO MED, V21, P641, DOI 10.1016/0891-5849(96)00131-1; SCRIMSHAW N S, 1975, Progress in Food and Nutrition Science, V1, P393; SCRIMSHAW NS, 1968, WHO MONOGRAPH SERIES, V57; Stadtman TC, 2000, ANN NY ACAD SCI, V899, P399, DOI 10.1111/j.1749-6632.2000.tb06203.x; VanDael P, 1995, ATOM SPECTROSC, V16, P251; Ward AC, 1997, VIRUS GENES, V14, P187, DOI 10.1023/A:1007979709403; Ward SG, 1998, BIOCHEM J, V333, P457, DOI 10.1042/bj3330457	49	206	212	2	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR 27	2001	15	6					1481	+		10.1096/fj.00-0721fje	http://dx.doi.org/10.1096/fj.00-0721fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387264				2022-12-25	WOS:000173705800003
J	Tomasetti, M; Alleva, R; Collins, AR				Tomasetti, M; Alleva, R; Collins, AR			In vivo supplementation with coenzyme Q(10) enhances the recovery of human lymphocytes from oxidative DNA damage	FASEB JOURNAL			English	Article						ubiquinone-10; ubiquinol-10; DNA oxidation; DNA recovery; DNA repair enzymes; comet assay	NF-KAPPA-B; DEGENERATIVE DISEASES; OXYGEN RADICALS; ANTIOXIDANTS; AP-1; CARCINOGENESIS; THIOREDOXIN; CONSUMPTION; ACTIVATION	We investigated the effect of in vitro and in vivo CoQ(10) supplementation on the recovery of lymphocytes from oxidative DNA damage. Furthermore, we investigated whether CoQ(10) supplementation modulates the activity of DNA repair enzymes by using cellular extracts from lymphocytes. Exposure of lymphocytes to oxidizing agents leads to an increase of DNA strand breaks, oxidized purines, and pyrimidines. Enrichment of cells with CoQ(10) prevents DNA strand-break formation and affects the kinetics of repair, which occurs faster in enriched than in native lymphocytes. In contrast, CoQ(10) supplementation neither prevents endogenous formation of oxidized bases nor affects their repair. DNA repair enzyme activity is enhanced by in vivo CoQ(10) supplementation. Changes in the redox state of several transcriptional factors have been proposed as mechanisms regulating cell proliferation and apoptosis. Because CoQ(10) is mainly present as ubiquinol-10, both in plasma and lymphocytes, it can feasibly modulate the intracellular redox potential involved in the regulation of gene expression. The redox mechanism implicated in the enzyme transactivation could explain the property of CoQ(10) to enhance the DNA repair activity and protect DNA from oxidative damage.	Rowett Res Inst, Aberdeen AB21 9SB, Scotland	University of Aberdeen	Tomasetti, M (corresponding author), Corso Mazzini, I-63039 San Benedetto Del Tr Asc, Italy.	ralleva@jth.it		Alleva, Renata/0000-0001-7327-3833				Alleva R, 1997, MOL ASPECTS MED, V18, pS105; AMES BN, 1993, ENVIRON HEALTH PERSP, V101, P35, DOI 10.2307/3431840; AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; COLLINS AR, 1993, CARCINOGENESIS, V14, P1733, DOI 10.1093/carcin/14.9.1733; Collins AR, 1997, ENVIRON MOL MUTAGEN, V29, P152; Duthie SJ, 1996, CANCER RES, V56, P1291; EPE B, 1988, CHEM-BIOL INTERACT, V67, P149, DOI 10.1016/0009-2797(88)90094-4; EPE B, 1995, REV PHYSL BIOCH PHAR, V127, P223; Fillion L, 1998, ACTA BIOCHIM POL, V45, P183, DOI 10.18388/abp.1998_4300; HALLIWELL B, 1994, NUTR REV, V52, P253; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; JEMOLARZEMINSKA M, 1996, CHEM PHYS LIPIDS, V79, P55; Kim GM, 1996, INT J HIGH SPEED COM, V8, P115, DOI 10.1142/S0129053396000094; Lee HS, 1998, FREE RADICAL BIO MED, V24, P1193, DOI 10.1016/S0891-5849(97)00427-9; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MOHR D, 1992, BIOCHIM BIOPHYS ACTA, V26, P347; Muller-Scharer H., 1997, Integrated Pest Management Reviews, V2, P45, DOI 10.1023/A:1018428412868; Navarro F, 1999, BIOFACTORS, V9, P163, DOI 10.1002/biof.5520090211; NEGRI E, 1991, INT J CANCER, V48, P350, DOI 10.1002/ijc.2910480307; PAHL HL, 1994, BIOESSAYS, V16, P497, DOI 10.1002/bies.950160709; Pool-Zobel BL, 1998, CANCER EPIDEM BIOMAR, V7, P891; Poulsen HE, 1998, EUR J CANCER PREV, V7, P9; POULSEN HE, 1996, J MOL MED, V74, P297; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; STOCKER R, 1991, P NATL ACAD SCI USA, V88, P1646, DOI 10.1073/pnas.88.5.1646; Tomasetti M, 1999, FREE RADICAL BIO MED, V27, P1027, DOI 10.1016/S0891-5849(99)00132-X; VERHAGEN H, 1995, CARCINOGENESIS, V16, P969, DOI 10.1093/carcin/16.4.969; WATTENBERG LW, 1992, CANCER RES, V52, pS2085; Weber C, 1997, MOL ASPECTS MED, V18, pS251; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x	31	108	113	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 27	2001	15	6					1425	+		10.1096/fj.00-0694fje	http://dx.doi.org/10.1096/fj.00-0694fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387245				2022-12-25	WOS:000173705800023
J	Liu, Y; Ranish, JA; Aebersold, R; Hahn, S				Liu, Y; Ranish, JA; Aebersold, R; Hahn, S			Yeast nuclear extract contains two major forms of RNA polymerase II mediator complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION; SACCHAROMYCES-CEREVISIAE; HOLOENZYME; PROTEINS; REQUIREMENT; REGULATORS; IDENTIFICATION; COACTIVATORS; COMPONENTS; DATABASE	The yeast Mediator complex is required for transcription by RNA polymerase II (pol II) in vivo and in vitro. This complex of over 20 polypeptides associates with pol II and is recruited to transcription complexes at promoters. Previous isolations of yeast Mediator-containing complexes in different laboratories have identified several distinct complexes. To identify the major forms of Mediator in yeast, Mediator was isolated from nuclear extracts using a two-step chromatographic procedure, avoiding ion exchange chromatography and high salt conditions to prevent dissociation of subunits during purification. Components of the Mediator complexes were identified by mass spectrometry and Western analysis. The major form of Mediator, termed pol II Med, contained pol II and Mediator, including the Srb8-11 module. A second lower molecular size complex was also identified, termed Mediator core (Medc), which lacked pol II, Srb8-11, Rox3, Nut1, and the Rgr1 module. Both of these complexes were active in transcription in vitro, although the Medc complex had significantly lower activity and could compete with the activity of the pol II Med complex in vitro.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA; Howard Hughes Med Inst, Seattle, WA 98109 USA; Inst Syst Biol, Seattle, WA 98105 USA	Fred Hutchinson Cancer Center; Howard Hughes Medical Institute; Institute for Systems Biology (ISB)	Hahn, S (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, 1100 Fairview Ave N,Mailstop A1-162,POB 19024, Seattle, WA 98109 USA.			Hahn, Steven/0000-0001-7240-2533				Akoulitchev S, 2000, NATURE, V407, P102, DOI 10.1038/35024111; Albright SR, 2000, GENE, V242, P1, DOI 10.1016/S0378-1119(99)00495-3; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Chang MP, 1999, MOL CELL BIOL, V19, P1056; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; GELBART M, 2001, IN PRESS MOL CELL BI; Gustafsson CM, 1998, J BIOL CHEM, V273, P30851, DOI 10.1074/jbc.273.47.30851; Hahn S, 1998, CELL, V95, P579, DOI 10.1016/S0092-8674(00)81625-6; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; Han SJ, 1999, MOL CELL BIOL, V19, P979; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; Koh SS, 1998, MOL CELL, V1, P895, DOI 10.1016/S1097-2765(00)80088-X; Koleske AJ, 1996, METHOD ENZYMOL, V273, P176; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; Lee DK, 1999, GENE DEV, V13, P2934, DOI 10.1101/gad.13.22.2934; Lee TI, 2000, ANNU REV GENET, V34, P77, DOI 10.1146/annurev.genet.34.1.77; Lee TI, 1998, GENE DEV, V12, P1398, DOI 10.1101/gad.12.10.1398; Lee YC, 1999, MOL CELL BIOL, V19, P2967; Lee YC, 1998, MOL CELL BIOL, V18, P5364, DOI 10.1128/MCB.18.9.5364; Li Y, 1996, METHOD ENZYMOL, V273, P172; LI Y, 1995, P NATL ACAD SCI USA, V92, P10864, DOI 10.1073/pnas.92.24.10864; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; Malik S, 2000, TRENDS BIOCHEM SCI, V25, P277, DOI 10.1016/S0968-0004(00)01596-6; McCormack AL, 1997, ANAL CHEM, V69, P767, DOI 10.1021/ac960799q; McNeil JB, 1998, GENE DEV, V12, P2510, DOI 10.1101/gad.12.16.2510; Myer VE, 1998, J BIOL CHEM, V273, P27757, DOI 10.1074/jbc.273.43.27757; Myers LC, 1997, METHODS, V12, P212, DOI 10.1006/meth.1997.0473; Myers LC, 1999, P NATL ACAD SCI USA, V96, P67, DOI 10.1073/pnas.96.1.67; Myers LC, 1998, GENE DEV, V12, P45, DOI 10.1101/gad.12.1.45; Myers LC, 2000, ANNU REV BIOCHEM, V69, P729, DOI 10.1146/annurev.biochem.69.1.729; RANISH JA, 1991, J BIOL CHEM, V266, P19320; Ranish JA, 1999, GENE DEV, V13, P49, DOI 10.1101/gad.13.1.49; Sun XQ, 1998, MOL CELL, V2, P213, DOI 10.1016/S1097-2765(00)80131-8; THOMPSON CM, 1995, P NATL ACAD SCI USA, V92, P4587, DOI 10.1073/pnas.92.10.4587; THOMPSON CM, 1993, CELL, V73, P1367; Wilson CJ, 1996, CELL, V84, P235, DOI 10.1016/S0092-8674(00)80978-2; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Yudkovsky N, 2000, NATURE, V408, P225, DOI 10.1038/35041603	43	83	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7169	7175		10.1074/jbc.M009586200	http://dx.doi.org/10.1074/jbc.M009586200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11383511	hybrid			2022-12-25	WOS:000167442900045
J	Hille, R; Anderson, RF				Hille, R; Anderson, RF			Coupled Electron/Proton transfer in complex flavoproteins - Solvent kinetic isotope effect studies of electron transfer in xanthine oxidase and trimethylamine dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CENTERS; SITE-DIRECTED MUTAGENESIS; MOLYBDENUM ENZYMES; CRYSTAL-STRUCTURE; REDUCTION POTENTIALS; RATE CONSTANTS; MECHANISM; FLAVIN; OXIDATION; OXIDOREDUCTASE	A solvent kinetic isotope effect study of electron transfer in two complex flavoproteins, xanthine oxidase and trimethylamine dehydrogenase, has been undertaken. With xanthine oxidase, electron transfer from the molybdenum center to the proximal iron-sulfur center of the enzyme occurs with a modest solvent kinetic isotope effect of 2.2, indicating that electron transfer out of the molybdenum center is at least partially coupled to deprotonation of the Mo(V) donor. A Marcus-type analysis yields a decay factor, beta, of 1.4 Angstrom (-1), indicating that, although the pyranopterin cofactor of the molybdenum center forms a nearly contiguous covalent bridge from the molybdenum atom to the proximal iron-sulfur center of the enzyme, it affords no exceptionally effective mode of electron transfer between the two centers. For trimethylamine dehydrogenase, rates of electron equilibration between the flavin and iron-sulfur center of the one-electron reduced enzyme have been determined, complementing previous studies of electron transfer in the two-electron reduced form. The results indicate a substantial solvent kinetic isotope effect of 10 +/- 4, consistent with a model for electron transfer that involves discrete protonation/deprotonation and electron transfer steps. This contrasts to the behavior seen with xanthine oxidase, and the basis for this difference is discussed in the context of the structures for the two proteins and the ionization properties of their flavin sites. With xanthine oxidase, a rationale is presented as to why it is desirable in certain cases that the physical layout of redox-active sites not be uniformly increasing in reduction potential in the direction of physiological electron transfer.	Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; Univ Auckland, Dept Chem, Auckland, New Zealand	University System of Ohio; Ohio State University; University of Auckland	Hille, R (corresponding author), Ohio State Univ, Dept Mol & Cellular Biochem, 333 Hamilton Hall,1645 Neil Ave, Columbus, OH 43210 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059953, R01GM058481] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM58481, GM59953] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson RF, 2000, J BIOL CHEM, V275, P30781, DOI 10.1074/jbc.M001256200; ANDERSON RF, 1986, J BIOL CHEM, V261, P5870; ANDERSON RF, 1984, J CHEM SOC FARAD T 1, V80, P2693, DOI 10.1039/f19848002693; ANDERSON RF, 1987, FLAVINS FLAVOPROTEIN, P279; BORDAS J, 1980, BIOCHEM J, V191, P499, DOI 10.1042/bj1910499; BRAY RC, 1969, BIOCHEM J, V114, P725, DOI 10.1042/bj1140725; Caldeira J, 2000, BIOCHEMISTRY-US, V39, P2700, DOI 10.1021/bi9921485; CAMMACK R, 1976, BIOCHEM J, V157, P469, DOI 10.1042/bj1570469; CRAMER SP, 1985, J AM CHEM SOC, V107, P8164, DOI 10.1021/ja00312a059; CRAMMER SP, 1981, J AM CHEM SOC, V102, P7721; Cukier RI, 1996, J PHYS CHEM-US, V100, P15428, DOI 10.1021/jp961025g; Cukier RI, 1998, ANNU REV PHYS CHEM, V49, P337, DOI 10.1146/annurev.physchem.49.1.337; Dobbek H, 1999, P NATL ACAD SCI USA, V96, P8884, DOI 10.1073/pnas.96.16.8884; Enroth C, 2000, P NATL ACAD SCI USA, V97, P10723, DOI 10.1073/pnas.97.20.10723; Gremer L, 2000, J BIOL CHEM, V275, P1864, DOI 10.1074/jbc.275.3.1864; GUTFREUND H, 1977, ENZYMES PHYSICAL PRI, P173; HILLE R, 1991, J BIOL CHEM, V266, P5608; HILLE R, 1985, J BIOL CHEM, V260, P569; Hille R, 1996, CHEM REV, V96, P2757, DOI 10.1021/cr950061t; HILLE R, 1991, BIOCHEMISTRY-US, V30, P8522, DOI 10.1021/bi00099a004; HILLE R, 1986, J BIOL CHEM, V261, P1241; HILLE R, 1981, J BIOL CHEM, V257, P8933; Huber R, 1996, P NATL ACAD SCI USA, V93, P8846, DOI 10.1073/pnas.93.17.8846; Ilich P, 1999, J PHYS CHEM B, V103, P5406, DOI 10.1021/jp9904825; Iwasaki T, 2000, J BIOCHEM, V127, P771, DOI 10.1093/oxfordjournals.jbchem.a022669; Jones RM, 1999, INORG CHEM, V38, P4963, DOI 10.1021/ic990154j; KASPRZAK AA, 1983, BIOCHEM J, V211, P15870; KIM JH, 1993, J BIOL CHEM, V268, P44; LIM LW, 1986, J BIOL CHEM, V261, P5140; LOWE DJ, 1978, BIOCHEM J, V169, P471, DOI 10.1042/bj1690471; LOWE DJ, 1972, BIOCHEM J, V130, P239, DOI 10.1042/bj1300239; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MARCUS RA, 1965, J CHEM PHYS, V43, P679, DOI 10.1063/1.1696792; MASSEY V, 1969, J BIOL CHEM, V244, P1682; Moser C C, 2000, Subcell Biochem, V35, P1; MOSER CC, 1995, J BIOENERG BIOMEMBR, V27, P263, DOI 10.1007/BF02110096; MULAZZANI QG, 1986, J PHYS CHEM-US, V90, P5347, DOI 10.1021/j100412a090; OLSON JS, 1974, J BIOL CHEM, V249, P4363; PACE CP, 1991, ARCH BIOCHEM BIOPHYS, V287, P97, DOI 10.1016/0003-9861(91)90393-W; PALMER G, 1969, J BIOL CHEM, V244, P2614; Pershad HR, 1999, BIOCHEMISTRY-US, V38, P8992, DOI 10.1021/bi990108v; PORRAS AG, 1982, J BIOL CHEM, V257, P1617; ROHLFS RJ, 1995, J BIOL CHEM, V270, P22196, DOI 10.1074/jbc.270.38.22196; ROHLFS RJ, 1991, J BIOL CHEM, V266, P15244; ROMAO MJ, 1995, SCIENCE, V270, P1170, DOI 10.1126/science.270.5239.1170; Rousset M, 1998, P NATL ACAD SCI USA, V95, P11625, DOI 10.1073/pnas.95.20.11625; SCHULER RH, 1980, J PHYS CHEM-US, V84, P2088, DOI 10.1021/j100453a020; STEENKAMP DJ, 1976, BIOCHIM BIOPHYS ACTA, V429, P705, DOI 10.1016/0005-2744(76)90319-3; Stiefel E. I., 1977, PROG INORG CHEM, V21, P1; STIEFEL EI, 1973, P NATL ACAD SCI USA, V70, P988, DOI 10.1073/pnas.70.4.988; Thauer RK, 1996, CHEM REV, V96, P3031, DOI 10.1021/cr9500601; VOLBEDA A, 1995, NATURE, V373, P580, DOI 10.1038/373580a0; Wilson EK, 1997, BIOCHEMISTRY-US, V36, P41, DOI 10.1021/bi961224q	53	28	29	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31193	31201		10.1074/jbc.M100673200	http://dx.doi.org/10.1074/jbc.M100673200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11395485	hybrid			2022-12-25	WOS:000170472900080
J	Wright, SK; Viola, RE				Wright, SK; Viola, RE			Alteration of the specificity of malate dehydrogenase by chemical modulation of an active site arginine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SUBSTRATE-SPECIFICITY; LACTATE-DEHYDROGENASE; AMINO-ACIDS; QUANTITATION; RESOLUTION; PROTEINS; COMPLEX; MODEL	Malate dehydrogenase from Escherichia coli is highly specific for the oxidation of malate to oxaloacetate. The technique of site-specific modulation has been used to alter the substrate binding site of this enzyme. Introduction of a cysteine in place of the active site binding residue arginine 153 results in a mutant enzyme with diminished catalytic activity, but with K-m values for malate and oxaloacetate that are surprisingly unaffected. Reaction of this introduced cysteine with a series of amino acid analog reagents leads to the incorporation of a range of functional groups at the active site of malate dehydrogenase. The introduction of a positively charged group such as an amine or an amidine at this position results in improved affinity for several inhibitors over that observed with the native enzyme. However, the recovery of catalytic activity is less dramatic, with less than one third of the native activity achieved with the optimal reagents. These modified enzymes do have altered substrate specificity, with a-ketoglutarate and hydroxypyruvate no longer functioning as alternative substrates.	Univ Toledo, Dept Chem, Toledo, OH 43606 USA	University System of Ohio; University of Toledo	Viola, RE (corresponding author), Univ Toledo, Dept Chem, 2801 W Bancroft St, Toledo, OH 43606 USA.		Viola, Ronald/C-5904-2011					Bell JK, 2001, J BIOL CHEM, V276, P31156, DOI 10.1074/jbc.M100902200; BOERNKE WE, 1995, ARCH BIOCHEM BIOPHYS, V322, P43, DOI 10.1006/abbi.1995.1434; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; GOWARD CR, 1994, PROTEIN SCI, V3, P1883, DOI 10.1002/pro.5560031027; GRAU UM, 1981, J MOL BIOL, V151, P289, DOI 10.1016/0022-2836(81)90516-7; HALL MD, 1991, J MOL BIOL, V220, P551, DOI 10.1016/0022-2836(91)90099-R; HALL MD, 1992, J MOL BIOL, V226, P867, DOI 10.1016/0022-2836(92)90637-Y; JONES DH, 1993, PCR PROTOCOLS CURREN, P269; NICHOLLS DJ, 1992, BIOCHEM BIOPH RES CO, V189, P1057, DOI 10.1016/0006-291X(92)92311-K; Schindler JF, 1996, J PROTEIN CHEM, V15, P737, DOI 10.1007/BF01887147; TARRAGONAFIOL A, 1993, PROTEIN ENG, V6, P901, DOI 10.1093/protein/6.8.901; WAKO H, 1994, J MOL BIOL, V238, P682, DOI 10.1006/jmbi.1994.1329; WILKS HM, 1988, SCIENCE, V242, P1541, DOI 10.1126/science.3201242; Wright SK, 1998, ANAL BIOCHEM, V265, P8, DOI 10.1006/abio.1998.2858; WRIGHT SK, 1995, ARCH BIOCHEM BIOPHYS, V321, P289, DOI 10.1006/abbi.1995.1397; Wright SK, 2000, J BIOL CHEM, V275, P31689, DOI 10.1074/jbc.M003652200	18	16	19	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31151	31155		10.1074/jbc.M100892200	http://dx.doi.org/10.1074/jbc.M100892200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11389140	hybrid			2022-12-25	WOS:000170472900074
J	Craggs, G; Finan, PM; Lawson, D; Wingfield, J; Perera, T; Gadher, S; Totty, NF; Kellie, S				Craggs, G; Finan, PM; Lawson, D; Wingfield, J; Perera, T; Gadher, S; Totty, NF; Kellie, S			A nuclear SH3 domain-binding protein that colocalizes with mRNA splicing factors and intermediate filament-containing perinuclear networks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAINS; PHAGOCYTE NADPH OXIDASE; PROLINE-RICH PEPTIDES; TYROSINE KINASES; SIGNALING MOLECULES; CRYSTAL-STRUCTURES; SRC; COMPONENTS; IDENTIFICATION; TRANSCRIPTION	A protein (SNP70) has been isolated that binds to the Src homology domain 3 of p47(phox), p85 alpha, and c-src. Cloning and sequencing of the polypeptide revealed it to be a 70-kDa protein that has a number of potential domains, including Src homology 3 binding motifs and several nuclear localization signals. Immunofluorescence using anti-peptide antibodies revealed SNP70 to be primarily concentrated in the nucleus but excluded from nucleoli, in interphase cells. However, it was distributed throughout the cytoplasm in dividing cells. Extraction and subfractionation experiments indicated that SNP70 did not bind directly to DNA but did bind to poly(G)-rich oligonucleotides and was resistant to extraction with nonionic detergents but was solubilized by treatment with RNase,. high salt, or ammonium sulfate. Double-immunofluorescence experiments showed that SNP70 co-localized with two pre-mRNA splicing factors SC35 and U2B " within the nucleus. A population of SNP70 was found outside the nucleus, and double-immunofluorescence and immunoelectron microscopy demonstrated that it associated with vimentin-containing intermediate filaments, particularly those surrounding the nucleus. The data suggest that SNP70 associates with nuclear or perinuclear filaments and may play a role in the regulation of pre-mRNA processing.	Yamanouchi Res Inst, Oxford OX4 4XS, England; UCL, Sch Med, Dept Mol Pathol, London W1, England; UCL, Ludwig Inst Canc Res, London W1P 8BT, England	University of London; University College London; UCL Medical School; Ludwig Institute for Cancer Research; University of London; University College London	Kellie, S (corresponding author), Yamanouchi Res Inst, Littlemore Pk, Oxford OX4 4XS, England.	skellie@yam-res.co.uk	Kellie, Stuart/A-6036-2010; Wingfield, Jonathan/AAA-2246-2020	Kellie, Stuart/0000-0002-8163-1474				BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; Bassell G, 1997, CURR OPIN CELL BIOL, V9, P109, DOI 10.1016/S0955-0674(97)80159-7; BOOKER GW, 1993, CELL, V73, P813, DOI 10.1016/0092-8674(93)90259-S; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Erpel T, 1996, J BIOL CHEM, V271, P16807, DOI 10.1074/jbc.271.28.16807; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FINAN P, 1994, J BIOL CHEM, V269, P13752; Finan P, 1996, J MOL BIOL, V261, P173, DOI 10.1006/jmbi.1996.0450; Finan PM, 1996, FEBS LETT, V389, P141, DOI 10.1016/0014-5793(96)00552-2; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HABETS WJ, 1989, J IMMUNOL, V143, P2560; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HE DC, 1990, J CELL BIOL, V110, P569, DOI 10.1083/jcb.110.3.569; HOBERT O, 1994, J BIOL CHEM, V269, P20225; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KOHDA D, 1993, CELL, V72, P953, DOI 10.1016/0092-8674(93)90583-C; Komuro A, 1999, J BIOL CHEM, V274, P36513, DOI 10.1074/jbc.274.51.36513; KOYAMA S, 1993, CELL, V72, P945, DOI 10.1016/0092-8674(93)90582-B; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; Lawe DC, 1997, ONCOGENE, V14, P223, DOI 10.1038/sj.onc.1200821; LAWSON D, 1983, J CELL BIOL, V97, P1891, DOI 10.1083/jcb.97.6.1891; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; MCPHAIL LC, 1994, J EXP MED, V180, P2011, DOI 10.1084/jem.180.6.2011; Misteli T, 2000, J CELL SCI, V113, P1841; Misteli T, 1998, CURR OPIN CELL BIOL, V10, P323, DOI 10.1016/S0955-0674(98)80007-0; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; Neubauer G, 1998, NAT GENET, V20, P46, DOI 10.1038/1700; NOBLE MEM, 1993, EMBO J, V12, P2617, DOI 10.1002/j.1460-2075.1993.tb05922.x; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PENMAN S, 1995, P NATL ACAD SCI USA, V92, P5251, DOI 10.1073/pnas.92.12.5251; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; Stein GS, 2000, J CELL SCI, V113, P2527; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; TOTTY NF, 1992, PROTEIN SCI, V1, P1215, DOI 10.1002/pro.5560010914; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; Wilson L, 1997, INFLAMM RES, V46, P265, DOI 10.1007/s000110050185; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	51	18	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30552	30560		10.1074/jbc.M103142200	http://dx.doi.org/10.1074/jbc.M103142200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11375989	hybrid			2022-12-25	WOS:000170558000124
J	Eubanks, S; Nguyen, TL; Deeb, R; Villafania, A; Alfadhli, A; Breslow, E				Eubanks, S; Nguyen, TL; Deeb, R; Villafania, A; Alfadhli, A; Breslow, E			Effects of diabetes insipidus mutations on neurophysin folding and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTANT VASOPRESSIN PRECURSORS; ENDOPLASMIC-RETICULUM; ARGININE-VASOPRESSIN; PEPTIDE INTERACTIONS; CRYSTAL-STRUCTURE; HORMONE-BINDING; WILD-TYPE; BOVINE; DIMERIZATION; IDENTIFICATION	Mechanisms underlying the pathogenicity of diabetes insipidus mutations were probed by studying their effects on the properties of bovine oxytocin-related neurophysin. The mutations G17V, Delta E47, G57S, G57R, and C67STOP were each shown to have structural consequences that would diminish the conformational stability and folding efficiency of the precursors in which they were incorporated, and factors contributing to the origins of these property changes were identified. Effects of the mutations on dimerization of the folded proteins were similarly analyzed. The projected relative impact of the above mutations on precursor folding properties qualitatively parallels the reported relative severity of their effects on the biological handling of the human vasopressin precursor, but quantitative differences between thermodynamic effects and biological impact are noted and explored. The sole mutation for which no clear thermodynamic basis was found for its pathogenicity was 87STOP, suggesting that the region of the precursor deleted by this mutation plays a role in targeting independent from effects on folding, or participates in stabilizing interactions unique to the human vasopressin precursor.	Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA; Portland State Univ, Dept Chem, Portland, OR 97207 USA	Cornell University; Portland State University	Breslow, E (corresponding author), Cornell Univ, Weill Med Coll, Dept Biochem, 1300 York Ave, New York, NY 10021 USA.	ebreslow@mail.med.cornell.edu			NIGMS NIH HHS [GM-17528] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDO S, 1987, J BIOL CHEM, V262, P12962; Arvan P, 1998, BIOCHEM J, V332, P593, DOI 10.1042/bj3320593; BAHNSEN U, 1992, EMBO J, V11, P19, DOI 10.1002/j.1460-2075.1992.tb05022.x; Beuret N, 1999, J BIOL CHEM, V274, P18965, DOI 10.1074/jbc.274.27.18965; BRESLOW E, 1977, BIOCHEMISTRY-US, V16, P3397, DOI 10.1021/bi00634a017; BRESLOW E, 1991, BIOCHEMISTRY-US, V30, P7990, DOI 10.1021/bi00246a017; BRESLOW E, 1971, J BIOL CHEM, V246, P5179; BRESLOW E, 1995, BIOCHEMISTRY-US, V34, P2137, DOI 10.1021/bi00007a006; BRESLOW E, 1993, REGUL PEPTIDES, V45, P15, DOI 10.1016/0167-0115(93)90175-8; BRESLOW E, 1990, ADV ENZYMOL RAMB, V63, P1; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; CHAUVET MT, 1983, P NATL ACAD SCI-BIOL, V80, P2839, DOI 10.1073/pnas.80.10.2839; CHEN LQ, 1991, P NATL ACAD SCI USA, V88, P4240, DOI 10.1073/pnas.88.10.4240; COLIGAN JE, 1995, CURRENT PROTOCOLS PR, V2; DEBREE FM, 1980, CELL MOL NEUROBIOL, V19, P3565; Deeb R, 1996, BIOCHEMISTRY-US, V35, P864, DOI 10.1021/bi951947u; Eubanks S, 1999, BIOCHEMISTRY-US, V38, P13530, DOI 10.1021/bi9912950; Eubanks S, 2000, BIOCHEMISTRY-US, V39, P8085, DOI 10.1021/bi0001527; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; HUANG HB, 1992, J BIOL CHEM, V267, P6750; HUANG HB, 1993, BIOCHEMISTRY-US, V32, P10743, DOI 10.1021/bi00091a027; ITO M, 1991, J CLIN INVEST, V87, P725, DOI 10.1172/JCI115052; Ito M, 1997, J CLIN INVEST, V99, P1897, DOI 10.1172/JCI119357; Ito M, 1999, J BIOL CHEM, V274, P9029, DOI 10.1074/jbc.274.13.9029; KANMERA T, 1985, J BIOL CHEM, V260, P8474; Kim JK, 1997, J AM SOC NEPHROL, V8, P1863; LAND H, 1982, NATURE, V295, P299, DOI 10.1038/295299a0; LAND H, 1983, NATURE, V302, P342, DOI 10.1038/302342a0; MENENDEZBOTET CJ, 1975, BIOCHEMISTRY-US, V14, P3825, DOI 10.1021/bi00688a015; NICOLAS P, 1980, BIOCHEMISTRY-US, V19, P3565, DOI 10.1021/bi00556a023; Nijenhuis M, 1999, J BIOL CHEM, V274, P21200, DOI 10.1074/jbc.274.30.21200; Nijenhuis M, 2000, MOL CELL ENDOCRINOL, V167, P55, DOI 10.1016/S0303-7207(00)00288-4; Olias G, 1996, DNA CELL BIOL, V15, P929, DOI 10.1089/dna.1996.15.929; PACE C N, 1975, Critical Reviews in Biochemistry, V3, P1, DOI 10.3109/10409237509102551; RABBANI LD, 1982, BIOCHEMISTRY-US, V21, P817, DOI 10.1021/bi00534a001; Rittig S, 1996, AM J HUM GENET, V58, P107; Rose JP, 1996, NAT STRUCT BIOL, V3, P163, DOI 10.1038/nsb0296-163; VIRMANISARDANA V, 1983, INT J PEPT PROT RES, V21, P182; Walther D, 1999, ACTA CRYSTALLOGR D, V55, P506, DOI 10.1107/S0907444998013353; Zheng CS, 1997, J PEPT RES, V50, P199	40	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29671	29680		10.1074/jbc.M103477200	http://dx.doi.org/10.1074/jbc.M103477200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11395505	hybrid			2022-12-25	WOS:000170558000012
J	Gupta, RA; Brockman, JA; Sarraf, P; Willson, TM; DuBois, RN				Gupta, RA; Brockman, JA; Sarraf, P; Willson, TM; DuBois, RN			Target genes of peroxisome proliferator-activated receptor gamma in colorectal cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE; GELATINASE-ASSOCIATED LIPOCALIN; IMMUNOGLOBULIN SUPERGENE FAMILY; HUMAN PROSTATE-CANCER; PPAR-GAMMA; CARCINOEMBRYONIC ANTIGEN; ORPHAN RECEPTORS; COLON-CANCER; REG PROTEIN; FATTY-ACIDS	Activation of the nuclear hormone peroxisome proliferator-activated receptor gamma (PPAR gamma) inhibits cell growth and promotes differentiation in a broad spectrum of epithelial derived tumor cell lines. Here we utilized microarray technology to identify PPAR gamma gene targets in intestinal epithelial cells. For each gene, the induction or repression was seen with two structurally distinct PPAR gamma agonists, and the change in expression could be blocked by co-treatment with a specific PPAR gamma antagonist. A majority of the genes could be regulated independently by a retinoid X receptor specific agonist. Genes implicated in lipid transport or storage (adipophilin and liver fatty acid-binding protein) were also activated by agonists of PPAR subtypes alpha and/or delta. In contrast, PPAR gamma -selective targets included genes linked to growth regulatory pathways (regenerating gene IA), colon epithelial cell maturation (GOB-4 and keratin 20), and immune modulation (neutrophil-gelatinase-associated lipocalin). Additionally, three different genes of the carcinoembryonic antigen family were induced by PPAR gamma. Cultured cells treated with PPAR gamma ligands demonstrated an increase in Ca2+-independent, carcinoembryonic antigen-dependent homotypic aggregation, suggesting a potential role for PPAR gamma in regulating intercellular adhesion. Collectively, these results will help define the mechanisms by which PPAR gamma regulates intestinal epithelial cell biology.	Vanderbilt Univ, Med Ctr, Dept Med GI, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Cell Biol, Nashville, TN 37232 USA; Vet Affairs Med Ctr, Nashville, TN 37232 USA; Res Genet Inc, Huntsville, AL 35801 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Canc Biol, Boston, MA 02115 USA; GlaxoSmithKline, Nucl Receptor Discovery Res, Res Triangle Pk, NC 27709 USA	Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; GlaxoSmithKline	DuBois, RN (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med GI, MCN C-2104,1161 21st Ave S, Nashville, TN 37232 USA.		DuBois, Raymond N./AAX-8869-2020; feinstein, doug/M-9414-2019		NCI NIH HHS [P01CA-77839] Funding Source: Medline; NIDDK NIH HHS [R01DK 47279] Funding Source: Medline; NIEHS NIH HHS [P030 ES-00267-29] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA077839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BENCHIMOL S, 1989, CELL, V57, P327, DOI 10.1016/0092-8674(89)90970-7; Bernard-Perrone FR, 1999, J HISTOCHEM CYTOCHEM, V47, P863, DOI 10.1177/002215549904700703; Bratt T, 1999, BBA-GEN SUBJECTS, V1472, P262, DOI 10.1016/S0304-4165(99)00131-2; Brockman JA, 1998, GASTROENTEROLOGY, V115, P1049, DOI 10.1016/S0016-5085(98)70072-1; Brown PJ, 2001, BIOORG MED CHEM LETT, V11, P1225, DOI 10.1016/S0960-894X(01)00188-3; Buckingham RE, 1998, DIABETES, V47, P1326, DOI 10.2337/diabetes.47.8.1326; CALNEK D, 1993, DIFFERENTIATION, V53, P95, DOI 10.1111/j.1432-0436.1993.tb00649.x; Carrere J, 1998, CLIN CHIM ACTA, V273, P185, DOI 10.1016/S0009-8981(98)00043-6; Castillo G, 1999, EMBO J, V18, P3676, DOI 10.1093/emboj/18.13.3676; Chang TH, 2000, CANCER RES, V60, P1129; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Cowland JB, 1997, GENOMICS, V45, P17, DOI 10.1006/geno.1997.4896; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; EIDELMAN FJ, 1993, J CELL BIOL, V123, P467, DOI 10.1083/jcb.123.2.467; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Frangsmyr L, 1999, TUMOR BIOL, V20, P277, DOI 10.1159/000030075; Gupta RA, 2000, P NATL ACAD SCI USA, V97, P13275, DOI 10.1073/pnas.97.24.13275; Heid HW, 1998, CELL TISSUE RES, V294, P309, DOI 10.1007/s004410051181; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; JugeAubry C, 1997, J BIOL CHEM, V272, P25252, DOI 10.1074/jbc.272.40.25252; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; Kjeldsen L, 2000, BBA-PROTEIN STRUCT M, V1482, P272, DOI 10.1016/S0167-4838(00)00152-7; Kliewer SA, 1998, CURR OPIN GENET DEV, V8, P576, DOI 10.1016/S0959-437X(98)80014-2; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Kobayashi S, 2000, J BIOL CHEM, V275, P10723, DOI 10.1074/jbc.275.15.10723; Komiya T, 1999, BBA-GENE STRUCT EXPR, V1444, P434, DOI 10.1016/S0167-4781(99)00010-X; Kubota T, 1998, CANCER RES, V58, P3344; LEBLANC BP, 1995, GENE DEV, V9, P1811, DOI 10.1101/gad.9.15.1811; Lefebvre AM, 1999, J ENDOCRINOL, V162, P331, DOI 10.1677/joe.0.1620331; Lefebvre AM, 1998, NAT MED, V4, P1053, DOI 10.1038/2036; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LEVINE AE, 1985, CANCER RES, V45, P2248; Li M, 2000, MOL CELL BIOL, V20, P4699, DOI 10.1128/MCB.20.13.4699-4707.2000; Lim H, 1999, GENE DEV, V13, P1561, DOI 10.1101/gad.13.12.1561; Macadam RCA, 2000, BRIT J CANCER, V83, P188; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Mansen A, 1996, BIOCHEM BIOPH RES CO, V222, P844, DOI 10.1006/bbrc.1996.0832; Medhurst AD, 2000, J NEUROSCI METH, V98, P9, DOI 10.1016/S0165-0270(00)00178-3; MOLL R, 1993, DIFFERENTIATION, V53, P75, DOI 10.1111/j.1432-0436.1993.tb00648.x; Mueller E, 2000, P NATL ACAD SCI USA, V97, P10990, DOI 10.1073/pnas.180329197; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; Nakajima A, 2001, GASTROENTEROLOGY, V120, P460, DOI 10.1053/gast.2001.21191; Obrink B, 1997, CURR OPIN CELL BIOL, V9, P616, DOI 10.1016/S0955-0674(97)80114-7; Okamoto H, 1997, ADV EXP MED BIOL, V426, P301; Oliver WR, 2001, P NATL ACAD SCI USA, V98, P5306, DOI 10.1073/pnas.091021198; Poirier H, 1997, FEBS LETT, V412, P480, DOI 10.1016/S0014-5793(97)00830-2; Poirier H, 2001, BIOCHEM J, V355, P481, DOI 10.1042/0264-6021:3550481; Rechreche H, 1999, INT J CANCER, V81, P688, DOI 10.1002/(SICI)1097-0215(19990531)81:5<688::AID-IJC3>3.0.CO;2-R; ROJAS M, 1990, CELL GROWTH DIFFER, V1, P527; Saez E, 1998, NAT MED, V4, P1058, DOI 10.1038/2042; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Sarraf P, 1999, MOL CELL, V3, P799, DOI 10.1016/S1097-2765(01)80012-5; Shinozaki S, 2001, GUT, V48, P623, DOI 10.1136/gut.48.5.623; Su CG, 1999, J CLIN INVEST, V104, P383, DOI 10.1172/JCI7145; Su JL, 1998, HYBRIDOMA, V17, P47, DOI 10.1089/hyb.1998.17.47; Suh N, 1999, CANCER RES, V59, P5671; Takahashi N, 1999, FEBS LETT, V455, P135, DOI 10.1016/S0014-5793(99)00871-6; Tanaka T, 2001, CANCER RES, V61, P2424; TERAZONO K, 1988, J BIOL CHEM, V263, P2111; Willson TM, 1996, ANN NY ACAD SCI, V804, P276, DOI 10.1111/j.1749-6632.1996.tb18622.x; Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g; Yamaoka T, 2000, BIOCHEM BIOPH RES CO, V278, P368, DOI 10.1006/bbrc.2000.3813; Yan ZF, 1997, J BIOL CHEM, V272, P27902, DOI 10.1074/jbc.272.44.27902; ZHOU H, 1990, CELL GROWTH DIFFER, V1, P209	69	166	181	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29681	29687		10.1074/jbc.M103779200	http://dx.doi.org/10.1074/jbc.M103779200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11397807	hybrid			2022-12-25	WOS:000170558000013
J	Mitrasinovic, OM; Perez, GV; Zhao, FF; Lee, YL; Poon, C; Murphy, GM				Mitrasinovic, OM; Perez, GV; Zhao, FF; Lee, YL; Poon, C; Murphy, GM			Overexpression of macrophage colony-stimulating factor receptor on microglial cells induces an inflammatory response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; ORGANOTYPIC SLICE CULTURES; CENTRAL-NERVOUS-SYSTEM; NECROSIS-FACTOR-ALPHA; ALZHEIMERS-DISEASE; FACTOR-I; HUMAN MONOCYTES; MOUSE MODEL; CYTOKINE PRODUCTION; INTERFERON-GAMMA	Microglia are important in the inflammatory response in Alzheimer's disease (AD). We showed previously that macrophage colony-stimulating factor receptor (M-CSFR), encoded by the c-fins protooncogene, is overexpressed on microglia surrounding amyloid beta (A beta) deposits in the APP(V717F) mouse model for AD. The M-CSFR is also increased on microglia after experimental brain injury and in AD. To determine the relevance of these findings, we transiently expressed M-CSFR on murine BV-2 and human SV-A3 microglial cell lines using an SV40-promoted c-fms construct. M-CSFR overexpression resulted in microglial proliferation and increased expression of inducible nitric-oxide synthase, the proinflammatory cytokines interleukin-1 alpha, macrophage inflammatory protein 1-alpha, and interleukin-6 and of macrophage colony-stimulating factor (M-CSF) itself. Antibody neutralization of M-CSF showed that the M-CSFR-induced proinflammatory response was dependent on M-CSF in the culture media. By using a co-culture of c-fins-transfected murine microglia and rat organotypic hippocampal slices and. a species-specific real time reverse transcriptase-polymerase chain reaction assay and enzyme-linked immunosorbent assay, we showed that M-CSFR overexpression on exogenous microglia induced expression of interleukin-1 alpha by the organotypic culture. These results show that increased M-CSFR expression induces microglial proliferation, cytokine expression, and a paracrine inflammatory response, suggesting that in APP(V717F) mice increased M-CSFR on microglia could be an important factor in Ap-induced inflammatory response.	Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Neurosci Res Labs, Stanford, CA 94305 USA; Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Murphy, GM (corresponding author), Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Neurosci Res Labs, MSLS P-104, Stanford, CA 94305 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH057833] Funding Source: NIH RePORTER; NIMH NIH HHS [MH57833] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; AKIYAMA H, 1994, BRAIN RES, V639, P171, DOI 10.1016/0006-8993(94)91779-5; Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Anthony JC, 2000, NEUROLOGY, V54, P2066, DOI 10.1212/WNL.54.11.2066; ARAUJO DM, 1992, BRAIN RES, V569, P141, DOI 10.1016/0006-8993(92)90380-R; Bales KR, 2000, NEUROBIOL AGING, V21, P427, DOI 10.1016/S0197-4580(00)00143-3; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Bitting L, 1996, J BIOL CHEM, V271, P16084, DOI 10.1074/jbc.271.27.16084; BLASI E, 1990, J NEUROIMMUNOL, V27, P229, DOI 10.1016/0165-5728(90)90073-V; BOCCHINI V, 1992, J NEUROSCI RES, V31, P616, DOI 10.1002/jnr.490310405; Bornemann KD, 2001, AM J PATHOL, V158, P63, DOI 10.1016/S0002-9440(10)63945-4; Bourette RP, 2000, GROWTH FACTORS, V17, P155, DOI 10.3109/08977190009001065; CARLBERG K, 1994, MOL BIOL CELL, V5, P81, DOI 10.1091/mbc.5.1.81; CARPENTER AF, 1993, J NEUROPATH EXP NEUR, V52, P601, DOI 10.1097/00005072-199311000-00007; CHUNG Y, 1994, J NEUROIMMUNOL, V52, P9; Coltman BW, 1996, INT J DEV NEUROSCI, V14, P707, DOI 10.1016/S0736-5748(96)00071-8; Czapiga M, 1999, J NEUROSCI RES, V56, P644, DOI 10.1002/(SICI)1097-4547(19990615)56:6<644::AID-JNR10>3.0.CO;2-9; Ding M, 1997, MOL PSYCHIATR, V2, P117, DOI 10.1038/sj.mp.4000222; Ding MZ, 1997, J BIOL CHEM, V272, P11327; Du Y, 2000, NEUROLOGY, V55, P480, DOI 10.1212/WNL.55.4.480; Eikelenboom P, 1999, EXP GERONTOL, V34, P453, DOI 10.1016/S0531-5565(99)00022-4; Frautschy SA, 1998, AM J PATHOL, V152, P307; Gahtan E, 1999, NEUROSCI BIOBEHAV R, V23, P615, DOI 10.1016/S0149-7634(98)00058-X; GANTER S, 1992, J NEUROSCI RES, V33, P218, DOI 10.1002/jnr.490330205; GIULIAN D, 1988, J NEUROSCI, V8, P4707; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; Good PF, 1996, AM J PATHOL, V149, P21; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; Grimaldi LME, 2000, ANN NEUROL, V47, P361, DOI 10.1002/1531-8249(200003)47:3<361::AID-ANA12>3.3.CO;2-E; HAGA S, 1989, ACTA NEUROPATHOL, V77, P569, DOI 10.1007/BF00687883; Hamilton JA, 1997, IMMUNOL TODAY, V18, P313, DOI 10.1016/S0167-5699(97)01084-0; HAO C, 1990, J NEUROSCI RES, V27, P314, DOI 10.1002/jnr.490270310; Keshava N, 1999, J SOC GYNECOL INVEST, V6, P41, DOI 10.1016/S1071-5576(98)00041-0; Kloss CUA, 1997, J NEUROSCI RES, V49, P248; Lee SC, 1999, J NEUROPATH EXP NEUR, V58, P1163, DOI 10.1097/00005072-199911000-00006; LEE SC, 1993, J IMMUNOL, V150, P2659; LEE SC, 1993, J NEUROIMMUNOL, V46, P19, DOI 10.1016/0165-5728(93)90229-R; Licastro F, 2000, J NEUROIMMUNOL, V103, P97, DOI 10.1016/S0165-5728(99)00226-X; Lim GP, 2000, J NEUROSCI, V20, P5709, DOI 10.1523/JNEUROSCI.20-15-05709.2000; Liu J, 1996, J IMMUNOL, V157, P3569; LIVAK KJ, 1995, PCR METH APPL, V4, P357; Lorton D, 1996, J NEUROIMMUNOL, V67, P21, DOI 10.1016/S0165-5728(96)00030-6; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MCGEER PL, 1989, CAN J NEUROL SCI, V16, P516, DOI 10.1017/S0317167100029863; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; Meda L, 1999, J NEUROIMMUNOL, V93, P45, DOI 10.1016/S0165-5728(98)00188-X; MERRILL JE, 1991, DEV NEUROSCI-BASEL, V13, P130, DOI 10.1159/000112150; MURPHY GM, 1995, J NEUROSCI RES, V40, P755, DOI 10.1002/jnr.490400607; Murphy GM, 1998, J BIOL CHEM, V273, P20967, DOI 10.1074/jbc.273.33.20967; Murphy GM, 2000, AM J PATHOL, V157, P895, DOI 10.1016/S0002-9440(10)64603-2; Nicoll JAR, 2000, ANN NEUROL, V47, P365, DOI 10.1002/1531-8249(200003)47:3<365::AID-ANA13>3.0.CO;2-G; NOHAVA K, 1992, EUR J IMMUNOL, V22, P2539, DOI 10.1002/eji.1830221012; O'Barr S, 2000, J NEUROIMMUNOL, V109, P87, DOI 10.1016/S0165-5728(00)00291-5; Peterson PK, 1997, J INFECT DIS, V175, P478, DOI 10.1093/infdis/175.2.478; Pratico D, 2000, NEUROBIOL AGING, V21, P441, DOI 10.1016/S0197-4580(00)00141-X; Raivich G, 1998, J COMP NEUROL, V395, P342, DOI 10.1002/(SICI)1096-9861(19980808)395:3<342::AID-CNE6>3.0.CO;2-2; ROTHWELL VM, 1987, ONCOGENE RES, V1, P311; SAWADA M, 1990, BRAIN RES, V509, P119, DOI 10.1016/0006-8993(90)90317-5; SHAFITZAGARDO B, 1993, INT J DEV NEUROSCI, V11, P189, DOI 10.1016/0736-5748(93)90078-R; SHENG JG, 1995, NEUROPATH APPL NEURO, V21, P290, DOI 10.1111/j.1365-2990.1995.tb01063.x; Smith MA, 1997, J NEUROSCI, V17, P2653; Stacey KJ, 1996, J IMMUNOL, V157, P2116; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Szabo C, 1995, Adv Pharmacol, V34, P113; THERY C, 1992, J NEUROCHEM, V59, P1183, DOI 10.1111/j.1471-4159.1992.tb08366.x; ULVESTAD E, 1994, J NEUROPATH EXP NEUR, V53, P492, DOI 10.1097/00005072-199409000-00008; vanMuiswinkel FL, 1996, J NEUROCHEM, V66, P2468; Wallace MN, 1997, EXP NEUROL, V144, P266, DOI 10.1006/exnr.1996.6373; Wang YQ, 1999, J NEUROSCI RES, V57, P616, DOI 10.1002/(SICI)1097-4547(19990901)57:5<616::AID-JNR4>3.0.CO;2-E; Weltzien RB, 2000, J NEUROSCI RES, V59, P522, DOI 10.1002/(SICI)1097-4547(20000215)59:4<522::AID-JNR7>3.3.CO;2-C; WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828; WILLIAMS K, 1992, J NEUROPATH EXP NEUR, V51, P538, DOI 10.1097/00005072-199209000-00009; Yan SD, 1997, P NATL ACAD SCI USA, V94, P5296, DOI 10.1073/pnas.94.10.5296	73	48	58	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30142	30149		10.1074/jbc.M104265200	http://dx.doi.org/10.1074/jbc.M104265200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11387343	hybrid			2022-12-25	WOS:000170558000073
J	Sanlioglu, S; Williams, CM; Samavati, L; Butler, NS; Wang, GS; McCray, PB; Ritchie, TC; Hunninghake, GW; Zandi, E; Engelhardt, JF				Sanlioglu, S; Williams, CM; Samavati, L; Butler, NS; Wang, GS; McCray, PB; Ritchie, TC; Hunninghake, GW; Zandi, E; Engelhardt, JF			Lipopolysaccharide induces Rac1-dependent reactive oxygen species formation and coordinates tumor necrosis factor-alpha secretion through IKK regulation of NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR-2; LPS-BINDING-PROTEIN; RECOMBINANT ADENOASSOCIATED VIRUS; PERMEABILITY-INCREASING PROTEIN; HUMAN MONOCLONAL-ANTIBODY; PLACEBO-CONTROLLED TRIAL; FREE-RADICAL GENERATION; BACTERIAL LIPOPOLYSACCHARIDE; ENDOTHELIAL-CELLS; GENE-EXPRESSION	Reactive oxygen species (ROS) are important second messengers generated in response to many types of environmental stress. In this setting, changes in intracellular ROS can activate signal transduction pathways that influence how cells react to their environment. In sepsis, a dynamic proinflammatory cellular response to bacterial toxins (e.g., lipopolysaccharide or LPS) leads to widespread organ damage and death. The present study demonstrates for the first time that the activation of Rac1 (a GTP-binding protein), and the subsequent production of ROS, constitutes a major pathway involved in NF kappaB-mediated tumor necrosis factor-alpha (TNF alpha) secretion following LPS challenge in macrophages. Expression of a dominant negative mutant of Rac1. (N17Rac1) reduced Rac1 activation, ROS formation, NF kappaB activation, and TNF alpha secretion following LPS stimulation. In contrast, expression of a dominant active form of Rac1 (V12Rac1) mimicked these effects in the absence of LPS stimulation. IKK alpha and IKK beta were both required downstream modulators of LPS-activated Rac1, since the expression of either of the IKK dominant mutants (IKK alpha KM or IKK beta KA) drastically reduced NF kappaB-dependent TNF alpha secretion. Moreover, studies using CD14 blocking antibodies suggest that Rac1 induces TNF alpha secretion through a pathway independent of CD14. However, a maximum therapeutic inhibition of LPS-induced TNF alpha secretion occurred when both CD14 and Rac1 pathways were inhibited. Our results suggest that targeting both Rac1- and CD14-dependent pathways could be a useful therapeutic strategy for attenuating the proinflammatory cytokine response during the course of sepsis.	Univ Iowa, Coll Med, Dept Anat & Cell Biol, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Internal Med, Div Pulm & Crit Care, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Ctr Gene Therapy, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Pediat, Iowa City, IA 52242 USA; Norris Canc Ctr, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA; Akdeniz Univ, Coll Med, Dept Med Biol & Genet, TR-07070 Antalya, Turkey	University of Iowa; University of Iowa; University of Iowa; University of Iowa; Akdeniz University	Engelhardt, JF (corresponding author), Univ Iowa, Coll Med, Dept Anat & Cell Biol, 51 Newton Rd,Rm 1-111 BSB, Iowa City, IA 52242 USA.		Sanlioglu, Salih/F-9305-2016	Sanlioglu, Salih/0000-0001-8379-5678; Butler, Noah/0000-0002-1429-0796; McCray, Paul/0000-0002-4067-577X; Engelhardt, John/0000-0003-2389-9277	NHLBI NIH HHS [HL60316] Funding Source: Medline; NIDDK NIH HHS [DK54759] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL060316] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK054759] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson RD, 2000, GENE THER, V7, P1034, DOI 10.1038/sj.gt.3301197; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797; ARUOMA OI, 1989, FREE RADICAL BIO MED, V6, P593, DOI 10.1016/0891-5849(89)90066-X; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Beutler B, 2000, CURR OPIN IMMUNOL, V12, P20, DOI 10.1016/S0952-7915(99)00046-1; Bone RC, 1997, CHEST, V112, P235, DOI 10.1378/chest.112.1.235; BONE RC, 1995, CRIT CARE MED, V23, P994, DOI 10.1097/00003246-199506000-00003; Bone RC, 1996, JAMA-J AM MED ASSOC, V276, P565, DOI 10.1001/jama.276.7.565; BONE RC, 1991, CHEST, V100, P802, DOI 10.1378/chest.100.3.802; BONE RC, 1995, CHEST, V107, P298, DOI 10.1378/chest.107.2.298; BOXER GJ, 1985, HOSP PRACT, V20, P69; Brown MR, 1999, CIRC RES, V85, P524, DOI 10.1161/01.RES.85.6.524; CARTER WO, 1994, J LEUKOCYTE BIOL, V55, P253; Chandel NS, 2000, J IMMUNOL, V165, P1013, DOI 10.4049/jimmunol.165.2.1013; CORRADIN SB, 1992, J LEUKOCYTE BIOL, V52, P363, DOI 10.1002/jlb.52.4.363; De Deken X, 2000, J BIOL CHEM, V275, P23227, DOI 10.1074/jbc.M000916200; DeLeo FR, 1998, J CLIN INVEST, V101, P455, DOI 10.1172/JCI949; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DENTENER MA, 1993, J IMMUNOL, V150, P2885; DENTENER MA, 1993, J IMMUNOL, V151, P4258; DOE WF, 1978, J EXP MED, V148, P557, DOI 10.1084/jem.148.2.557; ENGELHARDT JF, 1993, NAT GENET, V4, P27, DOI 10.1038/ng0593-27; FEARNS C, 1995, J EXP MED, V181, P857, DOI 10.1084/jem.181.3.857; FINKELSTEIN E, 1980, ARCH BIOCHEM BIOPHYS, V200, P1, DOI 10.1016/0003-9861(80)90323-9; Fisher KJ, 1996, J VIROL, V70, P520, DOI 10.1128/JVI.70.1.520-532.1996; Flaherty SF, 1997, J SURG RES, V73, P85, DOI 10.1006/jsre.1997.5195; Gangloff SC, 1999, CLIN INFECT DIS, V28, P491, DOI 10.1086/515176; Gillissen A, 1997, RES EXP MED, V196, P389, DOI 10.1007/s004330050049; Glaven JA, 1999, J BIOL CHEM, V274, P2279, DOI 10.1074/jbc.274.4.2279; Gorlach A, 2000, CIRC RES, V87, P26, DOI 10.1161/01.RES.87.1.26; Hattor Y, 1997, BIOCHEM BIOPH RES CO, V233, P375, DOI 10.1006/bbrc.1997.6462; HEUMANN D, 1992, J IMMUNOL, V148, P3505; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Iimuro Y, 1998, J CLIN INVEST, V101, P802, DOI 10.1172/JCI483; INGALLS RR, 1995, J EXP MED, V181, P1473, DOI 10.1084/jem.181.4.1473; Ingalls RR, 1997, J IMMUNOL, V159, P433; Ingalls RR, 1998, PROG CLIN BIOL RES, V397, P107; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; Jungi TW, 1997, INFECT IMMUN, V65, P3577, DOI 10.1128/IAI.65.9.3577-3584.1997; Kim KS, 1998, J CLIN INVEST, V101, P1821, DOI 10.1172/JCI1830; Kimura S, 2000, SCAND J IMMUNOL, V51, P392, DOI 10.1046/j.1365-3083.2000.00696.x; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; Lien E, 2000, J CLIN INVEST, V105, P497, DOI 10.1172/JCI8541; Liu Y, 2001, INFECT IMMUN, V69, P2788, DOI 10.1128/IAI.69.5.2788-2796.2001; LYNN WA, 1993, INFECT IMMUN, V61, P4452, DOI 10.1128/IAI.61.10.4452-4461.1993; Matsuguchi T, 2000, J IMMUNOL, V165, P5767, DOI 10.4049/jimmunol.165.10.5767; MCCLOSKEY RV, 1994, ANN INTERN MED, V121, P1, DOI 10.7326/0003-4819-121-1-199407010-00001; Medvedev AE, 2000, J IMMUNOL, V164, P5564, DOI 10.4049/jimmunol.164.11.5564; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; MESZAROS K, 1994, BLOOD, V83, P2516; Miller FJ, 1998, CIRC RES, V82, P1298, DOI 10.1161/01.RES.82.12.1298; Miyata Y, 1997, INFECT IMMUN, V65, P3513, DOI 10.1128/IAI.65.9.3513-3519.1997; Moore KJ, 2000, J IMMUNOL, V165, P4272, DOI 10.4049/jimmunol.165.8.4272; MORRISON DC, 1978, AM J PATHOL, V93, P526; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Netea MG, 1998, IMMUNOLOGY, V94, P340, DOI 10.1046/j.1365-2567.1998.00532.x; Nomura F, 2000, J IMMUNOL, V164, P3476, DOI 10.4049/jimmunol.164.7.3476; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Peppelenbosch MP, 1999, BLOOD, V93, P4011, DOI 10.1182/blood.V93.11.4011.411a29_4011_4018; Perera PY, 2001, J IMMUNOL, V166, P574, DOI 10.4049/jimmunol.166.1.574; PERISTERIS P, 1992, CELL IMMUNOL, V140, P390, DOI 10.1016/0008-8749(92)90205-4; Pinner RW, 1996, JAMA-J AM MED ASSOC, V275, P189, DOI 10.1001/jama.275.3.189; RAETZ CRH, 1991, FASEB J, V5, P2652, DOI 10.1096/fasebj.5.12.1916089; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Sanlioglu S, 1999, GENE THER, V6, P1427, DOI 10.1038/sj.gt.3300967; SanliogluCrisman S, 1997, PROG BRAIN RES, V114, P3; SCHLETTER J, 1995, INFECT IMMUN, V63, P2576, DOI 10.1128/IAI.63.7.2576-2580.1995; Schletter J, 1995, ARCH MICROBIOL, V164, P383, DOI 10.1007/BF02529735; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; Schuster JM, 2000, J LEUKOCYTE BIOL, V67, P767, DOI 10.1002/jlb.67.6.767; Shi XL, 2000, ANN CLIN LAB SCI, V30, P209; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; Tapping RI, 2000, J IMMUNOL, V165, P5780, DOI 10.4049/jimmunol.165.10.5780; THEOFAN G, 1994, J IMMUNOL, V152, P3623; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; ULEVITCH RJ, 1993, ADV IMMUNOL, V53, P267, DOI 10.1016/S0065-2776(08)60502-7; Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605; Wahl C, 1998, J CLIN INVEST, V101, P1163, DOI 10.1172/JCI992; Werts C, 2001, NAT IMMUNOL, V2, P346, DOI 10.1038/86354; WRIGHT SD, 1989, J EXP MED, V169, P175, DOI 10.1084/jem.169.1.175; WRIGHT SD, 1986, J EXP MED, V164, P1876, DOI 10.1084/jem.164.6.1876; WRIGHT SD, 1991, J EXP MED, V173, P1281, DOI 10.1084/jem.173.5.1281; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701; ZIEGLERHEITBROCK HWL, 1993, IMMUNOL TODAY, V14, P121, DOI 10.1016/0167-5699(93)90212-4; ZWEIER JL, 1994, AM J PHYSIOL, V266, pC700, DOI 10.1152/ajpcell.1994.266.3.C700; ZWEIER JL, 1988, P NATL ACAD SCI USA, V85, P4046, DOI 10.1073/pnas.85.11.4046	94	346	357	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30188	30198		10.1074/jbc.M102061200	http://dx.doi.org/10.1074/jbc.M102061200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11402028	hybrid			2022-12-25	WOS:000170558000079
J	Wu, X; Davis, GE; Meininger, GA; Wilson, E; Davis, MJ				Wu, X; Davis, GE; Meininger, GA; Wilson, E; Davis, MJ			Regulation of the L-type calcium channel by alpha(5)beta(1) integrin requires signaling between focal adhesion proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; TYROSINE KINASE INHIBITOR; EXTRACELLULAR-MATRIX MOLECULES; ION CHANNELS; C-SRC; POTASSIUM CHANNEL; SODIUM-CHANNELS; CA2+ CHANNELS; K+ CHANNEL; PHOSPHORYLATION	The L-type calcium channel is the major calcium influx pathway in vascular smooth muscle and is regulated by integrin ligands, suggesting an important link between extracellular matrix and vascular tone regulation in tissue injury and remodeling. We examined the role of integrin-linked tyrosine kinases and focal adhesion proteins in regulation of L-type calcium current in single vascular myocytes. Soluble tyrosine kinase inhibitors blocked the increase in current produced by alpha (5) integrin antibody or fibronectin, whereas tyrosine phosphatase inhibition enhanced the effect. Cell dialysis with an antibody to focal adhesion kinase or with FRNK, the C-terminal noncatalytic domain of focal adhesion kinase, produced moderate (24 or 18%, respectively) inhibition of basal current but much greater inhibition (63 or 68%, respectively) of integrin-enhanced current. A c-Src antibody and peptide inhibitors of the Src homology-2 domain or a putative Src tyrosine phosphorylation site on the channel produced similar inhibition. Antibodies to the cytoskeletal proteins paxillin and vinculin, but not a-actinin, inhibited integrin-dependent current by 65-80%. Therefore, alpha (5)beta (1). integrin appears to regulate a tyrosine phosphorylation cascade involving Src and various focal adhesion proteins that control the function of the L-type calcium channel. This interaction may represent a novel mechanism for control of calcium influx in vascular smooth muscle and other cell types.	Texas A&M Univ, Hlth Sci Ctr, Dept Med Physiol, College Stn, TX 77843 USA; Texas A&M Univ, Hlth Sci Ctr, Cardiovasc Res Inst, College Stn, TX 77843 USA; Texas A&M Univ, Hlth Sci Ctr, Dept Pathol & Lab Med, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Davis, MJ (corresponding author), Texas A&M Univ, Hlth Sci Ctr, Dept Med Physiol, 336 Reynolds Med Bldg, College Stn, TX 77843 USA.			wu, xin/0000-0002-5005-6358	NHLBI NIH HHS [HL-55050, HL-59971, HL-60180, HL-46502] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060180, R01HL046502, R01HL059971] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; Arnoult C, 1997, EMBO J, V16, P1593, DOI 10.1093/emboj/16.7.1593; Bence-Hanulec KK, 2000, NEURON, V27, P121, DOI 10.1016/S0896-6273(00)00014-3; BJORGE JD, 1995, J BIOL CHEM, V270, P24222, DOI 10.1074/jbc.270.41.24222; Blair LAC, 1997, NEURON, V19, P421, DOI 10.1016/S0896-6273(00)80950-2; Boudreau J, 1999, BIOCHEM J, V339, P481, DOI 10.1042/0264-6021:3390481; Bowlby MR, 1997, J GEN PHYSIOL, V110, P601, DOI 10.1085/jgp.110.5.601; Chicurel ME, 1998, NATURE, V392, P730, DOI 10.1038/33719; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Cooley MA, 2000, MOL BIOL CELL, V11, P3247, DOI 10.1091/mbc.11.9.3247; DAngelo G, 1997, AM J PHYSIOL-HEART C, V273, pH175, DOI 10.1152/ajpheart.1997.273.1.H175; Davis GE, 2000, AM J PATHOL, V156, P1489, DOI 10.1016/S0002-9440(10)65020-1; Doughty JM, 1998, J PHYSIOL-LONDON, V507, P433, DOI 10.1111/j.1469-7793.1998.433bt.x; Ekinci FJ, 1999, J BIOL CHEM, V274, P30322, DOI 10.1074/jbc.274.42.30322; Ertel EA, 2000, NEURON, V25, P533, DOI 10.1016/S0896-6273(00)81057-0; Evans GJO, 1999, EUR J NEUROSCI, V11, P279, DOI 10.1046/j.1460-9568.1999.00427.x; FLEMING I, 1995, CIRC RES, V76, P522, DOI 10.1161/01.RES.76.4.522; Fraser IDC, 1999, NEURON, V23, P423, DOI 10.1016/S0896-6273(00)80795-3; Gerhardstein BL, 2000, J BIOL CHEM, V275, P8556, DOI 10.1074/jbc.275.12.8556; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hill MA, 1996, J PHARMACOL EXP THER, V276, P867; Holmes TC, 1996, SCIENCE, V274, P2089, DOI 10.1126/science.274.5295.2089; Hu XQ, 1998, J BIOL CHEM, V273, P5337, DOI 10.1074/jbc.273.9.5337; Huang RQ, 2000, NEUROPHARMACOLOGY, V39, P2195, DOI 10.1016/S0028-3908(00)00046-0; Hughes AD, 1995, J VASC RES, V32, P353, DOI 10.1159/000159111; KOCH WJ, 1990, J BIOL CHEM, V265, P17786; Levitan IB, 1999, ADV SEC MESS PHOSPH, V33, P3; LEVITAN IB, 1994, ANNU REV PHYSIOL, V56, P193, DOI 10.1146/annurev.ph.56.030194.001205; Ling SZ, 2000, J BIOL CHEM, V275, P30683, DOI 10.1074/jbc.M004292200; Maguire G, 1998, NEUROREPORT, V9, P665, DOI 10.1097/00001756-199803090-00019; MCNAMEE HP, 1993, J CELL BIOL, V121, P673, DOI 10.1083/jcb.121.3.673; MIRONNEAU J, 1995, CELL SIGNAL, V7, P471, DOI 10.1016/0898-6568(95)00014-G; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; Mogford JE, 1997, J CLIN INVEST, V100, P1647, DOI 10.1172/JCI119689; Mogford JE, 1996, CIRC RES, V79, P821, DOI 10.1161/01.RES.79.4.821; OLIVER JM, 1994, J BIOL CHEM, V269, P29697; Paillart C, 1997, J PHARMACOL EXP THER, V280, P521; RAE JL, 1991, NEWS PHYSIOL SCI, V6, P273; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; Rogalski SL, 2000, J BIOL CHEM, V275, P25082, DOI 10.1074/jbc.M000183200; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; Sachs F, 1997, SOC GEN PHY, V52, P209; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SELINFREUND RH, 1994, MOL PHARMACOL, V45, P1215; SMIRNOV SV, 1995, CIRC RES, V76, P310, DOI 10.1161/01.RES.76.2.310; Srinivasan J, 1998, P NATL ACAD SCI USA, V95, P15753, DOI 10.1073/pnas.95.26.15753; Strauss O, 2000, BIOCHEM BIOPH RES CO, V270, P806, DOI 10.1006/bbrc.2000.2513; Szabo I, 1996, J BIOL CHEM, V271, P20465, DOI 10.1074/jbc.271.34.20465; Vuori K, 1998, J MEMBRANE BIOL, V165, P191, DOI 10.1007/s002329900433; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; Wijetunge S, 1996, FEBS LETT, V399, P63, DOI 10.1016/S0014-5793(96)01177-5; Wijetunge S, 1995, BIOCHEM BIOPH RES CO, V217, P1039, DOI 10.1006/bbrc.1995.2874; Wiser O, 1999, P NATL ACAD SCI USA, V96, P248, DOI 10.1073/pnas.96.1.248; Wu X, 1998, J CELL BIOL, V143, P241, DOI 10.1083/jcb.143.1.241; XIONG ZL, 1995, J MOL CELL CARDIOL, V27, P75, DOI 10.1016/S0022-2828(08)80009-0; Xu WX, 1996, PFLUG ARCH EUR J PHY, V432, P159, DOI 10.1007/s004240050119; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; Zhou DX, 1998, J CELL BIOL, V143, P1295, DOI 10.1083/jcb.143.5.1295	60	137	139	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30285	30292		10.1074/jbc.M102436200	http://dx.doi.org/10.1074/jbc.M102436200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11382763	hybrid			2022-12-25	WOS:000170558000090
J	Ballesteros, JA; Jensen, AD; Liapakis, G; Rasmussen, SGF; Shi, L; Gether, U; Javitch, JA				Ballesteros, JA; Jensen, AD; Liapakis, G; Rasmussen, SGF; Shi, L; Gether, U; Javitch, JA			Activation of the beta(2)-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA(2) ADRENERGIC-RECEPTOR; CONSTITUTIVE ACTIVATION; STRUCTURAL INSTABILITY; HORMONE RECEPTOR; ALPHA-HELICES; ALPHA(1B)-ADRENERGIC RECEPTOR; BINDING-SITES; DRY MOTIF; RHODOPSIN	The movements of transmembrane segments (TMs) 3 and 6 at the cytoplasmic side of the membrane play an important role in the activation of G-protein-coupled receptors. Here we provide evidence for the, existence of an ionic lock that constrains the relative mobility of the cytoplasmic ends of TM3 and TM6 in the inactive state of the beta (2)-adrenergic receptor. We propose that the highly conserved Arg-131(3.50) at the cytoplasmic end of TM3 interacts both with the adjacent Asp-130(3.49) and with Glu268(6.30) at the cytoplasmic end of TM6. Such a network of ionic interactions has now been directly supported by the high-resolution structure of the inactive state of rhodopsin. We hypothesized that the network of interactions would serve to constrain the receptor in the inactive state, and the release of this ionic lock could be a key step in receptor activation. To test this hypothesis, we made charge-neutralizing mutations of Glu-268(6.30) and of Asp-130(3.49) in the beta (2)-adrenergic receptor. Alone and in combination, we observed a significant increase in basal and pindolol-stimulated cAMP accumulation in COS-7 cells transiently transfected with the mutant receptors. Moreover, based on the increased accessibility of Cys-285(6.47) in TM6, we provide evidence for a conformational rearrangement of TM6 that is highly correlated with the extent of constitutive activity of the different mutants. The present experimental data together with the recent high-resolution structure of rhodopsin suggest that ionic interactions between Asp/Glu(3.49), Arg(3.50), and Glu(6.30) may constitute a common switch governing the activation of many rhodopsin-like G-protein-coupled receptors.	Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA; Novasite Pharmaceut Inc, San Diego, CA 92121 USA; Univ Copenhagen, Panum Inst, Dept Med Physiol, Div Cellular & Mol Physiol, DK-2200 Copenhagen, Denmark; Columbia Univ Coll Phys & Surg, Ctr Mol Recognit, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA; Univ Crete, Sch Med, Dept Pharmacol, GR-71110 Iraklion, Greece	Columbia University; University of Copenhagen; Columbia University; Columbia University; University of Crete	Javitch, JA (corresponding author), Columbia Univ Coll Phys & Surg, Dept Psychiat, 630 W 168th St,P&S 11-401, New York, NY 10032 USA.		Shi, Lei/AAV-1321-2020	Shi, Lei/0000-0002-4137-096X; Gether, Ulrik/0000-0002-0020-3807; Javitch, Jonathan/0000-0001-7395-2967; Rasmussen, Soren/0000-0002-1853-1841	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH054137] Funding Source: NIH RePORTER; NIMH NIH HHS [MH57324, MH54137] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Alewijnse AE, 2000, MOL PHARMACOL, V57, P890; ARNIS S, 1994, J BIOL CHEM, V269, P23879; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; Ballesteros J, 1998, J BIOL CHEM, V273, P10445, DOI 10.1074/jbc.273.17.10445; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; COHEN GB, 1993, BIOCHEMISTRY-US, V32, P6111, DOI 10.1021/bi00074a024; FAHMY K, 1993, P NATL ACAD SCI USA, V90, P10206, DOI 10.1073/pnas.90.21.10206; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Gether U, 1997, J BIOL CHEM, V272, P2587, DOI 10.1074/jbc.272.5.2587; GETHER U, 1992, FEBS LETT, V296, P241, DOI 10.1016/0014-5793(92)80295-R; Ghanouni P, 2000, J BIOL CHEM, V275, P3121, DOI 10.1074/jbc.275.5.3121; GUAN XM, 1992, J BIOL CHEM, V267, P21995; Hjorth SA, 1998, MOL ENDOCRINOL, V12, P78, DOI 10.1210/mend.12.1.0045; JAVITCH JA, 1995, NEURON, V14, P825, DOI 10.1016/0896-6273(95)90226-0; Javitch JA, 1997, J BIOL CHEM, V272, P18546, DOI 10.1074/jbc.272.30.18546; Jensen AD, 2001, J BIOL CHEM, V276, P9279, DOI 10.1074/jbc.M004871200; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; JOHANSEN TE, 1990, FEBS LETT, V267, P289, DOI 10.1016/0014-5793(90)80947-H; Kosugi S, 1998, MOL PHARMACOL, V53, P894; LAUE L, 1995, P NATL ACAD SCI USA, V92, P1906, DOI 10.1073/pnas.92.6.1906; MIN KC, 1993, J BIOL CHEM, V268, P9400; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; Rasmussen SGF, 1999, MOL PHARMACOL, V56, P175, DOI 10.1124/mol.56.1.175; Rees S, 1996, BIOTECHNIQUES, V20, P102; ROBERTS DD, 1986, BIOCHEMISTRY-US, V25, P5595, DOI 10.1021/bi00367a038; ROSENTHAL W, 1993, J BIOL CHEM, V268, P13030; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SANKARARAMAKRISHNAN R, 1992, INT J PEPT PROT RES, V39, P356; SANKARARAMAKRISHNAN R, 1990, BIOPOLYMERS, V30, P287, DOI 10.1002/bip.360300307; Sansom MSP, 2000, TRENDS PHARMACOL SCI, V21, P445; Scheer A, 1997, P NATL ACAD SCI USA, V94, P808, DOI 10.1073/pnas.94.3.808; Scheer A, 1996, EMBO J, V15, P3566, DOI 10.1002/j.1460-2075.1996.tb00726.x; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; Seibold A, 1998, RECEPTOR CHANNEL, V5, P375; Sheikh SP, 1999, J BIOL CHEM, V274, P17033, DOI 10.1074/jbc.274.24.17033; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; STAUFFER DA, 1994, BIOCHEMISTRY-US, V33, P6840, DOI 10.1021/bi00188a013; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316	44	508	523	2	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29171	29177		10.1074/jbc.M103747200	http://dx.doi.org/10.1074/jbc.M103747200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11375997	hybrid			2022-12-25	WOS:000170346000073
J	Thomas, DDH; Taft, WB; Kaspar, KM; Groblewski, GE				Thomas, DDH; Taft, WB; Kaspar, KM; Groblewski, GE			CRHSP-28 regulates Ca2+-stimulated secretion in permeabilized acinar cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE STRING PROTEIN; RAT PANCREATIC ACINI; ACTIN CYTOSKELETON; MEMBRANE RETRIEVAL; ZYMOGEN GRANULES; GENE FAMILY; EXOCYTOSIS; IDENTIFICATION; CHOLECYSTOKININ; CLONING	CRHSP-28 is a Ca2+-regulated heat-stable phosphoprotein, abundant in the apical cytoplasm of epithelial cells that are specialized in exocrine protein secretion. To define a functional role for the protein in pancreatic secretion, recombinant CRHSP-28 (rCRHSP-28) was introduced into streptolysin-O-permeabilized acinar cells, and amylase secretion in response to elevated Ca2+ was determined. Secretion was enhanced markedly by rCRHSP-28 over a time course that closely corresponded with the loss of the native protein from the intracellular compartment. No effects of rCRHSP-28 were detected until similar to 50% of the native protein was lost from the cytosol. Secretion was enhanced by rCRHSP-28 over a physiological range of Ca2+ concentrations with 2-3-fold increases in amylase release occurring in response to low micromolar levels of free Ca2+. Further, rCRHSP-28 augmented secretion in a concentration-dependent manner with minimal and maximal effects occurring at 1 and 25 mug/ml, respectively. Covalent cross-linking experiments demonstrated that native CRHSP-28 was present in a 60-kDa complex in cytosolic fractions and in a high molecular mass complex in particulate fractions, consistent with the slow leak rate of the protein from streptolysin-O-permeabilized cells. Probing acinar lysates with rCRHSP-28 in a gel-overlay assay identified two CRHSP-28-binding proteins of 35 (pp35) and 70 kDa (pp70). Interestingly, preparation of lysates in the presence of 1 mm Ca2+ resulted in a marked redistribution of both proteins from a cytosolic to a Triton X-100-insoluble fraction, suggesting a Ca2+- sensitive interaction of these proteins with the acinar cell cytoskeleton. In agreement with our previous study immunohistochemically localizing CRHSP-28 around secretory granules in acinar cells, gel-overlay analysis revealed pp70 copurified with acinar cell secretory granule membranes. These findings demonstrate an important cell physiological function for CRHSP-28 in the Ca2+-regulated secretory pathway of acinar cells.	Univ Wisconsin, Dept Nutr Sci, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Groblewski, GE (corresponding author), Univ Wisconsin, Dept Nutr Sci, 1415 Linden Dr, Madison, WI 53706 USA.							BRAUN JEA, 1995, NEUROPHARMACOLOGY, V34, P1361, DOI 10.1016/0028-3908(95)00114-L; Brown H, 1998, EMBO J, V17, P5048, DOI 10.1093/emboj/17.17.5048; BURNHAM DB, 1988, AM J PHYSIOL, V254, pG130, DOI 10.1152/ajpgi.1988.254.1.G130; BURNHAM DB, 1982, J BIOL CHEM, V257, P523; BYRNE JA, 1995, CANCER RES, V55, P2896; Byrne JA, 1996, GENOMICS, V35, P523, DOI 10.1006/geno.1996.0393; Byrne JA, 1998, ONCOGENE, V16, P873, DOI 10.1038/sj.onc.1201604; Chen SL, 1997, ONCOGENE, V15, P2577, DOI 10.1038/sj.onc.1201437; Chen SL, 1996, ONCOGENE, V12, P741; Frisch SM, 1997, BIOESSAYS, V19, P705, DOI 10.1002/bies.950190811; Gaisano HY, 2000, PANCREAS, V20, P217, DOI 10.1097/00006676-200004000-00001; GROBLEWSKI GE, 1995, J BIOL CHEM, V270, P1437, DOI 10.1074/jbc.270.3.1437; Groblewski GE, 1999, AM J PHYSIOL-GASTR L, V276, pG219, DOI 10.1152/ajpgi.1999.276.1.G219; Groblewski GE, 1996, J BIOL CHEM, V271, P31502, DOI 10.1074/jbc.271.49.31502; Hansen NJ, 1999, J BIOL CHEM, V274, P22871, DOI 10.1074/jbc.274.32.22871; KITAGAWA M, 1990, AM J PHYSIOL, V259, pG157, DOI 10.1152/ajpgi.1990.259.2.G157; Kraemer J, 1999, EUR J CELL BIOL, V78, P265, DOI 10.1016/S0171-9335(99)80060-0; Ku NO, 1999, AM J PHYSIOL-GASTR L, V277, pG1108, DOI 10.1152/ajpgi.1999.277.6.G1108; Lantz VA, 1998, J CELL BIOL, V140, P897, DOI 10.1083/jcb.140.4.897; Marlowe KJ, 1998, EUR J CELL BIOL, V75, P140, DOI 10.1016/S0171-9335(98)80056-3; Matovcik LM, 1996, J HISTOCHEM CYTOCHEM, V44, P1243, DOI 10.1177/44.11.8918899; MORGAN A, 1995, EMBO J, V14, P232, DOI 10.1002/j.1460-2075.1995.tb06996.x; Muallem S, 1997, CELL CALCIUM, V22, P1, DOI 10.1016/S0143-4160(97)90083-X; MUALLEM S, 1995, J CELL BIOL, V128, P589, DOI 10.1083/jcb.128.4.589; Nourse CR, 1998, BBA-GENE STRUCT EXPR, V1443, P155, DOI 10.1016/S0167-4781(98)00211-5; Ohnishi H, 1996, AM J PHYSIOL-GASTR L, V271, pG531, DOI 10.1152/ajpgi.1996.271.3.G531; Padfield PJ, 2000, FEBS LETT, V484, P129, DOI 10.1016/S0014-5793(00)02126-8; PADFIELD PJ, 1995, AM J PHYSIOL-GASTR L, V269, pG647, DOI 10.1152/ajpgi.1995.269.5.G647; Parente JA, 1996, J BIOL CHEM, V271, P20096, DOI 10.1074/jbc.271.33.20096; POUNCELLHATTON S, 1997, GASTROENTEROLOGY, V113, P649; Proux V, 1996, J BIOL CHEM, V271, P30790, DOI 10.1074/jbc.271.48.30790; Schafer C, 1998, J BIOL CHEM, V273, P24173, DOI 10.1074/jbc.273.37.24173; Torgerson RR, 2000, J CELL PHYSIOL, V182, P438, DOI 10.1002/(SICI)1097-4652(200003)182:3<438::AID-JCP15>3.0.CO;2-N; Ueda N, 2000, GASTROENTEROLOGY, V119, P1123, DOI 10.1053/gast.2000.18145; Valentijn JA, 2000, P NATL ACAD SCI USA, V97, P1091, DOI 10.1073/pnas.97.3.1091; Valentijn K, 1999, BIOCHEM BIOPH RES CO, V266, P652, DOI 10.1006/bbrc.1999.1883; Valentijn KM, 1999, J CELL SCI, V112, P81; Wang L, 2000, J BIOL CHEM, V275, P22862, DOI 10.1074/jbc.M001447200; Williams JA, 1997, DIGESTION, V58, P42, DOI 10.1159/000201524; Williams John A., 1993, P167; WISHART MJ, 1994, AM J PHYSIOL-GASTR L, V267, pG676, DOI 10.1152/ajpgi.1994.267.4.G676; Yule DI, 1997, J BIOL CHEM, V272, P9093	42	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28866	28872		10.1074/jbc.M102214200	http://dx.doi.org/10.1074/jbc.M102214200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11384973	hybrid			2022-12-25	WOS:000170346000032
J	Utani, A; Nomizu, M; Matsuura, H; Kato, K; Kobayashi, T; Takeda, U; Aota, S; Nielsen, PK; Shinkai, H				Utani, A; Nomizu, M; Matsuura, H; Kato, K; Kobayashi, T; Takeda, U; Aota, S; Nielsen, PK; Shinkai, H			A unique sequence of the laminin alpha 3 G domain binds to heparin and promotes cell adhesion through syndecan-2 and -4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT G-DOMAIN; BASEMENT-MEMBRANES; EPITHELIAL-CELLS; INTEGRIN ALPHA-3-BETA-1; EPIDERMOLYSIS-BULLOSA; DYSTROGLYCAN BINDING; PERIPHERAL-NERVE; GAMMA-2 CHAIN; VII COLLAGEN; GENE LAMC2	Laminin-5, consisting of the alpha3, beta3, and gamma2 chains, is localized in the skin basement membrane and supports the structural stability of the epidermo-dermal linkage and regulates various cellular functions. The alpha chains of laminins have been shown to have various biological activities. In this study, we identified a sequence of the alpha3 chain C-terminal globular domain (LG1-LG5 modules) required for both heparin binding and cell adhesion using recombinant proteins and synthetic peptides. We found that the LG3 and LG4 modules have activity for heparin binding and that LG4 has activity for cell adhesion. Studies with synthetic peptides delineated the A3G75aR sequence (NSFMALYLSKGR, residues 1412-1423) within LG4 as a major site for both heparin and cell binding. Substitution mutations in LG4 and A3G75aR identified the Lys and Arg of the A3G75aR sequence as critical for these activities. Cell adhesion to LG4 and A3G75aR was inhibited by heparitinase I treatment of cells, suggesting that cell binding to the A3G75aR site was mediated by cell surface heparan sulfate proteoglycans. We showed by affinity chromatography that syndecan-2 from fibroblasts bound to LG4. Solid-phase assays confirmed that syndecan-2 interacted with the A3G75aR peptide sequence. Stably transfected 293T cells with expression vectors for syndecan-2 and -4, but not glypican-1, specifically adhered to LG4 and A3G75aR. These results indicate that the A3G75aR sequence within the laminin alpha3 LG4 module is responsible for cell adhesion and suggest that syndecan-2 and -4 mediate this activity.	Chiba Univ, Sch Med, Dept Dermatol, Chuou Ku, Chiba 260, Japan; Hokkaido Univ, Grad Sch Environm Earth Sci, Sapporo, Hokkaido 060, Japan; Biomol Engn Res Inst, Suita, Osaka 565, Japan; NIDCR, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA	Chiba University; Hokkaido University; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Utani, A (corresponding author), Chiba Univ, Sch Med, Dept Dermatol, Chuou Ku, 1-8-1 Inohana, Chiba 260, Japan.							ABERDAM D, 1994, NAT GENET, V6, P299, DOI 10.1038/ng0394-299; Amano S, 2000, J BIOL CHEM, V275, P22728, DOI 10.1074/jbc.M002345200; Andac Z, 1999, J MOL BIOL, V287, P253, DOI 10.1006/jmbi.1999.2606; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; Chen M, 1997, J BIOL CHEM, V272, P14516, DOI 10.1074/jbc.272.23.14516; Chiba A, 1997, J BIOL CHEM, V272, P2156; Couchman JR, 1999, J CELL SCI, V112, P3415; Durbeej M, 1998, CURR OPIN CELL BIOL, V10, P594, DOI 10.1016/S0955-0674(98)80034-3; Gallo R, 1996, J INVEST DERMATOL, V107, P676, DOI 10.1111/1523-1747.ep12365571; Goldfinger LE, 1999, J CELL SCI, V112, P2615; Goldfinger LE, 1998, J CELL BIOL, V141, P255, DOI 10.1083/jcb.141.1.255; Henry MD, 1999, CURR OPIN CELL BIOL, V11, P602, DOI 10.1016/S0955-0674(99)00024-1; Hirosaki T, 2000, J BIOL CHEM, V275, P22495, DOI 10.1074/jbc.M001326200; Hoffman MP, 1998, J BIOL CHEM, V273, P28633, DOI 10.1074/jbc.273.44.28633; Hohenester E, 1999, MOL CELL, V4, P783, DOI 10.1016/S1097-2765(00)80388-3; Iba K, 2000, J CELL BIOL, V149, P1143, DOI 10.1083/jcb.149.5.1143; Iivanainen A, 1999, J BIOL CHEM, V274, P14107, DOI 10.1074/jbc.274.20.14107; JACKSON RJ, 1990, TRENDS BIOCHEM SCI, V15, P477, DOI 10.1016/0968-0004(90)90302-R; Koch M, 1999, J CELL BIOL, V145, P605, DOI 10.1083/jcb.145.3.605; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; LACALLE RA, 1989, GENE, V79, P375, DOI 10.1016/0378-1119(89)90220-5; Lampe PD, 1998, J CELL BIOL, V143, P1735, DOI 10.1083/jcb.143.6.1735; Lebakken CS, 1996, J CELL BIOL, V132, P1209, DOI 10.1083/jcb.132.6.1209; Longley RL, 1999, J CELL SCI, V112, P3421; MARCHISIO PC, 1993, EXP CELL RES, V205, P205, DOI 10.1006/excr.1993.1078; MARINKOVICH MP, 1992, J BIOL CHEM, V267, P17900; Nguyen BP, 2000, J BIOL CHEM, V275, P31896, DOI 10.1074/jbc.M006379200; Nguyen BP, 2000, CURR OPIN CELL BIOL, V12, P554, DOI 10.1016/S0955-0674(00)00131-9; Nielsen PK, 2000, J BIOL CHEM, V275, P14517, DOI 10.1074/jbc.275.19.14517; NUMA F, 1995, CANCER RES, V55, P4676; Pall EA, 1996, J BIOL CHEM, V271, P3817; PULKKINEN L, 1994, NAT GENET, V6, P293, DOI 10.1038/ng0394-293; Rapraeger AC, 1993, CURR OPIN CELL BIOL, V5, P844, DOI 10.1016/0955-0674(93)90034-N; Rees S, 1996, BIOTECHNIQUES, V20, P102; ROUSSELLE P, 1994, J CELL BIOL, V125, P205, DOI 10.1083/jcb.125.1.205; Rousselle P, 1997, J CELL BIOL, V138, P719, DOI 10.1083/jcb.138.3.719; Ryan MC, 1999, J CELL BIOL, V145, P1309, DOI 10.1083/jcb.145.6.1309; SONNENBERG A, 1993, J CELL SCI, V106, P1083; Talts JF, 2000, J BIOL CHEM, V275, P35192, DOI 10.1074/jbc.M003261200; Talts JF, 1999, EMBO J, V18, P863, DOI 10.1093/emboj/18.4.863; Talts JF, 1998, FEBS LETT, V426, P71, DOI 10.1016/S0014-5793(98)00312-3; Timpl R, 1996, CURR OPIN CELL BIOL, V8, P618, DOI 10.1016/S0955-0674(96)80102-5; Timpl R, 1996, BIOESSAYS, V18, P123, DOI 10.1002/bies.950180208; Timpl R, 2000, MATRIX BIOL, V19, P309, DOI 10.1016/S0945-053X(00)00072-X; Utani A, 1997, J BIOL CHEM, V272, P2814, DOI 10.1074/jbc.272.5.2814; UTANI A, 1995, J BIOL CHEM, V270, P3292, DOI 10.1074/jbc.270.7.3292; UTANI A, 1994, J BIOL CHEM, V269, P19167; Yamada H, 1996, J NEUROCHEM, V66, P1518; Yamada H, 1996, J BIOL CHEM, V271, P23418, DOI 10.1074/jbc.271.38.23418; Yamaguchi H, 2000, J BIOL CHEM, V275, P29458, DOI 10.1074/jbc.M003103200; ZETTLMEISSL G, 1990, DNA CELL BIOL, V9, P347, DOI 10.1089/dna.1990.9.347	52	117	122	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28779	28788		10.1074/jbc.M101420200	http://dx.doi.org/10.1074/jbc.M101420200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11373281	hybrid			2022-12-25	WOS:000170346000020
J	Shida, T; Hattori, H; Ise, F; Sekiguchi, J				Shida, T; Hattori, H; Ise, F; Sekiguchi, J			Mutational analysis of catalytic sites of the cell wall lytic N-acetylmuramoyl-L-alanine amidases Cw1C and Cw1V	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; ESCHERICHIA-COLI K-12; BACILLUS-SUBTILIS; HYDROLASE GENE; AFFECTS GERMINATION; MOLECULAR-CLONING; AUTOLYSINS; LYSOZYME; ENZYME; IDENTIFICATION	The Bacillus subtilis CwlC and the Bacillus polymyxa var. colistinus CwIV are the cell wall lytic N-acetylmuramoyl-L-alanine amidases in the CwlB (LytC) family. Deletion in the CwlC amidase from the C terminus to residue 177 did not change the amidase activity. However, when the deletion was extended slightly toward the N terminus, the amidase activity was entirely lost. Further, the N-terminal deletion mutant without the first 19 amino acids did not have the amidase activity. These results indicate that the N-terminal half (residues 1-176) of the CwlC amidase, the region homologous to the truncated CwIV (CwlVt), is a catalytic domain. Site-directed mutagenesis was performed on 20 highly conserved amino acid residues within the catalytic domain of CwlC. The amidase activity was lost completely on single amino acid substitutions at two residues (Glu-24 and Glu-141). Similarly, the substitution of the two glutamic acid residues (E26Q and E142Q) of the truncated CwIV (CwIV1), which corresponded to Glu-24 and Glu-141 of CwIC, was critical to the amidase activity. The EDTA-treated CwIV1. did not have amidase activity. The amidase activity of the EDTA-treated CwIV1 was restored by the addition of Zn2+, Mn2+, and Co2+ but not by the addition of Me2+ and Ca2+. These results suggest that the amidases in the CwlB family are zinc amidases containing two glutamic acids as catalytic residues.	Shinshu Univ, Fac Text Sci & Technol, Dept Appl Biol, Nagano 3868567, Japan	Shinshu University	Sekiguchi, J (corresponding author), Shinshu Univ, Fac Text Sci & Technol, Dept Appl Biol, 3-15-1 Tokida, Nagano 3868567, Japan.	jsekigu@giptc.shinshu-u.ac.jp	Sekiguchi, Junichi/F-9963-2010					AKAMATSU T, 1987, AGR BIOL CHEM TOKYO, V51, P2901; ARCHIBALD AR, 1989, BIOTECHNOLOGY HDB, V2, P217; Auld DS, 1997, STRUCT BOND, V89, P29; BAGINSKI ES, 1967, CLIN CHEM, V13, P326; BLAKE CCF, 1965, NATURE, V206, P757, DOI 10.1038/206757a0; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; CHENG XD, 1994, P NATL ACAD SCI USA, V91, P4034, DOI 10.1073/pnas.91.9.4034; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; DEHART HP, 1995, APPL ENVIRON MICROB, V61, P1475, DOI 10.1128/AEM.61.4.1475-1479.1995; DOYLE RJ, 1987, CRC CR REV MICROBIOL, V15, P169, DOI 10.3109/10408418709104457; FEIN JE, 1976, J BACTERIOL, V127, P1427, DOI 10.1128/JB.127.3.1427-1442.1976; HARZ H, 1990, ANAL BIOCHEM, V190, P120, DOI 10.1016/0003-2697(90)90144-X; HOLTJE JV, 1991, J GEN MICROBIOL, V137, P441, DOI 10.1099/00221287-137-3-441; Imoto T., 1972, ENZYMES, V7, P665; Ishikawa S, 1998, J BACTERIOL, V180, P1375, DOI 10.1128/JB.180.6.1375-1380.1998; Ishikawa S, 1999, MOL GEN GENET, V262, P738, DOI 10.1007/s004380051136; Kaneko T, 1996, DNA Res, V3, P109; KELLY JA, 1979, NATURE, V282, P875, DOI 10.1038/282875a0; KURODA A, 1992, MOL GEN GENET, V234, P129, DOI 10.1007/BF00272354; KURODA A, 1993, J BACTERIOL, V175, P6260, DOI 10.1128/JB.175.19.6260-6268.1993; KURODA A, 1990, J GEN MICROBIOL, V136, P2209, DOI 10.1099/00221287-136-11-2209; KURODA A, 1991, J BACTERIOL, V173, P7304, DOI 10.1128/jb.173.22.7304-7312.1991; Kuroki R, 1997, J BIOL CHEM, V272, P19976, DOI 10.1074/jbc.272.32.19976; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mackenzie LF, 1997, J BIOL CHEM, V272, P3161, DOI 10.1074/jbc.272.6.3161; MIKI T, 1987, PROTEIN ENG, V1, P327, DOI 10.1093/protein/1.4.327; Moriyama R, 1996, J BACTERIOL, V178, P6059, DOI 10.1128/jb.178.20.6059-6063.1996; Nugroho FA, 1999, J BACTERIOL, V181, P6230, DOI 10.1128/JB.181.20.6230-6237.1999; PHILLIPS DC, 1966, SCI AM, V215, P78, DOI 10.1038/scientificamerican1166-78; RASHID MH, 1995, FEMS MICROBIOL LETT, V132, P131, DOI 10.1016/0378-1097(95)00299-K; SEKIGUCHI J, 1995, J BACTERIOL, V177, P5582, DOI 10.1128/jb.177.19.5582-5589.1995; Shida T, 2000, BIOSCI BIOTECH BIOCH, V64, P1522, DOI 10.1271/bbb.64.1522; SMITH HO, 1995, SCIENCE, V269, P538, DOI 10.1126/science.7542802; SMITH TJ, 1995, J BACTERIOL, V177, P3855, DOI 10.1128/jb.177.13.3855-3862.1995; Smith TJ, 2000, MICROBIOL-UK, V146, P249, DOI 10.1099/00221287-146-2-249; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; TROUP B, 1994, J BACTERIOL, V176, P673, DOI 10.1128/jb.176.3.673-680.1994; TSUI HCT, 1994, MOL MICROBIOL, V11, P189, DOI 10.1111/j.1365-2958.1994.tb00300.x; Vazeux G, 1996, J BIOL CHEM, V271, P9069, DOI 10.1074/jbc.271.15.9069; WU HC, 1986, CURR TOP MICROBIOL, V125, P127; XU KP, 1993, J BACTERIOL, V175, P4990, DOI 10.1128/JB.175.16.4990-4999.1993	43	44	45	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28140	28146		10.1074/jbc.M103903200	http://dx.doi.org/10.1074/jbc.M103903200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11375403	hybrid			2022-12-25	WOS:000170093400054
J	Cao, WH; Medvedev, AV; Daniel, KW; Collins, S				Cao, WH; Medvedev, AV; Daniel, KW; Collins, S			beta-adrenergic activation of p38 MAP kinase in adipocytes - cAMP induction of the uncoupling protein 1 (UCP1) gene requires p38 MAP kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWN ADIPOSE-TISSUE; BETA(3)-ADRENERGIC RECEPTOR; STIMULATING-HORMONE; CYCLIC-AMP; EXPRESSION; GAMMA; PATHWAY; PHOSPHORYLATION; DIFFERENTIATION; MECHANISM	Because of increasing evidence that G protein-coupled receptors activate multiple signaling pathways, it becomes important to determine the coordination of these pathways and their physiological significance. Here we show that the beta (3)-adrenergic receptor (beta (3)AR) stimulates p38 mitogen-activated protein kinase (p38 MAPK) via PKA in adipocytes and that cAMP-dependent transcription of the mitochondrial uncoupling protein 1 (UCP1) promoter by beta (3)AR requires p38 MAPK. The selective beta (3)AR agonist CL316,243 (CL) stimulates phosphorylation of MAP kinase kinase 3/6 and p38 MAPK in a time- and dose-dependent manner in both white and brown adipocytes, Isoproterenol and forskolin mimicked the effect of CL on p38 MAPK. In all cases activation was blocked by the specific p38 MAPK inhibitor SB202190 (SB; 1-10 muM). The involvement of PKA in beta (3)AR-dependent p38 MAPK activation was confirmed by the ability of the PKA inhibitors H89 (20 muM) and (R-p)-cAMP-S (1 mM) to block phosphorylation of p38 MAPK. Treatment of primary brown adipocytes with CL or forskolin induced the expression of UCP1 mRNA levels (6.8- +/- 0.8-fold), and this response was eliminated by PKA inhibitors and SB202190. A similar stimulation of a 3.7-kilobase UCP1 promoter by CL and forskolin was also completely inhibited by PKA inhibitors and SB202190, indicating that these effects on UCP1 expression are transcriptional. Moreover, the PKA-dependent transactivation of the UCP1 promoter, as well as its sensitivity to SB202190, was fully reproduced by a 220-nucleotide enhancer element from the UCP1 gene. We similarly observed that increased phosphorylation of ATF-2 by CL was sensitive to both H89 and SB202190, while phosphorylation of cAMP-response element-binding protein was inhibited only by H89. Together, these studies illustrate that p38 MAPK is an important downstream target of the beta -adrenergic/cAMP/PKA signaling pathway in adipocytes, and one of the functional consequences of this cascade is stimulation of UCP1 gene expression in brown adipocytes.	Duke Univ, Dept Pharmacol & Canc Biol, Med Ctr, Box 3557, Durham, NC 27710 USA; Duke Univ, Dept Psychiat & Behav Sci, Med Ctr, Durham, NC 27710 USA	Duke University; Duke University	Collins, S (corresponding author), Duke Univ, Dept Pharmacol & Canc Biol, Med Ctr, Box 3557, Durham, NC 27710 USA.	colli008@mc.duke.edu		Medvedev, Alexander/0000-0001-6983-1687	NIDDK NIH HHS [R01-DK53092, R01-DK57698] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057698, R01DK053092] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Bock BC, 2000, J BIOL CHEM, V275, P14231, DOI 10.1074/jbc.275.19.14231; Cao WH, 2000, J BIOL CHEM, V275, P38131, DOI 10.1074/jbc.C000592200; Cassard-Doulcier AM, 1998, BIOCHEM J, V333, P243, DOI 10.1042/bj3330243; CASSARDDOULCIER AM, 1993, MOL ENDOCRINOL, V7, P497, DOI 10.1210/me.7.4.497; COLLINS S, 1988, J BIOL CHEM, V263, P9067; COLLINS S, 1994, MOL ENDOCRINOL, V8, P518, DOI 10.1210/me.8.4.518; Collins S., 2001, Nutrient-gene interactions in health and disease, P261; Collins S, 2001, RECENT PROG HORM RES, V56, P309, DOI 10.1210/rp.56.1.309; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Feoktistov I, 2000, MOL PHARMACOL, V58, P903, DOI 10.1124/mol.58.5.903; Gerhardt CC, 1999, MOL PHARMACOL, V55, P255, DOI 10.1124/mol.55.2.255; GRANNEMAN JG, 1995, ENDOCRINOLOGY, V136, P2007, DOI 10.1210/en.136.5.2007; Gutkind J.S, 2000, SCI STKE; Irie Y, 1999, BIOCHEM BIOPH RES CO, V255, P221, DOI 10.1006/bbrc.1998.9999; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KOZAK LP, 1988, J BIOL CHEM, V263, P12274; KOZAK UC, 1994, MOL CELL BIOL, V14, P59, DOI 10.1128/MCB.14.1.59; Lazennec G, 2000, MOL ENDOCRINOL, V14, P1962, DOI 10.1210/me.14.12.1962; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Maizels ET, 1998, ENDOCRINOLOGY, V139, P3353, DOI 10.1210/en.139.7.3353; Medvedev AV, 2001, J BIOL CHEM, V276, P10817, DOI 10.1074/jbc.M010587200; MIYAMOTO NG, 1987, NUCLEIC ACIDS RES, V15, P9095, DOI 10.1093/nar/15.21.9095; Pomerance M, 2000, J BIOL CHEM, V275, P40539, DOI 10.1074/jbc.M002097200; Premont RT, 1996, J BIOL CHEM, V271, P13900, DOI 10.1074/jbc.271.23.13900; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; REHNMARK S, 1989, EXP CELL RES, V182, P75, DOI 10.1016/0014-4827(89)90280-2; RICQUIER D, 1983, BIOCHEM J, V210, P859, DOI 10.1042/bj2100859; ROBISON GA, 1970, CIRC RES, V27, pI147; ROHLFS EM, 1995, J BIOL CHEM, V270, P10723, DOI 10.1074/jbc.270.18.10723; ROSS SR, 1992, P NATL ACAD SCI USA, V89, P7561, DOI 10.1073/pnas.89.16.7561; Sears IB, 1996, MOL CELL BIOL, V16, P3410; Silva JE, 1997, EUR J ENDOCRINOL, V136, P251, DOI 10.1530/eje.0.1360251; Soeder KJ, 1999, J BIOL CHEM, V274, P12017, DOI 10.1074/jbc.274.17.12017; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; Yan SZ, 1998, MOL PHARMACOL, V53, P182, DOI 10.1124/mol.53.2.182; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhen XC, 1998, MOL PHARMACOL, V54, P453, DOI 10.1124/mol.54.3.453; Zheng M, 2000, J BIOL CHEM, V275, P40635, DOI 10.1074/jbc.M006325200	44	222	228	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27077	27082		10.1074/jbc.M101049200	http://dx.doi.org/10.1074/jbc.M101049200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11369767	hybrid			2022-12-25	WOS:000169966900047
J	Nguyen, TV; Fyjioka, H; Kang, AS; Rogers, WO; Fidock, DA; James, AA				Nguyen, TV; Fyjioka, H; Kang, AS; Rogers, WO; Fidock, DA; James, AA			Stage-dependent localization of a novel gene product of the malaria parasite, Plasmodium falciparum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCUMSPOROZOITE PROTEIN; POLYBASIC DOMAIN; SURFACE-ANTIGEN; NEW-GENERATION; SPOROZOITE; IDENTIFICATION; EXPRESSION; RICH; DNA; PALMITOYLATION	A novel Plasmodium falciparum gene, MB2, was identified by screening a sporozoite cDNA library with the serum of a human volunteer protected experimentally by the bites of P, falciparum-infected and irradiated mosquitoes. The single-exon, single-copy MB2 gene is predicted to encode a protein with an M-r of 187,000. The MB2 protein has an amino-terminal basic domain, a central acidic domain, and a carboxyl-terminal domain with similarity to the GTP-binding domain of the prokaryotic translation initiation factor 2. MB2 is expressed in sporozoites, the liver, and blood-stage parasites and gametocytes. The MB2 protein is distributed as a similar to 120-kDa moiety on the surface of sporozoites and is imported into the nucleus of blood-stage parasites as a similar to 66-kDa species. Proteolytic processing is favored as the mechanism regulating the distinct subcellular localization of the MB2 protein, This differential localization provides multiple opportunities to exploit the MB2 gene product as a vaccine or therapeutic target.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA; Diversa Corp, San Diego, CA 92121 USA; USN, Med Res Ctr, Silver Spring, MD 20910 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA	University of California System; University of California Irvine; Case Western Reserve University; United States Department of Defense; United States Navy; Yeshiva University; Albert Einstein College of Medicine	James, AA (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, 3205 Bio Sci 2, Irvine, CA 92697 USA.	aajames@uci.edu		James, Anthony/0000-0001-5577-3308; Kang, Angray/0000-0002-4672-4114; Fidock, David/0000-0001-6753-8938	NIAID NIH HHS [AI35827] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI035827] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AIKAWA M, 1990, ADV PARASIT, V29, P151, DOI 10.1016/S0065-308X(08)60106-2; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; ATKINSON CT, 1989, AM J TROP MED HYG, V41, P9, DOI 10.4269/ajtmh.1989.41.1.TM0410010009; BALLOU WR, 1987, LANCET, V1, P1277; Barale JC, 1997, MOL BIOCHEM PARASIT, V87, P169, DOI 10.1016/S0166-6851(97)00065-0; Barale JC, 1997, INFECT IMMUN, V65, P3003, DOI 10.1128/IAI.65.8.3003-3010.1997; CADWALLADER KA, 1994, MOL CELL BIOL, V14, P4722, DOI 10.1128/MCB.14.7.4722; CLYDE DF, 1973, AM J MED SCI, V266, P169, DOI 10.1097/00000441-197309000-00002; DAME JB, 1984, SCIENCE, V225, P593, DOI 10.1126/science.6204383; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; Fidock DA, 2000, EXP PARASITOL, V95, P220, DOI 10.1006/expr.2000.4528; FIDOCK DA, 1994, MOL BIOCHEM PARASIT, V64, P219, DOI 10.1016/0166-6851(94)00012-3; Fidock DA, 1998, EXP PARASITOL, V89, P125, DOI 10.1006/expr.1998.4262; GALEY B, 1990, INFECT IMMUN, V58, P2995, DOI 10.1128/IAI.58.9.2995-3001.1990; GYSIN J, 1993, J IMMUNOL METHODS, V159, P209, DOI 10.1016/0022-1759(93)90159-5; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HERRINGTON D, 1991, AM J TROP MED HYG, V45, P539, DOI 10.4269/ajtmh.1991.45.539; HERRINGTON DA, 1987, NATURE, V328, P257, DOI 10.1038/328257a0; HOFFMAN SL, 1993, MOL IMMUNOLOGICAL CO, P149; Hyde J E, 1993, Methods Mol Biol, V21, P133; HYDE JE, 1987, GENE, V61, P177, DOI 10.1016/0378-1119(87)90112-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOKESHWAR VB, 1990, J BIOL CHEM, V265, P1665; MCCUTCHAN TF, 1984, SCIENCE, V225, P625, DOI 10.1126/science.6330899; Miller LH, 1998, NAT MED, V4, P520, DOI 10.1038/nm0598supp-520; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; OSTMAN A, 1991, CELL REGUL, V2, P503, DOI 10.1091/mbc.2.7.503; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; ROGERS WO, 1992, P NATL ACAD SCI USA, V89, P9176, DOI 10.1073/pnas.89.19.9176; Sambrook J., 1989, IMMUNOLOGY; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMYTHE JA, 1988, P NATL ACAD SCI USA, V85, P5195, DOI 10.1073/pnas.85.14.5195; Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202; Stoute JA, 1998, J INFECT DIS, V178, P1139, DOI 10.1086/515657; Stratmann T, 1997, PROTEIN EXPRES PURIF, V11, P72, DOI 10.1006/prep.1997.0768; SUHRBIER A, 1988, EUR J CELL BIOL, V46, P25; USUI H, 1994, J NEUROSCI, V14, P4915; WEBER JL, 1987, GENE, V52, P103, DOI 10.1016/0378-1119(87)90399-4; WEISS WR, 1992, J IMMUNOL, V149, P2103; *WHO, 1998, FACT SHEET N, V94; YOSHIDA N, 1980, SCIENCE, V207, P71, DOI 10.1126/science.6985745; ZAVALA F, 1983, J EXP MED, V157, P1947, DOI 10.1084/jem.157.6.1947	44	21	21	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26724	26731		10.1074/jbc.M103375200	http://dx.doi.org/10.1074/jbc.M103375200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11371568	Green Accepted, hybrid			2022-12-25	WOS:000169823300140
J	Ruiz, FA; Rodrigues, CO; Docampo, R				Ruiz, FA; Rodrigues, CO; Docampo, R			Rapid changes in polyphosphate content within acidocalcisomes in response to cell growth, differentiation, and environmental stress in Trypanosoma cruzi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HALOTOLERANT ALGA DUNALIELLA; NUCLEAR-MAGNETIC-RESONANCE; INORGANIC POLYPHOSPHATE; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; LEISHMANIA-MAJOR; ACIDIC VACUOLES; ALKALINE STRESS; CALCIUM-PUMP; H+-ATPASE	Inorganic polyphosphate (polyP) has been identified and measured in different stages of Trypanosoma cruzi, Millimolar levels (in terms of Pi residues) in chains of less than 50 residues long, and micromolar levels in chains of about 700-800 residues long, were found in different stages of T, cruzi, Analysis of purified T, cruzi acidocalcisomes indicated that polyPs were preferentially located in these organelles. This was confirmed by visualization of polyPs in the acidocalcisomes using 4 ' ,6-diamidino-2-phenylindole. A rapid increase (within 2-4 h) in the levels of short and long chain polyPs was detected during trypomastigote to amastigote differentiation and during the lag phase of growth of epimastigotes (within 12-24 h), Levels rapidly decreased after the epimastigotes resumed growth. Short and long chain polyP levels rapidly decreased upon exposure of epimastigotes to hypo-osmotic or alkaline stresses, whereas levels increased after hyperosmotic stress. Ca2+ release from acidocalcisomes by a combination of ionophores (ionomycin and nigericin) was associated with the hydrolysis of short and long chain polyPs, In agreement with these results, acidocalcisomes were shown to contain polyphosphate kinase and exopolyphosphatase activities. Together, these results suggest a critical role for these organelles in the adaptation of the parasite to environmental changes.	Univ Illinois, Coll Vet Med, Dept Pathobiol, Mol Parasitol Lab, Urbana, IL 61802 USA	University of Illinois System; University of Illinois Urbana-Champaign	Docampo, R (corresponding author), Univ Illinois, Coll Vet Med, Dept Pathobiol, Mol Parasitol Lab, 2001 S Lincoln Ave, Urbana, IL 61802 USA.		Ruiz, Felix A./B-1032-2008	Ruiz, Felix A./0000-0003-0748-5015	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023259, R21AI023259] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-23259] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLAN RA, 1980, CAN J MICROBIOL, V26, P912, DOI 10.1139/m80-158; Ault-Riche D, 1998, J BACTERIOL, V180, P1841; BONE GJ, 1956, NATURE, V178, P308, DOI 10.1038/178308a0; Bringaud F, 1998, P NATL ACAD SCI USA, V95, P7963, DOI 10.1073/pnas.95.14.7963; CASTRO CD, 1995, APPL ENVIRON MICROB, V61, P4448, DOI 10.1128/AEM.61.12.4448-4453.1995; Castrol CD, 1999, BIOTECHNOL PROGR, V15, P65, DOI 10.1021/bp9800743; Chapman A G, 1977, Adv Microb Physiol, V15, P253, DOI 10.1016/S0065-2911(08)60318-5; CROOKE E, 1994, J BIOL CHEM, V269, P6290; DOCAMPO R, 1995, BIOCHEM J, V310, P1005, DOI 10.1042/bj3101005; Docampo R, 1999, PARASITOL TODAY, V15, P443, DOI 10.1016/S0169-4758(99)01531-8; Furuya T, 2000, J BIOL CHEM, V275, P6428, DOI 10.1074/jbc.275.9.6428; HAROLD FM, 1966, BACTERIOL REV, V30, P772, DOI 10.1128/MMBR.30.4.772-794.1966; Ho AM, 2000, SCIENCE, V289, P265, DOI 10.1126/science.289.5477.265; JACOBSON L, 1982, BIOCHEM J, V201, P473, DOI 10.1042/bj2010473; KORNBERG A, 1995, J BACTERIOL, V177, P491, DOI 10.1128/jb.177.3.491-496.1995; KORNBERG A, 1956, J BIOL CHEM, V218, P23; Kulaev I, 1999, J BIOSCI BIOENG, V88, P111, DOI 10.1016/S1389-1723(99)80189-3; Kulaev I S, 1999, Prog Mol Subcell Biol, V23, P27; KUMBLE KD, 1995, J BIOL CHEM, V270, P5818, DOI 10.1074/jbc.270.11.5818; Kumble KD, 1996, J BIOL CHEM, V271, P27146, DOI 10.1074/jbc.271.43.27146; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LeFurgey A, 2001, COMP BIOCHEM PHYS A, V128, P385, DOI 10.1016/S1095-6433(00)00319-6; LIU CM, 1978, J BIOL CHEM, V253, P5892; Lorenz B, 1997, ANAL BIOCHEM, V246, P176, DOI 10.1006/abio.1996.9998; Lu HG, 1998, MOL CELL BIOL, V18, P2309, DOI 10.1128/MCB.18.4.2309; Lu HG, 1997, J BIOL CHEM, V272, P9464, DOI 10.1074/jbc.272.14.9464; Meyer A., 1904, BOT Z, V62, P113; Miranda K, 2000, PARASITOL RES, V86, P373, DOI 10.1007/s004360050682; Moreno B, 2000, J BIOL CHEM, V275, P28356, DOI 10.1074/jbc.M003893200; Myler PJ, 1999, P NATL ACAD SCI USA, V96, P2902, DOI 10.1073/pnas.96.6.2902; Ogawa N, 2000, MOL BIOL CELL, V11, P4309, DOI 10.1091/mbc.11.12.4309; PICK U, 1991, PLANT PHYSIOL, V97, P1234, DOI 10.1104/pp.97.3.1234; PICK U, 1991, PLANT PHYSIOL, V97, P1226, DOI 10.1104/pp.97.3.1226; RANGELALDAO R, 1987, MOL BIOCHEM PARASIT, V22, P39, DOI 10.1016/0166-6851(87)90067-3; Rao NN, 1998, J BACTERIOL, V180, P2186, DOI 10.1128/JB.180.8.2186-2193.1998; Rao NN, 1996, J BACTERIOL, V178, P1394, DOI 10.1128/jb.178.5.1394-1400.1996; Rodrigues CO, 1999, BIOCHEM J, V340, P759, DOI 10.1042/0264-6021:3400759; Rodrigues CO, 1999, MOL CELL BIOL, V19, P7712; ROSENBERG H, 1969, BIOCHIM BIOPHYS ACTA, V184, P191, DOI 10.1016/0304-4165(69)90114-7; Scott DA, 1998, J BIOL CHEM, V273, P22151, DOI 10.1074/jbc.273.34.22151; Scott DA, 1997, J BIOL CHEM, V272, P28020, DOI 10.1074/jbc.272.44.28020; Scott DA, 2000, J BIOL CHEM, V275, P24215, DOI 10.1074/jbc.M002454200; TIJSSEN JPF, 1982, BIOCHIM BIOPHYS ACTA, V721, P394, DOI 10.1016/0167-4889(82)90094-5; Urbina JA, 1999, J BIOL CHEM, V274, P33609, DOI 10.1074/jbc.274.47.33609; Vanderheyden N, 1996, BIOCHEM J, V318, P103, DOI 10.1042/bj3180103; Vercesi AE, 1996, BIOCHEM J, V315, P265, DOI 10.1042/bj3150265; VERCESI AE, 1994, BIOCHEM J, V304, P227, DOI 10.1042/bj3040227; Vieira LL, 1997, MOL BIOCHEM PARASIT, V90, P449, DOI 10.1016/S0166-6851(97)00180-1; WEISS M, 1991, PLANT PHYSIOL, V97, P1241, DOI 10.1104/pp.97.3.1241; *WHO, 1997, 13 WHO UNDPWBTDR, P112; WILKINSON JF, 1960, INT REV CYTOL, V9, P1, DOI 10.1016/S0074-7696(08)62744-8; WURST H, 1994, J BIOL CHEM, V269, P10996; WURST H, 1995, J BACTERIOL, V177, P898, DOI 10.1128/jb.177.4.898-906.1995; YANG YC, 1993, BIOCHIM BIOPHYS ACTA, V1179, P141, DOI 10.1016/0167-4889(93)90135-C	54	126	128	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26114	26121		10.1074/jbc.M102402200	http://dx.doi.org/10.1074/jbc.M102402200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11371561	hybrid			2022-12-25	WOS:000169823300065
J	Yang, JB; Duan, ZJ; Yao, W; Lee, O; Yang, L; Yang, XY; Sun, X; Chang, CCY; Chang, TY; Li, BL				Yang, JB; Duan, ZJ; Yao, W; Lee, O; Yang, L; Yang, XY; Sun, X; Chang, CCY; Chang, TY; Li, BL			Synergistic transcriptional activation of human acyl-coenzyme A: Cholesterol acyltransterase-1 gene by interferon-gamma and all-trans-retinoic acid THP-1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCAVENGER RECEPTOR EXPRESSION; LOW-DENSITY-LIPOPROTEIN; HAMSTER OVARY CELLS; FOAM CELLS; MOLECULAR-CLONING; MAMMALIAN-CELLS; HUMAN MONOCYTES; LEUKEMIA-CELLS; ACAT-1 PROTEIN; DNA-BINDING	Acyl-coenzyme A:cholesterol acyltransferase (ACAT) is an intracellular enzyme involved in cellular cholesterol homeostasis and in atherosclerotic foam cell formation. Human ACAT-1 gene contains two promoters (P1 and P7), each located in a different chromosome (1 and 7) (Li, B. L., Li, X. L., Duan, Z. J., Lee, O., Lin, S., Ma, Z. M., Chang, C. C., Yang, X. Y., Park, J. P., Mohandas, T. K., Noll, W., Chan, L., and Chang, T. Y. (1999) J. Biol Chem. 274, 11060-11071), Interferon-gamma (IFN-gamma), a cytokine that exerts many pro-atherosclerotic: effects in vivo, causes up-regulation of ACAT-1 mRNA in human blood monocyte-derived macrophages and macrophage-like cells but not in other cell types. To examine the molecular nature of this observation, we identified within the ACAT-1 P1 promoter a 159-base pair core region. This region contains 4 Sp1 elements and an HFN-gamma activated sequence (GAS) that overlaps with the second Sp1 element. In the monocytic cell line THP-1 cell, the combination of IFN-gamma and all-trans-retinoic acid (a known differentiation agent) enhances the ACAT-1 P1 promoter but not the P7 promoter. Additional experiments showed that all-trans-retinoic acid causes large induction of the transcription factor STAT1, While IFN-gamma causes activation of STAT1 such that it binds to the GAS/Sp1 site in the ACAT-1 P1 promoter. Our work provides a molecular mechanism to account for the effect of IFN-gamma in causing transcriptional activation of ACAT-1 in macrophage-like cells.	Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA; Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China	Dartmouth College; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Chang, TY (corresponding author), Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA.		Yang, Jinbo/AAM-9580-2020	li, bo liang/0000-0002-7123-5638; Chang, Ta-Yuan/0000-0002-3249-0468	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036709, R37HL036709] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 36709] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; Alessio M, 1996, J BIOL CHEM, V271, P1770, DOI 10.1074/jbc.271.3.1770; Anderson RA, 1998, J BIOL CHEM, V273, P26747, DOI 10.1074/jbc.273.41.26747; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BANKA CL, 1991, J LIPID RES, V32, P35; BISHOP JE, 1980, ANAL BIOCHEM, V106, P344, DOI 10.1016/0003-2697(80)90531-X; BROWN MS, 1980, J BIOL CHEM, V255, P9344; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; Buhman KK, 2000, NAT MED, V6, P1341, DOI 10.1038/82153; CADIGAN KM, 1988, J LIPID RES, V29, P1683; Cases S, 1998, J BIOL CHEM, V273, P26755, DOI 10.1074/jbc.273.41.26755; Chang CCY, 2000, J BIOL CHEM, V275, P28083; CHANG CCY, 1995, J BIOL CHEM, V270, P29532; Chang CCY, 1998, J BIOL CHEM, V273, P35132, DOI 10.1074/jbc.273.52.35132; CHANG CCY, 1993, J BIOL CHEM, V268, P20747; Chang TY, 1997, ANNU REV BIOCHEM, V66, P613, DOI 10.1146/annurev.biochem.66.1.613; CHANG TY, 1980, J BIOL CHEM, V255, P7787; CHENG WL, 1995, AM J PHYSIOL-ENDOC M, V269, pE642, DOI 10.1152/ajpendo.1995.269.4.E642; CHRISTEN S, 1994, J CLIN INVEST, V93, P2149, DOI 10.1172/JCI117211; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; FIELDING CJ, 1992, FASEB J, V6, P3162, DOI 10.1096/fasebj.6.13.1327930; GENG YJ, 1992, J CLIN INVEST, V89, P1322, DOI 10.1172/JCI115718; GENG YJ, 1995, ARTERIOSCL THROM VAS, V15, P1995, DOI 10.1161/01.ATV.15.11.1995; Gianni M, 1997, BLOOD, V89, P1001, DOI 10.1182/blood.V89.3.1001; Gupta S, 1997, J CLIN INVEST, V99, P2752, DOI 10.1172/JCI119465; HANSSON GK, 1989, AM J PATHOL, V135, P169; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jiang CL, 1999, PEPTIDES, V20, P1385, DOI 10.1016/S0196-9781(99)00147-3; JONASSON L, 1985, J CLIN INVEST, V76, P125, DOI 10.1172/JCI111934; Lee O, 1998, J LIPID RES, V39, P1722; Lee RG, 2000, J LIPID RES, V41, P1991; Li BL, 1999, J BIOL CHEM, V274, P11060, DOI 10.1074/jbc.274.16.11060; LI H, 1993, ARTERIOSCLER THROMB, V13, P197, DOI 10.1161/01.ATV.13.2.197; LI HM, 1995, J CLIN INVEST, V95, P122, DOI 10.1172/JCI117628; Liu JW, 1997, J LIPID RES, V38, P2035; Mack KD, 1998, J IMMUNOL METHODS, V211, P79, DOI 10.1016/S0022-1759(97)00194-4; Mangelsdorf David J., 1994, P319; Matikainen S, 1998, LEUKEMIA LYMPHOMA, V30, P63, DOI 10.3109/10428199809050930; Matikainen S, 1997, CELL GROWTH DIFFER, V8, P687; Miyazaki A, 1998, ARTERIOSCL THROM VAS, V18, P1568, DOI 10.1161/01.ATV.18.10.1568; Oelkers P, 1998, J BIOL CHEM, V273, P26765, DOI 10.1074/jbc.273.41.26765; OOSTA GM, 1978, ANAL BIOCHEM, V89, P31, DOI 10.1016/0003-2697(78)90723-6; Panousis CG, 2000, ARTERIOSCL THROM VAS, V20, P1565, DOI 10.1161/01.ATV.20.6.1565; Panousis CG, 2000, J LIPID RES, V41, P75; POWELL JT, 1992, FEBS LETT, V303, P173, DOI 10.1016/0014-5793(92)80512-F; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sakamoto S, 1999, J IMMUNOL, V162, P4381; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; Shiffman D, 2000, J BIOL CHEM, V275, P37324, DOI 10.1074/jbc.M004732200; Tellides G, 2000, NATURE, V403, P207, DOI 10.1038/35003221; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; Walter MJ, 1997, J BIOL CHEM, V272, P28582, DOI 10.1074/jbc.272.45.28582; Wang HX, 1996, ARTERIOSCL THROM VAS, V16, P809, DOI 10.1161/01.ATV.16.6.809; Whitman SC, 1999, J LIPID RES, V40, P1017	56	42	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					20989	20998		10.1074/jbc.M011488200	http://dx.doi.org/10.1074/jbc.M011488200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11399774	hybrid			2022-12-25	WOS:000169297900027
J	Jansen, SM; Groener, JEM; Bax, W; Suter, A; Saftig, P; Somerharju, P; Poorthuis, BJHM				Jansen, SM; Groener, JEM; Bax, W; Suter, A; Saftig, P; Somerharju, P; Poorthuis, BJHM			Biosynthesis of phosphatidylcholine from a phosphocholine precursor pool derived from the late endosomal/lysosomal degradation of sphingomyelin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL ACID-PHOSPHATASE; TARTRATE-RESISTANT; ALKALINE-PHOSPHATASE; PHOSPHOLIPID ANALOG; SKIN FIBROBLASTS; KIDNEY CELLS; HEXADECYLPHOSPHOCHOLINE; LOCALIZATION; METABOLITES; SEPARATION	Previous studies suggest that the steps of the CDP-choline pathway of phosphatidylcholine synthesis are tightly linked in a so-called metabolon, Evidence has been presented that only choline that enters cells through the choline transporter, and not phosphocholine administered to cells by membrane permeabilization, is incorporated into phosphatidylcholine, Here, we show that [C-14]phosphocholine derived from the lysosomal degradation of [C-14]choline-labeled sphingomyelin is incorporated as such into phosphatidylcholine in human and mouse fibroblasts, Low density lipoprotein receptor-mediated endocytosis was used to specifically direct [C-14]sphingomyelin to the lysosomal degradation pathway, Free labeled choline was not found either intracellularly or in the medium, not even when the cells were energy-depleted. Deficiency of lysosomal acid phosphatases in mouse or alkaline phosphatase in human fibroblasts did not affect the incorporation of lysosomal [C-14]sphingomyelin-derived [C-14]phosphocholine into phosphatidylcholine, supporting our finding that phosphocholine is not degraded to choline prior to its incorporation into phosphatidylcholine. Inhibition studies and analysis of molecular species showed that exogenous [H-3]choline and sphingomyelin-derived [C-14]phosphocholine are incorporated into phosphatidylcholine via a common pathway of synthesis. Our findings provide evidence that, in fibroblasts, phosphocholine derived from sphingomyelin is transported out of the lysosome and subsequently incorporated into phosphatidylcholine without prior hydrolysis of phosphocholine to choline, The findings do not support the existence of a phosphatidylcholine synthesis metabolon in fibroblasts.	Leiden Univ, Med Ctr, Dept Pediat, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Clin Genet, NL-2300 RC Leiden, Netherlands; Univ Helsinki, Inst Biomed, Dept Med Chem, Helsinki 00016, Finland; Univ Gottingen, Zentrum Biochem & Mol Zellbiol, D-37073 Gottingen, Germany	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Helsinki; University of Gottingen	Poorthuis, BJHM (corresponding author), Leiden Univ, Med Ctr, Dept Pediat, Bldg 1,P3-P,POB 9600, NL-2300 RC Leiden, Netherlands.		Saftig, Paul/A-7966-2010					ARSENIS C, 1968, J BIOL CHEM, V243, P5702; Bladergroen BA, 1998, BIOCHEM J, V334, P511, DOI 10.1042/bj3340511; Boggs K, 1998, BBA-LIPID LIPID MET, V1389, P1, DOI 10.1016/S0005-2760(97)00145-8; CLARK SA, 1989, J BONE MINER RES, V4, P399; DECHAVES EP, 1995, BIOCHEM J, V312, P411, DOI 10.1042/bj3120411; DETMAR M, 1994, J INVEST DERMATOL, V102, P490, DOI 10.1111/1523-1747.ep12373109; DREXLER HG, 1994, LEUKEMIA, V8, P359; FEDDE KN, 1990, AM J HUM GENET, V47, P776; FEDDE KN, 1990, AM J HUM GENET, V47, P767; FOLCH J, 1957, J BIOL CHEM, V226, P497; GEILEN CC, 1992, J BIOL CHEM, V267, P6719; GEILEN CC, 1994, J LIPID RES, V35, P625; GEORGE TP, 1989, BIOCHIM BIOPHYS ACTA, V1004, P283, DOI 10.1016/0005-2760(89)90075-1; Hayman AR, 1996, DEVELOPMENT, V122, P3151; Jansen SM, 1999, BBA-MOL CELL BIOL L, V1436, P363, DOI 10.1016/S0005-2760(98)00129-5; KATES M, 1991, TECHNIQUES LIPIDOLOG, P251; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; Koivusalo M, 2001, J LIPID RES, V42, P663; KUNZE H, 1993, BIOCHIM BIOPHYS ACTA, V1169, P273, DOI 10.1016/0005-2760(93)90251-4; KUNZE H, 1993, J CHROMATOGR, V636, P221, DOI 10.1016/0021-9673(93)80235-Z; LOWRY OH, 1951, J BIOL CHEM, V193, P265; OBRIEN JS, 1970, NEW ENGL J MED, V283, P15, DOI 10.1056/NEJM197007022830104; PATTON GM, 1982, J LIPID RES, V23, P190; Saftig P, 1997, J BIOL CHEM, V272, P18628, DOI 10.1074/jbc.272.30.18628; VAN HELVOORT A, 1994, J BIOL CHEM, V269, P1763; WAHEED A, 1985, BIOCHEM GENET, V23, P309, DOI 10.1007/BF00504327; WAHEED A, 1988, EMBO J, V7, P2351, DOI 10.1002/j.1460-2075.1988.tb03079.x; WANDERS RJA, 1993, BIOCHIM BIOPHYS ACTA, V1181, P219, DOI 10.1016/0925-4439(93)90024-U; Wieder T, 1996, CANCER LETT, V100, P71, DOI 10.1016/0304-3835(95)04072-2; Zlatkine P, 1996, BIOCHEM J, V315, P983, DOI 10.1042/bj3150983	30	12	14	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					18722	18727		10.1074/jbc.M101817200	http://dx.doi.org/10.1074/jbc.M101817200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11376003	hybrid			2022-12-25	WOS:000169091000012
J	Sathyanarayanan, PV; Siems, WF; Jones, JP; Poovaiah, BW				Sathyanarayanan, PV; Siems, WF; Jones, JP; Poovaiah, BW			Calcium-stimulated autophosphorylation site of plant chimeric calcium/calmodulin-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING; STRUCTURAL BASIS; DOMAIN; PHOSPHORYLATION; INHIBITION; THREONINE; CDNA; IV; IDENTIFICATION; AUTOINHIBITION	The existence of two molecular switches regulating plant chimeric Ca2+/calmodulin-dependent protein kinase (CCaMK), namely the C-terminal visinin-like domain acting as Ca2+-sensitive molecular switch and calmodulin binding domain acting as Ca2+-stimulated autophosphorylation-sensitive molecular switch, has been described (Sathyanarayanan, P. V., Cremo, C. R., and Poovaiah, B. W. (2000) J. BioL Chem. 275, 30417-30422). Here we report the identification of Ca2+-stimulated autophosphorylation site of CCaMK by matrix-assisted laser desorption ionization time of flight-mass spectrometry. Thr(267) was confirmed as the Ca2+-stimulated autophosphorylation site by post-source decay experiments and by site-directed mutagenesis. The purified T267A mutant form of CCaMK did not show Ca2+-stimulated autophosphorylation, autophosphorylation-dependent variable calmodulin affinity, or Ca2+/calmodulin stimulation of kinase activity. Sequence comparison of CCaMK from monocotyledonous plant (lily) and dicotyledonous plant (tobacco) suggests that the autophosphorylation site is conserved. This is the first identification of a phosphorylation site specifically responding to activation by second messenger system (Ca2+ messenger system) in plants. Homology modeling of the kinase and calmodulin binding domain of CCaMK with the crystal structure of calcium/calmodulin-dependent protein kinase 1 suggests that the Ca2+-stimulated autophosphorylation site is located on the surface of the kinase and far from the catalytic site. Analysis of Ca2+-stimulated autophosphorylation with increasing concentration of CCaMK indicates the possibility that the Ca2+-stimulated phosphorylation occurs by an intermolecular mechanism.	Washington State Univ, Lab Plant Mol Biol & Physiol, Dept Hort, Pullman, WA 99164 USA; Washington State Univ, Dept Chem, Pullman, WA 99164 USA	Washington State University; Washington State University	Poovaiah, BW (corresponding author), Washington State Univ, Lab Plant Mol Biol & Physiol, Dept Hort, Pullman, WA 99164 USA.	poovaiah@wsu.edu						Asara JM, 1999, J AM SOC MASS SPECTR, V10, P35, DOI 10.1016/S1044-0305(98)00129-9; BEACH ME, 1995, CELL, V81, P905, DOI 10.1016/0092-8674(95)90010-1; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Berridge MJ, 1997, NATURE, V386, P759, DOI 10.1038/386759a0; Bevington P. R., 1969, DATA REDUCTION ERROR, P56; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COLBRAN RJ, 1989, J BIOL CHEM, V264, P4800; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; CRUZALEGUI FH, 1992, P NATL ACAD SCI USA, V89, P12127, DOI 10.1073/pnas.89.24.12127; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; GilleceCastro BL, 1996, METHOD ENZYMOL, V271, P427; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANLEY RM, 1988, BIOCHEM BIOPH RES CO, V152, P122, DOI 10.1016/S0006-291X(88)80688-0; HANLEY RM, 1989, NUCLEIC ACIDS RES, V17, P3992, DOI 10.1093/nar/17.10.3992; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; Harmon AC, 2000, TRENDS PLANT SCI, V5, P154, DOI 10.1016/S1360-1385(00)01577-6; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; JONES DA, 1991, FEBS LETT, V289, P105, DOI 10.1016/0014-5793(91)80919-T; KAMESHITA I, 1993, J BIOCHEM-TOKYO, V113, P583, DOI 10.1093/oxfordjournals.jbchem.a124087; KELLY PT, 1988, P NATL ACAD SCI USA, V85, P4991, DOI 10.1073/pnas.85.14.4991; Kussmann M, 1999, BIOCHEMISTRY-US, V38, P7780, DOI 10.1021/bi982888y; Liu ZH, 1998, PLANT MOL BIOL, V38, P889, DOI 10.1023/A:1006019001200; Lu YT, 1996, PLANTA, V199, P18; Neville DCA, 1997, PROTEIN SCI, V6, P2436; Pappin D J, 1997, Methods Mol Biol, V64, P165; PATIL S, 1995, P NATL ACAD SCI USA, V92, P4897, DOI 10.1073/pnas.92.11.4897; PATTON BL, 1990, J BIOL CHEM, V265, P11204; PAYNE ME, 1988, J BIOL CHEM, V263, P7190; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PICCIOTTO MR, 1993, J BIOL CHEM, V268, P26512; Poovaiah BW, 1999, PLANTA, V209, P161, DOI 10.1007/s004250050618; POOVAIAH BW, 1993, CRIT REV PLANT SCI, V12, P185, DOI 10.1080/713608046; Putkey JA, 1996, J BIOL CHEM, V271, P29619, DOI 10.1074/jbc.271.47.29619; Putney JW, 1998, SCIENCE, V279, P191, DOI 10.1126/science.279.5348.191; Ramachandiran S, 1997, J BIOCHEM-TOKYO, V121, P984; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sathyanarayanan PV, 2000, J BIOL CHEM, V275, P30417, DOI 10.1074/jbc.M000771200; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SMITH MK, 1992, J BIOL CHEM, V267, P1761; STULTS JT, 1995, CURR OPIN STRUC BIOL, V5, P691, DOI 10.1016/0959-440X(95)80063-8; Takezawa D, 1996, J BIOL CHEM, V271, P8126, DOI 10.1074/jbc.271.14.8126; THIEL G, 1988, P NATL ACAD SCI USA, V85, P6337, DOI 10.1073/pnas.85.17.6337; Vihinen H, 2000, J BIOL CHEM, V275, P27775; Wang Z, 1998, J NEUROCHEM, V71, P378; WATILLON B, 1993, PLANT PHYSIOL, V101, P1381, DOI 10.1104/pp.101.4.1381; Waxham MN, 1998, J BIOL CHEM, V273, P17579, DOI 10.1074/jbc.273.28.17579; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Zenke FT, 1999, J BIOL CHEM, V274, P32565, DOI 10.1074/jbc.274.46.32565	50	34	37	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32940	32947		10.1074/jbc.M009648200	http://dx.doi.org/10.1074/jbc.M009648200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11399751	hybrid			2022-12-25	WOS:000170746000076
J	Shang, ML; Koshikawa, N; Schenk, S; Quaranta, V				Shang, ML; Koshikawa, N; Schenk, S; Quaranta, V			The LG3 module of laminin-5 harbors a binding site for integrin alpha(3)beta(1) that promotes cell adhesion, spreading, and migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-3 CHAIN; LIGAND-BINDING; STRUCTURAL REQUIREMENT; DIRECTED MUTAGENESIS; SIGNAL-TRANSDUCTION; SECONDARY STRUCTURE; CIRCULAR-DICHROISM; CRYSTAL-STRUCTURE; EPITHELIAL-CELLS; GLOBULAR DOMAIN	Laminins are a family of extracellular matrix glycoproteins involved in cell adhesion and migration. A major obstacle to understanding their structure-function relationships is the lack of small laminin domains capable of replicating integrin-binding, cell-adhesive, and migratory functions of the intact molecule. Here, we show that the recombinant LG3 (rLG3) module (26 kDa) of laminin-5 (Ln-5) alpha (3) chain replicated key Ln-5 activities. rLG3 but not rLG1 or rLG2 supported cell adhesion and migration of at least two distinct cell lines, in an integrin alpha (3)beta (1)-dependent manner. Cell adhesion to rLG3 was regulated by divalent cations and accompanied by cell spreading and tyrosine phosphorylation of FAK focal adhesion kinase. The integrin binding activity of rLG3 was confirmed by rLG3 affinity chromatography of detergent cell lysates, which resulted in specific purification of integrin alpha (3)beta (1). To our knowledge, this is the first report directly demonstrating that a recombinant laminin LG module is an active domain capable of supporting integrin-dependent cell adhesion and migration.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Quaranta, V (corresponding author), Scripps Res Inst, Dept Cell Biol, SBR-12,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Quaranta, Vito/G-6512-2016	Quaranta, Vito/0000-0001-7491-8672	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046902] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46902] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AOTA S, 1991, J BIOL CHEM, V266, P15938; Ay J, 1998, P NATL ACAD SCI USA, V95, P6613, DOI 10.1073/pnas.95.12.6613; Baker SE, 1996, J CELL SCI, V109, P2509; Bazzoni G, 1998, TRENDS BIOCHEM SCI, V23, P30, DOI 10.1016/S0968-0004(97)01141-9; Bazzoni G, 1998, J BIOL CHEM, V273, P6670, DOI 10.1074/jbc.273.12.6670; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BOWDITCH RD, 1991, J BIOL CHEM, V266, P23323; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; CRENNELL S, 1994, STRUCTURE, V2, P535, DOI 10.1016/S0969-2126(00)00053-8; DELWEL GO, 1994, MOL BIOL CELL, V5, P203, DOI 10.1091/mbc.5.2.203; DEUTZMANN R, 1990, EUR J BIOCHEM, V191, P513, DOI 10.1111/j.1432-1033.1990.tb19151.x; DOMLOGEHULTSCH N, 1992, J CLIN INVEST, V90, P1628, DOI 10.1172/JCI116033; Eble JA, 1998, BIOCHEMISTRY-US, V37, P10945, DOI 10.1021/bi980175+; ENGEL J, 1992, BIOCHEMISTRY-US, V31, P10643, DOI 10.1021/bi00159a001; GALLIANO MF, 1995, J BIOL CHEM, V270, P21820, DOI 10.1074/jbc.270.37.21820; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; GIL SG, 1994, J INVEST DERMATOL, V103, pS31, DOI 10.1111/1523-1747.ep12398953; Gonzales M, 1999, MOL BIOL CELL, V10, P259, DOI 10.1091/mbc.10.2.259; Hintermann E, 2001, J CELL BIOL, V153, P465, DOI 10.1083/jcb.153.3.465; Hirosaki T, 2000, J BIOL CHEM, V275, P22495, DOI 10.1074/jbc.M001326200; Hohenester E, 1999, MOL CELL, V4, P783, DOI 10.1016/S1097-2765(00)80388-3; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; Humphries MJ, 1996, CURR OPIN CELL BIOL, V8, P632, DOI 10.1016/S0955-0674(96)80104-9; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; JOHNSON WC, 1988, ANNU REV BIOPHYS BIO, V17, P145, DOI 10.1146/annurev.bb.17.060188.001045; Kim MG, 2000, J IMMUNOL, V165, P192, DOI 10.4049/jimmunol.165.1.192; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; Lampe PD, 1998, J CELL BIOL, V143, P1735, DOI 10.1083/jcb.143.6.1735; LEONG L, 1995, J CELL SCI, V108, P3817; Malinda KM, 1996, INT J BIOCHEM CELL B, V28, P957, DOI 10.1016/1357-2725(96)00042-8; MARDON HJ, 1994, FEBS LETT, V340, P197, DOI 10.1016/0014-5793(94)80137-1; Mathus TL, 2000, METH MOL B, V139, P27; MIYAZAKI K, 1993, P NATL ACAD SCI USA, V90, P11767, DOI 10.1073/pnas.90.24.11767; Mizushima H, 1997, CELL GROWTH DIFFER, V8, P979; Nagai T, 1991, Seikagaku, V63, P507; Nguyen BP, 2000, CURR OPIN CELL BIOL, V12, P554, DOI 10.1016/S0955-0674(00)00131-9; NIESSEN CM, 1994, EXP CELL RES, V211, P360, DOI 10.1006/excr.1994.1099; OTT U, 1982, EUR J BIOCHEM, V123, P63, DOI 10.1111/j.1432-1033.1982.tb06499.x; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; Plopper GE, 1998, BREAST CANCER RES TR, V51, P57, DOI 10.1023/A:1006086218174; Redick SD, 2000, J CELL BIOL, V149, P521, DOI 10.1083/jcb.149.2.521; ROUSSELLE P, 1994, J CELL BIOL, V125, P205, DOI 10.1083/jcb.125.1.205; ROUSSELLE P, 1991, J CELL BIOL, V114, P567, DOI 10.1083/jcb.114.3.567; Rousselle P, 1997, J CELL BIOL, V138, P719, DOI 10.1083/jcb.138.3.719; ROUSSELLE P, 1995, J BIOL CHEM, V270, P13766, DOI 10.1074/jbc.270.23.13766; Rudenko G, 1999, CELL, V99, P93, DOI 10.1016/S0092-8674(00)80065-3; RYAN MC, 1994, J BIOL CHEM, V269, P22779; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Skyldberg B, 1999, J NATL CANCER I, V91, P1882, DOI 10.1093/jnci/91.21.1882; SONNENBERG A, 1990, J CELL BIOL, V110, P2145, DOI 10.1083/jcb.110.6.2145; SONNENBERG A, 1991, EXP CELL RES, V197, P234, DOI 10.1016/0014-4827(91)90428-W; Sordat I, 1998, J PATHOL, V185, P44, DOI 10.1002/(SICI)1096-9896(199805)185:1<44::AID-PATH46>3.0.CO;2-A; SUNG U, 1993, J CELL BIOL, V123, P1255, DOI 10.1083/jcb.123.5.1255; Takeda A, 1999, J INVEST DERMATOL, V113, P38, DOI 10.1046/j.1523-1747.1999.00645.x; Talts JF, 1998, FEBS LETT, V426, P71, DOI 10.1016/S0014-5793(98)00312-3; TAMURA RN, 1990, J CELL BIOL, V111, P1593, DOI 10.1083/jcb.111.4.1593; Tisi D, 2000, EMBO J, V19, P1432, DOI 10.1093/emboj/19.7.1432; Tozer EC, 1996, BIOCHEM CELL BIOL, V74, P785, DOI 10.1139/o96-085; Tsubota Y, 2000, BIOCHEM BIOPH RES CO, V278, P614, DOI 10.1006/bbrc.2000.3851; Tsunenaga M, 1998, MATRIX BIOL, V17, P603, DOI 10.1016/S0945-053X(98)90111-1; YURCHENCO PD, 1993, J BIOL CHEM, V268, P8356; Zhang K, 1996, EXP CELL RES, V227, P309, DOI 10.1006/excr.1996.0280; [No title captured]	65	81	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					33045	33053		10.1074/jbc.M100798200	http://dx.doi.org/10.1074/jbc.M100798200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11395486	hybrid			2022-12-25	WOS:000170746000089
J	Brasier, AR; Lu, MP; Hai, T; Lu, Y; Boldogh, I				Brasier, AR; Lu, MP; Hai, T; Lu, Y; Boldogh, I			NF-kappa B-inducible BCL-3 expression is an autoregulatory loop controlling nuclear p50/NF-kappa B1 residence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANDIDATE PROTOONCOGENE BCL-3; RENIN-ANGIOTENSIN SYSTEM; TRANSCRIPTION FACTOR; ONCOPROTEIN BCL-3; SIGNAL-TRANSDUCTION; ALPHA PROTEOLYSIS; EPITHELIAL-CELLS; FEEDBACK LOOP; TNF RECEPTOR; REL-A	NF-kappaB is a transcription factor whose nuclear residence is controlled by I kappaB family members. In the NF kappaB-I kappaB autoregulatory loop, activated (nuclear) ReI A.NF-kappa B1 induces the resynthesis of I kappaB alpha recapturing nuclear Rel A back into the cytoplasm within 1 h of stimulation. In contrast, NF-kappa B1 subunits redistribute more slowly into the cytoplasm (from 6 to 12 h). Here we examine the role of inducible cytoplasmic BCL-3 expression in terminating nuclear NF-kappaB 1. Although BCL-3 is a nuclear protein in B lymphocytes, surprisingly, BCL-3 is primarily a cytoplasmic protein in HepG2 cells. Cytoplasmic BCL-3 abundance is induced 6-12 h after tumor necrosis factor-a stimulation where it complexes with NF-kappa B1 homodimers. Moreover, BCL-3 mRNA and protein expression are induced by NF-kappaB-activating agents. Two observations are interpreted to indicate that bcl-3 is transactivated by NF-kappaB/Rel A: 1) expression of a dominant negative NF-kappaB inhibitor blocks tumor necrosis factor-a-induced BCL-3 expression and 2) expression of constitutively active Rel A is sufficient to induce BCL-3 expression. In gene transfer studies, we identify two high affinity NF-kappaB-binding sites, kappa B1 (located at -872 to -861 nucleotides) and kappa B2 (-106 to -96 nucleotides), and although both bind with high affinity to Rel A only kappa B2 is required for NF-v-B-dependent induction of the native BCL-3 promoter. Down-regulation of BCL-3 induction results in prolonged, enhanced NF-kappa B1 binding and increased NF-kappaB-dependent transcription. Together, these data suggest the presence of an N-F-kappaB-BCL-3 autoregulatory loop important in terminating NF-kappa B1 action and that individual NF-kappaB isoforms are actively terminated through coordinate induction of inhibitory I kappaB molecules to restore cellular homeostasis.	Univ Texas, Med Branch, Div Endocrinol, Dept Microbiol & Immunol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Internal Med, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Brasier, AR (corresponding author), Univ Texas, Med Branch, Div Endocrinol, Dept Microbiol & Immunol, MRB 8-138,301 Univ Blvd, Galveston, TX 77555 USA.		Hai, Tsonwin/E-3185-2011	Hai, Tsonwin/0000-0003-4510-0315; Brasier, Allan/0000-0002-5012-4090	NATIONAL CANCER INSTITUTE [R01CA084461] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA084461] Funding Source: Medline; NIEHS NIH HHS [ES06676, P30 ES006676] Funding Source: Medline; PHS HHS [55630] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; Brasier AR, 1998, J BIOL CHEM, V273, P3551, DOI 10.1074/jbc.273.6.3551; BRASIER AR, 1990, CURRENT PROTOCOLS MO; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Bundy DL, 1997, J BIOL CHEM, V272, P33132, DOI 10.1074/jbc.272.52.33132; CHENG Q, 1994, J BIOL CHEM, V269, P13551; Chu ZL, 1996, MOL CELL BIOL, V16, P5974; Dechend R, 1999, ONCOGENE, V18, P3316, DOI 10.1038/sj.onc.1202717; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; Garofalo R, 1996, J VIROL, V70, P8773, DOI 10.1128/JVI.70.12.8773-8781.1996; HAN Y, 1997, J BIOL CHEM, V272, P9823; Han YQ, 1999, J BIOL CHEM, V274, P787, DOI 10.1074/jbc.274.2.787; Han YQ, 1999, J BIOL CHEM, V274, P939, DOI 10.1074/jbc.274.2.939; Harhaj EW, 1999, MOL CELL BIOL, V19, P7088; Heissmeyer V, 1999, EMBO J, V18, P4766, DOI 10.1093/emboj/18.17.4766; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; ITO CY, 1994, NUCLEIC ACIDS RES, V22, P3787, DOI 10.1093/nar/22.18.3787; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; JAFFREY SR, 1993, NUCLEIC ACIDS RES, V21, P4627, DOI 10.1093/nar/21.19.4627; Jamaluddin M, 2000, MOL ENDOCRINOL, V14, P99, DOI 10.1210/me.14.1.99; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Klement JF, 1996, MOL CELL BIOL, V16, P2341; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; Li JY, 1996, MOL ENDOCRINOL, V10, P252, DOI 10.1210/me.10.3.252; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; PADMANABHAN R, 1993, METHOD ENZYMOL, V218, P637; Pastore L, 1999, CIRCULATION, V100, P1646, DOI 10.1161/01.CIR.100.15.1646; Rebollo A, 2000, MOL CELL BIOL, V20, P3407, DOI 10.1128/MCB.20.10.3407-3416.2000; Richard M, 1999, BLOOD, V93, P4318, DOI 10.1182/blood.V93.12.4318.412k09_4318_4327; RON D, 1990, MOL CELL BIOL, V10, P4389, DOI 10.1128/MCB.10.8.4389; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Song HY, 1996, P NATL ACAD SCI USA, V93, P6721, DOI 10.1073/pnas.93.13.6721; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Suyang H, 1996, MOL CELL BIOL, V16, P5444; Tam WF, 2000, MOL CELL BIOL, V20, P2269, DOI 10.1128/MCB.20.6.2269-2284.2000; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Tummala PE, 1999, CIRCULATION, V100, P1223, DOI 10.1161/01.CIR.100.11.1223; URBAN MB, 1990, GENE DEV, V4, P1975, DOI 10.1101/gad.4.11.1975; Watanabe N, 1997, EMBO J, V16, P3609, DOI 10.1093/emboj/16.12.3609; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; Zhang MY, 1998, BLOOD, V92, P1225, DOI 10.1182/blood.V92.4.1225.416k20_1225_1234; ZHANG Q, 1994, MOL CELL BIOL, V14, P3915, DOI 10.1128/MCB.14.6.3915; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	62	84	85	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32080	32093		10.1074/jbc.M102949200	http://dx.doi.org/10.1074/jbc.M102949200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11387332	hybrid			2022-12-25	WOS:000170613500084
J	Small, KM; Brown, KM; Forbes, SL; Liggett, SB				Small, KM; Brown, KM; Forbes, SL; Liggett, SB			Modification of the beta(2)-adrenergic receptor to engineer a receptor-effector complex for gene therapy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; CARDIAC-HYPERTROPHY; TRANSGENIC OVEREXPRESSION; DIFFERENTIALLY AFFECT; HEART; ACTIVATION; AGONIST; DESENSITIZATION; EXPRESSION; CELLS	Depressed G-protein-coupled receptor (GPCR) signaling has been implicated as a component of the pathophysiology of a number of complex diseases including heart failure and asthma, and augmentation or restoration of signaling by various means has been shown to improve organ function. Because some, properties of native GPCRs are disadvantageous for ectopic therapeutic expression, we utilized the beta (2)-adrenergic receptor (beta (2)AR) as a scaffold to construct a highly modified therapeutic receptor-effector complex (TREC) suitable for gene therapy. Altogether, 19 modifications were made to the receptor. The ligand-binding site was re-engineered in TM-3 so that a beta -hydroxylinethyl side chain acts as a proton donor for the binding of a novel ligand. In addition, sites critical for agonist-promoted down-regulation in the amino terminus and for phosphorylation by GPCR kinases, and protein kinases A and C, in the third intracellular loop and the carboxyl terminus of the receptor were altered. These modifications of the receptor resulted in depressed agonist-stimulated adenylyl cyclase activity (26.8 +/- 2.1 versus 41.4 +/- 8 pmol/min/mg for wild-type beta (2)AR). This was fully restored by fusing the carboxyl terminus of the modified receptor to G alpha (s) (43.3 +/- 2.7 pmol/min/mg). The fully modified fused receptor was not activated by beta -agonists but rather by a nonbiogenic amine agonist that itself failed to activate the wild-type beta (2)AR. This two-way selectivity thus provides targeted activation based on physiologic status. Furthermore, the TREC did not display tachyphylaxis to prolonged agonist exposure (desensitization was 1 +/- 5% versus 55 +/- 4% for wild-type beta (2)AR). Thus, despite extensive alterations in regions of conformational lability, the beta (2)AR can be tailored to have optimal signaling characteristics for gene therapy. As a general paradigm, TRECs for enhancement of other G-protein signaling appear to be feasible for modification of other pathologic states.	Univ Cincinnati, Coll Med, Dept Med, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Pharmacol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Liggett, SB (corresponding author), 231 Albert Sabin Way,Rm G062, Cincinnati, OH 45267 USA.	stephen.liggett@uc.edu	liggett, stephen b/E-7453-2012	Liggett, Stephen B./0000-0002-0128-3669				Bristow MR, 1997, CARDIOVASC DRUG THER, V11, P291, DOI 10.1023/A:1007748131847; BRISTOW MR, 1989, MOL PHARMACOL, V35, P295; BRISTOW MR, 1986, CIRC RES, V59, P297, DOI 10.1161/01.RES.59.3.297; Brodde OE, 1999, PHARMACOL REV, V51, P651; Choi DJ, 1999, CELL BIOCHEM BIOPHYS, V31, P321, DOI 10.1007/BF02738246; Coward P, 1998, P NATL ACAD SCI USA, V95, P352, DOI 10.1073/pnas.95.1.352; Dorn GW, 2000, MOL PHARMACOL, V57, P278; Dorn GW, 1999, P NATL ACAD SCI USA, V96, P6400, DOI 10.1073/pnas.96.11.6400; FORSAYETH JR, 1994, BIOTECHNIQUES, V17, P354; Freeman K, 2001, J CLIN INVEST, V107, P967, DOI 10.1172/JCI12083; GREEN SA, 1994, BIOCHEMISTRY-US, V33, P9414, DOI 10.1021/bi00198a006; GREEN SA, 1996, GENETICS ASTHMA, P67; GROVE A, 1995, BRIT J CLIN PHARMACO, V39, P109, DOI 10.1111/j.1365-2125.1995.tb04416.x; GROVE A, 1995, LANCET, V346, P201, DOI 10.1016/S0140-6736(95)91265-7; HADCOCK JR, 1992, J BIOL CHEM, V267, P4740; Harding VB, 2001, P NATL ACAD SCI USA, V98, P5809, DOI 10.1073/pnas.091102398; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; HOSODA K, 1995, MOL PHARMACOL, V48, P206; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Larson JE, 2000, MOL GENET METAB, V71, P470, DOI 10.1006/mgme.2000.3087; Liggett SB, 2000, CIRCULATION, V101, P1707; Liggett SB, 1993, REGULATION CELLULAR, P71; Lohse MJ, 1996, BASIC RES CARDIOL, V91, P29, DOI 10.1007/BF00795359; McGraw DW, 1999, J BIOL CHEM, V274, P32241, DOI 10.1074/jbc.274.45.32241; McGraw DW, 2000, AM J PHYSIOL-LUNG C, V279, pL379, DOI 10.1152/ajplung.2000.279.2.L379; McGraw DW, 1998, LUNG BIOL HEALTH DIS, V115, P255; MCGRAW DW, 2001, IN PRESS AM J PHYSL; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Rockman HA, 1998, P NATL ACAD SCI USA, V95, P7000, DOI 10.1073/pnas.95.12.7000; Seifert R, 1999, TRENDS PHARMACOL SCI, V20, P383, DOI 10.1016/S0165-6147(99)01368-1; Shah AS, 2000, J THORAC CARDIOV SUR, V120, P581, DOI 10.1067/mtc.2000.107519; Shah AS, 2000, CIRCULATION, V101, P408, DOI 10.1161/01.CIR.101.4.408; Small KM, 2000, BIOCHEMISTRY-US, V39, P2815, DOI 10.1021/bi992497z; STRADER CD, 1991, J BIOL CHEM, V266, P5; STRADER CD, 1988, J BIOL CHEM, V263, P10267; STRADER CD, 1989, J BIOL CHEM, V264, P13572; Tan S, 1997, LANCET, V350, P995, DOI 10.1016/S0140-6736(97)03211-X; TURKI J, 1995, AM J PHYSIOL-LUNG C, V269, pL709, DOI 10.1152/ajplung.1995.269.5.L709; Turki J, 1996, P NATL ACAD SCI USA, V93, P10483, DOI 10.1073/pnas.93.19.10483; White DC, 2000, P NATL ACAD SCI USA, V97, P5428, DOI 10.1073/pnas.090091197; Wieland K, 1996, P NATL ACAD SCI USA, V93, P9276, DOI 10.1073/pnas.93.17.9276	44	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31596	31601		10.1074/jbc.M102734200	http://dx.doi.org/10.1074/jbc.M102734200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11402033	hybrid			2022-12-25	WOS:000170613500019
J	Asano, S; Io, T; Kimura, T; Sakamoto, S; Takeguchi, N				Asano, S; Io, T; Kimura, T; Sakamoto, S; Takeguchi, N			Alanine-scanning mutagenesis of the sixth transmembrane segment of gastric H+,K+-ATPase alpha-subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; SARCOPLASMIC-RETICULUM; FUNCTIONAL CONSEQUENCES; MEMBRANE TOPOLOGY; AMINO-ACIDS; MUTATIONAL ANALYSIS; BINDING SITE; H+-ATPASE; NA,K-ATPASE; H,K-ATPASE	The sixth transmembrane (M6) segment of the catalytic subunit plays an important role in the ion recognition and transport in the type II P-type ATPase families. In this study, we singly mutated all amino acid residues in the M6 segment of gastric H+,K+-ATPase a-subunit with alanine, expressed the mutants in HEK-293 cells, and studied the effects of the mutation on the functions of H+,K+-ATPase; overall K+-stimulated ATPase, phosphorylation, and dephosphorylation. Four mutants, L819A, D826A, I827A, and L833A, completely lost the K+-ATPase activity. Mutant L819A was phosphorylated but hardly dephosphorylated in the presence of K+, whereas mutants D826A, I827A, and L833A were not phosphorylated from ATP. We found that almost all of these amino acid residues, which are important for the function, are located on the same side of the a-helix of the M6 segment. In addition, we found that amino acids involved in the phosphorylation are located exclusively in the cytoplasmic half of the M6 segment and those involved in the K+-dependent dephosphorylation are in the luminal half. Several mutants such as I821A, L823A, T825A, and P829A partly retained the K+-ATPase activity accompanying the decrease in the rate of phosphorylation.	Mol Genet Res Ctr, Toyama 9300194, Japan; Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Toyama 9300194, Japan	University of Toyama	Asano, S (corresponding author), Mol Genet Res Ctr, 2630 Sugitani, Toyama 9300194, Japan.	shinji@ms.toyama-mpu.ac.jp		Asano, Shinji/0000-0003-1443-8970				Ambesi A, 1996, J BIOL CHEM, V271, P22999, DOI 10.1074/jbc.271.38.22999; ANDERSEN JP, 1992, J BIOL CHEM, V267, P2767; Arguello JM, 1999, ARCH BIOCHEM BIOPHYS, V367, P341, DOI 10.1006/abbi.1999.1278; Asano S, 2000, J BIOCHEM, V127, P993, DOI 10.1093/oxfordjournals.jbchem.a022716; ASANO S, 1994, BIOCHEM J, V299, P59, DOI 10.1042/bj2990059; Asano S, 1997, J BIOL CHEM, V272, P17668, DOI 10.1074/jbc.272.28.17668; Asano S, 1996, J BIOL CHEM, V271, P2740, DOI 10.1074/jbc.271.5.2740; ASANO S, 1987, J BIOL CHEM, V262, P13263; BAMBERG K, 1994, J BIOL CHEM, V269, P16909; BAMBERG K, 1992, BIOCHIM BIOPHYS ACTA, V1131, P69, DOI 10.1016/0167-4781(92)90100-E; BESANCON M, 1993, BIOCHEMISTRY-US, V32, P2345, DOI 10.1021/bi00060a028; Besancon M, 1997, J BIOL CHEM, V272, P22438, DOI 10.1074/jbc.272.36.22438; Choe S, 1995, P NATL ACAD SCI USA, V92, P12046, DOI 10.1073/pnas.92.26.12046; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; Dutra MB, 1998, J BIOL CHEM, V273, P17411, DOI 10.1074/jbc.273.28.17411; FENG JN, 1994, BIOCHEMISTRY-US, V33, P4218, DOI 10.1021/bi00180a015; Gatto C, 1999, J BIOL CHEM, V274, P13737, DOI 10.1074/jbc.274.20.13737; Hermsen HPH, 2000, BIOCHEMISTRY-US, V39, P1330, DOI 10.1021/bi991396y; Hermsen HPH, 1998, BIOCHEM J, V331, P465, DOI 10.1042/bj3310465; Hu YK, 2000, J BIOL CHEM, V275, P19185, DOI 10.1074/jbc.M000641200; JEWELLMOTZ EA, 1993, BIOCHEMISTRY-US, V32, P13523, DOI 10.1021/bi00212a018; Kimura Y, 1998, J BIOL CHEM, V273, P14238, DOI 10.1074/jbc.273.23.14238; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambrecht N, 1998, J BIOL CHEM, V273, P13719, DOI 10.1074/jbc.273.22.13719; LUTSENKO S, 1995, P NATL ACAD SCI USA, V92, P7936, DOI 10.1073/pnas.92.17.7936; Melle-Milovanovic D, 1998, J BIOL CHEM, V273, P11075, DOI 10.1074/jbc.273.18.11075; Mense M, 2000, J BIOL CHEM, V275, P1749, DOI 10.1074/jbc.275.3.1749; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; Morii M, 1996, J BIOL CHEM, V271, P4068; Rice WJ, 1996, J BIOL CHEM, V271, P31412, DOI 10.1074/jbc.271.49.31412; Swarts HGP, 1998, EMBO J, V17, P3029, DOI 10.1093/emboj/17.11.3029; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; VILSEN B, 1989, J BIOL CHEM, V264, P21024; WALLMARK B, 1985, J BIOL CHEM, V260, P3681; Xie YH, 1996, J BIOL CHEM, V271, P2563, DOI 10.1074/jbc.271.5.2563; YODA A, 1970, BIOCHEM BIOPH RES CO, V40, P880, DOI 10.1016/0006-291X(70)90985-X; Zhang ZS, 2000, BIOCHEMISTRY-US, V39, P8758, DOI 10.1021/bi000185m	38	23	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31265	31273		10.1074/jbc.M103698200	http://dx.doi.org/10.1074/jbc.M103698200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11397805	hybrid			2022-12-25	WOS:000170472900089
J	Lambeir, AM; Proost, P; Durinx, C; Bal, G; Senten, K; Augustyns, K; Scharpe, S; Van Damme, J; De Meester, I				Lambeir, AM; Proost, P; Durinx, C; Bal, G; Senten, K; Augustyns, K; Scharpe, S; Van Damme, J; De Meester, I			Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE-DERIVED CHEMOKINE; HUMAN-IMMUNODEFICIENCY-VIRUS; T-CELL GROWTH; ANTI-HIV-1 ACTIVITY; CHEMOTACTIC ACTIVITY; FACTOR 1-ALPHA; HUMAN EOTAXIN; CD26; RECEPTOR; RANTES	Chemokines coordinate many aspects of leukocyte migration. As chemoattractants they play an important role in the innate and acquired immune response. There is good experimental evidence that N-terminal truncation by secreted or cell surface proteases is a way of modulating chemokine action. The localization of CD26/dipeptidyl peptidase IV on cell surfaces and in biological fluids, its primary specificity, and the type of naturally occurring truncated chemokines are consistent with such a function. We determined the steady-state catalytic parameters for a relevant selection of chemokines (CCL3b, CCL5, CCL11, CCL22, CXCL9, CXCL10, CXCL11, and CXCL12) previously reported to alter their chemotactic behavior due to CD26/dipeptidyl peptidase IV-catalyzed truncation. The results reveal a striking selectivity for stromal cell-derived factor-la (CXCL12) and macrophage-derived chemokine (CCL22). The kinetic parameters support the hypothesis that CD26/dipeptidyl peptidase IV contributes to the degradation of certain chemokines in vivo. The data not only provide insight into the selectivity of the enzyme for specific chemokines, but they also contribute to the general understanding of CD26/dipeptidyl peptidase IV secondary substrate specificity.	Univ Antwerp, Med Biochem Lab, Dept Pharmaceut Sci, B-2610 Antwerp, Belgium; Katholieke Univ Leuven, Rega Inst Med Res, Lab Mol Immunol, B-3000 Louvain, Belgium; Univ Antwerp, Dept Pharmaceut Sci, Med Chem Lab, B-2610 Antwerp, Belgium	University of Antwerp; KU Leuven; University of Antwerp	Lambeir, AM (corresponding author), Univ Antwerp, Med Biochem Lab, Dept Pharmaceut Sci, Univ Pl 1 S6, B-2610 Antwerp, Belgium.		Augustyns, Koen/ABG-2306-2020; De Meester, Ingrid/A-6881-2017; Proost, Paul/V-3052-2017; Lambeir, Anne-Marie/B-2477-2017; Augustyns, Koen/C-1102-2008	Augustyns, Koen/0000-0002-5203-4339; De Meester, Ingrid/0000-0002-3421-0124; Proost, Paul/0000-0002-0133-5545; Lambeir, Anne-Marie/0000-0001-9386-3777; Augustyns, Koen/0000-0002-5203-4339; Durinx, Christine/0000-0003-4237-8899				Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Belyaev A, 1999, J MED CHEM, V42, P1041, DOI 10.1021/jm981033g; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; BONGERS J, 1992, BIOCHIM BIOPHYS ACTA, V1122, P147, DOI 10.1016/0167-4838(92)90317-7; BREZINSCHEK RI, 1995, J IMMUNOL, V154, P3062; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; Crump MP, 1998, J BIOL CHEM, V273, P22471, DOI 10.1074/jbc.273.35.22471; Czaplewski LG, 1999, J BIOL CHEM, V274, P16077, DOI 10.1074/jbc.274.23.16077; De Meester I, 1999, IMMUNOL TODAY, V20, P367, DOI 10.1016/S0167-5699(99)01486-3; Delgado MB, 2001, EUR J IMMUNOL, V31, P699, DOI 10.1002/1521-4141(200103)31:3<699::AID-IMMU699>3.0.CO;2-6; DeMeester I, 1996, J IMMUNOL METHODS, V189, P99, DOI 10.1016/0022-1759(95)00239-1; DEMEESTER IA, 1995, J LEUKOCYTE BIOL, V58, P325, DOI 10.1002/jlb.58.3.325; Durinx C, 2000, EUR J BIOCHEM, V267, P5608, DOI 10.1046/j.1432-1327.2000.01634.x; Fulop V, 2001, J BIOL CHEM, V276, P1262, DOI 10.1074/jbc.M007003200; Garzino-Demo A, 2000, IMMUNOL REV, V177, P79, DOI 10.1034/j.1600-065X.2000.17711.x; Huhn J, 2000, IMMUNOL LETT, V72, P127, DOI 10.1016/S0165-2478(00)00170-X; Iwata S, 1999, INT IMMUNOL, V11, P417, DOI 10.1093/intimm/11.3.417; Kahne T, 1999, INT J MOL MED, V4, P3; Kinter A, 2000, IMMUNOL REV, V177, P88, DOI 10.1034/j.1600-065X.2000.17708.x; Lambeir AM, 1997, BBA-PROTEIN STRUCT M, V1340, P215, DOI 10.1016/S0167-4838(97)00045-9; Lee B, 1999, P NATL ACAD SCI USA, V96, P5215, DOI 10.1073/pnas.96.9.5215; Menten P, 1999, J CLIN INVEST, V104, pR1, DOI 10.1172/JCI7318; Mentlein R, 1999, REGUL PEPTIDES, V85, P9, DOI 10.1016/S0167-0115(99)00089-0; Murphy PM, 2000, PHARMACOL REV, V52, P145; Nibbs RJB, 1999, J BIOL CHEM, V274, P17478, DOI 10.1074/jbc.274.25.17478; Noso N, 1998, EUR J BIOCHEM, V253, P114, DOI 10.1046/j.1432-1327.1998.2530114.x; NOSO N, 1996, J IMMUNOL, V156, P1046; Ohtsuki T, 1998, FEBS LETT, V431, P236, DOI 10.1016/S0014-5793(98)00763-7; Oravecz T, 1997, J EXP MED, V186, P1865, DOI 10.1084/jem.186.11.1865; Pal R, 1997, SCIENCE, V278, P695, DOI 10.1126/science.278.5338.695; PAL R, 1998, SCIENCE, V281, P487; Pauly RP, 1996, J BIOL CHEM, V271, P23222, DOI 10.1074/jbc.271.38.23222; Pospisilik JA, 2001, REGUL PEPTIDES, V96, P133, DOI 10.1016/S0167-0115(00)00170-1; Proost P, 2000, BLOOD, V96, P1674, DOI 10.1182/blood.V96.5.1674.h8001674a_1674_1680; Proost P, 1998, FEBS LETT, V432, P73, DOI 10.1016/S0014-5793(98)00830-8; Proost P, 1999, J BIOL CHEM, V274, P3988, DOI 10.1074/jbc.274.7.3988; Proost P, 1998, EUR CYTOKINE NETW, V9, P73; Proost P, 1998, J BIOL CHEM, V273, P7222, DOI 10.1074/jbc.273.13.7222; Ruiz P, 1997, TRANSPL IMMUNOL, V5, P152, DOI 10.1016/S0966-3274(97)80056-1; Sallusto F, 1998, IMMUNOL TODAY, V19, P568, DOI 10.1016/S0167-5699(98)01346-2; SCHLECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157; Schols D, 1998, ANTIVIR RES, V39, P175, DOI 10.1016/S0166-3542(98)00039-4; Shioda T, 1998, P NATL ACAD SCI USA, V95, P6331, DOI 10.1073/pnas.95.11.6331; Simmons G, 2000, IMMUNOL REV, V177, P112, DOI 10.1034/j.1600-065X.2000.17719.x; SKELTON NJ, 1995, BIOCHEMISTRY-US, V34, P5329, DOI 10.1021/bi00016a004; Struyf S, 1999, J IMMUNOL, V162, P4903; Struyf S, 1998, J IMMUNOL, V161, P2672; Struyf S, 1998, EUR J IMMUNOL, V28, P1262, DOI 10.1002/(SICI)1521-4141(199804)28:04<1262::AID-IMMU1262>3.0.CO;2-G; Tensen CP, 1999, J INVEST DERMATOL, V112, P716, DOI 10.1046/j.1523-1747.1999.00581.x; Van Coillie E, 1998, BIOCHEMISTRY-US, V37, P12672, DOI 10.1021/bi980497d; VANHAM G, 1993, J ACQ IMMUN DEF SYND, V6, P749; Vulcano M, 2001, EUR J IMMUNOL, V31, P812, DOI 10.1002/1521-4141(200103)31:3<812::AID-IMMU812>3.0.CO;2-L; Willheim M, 1997, J ALLERGY CLIN IMMUN, V100, P348, DOI 10.1016/S0091-6749(97)70248-3; Wrenger S, 2000, J BIOL CHEM, V275, P22180, DOI 10.1074/jbc.M002338200; Wrenger S, 1997, J BIOL CHEM, V272, P30283, DOI 10.1074/jbc.272.48.30283; Wuyts A, 1999, EUR J BIOCHEM, V260, P421, DOI 10.1046/j.1432-1327.1999.00166.x; YARON A, 1993, CRIT REV BIOCHEM MOL, V28, P31, DOI 10.3109/10409239309082572; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X; Zlotnik A, 1999, CRIT REV IMMUNOL, V19, P1	59	225	244	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29839	29845		10.1074/jbc.M103106200	http://dx.doi.org/10.1074/jbc.M103106200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11390394	hybrid			2022-12-25	WOS:000170558000033
J	Zhou, TQ; Radaev, S; Rosen, BP; Gatti, DL				Zhou, TQ; Radaev, S; Rosen, BP; Gatti, DL			Conformational changes in four regions of the Escherichia coli ArsA ATPase link ATP hydrolysis to ion translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSITION-STATE ANALOG; CATALYTIC SUBUNIT; CRYSTAL-STRUCTURE; ANION PUMP; ACTIVE CONFORMATIONS; SIGNAL-TRANSDUCTION; PHOSPHORYL TRANSFER; ARSENITE PUMP; PROTEIN; MECHANISM	Structures of ArsA with ATP, AMP-PNP, or ADP-AIF(3) bound at the A2 nucleotide binding site were determined. Binding of different nucleotides modifies the coordination sphere of Mg2+. In particular, the changes elicited by ADP.AIF(3),, provide insights into the mechanism of ATP hydrolysis. In-line attack by water onto the gamma -phosphate of ATP would be followed first by formation of a trigonal intermediate and then by breaking of the scissile bond between the beta- and gamma -phosphates. Motions of amino acid side chains at, the A2 nucleotide binding site during ATP binding and hydrolysis propagate at a distance, producing conformational changes in four different regions of the protein corresponding to helices H4-H5, helices H9-H10, helices H13-H15, and to the S1-H2-S2 region. These elements are extensions of, respectively, the. Switch I and Switch II regions, the A-loop (a small loop near the nucleotide adenine moiety), and the P-loop. Based on the observed conformational changes, it is proposed that ArsA functions as a reciprocating engine that hydrolyzes 2 mol of ATP per each cycle of ion translocation across the membrane.	Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA	Wayne State University	Gatti, DL (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA.	mimo@david.med.wayne.edu	Zhou, Tongqing/A-6880-2010	Zhou, Tongqing/0000-0002-3935-4637; Rosen, Barry P./0000-0002-5230-4271	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043918] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055425, R37GM055425] Funding Source: NIH RePORTER; NIAID NIH HHS [AI43918] Funding Source: Medline; NIGMS NIH HHS [GM55425] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; BIGAY J, 1987, EMBO J, V6, P2907, DOI 10.1002/j.1460-2075.1987.tb02594.x; Braig K, 2000, STRUCTURE, V8, P567, DOI 10.1016/S0969-2126(00)00145-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHEN CM, 1986, J BIOL CHEM, V261, P5030; CHING MH, 1991, J BIOL CHEM, V266, P2327; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; COMBEAU C, 1988, J BIOL CHEM, V263, P17429; DALE MP, 1987, BIOCHEMISTRY-US, V26, P8365, DOI 10.1021/bi00399a051; DEY S, 1995, J BACTERIOL, V177, P385, DOI 10.1128/jb.177.2.385-389.1995; Ditzel L, 1998, CELL, V93, P125, DOI 10.1016/S0092-8674(00)81152-6; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Gatti D, 2000, J BIOL CHEM, V275, P34009, DOI 10.1074/jbc.R000012200; HOWARD JB, 1994, ANNU REV BIOCHEM, V63, P235, DOI 10.1146/annurev.bi.63.070194.001315; ISSARTEL JP, 1991, BIOCHEMISTRY-US, V30, P4726, DOI 10.1021/bi00233a013; Jang SB, 2000, BIOCHEMISTRY-US, V39, P14745, DOI 10.1021/bi001705g; KARKARIA CE, 1991, ARCH BIOCHEM BIOPHYS, V288, P107, DOI 10.1016/0003-9861(91)90170-N; KAUR P, 1994, BIOCHEMISTRY-US, V33, P6456, DOI 10.1021/bi00187a010; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuroda M, 1997, J BIOL CHEM, V272, P326; LINDQUIST RN, 1973, J AM CHEM SOC, V95, P8762, DOI 10.1021/ja00807a043; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mittal R, 1996, SCIENCE, V273, P115, DOI 10.1126/science.273.5271.115; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ramaswamy S, 1998, J BIOL CHEM, V273, P9243, DOI 10.1074/jbc.273.15.9243; RICHARDS FM, 1988, PROTEINS, V3, P71, DOI 10.1002/prot.340030202; Rosen BP, 1999, BBA-BIOMEMBRANES, V1461, P207, DOI 10.1016/S0005-2736(99)00159-5; ROSEN BP, 1988, J BIOL CHEM, V263, P3067; Rosen BP, 1999, TRENDS MICROBIOL, V7, P207, DOI 10.1016/S0966-842X(99)01494-8; Ryle MJ, 1996, BIOCHEMISTRY-US, V35, P4766, DOI 10.1021/bi960026w; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Schindelin N, 1997, NATURE, V387, P370, DOI 10.1038/387370a0; Schlichting I, 1997, BIOCHEMISTRY-US, V36, P9290, DOI 10.1021/bi970974c; Schlichting I, 1999, NAT STRUCT BIOL, V6, P721, DOI 10.1038/11485; SLEEP JA, 1980, J BIOL CHEM, V255, P4094; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Walmsley AR, 1999, J BIOL CHEM, V274, P16153, DOI 10.1074/jbc.274.23.16153; Walmsley AR, 2001, J BIOL CHEM, V276, P6378, DOI 10.1074/jbc.M008105200; WEBB MR, 1981, J BIOL CHEM, V256, P910; WESTHEIMER FH, 1987, SCIENCE, V235, P1173, DOI 10.1126/science.2434996; Xu YW, 1997, P NATL ACAD SCI USA, V94, P3579, DOI 10.1073/pnas.94.8.3579; Zhou TQ, 1999, ACTA CRYSTALLOGR D, V55, P921, DOI 10.1107/S0907444999000256; Zhou TQ, 2000, EMBO J, V19, P4838, DOI 10.1093/emboj/19.17.4838; Zhou TQ, 1997, J BIOL CHEM, V272, P19731, DOI 10.1074/jbc.272.32.19731	45	36	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30414	30422		10.1074/jbc.M103671200	http://dx.doi.org/10.1074/jbc.M103671200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11395509	hybrid			2022-12-25	WOS:000170558000106
J	Cochran, JR; Cameron, TO; Stone, JD; Lubetsky, JB; Stern, LJ				Cochran, JR; Cameron, TO; Stone, JD; Lubetsky, JB; Stern, LJ			Receptor proximity, not intermolecular orientation, is critical for triggering T-cell activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC-PEPTIDE COMPLEXES; CLASS-II MOLECULES; SIGNAL-TRANSDUCTION; ANTIGEN RECEPTOR; INFLUENZA HEMAGGLUTININ; MULTIVALENT STRUCTURE; ZETA-CHAIN; HLA-DR; DIMERIZATION; HLA-DR1	Engagement of antigen receptors on the surface of T-cells with peptides bound to major histocompatibility complex (MHC) proteins triggers T-cell activation in a mechanism involving receptor oligomerization. Receptor dimerization by soluble MHC oligomers is sufficient to induce several characteristic activation processes in T-cells including internalization of engaged receptors and up-regulation of cell surface proteins. In this work, the influence of intermolecular orientation within the activating receptor dimer was studied. Dimers of class II MHC proteins coupled in a variety of orientations and topologies each were able to activate CD4(+) T-cells, indicating that triggering was not dependent on a particular receptor orientation. In contrast to the minimal influence of receptor orientation, T-cell triggering was affected by the inter-molecular distance between MHC molecules, and MHC dimers coupled through shot-ter cross-linkers were consistently more potent than those coupled through longer cross-linkers. These results are consistent with a mechanism in which intermolecular receptor proximity, but not intermolecular orientation, is the key determinant for antigen-induced CD4(+) T-cell activation.	MIT, Dept Chem, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Stern, LJ (corresponding author), MIT, Dept Chem, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	stern@mit.edu			NIAID NIH HHS [N01AI95361] Funding Source: Medline; NIGMS NIH HHS [T32 GM08334] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI095361] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008334] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABASTADO JP, 1995, J EXP MED, V182, P439, DOI 10.1084/jem.182.2.439; Aivazian D, 2000, NAT STRUCT BIOL, V7, P1023; Anderson HA, 2000, NAT IMMUNOL, V1, P156, DOI 10.1038/77842; Appel H, 2000, J BIOL CHEM, V275, P312, DOI 10.1074/jbc.275.1.312; Bachmann MF, 1999, IMMUNOL TODAY, V20, P568, DOI 10.1016/S0167-5699(99)01543-1; BEKOFF M, 1986, J IMMUNOL, V137, P1411; Boniface JJ, 1998, IMMUNITY, V9, P459, DOI 10.1016/S1074-7613(00)80629-9; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BUBIS J, 1990, J BIOL CHEM, V265, P12995; Cameron TO, 2001, J IMMUNOL, V166, P741, DOI 10.4049/jimmunol.166.2.741; Casares S, 1999, J EXP MED, V190, P543, DOI 10.1084/jem.190.4.543; Chambers CA, 1999, CURR OPIN CELL BIOL, V11, P203, DOI 10.1016/S0955-0674(99)80027-1; Chambers CA, 2001, TRENDS IMMUNOL, V22, P217, DOI 10.1016/S1471-4906(01)01868-3; Cherry RJ, 1998, J CELL BIOL, V140, P71, DOI 10.1083/jcb.140.1.71; CHICZ RM, 1992, NATURE, V358, P764, DOI 10.1038/358764a0; Cochran JR, 2000, IMMUNITY, V12, P241, DOI 10.1016/S1074-7613(00)80177-6; Cochran JR, 2000, CHEM BIOL, V7, P683, DOI 10.1016/S1074-5521(00)00019-3; Cochran JR, 2001, TRENDS BIOCHEM SCI, V26, P304, DOI 10.1016/S0968-0004(01)01815-1; Delon J, 1998, IMMUNITY, V9, P467, DOI 10.1016/S1074-7613(00)80630-5; EXLEY M, 1995, MOL IMMUNOL, V32, P829, DOI 10.1016/0161-5890(95)00046-H; Falke JJ, 1997, ANNU REV CELL DEV BI, V13, P457, DOI 10.1146/annurev.cellbio.13.1.457; Fernandez-Miguel G, 1999, P NATL ACAD SCI USA, V96, P1547, DOI 10.1073/pnas.96.4.1547; Fields BA, 1996, IMMUNOL TODAY, V17, P330, DOI 10.1016/0167-5699(96)10020-7; FOX BS, 1987, J IMMUNOL, V138, P3367; Frayser M, 1999, PROTEIN EXPRES PURIF, V15, P105, DOI 10.1006/prep.1998.0987; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; Glimcher LH, 1999, CELL, V96, P13, DOI 10.1016/S0092-8674(00)80955-1; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Hamad ARA, 1998, J EXP MED, V188, P1633, DOI 10.1084/jem.188.9.1633; Hennecke J, 2001, CELL, V104, P1, DOI 10.1016/S0092-8674(01)00185-4; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; Itoh Y, 1999, J IMMUNOL, V162, P2073; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; Jiang GQ, 1999, CURR BIOL, V9, pR568, DOI 10.1016/S0960-9822(99)80357-1; Jose ES, 1998, EUR J IMMUNOL, V28, P12; Klemm JD, 1998, ANNU REV IMMUNOL, V16, P569, DOI 10.1146/annurev.immunol.16.1.569; LAMB JR, 1982, NATURE, V300, P66, DOI 10.1038/300066a0; Langlet C, 2000, CURR OPIN IMMUNOL, V12, P250, DOI 10.1016/S0952-7915(00)00084-4; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; Livnah O, 1998, NAT STRUCT BIOL, V5, P993, DOI 10.1038/2965; Ponka P, 1999, INT J BIOCHEM CELL B, V31, P1111, DOI 10.1016/S1357-2725(99)00070-9; Qian DP, 1997, CURR OPIN CELL BIOL, V9, P205, DOI 10.1016/S0955-0674(97)80064-6; Reay PA, 2000, J IMMUNOL, V164, P5626, DOI 10.4049/jimmunol.164.11.5626; ROCHE PA, 1990, J IMMUNOL, V144, P1849; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; Roucard C, 1996, J BIOL CHEM, V271, P13993, DOI 10.1074/jbc.271.24.13993; Schafer P H, 1995, Semin Immunol, V7, P389, DOI 10.1006/smim.1995.0043; Schafer PH, 1998, J IMMUNOL, V161, P2307; Sousa J, 2000, EUR J IMMUNOL, V30, P3219, DOI 10.1002/1521-4141(200011)30:11<3219::AID-IMMU3219>3.0.CO;2-7; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; TESTI R, 1994, IMMUNOL TODAY, V15, P479, DOI 10.1016/0167-5699(94)90193-7; Triantafilou K, 2000, HUM IMMUNOL, V61, P585, DOI 10.1016/S0198-8859(00)00112-9; Triantafilou K, 2000, CRIT REV IMMUNOL, V20, P359; Turley SJ, 2000, SCIENCE, V288, P522, DOI 10.1126/science.288.5465.522; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; VALITUTTI S, 1995, NATURE, V375, P148, DOI 10.1038/375148a0; van der Merwe PA, 2000, SEMIN IMMUNOL, V12, P5, DOI 10.1006/smim.2000.0203; Viola A, 1996, SCIENCE, V273, P104, DOI 10.1126/science.273.5271.104; WALDMANN TA, 1989, ANNU REV BIOCHEM, V58, P875, DOI 10.1146/annurev.bi.58.070189.004303; WATTS TH, 1988, J IMMUNOL, V141, P3708; Wulfing C, 1998, SCIENCE, V282, P2266, DOI 10.1126/science.282.5397.2266; YOON ST, 1994, IMMUNITY, V1, P563; Zarutskie JA, 1999, BIOCHEMISTRY-US, V38, P5878, DOI 10.1021/bi983048m	67	53	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28068	28074		10.1074/jbc.M103280200	http://dx.doi.org/10.1074/jbc.M103280200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11384988	hybrid			2022-12-25	WOS:000170093400044
J	Huecas, S; Villalba, M; Rodriguez, R				Huecas, S; Villalba, M; Rodriguez, R			Ole e 9, a major olive pollen allergen is a 1,3-beta-glucanase - Isolation, characterization, amino acid sequence, and tissue specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PATHOGENESIS-RELATED PROTEINS; DUST-MITE ALLERGEN; TREE POLLEN; EUROPEA POLLEN; E-I; BETA-1,3-GLUCANASE; TOBACCO; EXPRESSION; IDENTIFICATION; PURIFICATION	Olive pollen allergy is a clinical disorder affecting the human population of Mediterranean areas. A novel major allergen, Ole e 9, has been isolated from olive pollen by gel permeation, hydrophobic affinity, and reverse-phase high performance liquid chromatographies. It is involved in the allergic responses of 65% of patients suffering olive pollinosis. Ole e 9 (molecular mass of 46.4 kDa) displays 1,3-beta -endoglucanase activity (38.9 +/- 5.6 mg of glucose released/min x mu mol of protein at pH 4.5-6.0 using laminarin as substrate). It is the first 1,3-beta -glucanase, a member of the "pathogenesis-related" protein family, detected in pollen tissue. Seven tryptic peptides of the allergen were sequenced by Edman degradation and used for designing primers to clone the cDNA codifying the protein. Specific cDNA for Ole e 9 was synthesized from total RNA and amplified using the polymerase chain reaction. The allergen sequence showed an open reading frame of 460 amino acids comprising a putative signal peptide of 26 residues. It shows 39, 33, and 32% sequence identity including the catalytic residues when compared with 1,3-beta -glucanases from wheat, willow, and Arabidopsis thaliana, respectively. Northern blot analysis showed that Ole e 9 transcript is specifically expressed in the pollen tissue, and highly conserved counterparts were only detected in taxonomically related pollens.	Univ Complutense, Fac Quim, Dept Bioquim & Biol Mol 1, E-28040 Madrid, Spain	Complutense University of Madrid	Rodriguez, R (corresponding author), Univ Complutense, Fac Quim, Dept Bioquim & Biol Mol 1, Avda Complutense S-N, E-28040 Madrid, Spain.		Huecas, Sonia/P-2542-2019; Villalba, María Teresa/AAW-1067-2020; Villalba, Mayte/K-5365-2014; RODRIGUEZ, ROSALIA/K-4993-2014; Huecas, Sonia/K-1754-2014	Huecas, Sonia/0000-0002-6419-441X; Villalba, María Teresa/0000-0002-0042-9953; RODRIGUEZ, ROSALIA/0000-0002-4280-3691; Huecas, Sonia/0000-0002-6419-441X				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Arruda LK, 1997, J BIOL CHEM, V272, P20907, DOI 10.1074/jbc.272.33.20907; BALDO BA, 1992, MOL IMMUNOL, V29, P1209, DOI 10.1016/0161-5890(92)90057-5; BATANERO E, 1994, MOL IMMUNOL, V31, P31, DOI 10.1016/0161-5890(94)90135-X; Batanero E, 1997, FEBS LETT, V410, P293, DOI 10.1016/S0014-5793(97)00582-6; Batanero E, 1996, EUR J BIOCHEM, V241, P772, DOI 10.1111/j.1432-1033.1996.00772.x; BLANCA M, 1983, CLIN ALLERGY, V13, P473, DOI 10.1111/j.1365-2222.1983.tb02624.x; Boluda L, 1998, J ALLERGY CLIN IMMUN, V101, P210, DOI 10.1016/S0091-6749(98)70385-9; BOUSQUET J, 1984, CLIN ALLERGY, V14, P249, DOI 10.1111/j.1365-2222.1984.tb02204.x; Brehler R, 1997, ALLERGY, V52, P404, DOI 10.1111/j.1398-9995.1997.tb01019.x; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; BUCCIAGLIA PA, 1994, PLANT MOL BIOL, V24, P903, DOI 10.1007/BF00014444; CHEN L, 1993, J BIOL CHEM, V268, P13318; CHEN L, 1995, J BIOL CHEM, V270, P8093, DOI 10.1074/jbc.270.14.8093; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; CHYE ML, 1995, PLANT MOL BIOL, V29, P397, DOI 10.1007/BF00043663; CruzOrtega R, 1997, PLANT PHYSIOL, V114, P1453, DOI 10.1104/pp.114.4.1453; DELCAMPILLO E, 1992, PLANT PHYSIOL, V99, P1015, DOI 10.1104/pp.99.3.1015; Delp G, 1999, PLANT MOL BIOL, V39, P565, DOI 10.1023/A:1006194822666; DUDLER T, 1995, J IMMUNOL, V155, P2605; Futamura N, 2000, PLANT CELL PHYSIOL, V41, P16, DOI 10.1093/pcp/41.1.16; Garnier J, 1996, METHOD ENZYMOL, V266, P540; Gough L, 1999, J EXP MED, V190, P1897, DOI 10.1084/jem.190.12.1897; HIRD DL, 1993, PLANT J, V4, P1023, DOI 10.1046/j.1365-313X.1993.04061023.x; Hoffmann-Sommergruber K, 2000, INT ARCH ALLERGY IMM, V122, P155, DOI 10.1159/000024392; HOJ PB, 1995, PLANT J, V7, P367, DOI 10.1046/j.1365-313X.1995.7030367.x; Huecas S, 1999, EUR J BIOCHEM, V261, P539, DOI 10.1046/j.1432-1327.1999.00307.x; Juers DH, 1999, PROTEIN SCI, V8, P122; KING TP, 1978, BIOCHEMISTRY-US, V17, P5165, DOI 10.1021/bi00617a016; KING TP, 1995, J ALLERGY CLIN IMMUN, V96, P5, DOI 10.1016/S0091-6749(95)70027-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUZURICA P, 1988, MOL IMMUNOL, V25, P329, DOI 10.1016/0161-5890(88)90027-2; Ledesma A, 1998, ALLERGY, V53, P520, DOI 10.1111/j.1398-9995.1998.tb04090.x; Ledesma A, 2000, FEBS LETT, V466, P192, DOI 10.1016/S0014-5793(99)01790-1; Leubner-Metzger G, 1999, PATHOGENESIS-RELATED PROTEINS IN PLANTS, P49; LOTAN T, 1989, PLANT CELL, V1, P881, DOI 10.1105/tpc.1.9.881; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACCHIA L, 1991, ALLERGENIC POLLEN PO, P87; Meins F. Jr., 1992, Genes involved in plant defense., P245; MEMELINK J, 1990, PLANT MOL BIOL, V14, P119, DOI 10.1007/BF00018553; Nelson N, 1944, J BIOL CHEM, V153, P375; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; ORI N, 1990, EMBO J, V9, P3429, DOI 10.1002/j.1460-2075.1990.tb07550.x; Peumans WJ, 2000, EUR J BIOCHEM, V267, P1188, DOI 10.1046/j.1432-1327.2000.01117.x; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sessa G, 1995, PLANT MOL BIOL, V29, P969, DOI 10.1007/BF00014970; SHINSHI H, 1988, P NATL ACAD SCI USA, V85, P5541, DOI 10.1073/pnas.85.15.5541; SOMOGYI M, 1952, J BIOL CHEM, V195, P19; Stone BA, 1992, CHEM BIOL 1 3 BETA G; Subroto T, 1996, PHYTOCHEMISTRY, V43, P29, DOI 10.1016/0031-9422(96)00196-3; SUNDERASAN E, 1995, J RUBBER RES, V10, P82; TANIGUCHI Y, 1995, ALLERGY, V50, P90, DOI 10.1111/j.1398-9995.1995.tb02489.x; Tejera ML, 1999, J ALLERGY CLIN IMMUN, V104, P797, DOI 10.1016/S0091-6749(99)70290-3; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; Valenta R, 1998, INT ARCH ALLERGY IMM, V117, P160, DOI 10.1159/000024005; van Ree R, 2000, J BIOL CHEM, V275, P11451, DOI 10.1074/jbc.275.15.11451; VANLOON LC, 1970, VIROLOGY, V40, P199, DOI 10.1016/0042-6822(70)90395-8; vanRee R, 1997, ALLERGY, V52, P795; VELA C, 1982, INT ARCH ALLER A IMM, V68, P289, DOI 10.1159/000233116; VILLALBA M, 1994, J BIOL CHEM, V269, P15217; VILLALBA M, 1993, EUR J BIOCHEM, V216, P863, DOI 10.1111/j.1432-1033.1993.tb18208.x; VOGELILANGE R, 1994, PLANT J, V5, P273, DOI 10.1046/j.1365-313X.1994.05020273.x; WARD ER, 1991, PLANT PHYSIOL, V96, P390, DOI 10.1104/pp.96.2.390; WHEELER AW, 1992, CLIN EXP ALLERGY, V22, P1052, DOI 10.1111/j.1365-2222.1992.tb00129.x; WHEELER AW, 1990, MOL IMMUNOL, V27, P631, DOI 10.1016/0161-5890(90)90005-K; Yagami T, 1998, J ALLERGY CLIN IMMUN, V101, P379, DOI 10.1016/S0091-6749(98)70251-9	68	90	92	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27959	27966		10.1074/jbc.M103041200	http://dx.doi.org/10.1074/jbc.M103041200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11373288	hybrid			2022-12-25	WOS:000170093400030
J	Machin, A; Alonso, JMM; Parra, F				Machin, A; Alonso, JMM; Parra, F			Identification of the amino acid residue involved in rabbit hemorrhagic disease virus VPg uridylylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT RNA-POLYMERASE; DIVALENT-CATION MODULATION; POLIOVIRUS RNA; LINKED PROTEIN; CALICIVIRUS; GENOME; POLYPROTEIN; EXPRESSION; TEMPLATE; CLEAVAGE	The virus genome-linked protein (VPg) coding region from rabbit hemorrhagic disease virus (RHDV) (isolate AST/89) was expressed in Escherichia coli by using a glutathione S-transferase-based vector. The recombinant polypeptide could be purified in good yields and was uridylylated in vitro from [alpha-P-32]UTP in a reaction catalyzed by the recombinant RNA-dependent RNA polymerase from RHDV in the absence of added template RNA. The use of deletion and point mutants allowed the identification of Tyr-21 as the residue involved in uridylylation and consequently in the linkage between VPg and the viral genome. These data constitute the first report on the identity of the amino acid residue involved in VPg uridylylation in a member of the Caliciviridae family.	Univ Oviedo, Dept Bioquim & Biol Mol, Inst Univ Biotecnol Asturias, Consejo Super Invest Cient, E-33006 Oviedo, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Oviedo	Parra, F (corresponding author), Univ Oviedo, Dept Bioquim & Biol Mol, Inst Univ Biotecnol Asturias, Consejo Super Invest Cient, E-33006 Oviedo, Spain.	fparra@correo.uniovi.es	Parra, Francisco/D-5401-2009; Martin Alonso, Jose Manuel/C-7763-2013	Parra, Francisco/0000-0002-1885-9521; Martin Alonso, Jose Manuel/0000-0003-1725-6216				Alonso JMM, 1996, J VIROL, V70, P1261; AMBROS V, 1978, J BIOL CHEM, V253, P5263; Arnold JJ, 1999, J BIOL CHEM, V274, P37060, DOI 10.1074/jbc.274.52.37060; Boga J. A., 1999, Recent Research Developments in Virology, V1, P107; BURROUGHS JN, 1978, J GEN VIROL, V41, P443, DOI 10.1099/0022-1317-41-2-443; CIRINO NM, 1995, BIOCHEMISTRY-US, V34, P9936, DOI 10.1021/bi00031a016; Dunham DM, 1998, ARCH VIROL, V143, P2421, DOI 10.1007/s007050050471; Huang Y, 1997, BIOCHEMISTRY-US, V36, P13718, DOI 10.1021/bi971609o; Konig M, 1998, J VIROL, V72, P4492; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Meyers G, 2000, VIROLOGY, V276, P349, DOI 10.1006/viro.2000.0545; MEYERS G, 1991, VIROLOGY, V184, P677, DOI 10.1016/0042-6822(91)90437-G; OHLINGER VF, 1990, J VIROL, V64, P3331, DOI 10.1128/JVI.64.7.3331-3336.1990; PALMENBERG A, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1371, DOI 10.1073/pnas.71.4.1371; PARRA F, 1990, J VIROL, V64, P4013, DOI 10.1128/JVI.64.8.4013-4015.1990; Paul AV, 2000, J VIROL, V74, P10359, DOI 10.1128/JVI.74.22.10359-10370.2000; Paul AV, 1998, NATURE, V393, P280, DOI 10.1038/30529; Pringle C R, 1998, Arch Virol, V143, P1449, DOI 10.1007/s007050050389; ROTHBERG PG, 1978, P NATL ACAD SCI USA, V75, P4868, DOI 10.1073/pnas.75.10.4868; SOSNOVTSEV S, 1995, VIROLOGY, V210, P383, DOI 10.1006/viro.1995.1354; Sosnovtsev SV, 2000, VIROLOGY, V277, P193, DOI 10.1006/viro.2000.0579; TABOR S, 1989, P NATL ACAD SCI USA, V86, P4076, DOI 10.1073/pnas.86.11.4076; Vazquez AL, 2000, J VIROL, V74, P3888, DOI 10.1128/JVI.74.8.3888-3891.2000; Vazquez AL, 2001, ARCH VIROL, V146, P59, DOI 10.1007/s007050170191; Vazquez AL, 1998, J VIROL, V72, P2999; Wirblich C, 1996, J VIROL, V70, P7974, DOI 10.1128/JVI.70.11.7974-7983.1996; WIRBLICH C, 1995, J VIROL, V69, P7159, DOI 10.1128/JVI.69.11.7159-7168.1995	27	44	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27787	27792		10.1074/jbc.M100707200	http://dx.doi.org/10.1074/jbc.M100707200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11369764	hybrid			2022-12-25	WOS:000170093400008
J	Masuda, A; Matsuguchi, T; Yamaki, K; Hayakawa, T; Yoshikai, Y				Masuda, A; Matsuguchi, T; Yamaki, K; Hayakawa, T; Yoshikai, Y			Interleukin-15 prevents mouse mast cell apoptosis through STAT6-mediated Bcl-x(L) expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-KIT LIGAND; ACTIVATED KILLER-CELLS; BCL-X; IL-2 RECEPTOR; GROWTH-FACTOR; BETA-CHAIN; GENE-EXPRESSION; T-CELLS; SURVIVAL; DEATH	Interleukin (IL)-15 is a member of the cytokine family with T and natural killer (NK) cell growth-promoting activity. In mast cells, however, IL-15 uses a distinct receptor system different from that used in T and NK cells. We recently reported that IL-15 induces STAT6 activation and IL-4 production in a mouse mast cell line (MC/9) and bone marrow-derived mast cells. In the present study, we have demonstrated that IL-15 prevents MC/9 and bone marrow-derived mast cell apoptosis induced by factor withdrawal or anti-Fas antibody treatment, IL-15 increased mRNA and protein levels of an anti-apoptotic protein (Bcl-x(L)) in these cells, whereas bcl-2 mRNA remained unchanged. In addition, the transcriptional activity of the bcl-x(L), promoter was increased by IL-15 in MC/9 eels. In an electrophoretic mobility shift assay, IL-15 induced STAT6 binding to the STAT recognition site in the bcl-x(L) gene promoter. Furthermore, the expression of a dominant-negative form of STAT6 abrogated the effects of IL-15 on both bcl-x(L) mRNA up-regulation and prevention of apoptosis in mast cells. Altogether, our results suggest that IL-15 plays an important role in maintaining the number of mast cells through Bcl-xL expression mediated by STAT6.	Nagoya Univ, Sch Med, Dis Mechanism & Control Res Inst, Lab Host Def & Germfree Life,Showa Ku, Nagoya, Aichi 4688550, Japan; Nagoya Univ, Sch Med, Dept Internal Med 2, Nagoya, Aichi 4688550, Japan	Nagoya University; Nagoya University	Matsuguchi, T (corresponding author), Nagoya Univ, Sch Med, Dis Mechanism & Control Res Inst, Lab Host Def & Germfree Life,Showa Ku, Nagoya, Aichi 4688550, Japan.	tmatsugu@med.nagoya-u.ac.jp	Masuda, Akio/H-6323-2012					Arena A, 2000, MICROBIOLOGICA, V23, P105; BAMFORD RN, 1994, P NATL ACAD SCI USA, V91, P4940, DOI 10.1073/pnas.91.11.4940; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BROOME HE, 1995, J IMMUNOL, V155, P2311; BulfonePaus S, 1997, NAT MED, V3, P1124, DOI 10.1038/nm1097-1124; Bullock ED, 1996, J BIOL CHEM, V271, P27500, DOI 10.1074/jbc.271.44.27500; BURTON JD, 1994, P NATL ACAD SCI USA, V91, P4935, DOI 10.1073/pnas.91.11.4935; BUSSE WW, 1994, AM J RESP CRIT CARE, V150, pS77, DOI 10.1164/ajrccm/150.5_Pt_2.S77; BUSSE WW, 1989, CLIN EXP ALLERGY, V19, P1, DOI 10.1111/j.1365-2222.1989.tb02336.x; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; CHAO DT, 1995, J EXP MED, V182, P821, DOI 10.1084/jem.182.3.821; Chehimi J, 1997, J IMMUNOL, V158, P5978; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CHLEQDESCHAMPS CM, 1993, BLOOD, V81, P293; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; DEL PL, 1997, SCIENCE, V278, P687; Dumon S, 1999, ONCOGENE, V18, P4191, DOI 10.1038/sj.onc.1202796; Fujio Y, 1997, J CLIN INVEST, V99, P2898, DOI 10.1172/JCI119484; GIRI JG, 1995, EMBO J, V14, P3654, DOI 10.1002/j.1460-2075.1995.tb00035.x; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; HAIG DM, 1988, IMMUNOLOGY, V65, P205; Hartmann K, 1997, J IMMUNOL, V159, P4006; Hinton HJ, 1999, J IMMUNOL, V162, P7002; Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IEMURA A, 1994, AM J PATHOL, V144, P321; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; KIRSHENBAUM AS, 1992, J IMMUNOL, V148, P772; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; Leverrier Y, 1997, ONCOGENE, V14, P425, DOI 10.1038/sj.onc.1200845; Lin RH, 1997, J IMMUNOL, V158, P598; Lomo J, 1997, BLOOD, V89, P4415; Masuda A, 2000, J BIOL CHEM, V275, P29331, DOI 10.1074/jbc.M910290199; Matsuguchi T, 1997, J BIOL CHEM, V272, P17450, DOI 10.1074/jbc.272.28.17450; MEKORI YA, 1993, J IMMUNOL, V151, P3775; Miho Y, 1999, CELL DEATH DIFFER, V6, P463, DOI 10.1038/sj.cdd.4400506; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.immunol.11.1.245; Naora H, 1999, IMMUNOL LETT, V68, P359, DOI 10.1016/S0165-2478(99)00077-2; Pastorino JG, 1999, J BIOL CHEM, V274, P19411, DOI 10.1074/jbc.274.27.19411; REED JC, 1987, SCIENCE, V236, P1295, DOI 10.1126/science.3495884; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; RENNICK D, 1995, BLOOD, V85, P57, DOI 10.1182/blood.V85.1.57.bloodjournal85157; Schwenzer R, 1999, J BIOL CHEM, V274, P19368, DOI 10.1074/jbc.274.27.19368; Silva M, 1999, J BIOL CHEM, V274, P22165, DOI 10.1074/jbc.274.32.22165; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Tagaya Y, 1996, EMBO J, V15, P4928, DOI 10.1002/j.1460-2075.1996.tb00873.x; Tagaya Y, 1996, IMMUNITY, V4, P329, DOI 10.1016/S1074-7613(00)80246-0; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; THOMPSONSNIPES LA, 1991, J EXP MED, V173, P507, DOI 10.1084/jem.173.2.507; TSAI M, 1991, P NATL ACAD SCI USA, V88, P6382, DOI 10.1073/pnas.88.14.6382; TSAI M, 1991, J EXP MED, V174, P125, DOI 10.1084/jem.174.1.125; Vella A, 1997, J EXP MED, V186, P325, DOI 10.1084/jem.186.2.325; Waldmann TA, 1999, ANNU REV IMMUNOL, V17, P19, DOI 10.1146/annurev.immunol.17.1.19; Yang FC, 2000, IMMUNITY, V12, P557, DOI 10.1016/S1074-7613(00)80207-1; Yeatman CF, 2000, J EXP MED, V192, P1093, DOI 10.1084/jem.192.8.1093; YEE NS, 1994, J EXP MED, V179, P1777, DOI 10.1084/jem.179.6.1777; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	58	65	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26107	26113		10.1074/jbc.M011475200	http://dx.doi.org/10.1074/jbc.M011475200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11369758	hybrid			2022-12-25	WOS:000169823300064
J	Virts, EL; Raschke, WC				Virts, EL; Raschke, WC			The role of intron sequences in high level expression from CD45 cDNA constructs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; TISSUE-SPECIFIC EXPRESSION; LEUKOCYTE-COMMON ANTIGEN; CELL-RECEPTOR COMPLEX; ALTERNATE EXON USE; TRANSGENIC MICE; B-CELLS; GENE-EXPRESSION; T-CELLS; DEVELOPMENTAL EXPRESSION	Consistent expression from CD45 cDNA constructs has proven difficult to achieve. Through the use of new CD45 cDNA constructs and reporter genes, the role 5', 3', and intron sequences play in CD45 expression was determined. The CD45 polyadenylation signal sequence was fully functional in a beta -galactosidase reporter construct. Furthermore, the CD45 3'-untranslated region and downstream sequences were shown to contain no negative regulatory elements. Several new CD45 cDNA constructs were designed that contain either the cytomegalovirus promoter, the leukocyte function-associated antigen (LFA-1; CD11a) promoter, or various CD45 5' regions. Neither the cytomegalovirus nor the LFA-1 promoter was capable of generating detectable levels of expression in constructs with CD45 cDNA However, when CD45 intron sequences between exrons 3 and 9 were inserted in the cDNA construct to generate a CD45 minigene, the LFA-1 promoter was able to drive reproducible, significant expression of CD45. CD45 minigenes using the CD45 5' sequences up to 19 kilobases upstream of the transcriptional start produced very little protein. The LFA-1 CD45 minigene construct produced correct cell type-specific isoforms when expressed in T and B lymphocyte lines. Therefore, we conclude that the regulation of CD45 expression and cell type-specific splicing requires elements within the intron sequences.	Sidney Kimmel Canc Ctr, San Diego, CA 92121 USA		Raschke, WC (corresponding author), Sidney Kimmel Canc Ctr, 10835 Altman Row, San Diego, CA 92121 USA.	braschke@skcc.org			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI040259, R01AI040259] Funding Source: NIH RePORTER; NIAID NIH HHS [AI40259] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ashwell JD, 1999, IMMUNOL TODAY, V20, P412, DOI 10.1016/S0167-5699(99)01505-4; Baler R, 1999, BIOL CELL, V91, P699, DOI 10.1016/S0248-4900(00)88533-0; BERGER SA, 1994, J EXP MED, V180, P471, DOI 10.1084/jem.180.2.471; Blackwood EM, 1998, SCIENCE, V281, P60, DOI 10.1126/science.281.5373.60; Byth KF, 1996, J EXP MED, V183, P1707, DOI 10.1084/jem.183.4.1707; CALLIS J, 1987, GENE DEV, V1, P1183, DOI 10.1101/gad.1.10.1183; Chan RYY, 1999, P NATL ACAD SCI USA, V96, P4627, DOI 10.1073/pnas.96.8.4627; CHANG HL, 1991, J IMMUNOL, V147, P1687; CHANG HL, 1989, J IMMUNOL, V143, P315; CHOI T, 1991, MOL CELL BIOL, V11, P3070, DOI 10.1128/MCB.11.6.3070; CHUI D, 1994, EMBO J, V13, P798, DOI 10.1002/j.1460-2075.1994.tb06322.x; CHUNG S, 1989, MOL CELL BIOL, V9, P2075, DOI 10.1128/MCB.9.5.2075; CORNWELL RD, 1993, P NATL ACAD SCI USA, V90, P4221, DOI 10.1073/pnas.90.9.4221; D'Oro U, 1999, J IMMUNOL, V162, P1879; DECKER CJ, 1995, CURR OPIN CELL BIOL, V7, P386, DOI 10.1016/0955-0674(95)80094-8; DIMARTINO JF, 1994, INT IMMUNOL, V6, P1279, DOI 10.1093/intimm/6.8.1279; Galvagni F, 2000, J BIOL CHEM, V275, P3168, DOI 10.1074/jbc.275.5.3168; Gaunitz F, 1997, BIOL CHEM, V378, P11, DOI 10.1515/bchm.1997.378.1.11; GOROCHOV G, 1992, INT J CANCER, P53; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; Haghighi K, 1997, GENE, V203, P199, DOI 10.1016/S0378-1119(97)00514-3; Hall SR, 1999, EUR J IMMUNOL, V29, P2098, DOI 10.1002/(SICI)1521-4141(199907)29:07<2098::AID-IMMU2098>3.3.CO;2-2; HATHCOCK KS, 1992, J IMMUNOL, V149, P2286; Hoflich C, 1998, INT IMMUNOL, V10, P1837, DOI 10.1093/intimm/10.12.1837; JOHNSON P, 1989, J EXP MED, V169, P1179, DOI 10.1084/jem.169.3.1179; JUSTEMENT LB, 1991, SCIENCE, V252, P1839, DOI 10.1126/science.1648262; Katagiri T, 1999, J IMMUNOL, V163, P1321; KATAI H, 1992, MOL CELL BIOCHEM, V118, P119; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; LANE PJL, 1991, J IMMUNOL, V146, P715; Leitenberg D, 1996, J EXP MED, V183, P249, DOI 10.1084/jem.183.1.249; Leitenberg D, 1999, IMMUNITY, V10, P701, DOI 10.1016/S1074-7613(00)80069-2; LOZANO G, 1991, MOL CARCINOGEN, V4, P3, DOI 10.1002/mc.2940040103; Makar KW, 1998, J IMMUNOL, V160, P1268; MARTH JD, 1994, ADV EXP MED BIOL, V365, P149; McHeyzer-Williams LJ, 2000, J EXP MED, V191, P1149, DOI 10.1084/jem.191.7.1149; Mee PJ, 1999, EUR J IMMUNOL, V29, P2923, DOI 10.1002/(SICI)1521-4141(199909)29:09<2923::AID-IMMU2923>3.3.CO;2-P; Murakami K, 2000, INT IMMUNOL, V12, P169, DOI 10.1093/intimm/12.2.169; NOVAK TJ, 1994, IMMUNITY, V1, P109, DOI 10.1016/1074-7613(94)90104-X; NUEDA A, 1993, J BIOL CHEM, V268, P19305; OGIMOTO M, 1993, CELL IMMUNOL, V151, P97, DOI 10.1006/cimm.1993.1224; Oka S, 2000, IMMUNOLOGY, V100, P417, DOI 10.1046/j.1365-2567.2000.00063.x; ONG CJ, 1994, J IMMUNOL, V152, P3793; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; RASCHKE WC, 1995, IMMUNOGENETICS, V41, P144, DOI 10.1007/BF00182327; RASCHKE WC, 1987, P NATL ACAD SCI USA, V84, P161, DOI 10.1073/pnas.84.1.161; Renno T, 1998, EUR J IMMUNOL, V28, P540, DOI 10.1002/(SICI)1521-4141(199802)28:02<540::AID-IMMU540>3.3.CO;2-P; RITCHIE KA, 1995, BLOOD, V86, P147, DOI 10.1182/blood.V86.1.147.bloodjournal861147; ROTHSTEIN DM, 1992, J BIOL CHEM, V267, P7139; Sabourin JC, 1996, J BIOL CHEM, V271, P3469, DOI 10.1074/jbc.271.7.3469; SAGA Y, 1987, P NATL ACAD SCI USA, V84, P5364, DOI 10.1073/pnas.84.15.5364; SAGA Y, 1990, IMMUNOGENETICS, V31, P296, DOI 10.1007/BF02115003; SAGA Y, 1990, P NATL ACAD SCI USA, V87, P3728, DOI 10.1073/pnas.87.10.3728; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAWADA S, 1994, CELL, V77, P917, DOI 10.1016/0092-8674(94)90140-6; SELDIN MF, 1987, IMMUNOGENETICS, V26, P74, DOI 10.1007/BF00345457; Shamsher MK, 2000, HUM GENET, V107, P458; SHEN FW, 1985, P NATL ACAD SCI USA, V82, P7360, DOI 10.1073/pnas.82.21.7360; SIU G, 1994, EMBO J, V13, P3570, DOI 10.1002/j.1460-2075.1994.tb06664.x; STREULI M, 1989, EMBO J, V8, P787, DOI 10.1002/j.1460-2075.1989.tb03439.x; THOMAS ML, 1987, P NATL ACAD SCI USA, V84, P5360, DOI 10.1073/pnas.84.15.5360; Thomas ML, 1999, IMMUNOL TODAY, V20, P406, DOI 10.1016/S0167-5699(99)01506-6; THUDE H, 1995, EUR J IMMUNOL, V25, P2101, DOI 10.1002/eji.1830250745; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; Veillette A, 1999, J BIOL CHEM, V274, P14392, DOI 10.1074/jbc.274.20.14392; Virts E, 1998, MOL IMMUNOL, V35, P167, DOI 10.1016/S0161-5890(98)00025-X; Virts E, 1997, MOL IMMUNOL, V34, P1191, DOI 10.1016/S0161-5890(97)00142-9; WEAVER CT, 1991, MOL CELL BIOL, V11, P4415, DOI 10.1128/MCB.11.9.4415; Wickens M, 1997, CURR OPIN GENET DEV, V7, P220, DOI 10.1016/S0959-437X(97)80132-3; WILDIN RS, 1995, J IMMUNOL, V155, P1286; Zabel MD, 2000, J IMMUNOL, V165, P4437, DOI 10.4049/jimmunol.165.8.4437; Zebedee S L, 1991, Dev Immunol, V1, P243, DOI 10.1155/1991/52686	74	19	22	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					19913	19920		10.1074/jbc.M100448200	http://dx.doi.org/10.1074/jbc.M100448200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11389149	hybrid			2022-12-25	WOS:000169135100032
J	Douglas, P; Moorhead, GBG; Ye, RQ; Lees-Miller, SP				Douglas, P; Moorhead, GBG; Ye, RQ; Lees-Miller, SP			Protein phosphatases regulate DNA-dependent protein kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; CATALYTIC SUBUNIT; PHOSPHORYLATION; CELLS; AUTOPHOSPHORYLATION; INHIBITOR-2; DEFICIENT; 3-KINASE; GENE; PP2A	DNA-dependent protein kinase (DNA-PK) is a complex of DNA-PK catalytic subunit (DNA-PKcs) and the DNA end-binding Ku70/Ku80 heterodimer. DNA-PK is required for DNA double strand break repair by the process of nonhomologous end joining. Nonhomologous end joining is a major mechanism for the repair of DNA double strand breaks in mammalian cells. As such, DNA-PK plays essential roles in the cellular response to ionizing radiation and in V(D)J recombination. In vitro, DNA-PK undergoes phosphorylation of all three protein subunits (DNA-PK catalytic subunit, Ku70 and Ku80) and phosphorylation correlates with inactivation of the serine/threonine protein kinase activity of DNA-PK. Here we show that phosphorylation-induced loss of the protein kinase activity of DNA-PK is restored by the addition of the purified catalytic subunit of either protein phosphatase 1 or protein phosphatase 2A (PP2A) and that this reactivation is blocked by the potent protein phosphatase inhibitor, microcystin, We also show that treating human lymphoblastoid cells with either okadaic acid or fostriecin, at PP2A-selective concentrations, causes a 50-60% decrease in DNA-PK protein kinase activity, although the protein phosphatase 1 activity in these cells was unaffected. In vivo phosphorylation of DNA-PKcs, Ku70, and Ku80 was observed when cells were labeled with [P-32]inorganic phosphate in the presence of the protein phosphatase inhibitor, okadaic acid. Together, our data suggest that reversible protein phosphorylation is an important mechanism for the regulation of DNA-PK protein kinase activity and that the protein phosphatase responsible for reactivation in vivo is a PP2A-like enzyme.	Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada	University of Calgary	Lees-Miller, SP (corresponding author), Univ Calgary, Dept Biol Sci, 2500 Univ Dr 1 NW, Calgary, AB T2N 1N4, Canada.			Lees-Miller, Susan/0000-0001-5809-2516				ALLALUNISTURNER MJ, 1995, CANCER RES, V55, P5200; Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; Anderson CW, 1995, METHODS IN PROTEIN STRUCTURE ANALYSIS, P395; BOUBNOV NV, 1995, MOL CELL BIOL, V15, P5700; Chan DW, 1996, BIOCHEM CELL BIOL, V74, P67, DOI 10.1139/o96-007; Chan DW, 1999, BIOCHEMISTRY-US, V38, P1819, DOI 10.1021/bi982584b; Chan DW, 1996, J BIOL CHEM, V271, P8936, DOI 10.1074/jbc.271.15.8936; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1988, METHOD ENZYMOL, V159, P427; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; COHEN P, 1983, METHOD ENZYMOL, V99, P243; COHEN P, 1988, METHOD ENZYMOL, V159, P390; Cohen PTW, 1997, TRENDS BIOCHEM SCI, V22, P245, DOI 10.1016/S0968-0004(97)01060-8; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; FISCHER EDMOND H., 1958, JOUR BIOL CHEM, V231, P65; Fried LM, 1996, P NATL ACAD SCI USA, V93, P13825, DOI 10.1073/pnas.93.24.13825; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Huang HB, 1999, J BIOL CHEM, V274, P7870, DOI 10.1074/jbc.274.12.7870; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; Kurimasa A, 1999, MOL CELL BIOL, V19, P3877; Kutuzov MA, 1998, FEBS LETT, V440, P147, DOI 10.1016/S0014-5793(98)01428-8; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LeesMiller SP, 1996, BIOCHEM CELL BIOL, V74, P503, DOI 10.1139/o96-054; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; MACKINTOSH C, 1994, TRENDS BIOCHEM SCI, V19, P444, DOI 10.1016/0968-0004(94)90127-9; MACKINTOSH C, 1999, PROTEIN PHOSPHORYLAT; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Vanhaesebroeck B, 1999, EMBO J, V18, P1292, DOI 10.1093/emboj/18.5.1292; Walsh AH, 1997, FEBS LETT, V416, P230, DOI 10.1016/S0014-5793(97)01210-6; Yan Y, 1999, J BIOL CHEM, V274, P31917, DOI 10.1074/jbc.274.45.31917; YANEVA M, 1986, BIOCHEMISTRY-US, V25, P5057, DOI 10.1021/bi00366a013; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8	34	131	138	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					18992	18998		10.1074/jbc.M011703200	http://dx.doi.org/10.1074/jbc.M011703200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11376007	hybrid			2022-12-25	WOS:000169091000047
J	Liu, CJ; Dib-Hajj, SD; Waxman, SG				Liu, CJ; Dib-Hajj, SD; Waxman, SG			Fibroblast growth factor homologous factor 1B binds to the C terminus of the tetrodotoxin-resistant sodium channel rNa(v)1.9a (NaN)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROOT GANGLION NEURONS; NERVOUS-SYSTEM; SENSORY NEURONS; ALPHA-SUBUNIT; TRANSCRIPTION FACTOR; MESSENGER-RNAS; TENASCIN-R; FACTOR FGF; PROTEIN; EXPRESSION	In this study we demonstrate a direct interaction between a cytosolic fibroblast growth factor family member and a sodium channel. A yeast two hybrid screen for proteins that associate with the cytoplasmic domains of the tetrodotoxin-resistant sodium channel rNa(v)1.9a (NaN) led to the identification of fibroblast growth factor homologous factor 1B (FHF1B), a member of the fibroblast growth factor family, as an interacting partner of rNa(v)1.9a. FHF1B selectively interacts with the C-terminal region but not the other four intracellular segments of rNa(v)1.9a. FHF1B binds directly to the C-terminal polypeptide of rNa(v)1.9a both in vitro and in mammalian cell lines. The N-terminal 5-77 amino acid residues of FHF1B are essential for binding to rNa(v)1.9a. FHF1B did not interact with C termini of two other sodium channels hNa(v)1.7a (hNaNE) and rNa(v)1.8a (SNS), which share 50% similarity to the C-terminal polypeptide of rNa(v)1.9a. FHF1B is the first growth factor found to bind specifically to a sodium channel. Although the functional significance of this interaction is not clear, FHF1B may affect the rNa(v)1.9a channel directly or by recruiting other proteins to the channel complex. Alternatively, it is possible that rNa(v)1.9a may help deliver this factor to the cell membrane, where it exerts its function.	Yale Univ, Sch Med, Neurosci Res Ctr, PVA,EPVA, West Haven, CT 06516 USA; Yale Univ, Sch Med, Neurosci Res Ctr, Dept Neurol, West Haven, CT 06516 USA; Vet Affairs Med Ctr, Rehabil Res Ctr, West Haven, CT 06516 USA	Yale University; Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System	Dib-Hajj, SD (corresponding author), Yale Univ, Sch Med, Neurosci Res Ctr, PVA,EPVA, 127A,Bldg 34,950 Campbell Ave, West Haven, CT 06516 USA.	sulayman.dib-hajj@yale.edu	Waxman, Stephen/Z-2507-2019	Waxman, Stephen/0000-0001-5718-7177; liu, chuanju/0000-0002-7181-8032				Akopian AN, 1996, NATURE, V379, P257, DOI 10.1038/379257a0; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BARCHI RL, 1995, ANNU REV PHYSIOL, V57, P355; BECKH S, 1989, EMBO J, V8, P3611, DOI 10.1002/j.1460-2075.1989.tb08534.x; Braithwaite SP, 2000, NEUROPHARMACOLOGY, V39, P919, DOI 10.1016/S0028-3908(99)00171-9; Cannon SC, 1997, NEUROMUSCULAR DISORD, V7, P241, DOI 10.1016/S0960-8966(97)00430-6; Cantrell AR, 1999, J NEUROSCI, V19, P5301; Coulier F, 1997, J MOL EVOL, V44, P43, DOI 10.1007/PL00006120; Cummins TR, 2000, J NEUROSCI, V20, P8754; Cummins TR, 1999, J NEUROSCI, V19, DOI 10.1523/JNEUROSCI.19-24-j0001.1999; Dib-Hajj SD, 1999, FEBS LETT, V462, P117, DOI 10.1016/S0014-5793(99)01519-7; Dib-Hajj SD, 1998, P NATL ACAD SCI USA, V95, P8963, DOI 10.1073/pnas.95.15.8963; DibHajj SD, 1996, FEBS LETT, V384, P78, DOI 10.1016/0014-5793(96)00273-6; Dumaine R, 1996, CIRC RES, V78, P916, DOI 10.1161/01.RES.78.5.916; Felts PA, 1997, MOL BRAIN RES, V45, P71, DOI 10.1016/S0169-328X(96)00241-0; FENG GP, 1995, CELL, V82, P1001, DOI 10.1016/0092-8674(95)90279-1; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fjell J, 1999, MOL BRAIN RES, V67, P267, DOI 10.1016/S0169-328X(99)00070-4; Fjell J, 2000, NEUROREPORT, V11, P199, DOI 10.1097/00001756-200001170-00039; FLORKIEWICZ RZ, 1995, J CELL PHYSIOL, V162, P388, DOI 10.1002/jcp.1041620311; Florkiewicz RZ, 1998, J BIOL CHEM, V273, P544, DOI 10.1074/jbc.273.1.544; Gee SH, 1998, J NEUROSCI, V18, P128; Goldin AL, 2000, NEURON, V28, P365, DOI 10.1016/S0896-6273(00)00116-1; Hartung H, 1997, MECH DEVELOP, V64, P31, DOI 10.1016/S0925-4773(97)00042-7; HERZOG RI, 2000, SOC NEUR ABSTR, V26, P1111; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; ISOM LL, 1992, SCIENCE, V256, P839, DOI 10.1126/science.1375395; ISOM LL, 1995, CELL, V83, P433, DOI 10.1016/0092-8674(95)90121-3; Jeong SY, 2000, BIOCHEM BIOPH RES CO, V267, P262, DOI 10.1006/bbrc.1999.1916; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; Liu CJ, 2000, MOL CELL BIOL, V20, P7024, DOI 10.1128/MCB.20.18.7024-7036.2000; Liu CJ, 1999, EMBO J, V18, P2845, DOI 10.1093/emboj/18.10.2845; McCormick KA, 1999, J BIOL CHEM, V274, P32638, DOI 10.1074/jbc.274.46.32638; Mori M, 2000, BIOCHEMISTRY-US, V39, P1316, DOI 10.1021/bi9912600; Munoz-Sanjuan I, 1999, DEVELOPMENT, V126, P409; Munoz-Sanjuan I, 2000, J BIOL CHEM, V275, P2589, DOI 10.1074/jbc.275.4.2589; Nehring RB, 2000, J NEUROSCI, V20, P156, DOI 10.1523/JNEUROSCI.20-01-00156.2000; PATTON DE, 1994, J BIOL CHEM, V269, P17649; Ptacek LJ, 1997, NEUROMUSCULAR DISORD, V7, P250, DOI 10.1016/S0960-8966(97)00046-1; Qu YS, 1999, J BIOL CHEM, V274, P32647, DOI 10.1074/jbc.274.46.32647; Ratcliffe CF, 2000, NAT NEUROSCI, V3, P437, DOI 10.1038/74805; Rizzo MA, 1996, EUR NEUROL, V36, P3, DOI 10.1159/000117192; Roche KW, 1999, J NEUROSCI, V19, P3926; Sampo B, 2000, P NATL ACAD SCI USA, V97, P3666, DOI 10.1073/pnas.97.7.3666; Smallwood PM, 1996, P NATL ACAD SCI USA, V93, P9850, DOI 10.1073/pnas.93.18.9850; Srinivasan J, 1998, P NATL ACAD SCI USA, V95, P15753, DOI 10.1073/pnas.95.26.15753; Tate S, 1998, NAT NEUROSCI, V1, P653, DOI 10.1038/3652; Tibbs VC, 1998, J BIOL CHEM, V273, P25783, DOI 10.1074/jbc.273.40.25783; Trudel C, 2000, J CELL PHYSIOL, V185, P260, DOI 10.1002/1097-4652(200011)185:2<260::AID-JCP11>3.0.CO;2-X; Verdier AS, 1997, GENOMICS, V40, P151, DOI 10.1006/geno.1996.4492; Voit R, 1997, MOL CELL BIOL, V17, P4230, DOI 10.1128/MCB.17.8.4230; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wang H, 2000, J BIOL CHEM, V275, P27377; Waxman SG, 1999, P NATL ACAD SCI USA, V96, P7635, DOI 10.1073/pnas.96.14.7635; Waxman SG, 2000, BRAIN RES, V886, P5, DOI 10.1016/S0006-8993(00)02774-8; Xiao ZC, 1999, J BIOL CHEM, V274, P26511, DOI 10.1074/jbc.274.37.26511	56	104	106	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					18925	18933		10.1074/jbc.M101606200	http://dx.doi.org/10.1074/jbc.M101606200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11376006	hybrid			2022-12-25	WOS:000169091000038
J	Majumder, A; Fang, M; Tsai, KJ; Ueguchi, C; Mizuno, T; Wu, HY				Majumder, A; Fang, M; Tsai, KJ; Ueguchi, C; Mizuno, T; Wu, HY			LeuO expression in response to starvation for branched-chain amino acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; LEU-500 PROMOTER; GENE; MUTATION; PPGPP; DNA; ACTIVATION; MUTANTS; RELAY	The recently identified role of LeuO in the regulation of transcription has prompted us to search for the specific function(s) of LeuO in bacterial physiology, The cryptic nature of expression of leuO has previously limited such analysis. A conditional leuO expression was found when bacteria enter stationary phase and was shown to be guanosine 3 ' ,5 ' -bispyrophosphate-dependent, Multiple physiological events, including the stringent response, are induced upon the increase of the bacterial stress signal, guanosine 3 ' ,5 ' -bispyrophosphate, In this study, we tested whether LeuO was directly involved in the bacterial stringent response. LeuO was shown to be indispensable for growth resumption following a 2-h growth arrest caused by starvation for branched-chain amino acids in an E, coli K-12 relA1 strain. This result supports a functional role for LeuO in the bacterial stringent response.	Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA; Chung Shan Med & Dent Coll, Sch Med Technol, Taichung 402, Taiwan; Nagoya Univ, Sch Agr, Biosci Ctr, Chikusa Ku, Nagoya, Aichi 4648601, Japan; Nagoya Univ, Sch Agr, Mol Microbiol Lab, Chikusa Ku, Nagoya, Aichi 4648601, Japan	Wayne State University; Chung Shan Medical University; Nagoya University; Nagoya University	Wu, HY (corresponding author), Wayne State Univ, Sch Med, Dept Pharmacol, 540 E Canfield Ave, Detroit, MI 48201 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053617, R29GM053617] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53617] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALFOLDI L, 1964, BIOCHIM BIOPHYS ACTA, V91, P155, DOI 10.1016/0926-6550(64)90179-3; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CASHEL M, 1996, ESCHERICHIA COLI SAL, V1, P1458; Chen CC, 2001, J BIOL CHEM, V276, P9478, DOI 10.1074/jbc.M010501200; Fang M, 1998, J BIOL CHEM, V273, P29929, DOI 10.1074/jbc.273.45.29929; Fang M, 2000, BIOCHEM BIOPH RES CO, V276, P64, DOI 10.1006/bbrc.2000.3440; Fang M, 1998, J BACTERIOL, V180, P626, DOI 10.1128/JB.180.3.626-633.1998; FILL N., 1968, J BACTERIOL, V95, P729; GEMMILL RM, 1983, J MOL BIOL, V170, P39, DOI 10.1016/S0022-2836(83)80226-5; HAUGHN GW, 1985, J BACTERIOL, V163, P186, DOI 10.1128/JB.163.1.186-198.1985; Klauck E, 1997, MOL MICROBIOL, V25, P559, DOI 10.1046/j.1365-2958.1997.4911852.x; Landgraf JR, 1996, J BACTERIOL, V178, P6930, DOI 10.1128/jb.178.23.6930-6936.1996; LANGE R, 1995, J BACTERIOL, V177, P4676, DOI 10.1128/jb.177.16.4676-4680.1995; METZGER S, 1989, J BIOL CHEM, V264, P21146; PAO CC, 1978, MOL GEN GENET, V158, P271, DOI 10.1007/BF00267198; RICHARDSON SMH, 1988, EMBO J, V7, P1863, DOI 10.1002/j.1460-2075.1988.tb03019.x; RICHARDSON SMH, 1984, EMBO J, V3, P1745, DOI 10.1002/j.1460-2075.1984.tb02041.x; SHI XL, 1995, J BACTERIOL, V177, P810, DOI 10.1128/jb.177.3.810-814.1995; TAN JY, 1994, J BACTERIOL, V176, P1077, DOI 10.1128/JB.176.4.1077-1086.1994; Ueguchi C, 1998, J BACTERIOL, V180, P190, DOI 10.1128/JB.180.1.190-193.1998; UMBARGER HE, 1996, ESCHERICHIA COLI SAL, V1, P442; UZAN M, 1978, MOL GEN GENET, V165, P21, DOI 10.1007/BF00270372; UZAN M, 1976, BIOCHEM BIOPH RES CO, V69, P751, DOI 10.1016/0006-291X(76)90939-6; WANG Q, 1993, EMBO J, V12, P2495, DOI 10.1002/j.1460-2075.1993.tb05904.x; WU HY, 1995, CELL, V82, P445, DOI 10.1016/0092-8674(95)90433-6; XIAO H, 1991, J BIOL CHEM, V266, P5980	26	35	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19046	19051		10.1074/jbc.M100945200	http://dx.doi.org/10.1074/jbc.M100945200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11376008	hybrid			2022-12-25	WOS:000169091000055
J	Butt, E; Immler, D; Meyer, HE; Kotlyarov, A; Laass, K; Gaestel, M				Butt, E; Immler, D; Meyer, HE; Kotlyarov, A; Laass, K; Gaestel, M			Heat shock protein 27 is a substrate of cGMP-dependent protein kinase in intact human platelets - Phosphorylation-induced actin polymerization caused by Hsp27 mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASODILATOR-STIMULATED PHOSPHOPROTEIN; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; NITRIC-OXIDE; MAPKAP KINASE-2; IN-VITRO; CALCIUM; INHIBITION; IDENTIFICATION; ACTIVATION; ADHESION	Phosphorylation of heat shock protein 27 (Hsp27) in human platelets by mitogen activated protein kinase-activated protein kinase (MAPKAP) 2 is associated with signaling events involved in platelet aggregation and regulation of microfilament organization. We now show that Hsp27 is also phosphorylated by cGMP-dependent protein kinase (cGK), a signaling system important for the inhibition of platelet aggregation. Stimulation of washed platelets with 8-para-chlorophenylthio-cGMP, a cGK specific activator, resulted in a time-dependent phosphorylation of Hsp27. This is supported by the ability of cGK to phosphorylate Hsp27 in vitro to an extent comparable with the cGK-mediated phosphorylation of its established substrate vasodilator-stimulated phosphoprotein. Studies with Hsp27 mutants identified threonine 143 as a yet uncharacterized phosphorylation site in Hsp27 specifically targeted by cGK. To test the hypothesis that cGK could inhibit platelet aggregation by phosphorylating Hsp27 and interfering with the MAP-KAP kinase phosphorylation of Hsp27, the known MAP-KAP kinase 2-phosphorylation sites (Ser(15), Ser(78), and Ser(82)) as well as Thr(143) were replaced by negatively charged amino acids, which are considered to mimic phosphate groups, and tested in actin polymerization experiments. Mimicry at the MAPKAP kinase 2 phosphorylation sites led to mutants with a stimulating effect on actin polymerization, Mutation of the cGK-specific site Thr(143) alone had no effect on actin polymerization, but in the MAPKAP kinase 2 phosphorylation-mimicking mutant, this mutation reduced the stimulation of actin polymerization significantly. These data suggest that phosphorylation of Hsp27 and Hsp27-dependent regulation of actin microfilaments contribute to the inhibitory effects of cGK on platelet function.	Univ Wurzburg, Med Clin, Inst Clin Biochem & Pathobiochem, D-97080 Wurzburg, Germany; Bayer AG, ZAS, ZF, D-5090 Leverkusen, Germany; Ruhr Univ Bochum, Inst Physiol Chem, Prot Struct Lab, D-44780 Bochum, Germany; Univ Halle, Inst Pharmaceut Biol, D-06120 Halle, Germany	University of Wurzburg; Bayer AG; Ruhr University Bochum; Martin Luther University Halle Wittenberg	Butt, E (corresponding author), Univ Wurzburg, Med Clin, Inst Clin Biochem & Pathobiochem, Josef Schneider Str 2, D-97080 Wurzburg, Germany.		Gaestel, Matthias/A-6560-2013	Gaestel, Matthias/0000-0002-4944-4652				Beall A, 1999, J BIOL CHEM, V274, P11344, DOI 10.1074/jbc.274.16.11344; Beall AC, 1997, J BIOL CHEM, V272, P11283; BENNDORF R, 1994, J BIOL CHEM, V269, P20780; Brophy CM, 1999, J BIOL CHEM, V274, P6324, DOI 10.1074/jbc.274.10.6324; Butt E, 2000, J BIOL CHEM, V275, P5179, DOI 10.1074/jbc.275.7.5179; BUTT E, 1994, J BIOL CHEM, V269, P14509; BUTT E, 1997, ADV MOL CEL, V18, P311; Corbin JD, 2000, EUR J BIOCHEM, V267, P2760, DOI 10.1046/j.1432-1327.2000.01297.x; ElDaher SS, 1996, THROMB HAEMOSTASIS, V76, P1063; Fotis H, 1999, EUR J BIOCHEM, V260, P904, DOI 10.1046/j.1432-1327.1999.00237.x; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GAESTEL M, 1991, J BIOL CHEM, V266, P14721; GAESTEL M, 1992, J BIOL CHEM, V267, P21607; GEIGER J, 1992, P NATL ACAD SCI USA, V89, P1031, DOI 10.1073/pnas.89.3.1031; Gevaert K, 1996, ELECTROPHORESIS, V17, P918, DOI 10.1002/elps.1150170513; Hall KU, 1999, J BIOL CHEM, V274, P3485, DOI 10.1074/jbc.274.6.3485; Harbeck B, 2000, J BIOL CHEM, V275, P30817, DOI 10.1074/jbc.M005066200; Haslam RJ, 1999, THROMB HAEMOSTASIS, V82, P412; Haug LS, 1999, J BIOL CHEM, V274, P7467, DOI 10.1074/jbc.274.11.7467; Hofmann F, 2000, J CELL SCI, V113, P1671; HORSTRUP K, 1994, EUR J BIOCHEM, V225, P21, DOI 10.1111/j.1432-1033.1994.00021.x; JAKOB U, 1993, J BIOL CHEM, V268, P1517; Khan IU, 1998, P NATL ACAD SCI USA, V95, P10425, DOI 10.1073/pnas.95.18.10425; Komalavilas P, 1996, J BIOL CHEM, V271, P21933, DOI 10.1074/jbc.271.36.21933; KRAMER RM, 1995, J BIOL CHEM, V270, P27395, DOI 10.1074/jbc.270.46.27395; LANDRY J, 1992, J BIOL CHEM, V267, P794; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; Maizels ET, 1998, BIOCHEM J, V332, P703, DOI 10.1042/bj3320703; Massberg S, 1999, J EXP MED, V189, P1255, DOI 10.1084/jem.189.8.1255; MENDELSOHN ME, 1991, P NATL ACAD SCI USA, V88, P11212, DOI 10.1073/pnas.88.24.11212; NISHIKAWA M, 1984, J BIOL CHEM, V259, P8429; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; POHLER D, 1995, FEBS LETT, V374, P419, DOI 10.1016/0014-5793(95)01168-E; Reep BR, 1996, BIOCHEM BIOPH RES CO, V219, P1, DOI 10.1006/bbrc.1996.0171; RINK TJ, 1990, ANNU REV PHYSIOL, V52, P431, DOI 10.1146/annurev.ph.52.030190.002243; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SAKLATVALA J, 1996, J BIOL CHEM, V271, P6486; Scheler C, 1999, ELECTROPHORESIS, V20, P3623, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3623::AID-ELPS3623>3.0.CO;2-R; Schlossmann J, 2000, NATURE, V404, P197, DOI 10.1038/35004606; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; TORTI M, 1992, P NATL ACAD SCI USA, V89, P7796, DOI 10.1073/pnas.89.16.7796; VONBRUCHHAUSEN F, 1997, HDB EXP PHARM, V126, P181; WALTER U, 1980, J BIOL CHEM, V255, P3757; Wang GR, 1998, P NATL ACAD SCI USA, V95, P4888, DOI 10.1073/pnas.95.9.4888; ZHU Y, 1994, J BIOL CHEM, V269, P22379; ZHU Y, 1994, BLOOD, V84, P3715, DOI 10.1182/blood.V84.11.3715.bloodjournal84113715	47	102	106	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7108	7113		10.1074/jbc.M009234200	http://dx.doi.org/10.1074/jbc.M009234200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11383510	hybrid			2022-12-25	WOS:000167442900036
J	Greenberg, RB; Alberti, M; Hearst, JE; Chua, MA; Saffran, WA				Greenberg, RB; Alberti, M; Hearst, JE; Chua, MA; Saffran, WA			Recombinational and mutagenic repair of psoralen interstrand cross-links in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; MAMMALIAN-CELL EXTRACTS; GENE CONVERSION TRACTS; DOUBLE-STRAND BREAKS; ESCHERICHIA-COLI; DNA-POLYMERASE; RECIPROCAL RECOMBINATION; 8-METHOXYPSORALEN PLUS; PLASMID RECOMBINATION; THYMINE DIMER	Psoralen photoreacts with DNA to form interstrand cross-links, which can be repaired by both nonmutagenic nucleotide excision repair and recombinational repair pathways and by mutagenic pathways. In the yeast Saccharomyces cerevisiae, psoralen cross-links are processed by nucleotide excision repair to form double-strand breaks (DSBs). In yeast, DSBs are repaired primarily by homologous recombination, predicting that cross-link and DSB repair should induce similar recombination end points. We compared psoralen cross-link, psoralen monoadduct, and DSB repair using plasmid substrates with site-specific lesions and measured the patterns of gene conversion, crossing over, and targeted mutation. Psoralen cross-link induced both recombination and mutations, whereas DSBs induced only recombination, and monoadducts were neither recombinogenic nor mutagenic. Although the cross-link- and DSB-induced patterns of plasmid integration and gene conversion were similar in most respects, they showed opposite asymmetries in their unidirectional conversion tracts: primarily upstream from the damage site for cross-links but downstream for DSBs. Cross-links induced targeted mutations in 5% of the repaired plasmids; all were base substitutions, primarily T --> C transitions. The major pathway of psoralen cross-link repair in yeast is error-free and involves the formation of DSB intermediates followed by homologous recombination. A fraction of the cross-links enter an error-prone pathway, resulting in mutations at the damage site.	CUNY Queens Coll, Dept Chem & Biochem, Flushing, NY 11367 USA; Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Dept Chem, Berkeley, CA 94720 USA	City University of New York (CUNY) System; Queens College NY (CUNY); United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Saffran, WA (corresponding author), CUNY Queens Coll, Dept Chem & Biochem, 65-30 Kissena Blvd, Flushing, NY 11367 USA.	Wilma_Saffran@qc.edu			NATIONAL CANCER INSTITUTE [R01CA042377] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047945] Funding Source: NIH RePORTER; NCI NIH HHS [CA42377] Funding Source: Medline; NIGMS NIH HHS [GM47945] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGUILERA A, 1989, GENETICS, V123, P683; AHN BY, 1986, MOL CELL BIOL, V6, P3685, DOI 10.1128/MCB.6.11.3685; ALANI E, 1994, GENETICS, V137, P19; AVERBECK D, 1989, PHOTOCHEM PHOTOBIOL, V50, P859, DOI 10.1111/j.1751-1097.1989.tb02917.x; Averbeck D, 1998, PHOTOCHEM PHOTOBIOL, V68, P289, DOI 10.1111/j.1751-1097.1998.tb09683.x; Barre FX, 1999, J MOL BIOL, V286, P1379, DOI 10.1006/jmbi.1999.2550; Barre FX, 1999, NUCLEIC ACIDS RES, V27, P743, DOI 10.1093/nar/27.3.743; Baynton K, 1998, MOL CELL BIOL, V18, P960, DOI 10.1128/MCB.18.2.960; Bessho T, 1997, MOL CELL BIOL, V17, P6822, DOI 10.1128/MCB.17.12.6822; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; CHENG S, 1988, J BIOL CHEM, V263, P15110; CHENG S, 1991, NUCLEIC ACIDS RES, V19, P657, DOI 10.1093/nar/19.3.657; CHIOU CC, 1995, CARCINOGENESIS, V16, P1357, DOI 10.1093/carcin/16.6.1357; Cho JW, 1998, CURR GENET, V34, P269; CIMINO GD, 1985, ANNU REV BIOCHEM, V54, P1151, DOI 10.1146/annurev.bi.54.070185.005443; COLE RS, 1976, J MOL BIOL, V103, P39, DOI 10.1016/0022-2836(76)90051-6; COLE RS, 1973, P NATL ACAD SCI USA, V70, P1064, DOI 10.1073/pnas.70.4.1064; DARDALHON M, 1995, MUTAT RES-DNA REPAIR, V336, P49, DOI 10.1016/0921-8777(94)00037-7; De Silva IU, 2000, MOL CELL BIOL, V20, P7980, DOI 10.1128/MCB.20.21.7980-7990.2000; Ferguson DO, 1996, P NATL ACAD SCI USA, V93, P5419, DOI 10.1073/pnas.93.11.5419; HAN EK, 1992, MOL GEN GENET, V236, P8, DOI 10.1007/BF00279637; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; JACHYMCZYK WJ, 1981, MOL GEN GENET, V182, P196, DOI 10.1007/BF00269658; JONES BK, 1990, J BIOL CHEM, V265, P3489; Kohn KW, 1996, CANCER RES, V56, P5533; Kumaresan KR, 1995, J BIOL CHEM, V270, P30709, DOI 10.1074/jbc.270.51.30709; Kumaresan KR, 2000, CARCINOGENESIS, V21, P741, DOI 10.1093/carcin/21.4.741; LAQUERBE A, 1995, J MOL BIOL, V254, P38, DOI 10.1006/jmbi.1995.0597; Li L, 1999, MOL CELL BIOL, V19, P5619; MAGANASCHWENCKE N, 1982, P NATL ACAD SCI-BIOL, V79, P1722, DOI 10.1073/pnas.79.6.1722; McHugh PJ, 2000, MOL CELL BIOL, V20, P3425, DOI 10.1128/MCB.20.10.3425-3433.2000; MEIRA LB, 1995, NUCLEIC ACIDS RES, V23, P1614, DOI 10.1093/nar/23.9.1614; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MILLER RD, 1982, MOL CELL BIOL, V2, P939, DOI 10.1128/MCB.2.8.939; Mu D, 2000, MOL CELL BIOL, V20, P2446, DOI 10.1128/MCB.20.7.2446-2454.2000; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; Nickoloff JA, 1999, GENETICS, V153, P665; PAPADOPOULO D, 1993, MUTAT RES, V294, P167, DOI 10.1016/0921-8777(93)90025-C; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; ROCCANOVA LP, 1999, THESIS CITY U NEW YO; ROTHSTEIN RJ, 1981, METHOD ENZYMOL, V194, P281; SAFFRAN WA, 1994, NUCLEIC ACIDS RES, V22, P2823, DOI 10.1093/nar/22.14.2823; SAFFRAN WA, 1992, MUTAT RES, V274, P1, DOI 10.1016/0921-8777(92)90038-5; SAFFRAN WA, 1991, NUCLEIC ACIDS RES, V19, P5681, DOI 10.1093/nar/19.20.5681; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SASTRY SS, 1992, J PHOTOCH PHOTOBIO B, V14, P65, DOI 10.1016/1011-1344(92)85083-7; Sherman F., 1986, METHODS YEAST GENETI; SLADEK FM, 1989, J BIOL CHEM, V264, P6755; SPIELMANN HP, 1992, P NATL ACAD SCI USA, V89, P4514, DOI 10.1073/pnas.89.10.4514; Stern RS, 1998, ARCH DERMATOL, V134, P1582, DOI 10.1001/archderm.134.12.1582; STINCHCOMB DT, 1980, P NATL ACAD SCI-BIOL, V77, P4559, DOI 10.1073/pnas.77.8.4559; STRATHERN JN, 1991, METHOD ENZYMOL, V194, P319; SVOBODA DL, 1993, J BIOL CHEM, V268, P1931; SWEETSER DB, 1994, MOL CELL BIOL, V14, P3863, DOI 10.1128/MCB.14.6.3863; TESSMAN JW, 1985, BIOCHEMISTRY-US, V24, P1669, DOI 10.1021/bi00328a015; VANHOUTEN B, 1986, P NATL ACAD SCI USA, V83, P8077; Wang X, 2001, MOL CELL BIOL, V21, P713, DOI 10.1128/MCB.21.3.713-720.2001	57	29	30	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31551	31560		10.1074/jbc.M103588200	http://dx.doi.org/10.1074/jbc.M103588200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11390398	hybrid			2022-12-25	WOS:000170613500013
J	Fernandez-Velasco, JG; Jamshidi, A; Gong, XS; Zhou, JH; Ueng, RY				Fernandez-Velasco, JG; Jamshidi, A; Gong, XS; Zhou, JH; Ueng, RY			Photosynthetic electron transfer through the cytochrome b(6)f complex can bypass cytochrome f	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; BC(1) COMPLEX; PLASTOCYANIN; DOMAIN; PLASTOQUINONE; CHLOROPLASTS; PURIFICATION; CONVERSION; REDUCTION; TRANSPORT	The cytochrome b(6)f complex is an obligatory electron transfer and proton-translocating enzyme in all oxygenic photosynthesis. Its operation has been described by the "Q-cycle." This model proposes that electrons are transferred from plastoquinol to plastocyanin (the reductant of P700 in Photosystem I) through, obligatorily in series, the iron-sulfur and the cytochrome f redox centers in the cytochrome b6f complex. However, here we demonstrate that (a) the iron-sulfur center-dependent reductions of plastocyanin and P700 are much faster than cytochrome f reduction, both in Chlamydomonas reinhardtii cytochrome f mutants and in the wild type, and (b) the steady-state photosynthetic electron transport does not correlate with strongly inhibited cytochrome f reduction kinetics in the mutants. Thus, cytochrome f is not an obligatory intermediate for electrons flowing through the cytochrome b6f complex. The oxidation equivalents from Photosystem I are delivered to the high potential chain of the cytochrome b,f complex both at the cytochrome f level and, independently, at another site connected to the quinol-oxidizing site, possibly the iron-sulfur center.	Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Fernandez-Velasco, JG (corresponding author), Univ Calif Berkeley, Dept Plant & Microbial Biol, 421 Koshland Hall, Berkeley, CA 94720 USA.	jfernand@nature.berkeley.edu			NIGMS NIH HHS [GM-20571] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020571] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berry EA, 2000, ANNU REV BIOCHEM, V69, P1005, DOI 10.1146/annurev.biochem.69.1.1005; Carrell CJ, 1997, STRUCTURE, V5, P1613, DOI 10.1016/S0969-2126(97)00309-2; Chi YI, 2000, BIOCHEMISTRY-US, V39, P7689, DOI 10.1021/bi000090k; Comolli LR, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P1589; CROFTS AR, 1983, BIOCHIM BIOPHYS ACTA, V726, P149, DOI 10.1016/0304-4173(83)90004-6; DELOSME R, 1987, BIOCHIM BIOPHYS ACTA, V893, P1, DOI 10.1016/0005-2728(87)90141-1; Drepper F, 1996, BIOCHEMISTRY-US, V35, P1282, DOI 10.1021/bi951471e; ERECINSKA M, 1972, P NATL ACAD SCI USA, V69, P50, DOI 10.1073/pnas.69.1.50; Fernandez-Velasco JG, 1999, BIOPHYS J, V76, pA20; Gong XS, 2001, J BIOL CHEM, V276, P24365, DOI 10.1074/jbc.M010721200; GRAY JC, 1992, PHOTOSYNTH RES, V34, P359, DOI 10.1007/BF00029811; HAEHNEL W, 1977, BIOCHIM BIOPHYS ACTA, V459, P418, DOI 10.1016/0005-2728(77)90043-3; HAEHNEL W, 1973, BIOCHIM BIOPHYS ACTA, V305, P618, DOI 10.1016/0005-2728(73)90081-9; Harris E.H., 1989, CHLAMYDOMONAS SOURCE, P26; Hauska G, 1996, ADV PHOTOSYNTH, V4, P377; He W. Z., 1998, P29; Hippler M, 1998, BBA-BIOENERGETICS, V1367, P1, DOI 10.1016/S0005-2728(98)00136-4; HIYAMA T, 1972, BIOCHIM BIOPHYS ACTA, V267, P160, DOI 10.1016/0005-2728(72)90147-8; HOPE AB, 1993, BIOCHIM BIOPHYS ACTA, V1143, P1, DOI 10.1016/0005-2728(93)90210-7; JOLIOT P, 1994, P NATL ACAD SCI USA, V91, P1034, DOI 10.1073/pnas.91.3.1034; JUNGE W, 1977, PHOTOSYNTHESIS, V1, P59; KATOH S, 1962, J BIOCHEM-TOKYO, V51, P32, DOI 10.1093/oxfordjournals.jbchem.a127497; KSENZHEK OS, 1998, PLANT ENERGETICS, P1; KURAS R, 1995, BIOCHEMISTRY-US, V34, P7468, DOI 10.1021/bi00022a021; MALKIN R, 1975, BIOCHEM BIOPH RES CO, V63, P1157, DOI 10.1016/0006-291X(75)90690-7; Martinez SE, 1996, PROTEIN SCI, V5, P1081; MARTINEZ SE, 1994, STRUCTURE, V2, P95, DOI 10.1016/S0969-2126(00)00012-5; MCCARTY RE, 1996, OXYGENIC PHOTOSYNTHE, P439; Melandri B.A., 1997, BIOENERGETICS, P95; MITCHELL P, 1966, BIOL REV, V41, P445, DOI 10.1111/j.1469-185X.1966.tb01501.x; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; Mulkidjanian A, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL II, P547; NITSCHKE W, 1989, BIOCHIM BIOPHYS ACTA, V974, P223, DOI 10.1016/S0005-2728(89)80376-7; ORT DR, 1986, PHOTOSYNTHESIS, V3, P143; PETERS FALJ, 1984, BIOCHIM BIOPHYS ACTA, V766, P179, DOI 10.1016/0005-2728(84)90230-5; PIERRE Y, 1995, J BIOL CHEM, V270, P29342, DOI 10.1074/jbc.270.49.29342; Ponamarev MV, 1998, BIOCHEMISTRY-US, V37, P17199, DOI 10.1021/bi981814j; Ponamarev MV, 2000, BIOCHEMISTRY-US, V39, P5971, DOI 10.1021/bi9928997; SANDERSON DG, 1986, BIOCHIM BIOPHYS ACTA, V852, P269, DOI 10.1016/0005-2728(86)90232-X; SELAK MA, 1982, FEBS LETT, V150, P286, DOI 10.1016/0014-5793(82)80753-9; Soriano GM, 1999, J BIOENERG BIOMEMBR, V31, P201, DOI 10.1023/A:1005463527752; TREBST A, 1985, COENZYME Q, P257; Whitmarsh J., 1998, P87; WIKSTROM MK, 1972, BIOCHIM BIOPHYS ACTA, V283, P403, DOI 10.1016/0005-2728(72)90258-7; WITT HT, 1979, BIOCHIM BIOPHYS ACTA, V505, P355, DOI 10.1016/0304-4173(79)90008-9; WOOD PM, 1978, EUR J BIOCHEM, V87, P9, DOI 10.1111/j.1432-1033.1978.tb12346.x; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612; Zhou JH, 1996, J BIOL CHEM, V271, P6225, DOI 10.1074/jbc.271.11.6225	49	20	20	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30598	30607		10.1074/jbc.M102241200	http://dx.doi.org/10.1074/jbc.M102241200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11395492	hybrid			2022-12-25	WOS:000170472900004
J	Gupta, RA; Polk, DB; Krishna, U; Israel, DA; Yan, F; DuBois, RN; Peek, RM				Gupta, RA; Polk, DB; Krishna, U; Israel, DA; Yan, F; DuBois, RN; Peek, RM			Activation of peroxisome proliferator-activated receptor gamma suppresses nuclear factor kappa B-mediated apoptosis induced by Helicobacter pylori in gastric epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PPAR-GAMMA; CYCLOOXYGENASE-2 EXPRESSION; TRANSCRIPTION FACTOR; GENE-EXPRESSION; INFLAMMATORY RESPONSE; ALPHA PHOSPHORYLATION; PATHOGENICITY ISLAND; ATROPHIC GASTRITIS; IMMUNE-RESPONSES; INCREASED RISK	Helicobacter pylori colonization leads to epithelial cell hyperproliferation within inflamed mucosa, but levels of apoptosis vary, suggesting that imbalances between rates of cell production and loss may contribute to differences in gastric cancer risk among infected populations. Peroxisome proliferator-activated receptor gamma (PPAR gamma) regulates inflammatory and growth responses of intestinal epithelial cells. We determined whether activation of PPAR gamma modified H. pylori-induced apoptosis in gastric epithelial cells. PPAR gamma was expressed and functionally active in gastric epithelial cell lines sensitive to H. pylori-induced apoptosis. PPAR gamma ligands 15d-PGJ(2) and BRL-49653 significantly attenuated H. pylori-induced apoptosis, effects that could be reversed by co-treatment with a specific PPAR gamma antagonist., Cyclopentanone prostaglandins that do not bind and activate PPAR gamma had no effects on H. pylori-induced apoptosis. The ability of H. pylori to activate nuclear factor (NF)-kappaB and increase levels of the NF-kappaB target IL-8 was blocked by co-treatment with PPAR gamma agonists, and direct inhibition of NF-kappaB also abolished H. pylori-stimulated apoptosis. These results suggest that activation of the PPAR gamma pathway attenuates the ability of H. pylori to induce NF-kappaB-mediated apoptosis in gastric epithelial cells. Because PPAR gamma regulates a multitude of host responses, activation of this receptor may contribute to varying levels of cellular turnover as well as the diverse pathologic outcomes associated with chronic H. pylori colonization.	Vanderbilt Univ, Sch Med, Div Gastroenterol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Div Pediat Gastroenterol, Nashville, TN 37232 USA; Dept Vet Affairs Med Ctr, Nashville, TN 37212 USA	Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Peek, RM (corresponding author), Vanderbilt Univ, Sch Med, Div Gastroenterol, C-2104 Med Ctr N, Nashville, TN 37232 USA.		DuBois, Raymond N./AAX-8869-2020		NATIONAL CANCER INSTITUTE [R29CA077955, R01CA077955] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002381] Funding Source: NIH RePORTER; NCI NIH HHS [CA77955] Funding Source: Medline; NIDDK NIH HHS [DK02381, DK56008] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akopyants NS, 1998, MOL MICROBIOL, V28, P37, DOI 10.1046/j.1365-2958.1998.00770.x; Akre K, 2001, BRIT J CANCER, V84, P965, DOI 10.1054/bjoc.2001.1702; Anti M, 1998, ITAL J GASTROENTEROL, V30, P153; Asahi M, 2000, J EXP MED, V191, P593, DOI 10.1084/jem.191.4.593; Bamford KB, 1998, GASTROENTEROLOGY, V114, P482, DOI 10.1016/S0016-5085(98)70531-1; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BLASER MJ, 1995, CANCER RES, V55, P2111; CAHILL RJ, 1995, DIGEST DIS SCI, V40, P1627, DOI 10.1007/BF02212681; Censini S, 1996, P NATL ACAD SCI USA, V93, P14648, DOI 10.1073/pnas.93.25.14648; Chen G, 1997, BIOCHEM BIOPH RES CO, V239, P626, DOI 10.1006/bbrc.1997.7485; CORREA P, 1994, AM J CLIN PATHOL, V101, P656, DOI 10.1093/ajcp/101.5.656; CRABTREE JE, 1993, GUT, V34, P1339, DOI 10.1136/gut.34.10.1339; CRABTREE JE, 1991, LANCET, V338, P332, DOI 10.1016/0140-6736(91)90477-7; El-Omar EM, 2000, NATURE, V404, P398, DOI 10.1038/35006081; Fan XJ, 1998, J EXP MED, V187, P1659, DOI 10.1084/jem.187.10.1659; Fan XJ, 2000, J IMMUNOL, V165, P1918, DOI 10.4049/jimmunol.165.4.1918; Farrow DC, 1998, CANCER EPIDEM BIOMAR, V7, P97; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Fox JG, 2000, NAT MED, V6, P536, DOI 10.1038/75015; Fox JG, 1999, CANCER RES, V59, P4823; FRASER AG, 1994, ALIMENT PHARM THERAP, V8, P167; Fu SD, 1999, GASTROENTEROLOGY, V116, P1319, DOI 10.1016/S0016-5085(99)70496-8; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; Havard TJ, 1996, J CLIN PATHOL, V49, P68, DOI 10.1136/jcp.49.1.68; Hirasawa R, 1999, AM J GASTROENTEROL, V94, P2398; Houghton J, 2000, INFECT IMMUN, V68, P1189, DOI 10.1128/IAI.68.3.1189-1195.2000; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Israel DA, 2001, J CLIN INVEST, V107, P611, DOI 10.1172/JCI11450; Jones NL, 1997, AM J PATHOL, V151, P1695; Kaiser GC, 1999, GASTROENTEROLOGY, V116, P602, DOI 10.1016/S0016-5085(99)70182-4; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Keates S, 1999, J IMMUNOL, V163, P5552; Keates S, 1997, GASTROENTEROLOGY, V113, P1099, DOI 10.1053/gast.1997.v113.pm9322504; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; Kitamura S, 1999, BIOCHEM BIOPH RES CO, V265, P453, DOI 10.1006/bbrc.1999.1715; Kliewer SA, 1998, CURR OPIN GENET DEV, V8, P576, DOI 10.1016/S0959-437X(98)80014-2; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KUIPERS EJ, 1995, J NATL CANCER I, V87, P1777, DOI 10.1093/jnci/87.23.1777; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Lukiw WJ, 1998, P NATL ACAD SCI USA, V95, P3914, DOI 10.1073/pnas.95.7.3914; Luo XL, 1999, GASTROENTEROLOGY, V116, pA767; LYNCH DAF, 1995, GUT, V36, P346, DOI 10.1136/gut.36.3.346; Maeda S, 2000, GASTROENTEROLOGY, V119, P97, DOI 10.1053/gast.2000.8540; Mannick EE, 1996, CANCER RES, V56, P3238; McCarthy CJ, 1999, AM J GASTROENTEROL, V94, P1218, DOI 10.1111/j.1572-0241.1999.01070.x; Mohammadi M, 1996, J IMMUNOL, V156, P4729; Moss SF, 2001, CANCER RES, V61, P1406; Moss SF, 1996, GUT, V38, P498, DOI 10.1136/gut.38.4.498; Nakajima A, 2001, GASTROENTEROLOGY, V120, P460, DOI 10.1053/gast.2001.21191; NOMURA A, 1991, NEW ENGL J MED, V325, P1132, DOI 10.1056/NEJM199110173251604; Odenbreit S, 2000, SCIENCE, V287, P1497, DOI 10.1126/science.287.5457.1497; Parsonnet J, 1997, GUT, V40, P297, DOI 10.1136/gut.40.3.297; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; PEEK RM, 1995, J CLIN MICROBIOL, V33, P28, DOI 10.1128/JCM.33.1.28-32.1995; Peek RM, 1999, CANCER RES, V59, P6124; Peek RM, 1997, JNCI-J NATL CANCER I, V89, P863, DOI 10.1093/jnci/89.12.863; Peek RM, 2000, GASTROENTEROLOGY, V118, P48, DOI 10.1016/S0016-5085(00)70413-6; Peek RM, 1995, LAB INVEST, V73, P760; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Ristimaki A, 1997, CANCER RES, V57, P1276; Rokkas T, 1999, DIGEST DIS SCI, V44, P487, DOI 10.1023/A:1026636803101; Romano M, 1998, J BIOL CHEM, V273, P28560, DOI 10.1074/jbc.273.44.28560; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Rudi J, 1998, J CLIN INVEST, V102, P1506, DOI 10.1172/JCI2808; Sawai N, 1999, INFECT IMMUN, V67, P279, DOI 10.1128/IAI.67.1.279-285.1999; Sawaoka H, 1998, PROSTAG LEUKOTR ESS, V59, P313, DOI 10.1016/S0952-3278(98)90079-5; Sharma SA, 1998, J IMMUNOL, V160, P2401; Smythies LE, 2000, J IMMUNOL, V165, P1022, DOI 10.4049/jimmunol.165.2.1022; Stein M, 2000, P NATL ACAD SCI USA, V97, P1263, DOI 10.1073/pnas.97.3.1263; Su CG, 1999, J CLIN INVEST, V104, P383, DOI 10.1172/JCI7145; Subbaramaiah K, 2001, J BIOL CHEM, V276, P12440, DOI 10.1074/jbc.M007237200; Sung JJY, 2000, AM J PATHOL, V157, P729, DOI 10.1016/S0002-9440(10)64586-5; Tanaka T, 2001, CANCER RES, V61, P2424; Tatsuguchi A, 2000, GUT, V46, P782, DOI 10.1136/gut.46.6.782; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Uefuji K, 1998, J SURG ONCOL, V69, P168, DOI 10.1002/(SICI)1096-9098(199811)69:3<168::AID-JSO9>3.0.CO;2-0; VAN AD, 1996, SCIENCE, V274, P787; Wagner S, 1997, GASTROENTEROLOGY, V113, P1836, DOI 10.1016/S0016-5085(97)70003-9; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang JD, 2000, INFECT IMMUN, V68, P4303, DOI 10.1128/IAI.68.7.4303-4311.2000; Wang TC, 1998, GASTROENTEROLOGY, V114, P675, DOI 10.1016/S0016-5085(98)70581-5; Williams CS, 1997, J CLIN INVEST, V100, P1325, DOI 10.1172/JCI119651; Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g; Yan F, 1999, J BIOL CHEM, V274, P36631, DOI 10.1074/jbc.274.51.36631; Zaridze D, 1999, INT J CANCER, V82, P473, DOI 10.1002/(SICI)1097-0215(19990812)82:4<473::AID-IJC1>3.0.CO;2-K	86	90	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31059	31066		10.1074/jbc.M104141200	http://dx.doi.org/10.1074/jbc.M104141200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11397815	hybrid			2022-12-25	WOS:000170472900063
J	Boudin, H; Craig, AM				Boudin, H; Craig, AM			Molecular determinants for PICK1 synaptic aggregation and mGluR7a receptor coclustering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN-CONTAINING PROTEINS; KINASE-C-ALPHA; AMPA RECEPTOR; GLUTAMATE RECEPTORS; BINDING-PROTEIN; PDZ DOMAINS; CHANNEL; PSD-95; YEAST; GLUR2	PSD-95/Disc-large/ZO-1 (PDZ) domain-containing proteins play a central role in synaptic organization by their involvement in neurotransmitter receptor clustering and signaling complex assembly. The protein interacting. with protein kinase C (PICK1), a synaptic PDZ domain protein that also contains a coiled-coil and acidic domain, binds to several synaptic components including the metabotropic glutamate receptor mGluR7a. Coexpression of PICK1 and mGluR7a in heterologous cells induces coclustering of these two proteins. To examine the role of the different structural motifs of PICK1 in synaptic aggregation of PICK1. and mGluR7a coclustering, several PICK1 mutants were generated to analyze their distribution in transfected hippocampal cultured neurons and to test their ability to induce coclusters with mGluR7a when coexpressed in fibroblast cells. The PDZ and coiled-coil domains are both required, whereas the acidic region plays an inhibitory role in these processes. Our data suggest that synaptic aggregation and receptor coclustering depend on PICK1 binding to a target membrane receptor, e.g. mGluR7a, by a PDZ-mediated interaction and on PICK1 oligomerization through the coiled-coil domain. This study defined three structural signals within PICK1 regulating its synaptic localization and receptor coclustering activity, which could represent molecular substrates involved in synaptic development and plasticity.	Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Craig, AM (corresponding author), Washington Univ, Sch Med, Dept Anat & Neurobiol, 660 S Euclid Ave,Box 8108,958 McDonnell Sci Bldg, St Louis, MO 63110 USA.		Boudin, Helene/K-2400-2015; Craig, Ann Marie/M-2054-2014	Boudin, Helene/0000-0002-9714-2384	NINDS NIH HHS [NS39286] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039286] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arnold DB, 1999, NEURON, V23, P149, DOI 10.1016/S0896-6273(00)80761-8; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO, V2; BAKSH S, 1991, J BIOL CHEM, V266, P21458; Boudin H, 2000, NEURON, V28, P485, DOI 10.1016/S0896-6273(00)00127-6; Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5; Carroll RC, 1999, P NATL ACAD SCI USA, V96, P14112, DOI 10.1073/pnas.96.24.14112; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; Chung HJ, 2000, J NEUROSCI, V20, P7258; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Daw MI, 2000, NEURON, V28, P873, DOI 10.1016/S0896-6273(00)00160-4; Dev KK, 1999, NEUROPHARMACOLOGY, V38, P635, DOI 10.1016/S0028-3908(98)00230-5; Dev KK, 2000, J NEUROSCI, V20, P7252; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Firestein BL, 1999, NEURON, V24, P659, DOI 10.1016/S0896-6273(00)81120-4; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; Goslin K., 1998, RAT HIPPOCAMPAL NEUR, P339; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Hsueh YP, 1997, NEURON, V18, P803, DOI 10.1016/S0896-6273(00)80319-0; James P, 1996, GENETICS, V144, P1425; Li HS, 2000, J CELL BIOL, V150, P1411, DOI 10.1083/jcb.150.6.1411; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Man HY, 2000, NEURON, V25, P649, DOI 10.1016/S0896-6273(00)81067-3; Matsuda S, 2000, EMBO J, V19, P2765, DOI 10.1093/emboj/19.12.2765; Naren AP, 1999, SCIENCE, V286, P544, DOI 10.1126/science.286.5439.544; OHNISHI M, 1987, BIOCHEMISTRY-US, V26, P7458, DOI 10.1021/bi00397a039; Osten P, 2000, NEURON, V27, P313, DOI 10.1016/S0896-6273(00)00039-8; Ramarao MK, 2001, J BIOL CHEM, V276, P7475, DOI 10.1074/jbc.M009888200; Rao A, 2000, J NEUROSCI, V20, P8344, DOI 10.1523/JNEUROSCI.20-22-08344.2000; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; Shigemoto R, 1996, NATURE, V381, P523, DOI 10.1038/381523a0; Srivastava S, 1998, NEURON, V21, P581, DOI 10.1016/S0896-6273(00)80568-1; STAUDINGER J, 1995, J CELL BIOL, V128, P263, DOI 10.1083/jcb.128.3.263; Staudinger J, 1997, J BIOL CHEM, V272, P32019, DOI 10.1074/jbc.272.51.32019; Takumi Y, 1999, ANN NY ACAD SCI, V868, P474, DOI 10.1111/j.1749-6632.1999.tb11316.x; Torres GE, 2001, NEURON, V30, P121, DOI 10.1016/S0896-6273(01)00267-7; Torres R, 1998, NEURON, V21, P1453, DOI 10.1016/S0896-6273(00)80663-7; Tsunoda S, 2001, J NEUROSCI, V21, P150, DOI 10.1523/JNEUROSCI.21-01-00150.2001; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Xia J, 2000, NEURON, V28, P499, DOI 10.1016/S0896-6273(00)00128-8; Xia J, 1999, NEURON, V22, P179, DOI 10.1016/S0896-6273(00)80689-3; Xiang Y, 2000, MOL BIOL CELL, V11, P1257, DOI 10.1091/mbc.11.4.1257	42	35	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30270	30276		10.1074/jbc.M102991200	http://dx.doi.org/10.1074/jbc.M102991200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11375398	hybrid			2022-12-25	WOS:000170558000088
J	Evans, JH; Spencer, DM; Zweifach, A; Leslie, CC				Evans, JH; Spencer, DM; Zweifach, A; Leslie, CC			Intracellular calcium signals regulating cytosolic phospholipase A(2) translocation to internal membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; ACTIVATED PROTEIN-KINASE; CANINE KIDNEY-CELLS; C2 DOMAIN; NUCLEAR-ENVELOPE; HYDROLYZING PHOSPHOLIPASE-A2; ENDOPLASMIC-RETICULUM; CRYSTAL-STRUCTURE; BINDING DOMAIN; GOLGI-COMPLEX	Increased intracellular Ca2+ concentrations ([Ca2+](i)) promote cytosolic phospholipase A(2) (cPLA(2)) translocation to intracellular membranes. The specific membranes to which cPLA(2) translocates and the [Ca2+](i) signals required were investigated. Plasmids of EGFP fused to full-length cPLA(2) (EGFP-FL) or to the cPLA(2) C2 domain (EGFP-C2) were used in C2+/EGFP imaging experiments of cells treated with [Ca2+](i)-mobilizing agonists. EGFP-FL, and -C2 translocated to Golgi in response, to sustained [Ca2+](i) greater than similar to 100-125 nM and to Golgi,. ER, and perinuclear membranes (PNM) at [Ca2+](i) greater than similar to 210-280 nm. In response to short duration [Ca2+](i) transients, EGFP-C2 translocated to Golgi, ER, and PNM, but EGFP-FL translocation was restricted to Golgi. However, EGFP-FL translocated to Golgi, ER, and PNM in response to long, duration transients. In response to declining, [Ca2+](i), EGFP-C2 readily dissociated from Golgi, but EGFP FL dissociation was delayed. Agonist-induced arachidonic acid release was proportional to the [Ca2+](i) and to the extent of cPLA(2) translocation. In summary, we, find that the differential translocation of cPLA(2) to Golgi or to ER and PNM is a function of [Ca2+](i) amplitude and duration., These results suggest that the cPLA(2), C2 domain regulates differential, Ca2+-dependent membrane targeting and that the catalytic domain regulates both the rate of translocation and enzyme residence.	Natl Jewish Med & Res Ctr, Dept Pediat, Cell Biol Program, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Dept Immunol, Denver, CO 80206 USA; Univ Colorado, Sch Med, Dept Pathol, Denver, CO 80262 USA; Univ Colorado, Sch Med, Dept Physiol, Denver, CO 80262 USA	National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Leslie, CC (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Cell Biol Program, 1400 Jackson St, Denver, CO 80206 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034303, R01HL061378, F32HL010507] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL10507, HL34303, HL61378, P01 HL034303] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ball A, 1999, P NATL ACAD SCI USA, V96, P6637, DOI 10.1073/pnas.96.12.6637; Bayburt T, 1997, BIOCHEMISTRY-US, V36, P3216, DOI 10.1021/bi961659d; BROOKS RC, 1989, J BIOL CHEM, V264, P20147; Bunt G, 1997, J CELL SCI, V110, P2449; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; Chen XS, 2001, J BIOL CHEM, V276, P811, DOI 10.1074/jbc.M008203200; Choukroun GJ, 2000, J CLIN INVEST, V106, P983, DOI 10.1172/JCI8914; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; Cole NB, 1996, MOL BIOL CELL, V7, P631, DOI 10.1091/mbc.7.4.631; de Figueiredo P, 1998, P NATL ACAD SCI USA, V95, P8642, DOI 10.1073/pnas.95.15.8642; de Figueiredo P, 1999, MOL BIOL CELL, V10, P1763, DOI 10.1091/mbc.10.6.1763; Dessen A, 1999, CELL, V97, P349, DOI 10.1016/S0092-8674(00)80744-8; Drecktrah D, 1999, MOL BIOL CELL, V10, P4021, DOI 10.1091/mbc.10.12.4021; Evans JH, 1999, AM J PHYSIOL-LUNG C, V277, pL30, DOI 10.1152/ajplung.1999.277.1.L30; Gijon MA, 2000, J BIOL CHEM, V275, P20146, DOI 10.1074/jbc.M908941199; Gijon MA, 1999, J CELL BIOL, V145, P1219, DOI 10.1083/jcb.145.6.1219; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; GRIFFITHS G, 1984, J CELL BIOL, V98, P2133, DOI 10.1083/jcb.98.6.2133; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hirabayashi T, 1999, J BIOL CHEM, V274, P5163, DOI 10.1074/jbc.274.8.5163; Hirose K, 1999, SCIENCE, V284, P1527, DOI 10.1126/science.284.5419.1527; HONDA Z, 1994, J BIOL CHEM, V269, P2307; Kim SW, 2001, FEBS LETT, V489, P243, DOI 10.1016/S0014-5793(00)02326-7; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LESLIE CC, 1991, J BIOL CHEM, V266, P11366; Liou JY, 2000, J BIOL CHEM, V275, P15314, DOI 10.1074/jbc.275.20.15314; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Marsh BJ, 2001, P NATL ACAD SCI USA, V98, P2399, DOI 10.1073/pnas.051631998; MAYORGA LS, 1993, P NATL ACAD SCI USA, V90, P10255, DOI 10.1073/pnas.90.21.10255; Nakatani Y, 2000, J BIOL CHEM, V275, P1161, DOI 10.1074/jbc.275.2.1161; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; Nalefski EA, 1997, BIOCHEMISTRY-US, V36, P12011, DOI 10.1021/bi9717340; Perisic O, 1999, J BIOL CHEM, V274, P14979, DOI 10.1074/jbc.274.21.14979; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; PetersGolden M, 1996, BIOCHEM J, V318, P797, DOI 10.1042/bj3180797; Qiu ZH, 1998, J BIOL CHEM, V273, P8203, DOI 10.1074/jbc.273.14.8203; Rottingen JA, 1997, CELL CALCIUM, V21, P195, DOI 10.1016/S0143-4160(97)90044-0; SAKANAKA C, 1994, BIOCHEM BIOPH RES CO, V205, P18, DOI 10.1006/bbrc.1994.2623; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; Schmidt A, 1999, NATURE, V401, P133, DOI 10.1038/43613; Seemann J, 2000, NATURE, V407, P1022, DOI 10.1038/35039538; Slomiany A, 1998, ALCOHOL CLIN EXP RES, V22, P167, DOI 10.1097/00000374-199802000-00023; SLOMIANY A, 1992, INT J BIOCHEM, V24, P1397, DOI 10.1016/0020-711X(92)90065-9; TAGAYA M, 1993, FEBS LETT, V324, P201, DOI 10.1016/0014-5793(93)81393-E; Wu T, 1997, J BIOL CHEM, V272, P17145, DOI 10.1074/jbc.272.27.17145; Xing MB, 1996, J CLIN INVEST, V97, P1302, DOI 10.1172/JCI118546; Xing MZ, 1997, J CLIN INVEST, V99, P805, DOI 10.1172/JCI119227; Xing MZ, 1999, J BIOL CHEM, V274, P10035, DOI 10.1074/jbc.274.15.10035; Xu GY, 1998, J MOL BIOL, V280, P485, DOI 10.1006/jmbi.1998.1874	50	208	209	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30150	30160		10.1074/jbc.M100943200	http://dx.doi.org/10.1074/jbc.M100943200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11375391	hybrid			2022-12-25	WOS:000170558000074
J	Janiyani, K; Bordelon, T; Waldrop, GL; Cronan, JE				Janiyani, K; Bordelon, T; Waldrop, GL; Cronan, JE			Function of Escherichia coli biotin carboxylase requires catalytic activity of both subunits of the homodimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-COA CARBOXYLASE; COENZYME-A CARBOXYLASE; SITE	Biotin carboxylase catalyzes the ATP-dependent carboxylation of biotin and is one component of the multienzyme. complex acetyl-CoA carboxylase that catalyzes the first committed step in fatty acid synthesis. The Escherichia coli biotin carboxylase is readily isolated from the other components of the acetyl-CoA carboxylase complex such that enzymatic activity is retained. The three-dimensional structure of biotin carboxylase, determined by x-ray crystallography, demonstrated that the enzyme is a homodimer consisting of two active sites in which each subunit contains a complete active site. To understand how each subunit contributes to the overall function of biotin carboxylase, we made hybrid molecules in which one subunit had a wild-type active site, and the other subunit contained an active site mutation known to significantly affect the activity of the enzyme. One of the two genes encoded a poly-histidine tag at its N terminus, whereas the other gene had an N-terminal FLAG epitope tag. The two genes were assembled into a mini-operon that was induced to give high level expression of both enzymes. "Hybrid" dimers composed of one subunit with a wild-type active site and a second subunit having a mutant, active site were obtained by sequential chromatographic steps on columns of immobilized nickel chelate and anti-FLAG affinity matrices. In vitro kinetic studies of biotin carboxylase dimers in which both subunits were wild type revealed that the presence of the N-terminal tags did not alter the activity of the enzyme. However, kinetic assays of hy brid dimer biotin carboxylase molecules in which one subunit had an active site mutation (R292A, N290A, K238Q or E288K) and the other subunit had a wild-type active site resulted in 39-, 28-, 94-, and 285-fold decreases in the activity of these enzymes, respectively. The dominant negative effects of these mutant subunits were also detected in vivo by monitoring the rate of fatty acid biosynthesis by [C-14]acetate labeling of cellular lipids. Expression of the mutant biotin carboxylase genes from an inducible arabinose promoter resulted in a significantly reduced rate of fatty acid synthesis relative to the same strain that expressed the wild type gene. Thus, both the in vitro and in vivo data indicate that both subunits of biotin carboxylase are required for activity and that the two subunits must be in communication during enzyme function.	Univ Illinois, Dept Microbiol, Urbana, IL 61801 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; Louisiana State Univ, Div Biochem & Mol Biol, Baton Rouge, LA 70803 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; Louisiana State University System; Louisiana State University	Cronan, JE (corresponding author), Univ Illinois, Dept Microbiol, Urbana, IL 61801 USA.		Cronan, John/V-6626-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015650, R37AI015650] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051261] Funding Source: NIH RePORTER; NIAID NIH HHS [AI15650] Funding Source: Medline; NIGMS NIH HHS [GM51261] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blanchard CZ, 1999, BIOCHEMISTRY-US, V38, P3393, DOI 10.1021/bi982660a; CHAMBERS SP, 1988, GENE, V68, P139, DOI 10.1016/0378-1119(88)90606-3; Davis MS, 2000, J BIOL CHEM, V275, P28593, DOI 10.1074/jbc.M004756200; Dennis JJ, 1998, APPL ENVIRON MICROB, V64, P2710; EISENSTEIN E, 1992, J BIOL CHEM, V267, P22148; GIBBONS I, 1976, BIOCHEMISTRY-US, V15, P52, DOI 10.1021/bi00646a009; GUCHHAIT RB, 1974, J BIOL CHEM, V249, P6633; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; KAPLAN NO, 1968, ANN NY ACAD SCI, V151, P382, DOI 10.1111/j.1749-6632.1968.tb11902.x; LARIMER FW, 1987, J BIOL CHEM, V262, P15327; Levert KL, 2000, BIOCHEMISTRY-US, V39, P4122, DOI 10.1021/bi992662a; LI SJ, 1992, J BIOL CHEM, V267, P855; PENHOET EE, 1971, J BIOL CHEM, V246, P318; TANABE T, 1975, EUR J BIOCHEM, V57, P15, DOI 10.1111/j.1432-1033.1975.tb02272.x; Thoden JB, 2000, J BIOL CHEM, V275, P16183, DOI 10.1074/jbc.275.21.16183; WALDROP GL, 1994, BIOCHEMISTRY-US, V33, P10249, DOI 10.1021/bi00200a004; WENTE SR, 1987, P NATL ACAD SCI USA, V84, P301	17	53	54	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29864	29870		10.1074/jbc.M104102200	http://dx.doi.org/10.1074/jbc.M104102200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11390406	hybrid			2022-12-25	WOS:000170558000036
J	Lee, SP; Hwang, YS; Kim, YJ; Kwon, KS; Kim, HJ; Kim, K; Chae, HZ				Lee, SP; Hwang, YS; Kim, YJ; Kwon, KS; Kim, HJ; Kim, K; Chae, HZ			Cyclophilin a binds to peroxiredoxins and activates its peroxidase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOL-SPECIFIC ANTIOXIDANT; MITOCHONDRIAL PERMEABILITY TRANSITION; NF-KAPPA-B; CYCLOSPORINE-A; MAMMALIAN PEROXIREDOXIN; THIOREDOXIN PEROXIDASE; ESCHERICHIA-COLI; GLUTATHIONE-PEROXIDASE; OXIDATIVE STRESS; REDUCE PEROXIDES	Six distinct peroxiredoxin (Prx) proteins (Prx I-VI) from distinct genes have been identified in mammalian tissues. Prxs are members of a group of peroxidases that have conserved reactive cysteine residue(s) in the active site(s). An immediate physiological electron donor for the peroxidase catalysis for five Prx proteins (Prx I-V) has been identified as thioredoxin (Trx), but that for Prx VI (I-Cys Prx) is still unclear. To identify an immediate electron donor and a binding protein for Prx VI, we performed a Prx VI protein overlay assay. A 20-kDa binding protein was identified by the Prx VI protein overlay assay with flow-through fractions from a High-Q column with rat lung crude extracts. Using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF) and MS-Fit, we identified the 20-kDa Prx Vl-binding protein as a cyclophilin A (CyP-A). The binding of recombinant human CyP-A (hCyP-A) to Prx VI was confirmed by using the hCyP-A protein overlay assay and Western immunoblot analysis with hCyP-A-specific antibodies. hCyP-A enhanced the antioxidant activity of Prx VI, as well as the other known mammalian Prx isotypes. hCyP-A supported antioxidant activity of Prx II and Prx VI both against thiol (dithiothreitol)-containing metal-catalyzed oxidation (MCO) systems and ascorbate-containing MCO systems. Prx II was reduced by hCyP-A without help from any other reductant, and the reduction was cyclosporin A-independent. These results strongly suggest that CyP-A not only binds to Prx proteins but also supports its peroxidase activity as an immediate electron donor. In addition, Cys(115) and Cys(161) of hCyP-A were found to be involved in the activation and the reduction of Prx.	Chonnam Natl Univ, Coll Nat Sci, Dept Sci Biol, Buk Ku, Kwangju 500757, South Korea; Chonnam Natl Univ, Dept Food & Nutr, Kwangju 500757, South Korea; Chonnam Natl Univ, Mol Endocrinol Program, Kwangju 500757, South Korea; Yonsei Univ, Coll Med, Dept Internal Med, Seoul 135270, South Korea; Korea Res Inst Biosci & Biotechnol, Taejon 30560, South Korea	Chonnam National University; Chonnam National University; Chonnam National University; Yonsei University; Yonsei University Health System; Korea Research Institute of Bioscience & Biotechnology (KRIBB)	Chae, HZ (corresponding author), Chonnam Natl Univ, Coll Nat Sci, Dept Sci Biol, Buk Ku, Kwangju 500757, South Korea.							AALEN RB, 1994, PLANT J, V5, P385, DOI 10.1111/j.1365-313X.1994.00385.x; BROEKEMEIER KM, 1992, FEBS LETT, V304, P192, DOI 10.1016/0014-5793(92)80616-O; Bryk R, 2000, NATURE, V407, P211, DOI 10.1038/35025109; CHA MK, 1995, J BIOL CHEM, V270, P28635, DOI 10.1074/jbc.270.48.28635; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; Chae HZ, 1999, DIABETES RES CLIN PR, V45, P101, DOI 10.1016/S0168-8227(99)00037-6; Chae HZ, 1999, METHOD ENZYMOL, V300, P219; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7022, DOI 10.1073/pnas.91.15.7022; Chen JW, 2000, J BIOL CHEM, V275, P28421, DOI 10.1074/jbc.M005073200; Cheong NE, 1999, PLANT MOL BIOL, V40, P825, DOI 10.1023/A:1006271823973; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Crompton M, 1998, EUR J BIOCHEM, V258, P729, DOI 10.1046/j.1432-1327.1998.2580729.x; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; Doyle V, 1999, BIOCHEM J, V341, P127, DOI 10.1042/0264-6021:3410127; FEJZO J, 1994, BIOCHEMISTRY-US, V33, P5711, DOI 10.1021/bi00185a007; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Fisher AB, 1999, J BIOL CHEM, V274, P21326, DOI 10.1074/jbc.274.30.21326; GALAT A, 1998, PROTEIN PROFILE PEPT; GOGVADZE V, 1993, FEBS LETT, V333, P334, DOI 10.1016/0014-5793(93)80682-K; GRIFFITHS EJ, 1993, J MOL CELL CARDIOL, V25, P1461, DOI 10.1006/jmcc.1993.1162; HAENDLER B, 1987, EMBO J, V6, P947, DOI 10.1002/j.1460-2075.1987.tb04843.x; Haridas V, 1998, J IMMUNOL, V161, P1; Jaschke A, 1998, J MOL BIOL, V277, P763, DOI 10.1006/jmbi.1998.1644; Jeong JS, 1999, BIOCHEMISTRY-US, V38, P776, DOI 10.1021/bi9817818; Jin DY, 1997, J BIOL CHEM, V272, P30952, DOI 10.1074/jbc.272.49.30952; Kang SW, 1998, J BIOL CHEM, V273, P6303, DOI 10.1074/jbc.273.11.6303; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; KIM KW, 1988, J BIOL CHEM, V263, P4704; Kim TS, 1997, J BIOL CHEM, V272, P2542; Kowaltowski AJ, 1998, J BIOL CHEM, V273, P12766, DOI 10.1074/jbc.273.21.12766; Lee KO, 2000, FEBS LETT, V486, P103, DOI 10.1016/S0014-5793(00)02230-4; Leventhal L, 2000, J COMP NEUROL, V425, P471, DOI 10.1002/1096-9861(20001002)425:4<471::AID-CNE1>3.0.CO;2-U; LIM YS, 1994, BIOCHEM BIOPH RES CO, V199, P199, DOI 10.1006/bbrc.1994.1214; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; LIU J, 1990, P NATL ACAD SCI USA, V87, P2304, DOI 10.1073/pnas.87.6.2304; Munz B, 1997, BIOCHEM J, V326, P579, DOI 10.1042/bj3260579; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; PASTORINO JG, 1993, J BIOL CHEM, V268, P13791; RHEE SG, 1985, METHOD ENZYMOL, V113, P213; Seo MS, 2000, J BIOL CHEM, V275, P20346, DOI 10.1074/jbc.M001943200; Singh AK, 1998, J BIOL CHEM, V273, P26171, DOI 10.1074/jbc.273.40.26171; Wen ST, 1997, GENE DEV, V11, P2456, DOI 10.1101/gad.11.19.2456; Wong A, 1997, BIOCHEM BIOPH RES CO, V239, P139, DOI 10.1006/bbrc.1997.7443; Zhang P, 1997, J BIOL CHEM, V272, P30615, DOI 10.1074/jbc.272.49.30615; Zhou Y, 2000, BIOCHEM BIOPH RES CO, V268, P921, DOI 10.1006/bbrc.2000.2231	46	316	337	3	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29826	29832		10.1074/jbc.M101822200	http://dx.doi.org/10.1074/jbc.M101822200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11390385	hybrid			2022-12-25	WOS:000170558000031
J	Sagami, I; Daff, S; Shimizu, T				Sagami, I; Daff, S; Shimizu, T			Intra-subunit and inter-subunit electron transfer in neuronal nitric-oxide synthase - Effect of calmodulin on heterodimer catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGENASE DOMAIN; L-ARGININE; HEME; ACTIVATION; BINDING; PTERIN; FLAVIN; SITE; TETRAHYDROBIOPTERIN; IDENTIFICATION	In neuronal nitric-oxide synthase (nNOS), calmodulin (CaM) binding is thought to trigger electron transfer from the reductase domain to the heme domain, which is essential for O-2 activation and NO formation. To elucidate the electron-transfer mechanism, we characterized a series of heterodimers consisting of one full-length nNOS subunit and one oxygenase-domain subunit. The results support aft inter-subunit electron-transfer mechanism for the wild type nNOS, in that electrons for catalysis transfer in a Ca2+/CaM-dependent way from the reductase domain of one subunit to the heme of the other subunit, as proposed for inducible NOS. This suggests that the two different isoforms form similar dimeric complexes. In a series of heterodimers containing a Ca2+/CaM-insensitive mutant (delta40), electrons transferred from the reductase domain to both hemes in a Ca2+/CaM-independent way. Thus, in the delta40 mutant electron transfer from the reductase domains to the heme domains can occur via both inter-subunit and intra-subunit mechanisms. However, NO formation activity was exclusively linked to inter-subunit electron transfer and was observed only in the presence of Ca2+/CaM. This suggests that the mechanism of activation of nNOS hy CaM is not solely dependent on the activation of electron transfer to the nNOS hemes but may involve additional structural factors linked to the catalytic action of the heme domain.	Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Aoba Ku, Sendai, Miyagi 9808577, Japan; Univ Edinburgh, Dept Chem, Edinburgh EH9 3JJ, Midlothian, Scotland	Tohoku University; University of Edinburgh	Sagami, I (corresponding author), Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Aoba Ku, 2-1-1 Katahira, Sendai, Miyagi 9808577, Japan.							ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; Bec N, 1998, J BIOL CHEM, V273, P13502, DOI 10.1074/jbc.273.22.13502; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; Chen PF, 2000, J BIOL CHEM, V275, P13155, DOI 10.1074/jbc.275.17.13155; Chen PF, 1997, J BIOL CHEM, V272, P6114, DOI 10.1074/jbc.272.10.6114; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Daff S, 1999, J BIOL CHEM, V274, P30589, DOI 10.1074/jbc.274.43.30589; Feelisch M., 1996, METHODS NITRIC OXIDE; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; Gachhui R, 1996, J BIOL CHEM, V271, P20594, DOI 10.1074/jbc.271.34.20594; Ghosh DK, 1997, BIOCHEMISTRY-US, V36, P10609, DOI 10.1021/bi9702290; Hellermann GR, 1997, J BIOL CHEM, V272, P12030, DOI 10.1074/jbc.272.18.12030; Hurshman AR, 1999, BIOCHEMISTRY-US, V38, P15689, DOI 10.1021/bi992026c; Ignarro LJ, 2000, NITRIC OXIDE BIOL PA; Li HY, 1999, J BIOL CHEM, V274, P21276, DOI 10.1074/jbc.274.30.21276; MASTERS BSS, 1994, ANNU REV NUTR, V14, P131, DOI 10.1146/annurev.nu.14.070194.001023; MATSUOKA A, 1994, J BIOL CHEM, V269, P20335; Mayer B, 2000, NITRIC OXIDE; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; Montgomery HJ, 2000, J BIOL CHEM, V275, P5052, DOI 10.1074/jbc.275.7.5052; Nishida CR, 1999, J BIOL CHEM, V274, P14692, DOI 10.1074/jbc.274.21.14692; Noble MA, 1999, BIOCHEMISTRY-US, V38, P16413, DOI 10.1021/bi992150w; Noguchi T, 2001, BIOCHEM BIOPH RES CO, V282, P1092, DOI 10.1006/bbrc.2001.4697; Panda K, 2001, J BIOL CHEM, V276, P23349, DOI 10.1074/jbc.M100687200; Presta A, 1998, J AM CHEM SOC, V120, P9460, DOI 10.1021/ja9740374; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; RAMAN CS, 2000, PORPHYRIN HDB, V4, P293; Sagami I, 1998, J BIOL CHEM, V273, P2105, DOI 10.1074/jbc.273.4.2105; Sagami I, 2000, J BIOL CHEM, V275, P26150, DOI 10.1074/jbc.M000534200; Shimanuki T, 1999, J BIOL CHEM, V274, P26956, DOI 10.1074/jbc.274.38.26956; Siddhanta U, 1998, J BIOL CHEM, V273, P18950, DOI 10.1074/jbc.273.30.18950; Siddhanta U, 1996, J BIOL CHEM, V271, P7309, DOI 10.1074/jbc.271.13.7309; Stuehr DJ, 1997, ANNU REV PHARMACOL, V37, P339, DOI 10.1146/annurev.pharmtox.37.1.339; Venema RC, 1997, J BIOL CHEM, V272, P1276, DOI 10.1074/jbc.272.2.1276; Wei CC, 2001, J BIOL CHEM, V276, P315, DOI 10.1074/jbc.M008441200	35	83	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30036	30042		10.1074/jbc.M104123200	http://dx.doi.org/10.1074/jbc.M104123200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11395516	hybrid			2022-12-25	WOS:000170558000058
J	Van Huffel, S; Delaei, F; Heyninck, K; De Valck, D; Beyaert, R				Van Huffel, S; Delaei, F; Heyninck, K; De Valck, D; Beyaert, R			Identification of a novel A20-binding inhibitor of nuclear factor-kappa B activation termed ABIN-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEIN; DEPENDENT GENE-EXPRESSION; CELL-DEATH; INDUCED APOPTOSIS; TNF RECEPTOR; KINASE-ALPHA; IKK-GAMMA; I TAX; A20; RIP	The nuclear factor kappaB (NF-kappaB) plays a central role in the regulation of genes implicated immune responses, inflammatory processes, and apoptotic cell death. The zinc finger protein A20 is a cellular inhibitor of NF-kappaB activation by various stimuli and plays a critical role in terminating NF-kappaB responses. The underlying mechanism for NF-kappaB inhibition by A20 is still unknown. A20 has been shown to interact with several proteins including tumor necrosis factor (TNF) receptor-associated factors 2 and 6, as well as the inhibitory protein of kappaB kinase (IKK) gamma protein. Here we report the cloning and characterization of ABIN-2, a previously unknown protein that binds to the COOH-terminal zinc finger domain of A20. NF-kappaB activation induced by TNF and interleukin-1 is inhibited by overexpression. of ABIN-2. The latter also inhibits NF-kappaB activation induced by overexpression of receptor-interacting protein or TNF receptor-associated factor 2. In contrast, NF-kappaB activation by overexpression of IKK beta or direct activators of the IKK complex, such as Tax, cannot be inhibited by ABIN-2. These results indicate that ABIN-2 interferes with NF-kappaB activation upstream of the IKK complex and that it might contribute to the NF-kappaB-inhibitory function of A20.	Flanders Interuniv Inst Biotechnol, Dept Mol Biol, Unit Mol Signal Transduct Inflammat, B-9000 Ghent, Belgium; Univ Ghent, B-9000 Ghent, Belgium	Ghent University	Beyaert, R (corresponding author), Flanders Interuniv Inst Biotechnol, Dept Mol Biol, Unit Mol Signal Transduct Inflammat, KL Ledeganckstr 35, B-9000 Ghent, Belgium.	rudi.beyaert@dmb.rug.ac.be	Beyaert, Rudi/B-2589-2009	Beyaert, Rudi/0000-0002-5704-582X				BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Beyaert R, 2000, BIOCHEM PHARMACOL, V60, P1143, DOI 10.1016/S0006-2952(00)00404-4; Chen F, 1999, CLIN CHEM, V45, P7; Cooper JT, 1996, J BIOL CHEM, V271, P18068, DOI 10.1074/jbc.271.30.18068; Desmedt M, 1998, J IMMUNOL, V160, P5300; DeValck D, 1996, FEBS LETT, V384, P61, DOI 10.1016/0014-5793(96)00283-9; DeValck D, 1997, BIOCHEM BIOPH RES CO, V238, P590, DOI 10.1006/bbrc.1997.7343; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Devin A, 2001, MOL CELL BIOL, V21, P3986, DOI 10.1128/MCB.21.12.3986-3994.2001; DIXIT VM, 1990, J BIOL CHEM, V265, P2973; Heyninck K, 1999, J CELL BIOL, V145, P1471, DOI 10.1083/jcb.145.7.1471; Heyninck K, 1999, FEBS LETT, V442, P147, DOI 10.1016/S0014-5793(98)01645-7; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Inohara N, 2000, J BIOL CHEM, V275, P27823; Jaattela M, 1996, J IMMUNOL, V156, P1166; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Kajino S, 2000, ONCOGENE, V19, P2233, DOI 10.1038/sj.onc.1203560; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Klinkenberg M, 2001, FEBS LETT, V498, P93, DOI 10.1016/S0014-5793(01)02504-2; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; Lademann U, 2001, CELL DEATH DIFFER, V8, P265, DOI 10.1038/sj.cdd.4400805; LAHERTY CD, 1993, J BIOL CHEM, V268, P5032; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Matsushima A, 2001, J EXP MED, V193, P631, DOI 10.1084/jem.193.5.631; Mori T, 2000, FEBS LETT, V465, P124, DOI 10.1016/S0014-5793(99)01726-3; Natoli G, 1998, J BIOL CHEM, V273, P31262, DOI 10.1074/jbc.273.47.31262; Olsen Ole, 1992, Methods in Molecular and Cellular Biology, V3, P159; OMAHONEY JV, 1994, DNA CELL BIOL, V13, P1227, DOI 10.1089/dna.1994.13.1227; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Poyet JL, 2000, J BIOL CHEM, V275, P37966, DOI 10.1074/jbc.M006643200; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; SARMA V, 1995, J BIOL CHEM, V270, P12343, DOI 10.1074/jbc.270.21.12343; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; Song HY, 1996, P NATL ACAD SCI USA, V93, P6721, DOI 10.1073/pnas.93.13.6721; TEWARI M, 1995, J IMMUNOL, V154, P1699; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VANHAESEBROECK B, 1991, CANCER RES, V51, P2469; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Xia Y, 2000, P NATL ACAD SCI USA, V97, P5243, DOI 10.1073/pnas.97.10.5243; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yang JP, 1999, ONCOGENE, V18, P5177, DOI 10.1038/sj.onc.1202904; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yin L, 2001, SCIENCE, V291, P2162, DOI 10.1126/science.1058453; Yujiri T, 2000, P NATL ACAD SCI USA, V97, P7272, DOI 10.1073/pnas.130176697; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	56	81	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30216	30223		10.1074/jbc.M100048200	http://dx.doi.org/10.1074/jbc.M100048200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11390377	hybrid			2022-12-25	WOS:000170558000082
J	Cordeaux, Y; Nickolls, SA; Flood, LA; Graber, SG; Strange, PG				Cordeaux, Y; Nickolls, SA; Flood, LA; Graber, SG; Strange, PG			Agonist regulation of D-2 dopamine receptor/G protein interaction - Evidence for agonist selection of G protein subtype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERNARY COMPLEX MODEL; BETA-ADRENERGIC-RECEPTOR; LIGAND-BINDING; CELL-MEMBRANES; MOLECULAR DETERMINANTS; FUNCTIONAL ASSAYS; COUPLED RECEPTORS; ADENYLYL-CYCLASE; ALPHA-SUBUNITS; INSECT CELLS	The D-2 dopamine receptor has been expressed in Sf21. insect cells together with the G proteins G(o) and G(i2), using the baculovirus system. Expression levels of receptor and G protein (alpha, beta, and gamma subunits) in the two preparations were similar as shown by binding of [H-3]spiperone and quantitative Western blot, respectively. For several agonists, binding data were fitted best by a two-binding site model in either preparation, showing interaction of expressed receptor and G protein. For some agonists, binding to the higher affinity site was of higher affinity in D-2/G(o) than in the D-2/G(i2), preparation. Some agonists exhibited binding data that were best fitted by a two-binding site model in D-2/G(o) and a one-binding site model in D-2/G(i2.) Therefore, receptor/G protein interaction seemed to be stronger in the D-2/G(o) preparation. Agonist stimulation of [S-35]GTP gammaS (guanosine 5'-3-O-(thio)triphosphate) binding in the two preparations also gave evidence for higher affinity D-2/G(o), interaction. In the D-2/G(o) preparation, agonist stimulation of [S-35]GTP gammaS binding occurred at higher potency for several agonists, and a higher stimulation (relative to dopamine) was achieved in D-2/G(o) compared with D2/Gi2, Some agonists were able to stimulate [S-35]GTP gammaS binding in the D-2/G(o) preparation but not in D2/Gi2. The extent of D2 receptor selectivity for Go over Gi2 is therefore dependent on the agonist used, and thus agonists may stabilize different conformations of the receptor with different abilities to couple to and activate G proteins.	Univ Reading, Sch Anim & Microbial Sci, Reading RG6 6AJ, Berks, England; W Virginia Univ, Dept Pharmacol & Toxicol, Morgantown, WV 26506 USA	University of Reading; West Virginia University	Strange, PG (corresponding author), Univ Reading, Sch Anim & Microbial Sci, Reading RG6 6AJ, Berks, England.							Airriess CN, 1997, BRIT J PHARMACOL, V122, P191, DOI 10.1038/sj.bjp.0701348; Bae H, 1997, J BIOL CHEM, V272, P32071, DOI 10.1074/jbc.272.51.32071; Barr AJ, 1997, J BIOL CHEM, V272, P32979, DOI 10.1074/jbc.272.52.32979; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BLACK JW, 1983, PROC R SOC SER B-BIO, V220, P141, DOI 10.1098/rspb.1983.0093; Boundy VA, 1996, J PHARMACOL EXP THER, V276, P784; CASTRO SW, 1993, FEBS LETT, V315, P223, DOI 10.1016/0014-5793(93)81168-Y; CASTRO SW, 1993, J NEUROCHEM, V60, P372, DOI 10.1111/j.1471-4159.1993.tb05863.x; Chidiac P, 1998, BIOCHEM PHARMACOL, V55, P549, DOI 10.1016/S0006-2952(97)00361-4; Clarke WP, 1998, TRENDS PHARMACOL SCI, V19, P270, DOI 10.1016/S0165-6147(97)01138-3; Clawges HM, 1997, BIOCHEMISTRY-US, V36, P12930, DOI 10.1021/bi970112b; DELEAN A, 1980, J BIOL CHEM, V255, P7108; EDGERTON MD, 1994, FEBS LETT, V354, P195, DOI 10.1016/0014-5793(94)01101-X; Figler RA, 1996, MOL PHARMACOL, V50, P1587; Gardner B, 1998, BRIT J PHARMACOL, V124, P978, DOI 10.1038/sj.bjp.0701926; Gardner B, 1996, BRIT J PHARMACOL, V118, P1544, DOI 10.1111/j.1476-5381.1996.tb15572.x; Gardner BR, 1997, J NEUROCHEM, V69, P2589; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; GETTYS TW, 1994, BIOCHEMISTRY-US, V33, P4283, DOI 10.1021/bi00180a024; Ghahremani MH, 1999, J BIOL CHEM, V274, P9238, DOI 10.1074/jbc.274.14.9238; GRABER SG, 1992, J BIOL CHEM, V267, P1271; Grunewald S, 1996, BIOCHEMISTRY-US, V35, P15162, DOI 10.1021/bi960757w; HAUSDORFF WP, 1990, J BIOL CHEM, V265, P1388; Jakubik J, 1998, MOL PHARMACOL, V54, P899, DOI 10.1124/mol.54.5.899; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P232, DOI 10.1016/S0165-6147(00)89032-X; Kenakin TP., 1993, PHARM ANAL DRUG RECE, V2; LEE TWT, 1986, BIOCHEMISTRY-US, V25, P7009, DOI 10.1021/bi00370a038; LIU YF, 1994, J BIOL CHEM, V269, P13880; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCALLUM JF, 1995, BIOCHEM J, V310, P1021, DOI 10.1042/bj3101021; MELLER E, 1992, J PHARMACOL EXP THER, V263, P462; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; Neve KA, 1997, DOPAMINE RECEPTORS; RANSNAS LA, 1988, J BIOL CHEM, V263, P9482; RANSNAS LA, 1992, BIOCHEM J, V283, P519, DOI 10.1042/bj2830519; Raymond JR, 1999, BRIT J PHARMACOL, V127, P1751, DOI 10.1038/sj.bjp.0702723; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SANDERSON EM, 1995, BRIT J PHARMACOL, V115, P102; Selley DE, 1997, MOL PHARMACOL, V51, P87, DOI 10.1124/mol.51.1.87; SIBLEY DR, 1983, MOL PHARMACOL, V23, P585; Strange PG, 1997, NEUROPSYCHOPHARMACOL, V16, P116; Strange PG, 1998, TRENDS PHARMACOL SCI, V19, P85, DOI 10.1016/S0165-6147(98)01175-4; Strange PG, 1999, BIOCHEM PHARMACOL, V58, P1081; SUMMERS MD, 1987, TEX AGR EXP STA B, V1555, P5; Svoboda P, 1996, MOL PHARMACOL, V49, P646; Weiss JM, 1996, J THEOR BIOL, V178, P151, DOI 10.1006/jtbi.1996.0014; Wenzel-Seifert K, 2000, MOL PHARMACOL, V58, P954, DOI 10.1124/mol.58.5.954; Wenzel-Seifert K, 1998, J BIOL CHEM, V273, P24181, DOI 10.1074/jbc.273.37.24181; WREGGETT KA, 1984, MOL PHARMACOL, V26, P214; Yang Q, 1999, MOL PHARMACOL, V56, P651, DOI 10.1124/mol.56.3.651	50	60	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28667	28675		10.1074/jbc.M008644200	http://dx.doi.org/10.1074/jbc.M008644200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11369753	hybrid, Green Submitted			2022-12-25	WOS:000170346000006
J	Puri, N; Majumdar, A; Cuenoud, B; Natt, F; Martin, P; Boyd, A; Miller, PS; Seidman, MM				Puri, N; Majumdar, A; Cuenoud, B; Natt, F; Martin, P; Boyd, A; Miller, PS; Seidman, MM			Targeted gene knockout by 2 '-O-aminoethyl modified triplex forming oligonucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-SPECIFIC RECOGNITION; PHOTO-CROSS-LINKING; DOUBLE-STRANDED DNA; DOUBLE-HELICAL DNA; MAMMALIAN-CELLS; 3RD STRAND; EXONUCLEASE RESISTANCE; BACKBONE COMPOSITION; BIOLOGICAL-ACTIVITY; PURINE-MOTIF	Triplex forming oligonucleotides (TFOs) are of interest because of their potential for facile gene targeting. However, the failure of TFOs to bind target sequences at physiological pH and Mg2+ concentration has limited their biological applications. Recently, pyrimidine TFOs with 2 ' -O-aminoethyl (AE) substitutions were shown to have enhanced kinetics and stability of triplex formation (Cuenoud, B., Casset, F., Husken, D., Natt, F., Wolf, R. M., Altmann, K. H., Martin, P., and Moser H. E. (1998) Angew. Chem. Int, Ed. 37,1288-1291). We have prepared psoralen-linked TFOs with varying amounts of the AE-modified residues, and have characterized them in biochemical assays in vitro, and in stability and HPRT gene knockout assays in vivo. The AE TFOs showed higher affinity for the target in vitro than a TFO with uniform 2 ' -OMe substitution, with relatively little loss of affinity when the assay was performed in reduced Mg2+. Once formed they were also more stable in "physiological" buffer, with the greatest affinity and stability displayed by the TFO with all but one residue in the AE format. However, TFOs with lesser amounts of the AE modification formed the most stable triplexes in vivo, and showed the highest HPRT gene knockout activity. We conclude that the AE modification can enhance the biological activity of pyrimidine TFOs, but that extensive substitution is deleterious.	NIA, LMG, NIH, Baltimore, MD 21224 USA; Novartis Horshan Res Ctr, Horsham RH12 4AB, W Sussex, England; Novartis Pharma Ltd, CH-4002 Basel, Switzerland; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Biochem & Mol Biol, Baltimore, MD 21205 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Novartis; Novartis; Johns Hopkins University	Seidman, MM (corresponding author), NIA, LMG, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.				NATIONAL INSTITUTE ON AGING [Z01AG000738, ZIAAG000738] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Asensio JL, 1999, J AM CHEM SOC, V121, P11063, DOI 10.1021/ja991949s; Barre FX, 2000, P NATL ACAD SCI USA, V97, P3084, DOI 10.1073/pnas.050368997; BEAL PA, 1992, NUCLEIC ACIDS RES, V20, P2773, DOI 10.1093/nar/20.11.2773; Bijapur J, 1999, NUCLEIC ACIDS RES, V27, P1802, DOI 10.1093/nar/27.8.1802; Blommers MJJ, 1998, BIOCHEMISTRY-US, V37, P17714, DOI 10.1021/bi9816352; Blume SW, 1999, NUCLEIC ACIDS RES, V27, P695, DOI 10.1093/nar/27.2.695; Boal JH, 1996, NUCLEIC ACIDS RES, V24, P3115, DOI 10.1093/nar/24.15.3115; Brosh RM, 2001, J BIOL CHEM, V276, P3024, DOI 10.1074/jbc.M006784200; Cassidy RA, 2000, BIOCHEMISTRY-US, V39, P8683, DOI 10.1021/bi000657x; Chan PP, 1997, J MOL MED, V75, P267, DOI 10.1007/s001090050112; Cheng AJ, 1998, ANTISENSE NUCLEIC A, V8, P215, DOI 10.1089/oli.1.1998.8.215; Chu G, 1997, J BIOL CHEM, V272, P24097, DOI 10.1074/jbc.272.39.24097; Cuenoud B, 1998, ANGEW CHEM INT EDIT, V37, P1288, DOI 10.1002/(SICI)1521-3773(19980518)37:9<1288::AID-ANIE1288>3.0.CO;2-U; Dagneaux C, 1995, BIOCHEMISTRY-US, V34, P16618, DOI 10.1021/bi00051a009; ESCUDE C, 1992, CR ACAD SCI III-VIE, V315, P521; ESCUDE C, 1993, NUCLEIC ACIDS RES, V21, P5547, DOI 10.1093/nar/21.24.5547; Faria M, 2001, J MOL BIOL, V306, P15, DOI 10.1006/jmbi.2000.4386; FELSENFELD G, 1957, J AM CHEM SOC, V79, P2023, DOI 10.1021/ja01565a074; FOSSELLA JA, 1993, NUCLEIC ACIDS RES, V21, P4511, DOI 10.1093/nar/21.19.4511; FRANKKAMENETSKII MD, 1995, ANNU REV BIOCHEM, V64, P65, DOI 10.1146/annurev.bi.64.070195.000433; GREENBERG WA, 1995, J AM CHEM SOC, V117, P5016, DOI 10.1021/ja00123a002; Griffey RH, 1996, J MED CHEM, V39, P5100, DOI 10.1021/jm950937o; HAN HY, 1993, P NATL ACAD SCI USA, V90, P3806, DOI 10.1073/pnas.90.9.3806; Hildbrand S, 1997, J AM CHEM SOC, V119, P5499, DOI 10.1021/ja9704904; Kobertz WR, 1997, J AM CHEM SOC, V119, P5960, DOI 10.1021/ja9703178; Lacroix L, 2000, BIOCHEM BIOPH RES CO, V270, P363, DOI 10.1006/bbrc.2000.2438; Lacroix L, 1999, BIOCHEMISTRY-US, V38, P1893, DOI 10.1021/bi982290q; LEE JS, 1984, NUCLEIC ACIDS RES, V12, P6603, DOI 10.1093/nar/12.16.6603; Levy DD, 1996, J MOL BIOL, V255, P435, DOI 10.1006/jmbi.1996.0036; Lin FLM, 2000, J BIOL CHEM, V275, P39117, DOI 10.1074/jbc.M005404200; Maher L J 3rd, 1991, Antisense Res Dev, V1, P277; MAHER LJ, 1990, BIOCHEMISTRY-US, V29, P8820, DOI 10.1021/bi00489a045; Maher LJ, 1996, CANCER INVEST, V14, P66, DOI 10.3109/07357909609018437; Majumdar A, 1998, NAT GENET, V20, P212, DOI 10.1038/2530; Maksimenko AV, 2000, EUR J BIOCHEM, V267, P3592, DOI 10.1046/j.1432-1327.2000.01388.x; MANOR H, 1988, J MOL EVOL, V27, P96, DOI 10.1007/BF02138367; Marquez VE, 1996, J MED CHEM, V39, P3739, DOI 10.1021/jm960306+; Mullah B, 1997, TETRAHEDRON LETT, V38, P5751, DOI 10.1016/S0040-4039(97)01286-0; Neidle S, 1997, ANTI-CANCER DRUG DES, V12, P433; NOONBERG SB, 1995, NUCLEIC ACIDS RES, V23, P1956, DOI 10.1093/nar/23.11.1956; PEDEN KWC, 1980, SCIENCE, V209, P1392, DOI 10.1126/science.6251547; PIELES U, 1989, NUCLEIC ACIDS RES, V17, P285, DOI 10.1093/nar/17.1.285; POVSIC TJ, 1989, J AM CHEM SOC, V111, P3059, DOI 10.1021/ja00190a047; Pradeepkumar PI, 2000, TETRAHEDRON LETT, V41, P8601, DOI 10.1016/S0040-4039(00)01510-0; RADHAKRISHNAN I, 1994, BIOCHEMISTRY-US, V33, P11405, DOI 10.1021/bi00204a001; ROBERTS RW, 1992, SCIENCE, V258, P1463, DOI 10.1126/science.1279808; SEIDMAN MM, 1985, GENE, V38, P233, DOI 10.1016/0378-1119(85)90222-7; SHIMIZU M, 1992, FEBS LETT, V302, P155, DOI 10.1016/0014-5793(92)80428-J; SVINARCHUK F, 1995, J BIOL CHEM, V270, P14068, DOI 10.1074/jbc.270.23.14068; SVINARCHUK F, 1995, NUCLEIC ACIDS RES, V23, P3831, DOI 10.1093/nar/23.19.3831; Teplova M, 1999, P NATL ACAD SCI USA, V96, P14240, DOI 10.1073/pnas.96.25.14240; THUONG NT, 1993, ANGEW CHEM INT EDIT, V32, P666, DOI 10.1002/anie.199306661; Torigoe H, 2001, J BIOL CHEM, V276, P2354, DOI 10.1074/jbc.M007783200; Vasquez KM, 1998, TRENDS BIOCHEM SCI, V23, P4, DOI 10.1016/S0968-0004(97)01158-4; Vasquez KM, 1996, BIOCHEMISTRY-US, V35, P10712, DOI 10.1021/bi960881f; WANG G, 1995, MOL CELL BIOL, V15, P1759; Wang G, 1996, SCIENCE, V271, P802, DOI 10.1126/science.271.5250.802	57	51	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28991	28998		10.1074/jbc.M103409200	http://dx.doi.org/10.1074/jbc.M103409200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11389147	hybrid			2022-12-25	WOS:000170346000049
J	Fabini, G; Freilinger, A; Altmann, F; Wilson, IBH				Fabini, G; Freilinger, A; Altmann, F; Wilson, IBH			Identification of core alpha 1,3-fucosylated glycans and cloning of the requisite fucosyltransferase cDNA from Drosophila melanogaster - Potential basis of the neural anti-horseradish peroxidase epitope	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-LINKED OLIGOSACCHARIDES; GDP-L-FUCOSE; ALPHA-1,3-LINKED FUCOSE; CARBOHYDRATE MOIETY; CELL-SURFACE; INSECT CELLS; GLYCOPROTEINS; ANTIBODIES; EXPRESSION; PROTEINS	For many years, polyclonal antibodies raised against the plant glycoprotein horseradish peroxidase have been used to specifically stain the neural and male reproductive tissue of Drosophila melanogaster. This epitope is considered to be of carbohydrate origin, but no glycan structure from Drosophila has yet been isolated that could account for this cross-reactivity. Here we report that N-glycan core alpha1,3-linked fucose is, as judged by pre-absorption experiments, indispensable for recognition of Drosophila embryonic nervous system by anti-horseradish peroxidase antibody. Further, we describe the identification by matrix-assisted laser desorption-ionization time-of-flight mass spectrometry and high performance liquid chromatography of two Drosophila N-glycans that, as already detected in other insects, carry both alpha1,3- and alpha1,6-linked fucose residues on the proximal core GlcNAc. Moreover, we have isolated three cDNAs encoding alpha1,3-fucosyltransferase homologues from Drosophila. One of the cDNAs, when transformed into Pichia pastoris, was found to direct expression of core alpha1,3-fucosyltransferase activity. This recombinant enzyme preferred as substrate a biantennary core alpha1,6-fucosylated N-glycan carrying two non-reducing N-acetylglucosamine residues (GnGnF(6), K-m 11 muM) over the same structure lacking a core fucose residue (GnGn; K-m 46 muM). The Drosophila core alpha1,3-fucosyltransferase enzyme was also shown to be able to fucosylate N-glycan structures of human transferrin in. vitro, this modification correlating with the acquisition of binding to anti-horseradish peroxidase antibody.	Univ Bodenkultur Wien, Inst Chem, Glycobiol Div, A-1190 Vienna, Austria	University of Natural Resources & Life Sciences, Vienna	Wilson, IBH (corresponding author), Univ Bodenkultur Wien, Inst Chem, Glycobiol Div, Muthgasse 18, A-1190 Vienna, Austria.	iwilson@edv2.boku.ac.at	Wilson, Iain/B-3326-2009	Wilson, Iain/0000-0001-8996-1518; Altmann, Friedrich/0000-0002-0112-7877				ALTMANN F, 1995, J BIOL CHEM, V270, P17344, DOI 10.1074/jbc.270.29.17344; ALTMANN F, 1992, ANAL BIOCHEM, V204, P215, DOI 10.1016/0003-2697(92)90164-3; ALTMANN F, 1993, GLYCOBIOLOGY, V3, P619, DOI 10.1093/glycob/3.6.619; Breton C, 1998, GLYCOBIOLOGY, V8, P87, DOI 10.1093/glycob/8.1.87; DESAI CJ, 1994, J NEUROSCI, V14, P7272; FAYE L, 1993, ANAL BIOCHEM, V209, P104, DOI 10.1006/abio.1993.1088; FAYE L, 1988, GLYCOCONJUGATE J, V5, P245, DOI 10.1007/BF01049085; HASE S, 1984, J BIOCHEM-TOKYO, V95, P197, DOI 10.1093/oxfordjournals.jbchem.a134585; Haslam SM, 1996, J BIOL CHEM, V271, P30561, DOI 10.1074/jbc.271.48.30561; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; KATZ F, 1988, EMBO J, V7, P3471, DOI 10.1002/j.1460-2075.1988.tb03222.x; Khoo KH, 1997, GLYCOBIOLOGY, V7, P663, DOI 10.1093/glycob/7.5.663; Kolarich D, 2000, ANAL BIOCHEM, V285, P64, DOI 10.1006/abio.2000.4737; KUBELKA V, 1995, GLYCOCONJUGATE J, V12, P77, DOI 10.1007/BF00731872; KUBELKA V, 1994, ARCH BIOCHEM BIOPHYS, V308, P148, DOI 10.1006/abbi.1994.1021; KUBELKA V, 1993, EUR J BIOCHEM, V213, P1193, DOI 10.1111/j.1432-1033.1993.tb17870.x; KUROSAKA A, 1991, J BIOL CHEM, V266, P4168; Leiter H, 1999, J BIOL CHEM, V274, P21830, DOI 10.1074/jbc.274.31.21830; LONGMORE GD, 1982, CARBOHYD RES, V100, P365, DOI 10.1016/S0008-6215(00)81049-6; MCMANUS MT, 1988, PLANTA, V175, P506, DOI 10.1007/BF00393072; Oriol R, 1999, GLYCOBIOLOGY, V9, P323, DOI 10.1093/glycob/9.4.323; PRENNER C, 1992, BIOCHEM J, V284, P377, DOI 10.1042/bj2840377; Roitinger A, 1998, GLYCOCONJUGATE J, V15, P89, DOI 10.1023/A:1006951802623; Sarkar M, 2001, BIOL CHEM, V382, P209, DOI 10.1515/BC.2001.028; Seppo A, 1999, GLYCOBIOLOGY, V9, P1138; Seppo A, 2000, GLYCOBIOLOGY, V10, P751, DOI 10.1093/glycob/10.8.751; SIDDIQUI SS, 1991, J NEUROGENET, V7, P193, DOI 10.3109/01677069109167433; SNOW PM, 1987, J NEUROSCI, V7, P4137; Staudacher E, 1998, GLYCOCONJUGATE J, V15, P355, DOI 10.1023/A:1006969701231; Struppe E, 2000, BBA-GEN SUBJECTS, V1475, P360, DOI 10.1016/S0304-4165(00)00092-1; SUN BH, 1995, J NEUROCHEM, V65, P434, DOI 10.1046/j.1471-4159.1995.65010434.x; TRETTER V, 1993, INT ARCH ALLERGY IMM, V102, P259, DOI 10.1159/000236534; van Die I, 1999, FEBS LETT, V463, P189, DOI 10.1016/S0014-5793(99)01508-2; WANG X, 1994, INSECT BIOCHEM MOLEC, V24, P233, DOI 10.1016/0965-1748(94)90002-7; WHITLOCK KE, 1993, DEVELOPMENT, V117, P1251; WILLIAMS PJ, 1991, BIOCHIM BIOPHYS ACTA, V1075, P146, DOI 10.1016/0304-4165(91)90245-C; Wilson IBH, 2001, GLYCOBIOLOGY, V11, P261, DOI 10.1093/glycob/11.4.261; Wilson IBH, 1998, GLYCOBIOLOGY, V8, P651, DOI 10.1093/glycob/8.7.651; Wilson IBH, 1998, GLYCOCONJUGATE J, V15, P1055, DOI 10.1023/A:1006960401562; Wilson IBH, 2001, BBA-GEN SUBJECTS, V1527, P88, DOI 10.1016/S0304-4165(01)00151-9; Yang BY, 1996, CARBOHYD RES, V287, P203, DOI 10.1016/0008-6215(96)00073-0; Zeleny R, 1997, ANAL BIOCHEM, V246, P96, DOI 10.1006/abio.1996.9973	42	133	140	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28058	28067		10.1074/jbc.M100573200	http://dx.doi.org/10.1074/jbc.M100573200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11382750	hybrid			2022-12-25	WOS:000170093400043
J	Fujii, Y; Kimoto, H; Ishikawa, K; Watanabe, K; Yokota, Y; Nakai, N; Taketo, A				Fujii, Y; Kimoto, H; Ishikawa, K; Watanabe, K; Yokota, Y; Nakai, N; Taketo, A			Taxon-specific zeta-crystallin in Japanese tree frog (Hyla japonica) lens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUINEA-PIG LENS; STRUCTURAL PROTEINS; BOVINE LUNG; EYE LENS; PURIFICATION; RECRUITMENT; NADPH	The present study demonstrated that the 38-kDa protein, instead of rho -crystallin (36 kDa), is expressed taxon specifically in the lens of Japanese tree frog (Hyla japonica). The 38-kDa protein was distinguished from rho -crystallin expressed in the lenses of bullfrog (Rana catesbeiana) and European common frog (Rana temporaria) immunochemically. Although the N terminus of the 38-kDa protein was blocked, the analyses of partial amino acid sequences showed that the protein was zeta -crystallin. Analysis of cDNA sequence encoding zeta -crystallin of the tree frog lens demonstrated that the deduced protein consisted of 329 amino acids including initial methionine and having 62.2 and 62.9% identity with zeta -crystallin of camel and guinea pig lenses, respectively. The molecular mass of the deduced structure was calculated to be 35,564 Da. zeta -Crystallin of the tree frog lens exhibited the intrinsic enzymatic activity of quinone reductase (EC 1.6.99.2, NADPH:quinone oxidoreductase). The crystallin specifically catalyzed the reduction of 9,10-phenanthrenequinone (K-m, 42 mum) using NADPH (K-m, 60 mum) as a cofactor. The enzymatic activity was inhibited by dicumarol, anti-coagulant drug, with IC50 of 4 mum. On gel filtration chromatography, the crystallin was recovered as 150-kDa molecular mass complex, indicating that the crystallin was homotetramer consisting of 38-kDa subunits. The crystallin gene was expressed specifically in the lens. These results show that taxon-specific crystallins such as zeta- and rho -crystallins maybe available for the biochemical discrimination of Hyla- and Rana groups among frogs.	Fukui Med Univ, Fac Med, Dept Chem, Fukui 9101193, Japan; Fukui Med Univ, Fac Med, Dept Biochem, Fukui 9101193, Japan; Univ E Asia, Grad Sch Integrated Sci & Arts, Div Appl Life Sci, Yamaguchi 7518503, Japan; Fukui Univ Technol, Dept Appl Phys & Chem, Fukui 9108505, Japan	University of Fukui; University of Fukui	Fujii, Y (corresponding author), Fukui Med Univ, Fac Med, Dept Chem, 23-3 Shimoaizuki, Fukui 9101193, Japan.			Fujii, Yutaka/0000-0001-6357-3795				BOHREN KM, 1989, J BIOL CHEM, V264, P9547; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Duhaiman AS, 1996, BIOCHEM MOL BIOL INT, V38, P251; FUJII Y, 1990, J BIOL CHEM, V265, P9914; GONZALEZ P, 1995, MOL BIOL EVOL, V12, P773; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HUNG QL, 1990, EXP EYE RES, V50, P317; KURIBAYASHI K, 1988, NUCLEIC ACIDS RES S, V19, P61; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAEDA N, 1990, FROGS TOADS JAPAN, P8; RAO PV, 1992, EXP EYE RES, V54, P627, DOI 10.1016/0014-4835(92)90142-F; RAO PV, 1992, J BIOL CHEM, V267, P96; RAO PV, 1990, BIOCHEM BIOPH RES CO, V167, P1221, DOI 10.1016/0006-291X(90)90654-6; RODOKANAKI A, 1989, GENE, V78, P215, DOI 10.1016/0378-1119(89)90224-2; TOMAREV SI, 1984, FEBS LETT, V171, P297, DOI 10.1016/0014-5793(84)80508-6; WATANABE K, 1985, J BIOL CHEM, V260, P7035; WATANABE K, 1988, P NATL ACAD SCI USA, V85, P11, DOI 10.1073/pnas.85.1.11; Wermuth B, 1985, Prog Clin Biol Res, V174, P209; WISTOW G, 1987, SCIENCE, V236, P1554, DOI 10.1126/science.3589669; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; ZIGLER JS, 1991, FASEB J, V5, P223, DOI 10.1096/fasebj.5.2.2004667	22	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28134	28139		10.1074/jbc.M102880200	http://dx.doi.org/10.1074/jbc.M102880200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11371565	hybrid			2022-12-25	WOS:000170093400053
J	Miller, MJ; Rauer, H; Tomita, H; Rauer, H; Gargus, JJ; Gutman, GA; Cahalan, MD; Chandy, KG				Miller, MJ; Rauer, H; Tomita, H; Rauer, H; Gargus, JJ; Gutman, GA; Cahalan, MD; Chandy, KG			Nuclear localization and dominant-negative suppression by a mutant SKCa3N-terminal channel fragment identified in a patient with schizophrenia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED POTASSIUM CHANNELS; CA2+-ACTIVATED K+ CHANNEL; NIGRAL DOPAMINE NEURONS; POLYMORPHIC CAG REPEAT; SMALL-CONDUCTANCE; CHROMOSOME 1Q21; GENE HSKCA3; BIPOLAR DISORDER; NO EVIDENCE; HKCA3 GENE	The small conductance calcium-activated K+ channel gene SKCa3/KCNN3 maps to 1q2l, a region strongly linked to schizophrenia. Recently, a 4-base pair deletion in SKCa3 was reported in a patient with schizophrenia, which truncates the protein at the end of the N-terminal cytoplasmic region (SKCa3 Delta). We generated a green fluorescent protein-SKCa3 N-terminal construct (SKCa3-1/285) that is identical to SKCa3 Delta except for the last two residues. Using confocal microscopy we demonstrate that SKCa3-1/285 localizes rapidly and exclusively to the nucleus of mammalian cells like several other pathogenic polyglutamine-containing proteins. This nuclear targeting is mediated in part by two polybasic sequences present at the C-terminal end of SKCa3-1/285. In contrast, full-length SKCa3, SKCa2, and IKCal polypeptides are all excluded from the nucleus and express as functional channels. When overexpressed in human Jurkat T cells, SKCa3-1/285 can suppress endogenous SKCa2 currents but not voltage-gated K+ currents. This dominant-negative suppression is most likely mediated through the co-assembly of SKCa3-1/285 with native subunits and the formation of non-functional tetramers. The nuclear localization of SKCa3-1/285 may alter neuronal architecture, and its ability to dominantly suppress endogenous small conductance K-Ca currents may affect patterns of neuronal firing. Together, these two effects may play a part in the pathogenesis of schizophrenia and other neuropsychiatric disorders.	Univ Calif Irvine, Sch Med, Dept Physiol & Biophys, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Pediat, Div Human Genet, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine	Chandy, KG (corresponding author), Univ Calif Irvine, Sch Med, Dept Physiol & Biophys, Irvine, CA 92697 USA.	gchandy@uci.edu		Tomita, Hiroaki/0000-0003-2628-880X; Miller, Mark/0000-0001-5676-389X	NIMH NIH HHS [MH59222] Funding Source: Medline; NINDS NIH HHS [NS14609] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH059222] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS014609, R01NS014609] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Antonarakis SE, 1999, AM J MED GENET, V88, P348, DOI 10.1002/(SICI)1096-8628(19990820)88:4<348::AID-AJMG11>3.3.CO;2-E; Bonnet-Brilhault F, 1999, EUR J HUM GENET, V7, P247, DOI 10.1038/sj.ejhg.5200278; Bowen T, 1998, MOL PSYCHIATR, V3, P266, DOI 10.1038/sj.mp.4000400; Bowen T, 2001, MOL PSYCHIATR, V6, P259, DOI 10.1038/sj.mp.4000128; Brzustowicz LM, 2000, SCIENCE, V288, P678, DOI 10.1126/science.288.5466.678; Cardno AG, 1999, BIOL PSYCHIAT, V45, P1592, DOI 10.1016/S0006-3223(99)00033-5; Chandy KG, 1998, MOL PSYCHIATR, V3, P32, DOI 10.1038/sj.mp.4000353; Chowdari KV, 2000, MOL PSYCHIATR, V5, P237, DOI 10.1038/sj.mp.4000694; Cooper JK, 1998, HUM MOL GENET, V7, P783, DOI 10.1093/hmg/7.5.783; Dawson LA, 1995, BRIT J PHARMACOL, V116, P3260, DOI 10.1111/j.1476-5381.1995.tb15133.x; Desai R, 2000, J BIOL CHEM, V275, P39954, DOI 10.1074/jbc.M001562200; Dror V, 1999, MOL PSYCHIATR, V4, P254, DOI 10.1038/sj.mp.4000508; Fanger CM, 1999, J BIOL CHEM, V274, P5746, DOI 10.1074/jbc.274.9.5746; Fanger CM, 2001, J BIOL CHEM, V276, P12249, DOI 10.1074/jbc.M011342200; Farde L, 1997, SCHIZOPHR RES, V28, P157, DOI 10.1016/S0920-9964(97)00121-7; Ghanshani S, 2000, J BIOL CHEM, V275, P37137, DOI 10.1074/jbc.M003941200; Hackam AS, 1999, HUM MOL GENET, V8, P25, DOI 10.1093/hmg/8.1.25; Hackam AS, 1998, J CELL BIOL, V141, P1097, DOI 10.1083/jcb.141.5.1097; Halliday GM, 2001, CLIN EXP PHARMACOL P, V28, P64, DOI 10.1046/j.1440-1681.2001.03398.x; Hawi Z, 1999, MOL PSYCHIATR, V4, P488, DOI 10.1038/sj.mp.4000560; HILLE B, 1992, IONIC CHANNELS EXCIT, P121; Imbert G, 1996, NAT GENET, V14, P285, DOI 10.1038/ng1196-285; Ishii TM, 1997, J BIOL CHEM, V272, P23195, DOI 10.1074/jbc.272.37.23195; Jager H, 2000, FEBS LETT, V469, P196, DOI 10.1016/S0014-5793(00)01236-9; Joober R, 1999, AM J MED GENET, V88, P154, DOI 10.1002/(SICI)1096-8628(19990416)88:2<154::AID-AJMG11>3.3.CO;2-1; Kohler M, 1996, SCIENCE, V273, P1709, DOI 10.1126/science.273.5282.1709; LATORRE R, 1989, ANNU REV PHYSIOL, V51, P385, DOI 10.1146/annurev.ph.51.030189.002125; MANLEY LD, 1992, J NEUROCHEM, V58, P1491, DOI 10.1111/j.1471-4159.1992.tb11369.x; Martindale D, 1998, NAT GENET, V18, P150, DOI 10.1038/ng0298-150; McGlashan TH, 2000, ARCH GEN PSYCHIAT, V57, P637, DOI 10.1001/archpsyc.57.7.637; Morikawa H, 2000, J NEUROSCI, V20, part. no.; O'Donovan MC, 1999, AM J HUM GENET, V65, P587, DOI 10.1086/302560; Pedarzani P, 2001, J BIOL CHEM, V276, P9762, DOI 10.1074/jbc.M010001200; Ping HX, 1999, J NEUROPHYSIOL, V81, P977, DOI 10.1152/jn.1999.81.3.977; Ping HX, 1996, NEUROREPORT, V7, P809, DOI 10.1097/00001756-199602290-00031; Rimini R, 2000, MOL BRAIN RES, V85, P218, DOI 10.1016/S0169-328X(00)00255-2; Sah P, 1996, TRENDS NEUROSCI, V19, P150, DOI 10.1016/S0166-2236(96)80026-9; Schilling G, 1999, HUM MOL GENET, V8, P397, DOI 10.1093/hmg/8.3.397; SHEPARD PD, 1988, BRAIN RES, V463, P380, DOI 10.1016/0006-8993(88)90414-3; STEKETEE JD, 1990, J PHARMACOL EXP THER, V254, P711; Stober G, 1998, NEUROREPORT, V9, P3595; Stober G, 2000, EUR ARCH PSY CLIN N, V250, P163, DOI 10.1007/s004060070020; Stocker M, 2000, MOL CELL NEUROSCI, V15, P476, DOI 10.1006/mcne.2000.0842; Tacconi S, 2001, NEUROSCIENCE, V102, P209, DOI 10.1016/S0306-4522(00)00486-3; TU LW, 1995, BIOPHYS J, V68, P147, DOI 10.1016/S0006-3495(95)80169-4; Wittekindt O, 1998, NEUROGENETICS, V1, P259, DOI 10.1007/s100480050038; Wolfart J, 2001, J NEUROSCI, V21, P3443, DOI 10.1523/JNEUROSCI.21-10-03443.2001; Wulff H, 2000, P NATL ACAD SCI USA, V97, P8151, DOI 10.1073/pnas.97.14.8151; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758	49	45	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27753	27756		10.1074/jbc.C100221200	http://dx.doi.org/10.1074/jbc.C100221200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11395478	hybrid			2022-12-25	WOS:000170093400003
J	Li, LY; Shih, HM; Liu, MY; Chen, JY				Li, LY; Shih, HM; Liu, MY; Chen, JY			The cellular protein PRA1 modulates the anti-apoptotic activity of Epstein-Barr virus BHRF1, a homologue of Bcl-2, through direct interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NASOPHARYNGEAL CARCINOMA; VIRAL HOMOLOG; CYTOCHROME-C; B-CELLS; EPITHELIAL-CELLS; MAMMALIAN-CELLS; PRENYLATED RAB; GENE-PRODUCT; FAMILY; DEATH	The Epstein-Barr virus-encoded early protein, BHRF1, is a structural and functional homologue of the anti-apoptotic protein, Bcl-2. There is accumulating evidence that BHRF1 protects a variety of cell types from apoptosis induced by various external stimuli. To identify specific proteins from normal epithelial cells that interact with BHRF1 and that might promote or inhibit its anti-apoptotic activity, we screened a yeast two-hybrid cDNA library derived from human normal foreskin keratinocytes and identified a cellular gene encoding human prenylated rab acceptor 1 (hPRA1). The interaction of hPRA1. with BHRF1 was confirmed using glutathione S-transferase pull-down assays, confocal laser scanning microscopy, and co-immunoprecipitation. Two regions of PRA1, amino acids 30-53 and the carboxyl-terminal 21 residues, are important for BHRF1 interactions and two regions of BHRF1, amino acids 1-18 and 89-142, including the Bcl-2 homology domains BH4 and BH1, respectively, are crucial for PRA1 interactions. PRA1 expression interferes with the anti-apoptotic activity of BHRF1, although not of Bcl-2. These results indicate that the PRA1 interacts selectively with BHRF1 to reduce its anti-apoptotic activity and might play a role in the impeding completion of virus maturation.	Natl Taiwan Univ, Coll Med, Grad Inst Microbiol, Taipei 100, Taiwan; Natl Hlth Res Inst, Div Mol & Genom Med, Taipei 115, Taiwan; Natl Taipei Coll Nursing, Dept Gen Educ, Taipei 112, Taiwan	National Taiwan University; National Health Research Institutes - Taiwan	Chen, JY (corresponding author), Natl Taiwan Univ, Coll Med, Grad Inst Microbiol, Rm 743,Number 1,Sevt 1,Jen Ai Rd, Taipei 100, Taiwan.		Shih, Hsiu-Ming/S-7023-2018; Chen, Jen-Yang/D-2085-2010	Li, Long-Yuan/0000-0001-7472-8318				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Antonsson B, 2000, EXP CELL RES, V256, P50, DOI 10.1006/excr.2000.4839; Bartel P. L., 1993, CELLULAR INTERACTION, P153; Bellows DS, 2000, J VIROL, V74, P5024, DOI 10.1128/JVI.74.11.5024-5031.2000; BORNER C, 1994, BIOCHEM CELL BIOL, V72, P463, DOI 10.1139/o94-062; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; Bucci C, 1999, BIOCHEM BIOPH RES CO, V258, P657, DOI 10.1006/bbrc.1999.0651; Chang BS, 1997, EMBO J, V16, P968, DOI 10.1093/emboj/16.5.968; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen MR, 2000, J VIROL METHODS, V85, P35, DOI 10.1016/S0166-0934(99)00148-2; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; DAWSON CW, 1995, ONCOGENE, V10, P69; Everett H, 1999, TRENDS MICROBIOL, V7, P160, DOI 10.1016/S0966-842X(99)01487-0; Farrow SN, 1996, CURR OPIN GENET DEV, V6, P45, DOI 10.1016/S0959-437X(96)90009-X; Foghsgaard L, 1997, J VIROL, V71, P7509, DOI 10.1128/JVI.71.10.7509-7517.1997; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; HELLER M, 1981, J VIROL, V38, P632, DOI 10.1128/JVI.38.2.632-648.1981; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; HICKISH T, 1994, CANCER RES, V54, P2808; Huang H, 1999, ANN OTO RHINOL LARYN, V108, P481; Huang H, 1997, J LARYNGOL OTOL, V111, P1147, DOI 10.1017/S0022215100139568; Hutt DM, 2000, J BIOL CHEM, V275, P18511, DOI 10.1074/jbc.M909309199; Kawanishi M, 1997, J VIROL, V71, P3319, DOI 10.1128/JVI.71.4.3319-3322.1997; Khanim F, 1997, J GEN VIROL, V78, P2987, DOI 10.1099/0022-1317-78-11-2987; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; Lee JH, 1999, ONCOGENE, V18, P6183, DOI 10.1038/sj.onc.1203043; LEE MA, 1992, J VIROL, V66, P1899, DOI 10.1128/JVI.66.4.1899-1906.1992; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998; Liu MY, 2000, J MED VIROL, V61, P241, DOI 10.1002/(SICI)1096-9071(200006)61:2&lt;241::AID-JMV11&gt;3.0.CO;2-2; Liu MY, 1998, J MED VIROL, V56, P179, DOI 10.1002/(SICI)1096-9071(199811)56:3<179::AID-JMV1>3.0.CO;2-4; MARCHINI A, 1991, J VIROL, V65, P5991, DOI 10.1128/JVI.65.11.5991-6000.1991; Martincic I, 1997, J BIOL CHEM, V272, P26991, DOI 10.1074/jbc.272.43.26991; Nicholson DW, 1996, NAT BIOTECHNOL, V14, P297, DOI 10.1038/nbt0396-297; ODA K, 1993, AM J PATHOL, V143, P1063; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; PALLESEN G, 1991, LANCET, V337, P320, DOI 10.1016/0140-6736(91)90943-J; PEARSON GR, 1987, VIROLOGY, V160, P151, DOI 10.1016/0042-6822(87)90055-9; Poommipanit PB, 1999, J BIOL CHEM, V274, P1033, DOI 10.1074/jbc.274.2.1033; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; RHIM JS, 1989, ANTICANCER RES, V9, P1345; Rickinson AB, 1996, VIROLOGY, P2397; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; SU IJ, 1992, LEUKEMIA LYMPHOMA, V7, P47, DOI 10.3109/10428199209053601; Tagami S, 2000, ONCOGENE, V19, P5736, DOI 10.1038/sj.onc.1203948; TARODI B, 1994, VIROLOGY, V201, P404, DOI 10.1006/viro.1994.1309; Theodorakis P, 1996, ONCOGENE, V12, P1707; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tsai CH, 1997, J BIOMED SCI, V4, P69, DOI 10.1007/BF02255596; TSUJIMOTO Y, 1989, P NATL ACAD SCI USA, V86, P1958, DOI 10.1073/pnas.86.6.1958; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; WANG HG, 1994, ONCOGENE, V9, P2751; Xu QL, 1998, MOL CELL, V1, P337, DOI 10.1016/S1097-2765(00)80034-9; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang H, 2000, P NATL ACAD SCI USA, V97, P2597, DOI 10.1073/pnas.97.6.2597; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x	68	34	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27354	27362		10.1074/jbc.M103821200	http://dx.doi.org/10.1074/jbc.M103821200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11373297	hybrid			2022-12-25	WOS:000169966900083
J	Yin, BWT; Lloyd, KO				Yin, BWT; Lloyd, KO			Molecular cloning of the CA125 ovarian cancer antigen - Identification as a new mucin, MUC16	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; CA-125 ANTIGEN; TYROSINE PHOSPHORYLATION; GENE; PROTEINS; CELLS; SPECIFICITY; EXPRESSION; SITES	CA125 is an ovarian cancer antigen that is the basis for a widely used serum assay for the monitoring of patients with ovarian cancer; however, detailed information on its biochemical and molecular nature is lacking. We now report the isolation of a long, but partial, cDNA that corresponds to the CA125 antigen. A rabbit polyclonal antibody produced to purified CA125 antigen was used to screen a lambda ZAP cDNA library from OVCAR-3 cells in Escherichia coli. The longest insert from the 54 positive isolated clones had a 5797-base pair sequence containing a stop codon and a poly(A) sequence but no clear 5' initiation sequence. The deduced amino acid sequence has many of the attributes of a mucin molecule and was designated CA125/MUC16 (gene MUC16). These features include a high serine, threonine, and proline content in an N-terminal region of nine partially conserved tandem repeats (156 amino acids each) and a C-terminal region non-tandem repeat sequence containing a possible transmembrane region and a potential tyrosine phosphorylation site. Northern blotting showed that the level of MUC16 mRNA correlated with the expression of CA125 in a panel of cell lines. The molecular cloning of the CA125 antigen will lead to a better understanding of its role in ovarian cancer.	Mem Sloan Kettering Canc Ctr, Program Immunol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Lloyd, KO (corresponding author), Mem Sloan Kettering Canc Ctr, Program Immunol, 1275 York Ave, New York, NY 10021 USA.				NATIONAL CANCER INSTITUTE [P30CA008748, P01CA052477] Funding Source: NIH RePORTER; NCI NIH HHS [CA 52477, CA 08748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAST RC, 1983, NEW ENGL J MED, V309, P883, DOI 10.1056/NEJM198310133091503; BAST RC, 1981, J CLIN INVEST, V68, P1331, DOI 10.1172/JCI110380; Bast RC, 1998, INT J BIOL MARKER, V13, P179, DOI 10.1177/172460089801300402; BORK P, 1995, PROTEIN SCI, V49, P1421; BOSHELL M, 1992, BIOCHEM BIOPH RES CO, V185, P1, DOI 10.1016/S0006-291X(05)80946-5; CAMPBELL IG, 1994, HUM MOL GENET, V3, P589, DOI 10.1093/hmg/3.4.589; Chambers JA, 1996, GENOMICS, V38, P305, DOI 10.1006/geno.1996.0633; COOPER JA, 1984, J BIOL CHEM, V259, P7835; DAVIS HM, 1986, CANCER RES, V46, P6143; DELOSFRAILES MT, 1993, TUMOR BIOL, V14, P18, DOI 10.1159/000217821; Fendrick JL, 1997, TUMOR BIOL, V18, P278, DOI 10.1159/000218041; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; HANSEN JE, 1995, BIOCHEM J, V308, P801, DOI 10.1042/bj3080801; KIM YS, 1991, AM REV RESPIR DIS, V144, pS10, DOI 10.1164/ajrccm/144.3_pt_2.S10; KOBAYASHI H, 1993, AM J OBSTET GYNECOL, V169, P725, DOI 10.1016/0002-9378(93)90652-Y; LIGTENBERG MJL, 1992, J BIOL CHEM, V267, P6171; Lloyd KO, 1997, INT J CANCER, V71, P842, DOI 10.1002/(SICI)1097-0215(19970529)71:5<842::AID-IJC24>3.0.CO;2-8; Lloyd KO, 2001, TUMOR BIOL, V22, P77, DOI 10.1159/000050600; Lloyd KO, 2000, BBA-GEN SUBJECTS, V1474, P410, DOI 10.1016/S0304-4165(00)00037-4; MATSUOKA Y, 1987, CANCER RES, V47, P6335; Meden H, 1998, INT J BIOL MARKER, V13, P231, DOI 10.1177/172460089801300411; Menon U, 2000, CURR OPIN OBSTET GYN, V12, P39, DOI 10.1097/00001703-200002000-00007; Meyer T, 2000, BRIT J CANCER, V82, P1535; NAGATA A, 1991, TUMOR BIOL, V12, P279, DOI 10.1159/000217716; Nustad K, 1996, TUMOR BIOL, V17, P196, DOI 10.1159/000217982; PANDEY P, 1995, CANCER RES, V55, P4000; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; Perez-Vilar J, 1999, J BIOL CHEM, V274, P31751, DOI 10.1074/jbc.274.45.31751; Seregni E, 1997, TUMORI J, V83, P625, DOI 10.1177/030089169708300301; TAYLOR-PAPADIMITRIOU J-T, 1988, Cancer Reviews, V11-12, P11; TORIBARA NW, 1993, J BIOL CHEM, V268, P5879; Verheijen RHM, 1999, SEMIN CANCER BIOL, V9, P117, DOI 10.1006/scbi.1998.0114; Williams SJ, 1999, CANCER RES, V59, P4083; Williams SJ, 2001, J BIOL CHEM, V276, P18327, DOI 10.1074/jbc.M008850200; WREISCHNER DH, 2000, P 6 INT WORKSH CARC, P25; ZRIHANLICHT S, 1994, FEBS LETT, V356, P130, DOI 10.1016/0014-5793(94)01251-2; ZURAWSKI V R JR, 1988, Cancer Reviews, V11-12, P102	37	465	537	0	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27371	27375		10.1074/jbc.M103554200	http://dx.doi.org/10.1074/jbc.M103554200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11369781	hybrid			2022-12-25	WOS:000169966900085
J	Rudling, M; Angelin, B				Rudling, M; Angelin, B			Growth hormone reduces plasma cholesterol in LDL receptor-deficient mice	FASEB JOURNAL			English	Article						hypercholesterolemia; familial; cholesterol 7 alpha-monooxygenase; statins; resins	LOW-DENSITY-LIPOPROTEIN; MEDIATED GENE DELIVERY; BILE-ACID SYNTHESIS; RAT-LIVER; KNOCKOUT MICE; 7-ALPHA-HYDROXYLASE; HYPERCHOLESTEROLEMIA; ENZYME; INVIVO; METABOLISM	Growth hormone (GH) has pleiotropic effects on cholesterol and lipoprotein metabolism. Pituitary GH is important for the normal regulation of hepatic LDL receptors (LDLR), for the enzymatic activity of bile acid regulatory cholesterol 7 alpha -hydroxylase (C7 alpha OH), and for the maintenance of resistance to dietary cholesterol. The present study aimed to determine whether GH has beneficial effects on plasma lipids and hepatic cholesterol metabolism in mice devoid of LDLR. Compared with wild-type controls, LDLR-deficient mice had similar to 250% elevated plasma total cholesterol and similar to 50% increased hepatic cholesterol levels; hepatic HMG CoA reductase activity was reduced by 70%, whereas C7 alpha OH activity was increased by 40%. In LDLR mice, GH infusion reduced plasma cholesterol and triglycerides up to 40%, whereas HMG CoA reductase and C7 alpha OH activities were stimulated by similar to 50% and 110% respectively. GH also stimulated HMG CoA reductase and C7 alpha OH activities in control mice, whereas hepatic LDLR and plasma lipoproteins were unchanged. The effects of cholestyramine and atorvastatin on C7 alpha OH in LDLR-deficient mice were potentiated by GH, and this was associated with a further reduction in plasma cholesterol. GH treatment reduces plasma cholesterol and triglycerides and stimulates C7 alpha OH activity in mice devoid of LDLR, particularly in combination with resin or statin treatment. The potential of GH therapy in patients with homozygous familial hypercholesterolemia should be evaluated.	Huddinge Univ Hosp, Ctr Metab & Endocrinol, Metab Unit, Dept Med, S-14186 Huddinge, Sweden; Huddinge Univ Hosp, Karolinska Inst, Novum, Ctr Nutr & Toxicol,Mol Nutr Unit, S-14186 Huddinge, Sweden	Karolinska Institutet; Karolinska Institutet	Rudling, M (corresponding author), Huddinge Univ Hosp, Ctr Metab & Endocrinol, Metab Unit, Dept Med, M63, S-14186 Huddinge, Sweden.	mats.rudling@cnt.ki.se						ANGELIN B, 1984, J LIPID RES, V25, P1159; Angelin Bo, 1994, Current Opinion in Lipidology, V5, P160, DOI 10.1097/00041433-199405030-00002; EDEN S, 1993, ARTERIOSCLER THROMB, V13, P296, DOI 10.1161/01.ATV.13.2.296; EINARSSON K, 1986, J LIPID RES, V27, P82; ELAM MB, 1992, ENDOCRINOLOGY, V131, P2717, DOI 10.1210/en.131.6.2717; FRIEDMAN M, 1970, NATURE, V255, P464; Goldstein J, 1995, FAMILIAL HYPERCHOLES, P1981; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; KITA T, 1981, P NATL ACAD SCI-BIOL, V78, P2268, DOI 10.1073/pnas.78.4.2268; OSCARSSON J, 1991, METABOLISM, V40, P1191, DOI 10.1016/0026-0495(91)90215-I; Parini P, 1999, ARTERIOSCL THROM VAS, V19, P832, DOI 10.1161/01.ATV.19.4.832; RUDLING M, 1993, P NATL ACAD SCI USA, V90, P8851, DOI 10.1073/pnas.90.19.8851; Rudling M, 1997, J CLIN INVEST, V99, P2239, DOI 10.1172/JCI119398; RUDLING M, 1992, J LIPID RES, V33, P493; RUDLING M, 1992, P NATL ACAD SCI USA, V89, P6983, DOI 10.1073/pnas.89.15.6983; RUDLING M, 1993, J CLIN INVEST, V91, P2796, DOI 10.1172/JCI116522; SJOBERG A, 1992, ENDOCRINOLOGY, V130, P3356, DOI 10.1210/en.130.6.3356; SPADY DK, 1995, J CLIN INVEST, V96, P700, DOI 10.1172/JCI118113; Spady DK, 1998, J BIOL CHEM, V273, P126, DOI 10.1074/jbc.273.1.126; Teng BB, 1997, ARTERIOSCL THROM VAS, V17, P889, DOI 10.1161/01.ATV.17.5.889; XU GR, 1995, J CLIN INVEST, V95, P1497, DOI 10.1172/JCI117821; Zsigmond E, 1997, HUM GENE THER, V8, P1921, DOI 10.1089/hum.1997.8.16-1921	22	24	24	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2001	15	8					1350	1356		10.1096/fj.00-0715com	http://dx.doi.org/10.1096/fj.00-0715com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11387232				2022-12-25	WOS:000169261200002
J	Hjalm, G; MacLeod, RJ; Kifor, O; Chattopadhyay, N; Brown, EM				Hjalm, G; MacLeod, RJ; Kifor, O; Chattopadhyay, N; Brown, EM			Filamin-A binds to the carboxyl-terminal tail of the calcium-sensing receptor, an interaction that participates in CaR-mediated activation of mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR CA2+-SENSING RECEPTOR; CYTOPLASMIC DOMAIN; MEMBRANE DOMAINS; PLASMA-MEMBRANE; ACTIN; IDENTIFICATION; TRANSDUCTION; MIGRATION; CLONING; ABP-280	The G protein-coupled, extracellular calcium-sensing receptor (CaR) regulates parathyroid hormone secretion and parathyroid cellular proliferation as well as the functions of diverse other cell types. The CaR resides in caveolae-plasma membrane microdomains containing receptors and associated signaling molecules that are thought to serve as cellular "message centers." An additional mechanism for coordinating cellular signaling is the presence of scaffold proteins that bind and organize components of signal transduction cascades. With the use of the yeast two-hybrid system, we identified filamin-A (an actin-cross-linking, putative scaffold protein that binds mitogen-activated protein kinase (MAPK) components activated by the CaR) as an intracellular binding partner of the CaR's carboxyl (COOH)-terminal tail. A direct interaction of the two proteins was confirmed by an in vitro binding assay. Moreover, confocal microscopy combined with two color immunofluorescence showed co-localization of the CaR and filamin-A within parathyroid cells as well as HEK-293 cells stably transfected with the CaR. Deletion mapping localized the sites of interaction between the two proteins to a stretch of 60 amino acid residues within the distal portion of the CaR's COOH-terminal tail and domains 14 and 15 in filamin-A, respectively. Finally, introducing the portion of filamin-A interacting with the CaR into CaR-transfected HEK-293 cells using protein transduction with a His-tagged, Tat-filamin-A fusion protein nearly abolished CaR-mediated activation of ERK1/2 MAPK but had no effect on ERK1/2 activity stimulated by ADP. Therefore, the binding of the CaR's COOH-terminal tail to filamin-A may contribute to its localization in caveolae, link it to the actin-based cytoskeleton, and participate in CaR-mediated activation of MAPK.	Brigham & Womens Hosp, Dept Med, Div Endocrine Hypertens, Calcium Sect, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Membrane Biol Program, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Brown, EM (corresponding author), Brigham & Womens Hosp, Dept Med, Div Endocrine Hypertens, Calcium Sect, 221 Longwood Ave, Boston, MA 02115 USA.	embrown@rics.bwh.harvard.edu	Chattopadhyay, Naibedya/AAQ-3213-2021; Chattopadhyay, Naibedya/AAF-2058-2019	Chattopadhyay, Naibedya/0000-0003-2473-0246; 	NIDDK NIH HHS [DK41415, DK48330, DK52005] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041415, R01DK048330, R01DK052005] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson RGW, 1993, CURR OPIN CELL BIOL, V5, P647, DOI 10.1016/0955-0674(93)90135-D; Arthur JM, 2000, BIOCHEM BIOPH RES CO, V275, P538, DOI 10.1006/bbrc.2000.3226; BROWN EM, 1976, ENDOCRINOLOGY, V99, P1582, DOI 10.1210/endo-99-6-1582; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Brown EM, 1999, VITAM HORM, V55, P1; Chattopadhyay N, 1998, TRENDS ENDOCRIN MET, V9, P354, DOI 10.1016/S1043-2760(98)00090-3; Dimitratos SD, 1999, BIOESSAYS, V21, P912, DOI 10.1002/(SICI)1521-1878(199911)21:11<912::AID-BIES3>3.0.CO;2-Z; Fox JW, 1998, NEURON, V21, P1315, DOI 10.1016/S0896-6273(00)80651-0; GARRETT JE, 1995, J BIOL CHEM, V270, P12919, DOI 10.1074/jbc.270.21.12919; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; Handlogten ME, 2001, J BIOL CHEM, V276, P13941, DOI 10.1074/jbc.M007306200; Kifor O, 1997, J BONE MINER RES, V12, P715, DOI 10.1359/jbmr.1997.12.5.715; Kifor O, 2001, AM J PHYSIOL-RENAL, V280, pF291, DOI 10.1152/ajprenal.2001.280.2.F291; Kifor O, 1998, J BIOL CHEM, V273, P21708, DOI 10.1074/jbc.273.34.21708; Leonardi A, 2000, J BIOL CHEM, V275, P271, DOI 10.1074/jbc.275.1.271; Li M, 2000, MOL PHARMACOL, V57, P446, DOI 10.1124/mol.57.3.446; Liu GP, 1997, J CELL BIOL, V139, P1719, DOI 10.1083/jcb.139.7.1719; Loo DT, 1998, J BIOL CHEM, V273, P23304, DOI 10.1074/jbc.273.36.23304; Marti A, 1997, J BIOL CHEM, V272, P2620, DOI 10.1074/jbc.272.5.2620; McNeil SE, 1998, J BIOL CHEM, V273, P1114, DOI 10.1074/jbc.273.2.1114; Meyer SC, 1997, J BIOL CHEM, V272, P2914, DOI 10.1074/jbc.272.5.2914; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Ott I, 1998, J CELL BIOL, V140, P1241, DOI 10.1083/jcb.140.5.1241; Schlegel A, 1998, CELL SIGNAL, V10, P457, DOI 10.1016/S0898-6568(98)00007-2; Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2; Stahlhut M, 2000, MOL BIOL CELL, V11, P325, DOI 10.1091/mbc.11.1.325; Yamaguchi T, 2000, BIOCHEM BIOPH RES CO, V279, P363, DOI 10.1006/bbrc.2000.3955	29	159	162	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 14	2001	276	37					34880	34887		10.1074/jbc.M100784200	http://dx.doi.org/10.1074/jbc.M100784200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	473DK	11390380	hybrid			2022-12-25	WOS:000171024600072
J	Hansen, GH; Immerdal, L; Thorsen, E; Niels-Christiansen, LL; Nystrom, BT; Demant, EJF; Danielsen, EM				Hansen, GH; Immerdal, L; Thorsen, E; Niels-Christiansen, LL; Nystrom, BT; Demant, EJF; Danielsen, EM			Lipid rafts exist as stable cholesterol-independent microdomains in the brush border membrane of enterocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHORED PROTEINS; APICAL SURFACE; AMINOPEPTIDASE-N; CAVEOLAE; DOMAINS; FAMILY; MODEL; BIOSYNTHESIS; RESOLUTION; COMPLEXES	Glycosphingolipid/cholesterol-rich membranes ("rafts")can be isolated from many types of cells, but their existence as stable microdomains in the cell membrane has been elusive. Addressing this problem, we studied the distribution of galectin-4, a raft marker, and lactase, a protein excluded from rafts, on microvillar vesicles from the enterocyte brush border membrane. Magnetic beads coated with either anti-galectin-4 or anti-lactase antibodies were used for immunoisolation of vesicles followed by double immunogold labeling of the two proteins. A morphometric analysis revealed subpopulations of raft-rich and raft-poor vesicles by the following criteria: 1) the lactase/galectin-4 labeling ratio/vesicle captured by the anti-lactase beads was significantly higher (p less than or equal to 0.01) than that of vesicles captured by anti-galectin-4 beads, 2) subpopulations of vesicles labeled by only one of the two antibodies were preferentially captured by beads coated with the respective antibody (p less than or equal to 0.01), 3) the average diameter of "galectin-4 positive only" vesicles was smaller than that of vesicles labeled for lactase. Surprisingly, pretreatment with methyl-beta -cyclodextrin, which removed > 70% of microvillar cholesterol, did not affect the microdomain localization of galectin-4. We conclude that stable, cholesterol-independent raft microdomains exist in the enterocyte brush border.	Univ Copenhagen, Panum Inst, Dept Med Biochem & Genet, DK-2200 Copenhagen N, Denmark	University of Copenhagen	Danielsen, EM (corresponding author), Univ Copenhagen, Panum Inst, Dept Med Biochem & Genet, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark.	midan@imbg.ku.dk						Ahmed SN, 1997, BIOCHEMISTRY-US, V36, P10944, DOI 10.1021/bi971167g; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; Booth A G, 1974, Biochem J, V142, P575; BOOTH AG, 1976, J CELL SCI, V21, P449; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CHRISTIANSEN K, 1981, BIOCHIM BIOPHYS ACTA, V647, P188, DOI 10.1016/0005-2736(81)90245-5; Danielsen EM, 1997, MOL BIOL CELL, V8, P2241, DOI 10.1091/mbc.8.11.2241; DANIELSEN EM, 1995, BIOCHEMISTRY-US, V34, P1596, DOI 10.1021/bi00005a016; DANIELSEN EM, 1995, J CELL BIOL, V131, P939, DOI 10.1083/jcb.131.4.939; DANIELSEN EM, 1995, GASTROENTEROLOGY, V109, P1039, DOI 10.1016/0016-5085(95)90561-8; DANIELSEN EM, 1982, BIOCHEM J, V202, P647, DOI 10.1042/bj2020647; Dietrich C, 2001, BIOPHYS J, V80, P1417, DOI 10.1016/S0006-3495(01)76114-0; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; Fujimoto T, 1996, J HISTOCHEM CYTOCHEM, V44, P929, DOI 10.1177/44.8.8756764; GAMBLE W, 1978, J LIPID RES, V19, P1068; Gheber LA, 1999, BIOPHYS J, V77, P3163, DOI 10.1016/S0006-3495(99)77147-X; HANNAN LA, 1993, J CELL BIOL, V120, P353, DOI 10.1083/jcb.120.2.353; Hansen GH, 2000, J BIOL CHEM, V275, P5136, DOI 10.1074/jbc.275.7.5136; Hansen GH, 1999, GASTROENTEROLOGY, V116, P610, DOI 10.1016/S0016-5085(99)70183-6; HANSEN GH, 1992, HISTOCHEM J, V24, P132, DOI 10.1007/BF01047462; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; HARRISON FL, 1991, J CELL SCI, V100, P9; Hooper NM, 1998, CURR BIOL, V8, pR114, DOI 10.1016/S0960-9822(98)70984-4; Hooper NM, 1999, MOL MEMBR BIOL, V16, P145, DOI 10.1080/096876899294607; Hughes RC, 1999, BBA-GEN SUBJECTS, V1473, P172, DOI 10.1016/S0304-4165(99)00177-4; Jacobson K, 1999, TRENDS CELL BIOL, V9, P87, DOI 10.1016/S0962-8924(98)01495-0; Kenworthy AK, 2000, MOL BIOL CELL, V11, P1645, DOI 10.1091/mbc.11.5.1645; Kenworthy AK, 1998, J CELL BIOL, V142, P69, DOI 10.1083/jcb.142.1.69; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAYOR S, 1994, SCIENCE, V264, P1948, DOI 10.1126/science.7516582; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997; Riemann D, 2001, BIOCHEM J, V354, P47, DOI 10.1042/0264-6021:3540047; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; Schroeder RJ, 1998, J BIOL CHEM, V273, P1150, DOI 10.1074/jbc.273.2.1150; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; SKOVBJERG H, 1982, BIOCHIM BIOPHYS ACTA, V707, P89, DOI 10.1016/0167-4838(82)90400-9; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; SUZUKI K, 1965, J NEUROCHEM, V12, P629, DOI 10.1111/j.1471-4159.1965.tb04256.x; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Verkade P, 2000, J CELL BIOL, V148, P727, DOI 10.1083/jcb.148.4.727	48	103	107	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32338	32344		10.1074/jbc.M102667200	http://dx.doi.org/10.1074/jbc.M102667200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11389144	hybrid			2022-12-25	WOS:000170613500116
J	Miranda-Vizuete, A; Ljung, J; Damdimopoulos, AE; Gustafsson, JA; Oko, R; Pelto-Huikko, M; Spyrou, G				Miranda-Vizuete, A; Ljung, J; Damdimopoulos, AE; Gustafsson, JA; Oko, R; Pelto-Huikko, M; Spyrou, G			Characterization of Sptrx, a novel member of the thioredoxin family specifically expressed in human spermatozoa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN THIOREDOXIN; PROTEIN; SPERM; CLONING; GENE; SEQUENCES; REDUCTASE; DATABASE; REGION; SHEATH	Thioredoxins (Trx) are small ubiquitous proteins that participate in different cellular processes via redox-mediated reactions. We report here the identification and characterization of a novel member of the thioredoxin family in humans, named Sptrx ( perm-specific trx), the first with a tissue-specific distribution, located exclusively in spermatozoa. Sptrx open reading frame encodes for a protein of 486 amino acids composed of two clear domains: an N-terminal domain consisting of 23 highly conserved repetitions of a 15-residue motif and a C-terminal domain typical of thioredoxins. Northern analysis and in situ hybridization shows that Sptrx mRNA is only expressed in human testis, specifically in round and elongating spermatids. Immunostaining of human testis sections identified Sptrx protein in spermatids, while immunofluorescence and immunogold electron microscopy analysis demonstrated Sptrx localization in the cytoplasmic droplet of ejaculated sperm. Sptrx appears to have a multimeric structure in native conditions and is able to reduce insulin disulfide bonds in the presence of NADPH and thioredoxin reductase. During mammalian spermiogenesis in testis seminiferous tubules and later maturation in epididymis, extensive reorganization of disulfide bonds is required to stabilize cytoskeletal sperm structures. However, the molecular mechanisms that control these processes are not known. The identification of Sptrx with an expression pattern restricted to the postmeiotic phase of spermatogenesis, when the sperm tail is organized, suggests that Sptrx might be an important factor in regulating critical steps of human spermiogenesis.	Karolinska Inst, Novum, Dept Biosci, Ctr Biotechnol, S-14157 Huddinge, Sweden; Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; Queens Univ, Dept Anat & Cell Biol, Kingston, ON K7L 3N6, Canada; Tampere Univ, Sch Med, Dept Dev Biol, FIN-33101 Tampere, Finland; Tampere Univ Hosp, FIN-33101 Tampere, Finland	Karolinska Institutet; Karolinska Institutet; Queens University - Canada; Tampere University; Tampere University; Tampere University Hospital	Miranda-Vizuete, A (corresponding author), Karolinska Inst, Novum, Dept Biosci, Ctr Biotechnol, S-14157 Huddinge, Sweden.	anmi@biosci.ki.se	IBIS, REDOX/J-7473-2017; Miranda-Vizuete, Antonio/D-6927-2012	Miranda-Vizuete, Antonio/0000-0002-6856-5396; Damdimopoulos, Anastasios/0000-0003-4425-1189				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Avellar MCW, 1997, J BIOL CHEM, V272, P17623, DOI 10.1074/jbc.272.28.17623; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; BISHOP DF, 1988, P NATL ACAD SCI USA, V85, P3903, DOI 10.1073/pnas.85.11.3903; Brewis IA, 1999, REV REPROD, V4, P135; Brosius J, 1999, GENE, V238, P115, DOI 10.1016/S0378-1119(99)00227-9; BROSIUS J, 1991, SCIENCE, V251, P753, DOI 10.1126/science.1990437; CHEMES HE, 1987, FERTIL STERIL, V48, P664; Curry M., 1995, GAMETES SPERMATOZOON, P45; Eddy E. M., 1994, P29; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; HARENDZA CJ, 1990, P NATL ACAD SCI USA, V87, P2531, DOI 10.1073/pnas.87.7.2531; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Iguchi N, 1999, FEBS LETT, V456, P315, DOI 10.1016/S0014-5793(99)00967-9; JULIEN JP, 1988, GENE, V68, P307, DOI 10.1016/0378-1119(88)90033-9; KONONEN J, 1997, TECHNICAL TIPS ONLIN; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Miranda-Vizuete A, 2000, ANTIOXID REDOX SIGN, V2, P801, DOI 10.1089/ars.2000.2.4-801; O'Bryan MK, 2001, MOL REPROD DEV, V58, P116, DOI 10.1002/1098-2795(200101)58:1&lt;116::AID-MRD14&gt;3.0.CO;2-8; O'Rand MG, 2000, SERONO SYMP, P143; Oko R, 1998, ANDROLOGIA, V30, P193; RAINES CA, 1991, PLANT MOL BIOL, V16, P663, DOI 10.1007/BF00023430; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Rybnikova E, 2000, EUR J NEUROSCI, V12, P1669, DOI 10.1046/j.1460-9568.2000.00059.x; Shao XP, 1999, DEV BIOL, V211, P109, DOI 10.1006/dbio.1999.9297; Shao XP, 1997, J BIOL CHEM, V272, P6105, DOI 10.1074/jbc.272.10.6105; Spyrou G, 1997, J BIOL CHEM, V272, P2936, DOI 10.1074/jbc.272.5.2936; Sun QA, 1999, J BIOL CHEM, V274, P24522, DOI 10.1074/jbc.274.35.24522; Sutovsky P, 2001, HUM REPROD, V16, P250, DOI 10.1093/humrep/16.2.250; Sutovsky P, 1997, MOL REPROD DEV, V47, P79, DOI 10.1002/(SICI)1098-2795(199705)47:1&lt;79::AID-MRD11&gt;3.0.CO;2-V; TONISSEN KF, 1991, GENE, V102, P221, DOI 10.1016/0378-1119(91)90081-L; Tseng TC, 1998, DNA CELL BIOL, V17, P823, DOI 10.1089/dna.1998.17.823; Ursini F, 1999, SCIENCE, V285, P1393, DOI 10.1126/science.285.5432.1393; WOLLMAN E, 1938, J BIOL CHEM, V263, P15506; Zhao J, 1999, MICROBIOL MOL BIOL R, V63, P405, DOI 10.1128/MMBR.63.2.405-445.1999	38	120	130	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31567	31574		10.1074/jbc.M101760200	http://dx.doi.org/10.1074/jbc.M101760200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11399755	hybrid, Green Submitted			2022-12-25	WOS:000170613500015
J	Svanem, BIG; Strand, WI; Ertesvag, H; Skjak-Braek, G; Hartmann, M; Barbeyron, T; Valla, S				Svanem, BIG; Strand, WI; Ertesvag, H; Skjak-Braek, G; Hartmann, M; Barbeyron, T; Valla, S			The catalytic activities of the bifunctional Azotobacter vinelandii mannuronan C-5-epimerase and alginate lyase AlgE7 probably originate from the same active site in the enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-AERUGINOSA ALGG; O-ACETYL GROUPS; NITROGEN-FIXATION; CLONING; BIOSYNTHESIS; SEQUENCE; GENE; EXPRESSION; PROTEIN; ACID	The Azotobacter vinelandii genome encodes a family of seven secreted Ca2+-dependent epimerases (AlgE1-7) catalyzing the polymer level epimerization of beta -D-mannuronic. acid. (Al) to alpha -L-guluronic acid (G) in the commercially important polysaccharide alginate. AlgE1-7 are composed of two types of protein modules, A and R, and the A-modules have previously been found to be sufficient for epimerization. AlgE7 is both an epimerase and an alginase, and here we show that the lyase activity is Ca2+-dependent and also responds similarly to the epimerases in the presence of other divalent cations. The AlgE7 lyase degraded M-rich alginates and a relatively G-rich alginate from the brown algae Macrocystis pyrifera most effectively, producing oligomers of 4 (mannuronan) to 7 units. The sequences cleaved were mainly G down arrow MM and/or G down arrow GM. Since G-moieties dominated at the reducing ends even when mannuronan was used as substrate, the AlgE7 epimerase probably stimulates the lyase pathway, indicating a complex interplay between the two activities. A truncated form of AlgE1 (AlgE1-1) was converted to a combined epimerase and lyase by replacing the 5 ' -798 base pairs in the algE1-1 gene with the corresponding A-module-encoding DNA sequence from algE7. Furthermore, substitution of an aspartic acid residue at position 152 with glycine in AlgE7A eliminated almost all of both the lyase and epimerase activities. Epimerization and lyase activity are believed to be mechanistically related, and the results reported here strongly support this hypothesis by suggesting that the same enzymatic site can catalyze both reactions.	Norwegian Univ Sci & Technol, Dept Biotechnol, N-7491 Trondheim, Norway; CNRS, Ctr Etudes Oceanol & Biol Marine, F-29680 Roscoff, France	Norwegian University of Science & Technology (NTNU); Centre National de la Recherche Scientifique (CNRS)	Valla, S (corresponding author), Norwegian Univ Sci & Technol, Dept Biotechnol, N-7491 Trondheim, Norway.	svein.valla@chembio.ntnu.no		Ertesvag, helga/0000-0001-9437-9469				BAUMANN U, 1993, EMBO J, V12, P3357, DOI 10.1002/j.1460-2075.1993.tb06009.x; Bertsova YV, 1997, FEBS LETT, V414, P369, DOI 10.1016/S0014-5793(97)01047-8; Bertsova YV, 1998, BBA-BIOENERGETICS, V1363, P125, DOI 10.1016/S0005-2728(97)00094-7; Binet R, 1997, GENE, V192, P7, DOI 10.1016/S0378-1119(96)00829-3; BULEN WA, 1964, BIOCHEM BIOPH RES CO, V17, P265, DOI 10.1016/0006-291X(64)90395-X; Campos ME, 1996, J BACTERIOL, V178, P1793, DOI 10.1128/jb.178.7.1793-1799.1996; CHITNIS CE, 1990, J BACTERIOL, V172, P2894, DOI 10.1128/jb.172.6.2894-2900.1990; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; Clementi F, 1997, CRIT REV BIOTECHNOL, V17, P327, DOI 10.3109/07388559709146618; DARZINS A, 1984, J BACTERIOL, V159, P9, DOI 10.1128/JB.159.1.9-18.1984; DAVIDSON IW, 1977, J GEN MICROBIOL, V98, P603, DOI 10.1099/00221287-98-2-603; DAVIDSON IW, 1977, J GEN MICROBIOL, V98, P223, DOI 10.1099/00221287-98-1-223; Ertesvag H, 1998, J BIOL CHEM, V273, P30927, DOI 10.1074/jbc.273.47.30927; ERTESVAG H, 1995, MOL MICROBIOL, V16, P719, DOI 10.1111/j.1365-2958.1995.tb02433.x; ERTESVAG H, 1994, J BACTERIOL, V176, P2846; Ertesvag H, 1999, J BACTERIOL, V181, P3033; Ertesvag H, 1998, J BACTERIOL, V180, P3779; Ertesvag H, 1999, METAB ENG, V1, P262, DOI 10.1006/mben.1999.0130; FEINGOLD DS, 1987, FEBS LETT, V223, P207, DOI 10.1016/0014-5793(87)80290-9; FISCHER FG, 1955, H-S Z PHYSIOL CHEM, V302, P186, DOI 10.1515/bchm2.1955.302.1-2.186; FRANKLIN MJ, 1994, J BACTERIOL, V176, P1821, DOI 10.1128/JB.176.7.1821-1830.1994; GACESA P, 1992, INT J BIOCHEM, V24, P545, DOI 10.1016/0020-711X(92)90325-U; GACESA P, 1987, FEBS LETT, V212, P199, DOI 10.1016/0014-5793(87)81344-3; GRASDALEN H, 1979, CARBOHYD RES, V68, P23, DOI 10.1016/S0008-6215(00)84051-3; GRASDALEN H, 1983, CARBOHYD RES, V118, P255, DOI 10.1016/0008-6215(83)88053-7; GREENER A, 1990, STRATEGIES MOL BIOL, V3, P5; HAUG A, 1974, CARBOHYD RES, V32, P217, DOI 10.1016/S0008-6215(00)82100-X; HAUG A, 1967, ACTA CHEM SCAND, V21, P691, DOI 10.3891/acta.chem.scand.21-0691; Heyraud A, 1996, CARBOHYD RES, V289, P11, DOI 10.1016/0008-6215(96)00060-2; Hoidal HK, 1999, J BIOL CHEM, V274, P12316, DOI 10.1074/jbc.274.18.12316; Hoidal HK, 2000, ENVIRON MICROBIOL, V2, P27, DOI 10.1046/j.1462-2920.2000.00074.x; KENNEDY L, 1992, J GEN MICROBIOL, V138, P2465, DOI 10.1099/00221287-138-11-2465; LARSEN B, 1971, CARBOHYD RES, V17, P287, DOI 10.1016/S0008-6215(00)82536-7; LINKERHAGNER K, 1995, J BACTERIOL, V177, P5289, DOI 10.1128/jb.177.18.5289-5293.1995; MAGDWICK J, 1973, ACTA CHEM SCAND, V27, P3592; Mejia-Ruiz H, 1997, FEMS MICROBIOL LETT, V156, P101, DOI 10.1016/S0378-1097(97)00409-6; Moreno S, 1998, J BACTERIOL, V180, P2766, DOI 10.1128/JB.180.10.2766-2769.1998; PAGE WJ, 1975, J BACTERIOL, V122, P145, DOI 10.1128/JB.122.1.145-151.1975; Pecina A, 1999, J BACTERIOL, V181, P1409; PREISS J, 1962, J BIOL CHEM, V237, P309; PUPPO A, 1986, FEBS LETT, V201, P187, DOI 10.1016/0014-5793(86)80605-6; Ramstad MV, 2001, ENZYME MICROB TECH, V28, P57, DOI 10.1016/S0141-0229(00)00273-8; Ramstad MV, 1999, ENZYME MICROB TECH, V24, P636, DOI 10.1016/S0141-0229(98)00148-3; Rehm BH, 1996, J BACTERIOL, V178, P5884, DOI 10.1128/jb.178.20.5884-5889.1996; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHERINGS G, 1977, EUR J BIOCHEM, V77, P621, DOI 10.1111/j.1432-1033.1977.tb11706.x; SKJAKBRAEK G, 1986, CARBOHYD RES, V154, P239; SKJAKBRAEK G, 1986, INT J BIOL MACROMOL, V8, P330, DOI 10.1016/0141-8130(86)90051-6; SKJAKBRAEK G, 1989, CARBOHYD RES, V185, P119, DOI 10.1016/0008-6215(89)84027-3; SKJAKBRAEK G, 1985, CARBOHYD RES, V145, P169; SKJAKBRAEK G, 1982, CARBOHYD RES, V103, P133, DOI 10.1016/S0008-6215(82)80013-X; SOCOLOFSKY MD, 1962, J BACTERIOL, V84, P119, DOI 10.1128/JB.84.1.119-124.1962; Sutherland IW, 1999, CARBOHYD POLYM, V38, P319, DOI 10.1016/S0144-8617(98)00114-3; SUTHERLAND IW, 1995, FEMS MICROBIOL REV, V16, P323, DOI 10.1016/0168-6445(95)00020-D; Svanem BIG, 1999, J BACTERIOL, V181, P68, DOI 10.1128/JB.181.1.68-77.1999; THORNELEY RNF, 1989, BIOCHEM J, V261, P181, DOI 10.1042/bj2610181; Wong TY, 2000, ANNU REV MICROBIOL, V54, P289, DOI 10.1146/annurev.micro.54.1.289; WYSS O, 1961, J BIOPHYS BIOCHEM CY, V10, P555, DOI 10.1083/jcb.10.4.555; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	59	48	53	1	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31542	31550		10.1074/jbc.M102562200	http://dx.doi.org/10.1074/jbc.M102562200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11390391	hybrid			2022-12-25	WOS:000170613500012
J	Bisaillon, M; Shuman, S				Bisaillon, M; Shuman, S			Functional groups required for the stability of yeast RNA triphosphatase in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE TRIPHOSPHATASE; CAPPING APPARATUS; COMPONENT; 5'-TRIPHOSPHATASE; MECHANISM; SUBUNIT	Cet1, the RNA triphosphatase component of the yeast mRNA capping apparatus, catalyzes metal-dependent T-phosphate hydrolysis within the hydrophilic interior of an eight-strand beta barrel (the "triphosphate tunnel"), which rests upon a globular protein core (the "pedestal"). We performed a structure-guided alanine scan of 17 residues located in the tunnel (Ser(373), Thr(375), Gln(405), His(411), ser(429), Glu(488), Thr(490)), on the tunnel's outer surface (Ser(378), Ser(487), Thr(489), His(491)), at the tunnel-pedestal interface (IIe(304), Met(308)) and in the pedestal (Asp(315), Lys(317) Arg(321), Asp(425)). Alanine mutations at 14 positions had no significant effect on Cet1 phosphohydrolase activity in vitro and had no effect on Cet1 function in vivo. Two of the mutations (R321A and D425A) elicited a thermosensitive (ts) yeast growth phenotype. The R321A and D425A proteins had full phosphohydrolase activity in vitro, but were profoundly thermolabile. Arg(321) and Asp(425) interact to form a salt bridge within the pedestal that, tethers two of the strands of the tunnel. Mutations R321Q and D411N resulted in ts defects in vivo and in vitro, as did the double-mutant R321A-D435A, whereas the R321K protein was fully stable in vivo and in vitro. These results highlight the critical role of the buried salt bridge in Cet1 stability. Replacement of Ser(429) by alanine or valine elicited a cold-sensitive (es) yeast growth phenotype. The S429A and S429V proteins were fully active when produced in bacteria at 37 degreesC,, but were inactive when produced at 17 degreesC. Replacement of Ser(429) by threonine partially suppressed the cold sensitivity of the Cet1 phosphohydrolase, but did not suppress the cs growth defect in yeast.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.	s-shuman@ski.mskcc.org			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052470] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52470] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bisaillon M, 2001, J BIOL CHEM, V276, P17261, DOI 10.1074/jbc.M100980200; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Gross CH, 1998, J VIROL, V72, P10020, DOI 10.1128/JVI.72.12.10020-10028.1998; Ho CK, 2001, P NATL ACAD SCI USA, V98, P3050, DOI 10.1073/pnas.061636198; Ho CK, 1998, J BIOL CHEM, V273, P34151, DOI 10.1074/jbc.273.51.34151; Ho CK, 2001, J VIROL, V75, P1744, DOI 10.1128/JVI.75.4.1744-1750.2001; Ho CK, 1998, MOL CELL BIOL, V18, P5189, DOI 10.1128/MCB.18.9.5189; Ho CK, 2000, J VIROL, V74, P5486, DOI 10.1128/JVI.74.12.5486-5494.2000; Jin JP, 1998, J VIROL, V72, P10011, DOI 10.1128/JVI.72.12.10011-10019.1998; Lehman K, 2001, J BIOL CHEM, V276, P14996, DOI 10.1074/jbc.M100588200; Lima CD, 1999, CELL, V99, P533, DOI 10.1016/S0092-8674(00)81541-X; Pei Y, 2000, NUCLEIC ACIDS RES, V28, P1885, DOI 10.1093/nar/28.9.1885; Pei Y, 1999, J BIOL CHEM, V274, P28865, DOI 10.1074/jbc.274.41.28865; Pei Y, 2001, NUCLEIC ACIDS RES, V29, P387, DOI 10.1093/nar/29.2.387; Rodriguez CR, 1999, NUCLEIC ACIDS RES, V27, P2181, DOI 10.1093/nar/27.10.2181; Sheinerman FB, 2000, CURR OPIN STRUC BIOL, V10, P153, DOI 10.1016/S0959-440X(00)00065-8; Tsukamoto T, 1997, BIOCHEM BIOPH RES CO, V239, P116, DOI 10.1006/bbrc.1997.7439	17	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30514	30520		10.1074/jbc.M104936200	http://dx.doi.org/10.1074/jbc.M104936200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11395522	hybrid			2022-12-25	WOS:000170558000119
J	Shintani, T; Suzuki, K; Kamada, Y; Noda, T; Ohsumi, Y				Shintani, T; Suzuki, K; Kamada, Y; Noda, T; Ohsumi, Y			Apg2p functions in autophagosome formation on the perivacuolar structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; VACUOLE TARGETING PATHWAY; AMINOPEPTIDASE-I; CYTOPLASM; COMPLEX; SYSTEM; MACROAUTOPHAGY; APG7P/CVT2P; BIOGENESIS; COMPONENT	Autophagy is a degradative process in which cytoplasmic components are non-selectively sequestered by double-membrane structures, termed autophagosomes, and transported to the vacuole. We have identified and characterized a novel protein Apg2p essential for autophagy in yeast. Biochemical and fluorescence microscopic analyses indicate that Apg2p functions at the step of autophagosome formation. Apg2p localizes to some membranous structure distinct from any known organelle. Using fluorescent protein-tagged Apg2p, we showed that Apg2p localizes to a dot structure close to the vacuole, where Apg8p also exists, but not on autophagosomes unlike Apg8p. This punctate localization of Apg2p depends on the function of Apg1p kinase, phosphatidylinositol 3-kinase complex and Apg9p. Apg2p(G83E), encoded by an apg2-2 allele, shows a severely reduced activity of autophagy and a dispersed localization in the cytoplasm. Overexpression of the mutant Apg2p lessens the defect in autophagy. These results suggest that the dot structure is physiologically important. Apg2p and Apg8p are independently recruited to the structure but coordinately function there to form the autophagosome.	Natl Inst Basic Biol, Dept Cell Biol, Okazaki, Aichi 4448585, Japan; Grad Univ Adv Studies, Sch Life Sci, Dept Mol Biomech, Okazaki, Aichi 4448585, Japan	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Graduate University for Advanced Studies - Japan	Ohsumi, Y (corresponding author), Natl Inst Basic Biol, Dept Cell Biol, Okazaki, Aichi 4448585, Japan.		SHINTANI, Takahiro/ABE-1267-2020; Ohsumi, Yoshinori/C-6449-2009; Noda, Takeshi/B-7240-2008	Ohsumi, Yoshinori/0000-0003-2384-2166; Noda, Takeshi/0000-0003-3581-7961; Kamada, Yoshiaki/0000-0001-7395-660X; Shintani, Takahiro/0000-0001-6630-5892				Abeliovich H, 1999, EMBO J, V18, P6005, DOI 10.1093/emboj/18.21.6005; Abeliovich H, 2000, J CELL BIOL, V151, P1025, DOI 10.1083/jcb.151.5.1025; Baba M, 1997, J CELL BIOL, V139, P1687, DOI 10.1083/jcb.139.7.1687; Baba M, 1995, CELL STRUCT FUNCT, V20, P465, DOI 10.1247/csf.20.465; BABA M, 1994, J CELL BIOL, V124, P903, DOI 10.1083/jcb.124.6.903; Bryant NJ, 1998, MICROBIOL MOL BIOL R, V62, P230, DOI 10.1128/MMBR.62.1.230-247.1998; George MD, 2000, MOL BIOL CELL, V11, P969, DOI 10.1091/mbc.11.3.969; HAAS A, 1995, EMBO J, V14, P5258, DOI 10.1002/j.1460-2075.1995.tb00210.x; Harding TM, 1996, J BIOL CHEM, V271, P17621, DOI 10.1074/jbc.271.30.17621; Huang WP, 2000, J BIOL CHEM, V275, P5845, DOI 10.1074/jbc.275.8.5845; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; IRIE K, 1993, MOL CELL BIOL, V13, P3076, DOI 10.1128/MCB.13.5.3076; Jones EW., 1997, MOL CELLULAR BIOL YE, VIII, P363; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kamada Y, 2000, J CELL BIOL, V150, P1507, DOI 10.1083/jcb.150.6.1507; Kihara A, 2001, J CELL BIOL, V152, P519, DOI 10.1083/jcb.152.3.519; Kim J, 1999, MOL BIOL CELL, V10, P1337, DOI 10.1091/mbc.10.5.1337; Kim J, 2000, ANNU REV BIOCHEM, V69, P303, DOI 10.1146/annurev.biochem.69.1.303; Kim J, 2001, J CELL BIOL, V152, P51, DOI 10.1083/jcb.152.1.51; Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Mizushima N, 1999, EMBO J, V18, P3888, DOI 10.1093/emboj/18.14.3888; NODA T, 1995, BIOCHEM BIOPH RES CO, V210, P126, DOI 10.1006/bbrc.1995.1636; Noda T, 2000, J CELL BIOL, V148, P465, DOI 10.1083/jcb.148.3.465; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; Saiz JE, 1999, YEAST, V15, P155, DOI 10.1002/(SICI)1097-0061(19990130)15:2<155::AID-YEA342>3.0.CO;2-U; Sambrook J., 2002, MOL CLONING LAB MANU; Scott SV, 2000, J BIOL CHEM, V275, P25840, DOI 10.1074/jbc.M002813200; Scott SV, 1996, P NATL ACAD SCI USA, V93, P12304, DOI 10.1073/pnas.93.22.12304; Scott SV, 1997, J CELL BIOL, V138, P37, DOI 10.1083/jcb.138.1.37; Shintani T, 1999, EMBO J, V18, P5234, DOI 10.1093/emboj/18.19.5234; TAKESHIGE K, 1992, J CELL BIOL, V119, P301, DOI 10.1083/jcb.119.2.301; Tanida I, 1999, MOL BIOL CELL, V10, P1367, DOI 10.1091/mbc.10.5.1367; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; Wurmser AE, 2000, J CELL BIOL, V151, P551, DOI 10.1083/jcb.151.3.551	40	95	97	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30452	30460		10.1074/jbc.M102346200	http://dx.doi.org/10.1074/jbc.M102346200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11382761	hybrid			2022-12-25	WOS:000170558000111
J	Eto, M; Kitazawa, T; Yazawa, A; Mukai, H; Ono, Y; Brautigan, DL				Eto, M; Kitazawa, T; Yazawa, A; Mukai, H; Ono, Y; Brautigan, DL			Histamine-induced vasoconstriction involves phosphorylation of a specific inhibitor protein for myosin phosphatase by protein kinase C alpha and delta isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN PHOSPHATASE; VASCULAR SMOOTH-MUSCLE; SULFATE-POLYACRYLAMIDE GEL; RHO-KINASE; CA2+ SENSITIZATION; CALCIUM SENSITIZATION; SIGNAL-TRANSDUCTION; ANGIOTENSIN-II; IN-VIVO; ACTIVATION	Histamine stimulus triggers inhibition of myosin phosphatase-enhanced phosphorylation of myosin and contraction of vascular smooth muscle. In response to histamine stimulation of intact femoral artery, a smooth muscle-specific protein called CPI-17 (for protein kinase C-potentiated inhibitory protein for heterotrimeric myosin light chain phosphatase of 17 kDa) is phosphorylated and converted to a potent inhibitor for myosin phosphatase. Phosphorylation of CPI-17 is diminished by pretreatment with either Y27632 or GF109203x, suggesting involvement of multiple kinases (Kitazawa, T., Eto, M., Woodsome, T. P., and Brautigan, D. L. (2000) J. Biol. Chem. 275, 9897-9900). Here we purified and identified CPI-17 kinases endogenous to pig artery that phosphorylate CPI-17. DEAE-Toyopearl column chromatography of aorta extracts separated two CPI-17 kinases. One kinase was protein kinase C (PKC) alpha, and the second kinase was purified to homogeneity as a 45-kDa protein, and identified by sequencing as PKC delta. Purified PKC delta was 3-fold more reactive with CPI-17 compared with myelin basic protein, whereas purified PKC alpha and recombinant RhoA-activated kinases (Rho-associated coiled-coil forming protein Ser/Thr kinase and protein kinase N) showed equal activity with CPI-17 and myelin basic protein. Y27632 inhibited CPI-17 phosphorylation by purified PKC delta with IC50 of 0.6 mum (in the presence of 0.1 mm ATP) or 14 mum (2.0 mm ATP). Y27632 significantly suppressed CPI-17 phosphorylation in smooth muscle cells, and the contraction of permeabilized rabbit femoral artery induced by stimulation with phorbol ester. GF109203x inhibited phorbol ester-induced contraction of rabbit femoral artery by 80%, whereas a PKC alpha/beta inhibitor, Go6976, reduced contraction by 47%. The results imply that histamine stimulation elicits contraction of vascular smooth muscle through activation of PKCa and especially PKC delta to phosphorylate CPI-17.	Univ Virginia, Sch Med, Ctr Cell Signaling, Charlottesville, VA 22908 USA; Georgetown Univ, Sch Med, Dept Physiol & Biophys, Washington, DC 20007 USA; Hokkaido Univ, Grad Sch Sci, Div Chem, Sapporo, Hokkaido 0600810, Japan; Kobe Univ, Biosignal Res Ctr, Kobe, Hyogo 6578501, Japan	University of Virginia; Georgetown University; Hokkaido University; Kobe University	Eto, M (corresponding author), Univ Virginia, Sch Med, Ctr Cell Signaling, Box 800577,MSB7225, Charlottesville, VA 22908 USA.	me2h@virginia.edu	Eto, Masumi/ABE-4700-2020	Eto, Masumi/0000-0002-0651-5836; Mukai, Hideyuki/0000-0002-0167-8695	NCI NIH HHS [CA40042] Funding Source: Medline; NHLBI NIH HHS [HL51824] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051824] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abedi H, 1998, FEBS LETT, V427, P209, DOI 10.1016/S0014-5793(98)00427-X; ASSENDER JW, 1994, FEBS LETT, V342, P76, DOI 10.1016/0014-5793(94)80588-1; DIANOUX AC, 1989, BIOCHEMISTRY-US, V28, P424, DOI 10.1021/bi00428a003; DIXON BS, 1994, AM J PHYSIOL, V266, pC1406, DOI 10.1152/ajpcell.1994.266.5.C1406; Eto M, 1997, FEBS LETT, V410, P356, DOI 10.1016/S0014-5793(97)00657-1; ETO M, 1995, J BIOCHEM, V118, P1104, DOI 10.1093/oxfordjournals.jbchem.a124993; Eto M, 2000, CELL MOTIL CYTOSKEL, V46, P222, DOI 10.1002/1097-0169(200007)46:3<222::AID-CM6>3.3.CO;2-2; Feng JH, 1999, J BIOL CHEM, V274, P37385, DOI 10.1074/jbc.274.52.37385; Feng JH, 1999, J BIOL CHEM, V274, P3744, DOI 10.1074/jbc.274.6.3744; FRIEDENAUER S, 1989, ANAL BIOCHEM, V178, P263, DOI 10.1016/0003-2697(89)90636-2; Fu XH, 1998, FEBS LETT, V440, P183, DOI 10.1016/S0014-5793(98)01455-0; Fujihara H, 1997, MOL BIOL CELL, V8, P2437, DOI 10.1091/mbc.8.12.2437; Gong MC, 1996, P NATL ACAD SCI USA, V93, P1340, DOI 10.1073/pnas.93.3.1340; Gong MC, 1997, J BIOL CHEM, V272, P10704; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Hamaguchi T, 2000, BIOCHEM BIOPH RES CO, V274, P825, DOI 10.1006/bbrc.2000.3225; Hartshorne DJ, 1998, J MUSCLE RES CELL M, V19, P325, DOI 10.1023/A:1005385302064; Hill SJ, 1997, PHARMACOL REV, V49, P253; HIRATA K, 1992, J BIOL CHEM, V267, P8719; Ichikawa K, 1996, J BIOL CHEM, V271, P4733; Iizuka K, 1999, BRIT J PHARMACOL, V128, P925, DOI 10.1038/sj.bjp.0702864; Ishizaki T, 2000, MOL PHARMACOL, V57, P976; ITOH H, 1993, AM J PHYSIOL, V265, pC1319; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; Kamm KE, 2001, J BIOL CHEM, V276, P4527, DOI 10.1074/jbc.R000028200; Kawano Y, 1999, J CELL BIOL, V147, P1023, DOI 10.1083/jcb.147.5.1023; KHALIL RA, 1992, AM J PHYSIOL, V263, pC714, DOI 10.1152/ajpcell.1992.263.3.C714; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kitazawa T, 1999, J PHYSIOL-LONDON, V520, P139, DOI 10.1111/j.1469-7793.1999.00139.x; Kitazawa T, 2000, J BIOL CHEM, V275, P9897, DOI 10.1074/jbc.275.14.9897; KITAZAWA T, 1989, J BIOL CHEM, V264, P5339; Koyama M, 2000, FEBS LETT, V475, P197, DOI 10.1016/S0014-5793(00)01654-9; KUBOTA Y, 1992, AM J PHYSIOL, V262, pC405, DOI 10.1152/ajpcell.1992.262.2.C405; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Le YH, 1999, J PHYSIOL-LONDON, V517, P709, DOI 10.1111/j.1469-7793.1999.0709s.x; Li L, 1998, J PHYSIOL-LONDON, V508, P871, DOI 10.1111/j.1469-7793.1998.871bp.x; MacDonald JA, 2001, P NATL ACAD SCI USA, V98, P2419, DOI 10.1073/pnas.041331498; MacDonald JA, 2001, FEBS LETT, V493, P91, DOI 10.1016/S0014-5793(01)02277-3; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MASUO M, 1994, J GEN PHYSIOL, V104, P265, DOI 10.1085/jgp.104.2.265; Nagumo H, 2000, AM J PHYSIOL-CELL PH, V278, pC57, DOI 10.1152/ajpcell.2000.278.1.C57; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; NISHIMURA J, 1988, BIOCHEM BIOPH RES CO, V157, P677, DOI 10.1016/S0006-291X(88)80303-6; PORZIO MA, 1977, BIOCHIM BIOPHYS ACTA, V490, P27, DOI 10.1016/0005-2795(77)90102-7; Senba S, 1999, J BIOCHEM-TOKYO, V125, P354, DOI 10.1093/oxfordjournals.jbchem.a022294; Somlyo AP, 1998, ACTA PHYSIOL SCAND, V164, P437; Somlyo AP, 2000, J PHYSIOL-LONDON, V522, P177, DOI 10.1111/j.1469-7793.2000.t01-2-00177.x; Sward K, 2000, J PHYSIOL-LONDON, V522, P33, DOI 10.1111/j.1469-7793.2000.0033m.x; Takahashi M, 1998, P NATL ACAD SCI USA, V95, P11566, DOI 10.1073/pnas.95.20.11566; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TRINKLEMULCAHY L, 1995, J BIOL CHEM, V270, P18191, DOI 10.1074/jbc.270.31.18191; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Walsh AH, 1997, FEBS LETT, V416, P230, DOI 10.1016/S0014-5793(97)01210-6; Walsh MP, 1996, BIOCHEM CELL BIOL, V74, P485, DOI 10.1139/o96-053; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335; WOODSOME TP, 2001, IN PRESS J PHYSL	56	180	183	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29072	29078		10.1074/jbc.M103206200	http://dx.doi.org/10.1074/jbc.M103206200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11397799	hybrid			2022-12-25	WOS:000170346000060
J	Poyet, JL; Srinivasula, SM; Tnani, M; Razmara, M; Fernandes-Alnemri, T; Alnemri, ES				Poyet, JL; Srinivasula, SM; Tnani, M; Razmara, M; Fernandes-Alnemri, T; Alnemri, ES			Identification of Ipaf, a human caspase-1-activating protein related to Apaf-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; CYTOCHROME-C; CYSTEINE PROTEASE; MICE DEFICIENT; FAMILY-MEMBER; ACTIVATION; ENZYME; OLIGOMERIZATION; PROCASPASE-9; EXPRESSION	Procaspase-9 contains an NH2-terminal caspase-associated recruitment domain (CARD), which is essential for direct association with Apaf-1 and activation. Procaspase-1 also contains an NH2-terminal CARD domain, suggesting that its mechanism of activation, like that of procaspase-9, involves association with an Apaf-1-related molecule. Here we describe the identification of a human Apaf-1-related protein, named Ipaf that contains an NH2-terminal CARD domain, a central nucleotide-binding domain, and a COOH-terminal regulatory leucine-rich repeat domain (LRR). Ipaf associates directly and specifically with the CARD domain of procaspase-1 through CARD-CARD interaction. A constitutively active Ipaf lacking its COOH-terminal LRR domain can induce autocatalytic processing and activation of procaspase-1 and caspase-1-dependent apoptosis in transfected cells. Our results suggest that Ipaf is a specific and direct activator of procaspase-1 and could be involved in activation of caspase-1 in response to pro-inflammatory and apoptotic stimuli.	Thomas Jefferson Univ, Kimmel Canc Inst, Ctr Apoptosis Res, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Alnemri, ES (corresponding author), Thomas Jefferson Univ, Kimmel Canc Inst, Ctr Apoptosis Res, Bluemle Life Sci Bldg,Rm 904,233 S 10th St, Philadelphia, PA 19107 USA.	E_Alnemri@lac.jci.tju.edu	Alnemri, Emad S/B-4526-2010; Poyet, Jean-Luc/G-7114-2017	Poyet, Jean-Luc/0000-0002-3747-255X	NATIONAL INSTITUTE ON AGING [R01AG014357] Funding Source: NIH RePORTER; NIA NIH HHS [AG14357] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ahmad M, 1997, CANCER RES, V57, P615; ALNEMRI ES, 1995, J BIOL CHEM, V270, P4312, DOI 10.1074/jbc.270.9.4312; Benedict MA, 2000, J BIOL CHEM, V275, P8461, DOI 10.1074/jbc.275.12.8461; Bertin J, 1999, J BIOL CHEM, V274, P12955, DOI 10.1074/jbc.274.19.12955; DRUILHE A, 2001, IN PRESS CELL DEATH; Ghayur T, 1997, NATURE, V386, P619, DOI 10.1038/386619a0; Hengartner MO, 1996, CURR OPIN GENET DEV, V6, P34, DOI 10.1016/S0959-437X(96)90007-6; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Horvitz HR, 1999, CANCER RES, V59, p1701S; Humke EW, 2000, CELL, V103, P99, DOI 10.1016/S0092-8674(00)00108-2; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Inohara N, 1998, J BIOL CHEM, V273, P12296, DOI 10.1074/jbc.273.20.12296; KOBE B, 1995, CURR OPIN STRUC BIOL, V5, P409, DOI 10.1016/0959-440X(95)80105-7; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; Metzstein MM, 1998, TRENDS GENET, V14, P410, DOI 10.1016/S0168-9525(98)01573-X; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Siegel RM, 1998, J CELL BIOL, V141, P1243, DOI 10.1083/jcb.141.5.1243; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Thome M, 1998, CURR BIOL, V8, P885, DOI 10.1016/S0960-9822(07)00352-1; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; Yang XL, 1998, SCIENCE, V281, P1355, DOI 10.1126/science.281.5381.1355; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	31	329	343	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28309	28313		10.1074/jbc.C100250200	http://dx.doi.org/10.1074/jbc.C100250200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11390368	hybrid			2022-12-25	WOS:000170093400076
J	Reddy, KB; Bialkowska, K; Fox, JEB				Reddy, KB; Bialkowska, K; Fox, JEB			Dynamic modulation of cytoskeletal proteins linking integrins to signaling complexes in spreading cells - Role of skelemin in initial integrin-induced spreading	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; FOCAL ADHESION KINASE; CYTOPLASMIC DOMAIN MUTANTS; BETA(3) SUBUNIT; ALPHA-ACTININ; GPIIB-IIIA; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; MEDIATED ACTIVATION; CALPAIN CLEAVAGE	Recently we showed that signaling across beta (3)-integrin leads to activation of calpain and formation of integrin clusters that are involved in Rac activation. The subsequent activation of Rac and Rho leads to the formation of focal complexes and focal adhesions, respectively. The goal of the present study was to determine whether different, proteins link the integrin to the cytoskeleton in the different complexes. We show that talin is present in focal adhesions but not in the calpain-induced clusters. alpha -Actinin colocalized with integrin at various sites, including the calpain-induced clusters. Skelemin, a protein shown recently to interact with beta (1)- and beta (3)-integrin in vitro, colocalized with integrin in calpain-induced clusters but was absent from focal adhesions. Cells transiently expressing skelemin C2 motifs, which contain the integrin binding site, failed to form integrin clusters or to spread on a substrate for beta (1)- and beta (3)-integrins. These results 1) suggest a dynamic reorganization of integrin complexes during cell spreading, 2) show that different cytoskeletal proteins link integrins in different complexes, and 3) demonstrate that skelemin is responsible for linking integrin to the calpain-induced clusters, and 4) show that the integrin-skelemin interaction is essential for transmission of signals leading to the initial steps of cell spreading.	Cleveland Clin Fdn, Lerner Res Inst, Joseph J Jacobs Ctr Thrombosis & Vasc Biol NB5, Dept Mol Cardiol, Cleveland, OH 44195 USA; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Case Western Reserve University	Fox, JEB (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Joseph J Jacobs Ctr Thrombosis & Vasc Biol NB5, Dept Mol Cardiol, 9500 Euclid Ave, Cleveland, OH 44195 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056264, R23HL030657, R37HL030657, R01HL030657] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30657, HL56264] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Auerbach D, 1999, MOL BIOL CELL, V10, P1297, DOI 10.1091/mbc.10.5.1297; Belkin AM, 1998, J BIOL CHEM, V273, P15234, DOI 10.1074/jbc.273.24.15234; Bialkowska K, 2000, J CELL BIOL, V151, P685, DOI 10.1083/jcb.151.3.685; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; CHEN WT, 1982, J CELL BIOL, V95, P205, DOI 10.1083/jcb.95.1.205; CHRZANOWSKAWODNICKA M, 1992, BIOESSAYS, V14, P777, DOI 10.1002/bies.950141110; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; Cooray P, 1996, BIOCHEM J, V318, P41, DOI 10.1042/bj3180041; DU XP, 1995, J BIOL CHEM, V270, P26146, DOI 10.1074/jbc.270.44.26146; EARNEST JP, 1995, J BIOL CHEM, V270, P27259, DOI 10.1074/jbc.270.45.27259; FERAMISCO JR, 1979, P NATL ACAD SCI USA, V76, P3967, DOI 10.1073/pnas.76.8.3967; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; Fox J. E. B, 1999, CALPAIN PHARM TOXICO, P103; FOX JEB, 1983, J BIOL CHEM, V258, P9973; FOX JEB, 1993, J CELL BIOL, V120, P1501, DOI 10.1083/jcb.120.6.1501; FOX JEB, 1995, J CELL BIOCH B S, V19, pA136; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; GINSBERG MH, 1990, CELL DIFFER DEV, V32, P203, DOI 10.1016/0922-3371(90)90033-S; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; Harlow E., 1988, ANTIBODIES LAB MANUA; Huttenlocher A, 1997, J BIOL CHEM, V272, P32719, DOI 10.1074/jbc.272.52.32719; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Kaapa A, 1999, EXP CELL RES, V250, P524, DOI 10.1006/excr.1999.4533; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Knezevic I, 1996, J BIOL CHEM, V271, P16416, DOI 10.1074/jbc.271.27.16416; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; LaFlamme SE, 1996, SEMIN CANCER BIOL, V7, P111, DOI 10.1006/scbi.1996.0016; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lee JW, 2000, MOL BIOL CELL, V11, P1973, DOI 10.1091/mbc.11.6.1973; LEWIS JM, 1995, MOL BIOL CELL, V6, P151, DOI 10.1091/mbc.6.2.151; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; Lyman S, 1997, J BIOL CHEM, V272, P22538, DOI 10.1074/jbc.272.36.22538; Meredith J, 1998, J BIOL CHEM, V273, P19525, DOI 10.1074/jbc.273.31.19525; Meredith JE, 1996, ENDOCR REV, V17, P207, DOI 10.1210/er.17.3.207; MURACHI T, 1981, ADV ENZYME REGUL, V19, P407; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Norris FA, 1997, J BIOL CHEM, V272, P10987; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; OTEY CA, 1993, J BIOL CHEM, V268, P21193; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; OTOOLE TE, 1995, J BIOL CHEM, V270, P8553, DOI 10.1074/jbc.270.15.8553; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; OTOOLE TE, 1989, BLOOD, V74, P14; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; Patil S, 1999, J BIOL CHEM, V274, P28575, DOI 10.1074/jbc.274.40.28575; Pfaff M, 1999, FEBS LETT, V460, P17, DOI 10.1016/S0014-5793(99)01250-8; PHILLIPS DR, 1988, BLOOD, V71, P831; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; PRICE MG, 1987, J CELL BIOL, V104, P1325, DOI 10.1083/jcb.104.5.1325; PRICE MG, 1993, J BIOL CHEM, V268, P21800; Reddy KB, 1998, J BIOL CHEM, V273, P35039, DOI 10.1074/jbc.273.52.35039; SAMUELSSON SJ, 1993, J CELL BIOL, V122, P485, DOI 10.1083/jcb.122.2.485; Sastry SK, 1999, J CELL BIOL, V144, P1295, DOI 10.1083/jcb.144.6.1295; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; TAPLEY P, 1989, ONCOGENE, V4, P325; Whitlock BB, 2000, J CELL BIOL, V151, P1305, DOI 10.1083/jcb.151.6.1305; YLANNE J, 1995, J BIOL CHEM, V270, P9550; YLANNE J, 1991, Journal of Cell Biology, V115, p132A	63	26	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28300	28308		10.1074/jbc.M102794200	http://dx.doi.org/10.1074/jbc.M102794200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11382766	hybrid			2022-12-25	WOS:000170093400075
J	Fukuda, M; Saegusa, C; Kanno, E; Mikoshiba, K				Fukuda, M; Saegusa, C; Kanno, E; Mikoshiba, K			The C2A domain of double C2 protein gamma contains a functional nuclear localization signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-DEPENDENT OLIGOMERIZATION; PHOSPHOLIPID-BINDING; SYNAPTIC VESICLE; SYNAPTOTAGMIN-I; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; DOC2; FAMILY; EXOCYTOSIS; ISOFORMS	The C2 domain was originally defined as a homologous domain to the C2 regulatory region of Ca2+-dependent protein kinase C and has been identified in more than 50 different signaling molecules. The original C2 domain of protein kinase C alpha functions as a Ca2+ binding module, and the Ca2+ binding to the C2 domain allows translocation of proteins to phospholipid membranes. By contrast, however, some C2 domains do not exhibit Ca2+ binding activity because of amino acid substitutions at Ca2+-binding sites, and their physiological meanings remain largely unknown. In this study, we discovered an unexpected function of the Ca2+-independent C2A domain of double C2 protein gamma (Doc2 gamma) in nuclear localization. Deletion and mutation analyses revealed that the putative Ca2+ binding loop 3 of Doc2 gamma contains six Arg residues ((RLRRRRR183)-R-177) and that this basic cluster is both necessary and sufficient for nuclear localization of Doc2 gamma. Because of the presence of the basic cluster, the C2A domain of Doc2 gamma did not show Ca2+ dependent phospholipid binding activity. Our findings indicate that by changing the nature of the putative Ca2+ binding loops the C2 domain has more diversified function in cellular signaling than a simple Ca2+ binding moth.	RIKEN, Inst Phys & Chem Res, Dev Neurobiol Lab, Brain Sci Inst, Wako, Saitama 3510198, Japan; Univ Tokyo, Inst Med Sci, Dept Basic Med Sci, Div Mol Neurobiol,Minato Ku, Tokyo 1088639, Japan	RIKEN; University of Tokyo	Fukuda, M (corresponding author), RIKEN, Inst Phys & Chem Res, Dev Neurobiol Lab, Brain Sci Inst, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	mnfukuda@brain.riken.go.jp	Mikoshiba, Katsuhiko/N-7943-2015; Fukuda, MItsunori/I-1511-2015	Fukuda, MItsunori/0000-0002-8620-5853				CHAPMAN ER, 1994, J BIOL CHEM, V269, P5735; Chapman ER, 1998, J BIOL CHEM, V273, P32966, DOI 10.1074/jbc.273.49.32966; Damer CK, 1996, J NEUROCHEM, V67, P1661; DAVIETOV BA, 1993, J BIOL CHEM, V268, P26386; Duncan RR, 2000, BIOCHIMIE, V82, P421, DOI 10.1016/S0300-9084(00)00214-5; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; Fukuda M, 2000, BIOCHEM BIOPH RES CO, V276, P626, DOI 10.1006/bbrc.2000.3520; Fukuda M, 2000, J BIOL CHEM, V275, P28180; Fukuda M, 1997, BIOESSAYS, V19, P593, DOI 10.1002/bies.950190710; Fukuda M, 1999, J BIOL CHEM, V274, P31421, DOI 10.1074/jbc.274.44.31421; Fukuda M, 1999, J BIOL CHEM, V274, P31428, DOI 10.1074/jbc.274.44.31428; Fukuda M, 1996, J BIOL CHEM, V271, P8430, DOI 10.1074/jbc.271.14.8430; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; FUKUDA M, 1995, J BIOL CHEM, V270, P26523, DOI 10.1074/jbc.270.44.26523; Fukuda M, 1997, BIOCHEM J, V323, P421, DOI 10.1042/bj3230421; Fukuda M, 2001, BIOCHEM J, V354, P249, DOI 10.1042/0264-6021:3540249; Fukuda M, 2001, BIOCHEM BIOPH RES CO, V281, P1226, DOI 10.1006/bbrc.2001.4512; Fukuda M, 2000, J BIOCHEM, V128, P637, DOI 10.1093/oxfordjournals.jbchem.a022796; Ibata K, 1998, J BIOL CHEM, V273, P12267, DOI 10.1074/jbc.273.20.12267; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; Kojima T, 1996, J BIOCHEM-TOKYO, V120, P671; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; Lin RC, 2000, ANNU REV CELL DEV BI, V16, P19, DOI 10.1146/annurev.cellbio.16.1.19; Marqueze B, 2000, BIOCHIMIE, V82, P409, DOI 10.1016/S0300-9084(00)00220-0; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Mizutani A, 2000, J BIOL CHEM, V275, P9823, DOI 10.1074/jbc.275.13.9823; Mochida S, 1998, P NATL ACAD SCI USA, V95, P11418, DOI 10.1073/pnas.95.19.11418; Naito A, 1997, MOL BRAIN RES, V44, P198, DOI 10.1016/S0169-328X(96)00198-2; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Orita S, 1997, J BIOL CHEM, V272, P16081, DOI 10.1074/jbc.272.26.16081; ORITA S, 1995, BIOCHEM BIOPH RES CO, V206, P439, DOI 10.1006/bbrc.1995.1062; Orita S, 1996, J BIOL CHEM, V271, P7257, DOI 10.1074/jbc.271.13.7257; Osborne SL, 1999, J BIOL CHEM, V274, P59, DOI 10.1074/jbc.274.1.59; Ponting CP, 1996, PROTEIN SCI, V5, P162; Sakaguchi G, 1995, BIOCHEM BIOPH RES CO, V217, P1053, DOI 10.1006/bbrc.1995.2876; Sakaguchi G, 1999, EUR J NEUROSCI, V11, P4262, DOI 10.1046/j.1460-9568.1999.00855.x; SCHIAVO G, 1995, NATURE, V378, P733, DOI 10.1038/378733a0; Schiavo G, 1998, BIOCHEM BIOPH RES CO, V248, P1, DOI 10.1006/bbrc.1998.8527; Schiavo G, 1997, P NATL ACAD SCI USA, V94, P997, DOI 10.1073/pnas.94.3.997; Schivell AE, 1996, J BIOL CHEM, V271, P27770, DOI 10.1074/jbc.271.44.27770; Sheng ZH, 1997, P NATL ACAD SCI USA, V94, P5405, DOI 10.1073/pnas.94.10.5405; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; Sugita S, 1996, J BIOL CHEM, V271, P1262, DOI 10.1074/jbc.271.3.1262; Sutton RB, 1999, J CELL BIOL, V147, P589, DOI 10.1083/jcb.147.3.589; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; Ubach J, 1998, EMBO J, V17, P3921, DOI 10.1093/emboj/17.14.3921; Verhage M, 1997, NEURON, V18, P453, DOI 10.1016/S0896-6273(00)81245-3; Wang J, 1999, J BIOL CHEM, V274, P28542, DOI 10.1074/jbc.274.40.28542; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	53	18	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24441	24444		10.1074/jbc.C100119200	http://dx.doi.org/10.1074/jbc.C100119200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11371549	hybrid			2022-12-25	WOS:000169800700003
J	Koh, YH; Suzuki, K; Che, WY; Park, YS; Miyamoto, Y; Higashiyama, S; Taniguchi, N				Koh, YH; Suzuki, K; Che, WY; Park, YS; Miyamoto, Y; Higashiyama, S; Taniguchi, N			Inactivation of glutathione peroxidase by nitric oxide leads to the accumulation of H2O2 and the induction of HB-EGF via c-Jun NH2-terminal kinase in rat aortic smooth muscle cells	FASEB JOURNAL			English	Article						gluthathione peroxidase; nitric oxide; JNK; HB-EGF; apoptosis	NECROSIS-FACTOR-ALPHA; GROWTH-FACTOR; SUPEROXIDE-DISMUTASE; SURVIVAL FACTOR; UP-REGULATION; ACTIVATION; APOPTOSIS; PEROXYNITRITE; VASODILATORS; SUPPRESSION	We describe the effect of nitric oxide (NO) on the expression of the heparin-binding EGF-like growth factor (HB-EGF), a potent chemoattractant and mitogen for smooth muscle cells, and its anti-apoptotic effect against NO cytotoxicity. Previous studies have shown that glutathione peroxidase (GPx), a major peroxide scavenging enzyme is selectively inactivated by an NO donor, S-nitroso-N-acetyl-DL-penicillamine (SNAP), in vitro and in vivo and results in the accumulation of peroxide (6, 7). The SNAP or peroxynitrite induces HB-EGF through the inactivation of GPx and the accumulation of peroxide. This induction is accompanied by JNK and c-Jun/AP-1 activation. The blocking of the HB-EGF induction by curcumin, c-jun antisense oligonucleotide, and a dominant-negative mutant of JNK1 provides support for these results. A longer pretreatment of rat aortic smooth muscle cells (RASMCs) by SNAP induces HB-EGF and reduces the TNFalpha+actinomycin D-induced apoptosis. This protection is blocked by antisense HB-EGF s-oligonucleotide. These findings indicate that the induction of HB-EGF by NO would be an adaptive response as an autocrine protective factor against apoptosis by NO in RASMCs.	Osaka Univ, Sch Med, Dept Biochem, Suita, Osaka 5650871, Japan; Hyogo Med Univ, Dept Biochem, Nishinomiya, Hyogo, Japan	Osaka University; Hyogo College of Medicine; University of Hyogo	Taniguchi, N (corresponding author), Osaka Univ, Sch Med, Dept Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	proftani@biochem.med.osaka-u.ac.jp	Park, Yong Seek/ABG-6398-2021; Taniguchi, Naoyuki/I-4182-2014	Park, Yong Seek/0000-0002-9260-3102; Taniguchi, Naoyuki/0000-0001-5889-5968				Arkonac BM, 1998, J BIOL CHEM, V273, P4400, DOI 10.1074/jbc.273.8.4400; ASAHI M, 1995, J BIOL CHEM, V270, P21035, DOI 10.1074/jbc.270.36.21035; Asahi M, 1997, J BIOL CHEM, V272, P19152, DOI 10.1074/jbc.272.31.19152; Asakawa H, 1996, CELL BIOCHEM FUNCT, V14, P181; Beauchamp Charles, ANAL BIOCHEM, V44, P276, DOI [10.1016/0003-2697(71)90370-8, DOI 10.1016/0003-2697(71)90370-8]; Che WY, 1997, J BIOL CHEM, V272, P18453, DOI 10.1074/jbc.272.29.18453; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; Fukuo K, 1996, HYPERTENSION, V27, P823, DOI 10.1161/01.HYP.27.3.823; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; Go YM, 1999, AM J PHYSIOL-HEART C, V277, pH1647, DOI 10.1152/ajpheart.1999.277.4.H1647; GUNTHER S, 1982, J CELL BIOL, V92, P289, DOI 10.1083/jcb.92.2.289; Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; Horikawa M, 1999, FEBS LETT, V459, P100, DOI 10.1016/S0014-5793(99)01213-2; HUANG TS, 1991, P NATL ACAD SCI USA, V88, P5292, DOI 10.1073/pnas.88.12.5292; IGNARRO LJ, 1989, FASEB J, V3, P31, DOI 10.1096/fasebj.3.1.2642868; KARIYA K, 1989, ATHEROSCLEROSIS, V80, P143, DOI 10.1016/0021-9150(89)90022-1; KAYANOKI Y, 1994, J BIOL CHEM, V269, P15488; Kim YM, 1997, J BIOL CHEM, V272, P1402, DOI 10.1074/jbc.272.2.1402; Koppenol WH, 1996, METHOD ENZYMOL, V269, P296; LAWRENCE RA, 1976, BIOCHEM BIOPH RES CO, V71, P952, DOI 10.1016/0006-291X(76)90747-6; MAGRINAT G, 1992, BLOOD, V80, P1880; MIYAGAWA J, 1995, J CLIN INVEST, V95, P404, DOI 10.1172/JCI117669; Miyazaki Y, 1996, BIOCHEM BIOPH RES CO, V226, P542, DOI 10.1006/bbrc.1996.1391; Miyoshi E, 1997, J BIOL CHEM, V272, P14349, DOI 10.1074/jbc.272.22.14349; NAKAKI T, 1990, EUR J PHARM-MOLEC PH, V189, P347, DOI 10.1016/0922-4106(90)90031-R; NAKATA T, 1993, INT J CANCER, V55, P646, DOI 10.1002/ijc.2910550422; Nishio E, 1996, BIOCHEM BIOPH RES CO, V221, P163, DOI 10.1006/bbrc.1996.0563; Pascall JC, 2000, BBA-GENE STRUCT EXPR, V1492, P434, DOI 10.1016/S0167-4781(00)00123-8; Pollman MJ, 1996, CIRC RES, V79, P748, DOI 10.1161/01.RES.79.4.748; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; Schieke SM, 1999, FEBS LETT, V448, P301, DOI 10.1016/S0014-5793(99)00372-5; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Takemura T, 1997, J BIOL CHEM, V272, P31036, DOI 10.1074/jbc.272.49.31036; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	42	27	29	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 27	2001	15	6					1472	+		10.1096/fj.00-0572fje	http://dx.doi.org/10.1096/fj.00-0572fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387261				2022-12-25	WOS:000173705800006
J	Buschmann, T; Lerner, D; Lee, CG; Ronai, Z				Buschmann, T; Lerner, D; Lee, CG; Ronai, Z			The Mdm-2 amino terminus is required for Mdm2 binding and SUMO-1 conjugation by the E2 SUMO-1 conjugating enzyme Ubc9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-RELATED PROTEIN; TUMOR-SUPPRESSOR P53; COVALENT MODIFICATION; LIGASE ACTIVITY; C-JUN; YEAST; DEGRADATION; PATHWAY; SYSTEM; LOCALIZATION	Covalent attachment of SUMO-1 to Mdm2 requires the activation of a heterodimeric Aos1-Uba2 enzyme (ubiquitin-activating enzyme (El)) followed by the conjugation of Sumo-1 to Mdm2 by Ubc9, a protein with a strong sequence similarity to ubiquitin carrier proteins (E2s). Upon Sumo-1 conjugation, Mdm2 is protected from self-ubiquitination and elicits greater ubiquitin-protein isopeptide ligase (E3) activity toward p53, thereby increasing its oncogenic potential. Because of the biological implication of Mdm2 sumoylation, we mapped Ubc9 binding on Mdm2. Here we demonstrate that Ubc9 can associate with Mdm2 only if amino acids 40-59 within the N terminus of Mdm2 are present. Mdm2 from which amino acids 40-59 have been deleted can no longer be sumoylated. Furthermore, addition of a peptide that corresponds to amino acids 40-59 on Mdm2 to a sumoylation reaction efficiently inhibits Mdm2 sumoylation in vitro and in vivo. In UV-treated cells Mdm2 exhibits reduced association with Ubc9, which coincides with decreased Mdm2 sumoylation. Our findings regarding the association of Ubc9 with Mdm2, and the effect of UV-irradiation on Ubc9 binding, point to an additional level in the regulation of Mdm2 sumoylation under normal growth conditions as well as in response to stress conditions.	Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA; Univ Med & Dent New Jersey, Dept Biochem & Mol Biol, Newark, NJ 07013 USA	Icahn School of Medicine at Mount Sinai; Rutgers State University New Brunswick; Rutgers State University Medical Center	Ronai, Z (corresponding author), Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA.	zeev.ronai@mssm.edu		RONAI, ZEEV/0000-0002-3859-0400	NATIONAL CANCER INSTITUTE [R01CA059908] Funding Source: NIH RePORTER; NCI NIH HHS [CA59908] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Becker K, 1997, FEBS LETT, V412, P102, DOI 10.1016/S0014-5793(97)00758-8; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; Ciechanover A, 2000, J CELL BIOCHEM, P40; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Duprez E, 1999, J CELL SCI, V112, P381; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Firestein R, 1998, J BIOL CHEM, V273, P5892, DOI 10.1074/jbc.273.10.5892; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Gottlicher M, 1996, STEROIDS, V61, P257, DOI 10.1016/0039-128X(96)00032-3; Hahn SL, 1997, ONCOGENE, V15, P1489, DOI 10.1038/sj.onc.1201301; Hateboer G, 1996, J BIOL CHEM, V271, P25906, DOI 10.1074/jbc.271.42.25906; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643; Hofmann H, 2000, J VIROL, V74, P2510, DOI 10.1128/JVI.74.6.2510-2524.2000; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Hu G, 1997, GENE DEV, V11, P2701, DOI 10.1101/gad.11.20.2701; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Kamitani T, 1997, J BIOL CHEM, V272, P14001, DOI 10.1074/jbc.272.22.14001; Kawabe Y, 2000, J BIOL CHEM, V275, P20963, DOI 10.1074/jbc.C000273200; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lehembre F, 2000, MOL CELL BIOL, V20, P1072, DOI 10.1128/MCB.20.3.1072-1082.2000; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Liu Q, 1999, BIOCHEMISTRY-US, V38, P1415, DOI 10.1021/bi981840h; Liu Q, 1999, J BIOL CHEM, V274, P16979, DOI 10.1074/jbc.274.24.16979; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mao Y, 2000, J BIOL CHEM, V275, P26066, DOI 10.1074/jbc.M001831200; Mao Y, 2000, P NATL ACAD SCI USA, V97, P4046, DOI 10.1073/pnas.080536597; Masson M, 1997, GENE, V190, P287, DOI 10.1016/S0378-1119(97)00015-2; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; Mossessova E, 2000, MOL CELL, V5, P865, DOI 10.1016/S1097-2765(00)80326-3; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; Rangasamy D, 2000, J BIOL CHEM, V275, P30487, DOI 10.1074/jbc.M003898200; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Saitoh H, 1998, CURR BIOL, V8, P121, DOI 10.1016/S0960-9822(98)70044-2; Saitoh H, 1997, P NATL ACAD SCI USA, V94, P3736, DOI 10.1073/pnas.94.8.3736; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; Schwarz SE, 1998, P NATL ACAD SCI USA, V95, P560, DOI 10.1073/pnas.95.2.560; Shen ZY, 1996, GENOMICS, V37, P183, DOI 10.1006/geno.1996.0540; Sternsdorf T, 1999, J BIOL CHEM, V274, P12555, DOI 10.1074/jbc.274.18.12555; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Varshavsky A, 2000, BIOL CHEM, V381, P779, DOI 10.1515/BC.2000.101; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6	55	47	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 2	2001	276	44					40389	40395		10.1074/jbc.M103786200	http://dx.doi.org/10.1074/jbc.M103786200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	488FM	11384992	hybrid			2022-12-25	WOS:000171925600006
J	De Falco, S; Ruvoletto, MG; Verdoliva, A; Ruvo, M; Raucci, A; Marino, M; Senatore, S; Cassani, G; Alberti, A; Pontisso, P; Fassina, G				De Falco, S; Ruvoletto, MG; Verdoliva, A; Ruvo, M; Raucci, A; Marino, M; Senatore, S; Cassani, G; Alberti, A; Pontisso, P; Fassina, G			Cloning and expression of a novel hepatitis B virus-binding protein from HepG2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER PLASMA-MEMBRANES; ADULT HUMAN HEPATOCYTES; CARCINOMA ANTIGEN; PRES1 DOMAIN; HUMAN-SERUM; ANNEXIN-V; RECEPTOR; HBV; SERPIN; INHIBITOR	A direct involvement of the hepatitis B virus (HBV) preS1-(21-47) sequence in virus attachment to cell membrane receptor(s) and the presence on the plasma membranes of HepG2 cells of protein(s) with receptor activity for HBV have been suggested by many previous experiments. In this study, by using a tetravalent derivative of the preS1-(21-47) sequence, we have isolated by affinity chromatography from detergent-solubilized HepG2 plasma membranes a 44-kDa protein (HBV-binding protein; HBV-BP), which was found to closely correspond to the human squamous cell carcinoma antigen I (SCCA1), a member of the ovalbumin family of serine protease inhibitors. Comparison of SCCA1 sequence with the sequence of the corresponding HBV-BP cDNA, cloned by polymerase chain reaction starting from RNA poly(A)(+) fractions extracted from HepG2 cells, indicated the presence of only four nucleotide substitutions in the coding region, leading to three amino acid changes. Intact recombinant HBV-BP lacked inhibitory activity for serine proteases such as alpha -chymotrypsin and trypsin but inhibited with high potency cysteine proteases such as papain and cathepsin L. Direct binding experiments confirmed the interaction of recombinant HBV-BP with the HBV preS1 domain. HepG2 cells overexpressing HBV-BP after transfection of corresponding cDNA showed a virus binding capacity increased by 2 orders of magnitude compared with untransfected cells, while Chinese hamster ovary cells, which normally do not bind to HBV, acquired susceptibility to HBV binding after transfection. Native HBV particle entry was enhanced in transfected cells. Both recombinant HBV-BP and antibodies to recombinant HBV-BP blocked virus binding and internalization in transfected cells as well as in primary human helpatocytes in a dose-dependent manner. Our findings suggest that this protein plays a major role in HBV infection.	TECNOGEN SCpA, I-81015 Caserta, CE, Italy; Univ Padua, Dipartimento Med Clin & Sperimentale, Clin Med 5, I-35128 Padua, Italy	University of Padua	Fassina, G (corresponding author), TECNOGEN SCpA, Parco Sci, I-81015 Caserta, CE, Italy.	fassina@tecnogen.it	De Falco, Sandro/P-6724-2015; Fassina, Giorgio/I-7127-2012; Raucci, Angela/K-3722-2018; PONTISSO, PATRIZIA/K-3574-2018	Fassina, Giorgio/0000-0003-1845-2657; De Falco, Sandro/0000-0002-6501-1697; PONTISSO, PATRIZIA/0000-0003-2077-9202; Raucci, Angela/0000-0003-1333-9671; ALBERTI, ALFREDO/0000-0001-9926-2382				ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; BIBB JA, 1994, J VIROL, V68, P6111, DOI 10.1128/JVI.68.9.6111-6115.1994; BOLANDER FF, 1994, J CELL PHYSIOL, V161, P124, DOI 10.1002/jcp.1041610115; Breiner KM, 1998, J VIROL, V72, P8098, DOI 10.1128/JVI.72.10.8098-8104.1998; BUDKOWSKA A, 1993, J VIROL, V67, P4316, DOI 10.1128/JVI.67.7.4316-4322.1993; BURCHELL A, 1988, CLIN CHIM ACTA, V173, P183, DOI 10.1016/0009-8981(88)90256-2; De Falco S, 2001, J PEPT RES, V57, P390, DOI 10.1034/j.1399-3011.2001.00848.x; De Moliner L, 1998, GUT, V42, P856, DOI 10.1136/gut.42.6.856; FASSINA G, 1992, ARCH BIOCHEM BIOPHYS, V296, P137, DOI 10.1016/0003-9861(92)90555-B; FRANCO A, 1992, J EXP MED, V175, P1195, DOI 10.1084/jem.175.5.1195; FREISTADT MS, 1995, ANN NY ACAD SCI, V25, P37; GALLE PR, 1994, GASTROENTEROLOGY, V106, P664, DOI 10.1016/0016-5085(94)90700-5; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; Gong ZJ, 1999, HEPATOLOGY, V29, P576, DOI 10.1002/hep.510290238; GRIPON P, 1993, VIROLOGY, V192, P534, DOI 10.1006/viro.1993.1069; GUIDOTTI LG, 1995, J VIROL, V58, P945; HERTOGS K, 1993, VIROLOGY, V197, P549, DOI 10.1006/viro.1993.1628; HUBBARD AL, 1983, J CELL BIOL, V96, P217, DOI 10.1083/jcb.96.1.217; HUNT LT, 1980, BIOCHEM BIOPH RES CO, V95, P864, DOI 10.1016/0006-291X(80)90867-0; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; HWANG SR, 1994, P NATL ACAD SCI USA, V74, P5463; KATO H, 1977, CANCER, V40, P1621, DOI 10.1002/1097-0142(197710)40:4<1621::AID-CNCR2820400435>3.0.CO;2-I; Kato H., 1992, SEROLOGICAL CANC MAR, P437; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; Mabit H, 1996, J HEPATOL, V24, P403, DOI 10.1016/S0168-8278(96)80160-7; MANTERO G, 1991, CLIN CHEM, V37, P422; MARSH M, 1989, ADV VIRUS RES, V36, P107, DOI 10.1016/S0065-3527(08)60583-7; MEHDI H, 1994, J VIROL, V68, P2415, DOI 10.1128/JVI.68.4.2415-2424.1994; MILLER RH, 1984, VIROLOGY, V137, P390, DOI 10.1016/0042-6822(84)90231-9; Nagai Yoshiyuki, 1993, Trends in Microbiology, V1, P81, DOI 10.1016/0966-842X(93)90112-5; Nawata S, 1997, ELECTROPHORESIS, V18, P784, DOI 10.1002/elps.1150180521; NAWATA S, 1995, ELECTROPHORESIS, V16, P1027, DOI 10.1002/elps.11501601173; NEURATH AR, 1986, CELL, V46, P429, DOI 10.1016/0092-8674(86)90663-X; NEURATH AR, 1994, VIROLOGY, V204, P475, DOI 10.1006/viro.1994.1558; NEURATH AR, 1990, VIROLOGY, V178, P631, DOI 10.1016/0042-6822(90)90368-2; NEURATH AR, 1992, J EXP MED, V176, P1561, DOI 10.1084/jem.176.6.1561; NEURATH AR, 1985, NATURE, V315, P154, DOI 10.1038/315154a0; NEURATH AR, 1992, J EXP MED, V175, P461, DOI 10.1084/jem.175.2.461; PONTISSO P, 1993, GASTROENTEROLOGY, V105, P1529, DOI 10.1016/0016-5085(93)90161-5; PONTISSO P, 1992, J GEN VIROL, V73, P2041, DOI 10.1099/0022-1317-73-8-2041; PONTISSO P, 1985, J MED VIROL, V17, P145, DOI 10.1002/jmv.1890170207; PONTISSO P, 1989, J VIROL, V63, P1981, DOI 10.1128/JVI.63.5.1981-1988.1989; PONTISSO P, 1989, VIROLOGY, V173, P522, DOI 10.1016/0042-6822(89)90564-3; QIAO M, 1994, VIROLOGY, V201, P356, DOI 10.1006/viro.1994.1301; REMOLDODONNELL E, 1993, FEBS LETT, V315, P105, DOI 10.1016/0014-5793(93)81143-N; RIJNTJES PJM, 1986, J HEPATOL, V3, P7, DOI 10.1016/S0168-8278(86)80140-4; ROJKIND M, 1980, J CELL BIOL, V87, P255, DOI 10.1083/jcb.87.1.255; RUVO M, 1999, PEPTIDES, V97, P537; Ryu CJ, 2000, J VIROL, V74, P110, DOI 10.1128/JVI.74.1.110-116.2000; Schick C, 1997, J BIOL CHEM, V272, P1849, DOI 10.1074/jbc.272.3.1849; SCHNEIDER SS, 1995, P NATL ACAD SCI USA, V92, P3147, DOI 10.1073/pnas.92.8.3147; SHIH CH, 1989, P NATL ACAD SCI USA, V86, P6323, DOI 10.1073/pnas.86.16.6323; SINCLAIR AJ, 1995, J VIROL, V69, P5461, DOI 10.1128/JVI.69.9.5461-5468.1995; SUMINAMI Y, 1991, BIOCHEM BIOPH RES CO, V181, P51, DOI 10.1016/S0006-291X(05)81380-4; SUREAU C, 1986, CELL, V47, P37, DOI 10.1016/0092-8674(86)90364-8; TAKEDA A, 1995, FEBS LETT, V359, P78, DOI 10.1016/0014-5793(94)01456-B; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; Tong SP, 1999, J VIROL, V73, P8696, DOI 10.1128/JVI.73.10.8696-8702.1999; TREICHEL U, 1994, J GEN VIROL, V75, P3021, DOI 10.1099/0022-1317-75-11-3021; Uemura Y, 2000, INT J CANCER, V89, P368, DOI 10.1002/1097-0215(20000720)89:4<368::AID-IJC9>3.0.CO;2-6	60	62	64	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36613	36623		10.1074/jbc.M102377200	http://dx.doi.org/10.1074/jbc.M102377200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11389143	hybrid			2022-12-25	WOS:000171194500075
J	Das, D; Scovell, WM				Das, D; Scovell, WM			The binding interaction of HMG-1 with the TATA-binding protein/TATA complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOBILITY-GROUP PROTEIN-1; RNA-POLYMERASE-II; GROUP CHROMOSOMAL-PROTEINS; N-TERMINAL DOMAIN; TRANSCRIPTION FACTOR; DNA-BINDING; FUNCTIONAL DOMAINS; CORE DOMAIN; BOX DOMAINS; IN-VITRO	High mobility protein-1 (HMG-1) has been shown to regulate transcription by RNA polymerase II. In the context that it acts as a transcriptional repressor, it binds to the TATA-binding protein (TBP) to form the HMG-1/ TBP/TATA complex, which is proposed to inhibit the assembly of the preinitiation complex. By using electrophoretic mobility shift assays, we show that the acidic C-terminal domain of HMG-1 and the N terminus of human TBP are the domains that are essential for the formation of a stable HMG-1/TBP/TATA complex. HMG-1 binding increases the affinity of TBP for the TATA element by 20-fold, which is reflected in a significant stimulation of the rate of TBP binding, with little effect on the dissociation rate constant. In support of the binding target of HMG-1 being the N terminus of hTBP, the N-terminal polypeptide of human TBP competes with and inhibits HMG-1/TBP/TATA complex formation. Deletion of segments of the N terminus of human TBP was used to map the region(s) where HMG-1 binds. These findings indicate that interaction of HMG-1 with the Q-tract (amino acids 55-95) in hTBP is primarily responsible for stable complex formation. In addition, HMG-1 and the monoclonal antibody, 1C2, specific to the Q-tract, compete for the same site. Furthermore, calf thymus HMG-1 forms a stable complex with the TBP/TATA complex that contains TBP from either human or Drosophila but not yeast. This is again consistent with the importance of the Q-tract for this stable interaction and shows that the interaction extends over many species but does not include yeast TBP.	Bowling Green State Univ, Dept Chem, Bowling Green, OH 43403 USA; Bowling Green State Univ, Dept Biol Sci, Bowling Green, OH 43403 USA	University System of Ohio; Bowling Green State University; University System of Ohio; Bowling Green State University	Scovell, WM (corresponding author), Bowling Green State Univ, Dept Chem, Bowling Green, OH 43403 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM054357] Funding Source: NIH RePORTER; NIGMS NIH HHS [R15GM54357] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIANCHI ME, 1992, EMBO J, V11, P1055, DOI 10.1002/j.1460-2075.1992.tb05144.x; Boonyaratanakornkit V, 1998, MOL CELL BIOL, V18, P4471, DOI 10.1128/MCB.18.8.4471; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; Bustin M, 1999, MOL CELL BIOL, V19, P5237; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; Carrozza MJ, 1998, J VIROL, V72, P6752, DOI 10.1128/JVI.72.8.6752-6757.1998; Ellwood KB, 2000, MOL CELL BIOL, V20, P4359, DOI 10.1128/MCB.20.12.4359-4370.2000; Fry CJ, 1999, J BIOL CHEM, V274, P29583, DOI 10.1074/jbc.274.42.29583; GE H, 1994, J BIOL CHEM, V269, P17136; Grasser KD, 1998, EUR J BIOCHEM, V253, P787, DOI 10.1046/j.1432-1327.1998.2530787.x; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HASHIMOTO S, 1992, NUCLEIC ACIDS RES, V20, P3788, DOI 10.1093/nar/20.14.3788; Henry RW, 1998, COLD SPRING HARB SYM, V63, P111, DOI 10.1101/sqb.1998.63.111; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; Hoffmann A, 1997, P NATL ACAD SCI USA, V94, P8928, DOI 10.1073/pnas.94.17.8928; HOFFMANN A, 1990, GENE DEV, V4, P1141, DOI 10.1101/gad.4.7.1141; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; HORIKOSHI M, 1990, CELL, V61, P1171, DOI 10.1016/0092-8674(90)90681-4; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; IMBALZANO AN, 1994, J BIOL CHEM, V269, P8280; Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; LANDSMAN D, 1993, BIOESSAYS, V15, P539, DOI 10.1002/bies.950150807; LEE DK, 1992, MOL CELL BIOL, V12, P5189, DOI 10.1128/MCB.12.11.5189; LESCURE A, 1994, EMBO J, V13, P1166, DOI 10.1002/j.1460-2075.1994.tb06366.x; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; Lu W, 2000, J BIOL CHEM, V275, P35006, DOI 10.1074/jbc.M004735200; MAJUMDAR A, 1991, NUCLEIC ACIDS RES, V19, P6643, DOI 10.1093/nar/19.23.6643; MAREKOV LN, 1984, BIOCHIM BIOPHYS ACTA, V789, P63, DOI 10.1016/0167-4838(84)90061-X; Mittal V, 1997, SCIENCE, V275, P1136, DOI 10.1126/science.275.5303.1136; NAKASHIMA K, 1995, GENE, V152, P209, DOI 10.1016/0378-1119(94)00681-H; Nikolov DB, 1997, P NATL ACAD SCI USA, V94, P15, DOI 10.1073/pnas.94.1.15; NIKOLOV DB, 1994, NAT STRUCT BIOL, V1, P621, DOI 10.1038/nsb0994-621; ONATE SA, 1994, MOL CELL BIOL, V14, P3376, DOI 10.1128/MCB.14.5.3376; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; PUGH F, 1995, METHOD MOL BIOL, V37, P359; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; SHEFLIN LG, 1993, BIOCHEMISTRY-US, V32, P3238, DOI 10.1021/bi00064a005; STELZER G, 1994, MOL CELL BIOL, V14, P4712, DOI 10.1128/MCB.14.7.4712; STROS M, 1994, FEBS LETT, V344, P201, DOI 10.1016/0014-5793(94)00364-5; STROS M, 1994, NUCLEIC ACIDS RES, V22, P1044, DOI 10.1093/nar/22.6.1044; Sutrias-Grau M, 1999, J BIOL CHEM, V274, P1628, DOI 10.1074/jbc.274.3.1628; TAMURA T, 1991, NUCLEIC ACIDS RES, V19, P3861, DOI 10.1093/nar/19.14.3861; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0; Verrier CS, 1997, MOL ENDOCRINOL, V11, P1009, DOI 10.1210/me.11.8.1009; Weideman CA, 1997, J MOL BIOL, V271, P61, DOI 10.1006/jmbi.1997.1152; WEN L, 1989, NUCLEIC ACIDS RES, V17, P1197, DOI 10.1093/nar/17.3.1197; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; Wolner BS, 2001, J BIOL CHEM, V276, P6260, DOI 10.1074/jbc.M008273200; Zappavigna V, 1996, EMBO J, V15, P4981, DOI 10.1002/j.1460-2075.1996.tb00878.x	57	68	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32597	32605		10.1074/jbc.M011792200	http://dx.doi.org/10.1074/jbc.M011792200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11390376	hybrid			2022-12-25	WOS:000170746000031
J	Billiard, J; Grewal, SS; Lukaesko, L; Stork, PJS; Rotwein, P				Billiard, J; Grewal, SS; Lukaesko, L; Stork, PJS; Rotwein, P			Hormonal control of insulin-like growth factor I gene transcription in human osteoblasts - Dual actions of cAMP-dependent protein kinase on CCAAT/enhancer-binding protein delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RIBONUCLEIC-ACID; FETAL-RAT BONE; CYCLIC ADENOSINE-3',5'-MONOPHOSPHATE CAMP; PARATHYROID-HORMONE; CATALYTIC SUBUNIT; RESPONSE ELEMENT; IGF-I; ENRICHED CULTURES; NUCLEAR-LOCALIZATION; C/EBP-BETA	Insulin-like growth factor-I (IGF-I) is essential for somatic growth and promotes bone cell replication and differentiation. IGF-I production by rat osteoblasts is stimulated by activation of cAMP-dependent protein kinase (PKA). In this report, we define two interacting PKA-regulated pathways that control IGF-I gene transcription in cultured human osteoblasts. Stimulation of cAMP led to a 12-fold increase in IGF-I mRNA and enhanced IGF-I promoter activity through a DNA response element termed HS3D and the transcription factor CCAAT/enhancer-binding protein delta (C/EBP delta). Under basal conditions, C/EBP delta was found in osteoblast nuclei but was transcriptionally silent. Treatment with the PKA inhibitor H-89 caused redistribution of C/EBP delta to the cytoplasm. After hormone treatment, the catalytic subunit of PKA accumulated in osteoblast nuclei. Inhibition of active PKA with targeted nuclear expression of PKA inhibitor had no effect on the subcellular location of C/EBP delta but prevented hormone-induced IGF-I gene activation, while cytoplasmic PKA inhibitor additionally caused the removal of C/EBP delta from the nucleus. These results show that IGF-I gene expression is controlled in human osteoblasts by two PKA-dependent pathways. Cytoplasmic PKA mediates nuclear localization of C/EBP delta under basal conditions, and nuclear PKA stimulates its transcriptional activity upon hormone treatment. Both mechanisms are indirect, since PKA failed to phosphorylate human C/EBP delta in vitro.	Oregon Hlth & Sci Univ, Div Mol Med, Dept Med, Portland, OR 97201 USA; Vollum Inst, Portland, OR 97201 USA	Oregon Health & Science University	Rotwein, P (corresponding author), Oregon Hlth & Sci Univ, Div Mol Med, Dept Med, 3181 SW Sam Jackson Pk Rd,Mail Code NRC3, Portland, OR 97201 USA.	rotweinp@ohsu.edu	Rotwein, Peter/R-5783-2019	Rotwein, Peter/0000-0002-9505-1817	NIDDK NIH HHS [5F32-DK09802, T32 DK007674, 5-RO1-DK37449] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007674, R01DK037449, F32DK009802] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BICHELL DP, 1993, ENDOCRINOLOGY, V133, P1020, DOI 10.1210/en.133.3.1020; Billiard J, 2001, J BIOL CHEM, V276, P15354, DOI 10.1074/jbc.M009973200; BURR DB, 1989, BONE, V10, P223, DOI 10.1016/8756-3282(89)90057-4; CANALIS E, 1988, ENDOCRINOLOGY, V122, P22, DOI 10.1210/endo-122-1-22; CANALIS E, 1988, CALCIFIED TISSUE INT, V43, P346, DOI 10.1007/BF02553277; CANALIS E, 1989, J CLIN INVEST, V83, P60, DOI 10.1172/JCI113885; CHENU C, 1990, BONE, V11, P81, DOI 10.1016/8756-3282(90)90054-3; Dohrman DP, 1996, P NATL ACAD SCI USA, V93, P10217, DOI 10.1073/pnas.93.19.10217; FANTOZZI DA, 1994, J BIOL CHEM, V269, P2676; Feliciello A, 2000, CELL GROWTH DIFFER, V11, P649; GALLO A, 1992, GENE DEV, V6, P1621, DOI 10.1101/gad.6.9.1621; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; HALL LJ, 1992, DNA CELL BIOL, V11, P301, DOI 10.1089/dna.1992.11.301; HAROOTUNIAN AT, 1993, MOL BIOL CELL, V4, P993, DOI 10.1091/mbc.4.10.993; HOCK JM, 1988, ENDOCRINOLOGY, V122, P254, DOI 10.1210/endo-122-1-254; HOWARD GA, 1981, P NATL ACAD SCI-BIOL, V78, P3204, DOI 10.1073/pnas.78.5.3204; Ishizuya T, 1997, J CLIN INVEST, V99, P2961, DOI 10.1172/JCI119491; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KAGEYAMA R, 1991, J BIOL CHEM, V266, P15525; KANZAKI S, 1995, J BONE MINER RES, V10, P854; KASSEM M, 1993, CALCIFIED TISSUE INT, V52, P222, DOI 10.1007/BF00298723; KIM SW, 1991, MOL ENDOCRINOL, V5, P1964, DOI 10.1210/mend-5-12-1964; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Mandrup S, 1997, J BIOL CHEM, V272, P5367, DOI 10.1074/jbc.272.9.5367; MCCARTHY TL, 1990, J BIOL CHEM, V265, P15353; MCCARTHY TL, 1995, ENDOCRINOLOGY, V136, P3901, DOI 10.1210/en.136.9.3901; MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P301, DOI 10.1210/endo-124-1-301; MCCARTHY TL, 1991, ENDOCRINOLOGY, V128, P2895, DOI 10.1210/endo-128-6-2895; MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P1247, DOI 10.1210/endo-124-3-1247; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MIDDLETON J, 1995, BONE, V16, P287, DOI 10.1016/8756-3282(94)00040-9; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Mittanck DW, 1997, MOL CELL ENDOCRINOL, V126, P153, DOI 10.1016/S0303-7207(96)03979-2; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; MUNDY GR, 1993, J BONE MINER RES, V8, pS505, DOI 10.1002/jbmr.5650081315; MURPHY LJ, 1987, ENDOCRINOLOGY, V120, P1279, DOI 10.1210/endo-120-4-1279; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; Ohlsson C, 1998, EUR J CLIN INVEST, V28, P184; OKAZAKI R, 1995, BIOCHEM BIOPH RES CO, V207, P963, DOI 10.1006/bbrc.1995.1279; OKAZAKI R, 1995, J BONE MINER RES, V10, P788; OKIMURA Y, 1994, MOL ENDOCRINOL, V8, P1559, DOI 10.1210/me.8.11.1559; RAAP AK, 1991, EXP CELL RES, V197, P319, DOI 10.1016/0014-4827(91)90439-2; Richards JP, 1996, J BIOL CHEM, V271, P13716, DOI 10.1074/jbc.271.23.13716; Rittmaster RS, 2000, J CLIN ENDOCR METAB, V85, P2129, DOI 10.1210/jc.85.6.2129; ROTWEIN P, 1987, J BIOL CHEM, V262, P11807; SCHLECHTER NL, 1986, P NATL ACAD SCI USA, V83, P7932, DOI 10.1073/pnas.83.20.7932; SCHMID C, 1989, ENDOCRINOLOGY, V125, P1575, DOI 10.1210/endo-125-3-1575; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; SHINAR DM, 1993, ENDOCRINOLOGY, V132, P1158, DOI 10.1210/en.132.3.1158; Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005; STROM P, 1994, BIOCHEM BIOPH RES CO, V199, P78, DOI 10.1006/bbrc.1994.1196; SUN PQ, 1992, MOL ENDOCRINOL, V6, P1858, DOI 10.1210/me.6.11.1858; Swolin D, 1996, J ENDOCRINOL, V149, P397, DOI 10.1677/joe.0.1490397; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; Thomas MJ, 1996, J BIOL CHEM, V271, P21835, DOI 10.1074/jbc.271.36.21835; Umayahara Y, 1999, J BIOL CHEM, V274, P10609, DOI 10.1074/jbc.274.15.10609; Umayahara Y, 1997, J BIOL CHEM, V272, P31793, DOI 10.1074/jbc.272.50.31793; WEDEL A, 1995, IMMUNOBIOLOGY, V193, P171, DOI 10.1016/S0171-2985(11)80541-3; Wiley JC, 1999, J BIOL CHEM, V274, P6381, DOI 10.1074/jbc.274.10.6381; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; Yin M, 1996, J BIOL CHEM, V271, P17974, DOI 10.1074/jbc.271.30.17974	62	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31238	31246		10.1074/jbc.M103634200	http://dx.doi.org/10.1074/jbc.M103634200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11390399	hybrid			2022-12-25	WOS:000170472900086
J	Gerber, D; Shai, Y				Gerber, D; Shai, Y			In vivo detection of hetero-association of glycophorin-A and its mutants within the membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE ALPHA-HELICES; PORE-FORMING DOMAIN; THURINGIENSIS DELTA-ENDOTOXIN; CELL ANTIGEN RECEPTOR; PHOSPHOLIPID-BILAYERS; ANTIMICROBIAL PEPTIDE; ION-CHANNEL; ORGANIZATION; DIMERIZATION; SEGMENT	Protein recognition within the membrane is a crucial process for numerous biological activities. Detection of such interaction is limited because of difficulties that arise from the hydrophobic environment of the membrane. We detected direct hetero-oligomerization of the glycophorin-A (GPA) transmembrane segments in vivo through inhibition of ToxR transcription activator dimer formation. We investigated the amino acids important for hetero-oligomerization within the membrane, using peptide analog segments of the transmembrane domain of glycophorin A. The wild type ([WT]GPA) and alanine mutant ([A]GPA) were able to interfere with and inhibit the proper dimerization of the ToxR-GPA transcription factor. Conversely, a second alanine mutant ([A(2)]GPA), a glycine mutant ([G]GPA), and a scrambled analog ([SC]GPA) were virtually inactive. Binding studies reveal similar membrane partitions for [WT]GPA, [G]GPA, and [SC]GPA, whereas membrane partition of [A]GPA and [A]GPA are lower. Spectral analysis of fluorescent-labeled analogs revealed a significant blue shift, indicating membrane insertion. Our results suggest that the GXXXG motif, found in homo-oligomerization, is not sufficient for hetero-oligomerization in a biological membrane, whereas an extended motif, LIXXGXXXGXXXT, is sufficient. Interfering with hetero-oligomerization within the membrane can be a useful strategy for characterizing such interactions and possibly modulating membrane protein activity.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Shai, Y (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.							ADAIR BD, 1994, BIOCHEMISTRY-US, V33, P5539, DOI 10.1021/bi00184a024; ARKIN IT, 1994, EMBO J, V13, P4757, DOI 10.1002/j.1460-2075.1994.tb06801.x; BESCHIASCHVILI G, 1991, BIOCHIM BIOPHYS ACTA, V1061, P78, DOI 10.1016/0005-2736(91)90270-I; BIBI E, 1991, P NATL ACAD SCI USA, V88, P7271, DOI 10.1073/pnas.88.16.7271; Bowie JU, 2000, CURR OPIN STRUC BIOL, V10, P435, DOI 10.1016/S0959-440X(00)00111-1; Brosig B, 1998, PROTEIN SCI, V7, P1052; COSSON P, 1992, SCIENCE, V258, P659, DOI 10.1126/science.1329208; De Beeck AO, 2000, J BIOL CHEM, V275, P31428, DOI 10.1074/jbc.M003003200; DEBER CM, 1993, P NATL ACAD SCI USA, V90, P11648, DOI 10.1073/pnas.90.24.11648; Eckert DM, 1999, CELL, V99, P103, DOI 10.1016/S0092-8674(00)80066-5; FREY S, 1990, BIOCHEM J, V272, P713, DOI 10.1042/bj2720713; GAZIT E, 1995, J BIOL CHEM, V270, P2571, DOI 10.1074/jbc.270.6.2571; Gazit E, 1998, P NATL ACAD SCI USA, V95, P12289, DOI 10.1073/pnas.95.21.12289; Gerber D, 2000, J BIOL CHEM, V275, P23602, DOI 10.1074/jbc.M002596200; Han X, 2000, P NATL ACAD SCI USA, V97, P13097, DOI 10.1073/pnas.230212097; Hetru C, 2000, BIOCHEM J, V345, P653, DOI 10.1042/0264-6021:3450653; KAHN TW, 1992, BIOCHEMISTRY-US, V31, P6144, DOI 10.1021/bi00141a027; KEMBLE GW, 1994, CELL, V76, P383, DOI 10.1016/0092-8674(94)90344-1; Laage R, 1997, EUR J BIOCHEM, V249, P540, DOI 10.1111/j.1432-1033.1997.00540.x; Laage R, 2000, J BIOL CHEM, V275, P17481, DOI 10.1074/jbc.M910092199; Ladokhin AS, 2000, ANAL BIOCHEM, V285, P235, DOI 10.1006/abio.2000.4773; Langosch D, 1996, J MOL BIOL, V263, P525, DOI 10.1006/jmbi.1996.0595; LEMMON MA, 1992, J BIOL CHEM, V267, P7683; Manolios N, 1997, NAT MED, V3, P84, DOI 10.1038/nm0197-84; MANOLIOS N, 1990, SCIENCE, V249, P274, DOI 10.1126/science.2142801; Marti T, 1998, J BIOL CHEM, V273, P9312, DOI 10.1074/jbc.273.15.9312; Masson L, 1999, J BIOL CHEM, V274, P31996, DOI 10.1074/jbc.274.45.31996; MERRIFIELD RB, 1982, BIOCHEMISTRY-US, V21, P5020, DOI 10.1021/bi00263a028; Murray D, 1999, BIOPHYS J, V77, P3176, DOI 10.1016/S0006-3495(99)77148-1; Oren Z, 1999, BIOCHEM J, V341, P501, DOI 10.1042/0264-6021:3410501; RAJARATHNAM K, 1989, BIOCHEMISTRY-US, V28, P3168, DOI 10.1021/bi00434a009; RAPAPORT D, 1992, BIOCHEMISTRY-US, V31, P8868, DOI 10.1021/bi00152a025; Russ WP, 1999, P NATL ACAD SCI USA, V96, P863, DOI 10.1073/pnas.96.3.863; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; RUTLEDGE T, 1992, EMBO J, V11, P3245, DOI 10.1002/j.1460-2075.1992.tb05402.x; Senes A, 2000, J MOL BIOL, V296, P921, DOI 10.1006/jmbi.1999.3488; SHAI Y, 1995, TRENDS BIOCHEM SCI, V20, P460, DOI 10.1016/S0968-0004(00)89101-X; TREUTLEIN HR, 1992, BIOCHEMISTRY-US, V31, P12726, DOI 10.1021/bi00166a003; Wimley WC, 2000, BIOCHEMISTRY-US, V39, P4432, DOI 10.1021/bi992746j; Zhou FX, 2000, NAT STRUCT BIOL, V7, P154	40	38	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31229	31232		10.1074/jbc.M101889200	http://dx.doi.org/10.1074/jbc.M101889200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11402026	hybrid			2022-12-25	WOS:000170472900084
J	Dimitrov, AS; Xiao, XD; Dimitrov, DS; Blumenthal, R				Dimitrov, AS; Xiao, XD; Dimitrov, DS; Blumenthal, R			Early intermediates in HIV-1 envelope glycoprotein-mediated fusion triggered by CD4 and co-receptor complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MEMBRANE-FUSION; INFLUENZA HEMAGGLUTININ; CONFORMATIONAL-CHANGES; ATOMIC-STRUCTURE; LIPID BILAYERS; VIRAL MEMBRANE; COILED COILS; TYPE-1 GP120; SOLUBLE CD4	An early step in the process of HIV-1 entry into target cells is the activation of its envelope glycoprotein (GP120-GP41) to a fusogenic state upon binding to target cell CD4 and cognate co-receptor. Incubation of human immunodeficiency virus (HIV)-1 Env-expressing cells with an excess of CD4 and co-recepeptor-bearing target cells resulted in an influx of an impermeant nucleic acid-staining fluorescent dye into the Env-expressing cells. The dye influx occurred concomitant with cell fusion. No influx of dye into target cells was observed if they were incubated with an excess of Env-expressing cells. The permeabilization of Env-expressing cells was also triggered by CD4.co-receptor complexes attached to Protein G-Sepharose beads in the absence of target cells. The CD4 and co-receptor-induced permeabilization of Env-expressing cells occurred with the same specificity with respect to co-receptor usage as cell fusion. Natural ligands for the co-receptors and C-terminal GP41 peptide inhibitors of HIV-1 fusion blocked this effect. Our results indicate that the process of HIV-1 Env-mediated fusion is initiated by the destabilization of HIV-1 Env-expressing membranes. Further elucidation of these early intermediates may help identify and develop potential inhibitors of HIV-1 entry into cells.	NCI, Canc Res Ctr, Lab Expt & Computat Biol, NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Blumenthal, R (corresponding author), NCI, Canc Res Ctr, Lab Expt & Computat Biol, NIH, POB B,Bldg 469,Rm 216A,Miller Dr, Frederick, MD 21702 USA.							Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Bentz J, 2000, BIOPHYS J, V78, P886, DOI 10.1016/S0006-3495(00)76646-X; BERGER EA, 1997, AIDS, V11, P3; Blumenthal R, 1999, MOL MEMBR BIOL, V16, P43, DOI 10.1080/096876899294742; BRODER CC, 1995, P NATL ACAD SCI USA, V92, P9004, DOI 10.1073/pnas.92.19.9004; Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572; Chabot DJ, 2000, J VIROL, V74, P4404, DOI 10.1128/JVI.74.9.4404-4413.2000; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, P NATL ACAD SCI USA, V95, P15613, DOI 10.1073/pnas.95.26.15613; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; CHEN CH, 1995, J VIROL, V69, P3771, DOI 10.1128/JVI.69.6.3771-3777.1995; Dimitrov DS, 2000, CELL, V101, P697, DOI 10.1016/S0092-8674(00)80882-X; DIMITROV DS, 1992, AIDS, V60, P249; Doms RW, 1997, VIROLOGY, V235, P179, DOI 10.1006/viro.1997.8703; EARL PL, 1991, J VIROL, V65, P31, DOI 10.1128/JVI.65.1.31-41.1991; FREED EO, 1992, P NATL ACAD SCI USA, V89, P70, DOI 10.1073/pnas.89.1.70; FU YK, 1993, J VIROL, V67, P3818, DOI 10.1128/JVI.67.7.3818-3825.1993; Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276; GALLAHER WR, 1989, AIDS RES HUM RETROV, V5, P431, DOI 10.1089/aid.1989.5.431; GUY HR, 1992, BIOPHYS J, V62, P95, DOI 10.1016/S0006-3495(92)81790-3; JIANG SB, 1993, BIOCHEM BIOPH RES CO, V195, P533, DOI 10.1006/bbrc.1993.2078; Jones PLS, 1998, J BIOL CHEM, V273, P404, DOI 10.1074/jbc.273.1.404; KASURINEN J, 1992, BIOCHEM BIOPH RES CO, V187, P1594, DOI 10.1016/0006-291X(92)90485-4; Kliger Y, 1997, J BIOL CHEM, V272, P13496, DOI 10.1074/jbc.272.21.13496; Kliger Y, 1997, BIOCHEMISTRY-US, V36, P5157, DOI 10.1021/bi962935r; Kliger Y, 2001, J BIOL CHEM, V276, P1391, DOI 10.1074/jbc.M004113200; KOWALSKI M, 1987, SCIENCE, V237, P1351, DOI 10.1126/science.3629244; Kozlov MM, 1998, BIOPHYS J, V75, P1384, DOI 10.1016/S0006-3495(98)74056-1; Kuhmann SE, 2000, J VIROL, V74, P7005, DOI 10.1128/JVI.74.15.7005-7015.2000; Kwong PD, 2000, J VIROL, V74, P1961, DOI 10.1128/JVI.74.4.1961-1972.2000; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Lawless MK, 1996, BIOCHEMISTRY-US, V35, P13697, DOI 10.1021/bi9606962; Longo ML, 1997, BIOPHYS J, V73, P1430, DOI 10.1016/S0006-3495(97)78175-X; MILLER MA, 1993, VIROLOGY, V196, P89, DOI 10.1006/viro.1993.1457; Mirzabekov T, 1999, J BIOL CHEM, V274, P28745, DOI 10.1074/jbc.274.40.28745; MOBLEY PW, 1992, BIOCHIM BIOPHYS ACTA, V1139, P251, DOI 10.1016/0925-4439(92)90098-8; Moore JP, 1997, CURR OPIN IMMUNOL, V9, P551, DOI 10.1016/S0952-7915(97)80110-0; MOORE JP, 1990, SCIENCE, V250, P1139, DOI 10.1126/science.2251501; Munoz-Barroso I, 1998, J CELL BIOL, V140, P315, DOI 10.1083/jcb.140.2.315; NIEVA JL, 1994, BIOCHEMISTRY-US, V33, P3201, DOI 10.1021/bi00177a009; RAFALSKI M, 1990, BIOCHEMISTRY-US, V29, P7917, DOI 10.1021/bi00486a020; Raphael RM, 1996, BIOPHYS J, V71, P1374, DOI 10.1016/S0006-3495(96)79340-2; Salzwedel K, 2000, J VIROL, V74, P326, DOI 10.1128/JVI.74.1.326-333.2000; Singer II, 2001, J VIROL, V75, P3779, DOI 10.1128/JVI.75.8.3779-3790.2001; Skehel JJ, 1998, CELL, V95, P871, DOI 10.1016/S0092-8674(00)81710-9; SLEPUSHKIN VA, 1990, BIOCHEM BIOPH RES CO, V172, P952, DOI 10.1016/0006-291X(90)90768-I; SRINIVAS SK, 1992, J BIOL CHEM, V267, P7121; Sullivan N, 1998, J VIROL, V72, P4694, DOI 10.1128/JVI.72.6.4694-4703.1998; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; THALI M, 1992, J VIROL, V66, P5516, DOI 10.1128/JVI.66.9.5516-5524.1992; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; WEBER T, 1994, J BIOL CHEM, V269, P18353; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; WEISS CD, 1990, J VIROL, V64, P5674, DOI 10.1128/JVI.64.11.5674-5677.1990; Weissenhorn W, 1999, MOL MEMBR BIOL, V16, P3, DOI 10.1080/096876899294706; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WHARTON SA, 1995, EMBO J, V14, P240, DOI 10.1002/j.1460-2075.1995.tb06997.x; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770; Wu LJ, 1997, J EXP MED, V185, P1681, DOI 10.1084/jem.185.9.1681; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884; Xiao XD, 1999, P NATL ACAD SCI USA, V96, P7496, DOI 10.1073/pnas.96.13.7496; Xiao XD, 2000, EXP MOL PATHOL, V68, P139, DOI 10.1006/exmp.1999.2299; Zhang WT, 1999, BIOCHEMISTRY-US, V38, P9405, DOI 10.1021/bi990654o	64	46	48	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30335	30341		10.1074/jbc.M103788200	http://dx.doi.org/10.1074/jbc.M103788200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11397808	hybrid			2022-12-25	WOS:000170558000096
J	Kaufmann, H; Marone, R; Olayioye, MA; Bailey, JE; Fussenegger, M				Kaufmann, H; Marone, R; Olayioye, MA; Bailey, JE; Fussenegger, M			Characterization of an N-terminally truncated cyclin a isoform in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; DNA-REPLICATION; S-PHASE; EXPRESSION; KINASE; P27(KIP1); GENE; E2F; COMPLEX; CDK2	Cyclin A is essential for regulating key transitions in the eukaryotic cell cycle including initiation of DNA replication and mitosis. This paper describes the characterization of a truncated cyclin A isoform (cyclin A(t)) in vitro in cultured mammalian cells and in mouse tissues. The presence of cyclin A(t) in specific cell types correlates with the ability of cell extracts to cleave in vitro translated cyclin A. In CHO-K1 cells, cyclin A processing to cyclin A(t) occurs at the N terminus; it does not involve the 26 S proteasome, nor could it be induced by conditional overexpression of the cyclin-dependent kinase inhibitor p27(Kip1). However, high cell densities lead to increased cyclin A(t) levels. Unlike full-length cyclin A, cyclin A(t) localizes to the cytoplasm, where it binds Cdk2. The data suggest that cyclin A processing occurs in vivo to yield an N-terminally truncated isoform by an unknown mechanism that is regulated by cell density. Differential subcellular localization may provide the first insights into the physiological role of cyclin At.	ETH Honggerberg HPT, Swiss Fed Inst Technol, Inst Biotechnol, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Fussenegger, M (corresponding author), ETH Honggerberg HPT, Swiss Fed Inst Technol, Inst Biotechnol, CH-8093 Zurich, Switzerland.			Marone, Romina/0000-0003-1474-1689				Aaltomaa S, 1999, BRIT J CANCER, V80, P2001, DOI 10.1038/sj.bjc.6690634; Allan K, 2000, ARCH PATHOL LAB MED, V124, P216; Bastians H, 1998, P NATL ACAD SCI USA, V95, P15374, DOI 10.1073/pnas.95.26.15374; BRECHOT C, 1993, CURR OPIN GENET DEV, V3, P11, DOI 10.1016/S0959-437X(05)80335-1; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; Clute P, 1999, NAT CELL BIOL, V1, P82, DOI 10.1038/10049; den Elzen N, 2001, J CELL BIOL, V153, P121, DOI 10.1083/jcb.153.1.121; Desdouets C, 1995, Prog Cell Cycle Res, V1, P115; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; Furuno N, 1999, J CELL BIOL, V147, P295, DOI 10.1083/jcb.147.2.295; Fussenegger M, 1998, NAT BIOTECHNOL, V16, P468, DOI 10.1038/nbt0598-468; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; Handa K, 1999, INT J CANCER, V84, P225, DOI 10.1002/(SICI)1097-0215(19990621)84:3<225::AID-IJC5>3.0.CO;2-A; Hengst L, 1998, CURR TOP MICROBIOL, V227, P25; Herrada J, 1997, CLIN CANCER RES, V3, P1565; Huet X, 1996, MOL CELL BIOL, V16, P3789; Huuhtanen RL, 1999, CANCER RES, V59, P2885; Kaufmann H, 2001, BIOTECHNOL BIOENG, V72, P592, DOI 10.1002/1097-0290(20010320)72:6<592::AID-BIT1024>3.0.CO;2-J; KEYOMARSI K, 1995, ONCOGENE, V11, P941; KNOBLICH JA, 1993, EMBO J, V12, P65, DOI 10.1002/j.1460-2075.1993.tb05632.x; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; Liu NS, 1998, ONCOGENE, V16, P2957, DOI 10.1038/sj.onc.1201838; LORCA T, 1992, FEBS LETT, V306, P90, DOI 10.1016/0014-5793(92)80844-7; Lukas C, 1999, NATURE, V401, P815, DOI 10.1038/44611; Mazur X, 1998, BIOTECHNOL PROGR, V14, P705, DOI 10.1021/bp980062h; Murphy M, 1997, NAT GENET, V15, P83, DOI 10.1038/ng0197-83; Murphy M, 1999, NAT GENET, V23, P481, DOI 10.1038/70612; Orend G, 1998, ONCOGENE, V16, P2575, DOI 10.1038/sj.onc.1201791; Orian A, 1999, MOL CELL BIOL, V19, P3664; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; Philips A, 1999, ONCOGENE, V18, P6222, DOI 10.1038/sj.onc.1203017; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SIGRIST S, 1995, EMBO J, V14, P4827, DOI 10.1002/j.1460-2075.1995.tb00164.x; SOBCZAKTHEPOT J, 1993, EXP CELL RES, V206, P43, DOI 10.1006/excr.1993.1118; Tokumoto T, 1997, J CELL BIOL, V138, P1313, DOI 10.1083/jcb.138.6.1313; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; Yam CH, 2001, P NATL ACAD SCI USA, V98, P497, DOI 10.1073/pnas.240461397; Yang J, 1999, TRENDS CELL BIOL, V9, P207, DOI 10.1016/S0962-8924(99)01577-9; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407; Zhai YL, 1999, INT J CANCER, V84, P244, DOI 10.1002/(SICI)1097-0215(19990621)84:3<244::AID-IJC8>3.0.CO;2-2; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	50	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29987	29993		10.1074/jbc.M005452200	http://dx.doi.org/10.1074/jbc.M005452200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11402021	hybrid			2022-12-25	WOS:000170558000051
J	Kumari, M				Kumari, M			Differential effects of chronic ethanol treatment on N-methyl-D-aspartate R1 splice variants in fetal cortical neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMDA RECEPTOR SUBUNIT; MESSENGER-RNA EXPRESSION; MOLECULAR-BIOLOGY; GENE-EXPRESSION; TERMINAL DOMAIN; UP-REGULATION; NR1; BRAIN; POTENTIATION; ISOFORMS	Functional N-methyl-D-aspartate receptors consisting of NR1 and NR2 subunits are an important site of action of ethanol. Chronic ethanol treatment increases the NR1 polypeptide levels in vivo and in vitro. Chronic ethanol treatment in vitro does not significantly alter the NR1 mRNA levels, even though under similar culture conditions ethanol (50 mM, 5 days) enhances the half-life of NR1 mRNA in fetal cortical neurons. To address this phenomenon, we determined by reverse transcription-polymerase chain reaction and Western blotting whether ethanol (50 mM, 5 days) has a splice variant-specific effect on the expression of the NR1 subunit in mouse fetal cortical neurons. This report analyzes for the first time the distribution of all NR1 splice variants in these neurons. Our data indicate the presence of NR1-3a,b and NR1-4a,b splice variants in cortical neurons. Chronic, ethanol treatment significantly decreased the mRNA levels of exon 5-containing NR1 splice variants (NR1-3b and NR1-4b) (-E5/+E5 = 4.6 in untreated neurons and 6.1 in ethanol-treated neurons) and had no effect on the mRNA levels of NR1-3 (+E21/-E22) and NR1-4 (-E21/-E22) splice variants. At the polypeptide level,. chronic ethanol treatment significantly reduced exon 5-containing splice variants (NR1-3b and NR1-4b). However, ethanol (50 mm, 5 days) induced a significant increase in polypeptide levels of NR1-4 (-E21/-E22), without any effect on NR1-3 (+E21/-E22) polypeptide levels. These results demonstrate that chronic ethanol treatment, has a selective effect on the expression of NR1 splice variants at both the mRNA and polypeptide levels in mouse fetal cortical neurons.	Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Kumari, M (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pharmacol, 7703 Floyd Curl Dr,Mail Code 7764, San Antonio, TX 78229 USA.	kumari@uthscsa.edu			NIAAA NIH HHS [AA12070] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA012070] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Danysz W, 1998, PHARMACOL REV, V50, P597; Darstein MB, 2000, N-S ARCH PHARMACOL, V361, P206, DOI 10.1007/s002109900180; Dunn RJ, 1999, J EXP BIOL, V202, P1319; DURAND GM, 1992, P NATL ACAD SCI USA, V89, P9359, DOI 10.1073/pnas.89.19.9359; DURAND GM, 1993, P NATL ACAD SCI USA, V90, P6731, DOI 10.1073/pnas.90.14.6731; Ehlers MD, 1998, J NEUROSCI, V18, P720; FOLLESA P, 1995, MOL BRAIN RES, V29, P99, DOI 10.1016/0169-328X(94)00235-7; Follesa P, 1996, J BIOL CHEM, V271, P13297, DOI 10.1074/jbc.271.23.13297; FORREST D, 1994, NEURON, V13, P325, DOI 10.1016/0896-6273(94)90350-6; Hardy PA, 1999, BRAIN RES, V819, P33, DOI 10.1016/S0006-8993(98)01340-7; HOLLMANN M, 1993, NEURON, V10, P943, DOI 10.1016/0896-6273(93)90209-A; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Hollmann M., 1999, V141, P3; HOLLMANN M, 1994, RENAL PHYSIOL BIOCH, V17, P182; Hu XJ, 1996, MOL BRAIN RES, V36, P211, DOI 10.1016/0169-328X(95)00223-F; Katsura M, 1995, MOL BRAIN RES, V34, P355, DOI 10.1016/0169-328X(95)00192-U; Kumari M, 1998, J NEUROCHEM, V70, P1467; Kumari M, 2000, PROG DRUG RES, V54, P152; LAURIE DJ, 1994, J NEUROSCI, V14, P3180; LAURIE DJ, 1995, MOL BRAIN RES, V32, P94, DOI 10.1016/0169-328X(95)00067-3; LI YQ, 1994, CELL, V76, P427, DOI 10.1016/0092-8674(94)90108-2; Logan SM, 1999, J NEUROSCI, V19, P974; Lovinger DM, 1996, ALCOHOL CLIN EXP RES, V20, pA187, DOI 10.1111/j.1530-0277.1996.tb01773.x; MHATRE MC, 1992, MOL PHARMACOL, V42, P415; MONTPIED P, 1991, MOL PHARMACOL, V39, P157; MORI H, 1995, NEUROPHARMACOLOGY, V34, P1219, DOI 10.1016/0028-3908(95)00109-J; Okabe S, 1999, J NEUROSCI, V19, P7781; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SIGNS SA, 1994, MOL CELL BIOCHEM, V139, P21, DOI 10.1007/BF00944199; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; TREVISAN L, 1994, J NEUROCHEM, V62, P1635; VEDOVA FD, 1994, NEUROREPORT, V5, P581; Vezzani A, 1995, EUR J NEUROSCI, V7, P2513, DOI 10.1111/j.1460-9568.1995.tb01050.x; Weiss SW, 1998, J NEUROSCI, V18, P1725; Winkler A, 1999, MOL BRAIN RES, V72, P166, DOI 10.1016/S0169-328X(99)00218-1; Ying Z, 1998, J NEUROPATH EXP NEUR, V57, P47; ZHANG L, 1994, P NATL ACAD SCI USA, V91, P10883, DOI 10.1073/pnas.91.23.10883; ZHENG X, 1994, NEURON, V12, P811; ZHONG J, 1995, J NEUROCHEM, V64, P531; ZUKIN RS, 1995, TRENDS NEUROSCI, V18, P306, DOI 10.1016/0166-2236(95)93920-S	41	29	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29764	29771		10.1074/jbc.M100317200	http://dx.doi.org/10.1074/jbc.M100317200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11387318	hybrid			2022-12-25	WOS:000170558000023
J	Lee, SJ; Gralla, JD				Lee, SJ; Gralla, JD			Sigma38 (rpoS) RNA polymerase promoter engagement via-10 region on nucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORK JUNCTION DNA; ESCHERICHIA-COLI; TRANSCRIPTION; RECOGNITION; GENE; SIGMA(38); SEQUENCE; SELECTIVITY; HOLOENZYME; GROWTH	Band shift assays using DNA probes that mimic closed and open complexes were used to explore the determinants of promoter recognition by sigma38 (rpoS) RNA polymerase. Duplex recognition was found to be much weaker than that observed in sigma70 promoter usage. However, binding to fork junction probes, which attempt to mimic melted DNA, was very strong. This binding occurs via the non-template strand with the identity of the two conserved junction nucleotides (-12T and -11A) being of paramount importance. A modified promoter consensus sequence identified these two nucleotides as among only four (underlined) that are highly conserved, and all four were in the -10 region (CTAcacT from -13 to -7). The remaining two nucleotides were shown to have different roles, -13C in pre-venting recognition by the heterologous sigma70 polymerase and -7T in directing enzyme isomerization. These -10 region nucleotides appear to have their primary function prior to fall melting because probes that had a melted start site were relatively insensitive to substitution at these positions. These results suggest the sigma38 mechanism differs from the sigma70 mechanism, and this difference likely contributes to selective use of sigma38 under conditions that exist during stationery phase.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Gralla, JD (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, POB 951569, Los Angeles, CA 90095 USA.	gralla@chem.ucla.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035754] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35754] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADHYA S, 1993, GENE, V132, P1, DOI 10.1016/0378-1119(93)90507-Y; ALTUVIA S, 1994, MOL MICROBIOL, V13, P265, DOI 10.1111/j.1365-2958.1994.tb00421.x; Becker G, 2001, MOL MICROBIOL, V39, P1153, DOI 10.1046/j.1365-2958.2001.02313.x; Bordes P, 2000, MOL MICROBIOL, V35, P845, DOI 10.1046/j.1365-2958.2000.01758.x; Chen YF, 1997, J MOL BIOL, V267, P47, DOI 10.1006/jmbi.1996.0853; Colland F, 1999, EMBO J, V18, P4049, DOI 10.1093/emboj/18.14.4049; Colland F, 2000, EMBO J, V19, P3028, DOI 10.1093/emboj/19.12.3028; Conter A, 1997, J MOL BIOL, V273, P75, DOI 10.1006/jmbi.1997.1308; DING QQ, 1995, MOL MICROBIOL, V16, P649, DOI 10.1111/j.1365-2958.1995.tb02427.x; Dombroski AJ, 1997, J BIOL CHEM, V272, P3487; EspinosaUrgel M, 1996, MOL MICROBIOL, V21, P657; Fenton MS, 2000, EMBO J, V19, P1130, DOI 10.1093/emboj/19.5.1130; FENTON MS, 2001, IN PRESS P NATL ACAD; Guo Y, 1998, P NATL ACAD SCI USA, V95, P11655, DOI 10.1073/pnas.95.20.11655; Guo YL, 1999, EMBO J, V18, P3736, DOI 10.1093/emboj/18.13.3736; Hengge-Aronis R, 1999, CURR OPIN MICROBIOL, V2, P148, DOI 10.1016/S1369-5274(99)80026-5; Hiratsu K, 1995, MOL MICROBIOL, V18, P841, DOI 10.1111/j.1365-2958.1995.18050841.x; Kusano S, 1996, J BIOL CHEM, V271, P1998, DOI 10.1074/jbc.271.4.1998; Kusano S, 1997, J BACTERIOL, V179, P3649, DOI 10.1128/jb.179.11.3649-3654.1997; LISSER S, 1993, NUCLEIC ACIDS RES, V21, P1507, DOI 10.1093/nar/21.7.1507; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; Marschall C, 1998, J MOL BIOL, V276, P339, DOI 10.1006/jmbi.1997.1533; Matlock DL, 2000, BIOCHEMISTRY-US, V39, P12274, DOI 10.1021/bi001433h; Naryshkin N, 2000, CELL, V101, P601, DOI 10.1016/S0092-8674(00)80872-7; Nguyen LH, 1997, BIOCHEMISTRY-US, V36, P1748, DOI 10.1021/bi961175h; OHLSEN KL, 1992, MOL MICROBIOL, V6, P2243, DOI 10.1111/j.1365-2958.1992.tb01400.x; Qi HY, 1997, J MOL BIOL, V267, P481, DOI 10.1006/jmbi.1997.0901; Schellhorn HE, 1998, J BACTERIOL, V180, P6283; TANAKA K, 1995, NUCLEIC ACIDS RES, V23, P827, DOI 10.1093/nar/23.5.827; TANAKA K, 1993, P NATL ACAD SCI USA, V90, P3511, DOI 10.1073/pnas.90.8.3511; Villarroya M, 1998, EMBO J, V17, P1829, DOI 10.1093/emboj/17.6.1829; Wilson C, 1997, J MOL BIOL, V267, P60, DOI 10.1006/jmbi.1997.0875; Wise A, 1996, J BACTERIOL, V178, P2785, DOI 10.1128/jb.178.10.2785-2793.1996; Xu JM, 1997, J MOL BIOL, V270, P346, DOI 10.1006/jmbi.1997.1133	34	77	80	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30064	30071		10.1074/jbc.M102886200	http://dx.doi.org/10.1074/jbc.M102886200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11375988	hybrid			2022-12-25	WOS:000170558000062
J	McAleese, FM; Walsh, EJ; Sieprawska, M; Potempa, J; Foster, TJ				McAleese, FM; Walsh, EJ; Sieprawska, M; Potempa, J; Foster, TJ			Loss of clumping factor B fibrinogen binding activity by Staphylococcus aureus involves cessation of transcription, shedding and cleavage by metalloprotease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR PROTEOLYTIC-ENZYMES; PROTEIN-A; EXPRESSION; GENE; SAR; IDENTIFICATION; ACTIVATION; RECEPTOR; DOMAIN	The fibrinogen-binding protein clumping factor B (ClfB) of Staphylococcus aureus is present on the surface of cells from the early exponential phase of growth in greater amounts than on cells from late exponential phase and is barely detectable on cells from stationary phase. Expression of a clfB-lacZ fusion indicated that transcription stopped before the end of exponential phase. Mutations in the global regulators agr and sar had no effect on clfB transcription. The loss of ClfB protein from cells in stationary phase was due to expression ending before cells stopped growing, combined with shedding of some of the protein into the growth medium and dilution of those molecules remaining on the cell surface during the two to three cell division events leading to stationary phase. Two forms of the protein occurred on the cell surface, the smaller of which was generated by loss of a domain from the N terminus. The proportion of the smaller form increased as the cultures grew. The metalloprotease aureolysin was shown to be responsible for cleavage of ClfB. Cleavage was inhibited by EDTA and o-phenanthroline and did not occur in an aureolysin-deficient mutant. Purified aureolysin promoted cleavage of cell surface-located ClfB as well as the recombinant A domain of ClfB. Cleavage was detected at two sites, one located between residues Ser(197) and Leu(198) and the other between Ala(199) and Val(200). The truncated form of ClfB did not bind fibrinogen.	Trinity Coll Dublin, Moyne Inst Prevent Med, Dept Microbiol, Dublin 2, Ireland; Jagiellonian Univ, Inst Mol Biol, Dept Microbiol, PL-31120 Krakow, Poland	Trinity College Dublin; Jagiellonian University	Foster, TJ (corresponding author), Trinity Coll Dublin, Moyne Inst Prevent Med, Dept Microbiol, Dublin 2, Ireland.	tfoster@tcd.ie						ARVIDSON S, 1973, BIOCHIM BIOPHYS ACTA, V302, P149, DOI 10.1016/0005-2744(73)90017-X; ARVIDSON SO, 1983, STAPHYLOCOCCI STAPHY, V2, P745; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BJORKLIND A, 1974, BIOCHIM BIOPHYS ACTA, V370, P524, DOI 10.1016/0005-2744(74)90113-2; Blevins JS, 1999, MOL MICROBIOL, V33, P317, DOI 10.1046/j.1365-2958.1999.01475.x; Chan PF, 1998, J BACTERIOL, V180, P6232; Chan PF, 1998, MICROBIOL-SGM, V144, P2469, DOI 10.1099/00221287-144-9-2469; CHEUNG AL, 1992, P NATL ACAD SCI USA, V89, P6462, DOI 10.1073/pnas.89.14.6462; Cheung AL, 1997, INFECT IMMUN, V65, P2243, DOI 10.1128/IAI.65.6.2243-2249.1997; CROSSLEY KB, 1997, STAPHYLOCOCCI HUMAN; DRAPEAU GR, 1978, J BACTERIOL, V136, P607, DOI 10.1128/JB.136.2.607-613.1978; DUTHIE ES, 1952, J GEN MICROBIOL, V6, P95, DOI 10.1099/00221287-6-1-2-95; Eidhin DN, 1998, MOL MICROBIOL, V30, P245; Entenza JM, 2000, INFECT IMMUN, V68, P5443, DOI 10.1128/IAI.68.9.5443-5446.2000; Fa W., 1995, PRINCIPLES PRACTICES, V4, P1754; Foster TJ, 1998, METHOD MICROBIOL, V27, P433; Foster TJ, 1998, TRENDS MICROBIOL, V6, P484, DOI 10.1016/S0966-842X(98)01400-0; Francois P, 2000, J LAB CLIN MED, V135, P32, DOI 10.1016/S0022-2143(00)70018-7; Gillaspy AF, 1998, INFECT IMMUN, V66, P3170, DOI 10.1128/IAI.66.7.3170-3178.1998; Hartford O, 1999, MICROBIOL-SGM, V145, P2497, DOI 10.1099/00221287-145-9-2497; Hartford O, 1997, MOL MICROBIOL, V25, P1065, DOI 10.1046/j.1365-2958.1997.5291896.x; Hartleib J, 2000, BLOOD, V96, P2149; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; HOOK M, 1999, GRAM POSITIVE BACTER, P386; KEMP EH, 1991, J BACTERIOL, V173, P4646, DOI 10.1128/jb.173.15.4646-4652.1991; KREISWIRTH BN, 1983, NATURE, V305, P709, DOI 10.1038/305709a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; McDevitt D, 1997, EUR J BIOCHEM, V247, P416, DOI 10.1111/j.1432-1033.1997.00416.x; MCDEVITT D, 1995, MOL MICROBIOL, V16, P895, DOI 10.1111/j.1365-2958.1995.tb02316.x; MCDEVITT D, 1994, MOL MICROBIOL, V11, P237, DOI 10.1111/j.1365-2958.1994.tb00304.x; MOREILLON P, 1995, INFECT IMMUN, V63, P4738, DOI 10.1128/IAI.63.12.4738-4743.1995; NOVICK R, 1967, VIROLOGY, V33, P155, DOI 10.1016/0042-6822(67)90105-5; NOVICK RP, 1993, EMBO J, V12, P3967, DOI 10.1002/j.1460-2075.1993.tb06074.x; O'Connell DP, 1998, J BIOL CHEM, V273, P6821, DOI 10.1074/jbc.273.12.6821; OSKOUIAN B, 1990, J BACTERIOL, V172, P3804, DOI 10.1128/jb.172.7.3804-3812.1990; PATTI JM, 1994, ANNU REV MICROBIOL, V48, P585, DOI 10.1146/annurev.mi.48.100194.003101; POTEMPA J, 1991, J BIOL CHEM, V266, P21482; POTEMPA J, 1986, J BIOL CHEM, V261, P14330; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SaraviaOtten P, 1997, J BACTERIOL, V179, P5259, DOI 10.1128/jb.179.17.5259-5263.1997; SCHNEEWIND O, 1995, SCIENCE, V268, P103, DOI 10.1126/science.7701329; VAUDAUX PE, 1995, INFECT IMMUN, V63, P585, DOI 10.1128/IAI.63.2.585-590.1995; Wann ER, 2000, J BIOL CHEM, V275, P13863, DOI 10.1074/jbc.275.18.13863; WEGRZYNOWICZ Z, 1980, J CLIN MICROBIOL, V12, P138, DOI 10.1128/JCM.12.2.138-139.1980; WOIZ C, 1996, INFECT IMMUN, V64, P3142; Youngman P., 1990, MOL BIOL METHODS BAC, P221	46	115	122	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29969	29978		10.1074/jbc.M102389200	http://dx.doi.org/10.1074/jbc.M102389200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11399757	Green Published, hybrid			2022-12-25	WOS:000170558000049
J	Niiro, N; Ikebe, M				Niiro, N; Ikebe, M			Zipper-interacting protein kinase induces Ca2+-free smooth muscle contraction via myosin light chain phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULUS-SPECIFIC PATTERNS; OKADAIC ACID; SERINE/THREONINE KINASE; PHOSPHATASE INHIBITOR; CALYCULIN-A; RHO-KINASE; CALCIUM; CA-2+; ARTERY; ACTIVATION	The inhibition of myosin phosphatase evokes smooth muscle contraction in the absence of Ca2+, yet the underlying mechanisms are not understood. To this end, we have cloned smooth muscle zipper-interacting pro. tein (ZIP) kinase cDNA. ZIP kinase is present in various smooth muscle tissues including arteries. Triton X-100 skinning did not diminish ZIP kinase content, suggesting that ZIP kinase associates with the filamentous component in smooth muscle. Smooth muscle ZIP kinase phosphorylated smooth muscle myosin as well as the isolated 20-kDa myosin light chain in a Ca2+/calmodulin-independent manner. ZIP kinase phosphorylated myosin light chain at both Ser(19) and Thr(18) residues with the same rate constant. The actin-activated ATPase activity of myosin increased significantly following ZIP kinase-induced phosphorylation. Introduction of ZIP kinase into Triton X-100-permeabilized rabbit mesenteric artery provoked a Ca2+-free contraction. A protein phosphatase inhibitor, microcystin LR, also induced contraction in the absence of Ca2+, which was accompanied by an increase in both mono- and diphosphorylation of myosin light chain. The observed sensitivity of the microcystin-induced contraction to various protein kinase inhibitors was identical to the sensitivity of isolated ZIP kinase to these inhibitors. These results suggest that ZIP kinase is responsible for Ca2+ independent myosin phosphorylation and contraction in smooth muscle.	Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Ikebe, M (corresponding author), Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01655 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061426, R01HL060831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041653] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL61426, HL60831] Funding Source: Medline; NIAMS NIH HHS [AR41653] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALESSI D, 1992, EUR J BIOCHEM, V210, P1023, DOI 10.1111/j.1432-1033.1992.tb17508.x; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; CHIEN YH, 1984, MOL CELL BIOL, V4, P507, DOI 10.1128/MCB.4.3.507; COLBURN JC, 1988, J BIOL CHEM, V263, P19166; Deng JT, 2001, J BIOL CHEM, V276, P16365, DOI 10.1074/jbc.M011634200; EDELMAN AM, 1990, MOL CELL BIOCHEM, V97, P87; ETO M, 1995, J BIOCHEM, V118, P1104, DOI 10.1093/oxfordjournals.jbchem.a124993; GERTHOFFER WT, 1989, AM J PHYSIOL, V257, pC1062, DOI 10.1152/ajpcell.1989.257.6.C1062; GONG MC, 1992, J BIOL CHEM, V267, P21492; GONG MC, 1992, J BIOL CHEM, V267, P14662; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, V1, P423; HIGHASHIHARA M, 1989, J BIOL CHEM, V264, P5218; HIRANO K, 1989, BRIT J PHARMACOL, V98, P1261, DOI 10.1111/j.1476-5381.1989.tb12672.x; HORI M, 1991, FEBS LETT, V285, P145, DOI 10.1016/0014-5793(91)80745-O; IKEBE M, 1987, J BIOL CHEM, V262, P9569; IKEBE M, 1994, J BIOL CHEM, V269, P28165; IKEBE M, 1985, J BIOL CHEM, V260, P3146; Ikebe M, 1998, J BIOL CHEM, V273, P17702, DOI 10.1074/jbc.273.28.17702; IKEBE M, 1987, J BIOL CHEM, V262, P13828; IKEBE M, 1985, J BIOL CHEM, V260, P27; Ikebe M, 1996, BIOCHEM BIOPH RES CO, V225, P370, DOI 10.1006/bbrc.1996.1182; ISHIHARA H, 1989, J PHARMACOL EXP THER, V250, P388; KAMM KE, 1989, ANNU REV PHYSIOL, V51, P299; KARAKI H, 1988, EUR J PHARMACOL, V151, P325, DOI 10.1016/0014-2999(88)90817-5; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KITAZAWA T, 1989, J BIOL CHEM, V264, P5339; Kogel D, 1998, ONCOGENE, V17, P2645, DOI 10.1038/sj.onc.1202204; Komatsu S, 2000, J BIOL CHEM, V275, P34512, DOI 10.1074/jbc.M003019200; Komatsu S, 1996, BIOCHEM BIOPH RES CO, V223, P741, DOI 10.1006/bbrc.1996.0966; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MacDonald JA, 2001, P NATL ACAD SCI USA, V98, P2419, DOI 10.1073/pnas.041331498; MASUO M, 1994, J GEN PHYSIOL, V104, P265, DOI 10.1085/jgp.104.2.265; MORGAN JP, 1984, J PHYSIOL-LONDON, V351, P155, DOI 10.1113/jphysiol.1984.sp015239; Murata-Hori M, 1999, FEBS LETT, V451, P81, DOI 10.1016/S0014-5793(99)00550-5; NISHIMURA J, 1988, BIOCHEM BIOPH RES CO, V157, P677, DOI 10.1016/S0006-291X(88)80303-6; OBARA K, 1989, PFLUG ARCH EUR J PHY, V414, P134, DOI 10.1007/BF00580954; OZAKI H, 1987, J PHARMACOL EXP THER, V243, P1167; PERRIE WT, 1970, BIOCHEM J, V119, P31, DOI 10.1042/bj1190031; PERSECHINI A, 1986, J BIOL CHEM, V261, P6293; REMBOLD CM, 1988, CIRC RES, V63, P593, DOI 10.1161/01.RES.63.3.593; SETO M, 1990, PFLUG ARCH EUR J PHY, V415, P484, DOI 10.1007/BF00373627; SHIRAZI A, 1994, J BIOL CHEM, V269, P31598; SINGER HA, 1990, AM J PHYSIOL, V259, pC631, DOI 10.1152/ajpcell.1990.259.4.C631; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SUZUKI A, 1993, BRIT J PHARMACOL, V109, P703, DOI 10.1111/j.1476-5381.1993.tb13631.x; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; TOKUI T, 1995, BIOCHEMISTRY-US, V34, P5173, DOI 10.1021/bi00015a031; Van Eyk JE, 1998, J BIOL CHEM, V273, P23433, DOI 10.1074/jbc.273.36.23433; WALSH MP, 1983, METHOD ENZYMOL, V99, P279; Weber LP, 1999, J PHYSIOL-LONDON, V516, P805, DOI 10.1111/j.1469-7793.1999.0805u.x; YANO K, 1993, BIOCHEMISTRY-US, V32, P12054, DOI 10.1021/bi00096a016	53	141	153	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29567	29574		10.1074/jbc.M102753200	http://dx.doi.org/10.1074/jbc.M102753200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11384979	hybrid			2022-12-25	WOS:000170346000122
J	Hamilton, SR; Yao, SYM; Ingram, JC; Hadden, DA; Ritzel, MWL; Gallagher, MP; Henderson, PJF; Cass, CE; Young, JD; Baldwin, SA				Hamilton, SR; Yao, SYM; Ingram, JC; Hadden, DA; Ritzel, MWL; Gallagher, MP; Henderson, PJF; Cass, CE; Young, JD; Baldwin, SA			Subcellular distribution and membrane topology of the mammalian concentrative Na+-nucleoside cotransporter rCNT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; GLUCOSE-TRANSPORTER; PYRIMIDINE NUCLEOSIDES; TRANSMEMBRANE SEGMENTS; ADENOSINE RECEPTORS; PURINE NUCLEOSIDES; MOLECULAR-CLONING; XENOPUS-LAEVIS; PROTEINS; SYSTEM	The rat transporter rCNT1 is the archetype of a family of concentrative nucleoside transporters (CNTs) found both in eukaryotes and in prokaryotes. In the present study we have used antibodies to investigate the subcellular distribution and membrane topology of this protein. rCNT1 was found to be expressed predominantly in the brush-border membranes of the polarized epithelial cells of rat jejunum and renal cortical tubules and in the bile canalicular membranes of liver parenchymal cells, consistent with roles in the absorption of dietary nucleosides, of nucleosides in the glomerular filtrate, or of nucleosides arising from the action of extracellular nucleotidases, respectively. The effect of endoglycosidase F treatment on wild-type and mutant rCNT1 expressed in Xenopus oocytes revealed that the recombinant transporter could be glycosylated at either or both of Asn(605) and Asn(643), indicating that its C terminus is extracellular. In contrast, potential N-glycosylation sites introduced near the N terminus, or between putative transmembrane (TM) helices 4 and 5, were not glycosylated. The deduced orientation of the N terminus in the cytoplasm was confirmed by immunocytochemistry on intact and saponin-permeabilized Chinese hamster ovary cells expressing recombinant rCNT1. These results, in conjunction with extensive analyses of CNT family protein sequences using predictive algorithms, lead us to propose a revised topological model, in which rCNT1 possesses 13 TM helices with the hydrophilic N-terminal and C-terminal domains on the cytoplasmic and extracellular sides of the membrane, respectively. Furthermore, we show that the first three TM helices, which are absent from prokaryote CNTs, are not essential for transporter function; truncated proteins lacking these helices, derived either from rCNT1 or from its human homolog hCNT1, were found to retain significant sodium-dependent uridine transport activity when expressed in oocytes.	Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England; Univ Edinburgh, Inst Cell & Mol Biol, Edinburgh EH9 3JR, Midlothian, Scotland; Univ Alberta, Dept Physiol, Membrane Transport Res Grp, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Cross Canc Inst, Dept Oncol, Edmonton, AB T6G 2H7, Canada	University of Leeds; University of Edinburgh; University of Alberta; University of Alberta	Baldwin, SA (corresponding author), Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England.	s.a.balswin@leeds.ac.uk	Gallagher, Maurice P/A-3781-2014; Henderson, Peter JF/Q-1907-2018; Cass, Carol E/F-5861-2010	Henderson, Peter/0000-0002-9187-0938				Baldwin SA, 1999, MOL MED TODAY, V5, P216, DOI 10.1016/S1357-4310(99)01459-8; CASS CE, 1999, MEMBRANE TRANSPORTER, P313; CHE MX, 1992, J BIOL CHEM, V267, P9684; CHE MX, 1995, J BIOL CHEM, V270, P13596, DOI 10.1074/jbc.270.23.13596; CRAIG JE, 1994, MOL MICROBIOL, V11, P1159, DOI 10.1111/j.1365-2958.1994.tb00392.x; DAVIES A, 1990, BIOCHEM J, V266, P799; Felipe A, 1998, BIOCHEM J, V330, P997, DOI 10.1042/bj3300997; FUKUMOTO H, 1989, J BIOL CHEM, V264, P7776; Griffith DA, 1996, BBA-REV BIOMEMBRANES, V1286, P153, DOI 10.1016/S0304-4157(96)00008-1; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; Hamilton SR, 1997, J PHYSIOL-LONDON, V499P, pP50; HASPEL HC, 1985, J BIOL CHEM, V260, P7219; HRESKO RC, 1994, J BIOL CHEM, V269, P20482; HUANG QQ, 1994, J BIOL CHEM, V269, P17757; HUANG QQ, 1993, J BIOL CHEM, V268, P20613; Iseki K, 1996, BBA-BIOMEMBRANES, V1278, P105, DOI 10.1016/0005-2736(95)00198-0; Kaiser SM, 1999, DRUG DISCOV TODAY, V4, P542, DOI 10.1016/S1359-6446(99)01421-X; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; LEHIR M, 1990, RENAL PHYSIOL BIOCH, V13, P154; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Loewen SK, 1999, J BIOL CHEM, V274, P24475, DOI 10.1074/jbc.274.35.24475; Mackey JR, 1998, DRUG RESIST UPDATE, V1, P310, DOI 10.1016/S1368-7646(98)80047-2; MOSELEY RH, 1991, AM J PHYSIOL, V261, pG716, DOI 10.1152/ajpgi.1991.261.5.G716; MURRAY AW, 1971, ANNU REV BIOCHEM, V40, P811, DOI 10.1146/annurev.bi.40.070171.004115; Patil SD, 1997, AM J PHYSIOL-GASTR L, V272, pG1314, DOI 10.1152/ajpgi.1997.272.6.G1314; PERSSON B, 1994, J MOL BIOL, V237, P182, DOI 10.1006/jmbi.1994.1220; Popov M, 1997, J BIOL CHEM, V272, P18325, DOI 10.1074/jbc.272.29.18325; Ritzel MWL, 1998, MOL MEMBR BIOL, V15, P203; Ritzel MWL, 1997, AM J PHYSIOL-CELL PH, V272, pC707, DOI 10.1152/ajpcell.1997.272.2.C707; Ritzel MWL, 2001, J BIOL CHEM, V276, P2914, DOI 10.1074/jbc.M007746200; RODEN M, 1991, GASTROENTEROLOGY, V100, P1553, DOI 10.1016/0016-5085(91)90652-2; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; RUIZMONTASELL B, 1992, J MEMBRANE BIOL, V128, P227; Shryock JC, 1997, AM J CARDIOL, V79, P2, DOI 10.1016/S0002-9149(97)00256-7; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; THORENS B, 1990, AM J PHYSIOL, V259, pC286; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; Wang J, 1999, J BIOL CHEM, V274, P2298, DOI 10.1074/jbc.274.4.2298; Wang J, 1997, PHARM RES-DORDR, V14, P1524, DOI 10.1023/A:1012113931332; Yao SYM, 1996, MOL PHARMACOL, V50, P1529; YOUNG JD, 2000, GASTROINTESTINAL TRA, P329	41	78	80	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27981	27988		10.1074/jbc.M100518200	http://dx.doi.org/10.1074/jbc.M100518200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11375981	hybrid			2022-12-25	WOS:000170093400033
J	Takatsu, H; Katoh, Y; Shiba, Y; Nakayama, K				Takatsu, H; Katoh, Y; Shiba, Y; Nakayama, K			Golgi-localizing, gamma-adaptin ear homology domain, ADP-ribosylation factor-binding (GGA) proteins interact with acidic dileucine sequences within the cytoplasmic domains of sorting receptors through their Vps27p/Hrs/STAM (VHS) domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI; ARF PROTEINS; FAMILY; IDENTIFICATION; TRAFFICKING; LOCALIZATION; NETWORK; PATHWAY; FURIN; SITE	GGA (Golgi-localizing, <(<gamma>)under bar>-adaptin ear homology domain, ARF-binding) proteins are potential effectors of ADP-ribosylation factors, are associated with the trans-Golgi network (TGN), and are involved in protein transport from this compartment. By yeast two-hybrid screening and subsequent two-hybrid and pull-down analyses, we have shown that GGA proteins, through their VHS (Vps27p/Hrs/STAM) domains, interact with acidic dileucine sequences found in the cytoplasmic domains of TGN-localized sorting receptors such as sortilin and mannose 6-phosphate receptor. A mutational analysis has revealed that a leucine pair and a cluster of acidic residues adjacent to the pair are mainly responsible for the interaction. A chimeric receptor with the sortilin cytoplasmic domain localizes to the TGN, whereas the chimeric receptor with a mutation at the leucine pair or the acidic cluster is mislocalized to punctate structures reminiscent of early endosomes. These results indicate that GGA proteins regulate the localization to or exit from the TGN of the sorting receptors.	Univ Tsukuba, Inst Biol Sci, Tsukuba, Ibaraki 3058572, Japan; Univ Tsukuba, Gene Expt Ctr, Tsukuba, Ibaraki 3058572, Japan	University of Tsukuba; University of Tsukuba	Nakayama, K (corresponding author), Univ Tsukuba, Inst Biol Sci, Tsukuba, Ibaraki 3058572, Japan.	kazunaka@sakura.cc.tsukuba.ac.jp	Shiba, Yoko/AAX-3885-2020; Katoh, Yohei/AAA-3378-2020; Nakayama, Kazuhisa/ABF-2924-2020	Shiba, Yoko/0000-0001-8229-541X; Katoh, Yohei/0000-0003-1649-4917; Nakayama, Kazuhisa/0000-0001-7701-7183				Black MW, 2000, J CELL BIOL, V151, P587, DOI 10.1083/jcb.151.3.587; Boman AL, 2000, MOL BIOL CELL, V11, P1241, DOI 10.1091/mbc.11.4.1241; BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; Chen HJ, 1997, J BIOL CHEM, V272, P7003, DOI 10.1074/jbc.272.11.7003; Dell'Angelica EC, 2000, J CELL BIOL, V149, P81, DOI 10.1083/jcb.149.1.81; Futatsumori M, 2000, J BIOCHEM-TOKYO, V128, P793, DOI 10.1093/oxfordjournals.jbchem.a022817; HILLEREHFELD A, 1995, BBA-REV BIOMEMBRANES, V1241, P177, DOI 10.1016/0304-4157(95)00004-B; Hirst J, 2000, J CELL BIOL, V149, P67, DOI 10.1083/jcb.149.1.67; HORAZDOVSKY BF, 1995, CURR OPIN CELL BIOL, V7, P544, DOI 10.1016/0955-0674(95)80012-3; Hyman J, 2000, J CELL BIOL, V149, P537, DOI 10.1083/jcb.149.3.537; Ishii H, 1998, GENOMICS, V51, P132, DOI 10.1006/geno.1998.5339; Itoh T, 2001, SCIENCE, V291, P1047, DOI 10.1126/science.291.5506.1047; JONES BG, 1995, EMBO J, V14, P5869, DOI 10.1002/j.1460-2075.1995.tb00275.x; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; Le Borgne R, 1998, BBA-MOL CELL RES, V1404, P195, DOI 10.1016/S0167-4889(98)00057-3; Lohi O, 1998, FEBS LETT, V440, P255, DOI 10.1016/S0014-5793(98)01401-X; Mao YX, 2000, CELL, V100, P447, DOI 10.1016/S0092-8674(00)80680-7; Misra S, 2000, BIOCHEMISTRY-US, V39, P11282, DOI 10.1021/bi0013546; Molloy SS, 1999, TRENDS CELL BIOL, V9, P28, DOI 10.1016/S0962-8924(98)01382-8; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; Moss J, 1998, J BIOL CHEM, V273, P21431, DOI 10.1074/jbc.273.34.21431; Nielsen MS, 2001, EMBO J, V20, P2180, DOI 10.1093/emboj/20.9.2180; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Petersen CM, 1997, J BIOL CHEM, V272, P3599, DOI 10.1074/jbc.272.6.3599; Poussu A, 2000, J BIOL CHEM, V275, P7176, DOI 10.1074/jbc.275.10.7176; Puertollano R, 2001, CELL, V105, P93, DOI 10.1016/S0092-8674(01)00299-9; Takatsu H, 2000, BIOCHEM BIOPH RES CO, V271, P719, DOI 10.1006/bbrc.2000.2700; Takatsu H, 1998, J BIOL CHEM, V273, P24693, DOI 10.1074/jbc.273.38.24693; TORII S, 1995, J BIOL CHEM, V270, P11574, DOI 10.1074/jbc.270.19.11574; Wan L, 1998, CELL, V94, P205, DOI 10.1016/S0092-8674(00)81420-8; Zhdankina O, 2001, YEAST, V18, P1, DOI 10.1002/1097-0061(200101)18:1<1::AID-YEA644>3.0.CO;2-5	32	160	170	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28541	28545		10.1074/jbc.C100218200	http://dx.doi.org/10.1074/jbc.C100218200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11390366	hybrid			2022-12-25	WOS:000170093400106
J	Ufret-Vincenty, CA; Baro, DJ; Lederer, WJ; Rockman, HA; Quinones, LE; Santana, LF				Ufret-Vincenty, CA; Baro, DJ; Lederer, WJ; Rockman, HA; Quinones, LE; Santana, LF			Role of sodium channel deglycosylation in the genesis of cardiac arrhythmias in heart failure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-QT; MOLECULAR-GENETICS; IONIC CURRENTS; DYNAMIC-MODEL; SUDDEN-DEATH; CALCIUM; EXPRESSION; MECHANISM; MUTATION; DOMAIN	We investigated the cellular and molecular mechanisms underlying arrhythmias in heart failure. A genetically engineered mouse lacking the expression of the muscle LIM protein (MLP-/-) was used in this study as a model of heart failure. We used electrocardiography and patch clamp techniques to examine the electrophysiological properties of MLP-/- hearts. We found that MLP-/- myocytes had smaller Na+ currents with altered voltage dependencies of activation and inactivation and slower rates of inactivation than control myocytes. These changes in Na+ currents contributed to longer action potentials and to a higher probability of early afterdepolarizations in MLP-/- than in control myocytes. Western blot analysis suggested that the smaller Na+ current in MLP-/- myocytes resulted from a reduction in Na+ channel protein. Interestingly, the blots also revealed that the a-subunit of the Na+ channel from the MLP-/- heart had a lower average molecular weight than in the control heart. Treating control myocytes with the sialidase neuraminidase mimicked the changes in voltage dependence and rate of inactivation of Na+ currents observed in MLP-/- myocytes. Neuraminidase had no effect on MLP-/- cells thus suggesting that Na+ channels in these cells were sialic acid-deficient. We conclude that deficient glycosylation of Na+ channel contributes to Na+ current-dependent arrhythmogenesis in heart failure.	Univ Puerto Rico, Inst Neurobiol, San Juan, PR 00901 USA; Univ Puerto Rico, Dept Biochem, San Juan, PR 00936 USA; Univ Maryland, Sch Med, Ctr Med Biotechnol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; Duke Univ, Med Ctr, Dept Med & Cell Biol, Durham, NC 27710 USA	University of Puerto Rico; University of Puerto Rico; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Duke University	Santana, LF (corresponding author), Univ Washington, Dept Physiol & Biophys, Box 357290, Seattle, WA 98195 USA.	lsantana@neurobio.upr.clu.edu	Santana, Luis/AAF-9298-2019; Lederer, William/B-1285-2010	Santana, Luis/0000-0002-4297-8029; 	NCRR NIH HHS [G12RR-03051] Funding Source: Medline; NHLBI NIH HHS [R01 HL67927] Funding Source: Medline; NINDS NIH HHS [R01 NS38770, 1 U54 NS39405-02] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [G12RR003051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [U54NS039405, R01NS038770] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; Baro DJ, 2000, J NEUROSCI, V20, P6619, DOI 10.1523/JNEUROSCI.20-17-06619.2000; Bennett E, 1997, J GEN PHYSIOL, V109, P327, DOI 10.1085/jgp.109.3.327; BENNETT PB, 1995, NATURE, V376, P683, DOI 10.1038/376683a0; BEUCKELMANN DJ, 1993, CIRC RES, V73, P379, DOI 10.1161/01.RES.73.2.379; Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; Esposito G, 2000, AM J PHYSIOL-HEART C, V279, pH3101, DOI 10.1152/ajpheart.2000.279.6.H3101; FRANKENHAEUSER B, 1957, J PHYSIOL-LONDON, V137, P218, DOI 10.1113/jphysiol.1957.sp005808; George AL, 1996, NEPHROL DIAL TRANSPL, V11, P1730; HILLE B, 1975, J PHYSIOL-LONDON, V250, pP34; Kaab S, 1998, CIRCULATION, V98, P1383, DOI 10.1161/01.CIR.98.14.1383; Kambouris NG, 2000, J CLIN INVEST, V105, P1133, DOI 10.1172/JCI9212; KANNEL WB, 1988, AM HEART J, V115, P869, DOI 10.1016/0002-8703(88)90891-5; Kass RS, 1996, CARDIOVASC RES, V32, P443, DOI 10.1016/S0008-6363(96)00122-8; KASS RS, 1978, J PHYSIOL-LONDON, V281, P187, DOI 10.1113/jphysiol.1978.sp012416; Knollmann BC, 2000, J PHYSIOL-LONDON, V525, P483, DOI 10.1111/j.1469-7793.2000.t01-1-00483.x; London B, 1998, P NATL ACAD SCI USA, V95, P2926, DOI 10.1073/pnas.95.6.2926; LUO CH, 1994, CIRC RES, V74, P1097, DOI 10.1161/01.RES.74.6.1097; LUO CH, 1994, CIRC RES, V74, P1071, DOI 10.1161/01.RES.74.6.1071; MA TS, 1979, CARDIOVASC RES, V13, P568, DOI 10.1093/cvr/13.10.568; Minamisawa S, 1999, CELL, V99, P313, DOI 10.1016/S0092-8674(00)81662-1; O'Rourke B, 1999, CIRC RES, V84, P562, DOI 10.1161/01.RES.84.5.562; Pak PH, 1997, J AM COLL CARDIOL, V30, P576, DOI 10.1016/S0735-1097(97)00193-9; Pogwizd SM, 1999, CIRC RES, V85, P1009; Rockman HA, 1998, P NATL ACAD SCI USA, V95, P7000, DOI 10.1073/pnas.95.12.7000; Russell MW, 1996, CURR OPIN CARDIOL, V11, P45, DOI 10.1097/00001573-199601000-00008; Sanguinetti MC, 1997, NEUROPHARMACOLOGY, V36, P755, DOI 10.1016/S0028-3908(97)00029-4; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Santana LF, 1997, J PHYSIOL-LONDON, V503, P21, DOI 10.1111/j.1469-7793.1997.021bi.x; Satler CA, 1996, AM J MED GENET, V65, P27, DOI 10.1002/(SICI)1096-8628(19961002)65:1<27::AID-AJMG4>3.3.CO;2-J; Wang DW, 1996, P NATL ACAD SCI USA, V93, P13200, DOI 10.1073/pnas.93.23.13200; Wattanasirichaigoon Duangrurdee, 1998, Current Opinion in Pediatrics, V10, P628; Wehrens XHT, 2000, CIRCULATION, V102, P584; Wilde AAM, 1997, PACE, V20, P2048, DOI 10.1111/j.1540-8159.1997.tb03625.x; Zhang Y, 1999, J MEMBRANE BIOL, V171, P195, DOI 10.1007/s002329900571; Zolk O, 2000, CIRCULATION, V101, P2674, DOI 10.1161/01.CIR.101.23.2674	36	101	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28197	28203		10.1074/jbc.M102548200	http://dx.doi.org/10.1074/jbc.M102548200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11369778	hybrid			2022-12-25	WOS:000170093400062
J	Liu, LH; Boivin, GP; Prasad, V; Periasamy, M; Shull, GE				Liu, LH; Boivin, GP; Prasad, V; Periasamy, M; Shull, GE			Squamous cell tumors in mice heterozygous for a null allele of Atp2a2, encoding the sarco(endo)plasmic reticulum Ca2+-ATPase isoform 2 Ca2+ pump	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR FREE CALCIUM; DARIERS-DISEASE; MOUSE KERATINOCYTES; GENE-EXPRESSION; ACINAR-CELLS; SERCA2 GENE; THAPSIGARGIN; CARCINOMA; DIFFERENTIATION; PROMOTER	Mutations in the human ATP2A2 gene, encoding sarco(endo)plasmic reticulum Ca2+-ATPase isoform 2 (SERCA2), cause Darier disease, an autosomal dominant skin disease characterized by multiple keratotic papules in the seborrheic regions of the body. Mice with a single functional Atp2a2 allele (the mouse homolog of ATP2A2) were shown previously to have reduced levels of SERCA2 in heart and mildly impaired cardiac contractility and relaxation, Here we show that aged heterozygous mutant (Atp2a2(+/-)) mice develop squamous cell tumors of the forestomach, esophagus, oral mucosa, tongue, and skin, Squamous cell tumors occurred in 13/14 Atp2a2(+/-) mice but were not observed in age- and sex-matched wild-type controls. Hyperkeratinized squamous cell papillomas and carcinomas of the upper digestive tract were the most frequent finding among Atp2a2(+/-) mice, and many animals had multiple tumors. Western blot analyses showed that SERCA2 protein levels were reduced in skin and other affected tissues of heterozygous mice. The development of squamous cell tumors in aged Atp2a2(+/-) mice indicates that SERCA2 haploinsufficiency predisposes murine keratinocytes to neoplasia, These findings provide the first direct demonstration that a perturbation of Ca2+ homeostasis or signaling can serve as a primary initiating event in cancer.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Pathol & Lab Med, Cincinnati, OH 45267 USA; Ohio State Univ, Coll Med & Publ Hlth, Dept Physiol & Cell Biol, Columbus, OH 43210 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; Ohio State University	Shull, GE (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, 231 Bethesda Ave, Cincinnati, OH 45267 USA.			Periasamy, Muthu/0000-0001-8834-5975	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007382, R01HL064140, R01HL061974] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050594, R37DK050594] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL64140, HL61974, TG-HL07382] Funding Source: Medline; NIDDK NIH HHS [DK50594] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACHS O, 1992, BIOCHIM BIOPHYS ACTA, V1113, P259, DOI 10.1016/0304-4157(92)90041-8; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BURGE SM, 1992, J AM ACAD DERMATOL, V27, P40, DOI 10.1016/0190-9622(92)70154-8; Cheng GM, 1996, ARCH BIOCHEM BIOPHYS, V329, P65, DOI 10.1006/abbi.1996.0192; COLE K, 1994, CANCER METAST REV, V13, P31, DOI 10.1007/BF00690417; Downs AMR, 1997, CLIN EXP DERMATOL, V22, P277; Gafter U, 1997, J LAB CLIN MED, V130, P33, DOI 10.1016/S0022-2143(97)90056-1; GUNTESKIHAMBLIN AM, 1988, J BIOL CHEM, V263, P15032; HAKII H, 1986, J CANCER RES CLIN, V111, P177, DOI 10.1007/BF00389230; HASEMAN JK, 1999, PATHOLOGY MOUSE, P679; Ji Y, 2000, J BIOL CHEM, V275, P38073, DOI 10.1074/jbc.M004804200; JONES KT, 1994, EXP CELL RES, V210, P71, DOI 10.1006/excr.1994.1011; KOHN EC, 1995, CANCER RES, V55, P1856; KRUSZEWSKI FH, 1991, AM J PHYSIOL, V261, pC767, DOI 10.1152/ajpcell.1991.261.5.C767; LI LW, 1995, CELL GROWTH DIFFER, V6, P1171; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; LINU JM, 1998, J CELL BIOL, V142, P963; Lowry DT, 1996, CARCINOGENESIS, V17, P699, DOI 10.1093/carcin/17.4.699; LYTTON J, 1988, J BIOL CHEM, V263, P15024; MITTING H, 1900, J CUTAN PATHOL, V17, P388; ORIHUELA E, 1995, J UROLOGY, V153, P1940, DOI 10.1016/S0022-5347(01)67363-4; Periasamy M, 1999, J BIOL CHEM, V274, P2556, DOI 10.1074/jbc.274.4.2556; PETERSEN CCH, 1993, J BIOL CHEM, V268, P22262; Rodland KD, 1997, MOL ENDOCRINOL, V11, P281, DOI 10.1210/me.11.3.281; Sakuntabhai A, 1999, NAT GENET, V21, P271, DOI 10.1038/6784; SCHWEIZER J, 1988, CELL TISSUE RES, V253, P221; Shimizu H, 2000, EUR J DERMATOL, V10, P470; Shull GE, 2000, EUR J BIOCHEM, V267, P5284, DOI 10.1046/j.1432-1327.2000.01568.x; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TWIGG J, 1988, NATURE, V332, P366, DOI 10.1038/332366a0; Wu YG, 1997, CLIN CANCER RES, V3, P1915	31	84	89	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26737	26740		10.1074/jbc.C100275200	http://dx.doi.org/10.1074/jbc.C100275200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11389134	hybrid			2022-12-25	WOS:000169966900002
J	Rah, JC; Kim, HS; Kim, SS; Bach, JH; Jeong, SJ; Seo, JH; Park, CH; Kim, YS; Suh, YH				Rah, JC; Kim, HS; Kim, SS; Bach, JH; Jeong, SJ; Seo, JH; Park, CH; Kim, YS; Suh, YH			Effects of the carboxyl-terminal fragment of Alzheimer's amyloid precursor protein and amyloid beta-peptide on the production of cytokines and nitric oxide in glial cells	FASEB JOURNAL			English	Article						Alzheimer's disease; chemokines; inflammation; cell death	SELECTIVE NEUROTOXICITY; REACTIVE ASTROCYTES; TNF-ALPHA; DISEASE; SYNTHASE; BRAIN; INDUCTION; IMMUNOREACTIVITY; ALPHA-1-ANTICHYMOTRYPSIN; INTERLEUKIN-1	In a brain with Alzheimer's disease (AD), activated glial cells are observed surrounding amyloid plaque. In this study, to investigate the roles of carboxyl-terminal fragments (CTs) of amyloid precursor protein (APP) and amyloid beta-peptide (Abeta) in inflammatory processes possibly linked to neurodegeneration associated with AD, we examined the effects of the CT of APP with 105 amino acid residues (CT105) on the alteration of inflammatory mediators in rat cortical astrocytes and microglial cells and compared these effects to those of Abeta. We found that cytokines including interleukin 1beta (IL-1beta) and tumor necrosis factor a and chemokines such as macrophage inflammatory protein 1alpha, monocyte chemoattractant protein 1, and RANTES (regulated on activation, normal T expressed and secreted) were highly induced by 100 nM CT105 in a time-dependent manner, whereas the same amount of Abeta(1-42) did not significantly induce these mediators. In addition, inducible nitric oxide synthase (iNOS) expression and nitrite accumulation induced by CT105 were inhibited by IL-1 receptor antagonist (IL-1ra). Furthermore, the addition of conditioned media from CT105-treated astrocytes to rat cortical neurons caused a decrease in cell viability. Pretreatment with IL-1ra, N-G-nitro-L-arginine methyl ester (a specific inhibitor of NOS), and pyrollidine dithiocarbamate [an inhibitor of nuclear factor-kappaB (NF-kappaB)] prevented neuronal cell death caused by conditioned media from CT105-treated astrocytes. Our results indicate that the activation of astrocytes by CT105 leads to neuronal cell death in vitro, presumably caused by the increase in nitric oxide derived from the induction of iNOS through the activation of cytokines and NF-kappaB. Thus, CT105 may contribute to stimulation of inflammatory processes linked to delayed neuro degeneration in AD.	Seoul Natl Univ, Natl Creat Res Initiat Ctr Alzheimers Dementia, Coll Med, Dept Pharmacol, Seoul 110799, South Korea; Seoul Natl Univ, MRC, Neurosci Res Inst, Seoul 110799, South Korea; Chung Ang Univ, Coll Med, Dept Anat, Seoul 156756, South Korea	Seoul National University (SNU); Seoul National University (SNU); Chung Ang University; Chung Ang University Hospital	Suh, YH (corresponding author), Seoul Natl Univ, Natl Creat Res Initiat Ctr Alzheimers Dementia, Coll Med, Dept Pharmacol, Seoul 110799, South Korea.	yhsuh@plaza.snu.ac.kr	Kim, Yong-Sik/J-5418-2012; Suh, Yoo-Hun/J-2761-2012; Kim, Hye Sun/J-2752-2012	Kim, Yong-Sik/0000-0003-3763-4544; Rah, Jong-Cheol/0000-0003-3780-0522				ABRAHAM CR, 1988, CELL, V52, P487, DOI 10.1016/0092-8674(88)90462-X; Akama KT, 2000, J BIOL CHEM, V275, P7918, DOI 10.1074/jbc.275.11.7918; Chan ED, 1998, BIOCHEM BIOPH RES CO, V253, P790, DOI 10.1006/bbrc.1998.9857; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHONG YH, 1994, LIFE SCI, V54, P1259; Cuzzocrea S, 1998, LIFE SCI, V63, P789, DOI 10.1016/S0024-3205(98)00334-8; DYRKS T, 1992, J BIOL CHEM, V267, P18210; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; Eissa NT, 1996, J BIOL CHEM, V271, P27184, DOI 10.1074/jbc.271.43.27184; Evans TJ, 1996, P NATL ACAD SCI USA, V93, P9553, DOI 10.1073/pnas.93.18.9553; Ferrer I, 1998, NEUROPATH APPL NEURO, V24, P271; Fiala M, 1998, MOL MED, V4, P480, DOI 10.1007/BF03401753; FUKUCHI K, 1993, NEUROSCI LETT, V154, P145, DOI 10.1016/0304-3940(93)90192-N; FUKUCHI K, 1992, MOL BRAIN RES, V16, P37, DOI 10.1016/0169-328X(92)90191-D; GALEA E, 1992, P NATL ACAD SCI USA, V89, P10945, DOI 10.1073/pnas.89.22.10945; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; Gura T, 1996, SCIENCE, V272, P954, DOI 10.1126/science.272.5264.954; Hardy J, 1998, NAT NEUROSCI, V1, P355, DOI 10.1038/1565; Johnstone M, 1999, J NEUROIMMUNOL, V93, P182, DOI 10.1016/S0165-5728(98)00226-4; KAMETANI F, 1994, FEBS LETT, V351, P165, DOI 10.1016/0014-5793(94)00851-5; KAMMESHEIDT A, 1992, P NATL ACAD SCI USA, V89, P10857, DOI 10.1073/pnas.89.22.10857; Koeberle PD, 1999, EXP NEUROL, V158, P366, DOI 10.1006/exnr.1999.7113; KOZLOWSKI MR, 1992, J NEUROSCI, V12, P1679; Lee JP, 2000, J NEUROSCI RES, V60, P565, DOI 10.1002/(SICI)1097-4547(20000515)60:4<565::AID-JNR16>3.0.CO;2-I; Licastro F, 2000, J NEUROIMMUNOL, V103, P97, DOI 10.1016/S0165-5728(99)00226-X; Lombardi VRM, 1999, J NEUROIMMUNOL, V97, P163, DOI 10.1016/S0165-5728(99)00046-6; Lu DC, 2000, NAT MED, V6, P397, DOI 10.1038/74656; Markesbery WR, 1999, BRAIN PATHOL, V9, P133; MARUYAMA K, 1990, NATURE, V347, P566, DOI 10.1038/347566a0; MATSUMOTO A, 1994, BBA-MOL BASIS DIS, V1225, P304, DOI 10.1016/0925-4439(94)90011-6; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; McGeer PL, 1996, NEUROLOGY, V47, P425, DOI 10.1212/WNL.47.2.425; Meda L, 1999, J NEUROIMMUNOL, V93, P45, DOI 10.1016/S0165-5728(98)00188-X; MRAK RE, 1995, HUM PATHOL, V26, P816, DOI 10.1016/0046-8177(95)90001-2; Murphy MP, 1999, BBA-BIOENERGETICS, V1411, P401, DOI 10.1016/S0005-2728(99)00029-8; OsterGranite ML, 1996, J NEUROSCI, V16, P6732; PODLISNY MB, 1993, AM J PATHOL, V142, P17; ROGERS J, 1992, P NATL ACAD SCI USA, V89, P10016, DOI 10.1073/pnas.89.21.10016; SELKOE DJ, 1994, J NEUROPATH EXP NEUR, V53, P438, DOI 10.1097/00005072-199409000-00003; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SHEARMAN MS, 1995, J NEUROCHEM, V65, P218, DOI 10.1046/j.1471-4159.1995.65010218.x; Suh YH, 1997, J NEUROCHEM, V68, P1781; Taylor BS, 1998, J BIOL CHEM, V273, P15148, DOI 10.1074/jbc.273.24.15148; Wallace MN, 1997, EXP NEUROL, V144, P266, DOI 10.1006/exnr.1996.6373; Xia MQ, 1999, J NEUROVIROL, V5, P32, DOI 10.3109/13550289909029743; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201	47	22	23	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR 27	2001	15	6					1463	+		10.1096/fj.00-0724fje	http://dx.doi.org/10.1096/fj.00-0724fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387258				2022-12-25	WOS:000173705800013
J	Belka, C; Schmid, B; Marini, P; Durand, E; Rudner, J; Faltin, H; Bamberg, M; Schulze-Osthoff, K; Budach, W				Belka, C; Schmid, B; Marini, P; Durand, E; Rudner, J; Faltin, H; Bamberg, M; Schulze-Osthoff, K; Budach, W			Sensitization of resistant lymphoma cells to irradiation-induced apoptosis by the death ligand TRAIL	ONCOGENE			English	Article						TRAIL; radiation; caspase-8; Bcl-2; apoptosis	RADIATION-INDUCED APOPTOSIS; CYTOCHROME-C; TUMOR-CELLS; EXPRESSION; GENE; CASPASE-8; RECEPTORS; SURVIVAL; RELEASE; FADD	A combination of antitumor approaches acting on different death pathways seems ideal for increasing therapeutic responses, especially when defined resistance mechanisms interfere with individual cellular processes. Apoptosis pathways triggered by ionizing radiation (XRT) and the death ligand TRAIL were analysed in Jurkat lymphoma cells. Both induced the activation of caspase-8, caspase-3, BID and mitochondrial potential loss, TRAIL induced apoptosis required caspase-8, whereas it was not essential for radiation induced apoptosis. The inhibition of mitochondrial damage by Bcl-2 abrogated XRT induced apoptosis and caspase activation, but only marginally attenuated TRAIL induced cell death. The combined treatment with TRAIL and XRT exerted additive apoptotic effects in control cells, whereas highly synergistic effects occurred in cells overexpressing Bcl-2. In addition, a strong effect of TRAIL on radiation induced clonogenic cell death was found. In conclusion, TRAIL seems to be of high potential value for a combination with ionizing radiation in tumor therapy.	Univ Tubingen, Dept Radiat Oncol, D-72076 Tubingen, Germany; Univ Munster, Inst Expt Dermatol, Dept Immunol & Cell Biol, D-48149 Muenster, Germany	Eberhard Karls University of Tubingen; University of Munster	Belka, C (corresponding author), Univ Tubingen, Dept Radiat Oncol, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.		Rudner, Justine/ABD-1397-2021; Schulze-Osthoff, Klaus/N-9025-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720				ALDRIDGE DR, 1995, BRIT J CANCER, V71, P571, DOI 10.1038/bjc.1995.111; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; BARGOU RC, 1995, INT J CANCER, V60, P854, DOI 10.1002/ijc.2910600622; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Gong BD, 2000, CANCER RES, V60, P5754; GRECO WR, 1995, PHARMACOL REV, V47, P331; GREEN MHL, 1991, INT J RADIAT BIOL, V59, P749, DOI 10.1080/09553009114550661; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MIYASHITA T, 1995, CELL, V80, P293; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nitsch R, 2000, LANCET, V356, P827, DOI 10.1016/S0140-6736(00)02659-3; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Sheikh MS, 1998, CANCER RES, V58, P1593; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; STEEL GG, 1979, INT J RADIAT ONCOL, V5, P85; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Walczak H, 2000, CANCER RES, V60, P3051; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730	29	116	122	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 19	2001	20	17					2190	2196		10.1038/sj.onc.1204318	http://dx.doi.org/10.1038/sj.onc.1204318			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	422KH	11360204				2022-12-25	WOS:000168116700015
J	Wheeler, DG; Cooper, E				Wheeler, DG; Cooper, E			Depolarization strongly induces human cytomegalovirus major immediate-early promoter/enhancer activity in neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SYMPATHETIC NEURONS; GENE-EXPRESSION; EARLY PROMOTER; ADENOVIRUS VECTOR; TRANSGENIC MICE; EARLY ENHANCER; CYCLIC-AMP; VIRUS; INDUCTION; TRANSCRIPTION	Activity-dependent changes in gene expression involving the transcription factor cAMP-response element-binding protein (CREB) occur in learning and memory, pain, and drug addiction. This mechanism may also be important for cytomegaloviral infections of the brain. The human cytomegalovirus major immediate-early promoter/enhancer (hCMV promoter), rate-limiting for productive cytomegalovirus infection, contains five cAMP-response elements (CREs). Indirect evidence suggests that this promoter does not function in unstimulated neurons. Here we test the hypothesis that expression from the hCMV promoter in neurons is induced by membrane depolarization. For these experiments, we infected cultured sympathetic and hippocampal neurons with hCMV-green fluorescent protein (GFP) promoter/reporter constructs using adenoviral gene transfer techniques and measured transgene expression by quantifying GFP fluorescence and GFP mRNA levels. We found that depolarization up-regulates promoter activity by > 90-fold. Moreover, our results from pharmacological experiments suggest that this induction occurred through a CREB-dependent pathway. Importantly, site-directed mutagenesis of all five CREs in the promoter blocked this up-regulation almost completely, whereas mutating four of them had no effect. We conclude that the bCMV promoter acts as a molecular switch in neurons and is strongly induced by membrane depolarization, neuronal activity, or other stimuli that activate CREB. These results may provide insight into molecular mechanisms of cytomegalovirus-related diseases of the brain.	McGill Univ, Dept Physiol, Montreal, PQ H3G 1Y6, Canada	McGill University	Cooper, E (corresponding author), McGill Univ, Dept Physiol, McIntyre Med Sci Bldg,3655 Promenade Sir William, Montreal, PQ H3G 1Y6, Canada.	Ecooper@med.mcgill.ca						Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8; Canaff L, 1998, ENDOCRINOLOGY, V139, P1184, DOI 10.1210/en.139.3.1184; Clifford DB, 1999, SEMIN NEUROL, V19, P185, DOI 10.1055/s-2008-1040836; Cohen Bruce A., 1997, P595; DeKoninck P, 1995, J NEUROSCI, V15, P7966; FICKENSCHER H, 1989, J GEN VIROL, V70, P107, DOI 10.1099/0022-1317-70-1-107; Fritschy JM, 1996, J NEUROSCI, V16, P2275; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HUETTNER JE, 1986, J NEUROSCI, V6, P3044; HUNNINGHAKE GW, 1989, J VIROL, V63, P3026, DOI 10.1128/JVI.63.7.3026-3033.1989; Impey S, 1996, NEURON, V16, P973, DOI 10.1016/S0896-6273(00)80120-8; Kordower JH, 2000, SCIENCE, V290, P767, DOI 10.1126/science.290.5492.767; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LASALLE GL, 1993, SCIENCE, V259, P988, DOI 10.1126/science.8382374; MANDELZYS A, 1994, J NEUROSCI, V14, P2357; Meier JL, 1996, INTERVIROLOGY, V39, P331, DOI 10.1159/000150504; Millhouse S, 2000, J NEUROVIROL, V6, P6, DOI 10.3109/13550280009006378; Mocarski ES, 1996, P NATL ACAD SCI USA, V93, P11321, DOI 10.1073/pnas.93.21.11321; NybergHoffman C, 1997, NAT MED, V3, P808, DOI 10.1038/nm0797-808; RIDEG K, 1994, DIFFERENTIATION, V56, P119, DOI 10.1007/s002580050028; Schorge S, 1999, NAT NEUROSCI, V2, P785, DOI 10.1038/12153; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Shering AF, 1997, J GEN VIROL, V78, P445, DOI 10.1099/0022-1317-78-2-445; STAMMINGER T, 1990, J GEN VIROL, V71, P105, DOI 10.1099/0022-1317-71-1-105; Thomas CE, 2000, P NATL ACAD SCI USA, V97, P7482, DOI 10.1073/pnas.120474397; van den Pol AN, 1998, J NEUROSCI, V18, P10640; WHEELER DG, 2000, 30 ANN SOC NEUR M NO; Whitley Richard J., 1997, P223; WILEY CA, 1986, J NEUROPATH EXP NEUR, V45, P127, DOI 10.1097/00005072-198603000-00003; WILKINSON GWG, 1992, NUCLEIC ACIDS RES, V20, P2233, DOI 10.1093/nar/20.9.2233	31	46	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					31978	31985		10.1074/jbc.M103667200	http://dx.doi.org/10.1074/jbc.M103667200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11397804	hybrid			2022-12-25	WOS:000170613500070
J	Yuan, YR; Blecker, S; Martsinkevich, O; Millen, L; Thomas, PJ; Hunt, JF				Yuan, YR; Blecker, S; Martsinkevich, O; Millen, L; Thomas, PJ; Hunt, JF			The crystal structure of the MJ0796 ATP-binding cassette - Implications for the structural consequences of ATP hydrolysis in the active site of an ABC transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARCHAEON THERMOCOCCUS-LITORALIS; SALMONELLA-TYPHIMURIUM; HISTIDINE PERMEASE; ESCHERICHIA-COLI; ANOMALOUS DIFFRACTION; SUBUNIT INTERACTIONS; PROTEIN-STRUCTURE; P-GLYCOPROTEIN; MALK SUBUNIT; MALTOSE	The crystal structure of the MJ0796 ATP-binding cassette, a member of the o228/LolD transporter family, has been determined at 2.7-Angstrom resolution with MgADP bound at its active site. Comparing this structure with that of the ATP-bound form of the HisP ATP-binding cassette (Hung, L. W., Wang, I. X., Nikaido, K., Liu, P. Q., Ames, G. F., and Kim, S. H. (1998) Nature 396, 703-707) shows a 5-Angstrom withdrawal of a phylogenetically invariant glutamine residue from contact with the gamma -phosphate of ATP in the active site. This glutamine is located in a protein segment that links the rigid F-1-type ATP-binding core of the enzyme to an ABC transporter-specific alpha -helical subdomain that moves substantially away from the active site in the MgADP-bound structure of MJ0796 compared with the ATP-bound structure of HisP. A similar conformational effect is observed in the MgADP-bound structure of MJ1267 (Karpowich, N., et al (2001) Structure, in press), establishing the withdrawal of the glutamine and the coupled outward rotation of the alpha -helical subdomain as consistent consequences of gamma -phosphate release from the active site of the transporter. Considering this subdomain movement in the context of a leading model for the physiological dimer of cassettes present in ABC transporters indicates that it produces a modest mechanical change that is likely to play a role in facilitating nucleotide exchange out of the ATPase active site. Finally, it is noteworthy that one of the intersubunit packing interactions in the MJ0796 crystal involves antiparallel beta -type hydrogen bonding interactions between the outermost beta -strands in the two core beta -sheets, leading to their fusion into a single extended beta -sheet, a type of structural interaction that has been proposed to play a role in mediating the aggregation of beta -sheet-containing proteins.	Columbia Univ, Dept Biol Sci, Fairchild Ctr 702A, New York, NY 10027 USA; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA	Columbia University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Hunt, JF (corresponding author), Columbia Univ, Dept Biol Sci, Fairchild Ctr 702A, MC2434, New York, NY 10027 USA.		Thomas, Philip J/F-7115-2012					ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, XPLOR SYSTEM CRYSTAL; Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P487, DOI 10.1107/S0907444997011980; Davidson AL, 1996, J BIOL CHEM, V271, P4858; DELEPELAIRE P, 1991, MOL MICROBIOL, V5, P2427, DOI 10.1111/j.1365-2958.1991.tb02088.x; Diederichs K, 2000, EMBO J, V19, P5951, DOI 10.1093/emboj/19.22.5951; Drenth J, 1994, PRINCIPLES PROTEIN X; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FINCH JT, 1973, P NATL ACAD SCI USA, V70, P718, DOI 10.1073/pnas.70.3.718; Gottesman MM, 1996, CURR OPIN GENET DEV, V6, P610, DOI 10.1016/S0959-437X(96)80091-8; Greller G, 1999, J BIOL CHEM, V274, P20259, DOI 10.1074/jbc.274.29.20259; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HOBOHM U, 1992, PROTEIN SCI, V1, P409; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Hunke S, 2000, J BIOL CHEM, V275, P15526, DOI 10.1074/jbc.275.20.15526; HUNKE S, 1995, BIOCHEM BIOPH RES CO, V216, P589, DOI 10.1006/bbrc.1995.2663; Janin J, 1997, NAT STRUCT BIOL, V4, P973, DOI 10.1038/nsb1297-973; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Karpowich N, 2001, STRUCTURE, V9, P571, DOI 10.1016/S0969-2126(01)00617-7; Kelly JW, 1997, STRUCTURE, V5, P595, DOI 10.1016/S0969-2126(97)00215-3; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; Linton KJ, 1998, MOL MICROBIOL, V28, P5, DOI 10.1046/j.1365-2958.1998.00764.x; Lippincott J, 1997, J BACTERIOL, V179, P1337, DOI 10.1128/jb.179.4.1337-1343.1997; Liu CE, 1997, J BIOL CHEM, V272, P21883, DOI 10.1074/jbc.272.35.21883; Liu PQ, 1999, J BIOL CHEM, V274, P18310, DOI 10.1074/jbc.274.26.18310; MCCUTCHEN SL, 1995, BIOCHEMISTRY-US, V34, P13527, DOI 10.1021/bi00041a032; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MORBACH S, 1993, J BIOL CHEM, V268, P18617; MOSSER J, 1993, NATURE, V361, P726, DOI 10.1038/361726a0; Mourez M, 1998, MOL MICROBIOL, V30, P353, DOI 10.1046/j.1365-2958.1998.01070.x; Mourez M, 1997, EMBO J, V16, P3066, DOI 10.1093/emboj/16.11.3066; Nicholls A., 1992, GRASP GRAPHICAL REPR; Nikaido K, 1997, J BIOL CHEM, V272, P27745, DOI 10.1074/jbc.272.44.27745; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PADLAN EA, 1985, J BIOL CHEM, V260, P8280; Paulsen IT, 1998, J MOL BIOL, V277, P573, DOI 10.1006/jmbi.1998.1609; Qu BH, 1996, J BIOL CHEM, V271, P7261, DOI 10.1074/jbc.271.13.7261; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Saurin W, 1999, J MOL EVOL, V48, P22, DOI 10.1007/PL00006442; Schmees G, 1999, EUR J BIOCHEM, V266, P420, DOI 10.1046/j.1432-1327.1999.00871.x; SCHNEIDER E, 1994, J BIOL CHEM, V269, P20456; Senior AE, 1997, SEMIN CANCER BIOL, V8, P143, DOI 10.1006/scbi.1997.0065; Sunde M, 1998, Q REV BIOPHYS, V31, P1, DOI 10.1017/S0033583598003400; Tatusov RL, 2000, NUCLEIC ACIDS RES, V28, P33, DOI 10.1093/nar/28.1.33; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; van Veen HW, 2000, EMBO J, V19, P2503, DOI 10.1093/emboj/19.11.2503; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Wilken S, 1996, MOL MICROBIOL, V22, P655, DOI 10.1046/j.1365-2958.1996.d01-1724.x; WILMOT CM, 1990, PROTEIN ENG, V3, P479, DOI 10.1093/protein/3.6.479	57	219	223	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32313	32321		10.1074/jbc.M100758200	http://dx.doi.org/10.1074/jbc.M100758200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11402022	hybrid			2022-12-25	WOS:000170613500113
J	Basanez, G; Zhang, J; Chau, BN; Maksaev, GI; Frolov, VA; Brandt, TA; Burch, J; Hardwick, JM; Zimmerberg, J				Basanez, G; Zhang, J; Chau, BN; Maksaev, GI; Frolov, VA; Brandt, TA; Burch, J; Hardwick, JM; Zimmerberg, J			Pro-apoptotic cleavage products of Bcl-x(L) form cytochrome c-conducting pores in pure lipid membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 FAMILY-MEMBERS; ION-CHANNEL; CELL-DEATH; MITOCHONDRIAL DYSFUNCTION; BAX OLIGOMERIZATION; CASPASE ACTIVATION; PROAPOPTOTIC BAX; RELEASE; PROTEIN; INHIBITION	During apoptotic cell death, cells usually release apoptogenic proteins such as cytochrome c from the mitochondrial intermembrane space. If Bcl-2 family proteins induce such release by increasing outer mitochondrial membrane permeability, then the pro-apoptotic, but not anti-apoptotic activity of these proteins should correlate with their permeabilization of membranes to cytochrome c. Here, we tested this hypothesis using pro-survival full-length Bcl-x(L) and pro-death Bcl-x(L) cleavage products (Delta N612Bcl-x(L) and Delta N76Bcl-x(L)). Unlike Bcl-x(L), Delta N61Bcl-x(L) and Delta N76Bcl-x(L) caused the release of cytochrome c from mitochondria in vivo and in vitro. Recombinant Delta N61Bcl-x(L) and Delta N76Bcl-x(L), as well as Bcl-xL, cleaved in situ by caspase 3-possessed intrinsic pore-forming activity as demonstrated by their ability to efficiently permeabilize pure lipid vesicles. Furthermore, only Delta N61Bcl-x(L) and Delta N76Bcl-x(L), but not Bcl-x(L), formed pores large enough to release cytochrome c and to destabilize planar lipid bilayer membranes through reduction of pore line tension. Because Bcl-x(L) and its C-terminal cleavage products bound similarly to lipid membranes and formed oligomers of the same size, neither lipid affinity nor protein-protein interactions appear to be solely responsible for the increased membrane-perturbing activity elicited by Bcl-x(L) cleavage. Taken together, these data are consistent with the hypothesis that Bax-like proteins oligomerize to form lipid-containing pores in the outer mitochondrial membrane, thereby releasing intermembrane apoptogenic factors into the cytosol.	NICHHD, Lab Cellular & Mol Biophys, NIH, Bethesda, MD 20892 USA; Johns Hopkins Univ, Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Publ Hlth, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Publ Hlth, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Russian Acad Sci, Frumkin Inst Electrochem, Moscow 117071, Russia	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Russian Academy of Sciences; Frumkin Institute of Physical Chemistry & Electrochemistry	Basanez, G (corresponding author), NICHHD, Lab Cellular & Mol Biophys, NIH, 10 Ctr Dr, Bethesda, MD 20892 USA.	basanezg@mail.nih.gov; joshz@helix.nih.gov	Frolov, Vadim/ABH-3889-2020; Basanez, Gorka/L-9509-2014	Frolov, Vadim/0000-0002-0653-5669; Basanez, Gorka/0000-0002-7475-7861	NINDS NIH HHS [NS34175, NS37402] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001409] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034175, R01NS037402] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Alimonti JB, 2001, J BIOL CHEM, V276, P6974, DOI 10.1074/jbc.M008444200; Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Aritomi M, 1997, J BIOL CHEM, V272, P27886, DOI 10.1074/jbc.272.44.27886; Basanez G, 1999, P NATL ACAD SCI USA, V96, P5492, DOI 10.1073/pnas.96.10.5492; Bonev BB, 2001, J BIOL CHEM, V276, P5714, DOI 10.1074/jbc.M005126200; Butko P, 1996, BIOCHEMISTRY-US, V35, P11355, DOI 10.1021/bi960970s; Chen MC, 2000, J BIOL CHEM, V275, P38794, DOI 10.1074/jbc.M003292200; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CHERNOMORDIK LV, 1987, BIOCHIM BIOPHYS ACTA, V906, P309, DOI 10.1016/0304-4157(87)90016-5; Chernomordik LV, 1998, J CELL BIOL, V140, P1369, DOI 10.1083/jcb.140.6.1369; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Condorelli F, 2001, MOL CELL BIOL, V21, P3025, DOI 10.1128/MCB.21.9.3025-3036.2001; Darley-Usmar V.M., 1987, MITOCHONDRIA PRACTIC, P4; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Fadeel B, 1999, LEUKEMIA, V13, P719, DOI 10.1038/sj.leu.2401411; Fadeel B, 1999, FASEB J, V13, P1647, DOI 10.1096/fasebj.13.13.1647; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Fujita N, 1998, BIOCHEM BIOPH RES CO, V246, P484, DOI 10.1006/bbrc.1998.8587; Fujita N, 1998, ONCOGENE, V17, P1295, DOI 10.1038/sj.onc.1202065; Gao G, 2000, J CELL BIOCHEM, V80, P53; Gilbert RJC, 1999, CELL, V97, P647, DOI 10.1016/S0092-8674(00)80775-8; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Heibein JA, 2000, J EXP MED, V192, P1391, DOI 10.1084/jem.192.10.1391; Hirotani M, 1999, J BIOL CHEM, V274, P20415, DOI 10.1074/jbc.274.29.20415; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kim YM, 1998, J BIOL CHEM, V273, P31437, DOI 10.1074/jbc.273.47.31437; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Kluck RM, 1999, J CELL BIOL, V147, P809, DOI 10.1083/jcb.147.4.809; Kudla G, 2000, J BIOL CHEM, V275, P22713, DOI 10.1074/jbc.M003807200; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lin JH, 2000, BIOPHYS J, V78, P1714, DOI 10.1016/S0006-3495(00)76723-3; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Matsuzaki K, 1998, BIOCHEMISTRY-US, V37, P11856, DOI 10.1021/bi980539y; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Melikov KC, 2001, BIOPHYS J, V80, P1829, DOI 10.1016/S0006-3495(01)76153-X; Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Petros AM, 2001, P NATL ACAD SCI USA, V98, P3012, DOI 10.1073/pnas.041619798; Saito M, 2000, NAT CELL BIOL, V2, P553, DOI 10.1038/35019596; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Schendel SL, 1999, J BIOL CHEM, V274, P21932, DOI 10.1074/jbc.274.31.21932; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; STEWART JCM, 1980, ANAL BIOCHEM, V104, P10, DOI 10.1016/0003-2697(80)90269-9; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Sutton VR, 2000, J EXP MED, V192, P1403, DOI 10.1084/jem.192.10.1403; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Tomicic MT, 2001, BIOCHEM BIOPH RES CO, V281, P404, DOI 10.1006/bbrc.2001.4367; Valcarcel CA, 2001, BIOPHYS J, V80, P2761, DOI 10.1016/S0006-3495(01)76244-3; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; von Ahsen O, 2000, J CELL BIOL, V150, P1027, DOI 10.1083/jcb.150.5.1027; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Wood DE, 2000, EXP CELL RES, V256, P375, DOI 10.1006/excr.2000.4859; Yang L, 2000, BIOPHYS J, V79, P2002, DOI 10.1016/S0006-3495(00)76448-4; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; Zhang XM, 1999, BIOCHEM J, V340, P127, DOI 10.1042/0264-6021:3400127; Zimmerberg J, 2000, TRAFFIC, V1, P366, DOI 10.1034/j.1600-0854.2000.010409.x	71	123	127	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31083	31091		10.1074/jbc.M103879200	http://dx.doi.org/10.1074/jbc.M103879200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11399768	hybrid			2022-12-25	WOS:000170472900066
J	Ragimbeau, J; Dondi, E; Vasserot, A; Romero, P; Uze, G; Pellegrini, S				Ragimbeau, J; Dondi, E; Vasserot, A; Romero, P; Uze, G; Pellegrini, S			The receptor interaction region of Tyk2 contains a motif required for its nuclear localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON-ALPHA/BETA RECEPTOR; TYROSINE KINASE TYK2; DNA-BINDING DOMAIN; SIGNAL-TRANSDUCTION; TRANSCRIPTION FACTOR; EXPORT SIGNAL; IN-VITRO; PHOSPHORYLATION; STAT1; FAMILY	Janus kinases have so far been viewed as enzymatic intermediates that couple a variety of cell surface receptors to downstream substrates with diverse effector functions. Tyk2 is a member of this family that is involved in the interferon-alpha/beta and interleukin-12 signaling pathways via its specific interaction with the IFNAR1 and the beta1 receptor subunits. Here, we have analyzed the subcellular distribution of the wild-type Tyk2 protein and of several mutants expressed in Tyk2-deficient human cells. Direct GFP-associated fluorescence and immunostaining showed a diffuse localization of Tyk2 throughout the cell, including the nuclear compartment. The nuclear localization of Tyk2 requires a nuclear localization signal-like motif rich in arginine residues that maps within the region mediating interaction with cytokine receptors. To address the question of the role of the Tyk2 nuclear pool in interferon-alpha/beta -induced biological effects, cells expressing a membrane-targeted form of Tyk2-green fluorescent protein were analyzed for their interferon-alpha responses. Our studies demonstrate that Tyk2 can reside in the nucleus independently of receptor binding and that the nuclear pool is dispensable for the transcriptional and anti-vesicular stomatitis virus responses induced by interferon-alpha.	Inst Pasteur, Lab Signalisat Cytokines, F-75724 Paris 15, France; CNRS, Inst Mol Genet, EP2030, F-34293 Montpellier, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Pellegrini, S (corresponding author), Inst Pasteur, Lab Signalisat Cytokines, 25 Rue Dr Roux, F-75724 Paris 15, France.		Pellegrini, Sandra -/G-5546-2015; Uzé, Gilles/O-6383-2019; Pellegrini, Sandra/Y-6351-2019	Pellegrini, Sandra -/0000-0001-5837-7589; Pellegrini, Sandra/0000-0001-5837-7589; Dondi, Elisabetta/0000-0003-0975-459X; Uze, Gilles/0000-0002-4150-5772				BACON CM, 1995, J EXP MED, V181, P399, DOI 10.1084/jem.181.1.399; BADER T, 1994, P NATL ACAD SCI USA, V91, P11831, DOI 10.1073/pnas.91.25.11831; Begitt A, 2000, P NATL ACAD SCI USA, V97, P10418, DOI 10.1073/pnas.190318397; Bork P, 1996, METHOD ENZYMOL, V266, P162; BURWEN SJ, 1987, TRENDS BIOCHEM SCI, V12, P159, DOI 10.1016/0968-0004(87)90074-0; Cans C, 2000, BIOCHEM PHARMACOL, V60, P1203, DOI 10.1016/S0006-2952(00)00434-2; Constantinescu SN, 2001, MOL CELL, V7, P377, DOI 10.1016/S1097-2765(01)00185-X; Cornell RB, 2000, TRENDS BIOCHEM SCI, V25, P441, DOI 10.1016/S0968-0004(00)01625-X; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Decker T, 1999, CELL MOL LIFE SCI, V55, P1535, DOI 10.1007/s000180050393; Gately MK, 1998, ANNU REV IMMUNOL, V16, P495, DOI 10.1146/annurev.immunol.16.1.495; Gauzzi MC, 1997, P NATL ACAD SCI USA, V94, P11839, DOI 10.1073/pnas.94.22.11839; Gauzzi MC, 1996, J BIOL CHEM, V271, P20494, DOI 10.1074/jbc.271.34.20494; Girault JA, 1999, TRENDS BIOCHEM SCI, V24, P54, DOI 10.1016/S0968-0004(98)01331-0; Girault JA, 1998, MOL MED, V4, P751, DOI 10.1007/BF03401769; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Haspel RL, 1999, P NATL ACAD SCI USA, V96, P10188, DOI 10.1073/pnas.96.18.10188; Hilton DJ, 1999, CELL MOL LIFE SCI, V55, P1568, DOI 10.1007/s000180050396; Jans DA, 1997, FEBS LETT, V406, P315, DOI 10.1016/S0014-5793(97)00293-7; Johnson HM, 1998, BIOCHEM BIOPH RES CO, V244, P607, DOI 10.1006/bbrc.1998.8254; Ju H, 2000, BIOCHEM J, V351, P257, DOI 10.1042/0264-6021:3510257; Kaffman A, 1999, ANNU REV CELL DEV BI, V15, P291, DOI 10.1146/annurev.cellbio.15.1.291; Kampa D, 2000, BIOCHEM BIOPH RES CO, V278, P175, DOI 10.1006/bbrc.2000.3757; Karaghiosoff M, 2000, IMMUNITY, V13, P549, DOI 10.1016/S1074-7613(00)00054-6; Kusch A, 2000, J BIOL CHEM, V275, P39466, DOI 10.1074/jbc.M003626200; KUSHNARYOV VM, 1985, P NATL ACAD SCI USA, V82, P3281, DOI 10.1073/pnas.82.10.3281; Lau JF, 2000, P NATL ACAD SCI USA, V97, P7278, DOI 10.1073/pnas.97.13.7278; Lavoie C, 2000, P NATL ACAD SCI USA, V97, P13637, DOI 10.1073/pnas.240278097; Lobie PE, 1996, ENDOCRINOLOGY, V137, P4037, DOI 10.1210/en.137.9.4037; Mahanty SK, 1999, CELL, V98, P501, DOI 10.1016/S0092-8674(00)81978-9; McBride KM, 2000, EMBO J, V19, P6196, DOI 10.1093/emboj/19.22.6196; Mowen K, 2000, MOL CELL BIOL, V20, P7273, DOI 10.1128/MCB.20.19.7273-7281.2000; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; Presky DH, 1996, P NATL ACAD SCI USA, V93, P14002, DOI 10.1073/pnas.93.24.14002; Ram PA, 1997, J BIOL CHEM, V272, P17694, DOI 10.1074/jbc.272.28.17694; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; Richter MF, 1998, J BIOL CHEM, V273, P24723, DOI 10.1074/jbc.273.38.24723; Rogge L, 1999, J IMMUNOL, V162, P3926; Savory JGA, 1999, MOL CELL BIOL, V19, P1025; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Sekimoto T, 1997, EMBO J, V16, P7067, DOI 10.1093/emboj/16.23.7067; Shimada Y, 2000, NAT CELL BIOL, V2, P117, DOI 10.1038/35000073; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; SORENSON RL, 1995, ENDOCRINOLOGY, V136, P4092, DOI 10.1210/en.136.9.4092; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Takaoka A, 2000, SCIENCE, V288, P2357, DOI 10.1126/science.288.5475.2357; Tsukita S, 1997, CURR OPIN CELL BIOL, V9, P70, DOI 10.1016/S0955-0674(97)80154-8; VELAZQUEZ L, 1995, J BIOL CHEM, V270, P3327, DOI 10.1074/jbc.270.7.3327; Wu CY, 1996, EUR J IMMUNOL, V26, P345, DOI 10.1002/eji.1830260212; Yeh TC, 2000, P NATL ACAD SCI USA, V97, P8991, DOI 10.1073/pnas.160130297; Yeh TC, 1999, CELL MOL LIFE SCI, V55, P1523, DOI 10.1007/s000180050392; Zou J, 1997, J BIOL CHEM, V272, P6073, DOI 10.1074/jbc.272.9.6073	52	27	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30812	30818		10.1074/jbc.M103559200	http://dx.doi.org/10.1074/jbc.M103559200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11399767	hybrid			2022-12-25	WOS:000170472900032
J	Santiago-Garcia, J; Mas-Oliva, J; Innerarity, TL; Pitas, RE				Santiago-Garcia, J; Mas-Oliva, J; Innerarity, TL; Pitas, RE			Secreted forms of the amyloid-beta precursor protein are ligands for the class A scavenger receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; SULFATE PROTEOGLYCAN FORM; BOVINE SERUM-ALBUMIN; ALZHEIMERS-DISEASE; NEXIN-II; INHIBITORY PROPERTIES; IN-VIVO; MACROPHAGE; BINDING; CELLS	Upon activation, platelets secrete a 120-kDa protein that competes for the binding and internalization of acetyl low density lipoproteins (AcLDL) by macrophages. From the amino-terminal amino acid sequence, amino acid composition, and immunoblot analysis, we identified the active factor in platelet secretion products as sAPP, an alpha -secretase cleavage product of the beta -amyloid precursor protein (APP), that contains a Kunitz-type protease inhibitor (KPI) domain. We showed that both sAPP751 (also called Nexin II) and sAPP695, which does not contain a KPI domain, are ligands for the class A scavenger receptor (SR-A). Chinese hamster ovary cells stably transfected to express the SR-A bound and internalized 4-fold more human platelet-derived sAPP than control cells. The binding and internalization of sAPP were inhibited by the SR-A antagonist fucoidin. In addition, sAPP competed as effectively as fucoidin for SR-A-mediated cell association and degradation of I-125-AcLDL. To determine if the KPI domain is required for the binding of sAPP to the SR-A, APP751 and APP695 were expressed in Chinese hamster ovary cells, and sAPP751 and sAPP695 purified from the medium were tested for their binding to the SR-A. sAPP751 and sAPP695 were equally effective in competing for the cell association of I-125-AeLDL by SR-A-expressing cells, demonstrating that the KPI domain is not essential for binding. We also found that sAPP751 is present in extracts of atherosclerotic lesions and that sAPP competes for the SR-A-mediated cell association of oxidized low density lipoprotein. Deletion mutagenesis indicated that a negatively charged region of APP (residues 191-264) contributes to binding to the SR-A. These results suggest that the SR-A contributes to the clearance of sAPP and that sAPP competes for the cell association of other SR-A ligands.	Univ Calif San Francisco, Gladstone Inst Neurol Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94141 USA; Natl Autonomous Univ Mexico, Inst Fisiol Celular, Mexico City 04510, DF, Mexico	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Universidad Nacional Autonoma de Mexico	Pitas, RE (corresponding author), Univ Calif San Francisco, Gladstone Inst Neurol Dis, POB 418100, San Francisco, CA 94141 USA.			Santiago-Garcia, Juan/0000-0003-1737-0270	NIA NIH HHS [AG13619] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG013619] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARNOLD KS, 1992, LIPOPROTEIN ANAL PRA, P145; Babaev VR, 2000, ARTERIOSCL THROM VAS, V20, P2593, DOI 10.1161/01.ATV.20.12.2593; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BELL MD, 1994, J NEUROCYTOL, V23, P605, DOI 10.1007/BF01191555; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; BUSH AI, 1990, J BIOL CHEM, V265, P15977; Christie RH, 1996, AM J PATHOL, V148, P399; DEJAGER S, 1993, ARTERIOSCLER THROMB, V13, P371, DOI 10.1161/01.ATV.13.3.371; DRESEL HA, 1987, EMBO J, V6, P319, DOI 10.1002/j.1460-2075.1987.tb04757.x; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; FREEMAN M, 1991, P NATL ACAD SCI USA, V88, P4931, DOI 10.1073/pnas.88.11.4931; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HAASS C, 1991, J NEUROSCI, V11, P3783; Henry A, 1997, PROTEIN EXPRES PURIF, V10, P283, DOI 10.1006/prep.1997.0748; Huang F, 1999, AM J PATHOL, V155, P1741, DOI 10.1016/S0002-9440(10)65489-2; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; Knauer MF, 1996, BRAIN RES, V740, P6, DOI 10.1016/S0006-8993(96)00711-1; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; MASOLIVA J, 1994, J BIOL CHEM, V269, P10177; MCGEER PL, 1992, J NEUROSCI RES, V31, P428, DOI 10.1002/jnr.490310305; NOZAKI S, 1995, J CLIN INVEST, V96, P1859, DOI 10.1172/JCI118231; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; OTTNAD E, 1990, BIOCHEM J, V265, P689, DOI 10.1042/bj2650689; OTTNAD E, 1992, BIOCHEM J, V281, P745, DOI 10.1042/bj2810745; Pangalos MN, 1996, NEURODEGENERATION, V5, P445, DOI 10.1006/neur.1996.0061; Paresce DM, 1996, NEURON, V17, P553, DOI 10.1016/S0896-6273(00)80187-7; PHILLIPS DR, 1985, NATURE, V316, P746, DOI 10.1038/316746a0; PITAS RE, 1980, J BIOL CHEM, V255, P5454; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; RAMPRASAD MP, 1995, P NATL ACAD SCI USA, V92, P9580, DOI 10.1073/pnas.92.21.9580; REFOLO LM, 1989, BIOCHEM BIOPH RES CO, V164, P664, DOI 10.1016/0006-291X(89)91511-8; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; Sakaguchi H, 1998, LAB INVEST, V78, P423; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHIOI J, 1995, J BIOL CHEM, V270, P11839, DOI 10.1074/jbc.270.20.11839; SHIOI J, 1992, J BIOL CHEM, V267, P13819; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SINHA S, 1990, J BIOL CHEM, V265, P8983; SMITH RP, 1992, BLOOD, V80, P2252; SMITH RP, 1990, SCIENCE, V248, P1126, DOI 10.1126/science.2111585; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; VANNOSTRAND WE, 1991, BIOCHEM BIOPH RES CO, V175, P15, DOI 10.1016/S0006-291X(05)81193-3; VANNOSTRAND WE, 1990, SCIENCE, V248, P745, DOI 10.1126/science.2110384; VANNOSTRAND WE, 1991, P NATL ACAD SCI USA, V88, P10302, DOI 10.1073/pnas.88.22.10302; VANNOSTRAND WE, 1990, J BIOL CHEM, V265, P9591; VANNOSTRAND WE, 1989, NATURE, V341, P546; VanVelzen AG, 1997, BIOCHEM J, V322, P411; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551; Yan SD, 1999, AM J PATHOL, V155, P1403, DOI 10.1016/S0002-9440(10)65452-1	58	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30655	30661		10.1074/jbc.M102879200	http://dx.doi.org/10.1074/jbc.M102879200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11389145	hybrid			2022-12-25	WOS:000170472900011
J	Anthonsen, MW; Solhaug, A; Johansen, B				Anthonsen, MW; Solhaug, A; Johansen, B			Functional coupling between secretory and cytosolic phospholipase A(2) modulates tumor necrosis factor-alpha- and interleukin-1 beta-induced NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ARACHIDONIC-ACID RELEASE; SIGNAL-TRANSDUCTION; HUMAN NEUTROPHILS; CELL-LINE; GROUP-IIA; P388D(1) MACROPHAGES; TRANSCRIPTION FACTOR; PROSTAGLANDIN D-2; MAST-CELLS	Tumor necrosis factor (TNF)-alpha and interleukin (IL)-1 beta are potent activators of the transcription factor NF-kappaB, induced during inflammatory conditions. We have previously shown that both secretory and cytosolic phospholipase A(2) (PLA(2)) are involved in TNF-alpha- and IL-1 beta -induced NF-kappaB activation. In this study, we have addressed the mechanism of PLA, involvement with respect to downstream arachidonic acid (AA) metabolites and the functional coupling between PLA(2)s mediating NF-kappaB activation. We show that in addition to inhibitors of secretory and cytosolic PLA2s, 5-lipoxygenase inhibitors attenuate TNF-alpha- and IL-1 beta -stimulated NF-KB activation. Exogenous addition of leukotriene B-4 (LTB4) restored NF-kappaB activation reduced by 5-lipoxygenase inhibitors or an LTB4 receptor antagonist, thus identifying LTB4 as a mediator in signaling to NF-kappaB. TNF-alpha- and IL-1 beta -induced AA release from cellular membranes was accompanied by phosphorylation of cytosolic PLA(2). Inhibitors of secretory PLA(2) and of 5-lipoxygenase/LTB4 functionality markedly reduced AA release and nearly completely abolished cytosolic PLA2 phosphorylation. This demonstrates that secretory PLA(2) through 5-lipoxygenase metabolites, is an essential upstream regulator of cytosolic PLA2 and AA release. Our results therefore suggest the existence of a functional link between secretory and cytosolic PLA2 in cytokine-activated keratinocytes, providing a molecular explanation for the participation of both secretory and cytosolic PLA(2) in arachidonic acid signaling and NF-KB activation in response to proinflammatory cytokines.	Norwegian Univ Sci & Technol, Fac Chem & Biol, Ctr Mol Biol, UNIGEN, N-7489 Trondheim, Norway	Norwegian University of Science & Technology (NTNU)	Anthonsen, MW (corresponding author), Norwegian Univ Sci & Technol, Fac Chem & Biol, Ctr Mol Biol, UNIGEN, N-7489 Trondheim, Norway.		Solhaug, Anita/AAJ-1063-2020	Solhaug, Anita/0000-0002-1908-406X				Al-Aoukaty A, 1999, J IMMUNOL, V162, P3249; Andersen S, 1996, SARCOIDOSIS VASC DIF, V13, P70; ANDERSEN S, 1994, INFLAMMATION, V18, P1, DOI 10.1007/BF01534593; Anthonsen MW, 2000, ARTERIOSCL THROM VAS, V20, P1276, DOI 10.1161/01.ATV.20.5.1276; Ashraf MDM, 1996, BIOCHEM BIOPH RES CO, V229, P726, DOI 10.1006/bbrc.1996.1872; Baek SH, 2000, J IMMUNOL, V164, P6359, DOI 10.4049/jimmunol.164.12.6359; Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; Balsinde J, 1999, ANNU REV PHARMACOL, V39, P175, DOI 10.1146/annurev.pharmtox.39.1.175; Balsinde J, 1998, P NATL ACAD SCI USA, V95, P7951, DOI 10.1073/pnas.95.14.7951; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; Belich MP, 1999, NATURE, V397, P363, DOI 10.1038/16946; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Bezzine S, 2000, J BIOL CHEM, V275, P3179, DOI 10.1074/jbc.275.5.3179; Bidgood MJ, 2000, J IMMUNOL, V165, P2790, DOI 10.4049/jimmunol.165.5.2790; Bonizzi G, 1997, J IMMUNOL, V159, P5264; Bonizzi G, 1999, MOL CELL BIOL, V19, P1950; BROCK TG, 1995, J BIOL CHEM, V270, P21652, DOI 10.1074/jbc.270.37.21652; Burgermeister E, 1999, EUR J PHARMACOL, V369, P373, DOI 10.1016/S0014-2999(99)00011-4; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Chen F, 1999, CLIN CHEM, V45, P7; CHEN J, 1994, J BIOL CHEM, V269, P2365; CHEN J, 1994, J BIOL CHEM, V269, P23018; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Cho W, 2000, BBA-MOL CELL BIOL L, V1488, P48, DOI 10.1016/S1388-1981(00)00109-8; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; Cupillard L, 1999, J BIOL CHEM, V274, P7043, DOI 10.1074/jbc.274.11.7043; Cupillard L, 1997, J BIOL CHEM, V272, P15745, DOI 10.1074/jbc.272.25.15745; DEJONG EMGJ, 1992, CLIN EXP DERMATOL, V17, P413; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; Flati V, 1996, EMBO J, V15, P1566, DOI 10.1002/j.1460-2075.1996.tb00501.x; FURSTENBERGER G, 1981, CANCER LETT, V11, P191, DOI 10.1016/0304-3835(81)90107-5; Gijon MA, 1999, J CELL BIOL, V145, P1219, DOI 10.1083/jcb.145.6.1219; Hefner Y, 2000, J BIOL CHEM, V275, P37542, DOI 10.1074/jbc.M003395200; Hernandez M, 1999, J NEUROCHEM, V73, P1641, DOI 10.1046/j.1471-4159.1999.0731641.x; Hernandez M, 1998, J BIOL CHEM, V273, P606, DOI 10.1074/jbc.273.1.606; HERRON DK, 1992, J MED CHEM, V35, P1818, DOI 10.1021/jm00088a018; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Huang Z., 1994, MEDIAT INFLAMM, V3, P307; Ishizaki J, 1999, J BIOL CHEM, V274, P24973, DOI 10.1074/jbc.274.35.24973; JAKOBSSON PJ, 1992, P NATL ACAD SCI USA, V89, P3521, DOI 10.1073/pnas.89.8.3521; JANSSENTIMMEN U, 1995, P NATL ACAD SCI USA, V92, P6966, DOI 10.1073/pnas.92.15.6966; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; Kuwata H, 1998, J BIOL CHEM, V273, P1733, DOI 10.1074/jbc.273.3.1733; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIN LL, 1992, J BIOL CHEM, V267, P23451; Lin WW, 1999, BRIT J PHARMACOL, V126, P1419, DOI 10.1038/sj.bjp.0702436; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; MARSHALL LA, 1995, J PHARMACOL EXP THER, V274, P1254; Marshall LA, 1997, J BIOL CHEM, V272, P759, DOI 10.1074/jbc.272.2.759; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; METTERS KM, 1995, J LIPID MEDIAT CELL, V12, P413, DOI 10.1016/0929-7855(95)00027-N; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Murakami M, 2001, J BIOL CHEM, V276, P10083, DOI 10.1074/jbc.M007877200; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; NEGISHI M, 1995, BBA-LIPID LIPID MET, V1259, P109, DOI 10.1016/0005-2760(95)00146-4; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; OFlaherty JT, 1996, J BIOL CHEM, V271, P17821, DOI 10.1074/jbc.271.30.17821; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; PFEILSCHIFTER J, 1993, J CLIN INVEST, V92, P2516, DOI 10.1172/JCI116860; Pickard RT, 1999, J BIOL CHEM, V274, P8823, DOI 10.1074/jbc.274.13.8823; Reddy ST, 1997, J BIOL CHEM, V272, P3231, DOI 10.1074/jbc.272.6.3231; RIENDEAU D, 1994, J BIOL CHEM, V269, P15619; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SAKSELA K, 1993, MOL CELL BIOL, V13, P3698, DOI 10.1128/MCB.13.6.3698; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; Schadow A, 2001, J INVEST DERMATOL, V116, P31, DOI 10.1046/j.1523-1747.2001.00179.x; SCHEVITZ RW, 1995, NAT STRUCT BIOL, V2, P458, DOI 10.1038/nsb0695-458; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SCHUTZE S, 1991, J EXP MED, V174, P975, DOI 10.1084/jem.174.5.975; Sjursen W, 2000, CYTOKINE, V12, P1189, DOI 10.1006/cyto.1999.0727; Spanbroek R, 1998, P NATL ACAD SCI USA, V95, P663, DOI 10.1073/pnas.95.2.663; STREET IP, 1993, BIOCHEMISTRY-US, V32, P5935, DOI 10.1021/bi00074a003; Syrbu SI, 1999, J IMMUNOL, V162, P2334; Takasaki J, 1998, J IMMUNOL, V160, P5066; Terry CM, 1999, AM J PHYSIOL-HEART C, V276, pH1493, DOI 10.1152/ajpheart.1999.276.5.H1493; Thommesen L, 1998, J IMMUNOL, V161, P3421; VADAS P, 1993, J LIPID MEDIATOR, V8, P1; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Wang YM, 1999, J NEUROSCI RES, V55, P293, DOI 10.1002/(SICI)1097-4547(19990201)55:3<293::AID-JNR4>3.3.CO;2-0; WEIDTMANN A, 1995, ARTERIOSCL THROM VAS, V15, P1131, DOI 10.1161/01.ATV.15.8.1131; Werz O, 2000, P NATL ACAD SCI USA, V97, P5261, DOI 10.1073/pnas.050588997; WIJKANDER J, 1995, J BIOL CHEM, V270, P26543, DOI 10.1074/jbc.270.44.26543; Zhao Q, 1999, J BIOL CHEM, V274, P8355, DOI 10.1074/jbc.274.13.8355	93	74	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30527	30536		10.1074/jbc.M008481200	http://dx.doi.org/10.1074/jbc.M008481200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11390371	hybrid			2022-12-25	WOS:000170558000121
J	Lauber, K; Appel, HAE; Schlosser, SF; Gregor, M; Schulze-Osthoff, K; Wesselborg, S				Lauber, K; Appel, HAE; Schlosser, SF; Gregor, M; Schulze-Osthoff, K; Wesselborg, S			The adapter protein apoptotic protease-activating factor-1 (Apaf-1) is proteolytically processed during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DRUG-INDUCED APOPTOSIS; WD-40 REPEAT REGION; CYTOCHROME-C; CASPASE ACTIVATION; CELL-DEATH; PROCASPASE-9 ACTIVATION; BCL-2 FAMILY; COMPLEX; CASPASE-8/FLICE; OLIGOMERIZATION	Apoptotle protease-activating factor-1 (Apaf-1), a key regulator of the mitochondrial apoptosis pathway, consists of three functional regions. (i) an N-terminal caspase recruitment domain (CARD) that can bind to procaspase-9, (ii) a CED-4-like region enabling self-oligomerization, and (iii) a regulatory C terminus with WD-40 repeats masking the CARD and CED-4 region. During apoptosis, cytochrome c and dATP can relieve the inhibitory action of the WD-40 repeats and thus enable the oligomerization of Apaf-1 and the subsequent recruitment and activation of procaspase-9. Here, we report that different apoptotic stimuli induced the caspase-mediated cleavage of Apaf-1 into an 84-kDa fragment. The same Apaf-1 fragment was obtained in vitro by incubation of cell lysates with either cytochrome c/dATP or caspase-3 but not with caspase-6 or caspase-8. Apaf-1 was cleaved at the N terminus, leading to the removal of its CARD HI helix. An additional cleavage site was located within the WD-40 repeats and enabled the oligomerization of p84 into a similar to 440-kDa Apaf-1 multimer even in the absence of cytochrome c. Due to the partial loss of its CARD, the p84 multimer was devoid of caspase-9 or other caspase activity. Thus, our data indicate that Apaf-1 cleavage causes the release of caspases from the apoptosome in the course of apoptosis.	Univ Tubingen, Dept Internal Med 1, D-72076 Tubingen, Germany; Univ Munster, Dept Immunol & Cell Biol, D-48149 Munster, Germany	Eberhard Karls University of Tubingen; University of Munster	Wesselborg, S (corresponding author), Univ Tubingen, Dept Internal Med 1, Otfried Muller Str 10, D-72076 Tubingen, Germany.		Schulze-Osthoff, Klaus/N-9025-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720; Wesselborg, Sebastian/0000-0002-5236-942X				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Adrain C, 1999, J BIOL CHEM, V274, P20855, DOI 10.1074/jbc.274.30.20855; Bantel H, 1999, CANCER RES, V59, P2083; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Bratton SB, 2000, EXP CELL RES, V256, P27, DOI 10.1006/excr.2000.4835; Bratton SB, 2001, CELL DEATH DIFFER, V8, P425, DOI 10.1038/sj.cdd.4400834; Cain K, 2000, J BIOL CHEM, V275, P6067, DOI 10.1074/jbc.275.9.6067; Cain K, 1999, J BIOL CHEM, V274, P22686, DOI 10.1074/jbc.274.32.22686; Day CL, 1999, CELL DEATH DIFFER, V6, P1125, DOI 10.1038/sj.cdd.4400584; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Faleiro L, 2000, J CELL BIOL, V151, P951, DOI 10.1083/jcb.151.5.951; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; Fesik SW, 2000, CELL, V103, P273, DOI 10.1016/S0092-8674(00)00119-7; Hausmann G, 2000, J CELL BIOL, V149, P623, DOI 10.1083/jcb.149.3.623; Hu YM, 1998, J BIOL CHEM, V273, P33489, DOI 10.1074/jbc.273.50.33489; Hu YM, 1999, EMBO J, V18, P3586, DOI 10.1093/emboj/18.13.3586; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Qin HX, 1999, NATURE, V399, P549, DOI 10.1038/21124; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Slee EA, 1999, CELL DEATH DIFFER, V6, P1067, DOI 10.1038/sj.cdd.4400601; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhivotovsky B, 1999, CELL DEATH DIFFER, V6, P644, DOI 10.1038/sj.cdd.4400536; Zhou P, 1999, P NATL ACAD SCI USA, V96, P11265, DOI 10.1073/pnas.96.20.11265; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	50	68	71	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29772	29781		10.1074/jbc.M101524200	http://dx.doi.org/10.1074/jbc.M101524200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11387322	hybrid			2022-12-25	WOS:000170558000024
J	Pacello, F; Langford, PR; Kroll, JS; Indiani, C; Smulevich, G; Desideri, A; Rotilio, G; Battistoni, A				Pacello, F; Langford, PR; Kroll, JS; Indiani, C; Smulevich, G; Desideri, A; Rotilio, G; Battistoni, A			A novel heme protein, the Cu,Zn-superoxide dismutase from Haemophilus ducreyi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CU,ZN SUPEROXIDE-DISMUTASE; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; COPPER-BINDING; CLONING; VIRULENCE; BACTERIAL; MUTANTS; PEROXIDASE; ENZYME	Haemophilus ducreyi, the causative agent of the genital ulcerative disease known as chancroid, is unable to synthesize heme, which it acquires from humans, its only known host. Here we provide evidence that the periplasmic Cu,Zn-superoxide dismutase from this organism is a heme-binding protein, unlike all the other known Cu,Zn-superoxide dismutases from bacterial and eukaryotic species. When the H. ducreyi enzyme was expressed in Escherichia coli cells, grown in standard LB medium, it contained only limited amounts of heme covalently bound to the polypeptide but was able efficiently to bind exogenously added hemin. Resonance Raman and electronic spectra at neutral pH indicate that H. ducreyi Cu,Zn-superoxide dismutase contains a 6-coordinated low spin heme, with two histidines as the most likely axial ligands. By site-directed mutagenesis and analysis of a structural model of the enzyme, we identified as a putative axial ligand a histidine residue (His-64) that is present only in the H. ducreyi enzyme and that was located at the bottom of the dimer interface. The introduction of a histidine residue in the corresponding position of the Cu,Zn-superoxide dismutase from Haemophilus parainfluenzae was not sufficient to confer the ability to bind heme, indicating that other residues neighboring His-64 are involved in the formation of the heme-binding pocket. Our results suggest that periplasmic Cu,Zn-superoxide dismutase plays a role in heme metabolism of H. ducreyi and provide further evidence for the structural flexibility of bacterial enzymes of this class.	Univ Roma Tor Vergata, Dipartimento Biol, I-00133 Rome, Italy; Univ Roma Tor Vergata, INFM, I-00133 Rome, Italy; Univ London Imperial Coll Sci Technol & Med, St Marys Hosp, Sch Med, Dept Paediat,Mol Infect Dis Grp, London W2 1PG, England; Univ Florence, Dipartimento Chim, I-50121 Florence, Italy	University of Rome Tor Vergata; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Rome Tor Vergata; Imperial College London; University of Florence	Battistoni, A (corresponding author), Univ Roma Tor Vergata, Dipartimento Biol, Via Ric Sci, I-00133 Rome, Italy.	andrea.battistoni@uniroma2.it	Battistoni, Andrea/A-4778-2016; smulevich, giulietta/A-6510-2008; Langford, Paul/AAU-4189-2020; Langford, Paul R/B-9092-2008	Battistoni, Andrea/0000-0003-4085-7917; Langford, Paul/0000-0002-6368-4724; Langford, Paul R/0000-0002-6368-4724; desideri, alessandro/0000-0003-1541-4217				Al-Tawfiq JA, 2000, J INFECT DIS, V181, P1049, DOI 10.1086/315309; Banci L, 2000, BIOCHEMISTRY-US, V39, P9108, DOI 10.1021/bi000067z; Battistoni A, 1998, BIOCHEM BIOPH RES CO, V243, P804, DOI 10.1006/bbrc.1998.8182; Battistoni A, 1996, BIOCHEM J, V320, P713, DOI 10.1042/bj3200713; Battistoni A, 1998, J BIOL CHEM, V273, P5655, DOI 10.1074/jbc.273.10.5655; BATTISTONI A, 1995, FEBS LETT, V374, P199, DOI 10.1016/0014-5793(95)01106-O; Battistoni A, 1999, FEBS LETT, V443, P313, DOI 10.1016/S0014-5793(98)01725-6; Battistoni A, 2001, J BIOL CHEM, V276, P30315, DOI 10.1074/jbc.M010527200; Bordo D, 1999, J MOL BIOL, V285, P283, DOI 10.1006/jmbi.1998.2267; BORDO D, 1994, J MOL BIOL, V238, P366, DOI 10.1006/jmbi.1994.1298; Bourne Y, 1996, P NATL ACAD SCI USA, V93, P12774, DOI 10.1073/pnas.93.23.12774; Brentjens RJ, 1996, J BACTERIOL, V178, P808, DOI 10.1128/jb.178.3.808-816.1996; CAMPAGNARI AA, 1991, INFECT IMMUN, V59, P2601, DOI 10.1128/IAI.59.8.2601-2608.1991; CARLIOZ A, 1986, EMBO J, V5, P623, DOI 10.1002/j.1460-2075.1986.tb04256.x; CARRI MT, 1994, FEBS LETT, V356, P314, DOI 10.1016/0014-5793(94)01295-4; CHOI S, 1982, J AM CHEM SOC, V104, P4345, DOI 10.1021/ja00380a006; Cope LD, 1997, P NATL ACAD SCI USA, V94, P4056, DOI 10.1073/pnas.94.8.4056; D'Orazio M, 2000, BIOCHEM BIOPH RES CO, V272, P81, DOI 10.1006/bbrc.2000.2730; DeGroote MA, 1997, P NATL ACAD SCI USA, V94, P13997, DOI 10.1073/pnas.94.25.13997; DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1645, DOI 10.1093/nar/11.6.1645; DePillis GD, 1997, J BIOL CHEM, V272, P8857; Di Iorio E E, 1981, Methods Enzymol, V76, P57; ELKINS C, 1995, INFECT IMMUN, V63, P1241, DOI 10.1128/IAI.63.4.1241-1245.1995; Fang FC, 1999, P NATL ACAD SCI USA, V96, P7502, DOI 10.1073/pnas.96.13.7502; Farrant JL, 1997, MOL MICROBIOL, V25, P785, DOI 10.1046/j.1365-2958.1997.5151877.x; Fayadat L, 1999, J BIOL CHEM, V274, P10533, DOI 10.1074/jbc.274.15.10533; Fiedler TJ, 2000, J BIOL CHEM, V275, P11964, DOI 10.1074/jbc.275.16.11964; Figueroa-Bossi N, 1999, MOL MICROBIOL, V33, P167, DOI 10.1046/j.1365-2958.1999.01461.x; Folcarelli S, 1998, BIOCHEM BIOPH RES CO, V244, P908, DOI 10.1006/bbrc.1998.8364; Forest KT, 2000, J MOL BIOL, V296, P145, DOI 10.1006/jmbi.1999.3448; Foti D, 1997, BIOCHEMISTRY-US, V36, P7109, DOI 10.1021/bi963020f; GUERINOT ML, 1994, ANNU REV MICROBIOL, V48, P743, DOI 10.1146/annurev.mi.48.100194.003523; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; Hu SZ, 1996, J AM CHEM SOC, V118, P12638, DOI 10.1021/ja962239e; KROLL JS, 1991, J BACTERIOL, V173, P7449, DOI 10.1128/jb.173.23.7449-7457.1991; KROLL JS, 1995, MICROBIOL-UK, V141, P2271, DOI 10.1099/13500872-141-9-2271; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langford PR, 1997, FEMS IMMUNOL MED MIC, V17, P235, DOI 10.1016/S0928-8244(97)00011-4; LEE BC, 1991, J MED MICROBIOL, V34, P317, DOI 10.1099/00222615-34-6-317; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARKLUND S, 1974, EUR J BIOCHEM, V47, P469; MEISSNER PS, 1987, P NATL ACAD SCI USA, V84, P4171, DOI 10.1073/pnas.84.12.4171; MESSING J, 1977, P NATL ACAD SCI USA, V74, P3642, DOI 10.1073/pnas.74.9.3642; NAKAYASHIKI T, 1995, MOL GEN GENET, V249, P139, DOI 10.1007/BF00290359; Oxvig C, 1999, J BIOL CHEM, V274, P16953, DOI 10.1074/jbc.274.24.16953; Palmer KL, 1995, MOL MICROBIOL, V18, P821, DOI 10.1111/j.1365-2958.1995.18050821.x; Pesce A, 1997, J MOL BIOL, V274, P408, DOI 10.1006/jmbi.1997.1400; Pesce A, 2000, J MOL BIOL, V302, P465, DOI 10.1006/jmbi.2000.4074; PETTIGREW GW, 1990, CYTOCHROME C EVOLUTI; Sambrook J., 1989, MOL CLONING LABORATO, V3, pA3; San Mateo LR, 1998, MOL MICROBIOL, V27, P391, DOI 10.1046/j.1365-2958.1998.00687.x; San Mateo LR, 1999, INFECT IMMUN, V67, P5345, DOI 10.1128/IAI.67.10.5345-5351.1999; Smith L, 1978, Methods Enzymol, V53, P202; SMULEVICH G, 1991, BIOCHEMISTRY-US, V30, P9546, DOI 10.1021/bi00103a023; Spiro TG, 1988, BIOL APPL RAMAN SPEC, V3, P1; STEINMAN HM, 1990, J BACTERIOL, V172, P2901, DOI 10.1128/jb.172.6.2901-2910.1990; STRITTMATTER P, 1956, J BIOL CHEM, V221, P253; Stroppolo ME, 2000, FEBS LETT, V483, P17, DOI 10.1016/S0014-5793(00)01967-0; TATUM FM, 1992, INFECT IMMUN, V60, P2863, DOI 10.1128/IAI.60.7.2863-2869.1992; TELZAK EE, 1993, ANN INTERN MED, V119, P1181, DOI 10.7326/0003-4819-119-12-199312150-00005; Thomas CE, 1998, INFECT IMMUN, V66, P4254; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; THONYMEYER L, 1995, J BACTERIOL, V177, P4321; ThonyMeyer L, 1997, MICROBIOL MOL BIOL R, V61, P337; TOTTEN PA, 1994, J CLIN MICROBIOL, V32, P2019, DOI 10.1128/JCM.32.8.2019-2023.1994; Wandersman C, 2000, CURR OPIN MICROBIOL, V3, P215, DOI 10.1016/S1369-5274(00)00078-3; WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001; Wilks KE, 1998, INFECT IMMUN, V66, P213, DOI 10.1128/IAI.66.1.213-217.1998	69	27	27	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30326	30334		10.1074/jbc.M010488200	http://dx.doi.org/10.1074/jbc.M010488200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11369755	hybrid			2022-12-25	WOS:000170558000095
J	Gardezi, SA; Nguyen, C; Malloy, PJ; Posner, GH; Feldman, D; Peleg, S				Gardezi, SA; Nguyen, C; Malloy, PJ; Posner, GH; Feldman, D; Peleg, S			A rationale for treatment of hereditary vitamin D-resistant rickets with analogs of 1 alpha,25-dihydroxyvitamin D-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-BINDING DOMAIN; RETINOID-X-RECEPTOR; NUCLEAR RECEPTOR; LIGAND-BINDING; INDUCED HETERODIMERIZATION; 20-EPI ANALOGS; CELL-GROWTH; 1,25-DIHYDROXYVITAMIN-D; TRANSCRIPTION; ACTIVATION	Hereditary vitamin D-resistant rickets (HVDRR) is caused by heterogeneous inactivating mutations in the vitamin D receptor (VDR). Treatment of HVDRR patients with high doses of oral calcium and supraphysiologic doses of 1 alpha ,25-dihydroxyvitamin D-3 (1,25D(3)) has had limited success. In this study we explored the use of vitamin D analogs as a potential therapy for this disorder. The rationale for the use of vitamin D analogs is that they bind the VDR at different amino acid residues than 1,25D(3), and their ability to modulate VDR functions differs from that of the natural hormone. In this report, we examined the VDR from three HVDRR patients with mutations in the ligand-binding domain of the VDR (histidine 305 to glut mine, arginine 274 to leucine, and phenylalanine 251 to cysteine) for their responses to two vitamin D analogs, 20-epi-1,25D(3) and 1 beta -hydroxymethyl-3-epi-16-ene-26a,27a-bishomo-25D(3) (JK-1626-2). Our results reveal that vitamin D analogs partially or completely restore the responsiveness of the mutated VDR. Analog treatment seemed to be more successful when the mutation affects the amino acids directly involved in ligand binding rather than amino acids that contribute to a functional VDR interface with dimerization partners or coactivators of transcription.	Univ Texas, MD Anderson Canc Ctr, Dept Endocrine Neoplasia & Hormonal Disorders, Houston, TX 77030 USA; Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA; Johns Hopkins Univ, Dept Chem, Baltimore, MD 21218 USA	University of Texas System; UTMD Anderson Cancer Center; Stanford University; Johns Hopkins University	Peleg, S (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Endocrine Neoplasia & Hormonal Disorders, 1515 Holcombe Blvd,Box 435, Houston, TX 77030 USA.				NCI NIH HHS [CA 44530] Funding Source: Medline; NIDDK NIH HHS [DK 50583, DK 42482] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA044530] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050583, R56DK042482, R01DK042482] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arbour NC, 1998, ANAL BIOCHEM, V255, P148, DOI 10.1006/abio.1997.2439; BALSAN S, 1983, J CLIN ENDOCR METAB, V57, P803, DOI 10.1210/jcem-57-4-803; Baudino TA, 1998, J BIOL CHEM, V273, P16434, DOI 10.1074/jbc.273.26.16434; BINDERUP L, 1991, BIOCHEM PHARMACOL, V42, P1569, DOI 10.1016/0006-2952(91)90426-6; BLIZIOTES M, 1988, J CLIN ENDOCR METAB, V66, P294, DOI 10.1210/jcem-66-2-294; BOUILLON R, 1995, ENDOCR REV, V16, P200, DOI 10.1210/er.16.2.200; BROOKS MH, 1978, NEW ENGL J MED, V298, P996, DOI 10.1056/NEJM197805042981804; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; GARDEZI A, 2000, VITAMIN D ENDOCRINE, P931; Haussler M. R., 1997, Vitamin D., P149; HOCHBERG Z, 1992, J PEDIATR-US, V121, P803, DOI 10.1016/S0022-3476(05)81919-5; HUGHES MR, 1988, SCIENCE, V242, P1702, DOI 10.1126/science.2849209; Jurutka PW, 2000, MOL ENDOCRINOL, V14, P401, DOI 10.1210/me.14.3.401; KRISTJANSSON K, 1993, J CLIN INVEST, V92, P12, DOI 10.1172/JCI116539; LIBERMAN UA, 1980, LANCET, V1, P504; Liu YY, 2000, MOL ENDOCRINOL, V14, P1776, DOI 10.1210/me.14.11.1776; Liu YY, 1997, J BIOL CHEM, V272, P3336, DOI 10.1074/jbc.272.6.3336; Malloy PJ, 1997, J CLIN INVEST, V99, P297, DOI 10.1172/JCI119158; Malloy PJ, 1999, ENDOCR REV, V20, P156, DOI 10.1210/er.20.2.156; MALLOY PJ, 1993, ENDOCRINOLOGY, V132, P1952; MALLOY PJ, 2001, IN PRESS MOL GENET M; MCDONNELL DP, 1989, MOL ENDOCRINOL, V3, P635, DOI 10.1210/mend-3-4-635; NAKAJIMA S, 1994, MOL ENDOCRINOL, V8, P159, DOI 10.1210/me.8.2.159; Norman AW, 1999, J CELL BIOCHEM, V74, P323, DOI 10.1002/(SICI)1097-4644(19990901)74:3<323::AID-JCB2>3.0.CO;2-V; Okamura W. H., 1997, Vitamin D., P939; Omdahl J., 1997, Vitamin D., P69; PELEG S, 1995, J BIOL CHEM, V270, P10551, DOI 10.1074/jbc.270.18.10551; Peleg S, 1998, MOL ENDOCRINOL, V12, P525, DOI 10.1210/me.12.4.525; PELEG S, 1994, VITAMIN D, P1011; RITCHIE HH, 1989, P NATL ACAD SCI USA, V86, P9783, DOI 10.1073/pnas.86.24.9783; Rochel N, 2000, MOL CELL, V5, P173, DOI 10.1016/S1097-2765(00)80413-X; ROSEN ED, 1993, J BIOL CHEM, V268, P11534; ROSEN JF, 1979, J PEDIATR-US, V94, P729, DOI 10.1016/S0022-3476(79)80139-0; Vaisanen S, 1997, EUR J BIOCHEM, V248, P156, DOI 10.1111/j.1432-1033.1997.t01-1-00156.x; VAN ML, 1996, AM J MED GENET, V64, P506; Wecksler W R, 1980, Methods Enzymol, V67, P488; WHITFIELD GK, 1995, MOL ENDOCRINOL, V9, P1166, DOI 10.1210/me.9.9.1166; Yamamoto K, 2000, P NATL ACAD SCI USA, V97, P1467, DOI 10.1073/pnas.020522697; Yang W, 1999, J BIOL CHEM, V274, P16838, DOI 10.1074/jbc.274.24.16838; Zhao XY, 1997, MOL ENDOCRINOL, V11, P366, DOI 10.1210/me.11.3.366; ZHOU JY, 1989, BLOOD, V74, P82	41	34	34	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29148	29156		10.1074/jbc.M100898200	http://dx.doi.org/10.1074/jbc.M100898200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11369766	hybrid			2022-12-25	WOS:000170346000070
J	Griesbeck, O; Baird, GS; Campbell, RE; Zacharias, DA; Tsien, RY				Griesbeck, O; Baird, GS; Campbell, RE; Zacharias, DA; Tsien, RY			Reducing the environmental sensitivity of yellow fluorescent protein - Mechanism and applications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; LIVING CELLS; ENDOPLASMIC-RETICULUM; LIVE CELLS; IN-VIVO; CA2+; VARIANTS; PH; INDICATOR; BINDING	Yellow mutants of the green fluorescent protein (YFP) are crucial constituents of genetically encoded indicators of signal transduction and fusions to monitor protein-protein interactions. However, previous YFPs show excessive pH sensitivity, chloride interference, poor photostability, or poor expression at 37 degreesC. Protein evolution in Escherichia coli has produced a new YFP named Citrine, in which the mutation Q69M confers a much lower pK(a) (5.7) than for previous YFPs, indifference to chloride, twice the photostability of previous YFPs, and much better expression at 37 degreesC and in organelles. The halide resistance is explained by a 2.2-Angstrom x-ray crystal structure of Citrine, showing that the methionine side chain fills what was once a large halide-binding cavity adjacent to the chromophore. Insertion of calmodulin within Citrine or fusion of cyan fluorescent protein, calmodulin, a calmodulin-binding peptide and Citrine has generated improved calcium indicators. These chimeras can be targeted to multiple cellular locations and have permitted the first single-cell imaging of free [Ca2+] in the Golgi. Citrine is superior to all previous YFPs except when pH or halide sensitivity is desired and is particularly advantageous within genetically encoded fluorescent indicators of physiological signals.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Calif San Diego, Med Scientist Training Program, La Jolla, CA 92093 USA; Univ Calif San Diego, Biomed Sci Grad Program, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Tsien, RY (corresponding author), Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.	rtsien@ucsd.edu		Griesbeck, Oliver/0000-0001-5883-5594; Campbell, Robert E./0000-0003-0604-092X	NCI NIH HHS [5P0CA23100-16] Funding Source: Medline; NINDS NIH HHS [NS-27177] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA023100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS027177, R01NS027177] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baird GS, 2000, P NATL ACAD SCI USA, V97, P11984, DOI 10.1073/pnas.97.22.11984; Baird GS, 1999, P NATL ACAD SCI USA, V96, P11241, DOI 10.1073/pnas.96.20.11241; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHESLER M, 1992, TRENDS NEUROSCI, V15, P396, DOI 10.1016/0166-2236(92)90191-A; Damelin M, 2000, MOL CELL, V5, P133, DOI 10.1016/S1097-2765(00)80409-8; Dickson RM, 1997, NATURE, V388, P355, DOI 10.1038/41048; Ellenberg J, 1999, TRENDS CELL BIOL, V9, P52, DOI 10.1016/S0962-8924(98)01420-2; Elsliger MA, 1999, BIOCHEMISTRY-US, V38, P5296, DOI 10.1021/bi9902182; Green G, 2000, METHOD ENZYMOL, V327, P89, DOI 10.1016/S0076-6879(00)27269-8; Heikal AA, 2000, P NATL ACAD SCI USA, V97, P11996, DOI 10.1073/pnas.97.22.11996; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; Honda A, 2001, P NATL ACAD SCI USA, V98, P2437, DOI 10.1073/pnas.051631298; Janetopoulos C, 2001, SCIENCE, V291, P2408, DOI 10.1126/science.1055835; Jayaraman S, 2000, J BIOL CHEM, V275, P6047, DOI 10.1074/jbc.275.9.6047; KENDALL JM, 1992, BIOCHEM BIOPH RES CO, V189, P1008, DOI 10.1016/0006-291X(92)92304-G; Kim JH, 1998, P NATL ACAD SCI USA, V95, P2997, DOI 10.1073/pnas.95.6.2997; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuner T, 2000, NEURON, V27, P447, DOI 10.1016/S0896-6273(00)00056-8; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAWRENCE MC, 2000, J APPL CRYSTALLOGR, V33, P990; Llopis J, 2000, P NATL ACAD SCI USA, V97, P4363, DOI 10.1073/pnas.97.8.4363; Llopis J, 1998, P NATL ACAD SCI USA, V95, P6803, DOI 10.1073/pnas.95.12.6803; Mahajan NP, 1999, CHEM BIOL, V6, P401, DOI 10.1016/S1074-5521(99)80051-9; Matsuyama S, 2000, NAT CELL BIOL, V2, P318, DOI 10.1038/35014006; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Miyawaki A, 1999, P NATL ACAD SCI USA, V96, P2135, DOI 10.1073/pnas.96.5.2135; Miyawaki A, 2000, METHOD ENZYMOL, V327, P472, DOI 10.1016/S0076-6879(00)27297-2; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Nagai T, 2001, P NATL ACAD SCI USA, V98, P3197, DOI 10.1073/pnas.051636098; Nagai Y, 2000, NAT BIOTECHNOL, V18, P313, DOI 10.1038/73767; Nakai J, 2001, NAT BIOTECHNOL, V19, P137, DOI 10.1038/84397; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Overton MC, 2000, CURR BIOL, V10, P341, DOI 10.1016/S0960-9822(00)00386-9; Pearce LL, 2000, P NATL ACAD SCI USA, V97, P477, DOI 10.1073/pnas.97.1.477; Persechini A, 1997, CELL CALCIUM, V22, P209, DOI 10.1016/S0143-4160(97)90014-2; Persechini A, 1999, J BIOL CHEM, V274, P6827, DOI 10.1074/jbc.274.11.6827; Pinton P, 1998, EMBO J, V17, P5298, DOI 10.1093/emboj/17.18.5298; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; Romoser VA, 1997, J BIOL CHEM, V272, P13270, DOI 10.1074/jbc.272.20.13270; Ruehr ML, 1999, J BIOL CHEM, V274, P33092, DOI 10.1074/jbc.274.46.33092; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; Sato M, 2000, ANAL CHEM, V72, P5918, DOI 10.1021/ac0006167; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Tsien RY, 1998, SCIENCE, V280, P1954, DOI 10.1126/science.280.5371.1954; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Vanderklish PW, 2000, P NATL ACAD SCI USA, V97, P2253, DOI 10.1073/pnas.040565597; Wachter RM, 2000, J MOL BIOL, V301, P157, DOI 10.1006/jmbi.2000.3905; Wachter RM, 1999, CURR BIOL, V9, pR628, DOI 10.1016/S0960-9822(99)80408-4; Wachter RM, 1998, STRUCTURE, V6, P1267, DOI 10.1016/S0969-2126(98)00127-0; Zacharias DA, 2000, CURR OPIN NEUROBIOL, V10, P416, DOI 10.1016/S0959-4388(00)00101-X	51	792	841	4	117	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29188	29194		10.1074/jbc.M102815200	http://dx.doi.org/10.1074/jbc.M102815200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11387331	hybrid			2022-12-25	WOS:000170346000075
J	Park, SY; Seo, SB; Lee, SJ; Na, JG; Kim, YJ				Park, SY; Seo, SB; Lee, SJ; Na, JG; Kim, YJ			Mutation in PMR1, a Ca2+-ATPase in Golgi, confers salt tolerance in Saccharomyces cerevisiae by inducing expression of PMR2, an Na+-ATPase in plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATASE CALCINEURIN; TRANSCRIPTION FACTOR; SECRETORY PATHWAY; H+/CA2+ EXCHANGE; GENE-EXPRESSION; NACL TOLERANCE; CA2+ ATPASES; YEAST-CELLS; STRESS; TRANSPORT	Sodium tolerance in yeast is enhanced by continuous activation of calcineurin, a Ca2+/calmodulin-dependent protein phosphatase that is required for modulation of the Na+ efflux mechanism. We isolated several salt-tolerant mutations with the treatment of ethylmethane sulfonate under high salt stress. One of the mutations was mapped in the PMR1 gene. Pmr1p, the P-type Ca2+- ATPase in the Golgi apparatus, regulates a cytosolic Ca2+ level in various responses. Cytosolic Ca2+ concentration in the pmr1 mutant is highly maintained, and thus calcineurin is activated continuously. The treatment of FK506, a specific inhibitor of calcineurin, abolishes the salt-tolerant phenotype of the pmr1 mutant. Activated calcineurin induces the expression of PMR2, encoding the P-type Na+-ATPase, through the specific transcription factor, Tcn1p/Crz1p. Also, expression of the PMR2::lacZ reporter gene in the pmr1 mutant was higher than that in wild type. We propose that the pmr1 mutation confers salt tolerance through continuous activation of calcineurin and that Pmr1p might act as a major Ca2+-ATPase under high salt stress.	Pusan Natl Univ, Dept Mol Biol, Pusan 609735, South Korea; Kunsan Natl Univ, Sch Sci & Technol, Kunsan 573701, South Korea	Pusan National University; Kunsan National University	Kim, YJ (corresponding author), Pusan Natl Univ, Dept Mol Biol, Pusan 609735, South Korea.							ALBERTYN J, 1994, MOL CELL BIOL, V14, P4125; ANTIBI A, 1992, MOL BIOL CELL, V3, P633; CARDENAS ME, 1995, CURR OPIN NEPHROL HY, V4, P427; CUNNINGHAM KW, 1994, J EXP BIOL, V196, P157; Cunningham KW, 1996, MOL CELL BIOL, V16, P2226; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; DANIEL G, 1992, NUCLEIC ACIDS RES, V20, P1425; Danielsson A, 1996, CURR GENET, V30, P476, DOI 10.1007/s002940050159; DUNN T, 1994, J BIOL CHEM, V269, P7273; GABER RF, 1988, MOL CELL BIOL, V8, P2848, DOI 10.1128/MCB.8.7.2848; GARCIADEBLAS B, 1993, MOL GEN GENET, V236, P363, DOI 10.1007/BF00277134; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HARO R, 1991, FEBS LETT, V291, P189, DOI 10.1016/0014-5793(91)81280-L; HARO R, 1993, PHYSIOL PLANTARUM, V89, P868, DOI 10.1111/j.1399-3054.1993.tb05298.x; HIRATA D, 1995, MOL GEN GENET, V249, P257, DOI 10.1007/BF00290525; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; KO CH, 1991, MOL CELL BIOL, V11, P4266, DOI 10.1128/MCB.11.8.4266; LAPINSKAS PJ, 1995, MOL CELL BIOL, V15, P1382; Marchi V, 1999, FEBS LETT, V454, P181, DOI 10.1016/S0014-5793(99)00803-0; Marquez JA, 1996, FEBS LETT, V382, P89, DOI 10.1016/0014-5793(96)00157-3; Matheos DP, 1997, GENE DEV, V11, P3445, DOI 10.1101/gad.11.24.3445; Mendoza I, 1996, J BIOL CHEM, V271, P23061, DOI 10.1074/jbc.271.38.23061; MENDOZA I, 1994, J BIOL CHEM, V269, P8792; NAKAMURA T, 1993, EMBO J, V12, P4063, DOI 10.1002/j.1460-2075.1993.tb06090.x; Pope B, 1996, NUCLEIC ACIDS RES, V24, P536, DOI 10.1093/nar/24.3.536; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; Serrano R, 1996, INT REV CYTOL, V165, P1, DOI 10.1016/S0074-7696(08)62219-6; Sorin A, 1997, J BIOL CHEM, V272, P9895; Stathopoulos AM, 1997, GENE DEV, V11, P3432, DOI 10.1101/gad.11.24.3432; Strayle J, 1999, EMBO J, V18, P4733, DOI 10.1093/emboj/18.17.4733; WIELAND J, 1995, EMBO J, V14, P3870, DOI 10.1002/j.1460-2075.1995.tb00059.x	33	31	31	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28694	28699		10.1074/jbc.M101185200	http://dx.doi.org/10.1074/jbc.M101185200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11387321	hybrid			2022-12-25	WOS:000170346000009
J	Ueno, M; Yamada, S; Zako, M; Bernfield, M; Sugahara, K				Ueno, M; Yamada, S; Zako, M; Bernfield, M; Sugahara, K			Structural characterization of heparan sulfate and chondroitin sulfate of syndecan-1 purified from normal murine mammary gland epithelial cells - Common phosphorylation of xylose and differential sulfation of galactose in the protein linkage region tetrasaccharide sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE INTESTINAL HEPARIN; SWARM RAT CHONDROSARCOMA; SHARK CARTILAGE; N-ACETYLGALACTOSAMINE; SURFACE PROTEOGLYCAN; NEURITE OUTGROWTH; TRYPSIN-INHIBITOR; NERVOUS-SYSTEM; ZETA/RPTP-BETA; FACTOR MIDKINE	Syndecan-1, present on the surfaces of normal murine mammary gland epithelial cells, is a transmembrane hybrid proteoglycan, which bears glycosaminoglycan (GAG) side chains of heparan sulfate (HS) and chondroitin sulfate WS). Purified syndecan-1 ectodomains were analyzed for disaccharide composition and the GAG-protein linkage region after digestion with bacterial lyases. The HS chains contained predominantly a nonsulfated unit with smaller proportions of two monosulfated, two disulfated, and a trisulfated unit, whereas CS chains were demonstrated for the first time to bear GlcUA-GalNAc(4-O-sulfate) as a major component as well as GlcUA-GalNAc, GlcUA-GalNAc(6-O-sulfate), and an E disaccharide unit GlcUA-GalNAc(4,6-O-disulfate) as minor yet appreciable components. Two kinds of linkage region tetrasaccharides, GlcUA-Gal-Gal-Xyl and GlcUA-Gal-Gal-Xyl(2-O-phosphate), were found for the HS chains in a molar ratio of 55:45. In marked contrast, an additional sulfated tetrasaccharide, GlcUA-Gal(4-O-sulfate)-Gal-Xyl, was demonstrated only for the CS chains, and the unmodified phosphorylated and sulfated components were present at a molar ratio of 55:26:19. The present study thus provided conclusive evidence for the hypothesis that 4-O-sulfation of Gal is peculiar to CS chains in contrast to the phosphorylation of Xyl, which is common to both HS and CS chains. These modifications may be required for biosynthetic maturation of the linkage region tetrasaccharide sequence, which is a prerequisite for creating the repeating disaccharide region of GAG chains and/or biosynthetic selective chain assembly of CS and HS chains.	Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan; Harvard Univ, Childrens Hosp, Sch Med, Dept Pediat, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Kobe Pharmaceutical University; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School	Sugahara, K (corresponding author), Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan.				NCI NIH HHS [CA28734] Funding Source: Medline; NICHD NIH HHS [HD06763] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD006763, R37HD006763] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [U10CA028734] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; Chen RL, 2001, J BIOL CHEM, V276, P7507, DOI 10.1074/jbc.M008283200; Cheng F, 1996, J BIOL CHEM, V271, P28572, DOI 10.1074/jbc.271.45.28572; Clement AM, 1999, NEUROSCI LETT, V269, P125, DOI 10.1016/S0304-3940(99)00432-2; DAVID G, 1981, J NATL CANCER I, V67, P719; DeBeer T, 1996, EUR J BIOCHEM, V240, P789; DEWAARD P, 1992, J BIOL CHEM, V267, P6036; Dolan M, 1997, J BIOL CHEM, V272, P4316, DOI 10.1074/jbc.272.7.4316; EDWARDS IJ, 1995, ARTERIOSCL THROM VAS, V15, P400, DOI 10.1161/01.ATV.15.3.400; Filla MS, 1998, J CELL PHYSIOL, V174, P310, DOI 10.1002/(SICI)1097-4652(199803)174:3<310::AID-JCP5>3.0.CO;2-R; FRANSSON LA, 1985, J BIOL CHEM, V260, P4722; FRANSSON LA, 1987, TRENDS BIOCHEM SCI, V12, P406, DOI 10.1016/0968-0004(87)90197-6; FRITZ TA, 1994, J BIOL CHEM, V269, P28809; Fuki IV, 1997, J CLIN INVEST, V100, P1611, DOI 10.1172/JCI119685; HEINEGAR.D, 1972, BIOCHIM BIOPHYS ACTA, V285, P193, DOI 10.1016/0005-2795(72)90191-2; JALKANEN M, 1988, J CELL BIOL, V106, P953, DOI 10.1083/jcb.106.3.953; JALKANEN M, 1985, J CELL BIOL, V101, P976, DOI 10.1083/jcb.101.3.976; KATO M, 1994, J BIOL CHEM, V269, P18881; Kato M, 1998, NAT MED, V4, P691, DOI 10.1038/nm0698-691; Kim BT, 2001, P NATL ACAD SCI USA, V98, P7176, DOI 10.1073/pnas.131188498; Kinoshita A, 1999, ANAL BIOCHEM, V269, P367, DOI 10.1006/abio.1999.4027; Kitagawa H, 1999, J BIOL CHEM, V274, P13933, DOI 10.1074/jbc.274.20.13933; KODA JE, 1985, J BIOL CHEM, V260, P8157; KOKENYESI R, 1994, J BIOL CHEM, V269, P12304; Lander A D, 1993, Curr Opin Neurobiol, V3, P716, DOI 10.1016/0959-4388(93)90143-M; Lauder RM, 2000, BIOCHEM J, V347, P339, DOI 10.1042/0264-6021:3470339; Lindahl U., 1972, GLYCOPROTEINS THEIR, P491; Maeda N, 1999, J BIOL CHEM, V274, P12474, DOI 10.1074/jbc.274.18.12474; Maeda N, 1996, J BIOL CHEM, V271, P21446, DOI 10.1074/jbc.271.35.21446; Moses J, 1997, EUR J BIOCHEM, V248, P767, DOI 10.1111/j.1432-1033.1997.t01-1-00767.x; Moses J, 1999, EUR J BIOCHEM, V260, P879, DOI 10.1046/j.1432-1327.1999.00228.x; Moses J, 1997, EUR J BIOCHEM, V248, P521, DOI 10.1111/j.1432-1033.1997.00521.x; Munakata H, 1999, GLYCOBIOLOGY, V9, P1023, DOI 10.1093/glycob/9.10.1023; Nadanaka S, 1998, J BIOL CHEM, V273, P33728, DOI 10.1074/jbc.273.50.33728; Nadanaka S, 1999, BIOCHEM J, V340, P353, DOI 10.1042/0264-6021:3400353; Nadanaka S, 1998, J BIOL CHEM, V273, P3296, DOI 10.1074/jbc.273.6.3296; Nakanishi T, 1997, J BIOCHEM-TOKYO, V121, P197; OEGEMA TR, 1984, J BIOL CHEM, V259, P1720; Oohira A, 2000, ARCH BIOCHEM BIOPHYS, V374, P24, DOI 10.1006/abbi.1999.1598; Pedersen LC, 2000, J BIOL CHEM, V275, P34580, DOI 10.1074/jbc.M007399200; Penc SF, 1998, J BIOL CHEM, V273, P28116, DOI 10.1074/jbc.273.43.28116; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; ROHRMANN K, 1985, EUR J BIOCHEM, V148, P463, DOI 10.1111/j.1432-1033.1985.tb08862.x; ROSENFELD L, 1988, J BIOL CHEM, V263, P262; Sakaguchi H, 2001, J BIOCHEM-TOKYO, V129, P107, DOI 10.1093/oxfordjournals.jbchem.a002820; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; SHIBATA S, 1992, J BIOL CHEM, V267, P6548; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stoica GE, 2001, J BIOL CHEM, V276, P16772, DOI 10.1074/jbc.M010660200; SUGAHARA K, 1992, EUR J BIOCHEM, V204, P401, DOI 10.1111/j.1432-1033.1992.tb16649.x; SUGAHARA K, 1995, J BIOL CHEM, V270, P7204, DOI 10.1074/jbc.270.13.7204; SUGAHARA K, 1991, EUR J BIOCHEM, V202, P805, DOI 10.1111/j.1432-1033.1991.tb16436.x; SUGAHARA K, 1994, CARBOHYD RES, V255, P145, DOI 10.1016/S0008-6215(00)90976-5; SUGAHARA K, 1992, J BIOL CHEM, V267, P6027; SUGAHARA K, 1988, J BIOL CHEM, V263, P10168; Sugahara K, 2000, CURR OPIN STRUC BIOL, V10, P518, DOI 10.1016/S0959-440X(00)00125-1; SUGAHARA K, 1995, J BIOL CHEM, V270, P22914, DOI 10.1074/jbc.270.39.22914; Sugahara K, 2000, TRENDS GLYCOSCI GLYC, V12, P321, DOI 10.4052/tigg.12.321; TSUKADA T, 1987, COMP BIOCHEM PHYS B, V86, P565, DOI 10.1016/0305-0491(87)90449-4; Tumova S, 2000, INT J BIOCHEM CELL B, V32, P269, DOI 10.1016/S1357-2725(99)00116-8; Ueoka C, 2000, J BIOL CHEM, V275, P37407, DOI 10.1074/jbc.M002538200; VERTEL BM, 1993, J BIOL CHEM, V268, P11105; YAMADA S, 1992, J BIOCHEM-TOKYO, V112, P440, DOI 10.1093/oxfordjournals.jbchem.a123919; YAMADA S, 1995, GLYCOBIOLOGY, V5, P335, DOI 10.1093/glycob/5.3.335; YAMADA S, 1995, EUR J BIOCHEM, V233, P687, DOI 10.1111/j.1432-1033.1995.687_2.x; YAMADA S, 1994, GLYCOBIOLOGY, V4, P69, DOI 10.1093/glycob/4.1.69; Yamada SH, 1998, TRENDS GLYCOSCI GLYC, V10, P95, DOI 10.4052/tigg.10.95; YAMAGATA T, 1968, J BIOL CHEM, V243, P1523; ZHANG LJ, 1994, J BIOL CHEM, V269, P19295; ZHANG LJ, 1995, J BIOL CHEM, V270, P27127, DOI 10.1074/jbc.270.45.27127	72	62	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29134	29140		10.1074/jbc.M102089200	http://dx.doi.org/10.1074/jbc.M102089200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11384972	hybrid			2022-12-25	WOS:000170346000068
J	Borza, DB; Bondar, O; Ninomiya, Y; Sado, Y; Naito, I; Todd, P; Hudson, BG				Borza, DB; Bondar, O; Ninomiya, Y; Sado, Y; Naito, I; Todd, P; Hudson, BG			The NCI domain of collagen IV encodes a novel network composed of the alpha 1, alpha 2, alpha 5, and alpha 6 chains in smooth muscle basement membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED ALPORT SYNDROME; NONCOLLAGENOUS DOMAIN; GOODPASTURE ANTIGEN; DIFFERENTIAL EXPRESSION; DIFFUSE LEIOMYOMATOSIS; MONOCLONAL-ANTIBODIES; GLOBULAR DOMAIN; IDENTIFICATION; ORGANIZATION; COL4A5	Type IV collagen, the major component of basement membranes (BMs), is a family of six homologous chains (alpha1-alpha6) that have a tissue-specific distribution. The chains assemble into supramolecular networks that differ in the chain composition. In this study, a novel network was identified and characterized in the smooth muscle BMs of aorta and bladder. The noncollagenous (NC1) hexamers solubilized by collagenase digestion were fractionated by affinity chromatography using monoclonal antibodies against the alpha5 and alpha6 NC1 domains and then characterized by two-dimensional gel electrophoresis and Western blotting. Both BMs were found to contain a novel alpha1.alpha2.alpha5.alpha6 network besides the classical alpha1.alpha2 network. The alpha1.alpha2.alpha5.alpha6 network represents a new arrangement in which a protomer (triple-helical isoform) containing the alpha5 and alpha6 chains is linked through NC1-NC1 interactions to an adjoining protomer composed of the alpha1 and alpha2 chains. Re-association studies revealed that the NCI domains contain recognition sequences sufficient to encode the assembly of both networks. These findings, together with previous ones, indicate that the six chains of type IV collagen are distributed in three major networks (alpha1.alpha2 alpha3.alpha4.alpha5, and alpha1.alpha2.alpha5.alpha6) whose chain composition is encoded by the NCI domains. The existence of the alpha1.alpha2.alpha5.alpha6 network provides a molecular explanation for the concomitant loss of alpha5 and alpha6 chains from the BMs of patients with X-linked Alport's syndrome.	Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA; Okayama Univ, Sch Med, Dept Mol Biol & Biochem, Okayama 700, Japan; Shigei Med Res Inst, Div Immunol & Ultrastruct Biol, Okayama 701, Japan	University of Kansas; University of Kansas Medical Center; Okayama University	Hudson, BG (corresponding author), Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.		Borza, Dorin-Bogdan/AAF-2156-2020	Borza, Dorin-Bogdan/0000-0003-4568-279X; Hudson, Billy/0000-0002-5420-4100	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018381, P01DK053763, R37DK018381] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK18381, DK53763] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANTIGNAC C, 1992, KIDNEY INT, V42, P1178, DOI 10.1038/ki.1992.402; BEJARANO PA, 1989, INFECT IMMUN, V57, P3783, DOI 10.1128/IAI.57.12.3783-3787.1989; BLUMBERG B, 1986, J CELL BIOL, V103, P1711, DOI 10.1083/jcb.103.5.1711; Borza DB, 2000, J BIOL CHEM, V275, P6030, DOI 10.1074/jbc.275.8.6030; Boutaud A, 2000, J BIOL CHEM, V275, P30716, DOI 10.1074/jbc.M004569200; DERRY CJ, 1994, EXP NEPHROL, V2, P249; FESSLER LI, 1982, J BIOL CHEM, V257, P9804; GRUNDMANN M, 1995, J NONLINEAR OPT PHYS, V4, P99, DOI 10.1142/S0218863595000069; GUNWAR S, 1991, J BIOL CHEM, V266, P14088; GUNWAR S, 1990, J BIOL CHEM, V265, P5466; GUNWAR S, 1991, J BIOL CHEM, V266, P15318; GUNWAR S, 1991, AM J RESP CELL MOL, V5, P107, DOI 10.1165/ajrcmb/5.2.107; Gunwar S, 1998, J BIOL CHEM, V273, P8767, DOI 10.1074/jbc.273.15.8767; Harvey SJ, 1998, KIDNEY INT, V54, P1857, DOI 10.1046/j.1523-1755.1998.00188.x; Hino S, 1996, PEDIATR NEPHROL, V10, P742, DOI 10.1007/s004670050206; HUDSON BG, 1993, J BIOL CHEM, V268, P26033; JOHANSSON C, 1991, CONNECT TISSUE RES, V25, P229, DOI 10.3109/03008209109029159; JOHANSSON C, 1992, J BIOL CHEM, V267, P24533; Kahsai TZ, 1997, J BIOL CHEM, V272, P17023, DOI 10.1074/jbc.272.27.17023; Kalluri R, 1997, J CLIN INVEST, V99, P2470, DOI 10.1172/JCI119431; KUHN K, 1985, ANN NY ACAD SCI, V460, P14, DOI 10.1111/j.1749-6632.1985.tb51153.x; LANGEVELD JPM, 1988, J BIOL CHEM, V263, P10481; Naito I, 1996, KIDNEY INT, V50, P304, DOI 10.1038/ki.1996.316; NINOMIYA Y, 1995, J CELL BIOL, V130, P1219, DOI 10.1083/jcb.130.5.1219; PEISSEL B, 1995, J CLIN INVEST, V96, P1948, DOI 10.1172/JCI118241; REDDY GK, 1993, BIOCHIM BIOPHYS ACTA, V1157, P241, DOI 10.1016/0304-4165(93)90106-I; Sado Y, 1998, KIDNEY INT, V53, P664, DOI 10.1046/j.1523-1755.1998.00795.x; Saito K, 2000, J BIOCHEM, V128, P427, DOI 10.1093/oxfordjournals.jbchem.a022770; SAUS J, 1988, J BIOL CHEM, V263, P13374; Seki T, 1998, HISTOCHEM CELL BIOL, V110, P359, DOI 10.1007/s004180050296; SIEBOLD B, 1988, EUR J BIOCHEM, V176, P617, DOI 10.1111/j.1432-1033.1988.tb14321.x; TIMPL R, 1981, EUR J BIOCHEM, V120, P203, DOI 10.1111/j.1432-1033.1981.tb05690.x; TRUEB B, 1982, J BIOL CHEM, V257, P5239; WEBER S, 1984, EUR J BIOCHEM, V139, P401, DOI 10.1111/j.1432-1033.1984.tb08019.x; Zheng KQ, 1999, AM J PATHOL, V154, P1883, DOI 10.1016/S0002-9440(10)65446-6; ZHOU J, 1993, SCIENCE, V261, P1167, DOI 10.1126/science.8356449	36	104	119	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28532	28540		10.1074/jbc.M103690200	http://dx.doi.org/10.1074/jbc.M103690200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11375996	hybrid			2022-12-25	WOS:000170093400105
J	Roche, ED; Sauer, RT				Roche, ED; Sauer, RT			Identification of endogenous SsrA-tagged proteins reveals tagging at positions corresponding to stop codons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL STABLE RNA; ESCHERICHIA-COLI; 10SA RNA; TRANSLATION TERMINATION; BACILLUS-SUBTILIS; LAMBDA-REPRESSOR; MESSENGER-RNA; TMRNA; DEGRADATION; BINDING	The SsrA.SmpB quality control system adds a C-terminal degradation peptide (AANDENYALAA) to nascent chains on stalled ribosomes, thereby freeing the ribosome and ensuring proteolysis of the tagged protein. An SsrA mutant with the tag sequence AANDEHHHHHH was used to slow degradation and facilitate, Ni2+-nitrilotriacetic acid affinity purification. Display of affinity-purified Escherichia coli proteins on two-dimensional gels revealed small quantities of a diverse set of SsrA-H-6-tagged proteins, and mass spectroscopy identified LaeI repressor, lambda cI repressor, YbeL, GalE, RbsK, and a SlyD-kan(R) fusion protein as members of this set. For A repressor and YbeL, the SsrA-H-6 tag was added after the natural C terminus of the protein, suggesting that tagging occurred while the ribosome idled at the termination codon of these genes. Potential causes of tagging for the other proteins include interference from translation of downstream reading frames, rare codons, and gene disruption. These and previous results support a broad role for the SsrA.SmpB system in freeing stalled ribosomes and in directing degradation of the products of these frustrated protein synthesis reactions.	MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Sauer, RT (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.			Sauer, Robert/0000-0002-1719-5399	NIAID NIH HHS [AI-16892] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016892] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abo T, 2000, EMBO J, V19, P3762, DOI 10.1093/emboj/19.14.3762; ARKOV AL, 1993, NUCLEIC ACIDS RES, V21, P2891, DOI 10.1093/nar/21.12.2891; Bjornsson A, 1996, EMBO J, V15, P1696, DOI 10.1002/j.1460-2075.1996.tb00515.x; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BREYER RM, 1989, J BIOL CHEM, V264, P13355; DESMIT MH, 1994, J MOL BIOL, V235, P173, DOI 10.1016/S0022-2836(05)80024-5; Felden B, 1997, RNA, V3, P89; Gottesman S, 1998, GENE DEV, V12, P1338, DOI 10.1101/gad.12.9.1338; Herman C, 1998, GENE DEV, V12, P1348, DOI 10.1101/gad.12.9.1348; Huang CH, 2000, EMBO J, V19, P1098, DOI 10.1093/emboj/19.5.1098; Hutchison CA, 1999, SCIENCE, V286, P2165, DOI 10.1126/science.286.5447.2165; Karzai AW, 2000, NAT STRUCT BIOL, V7, P449; Karzai AW, 1999, EMBO J, V18, P3793, DOI 10.1093/emboj/18.13.3793; Keiler KC, 2000, P NATL ACAD SCI USA, V97, P7778, DOI 10.1073/pnas.97.14.7778; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; KIRBY JE, 1994, J BACTERIOL, V176, P2068, DOI 10.1128/jb.176.7.2068-2081.1994; KOMINE Y, 1994, P NATL ACAD SCI USA, V91, P9223, DOI 10.1073/pnas.91.20.9223; MILLA ME, 1993, PROTEIN SCI, V2, P2198, DOI 10.1002/pro.5560021219; Mottagui-Tabar S, 1998, GENE, V212, P189, DOI 10.1016/S0378-1119(98)00176-0; Muto A, 2000, GENES CELLS, V5, P627, DOI 10.1046/j.1365-2443.2000.00356.x; Nakamura Y, 1996, CELL, V87, P147, DOI 10.1016/S0092-8674(00)81331-8; NELSON HCM, 1985, CELL, V42, P549, DOI 10.1016/0092-8674(85)90112-6; OH BK, 1991, MOL GEN GENET, V229, P52, DOI 10.1007/BF00264212; PARSELL DA, 1990, GENE DEV, V4, P277, DOI 10.1101/gad.4.2.277; Ptashne M., 1986, A GENETIC SWITCH; RETALLACK DM, 1994, J BACTERIOL, V176, P2082, DOI 10.1128/jb.176.7.2082-2089.1994; RETALLACK DM, 1995, CELL, V83, P227, DOI 10.1016/0092-8674(95)90164-7; Roche ED, 1999, EMBO J, V18, P4579, DOI 10.1093/emboj/18.16.4579; SAUER RT, 1981, BIOCHEMISTRY-US, V20, P3591, DOI 10.1021/bi00515a044; SAUER RT, 1978, NATURE, V276, P301, DOI 10.1038/276301a0; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; TU GF, 1995, J BIOL CHEM, V270, P9322, DOI 10.1074/jbc.270.16.9322; USHIDA C, 1994, NUCLEIC ACIDS RES, V22, P3392, DOI 10.1093/nar/22.16.3392; Williams KP, 1996, RNA, V2, P1306; Withey J, 1999, J BACTERIOL, V181, P2148, DOI 10.1128/JB.181.7.2148-2157.1999; Zhang SP, 1998, J MOL BIOL, V284, P1243, DOI 10.1006/jmbi.1998.2319	36	100	107	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28509	28515		10.1074/jbc.M103864200	http://dx.doi.org/10.1074/jbc.M103864200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11373298	hybrid			2022-12-25	WOS:000170093400102
J	Paroni, G; Henderson, C; Schneider, C; Brancolini, C				Paroni, G; Henderson, C; Schneider, C; Brancolini, C			Caspase-2-induced apoptosis is dependent on caspase-9, but its processing during UV- or tumor necrosis factor-dependent cell death requires caspase-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROFILAMENT REORGANIZATION; SUBSTRATE SPECIFICITIES; ACTIVATION; PROTEIN; FAMILY; GENE; LOCALIZATION; MITOCHONDRIA; INDUCTION; PRODOMAIN	Mammalian caspases are a family of cysteine proteases that plays a critical role in apoptosis, We have analyzed caspase-2 processing in human cell lines containing defined mutations in caspase-3 and caspase-9, Here we demonstrate that caspase-2 processing, during cell death induced by UV irradiation, depends both on caspase-9 and caspase-3 activity, while, during TNF-alpha -dependent apoptosis, capase-2 processing is independent of caspase-9 but still requires caspase-3, In vitro procaspase-2 is the preferred caspase cleaved by caspase-3, while caspase-7 cleaves procaspase-2 with reduced efficiency. We have also demonstrated that caspase-2-mediated apoptosis requires caspase-9 and that cells co-expressing caspase-2 and a dominant negative form of caspase-9 are impaired in activating a normal apoptotic response and release cytochrome c into the cytoplasm, Our findings suggest a role played by caspase-2 as a regulator of the mitochondrial integrity and open questions on the mechanisms responsible for its activation during cell death.	Univ Udine, Dipartimento Sci & Tecnol Biomed, Sez Biol, I-33100 Udine, Italy; Lab Nazl Consorzio Interuniv Biotecnol, I-34142 Trieste, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Udine	Brancolini, C (corresponding author), Univ Udine, Dipartimento Sci & Tecnol Biomed, Sez Biol, P Kolbe 4, I-33100 Udine, Italy.	cbrancolini@makek.dstb.uniud.it	Paroni, Gabriela/J-4848-2018	Paroni, Gabriela/0000-0003-0132-0869; BRANCOLINI, Claudio/0000-0002-6597-5373				Ahmad M, 1997, CANCER RES, V57, P615; Allet B, 1996, J CELL BIOL, V135, P479, DOI 10.1083/jcb.135.2.479; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Brancolini C, 1998, CELL DEATH DIFFER, V5, P1042, DOI 10.1038/sj.cdd.4400443; BRANCOLINI C, 1995, EMBO J, V14, P5179, DOI 10.1002/j.1460-2075.1995.tb00202.x; Butt AJ, 1998, J BIOL CHEM, V273, P6763, DOI 10.1074/jbc.273.12.6763; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Colussi PA, 1998, J BIOL CHEM, V273, P24535, DOI 10.1074/jbc.273.38.24535; Colussi PA, 1998, J BIOL CHEM, V273, P26566, DOI 10.1074/jbc.273.41.26566; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Faleiro L, 2000, J CELL BIOL, V151, P951, DOI 10.1083/jcb.151.5.951; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; Germain M, 1999, J BIOL CHEM, V274, P28379, DOI 10.1074/jbc.274.40.28379; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Huang SS, 1999, J BIOL CHEM, V274, P27754, DOI 10.1074/jbc.274.39.27754; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Jesenberger V, 2000, J EXP MED, V192, P1035, DOI 10.1084/jem.192.7.1035; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Li HL, 1997, J BIOL CHEM, V272, P21010, DOI 10.1074/jbc.272.34.21010; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Pastorino JG, 1999, J BIOL CHEM, V274, P31734, DOI 10.1074/jbc.274.44.31734; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Sgorbissa A, 1999, J CELL SCI, V112, P4475; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Troy CM, 2000, J NEUROSCI, V20, P1386; Van de Craen M, 1999, CELL DEATH DIFFER, V6, P1117, DOI 10.1038/sj.cdd.4400589; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761; Zhivotovsky B, 1999, CELL DEATH DIFFER, V6, P644, DOI 10.1038/sj.cdd.4400536	48	95	96	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21907	21915		10.1074/jbc.M011565200	http://dx.doi.org/10.1074/jbc.M011565200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11399776	hybrid			2022-12-25	WOS:000169297900144
J	Outten, FW; Huffman, DL; Hale, JA; O'Halloran, TV				Outten, FW; Huffman, DL; Hale, JA; O'Halloran, TV			The independent cue and cus systems confer copper tolerance during aerobic and anaerobic growth in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTEROCOCCUS-HIRAE; ASCORBATE OXIDASE; CRYSTAL-STRUCTURE; MULTIDRUG EFFLUX; PROTEIN EXPORT; TRANSPORT; ZUCCHINI; CLUSTER; BINDING; ATPASE	Copper is essential but can be toxic even at low concentrations. Coping with this duality requires multiple pathways to control intracellular copper availability. Three copper-inducible promoters, controlling expression of six copper tolerance genes, were recently identified in Escherichia coli. The cue system employs an inner membrane copper transporter, whereas the cus system includes a tripartite transporter spanning the entire cell envelope. Although cus is not essential for aerobic copper tolerance, we show here that a copper-sensitive phenotype can be observed when cus is inactivated in a cueR background. Furthermore, a clear copper-sensitive phenotype for the cus system is revealed in the absence Of O-2. These results indicate that the cue pathway, which includes a copper exporter, CopA, and a periplasmic oxidase, CueO, is the primary aerobic system for copper tolerance. During anaerobic growth, however, copper toxicity increases, and the independent cus copper exporter is also necessary for full copper tolerance. We conclude that the cytosolic (CueR) and periplasmic (CusRS) sensor systems differentially regulate copper export systems in response to changes in copper and oxygen availability. These results underscore the increased toxicity of copper under anaerobic conditions and the complex adaptation of copper export in E. coli.	Northwestern Univ, Dept Chem, Evanston, IL 60208 USA; Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	Northwestern University; Northwestern University	O'Halloran, TV (corresponding author), Northwestern Univ, Dept Chem, 2145 Sheridan Rd, Evanston, IL 60208 USA.	t-ohalloran@northwestern.edu	O'Halloran, Thomas/ABE-6125-2021	O'Halloran, Thomas/0000-0001-8732-5059; Outten, Franklin/0000-0002-9095-0194	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007284] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038784, T32GM008061, R01GM054111] Funding Source: NIH RePORTER; NIEHS NIH HHS [T32 ES07284] Funding Source: Medline; NIGMS NIH HHS [R01 GM054111, R01 GM38784, T32 GM08061] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES GF, 1984, J BACTERIOL, V160, P1181, DOI 10.1128/JB.160.3.1181-1183.1984; Berks BC, 2000, MOL MICROBIOL, V35, P260, DOI 10.1046/j.1365-2958.2000.01719.x; BESWICK PH, 1976, CHEM-BIOL INTERACT, V14, P347, DOI 10.1016/0009-2797(76)90113-7; Blackburn NJ, 2000, BIOCHEMISTRY-US, V39, P2316, DOI 10.1021/bi992334a; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULL PC, 1994, TRENDS GENET, V10, P246, DOI 10.1016/0168-9525(94)90172-4; CASELLA L, 1988, BIOCHEM J, V251, P441, DOI 10.1042/bj2510441; Cole AP, 1996, SCIENCE, V273, P1848, DOI 10.1126/science.273.5283.1848; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Franke S, 2001, MICROBIOL-SGM, V147, P965, DOI 10.1099/00221287-147-4-965; Grass G, 2001, J BACTERIOL, V183, P2145, DOI 10.1128/JB.183.6.2145-2147.2001; Kiley PJ, 1998, FEMS MICROBIOL REV, V22, P341, DOI 10.1111/j.1574-6976.1998.tb00375.x; Koronakis V, 2000, NATURE, V405, P914, DOI 10.1038/35016007; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LEHMANN HP, 1974, CLIN CHEM, V20, P1564; MESSERSCHMIDT A, 1989, J MOL BIOL, V206, P513, DOI 10.1016/0022-2836(89)90498-1; Millardet A, 1845, DISCOVERY BORDEAUX M; Munson GP, 2000, J BACTERIOL, V182, P5864, DOI 10.1128/JB.182.20.5864-5871.2000; Munson GP., 1997, THESIS NW U EVANSTON; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; ODERMATT A, 1994, BIOCHEM BIOPH RES CO, V202, P44, DOI 10.1006/bbrc.1994.1891; OLIVER DB, 1996, ESCHERICHIA COLI SAL, V1, P88; Outten FW, 2000, J BIOL CHEM, V275, P31024, DOI 10.1074/jbc.M006508200; Paulsen IT, 1997, FEMS MICROBIOL LETT, V156, P1, DOI 10.1111/j.1574-6968.1997.tb12697.x; Pena MMO, 1999, J NUTR, V129, P1251, DOI 10.1093/jn/129.7.1251; Petersen C, 2000, GENE, V261, P289, DOI 10.1016/S0378-1119(00)00509-6; Rensing C, 2000, P NATL ACAD SCI USA, V97, P652, DOI 10.1073/pnas.97.2.652; SAIER MH, 1994, MOL MICROBIOL, V11, P841, DOI 10.1111/j.1365-2958.1994.tb00362.x; Sawers G, 1999, CURR OPIN MICROBIOL, V2, P181, DOI 10.1016/S1369-5274(99)80032-0; SOLIOZ M, 1995, J BIOL CHEM, V270, P9217, DOI 10.1074/jbc.270.16.9217; Solomon EI, 1996, CHEM REV, V96, P2563, DOI 10.1021/cr950046o; Stanley NR, 2000, J BIOL CHEM, V275, P11591, DOI 10.1074/jbc.275.16.11591; Strain J, 1996, MOL GEN GENET, V251, P139; Zgurskaya HI, 1999, P NATL ACAD SCI USA, V96, P7190, DOI 10.1073/pnas.96.13.7190	34	395	410	7	66	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30670	30677		10.1074/jbc.M104122200	http://dx.doi.org/10.1074/jbc.M104122200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11399769	hybrid			2022-12-25	WOS:000170472900013
J	Powell, RM; Parkhurst, KM; Brenowitz, M; Parkhurst, LJ				Powell, RM; Parkhurst, KM; Brenowitz, M; Parkhurst, LJ			Marked stepwise differences within a common kinetic mechanism characterize TATA-binding protein interactions with two consensus promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; RNA-POLYMERASE-II; CRYSTAL-STRUCTURE; B-DNA; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; MINOR-GROOVE; A-T; EUKARYOTIC TRANSCRIPTION; DIMER DISSOCIATION	Binding of the TATA-binding protein (TBP) to promoter DNA bearing the TATA sequence is an obligatory initial step in RNA polymerase II transcription initiation. The interactions. of Saccharomyces cerevisiae TBP with the E4 (TATATATA) and adenovirus major late (TATAAAAG) promoters have been modeled via global analysis of kinetic and thermodynamic data obtained using fluorescence resonance energy transfer. A linear two-intermediate kinetic mechanism describes the reaction of both of these consensus strong promoters with TBP. Qualitative features common to both interactions include tightly bound TBP-DNA complexes with similar solution geometries, simultaneous DNA binding and bending, and the presence of intermediate TBP-DNA conformers at high mole fraction throughout most of the reaction and at equilibrium. Despite very similar energetic changes overall, the stepwise entropic and enthalpic compensations along the two pathways differ markedly following the initial binding/bending event. Furthermore, TBP-E4 dissociation ensues from both replacement and displacement processes, in contrast to replacement alone for TBP-adenovirus major late promoter. A model is proposed that explicitly correlates these similarities and differences with the sequence-specific structural properties inherent to each promoter. This detailed mechanistic comparison of two strong promoters interacting with TBP provides a foundation for subsequent comparison between consensus and variant promoter sequences reacting with TBP.	Univ Nebraska, Dept Chem, Lincoln, NE 68588 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	University of Nebraska System; University of Nebraska Lincoln; Yeshiva University; Albert Einstein College of Medicine	Powell, RM (corresponding author), Univ Nebraska, Dept Chem, Lincoln, NE 68588 USA.				NCI NIH HHS [CA76049] Funding Source: Medline; NCRR NIH HHS [RR15635] Funding Source: Medline; NIGMS NIH HHS [GM39929, GM59346] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076049] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059346, R01GM039929, R29GM039929] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bareket-Samish A, 2000, J MOL BIOL, V299, P965, DOI 10.1006/jmbi.2000.3797; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CALLADINE CR, 1982, J MOL BIOL, V161, P343, DOI 10.1016/0022-2836(82)90157-7; Campbell KM, 2000, BIOCHEMISTRY-US, V39, P2633, DOI 10.1021/bi9922998; CHEUNG HC, 1991, TOPICS FLUORESCENCE, P157; Coleman RA, 1997, P NATL ACAD SCI USA, V94, P7221, DOI 10.1073/pnas.94.14.7221; COLEMAN RA, 1995, J BIOL CHEM, V270, P13842, DOI 10.1074/jbc.270.23.13842; Daugherty MA, 2000, BIOCHEMISTRY-US, V39, P4869, DOI 10.1021/bi992423n; Daugherty MA, 1999, J MOL BIOL, V285, P1389, DOI 10.1006/jmbi.1998.2427; de Souza ON, 1998, BIOPOLYMERS, V46, P403; DICKERSON RE, 1983, J MOL BIOL, V166, P419, DOI 10.1016/S0022-2836(83)80093-X; FRIED MG, 1984, J MOL BIOL, V172, P263, DOI 10.1016/S0022-2836(84)80026-1; GOODSELL DS, 1994, NUCLEIC ACIDS RES, V22, P5497, DOI 10.1093/nar/22.24.5497; GOODSELL DS, 1994, J MOL BIOL, V239, P79, DOI 10.1006/jmbi.1994.1352; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; Hoopes BC, 1998, J MOL BIOL, V277, P1015, DOI 10.1006/jmbi.1998.1651; HORIKOSHI M, 1992, P NATL ACAD SCI USA, V89, P1060, DOI 10.1073/pnas.89.3.1060; Jackson-Fisher AJ, 1999, BIOCHEMISTRY-US, V38, P11340, DOI 10.1021/bi990911p; Juo ZS, 1996, J MOL BIOL, V261, P239, DOI 10.1006/jmbi.1996.0456; KIM JL, 1994, NAT STRUCT BIOL, V1, P638, DOI 10.1038/nsb0994-638; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KLUG A, 1979, J MOL BIOL, V131, P669, DOI 10.1016/0022-2836(79)90196-7; KLUG A, 1993, NATURE, V365, P486, DOI 10.1038/365486a0; Lakowicz J R, 1999, PRINCIPLES FLUORESCE, P367, DOI 10.1007/978-1-4757-3061-6; LEVENE SD, 1983, J BIOMOL STRUCT DYN, V1, P429, DOI 10.1080/07391102.1983.10507452; MALDONADO E, 1995, CURR OPIN CELL BIOL, V7, P352, DOI 10.1016/0955-0674(95)80090-5; McKnight SL, 1996, GENE DEV, V10, P367, DOI 10.1101/gad.10.4.367; Munteanu MG, 1998, TRENDS BIOCHEM SCI, V23, P341, DOI 10.1016/S0968-0004(98)01265-1; Nikolov DB, 1996, P NATL ACAD SCI USA, V93, P4862, DOI 10.1073/pnas.93.10.4862; Packer MJ, 2000, J MOL BIOL, V295, P85, DOI 10.1006/jmbi.1999.3237; Parkhurst KM, 1999, J MOL BIOL, V289, P1327, DOI 10.1006/jmbi.1999.2835; Parkhurst KM, 1996, BIOCHEMISTRY-US, V35, P7459, DOI 10.1021/bi9530301; PARKHURST KM, 1995, BIOCHEMISTRY-US, V34, P285, DOI 10.1021/bi00001a035; PARKHURST KM, 1995, BIOCHEMISTRY-US, V34, P293, DOI 10.1021/bi00001a036; PARKHURST LJ, 1994, P SOC PHOTO-OPT INS, V2137, P475, DOI 10.1117/12.182758; Pastor N, 2000, J MOL BIOL, V304, P55, DOI 10.1006/jmbi.2000.4173; PEREZHOWARD GM, 1995, BIOCHEMISTRY-US, V34, P8005, DOI 10.1021/bi00025a006; PETRI V, 1995, BIOCHEMISTRY-US, V34, P9977, DOI 10.1021/bi00031a020; Petri V, 1998, BIOCHEMISTRY-US, V37, P15842, DOI 10.1021/bi981072u; QUINTANA JR, 1991, BIOCHEMISTRY-US, V30, P10294, DOI 10.1021/bi00106a030; SUZUKI M, 1995, NUCLEIC ACIDS RES, V23, P2083, DOI 10.1093/nar/23.12.2083; VISWAMITRA MA, 1978, NATURE, V273, P687, DOI 10.1038/273687a0; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859; WONG JM, 1994, NUCLEIC ACIDS RES, V22, P1890, DOI 10.1093/nar/22.10.1890; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; Wu J, 2001, J BIOL CHEM, V276, P14614, DOI 10.1074/jbc.M004402200; Wu JO, 2001, J BIOL CHEM, V276, P14623, DOI 10.1074/jbc.M004401200; WU PG, 1994, ANAL BIOCHEM, V218, P1, DOI 10.1006/abio.1994.1134; WU PG, 1992, BIOCHEMISTRY-US, V31, P7939, DOI 10.1021/bi00149a027	51	29	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29782	29791		10.1074/jbc.M104099200	http://dx.doi.org/10.1074/jbc.M104099200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11387341	hybrid			2022-12-25	WOS:000170558000025
J	Amici, C; Belardo, G; Rossi, A; Santoro, MG				Amici, C; Belardo, G; Rossi, A; Santoro, MG			Activation of I kappa B kinase by herpes simplex virus type 1 - A novel target for anti-herpetic therapy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TRANSCRIPTION FACTOR; CYCLOPENTENONE PROSTAGLANDINS; REPLICATION; INHIBITION; INFECTION; INDUCTION; CYTOKINES; HEPATITIS; PROMOTER	Herpes simplex viruses (HSV) are ubiquitous pathogens causing a variety of diseases ranging from mild illness to severe life-threatening infections. HSV utilize cellular signaling pathways and transcription factors to promote their replication. Here we report that HSV type 1 (HSV-1) induces persistent activation of transcription factor NF-kappaB, a critical regulator of genes involved in inflammation, by activating the I kappaB kinase (IKK) in the early phase of infection. Activated NF-kappaB enhances HSV-1 gene expression. HSV-1-induced NF-kappaB activation is dependent on viral early protein synthesis and is not blocked by the anti-herpetic drug acyclovir. IKK inhibition by the anti-inflammatory cyclopentenone prostaglandin A(1) blocks HSV-1 gene expression and reduces virus yield by more than 3000-fold. The results identify IKK as a potential target for anti-herpetic drugs and suggest that cyclopentenone prostaglandins or their derivatives could be used in the treatment of HSV infection.	Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; CNR, Inst Neurobiol & Mol Med, I-00133 Rome, Italy	University of Rome Tor Vergata; Consiglio Nazionale delle Ricerche (CNR)	Santoro, MG (corresponding author), Univ Roma Tor Vergata, Dept Biol, Via Ric Sci, I-00133 Rome, Italy.		Li, Chia Cheng/D-9906-2015	Santoro, Maria Gabriella/0000-0003-1432-4949; ROSSI, ANTONIO/0000-0003-0383-3828				Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; CHERRINGTON JM, 1989, J VIROL, V63, P1435, DOI 10.1128/JVI.63.3.1435-1440.1989; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DISNEY GH, 1990, J GEN VIROL, V71, P2999, DOI 10.1099/0022-1317-71-12-2999; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; MARGOLIS DM, 1992, VIROLOGY, V186, P788, DOI 10.1016/0042-6822(92)90048-T; MAVROMARANAZOS P, 1986, VIROLOGY, V149, P152, DOI 10.1016/0042-6822(86)90117-0; McLean TI, 1999, J VIROL, V73, P8415, DOI 10.1128/JVI.73.10.8415-8426.1999; Mikloska Z, 1998, J INFECT DIS, V177, P827, DOI 10.1086/515236; Mole L, 1997, J INFECT DIS, V176, P766, DOI 10.1086/517297; Morimoto RI, 1998, NAT BIOTECHNOL, V16, P833, DOI 10.1038/nbt0998-833; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NABEL GJ, 1988, SCIENCE, V239, P1288; Patel A, 1998, VIROLOGY, V247, P212, DOI 10.1006/viro.1998.9243; RONG BL, 1992, VIROLOGY, V189, P750, DOI 10.1016/0042-6822(92)90599-K; ROSENBERG ZF, 1991, FASEB J, V5, P2382, DOI 10.1096/fasebj.5.10.1676689; Rossi A, 1998, J BIOL CHEM, V273, P16446, DOI 10.1074/jbc.273.26.16446; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Rossi A, 1997, P NATL ACAD SCI USA, V94, P746, DOI 10.1073/pnas.94.2.746; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Rozera C, 1996, J CLIN INVEST, V97, P1795, DOI 10.1172/JCI118609; SANTORO MG, 1980, SCIENCE, V209, P1032, DOI 10.1126/science.6157190; Santoro MG, 1997, TRENDS MICROBIOL, V5, P276, DOI 10.1016/S0966-842X(97)01066-4; SASSONECORSI P, 1985, NATURE, V313, P458, DOI 10.1038/313458a0; Serhan CN, 1996, FASEB J, V10, P1147, DOI 10.1096/fasebj.10.10.8751717; SHIELD MJ, 1995, PHARMACOL THERAPEUT, V65, P125, DOI 10.1016/0163-7258(94)00060-G; SIDDIQUI A, 1989, VIROLOGY, V169, P479, DOI 10.1016/0042-6822(89)90177-3; SINCLAIR SB, 1989, J CLIN INVEST, V84, P1063, DOI 10.1172/JCI114268; Ushikubi F, 1998, NATURE, V395, P281, DOI 10.1038/26233; VANE JR, 1993, THERAPEUTIC APPL PRO; YAMAMOTO N, 1987, BIOCHEM BIOPH RES CO, V146, P1425, DOI 10.1016/0006-291X(87)90809-6; Zachos G, 1999, J BIOL CHEM, V274, P5097, DOI 10.1074/jbc.274.8.5097; Zachos G, 2001, J VIROL, V75, P2710, DOI 10.1128/JVI.75.6.2710-2728.2001	35	108	112	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28759	28766		10.1074/jbc.M103408200	http://dx.doi.org/10.1074/jbc.M103408200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11387335	hybrid			2022-12-25	WOS:000170346000017
J	Baruch, A; Greenbaum, D; Levy, ET; Nielsen, PA; Gilula, NB; Kumar, NM; Bogyo, M				Baruch, A; Greenbaum, D; Levy, ET; Nielsen, PA; Gilula, NB; Kumar, NM; Bogyo, M			Defining a link between gap junction communication, proteolysis, and cataract formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-D-CRYSTALLIN; INTACT RAT LENS; ALPHA(3) CONNEXIN; CALPAIN; GENE; MICE; ACTIVATION; MUTATIONS; MEMBRANE; CHANNEL	Disruption of the connexin alpha3 (Cx46) gene (alpha3 (-/-)) in mice results in severe cataracts within the nuclear portion of the lens. These cataracts are associated with proteolytic processing of the abundant lens protein gamma -crystallin, leading to its aggregation and subsequent opacification of the lens. The general cysteine protease inhibitor, E-64, blocked cataract formation and gamma -crystallin cleavage in alpha3 (-/-) lenses. Using a new class of activity-based cysteine protease affinity probes, we identified the calcium-dependent proteases, m-calpain and Lp82, as the primary targets of E-64 in the lens. Profiling changes in protease activities throughout cataractogenesis indicated that Lp82 activity was dramatically increased in alpha3 (-/-) lenses and correlated both spatially and temporally with cataract formation. Increased Lp82 activity was due to calcium accumulation as a result of increased influx and decreased outflux of calcium ions in alpha3 (-/-) lenses. These data establish a role for alpha3 gap junctions in maintaining calcium homeostasis that in turn is required to control activity of the calcium-dependent cysteine protease Lp82, shown here to be a key initiator of the process of cataractogenesis.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	Scripps Research Institute; University of California System; University of California San Francisco	Bogyo, M (corresponding author), Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA.			Bogyo, Matthew/0000-0003-3753-4412	NATIONAL EYE INSTITUTE [R01EY012142] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM037904, R01GM037904] Funding Source: NIH RePORTER; NEI NIH HHS [EY12142] Funding Source: Medline; NIGMS NIH HHS [GM37904] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersson M, 1996, OPHTHALMIC RES, V28, P51, DOI 10.1159/000267944; Azuma M, 1997, EXP EYE RES, V64, P529, DOI 10.1006/exer.1996.0234; AZUMA M, 1992, BIOCHIM BIOPHYS ACTA, V1180, P215, DOI 10.1016/0925-4439(92)90071-T; Bogyo M, 1997, P NATL ACAD SCI USA, V94, P6629, DOI 10.1073/pnas.94.13.6629; BRAKENHOFF RH, 1994, HUM MOL GENET, V3, P279, DOI 10.1093/hmg/3.2.279; CHURCH RL, 1995, CURR EYE RES, V14, P979, DOI 10.3109/02713689508995138; CROW JM, 1994, INVEST OPHTH VIS SCI, V35, P3332; Gong XH, 1997, CELL, V91, P833, DOI 10.1016/S0092-8674(00)80471-7; Gong XH, 1998, P NATL ACAD SCI USA, V95, P15303, DOI 10.1073/pnas.95.26.15303; Goodenough D.A., 1992, Seminars in Cell Biology, V3, P49; Greenbaum D, 2000, CHEM BIOL, V7, P569, DOI 10.1016/S1074-5521(00)00014-4; Horwitz J, 1999, EYE, V13, P403, DOI 10.1038/eye.1999.114; Klopp N, 1998, GENOMICS, V52, P152, DOI 10.1006/geno.1998.5417; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; Lin JS, 1997, EUR J CELL BIOL, V73, P141; Lo CW, 1999, DEV GENET, V24, P1, DOI 10.1002/(SICI)1520-6408(1999)24:1/2<1::AID-DVG1>3.0.CO;2-U; Ma H, 1999, EXP EYE RES, V68, P447, DOI 10.1006/exer.1998.0625; Ma H, 2000, CURR EYE RES, V20, P183, DOI 10.1076/0271-3683(200003)20:3;1-9;FT183; MANDAL K, 1987, J BIOL CHEM, V262, P8096; Mathias RT, 1997, PHYSIOL REV, V77, P21, DOI 10.1152/physrev.1997.77.1.21; NIXON RA, 1994, ANN NY ACAD SCI, V747, P77; Paemeleire K, 2000, MOL BIOL CELL, V11, P1815, DOI 10.1091/mbc.11.5.1815; Pal JD, 2000, AM J PHYSIOL-CELL PH, V279, pC596, DOI 10.1152/ajpcell.2000.279.3.C596; Paterson CA, 1997, CURR EYE RES, V16, P333, DOI 10.1076/ceyr.16.4.333.10689; PAUL DL, 1991, J CELL BIOL, V115, P1077, DOI 10.1083/jcb.115.4.1077; Plum A, 2000, CURR BIOL, V10, P1083, DOI 10.1016/S0960-9822(00)00690-4; ROBINSON KR, 1983, CURR EYE RES, V2, P843, DOI 10.3109/02713688209020020; Sanderson J, 1996, BIOCHEM BIOPH RES CO, V218, P893, DOI 10.1006/bbrc.1996.0159; Shearer T R, 1997, Mol Vis, V3, P8; Shiels A, 1998, AM J HUM GENET, V62, P526, DOI 10.1086/301762; Srivastava OP, 1998, BIOCHEM BIOPH RES CO, V253, P288, DOI 10.1006/bbrc.1998.9728; Srivastava SK, 1997, INVEST OPHTH VIS SCI, V38, P2300; Stephan DA, 1999, P NATL ACAD SCI USA, V96, P1008, DOI 10.1073/pnas.96.3.1008; Thomas GR, 1999, J PHYSIOL-LONDON, V516, P191, DOI 10.1111/j.1469-7793.1999.191ab.x; Trexler EB, 1996, P NATL ACAD SCI USA, V93, P5836, DOI 10.1073/pnas.93.12.5836; TRUSCOTT RJW, 1990, INVEST OPHTH VIS SCI, V31, P2405; White TW, 1998, J CELL BIOL, V143, P815, DOI 10.1083/jcb.143.3.815; White TW, 2000, BRAIN RES REV, V32, P130, DOI 10.1016/S0165-0173(99)00072-7	38	96	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28999	29006		10.1074/jbc.M103628200	http://dx.doi.org/10.1074/jbc.M103628200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11395508	hybrid			2022-12-25	WOS:000170346000050
J	Goldfarb, AN; Delehanty, LL; Wang, DY; Racke, FK; Hussaini, IM				Goldfarb, AN; Delehanty, LL; Wang, DY; Racke, FK; Hussaini, IM			Stromal inhibition of megakaryocytic differentiation correlates with blockade of signaling by protein kinase C-epsilon and ERK/MAPK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-PROLIFERATION; ACTIVATION; PATHWAY; EXPRESSION; MODEL	Contact with bone marrow stromal. cells maintains normal and leukemic hematopoietic progenitors in an undifferentiated state. Recently, stromal contact has been shown to diminish the yield of megakaryocytes in cultures of primary human hematopoietic stem cells. This inhibition may explain the poor megakaryocytic engraftment frequently observed after bone marrow transplantation. In the current study, stromal co-culture is shown to render K562 cells refractory to megakaryocytic induction. This stromal. inhibition correlated with the selective down-regulation in K562 cells of protein kinase C-E (PKC-E), which has recently been implicated in regulation of megakaryocytic lineage commitment. In addition, the stromal. inhibition correlated with inactivation of the ERK/MAPK pathway, which has also been implicated in promoting megakaryocytic development. Forced expression of PKC-E by retroviral transduction was insufficient to reverse the stromal blockade of ERK/MAPK signaling or of megakaryocytic induction. Thus stromal. interruption of ERK/MAPK signaling occurred independently of PKC-E levels and correlated more closely with megakaryocytic blockade. These findings provide potential mechanisms for stromal inhibition of hematopoietic differentiation and possibly for the poor megakaryocytic engraftment seen after bone marrow transplantation.	Univ Virginia, Hlth Sci Ctr, Dept Pathol, Charlottesville, VA 22908 USA; Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21287 USA	University of Virginia; Johns Hopkins University; Johns Hopkins Medicine	Goldfarb, AN (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Pathol, Box 800214, Charlottesville, VA 22908 USA.	ang3x@virginia.edu			NATIONAL CANCER INSTITUTE [R29CA072704] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS035122, R01NS035122] Funding Source: NIH RePORTER; NCI NIH HHS [CA-72704] Funding Source: Medline; NHLBI NIH HHS [HL-04017] Funding Source: Medline; NINDS NIH HHS [NS-35122] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALITALO R, 1990, LEUKEMIA RES, V14, P501, DOI 10.1016/0145-2126(90)90002-Q; DAI W, 1993, BLOOD, V81, P1214; DEXTER TM, 1977, J CELL PHYSIOL, V91, P335, DOI 10.1002/jcp.1040910303; Dorsch M, 1999, BLOOD, V94, P2676, DOI 10.1182/blood.V94.8.2676.420k28_2676_2685; Fichelson S, 1999, BLOOD, V94, P1601, DOI 10.1182/blood.V94.5.1601.417k19_1601_1613; Hussaini IM, 2000, J BIOL CHEM, V275, P22348, DOI 10.1074/jbc.M003203200; Lam LT, 2000, J BIOL CHEM, V275, P19676, DOI 10.1074/jbc.M002866200; Li LH, 1998, IMMUNITY, V8, P43, DOI 10.1016/S1074-7613(00)80457-4; LONG MW, 1984, J CLIN INVEST, V74, P1686, DOI 10.1172/JCI111585; Lumelsky NL, 1997, BBA-MOL CELL RES, V1358, P79, DOI 10.1016/S0167-4889(97)00051-7; Matsumura I, 1998, MOL CELL BIOL, V18, P4282, DOI 10.1128/MCB.18.7.4282; Mudry RE, 2000, BLOOD, V96, P1926, DOI 10.1182/blood.V96.5.1926.h8001926_1926_1932; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Racke FK, 1997, J BIOL CHEM, V272, P23366, DOI 10.1074/jbc.272.37.23366; Racke FK, 2001, J BIOL CHEM, V276, P522, DOI 10.1074/jbc.M005236200; Rouyez MC, 1997, MOL CELL BIOL, V17, P4991, DOI 10.1128/MCB.17.9.4991; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Soh JW, 1999, MOL CELL BIOL, V19, P1313; Torok-Storb B, 1999, ANN NY ACAD SCI, V872, P164, DOI 10.1111/j.1749-6632.1999.tb08461.x; Tsuji T, 1998, BLOOD, V91, P1263, DOI 10.1182/blood.V91.4.1263; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947; WHITLOCK CA, 1982, P NATL ACAD SCI-BIOL, V79, P3608, DOI 10.1073/pnas.79.11.3608; Zaidi Z, 2000, BLOOD, V96, p77A; Zweegman S, 1999, LEUKEMIA, V13, P935, DOI 10.1038/sj.leu.2401422; Zweegman S, 2000, EXP HEMATOL, V28, P401, DOI 10.1016/S0301-472X(00)00128-4	26	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29526	29530		10.1074/jbc.M103825200	http://dx.doi.org/10.1074/jbc.M103825200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11395513	hybrid			2022-12-25	WOS:000170346000117
J	Ronca, F; Andersen, JS; Paech, V; Margolis, RU				Ronca, F; Andersen, JS; Paech, V; Margolis, RU			Characterization of Slit protein interactions with glypican-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; CHONDROITIN SULFATE; AXON GUIDANCE; NEURONAL MIGRATION; NERVOUS-TISSUE; BRAIN; DROSOPHILA; REPELLENT; MIDLINE; GROWTH	We have demonstrated previously that the Slit proteins, which are involved in axonal guidance and related developmental processes in nervous tissue, are ligands of the glycosylphosphatidylinositol-anchored heparan sulfate proteoglycan glypican-1 in brain (Liang, Y., Annan, R. S., Carr, S. A., Popp, S., Mevissen, M., Margolis, R. K., and Margolis, R. U. (1999) J. Biol. Chem. 274,17885-17892). To characterize these interactions in more detail, recombinant human Slit-2 protein and the N- and C-terminal portions generated by in vivo proteolytic processing were used in an enzyme-linked immunosorbent assay to measure the binding of a glypican-Fc fusion protein. Saturable and reversible high affinity binding to the full-length protein and to the C-terminal portion that is released from the cell membrane was seen, with dissociation constants in the 80-110 mi range, whereas only a relatively low level of binding to the larger N-terminal segment was detected. Co-transfection of 293 cells with Slit and glypican-1 cDNAs followed by immunoprecipitation demonstrated that these interactions also occur in vivo, and immunocytochemical studies showed colocalization in the embryonic and adult central nervous system. The binding affinity of the glypican core protein to Slit is an order of magnitude lower than that of the glycanated proteoglycan. Glypican binding to Slit was also decreased 80-90% by heparin (2 mug/ml), enzymatic removal of the heparan sulfate chains, and by chlorate inhibition of glypican sulfation. The differential effects of N- or O-desulfated heparin on glypican binding also indicate that O-sulfate groups on the heparan sulfate chains play a critical role in heparin interactions with Slit. Our data suggest that glypican binding to the releasable C-terminal portion of Slit may serve as a mechanism for regulating the biological activity of Slit and/or the proteoglycan.	NYU, Ctr Med, Dept Pharmacol, New York, NY 10016 USA	New York University	Margolis, RU (corresponding author), NYU, Ctr Med, Dept Pharmacol, 550 1St Ave, New York, NY 10016 USA.	margor01@med.nya.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS013876] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-09348, NS-13876] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ba-Charvet KTN, 1999, NEURON, V22, P463, DOI 10.1016/S0896-6273(00)80702-3; Battye R, 1999, DEVELOPMENT, V126, P2475; Bhamidipati A, 2000, J CELL BIOL, V149, P1087, DOI 10.1083/jcb.149.5.1087; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brickman YG, 1998, J BIOL CHEM, V273, P4350, DOI 10.1074/jbc.273.8.4350; Brose K, 1999, CELL, V96, P795, DOI 10.1016/S0092-8674(00)80590-5; Brose K, 2000, CURR OPIN NEUROBIOL, V10, P95, DOI 10.1016/S0959-4388(99)00066-5; Erskine L, 2000, J NEUROSCI, V20, P4975; GOWDA DC, 1989, J BIOL CHEM, V264, P11436; GREVE H, 1988, J BIOL CHEM, V263, P12886; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; Hong KS, 1999, CELL, V97, P927, DOI 10.1016/S0092-8674(00)80804-1; Hu HY, 1999, NEURON, V23, P703, DOI 10.1016/S0896-6273(01)80029-5; KARTHIKEYAN L, 1992, BIOCHEM BIOPH RES CO, V188, P395, DOI 10.1016/0006-291X(92)92398-H; KARTHIKEYAN L, 1994, J CELL SCI, V107, P3213; Kidd T, 1999, CELL, V96, P785, DOI 10.1016/S0092-8674(00)80589-9; KLINGER MM, 1985, J BIOL CHEM, V260, P4082; Li HS, 1999, CELL, V96, P807, DOI 10.1016/S0092-8674(00)80591-7; Liang Y, 1999, J BIOL CHEM, V274, P17885, DOI 10.1074/jbc.274.25.17885; Liang Y, 1997, J CELL BIOL, V139, P851, DOI 10.1083/jcb.139.4.851; Margolis RU, 1997, CELL TISSUE RES, V290, P343, DOI 10.1007/s004410050939; MeyerPuttlitz B, 1996, J COMP NEUROL, V366, P44, DOI 10.1002/(SICI)1096-9861(19960226)366:1<44::AID-CNE4>3.0.CO;2-K; NAKATO H, 1995, DEVELOPMENT, V121, P3687; Niclou SP, 2000, J NEUROSCI, V20, P4962; Pilia G, 1996, NAT GENET, V12, P241, DOI 10.1038/ng0396-241; RAUCH U, 1991, J BIOL CHEM, V266, P14785; Ringstedt T, 2000, J NEUROSCI, V20, P4983; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; Safaiyan F, 1999, J BIOL CHEM, V274, P36267, DOI 10.1074/jbc.274.51.36267; TEKOTTE H, 1994, J NEUROCHEM, V62, P1126; Wang KH, 1999, CELL, V96, P771, DOI 10.1016/S0092-8674(00)80588-7; Wu W, 1999, NATURE, V400, P331, DOI 10.1038/22477; Zoo YM, 2000, CELL, V102, P363, DOI 10.1016/S0092-8674(00)00041-6	33	99	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29141	29147		10.1074/jbc.M100240200	http://dx.doi.org/10.1074/jbc.M100240200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11375980	hybrid			2022-12-25	WOS:000170346000069
J	Sun, J; Zhao, J; Schwartz, MA; Wang, JYJ; Wiedmer, T; Sims, PJ				Sun, J; Zhao, J; Schwartz, MA; Wang, JYJ; Wiedmer, T; Sims, PJ			c-Abl tyrosine kinase binds and phosphorylates phospholipid scramblase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE PHOSPHOLIPIDS; TRANSBILAYER MOVEMENT; APOPTOTIC CELLS; MESSENGER-RNA; GENE FAMILY; BCR-ABL; PROTEIN; PHOSPHATIDYLSERINE; ACTIVATION; GROWTH	Phospholipid scramblase 1 (PLSCR1) is a plasma membrane protein that has been proposed to play a role in the transbilayer movement of plasma membrane phospholipids. PLSCR1 contains multiple proline-rich motifs resembling Src homology 3 (SH3) domain-binding sites. An initial screen against 13 different SH3 domains revealed a marked specificity of PLSCR1 for binding to the Abl SH3 domain. Binding between intracellular PLSCR1 and c-Abl was demonstrated by co-immunoprecipitation of both proteins from several cell lines. Deletion of the proline-rich segment in PLSCR1 (residues 1-118) abolished its binding to the Abl SH3 domain. PLSCR1 was Tyr-phosphorylated by c-Abl in vitro. Phosphorylation was abolished by mutation of Tyr residues Tyr(69)/Tyr(74) within the tandem repeat sequence (VYN)-V-68-QPVYNQP(77) of PLSCR1, implying that these residues are the likely sites of phosphorylation. Cellular PLSCR1 was found to be constitutively Tyr-phosphorylated in several cell lines. The Tyr phosphorylation of PLSCR1 was increased upon overexpression of c-Abl and significantly reduced either upon cell treatment with the Abl kinase inhibitor ST1571, or in Abl-/- mouse fibroblasts, suggesting that cellular PLSCR1 is a normal substrate of c-Abl. Cell treatment with the DNA-damaging agent cisplatin activated c-Abl kinase and increased Tyr phosphorylation of PLSCR1. The cisplatin-induced phosphorylation of PLSCR1 was inhibited by ST1571 and was not observed in Abl-/- fibroblasts. These findings indicate that c-Abl binds and phosphorylates PLSCR1, and raise the possibility that an interaction between c-Abl and plasma membrane PLSCR1 might contribute to the cellular response to genotoxic stress.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA; Univ Calif San Diego, Div Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA	Scripps Research Institute; Scripps Research Institute; University of California System; University of California San Diego; University of California System; University of California San Diego	Sims, PJ (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, MEM-275, La Jolla, CA 92037 USA.			schwartz, martin/0000-0002-2071-1243	NCI NIH HHS [R37 CA043054, R01 CA043054] Funding Source: Medline; NHLBI NIH HHS [HL63819, HL61200, HL36946] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043054, R37CA043054] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063819, R01HL061200, R01HL036946] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agami R, 1999, NATURE, V399, P809; Basse F, 1996, J BIOL CHEM, V271, P17205, DOI 10.1074/jbc.271.29.17205; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; Bevers EM, 1998, LUPUS, V7, pS126, DOI 10.1177/096120339800700228; Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139; Carroll M, 1997, BLOOD, V90, P4947, DOI 10.1182/blood.V90.12.4947.4947_4947_4952; Cong F, 1999, P NATL ACAD SCI USA, V96, P13819, DOI 10.1073/pnas.96.24.13819; DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; Gong JG, 1999, NATURE, V399, P806; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kasukabe T, 1997, BLOOD, V89, P2975, DOI 10.1182/blood.V89.8.2975; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Krahling S, 1999, CELL DEATH DIFFER, V6, P183, DOI 10.1038/sj.cdd.4400473; Levrero M, 1999, CELL DEATH DIFFER, V6, P1146, DOI 10.1038/sj.cdd.4400624; Lewis JM, 1998, J BIOL CHEM, V273, P14225, DOI 10.1074/jbc.273.23.14225; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Marguet D, 1999, NAT CELL BIOL, V1, P454, DOI 10.1038/15690; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Raitano A. B., 1997, BIOCHIM BIOPHYS ACTA, V1333, P201, DOI 10.1016/S0304-419X(97)00023-1; RENSHAW MW, 1988, MOL CELL BIOL, V8, P4547, DOI 10.1128/MCB.8.10.4547; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Stout JG, 1997, J CLIN INVEST, V99, P2232, DOI 10.1172/JCI119397; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Till JH, 1999, J BIOL CHEM, V274, P4995, DOI 10.1074/jbc.274.8.4995; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; Vigneri P, 2001, NAT MED, V7, P228, DOI 10.1038/84683; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; Wiedmer T, 2000, BBA-BIOMEMBRANES, V1467, P244, DOI 10.1016/S0005-2736(00)00236-4; Zhao J, 1998, J BIOL CHEM, V273, P6603, DOI 10.1074/jbc.273.12.6603; Zhao J, 1998, BIOCHEMISTRY-US, V37, P6361, DOI 10.1021/bi980218m; Zhou QS, 2000, BLOOD, V95, P2593, DOI 10.1182/blood.V95.8.2593.008k32_2593_2599; Zhou QS, 1998, BIOCHEMISTRY-US, V37, P2356, DOI 10.1021/bi972625o; Zhou QS, 1997, J BIOL CHEM, V272, P18240, DOI 10.1074/jbc.272.29.18240; Zou XM, 1999, J BIOL CHEM, V274, P18141, DOI 10.1074/jbc.274.26.18141	40	57	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28984	28990		10.1074/jbc.M102505200	http://dx.doi.org/10.1074/jbc.M102505200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11390389	hybrid			2022-12-25	WOS:000170346000048
J	Levine, RL; Miller, H; Grollman, A; Ohashi, E; Ohmori, H; Masutani, C; Hanaoka, F; Moriya, M				Levine, RL; Miller, H; Grollman, A; Ohashi, E; Ohmori, H; Masutani, C; Hanaoka, F; Moriya, M			Translesion DNA synthesis catalyzed by human pol eta and pol kappa across 1,N-6-ethenodeoxyadenosine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRONE LESION BYPASS; POLYMERASE-KAPPA; MOUSE HOMOLOGS; FIDELITY; REPLICATION; CELLS; ENCODES; PROTEIN; ADDUCT; DINB1	1,N-6-Ethenodeoxyadenosine, a DNA adduct generated by exogenous and endogenous sources, severely blocks DNA synthesis and induces miscoding events in human cells. To probe the mechanism for in vivo translesion DNA synthesis across this adduct, in vitro primer extension studies were conducted using newly identified human DNA polymerases (pol) eta and kappa, which have been shown to catalyze translesion DNA synthesis past several DNA lesions. Steady-state kinetic analyses and analysis of translesion products have revealed that the synthesis is > 100-fold more efficient with pol eta than with pol K and that both error-free and error-prone syntheses are observed with these enzymes. The miscoding events include both base substitution and frameshift mutations. These results suggest that both polymerases, particularly pol eta, may contribute to the translesion DNA synthesis events observed for 1,N-6-ethenodeoxyadenosine in human cells.	SUNY Stony Brook, Dept Pharmacol Sci, Chim Biol Lab, Stony Brook, NY 11794 USA; Osaka Univ, Inst Mol & Cellular Biol, Suita, Osaka 5650871, Japan; Kyoto Univ, Inst Virus Res, Dept Genet & Mol Biol, Lab Genet Informat Anal, Kyoto 6068507, Japan	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Osaka University; Kyoto University	Moriya, M (corresponding author), SUNY Stony Brook, Dept Pharmacol Sci, Chim Biol Lab, Stony Brook, NY 11794 USA.	maki@pharm.sunysb.edu	Masutani, Chikahide/I-6160-2014; Ohashi, Eiji/AAO-5794-2021; Miller, Holly/I-6942-2015; levine, ross/AAE-7658-2019	Ohashi, Eiji/0000-0002-1771-5585; Miller, Holly/0000-0002-9076-5335; Masutani, Chikahide/0000-0002-8600-8227	NCI NIH HHS [CA76163] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076163, R56CA076163] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Creighton S, 1995, METHOD ENZYMOL, V262, P232; Efrati E, 1997, J BIOL CHEM, V272, P2559; Gerlach VL, 1999, P NATL ACAD SCI USA, V96, P11922, DOI 10.1073/pnas.96.21.11922; Gibbs PEM, 1998, P NATL ACAD SCI USA, V95, P6876, DOI 10.1073/pnas.95.12.6876; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; Haracska L, 2000, NAT GENET, V25, P458, DOI 10.1038/78169; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Johnson RE, 2000, J BIOL CHEM, V275, P7447, DOI 10.1074/jbc.275.11.7447; Johnson RE, 1999, P NATL ACAD SCI USA, V96, P12224, DOI 10.1073/pnas.96.22.12224; LEHMANN AR, 1975, P NATL ACAD SCI USA, V72, P219, DOI 10.1073/pnas.72.1.219; Levine RL, 2000, CANCER RES, V60, P4098; Masutani C, 2000, EMBO J, V19, P3100, DOI 10.1093/emboj/19.12.3100; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Masutani C, 1999, EMBO J, V18, P3491, DOI 10.1093/emboj/18.12.3491; Matsuda T, 2000, NATURE, V404, P1011, DOI 10.1038/35010014; McDonald JP, 1999, GENOMICS, V60, P20, DOI 10.1006/geno.1999.5906; Mozzherin DJ, 1999, J BIOL CHEM, V274, P19862, DOI 10.1074/jbc.274.28.19862; Napolitano R, 2000, EMBO J, V19, P6259, DOI 10.1093/emboj/19.22.6259; NG L, 1991, J BIOL CHEM, V266, P11699; Ogi T, 1999, GENES CELLS, V4, P607, DOI 10.1046/j.1365-2443.1999.00289.x; Ohashi E, 2000, GENE DEV, V14, P1589; Ohashi E, 2000, J BIOL CHEM, V275, P39678, DOI 10.1074/jbc.M005309200; Pandya GA, 1996, BIOCHEMISTRY-US, V35, P11487, DOI 10.1021/bi960170h; Sagi J, 1999, IARC SCI PUBL, P191; Shibutani S, 1996, BIOCHEMISTRY-US, V35, P14992, DOI 10.1021/bi961446o; Tissier A, 2000, GENE DEV, V14, P1642; WANG YC, 1991, P NATL ACAD SCI USA, V88, P7810, DOI 10.1073/pnas.88.17.7810; Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4717, DOI 10.1093/nar/28.23.4717; Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4138, DOI 10.1093/nar/28.21.4138	29	84	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					18717	18721		10.1074/jbc.M102158200	http://dx.doi.org/10.1074/jbc.M102158200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11376002	hybrid			2022-12-25	WOS:000169091000011
J	Lindstedt, KA; Wang, YF; Shiota, N; Saarinen, J; Hyytiainen, M; Kokkonen, JO; Keski-Oja, J; Kovanen, PT				Lindstedt, KA; Wang, YF; Shiota, N; Saarinen, J; Hyytiainen, M; Kokkonen, JO; Keski-Oja, J; Kovanen, PT			Activation of paracrine TGF-beta 1 signaling upon stimulation and degranulation of rat serosal mast cells: a novel function for chymase	FASEB JOURNAL			English	Article						recombinant chymase; proteolysis; TGF-beta activation; TGF-beta receptors; gene regulation	GROWTH-FACTOR-BETA; LOW-DENSITY LIPOPROTEINS; NECROSIS-FACTOR-ALPHA; SMOOTH-MUSCLE-CELLS; LATENT TGF-BETA; EXTRACELLULAR-MATRIX; BINDING-PROTEIN; TRANSFORMING GROWTH-FACTOR-BETA-1; PERICELLULAR MATRIX; ENDOTHELIAL-CELLS	As a source of transforming growth factor beta1 (TGF-beta1), mast cells have been implicated as potential effector cells in many pathological processes. However, the mechanisms by which mast cells express, secrete, and activate TGF-beta1 have remained vague. We show here by means of RT-PCR, immunoblotting, and immunocytochemistry that isolated rat peritoneal mast cells synthesize and store large latent TGF-beta1 in their chymase 1-containing secretory granules. Mast cell stimulation and degranulation results in rapid secretion of the latent TGF-beta1, which is converted by chymase 1 into an active form recognized by the type II TGF-beta serine/threonine kinase receptor (T beta RII). Thus, mast cells secrete active TGF-beta1 by a unique secretory mechanism in which latent TGF-beta1 and the activating enzyme chymase 1 are coreleased. The activation of latent TGF-beta1 specifically by chymase was verified using recombinant human latent TGF-beta1 and recombinant human chymase. In isolated T beta RI- and T beta RII-expressing peritoneal macrophages, the activated TGF-beta1 induces the expression of the plasminogen activator inhibitor 1 (PAI-1), whereas in the mast cells, the levels of T beta RI, T beta RII, and PAI-1 expression were below detection. Selective stimulation of mast cells in vivo in the rat peritoneal cavity leads to rapid overexpression of TGF-beta1 in peritoneal mast cells and of T beta Rs in peritoneal macrophages. These data strongly suggest that mast cells can act as potent paracrine effector cells both by secreting active TGF-beta1 and by enhancing its response in target cells.	Wihuri Res Inst, FIN-00140 Helsinki, Finland; Univ Helsinki, Inst Biotechnol, Prot Chem Lab, FIN-00014 Helsinki, Finland; Univ Helsinki, Haartman Inst, Dept Pathol, FIN-00014 Helsinki, Finland; Univ Helsinki, Haartman Inst, Dept Virol, FIN-00014 Helsinki, Finland	Wihuri Research Institute; University of Helsinki; University of Helsinki; University of Helsinki	Lindstedt, KA (corresponding author), Wihuri Res Inst, Kalliolinnantie 4, FIN-00140 Helsinki, Finland.	ken.lindstedt@wri.fi						Bissonnette EY, 1997, AM J RESP CELL MOL, V16, P275, DOI 10.1165/ajrcmb.16.3.9070612; BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; BROIDE DH, 1990, J IMMUNOL, V145, P1838; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; Caughey GH, 2000, BBA-PROTEIN STRUCT M, V1480, P245, DOI 10.1016/S0167-4838(00)00076-5; Chandrasekharan UM, 1996, SCIENCE, V271, P502, DOI 10.1126/science.271.5248.502; Chen HX, 1998, J EXP MED, V188, P1657, DOI 10.1084/jem.188.9.1657; Clouthier DE, 1997, J CLIN INVEST, V100, P2697, DOI 10.1172/JCI119815; D'Angelo M, 2001, J BIOL CHEM, V276, P11347, DOI 10.1074/jbc.M009725200; DVORAK AM, 1986, LAB INVEST, V54, P663; GENTRY LE, 1990, BIOCHEMISTRY-US, V29, P6851, DOI 10.1021/bi00481a014; GORDON JR, 1994, J EXP MED, V180, P2027, DOI 10.1084/jem.180.6.2027; GORDON JR, 1990, NATURE, V346, P274, DOI 10.1038/346274a0; HEDMAN K, 1979, J CELL BIOL, V81, P83, DOI 10.1083/jcb.81.1.83; IEMURA A, 1994, AM J PATHOL, V144, P321; ISHIZAKA T, 1984, PROG ALLERGY, V34, P188; Kanbe N, 1999, CLIN EXP ALLERGY, V29, P105; KANZAKI T, 1990, CELL, V61, P1051, DOI 10.1016/0092-8674(90)90069-Q; KAWAMOTO K, 1995, BLOOD, V86, P4638, DOI 10.1182/blood.V86.12.4638.bloodjournal86124638; KOKKONEN JO, 1985, J BIOL CHEM, V260, P4756; KOKKONEN JO, 1987, P NATL ACAD SCI USA, V84, P2287, DOI 10.1073/pnas.84.8.2287; KOKKONEN JO, 1989, J LIPID RES, V30, P1341; KOVANEN PT, 1993, EUR HEART J, V14, P105; LAWRENCE D, 1985, BIOCHEM BIOPH RES CO, V133, P1026, DOI 10.1016/0006-291X(85)91239-2; LI QY, 1992, TRANSPLANTATION, V53, P1047, DOI 10.1097/00007890-199205000-00015; LINDSTEDT KA, 1992, J LIPID RES, V33, P65; Lindstedt L, 1996, J CLIN INVEST, V97, P2174, DOI 10.1172/JCI118658; LIU MC, 1986, J IMMUNOL, V136, P2588; Lutzelschwab C, 1997, J EXP MED, V185, P13, DOI 10.1084/jem.185.1.13; Lyon M, 1997, J BIOL CHEM, V272, P18000, DOI 10.1074/jbc.272.29.18000; LYONS RM, 1988, J CELL BIOL, V106, P1659, DOI 10.1083/jcb.106.5.1659; METCALFE DD, 1981, CRC CR REV IMMUNOL, V3, P23; MIYAZONO K, 1991, EMBO J, V10, P1091, DOI 10.1002/j.1460-2075.1991.tb08049.x; Patella V, 1998, CIRCULATION, V97, P971; PENNINGTON DW, 1992, J CLIN INVEST, V90, P35, DOI 10.1172/JCI115853; Pinxteren JA, 1998, EMBO J, V17, P6210, DOI 10.1093/emboj/17.21.6210; QIAN SW, 1991, CELL REGUL, V2, P241, DOI 10.1091/mbc.2.3.241; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; ROHLICH P, 1971, J CELL BIOL, V51, P465, DOI 10.1083/jcb.51.2.465; Saharinen J, 1999, CYTOKINE GROWTH F R, V10, P99, DOI 10.1016/S1359-6101(99)00010-6; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sanker S, 1997, J BIOL CHEM, V272, P2963, DOI 10.1074/jbc.272.5.2963; SATO Y, 1990, J CELL BIOL, V111, P757, DOI 10.1083/jcb.111.2.757; SEDGWICK JD, 1981, CLIN EXP IMMUNOL, V45, P409; SEIBOLD JR, 1990, ARTHRITIS RHEUM, V33, P1702, DOI 10.1002/art.1780331114; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Sillalber C, 1999, J IMMUNOL, V162, P1032; TAIPALE J, 1995, J BIOL CHEM, V270, P4689, DOI 10.1074/jbc.270.9.4689; TAIPALE J, 1994, J CELL BIOL, V124, P171, DOI 10.1083/jcb.124.1.171; TAIPALE J, 1992, J BIOL CHEM, V267, P25378; Taipale J, 1997, FASEB J, V11, P51, DOI 10.1096/fasebj.11.1.9034166; URATA H, 1990, J BIOL CHEM, V265, P22348; WANG YF, 1995, ARTERIOSCL THROM VAS, V15, P801, DOI 10.1161/01.ATV.15.6.801; Yang LJ, 1999, AM J PATHOL, V154, P105, DOI 10.1016/S0002-9440(10)65256-X; Yu Q, 2000, GENE DEV, V14, P163	55	160	173	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2001	15	8					1377	1388		10.1096/fj.00-0273com	http://dx.doi.org/10.1096/fj.00-0273com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	442AF	11387235				2022-12-25	WOS:000169261200005
J	Favre, B; Fontao, L; Koster, J; Shafaatian, R; Jaunin, F; Saurat, JH; Sonnenberg, A; Borradori, L				Favre, B; Fontao, L; Koster, J; Shafaatian, R; Jaunin, F; Saurat, JH; Sonnenberg, A; Borradori, L			The hemidesmosomal protein bullous pemphigoid antigen 1 and the integrin beta 4 subunit bind to ERBIN - Molecular cloning of multiple alternative splice variants of ERBIN and analysis of their tissue expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOLATERAL PDZ PROTEIN; AMINO-ACID; ALPHA(6)BETA(4) INTEGRIN; TOPOLOGY PREDICTION; TERMINAL DOMAIN; CELL-MIGRATION; ALPHA-6-BETA-4; BP180; PLECTIN; CYTOSKELETON	The bullous pemphigoid antigen I (eBPAG1) is a constituent of hemidesmosomes (HDs), cell-substrate adhesion complexes in stratified epithelia. Although its COOH terminus interacts with intermediate filaments, its NH2 terminus is important for its recruitment into HDs. To identify proteins that interact with the NH2 terminus of human eBPAG1, we performed a yeast two-hybrid screen, which uncovered a protein belonging to the LAP/LERP (for LRR and PDZ domain) protein family with 16 NH2-terminal leucine-rich repeats and a COOH-terminal PDZ domain. The gene for this LAP/LERP protein comprises at least 26 exons located on the long arm of chromosome 5. In most human tissues, several transcripts were detected differing in the coding region situated upstream of or within the PDZ domain. One of the encoded variants was found to correspond to the recently described protein ERBIN. In yeast and in vitro binding experiments, ERBIN was shown to interact not only with eBPAG1 but also with the COOH-terminal region of the cytoplasmic domain of the integrin beta4 subunit, another component of HDs. Antibodies raised against the COOH terminus showed that ERBIN is expressed in keratinocytes. In transfected epithelial cells the protein, however, was not localized in HDs but was either diffusely distributed over the cytoplasm or concentrated at the basolateral plasma membrane. Because ERBIN had been shown previously to interact with the transmembrane tyrosine kinase receptor Erb-B2, which in turn associates with the integrin beta4 subunit, we suggest that ERBIN provides a link between HD assembly and Erb-B2 receptor signaling.	Univ Geneva, Sch Med, Dept Dermatol, CH-1211 Geneva 14, Switzerland; Netherlands Canc Inst, Div Cell Biol, NL-1066 CX Amsterdam, Netherlands	University of Geneva; Netherlands Cancer Institute	Borradori, L (corresponding author), Univ Hosp Geneva, Dept Dermatol, Rue Micheli Du crest 24, CH-1211 Geneva 14, Switzerland.		Lionel, Fontao/AGN-3640-2022; Koster, Jan/C-5934-2008	Koster, Jan/0000-0002-0890-7585; Fontao, Lionel/0000-0002-5950-564X				Aho S, 1998, BIOCHEM BIOPH RES CO, V243, P694, DOI 10.1006/bbrc.1998.8162; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Apperson ML, 1996, J NEUROSCI, V16, P6839; Balda MS, 2000, EMBO J, V19, P2024, DOI 10.1093/emboj/19.9.2024; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Borg JP, 2000, NAT CELL BIOL, V2, P407, DOI 10.1038/35017038; Borradori L, 1997, J CELL BIOL, V136, P1333, DOI 10.1083/jcb.136.6.1333; Borradori L, 1998, EXP CELL RES, V239, P463, DOI 10.1006/excr.1997.3923; Borradori L, 1999, J INVEST DERMATOL, V112, P411, DOI 10.1046/j.1523-1747.1999.00546.x; BROWN A, 1995, GENOMICS, V29, P777, DOI 10.1006/geno.1995.9936; Bryant PJ, 2000, NAT CELL BIOL, V2, pE141, DOI 10.1038/35019616; Burshtyn DN, 1997, J BIOL CHEM, V272, P13066, DOI 10.1074/jbc.272.20.13066; Chao C, 1996, CANCER RES, V56, P4811; Cowburn D, 1997, CURR OPIN STRUC BIOL, V7, P835, DOI 10.1016/S0959-440X(97)80155-8; Falcioni R, 1997, EXP CELL RES, V236, P76, DOI 10.1006/excr.1997.3695; Gambaletta D, 2000, J BIOL CHEM, V275, P10604, DOI 10.1074/jbc.275.14.10604; Geerts D, 1999, J CELL BIOL, V147, P417, DOI 10.1083/jcb.147.2.417; Giancotti FG, 1997, CURR OPIN CELL BIOL, V9, P691, DOI 10.1016/S0955-0674(97)80123-8; GIUDICE GJ, 1992, J INVEST DERMATOL, V99, P243, DOI 10.1111/1523-1747.ep12616580; Greaves S, 2000, NAT CELL BIOL, V2, pE140, DOI 10.1038/35019613; GUO LF, 1995, CELL, V81, P233, DOI 10.1016/0092-8674(95)90333-X; Harlow E., 1988, ANTIBODIES LAB MANUA; HASHIMOTO T, 1993, J INVEST DERMATOL, V100, P310, DOI 10.1111/1523-1747.ep12469916; Hopkinson SB, 2000, MOL BIOL CELL, V11, P277, DOI 10.1091/mbc.11.1.277; James P, 1996, GENETICS, V144, P1425; Jones JCR, 1998, BIOESSAYS, V20, P488, DOI 10.1002/(SICI)1521-1878(199806)20:6<488::AID-BIES7>3.0.CO;2-I; KENNEL SJ, 1990, HYBRIDOMA, V9, P243, DOI 10.1089/hyb.1990.9.243; Kowalczyk AP, 1997, J CELL BIOL, V139, P773, DOI 10.1083/jcb.139.3.773; Legouis R, 2000, NAT CELL BIOL, V2, P415, DOI 10.1038/35017046; Leung CL, 1999, J CELL BIOL, V144, P435, DOI 10.1083/jcb.144.3.435; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; Mainiero F, 1996, J CELL BIOL, V134, P241, DOI 10.1083/jcb.134.1.241; Nievers MG, 1998, J CELL SCI, V111, P1659; Nikolic B, 1996, J CELL BIOL, V134, P1455, DOI 10.1083/jcb.134.6.1455; Peifer M, 2000, SCIENCE, V289, P67, DOI 10.1126/science.289.5476.67; Rabinovitz I, 1997, J CELL BIOL, V139, P1873, DOI 10.1083/jcb.139.7.1873; Rezniczek GA, 1998, J CELL BIOL, V141, P209, DOI 10.1083/jcb.141.1.209; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; Ruhrberg C, 1997, CURR OPIN GENET DEV, V7, P392, DOI 10.1016/S0959-437X(97)80154-2; SAWAMURA D, 1991, J BIOL CHEM, V266, P17784; Schaapveld RQJ, 1998, J CELL BIOL, V142, P271, DOI 10.1083/jcb.142.1.271; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Sinclair NRS, 2000, CRIT REV IMMUNOL, V20, P89; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; STANLEY JR, 1988, J CLIN INVEST, V82, P1864, DOI 10.1172/JCI113803; STAPPENBECK TS, 1993, J CELL BIOL, V123, P691, DOI 10.1083/jcb.123.3.691; Sterk LMT, 2000, J CELL BIOL, V149, P969, DOI 10.1083/jcb.149.4.969; Strack S, 2000, J BIOL CHEM, V275, P25061, DOI 10.1074/jbc.C000319200; TANAKA T, 1990, J INVEST DERMATOL, V94, P617, DOI 10.1111/1523-1747.ep12876200; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; Wiche G, 1998, J CELL SCI, V111, P2477; Yang YM, 1999, CELL, V98, P229, DOI 10.1016/S0092-8674(00)81017-X; Yang YM, 1996, CELL, V86, P655, DOI 10.1016/S0092-8674(00)80138-5; Zimmermann P, 2001, MOL BIOL CELL, V12, P339, DOI 10.1091/mbc.12.2.339	56	64	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32427	32436		10.1074/jbc.M011005200	http://dx.doi.org/10.1074/jbc.M011005200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11375975	hybrid			2022-12-25	WOS:000170746000010
J	Kong, XT; Gao, HX; Stanbridge, EJ				Kong, XT; Gao, HX; Stanbridge, EJ			Mechanisms of differential activation of target gene promoters by p53 hinge domain mutants with impaired apoptotic function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE ARREST; TUMOR-SUPPRESSOR; TETRAMERIZATION DOMAIN; CRYSTAL-STRUCTURE; DNA-BINDING; MUTATIONS; CANCER; EXPRESSION; INDUCTION; INHIBITOR	Suppression of tumor cell growth by p53 results from the activation of both apoptosis and cell cycle arrest functions that have been shown to be separable activities of p53. We report here that some mutants in the p53 hinge domain, a short linker between the DNA binding and tetramerization domains, differentially activated the promoters of p53 target genes and possessed an impaired apoptotic function. Our results indicate that the hinge domain may play an important role in differentially regulating p53 cell cycle arrest and apoptotic functions. However, the mechanisms by which p53 hinge domain mutants differentially activate its target genes, e.g. p21(WAF1/CIP1) and Bax, remain unknown. To investigate the possible mechanisms, recombinant p21(WAF1/CIP1) and Bax promoters were constructed, resulting in rearrangement of the existing p53 binding sites within a given promoter or actually swapping p53 binding sites between the two promoters. Our results suggest that multiple mechanisms of differential transactivation occur, depending on the molecular nature of the relevant hinge domain mutant, such as the possibility that dual separate DNA binding sites in the p21(WAF1/CIP1) promoter are responsible for the selective transactivation activity of p53 hinge domain mutant del300-327, which has a large deletion in the hinge domain. Lack of ideal p53 binding sites in the Bax promoter results in less potent activation than that seen with the p21(WAF1/CIP1) promoter when it is transactivated by hinge domain point mutant mutR306P or short deletion mutant del300-308 proteins. How the single mutation or the short deletion affect the conformation of p53 and consequently the transactivation of the Bax promoter will require further investigation of the relevant p53 protein: DNA-binding domain by NMR and x-ray crystallographic techniques.	Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA	University of California System; University of California Irvine	Stanbridge, EJ (corresponding author), Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Med Sci 1,B210, Irvine, CA 92697 USA.				NCI NIH HHS [CA19401, CA68230] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA019401, R01CA068230, R37CA019401] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aurelio ON, 1998, CANCER RES, V58, P2190; Aurelio ON, 2000, MOL CELL BIOL, V20, P770, DOI 10.1128/MCB.20.3.770-778.2000; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Friedlander P, 1996, J BIOL CHEM, V271, P25468, DOI 10.1074/jbc.271.41.25468; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MIYASHITA T, 1995, CELL, V80, P293; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STENGER JE, 1994, EMBO J, V13, P6011, DOI 10.1002/j.1460-2075.1994.tb06947.x; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	30	21	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32990	33000		10.1074/jbc.M103681200	http://dx.doi.org/10.1074/jbc.M103681200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11395510	hybrid			2022-12-25	WOS:000170746000083
J	Boudreau, F; Zhu, Y; Traber, PG				Boudreau, F; Zhu, Y; Traber, PG			Sucrase-isomaltase gene transcription requires the hepatocyte nuclear factor-1 (HNF-1) regulatory element and is regulated by the ratio of HNF-1 alpha to HNF-1 beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; CRYPT-VILLUS AXIS; HOMEODOMAIN PROTEINS; LINE CACO-2; EXPRESSION; DIFFERENTIATION; ACTIVATION; CDX2; HETERODIMERS; ABUNDANCE	The mouse sucrase-isomaltase (SI) gene is an enterocyte-specific gene expressed in a complex developmental pattern. We previously reported that a short, evolutionarily conserved gene promoter regulates developmental expression of SI in mouse small intestine. Herein, we investigated the role of a hepatocyte nuclear factor-1 (HNF-1) cis-acting element to regulate SI gene expression in vivo. Transgenic SI gene constructs with a mutated HNF-1 element (SIF3) revealed a strong reduction in promoter activity in comparison with a wild-type construct in mice and during Caco-2 cell differentiation. Nuclear proteins isolated from enterocytes showed increased binding of the HNF-1 alpha complex with a concomitant decrease in the HNF-1 beta -containing complex to the SIF3 element both during the suckling-weaning developmental transition and Caco-2 cell differentiation. These changes coincided with a strong induction of SI gene transcription. In transfection experiments, HNF-1 alpha activated the ST promoter via the SIF3 element, and coexpression of HNF-1 beta impaired this transcriptional activation. These findings demonstrate the essential role of the HNF-1 regulatory element to support SI gene transcription in vivo and suggest that the ratio of HNF-1 alpha to HNF-1 beta plays a role in the transcriptional activity of this gene during intestinal development.	Univ Penn, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA	University of Pennsylvania	Traber, PG (corresponding author), 709 Swedeland Rd,POB 1539, King Of Prussia, PA 19406 USA.				NIDDK NIH HHS [P30-DK50306, R01-DK46704] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK050306, R01DK046704] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAUMHUETER S, 1990, GENE DEV, V4, P372, DOI 10.1101/gad.4.3.372; BEAULIEU JF, 1991, BIOCHEM J, V280, P599, DOI 10.1042/bj2800599; Boudreau F, 1998, DNA CELL BIOL, V17, P669, DOI 10.1089/dna.1998.17.669; Clifford J, 1996, EMBO J, V15, P4142, DOI 10.1002/j.1460-2075.1996.tb00789.x; EMENS LA, 1992, P NATL ACAD SCI USA, V89, P7300, DOI 10.1073/pnas.89.16.7300; Hu CB, 1999, AM J PHYSIOL-GASTR L, V276, pG1181, DOI 10.1152/ajpgi.1999.276.5.G1181; Lee YH, 1998, MOL CELL BIOL, V18, P3059, DOI 10.1128/MCB.18.5.3059; LIPSON KE, 1989, P NATL ACAD SCI USA, V86, P9774, DOI 10.1073/pnas.86.24.9774; LIU SY, 1995, DNA CELL BIOL, V14, P285, DOI 10.1089/dna.1995.14.285; Markowitz AJ, 1995, AM J PHYSIOL-GASTR L, V269, pG925, DOI 10.1152/ajpgi.1995.269.6.G925; MARKOWITZ AJ, 1993, AM J PHYSIOL, V265, pG526, DOI 10.1152/ajpgi.1993.265.3.G526; Menard D., 1994, MEMBRANE PHYSIOPATHO, P319; MENDEL DB, 1991, J BIOL CHEM, V266, P677; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; Mitchelmore C, 2000, BIOCHEM J, V346, P529, DOI 10.1042/0264-6021:3460529; PINTO M, 1983, BIOL CELL, V47, P323; Pontoglio M, 1996, CELL, V84, P575, DOI 10.1016/S0092-8674(00)81033-8; REYCAMPOS J, 1991, EMBO J, V10, P1445, DOI 10.1002/j.1460-2075.1991.tb07665.x; Silberg DG, 2000, GASTROENTEROLOGY, V119, P961, DOI 10.1053/gast.2000.18142; Song YH, 1998, J BIOL CHEM, V273, P28408, DOI 10.1074/jbc.273.43.28408; Soutoglou E, 2000, J BIOL CHEM, V275, P12515, DOI 10.1074/jbc.275.17.12515; Suh E, 1996, MOL CELL BIOL, V16, P619; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; Taylor JK, 1997, NUCLEIC ACIDS RES, V25, P2293, DOI 10.1093/nar/25.12.2293; Traber PG, 1998, PHILOS T ROY SOC B, V353, P911, DOI 10.1098/rstb.1998.0255; TRABER PG, 1990, BIOCHEM BIOPH RES CO, V173, P765, DOI 10.1016/S0006-291X(05)80853-8; TRABER PG, 1992, MOL CELL BIOL, V12, P3614, DOI 10.1128/MCB.12.8.3614; TRABER PG, 1992, AM J PHYSIOL, V262, pG123, DOI 10.1152/ajpgi.1992.262.1.G123; Tung J, 1997, AM J PHYSIOL-GASTR L, V273, pG83, DOI 10.1152/ajpgi.1997.273.1.G83; VACHON PH, 1992, GASTROENTEROLOGY, V103, P414, DOI 10.1016/0016-5085(92)90829-N; WU GD, 1994, J BIOL CHEM, V269, P17080; WU GD, 1992, J BIOL CHEM, V267, P7863; Zweibaum A, 1989, ADAPTATION DEV GASTR, P103	33	68	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32122	32128		10.1074/jbc.M102002200	http://dx.doi.org/10.1074/jbc.M102002200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11395488	hybrid			2022-12-25	WOS:000170613500089
J	Dirac, AMG; Huthoff, H; Kjems, J; Berkhout, B				Dirac, AMG; Huthoff, H; Kjems, J; Berkhout, B			The dimer initiation site hairpin mediates dimerization of the human immunodeficiency virus, type 2 RNA genome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KISSING-LOOP HAIRPIN; SECONDARY STRUCTURE; HIV-1(LAI) RNA; BINDING-SITES; LEADER RNA; SEQUENCES; LINKAGE; GAG; OLIGONUCLEOTIDE; ENCAPSIDATION	The untranslated leader of retroviral RNA genomes encodes multiple structural signals that are critical for virus replication. In the human immunodeficiency virus, type 1 (HIV-1) leader, a hairpin structure with a palindrome-containing loop is termed the dimer initiation site (DIS), because it triggers in vitro RNA dimerization through base pairing of the loop-exposed palindromes (kissing loops). Controversy remains regarding the region responsible for HIV-2 RNA dimerization. Different studies have suggested the involvement of the transactivation region, the primer binding site, and a hairpin structure that is the equivalent of the HIV-1 DIS hairpin. We have performed a detailed mutational analysis of the HIV-2 leader RNA, and we also used antisense oligonucleotides to probe the regions involved in dimerization. Our results unequivocally demonstrate that the DIS hairpin is the main determinant for HIV-2 RNA dimerization. The 6-mer palindrome sequence in the DIS loop is essential for dimer formation. Although the sequence can be replaced by other 6-mer palindromes, motifs that form more than two AX base pairs do not dimerize efficiently. The inability to form stable kissing-loop complexes precludes formation of dimers with more extended base pairing. Structure probing of the DIS hairpin in the context of the complete HIV-2 leader RNA suggests a 5-base pair elongation of the DIS stem as it is proposed in current RNA secondary structure models. This structure is supported by phylogenetic analysis of leader RNA sequences from different viral isolates, indicating that RNA genome dimerization occurs by a similar mechanism for all members of the human and simian immunodeficiency viruses.	Univ Amsterdam, Acad Med Ctr, Dept Human Retrovirol, NL-1100 DE Amsterdam, Netherlands; Aarhus Univ, Dept Mol & Struct Biol, DK-8000 Aarhus C, Denmark	University of Amsterdam; Academic Medical Center Amsterdam; Aarhus University	Berkhout, B (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Human Retrovirol, POB 22700, NL-1100 DE Amsterdam, Netherlands.	b.berkhout@amc.uva.nl	Kjems, Jorgen/I-3490-2016	Kjems, Jorgen/0000-0003-4128-9317				AWANG G, 1993, BIOCHEMISTRY-US, V32, P11453, DOI 10.1021/bi00093a024; BENDER W, 1976, CELL, V7, P595, DOI 10.1016/0092-8674(76)90210-5; Berkhout B, 1996, PROG NUCLEIC ACID RE, V54, P1, DOI 10.1016/S0079-6603(08)60359-1; Berkhout B, 1996, J VIROL, V70, P6723, DOI 10.1128/JVI.70.10.6723-6732.1996; Berkhout B, 2001, Science, V292, P7; BERKHOUT B, 1993, FASEB J, V7, P181, DOI 10.1096/fasebj.7.1.8422965; BIETH E, 1990, NUCLEIC ACIDS RES, V18, P119, DOI 10.1093/nar/18.1.119; Cain D, 2001, J VIROL, V75, P3731, DOI 10.1128/JVI.75.8.3731-3739.2001; CLEVER J, 1995, J VIROL, V69, P2101, DOI 10.1128/JVI.69.4.2101-2109.1995; Clever JL, 1997, J VIROL, V71, P3407, DOI 10.1128/JVI.71.5.3407-3414.1997; Clever JL, 1996, J VIROL, V70, P5902, DOI 10.1128/JVI.70.9.5902-5908.1996; COFFIN JM, 1984, RNA TUMOR VIRUSES; Damgaard CK, 1998, NUCLEIC ACIDS RES, V26, P3667, DOI 10.1093/nar/26.16.3667; DARLIX JL, 1990, J MOL BIOL, V216, P689, DOI 10.1016/0022-2836(90)90392-Y; Doherty EA, 2001, NAT STRUCT BIOL, V8, P339, DOI 10.1038/86221; Essink BBO, 1996, J MOL BIOL, V264, P243, DOI 10.1006/jmbi.1996.0638; FU W, 1994, J VIROL, V68, P5013, DOI 10.1128/JVI.68.8.5013-5018.1994; FU W, 1993, J VIROL, V67, P5443, DOI 10.1128/JVI.67.9.5443-5449.1993; Gotte M, 1999, ARCH BIOCHEM BIOPHYS, V365, P199, DOI 10.1006/abbi.1999.1209; Greatorex J, 1998, J GEN VIROL, V79, P2877, DOI 10.1099/0022-1317-79-12-2877; Greatorex JS, 1996, NUCLEIC ACIDS RES, V24, P2919, DOI 10.1093/nar/24.15.2919; Haddrick M, 1996, J MOL BIOL, V259, P58, DOI 10.1006/jmbi.1996.0301; Hoglund S, 1997, VIROLOGY, V233, P271, DOI 10.1006/viro.1997.8585; Huthoff H, 2001, RNA, V7, P143, DOI 10.1017/S1355838201001881; Jossinet F, 2001, J BIOL CHEM, V276, P5598, DOI 10.1074/jbc.M008642200; KATOH I, 1993, J VIROL, V67, P1830, DOI 10.1128/JVI.67.4.1830-1839.1993; LAUGHREA M, 1994, BIOCHEMISTRY-US, V33, P13464, DOI 10.1021/bi00249a035; Laughrea M, 1999, BIOCHEMISTRY-US, V38, P226, DOI 10.1021/bi981728j; Laughrea M, 1996, BIOCHEMISTRY-US, V35, P1589, DOI 10.1021/bi951838f; Laughrea M, 1997, J VIROL, V71, P3397, DOI 10.1128/JVI.71.5.3397-3406.1997; Lodmell JS, 2000, RNA, V6, P1267, DOI 10.1017/S1355838200000698; Lodmell JS, 1998, ANTISENSE NUCLEIC A, V8, P517, DOI 10.1089/oli.1.1998.8.517; MARQUET R, 1991, NUCLEIC ACIDS RES, V19, P2349, DOI 10.1093/nar/19.9.2349; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Muriaux D, 1996, J BIOL CHEM, V271, P33686, DOI 10.1074/jbc.271.52.33686; MURIAUX D, 1995, J BIOL CHEM, V270, P8209, DOI 10.1074/jbc.270.14.8209; Paillart JC, 1997, J MOL BIOL, V270, P36, DOI 10.1006/jmbi.1997.1096; PAILLART JC, 1994, J BIOL CHEM, V269, P27486; Sakuragi J, 1997, J VIROL, V71, P3250, DOI 10.1128/JVI.71.4.3250-3254.1997; SKRIPKIN E, 1994, P NATL ACAD SCI USA, V91, P4945, DOI 10.1073/pnas.91.11.4945; SUNDQUIST WI, 1993, P NATL ACAD SCI USA, V90, P3393, DOI 10.1073/pnas.90.8.3393; Takahashi KI, 2000, RNA, V6, P96, DOI 10.1017/S1355838200991635; Zuker M., 1999, RNA BIOCH BIOTECHNOL	43	37	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32345	32352		10.1074/jbc.M103462200	http://dx.doi.org/10.1074/jbc.M103462200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11397802	hybrid			2022-12-25	WOS:000170613500117
J	Chen, TP; Cote, J; Carvajal, HV; Richard, S				Chen, TP; Cote, J; Carvajal, HV; Richard, S			Identification of Sam68 arginine glycine-rich sequences capable of conferring nonspecific RNA binding to the GSG domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; TUMOR-SUPPRESSOR GENE; SPLICING FACTOR SF1; KH-DOMAIN; CAENORHABDITIS-ELEGANS; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; STAR PROTEIN; SRC; GLD-1	Sam68 is an RNA-binding protein that contains a heterogeneous nuclear ribonucleoprotein K homology domain embedded in a larger RNA binding domain called the GSG (GRP33, Sam68, GLD-1) domain. This family of proteins is often referred to as the STAR (signal transduction and activators of RNA metabolism) proteins. It is not known whether Sam68 is a general nonspecific RNA-binding protein or whether it recognizes specific response elements in mRNAs with high affinity. Sam68 has been shown to bind homopolymeric RNA and a synthetic RNA sequence called G8-5 that has a core UAAA motif. Here we performed a structure function analysis of Sam68 and identified two arginine glycine (RG)-rich regions that confer nonspecific RNA binding to the Sam68 GSG domain. In addition, by using chimeric proteins between Sam68 and QKI-7, we demonstrated that one of the Sam68 RG-rich sequences of 26 amino acids was sufficient to confer homopolymeric RNA binding to the GSG domain of QKI-7, another STAR protein. Fur. thermore, that minimal sequence can also give QKI-7 the ability (as Sam68) to functionally substitute for HIV-1 REV to facilitate the nuclear export of RNAs. Our studies suggest that neighboring RG-rich sequences may impose nonspecific RNA binding to GSG domains. Because the Sam68 RNA binding activity is negatively regulated by tyrosine phosphorylation, our data lead us to propose that Sam68 might be a specific RNA-binding protein when tyrosine phosphorylated.	Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, Montreal, PQ H3T 1E2, Canada; Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Bloomfield Ctr Res Aging, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; Lady Davis Institute; McGill University; McGill University; McGill University; McGill University	Richard, S (corresponding author), Lady Davis Inst Med Res, 3755 Cote St Catherine Rd, Montreal, PQ H3T 1E2, Canada.	sricha@po-box.mcgill.ca	Cote, Jocelyn/O-2351-2018	Cote, Jocelyn/0000-0001-9551-2284				Arning S, 1996, RNA, V2, P794; Baehrecke EH, 1997, DEVELOPMENT, V124, P1323; Barlat I, 1997, J BIOL CHEM, V272, P3129, DOI 10.1074/jbc.272.6.3129; Bedford MT, 2000, J BIOL CHEM, V275, P16030, DOI 10.1074/jbc.M909368199; Berglund JA, 1998, RNA, V4, P998, DOI 10.1017/S1355838298980499; Berglund JA, 1998, GENE DEV, V12, P858, DOI 10.1101/gad.12.6.858; BODE VC, 1984, GENETICS, V108, P457; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Chen TP, 1998, MOL CELL BIOL, V18, P4863, DOI 10.1128/MCB.18.8.4863; Chen TP, 1997, MOL CELL BIOL, V17, P5707, DOI 10.1128/MCB.17.10.5707; Chen TP, 1999, MOL BIOL CELL, V10, P3015, DOI 10.1091/mbc.10.9.3015; Clifford R, 2000, DEVELOPMENT, V127, P5265; Derry JJ, 2000, MOL CELL BIOL, V20, P6114, DOI 10.1128/MCB.20.16.6114-6126.2000; Di Fruscio M, 1998, J BIOL CHEM, V273, P30122, DOI 10.1074/jbc.273.46.30122; Di Fruscio M, 1999, P NATL ACAD SCI USA, V96, P2710, DOI 10.1073/pnas.96.6.2710; Ebersole TA, 1996, NAT GENET, V12, P260, DOI 10.1038/ng0396-260; FRANCIS R, 1995, GENETICS, V139, P579; FRANCIS R, 1995, GENETICS, V139, P607; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Gilbert C, 2001, J IMMUNOL, V166, P4664, DOI 10.4049/jimmunol.166.7.4664; Hardy RJ, 1996, J NEUROSCI, V16, P7941; Harfmann AM, 1999, MOL BIOL CELL, V10, P3909, DOI 10.1091/mbc.10.11.3909; HOGAN EL, 1984, MYELIN; Jan E, 1999, EMBO J, V18, P258, DOI 10.1093/emboj/18.1.258; JONES AR, 1995, GENE DEV, V9, P1491, DOI 10.1101/gad.9.12.1491; Lang V, 1997, EUR J IMMUNOL, V27, P3360, DOI 10.1002/eji.1830271235; Lin Q, 1997, J BIOL CHEM, V272, P27274, DOI 10.1074/jbc.272.43.27274; Liu K, 2000, J BIOL CHEM, V275, P40195, DOI 10.1074/jbc.M006194200; Pilotte J, 2001, GENE DEV, V15, P845, DOI 10.1101/gad.860301; Rain JC, 1998, RNA, V4, P551, DOI 10.1017/S1355838298980335; Reddy TR, 1999, NAT MED, V5, P635, DOI 10.1038/9479; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; Saccomanno L, 1999, P NATL ACAD SCI USA, V96, P12605, DOI 10.1073/pnas.96.22.12605; SIDMAN RL, 1964, SCIENCE, V144, P309, DOI 10.1126/science.144.3616.309; SIOMI H, 1994, CELL, V77, P33, DOI 10.1016/0092-8674(94)90232-1; TAYLOR SJ, 1995, J BIOL CHEM, V270, P10120, DOI 10.1074/jbc.270.17.10120; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; Vernet C, 1997, TRENDS GENET, V13, P479, DOI 10.1016/S0168-9525(97)01269-9; VOGEL LB, 1995, J BIOL CHEM, V270, P2506, DOI 10.1074/jbc.270.6.2506; WANG LL, 1995, J BIOL CHEM, V270, P2010, DOI 10.1074/jbc.270.5.2010; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; Wu J, 1999, J BIOL CHEM, V274, P29202, DOI 10.1074/jbc.274.41.29202; Zaffran S, 1997, DEVELOPMENT, V124, P2087; Zorn AM, 1997, GENE DEV, V11, P2176, DOI 10.1101/gad.11.17.2176	45	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30803	30811		10.1074/jbc.M102247200	http://dx.doi.org/10.1074/jbc.M102247200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11395494	hybrid			2022-12-25	WOS:000170472900031
J	El Far, O; Bofill-Cardona, E; Airas, JM; O'Connor, V; Boehm, S; Freissmuth, M; Nanoff, C; Betz, H				El Far, O; Bofill-Cardona, E; Airas, JM; O'Connor, V; Boehm, S; Freissmuth, M; Nanoff, C; Betz, H			Mapping of calmodulin and G beta gamma binding domains within the C-terminal region of the metabotropic glutamate receptor 7A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; A(1)-ADENOSINE RECEPTOR; ADENYLYL CYCLASES; CALCIUM CHANNELS; A(1) ADENOSINE; MODULATION; PHOSPHORYLATION; ASSOCIATION; PLASTICITY; STABILIZES	Ca2+/calmodulin (Ca2+/CaM) and the beta gamma subunits of heterotrimeric G-proteins (G beta gamma) have recently been shown to interact in a mutually exclusive fashion with the intracellular C terminus of the presynaptic metabotropic glutamate receptor 7 (mGluR 7). Here, we further characterized the core CaM and G beta gamma binding sequences. In contrast to a previous report, we find that the CaM binding motif localized in the N-terminal region of the cytoplasmic tail domain of mGluR 7 is conserved in the related group III mGluRs 4A and 8 and allows these receptors to also bind Ca2+/CaM. Mutational analysis of the Ca2+/CaM binding motif is consistent with group III receptors containing a conventional CaM binding site formed by an amphipathic alpha -helix. Substitutions adjacent to the core CaM target sequence selectively prevent G beta gamma binding, suggesting that the CaM-dependent regulation of signal transduction involves determinants that overlap with but are different from those mediating G beta gamma recruitment. In addition, we present evidence that G beta gamma uses distinct nonoverlapping interfaces for interaction with the mGluR 7 C-terminal tail and the effector enzyme adenylyl cyclase II, respectively. Although G beta gamma -mediated signaling is abolished in receptors lacking the core CaM binding sequence, alpha subunit activation, as assayed by agonist-dependent GTP gammaS binding, was not affected. This suggests that Ca2+/CaM may alter the mode of group III mGluR signaling from mono- (a) to bidirectional (alpha and beta gamma) activation of downstream effector cascades.	Max Planck Inst Brain Res, Dept Neurochem, D-60528 Frankfurt, Germany; Univ Vienna, Inst Pharmacol, A-1090 Vienna, Austria; Univ Southampton, Sch Biol Sci, Ctr Neurosci, Southampton SO16 7PX, Hants, England	Max Planck Society; University of Vienna; University of Southampton	Betz, H (corresponding author), Max Planck Inst Brain Res, Dept Neurochem, Deutschorden St 46, D-60528 Frankfurt, Germany.	neurochemie@mpih-frankfurt.mpg.de	Far, Oussama El/D-4225-2017; EL FAR, Oussama/P-9915-2019	Far, Oussama El/0000-0002-7473-8345; EL FAR, Oussama/0000-0002-7473-8345; Freissmuth, Michael/0000-0001-9398-1765; Boehm, Stefan/0000-0002-0205-2459; nanoff, christian/0000-0002-8857-2470				Airas JM, 2001, FEBS LETT, V494, P60, DOI 10.1016/S0014-5793(01)02311-0; Bofill-Cardona E, 2000, J BIOL CHEM, V275, P32672, DOI 10.1074/jbc.M002780200; Boudin H, 2000, NEURON, V28, P485, DOI 10.1016/S0896-6273(00)00127-6; Cartmell J, 2000, J NEUROCHEM, V75, P889, DOI 10.1046/j.1471-4159.2000.0750889.x; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Dev KK, 2000, J NEUROSCI, V20, P7252; El Far O, 2000, EUR J NEUROSCI, V12, P4215, DOI 10.1046/j.1460-9568.2000.01309.x; FREISSMUTH M, 1989, J BIOL CHEM, V264, P21907; Freissmuth M, 1999, TRENDS PHARMACOL SCI, V20, P237, DOI 10.1016/S0165-6147(99)01337-1; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; JOCKERS R, 1994, J BIOL CHEM, V269, P32077; JOHNSON RA, 1991, METHOD ENZYMOL, V195, P3; Kudlacek O, 2001, J BIOL CHEM, V276, P3010, DOI 10.1074/jbc.M007910200; Macek TA, 1998, J NEUROSCI, V18, P6138; Masugi M, 1999, J NEUROSCI, V19, P955; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; Nakajima Y, 1999, J BIOL CHEM, V274, P27573, DOI 10.1074/jbc.274.39.27573; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; Nakanishi S, 1998, BRAIN RES REV, V26, P230, DOI 10.1016/S0165-0173(97)00033-7; Nanoff C, 1997, NEUROPHARMACOLOGY, V36, P1211, DOI 10.1016/S0028-3908(97)00135-4; NANOFF C, 1995, MOL PHARMACOL, V48, P806; O'Connor V, 1999, SCIENCE, V286, P1180, DOI 10.1126/science.286.5442.1180; Osawa M, 1999, NAT STRUCT BIOL, V6, P819; Perroy J, 2000, J NEUROSCI, V20, P7896; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; PIN JP, 1995, CURR OPIN NEUROBIOL, V5, P342, DOI 10.1016/0959-4388(95)80047-6; Scott JK, 2001, EMBO J, V20, P767, DOI 10.1093/emboj/20.4.767; Shigemoto R, 1996, NATURE, V381, P523, DOI 10.1038/381523a0; Stowell JN, 1999, NEURON, V22, P525, DOI 10.1016/S0896-6273(00)80707-2; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; Waldhoer M, 1998, MOL PHARMACOL, V53, P808; Weitmann S, 1999, BIOCHEMISTRY-US, V38, P3409, DOI 10.1021/bi982229l	35	55	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30662	30669		10.1074/jbc.M102573200	http://dx.doi.org/10.1074/jbc.M102573200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11395497	hybrid			2022-12-25	WOS:000170472900012
J	Hatanaka, T; Hashimoto, M; Majima, E; Shinohara, Y; Terada, H				Hatanaka, T; Hashimoto, M; Majima, E; Shinohara, Y; Terada, H			Significant effect of the N-terminal region of the mitochondrial ADP/ATP carrier on its efficient expression in yeast mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP ATP CARRIER; SACCHAROMYCES-CEREVISIAE; PROTEIN TRANSLOCATION; TRANSPORT; MEMBRANE; BINDING; IMPORT; HEART; GENES	The low-level expression of the bovine heart mitochondrial ADP/ATP carrier (bovine type I ADP/ATP carrier (bAAC1)) in the yeast mitochondrial membrane is significantly improved by replacement of its N-terminal region with corresponding regions of the yeast type 1 and 2 carriers (yAAC1 and yAAC2) (Hashimoto, M., Shinohara, Y., Majima, E., Hatanaka, T., Yamazaki, N., and Terada, H. (1999) Biochim. Biophys. Acta 1409,113-124). To understand why the bAAC1 chimeras were highly expressed in yeast mitochondria, we examined the effects of the length and sequence of the N-terminal region extending into the cytosol on the expression of bAAC1 and yAAC2 derivatives in yeast mitochondria. For this, their N-terminal regions were replaced with peptide fragments of various lengths and sequences derived from those of bAAC1, yAAC1, and yAAC2. We found that a specific amino acid sequence and a definite length of the N-terminal region of yAAC2 were required for high expression of bAAC1 and yAAC2 in yeast mitochondria. We also examined the steady-state transcript levels and expression of these derivatives in whole yeast cells. Based on our results, we discuss the role of the N-terminal region in efficient expression of bAAC1 and yAAC2 in yeast mitochondria.	Univ Tokushima, Fac Pharmaceut Sci, Tokushima 7708505, Japan; APRO Life Sci Inst, Naruto 7720001, Japan	Tokushima University	Terada, H (corresponding author), Univ Tokushima, Fac Pharmaceut Sci, Shomachi 1, Tokushima 7708505, Japan.	hterada@ph.tokushima-u.ac.jp						ADRIAN GS, 1986, MOL CELL BIOL, V6, P626, DOI 10.1128/MCB.6.2.626; Dianoux AC, 2000, BIOCHEMISTRY-US, V39, P11477, DOI 10.1021/bi000618l; Endres M, 1999, EMBO J, V18, P3214, DOI 10.1093/emboj/18.12.3214; Fiore C, 1998, BIOCHIMIE, V80, P137, DOI 10.1016/S0300-9084(98)80020-5; Hashimoto M, 1999, BBA-BIOENERGETICS, V1409, P113, DOI 10.1016/S0005-2728(98)00155-8; Hatanaka T, 1999, BIOCHEM BIOPH RES CO, V262, P726, DOI 10.1006/bbrc.1999.1283; Hatanaka T, 2001, BIOL PHARM BULL, V24, P595, DOI 10.1248/bpb.24.595; HORVATH A, 1994, YEAST, V10, P1305, DOI 10.1002/yea.320101007; Kaldi K, 1998, BIOFACTORS, V8, P221, DOI 10.1002/biof.5520080308; KLINGENBERG M, 1989, ARCH BIOCHEM BIOPHYS, V270, P1, DOI 10.1016/0003-9861(89)90001-5; KOLAROV J, 1990, J BIOL CHEM, V265, P12711; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON JE, 1988, J BIOL CHEM, V263, P14812; Nelson DR, 1996, BBA-BIOENERGETICS, V1275, P133, DOI 10.1016/0005-2728(96)00063-1; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; PEDERSEN PL, 1993, J BIOENERG BIOMEMBR, V25, P431, DOI 10.1007/BF01108400; PFANNER N, 1987, J BIOL CHEM, V262, P14851; Pfanner N, 1997, ANNU REV CELL DEV BI, V13, P25, DOI 10.1146/annurev.cellbio.13.1.25; POWELL SJ, 1989, BIOCHEMISTRY-US, V28, P866, DOI 10.1021/bi00428a069; ROISE D, 1988, J BIOL CHEM, V263, P4509; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SCHULTHEISS HP, 1985, ARCH BIOCHEM BIOPHYS, V239, P273, DOI 10.1016/0003-9861(85)90836-7; SMAGULA C, 1988, J BIOL CHEM, V263, P6783; Terada H, 1997, PROG COLL POL SCI S, V106, P192, DOI 10.1007/BF01189519; Trezeguet V, 2000, BBA-BIOENERGETICS, V1457, P81, DOI 10.1016/S0005-2728(99)00115-2; Voos W, 1999, BBA-REV BIOMEMBRANES, V1422, P235, DOI 10.1016/S0304-4157(99)00007-6	26	8	8	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28881	28888		10.1074/jbc.M102535200	http://dx.doi.org/10.1074/jbc.M102535200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11384977	hybrid			2022-12-25	WOS:000170346000034
J	Cioffi, CC; Middleton, DL; Wilson, MR; Miller, NW; Clem, LW; Warr, GW				Cioffi, CC; Middleton, DL; Wilson, MR; Miller, NW; Clem, LW; Warr, GW			An IgH enhancer that drives transcription through basic helix-loop-helix and oct transcription factor binding motifs - Functional analysis of the E mu 3 ' enhancer of the catfish	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN ENHANCER; CHANNEL CATFISH; GENE ENHANCER; B-CELLS; EXPRESSION; SITES; TRANSACTIVATION; DETERMINANT; ACTIVATION; PREFERENCE	The transcriptional enhancer (E mu3') of the IgH locus of the channel catfish, Ictalurus punctatus, shows strong B cell-specific activity and differs from the mammalian E mu enhancer in both location and structure. It occurs between the mu and delta genes and contains numerous transcription factor binding sites, predominantly octamer and mu E5 motifs of consensus and variant sequences. It lacks the classical muA-mu E3(CBF)-mu beta core array of binding motifs seen within mammalian IgH E mu enhancers. To determine the functionally important motifs, a series of mutant enhancers was created using sequence-targeted polymerase chain reaction. Whereas the mutation of consensus and variant octamer motifs (individually or in multiples) decreased enhancer function, mutation of a single consensus mu E5 motif destroyed the function of this enhancer in mammalian plasmacytomas. Mutation of this consensus mu E5 site, combined with mutations of certain octamer sites, destroyed function in catfish B cells. Experiments using artificial enhancers containing multimers of motifs or short regions of the native enhancer suggested that the minimal E mu3' enhancer (a) contains a consensus mu E5 site and two octamer sites, (b) is B cell-specific, and (c) is active across species. The dependence of an Ig enhancer on sites that bind basic helix-loop-helix and Oct transcription factors has not previously been observed and confirms large differences in structure and function between fish and mammalian IgH enhancers.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA; Univ Mississippi, Med Ctr, Dept Microbiol, Jackson, MS 39216 USA	Medical University of South Carolina; Medical University of South Carolina; University of Mississippi; University of Mississippi Medical Center	Warr, GW (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 AShley Ave,POB 250509, Charleston, SC 29425 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI019530] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062317] Funding Source: NIH RePORTER; NIAID NIH HHS [R37-AI-19530] Funding Source: Medline; NIGMS NIH HHS [R01-GM62317] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANNWEILER A, 1994, NUCLEIC ACIDS RES, V22, P4250, DOI 10.1093/nar/22.20.4250; ANNWEILER A, 1992, MOL CELL BIOL, V12, P3107, DOI 10.1128/MCB.12.7.3107; Arulampalam V, 1997, IMMUNOL TODAY, V18, P549, DOI 10.1016/S0167-5699(97)01154-7; BACHL J, 1995, P NATL ACAD SCI USA, V5, P2396; Bengten E, 2000, CURR TOP MICROBIOL, V248, P189; CALAME K, 1995, IMMUNOGLOBULIN GENES, P397; CHEN JZ, 1993, EMBO J, V12, P4635, DOI 10.1002/j.1460-2075.1993.tb06152.x; COGNE M, 1994, CELL, V77, P737, DOI 10.1016/0092-8674(94)90057-4; Dang W, 1998, MOL CELL BIOL, V18, P6870, DOI 10.1128/MCB.18.11.6870; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Erman B, 1998, MOL CELL BIOL, V18, P1322, DOI 10.1128/MCB.18.3.1322; GENETTA T, 1994, MOL CELL BIOL, V14, P6153, DOI 10.1128/MCB.14.9.6153; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; Gregoire JM, 1999, J BIOL CHEM, V274, P6567, DOI 10.1074/jbc.274.10.6567; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; Magor BG, 1997, IMMUNOGENETICS, V46, P192, DOI 10.1007/s002510050261; MAGOR BG, 1994, J IMMUNOL, V153, P5556; MICHAELSON JS, 1995, NUCLEIC ACIDS RES, V23, P975, DOI 10.1093/nar/23.6.975; MILLER NW, 1994, J IMMUNOL, V152, P2180; NELSEN B, 1990, MOL CELL BIOL, V10, P3145, DOI 10.1128/MCB.10.6.3145; Nikolajczyk BS, 1996, MOL CELL BIOL, V16, P4544; Rao E, 1997, J BIOL CHEM, V272, P6722, DOI 10.1074/jbc.272.10.6722; RAST JP, 1995, IMMUNOGLOBULIN GENES, P315; Ross DA, 1999, DEV COMP IMMUNOL, V23, P199, DOI 10.1016/S0145-305X(99)00007-5; Ross DA, 1998, J IMMUNOL, V160, P3874; Sloan SR, 1996, MOL CELL BIOL, V16, P6900; STAUDT LM, 1991, ANNU REV IMMUNOL, V9, P373; Wilson M, 1997, P NATL ACAD SCI USA, V94, P4593, DOI 10.1073/pnas.94.9.4593; WIRTH T, 1995, IMMUNOBIOLOGY, V193, P161, DOI 10.1016/S0171-2985(11)80540-1	29	29	29	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27825	27830		10.1074/jbc.M100110200	http://dx.doi.org/10.1074/jbc.M100110200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11375977	hybrid			2022-12-25	WOS:000170093400013
J	Hsu, MH; Savas, V; Griffin, KJ; Johnson, EF				Hsu, MH; Savas, V; Griffin, KJ; Johnson, EF			Identification of peroxisome proliferator-responsive human genes by elevated expression of the peroxisome proliferator-activated receptor a in HepG2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; ALPHA PPAR-ALPHA; MITOCHONDRIAL 3-HYDROXY-3-METHYLGLUTARYL-COA SYNTHASE; PALMITOYLTRANSFERASE-I GENE; COENZYME-A OXIDASE; BETA-OXIDATION; LIPOPROTEIN METABOLISM; APOLIPOPROTEIN CIII; SPECIES-DIFFERENCES; OMEGA-HYDROXYLASE	In mice and other sensitive species, PPAR alpha mediates the induction of mitochondrial, microsomal, and peroxisomal fatty acid oxidation, peroxisome proliferation, liver enlargement, and tumors by peroxisome proliferators. In order to identify PPAR alpha -responsive human genes, HepG2 cells were engineered to express PPAR alpha at concentrations similar to mouse liver. This resulted in the dramatic induction of mRNAs encoding the mitochondrial HMG-CoA synthase and increases in fatty aryl-CoA synthetase (3-8-fold) and carnitine palmitoyl-CoA transferase IA (2-4-fold) mRNAs that were dependent on PPAR alpha expression and enhanced by exposure to the PPAR alpha agonist Wy14643. A PPAR response element was identified in the proximal promoter of the human HMG-COA synthase gene that is functional in its native context. These data suggest that humans retain a capacity for PPAR alpha regulation of mitochondrial fatty acid oxidation and ketogenesis. Human liver is refractory to peroxisome proliferation, and increased expression of mRNAs for the peroxisomal fatty acyl-CoA oxidase, bifunctional enzyme, or thiolase, which accompanies peroxisome proliferation in responsive species, was not evident following Wy14643 treatment of cells expressing elevated levels of PPAR alpha. Additionally, no significant differences were seen for the expression of apolipoprotein AI, All, or CIII; medium chain acyl-CoA dehydrogenase; or stearoyl-CoA desaturase mRNAs.	Scripps Res Inst, Dept Mol & Expt Med, Div Biochem, La Jolla, CA 92037 USA	Scripps Research Institute	Johnson, EF (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, Div Biochem, MEM-255,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NCRR NIH HHS [M01 RR0833] Funding Source: Medline; NICHD NIH HHS [HD 04445] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD004445] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD004445] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALDRIDGE TC, 1995, BIOCHEM J, V306, P473, DOI 10.1042/bj3060473; Aoyama T, 1998, J BIOL CHEM, V273, P5678, DOI 10.1074/jbc.273.10.5678; Bell AR, 1998, BIOCHEM J, V332, P689, DOI 10.1042/bj3320689; Berthou L, 1996, J CLIN INVEST, V97, P2408, DOI 10.1172/JCI118687; BRADY PS, 1989, BIOCHEM J, V260, P93, DOI 10.1042/bj2600093; Brandt JM, 1998, J BIOL CHEM, V273, P23786, DOI 10.1074/jbc.273.37.23786; BROCARD C, 1993, BIOL CELL, V77, P37, DOI 10.1016/S0248-4900(05)80172-8; CASTELEIN H, 1994, J BIOL CHEM, V269, P26754; Causevic M, 1999, FEBS LETT, V463, P205, DOI 10.1016/S0014-5793(99)01618-X; CHANCE DS, 1995, P SOC EXP BIOL MED, V208, P378; Clavey V, 1999, CELL PHYSIOL BIOCHEM, V9, P139, DOI 10.1159/000016311; CLINKENBEARD KD, 1975, J BIOL CHEM, V250, P3108; Cook WS, 2000, BIOCHEM BIOPH RES CO, V278, P250, DOI 10.1006/bbrc.2000.3739; DeLuca JG, 2000, MOL PHARMACOL, V58, P470, DOI 10.1124/mol.58.3.470; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Duclos S, 1997, EUR J CELL BIOL, V72, P314; Edvardsson U, 1999, J LIPID RES, V40, P1177; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Fredenrich A, 1998, DIABETES METAB, V24, P490; Gervois P, 1999, MOL ENDOCRINOL, V13, P1535, DOI 10.1210/me.13.9.1535; GIBBONS GF, 1994, J LIPID RES, V35, P1801; GIBSON GG, 1993, TOXICOL LETT, V68, P193, DOI 10.1016/0378-4274(93)90130-P; GULICK T, 1994, P NATL ACAD SCI USA, V91, P11012, DOI 10.1073/pnas.91.23.11012; Hasmall SC, 2000, ARCH TOXICOL, V74, P85, DOI 10.1007/s002040050657; Hegardt FG, 1999, BIOCHEM J, V338, P569, DOI 10.1042/0264-6021:3380569; Hsu MH, 1998, J BIOL CHEM, V273, P27988, DOI 10.1074/jbc.273.43.27988; HSU MH, 1995, MOL PHARMACOL, V48, P559; IDE T, 1982, METABOLISM, V31, P1065, DOI 10.1016/0026-0495(82)90153-6; Kawashima H, 2000, ARCH BIOCHEM BIOPHYS, V378, P333, DOI 10.1006/abbi.2000.1831; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Kroetz DL, 1998, J BIOL CHEM, V273, P31581, DOI 10.1074/jbc.273.47.31581; LAKE BG, 1995, ANNU REV PHARMACOL, V35, P483, DOI 10.1146/annurev.pa.35.040195.002411; Lazarow P B, 1981, Methods Enzymol, V72, P315; Le May C, 2000, FEBS LETT, V475, P163, DOI 10.1016/S0014-5793(00)01648-3; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; LOCK EA, 1989, ANNU REV PHARMACOL, V29, P145; Macdonald N, 1999, CANCER RES, V59, P4776; Mascaro C, 1998, J BIOL CHEM, V273, P8560, DOI 10.1074/jbc.273.15.8560; MCGARRY JD, 1980, ANNU REV BIOCHEM, V49, P395, DOI 10.1146/annurev.bi.49.070180.002143; Miller CW, 1996, P NATL ACAD SCI USA, V93, P9443, DOI 10.1073/pnas.93.18.9443; MUERHOFF AS, 1992, J BIOL CHEM, V267, P19051; MUKHERJEE R, 1994, J STEROID BIOCHEM, V51, P157, DOI 10.1016/0960-0760(94)90089-2; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; NILSSON R, 1991, CHEM-BIOL INTERACT, V78, P235, DOI 10.1016/0009-2797(91)90017-2; PALMER CNA, 1995, J BIOL CHEM, V270, P16114, DOI 10.1074/jbc.270.27.16114; Palmer CNA, 1998, MOL PHARMACOL, V53, P14, DOI 10.1124/mol.53.1.14; Peters JM, 1997, CARCINOGENESIS, V18, P2029, DOI 10.1093/carcin/18.11.2029; QUANT PA, 1989, BIOCHEM J, V262, P159, DOI 10.1042/bj2620159; REDDY JK, 1994, ANNU REV NUTR, V14, P343, DOI 10.1146/annurev.nu.14.070194.002015; REISENBICHLER H, 1993, MUTAT RES, V286, P135, DOI 10.1016/0027-5107(93)90177-H; RODRIGUEZ JC, 1994, J BIOL CHEM, V269, P18767; SCHOONJANS K, 1995, J BIOL CHEM, V270, P19269, DOI 10.1074/jbc.270.33.19269; Staels B, 1998, CIRCULATION, V98, P2088, DOI 10.1161/01.CIR.98.19.2088; STAELS B, 1995, J CLIN INVEST, V95, P705, DOI 10.1172/JCI117717; STANGL H, 1995, EUR J CLIN CHEM CLIN, V33, P775; Tugwood JD, 1998, ARCH TOXICOL, V72, P169, DOI 10.1007/s002040050483; Varanasi U, 1996, J BIOL CHEM, V271, P2147, DOI 10.1074/jbc.271.4.2147; VUDAC N, 1995, J CLIN INVEST, V96, P741, DOI 10.1172/JCI118118; Yu GS, 1998, J BIOL CHEM, V273, P32901, DOI 10.1074/jbc.273.49.32901; Zammit VA, 1999, BIOCHEM J, V343, P505, DOI 10.1042/0264-6021:3430505	62	148	151	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27950	27958		10.1074/jbc.M100258200	http://dx.doi.org/10.1074/jbc.M100258200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11371553	hybrid			2022-12-25	WOS:000170093400029
J	Miyamori, H; Takino, T; Kobayashi, Y; Tokai, H; Itoh, Y; Seiki, M; Sato, H				Miyamori, H; Takino, T; Kobayashi, Y; Tokai, H; Itoh, Y; Seiki, M; Sato, H			Claudin promotes activation of pro-matrix metalloproteinase-2 mediated by membrane-type matrix metalloproteinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIGHT JUNCTION STRANDS; CANINE KIDNEY-CELLS; TISSUE INHIBITOR; CATALYTIC DOMAIN; GELATINASE-A; CDNA LIBRARY; MT-MMPS; PROGELATINASE; SURFACE; IDENTIFICATION	Genes associated with regulation of membrane-type matrix metalloproteinase-1 (MT1-MMP)-mediated pro-MMP-2 processing were screened in 293T cells by a newly developed expression cloning method. One of the gene products, which promoted processing of pro-MMP-2 by MT1-MMP was claudin-5, a major component of endothelial tight junctions. Expression of claudin-5 not only replaced TIMP-2 in pro-MMP-2 activation by MT1-MMP but also promoted activation of pro-MMP-2 mediated by all MT-MMPs and MT1-MMP mutants lacking the transmembrane domain (Delta MT1-MMP). A carboxyl-terminal deletion mutant of pro-MMP-2 (pro Delta MMP-2) was processed to an intermediate form by MT1-MMP in 293T cells and was further converted to an activated form by introduction of claudin-5. In contrast to the stimulatory effect of TIMP-2 on pro-MMP-2 activation by MT1-MMP, activation of pro-MMP-2 by Delta MT1-MMP in the presence of claudin-5 and pro Delta MMP-2 processing by MT1-MMP were both inversely repressed by expression of exogenous TIMP-2. These results suggest that TIMP-2 is not involved in cluadin-5-induced pro-MMP-2 activation by MT-MMPs. Stimulation of MT-MMP-mediated pro-MMP-2 activation was also observed with other claudin family members, claudin-1, claudin-2, and claudin-3. Amino acid substitutions or deletions in ectodomain of claudin-1 abolished stimulatory effect. Direct interaction of claudin-1 with MT1-MMP and MMP-2 was demonstrated by immunoprecipitation analysis. MT1-MMP was co-localized with claudin-1 not only at cell-cell borders, but also at other parts of the cells. TIMP-2 enhanced cell surface localization of MMP-2 mediated by MT1-MMP, and claudin-1 also stimulated it. These results suggest that claudin recruits all MT-MMPs and pro-MMP-2 on the cell surface to achieve elevated focal concentrations and, consequently, enhances activation of pro-MMP-2.	Kanazawa Univ, Canc Res Inst, Dept Mol Oncol & Virol, Kanazawa, Ishikawa 9200934, Japan; Kanazawa Univ, Canc Res Inst, Ctr Dev Mol Target Drugs, Kanazawa, Ishikawa 9200934, Japan; Fuji Chem Ind Co Ltd, Toyama 9338511, Japan; Univ Tokyo, Inst Med Sci, Dept Canc Cell Res, Minato Ku, Tokyo 1088639, Japan	Kanazawa University; Kanazawa University; University of Tokyo	Sato, H (corresponding author), Kanazawa Univ, Canc Res Inst, Dept Mol Oncol & Virol, 13-1 Takara Machi, Kanazawa, Ishikawa 9200934, Japan.	vhsato@kenroku.kanazawa-u.ac.jp	Seiki, Motoharu/K-9443-2015; SATO, Hiroshi/D-8454-2015; TAKINO, Takahisa/D-8460-2015	Itoh, Yoshifumi/0000-0002-2128-2823				Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; CAO J, 1995, J BIOL CHEM, V270, P801, DOI 10.1074/jbc.270.2.801; Chen YH, 2000, MOL BIOL CELL, V11, P849, DOI 10.1091/mbc.11.3.849; English WR, 2000, J BIOL CHEM, V275, P14046, DOI 10.1074/jbc.275.19.14046; FUJIMOTO N, 1993, CLIN CHIM ACTA, V220, P31, DOI 10.1016/0009-8981(93)90004-N; Furuse M, 1999, J CELL BIOL, V147, P891, DOI 10.1083/jcb.147.4.891; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; Gregory M, 2001, ENDOCRINOLOGY, V142, P854, DOI 10.1210/en.142.2.854; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; HOWARD EW, 1991, J BIOL CHEM, V266, P17972; Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351; Itoh Y, 1999, J BIOL CHEM, V274, P34260, DOI 10.1074/jbc.274.48.34260; Kadono Y, 1998, CANCER RES, V58, P2240; Kinoshita T, 1996, CANCER RES, V56, P2535; Kinoshita T, 1998, J BIOL CHEM, V273, P16098, DOI 10.1074/jbc.273.26.16098; Kojima S, 2000, FEBS LETT, V480, P142, DOI 10.1016/S0014-5793(00)01919-0; Kolkenbrock H, 1999, BIOL CHEM, V380, P1103, DOI 10.1515/BC.1999.137; Lehti K, 2000, J BIOL CHEM, V275, P15006, DOI 10.1074/jbc.M910220199; Llano E, 1999, CANCER RES, V59, P2570; Miyamori H, 2000, BIOCHEM BIOPH RES CO, V267, P796, DOI 10.1006/bbrc.1999.2050; Morita K, 1999, J CELL BIOL, V147, P185, DOI 10.1083/jcb.147.1.185; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; Pei DQ, 1999, J BIOL CHEM, V274, P8925, DOI 10.1074/jbc.274.13.8925; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1996, FEBS LETT, V385, P238, DOI 10.1016/0014-5793(96)00389-4; Sato H, 1996, J BIOCHEM-TOKYO, V119, P209; Shimada T, 1999, EUR J BIOCHEM, V262, P907, DOI 10.1046/j.1432-1327.1999.00459.x; Steffensen B, 1998, J BIOL CHEM, V273, P20622, DOI 10.1074/jbc.273.32.20622; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; Tanaka M, 1997, FEBS LETT, V402, P219, DOI 10.1016/S0014-5793(96)01537-2; Toth M, 2000, J BIOL CHEM, V275, P41415, DOI 10.1074/jbc.M006871200; Tsukita S, 2000, J CELL BIOL, V149, P13, DOI 10.1083/jcb.149.1.13; Ueno H, 1997, CANCER RES, V57, P2055; Velasco G, 2000, CANCER RES, V60, P877; Wang YH, 1999, J BIOL CHEM, V274, P33043, DOI 10.1074/jbc.274.46.33043; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WOESSNER JF, 1991, J RHEUMATOL, V18, P99; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197; Zucker S, 1998, J BIOL CHEM, V273, P1216, DOI 10.1074/jbc.273.2.1216	45	190	198	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28204	28211		10.1074/jbc.M103083200	http://dx.doi.org/10.1074/jbc.M103083200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11382769	Green Submitted, hybrid			2022-12-25	WOS:000170093400063
J	Schofield, MJ; Nayak, S; Scott, TH; Du, CW; Hsieh, P				Schofield, MJ; Nayak, S; Scott, TH; Du, CW; Hsieh, P			Interaction of Escherichia coli MutS and MutL at a DNA mismatch	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPAIR PROTEIN MUTS; HETERODUPLEX DNA; ATP-HYDROLYSIS; TRANSLOCATION MECHANISM; CRYSTAL-STRUCTURE; MOLECULAR SWITCH; BINDING; COMPLEX; YEAST; RECOMBINATION	MutS and MutL are both required to activate downstream events in DNA mismatch repair. We examined the rate of dissociation of MutS from a mismatch using linear heteroduplex DNAs or heteroduplexes blocked at one or both ends by four-way DNA junctions in the presence and absence of MutL. In the presence of ATP, dissociation of MutS from linear heteroduplexes or heteroduplexes blocked at only one end occurs within 15 s. When both duplex ends are blocked, MutS remains associated with the DNA in complexes with half-lives of 30 min. DNase I footprinting of MutS complexes is consistent with migration of MutS throughout the DNA duplex region. When MutL is present, it associates with MutS and prevents ATP-dependent migration away from the mismatch in a manner that is dependent on the length of the heteroduplex. The rate and extent of mismatch-provoked cleavage at hemimethylated GATC sites by MutH in the presence of MutS, MutL, and ATP are the same whether the mismatch and GATC sites are in cis or in trans. These results suggest that a MutS-MutL complex in the vicinity of a mismatch is involved in activating MutH.	NIDDKD, Genet & Biochem Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Hsieh, P (corresponding author), NIDDKD, Genet & Biochem Branch, NIH, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK052015] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; Ban C, 1999, CELL, V97, P85, DOI 10.1016/S0092-8674(00)80717-5; Ban C, 1998, EMBO J, V17, P1526, DOI 10.1093/emboj/17.5.1526; BENDE SM, 1991, NUCLEIC ACIDS RES, V19, P1549, DOI 10.1093/nar/19.7.1549; Biswas I, 1997, J BIOL CHEM, V272, P13355, DOI 10.1074/jbc.272.20.13355; Biswas I, 2001, J MOL BIOL, V305, P805, DOI 10.1006/jmbi.2000.4367; Bjornson KP, 2000, BIOCHEMISTRY-US, V39, P3176, DOI 10.1021/bi992286u; Blackwell LJ, 1998, J BIOL CHEM, V273, P32055, DOI 10.1074/jbc.273.48.32055; Bowers J, 2001, J MOL BIOL, V306, P957, DOI 10.1006/jmbi.2001.4467; Drotschmann K, 1998, NUCLEIC ACIDS RES, V26, P948, DOI 10.1093/nar/26.4.948; FANG WH, 1993, J BIOL CHEM, V268, P11838; FENG G, 1995, BIOTECHNIQUES, V19, P956; Galio L, 1999, NUCLEIC ACIDS RES, V27, P2325, DOI 10.1093/nar/27.11.2325; GORBALENYA AE, 1990, J MOL BIOL, V213, P583, DOI 10.1016/S0022-2836(05)80243-8; Gradia S, 2000, J BIOL CHEM, V275, P3922, DOI 10.1074/jbc.275.6.3922; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; Gradia S, 1999, MOL CELL, V3, P255, DOI 10.1016/S1097-2765(00)80316-0; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; GRILLEY M, 1993, J BIOL CHEM, V268, P11830; Gu LY, 1998, NUCLEIC ACIDS RES, V26, P1173, DOI 10.1093/nar/26.5.1173; Habraken Y, 1997, CURR BIOL, V7, P790, DOI 10.1016/S0960-9822(06)00337-X; Habraken Y, 1998, J BIOL CHEM, V273, P9837, DOI 10.1074/jbc.273.16.9837; Hall MC, 1999, J BIOL CHEM, V274, P1306, DOI 10.1074/jbc.274.3.1306; Harfe BD, 2000, ANNU REV GENET, V34, P359, DOI 10.1146/annurev.genet.34.1.359; HSIEH P, 1995, NUCL ACIDS MOL BIOL, V9, P42; Jiricny J, 1998, MUTAT RES-DNA REPAIR, V409, P107, DOI 10.1016/S0921-8777(98)00056-1; Joshi A, 2000, NUCLEIC ACIDS RES, V28, P853, DOI 10.1093/nar/28.4.853; Junop MS, 2001, MOL CELL, V7, P1, DOI 10.1016/S1097-2765(01)00149-6; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; Lamers MH, 2000, NATURE, V407, P711, DOI 10.1038/35037523; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Murtin C, 1998, J MOL BIOL, V284, P949, DOI 10.1006/jmbi.1998.2256; Nash Howard A., 1996, P149; Obmolova G, 2000, NATURE, V407, P703, DOI 10.1038/35037509; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; Rice PA, 1996, CELL, V87, P1295, DOI 10.1016/S0092-8674(00)81824-3; Schofield MJ, 1998, BIOCHEMISTRY-US, V37, P7733, DOI 10.1021/bi980399s; Spampinato C, 2000, J BIOL CHEM, V275, P9863, DOI 10.1074/jbc.275.13.9863; WU TH, 1994, J BACTERIOL, V176, P5393, DOI 10.1128/JB.176.17.5393-5400.1994; Yang SW, 1995, EMBO J, V14, P6292, DOI 10.1002/j.1460-2075.1995.tb00319.x	40	116	119	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28291	28299		10.1074/jbc.M103148200	http://dx.doi.org/10.1074/jbc.M103148200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11371566	hybrid			2022-12-25	WOS:000170093400074
J	Huss, JM; Levy, FH; Kelly, DP				Huss, JM; Levy, FH; Kelly, DP			Hypoxia inhibits the peroxisome proliferator-activated receptor alpha/retinoid X receptor gene regulatory pathway in cardiac myocytes - A mechanism for O-2-dependent modulation of mitochondrial fatty acid oxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARNITINE PALMITOYLTRANSFERASE-I; INDUCIBLE FACTOR-1; TRANSCRIPTIONAL REGULATION; ERYTHROPOIETIN GENE; ENERGY-METABOLISM; RAT-HEART; BINDING; ALPHA; EXPRESSION; PROMOTERS	Hypoxia triggers a cascade of cellular energy metabolic responses including a decrease in mitochondrial oxidative flux. To characterize gene regulatory mechanisms by which mitochondrial fatty acid oxidative capacity is diminished in response to hypoxia, cardiac myocytes in culture were exposed to long-chain fatty acids (LCFA) under normoxic or hypoxic conditions. Hypoxia prevented the known LCFA-induced accumulation of mRNA encoding muscle carnitine palmitoyltransferase I (M-CPT I), an enzyme that catalyzes the rate-limiting step in mitochondrial fatty acid oxidation (FAO). Under hypoxic conditions, myocytes exhibited significant accumulation of intracellular neutral lipid consistent with reduced CPT I activity and diminished FAO capacity. Transient transfection experiments demonstrated that the hypoxia-mediated blunting of M-CPT I gene expression occurs at the transcriptional level, is localized to an LCFA/peroxisome proliferator-activated receptor alpha (PPAR alpha)/retinoid X receptor (RXR) response element within the M-CPT I gene promoter, and is PPAR alpha -dependent. DNA-protein binding studies demonstrated that exposure to hypoxia reduces PPAR alpha /RXR binding activity. Immunoblotting studies demonstrated that whereas hypoxia had no effect on nuclear levels of PPARa protein, nuclear and cellular RXR alpha levels were reduced. Hypoxia also diminished the 9-cis-retinoic acid-mediated activation of a reporter containing an RXR homodimer response element. These results demonstrate that hypoxia deactivates PPAR alpha by reducing the availability of its obligate partner RXR.	Washington Univ, Sch Med, Cardiovasc Res Ctr, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Cardiovasc Res Ctr, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Cardiovasc Res Ctr, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Kelly, DP (corresponding author), Washington Univ, Sch Med, Cardiovasc Res Ctr, Dept Med, Box 8086,660 S Euclid Ave, St Louis, MO 63110 USA.	dkelly@imgate.wustl.edu	Kelly, Daniel/ABG-2056-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003568, R01HL058493, P50HL061006, F32HL010410] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045416, P30DK052574, P30DK056341] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL58493, K08 HL03568, F32-HL10410, P50 HL61006] Funding Source: Medline; NIDDK NIH HHS [R01 DK45416, P30 DK52574, P30 DK56341] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abdel-aleem S, 1998, MOL CELL BIOCHEM, V180, P95, DOI 10.1023/A:1006843107922; Barger PM, 2000, J CLIN INVEST, V105, P1723, DOI 10.1172/JCI9056; BING RJ, 1955, HARVEY LECT, P27; Brandt JM, 1998, J BIOL CHEM, V273, P23786, DOI 10.1074/jbc.273.37.23786; CARTER ME, 1994, MOL CELL BIOL, V14, P4360, DOI 10.1128/MCB.14.7.4360; CORR PB, 1989, J CLIN INVEST, V83, P927, DOI 10.1172/JCI113978; Cresci S, 1996, AM J PHYSIOL-CELL PH, V270, pC1413, DOI 10.1152/ajpcell.1996.270.5.C1413; Disch DL, 1996, MOL CELL BIOL, V16, P4043; Discher DJ, 1998, J BIOL CHEM, V273, P26087, DOI 10.1074/jbc.273.40.26087; Djouadi F, 1998, J CLIN INVEST, V102, P1083, DOI 10.1172/JCI3949; Esser V, 1996, J BIOL CHEM, V271, P6972, DOI 10.1074/jbc.271.12.6972; FAHEY JT, 1989, PEDIATR RES, V26, P180, DOI 10.1203/00006450-198909000-00003; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; GALSON DL, 1995, MOL CELL BIOL, V15, P2135; GEBEL T, 1992, FEBS LETT, V309, P37, DOI 10.1016/0014-5793(92)80734-X; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; GULICK T, 1994, P NATL ACAD SCI USA, V91, P11012, DOI 10.1073/pnas.91.23.11012; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hochachka PW, 1996, P NATL ACAD SCI USA, V93, P9493, DOI 10.1073/pnas.93.18.9493; HOLDEN JE, 1995, J APPL PHYSIOL, V79, P222, DOI 10.1152/jappl.1995.79.1.222; Kopf E, 2000, J BIOL CHEM, V275, P33280, DOI 10.1074/jbc.M002840200; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; Levy FH, 1997, AM J PHYSIOL-CELL PH, V272, pC457, DOI 10.1152/ajpcell.1997.272.2.C457; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MCGARRY JD, 1989, DIABETES METAB REV, V5, P271, DOI 10.1002/dmr.5610050305; Nomura Y, 1999, BIOCHEM BIOPH RES CO, V260, P729, DOI 10.1006/bbrc.1999.0969; POIZAT C, 1993, ARCH INT PHYSIOL BIO, V101, P347, DOI 10.3109/13813459309046991; Rumsey WL, 1999, AM J PHYSIOL-HEART C, V276, pH71; Saikumar P, 1998, ONCOGENE, V17, P3341, DOI 10.1038/sj.onc.1202579; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WARSHAW JB, 1972, DEV BIOL, V28, P537, DOI 10.1016/0012-1606(72)90001-2; WEBSTER KA, 1995, J MOL CELL CARDIOL, V27, P453, DOI 10.1016/S0022-2828(08)80041-7; WU JY, 1994, AM J PHYSIOL, V266, pH1034, DOI 10.1152/ajpheart.1994.266.3.H1034; YAMADA KA, 1994, CIRC RES, V74, P83, DOI 10.1161/01.RES.74.1.83; Yamazaki N, 1997, FEBS LETT, V409, P401, DOI 10.1016/S0014-5793(97)00561-9; Yamazaki N, 1996, BBA-GENE STRUCT EXPR, V1307, P157, DOI 10.1016/0167-4781(96)00069-3; Yu GS, 1998, J BIOL CHEM, V273, P32901, DOI 10.1074/jbc.273.49.32901	41	144	151	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27605	27612		10.1074/jbc.M100277200	http://dx.doi.org/10.1074/jbc.M100277200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11371554	hybrid			2022-12-25	WOS:000169966900115
J	Mathai, JC; Sprott, GD; Zeidel, ML				Mathai, JC; Sprott, GD; Zeidel, ML			Molecular mechanisms of water and solute transport across archaebacterial lipid membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOTAL POLAR LIPIDS; TETRAETHER LIPIDS; BILAYER-MEMBRANES; SULFOLOBUS-ACIDOCALDARIUS; THERMOPLASMA-ACIDOPHILUM; BIOLOGICAL-MEMBRANES; HYDROTHERMAL VENT; PERMEANT SIZE; ETHER LIPIDS; PERMEABILITY	Archaebacteria thrive in environments characterized by anaeobiosis, saturated salt, and both high and low extremes of temperature and pH, The bulk of their membrane lipids are polar, characterized by the archaeal structural features typified by ether linkage of the glycerol backbone to isoprenoid chains of constant length, often fully saturated, and with sn-2,3 stereochemistry opposite that of glycerolipids of Bacteria and Eukarya, Also unique to these bacteria are macrocyclic archaeol and membrane spanning caldarchaeol lipids that are found in some extreme thermophiles and methanogens, To define the barrier function of archaebacterial membranes and to examine the effects of these unique structural features on permeabilities, we investigated the water, solute (urea and glycerol), proton, and ammonia permeability of liposomes formed by these lipids. Both the macrocyclic archaeol and caldarchaeol lipids reduced the water, ammonia, urea, and glycerol permeability of Liposomes significantly (6-120-fold) compared with diphytanylphosphatidylcholine liposomes, The presence of the ether bond and phytanyl chains did not significantly affect these permeabilities, However, the apparent proton permeability was reduced S-fold by the presence of an ether bond. The presence of macrocyclic archaeol and caldarchaeol structures further reduced apparent proton permeabilities by 10-17-fold, These results indicate that, the limiting mobility of the midplane hydrocarbon region of the membranes formed by macrocyclic archaeol and caldarchaeol lipids play a significant role in reducing the permeability properties of the lipid membrane. In addition, it appears that substituting ether for ester bonds presents an additional barrier to proton flux.	Univ Pittsburgh, Lab Epithelial Cell Biol, Renal Electrolyte Div, Dept Med, Pittsburgh, PA 15261 USA; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Research Council Canada	Mathai, JC (corresponding author), Univ Pittsburgh, Lab Epithelial Cell Biol, Renal Electrolyte Div, Dept Med, A1222 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	mathaij@msx.dept-med.pitt.edu						Bagatolli L, 2000, BIOPHYS J, V79, P416, DOI 10.1016/S0006-3495(00)76303-X; BEVERIDGE TJ, 1993, J BACTERIOL, V175, P1191, DOI 10.1128/JB.175.4.1191-1197.1993; CARRUTHERS A, 1983, BIOCHEMISTRY-US, V22, P5797, DOI 10.1021/bi00294a018; CHANG A, 1994, AM J PHYSIOL-CELL PH, V267, pC1483, DOI 10.1152/ajpcell.1994.267.5.C1483; Choquet CG, 1996, CAN J MICROBIOL, V42, P183, DOI 10.1139/m96-027; COMITA PB, 1983, SCIENCE, V222, P1329, DOI 10.1126/science.222.4630.1329; DARLAND G, 1970, SCIENCE, V170, P1416, DOI 10.1126/science.170.3965.1416; DEAMER DW, 1983, P NATL ACAD SCI-BIOL, V80, P165, DOI 10.1073/pnas.80.1.165; DEAMER DW, 1987, J BIOENERG BIOMEMBR, V19, P457; DEROSA M, 1980, PHYTOCHEMISTRY, V19, P827, DOI 10.1016/0031-9422(80)85120-X; DEROSA M, 1983, J MEMBRANE SCI, V16, P287, DOI 10.1016/S0376-7388(00)81316-2; DEROSA M, 1986, MICROBIOL REV, V50, P70, DOI 10.1128/MMBR.50.1.70-80.1986; ELFERINK MGL, 1994, BBA-BIOMEMBRANES, V1193, P247, DOI 10.1016/0005-2736(94)90160-0; FINKELSTEIN A, 1987, WATER MOVEMENT LIPID, P153; GROSSMAN EB, 1992, AM J PHYSIOL, V262, pC1109, DOI 10.1152/ajpcell.1992.262.5.C1109; HAINES TH, 1994, FEBS LETT, V346, P115, DOI 10.1016/0014-5793(94)00470-6; Hill WG, 2000, J BIOL CHEM, V275, P30176, DOI 10.1074/jbc.M003494200; Hill WG, 1999, J GEN PHYSIOL, V114, P405, DOI 10.1085/jgp.114.3.405; JANSEN M, 1995, BIOPHYS J, V68, P997, DOI 10.1016/S0006-3495(95)80275-4; Jarrell HC, 1998, BBA-BIOMEMBRANES, V1369, P259, DOI 10.1016/S0005-2736(97)00228-9; JONES WJ, 1983, ARCH MICROBIOL, V136, P254, DOI 10.1007/BF00425213; Kate M., 1993, BIOCH ARCHAEA ARCHAE, V26, P261, DOI DOI 10.1016/S0167-7306(08)60258-6; Komatsu H, 1998, BIOCHEMISTRY-US, V37, P107, DOI 10.1021/bi972163e; LANDE MB, 1994, AM J PHYSIOL, V267, pC367, DOI 10.1152/ajpcell.1994.267.2.C367; LANDE MB, 1995, J GEN PHYSIOL, V106, P67, DOI 10.1085/jgp.106.1.67; Lande MB, 1996, J BIOL CHEM, V271, P5552, DOI 10.1074/jbc.271.10.5552; Langworthy T.A., 1985, BACTERIA, V8, P459; Mathai JC, 1996, J BIOL CHEM, V271, P1309, DOI 10.1074/jbc.271.3.1309; Negrete HO, 1996, J BIOL CHEM, V271, P11627, DOI 10.1074/jbc.271.20.11627; NICHOLS JW, 1980, P NATL ACAD SCI-BIOL, V77, P2038, DOI 10.1073/pnas.77.4.2038; NISHIHARA M, 1987, J BIOCHEM-TOKYO, V101, P1007, DOI 10.1093/oxfordjournals.jbchem.a121942; NOZAKI Y, 1981, P NATL ACAD SCI-BIOL, V78, P4324, DOI 10.1073/pnas.78.7.4324; Paula S, 1996, BIOPHYS J, V70, P339, DOI 10.1016/S0006-3495(96)79575-9; Rivers R, 1998, AM J PHYSIOL-RENAL, V274, pF453, DOI 10.1152/ajprenal.1998.274.3.F453; Schafer G, 1999, MICROBIOL MOL BIOL R, V63, P570; SPROTT GD, 1991, J BACTERIOL, V173, P3907, DOI 10.1128/JB.173.12.3907-3910.1991; Sprott GD, 1997, CAN J MICROBIOL, V43, P467, DOI 10.1139/m97-066; Sprott GD, 1999, BBA-MOL CELL BIOL L, V1440, P275, DOI 10.1016/S1388-1981(99)00130-4; SPROTT GD, 1992, J BIOENERG BIOMEMBR, V24, P555, DOI 10.1007/BF00762348; Stein W., 2012, TRANSPORT DIFFUSION; Swain M, 1997, BBA-LIPID LIPID MET, V1345, P56, DOI 10.1016/S0005-2760(96)00163-4; TRINCONE A, 1992, SYST APPL MICROBIOL, V15, P11, DOI 10.1016/S0723-2020(11)80130-X; van de Vossenberg JLCM, 1999, EXTREMOPHILES, V3, P253, DOI 10.1007/s007920050124; WALTER A, 1986, J MEMBRANE BIOL, V90, P207, DOI 10.1007/BF01870127; XIANG TX, 1994, J MEMBRANE BIOL, V140, P111; XIANG TX, 1993, BIOPHYS J, V65, P1108, DOI 10.1016/S0006-3495(93)81156-1; Xiang TX, 1998, BIOPHYS J, V75, P2658, DOI 10.1016/S0006-3495(98)77711-2; Xiang TX, 1997, BIOPHYS J, V72, P223, DOI 10.1016/S0006-3495(97)78661-2; XIANG TX, 1992, BIOPHYS J, V63, P78, DOI 10.1016/S0006-3495(92)81581-3	49	117	120	4	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27266	27271		10.1074/jbc.M103265200	http://dx.doi.org/10.1074/jbc.M103265200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11373291	hybrid			2022-12-25	WOS:000169966900072
J	Nadeau, S; Rivest, S				Nadeau, S; Rivest, S			The complement system is an integrated part of the natural innate immune response in the brain	FASEB JOURNAL			English	Article						blood-brain barrier; circumventricular organs; infection; neuroinflammation; innate immune recognition; lipopolysaccharide; mice; microglia; septic shock	CENTRAL-NERVOUS-SYSTEM; KAPPA-B ACTIVITY; ANAPHYLATOXIN RECEPTORS; CELLULAR-POPULATIONS; HUMAN MONOCYTES; NUCLEAR-FACTOR; 3RD COMPONENT; C3A RECEPTOR; RAT-BRAIN; LIPOPOLYSACCHARIDE	The complement system consists of a group of proteins that play essential roles in coordinating the host defense to infection. It can be activated by two primary pathways, namely the classical and the alternative. This study aimed to determine the cellular distribution and the regulation of the genes encoding the proteins that are essential in guiding these pathways in the central nervous system (CNS) during innate immune recognition in mice. The results show a low-to-moderate C3 mRNA signal in few nonneuronal structures under basal conditions, whereas a robust C5 expression level was found in numerous populations of neuronal and nonneuronal cells. However, hybridization signal for the gene encoding the anaphylatoxin C5a receptor (C5aR) was low in the brain of vehicle-administered mice. The constitutive C5 mRNA levels remained unaltered during endotoxemia, but a strong and transient de novo expression of the other members of the complement protein family was found in the brain of mice that received a single systemic bolus of lipopolysaccharide (LPS). Indeed, transcriptional activation C3 and factor B genes occurred in the circumventricular organs and a wave of C3aR-expressing cells took place from the regions devoid of blood-brain barrier to deeper brain parenchyma. The C5aR mRNA levels also increased in the cerebral endothelium at 1 h post-LPS challenge, and the signal became gradually positive in microglial cells surrounding the capillaries and thereafter across the brain parenchyma. The present data provide evidence of an elegant pattern of expression and de novo transcription of key members of the complement system in the CNS, which underlies a sophisticated innate immune system that is triggered by circulating cell wall components of gram-negative bacteria.	Univ Laval, CHUL, Res Ctr, Mol Endocrinol Lab, Quebec City, PQ, Canada; Univ Laval, Dept Anat & Physiol, Quebec City, PQ, Canada	Laval University; Laval University	Rivest, S (corresponding author), Univ Laval, CHUL, Res Ctr, Mol Endocrinol Lab, 2705 Boul Laurier, Quebec City, PQ, Canada.	Serge.Rivest@crchul.ulaval.ca		Rivest, Serge/0000-0002-6082-770X				ARDITI M, 1995, J IMMUNOL, V155, P3994; BUCKLIN SE, 1993, INFECT IMMUN, V61, P3184, DOI 10.1128/IAI.61.8.3184-3189.1993; COLTEN HR, 1994, NATURE, V371, P474, DOI 10.1038/371474a0; Elmquist JK, 1997, TRENDS NEUROSCI, V20, P565, DOI 10.1016/S0166-2236(97)01138-7; FABRY Z, 1994, IMMUNOL TODAY, V15, P218, DOI 10.1016/0167-5699(94)90247-X; Fukuoka Y, 1998, BIOCHEM BIOPH RES CO, V242, P663, DOI 10.1006/bbrc.1997.8034; GASQUE P, 1995, J IMMUNOL, V154, P4726; Gasque P, 1998, J IMMUNOL, V160, P3543; Gasque P, 2000, IMMUNOPHARMACOLOGY, V49, P171, DOI 10.1016/S0162-3109(00)80302-1; GERARD C, 1994, ANNU REV IMMUNOL, V12, P775, DOI 10.1146/annurev.iy.12.040194.004015; HAMILTON AO, 1987, BIOCHEM J, V242, P809, DOI 10.1042/bj2420809; HOGASEN AKM, 1993, J IMMUNOL, V151, P3215; HOGASEN AKM, 1995, J LEUKOCYTE BIOL, V57, P287, DOI 10.1002/jlb.57.2.287; Lacroix S, 1998, BRAIN PATHOL, V8, P625, DOI 10.1111/j.1750-3639.1998.tb00189.x; Laflamme N, 1999, J NEUROCHEM, V73, P309, DOI 10.1046/j.1471-4159.1999.0730309.x; Laflamme N, 1999, J NEUROSCI, V19, P10923, DOI 10.1523/JNEUROSCI.19-24-10923.1999; Laflamme N, 2001, FASEB J, V15, P155, DOI 10.1096/fj.00-0339com; LEVISTRAUSS M, 1987, J IMMUNOL, V139, P2361; Mayhan WG, 1998, BRAIN RES, V792, P353, DOI 10.1016/S0006-8993(98)00259-5; Merino S, 1998, INFECT IMMUN, V66, P3825, DOI 10.1128/IAI.66.8.3825-3831.1998; Morgan BP, 1996, IMMUNOL TODAY, V17, P461, DOI 10.1016/0167-5699(96)20028-F; Nadeau S, 1999, J NEUROPATH EXP NEUR, V58, P61, DOI 10.1097/00005072-199901000-00008; Nadeau S, 2000, J NEUROSCI, V20, P3456, DOI 10.1523/JNEUROSCI.20-09-03456.2000; Nataf S, 1999, TRENDS NEUROSCI, V22, P397, DOI 10.1016/S0166-2236(98)01390-3; NONAKA M, 1990, MOL CELL BIOL, V10, P6283, DOI 10.1128/MCB.10.12.6283; Quan N, 1998, NEUROSCIENCE, V83, P281, DOI 10.1016/S0306-4522(97)00350-3; Quan N, 1997, P NATL ACAD SCI USA, V94, P10985, DOI 10.1073/pnas.94.20.10985; Rivest S, 2000, P SOC EXP BIOL MED, V223, P22, DOI 10.1046/j.1525-1373.2000.22304.x; RUS HG, 1992, J IMMUNOL, V148, P928; Stahel PF, 1997, J IMMUNOL, V159, P861; STRUNK RC, 1985, J CLIN INVEST, V76, P985, DOI 10.1172/JCI112099; SUTTON MBS, 1986, J IMMUNOL, V136, P1366; Swanson L. W., 1992, BRAIN MAPS STRUCTURE; Taylor P, 1998, CURR BIOL, V8, pR259, DOI 10.1016/S0960-9822(98)70167-8; Tornetta MA, 1997, J IMMUNOL, V158, P5277; Vallieres L, 1997, J NEUROCHEM, V69, P1668, DOI 10.1046/j.1471-4159.1997.69041668.x; WETSEL RA, 1995, CURR OPIN IMMUNOL, V7, P48, DOI 10.1016/0952-7915(95)80028-X	37	40	40	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR 27	2001	15	6					1410	+		10.1096/fj.00-0709fje	http://dx.doi.org/10.1096/fj.00-0709fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387240				2022-12-25	WOS:000173705800028
J	Paasche, JD; Attramadal, T; Sandberg, C; Johansen, HK; Attramadal, H				Paasche, JD; Attramadal, T; Sandberg, C; Johansen, HK; Attramadal, H			Mechanisms of endothelin receptor subtype-specific targeting to distinct intracellular trafficking pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA-ARRESTIN; CIRCULATING ENDOTHELIN-1; BINDING; DESENSITIZATION; PALMITOYLATION; BETA-ARRESTIN2; ENDOCYTOSIS; CLEARANCE; PEPTIDE	We recently reported that the endothelin (ET) receptor subtypes ETA and ETB are targeted to distinct intracellular destinations upon agonist stimulation (Bremnes, T., Paasche, J. D., Mehlum, A., Sandberg, C., Bremnes, B., and Attramadal, H. (2000) J. Biol. Chem. 275, 17596-17604). The ETA receptor was shown to follow the recycling route of transferrin, whereas ETB is targeted to lysosomes for degradation. In the present study we have investigated the mechanisms of ET receptor subtype-specific targeting to distinct intracellular trafficking pathways. Truncation mutants of the ETA and ETB receptors with deletions of the cytoplasmic carboxyl-terminal tail distal to the palmitoylation site were found to mediate inositol phosphate accumulation and to internalize upon agonist stimulation, although internalization occurred at a slower rate as compared with the wild-type receptors. However, the truncated ETA receptor was no longer able to undergo recycling. Rather, both truncation mutants were recognized by beta -arrestin for recruitment to endocytosis and were sorted to lysosomes by a dynamin-dependent internalization pathway. Furthermore, studies of chimeric ETA and ETB receptors where the cytoplasmic tail of ETA was swapped with the corresponding domain of ETB, and vice versa, revealed that the cytoplasmic tail of ETB is required for efficient lysosomal sorting and that signals for targeting to recycling reside in the cytoplasmic tail of the ETA receptor.	Univ Oslo, Natl Hosp, Inst Surg Res, Merck Sharp & Dohme Cardiovasc Res Ctr, N-0027 Oslo, Norway	University of Oslo; National Hospital Norway	Attramadal, H (corresponding author), Univ Oslo, Natl Hosp, Inst Surg Res, Merck Sharp & Dohme Cardiovasc Res Ctr, A3-1013, N-0027 Oslo, Norway.	havard.attramadal@klinmed.uio.no		Attramadal, Havard/0000-0001-9506-0687				ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; Berthiaume N, 2000, HYPERTENSION, V36, P1002, DOI 10.1161/01.HYP.36.6.1002; Bremnes T, 2000, J BIOL CHEM, V275, P17596, DOI 10.1074/jbc.M000142200; Cheng ZJ, 2000, J BIOL CHEM, V275, P2479, DOI 10.1074/jbc.275.4.2479; CHUN MY, 1995, J BIOL CHEM, V270, P10855, DOI 10.1074/jbc.270.18.10855; Cramer H, 1997, BIOCHEMISTRY-US, V36, P13325, DOI 10.1021/bi9708848; CYR CR, 1993, J BIOL CHEM, V268, P26071; Dupuis J, 1996, J APPL PHYSIOL, V81, P1510, DOI 10.1152/jappl.1996.81.4.1510; ELSHOURBAGY NA, 1993, J BIOL CHEM, V268, P3873; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; FUKURODA T, 1994, BIOCHEM BIOPH RES CO, V199, P1461, DOI 10.1006/bbrc.1994.1395; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Horstmeyer A, 1996, J BIOL CHEM, V271, P20811, DOI 10.1074/jbc.271.34.20811; KIESELBACH T, 1994, EUR J BIOCHEM, V226, P87, DOI 10.1111/j.1432-1033.1994.tb20029.x; KOSHIMIZU T, 1995, BIOCHEM BIOPH RES CO, V217, P354, DOI 10.1006/bbrc.1995.2784; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; MARSAULT R, 1993, AM J PHYSIOL, V264, pC687, DOI 10.1152/ajpcell.1993.264.3.C687; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Okamoto Y, 1997, J BIOL CHEM, V272, P21589, DOI 10.1074/jbc.272.34.21589; Oksche A, 2000, MOL PHARMACOL, V57, P1104; Opgenorth TJ, 2000, J CARDIOVASC PHARM, V36, pS292, DOI 10.1097/00005344-200036051-00086; SAKURAI T, 1992, TRENDS PHARMACOL SCI, V13, P103; Shibasaki T, 1999, BIOCHEM MOL BIOL INT, V47, P569; SHIBATA T, 1995, BIOMED RES-TOKYO, V16, P97, DOI 10.2220/biomedres.16.97; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Trejo J, 1999, J BIOL CHEM, V274, P2216, DOI 10.1074/jbc.274.4.2216; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Wu GY, 1997, J BIOL CHEM, V272, P17836, DOI 10.1074/jbc.272.28.17836; YANAGISAWA M, 1989, BIOCHEM PHARMACOL, V38, P1877; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; Zhang J, 1999, J BIOL CHEM, V274, P10999, DOI 10.1074/jbc.274.16.10999	34	52	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					34041	34050		10.1074/jbc.M103243200	http://dx.doi.org/10.1074/jbc.M103243200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11382773	hybrid			2022-12-25	WOS:000170910200101
J	Hogg, D; Woo, EJ; Bolam, DN; McKie, VA; Gilbert, HJ; Pickersgill, RW				Hogg, D; Woo, EJ; Bolam, DN; McKie, VA; Gilbert, HJ; Pickersgill, RW			Crystal structure of mannanase 26A from Pseudomonas cellulosa and analysis of residues involved in substrate binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSYL HYDROLASE; BETA-MANNANASE; FLUORESCENS; XYLANASE; SPECIFICITY; REFINEMENT; ANGSTROM; COMPLEX; ENZYMES; GENE	The crystal structure of Pseudomonas cellulosa mannanase 26A has been solved by multiple isomorphous replacement and refined at 1.85 Angstrom resolution to an R-factor of 0.182 (R-free = 0.211). The enzyme comprises (beta/alpha)(8)-barrel architecture with two catalytic glutamates at the ends of beta -strands 4 and 7 in precisely the same location as the corresponding glutamates in other 4/7-superfamily glycoside hydrolase enzymes (clan GH-A glycoside hydrolases). The family 26 glycoside hydrolases are therefore members of clan GH-A. Functional analyses of mannanase 26A, informed by the crystal structure of the enzyme, provided important insights into the role of residues close to the catalytic glutamates. These data showed that Trp-360 played a critical role in binding substrate at the -1 subsite, whereas Tyr-285 was important to the function of the nucleophile catalyst. His-211 in mannanase 26A does not have the same function as the equivalent asparagine in the other GH-A enzymes. The data also suggest that Trp-217 and Trp-162 are important for the activity of mannanase 26RA against mannooligosaccharides but are less important for activity against polysaccharides.	Queen Mary Univ London, Sch Biol Sci, London E1 4NS, England; Newcastle Univ, Dept Biol & Nutr Sci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	University of London; Queen Mary University London; Newcastle University - UK	Pickersgill, RW (corresponding author), Queen Mary Univ London, Sch Biol Sci, Med Sci Bldg,Mile End Rd, London E1 4NS, England.	r.w.pickersgill@qmw.ac.uk		Bolam, David/0000-0003-0314-3122; Woo, Eui-Jeon/0000-0001-6983-0270				Armand S, 2001, BIOCHEMISTRY-US, V40, P7404, DOI 10.1021/bi002704r; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BANNER DW, 1975, NATURE, V255, P609, DOI 10.1038/255609a0; Bolam DN, 1996, BIOCHEMISTRY-US, V35, P16195, DOI 10.1021/bi961866d; BRAITHWAITE KL, 1995, BIOCHEM J, V305, P1005, DOI 10.1042/bj3051005; Charnock SJ, 1998, J BIOL CHEM, V273, P32187, DOI 10.1074/jbc.273.48.32187; Charnock SJ, 1997, J BIOL CHEM, V272, P2942, DOI 10.1074/jbc.272.5.2942; Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P487, DOI 10.1107/S0907444997011980; Davies GJ, 1998, BIOCHEMISTRY-US, V37, P1926, DOI 10.1021/bi972162m; Garman E, 1999, STRUCT FOLD DES, V7, pR291, DOI 10.1016/S0969-2126(00)88335-5; HARJUNPAA V, 1995, EUR J BIOCHEM, V234, P278, DOI 10.1111/j.1432-1033.1995.278_c.x; Harris GW, 1996, ACTA CRYSTALLOGR D, V52, P393, DOI 10.1107/S0907444995013540; HARRIS GW, 1994, STRUCTURE, V2, P1107, DOI 10.1016/S0969-2126(94)00112-X; HENRISSAT B, 1995, P NATL ACAD SCI USA, V92, P7090, DOI 10.1073/pnas.92.15.7090; Hilge M, 1998, STRUCTURE, V6, P1433, DOI 10.1016/S0969-2126(98)00142-7; JENKINS J, 1995, FEBS LETT, V362, P281, DOI 10.1016/0014-5793(95)00252-5; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KOSHLAND DE, 1953, BIOL REV, V28, P416, DOI 10.1111/j.1469-185X.1953.tb01386.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MATSUI I, 1991, J BIOCHEM-TOKYO, V109, P566, DOI 10.1093/oxfordjournals.jbchem.a123420; MCCLEARY BV, 1983, CARBOHYD RES, V119, P191, DOI 10.1016/0008-6215(83)84056-7; MillwardSadler SJ, 1996, FEMS MICROBIOL LETT, V141, P183, DOI 10.1016/0378-1097(96)00219-4; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; STALBRAND H, 1995, APPL ENVIRON MICROB, V61, P1090; Stoll D, 1999, APPL ENVIRON MICROB, V65, P2598; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; Svensson B, 1999, ROY SOC CH, P272; Timell T. E., 1967, Wood Science and Technology, V1, P45, DOI 10.1007/BF00592255; Toorop PE, 1999, J PLANT PHYSIOL, V154, P679, DOI 10.1016/S0176-1617(99)80244-2	34	78	83	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31186	31192		10.1074/jbc.M010290200	http://dx.doi.org/10.1074/jbc.M010290200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11382747	hybrid			2022-12-25	WOS:000170472900079
J	Howell, SA; Withers-Martinez, C; Kocken, CHM; Thomas, AW; Blackman, MJ				Howell, SA; Withers-Martinez, C; Kocken, CHM; Thomas, AW; Blackman, MJ			Proteolytic processing and primary structure of Plasmodium falciparum apical membrane antigen-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-CELL INVASION; INTRAERYTHROCYTIC STAGE; SEQUENCE-ANALYSIS; MALARIA PARASITES; SURFACE-ANTIGEN; I AMA-1; PROTEIN; KNOWLESI; MEROZOITES; IDENTIFICATION	Plasmodium falciparum apical membrane antigen-1 (PfAMA-1) is a malaria merozoite integral membrane protein that plays an essential but poorly understood role in invasion of host erythrocytes. The PfAMA-1 ectodomain comprises three disulfide-constrained domains, the first of which (domain I) is preceded by an N-terminal prosequence. PfAMA-1 is initially routed to secretory organelles at the apical end of the merozoite, where the 83-kDa precursor (PfAMA-1(83)) is converted to a 66-kDa form (PfAMA-1(66)). At about the time of erythrocyte invasion, PfAMA-1(66) selectively translocates onto the merozoite surface. Here we use direct microsequencing and mass spectrometric peptide mass fingerprinting to characterize in detail the primary structure and proteolytic processing of PfAMA-1. We have determined the site at which processing takes place to convert PfAMA-1(83) to PfAMA-1(66) and have shown that both species possess a completely intact and unmodified transmembrane and cytoplasmic domain. Following relocation to the merozoite surface, PfAMA-166 is further proteolytically cleaved at one of two alternative sites, either between domains II and III, or at a membrane-proximal site following domain III. As a result, the bulk of the ectodomain is shed from the parasite surface in the form of two soluble fragments of 44 and 48 kDa. PfAMA-1 is not detectably modified by the addition of N-linked oligosaccharides.	Natl Inst Med Res, Div Parasitol, London NW7 1AA, England; Natl Inst Med Res, Div Prot Struct, London NW7 1AA, England; Biomed Primate Res Ctr, NL-2280 GJ Rijswijk, Netherlands	MRC National Institute for Medical Research; MRC National Institute for Medical Research	Blackman, MJ (corresponding author), Natl Inst Med Res, Div Parasitol, Mill Hill, London NW7 1AA, England.			Kocken, Clemens/0000-0002-4784-1734				ALTMANN F, 1995, GLYCOCONJUGATE J, V12, P84, DOI 10.1007/BF00731873; Anders RF, 2000, PARASITOL TODAY, V16, P444, DOI 10.1016/S0169-4758(00)01784-1; Berhe S, 2000, EXP PARASITOL, V94, P194, DOI 10.1006/expr.1999.4481; Blackman Michael J., 2000, Current Drug Targets, V1, P59, DOI 10.2174/1389450003349461; Blackman MJ, 1998, J BIOL CHEM, V273, P23398, DOI 10.1074/jbc.273.36.23398; BLACKMAN MJ, 1994, METHOD CELL BIOL, V45, P213; BLACKMAN MJ, 1990, J EXP MED, V172, P379, DOI 10.1084/jem.172.1.379; Carruthers VB, 1999, CELL MICROBIOL, V1, P225, DOI 10.1046/j.1462-5822.1999.00023.x; Carruthers VB, 2000, J BIOL CHEM, V275, P14346, DOI 10.1074/jbc.275.19.14346; CHENG Q, 1994, MOL BIOCHEM PARASIT, V65, P183, DOI 10.1016/0166-6851(94)90127-9; Chitnis CE, 2000, PARASITOL TODAY, V16, P411, DOI 10.1016/S0169-4758(00)01756-7; Cowman AF, 2000, FEBS LETT, V476, P84, DOI 10.1016/S0014-5793(00)01703-8; CREWTHER PE, 1990, EXP PARASITOL, V70, P193, DOI 10.1016/0014-4894(90)90100-Q; DEANS JA, 1984, MOL BIOCHEM PARASIT, V11, P189, DOI 10.1016/0166-6851(84)90065-3; DEANS JA, 1982, CLIN EXP IMMUNOL, V49, P297; DIECKMANNSCHUPPERT A, 1992, EUR J BIOCHEM, V205, P815, DOI 10.1111/j.1432-1033.1992.tb16846.x; Donahue CG, 2000, MOL BIOCHEM PARASIT, V111, P15, DOI 10.1016/S0166-6851(00)00289-9; DUTTA S, 1995, MOL BIOCHEM PARASIT, V73, P267, DOI 10.1016/0166-6851(95)00112-E; Gardner MJ, 1998, SCIENCE, V282, P1126, DOI 10.1126/science.282.5391.1126; Gowda DC, 1997, J BIOL CHEM, V272, P6428, DOI 10.1074/jbc.272.10.6428; Hehl AB, 2000, INFECT IMMUN, V68, P7078, DOI 10.1128/IAI.68.12.7078-7086.2000; Hodder AN, 1996, J BIOL CHEM, V271, P29446, DOI 10.1074/jbc.271.46.29446; Kappe S, 1999, J CELL BIOL, V147, P937, DOI 10.1083/jcb.147.5.937; Kappe SHI, 1996, MOL BIOCHEM PARASIT, V78, P279, DOI 10.1016/S0166-6851(96)02619-9; Kappe SHI, 1998, P NATL ACAD SCI USA, V95, P1230, DOI 10.1073/pnas.95.3.1230; Kimura EA, 1996, J BIOL CHEM, V271, P14452, DOI 10.1074/jbc.271.24.14452; Kocken CHM, 2000, MOL BIOCHEM PARASIT, V109, P147, DOI 10.1016/S0166-6851(00)00250-4; Kocken CHM, 1998, J BIOL CHEM, V273, P15119, DOI 10.1074/jbc.273.24.15119; Marshall VM, 1996, MOL BIOCHEM PARASIT, V77, P109, DOI 10.1016/0166-6851(96)02583-2; MARSHALL VM, 1989, MOL BIOCHEM PARASIT, V37, P281, DOI 10.1016/0166-6851(89)90160-6; NARUM DL, 1993, J CHROMATOGR A, V657, P357, DOI 10.1016/0021-9673(93)80291-F; NARUM DL, 1994, MOL BIOCHEM PARASIT, V67, P59, DOI 10.1016/0166-6851(94)90096-5; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; PAPPIN DJC, 1993, CURR BIOL, V3, P327, DOI 10.1016/0960-9822(93)90195-T; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; PETERSON MG, 1989, MOL CELL BIOL, V9, P3151, DOI 10.1128/MCB.9.7.3151; PETERSON MG, 1990, MOL BIOCHEM PARASIT, V39, P279, DOI 10.1016/0166-6851(90)90067-V; ROSE K, 1983, BIOCHEM J, V215, P273, DOI 10.1042/bj2150273; Sajid M, 2000, J BIOL CHEM, V275, P631, DOI 10.1074/jbc.275.1.631; THOMAS AW, 1984, MOL BIOCHEM PARASIT, V13, P187, DOI 10.1016/0166-6851(84)90112-9; TRETTER V, 1991, EUR J BIOCHEM, V199, P647, DOI 10.1111/j.1432-1033.1991.tb16166.x; Triglia T, 2000, MOL MICROBIOL, V38, P706, DOI 10.1046/j.1365-2958.2000.02175.x; VORM O, 1994, ANAL CHEM, V66, P3281, DOI 10.1021/ac00091a044; WATERS AP, 1990, J BIOL CHEM, V265, P17974; WATERS AP, 1991, MOL BIOCHEM PARASIT, V44, P141, DOI 10.1016/0166-6851(91)90230-4	45	130	135	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31311	31320		10.1074/jbc.M103076200	http://dx.doi.org/10.1074/jbc.M103076200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11399764	hybrid			2022-12-25	WOS:000170472900095
J	Maeda, T; Takahashi, Y; Suenaga, H; Suyama, A; Goto, M; Furukawa, K				Maeda, T; Takahashi, Y; Suenaga, H; Suyama, A; Goto, M; Furukawa, K			Functional analyses of Bph-Tod hybrid dioxygenase, which exhibits high degradation activity toward trichloroethylene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-PSEUDOALCALIGENES KF707; B-356 BIPHENYL DIOXYGENASE; SITE-DIRECTED MUTAGENESIS; TOLUENE DIOXYGENASE; POLYCHLORINATED-BIPHENYLS; EFFICIENT DEGRADATION; SUBSTRATE-SPECIFICITY; OXIDIZING BACTERIUM; OXYGENASE COMPONENT; ESCHERICHIA-COLI	Biphenyl dioxygenase (BphDox) in Pseudomonas pseudoalcaligenes KF707 is a multicomponent enzyme consisting of an iron-sulfur protein (ISP) that is composed of alpha (BphA1) and beta (BphA2) subunits, a ferredoxin (FDBphA3), and a ferredoxin reductase (FDRBphA4). A recombinant Escherichia coli strain expressing hybrid Dox that had replaced BphA1 with TodC1 (alpha subunit of toluene dioxygenase (TolDox) of Pseudomonas putida) exhibited high activity toward trichloroethylene (TCE) (Furukawa, K., Hirose, J., Hayashida, S., and Nakamura, K. (1994) J. Bacteriol. 176, 2121-2123). In this study, ISP, FD, and FDR were purified and characterized. Reconstitution of the dioxygenase components consisting of purified ISPTodC1BphA2 FDBphA3 and FDRBphA4 exhibited oxygenation activities toward biphenyl, toluene, and TCE. Native polyacrylamide gel electrophoresis followed by the Ferguson plot analyses demonstrated that ISPTodC1BphA2 and ISPBphA1A2 were present as heterohexamers, whereas ISPTodC1C2 was present as a heterotetramer. The molecular activity (k(0)) of the hybrid Dox for TCE was 4.1 min(-1), which is comparable to that of TolDox. The K-m value of the hybrid Dox for TCE was 130 muM, which was lower than 250 muM for TolDox. These results suggest that the alpha subunit of ISP is crucial for the determination of substrate specificity and that the change in the alpha subunit conformation of ISP from alpha (2)beta (2) to alpha (3)beta (3), results in the acquisition of higher affinity to TCE, which may lead to high TCE degradation activity.	Kyushu Univ, Fac Agr, Dept Biosci & Biotechnol, Appl Microbiol Lab, Fukuoka 8128581, Japan	Kyushu University	Furukawa, K (corresponding author), Kyushu Univ, Fac Agr, Dept Biosci & Biotechnol, Appl Microbiol Lab, Fukuoka 8128581, Japan.		KENSUKE, FURUKAWA/R-3105-2019					ARCIERO D, 1989, BIOCHEM BIOPH RES CO, V159, P640, DOI 10.1016/0006-291X(89)90042-9; ASHIUCHI M, 1995, J BIOCHEM, V117, P495, DOI 10.1093/oxfordjournals.jbchem.a124735; Bruhlmann F, 1999, BIOTECHNOL BIOENG, V63, P544, DOI 10.1002/(SICI)1097-0290(19990605)63:5<544::AID-BIT4>3.0.CO;2-6; ERICKSON BD, 1993, APPL ENVIRON MICROB, V59, P3858, DOI 10.1128/AEM.59.11.3858-3862.1993; FURUKAWA K, 1994, J BACTERIOL, V176, P2121, DOI 10.1128/jb.176.7.2121-2123.1994; FURUKAWA K, 1993, J BACTERIOL, V175, P5224, DOI 10.1128/JB.175.16.5224-5232.1993; Furukawa K, 2000, CURR OPIN BIOTECH, V11, P244, DOI 10.1016/S0958-1669(00)00091-4; GALLAGHER SR, 1995, CURRENT PROTOCOLS PR; Gibson DT, 2000, CURR OPIN BIOTECH, V11, P236, DOI 10.1016/S0958-1669(00)00090-2; GIBSON DT, 1993, J BACTERIOL, V175, P4561, DOI 10.1128/JB.175.14.4561-4564.1993; GOSSETT JM, 1987, ENVIRON SCI TECHNOL, V21, P202, DOI 10.1021/es00156a012; HADDOCK JD, 1995, J BACTERIOL, V177, P5834, DOI 10.1128/jb.177.20.5834-5839.1995; HIROSE J, 1994, GENE, V138, P27; Hurtubise Y, 1996, J BIOL CHEM, V271, P8152, DOI 10.1074/jbc.271.14.8152; HURTUBISE Y, 1995, J BACTERIOL, V177, P6610, DOI 10.1128/jb.177.22.6610-6618.1995; INFANTE PF, 1982, ENV SCI RES, V25, P301; Jiang HY, 1996, J BACTERIOL, V178, P3133, DOI 10.1128/jb.178.11.3133-3139.1996; Kimura N, 1997, J BACTERIOL, V179, P3936, DOI 10.1128/jb.179.12.3936-3943.1997; Kumamaru T, 1998, NAT BIOTECHNOL, V16, P663, DOI 10.1038/nbt0798-663; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee K, 1999, J BACTERIOL, V181, P2719, DOI 10.1128/JB.181.9.2719-2725.1999; LI SY, 1992, BIOCHEM BIOPH RES CO, V185, P443, DOI 10.1016/S0006-291X(05)81005-8; LITTLE CD, 1988, APPL ENVIRON MICROB, V54, P951, DOI 10.1128/AEM.54.4.951-956.1988; MAISON JR, 1992, ANNU REV MICROBIOL, V46, P277; Mondello FJ, 1997, APPL ENVIRON MICROB, V63, P3096, DOI 10.1128/AEM.63.8.3096-3103.1997; NELSON MJK, 1987, APPL ENVIRON MICROB, V53, P949, DOI 10.1128/AEM.53.5.949-954.1987; Newman LM, 1997, J BACTERIOL, V179, P90, DOI 10.1128/jb.179.1.90-96.1997; SHIELDS MS, 1991, APPL ENVIRON MICROB, V57, P1935, DOI 10.1128/AEM.57.7.1935-1941.1991; SUBRAMANIAN V, 1979, BIOCHEM BIOPH RES CO, V91, P1131, DOI 10.1016/0006-291X(79)91998-3; Suenaga H, 2001, J BIOL CHEM, V276, P22500, DOI 10.1074/jbc.M101323200; Suyama A, 1996, J BACTERIOL, V178, P4039, DOI 10.1128/jb.178.14.4039-4046.1996; TAIRA K, 1992, J BIOL CHEM, V267, P4844; *US EPA, 1985, NPLU3693 US EPA; WACKETT LP, 1988, APPL ENVIRON MICROB, V54, P1703, DOI 10.1128/AEM.54.7.1703-1708.1988; ZYLSTRA GJ, 1989, J BIOL CHEM, V264, P14940	35	22	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29833	29838		10.1074/jbc.M102025200	http://dx.doi.org/10.1074/jbc.M102025200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11390387	hybrid			2022-12-25	WOS:000170558000032
J	Tang, D; Okada, H; Ruland, J; Liu, LQ; Stambolic, V; Mak, TW; Ingram, AJ				Tang, D; Okada, H; Ruland, J; Liu, LQ; Stambolic, V; Mak, TW; Ingram, AJ			Akt is activated in response to an apoptotic signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PROTEIN-KINASE-B; CHEMOTHERAPY-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; CELL-DEATH; SURVIVAL SIGNALS; CERVICAL-CANCER; MYC PROTEIN; INHIBITION; RAS	Akt is a serine-threonine kinase known to exert anti-apoptotic effects through several downstream targets. Akt is cleaved during mitochondrial-mediated apoptosis in a caspase-dependent manner. The reason for this is not clear, however, because Akt has not been demonstrated to be activated in response to mitochondrial apoptotic stimuli. Accordingly, we explored whether the well described mitochondrial apoptotic stimuli staurosporine (STS) and etoposide activate Akt and whether such activation impacts apoptosis. Both STS and etoposide activated Akt in NIH 3T3 cells, maximally at 8 and 2 h, respectively, preceding the onset of apoptosis and poly(ADP-ribose) polymerase cleavage. The overexpression of Akt delayed STS-induced apoptosis with an even more pronounced delay observed with overexpression of constitutively active Akt. Akt activation by proapoptotic stimuli lay upstream of mitochondria, because neither caspase inhibitors nor overexpression of Bcl-2 or Bcl-x(L) could prevent it. Activation depended on phosphatidylinositol 3-kinase activity, however. Conversely, inhibition of phosphatidylinositol 3-kinase with wort-mannin sensitized cells to apoptosis initiated by STS. These data demonstrate that mitochondrial apoptotic stimuli also activate Akt and such activation modulates apoptosis in this setting.	McMaster Univ, Dept Med, Hamilton, ON L8N 1Y2, Canada; Amgen Inst, Toronto, ON M5G 2C1, Canada	McMaster University	Tang, D (corresponding author), McMaster Univ, Dept Med, 500-25 Charlton Ave E, Hamilton, ON L8N 1Y2, Canada.	damut@mcmaster.ca	Ruland, Jürgen/Q-6680-2018; Tang, Damu/AAQ-1786-2021	Ruland, Jürgen/0000-0002-8381-3597; Tang, Damu/0000-0002-3282-9521; Stambolic, Vuk/0000-0001-8853-3239				AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Facompre Michael, 2000, Molecular Cell Biology Research Communications, V4, P37, DOI 10.1006/mcbr.2000.0251; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Gao G, 2000, J CELL BIOCHEM, V80, P53; Gire V, 2000, ONCOGENE, V19, P2269, DOI 10.1038/sj.onc.1203544; Goswami R, 1999, J NEUROSCI RES, V57, P884, DOI 10.1002/(SICI)1097-4547(19990915)57:6<884::AID-JNR14>3.3.CO;2-1; Graff JR, 2000, J BIOL CHEM, V275, P24500, DOI 10.1074/jbc.M003145200; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Ma YY, 2000, ONCOGENE, V19, P2739, DOI 10.1038/sj.onc.1203597; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nakashio A, 2000, CANCER RES, V60, P5303; Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528; Ng SSW, 2000, CANCER RES, V60, P5451; O'Gorman DM, 2000, LEUKEMIA, V14, P602, DOI 10.1038/sj.leu.2401726; Ozes ON, 1999, NATURE, V401, P82; Page C, 2000, ANTICANCER RES, V20, P407; Page C, 2000, INT J ONCOL, V17, P23; Philpott KL, 1997, J CELL BIOL, V139, P809, DOI 10.1083/jcb.139.3.809; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; Rytomaa M, 2000, ONCOGENE, V19, P4461, DOI 10.1038/sj.onc.1203805; Shan B, 1996, P NATL ACAD SCI USA, V93, P679, DOI 10.1073/pnas.93.2.679; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; Tang DM, 1999, J BIOL CHEM, V274, P7245, DOI 10.1074/jbc.274.11.7245; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; Yuan ZQ, 2000, ONCOGENE, V19, P2324, DOI 10.1038/sj.onc.1203598; Zhou HL, 2000, J CELL BIOL, V151, P483, DOI 10.1083/jcb.151.3.483; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	51	82	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30461	30466		10.1074/jbc.M102045200	http://dx.doi.org/10.1074/jbc.M102045200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11399756	hybrid			2022-12-25	WOS:000170558000112
J	Harris, TE; Albrecht, JH; Nakanishi, M; Darlington, GJ				Harris, TE; Albrecht, JH; Nakanishi, M; Darlington, GJ			CCAAT/enhancer-binding protein-alpha cooperates with p21 to inhibit cyclin-dependent kinase-2 activity and induces growth arrest independent of DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL REGION; C/EBP-ALPHA; CELL-PROLIFERATION; TRANSCRIPTIONAL ACTIVATOR; NUCLEAR-LOCALIZATION; E7 ONCOPROTEIN; CDK INHIBITORS; NEWBORN MICE; DIFFERENTIATION; PCNA	CCAAT/enhancer-binding protein-alpha (C/EBP alpha) is a basic leucine zipper protein that controls transcription of genes important for liver function, white adipose tissue development, and granulocyte differentiation. In addition to its function in controlling gene expression in differentiated tissues, C/EBP alpha is also associated with an antimitotic activity. We have previously demonstrated that C/EBP alpha interacts with p21, a cyclin-dependent kinase (CDK) inhibitor, and that C/EBP alpha inhibits proliferation when expressed in several different cell types (Timchenko, N. A., Harris, T. E., Wilde, M., Bilyeu, T. A., Burgess-Beusse, B. L., Finegold, M. J., and Darlington, G. J. (1997) Mol. Cell. Biol. 17,7353-7361). Here we define the regions of C/EBP alpha required for interaction with p21 and demonstrate that CDK2 also interacts with C/EBP alpha. We show that C/EBP alpha can cooperate with p21. to inhibit CDK2 activity in vitro. The effect of C/EBP alpha on CDK2 activity requires the p21 and CDK2 interaction sites within C/EBP alpha. C/EBP alpha mutants incapable of inhibiting CDK2 activity in vitro do not inhibit proliferation in cultured cells. However, C/EBP alpha mutants defective in DNA binding inhibit proliferation as effectively as the wild-type protein. These findings show that C/EBP alpha -mediated growth arrest occurs through protein interactions and is independent of its transcriptional activity.	Baylor Coll Med, Roy M & Phyllis Gough Huffington Ctr Aging, Houston, TX 77030 USA; Baylor Coll Med, Cell & Mol Biol Program, Houston, TX 77030 USA; Hennepin Cty Med Ctr, Dept Med, Minneapolis, MN 55415 USA; Nagoya City Univ, Sch Med, Dept Biochem, Mizuho Ku, Nagoya, Aichi 4678601, Japan	Baylor College of Medicine; Baylor College of Medicine; Hennepin County Medical Center; Nagoya City University	Darlington, GJ (corresponding author), Baylor Coll Med, Roy M & Phyllis Gough Huffington Ctr Aging, Rm N810,1 Baylor Plaza, Houston, TX 77030 USA.				NIA NIH HHS [T32 AG-00183, AG-13663] Funding Source: Medline; NIDDK NIH HHS [DK-54921] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG013663, T32AG000183] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Albrecht JH, 1999, AM J PHYSIOL-GASTR L, V277, pG1207, DOI 10.1152/ajpgi.1999.277.6.G1207; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BUCK M, 1994, EMBO J, V13, P851, DOI 10.1002/j.1460-2075.1994.tb06328.x; Chen JJ, 1996, NUCLEIC ACIDS RES, V24, P1727, DOI 10.1093/nar/24.9.1727; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; Croniger C, 1998, J BIOL CHEM, V273, P31629, DOI 10.1074/jbc.273.48.31629; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Estanyol JM, 1999, J BIOL CHEM, V274, P33161, DOI 10.1074/jbc.274.46.33161; Fotedar R, 1996, ONCOGENE, V12, P2155; FRIEDMAN AD, 1990, GENE DEV, V4, P1416, DOI 10.1101/gad.4.8.1416; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HENDRICKSTAYLOR LR, 1995, NUCLEIC ACIDS RES, V23, P4726, DOI 10.1093/nar/23.22.4726; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; Kitaura H, 2000, J BIOL CHEM, V275, P10477, DOI 10.1074/jbc.275.14.10477; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; Li SL, 1997, BIOTECHNIQUES, V23, P588, DOI 10.2144/97234bm05; LIN FT, 1993, P NATL ACAD SCI USA, V90, P9606, DOI 10.1073/pnas.90.20.9606; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; Muller C, 1999, P NATL ACAD SCI USA, V96, P7276, DOI 10.1073/pnas.96.13.7276; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; NERLOV C, 1995, EMBO J, V14, P4318, DOI 10.1002/j.1460-2075.1995.tb00106.x; NERLOV C, 1994, GENE DEV, V8, P350, DOI 10.1101/gad.8.3.350; O'Rourke JP, 1999, J BIOL CHEM, V274, P16582, DOI 10.1074/jbc.274.23.16582; Ono T, 2000, J BIOL CHEM, V275, P31145, DOI 10.1074/jbc.M003031200; ORourke J, 1997, J BIOL CHEM, V272, P6291, DOI 10.1074/jbc.272.10.6291; PEI DQ, 1991, MOL CELL BIOL, V11, P1480, DOI 10.1128/MCB.11.3.1480; Slomiany BA, 2000, MOL CELL BIOL, V20, P5986, DOI 10.1128/MCB.20.16.5986-5997.2000; Taules M, 1999, J BIOL CHEM, V274, P24445, DOI 10.1074/jbc.274.35.24445; Timchenko NA, 1999, NUCLEIC ACIDS RES, V27, P3621, DOI 10.1093/nar/27.17.3621; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; Timchenko NA, 1997, MOL CELL BIOL, V17, P7353, DOI 10.1128/MCB.17.12.7353; Timchenko NA, 1999, MOL CELL BIOL, V19, P2936; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zhang JM, 1999, EMBO J, V18, P6983, DOI 10.1093/emboj/18.24.6983; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; Zhu SY, 1999, MOL CELL BIOL, V19, P7181	45	106	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29200	29209		10.1074/jbc.M011587200	http://dx.doi.org/10.1074/jbc.M011587200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11369759	hybrid			2022-12-25	WOS:000170346000077
J	Leung, GK; Schmidt, WK; Bergo, MO; Gavino, B; Wong, DH; Tam, A; Ashby, MN; Michaelis, S; Young, SG				Leung, GK; Schmidt, WK; Bergo, MO; Gavino, B; Wong, DH; Tam, A; Ashby, MN; Michaelis, S; Young, SG			Biochemical studies of Zmpste24-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHEROMONE A-FACTOR; SACCHAROMYCES-CEREVISIAE; CARBOXYL METHYLTRANSFERASE; RAS PROTEINS; STE14 GENE; YEAST; MATURATION; MEMBRANE; MISLOCALIZATION; PROTEOLYSIS	Genetic studies in Saccharomyces cerevisiae identified two genes, STE24 and RCE1, involved in cleaving the three carboxyl-terminal amino acids from isoprenylated proteins that terminate with a CAAX sequence motif. Ste24p cleaves the carboxyl-terminal "-AAX" from the yeast mating pheromone a-factor, whereas Rce1p cleaves the -AAX from both a-factor and Ras2p. Ste24p also cleaves the amino terminus of a-factor. The mouse genome contains orthologues for both yeast RCE1 and STE24. We previously demonstrated, with a gene-knockout experiment, that mouse Reel is essential for development and that Reel is entirely responsible for the carboxyl-terminal proteolytic processing of the mouse Ras proteins. In this study, we cloned mouse Zmpste24, the orthologue for yeast STE24 and showed that it could promote a-factor production when expressed in yeast. Then, to assess the importance of Zmpste24 in development, we generated Zmpste24-deficient mice. Unlike the Reel knockout mice, Zmpste24-deficient mice survived development and were fertile. Since no natural substrates for mammalian Zmpste24 have been identified, yeast a-factor was used as a surrogate substrate to investigate the biochemical activities in membranes from the cells and tissues of Zmpste24-deficient mice. We demonstrate that Zmpste24-deficient mouse membranes, like Ste24p-deficient yeast membranes, have diminished CAAX proteolytic activity and lack the ability to cleave the amino terminus of the a-factor precursor. Thus, both enzymatic activities of yeast Ste24p are conserved in mouse Zmpste24, but these enzymatic activities are not essential for mouse development or for fertility.	Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Inst Cardiovasc Res, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA; Johns Hopkins Univ, Sch Med, Dept Cell Biol & Anat, Baltimore, MD 21205 USA; Axys Pharmaceut, San Francisco, CA 94080 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Johns Hopkins University	Young, SG (corresponding author), Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, POB 419100, San Francisco, CA 94141 USA.	syoung@gladstone.ucsf.edu		Young, Stephen/0000-0001-7270-3176	NHLBI NIH HHS [HL41633] Funding Source: Medline; NIA NIH HHS [AG15451] Funding Source: Medline; NIGMS NIH HHS [GM41223] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041223] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015451] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ambroziak P., 2001, ENZYMES, P155; Ashby MN, 1998, CURR OPIN LIPIDOL, V9, P99, DOI 10.1097/00041433-199804000-00004; Bergo MO, 2000, J BIOL CHEM, V275, P17605, DOI 10.1074/jbc.C000079200; Bergo MO, 2001, J BIOL CHEM, V276, P5841, DOI 10.1074/jbc.C000831200; Boyartchuk VL, 1997, SCIENCE, V275, P1796, DOI 10.1126/science.275.5307.1796; Boyartchuk VL, 1998, GENETICS, V150, P95; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CHAN RK, 1982, MOL CELL BIOL, V2, P11, DOI 10.1128/MCB.2.1.11; Chen P, 1997, J CELL BIOL, V136, P251, DOI 10.1083/jcb.136.2.251; Chen YL, 1996, BIOCHEMISTRY-US, V35, P3227, DOI 10.1021/bi952529s; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; FujimuraKamada K, 1997, J CELL BIOL, V136, P271, DOI 10.1083/jcb.136.2.271; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; HANKS M, 1995, SCIENCE, V269, P679, DOI 10.1126/science.7624797; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HRYCYNA CA, 1992, J BIOL CHEM, V267, P10457; HRYCYNA CA, 1991, EMBO J, V10, P1699, DOI 10.1002/j.1460-2075.1991.tb07694.x; Hudson JR, 1997, GENOME RES, V7, P1169, DOI 10.1101/gr.7.12.1169; Kim E, 1997, P NATL ACAD SCI USA, V94, P6132, DOI 10.1073/pnas.94.12.6132; Kim E, 1999, J BIOL CHEM, V274, P8383, DOI 10.1074/jbc.274.13.8383; Meiner VL, 1996, P NATL ACAD SCI USA, V93, P14041, DOI 10.1073/pnas.93.24.14041; MICHAELIS S, 1988, MOL CELL BIOL, V8, P1309, DOI 10.1128/MCB.8.3.1309; MORTENSEN R, 1999, CURRENT PROTOCOLS MO, V2; Nijbroek GL, 1998, METHOD ENZYMOL, V292, P193; Otto JC, 1999, J BIOL CHEM, V274, P8379, DOI 10.1074/jbc.274.13.8379; Ploger R, 2000, NUCLEIC ACIDS RES, V28, P120, DOI 10.1093/nar/28.1.120; POWERS S, 1986, CELL, V47, P413, DOI 10.1016/0092-8674(86)90598-2; Romano JD, 1998, MOL BIOL CELL, V9, P2231, DOI 10.1091/mbc.9.8.2231; SAPPERSTEIN S, 1994, MOL CELL BIOL, V14, P1438, DOI 10.1128/MCB.14.2.1438; Schmidt WK, 2000, J BIOL CHEM, V275, P6227, DOI 10.1074/jbc.275.9.6227; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Tam A, 1998, J CELL BIOL, V142, P635, DOI 10.1083/jcb.142.3.635; Trueblood CE, 2000, MOL CELL BIOL, V20, P4381, DOI 10.1128/MCB.20.12.4381-4392.2000	33	71	74	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29051	29058		10.1074/jbc.M102908200	http://dx.doi.org/10.1074/jbc.M102908200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11399759	hybrid			2022-12-25	WOS:000170346000057
J	Melman, L; Cao, ZF; Rennke, S; Marzolo, MP; Wardell, MR; Bu, GJ				Melman, L; Cao, ZF; Rennke, S; Marzolo, MP; Wardell, MR; Bu, GJ			High affinity binding of receptor-associated protein to heparin and low density lipoprotein receptor-related protein requires similar basic amino acid sequence motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEPHRITIS ANTIGENIC COMPLEX; PLASMINOGEN-ACTIVATOR INHIBITOR-1; HUMAN APOLIPOPROTEIN-E; RAT HEPATOMA-CELLS; 39-KDA PROTEIN; ALPHA-2-MACROGLOBULIN RECEPTOR; LIGAND-BINDING; SPECIALIZED CHAPERONE; MOLECULAR CHAPERONE; TERMINAL DOMAIN	The 39-kDa receptor-associated protein (RAP) is a specialized chaperone for members of the low density lipoprotein receptor gene family, which also binds heparin. Previous studies have identified a triplicate repeat sequence within RAP that appears to exhibit differential functions. Here we generated a series of truncated and site-directed RAP mutants in order to define the sites within RAP that are important for interacting with heparin and low density lipoprotein receptor-related protein (LRP). We found that high affinity binding of RAP to heparin is mediated by the carboxyl-terminal repeat of RAP, whereas both the carboxyl-terminal repeat and a combination of amino and central repeats exhibit high affinity binding to LRP. Several motifs were found to mediate the binding of RAP to heparin, and each contained a cluster of basic amino acids; among them, an intact (RVSRSREK289)-V-282-S-285-E-287 motif is required for high affinity binding of RAP to heparin, whereas two other motifs, (RLRR206)-L-203-R-205 and R(314)ISR(317)AR(319), also contribute to this interaction. We also found that intact motifs of both (RLPR206)-L-203-R-205 and (RVSRSREK289)-V-282-S-285-E-287 are required for high affinity binding of RAP to LRP, with the third motif, R(314)ISR(317)AR(319), contributing little to RAP-LRP interaction. We conclude that electrostatic interactions likely contribute significantly in the binding of RAP to both heparin and LRP and that high affinity interaction with both heparin and LRP appears to require mostly overlapping sequence motifs within RAP.	Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA; Univ Chile, Dept Biol, Santiago, Chile	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Universidad de Chile	Bu, GJ (corresponding author), Washington Univ, Sch Med, Dept Pediat, CB 8208,660 S Euclid Ave, St Louis, MO 63110 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059150, R01HL060617] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK056783] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL60617, HL59150] Funding Source: Medline; NIDDK NIH HHS [DK56783] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIEMESDERFER D, 1993, AM J PHYSIOL, V264, pF1011, DOI 10.1152/ajprenal.1993.264.6.F1011; Bu GJ, 1998, CURR OPIN LIPIDOL, V9, P149, DOI 10.1097/00041433-199804000-00012; BU GJ, 1992, J BIOL CHEM, V267, P15595; Bu GJ, 1997, J CELL SCI, V110, P65; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; Bu GJ, 1996, J BIOL CHEM, V271, P22218, DOI 10.1074/jbc.271.36.22218; BU GJ, 1994, J BIOL CHEM, V269, P29874; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; Ellgaard L, 1997, EUR J BIOCHEM, V244, P544, DOI 10.1111/j.1432-1033.1997.00544.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; Horn IR, 1998, THROMB HAEMOSTASIS, V80, P822; Huang W, 2000, J BIOL CHEM, V275, P1089, DOI 10.1074/jbc.275.2.1089; IADONATO SP, 1993, BIOCHEM J, V296, P867, DOI 10.1042/bj2960867; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Li YH, 1998, J CELL BIOCHEM, V71, P149, DOI 10.1002/(SICI)1097-4644(19981101)71:2<149::AID-JCB1>3.0.CO;2-V; MCKAY EJ, 1981, THROMB RES, V21, P375, DOI 10.1016/0049-3848(81)90138-9; Medved LV, 1999, J BIOL CHEM, V274, P717, DOI 10.1074/jbc.274.2.717; MENZEL HJ, 1983, ARTERIOSCLEROSIS, V3, P310, DOI 10.1161/01.ATV.3.4.310; Nielsen PR, 1997, P NATL ACAD SCI USA, V94, P7521, DOI 10.1073/pnas.94.14.7521; Obermoeller LM, 1997, J BIOL CHEM, V272, P10761; Obermoeller LM, 1998, J BIOL CHEM, V273, P22374, DOI 10.1074/jbc.273.35.22374; OLSON ST, 1991, J BIOL CHEM, V266, P6342; ORLANDO RA, 1994, P NATL ACAD SCI USA, V91, P3161, DOI 10.1073/pnas.91.8.3161; ORLANDO RA, 1992, P NATL ACAD SCI USA, V89, P6698, DOI 10.1073/pnas.89.15.6698; ORLANDO RA, 1993, P NATL ACAD SCI USA, V90, P4082, DOI 10.1073/pnas.90.9.4082; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; Rall SC, 1998, J BIOL CHEM, V273, P24152, DOI 10.1074/jbc.273.37.24152; SANT AJ, 1994, CURR OPIN IMMUNOL, V6, P57, DOI 10.1016/0952-7915(94)90034-5; Sato A, 1999, BIOCHEM J, V341, P377, DOI 10.1042/0264-6021:3410377; Savonen R, 1999, J BIOL CHEM, V274, P25877, DOI 10.1074/jbc.274.36.25877; SHELBURNE FA, 1977, J CLIN INVEST, V60, P944, DOI 10.1172/JCI108849; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; VASSILIOU G, 1994, J BIOL CHEM, V269, P15172; Wardell MR, 1997, BIOCHEMISTRY-US, V36, P13133, DOI 10.1021/bi970664u; WARSHAWSKY I, 1993, J BIOL CHEM, V268, P22046; WARSHAWSKY I, 1994, J BIOL CHEM, V269, P3325; WARSHAWSKY I, 1995, BIOCHEMISTRY-US, V34, P3404, DOI 10.1021/bi00010a032; WEISGRABER KH, 1986, J BIOL CHEM, V261, P2068; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; Willnow TE, 1996, EMBO J, V15, P2632, DOI 10.1002/j.1460-2075.1996.tb00623.x; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; WILLNOW TE, 1995, P NATL ACAD SCI USA, V92, P4537, DOI 10.1073/pnas.92.10.4537; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194	43	25	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29338	29346		10.1074/jbc.M103717200	http://dx.doi.org/10.1074/jbc.M103717200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11382778	hybrid			2022-12-25	WOS:000170346000094
J	Akagi, K; Nagao, T; Urushidani, T				Akagi, K; Nagao, T; Urushidani, T			Reconstitution of acid secretion in digitonin-permeabilized rabbit gastric glands - Identification of cytosolic regulatory factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL TRANSFER PROTEIN; PARIETAL-CELL; CA2+-ACTIVATED SECRETION; CHROMAFFIN CELLS; EXOCYTOSIS; ACTIVATION; KINASE; BRAIN; EXO2	When isolated rabbit gastric glands were permeabilized with digitonin, they lost their ability to secrete acid, as monitored by [C-14]aminopyrine accumulation, and they never recovered by supplement with cytosol prepared from gastric mucosa. However, the permeabilized glands elicited acid secretion when brain cytosol was supplemented. Fractionation of gastric cytosol by gel filtration revealed that the fraction at 30 kDa stimulated permeabilized glands by itself, whereas the 200-kDa fraction potently inhibited brain cytosol-stimulated acid secretion. Brain cytosol contained only the former stimulatory factor. With further gel filtration, the 30-kDa activator was separated into two components, 20 kDa (peak 1) and 1.8 kDa (peak 2), both of which are necessary for full activity. We purified peak 1 from bovine brain, and phosphatidylinositol transfer protein (PITP) was identified as the main component of the activity. The stimulating activity in brain and gastric mucosa correlated with the contents of PITP, and recombinant PITP mimicked the effect of peak 1, suggesting that PITP is one of the essential components in gastric acid secretion. When gastric glands were stimulated, the inhibitory activity, but not stimulatory activity, in the cytosol was increased. This suggests a regulatory mechanism such as stimulation translocates the inhibitory component from the secretory site on the membrane to cytosol. These results demonstrate a high degree of usefulness for our present model, the reconstituted digitonin-permeabilized gastric glands.	Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Pharmacol & Toxicol, Tokyo 1130033, Japan	University of Tokyo	Urushidani, T (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Pharmacol & Toxicol, Tokyo 1130033, Japan.	urushi@mol.f.u-tokyo.ac.jp						Akagi K, 1999, AM J PHYSIOL-GASTR L, V277, pG736, DOI 10.1152/ajpgi.1999.277.3.G736; BERGLINDH T, 1990, METHOD ENZYMOL, V192, P93; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; Duman JG, 1999, AM J PHYSIOL-CELL PH, V277, pC361, DOI 10.1152/ajpcell.1999.277.3.C361; Edwardson JM, 1997, CELL, V90, P325, DOI 10.1016/S0092-8674(00)80340-2; Fujita-Yoshigaki J, 1999, J BIOL CHEM, V274, P23642, DOI 10.1074/jbc.274.33.23642; Geppert M, 1998, ANNU REV NEUROSCI, V21, P75, DOI 10.1146/annurev.neuro.21.1.75; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; HERSEY SJ, 1985, AM J PHYSIOL, V248, pG561, DOI 10.1152/ajpgi.1985.248.5.G561; MALINOWSKA DH, 1995, AM J PHYSIOL-CELL PH, V268, pC191, DOI 10.1152/ajpcell.1995.268.1.C191; Miller MD, 1996, AM J PHYSIOL-GASTR L, V270, pG962, DOI 10.1152/ajpgi.1996.270.6.G962; MORGAN A, 1993, EMBO J, V12, P3747, DOI 10.1002/j.1460-2075.1993.tb06052.x; MORGAN A, 1992, NATURE, V355, P833, DOI 10.1038/355833a0; Muto Y, 2001, AM J PHYSIOL-CELL PH, V280, pC155, DOI 10.1152/ajpcell.2001.280.1.C155; OHASHI M, 1995, NATURE, V377, P544, DOI 10.1038/377544a0; OMI N, 2001, IN PRESS AM J PHYSL; PAYNE NA, 1990, METHOD ENZYMOL, V187, P505; TANAKA S, 1994, J BIOCHEM-TOKYO, V115, P981, DOI 10.1093/oxfordjournals.jbchem.a124448; THIBODEAU A, 1994, BIOCHEM CELL BIOL, V72, P26, DOI 10.1139/o94-005; THOMAS GMH, 1993, CELL, V74, P919, DOI 10.1016/0092-8674(93)90471-2; Urushidani T, 1997, AM J PHYSIOL-GASTR L, V272, pG1122, DOI 10.1152/ajpgi.1997.272.5.G1122; Urushidani T, 1997, J MEMBRANE BIOL, V159, P99, DOI 10.1007/s002329900274; URUSHIDANI T, 1989, AM J PHYSIOL, V256, pG1070, DOI 10.1152/ajpgi.1989.256.6.G1070; VONMOLLARD GF, 1994, TRENDS BIOCHEM SCI, V19, P164, DOI 10.1016/0968-0004(94)90278-X; WALENT JH, 1992, CELL, V70, P765, DOI 10.1016/0092-8674(92)90310-9; Wiedemann C, 1998, TRENDS ENDOCRIN MET, V9, P324, DOI 10.1016/S1043-2760(98)00080-0	27	9	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28171	28178		10.1074/jbc.M101190200	http://dx.doi.org/10.1074/jbc.M101190200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11384966	hybrid			2022-12-25	WOS:000170093400058
J	Ichai, C; Guignot, L; El-Mir, MY; Nogueira, V; Guigas, B; Chauvin, C; Fontaine, E; Mithieux, G; Leverve, XM				Ichai, C; Guignot, L; El-Mir, MY; Nogueira, V; Guigas, B; Chauvin, C; Fontaine, E; Mithieux, G; Leverve, XM			Glucose 6-phosphate hydrolysis is activated by glucagon in a low temperature-sensitive manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT HEPATOCYTES; LIVER PYRUVATE-KINASE; MICROSOMAL GLUCOSE-6-PHOSPHATASE; HEPATIC GLUCONEOGENESIS; GLYCEROL METABOLISM; GLYCOGEN-SYNTHESIS; HORMONAL-CONTROL; GENE-EXPRESSION; ADIPOSE-TISSUE; FASTED RATS	Glucagon affects liver glucose metabolism mainly by activating glycogen breakdown and by inhibiting pyruvate kinase, whereas a possible effect on glucose-6-phosphatase has also been suggested. Although such a target is of physiological importance for liver glucose production it was never proven. By using a model of liver cells, perifused. with dihydroxyacetone, we show here that the acute stimulation of gluconeogenesis by glucagon (10(-7) M) was not related to the significant inhibition of pyruvate kinase but to a dramatic activation of the hydrolysis of glucose 6-phosphate. We failed to find an acute change in glucose-6-phosphatase activity by glucagon, but the increase in glucose 6-phosphate hydrolysis was abolished at 21 degreesC; conversely the effect on pyruvate kinase was not affected by temperature. The activation of glucose 6-phosphate hydrolysis by glucagon was confirmed in vivo, in postabsorptive rats receiving a constant infusion of glucagon, by the combination of a 2-fold increase in hepatic glucose production and a 60% decrease in liver glucose 6-phosphate concentration. Besides the description of a novel effect of glucagon on glucose 6-phosphate hydrolysis by a temperature-sensitive mechanism, this finding could represent an important breakthrough in the understanding of type II diabetes, because glucose 6-phosphate is proposed to be a key molecule in the transcriptional effect of glucose.	Univ Grenoble 1, Lab Bioenerget Fondamentale & Appl, F-38041 Grenoble, France; Fac Med Laennec, INSERM, U449, F-69372 Lyon, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm)	Leverve, XM (corresponding author), Univ Grenoble 1, Lab Bioenerget Fondamentale & Appl, BP 53X, F-38041 Grenoble, France.	Xavier.Leverve@ujf-grenoble.fr	Fontaine, Eric/ABA-8853-2020; Guigas, Bruno/M-2515-2015	Fontaine, Eric/0000-0002-5204-9477; Guigas, Bruno/0000-0002-8856-5799; Gilles, Mithieux/0000-0003-3579-8529				Aiston S, 1999, J BIOL CHEM, V274, P24559, DOI 10.1074/jbc.274.35.24559; ARGAUD D, 1991, BIOCHEM J, V280, P663, DOI 10.1042/bj2800663; ARGAUD D, 1993, EUR J BIOCHEM, V213, P1341, DOI 10.1111/j.1432-1033.1993.tb17886.x; ARION WJ, 1980, J BIOL CHEM, V255, P396; BAQUET A, 1990, J BIOL CHEM, V265, P955; BEGLEY PJ, 1981, BIOCHEM BIOPH RES CO, V103, P1029, DOI 10.1016/0006-291X(81)90912-8; BERGMEYER HU, 1974, METHOD ENZYMAT AN, V4, P1196; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; BIRNBAUM MJ, 1977, J BIOL CHEM, V252, P528; BONTEMPS F, 1978, BIOCHEM J, V174, P603, DOI 10.1042/bj1740603; BRIVET M, 1983, PEDIATR RES, V17, P157, DOI 10.1203/00006450-198302000-00015; BURCHELL A, 1990, FASEB J, V4, P2978, DOI 10.1096/fasebj.4.12.2168325; CLARK MG, 1974, J BIOL CHEM, V249, P5695; CLAUS TH, 1981, BIOCHEM BIOPH RES CO, V100, P716, DOI 10.1016/S0006-291X(81)80234-3; CLAUS TH, 1979, J BIOL CHEM, V254, P7855; Daniele N, 1999, J BIOL CHEM, V274, P3597, DOI 10.1074/jbc.274.6.3597; Engstrom L, 1978, Curr Top Cell Regul, V13, P28; FELIU JE, 1976, P NATL ACAD SCI USA, V73, P2762, DOI 10.1073/pnas.73.8.2762; Ferre P, 1999, P NUTR SOC, V58, P621, DOI 10.1017/S0029665199000816; FOUFELLE F, 1992, J BIOL CHEM, V267, P20543; Foufelle F, 1996, ADV ENZYME REGUL, V36, P199, DOI 10.1016/0065-2571(95)00010-0; GROEN AK, 1983, J BIOL CHEM, V258, P4346; GROEN AK, 1986, BIOCHEM J, V237, P379, DOI 10.1042/bj2370379; GROEN AK, 1982, EUR J BIOCHEM, V122, P87, DOI 10.1111/j.1432-1033.1982.tb05851.x; Guignot L, 1999, AM J PHYSIOL-ENDOC M, V277, pE984, DOI 10.1152/ajpendo.1999.277.6.E984; Guillam MT, 1998, P NATL ACAD SCI USA, V95, P12317, DOI 10.1073/pnas.95.21.12317; Guillam MT, 1997, NAT GENET, V17, P327, DOI 10.1038/ng1197-327; HAYNES RC, 1990, ARCH BIOCHEM BIOPHYS, V283, P51, DOI 10.1016/0003-9861(90)90611-2; HERS HG, 1983, ANNU REV BIOCHEM, V52, P617, DOI 10.1146/annurev.bi.52.070183.003153; Keppler D., 1974, METHOD ENZYMAT AN, V3, P1127, DOI DOI 10.1242/JEB.037275; Lang G., 1974, METHODS ENZYMATIC AN, P1238; Leclercq P, 1997, BIOCHEM J, V325, P519, DOI 10.1042/bj3250519; LEVERVE XM, 1986, EUR J BIOCHEM, V155, P551, DOI 10.1111/j.1432-1033.1986.tb09523.x; LEVERVE XM, 1994, EUR J BIOCHEM, V224, P967, DOI 10.1111/j.1432-1033.1994.00967.x; LLORENTE P, 1970, EUR J BIOCHEM, V13, P45, DOI 10.1111/j.1432-1033.1970.tb00897.x; MINASSIAN C, 1995, J NUTR, V125, P2727; Minassian C, 1999, BBA-MOL CELL RES, V1452, P172, DOI 10.1016/S0167-4889(99)00130-5; Mithieux G, 1997, EUR J ENDOCRINOL, V136, P137, DOI 10.1530/eje.0.1360137; Mittelman SD, 1997, J CLIN INVEST, V100, P3121, DOI 10.1172/JCI119867; NILSSON OS, 1978, EUR J BIOCHEM, V82, P627, DOI 10.1111/j.1432-1033.1978.tb12059.x; Odievre M, 1966, Rev Int Hepatol, V16, P1; Paquot N, 1996, DIABETOLOGIA, V39, P580; PILKIS SJ, 1976, J BIOL CHEM, V251, P7841; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; Piquet MA, 1996, BIOCHEM J, V317, P667, DOI 10.1042/bj3170667; POLLARDKNIGHT D, 1987, BIOCHEM J, V245, P625, DOI 10.1042/bj2450625; RIOU JP, 1978, J BIOL CHEM, V253, P656; Santer R, 1997, NAT GENET, V17, P324, DOI 10.1038/ng1197-324; SPETH M, 1981, BIOCHEM BIOPH RES CO, V99, P134, DOI 10.1016/0006-291X(81)91723-X; SUTHERLAND EW, 1958, J BIOL CHEM, V232, P1077; THORENS B, 1990, AM J PHYSIOL, V259, P279; Trinh KY, 1998, J BIOL CHEM, V273, P31615, DOI 10.1074/jbc.273.47.31615; Unger R H, 1982, Compr Ther, V8, P53; UNGER RH, 1985, DIABETOLOGIA, V28, P574, DOI 10.1007/BF00281991; VANDERMEER R, 1976, FEBS LETT, V67, P36, DOI 10.1016/0014-5793(76)80865-4; VENEZIALE CM, 1972, BIOCHEMISTRY-US, V11, P3286, DOI 10.1021/bi00767a025; ZUURENDONK PF, 1974, BIOCHIM BIOPHYS ACTA, V333, P393, DOI 10.1016/0005-2728(74)90022-X	57	15	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28126	28133		10.1074/jbc.M010186200	http://dx.doi.org/10.1074/jbc.M010186200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11371550	Green Published, hybrid			2022-12-25	WOS:000170093400052
J	Sambasivarao, D; Dawson, HA; Zhang, GJ; Shaw, G; Hu, J; Weiner, JH				Sambasivarao, D; Dawson, HA; Zhang, GJ; Shaw, G; Hu, J; Weiner, JH			Investigation of Escherichia coli dimethyl sulfoxide reductase assembly and processing in strains defective for the sec-independent protein translocation system membrane targeting and translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; EXPORT PATHWAY; BACTERIA; YIDC; EXPRESSION; TRANSPORT; COMPONENT; SEQUENCE; CLUSTER; OPERON	Dimethyl sulfoxide reductase is a heterotrimeric enzyme (DmsABC) localized to the cytoplasmic surface of the inner membrane. Targeting of the DmsA and DmsB catalytic subunits to the membrane requires the membrane targeting and translocation (Mtt) system. The DmsAB dimer is a member of a family of extrinsic, cytoplasmic facing membrane subunits that require Mtt in order to assemble on the membrane. We show that the MttA(2), MttB, and presumably MttA(1) but not the MttC proteins are required for targeting DmsAB to the membrane. Unlike other Mtt substrates such as trimethylamine N-oxide reductase, the soluble cytoplasmic DmsAB dimer that accumulates in the mtt deletions is very labile. Deletion of the mttA(2) or mttB genes also prevents anaerobic growth on fumarate even though fumarate reductase does not require Mtt for assembly. This was due to the lethality of membrane insertion of DmsC in the absence of the DmsAB subunits, In the absence of DmsC, DmsAB accumulates in the cytoplasm, A 45-amino acid leader on DmsA is removed during assembly. Processing does not require DmsC but does require Mtt, Translocation of DmsAB to the periplasm is not required for processing. The leader may be cleaved by a novel leader peptidase, or the long DmsA leader may traverse the membrane through the Mtt system resulting in cleavage by the periplasmic leader peptidase I followed by release of DmsA into the cytoplasm.	Univ Alberta, Dept Biochem, CIHR Grp Mol Bol Membrane Prot, Edmonton, AB T6G 2H7, Canada	University of Alberta	Weiner, JH (corresponding author), Univ Alberta, Dept Biochem, CIHR Grp Mol Bol Membrane Prot, 473 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.	joel.weiner@ualberta.ca						Benoit S, 1998, J BACTERIOL, V180, P6625, DOI 10.1128/JB.180.24.6625-6634.1998; Berks BC, 2000, MOL MICROBIOL, V35, P260, DOI 10.1046/j.1365-2958.2000.01719.x; Berks BC, 2000, BBA-BIOENERGETICS, V1459, P325, DOI 10.1016/S0005-2728(00)00168-7; Berks BC, 1996, MOL MICROBIOL, V22, P393, DOI 10.1046/j.1365-2958.1996.00114.x; BILOUS PT, 1988, J BACTERIOL, V170, P1511, DOI 10.1128/jb.170.4.1511-1518.1988; BILOUS PT, 1988, MOL MICROBIOL, V2, P785, DOI 10.1111/j.1365-2958.1988.tb00090.x; Bogsch EG, 1998, J BIOL CHEM, V273, P18003, DOI 10.1074/jbc.273.29.18003; Cristobal S, 1999, EMBO J, V18, P2982, DOI 10.1093/emboj/18.11.2982; Hecker KH, 1996, BIOTECHNIQUES, V20, P478; Houben ENG, 2000, FEBS LETT, V476, P229, DOI 10.1016/S0014-5793(00)01735-X; Hynds PJ, 1998, J BIOL CHEM, V273, P34868, DOI 10.1074/jbc.273.52.34868; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; NEU HC, 1965, J BIOL CHEM, V240, P3685; NIVIERE V, 1992, J GEN MICROBIOL, V138, P2173, DOI 10.1099/00221287-138-10-2173; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; ROTHERY RA, 1993, BIOCHEMISTRY-US, V32, P5855, DOI 10.1021/bi00073a019; ROTHERY RA, 1991, BIOCHEMISTRY-US, V30, P8296, DOI 10.1021/bi00098a003; RUSSELL CB, 1989, J BACTERIOL, V171, P2609, DOI 10.1128/jb.171.5.2609-2613.1989; SAMBASIVARAO D, 1991, CURR MICROBIOL, V23, P105, DOI 10.1007/BF02092258; SAMBASIVARAO D, 1991, J BACTERIOL, V173, P5935, DOI 10.1128/jb.173.19.5935-5943.1991; SAMBASIVARAO D, 1990, J BACTERIOL, V172, P5938, DOI 10.1128/jb.172.10.5938-5948.1990; Sambasivarao D, 2000, J BIOL CHEM, V275, P22526, DOI 10.1074/jbc.M909289199; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Samuelson JC, 2000, NATURE, V406, P637, DOI 10.1038/35020586; SANDERS C, 2000, EBEC SHORT REPORTS, V11, P266; Santini CL, 1998, EMBO J, V17, P101, DOI 10.1093/emboj/17.1.101; Sargent F, 1998, EMBO J, V17, P3640, DOI 10.1093/emboj/17.13.3640; Sargent F, 1999, J BIOL CHEM, V274, P36073, DOI 10.1074/jbc.274.51.36073; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Scotti PA, 2000, EMBO J, V19, P542, DOI 10.1093/emboj/19.4.542; Settles AM, 1998, TRENDS CELL BIOL, V8, P494, DOI 10.1016/S0962-8924(98)01387-7; Stanley NR, 2000, J BIOL CHEM, V275, P11591, DOI 10.1074/jbc.275.16.11591; Stanley NR, 2001, J BACTERIOL, V183, P139, DOI 10.1128/JB.183.1.139-144.2001; Thorstenson YR, 1997, J BACTERIOL, V179, P5333, DOI 10.1128/jb.179.17.5333-5339.1997; Turner RJ, 1997, PROTEIN ENG, V10, P285, DOI 10.1093/protein/10.3.285; van de Pas BA, 1999, J BIOL CHEM, V274, P20287, DOI 10.1074/jbc.274.29.20287; Weiner JH, 1998, CELL, V93, P93, DOI 10.1016/S0092-8674(00)81149-6; Wexler M, 2000, J BIOL CHEM, V275, P16717, DOI 10.1074/jbc.M000800200; Wu LF, 2000, J MOL MICROB BIOTECH, V2, P179	40	30	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20167	20174		10.1074/jbc.M010369200	http://dx.doi.org/10.1074/jbc.M010369200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11389150	hybrid			2022-12-25	WOS:000169135100067
J	Gao, TY; Toker, A; Newton, AC				Gao, TY; Toker, A; Newton, AC			The carboxyl terminus of protein kinase C provides a switch to regulate its interaction with the phosphoinositide-dependent kinase, PDK-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN-KINASE-1; CATALYTIC SUBUNIT; DUAL ROLE; IN-VIVO; PHOSPHORYLATION; ACTIVATION; DOMAIN; SITE; AUTOPHOSPHORYLATION; PHOSPHATIDYLSERINE	The function of protein kinase C family members depends on two tightly coupled phosphorylation mechanisms: phosphorylation of the activation loop by the phosphoinositide-dependent kinase, PDK-1, followed by autophosphorylation at two positions in the COOH terminus, the turn motif, and the hydrophobic motif, Here we address the molecular mechanisms underlying the regulation of protein kinase C PII by PDK-1, Co-immunoprecipitation studies reveal that PDK-1 associates preferentially with its substrate, unphosphorylated protein kinase C, by a direct mechanism. The exposed COOH terminus of protein kinase C provides the primary interaction site for PDK-1, with co-expression of constructs of the carboxyl terminus effectively disrupting the interaction in vivo, Disruption of this interaction promotes the autophosphorylation of protein kinase C, suggesting that the binding of PDK-1 to the carboxyl terminus protects it from autophosphorylation, Studies with constructs of the COOH terminus reveal that the intrinsic affinity of PDK-1 for phosphorylated COOH terminus is over an order of magnitude greater than that for unphosphorylated COOH terminus, contrasting with the finding that PDK-1 does not bind phosphorylated protein kinase C effectively. However, effective binding of the phosphorylated species can be induced by the activated conformation of protein kinase C, This suggests that the carboxyl terminus becomes masked following autophosphorylation, a process that can be reversed by the conformational changes accompanying activation, Our data suggest a model in which PDK-1 provides two points of regulation of protein kinase C: 1) phosphorylation of the activation loop, which is regulated by the intrinsic activity of PDK-1, and 2) phosphorylation of the carboxyl terminus, which is regulated by the release of PDK-1 to allow autophosphorylation.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Pathol, Boston, MA 02215 USA	University of California System; University of California San Diego; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Newton, AC (corresponding author), Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.				NATIONAL CANCER INSTITUTE [R01CA075134] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK054441] Funding Source: NIH RePORTER; NCI NIH HHS [CA75134] Funding Source: Medline; NIDDK NIH HHS [P01 DK54441] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Andjelkovic M, 1999, MOL CELL BIOL, V19, P5061; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Behn-Krappa A, 1999, CURR BIOL, V9, P728, DOI 10.1016/S0960-9822(99)80332-7; Biondi RM, 2000, EMBO J, V19, P979, DOI 10.1093/emboj/19.5.979; Bornancin F, 1996, CURR BIOL, V6, P1114, DOI 10.1016/S0960-9822(02)70678-7; Bornancin F, 1997, J BIOL CHEM, V272, P3544, DOI 10.1074/jbc.272.6.3544; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Dutil EM, 2000, J BIOL CHEM, V275, P10697, DOI 10.1074/jbc.275.14.10697; DUTIL EM, 1994, J BIOL CHEM, V269, P29359; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Edwards AS, 1997, J BIOL CHEM, V272, P18382, DOI 10.1074/jbc.272.29.18382; Edwards AS, 1999, J BIOL CHEM, V274, P6461, DOI 10.1074/jbc.274.10.6461; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; Johnson JE, 2000, BIOCHEMISTRY-US, V39, P11360, DOI 10.1021/bi000902c; Johnson LN, 1996, CURR OPIN STRUC BIOL, V6, P762, DOI 10.1016/S0959-440X(96)80005-4; Keranen LM, 1997, J BIOL CHEM, V272, P25959, DOI 10.1074/jbc.272.41.25959; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; ORR JW, 1994, J BIOL CHEM, V269, P27715; ORR JW, 1994, J BIOL CHEM, V269, P8383; ORR JW, 1992, J BIOL CHEM, V267, P15263; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Sweatt JD, 1998, J NEUROCHEM, V71, P1075; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Toker A, 2000, MOL PHARMACOL, V57, P652, DOI 10.1124/mol.57.4.652; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; YONEMOTO W, 1993, J BIOL CHEM, V268, P2348; Ziegler WH, 1999, CURR BIOL, V9, P522, DOI 10.1016/S0960-9822(99)80236-X	36	82	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19588	19596		10.1074/jbc.M101357200	http://dx.doi.org/10.1074/jbc.M101357200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11376011	hybrid			2022-12-25	WOS:000169091000123
J	Klocke, R; Bartels, T; Jennings, G; Brand, K; Halter, R; Strauss, M; Paul, D				Klocke, R; Bartels, T; Jennings, G; Brand, K; Halter, R; Strauss, M; Paul, D			Lack of p53 accelerates hepatocarcinogenesis in transgenic mice constitutively overexpressing c-myc in the liver	FASEB JOURNAL			English	Article						p53; hepatocellular carcinoma; c-myc; apoptosis; cell proliferation	GROWTH-FACTOR-ALPHA; HEPATOCELLULAR-CARCINOMA; IN-VIVO; P53-DEPENDENT APOPTOSIS; TUMOR PROGRESSION; DNA-BINDING; CELL-LINES; MOUSE; MUTATION; GENE	The role of the tumor suppressor function of p53 in the process of hepatocellular carcinoma (HCC) development is still enigmatic in view of uncertainties with respect to the phenotype of most p53 mutations found in human HCCs. We therefore analyzed the effect of the p53 knockout (p53KO) genotype, which imparts a clear-cut loss of function, on hepatocarcinogenesis in livers of transgenic mice prone to develop this tumor type. Deterministic HCC formation in mice overexpressing transgenes encoding murine c-myc, or c-myc plus the secretable human epidermal growth factor (EGF) analogue IgEGF, in the liver was accelerated in the p53KO background as indicated by enhanced relative liver weights and reduced survival times of mice. In contrast, HCC formation was not affected by lack of p53 in IgEGF transgenics. Because p53KO mice are not HCC prone, lack of p53 contributed to hepatocarcinogenesis during progression provided that c-myc was overexpressed in the liver. Thus, deterministic HCC development occurs not simply because of the accumulation of genetic changes in individual hepatocytes; the order in which these changes occur also determines the propensity for liver neoplasia. Enhanced proliferation of hepatocytes was accompanied by markedly reduced p21. levels in tumorous livers of c-myc/IgEGF/p53KO mice. Concomitantly with unaltered p53-independent apoptotic activities, it caused enhanced hyperplasia and accelerated HCC development in livers enlarged fivefold, which killed the mice at 1.9 months of age.	Fraunhofer Inst Toxicol & Aerosol Res, Dept Cell Biol, D-30625 Hannover, Germany; Free Univ Berlin, Inst Vet Pathol, D-14163 Berlin, Germany; HepaVec AG Gentherapie, D-13125 Berlin, Germany; Humboldt Univ, Max Delbruck Ctr Mol Med, Mol Cell Biol Grp, D-13122 Berlin, Germany	Fraunhofer Gesellschaft; Free University of Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Humboldt University of Berlin	Klocke, R (corresponding author), Ingenium Pharmaceut AG, Fraunhoferstr 13, D-82152 Martinsried, Germany.	rainer.klocke@ingenium-ag.com	Jennings, Garry/B-3914-2009					Baxi MK, 1996, VIRUS RES, V40, P33, DOI 10.1016/0168-1702(95)01255-9; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Donehower LA, 1996, BBA-REV CANCER, V1242, P171, DOI 10.1016/0304-419X(95)00013-6; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUMENCO L, 1995, HEPATOLOGY, V22, P1279, DOI 10.1016/0270-9139(95)90640-1; ELSON A, 1995, ONCOGENE, V11, P181; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; Feitelson MA, 1997, AM J PATHOL, V150, P1141; FRITH CH, 1979, J ENVIRON PATHOL TOX, V3, P329; FRITH CH, 1994, PATHOLOGY TUMORS LAB, V2, P223; GAN FY, 1993, J HISTOCHEM CYTOCHEM, V41, P1185, DOI 10.1177/41.8.7687263; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Ghebranious N, 1998, HEPATOLOGY, V27, P967, DOI 10.1002/hep.510270411; GHEBRANIOUS N, 1995, MOL CARCINOGEN, V13, P104, DOI 10.1002/mc.2940130207; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; HOWES KA, 1994, GENE DEV, V8, P1738; Hui AM, 1997, HEPATOLOGY, V25, P575, DOI 10.1002/hep.510250314; Jones JM, 1997, CELL GROWTH DIFFER, V8, P829; KEMP CJ, 1995, MOL CARCINOGEN, V12, P132, DOI 10.1002/mc.2940120304; KOOPMAN P, 1989, GENE DEV, V3, P16, DOI 10.1101/gad.3.1.16; KRESS S, 1992, MOL CARCINOGEN, V6, P148, DOI 10.1002/mc.2940060210; Kubicka S, 1997, HEPATOLOGY, V25, P867, DOI 10.1002/hep.510250414; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Loyer P, 1996, J BIOL CHEM, V271, P11484, DOI 10.1074/jbc.271.19.11484; McCormack SJ, 1998, ONCOGENE, V16, P2755, DOI 10.1038/sj.onc.1201804; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MIYASHITA T, 1995, CELL, V80, P293; NISHIDA N, 1993, CANCER RES, V53, P368; PONCHEL F, 1994, CANCER RES, V54, P2064; Santoni-Rugiu E, 1998, CANCER RES, V58, P123; SCHAFF Z, 1994, HUM PATHOL, V25, P644, DOI 10.1016/0046-8177(94)90296-8; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TANAKA S, 1993, CANCER RES, V53, P2884; TILGHMAN SM, 1982, P NATL ACAD SCI-BIOL, V79, P5254, DOI 10.1073/pnas.79.17.5254; TONJES RR, 1995, ONCOGENE, V10, P765; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; Ulrich RG, 1998, CELL BIOCHEM FUNCT, V16, P77; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	41	8	9	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR 27	2001	15	6					1404	+		10.1096/fj.00-0487fje	http://dx.doi.org/10.1096/fj.00-0487fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387238				2022-12-25	WOS:000173705800030
J	Smith, SM; Khoroshev, M; Marx, PA; Orenstein, J; Jeang, KT				Smith, SM; Khoroshev, M; Marx, PA; Orenstein, J; Jeang, KT			Constitutively dead, conditionally live, HIV-1 genomes - Ex vivo implications for a live virus vaccine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LONG TERMINAL REPEAT; NEF GENE; TYPE-1 REPLICATION; MAMMALIAN-CELLS; ATTENUATED SIV; TAT PROTEIN; IN-VIVO; TRANSCRIPTION; INFECTION	An effective vaccine against AIDS is unlikely to be available for many years. As we approach two decades since the first identification of human immunodeficiency virus, type 1 (HIV-1), currently, only one subunit vaccine candidate has reached phase 3 of clinical trials. The subunit approach has been criticized for its inability to elicit effectively cytotoxic T-lymphocyte (CTL) response, which is felt by many to be needed for protection against HIV-1 infection. In subhuman primates, a live attenuated simian immunodeficiency virus (SIV) vaccine candidate, capable of inducing CTL, has been found to confer prophylactic immunity sufficient to prevent simian AIDS. Because replication competent (live) attenuated viruses could over time revert to virulence, such a live attenuated approach has largely been dismissed for HIV-1. Here, we describe the creation of constitutively dead conditionally live (CDCL) HIV-1 genomes. These genomes are constitutively defective for the Tat/TAR axis and are conditionally dependent on tetracycline for attenuated replication with robust expression of viral antigens. Our results suggest that CDCL genomes merit consideration as safer "live" attenuated HIV-1 vaccine candidates.	NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, St Michaels Med Ctr, Newark, NJ 07102 USA; Tulane Reg Primate Res Ctr, Covington, LA 70433 USA; Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA; George Washington Univ, Sch Med, Dept Pathol, Washington, DC 20037 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Rutgers State University New Brunswick; Rutgers State University Medical Center; Tulane University; Rockefeller University; George Washington University	Jeang, KT (corresponding author), NIAID, Mol Microbiol Lab, NIH, Bldg 4,Rm 306,900 Rockville Pike, Bethesda, MD 20892 USA.		Jeang, Kuan-Teh/A-2424-2008; Smith, Stephen/GQQ-5975-2022	Smith, Stephen/0000-0002-9158-6136	NIAID NIH HHS [AI46316-02] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000547, ZIAAI000547, R21AI046316] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALMOND N, 1995, LANCET, V345, P1342, DOI 10.1016/S0140-6736(95)92540-6; Altman LK, 1998, NY TIMES; Baba TW, 1999, NAT MED, V5, P194, DOI 10.1038/5557; BABA TW, 1995, SCIENCE, V267, P1820, DOI 10.1126/science.7892606; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BERKHOUT B, 1992, J VIROL, V66, P139, DOI 10.1128/JVI.66.1.139-149.1992; Berkhout B, 1999, J VIROL, V73, P1138, DOI 10.1128/JVI.73.2.1138-1145.1999; Cafaro A, 1999, NAT MED, V5, P643, DOI 10.1038/9488; Chakrabarti BK, 1996, P NATL ACAD SCI USA, V93, P9810, DOI 10.1073/pnas.93.18.9810; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; Connor RI, 1998, J VIROL, V72, P7501, DOI 10.1128/JVI.72.9.7501-7509.1998; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; Das AT, 1998, J VIROL, V72, P9217, DOI 10.1128/JVI.72.11.9217-9223.1998; DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Guan YJ, 2000, J VIROL, V74, P8854, DOI 10.1128/JVI.74.19.8854-8860.2000; Harrich D, 1996, J VIROL, V70, P4017, DOI 10.1128/JVI.70.6.4017-4027.1996; Hennecke J, 2001, CELL, V104, P1, DOI 10.1016/S0092-8674(01)00185-4; HUANG LM, 1994, EMBO J, V13, P2886, DOI 10.1002/j.1460-2075.1994.tb06583.x; *INT AIDS VACC IN, 2000, AIDS VACC WORLD PREP; *INT AIDS VACC IN, 2000, IAVA SCI BLUEPR 2000; Jeang KT, 1999, J BIOL CHEM, V274, P28837, DOI 10.1074/jbc.274.41.28837; JEANG KT, 1993, J VIROL, V67, P6224, DOI 10.1128/JVI.67.10.6224-6233.1993; JEANG KT, 1993, J BIOL CHEM, V268, P24940; Johnson RP, 1996, CURR OPIN IMMUNOL, V8, P554, DOI 10.1016/S0952-7915(96)80046-X; Kelly JK, 1996, J THEOR BIOL, V180, P359, DOI 10.1006/jtbi.1996.0108; KIMPTON J, 1992, J VIROL, V66, P2232, DOI 10.1128/JVI.66.4.2232-2239.1992; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; Klasens BIF, 1999, BBA-GENE STRUCT EXPR, V1444, P355, DOI 10.1016/S0167-4781(99)00011-1; Learmont JC, 1999, NEW ENGL J MED, V340, P1715, DOI 10.1056/NEJM199906033402203; Liang C, 2000, J VIROL, V74, P6251, DOI 10.1128/JVI.74.14.6251-6261.2000; Liljeqvist S, 1999, J BIOTECHNOL, V73, P1, DOI 10.1016/S0168-1656(99)00107-8; MILLER MD, 1994, J EXP MED, V179, P101, DOI 10.1084/jem.179.1.101; Nathanson N, 2000, J INFECT DIS, V182, P579, DOI 10.1086/315707; Quinto I, 1999, J BIOL CHEM, V274, P17567, DOI 10.1074/jbc.274.25.17567; Salvi R, 1998, J VIROL, V72, P3646, DOI 10.1128/JVI.72.5.3646-3657.1998; Smith SM, 1996, P NATL ACAD SCI USA, V93, P7955, DOI 10.1073/pnas.93.15.7955; SPINA CA, 1994, J EXP MED, V179, P115, DOI 10.1084/jem.179.1.115; Verhoef K, 2001, J VIROL, V75, P979, DOI 10.1128/JVI.75.2.979-987.2001; Wyand MS, 1996, J VIROL, V70, P3724, DOI 10.1128/JVI.70.6.3724-3733.1996; 1997, J AM MED ASS, V277, P525	42	31	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32184	32190		10.1074/jbc.M101604200	http://dx.doi.org/10.1074/jbc.M101604200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11397795	hybrid			2022-12-25	WOS:000170613500097
J	Lavigne, M; Polomack, L; Buc, H				Lavigne, M; Polomack, L; Buc, H			DNA synthesis by HIV-1 reverse transcriptase at the central termination site - A kinetic study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROOVE BINDING TRACK; VERTICAL-SCANNING MUTAGENESIS; MINOR-GROOVE; CRITICAL TRYPTOPHAN; SECONDARY STRUCTURE; COMPLEX-FORMATION; THUMB SUBDOMAIN; INITIATION; MECHANISM; GENOME	Human immunodeficiency virus, type 1 (HIV-1) reverse transcriptase (RT) terminates plus-strand DNA synthesis at the center of the HIV-1 genome, a process important for HIV-1 infectivity. The central termination sequence contains two termination sites (Ter1 and Ter2) located at the 3 ' -end of A(n)T(m) motifs, and the narrowing of the DNA minor groove generated by these motifs is responsible for termination. Kinetic data associated with the binding of RT and its ability to elongate in vitro various DNA duplexes and triplexes surrounding the Ter2 terminator were analyzed using a simple kinetic scheme. At Ter2, RT still displays a reasonable affinity for the corresponding DNA, but the binding of the next nucleotide and above all its incorporation rate are markedly hampered. Features affecting the width of the minor groove act directly at this last step. The constraint exerted against elongation by the A(n)T(m). tract persists at two positions downstream of the terminator.	Inst Pasteur, Unite Physicochim Macromol Biol, URA1773, CNRS, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Lavigne, M (corresponding author), Massachusetts Gen Hosp, Dept Mol Biol, Wellman 10,Fruit St, Boston, MA 02114 USA.			LAVIGNE, Marc/0000-0002-3131-2539				Beard WA, 1998, J BIOL CHEM, V273, P30435, DOI 10.1074/jbc.273.46.30435; Beard WA, 1996, J BIOL CHEM, V271, P12213, DOI 10.1074/jbc.271.21.12213; BEARD WA, 1994, J BIOL CHEM, V269, P28091; BEBENEK K, 1995, J BIOL CHEM, V270, P19516, DOI 10.1074/jbc.270.33.19516; Bebenek K, 1997, NAT STRUCT BIOL, V4, P194, DOI 10.1038/nsb0397-194; BUC H, 1985, BIOCHEMISTRY-US, V24, P2712, DOI 10.1021/bi00332a018; CHARNEAU P, 1994, J MOL BIOL, V241, P651, DOI 10.1006/jmbi.1994.1542; Forgacs E, 1997, J BIOL CHEM, V272, P8525, DOI 10.1074/jbc.272.13.8525; Furge LL, 1999, BIOCHEMISTRY-US, V38, P4818, DOI 10.1021/bi982163u; HSIEH JC, 1993, J BIOL CHEM, V268, P24607; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Huang HF, 2000, CHEM BIOL, V7, P355, DOI 10.1016/S1074-5521(00)00113-7; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; KATI WM, 1992, J BIOL CHEM, V267, P25988; Lanchy JM, 1998, J BIOL CHEM, V273, P24425, DOI 10.1074/jbc.273.38.24425; Lanchy JM, 1996, EMBO J, V15, P7178, DOI 10.1002/j.1460-2075.1996.tb01109.x; LATHAM GJ, 1994, J BIOL CHEM, V269, P28527; Latham GJ, 2000, J BIOL CHEM, V275, P15025, DOI 10.1074/jbc.M000279200; Lavigne M, 1997, J MOL BIOL, V266, P507, DOI 10.1006/jmbi.1996.0805; Lavigne M, 2001, J BIOL CHEM, V276, P31439, DOI 10.1074/jbc.M102976200; Lavigne M, 1999, J MOL BIOL, V285, P977, DOI 10.1006/jmbi.1998.2367; MCCLURE WR, 1980, P NATL ACAD SCI-BIOL, V77, P5634, DOI 10.1073/pnas.77.10.5634; REARDON JE, 1993, J BIOL CHEM, V268, P8743; RITTINGER K, 1995, P NATL ACAD SCI USA, V92, P8046, DOI 10.1073/pnas.92.17.8046; Stetor SR, 1999, BIOCHEMISTRY-US, V38, P3656, DOI 10.1021/bi982764l; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P12459, DOI 10.1021/bi971217h; Suo ZC, 1999, BIOCHEMISTRY-US, V38, P715, DOI 10.1021/bi981854n; Suo ZC, 1998, J BIOL CHEM, V273, P27259, DOI 10.1074/jbc.273.42.27259; Thrall SH, 1998, BIOCHEMISTRY-US, V37, P13349; Tong WJ, 1997, BIOCHEMISTRY-US, V36, P5749, DOI 10.1021/bi962410z; UNGE T, 1990, AIDS RES HUM RETROV, V6, P1297, DOI 10.1089/aid.1990.6.1297; Wohrl BM, 1999, J MOL BIOL, V292, P333, DOI 10.1006/jmbi.1999.3057; Zennou V, 2000, CELL, V101, P173, DOI 10.1016/S0092-8674(00)80828-4	33	4	4	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31429	31438		10.1074/jbc.M102974200	http://dx.doi.org/10.1074/jbc.M102974200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11402036	hybrid			2022-12-25	WOS:000170472900109
J	Brenkman, AB; Heideman, MR; Truniger, V; Salas, M; van der Vliet, PC				Brenkman, AB; Heideman, MR; Truniger, V; Salas, M; van der Vliet, PC			The (I/Y)XGG motif of adenovirus DNA polymerase affects template DNA binding and the transition from initiation to elongation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKER-INSERTION MUTAGENESIS; TERMINAL PROTEIN-PRECURSOR; EXONUCLEASE ACTIVE-SITE; CRYSTAL-STRUCTURE; MUTATIONAL ANALYSIS; REPLICATION INVITRO; FUNCTIONAL DOMAINS; CONSERVED REGION; BACK MECHANISM; ALPHA	Adenovirus DNA polymerase (Ad poI) is a eukaryotic-type DNA polymerase involved in the catalysis of protein-primed initiation as well as DNA polymerization. The functional significance of the (I/Y)XGG motif, highly conserved among eukaryotic-type DNA polymerases, was analyzed in Ad pol by site-directed mutagenesis of four conserved amino acids. All mutant polymerases could bind primer-template DNA efficiently but were impaired in binding duplex DNA. Three mutant polymerases. required higher nucleotide concentrations for effective polymerization and showed higher exonuclease activity on double-stranded DNA. These observations suggest a local destabilization of DNA substrate at the polymerase active site. In agreement with this, the mutant polymerases showed reduced initiation activity and increased K-m(app) for the initiating nucleotide, dCMP. Interestingly, one mutant polymerase, while capable of elongating on the primer-template DNA, failed to elongate after protein priming. Further investigation of this mutant polymerase showed that polymerization activity decreased after each polymerization step and ceased completely after formation of the precursor terminal protein-trinucleotide (pTP-CAT) initiation intermediate. Our results suggest that residues in the conserved motif (I/Y)XGG in Ad pol are involved in binding the template strand in the polymerase active site and play an important role in the transition from initiation to elongation.	Univ Med Ctr, Dept Physiol Chem, Utrecht, Netherlands; Ctr Biomed Genet, Utrecht, Netherlands; Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Utrecht University; Utrecht University Medical Center; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	van der Vliet, PC (corresponding author), Universiteitsweg 100,POB 85060, NL-3508 AB Utrecht, Netherlands.	p.c.vandervliet@med.uu.nl	Truniger, Veronica/H-3554-2011; Salas, Margarita/J-9873-2014	Truniger, Veronica/0000-0001-8221-2434; Salas, Margarita/0000-0001-5939-3441	NIGMS NIH HHS [2RO1 GM27242-21] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027242] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEESE LS, 1993, BIOCHEMISTRY-US, V32, P14095, DOI 10.1021/bi00214a004; BERNAD A, 1989, CELL, V59, P219, DOI 10.1016/0092-8674(89)90883-0; BLANCO L, 1991, GENE, V100, P27, DOI 10.1016/0378-1119(91)90346-D; Blanco L, 1995, METHOD ENZYMOL, V262, P283; BLANCO L, 1992, GENE, V112, P139, DOI 10.1016/0378-1119(92)90316-H; BLASCO MA, 1995, J BIOL CHEM, V270, P2735, DOI 10.1074/jbc.270.6.2735; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; CHEN M, 1989, P NATL ACAD SCI USA, V86, P6116, DOI 10.1073/pnas.86.16.6116; COENJAERTS FEJ, 1994, EMBO J, V13, P5401, DOI 10.1002/j.1460-2075.1994.tb06875.x; Coenjaerts FEJ, 1995, METHOD ENZYMOL, V262, P548; Copeland WC, 1995, METHOD ENZYMOL, V262, P294; de Jong RN, 1999, GENE, V236, P1, DOI 10.1016/S0378-1119(99)00249-8; Dekker J, 1997, EMBO J, V16, P1455, DOI 10.1093/emboj/16.6.1455; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DOBBS L, 1990, VIROLOGY, V178, P43, DOI 10.1016/0042-6822(90)90377-4; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Dufour E, 2000, J MOL BIOL, V304, P289, DOI 10.1006/jmbi.2000.4216; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; HARRIS MPG, 1988, J MOL BIOL, V201, P57, DOI 10.1016/0022-2836(88)90438-X; HAY RT, 1996, ADENOVIRUS DNA REPLI; Hopfner KP, 1999, P NATL ACAD SCI USA, V96, P3600, DOI 10.1073/pnas.96.7.3600; HWANG CBC, 1992, J VIROL, V66, P1774, DOI 10.1128/JVI.66.3.1774-1776.1992; ITO J, 1991, NUCLEIC ACIDS RES, V19, P4045, DOI 10.1093/nar/19.15.4045; JOUNG I, 1992, J VIROL, V66, P5788, DOI 10.1128/JVI.66.10.5788-5796.1992; JOUNG I, 1991, VIROLOGY, V184, P235, DOI 10.1016/0042-6822(91)90840-8; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; King AJ, 1997, NUCLEIC ACIDS RES, V25, P1745, DOI 10.1093/nar/25.9.1745; KING AJ, 1994, EMBO J, V13, P5786, DOI 10.1002/j.1460-2075.1994.tb06917.x; King AJ, 1997, J BIOL CHEM, V272, P24617, DOI 10.1074/jbc.272.39.24617; LARDER BA, 1987, EMBO J, V6, P169, DOI 10.1002/j.1460-2075.1987.tb04735.x; Liu HT, 2000, J VIROL, V74, P11681, DOI 10.1128/JVI.74.24.11681-11689.2000; MENDEZ J, 1992, P NATL ACAD SCI USA, V89, P9579, DOI 10.1073/pnas.89.20.9579; MUL YM, 1993, NUCLEIC ACIDS RES, V21, P641, DOI 10.1093/nar/21.3.641; NAGATA K, 1983, P NATL ACAD SCI-BIOL, V80, P4266, DOI 10.1073/pnas.80.14.4266; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12742, DOI 10.1021/bi952955d; RehaKrantz LJ, 1995, METHOD ENZYMOL, V262, P323; Rodriguez AC, 2000, J MOL BIOL, V299, P447, DOI 10.1006/jmbi.2000.3728; ROOVERS DJ, 1991, VIROLOGY, V180, P273, DOI 10.1016/0042-6822(91)90032-7; ROOVERS DJ, 1993, J VIROL, V67, P265, DOI 10.1128/JVI.67.1.265-276.1993; SALAS M, 1991, ANNU REV BIOCHEM, V60, P39, DOI 10.1146/annurev.bi.60.070191.000351; Steitz TA, 1999, J BIOL CHEM, V274, P17395, DOI 10.1074/jbc.274.25.17395; STUNNENBERG HG, 1988, NUCLEIC ACIDS RES, V16, P2431, DOI 10.1093/nar/16.6.2431; SUSSENBACH JS, 1983, CURR TOP MICROBIOL, V109, P53; TEMPERLEY SM, 1992, EMBO J, V11, P761, DOI 10.1002/j.1460-2075.1992.tb05109.x; Truniger V, 1999, J MOL BIOL, V286, P57, DOI 10.1006/jmbi.1998.2477; Truniger V, 1996, EMBO J, V15, P3430, DOI 10.1002/j.1460-2075.1996.tb00709.x; Wang J, 1997, CELL, V89, P1087, DOI 10.1016/S0092-8674(00)80296-2; WONG SW, 1988, EMBO J, V7, P37, DOI 10.1002/j.1460-2075.1988.tb02781.x	48	14	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29846	29853		10.1074/jbc.M103159200	http://dx.doi.org/10.1074/jbc.M103159200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11390396	hybrid			2022-12-25	WOS:000170558000034
J	Bulteau, AL; Lundberg, KC; Humphries, KM; Sadek, HA; Szweda, PA; Friguet, B; Szweda, LI				Bulteau, AL; Lundberg, KC; Humphries, KM; Sadek, HA; Szweda, PA; Friguet, B; Szweda, LI			Oxidative modification and inactivation of the proteasome during coronary occlusion/reperfusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKED PROTEIN; KAPPA-B-ALPHA; 26S PROTEASOME; REPERFUSION INJURY; MULTICATALYTIC PROTEASE; OXYGEN RADICALS; DEGRADATION; STRESS; GLUCOSE-6-PHOSPHATE-DEHYDROGENASE; PATHWAY	Restoration of blood flow to ischemic myocardial tissue results in an increase in the production of oxygen radicals. Highly reactive, free radical species have the potential to damage cellular components. Clearly, maintenance of cellular viability is dependent, in part, on the removal of altered protein. The proteasome is a major intracellular proteolytic system which degrades oxidized and ubiquitinated forms of protein. Utilizing an in vivo rat model, we demonstrate that coronary occlusion/reperfusion resulted in declines in chymotrypsin-like, peptidylglutamyl-peptide hydrolase, and trypsin-like activities of the proteasome as assayed in cytosolic extracts. Analysis of purified 20 S proteasome revealed that declines in peptidase activities were accompanied by oxidative modification of the protein. We provide conclusive evidence that, upon coronary occlusion/reperfusion, the lipid peroxidation product 4-hydroxy-2-nonenal selectively modifies 20 S proteasome a-like subunits iota, C3, and an isoform of XAPC7. Occlusion/reperfusion-induced declines in trypsin-like activity were largely preserved upon proteasome purification. In contrast, loss in chymotrypsin-like and peptidylglutamyl-peptide hydrolase activities observed in cytosolic extracts were not evident upon purification. Thus, decreases in proteasome activity are likely due to both direct oxidative modification of the enzyme and inhibition of fluorogenic peptide hydrolysis by endogenous cytosolic inhibitory protein(s) and/or substrate(s). Along with inhibition of the proteasome, increases in cytosolic levels of oxidized and ubiquitinated protein(s) were observed. Taken together, our findings provide insight into potential mechanisms of coronary occlusion/reperfusion-induced proteasome inactivation and cellular consequences of these events.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Univ Paris 07, Dept Biochem, F-75251 Paris 05, France; Univ Paris 07, Dept Biol, F-75251 Paris 05, France	Case Western Reserve University; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Szweda, LI (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA.		bulteau, anne-laure/AAN-4004-2020	Friguet, Bertrand/0000-0001-8085-1961; Humphries, Kenneth/0000-0002-6167-3175	NIA NIH HHS [AG-16339] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG016339] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; AMBROSIO G, 1993, J BIOL CHEM, V268, P18532; AMBROSIO G, 1991, J CLIN INVEST, V87, P2056, DOI 10.1172/JCI115236; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; BLASIG IE, 1995, AM J PHYSIOL-HEART C, V269, pH14, DOI 10.1152/ajpheart.1995.269.1.H14; Bochtler M, 1999, ANNU REV BIOPH BIOM, V28, P295, DOI 10.1146/annurev.biophys.28.1.295; Bolli R, 1999, PHYSIOL REV, V79, P609, DOI 10.1152/physrev.1999.79.2.609; Breitschopf K, 2000, J BIOL CHEM, V275, P21648, DOI 10.1074/jbc.M001083200; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Conconi M, 1998, BIOCHEM J, V333, P407, DOI 10.1042/bj3330407; Conconi M, 1997, MOL BIOL REP, V24, P45, DOI 10.1023/A:1006852506884; Conconi M, 1996, ARCH BIOCHEM BIOPHYS, V331, P232, DOI 10.1006/abbi.1996.0303; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DAS DK, 1989, BIOCHEM BIOPH RES CO, V165, P1004, DOI 10.1016/0006-291X(89)92702-2; DAVIES KJA, 1987, J BIOL CHEM, V262, P8227; DeMartino GN, 1999, J BIOL CHEM, V274, P22123, DOI 10.1074/jbc.274.32.22123; Eble DM, 1999, CELL TISSUE RES, V296, P541, DOI 10.1007/s004410051315; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Ferrari R, 1996, J CARDIOVASC PHARM, V28, pS1; FRIGUET B, 1994, ARCH BIOCHEM BIOPHYS, V311, P168, DOI 10.1006/abbi.1994.1222; Friguet B, 1997, FEBS LETT, V405, P21, DOI 10.1016/S0014-5793(97)00148-8; FRIGUET B, 1994, J BIOL CHEM, V269, P21639; Grune T, 1997, FASEB J, V11, P526, DOI 10.1096/fasebj.11.7.9212076; Haynes RL, 2000, MOL PHARMACOL, V58, P788, DOI 10.1124/mol.58.4.788; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HOUGH R, 1987, J BIOL CHEM, V262, P8303; Humphries KM, 1998, BIOCHEMISTRY-US, V37, P15835, DOI 10.1021/bi981512h; Keller JN, 2000, J CEREBR BLOOD F MET, V20, P1467, DOI 10.1097/00004647-200010000-00008; KRAMER JH, 1994, ANN NY ACAD SCI, V723, P180, DOI 10.1111/j.1749-6632.1994.tb36725.x; LAING JG, 1995, J BIOL CHEM, V270, P26399, DOI 10.1074/jbc.270.44.26399; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; Li BY, 2000, P NATL ACAD SCI USA, V97, P3850, DOI 10.1073/pnas.070047997; Okada K, 1999, J BIOL CHEM, V274, P23787, DOI 10.1074/jbc.274.34.23787; PACIFICI RE, 1993, J BIOL CHEM, V268, P15405; Powers SK, 1998, AM J PHYSIOL-REG I, V275, pR1468, DOI 10.1152/ajpregu.1998.275.5.R1468; REIMER KA, 1992, HEART CARDIOVASCULAR, P1875; Reinheckel T, 1998, BIOCHEM J, V335, P637, DOI 10.1042/bj3350637; Reinheckel T, 2000, ARCH BIOCHEM BIOPHYS, V377, P65, DOI 10.1006/abbi.2000.1717; RIVETT AJ, 1994, METHOD ENZYMOL, V244, P331; RIVETT AJ, 1985, J BIOL CHEM, V260, P300; Sitte N, 2000, FASEB J, V14, P1490, DOI 10.1096/fj.14.11.1490; Sitte N, 2000, FASEB J, V14, P2495, DOI 10.1096/fj.00-0209com; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; SZWEDA LI, 1993, J BIOL CHEM, V268, P3342; SZWEDA LI, 1993, ARCH BIOCHEM BIOPHYS, V301, P391, DOI 10.1006/abbi.1993.1161; Tanaka K, 1997, MOL BIOL REP, V24, P3, DOI 10.1023/A:1006876904158; UCHIDA K, 1993, P NATL ACAD SCI USA, V90, P8742, DOI 10.1073/pnas.90.18.8742; UCHIDA K, 1993, J BIOL CHEM, V268, P6388; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; ZWEIER JL, 1988, J BIOL CHEM, V263, P1353	51	309	317	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30057	30063		10.1074/jbc.M100142200	http://dx.doi.org/10.1074/jbc.M100142200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11375979	hybrid			2022-12-25	WOS:000170558000061
J	Koumoto, Y; Shimada, T; Kondo, M; Hara-Nishimura, I; Nishimura, M				Koumoto, Y; Shimada, T; Kondo, M; Hara-Nishimura, I; Nishimura, M			Chloroplasts have a novel Cpn10 in addition to Cpn20 as co-chaperonins in Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; IN-VIVO; GROES; IDENTIFICATION; 2.8-ANGSTROM; SENESCENCE; SEQUENCE; PROTEINS; COMPLEX	Previously, we characterized a mitochondrial co-chaperonin (Cpn10) and a chloroplast co-chaperonin (Cpn20) from Arabidopsis thaliana (Koumoto, Y., Tsugeki, R., Shimada, T., Mori, H, Kondo, M, Hara-Nishimura, I, and Nishimura, M. (1996) Plant J.. 10, 1119-1125; Koumoto, Y., Shimada, T., Kondo, M., Taka, T., Shimonishi, Y., Hara-Nishimura, I, and Nishimura, M (1999) Plant J. 17, 467-477). Here, we report a third co-chaperonin. The cDNA was 603 base pairs long, encoding a protein of 139 amino acids. From a sequence analysis, the protein was predicted to have one Cpn10 domain with an amino-terminal extension that might work as a chloroplast transit peptide. This novel Cpn10 was confirmed to be localized in chloroplasts, and we refer to it as chloroplast Cpn10 (chI-Cpn10). The phylogenic tree that was generated with amino acid sequences of other co-chaperonins indicates that chl-Cpn10 is highly divergent from the others. In the GroEL-assisted protein folding assay,. about 30% of the substrates were refolded with chI-Cpn10. indicating that chI-Cpn10 works as a co-chaperonin. A Northern blot analysis revealed that mRNA for chI-Cpn10 is accumulated in the leaves and stems, but not in the roots. In germinating cotyledons, the accumulation of chI-Cpn10 was similar to that of chloroplastic proteins and accelerated by light. It was proposed that two kinds of co-chaperonins, Cpn20 and chI-Cpn10, work independently in the chloroplast.	Natl Inst Basic Biol, Dept Cell Biol, Okazaki, Aichi 4448585, Japan; Kyoto Univ, Grad Sch Sci, Dept Bot, Kyoto 6068502, Japan	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Kyoto University	Nishimura, M (corresponding author), Natl Inst Basic Biol, Dept Cell Biol, Okazaki, Aichi 4448585, Japan.	mikosome@nibb.ac.jp		Nishimura, Mikio/0000-0001-7960-9721				BANEYX F, 1995, J BIOL CHEM, V270, P10695, DOI 10.1074/jbc.270.18.10695; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BERTSCH U, 1992, P NATL ACAD SCI USA, V89, P8696, DOI 10.1073/pnas.89.18.8696; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; Braig K, 1998, CURR OPIN STRUC BIOL, V8, P159, DOI 10.1016/S0959-440X(98)80033-X; Chen LL, 1999, CELL, V99, P757, DOI 10.1016/S0092-8674(00)81673-6; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Dickson R, 2000, J BIOL CHEM, V275, P11829, DOI 10.1074/jbc.275.16.11829; Dubaquie Y, 1998, EMBO J, V17, P5868, DOI 10.1093/emboj/17.20.5868; Ewalt KL, 1997, CELL, V90, P491, DOI 10.1016/S0092-8674(00)80509-7; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; Hirohashi T, 1999, BBA-PROTEIN STRUCT M, V1429, P512, DOI 10.1016/S0167-4838(98)00268-4; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; Hunt JF, 1997, CELL, V90, P361, DOI 10.1016/S0092-8674(00)80343-8; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; JOFUKU KD, 1994, PLANT CELL, V6, P1211, DOI 10.1105/tpc.6.9.1211; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Kinoshita T, 1999, PLANT J, V19, P43, DOI 10.1046/j.1365-313X.1999.00497.x; Koumoto Y, 1999, PLANT J, V17, P467, DOI 10.1046/j.1365-313X.1999.00388.x; Koumoto Y, 1996, PLANT J, V10, P1119, DOI 10.1046/j.1365-313X.1996.10061119.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lowenstein JM, 1969, METHOD ENZYMOL, P3, DOI [10.1016/0076-6879(69)13005-0, DOI 10.1016/0076-6879(69)13005-0]; NISHIMURA M, 1993, PROTOPLASMA, V175, P131, DOI 10.1007/BF01385011; Nishio K, 1999, BIOCHEM BIOPH RES CO, V266, P584, DOI 10.1006/bbrc.1999.1868; Peltier JB, 2000, PLANT CELL, V12, P319, DOI 10.1105/tpc.12.3.319; Schlicher T, 1996, FEBS LETT, V379, P302, DOI 10.1016/0014-5793(95)01534-5; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944	29	38	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29688	29694		10.1074/jbc.M102330200	http://dx.doi.org/10.1074/jbc.M102330200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11402030	hybrid			2022-12-25	WOS:000170558000014
J	Li, Y; Takagi, Y; Jiang, YW; Tokunaga, M; Erdjument-Bromage, H; Tempst, P; Kornberg, RD				Li, Y; Takagi, Y; Jiang, YW; Tokunaga, M; Erdjument-Bromage, H; Tempst, P; Kornberg, RD			A multiprotein complex that interacts with RNA polymerase II elongator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE ACETYLTRANSFERASE; SACCHAROMYCES-CEREVISIAE; IN-VIVO; HOLOENZYME; TRANSCRIPTION; PROTEIN; COACTIVATORS; SUBUNIT	A three-subunit Hap complex that interacts with the RNA polymerase If Elongator was isolated fi-om yeast. Deletions of genes for two Hap subunits, HAP1 and HAP3, confer pGKL killer-insensitive and weak Elongator phenotypes. Preferential interaction of the Hap complex with free rather than RNA polymerase II-associated Elongator suggests a role in the regulation of Elongator activity.	Stanford Univ, Dept Biol Struct, Sch Med, Stanford, CA 94305 USA; Texas A&M Univ, Dept Med Biochem & Genet, Hlth Sci Ctr, College Stn, TX 77843 USA; Kagoshima Univ, Fac Agr, Kagoshima 8900065, Japan; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	Stanford University; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Kagoshima University; Memorial Sloan Kettering Cancer Center	Li, Y (corresponding author), Tularik Inc, 2 Corp Dr, San Francisco, CA 94080 USA.	yli@tularik.com		Erdjument-Bromage, Hediye/0000-0003-0224-3594; Tempst, Paul/0000-0002-6680-3987	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036659, R37GM036659] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM36659] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Cairns BR, 1996, GENE DEV, V10, P2131, DOI 10.1101/gad.10.17.2131; Cho H, 1998, MOL CELL BIOL, V18, P5355, DOI 10.1128/MCB.18.9.5355; Dou YL, 2000, MOL CELL, V6, P225, DOI 10.1016/S1097-2765(00)00024-1; Erdjument-Bromage H, 1998, J CHROMATOGR A, V826, P167, DOI 10.1016/S0021-9673(98)00705-5; Fellows J, 2000, J BIOL CHEM, V275, P12896, DOI 10.1074/jbc.275.17.12896; Kishida M, 1996, BIOSCI BIOTECH BIOCH, V60, P798, DOI 10.1271/bbb.60.798; Li Y, 1996, METHOD ENZYMOL, V273, P172; LI Y, 1995, P NATL ACAD SCI USA, V92, P10864, DOI 10.1073/pnas.92.24.10864; LUE NF, 1991, METHOD ENZYMOL, V194, P545; Lui M, 1996, ANAL BIOCHEM, V241, P156, DOI 10.1006/abio.1996.0393; MANN M, 1993, BIOL MASS SPECTROM, V22, P338, DOI 10.1002/bms.1200220605; Otero G, 1999, MOL CELL, V3, P109, DOI 10.1016/S1097-2765(00)80179-3; Stallcup MR, 2000, BIOCHEM SOC T, V28, P415, DOI 10.1042/0300-5127:0280415; Struhl K, 1999, CELL, V98, P1, DOI 10.1016/S0092-8674(00)80599-1; Svejstrup JQ, 1997, P NATL ACAD SCI USA, V94, P6075, DOI 10.1073/pnas.94.12.6075; Travers A, 1999, P NATL ACAD SCI USA, V96, P13634, DOI 10.1073/pnas.96.24.13634; Wittschieben BO, 2000, EMBO J, V19, P3060, DOI 10.1093/emboj/19.12.3060; Wittschieben BO, 1999, MOL CELL, V4, P123, DOI 10.1016/S1097-2765(00)80194-X; Yajima H, 1997, BIOSCI BIOTECH BIOCH, V61, P704, DOI 10.1271/bbb.61.704	21	56	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29628	29631		10.1074/jbc.C100274200	http://dx.doi.org/10.1074/jbc.C100274200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11390369	hybrid			2022-12-25	WOS:000170558000006
J	Sloper-Mould, KE; Jemc, JC; Pickart, CM; Hicke, L				Sloper-Mould, KE; Jemc, JC; Pickart, CM; Hicke, L			Distinct functional surface regions on ubiquitin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-FACTOR RECEPTOR; MULTIUBIQUITIN CHAIN; ACTIVATING ENZYME; SACCHAROMYCES-CEREVISIAE; POLYUBIQUITIN CHAIN; CONJUGATING ENZYME; YEAST; ENDOCYTOSIS; PROTEIN; SIGNAL	The characterized functions of the highly conserved polypeptide ubiquitin are to target proteins for proteasome degradation or endocytosis. The formation of a polyubiquitin chain of at least four units is required for efficient proteasome binding. By contrast, monoubiquitin serves as a signal for the endocytosis of plasma membrane proteins. We have defined surface residues that are important for ubiquitin's vital functions in Saccharomyces cerevisiae. Surprisingly, alanine scanning mutagenesis showed that only 16 of ubiquitin's 63 surface residues are essential for vegetative growth in yeast. Most of the essential residues localize to two hydrophobic clusters that participate in proteasome recognition and/or endocytosis. The others reside in or near the tail region, which is important for conjugation and deubiquitination. We also demonstrate that the essential residues comprise two distinct functional surfaces: residues surrounding Phe(4) are required for endocytosis, whereas residues surrounding Ile(14) are required for both endocytosis and proteasome degradation.	Johns Hopkins Univ, Sch Publ Hlth, Dept Biochem & Mol Biol, Baltimore, MD 21205 USA; Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	Johns Hopkins University; Northwestern University	Pickart, CM (corresponding author), Johns Hopkins Univ, Sch Publ Hlth, Dept Biochem & Mol Biol, 315 N Wolfe St, Baltimore, MD 21205 USA.	cpickart@welchlink.welch.jhu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053257, R01DK046984] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46984, DK53257] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; Baboshina OV, 1996, J BIOL CHEM, V271, P2823, DOI 10.1074/jbc.271.5.2823; Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; Beal RE, 1998, BIOCHEMISTRY-US, V37, P2925, DOI 10.1021/bi972514p; BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; BURCH TJ, 1994, BIOCHEMISTRY-US, V33, P7300, DOI 10.1021/bi00189a035; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; DUERKSENHUGHES PJ, 1987, BIOCHEMISTRY-US, V26, P6980, DOI 10.1021/bi00396a019; DULIC V, 1991, METHOD ENZYMOL, V194, P697; ECKER DJ, 1987, J BIOL CHEM, V262, P14213; ECKER DJ, 1987, J BIOL CHEM, V262, P3524; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GREGORI L, 1990, J BIOL CHEM, V265, P8354; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; HODGINS RRW, 1992, J BIOL CHEM, V267, P8807; Johnston SC, 1999, EMBO J, V18, P3877, DOI 10.1093/emboj/18.14.3877; Khorasanizadeh S, 1996, NAT STRUCT BIOL, V3, P193, DOI 10.1038/nsb0296-193; Lam YA, 1997, J BIOL CHEM, V272, P28438, DOI 10.1074/jbc.272.45.28438; Lemmon SK, 2000, CURR OPIN CELL BIOL, V12, P457, DOI 10.1016/S0955-0674(00)00117-4; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; Nakatsu F, 2000, J BIOL CHEM, V275, P26213, DOI 10.1074/jbc.M907720199; Overton MC, 2000, CURR BIOL, V10, P341, DOI 10.1016/S0960-9822(00)00386-9; Patnaik A, 2000, P NATL ACAD SCI USA, V97, P13069, DOI 10.1073/pnas.97.24.13069; Pham AD, 2000, SCIENCE, V289, P2357, DOI 10.1126/science.289.5488.2357; PICKART CM, 1994, J BIOL CHEM, V269, P7115; Piotrowski J, 1997, J BIOL CHEM, V272, P23712, DOI 10.1074/jbc.272.38.23712; RENEKE JE, 1988, CELL, V55, P221, DOI 10.1016/0092-8674(88)90045-1; Robzyk K, 2000, SCIENCE, V287, P501, DOI 10.1126/science.287.5452.501; Roth AF, 2000, J BIOL CHEM, V275, P8143, DOI 10.1074/jbc.275.11.8143; Roth AF, 1996, J CELL BIOL, V134, P661, DOI 10.1083/jcb.134.3.661; Rotin D, 2000, J MEMBRANE BIOL, V176, P1; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Schubert U, 2000, P NATL ACAD SCI USA, V97, P13057, DOI 10.1073/pnas.97.24.13057; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Shih SC, 2000, EMBO J, V19, P187, DOI 10.1093/emboj/19.2.187; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; Spence J, 2000, CELL, V102, P67, DOI 10.1016/S0092-8674(00)00011-8; Strack B, 2000, P NATL ACAD SCI USA, V97, P13063, DOI 10.1073/pnas.97.24.13063; Strous GJ, 1999, J CELL SCI, V112, P1417; Terrell J, 1998, MOL CELL, V1, P193, DOI 10.1016/S1097-2765(00)80020-9; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; VIJAYKUMAR S, 1985, P NATL ACAD SCI USA, V82, P3582, DOI 10.1073/pnas.82.11.3582; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6; Wesp A, 1997, MOL BIOL CELL, V8, P2291, DOI 10.1091/mbc.8.11.2291; Whitby FG, 1998, J BIOL CHEM, V273, P34983, DOI 10.1074/jbc.273.52.34983; WILKINSON KD, 1995, BIOCHEMISTRY-US, V34, P14535, DOI 10.1021/bi00044a032; Yao TT, 2000, J BIOL CHEM, V275, P36862, DOI 10.1074/jbc.M006050200; Yesilaltay A, 2000, MOL BIOL CELL, V11, P2873, DOI 10.1091/mbc.11.9.2873	54	192	194	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30483	30489		10.1074/jbc.M103248200	http://dx.doi.org/10.1074/jbc.M103248200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11399765	hybrid			2022-12-25	WOS:000170558000115
J	Dai, ZH; Kerzic, P; Schroeder, WG; McNiece, IK				Dai, ZH; Kerzic, P; Schroeder, WG; McNiece, IK			Deletion of the Src homology 3 domain and C-terminal proline-rich sequences in Bcr-Abl prevents Abl interactor 2 degradation and spontaneous cell migration and impairs leukemogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; ADAPTER PROTEIN CRKL; TYROSINE KINASE; BINDING-PROTEIN; MYELOPROLIFERATIVE DISEASE; PHILADELPHIA-CHROMOSOME; TRANSFORMING ACTIVITY; MICE; GROWTH; GENE	The hematopoietic cells from patients with Ber-Abl-positive chronic myelogenous leukemia exhibit multiple abnormalities of cytoskeletal function. The molecular events leading to these abnormalities are not fully understood. Previously we showed that Bcr-Abl elicits ubiquitin-dependent degradation of Abl. interactor proteins. Because recent studies have suggested a role of Abl interactor proteins in the pathway that regulates cytoskeletal function, we investigated whether mutations in Ber-Abl that interfere with the signaling to Abl interactor proteins affect its leukemogenic activity. We report here that the Src homology 3 domain and C-terminal proline-rich sequences of Bcr-Abl are required for its binding to Abl interactor 2 as well as for the induction of Abl interactor 2 degradation. Although the deletion of these regions did not affect the ability of the mutant Bcr-Abl to transform hematopoietic cells to growth factor independence, it abrogated its ability to stimulate spontaneous cell migration on fibronectin-coated surfaces. Furthermore, the mutant Bcr-Abl, defective in binding to Abl interactor 2 and inducing its degradation, failed to induce chronic myelogenous leukemia-like disease in mouse. These results are consistent with a role of Abl interactor proteins in the regulation of cytoskeletal function as well as in the pathogenesis of Bcr-Abl-induced leukemogenesis.	Univ Colorado, Hlth Sci Ctr, Bone Marrow Transplant Program, Expt Hematol Lab, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Dai, ZH (corresponding author), Univ Colorado, Hlth Sci Ctr, Bone Marrow Transplant Program, Expt Hematol Lab, Box B116,4200 E 9th Ave, Denver, CO 80262 USA.	zonghan.dai@uchsc.edu						Afar DEH, 1997, IMMUNITY, V6, P773, DOI 10.1016/S1074-7613(00)80452-5; Bhat A, 1997, J BIOL CHEM, V272, P16170, DOI 10.1074/jbc.272.26.16170; Biesova Z, 1997, ONCOGENE, V14, P233, DOI 10.1038/sj.onc.1200822; BRADLEY TR, 1978, J CELL PHYSIOL, V97, P517, DOI 10.1002/jcp.1040970327; Clarkson BD, 1997, LEUKEMIA, V11, P1404, DOI 10.1038/sj.leu.2400751; Cortez D, 1996, ONCOGENE, V13, P2589; Courtney KD, 2000, MOL CELL NEUROSCI, V16, P244, DOI 10.1006/mcne.2000.0865; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; Dai ZH, 1998, GENE DEV, V12, P1415, DOI 10.1101/gad.12.10.1415; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Fan PD, 2000, MOL CELL BIOL, V20, P7591, DOI 10.1128/MCB.20.20.7591-7601.2000; Gotoh A, 1997, Curr Opin Hematol, V4, P3; Gross AW, 1999, MOL CELL BIOL, V19, P6918; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HARLOW E, 1999, USING ANTIBODIES LAB, P74; Heaney C, 1997, BLOOD, V89, P297, DOI 10.1182/blood.V89.1.297.297_297_306; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; Huettner CS, 2000, NAT GENET, V24, P57, DOI 10.1038/71691; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; Raitano A. B., 1997, BIOCHIM BIOPHYS ACTA, V1333, P201, DOI 10.1016/S0304-419X(97)00023-1; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; Salgia R, 1997, J CLIN INVEST, V100, P46, DOI 10.1172/JCI119520; Salgia R, 1999, BLOOD, V94, P4233; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; Sattler M, 1998, LEUKEMIA, V12, P637, DOI 10.1038/sj.leu.2401010; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Scita G, 1999, NATURE, V401, P290, DOI 10.1038/45822; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; Skorski T, 1998, P NATL ACAD SCI USA, V95, P11858, DOI 10.1073/pnas.95.20.11858; Uemura N, 1999, J BIOL CHEM, V274, P37525, DOI 10.1074/jbc.274.53.37525; VAN AL, 1997, GENE DEV, V11, P2295; Wang BL, 1996, ONCOGENE, V12, P1921; Wen ST, 1997, GENE DEV, V11, P2456, DOI 10.1101/gad.11.19.2456; YAN XQ, 1995, BLOOD, V86, P4025, DOI 10.1182/blood.V86.11.4025.bloodjournal86114025; Zhang XW, 1998, BLOOD, V92, P3829, DOI 10.1182/blood.V92.10.3829; Ziemnicka-Kotula D, 1998, J BIOL CHEM, V273, P13681, DOI 10.1074/jbc.273.22.13681	42	31	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28954	28960		10.1074/jbc.M101170200	http://dx.doi.org/10.1074/jbc.M101170200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11387320	hybrid			2022-12-25	WOS:000170346000044
J	Dhar, SK; Delmolino, L; Dutta, A				Dhar, SK; Delmolino, L; Dutta, A			Architecture of the human origin recognition complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION; YEAST ORIGIN; PROTEINS; IDENTIFICATION; HOMOLOG; SUBUNIT; XENOPUS; MEMBER; CELLS; ORC5L	All the human homologs of the six subunits of Saccharomyces cerevisiae origin recognition complex have been reported so far. However, not much has been reported on the nature and the characteristics of the human origin recognition complex. In an attempt to purify recombinant human ORC from insect cells infected with baculoviruses expressing HsORC subunits, we found that human ORC2, -3, -4, and -5 form a core complex. HsORC1 and HsORC6 subunits did not enter into this core complex, suggesting that the interaction of these two subunits with the core ORC2-5 complex is extremely labile. We found that the C-terminal region of ORC2 interacts directly with the N-terminal region of ORC3. The C-terminal region of ORC3 was, however, necessary to bring ORC4 and ORC5 into the core complex. A fragment containing the N-terminal 200 residues of ORC3 (ORC3N) competitively inhibited the ORC2-ORC3 interaction. Overexpression of this fragment in U2OS cells blocked the cells in G(1), providing the first evidence that a mammalian ORC subunit is important for the G(1)-S transition in mammalian cells.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Dutta, A (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.		Dutta, Anindya/P-3203-2016	Dutta, Anindya/0000-0002-4319-0073	NATIONAL CANCER INSTITUTE [R01CA060499] Funding Source: NIH RePORTER; NCI NIH HHS [CA60499] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Austin RJ, 1999, GENE DEV, V13, P2639, DOI 10.1101/gad.13.20.2639; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Chesnokov I, 1999, GENE DEV, V13, P1289, DOI 10.1101/gad.13.10.1289; Dhar SK, 2000, J BIOL CHEM, V275, P34983, DOI 10.1074/jbc.M006069200; Dunn M J, 1994, Methods Mol Biol, V32, P113; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; GOSSEN M, 1995, SCIENCE, V270, P1674, DOI 10.1126/science.270.5242.1674; Ishiai M, 1997, GENOMICS, V46, P294, DOI 10.1006/geno.1997.5003; Kelly TJ, 2000, ANNU REV BIOCHEM, V69, P829, DOI 10.1146/annurev.biochem.69.1.829; Kreitz S, 2001, J BIOL CHEM, V276, P6337, DOI 10.1074/jbc.M009473200; Lee DG, 1997, MOL CELL BIOL, V17, P7159, DOI 10.1128/MCB.17.12.7159; Lin YL, 1996, J BIOL CHEM, V271, P17190, DOI 10.1074/jbc.271.29.17190; Moon KY, 1999, P NATL ACAD SCI USA, V96, P12367, DOI 10.1073/pnas.96.22.12367; Natale DA, 2000, EMBO J, V19, P2728, DOI 10.1093/emboj/19.11.2728; Pinto S, 1999, NEURON, V23, P45, DOI 10.1016/S0896-6273(00)80752-7; Quintana DG, 1997, J BIOL CHEM, V272, P28247, DOI 10.1074/jbc.272.45.28247; Quintana DG, 1998, J BIOL CHEM, V273, P27137, DOI 10.1074/jbc.273.42.27137; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; Takahara K, 1996, GENOMICS, V31, P119, DOI 10.1006/geno.1996.0018; Thome KC, 2000, J BIOL CHEM, V275, P35233, DOI 10.1074/jbc.M005765200; Tugal T, 1998, J BIOL CHEM, V273, P32421, DOI 10.1074/jbc.273.49.32421	22	87	87	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29067	29071		10.1074/jbc.M103078200	http://dx.doi.org/10.1074/jbc.M103078200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11395502	hybrid			2022-12-25	WOS:000170346000059
J	Reith, MEA; Berfield, JL; Wang, LC; Ferrer, JV; Javitch, JA				Reith, MEA; Berfield, JL; Wang, LC; Ferrer, JV; Javitch, JA			The uptake inhibitors cocaine and benztropine differentially alter the conformation of the human dopamine transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ETHYLMALEIMIDE-INDUCED REDUCTION; N-ETHYLMALEIMIDE; NEURONAL CARRIER; BINDING DOMAINS; H-3 MAZINDOL; <H-3>WIN-35,428 BINDING; UPTAKE SITES; ACCESSIBILITY; GBR-12783; WIN-35,428	The binding affinity of the cocaine analog [H-3]2 beta -carbomethoxy-3 beta-(4-fluorophenyl) tropane (WIN) for the dopamine transporter (DAT) is increased by the reaction of Cys-90, at the extracellular end of the first transmembrane segment, with methanethiosulfonate (NITS) reagents. Cocaine enhances the reaction of Cys-90 with the sulfhydryl reagents, thereby augmenting the increase in binding. In contrast, cocaine decreases the reaction of Cys-135 and Cys-342, endogenous cysteines in cytoplasmic loops, with NITS reagents. Because this reaction inhibits [H-3]WIN binding, cocaine protects against the loss of binding caused by reaction of these cysteines. In the present work, we compare the abilities of DAT inhibitors and substrates to affect the reaction of Cys-90, Cys-135, and Cys-342 with MTS ethyltrimethyl-ammonium (MTSET). The results indicate that the different abilities of compounds to protect against the MTSET-induced inhibition of binding are attributable to differences in their abilities to attenuate the inhibitory effects of modification of Cys-135 and Cys-342 as well as to enhance the reaction with Cys-90 and the resulting potentiation of binding. The inhibitor benztropine was unique in its inability to protect Cys-135. Moreover, whereas cocaine, WIN, mazindol, and dopamine enhanced the reaction of Cys-90 with MTSET, benztropine had no effect on this reaction. These two features combine to give benztropine its weak potency in protecting ligand binding to wild-type DAT from MTSET. These results indicate that different inhibitors of DAT, such as cocaine and benztropine, produce different conformational changes in the transporter. There are differences in the psychomotor stimulant-like effects of these compounds, and it is possible that the different behavioral effects of these DAT inhibitors stem from their different molecular actions on DAT.	Univ Illinois, Coll Med, Dept Biomed & Therapeut Sci, Peoria, IL 61656 USA; Columbia Univ Coll Phys & Surg, Ctr Mol Recognit, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA	University of Illinois System; University of Illinois Peoria; Columbia University; Columbia University; Columbia University	Reith, MEA (corresponding author), Univ Illinois, Coll Med, Dept Biomed & Therapeut Sci, Box 1649, Peoria, IL 61656 USA.		Reith, Maarten E./AAD-2303-2019; Reith, Maarten E/A-4601-2008	Reith, Maarten E./0000-0002-1900-842X; Javitch, Jonathan/0000-0001-7395-2967	NIDA NIH HHS [DA 08379, DA 11495] Funding Source: Medline; NIGMS NIH HHS [GMH 57324] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA008379, R01DA011495] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Acri JB, 1996, J PHARMACOL EXP THER, V277, P198; Berfield JL, 1999, J BIOL CHEM, V274, P4876, DOI 10.1074/jbc.274.8.4876; BONNET JJ, 1990, J PHARMACOL EXP THER, V253, P1206; CALLIGARO DO, 1988, MEMBRANE BIOCHEM, V7, P87, DOI 10.3109/09687688709039986; Cao YW, 1998, J NEUROSCI, V18, P7739; Chen JG, 2000, P NATL ACAD SCI USA, V97, P1044, DOI 10.1073/pnas.97.3.1044; Chen NH, 2000, J BIOL CHEM, V275, P1608, DOI 10.1074/jbc.275.3.1608; Do-Rego JC, 1999, J NEUROCHEM, V72, P396, DOI 10.1046/j.1471-4159.1999.0720396.x; Dwoskin L. P., 1996, Society for Neuroscience Abstracts, V22, P1576; Eshleman AJ, 1997, J NEUROCHEM, V69, P1459; Ferrer JV, 1998, P NATL ACAD SCI USA, V95, P9238, DOI 10.1073/pnas.95.16.9238; GIROS B, 1994, J BIOL CHEM, V269, P15985; HERON C, 1994, EUR J PHARMACOL, V264, P391, DOI 10.1016/0014-2999(94)00502-8; Itokawa M, 2000, MOL PHARMACOL, V57, P1093; IVERSEN LL, 1971, BRIT J PHARMACOL, V41, P571, DOI 10.1111/j.1476-5381.1971.tb07066.x; JAVITCH JA, 1984, MOL PHARMACOL, V26, P35; JOHNSON KM, 1992, EUR J PHARM-MOLEC PH, V227, P411, DOI 10.1016/0922-4106(92)90159-S; Karlin A, 1998, METHOD ENZYMOL, V293, P123; KUHAR MJ, 1991, TRENDS NEUROSCI, V14, P299, DOI 10.1016/0166-2236(91)90141-G; MADRAS BK, 1989, MOL PHARMACOL, V36, P518; MEIERGERD SM, 1994, J NEUROCHEM, V63, P1683; MELTZER PC, 1994, J MED CHEM, V37, P2001, DOI 10.1021/jm00039a014; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; POVLOCK SL, 1997, NEUROTRANSMITTER TRA, P1; REITH MEA, 1986, BIOCHEM PHARMACOL, V35, P1123, DOI 10.1016/0006-2952(86)90148-6; Reith MEA, 1996, N-S ARCH PHARMACOL, V354, P295; Reith MEA, 1996, BIOCHEM PHARMACOL, V52, P1435, DOI 10.1016/S0006-2952(96)00508-4; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; SAADOUNI S, 1994, EUR J PHARM-MOLEC PH, V268, P187, DOI 10.1016/0922-4106(94)90188-0; SCHWERI MM, 1992, J PHARMACOL EXP THER, V261, P936; SCHWERI MM, 1990, NEUROPHARMACOLOGY, V29, P901, DOI 10.1016/0028-3908(90)90140-M; UHL GR, 1993, ADV NEUROL, V60, P321; Vaughan RA, 1999, J NEUROSCI, V19, P630; Woolverton WL, 2000, PSYCHOPHARMACOLOGY, V147, P426, DOI 10.1007/s002130050012; Xu C, 1997, N-S ARCH PHARMACOL, V355, P64; Xu C, 1997, J PHARMACOL EXP THER, V282, P920; ZIMANYI I, 1989, SYNAPSE, V3, P239, DOI 10.1002/syn.890030310; [No title captured]	38	88	89	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29012	29018		10.1074/jbc.M011785200	http://dx.doi.org/10.1074/jbc.M011785200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11395483	hybrid			2022-12-25	WOS:000170346000052
J	Grammatikakis, N; Jaronczyk, K; Siganou, A; Vultur, A; Brownell, HL; Benzaquen, M; Rausch, C; Lapointe, R; Gjoerup, O; Roberts, TM; Raptis, L				Grammatikakis, N; Jaronczyk, K; Siganou, A; Vultur, A; Brownell, HL; Benzaquen, M; Rausch, C; Lapointe, R; Gjoerup, O; Roberts, TM; Raptis, L			Simian virus 40 large tumor antigen modulates the Raf signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE T-ANTIGEN; SV40 LARGE T; FULL NEOPLASTIC TRANSFORMATION; GENE ACTIVITY; J DOMAIN; ACTIVATION; PROTEIN; KINASE; PHOSPHORYLATION; CELLS	The large tumor antigen of simian virus 40 (SVLT) is a potent oncogene. Although inactivation of the p53 and pRb tumor suppressors has been causally linked to the transforming properties of SVLT, its exact mechanism of action remains undefined. Previous data indicated that Ras is activated in SVLT-expressing cells. In this report we show that SVLT also increases Raf kinase activity in both insect and mammalian cells, thus identifying the Raf kinase as an additional target of SVLT. Our results further show that SVLT was still able to activate Raf in cells where Ras levels had been drastically reduced through expression of an antisense construct, indicating that SVLT may activate Raf at least partly by a mechanism that is independent of its stimulatory effect on Ras.	Queens Univ, Dept Microbiol & Immunol, Kingston, ON K7L 3N6, Canada; Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA; Queens Univ, Dept Pathol, Kingston, ON K7L 3N6, Canada; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA	Queens University - Canada; Tufts University; Queens University - Canada; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Raptis, L (corresponding author), Queens Univ, Dept Microbiol & Immunol, Botterell Hall,Rm 715, Kingston, ON K7L 3N6, Canada.	raptisl@post.queensu.ca		Vultur, Adina/0000-0003-0068-9496				Bocchetta M, 2000, P NATL ACAD SCI USA, V97, P10214, DOI 10.1073/pnas.170207097; Brodsky JL, 1998, J VIROL, V72, P5329, DOI 10.1128/JVI.72.7.5329-5334.1998; Broome MA, 2000, ONCOGENE, V19, P2867, DOI 10.1038/sj.onc.1203608; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; Campbell KS, 1997, GENE DEV, V11, P1098, DOI 10.1101/gad.11.9.1098; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Chen QM, 1996, J BIOL CHEM, V271, P18122, DOI 10.1074/jbc.271.30.18122; DeCaprio JA, 1999, BIOLOGICALS, V27, P23, DOI 10.1006/biol.1998.0173; Grammatikakis N, 1999, MOL CELL BIOL, V19, P1661; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; Lednicky JA, 2001, METH MOL B, V165, P257; Lee KY, 1999, MOL CELL BIOL, V19, P7724; MANFREDI JJ, 1994, BBA-REV CANCER, V1198, P65, DOI 10.1016/0304-419X(94)90006-X; Mikula M, 2001, EMBO J, V20, P1952, DOI 10.1093/emboj/20.8.1952; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; MORRISON DK, 1995, METHOD ENZYMOL, V255, P301; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Raptis L, 2001, METH MOL B, V165, P151; Raptis L, 1997, CELL GROWTH DIFFER, V8, P891; RAPTIS L, 1991, J VIROL, V65, P5203, DOI 10.1128/JVI.65.10.5203-5210.1991; RAPTIS L, 1985, MOL CELL BIOL, V5, P2476, DOI 10.1128/MCB.5.9.2476; RAPTIS L, 1989, J VIROL, V63, P753, DOI 10.1128/JVI.63.2.753-758.1989; Raptis L, 2000, CELL GROWTH DIFFER, V11, P293; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Sheng Q, 1997, J VIROL, V71, P9410, DOI 10.1128/JVI.71.12.9410-9416.1997; Silverstein AM, 1998, J BIOL CHEM, V273, P20090, DOI 10.1074/jbc.273.32.20090; Simmons DT, 2000, ADV VIRUS RES, V55, P75, DOI 10.1016/S0065-3527(00)55002-7; Song JW, 2001, NAT CELL BIOL, V3, P276, DOI 10.1038/35060068; Srinivasan A, 1997, MOL CELL BIOL, V17, P4761, DOI 10.1128/MCB.17.8.4761; Stubdal H, 1997, MOL CELL BIOL, V17, P4979, DOI 10.1128/MCB.17.9.4979; Sullivan CS, 2001, J VIROL, V75, P1601, DOI 10.1128/JVI.75.4.1601-1610.2001; vanderStraten A, 1997, EMBO J, V16, P1961, DOI 10.1093/emboj/16.8.1961; WILLIAMS NG, 1994, CANCER METAST REV, V13, P105, DOI 10.1007/BF00690421; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; Zhai WG, 1999, MOL CELL BIOL, V19, P2791	36	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27840	27845		10.1074/jbc.M101987200	http://dx.doi.org/10.1074/jbc.M101987200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11382757	hybrid			2022-12-25	WOS:000170093400015
J	Huggins, GS; Bacani, CJ; Boltax, J; Aikawa, R; Leiden, JM				Huggins, GS; Bacani, CJ; Boltax, J; Aikawa, R; Leiden, JM			Friend of GATA 2 physically interacts with chicken ovalbumin upstream promoter-TF2 (COUP-TF2) and COUP-TF3 and represses COUP-TF2-dependent activation of the atrial natriuretic factor promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEIN; NUCLEAR ORPHAN RECEPTORS; LIGAND-BINDING DOMAIN; HEART TUBE FORMATION; TRANSCRIPTION FACTOR; GENE-EXPRESSION; VENTRAL MORPHOGENESIS; TERMINAL DOMAIN; N-COR; FOG-2	Friend of GATA (FOG)-2 is a multi-zinc finger transcriptional corepressor protein that binds specifically to GATA4. Gene targeting studies have demonstrated that FOG-2 is required for normal cardiac morphogenesis, including the development of the coronary vasculature, left ventricular compact zone, and heart valves. To better understand the molecular mechanisms by which FOG-2 regulates these cardiac developmental programs, we screened a mouse day 11 embryo library using a yeast two-hybrid interaction trap with the fifth and sixth zinc fingers of FOG-2 as bait. Using this approach, we isolated clones encoding the orphan nuclear receptors chicken ovalbumin upstream promoter-transcription factor (COUP-TF) 2 and COUP-TF3. COUP-TF2-null embryos die during embryonic development with defective angiogenesis and cardiac defects, a pattern that partly resembles the FOG-2-null phenotype. The interaction between COUP-TF2 and FOG-2 in mammalian cells was confirmed by co-immunoprecipitation of these proteins from transfected COS-7 cells. The sites of binding interaction between COUP-TF2 and FOG-2 were mapped to zinc fingers 5 and 6 and fingers 7 and 8 of FOG-2 and to the carboxyl terminus of the COUP-TF proteins. Binding to COUP-TF2 was specific because FOG-2 did not interact with the ligand-binding domains of retinoid X receptor alpha, glucocorticoid receptor, and peroxisome proliferating antigen receptor gamma, which are related to the COUP-TF proteins. Full-length FOG-2 markedly enhanced transcriptional repression by GAL4-COUP-TF2(117-414), but not by a COUP-TF2 repression domain mutant. Moreover, FOG-2 repressed COUP-TF2dependent synergistic activation of the atrial natriuretic factor promoter by both GATA4 and the FOG-2-independent mutant GATA4-E215K. Taken together, these findings suggest that FOG-2 functions as a corepressor for both GATA and COUP-TF proteins.	Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, Boston, MA 02115 USA; Massachusetts Gen Hosp, Cardiac Unit, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Abbott Labs, Abbott Pk, IL 60064 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Abbott Laboratories	Huggins, GS (corresponding author), Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, 677 Huntington Ave, Boston, MA 02115 USA.				NHLBI NIH HHS [K08 HL03667-01A1, R01 HL54592-06, R01 HL054592] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003667, R01HL054592] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Achatz G, 1997, MOL CELL BIOL, V17, P4914, DOI 10.1128/MCB.17.9.4914; Avram D, 1999, J BIOL CHEM, V274, P14331, DOI 10.1074/jbc.274.20.14331; Avram D, 2000, J BIOL CHEM, V275, P10315, DOI 10.1074/jbc.275.14.10315; Bailey PJ, 1997, J STEROID BIOCHEM, V63, P165, DOI 10.1016/S0960-0760(97)00079-4; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Cheng GM, 1999, J BIOL CHEM, V274, P12819, DOI 10.1074/jbc.274.18.12819; Collingwood TN, 1999, J MOL ENDOCRINOL, V23, P255, DOI 10.1677/jme.0.0230255; Crispino JD, 2001, GENE DEV, V15, P839, DOI 10.1101/gad.875201; Deconinck AE, 2000, DEVELOPMENT, V127, P2031; Dressel U, 1999, MOL CELL BIOL, V19, P3383; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; Fossett N, 2000, P NATL ACAD SCI USA, V97, P7348, DOI 10.1073/pnas.97.13.7348; Fox AH, 1998, J BIOL CHEM, V273, P33595, DOI 10.1074/jbc.273.50.33595; Fox AH, 1999, EMBO J, V18, P2812, DOI 10.1093/emboj/18.10.2812; HALL RK, 1995, P NATL ACAD SCI USA, V92, P412, DOI 10.1073/pnas.92.2.412; Huang EY, 2000, GENE DEV, V14, P45; Huggins GS, 1999, J BIOL CHEM, V274, P28690, DOI 10.1074/jbc.274.40.28690; IP HS, 1994, MOL CELL BIOL, V14, P7517, DOI 10.1128/MCB.14.11.7517; JONK LJC, 1994, MECH DEVELOP, V47, P81, DOI 10.1016/0925-4773(94)90098-1; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; Lazennec G, 1997, MOL CELL BIOL, V17, P5053, DOI 10.1128/MCB.17.9.5053; Lee Y, 1998, MOL CELL BIOL, V18, P3120, DOI 10.1128/MCB.18.6.3120; Lien CL, 1999, DEVELOPMENT, V126, P75; Lu JR, 1999, MOL CELL BIOL, V19, P4495; Matthews JM, 2000, EUR J BIOCHEM, V267, P1030, DOI 10.1046/j.1432-1327.2000.01095.x; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Pereira FA, 1999, GENE DEV, V13, P1037, DOI 10.1101/gad.13.8.1037; Perlmann T, 1997, CELL, V90, P391, DOI 10.1016/S0092-8674(00)80498-5; Pipaon C, 1999, MOL CELL BIOL, V19, P2734; Power SC, 1996, MOL CELL BIOL, V16, P778; Qiu Y, 1996, J STEROID BIOCHEM, V56, P81, DOI 10.1016/0960-0760(95)00225-1; Rosoff ML, 1998, J BIOL CHEM, V273, P9124, DOI 10.1074/jbc.273.15.9124; Scott DK, 1996, J BIOL CHEM, V271, P31909, DOI 10.1074/jbc.271.50.31909; Searcy RD, 1998, DEVELOPMENT, V125, P4461; Shibata H, 1997, MOL ENDOCRINOL, V11, P714, DOI 10.1210/me.11.6.714; Svensson EC, 2000, J BIOL CHEM, V275, P20762, DOI 10.1074/jbc.M001522200; Svensson EC, 2000, NAT GENET, V25, P353, DOI 10.1038/77146; Svensson EC, 1999, P NATL ACAD SCI USA, V96, P956, DOI 10.1073/pnas.96.3.956; Tevosian SG, 2000, CELL, V101, P729, DOI 10.1016/S0092-8674(00)80885-5; Tevosian SG, 1999, P NATL ACAD SCI USA, V96, P950, DOI 10.1073/pnas.96.3.950; Tsai SY, 1997, ENDOCR REV, V18, P229, DOI 10.1210/er.18.2.229; Tsang AP, 1998, GENE DEV, V12, P1176, DOI 10.1101/gad.12.8.1176; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87	46	56	61	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28029	28036		10.1074/jbc.M103577200	http://dx.doi.org/10.1074/jbc.M103577200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11382775	hybrid			2022-12-25	WOS:000170093400039
J	Klemm, DJ; Leitner, JW; Watson, P; Nesterova, A; Reusch, JEB; Goalstone, ML; Draznin, B				Klemm, DJ; Leitner, JW; Watson, P; Nesterova, A; Reusch, JEB; Goalstone, ML; Draznin, B			Insulin-induced adipocyte differentiation - Activation of CREB rescues adipogenesis from the arrest caused by inhibition of prenylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOSE-TISSUE CELLULARITY; BINDING-PROTEIN; GROWTH-FACTOR; 3T3-L1; FARNESYLTRANSFERASE; GENE; PHOSPHORYLATION; POTENTIATION; EXPRESSION; CULTURE	Insulin is a potent adipogenic hormone that triggers an induction of a series of transcription factors governing differentiation of pre-adipocytes into mature adipocytes. However, the exact link between the insulin signaling cascade and the intrinsic cascade of adipogenesis remains incompletely understood. Herein we demonstrate that inhibition of prenylation of p21(ras) and Rho-A arrests insulin-stimulated adipogenesis. Inhibition of farnesylation of p21(ras) also blocked the ability of insulin to activate mitogen-activated protein (MAP) kinase and cyclic AMP response element-binding (CREB) protein. Expression of two structurally different inducible constitutively active CREB constructs rescued insulin-stimulated adipocyte differentiation from the inhibitory influence of prenylation inhibitors. Constitutively active CREB constructs induced expression of PPAR gamma2, fatty acid synthase, GLUT-4, and leptin both in control and prenylation inhibitors-treated cells. It appears that insulin stimulated prenylation of the Ras family GTPases assures normal phosphorylation and activation of CREB that, in turn, triggers the intrinsic cascade of adipogenesis.	Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80220 USA; Vet Affairs Med Ctr, Res Serv, Denver, CO 80220 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Draznin, B (corresponding author), Vet Adm Hosp, 1055 Clermont St,151, Denver, CO 80220 USA.	Boris.Draznin@Med.VA.Gov		Reusch, Jane/0000-0001-8620-1003	NIDDK NIH HHS [DK53969] Funding Source: Medline; NIGMS NIH HHS [GM47117] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053969] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047117] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACCILI D, 1991, P NATL ACAD SCI USA, V88, P4708, DOI 10.1073/pnas.88.11.4708; Cardinaux JR, 2000, MOL CELL BIOL, V20, P1546, DOI 10.1128/MCB.20.5.1546-1552.2000; Chaika OV, 1997, J BIOL CHEM, V272, P11968, DOI 10.1074/jbc.272.18.11968; Chappell J, 2000, J BIOL CHEM, V275, P31792, DOI 10.1074/jbc.M004798200; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; DEHERREROS AG, 1989, J BIOL CHEM, V264, P9885; Draznin B, 2000, ENDOCRINOLOGY, V141, P1310, DOI 10.1210/en.141.4.1310; Fajas L, 1998, CURR OPIN CELL BIOL, V10, P165, DOI 10.1016/S0955-0674(98)80138-5; Gagnon A, 1999, DIABETES, V48, P691, DOI 10.2337/diabetes.48.4.691; Gagnon AM, 1998, OBES RES, V6, P157, DOI 10.1002/j.1550-8528.1998.tb00330.x; GINSBERGFELLNER F, 1981, PEDIATR RES, V15, P1381, DOI 10.1203/00006450-198110000-00016; Goalstone M, 1997, ENDOCRINOLOGY, V138, P5119, DOI 10.1210/en.138.12.5119; Goalstone ML, 1999, DIABETOLOGIA, V42, P310, DOI 10.1007/s001250051156; Goalstone ML, 1998, J BIOL CHEM, V273, P23892, DOI 10.1074/jbc.273.37.23892; Goalstone ML, 1996, J BIOL CHEM, V271, P27585, DOI 10.1074/jbc.271.44.27585; Goalstone ML, 2001, J BIOL CHEM, V276, P12805, DOI 10.1074/jbc.M009443200; Golovchenko I, 2000, CIRC RES, V87, P746, DOI 10.1161/01.RES.87.9.746; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HAUNER H, 1990, ENDOCRINOLOGY, V127, P865, DOI 10.1210/endo-127-2-865; Hill MM, 2000, J BIOL CHEM, V275, P24313, DOI 10.1074/jbc.M001823200; HIRSCH J, 1976, CLIN ENDOCRINOL META, V5, P299, DOI 10.1016/S0300-595X(76)80023-0; Hwang CS, 1997, ANNU REV CELL DEV BI, V13, P231, DOI 10.1146/annurev.cellbio.13.1.231; KIKUCHI A, 1994, J BIOL CHEM, V269, P20054; Klemm DJ, 1998, J BIOL CHEM, V273, P917, DOI 10.1074/jbc.273.2.917; MAGUS R, 1997, ENDOCRINOLOGY, V137, P3590; Mandrup S, 1997, J BIOL CHEM, V272, P5367, DOI 10.1074/jbc.272.9.5367; Nishio E, 1996, EUR J PHARMACOL, V301, P203, DOI 10.1016/0014-2999(96)00063-5; PAULAUSKIS JD, 1988, J BIOL CHEM, V263, P7049; Reusch JEB, 2000, MOL CELL BIOL, V20, P1008, DOI 10.1128/MCB.20.3.1008-1020.2000; Reusch JEB, 1999, ENDOCRINOLOGY, V140, P2935, DOI 10.1210/en.140.7.2935; Sakaue H, 1998, J BIOL CHEM, V273, P28945, DOI 10.1074/jbc.273.44.28945; SOSA H, 1995, BIOCHEM BIOPH RES CO, V212, P263; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Tomiyama K, 1999, JPN J PHARMACOL, V80, P375, DOI 10.1254/jjp.80.375; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	39	143	146	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28430	28435		10.1074/jbc.M103382200	http://dx.doi.org/10.1074/jbc.M103382200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11375992	hybrid			2022-12-25	WOS:000170093400091
J	Thompson, NA; Haefliger, JA; Senn, A; Tawadros, T; Magara, F; Ledermann, B; Nicod, P; Waeber, G				Thompson, NA; Haefliger, JA; Senn, A; Tawadros, T; Magara, F; Ledermann, B; Nicod, P; Waeber, G			Islet-brain1/JNK-interacting protein-1 is required for early embryogenesis in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-SECRETING CELLS; DIODE-LASER BEAM; C-JUN; SIGNAL-TRANSDUCTION; KINASE ACTIVATION; INDUCED APOPTOSIS; JNK; GENE; MOUSE; IB1	Islet-brain1/JNK-interacting protein-1 (IBl/JIP-1) is a scaffold protein that organizes the JNK, MKK7, and MLK1 to allow signaling specificity. Targeted disruption of the gene MAPK8IP1 encoding IB1/JIP-1 in mice led to embryonic death prior to blastocyst implantation. In culture, no IB1/JIP-1(-/-) embryos were identified indicating that accelerated cell death occurred during the first cell cycles. IB1/JIP-1 expression was detected in unfertilized oocytes, in spermatozoa, and in different stages of embryo development. Thus, despite the maternal and paternal transmission of the IB1/JIP-1 protein, early transcription of the MAPK8IP1 gene is required for the survival of the fertilized oocytes.	CHU Vaudois, Univ Hosp, Dept Internal Med, CH-1011 Lausanne, Switzerland; CHU Vaudois, Univ Hosp, Inst Cell Biol & Morphol, CH-1011 Lausanne, Switzerland; CHU Vaudois, Univ Hosp, Dept Obstet & Gynecol, Reprod Med Unit, CH-1011 Lausanne, Switzerland; Univ Zurich, CH-8057 Zurich, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Zurich	Waeber, G (corresponding author), CHU Vaudois, Univ Hosp, Dept Internal Med B, CH-1011 Lausanne, Switzerland.	gwaeber@chuv.hospvd.ch		Haefliger, Jacques-Antoine/0000-0003-2732-1667; Waeber, Gerard/0000-0003-4193-788X				Bagowski CP, 2001, J BIOL CHEM, V276, P1459, DOI 10.1074/jbc.M008050200; Bonny C, 2000, J BIOL CHEM, V275, P16466, DOI 10.1074/jbc.M908297199; Bonny C, 1998, J BIOL CHEM, V273, P1843, DOI 10.1074/jbc.273.4.1843; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Dong C, 2000, NATURE, V405, P91, DOI 10.1038/35011091; Ganiatsas S, 1998, P NATL ACAD SCI USA, V95, P6881, DOI 10.1073/pnas.95.12.6881; GERMOND M, 1995, FERTIL STERIL, V64, P604, DOI 10.1016/S0015-0282(16)57800-5; Germond M, 1996, HUM REPROD, V11, P1043; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Latham KE, 1999, INT REV CYTOL, V193, P71; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Meyer D, 1999, J BIOL CHEM, V274, P35113, DOI 10.1074/jbc.274.49.35113; Mooser V, 1999, GENOMICS, V55, P202, DOI 10.1006/geno.1998.5641; Pellet JB, 2000, EUR J NEUROSCI, V12, P621, DOI 10.1046/j.1460-9568.2000.00945.x; Sabapathy K, 1999, MECH DEVELOP, V89, P115, DOI 10.1016/S0925-4773(99)00213-0; Stockinger W, 2000, J BIOL CHEM, V275, P25625, DOI 10.1074/jbc.M004119200; Stronach BE, 1999, ONCOGENE, V18, P6172, DOI 10.1038/sj.onc.1203125; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; Waeber G, 2000, NAT GENET, V24, P291, DOI 10.1038/73523; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911	27	53	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27745	27748		10.1074/jbc.C100222200	http://dx.doi.org/10.1074/jbc.C100222200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11390367	hybrid			2022-12-25	WOS:000170093400001
J	Tao, Q; Backer, MV; Backer, JM; Terman, BI				Tao, Q; Backer, MV; Backer, JM; Terman, BI			Kinase insert domain receptor (KDR) extracellular immunoglobulin-like domains 4-7 contain structural features that block receptor dimerization and vascular endothelial growth factor-induced signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; TYROSINE KINASE; CATALYTIC SUBUNIT; CRYSTAL-STRUCTURE; LIGAND-BINDING; IN-VIVO; VEGF; IDENTIFICATION; PHOSPHORYLATION; EXPRESSION	The vascular endothelial growth factor (VEGF) receptor tyrosine kinase subtype kinase insert domain receptor (KDR) contains seven extracellular Ig-like domains, of which the three most amino-terminal contain the necessary structural features required for VEGF binding. To clarify the functional role of I(DR Ig-like domains 4-7, we compared VEGF-induced signaling in human embryonic kidney and porcine aortic endothelial cells expressing native versus mutant receptor proteins in which Ig-like domains 4-7, 4-6, or 7 had been deleted. Western blotting using an anti-receptor antibody indicated equivalent expression levels for each of the recombinant proteins. As expected, VEGF treatment robustly augmented native receptor autophosphorylation, In contrast, receptor autophosphorylation, as well as downstream signaling events, were VEGF-independent for cells expressing mutant receptors, I-125-VEGF(165) bound with equal or better affinity to mutant versus native receptor, although the number of radioligand binding sites was significantly reduced because a significant percentage of mutant, but not native, receptors were localized to the cell interior. As was the case for native KDR,I-125-VEGF(165) binding to the mutant receptors was dependent upon cell surface heparan sulfate proteoglycans, and I-125-VEGF(121) bound with an affinity equal to that of I-125-VEGF(165) to the native and mutant receptors. It is concluded that KDR Ig-like domains 4-7 contain structural features that inhibit receptor signaling by a mechanism that is independent of neuropilin-1 and heparan sulfate proteoglycans. We speculate that this provides a cellular mechanism for blocking unwanted signaling events in the absence of VEGF.	Albert Einstein Coll Med, Dept Med, Div Cardiol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA; Sibtech, Newington, CT USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Terman, BI (corresponding author), Albert Einstein Coll Med, Dept Med, Div Cardiol, Forchheimer 715,1300 Morris Pk Ave, Bronx, NY 10461 USA.	terman@aec-om.yu.edu			NATIONAL CANCER INSTITUTE [R01CA086289] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA86289-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457; Arevalo JC, 2000, MOL CELL BIOL, V20, P5908, DOI 10.1128/MCB.20.16.5908-5916.2000; BAEUERLE PA, 1986, BIOCHEM BIOPH RES CO, V141, P870, DOI 10.1016/S0006-291X(86)80253-4; BLECHMAN JM, 1995, CELL, V80, P103, DOI 10.1016/0092-8674(95)90455-7; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Dougher AM, 1997, GROWTH FACTORS, V14, P257, DOI 10.3109/08977199709021524; Dougher M, 1999, ONCOGENE, V18, P1619, DOI 10.1038/sj.onc.1202478; DOUGHERVERMAZEN M, 1994, BIOCHEM BIOPH RES CO, V205, P728, DOI 10.1006/bbrc.1994.2726; FAVA RA, 1994, J EXP MED, V180, P341, DOI 10.1084/jem.180.1.341; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; Fuh G, 1998, J BIOL CHEM, V273, P11197, DOI 10.1074/jbc.273.18.11197; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Gamm DM, 1996, J BIOL CHEM, V271, P15736, DOI 10.1074/jbc.271.26.15736; Gille H, 2001, J BIOL CHEM, V276, P3222, DOI 10.1074/jbc.M002016200; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; IruelaArispe ML, 1997, THROMB HAEMOSTASIS, V78, P672; Kaplan JB, 1997, GROWTH FACTORS, V14, P243, DOI 10.3109/08977199709021523; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Li J, 1996, AM J PHYSIOL-HEART C, V270, pH1803, DOI 10.1152/ajpheart.1996.270.5.H1803; Lu D, 2000, J BIOL CHEM, V275, P14321, DOI 10.1074/jbc.275.19.14321; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; McKeehan WL, 1999, J BIOL CHEM, V274, P21511, DOI 10.1074/jbc.274.31.21511; McLaren J, 1996, J CLIN INVEST, V98, P482, DOI 10.1172/JCI118815; Miao HQ, 1996, J BIOL CHEM, V271, P4879; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MOCHLYROSEN D, 1987, J BIOL CHEM, V262, P2291; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; Omura T, 1997, J BIOL CHEM, V272, P12676, DOI 10.1074/jbc.272.19.12676; ORR JW, 1992, J BIOL CHEM, V267, P15263; PEPPER MS, 1991, BIOCHEM BIOPH RES CO, V181, P823; PLONTNIKOV A, 1999, CELL, V98, P641; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Shen BQ, 1999, J BIOL CHEM, V274, P33057, DOI 10.1074/jbc.274.46.33057; SHIBUYA M, 1990, ONCOGENE, V5, P519; Shinkai A, 1998, J BIOL CHEM, V273, P31283, DOI 10.1074/jbc.273.47.31283; Siemeister G, 1998, J BIOL CHEM, V273, P11115, DOI 10.1074/jbc.273.18.11115; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; STOLETOV KV, 2001, IN PRESS J BIOL CHEM, V276; TAKESHITA S, 1994, J CLIN INVEST, V93, P662, DOI 10.1172/JCI117018; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TERMAN BI, 1991, ONCOGENE, V6, P1677; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Uren A, 1997, ONCOGENE, V14, P157, DOI 10.1038/sj.onc.1200810; VAISMAN N, 1990, J BIOL CHEM, V265, P19461; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	59	34	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21916	21923		10.1074/jbc.M100763200	http://dx.doi.org/10.1074/jbc.M100763200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11399777	hybrid			2022-12-25	WOS:000169297900145
J	Chu, A; Matusiewicz, N; Stochaj, U				Chu, A; Matusiewicz, N; Stochaj, U			Heat-induced nuclear accumulation of hsc70 proteins is regulated by phosphorylation and inhibited in confluent cells	FASEB JOURNAL			English	Article						nuclear transport; stress; heat shock proteins; protein phosphorylation	HELA-CELLS; IN-VITRO; SACCHAROMYCES-CEREVISIAE; OXIDATIVE STRESS; SHOCK PROTEIN-70; IMPORT; KINASE; EXPRESSION; HEAT-SHOCK-PROTEIN-70; TRANSLOCATION	Stress affects the general organization of cells and, in particular, the subcellular localization of molecules. Proteins of the hsp70/hsc70 family relocate to nuclei in response to heat shock, when classical nuclear protein import is inhibited. We have now further characterized the effect of stress on hsc70 protein localization in HeLa cells. Heat-induced nuclear concentration of hsc70 proteins depends on cell density, and low-density cultures efficiently imported hsc70 proteins into nuclei when exposed to heat. However, high-density cultures failed to accumulate hsc70 proteins in nuclei during heat shock. In low-density cultures, heat-induced hsc70 nuclear accumulation was insensitive to inhibitors of tyrosine kinases, Ser/Thr protein kinases, and rapamycin, which indicates that activation of mitogen-activated protein kinase family members or p70 S6 kinase is not required for this process. In contrast, inhibitors of Ser/Thr protein phosphatase and Tyr protein phosphatase abolished the nuclear concentration of hsc70 proteins. Likewise, inhibitors of protein phosphatases affected classical nuclear protein import in unstressed cells, but these transport pathways differed drastically in their sensitivities toward inhibitors. Although protein phosphorylation negatively regulates hsc70 nuclear accumulation in response to heat, protein kinase inhibitors were unable to overcome the block of hsc70 nuclear accumulation in high-density cultures, indicating that additional components control hsc70 nuclear transport.	McGill Univ, Dept Physiol, Montreal, PQ H3G 1Y6, Canada	McGill University	Chu, A (corresponding author), McGill Univ, Dept Physiol, 3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.	achu@med.mcgill.ca; stochaj@med.mcgill.ca	stochaj, ursula/AAC-1865-2021					Barth W, 1999, BIOCHEM CELL BIOL, V77, P355, DOI 10.1139/bcb-77-4-355; BENJAMIN LJ, 1994, BIOL HEAT SHOCK PROT, P533; Bonelli MA, 1999, EXP CELL RES, V252, P20, DOI 10.1006/excr.1999.4614; Chatterjee S, 1998, BIOTECHNIQUES, V24, P668, DOI 10.2144/98244rr04; Chen HC, 1999, KIDNEY INT, V56, P1270, DOI 10.1046/j.1523-1755.1999.00693.x; Constantinescu A, 1999, J BIOL CHEM, V274, P26985, DOI 10.1074/jbc.274.38.26985; Czubryt MP, 2000, J CELL BIOL, V148, P7, DOI 10.1083/jcb.148.1.7; Dynlacht JR, 1999, J CELL PHYSIOL, V178, P28, DOI 10.1002/(SICI)1097-4652(199901)178:1<28::AID-JCP4>3.3.CO;2-B; Gutsmann-Conrad A, 1998, EXP CELL RES, V241, P404, DOI 10.1006/excr.1998.4069; Hood JK, 1999, CURR OPIN CELL BIOL, V11, P241, DOI 10.1016/S0955-0674(99)80032-5; Kehlenbach RH, 2000, J BIOL CHEM, V275, P17848, DOI 10.1074/jbc.M001455200; Kim-Kaneyama JR, 2000, J BIOL CHEM, V275, P20685, DOI 10.1074/jbc.M908723199; Knowlton AA, 2000, AM J PHYSIOL-HEART C, V278, pH2143, DOI 10.1152/ajpheart.2000.278.6.H2143; Kobayashi S, 1997, J BIOL CHEM, V272, P16262, DOI 10.1074/jbc.272.26.16262; Kudo N, 1999, J BIOL CHEM, V274, P15151, DOI 10.1074/jbc.274.21.15151; Kuge S, 1997, EMBO J, V16, P1710, DOI 10.1093/emboj/16.7.1710; Lamian V, 1996, EXP CELL RES, V228, P84, DOI 10.1006/excr.1996.0302; Lin RZ, 1997, J BIOL CHEM, V272, P31196, DOI 10.1074/jbc.272.49.31196; Liu Y, 1996, EMBO J, V15, P6750, DOI 10.1002/j.1460-2075.1996.tb01064.x; Malek AM, 1997, AM J PHYSIOL-CELL PH, V273, pC1764, DOI 10.1152/ajpcell.1997.273.5.C1764; MANDELL RB, 1990, J CELL BIOL, V111, P1775, DOI 10.1083/jcb.111.5.1775; Manzerra P, 1996, EXP CELL RES, V229, P35, DOI 10.1006/excr.1996.0341; NERI LM, 1995, EXP CELL RES, V221, P301, DOI 10.1006/excr.1995.1379; NOWAK TS, 1994, BIOL HEAT SHOCK PROT, P553; PAHLAVANI MA, 1995, EXP CELL RES, V218, P310, DOI 10.1006/excr.1995.1160; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; Shulga N, 1996, J CELL BIOL, V135, P329, DOI 10.1083/jcb.135.2.329; Stochaj U, 2000, FASEB J, V14, P2130, DOI 10.1096/fj.99-0751fje; TAMAOKI T, 1991, METHOD ENZYMOL, V201, P340; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Virshup DM, 2000, CURR OPIN CELL BIOL, V12, P180, DOI 10.1016/S0955-0674(99)00074-5; Wang HCR, 2000, J BIOL CHEM, V275, P25850, DOI 10.1074/jbc.M000818200	33	32	32	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 27	2001	15	6					1478	+		10.1096/fj.00-0680fje	http://dx.doi.org/10.1096/fj.00-0680fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387263				2022-12-25	WOS:000173705800004
J	Furuya, T; Okura, M; Ruiz, FA; Scott, DA; Docampo, R				Furuya, T; Okura, M; Ruiz, FA; Scott, DA; Docampo, R			TcSCA complements yeast mutants defective in Ca2+ pumps and encodes a Ca2+-ATPase that localizes to the endoplasmic reticulum of Trypanosoma cruzi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SARCOPLASMIC-RETICULUM; CALCIUM-PUMP; SECRETORY PATHWAY; CELL INVASION; PROTEIN; THAPSIGARGIN; ATPASE; ACIDOCALCISOMES; EXPRESSION; MEMBRANE	Intracellular Ca2+ in Trypanosoma cruzi is mainly located in an acidic compartment named the acidocalcisome, which among other pumps and exchangers possesses a plasma membrane-type Ca2+-ATPase. Evidence for an endoplasmic reticulum-located Ca2+ uptake has been more elusive and based on indirect results. Here we report the cloning and sequencing of a gene encoding a sarcoplasmic-endoplasmic reticulum-type Ca2+-ATPase from T. cruzi. The protein (TeSCA) predicted from the nucleotide sequence of the gene has 1006 amino acids and a molecular mass of 109.7 kDa. Several sequence motifs found in sarcoplasmic-endoplasmic reticulum-type Ca2+-ATPases were present in TeSCA. Expression of TcSCA in yeast mutants deficient in the Golgi and vacuolar Ca2+ pumps (pmr1 pmc1 cnb 1) restored growth on EGTA. Membranes were isolated from the pmr1 pmc1 cnb1 mutant transformed with TcSCA, and it was found that the TcSCA polypeptide formed a Ca2+-dependent and hydroxylamine-sensitive P-32-labeled. phosphoprotein of 110 kDa in the presence of [gamma-P-32]ATP. Cyclopiazonic acid, but not thapsigargin, blocked this phosphoprotein formation. Transgenic parasites expressing constructs of TcSCA with green fluorescent protein exhibited co-localization of TcSCA with the endoplasmic reticulum proteins BiP and calreticulin. An endoplasmic reticulum location was also found in amastigotes and trypomastigotes using a polyclonal antibody against a COOH-terminal region of the protein. The ability of TcSCA to restore growth of mutant pmr1 pmc1 cnb 1 on medium containing Mn2+ suggests that TcSCA may also regulate Mn2+ homeostasis by pumping Mn2+ into the endoplasmic reticulum of T. cruzi.	Univ Illinois, Coll Vet Med, Dept Pathobiol, Mol Parasitol Lab, Urbana, IL 61802 USA	University of Illinois System; University of Illinois Urbana-Champaign	Docampo, R (corresponding author), Univ Illinois, Coll Vet Med, Dept Pathobiol, Mol Parasitol Lab, 2001 S Lincoln Ave, Urbana, IL 61802 USA.	rodoc@uiuc.edu	Ruiz, Felix A./B-1032-2008; Furuya, Tetsuya/J-5916-2013	Ruiz, Felix A./0000-0003-0748-5015; Furuya, Tetsuya/0000-0003-3979-7072; Scott, David/0000-0002-8668-2449	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023259, R21AI023259] Funding Source: NIH RePORTER; NIAID NIH HHS [AI23259] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEN G, 1976, FEBS LETT, V63, P188, DOI 10.1016/0014-5793(76)80223-2; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; BONE GJ, 1956, NATURE, V178, P308, DOI 10.1038/178308a0; Cancela JM, 2000, EMBO J, V19, P2549, DOI 10.1093/emboj/19.11.2549; Carafoli E, 2000, CURR OPIN CHEM BIOL, V4, P152, DOI 10.1016/S1367-5931(99)00069-1; Caspersen C, 2000, J BIOL CHEM, V275, P22363, DOI 10.1074/jbc.M001569200; CHEN DC, 1992, CURR GENET, V21, P83, DOI 10.1007/BF00318659; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; Degand I, 1999, MOL MICROBIOL, V31, P545, DOI 10.1046/j.1365-2958.1999.01195.x; DEMEIS L, 1988, METHOD ENZYMOL, V157, P190; DOCAMPO R, 1995, BIOCHEM J, V310, P1005, DOI 10.1042/bj3101005; Docampo R, 1999, PARASITOL TODAY, V15, P443, DOI 10.1016/S0169-4758(99)01531-8; Docampo R, 1996, PARASITOL TODAY, V12, P61, DOI 10.1016/0169-4758(96)80656-9; DOCAMPO R, 1993, MOL BIOCHEM PARASIT, V59, P305, DOI 10.1016/0166-6851(93)90228-P; Durr G, 1998, MOL BIOL CELL, V9, P1149, DOI 10.1091/mbc.9.5.1149; Ferrol N, 1996, PLANT CELL, V8, P1159, DOI 10.2307/3870359; Furuya T, 2000, J BIOL CHEM, V275, P6428, DOI 10.1074/jbc.275.9.6428; Geisler M, 2000, BBA-BIOMEMBRANES, V1465, P52, DOI 10.1016/S0005-2736(00)00131-0; Ghosh SK, 2000, MOL BIOCHEM PARASIT, V108, P125, DOI 10.1016/S0166-6851(00)00196-1; Ha DS, 1996, MOL BIOCHEM PARASIT, V77, P57, DOI 10.1016/0166-6851(96)02580-7; Hebert DN, 1995, COLD SPRING HARB SYM, V60, P405, DOI 10.1101/SQB.1995.060.01.045; KAUFMAN RJ, 1994, BIOCHEMISTRY-US, V33, P9813, DOI 10.1021/bi00199a001; KELLY JM, 1992, NUCLEIC ACIDS RES, V20, P3963, DOI 10.1093/nar/20.15.3963; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; KUZNETSOV G, 1992, J BIOL CHEM, V267, P3932; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Labriola C, 1999, MOL BIOL CELL, V10, P1381, DOI 10.1091/mbc.10.5.1381; Liang F, 1997, P NATL ACAD SCI USA, V94, P8579, DOI 10.1073/pnas.94.16.8579; Liang F, 1998, PLANT PHYSIOL, V118, P817, DOI 10.1104/pp.118.3.817; LODISH HF, 1990, J BIOL CHEM, V265, P10893; Lu HG, 1998, MOL CELL BIOL, V18, P2309, DOI 10.1128/MCB.18.4.2309; Lu HG, 1997, J BIOL CHEM, V272, P9464, DOI 10.1074/jbc.272.14.9464; Luo SH, 2001, EMBO J, V20, P55, DOI 10.1093/emboj/20.1.55; Mignaco JA, 1996, J BIOL CHEM, V271, P18423, DOI 10.1074/jbc.271.31.18423; MONIAKIS J, 1995, J BIOL CHEM, V270, P28276; MORENO SNJ, 1994, J EXP MED, V180, P1535, DOI 10.1084/jem.180.4.1535; MORENO SNJ, 1992, MOL BIOCHEM PARASIT, V52, P251, DOI 10.1016/0166-6851(92)90057-Q; NOLAN DP, 1994, J BIOL CHEM, V269, P26045; NORREGAARD A, 1994, J BIOL CHEM, V269, P26598; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; Periz G, 1999, EMBO J, V18, P5983, DOI 10.1093/emboj/18.21.5983; PICK U, 1981, FEBS LETT, V123, P127, DOI 10.1016/0014-5793(81)80035-X; REVELARD P, 1991, MOL BIOCHEM PARASIT, V46, P241, DOI 10.1016/0166-6851(91)90048-B; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKADI B, 1986, J BIOL CHEM, V261, P9552; Schatzmann H J, 1978, Ann N Y Acad Sci, V307, P125, DOI 10.1111/j.1749-6632.1978.tb41939.x; SCHATZMANN HJ, 1989, ANNU REV PHYSIOL, V51, P473, DOI 10.1146/annurev.ph.51.030189.002353; SCHMATZ DM, 1982, PARASITOLOGY, V85, P115, DOI 10.1017/S0031182000054202; Scott DA, 1998, J BIOL CHEM, V273, P22151, DOI 10.1074/jbc.273.34.22151; Scott DA, 1997, J BIOL CHEM, V272, P28020, DOI 10.1074/jbc.272.44.28020; Scott DA, 2000, J BIOL CHEM, V275, P24215, DOI 10.1074/jbc.M002454200; SKEIKY YAW, 1992, J EXP MED, V176, P201, DOI 10.1084/jem.176.1.201; Talla E, 1998, J BIOL CHEM, V273, P27831, DOI 10.1074/jbc.273.43.27831; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TOYOFUKU T, 1994, J BIOL CHEM, V269, P22929; VERCESI AE, 1991, CELL CALCIUM, V12, P361, DOI 10.1016/0143-4160(91)90052-G; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959; Zhong L, 1998, J BIOL CHEM, V273, P12994, DOI 10.1074/jbc.273.21.12994	61	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32437	32445		10.1074/jbc.M104000200	http://dx.doi.org/10.1074/jbc.M104000200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11382780	hybrid			2022-12-25	WOS:000170746000011
J	MacLeod, KJ; Fuller, RS; Scholten, JD; Ahn, K				MacLeod, KJ; Fuller, RS; Scholten, JD; Ahn, K			Conserved cysteine and tryptophan residues of the endothelin-converting enzyme-1 CXAW motif are critical for protein maturation and enzyme activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-BOUND METALLOPROTEASE; NEUTRAL ENDOPEPTIDASE; INTRACELLULAR COMPARTMENT; MOLECULAR-CLONING; SUBCELLULAR LOCALIZATIONS; SUBSTRATE-BINDING; 3 ISOFORMS; ECE-1; CELLS; IDENTIFICATION	The neprilysin (NEP)/endothelin-converting enzyme (ECE) family of metalloproteases contains a highly conserved carboxyl-terminal tetrapeptide sequence, CY-AW, where "C" is cysteine, "X" is a polar amino acid, "A" is an aliphatic residue, and "W" is tryptophan. Although this sequence strongly resembles a prenylation motif, human ECE-1 did not appear to be prenylated when labeled in vivo using various isoprenoid precursors in cell lines expressing ECE-1. We used site-directed mutagenesis to investigate the role of the CXAW motif and determined that the conserved cysteine residue of the CXAW motif in ECE-1, Cys(755), is critical for proper folding of the enzyme, its export from the endoplasmic reticulum, and its maturation in the secretory pathway. In addition, site-directed mutagenesis revealed that the conserved tryptophan residue of the sequence CEVW appears to be important for endoplasmic reticulum export and is essential for enzyme activity. Deletion of Trp(758) or substitution with alanine greatly slowed maturation of the enzyme, and resulted in more than a 90% loss of enzyme activity relative to the wild type. Conservative substitution of the tryptophan with phenylalanine did not reduce activity, whereas replacement with tyrosine, methionine, or leucine reduced enzyme activity by 50%, 75%, and 85%, respectively. Together, these data indicate that the conserved CEVW sequence does not serve as a prenylation signal and that both the conserved cysteine and tryptophan residues are necessary for proper folding and maturation of the enzyme. Furthermore, the conserved tryptophan appears to be critical for enzyme activity.	Pfizer Global Res & Dev, Dept Biochem, Ann Arbor Labs, Ann Arbor, MI 48105 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	Pfizer; University of Michigan System; University of Michigan	Ahn, K (corresponding author), Pfizer Global Res & Dev, Dept Biochem, Ann Arbor Labs, Ann Arbor, MI 48105 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050915, R01GM039697, R55GM039697] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50915, GM39697] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn K, 1998, ARCH BIOCHEM BIOPHYS, V359, P258, DOI 10.1006/abbi.1998.0913; Ahn K, 1998, BIOCHEM BIOPH RES CO, V243, P184, DOI 10.1006/bbrc.1998.8081; Andres DA, 1999, METH MOL B, V116, P107; [Anonymous], 1995, Nat Genet, V11, P130; Azarani A, 1998, BIOCHEM J, V333, P439, DOI 10.1042/bj3330439; Barnes K, 1998, HYPERTENSION, V31, P3, DOI 10.1161/01.HYP.31.1.3; Barnes K, 1996, J CELL SCI, V109, P919; BEAUMONT A, 1991, J BIOL CHEM, V266, P214; Cailler F, 1999, BIOCHEM J, V341, P119, DOI 10.1042/0264-6021:3410119; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; Corsini A, 1999, METH MOL B, V116, P125; EMOTO N, 1995, J BIOL CHEM, V270, P15262, DOI 10.1074/jbc.270.25.15262; Hayes JS, 1999, J BIOL CHEM, V274, P23707, DOI 10.1074/jbc.274.34.23707; Hoang MV, 1997, BIOCHEM J, V327, P23, DOI 10.1042/bj3270023; Ikeda K, 1999, J BIOL CHEM, V274, P32469, DOI 10.1074/jbc.274.45.32469; Johnson GD, 1999, J BIOL CHEM, V274, P4053, DOI 10.1074/jbc.274.7.4053; KIM CM, 1992, J BIOL CHEM, V267, P23113; Kiryu-Seo S, 2000, P NATL ACAD SCI USA, V97, P4345, DOI 10.1073/pnas.070509897; LEE S, 1991, P NATL ACAD SCI USA, V88, P6353, DOI 10.1073/pnas.88.14.6353; MALFROY B, 1988, FEBS LETT, V229, P206, DOI 10.1016/0014-5793(88)80828-7; Oefner C, 2000, J MOL BIOL, V296, P341, DOI 10.1006/jmbi.1999.3492; OHNAKA K, 1993, J BIOL CHEM, V268, P26759; Orzechowski HD, 1997, J MOL MED-JMM, V75, P512, DOI 10.1007/s001090050136; Schweizer A, 1997, BIOCHEM J, V328, P871, DOI 10.1042/bj3280871; Schweizer A, 1999, BIOCHEM J, V340, P649, DOI 10.1042/0264-6021:3400649; Shimada K, 1996, BIOCHEM J, V315, P863, DOI 10.1042/bj3150863; SHIMADA K, 1994, J BIOL CHEM, V269, P18275; TAKAHASHI M, 1993, J BIOL CHEM, V268, P21394; Trueblood CE, 1997, P NATL ACAD SCI USA, V94, P10774, DOI 10.1073/pnas.94.20.10774; Valdenaire O, 1999, MOL BRAIN RES, V64, P211, DOI 10.1016/S0169-328X(98)00321-0; Valdenaire O, 1999, EUR J BIOCHEM, V264, P341, DOI 10.1046/j.1432-1327.1999.00602.x; VALDENAIRE O, 1995, J BIOL CHEM, V270, P29794; Valdenaire O, 1999, J CELL SCI, V112, P3115; VARKI A, 1980, J BIOL CHEM, V255, P847; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1; YAMANE HK, 1991, P NATL ACAD SCI USA, V88, P286, DOI 10.1073/pnas.88.1.286; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	37	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					30608	30614		10.1074/jbc.M103928200	http://dx.doi.org/10.1074/jbc.M103928200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11397811	hybrid			2022-12-25	WOS:000170472900005
J	Ogino, K; Takeda, T; Matsui, E; Iiyama, H; Taniyama, C; Arai, K; Masai, H				Ogino, K; Takeda, T; Matsui, E; Iiyama, H; Taniyama, C; Arai, K; Masai, H			Bipartite binding of a kinase activator activates Cdc7-related kinase essential for S phase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE CDC7; IN-VITRO PHOSPHORYLATION; CELL-CYCLE REGULATION; BUDDING YEAST DBF4; PROTEIN-KINASE; DNA-REPLICATION; FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; CHROMOSOMAL LOCALIZATION; CHECKPOINT CONTROL	Dfp1/Him1 protein of fission yeast, Schizosaccharomyces pombe, encodes the regulatory subunit for Hsk1 kinase, a homologue of budding yeast Cdc7 kinase essential for initiation and progression of the S phase of the cell cycle. This protein binds and activates Hsk1 kinase, which phosphorylates the MCM2 protein. Comparison of the amino acid sequences of the Cdc7 regulatory subunits from various eukaryotes revealed the presence of three small stretches of conserved amino acid sequences, namely Dbf4 motifs N, M, and C. We report here that the Dbf4 motif M, a unique proline-rich motif, and the Dbf4 motif C, a C2H2-type zinc finger motif, are essential for mitotic functions of Dfp1/Him1 protein as well as for full-level activation of Hsk1 kinase. In vitro, a small segment containing the Dbf4 motif M or C alone binds to and partially activates Hsk1. Co-expression of these two segments augments the extent of activation. Furthermore, a fused polypeptide containing only Dbf4 motifs M and C without any spacer can activate Hsk1 and is capable of rescuing the growth defect of him1 null cells. Insertion of a long stretch of amino acids between the motif M and motif C can be tolerated for mitotic functions. On the other hand, internal deletion of Dbf4 motif N, which has some similarity with the BRCA C-terminal domain motif, results in a defect in hydroxyurea-induced checkpoint responses and sensitivity to methyl methane sulfonate, yet mitotic functions and kinase activation are intact. In one-hybrid assays with budding yeast Dbf4, motif N mutants exhibit reduced interaction with a replication origin. Our observations suggest the molecular architecture of Cdc7-Dbf4-related kinase complexes at the origins, in which they are tethered to replication machinery through Dbf4 motif N and the catalytic subunits are activated through bipartite binding of Dbf4 motifs M and C of the regulatory subunits.	Tokyo Metropolitan Inst Med Sci, Dept Cell Biol, Bunkyo Ku, Tokyo 1138613, Japan; Univ Tokyo, Inst Med Sci, Dept Mol & Dev Biol, Tokyo 1088639, Japan; JST, Japan Sci & Technol Corp, CREST, Tokyo 1088639, Japan	Tokyo Metropolitan Institute of Medical Science; University of Tokyo; Japan Science & Technology Agency (JST)	Masai, H (corresponding author), Tokyo Metropolitan Inst Med Sci, Dept Cell Biol, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138613, Japan.							ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; BAHMAN M, 1988, BIOCHIM BIOPHYS ACTA, V951, P335, DOI 10.1016/0167-4781(88)90104-2; Brown GW, 1999, P NATL ACAD SCI USA, V96, P8443, DOI 10.1073/pnas.96.15.8443; Brown GW, 1998, J BIOL CHEM, V273, P22083, DOI 10.1074/jbc.273.34.22083; Cheng LA, 1999, MOL CELL BIOL, V19, P4270; DOWELL SJ, 1994, SCIENCE, V265, P1243, DOI 10.1126/science.8066465; Ferreira MG, 2000, MOL CELL BIOL, V20, P242; Go M., 1985, Advances in Biophysics, V19, P91; Gutz H., 1974, HDB GENETICS, V1, P395; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hardy CFJ, 1996, MOL CELL BIOL, V16, P6775; HARTWELL LH, 1971, J MOL BIOL, V59, P183, DOI 10.1016/0022-2836(71)90420-7; HARTWELL LH, 1973, J BACTERIOL, V115, P966, DOI 10.1128/JB.115.3.966-974.1973; JACKSON AL, 1993, MOL CELL BIOL, V13, P2899, DOI 10.1128/MCB.13.5.2899; James SW, 1999, J CELL SCI, V112, P1313; Jiang W, 1999, EMBO J, V18, P5703, DOI 10.1093/emboj/18.20.5703; Jiang W, 1997, P NATL ACAD SCI USA, V94, P14320, DOI 10.1073/pnas.94.26.14320; JOHNSTON LH, 1982, MOL GEN GENET, V186, P439, DOI 10.1007/BF00729466; Johnston LH, 1999, TRENDS CELL BIOL, V9, P249, DOI 10.1016/S0962-8924(99)01586-X; Kihara M, 2000, J BIOL CHEM, V275, P35051, DOI 10.1074/jbc.M003491200; Kim JM, 1998, J BIOL CHEM, V273, P23248, DOI 10.1074/jbc.273.36.23248; KITADA K, 1992, GENETICS, V131, P21; Kumagai H, 1999, MOL CELL BIOL, V19, P5083; Lepke M, 1999, MOL GEN GENET, V262, P220, DOI 10.1007/s004380051078; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; Mackay JP, 1998, TRENDS BIOCHEM SCI, V23, P1, DOI 10.1016/S0968-0004(97)01168-7; Masai H, 2000, IUBMB LIFE, V49, P353; Masai H, 2000, BIOCHEM BIOPH RES CO, V275, P228, DOI 10.1006/bbrc.2000.3281; MASAI H, 1995, EMBO J, V14, P3094, DOI 10.1002/j.1460-2075.1995.tb07312.x; Masai H, 2000, J BIOL CHEM, V275, P29042, DOI 10.1074/jbc.M002713200; Masai H., 1999, FRONT BIOSCI, V4, pD834; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; Nakamura T, 2000, GENES CELLS, V5, P463, DOI 10.1046/j.1365-2443.2000.00343.x; Ohtoshi A, 1997, MOL GEN GENET, V254, P562, DOI 10.1007/s004380050452; OKAZAKI K, 1990, NUCLEIC ACIDS RES, V18, P6485, DOI 10.1093/nar/18.22.6485; RADZIOANDZELM E, 1995, STRUCTURE, V3, P1135; Sato N, 1997, EMBO J, V16, P4340, DOI 10.1093/emboj/16.14.4340; SCLAFANI RA, 1994, MOL MICROBIOL, V11, P805, DOI 10.1111/j.1365-2958.1994.tb00358.x; Sclafani RA, 2000, J CELL SCI, V113, P2111; Shellman YG, 1998, MOL GEN GENET, V259, P429, DOI 10.1007/s004380050833; Takeda T, 1999, MOL CELL BIOL, V19, P5535; Takeda T, 2001, MOL BIOL CELL, V12, P1257, DOI 10.1091/mbc.12.5.1257; Weinreich M, 1999, EMBO J, V18, P5334, DOI 10.1093/emboj/18.19.5334	43	48	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31376	31387		10.1074/jbc.M102197200	http://dx.doi.org/10.1074/jbc.M102197200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11402029	hybrid			2022-12-25	WOS:000170472900102
J	Battistoni, A; Pacello, F; Mazzetti, AP; Capo, C; Kroll, JS; Langford, PR; Sansone, A; Donnarumma, G; Valenti, P; Rotilio, G				Battistoni, A; Pacello, F; Mazzetti, AP; Capo, C; Kroll, JS; Langford, PR; Sansone, A; Donnarumma, G; Valenti, P; Rotilio, G			A histidine-rich metal binding domain at the N terminus of Cu,Zn-superoxide dismutases from pathogenic bacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CU,ZN SUPEROXIDE-DISMUTASE; ESCHERICHIA-COLI; COPPER CHAPERONE; SALMONELLA-TYPHIMURIUM; PROTEIN; ZINC; VIRULENCE; IDENTIFICATION; PURIFICATION; MUTANTS	A group of Cu,Zn-superoxide dismutases from pathogenic bacteria is characterized by histidine-rich N-terminal extensions that are in a highly exposed and mobile conformation. This feature allows these proteins to be readily purified in a single step by immobilized metal affinity chromatography. The Cu,Zn-superoxide dismutases from both Haemophilus ducreyi and Haemophilus parainfluenzae display anomalous absorption spectra in the visible region due to copper binding at the N-terminal region. Reconstitution experiments of copper-free enzymes demonstrate that, under conditions of limited copper availability, this metal ion is initially bound at the N-terminal region and subsequently transferred to an active site. Evidence is provided for intermolecular pathways of copper transfer from the N-terminal domain of an enzyme subunit to an active site located on a distinct dimeric molecule. Incubation with EDTA rapidly removes copper bound at the N terminus but is much less effective on the copper ion bound at the active site. This indicates that metal binding by the N-terminal histidines is kinetically favored, but the catalytic site binds copper with higher affinity. We suggest that the histidine-rich N-terminal region constitutes a metal binding domain involved in metal uptake under conditions of metal starvation in vivo. Particular biological importance for this domain is inferred by the observation that its presence enhances the protection offered by periplasmic Cu,Zn-superoxide dismutase toward phagocytic killing.	Univ Roma Tor Vergata, Dipartimento Biol, I-00133 Rome, Italy; Univ London Imperial Coll Sci Technol & Med, St Marys Hosp, Sch Med, Dept Paediat,Mol Infect Dis Grp, London W2 1PG, England; Univ Naples Federico II, Ist Microbiol 2, I-80138 Naples, Italy	University of Rome Tor Vergata; Imperial College London; University of Naples Federico II	Battistoni, A (corresponding author), Univ Roma Tor Vergata, Dipartimento Biol, Via Ric Sci, I-00133 Rome, Italy.	andrea.battistoni@uniroma2.it	Battistoni, Andrea/A-4778-2016; Langford, Paul R/B-9092-2008; Langford, Paul/AAU-4189-2020	Battistoni, Andrea/0000-0003-4085-7917; Langford, Paul R/0000-0002-6368-4724; Langford, Paul/0000-0002-6368-4724; DONNARUMMA, Giovanna/0000-0002-3087-1240; VALENTI, Piera/0000-0002-4354-3190; Sansone, Susanna-Assunta/0000-0001-5306-5690				Babior BM, 2000, AM J MED, V109, P33, DOI 10.1016/S0002-9343(00)00481-2; BANNISTER JV, 1987, CRC CR REV BIOCH MOL, V22, P111, DOI 10.3109/10409238709083738; Battistoni A, 1998, BIOCHEM BIOPH RES CO, V243, P804, DOI 10.1006/bbrc.1998.8182; Battistoni A, 1996, BIOCHEM J, V320, P713, DOI 10.1042/bj3200713; Battistoni A, 1998, J BIOL CHEM, V273, P5655, DOI 10.1074/jbc.273.10.5655; Battistoni A, 1999, FEBS LETT, V443, P313, DOI 10.1016/S0014-5793(98)01725-6; Benov L, 1997, ARCH BIOCHEM BIOPHYS, V340, P305, DOI 10.1006/abbi.1997.9940; Bordo D, 1999, J MOL BIOL, V285, P283, DOI 10.1006/jmbi.1998.2267; BORDO D, 1994, J MOL BIOL, V238, P366, DOI 10.1006/jmbi.1994.1298; Bourne Y, 1996, P NATL ACAD SCI USA, V93, P12774, DOI 10.1073/pnas.93.23.12774; Camilli A, 1995, MOL MICROBIOL, V18, P671, DOI 10.1111/j.1365-2958.1995.mmi_18040671.x; CARLIOZ A, 1986, EMBO J, V5, P623, DOI 10.1002/j.1460-2075.1986.tb04256.x; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; DeGroote MA, 1997, P NATL ACAD SCI USA, V94, P13997, DOI 10.1073/pnas.94.25.13997; Fang FC, 1999, P NATL ACAD SCI USA, V96, P7502, DOI 10.1073/pnas.96.13.7502; Farrant JL, 1997, MOL MICROBIOL, V25, P785, DOI 10.1046/j.1365-2958.1997.5151877.x; Figueroa-Bossi N, 1999, MOL MICROBIOL, V33, P167, DOI 10.1046/j.1365-2958.1999.01461.x; Folcarelli S, 1998, BIOCHEM BIOPH RES CO, V244, P908, DOI 10.1006/bbrc.1998.8364; Fontana A, 1997, FOLD DES, V2, pR17, DOI 10.1016/S1359-0278(97)00010-2; Forest KT, 2000, J MOL BIOL, V296, P145, DOI 10.1006/jmbi.1999.3448; Foti D, 1997, BIOCHEMISTRY-US, V36, P7109, DOI 10.1021/bi963020f; FU CL, 1995, P NATL ACAD SCI USA, V92, P2333, DOI 10.1073/pnas.92.6.2333; Gatti D, 2000, J BIOL CHEM, V275, P34009, DOI 10.1074/jbc.R000012200; Gort AS, 1999, MOL MICROBIOL, V32, P179, DOI 10.1046/j.1365-2958.1999.01343.x; GURUPRASAD K, 1990, PROTEIN ENG, V4, P155, DOI 10.1093/protein/4.2.155; Harrison MD, 2000, TRENDS BIOCHEM SCI, V25, P29, DOI 10.1016/S0968-0004(99)01492-9; HASSAN HM, 1979, J BIOL CHEM, V254, P846; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; JANKNECHT R, 1991, P NATL ACAD SCI USA, V88, P8972, DOI 10.1073/pnas.88.20.8972; KAMIZONO A, 1989, MOL GEN GENET, V219, P161, DOI 10.1007/BF00261172; KROLL JS, 1991, J BACTERIOL, V173, P7449, DOI 10.1128/jb.173.23.7449-7457.1991; KROLL JS, 1995, MICROBIOL-UK, V141, P2271, DOI 10.1099/13500872-141-9-2271; Kuroda M, 1999, MICROBIOL IMMUNOL, V43, P115, DOI 10.1111/j.1348-0421.1999.tb02382.x; Lamb AL, 1999, NAT STRUCT BIOL, V6, P724; Langford PR, 1997, FEMS IMMUNOL MED MIC, V17, P235, DOI 10.1016/S0928-8244(97)00011-4; LEE MH, 1993, PROTEIN SCI, V2, P1042, DOI 10.1002/pro.5560020617; Lewis DA, 1999, INFECT IMMUN, V67, P5060, DOI 10.1128/IAI.67.10.5060-5068.1999; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARKLUND S, 1974, EUR J BIOCHEM, V47, P469; MESSING J, 1977, P NATL ACAD SCI USA, V74, P3642, DOI 10.1073/pnas.74.9.3642; NAKAYASHIKI T, 1995, MOL GEN GENET, V249, P139, DOI 10.1007/BF00290359; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Pacello F, 2001, J BIOL CHEM, V276, P30326, DOI 10.1074/jbc.M010488200; PANTOLIANO MW, 1982, J AM CHEM SOC, V104, P6043; Pesce A, 1997, J MOL BIOL, V274, P408, DOI 10.1006/jmbi.1997.1400; Pesce A, 2000, J MOL BIOL, V302, P465, DOI 10.1006/jmbi.2000.4074; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; RIGO A, 1977, BIOCHEM J, V161, P27, DOI 10.1042/bj1610027; ROOF WD, 1994, J BIOL CHEM, V269, P2902; ROTILIO G, 1973, J BIOL CHEM, V248, P3855; San Mateo LR, 1999, INFECT IMMUN, V67, P5345, DOI 10.1128/IAI.67.10.5345-5351.1999; Schmidt PJ, 1999, J BIOL CHEM, V274, P23719, DOI 10.1074/jbc.274.34.23719; Sheehan BJ, 2000, INFECT IMMUN, V68, P4778, DOI 10.1128/IAI.68.8.4778-4781.2000; SOLIOZ M, 1995, J BIOL CHEM, V270, P9217, DOI 10.1074/jbc.270.16.9217; Stroppolo ME, 1998, BIOCHEMISTRY-US, V37, P12287, DOI 10.1021/bi980563b; TAINER JA, 1982, J MOL BIOL, V160, P181, DOI 10.1016/0022-2836(82)90174-7; Wang JY, 1996, P NATL ACAD SCI USA, V93, P10434, DOI 10.1073/pnas.93.19.10434; Watt RK, 1998, J BIOL CHEM, V273, P10019, DOI 10.1074/jbc.273.16.10019; Wilks KE, 1998, INFECT IMMUN, V66, P213, DOI 10.1128/IAI.66.1.213-217.1998; Wong PC, 2000, P NATL ACAD SCI USA, V97, P2886, DOI 10.1073/pnas.040461197; WULFING C, 1994, MOL MICROBIOL, V12, P685, DOI 10.1111/j.1365-2958.1994.tb01056.x	61	53	55	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30315	30325		10.1074/jbc.M010527200	http://dx.doi.org/10.1074/jbc.M010527200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11369756	hybrid			2022-12-25	WOS:000170558000094
J	Chen, XM; Johns, DC; Geiman, DE; Marban, E; Dang, DT; Hamlin, G; Sun, RG; Yang, VW				Chen, XM; Johns, DC; Geiman, DE; Marban, E; Dang, DT; Hamlin, G; Sun, RG; Yang, VW			Kruppel-like factor 4 (Gut-enriched Kruppel-like factor) inhibits cell proliferation by blocking G(1)/S progression of the cell cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; STRUCTURAL ELEMENTS; ECDYSONE RECEPTOR; NUCLEAR PROTEINS; GENE-EXPRESSION; MAMMALIAN-CELLS; HUMAN KERATIN-4; FINGER; PROMOTER; FAMILY	Kruppel-like factor 4 (KLF4) is an epithelial cell-enriched, zinc finger-containing transcription factor, the expression of which is associated with growth arrest. Previous studies show that constitutive expression of KLF4 inhibits DNA synthesis but the manner by which KLF4 exerts this effect is unclear. In the present study, we developed a system in which expression of KLF4 is controlled by a promoter that is induced upon treatment of cells containing the receptors for the insect hormone, eedysone, with ponasterone A, an eedysone analogue. The rate of proliferation of a stably transfected colon cancer cell line, RKO, was significantly decreased following addition of ponasterone A when compared with untreated cells. Flow cytometric analyses indicated that the inducible expression of KLF4 caused a block in the G(1)/S phase of the cell cycle. A similar block was observed when eedysone receptor-containing RKO cells were infected with a replication-defective recombinant adenovirus containing an inducible KLF4 and treated with ponasterone A. Results of these studies provide evidence that the inhibitory effect of KLF4 on cell proliferation is mainly exerted at the G(1)/S boundary of the cell cycle.	Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine	Yang, VW (corresponding author), Emory Univ, Sch Med, Div Digest Dis, Rm 2101 Woodruff Mem Bldg,1639 Pierce Dr, Atlanta, GA 30322 USA.	vyang@emory.edu	Marban, Eduardo/GWC-8514-2022		NATIONAL CANCER INSTITUTE [R01CA084197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052230] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA084197, CA84197, R01 CA084197-02] Funding Source: Medline; NIDDK NIH HHS [DK52230, R01 DK052230, R01 DK052230-04] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON KP, 1995, MOL CELL BIOL, V15, P5957; Chen ZY, 2000, FEBS LETT, V477, P67, DOI 10.1016/S0014-5793(00)01764-6; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; Dang DT, 2000, INT J BIOCHEM CELL B, V32, P1103, DOI 10.1016/S1357-2725(00)00059-5; Dang DT, 2000, FEBS LETT, V476, P203, DOI 10.1016/S0014-5793(00)01727-0; DANG DT, 2001, IN PRESS ONCOGENE; Dubravka D, 2000, CELL RES, V10, P1, DOI 10.1038/sj.cr.7290031; Foster KW, 1999, CELL GROWTH DIFFER, V10, P423; Foster KW, 2000, CANCER RES, V60, P6488; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; Geiman DE, 2000, NUCLEIC ACIDS RES, V28, P1106, DOI 10.1093/nar/28.5.1106; Glynne R, 2000, IMMUNOL REV, V176, P216; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Harper JW, 1997, CANCER SURV, V29, P91; Jenkins TD, 1998, J BIOL CHEM, V273, P10747, DOI 10.1074/jbc.273.17.10747; Johns DC, 1999, J NEUROSCI, V19, P1691; Johns DC, 1997, J BIOL CHEM, V272, P31598, DOI 10.1074/jbc.272.50.31598; Kuo CT, 1997, GENE DEV, V11, P2996, DOI 10.1101/gad.11.22.2996; Kuo CT, 1997, SCIENCE, V277, P1986, DOI 10.1126/science.277.5334.1986; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; Ohnishi S, 2000, DEV DYNAM, V217, P421, DOI 10.1002/(SICI)1097-0177(200004)217:4<421::AID-DVDY9>3.0.CO;2-1; Okano J, 2000, FEBS LETT, V473, P95, DOI 10.1016/S0014-5793(00)01468-X; Panigada M, 1999, MECH DEVELOP, V81, P103, DOI 10.1016/S0925-4773(98)00237-8; PERKINS AC, 1995, NATURE, V375, P318; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; SCHUH R, 1986, CELL, V47, P1025, DOI 10.1016/0092-8674(86)90817-2; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shie JL, 2000, AM J PHYSIOL-GASTR L, V279, pG806, DOI 10.1152/ajpgi.2000.279.4.G806; Shie JL, 2000, NUCLEIC ACIDS RES, V28, P2969, DOI 10.1093/nar/28.15.2969; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Turner J, 1999, TRENDS BIOCHEM SCI, V24, P236, DOI 10.1016/S0968-0004(99)01406-1; Wani MA, 1998, TRANSGENIC RES, V7, P229, DOI 10.1023/A:1008809809843; Wani MA, 1999, J BIOL CHEM, V274, P21180, DOI 10.1074/jbc.274.30.21180; YAO TP, 1993, NATURE, V366, P476, DOI 10.1038/366476a0; YAO TP, 1992, CELL, V71, P63, DOI 10.1016/0092-8674(92)90266-F; Zhang GH, 1996, BIOCHEM BIOPH RES CO, V227, P707, DOI 10.1006/bbrc.1996.1573; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200; Zhang WQ, 1998, J BIOL CHEM, V273, P17917, DOI 10.1074/jbc.273.28.17917	41	198	209	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30423	30428		10.1074/jbc.M101194200	http://dx.doi.org/10.1074/jbc.M101194200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11390382	hybrid, Green Accepted			2022-12-25	WOS:000170558000107
J	Gratton, JP; Morales-Ruiz, M; Kureishi, Y; Fulton, D; Walsh, K; Sessa, WC				Gratton, JP; Morales-Ruiz, M; Kureishi, Y; Fulton, D; Walsh, K; Sessa, WC			Akt down-regulation of p38 signaling provides a novel mechanism of vascular endothelial growth factor-mediated cytoprotection in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; MAP KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSDUCTION PATHWAY; ACTIN REORGANIZATION; TRANSCRIPTION FACTOR; APOPTOSIS; PHOSPHORYLATION	Vascular endothelial growth factor (VEGF) utilizes a phosphoinositide 3-kinase (PI 3-kinase)/Akt signaling pathway to protect endothelial cells from apoptotic death. Here we show that PI 3-kinase/Akt; signaling promotes endothelial cell survival by inhibiting p38 mitogen-activated protein kinase (MAPK)-dependent apoptosis. Blockade of the PI 3-kinase or Akt pathways in conjunction with serum withdrawal stimulates p38-dependent apoptosis. Blockade of PI 3-kinase/Akt also led to enhanced VEGF activation of p38 and apoptosis. In this context, the pro-apoptotic effect of VEGF is attenuated by the p38 MAPK inhibitor SE203580. VEGF stimulation of endothelial cells or infection with an adenovirus expressing constitutively active Akt; causes MEKK3 phosphorylation, which is associated with decreased MEKK3 kinase activity and down-regulation of MKK3/6 and p38 MAPK activation. Conversely, activation-deficient Akt decreases VEGF-stimulated MEKK3 phosphorylation and increases MKK/p38 activation. Activation of MKK3/6 is not dependent on Rac activation since dominant negative Rac does not decrease p38 activation triggered by inhibition of PI 3-kinase. Thus, cross-talk between the Akt and p38 MAPK pathways may regulate the level of cytoprotection versus apoptosis and is a new mechanism to explain the cytoprotective actions of Akt.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol, New Haven, CT 06536 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Mol Cardiobiol Program, New Haven, CT 06536 USA; St Elizabeths Med Ctr Boston, Div Cardiovasc Res, Boston, MA USA	Yale University; Yale University; St. Elizabeth's Medical Center	Sessa, WC (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06536 USA.		Morales-Ruiz, Manuel/L-1031-2014; Bando, Yasuko K./M-4831-2014; Morales-Ruiz, Manuel/AAM-1487-2020; Morales-Ruiz, Manuel/Z-2332-2019; Sessa, William C/B-6844-2011	Morales-Ruiz, Manuel/0000-0002-9074-2272; Bando, Yasuko K./0000-0003-4166-6784; Morales-Ruiz, Manuel/0000-0002-9074-2272; Sessa, William C/0000-0001-5759-1938; Gratton, Jean-Philippe/0000-0001-9877-8520	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD023681] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL010183, R01HL061371, R01HL050692, R37HL061371, R01HL064793] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG015052, R01AG015052] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32HL10183, HL 61371, HL 64793, HL 50692] Funding Source: Medline; NIAMS NIH HHS [AR 40197] Funding Source: Medline; NIA NIH HHS [AG 15052] Funding Source: Medline; NICHD NIH HHS [HD23681] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Coffer PJ, 1998, BIOCHEM J, V335, P1; DANGELO G, 1995, P NATL ACAD SCI USA, V92, P6374, DOI 10.1073/pnas.92.14.6374; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Deacon K, 1999, J BIOL CHEM, V274, P16604, DOI 10.1074/jbc.274.23.16604; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Ellinger-Ziegelbauer H, 1999, MOL CELL BIOL, V19, P3857; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Ferrara N, 1999, KIDNEY INT, V56, P794, DOI 10.1046/j.1523-1755.1999.00610.x; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gao ZY, 1996, DIABETES, V45, P854, DOI 10.2337/diabetes.45.7.854; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Hashimoto S, 1999, EUR RESPIR J, V13, P1357, DOI 10.1034/j.1399-3003.1999.13f21.x; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Kalman D, 1999, MOL BIOL CELL, V10, P1665, DOI 10.1091/mbc.10.5.1665; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Kwon T, 2000, J BIOL CHEM, V275, P423, DOI 10.1074/jbc.275.1.423; Liu ZY, 1997, J CLIN INVEST, V99, P1798, DOI 10.1172/JCI119344; Madge LA, 2000, J BIOL CHEM, V275, P15458, DOI 10.1074/jbc.M001237200; Morales-Ruiz M, 2000, CIRC RES, V86, P892, DOI 10.1161/01.RES.86.8.892; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; O'Connor DS, 2000, AM J PATHOL, V156, P393, DOI 10.1016/S0002-9440(10)64742-6; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Ozes ON, 1999, NATURE, V401, P82; Papapetropoulos A, 1998, P NATL ACAD SCI USA, V95, P4738, DOI 10.1073/pnas.95.8.4738; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Stefanec T, 2000, CHEST, V117, P841, DOI 10.1378/chest.117.3.841; Stein B, 1997, J BIOL CHEM, V272, P19509, DOI 10.1074/jbc.272.31.19509; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Tran J, 1999, BIOCHEM BIOPH RES CO, V264, P781, DOI 10.1006/bbrc.1999.1589; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Yang JH, 2000, NAT GENET, V24, P309, DOI 10.1038/73550; Yue TL, 1999, J BIOL CHEM, V274, P1479, DOI 10.1074/jbc.274.3.1479; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	46	242	245	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30359	30365		10.1074/jbc.M009698200	http://dx.doi.org/10.1074/jbc.M009698200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11387313	hybrid			2022-12-25	WOS:000170558000099
J	Martin-Romero, FJ; Kryukov, GV; Lobanov, AV; Carlson, BA; Lee, BJ; Gladyshev, VN; Hatfield, DL				Martin-Romero, FJ; Kryukov, GV; Lobanov, AV; Carlson, BA; Lee, BJ; Gladyshev, VN; Hatfield, DL			Selenium metabolism in Drosophila - Selenoproteins, selenoprotein mRNA expression, fertility, and mortality	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELENOPHOSPHATE SYNTHETASE; SELENOCYSTEINE INSERTION; SELD HOMOLOG; GENE; MELANOGASTER; TRANSLATION; EUKARYOTES; MECHANISM; TISSUES; GENOME	Selenocysteine is a rare amino acid in protein that is encoded by UGA with the requirement of a downstream mRNA stem-loop structure, the selenocysteine insertion sequence element. To detect selenoproteins in Drosophila, the entire genome was analyzed with a novel program that searches for selenocysteine insertion sequence elements, followed by selenoprotein gene signature analyses. This computational screen and subsequent metabolic labeling with (75)Se and characterization of selenoprotein mRNA expression resulted in identification of three selenoproteins: selenophosphate synthetase 2 and novel G-rich and BthD selenoproteins that had no homology to known proteins. To assess a biological role for these proteins, a simple chemically defined medium that supports growth of adult Drosophila and requires selenium supplementation for optimal survival was devised. Flies survived on this medium supplemented with 10(-8) to 10(-6) m selenium or on the commonly used yeast-based complete medium at about twice the rate as those on a medium without selenium or with > 10(-6) M selenium. This effect correlated with changes in selenoprotein mRNA expression. The number of eggs laid by Drosophila was reduced approximately in half in the chemically defined medium compared with the same medium supplemented with selenium. The data provide evidence that dietary selenium deficiency shortens, while supplementation of the diet with selenium normalizes the Drosophila life span by a process that may involve the newly identified selenoproteins.	NCI, Basic Res Lab, Sect Mol Biol Selenium, NIH, Bethesda, MD 20892 USA; Univ Nebraska, Beadle Ctr, Dept Biochem, Lincoln, NE 68588 USA; Seoul Natl Univ, Sch Biol Sci, Mol Genet Lab, Seoul 151742, South Korea	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Nebraska System; University of Nebraska Lincoln; Seoul National University (SNU)	Hatfield, DL (corresponding author), NCI, Basic Res Lab, Sect Mol Biol Selenium, NIH, Bethesda, MD 20892 USA.	hatfield@dc37a.nci.nih.gov	Gladyshev, Vadim N/J-6187-2013; Kryukov, Gregory V/A-9592-2008; Martin-Romero, Francisco Javier/A-7682-2012; Gladyshev, Vadim N/A-9894-2013	Martin-Romero, Francisco Javier/0000-0001-6796-7396; Gladyshev, Vadim/0000-0002-0372-7016; Kryukov, Gregory/0000-0002-6131-9483	NIGMS NIH HHS [GM61603] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061603] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alsina B, 1999, J CELL SCI, V112, P2875; Alsina B, 1998, MOL GEN GENET, V257, P113, DOI 10.1007/s004380050630; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Bock A, 2000, Biofactors, V11, P77; Copeland PR, 2000, EMBO J, V19, P306, DOI 10.1093/emboj/19.2.306; Fagegaltier D, 2000, EMBO J, V19, P4796, DOI 10.1093/emboj/19.17.4796; FOSTER HD, 1995, SCI TOTAL ENVIRON, V170, P133, DOI 10.1016/0048-9697(95)04626-C; Gladyshev V. N., 1999, Recent Research Developments in Biochemistry, V1, P145; Guimaraes MJ, 1996, P NATL ACAD SCI USA, V93, P15086, DOI 10.1073/pnas.93.26.15086; Hatfield D, 1999, COMPREHENSIVE NATURA, P353; Hirosawa-Takamori M, 2000, EMBO REP, V1, P441, DOI 10.1093/embo-reports/kvd087; KIM IY, 1995, P NATL ACAD SCI USA, V92, P7710, DOI 10.1073/pnas.92.17.7710; Kryukov GV, 1999, J BIOL CHEM, V274, P33888, DOI 10.1074/jbc.274.48.33888; Lescure A, 1999, J BIOL CHEM, V274, P38147, DOI 10.1074/jbc.274.53.38147; LI FS, 1990, MECH AGEING DEV, V54, P103, DOI 10.1016/0047-6374(90)90059-O; LOW SC, 1995, J BIOL CHEM, V270, P21659, DOI 10.1074/jbc.270.37.21659; Low SC, 1996, TRENDS BIOCHEM SCI, V21, P203, DOI 10.1016/0968-0004(96)10025-6; Myers EW, 2000, SCIENCE, V287, P2196, DOI 10.1126/science.287.5461.2196; Persson BC, 1997, J MOL BIOL, V274, P174, DOI 10.1006/jmbi.1997.1371; PHILLIPS JP, 1995, P NATL ACAD SCI USA, V92, P8574, DOI 10.1073/pnas.92.19.8574; Rother M, 2000, J MOL BIOL, V299, P351, DOI 10.1006/jmbi.2000.3756; Tower J, 2000, MECH AGEING DEV, V118, P1, DOI 10.1016/S0047-6374(00)00152-4; Tujebajeva RM, 2000, EMBO REP, V1, P158, DOI 10.1093/embo-reports/kvd033; Vernooy SY, 2000, J CELL BIOL, V150, pF69, DOI 10.1083/jcb.150.2.F69; WIESCHAUS E, 1984, DEV BIOL, V104, P172, DOI 10.1016/0012-1606(84)90046-0; Zhou X, 1999, J BIOL CHEM, V274, P18729, DOI 10.1074/jbc.274.26.18729	26	104	116	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29798	29804		10.1074/jbc.M100422200	http://dx.doi.org/10.1074/jbc.M100422200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11389138	hybrid, Green Published			2022-12-25	WOS:000170558000027
J	Sengupta, S; Chen, H; Togawa, T; DiBello, PM; Majors, AK; Budy, B; Ketterer, ME; Jacobsen, DW				Sengupta, S; Chen, H; Togawa, T; DiBello, PM; Majors, AK; Budy, B; Ketterer, ME; Jacobsen, DW			Albumin thiolate anion is an intermediate in the formation of albumin-S-S-homocysteine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONALLY MODIFIED ALBUMINS; HIGH-AFFINITY BINDING; REDOX STATUS; PROTEIN-BINDING; PLASMA HOMOCYSTEINE; SERUM; AMINOTHIOLS; CYSTEINE; ACID; ENDOCYTOSIS	An elevated concentration of plasma total homocysteine is an independent risk factor for cardiovascular disease. Greater than 80% of circulating homocysteine is covalently bound to plasma protein by disulfide bonds. It is known that albumin combines with cysteine in circulation to form albumin-Cys(34)-S-S-Cys. Studies are now presented to show that the formation of albumin-bound homocysteine proceeds through the generation of an albumin thiolate anion. Incubation of human plasma with L-S-35-homocysteine results in the association of > 90% of the protein-bound S-35-homocysteine with albumin as shown by nonreduced SDS-polyacrylamide gel electrophoresis. Treatment of the complex with beta -mercaptoethanol results in near quantitative release of the bound L-S-35-homocysteine, demonstrating that the binding of homocysteine to albumin is through a disulfide bond. Furthermore, using an in vitro model system to study the mechanisms of this disulfide bond formation, we show that homocysteine binds to albumin in two steps. In the first step homocysteine rapidly displaces cysteine from albumin-Cys(34)-S-S-Cys, forming albumin-Cys(34) thiolate anion and homocysteine-cysteine mixed disulfide. In the second step, albumin thiolate anion attacks homocysteine-cysteine mixed disulfide to yield primarily albumin-Cys(34)-S-S-Hcy and to a much lesser extent albumin-Cys(34)-S-S-Cys. The results clearly suggest that when reduced homocysteine enters circulation, it attacks albumin-Cys(34)-S-S-Cys to form albumin-Cys(34) thiolate anion, which in turn, reacts with homocysteine-cysteine mixed disulfide or homocystine to form albumin-bound homocysteine.	Cleveland Clin Fdn, Dept Cell Biol, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland State Univ, Dept Chem, Cleveland, OH 44115 USA; No Arizona Univ, Dept Chem, Flagstaff, AZ 86011 USA	Cleveland Clinic Foundation; University System of Ohio; Cleveland State University; Northern Arizona University	Jacobsen, DW (corresponding author), Cleveland Clin Fdn, Dept Cell Biol, Lerner Res Inst, 9500 Euclid Ave,NC-10, Cleveland, OH 44195 USA.	jacobs@ccf.org			NHLBI NIH HHS [R01 HL 52234] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052234] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON A, 1995, CLIN CHEM, V41, P361; BENESCH RE, 1955, J AM CHEM SOC, V77, P5877, DOI 10.1021/ja01627a030; Budy B, 2001, ANAL BIOCHEM, V291, P303, DOI 10.1006/abio.2000.5039; CARTER DC, 1994, ADV PROTEIN CHEM, V45, P153; CHRISTODOULOU J, 1994, EUR J BIOCHEM, V225, P363, DOI 10.1111/j.1432-1033.1994.00363.x; CHRISTODOULOU J, 1995, FEBS LETT, V376, P1, DOI 10.1016/0014-5793(95)01231-2; Clarke R, 1998, ARCH NEUROL-CHICAGO, V55, P1449, DOI 10.1001/archneur.55.11.1449; Curry S, 1998, NAT STRUCT BIOL, V5, P827, DOI 10.1038/1869; DUERRE JA, 1966, ANAL BIOCHEM, V17, P310, DOI 10.1016/0003-2697(66)90209-0; Eikelboom JW, 1999, ANN INTERN MED, V131, P363, DOI 10.7326/0003-4819-131-5-199909070-00008; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FINKELSTEIN JD, 1990, J NUTR BIOCHEM, V1, P228, DOI 10.1016/0955-2863(90)90070-2; FRIEDMAN M, 1965, J AM CHEM SOC, V87, P3672, DOI 10.1021/ja01094a025; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; HE XM, 1992, NATURE, V358, P209, DOI 10.1038/358209a0; HOUK RS, 1994, ACCOUNTS CHEM RES, V27, P333, DOI 10.1021/ar00047a003; Jacobsen DW, 2000, DEV CARDIOVASC MED, V230, P15; Jacobsen DW, 2001, HOMOCYSTEINE IN HEALTH AND DISEASE, P425; JACOBSEN DW, 1994, CLIN CHEM, V40, P873; Jakubowski H, 1999, FASEB J, V13, P2277, DOI 10.1096/fasebj.13.15.2277; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANSOOR MA, 1993, CLIN CHEM, V39, P980; MANSOOR MA, 1993, METABOLISM, V42, P1481, DOI 10.1016/0026-0495(93)90202-Y; MANSOOR MA, 1995, ARTERIOSCL THROM VAS, V15, P232, DOI 10.1161/01.ATV.15.2.232; MANSOOR MA, 1992, ANAL BIOCHEM, V200, P218, DOI 10.1016/0003-2697(92)90456-H; McCaddon A, 1998, INT J GERIATR PSYCH, V13, P235, DOI 10.1002/(SICI)1099-1166(199804)13:4<235::AID-GPS761>3.0.CO;2-8; MUDD SH, 1965, J BIOL CHEM, V240, P4382; Narazaki R, 1996, PHARMACEUT RES, V13, P1317, DOI 10.1023/A:1016057513490; Nygard O, 1999, J INTERN MED, V246, P425, DOI 10.1046/j.1365-2796.1999.00512.x; Peters T, 1996, ALL ALBUMIN BIOCH GE, P51; Rasmussen K, 1996, CLIN CHEM, V42, P630; REFSUM H, 1985, CLIN CHEM, V31, P624; ROYER RE, 1983, FEBS LETT, V157, P28, DOI 10.1016/0014-5793(83)81109-0; SCHNITZER JE, 1993, J BIOL CHEM, V268, P7562; SCHNITZER JE, 1992, J BIOL CHEM, V267, P24544; SCHNITZER JE, 1994, J BIOL CHEM, V269, P6072; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOGAMI M, 1984, INT J PEPT PROT RES, V24, P96; Tiruppathi C, 1996, P NATL ACAD SCI USA, V93, P250, DOI 10.1073/pnas.93.1.250; Togawa T, 2000, BIOCHEM BIOPH RES CO, V277, P668, DOI 10.1006/bbrc.2000.3723; UBBINK JB, 1995, CLIN CHEM, V41, P1033; Ullrich V, 1996, BIOCHEM PHARMACOL, V52, P15, DOI 10.1016/0006-2952(96)00109-8	42	147	150	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30111	30117		10.1074/jbc.M104324200	http://dx.doi.org/10.1074/jbc.M104324200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11371573	hybrid			2022-12-25	WOS:000170558000069
J	Song, J; Ugai, H; Ogawa, K; Wang, YF; Sarai, A; Obata, Y; Kanazawa, I; Sun, KL; Itakura, K; Yokoyama, KK				Song, J; Ugai, H; Ogawa, K; Wang, YF; Sarai, A; Obata, Y; Kanazawa, I; Sun, KL; Itakura, K; Yokoyama, KK			Two consecutive zinc fingers in Sp1 and in MAZ are essential for interactions with cis-elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR SP1; NF-KAPPA-B; DNA-BINDING; LYMPHOCYTE DEVELOPMENT; HUMAN GENE; 3 FINGERS; C-MYC; PROTEIN; PROMOTER; SEQUENCES	The zinc finger proteins Sp1 and Myc-associated zinc finger protein (MAZ) are transcription factors that control the expression of various genes. Regulation of transcription by these factors is based on interactions between GC-rich DNA-binding sites (GGGCGG for Spl and GGGAGGG for MAZ) and the carboxyl-terminal zinc finger motifs of the two proteins. Spl and MAZ have three and six zinc fingers, respectively, and the details of their interactions with cis-elements remain to be clarified. We demonstrate here that Sp1 and MAZ interact with the same GC-rich DNA-binding sites, apparently sharing DNA-binding sites with each other. We found that the DNA binding activities of Spl and MAZ depended mainly on consecutive zinc fingers, namely the second and third zinc fingers in Spl and the third and fourth zinc fingers in MAZ. Furthermore, the interactions of the zinc finger proteins with the same cis-elements appear to play a critical role in the regulation of gene expression. It seems plausible that two consecutive zinc finger motifs in a zinc finger protein might be essential for interaction of the protein with DNA.	RIKEN, Tsukuba Inst, Inst Phys & Chem Res, Tsukuba, Ibaraki 3050074, Japan; Univ Tokyo, Fac Med, Inst Brain Res, Dept Neurol, Tokyo 1130033, Japan; China Med Univ, Dept Med Genet, Shenyang 110001, Peoples R China; RIKEN, Lab Anim Res, Wako, Saitama 3510198, Japan; City Hope Natl Med Ctr, Beckman Res Inst, Dept Mol Genet, Duarte, CA 91010 USA	RIKEN; University of Tokyo; China Medical University; RIKEN; City of Hope; Beckman Research Institute of City of Hope	Yokoyama, KK (corresponding author), RIKEN, Tsukuba Inst, Inst Phys & Chem Res, 3-1-1 Koyadai, Tsukuba, Ibaraki 3050074, Japan.		Obata, Yuichi/A-5300-2016; Ugai, Hideyo/K-4920-2017	Obata, Yuichi/0000-0003-1839-4709; Ugai, Hideyo/0000-0002-9121-8480				ARAKI E, 1988, NUCLEIC ACIDS RES, V16, P1627, DOI 10.1093/nar/16.4.1627; Billon N, 1999, ONCOGENE, V18, P2872, DOI 10.1038/sj.onc.1202712; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; COUREY AJ, 1992, TRANSCRIPTIONAL REGU, P743; DUNCAN DD, 1995, MOL CELL BIOL, V15, P3179; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; Elrod-Erickson M, 1998, STRUCTURE, V6, P451, DOI 10.1016/S0969-2126(98)00047-1; Georgopoulos K, 1997, ANNU REV IMMUNOL, V15, P155, DOI 10.1146/annurev.immunol.15.1.155; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Hirano F, 1998, MOL CELL BIOL, V18, P1266, DOI 10.1128/MCB.18.3.1266; Houchens CR, 2000, NUCLEIC ACIDS RES, V28, P570, DOI 10.1093/nar/28.2.570; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Karantzoulis-Fegaras F, 1999, J BIOL CHEM, V274, P3076, DOI 10.1074/jbc.274.5.3076; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; Keller ET, 1996, J BIOL CHEM, V271, P26267, DOI 10.1074/jbc.271.42.26267; KENNEDY GC, 1992, P NATL ACAD SCI USA, V89, P11498, DOI 10.1073/pnas.89.23.11498; KRIWACKI RW, 1992, P NATL ACAD SCI USA, V89, P9759, DOI 10.1073/pnas.89.20.9759; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; Li XA, 1999, BBA-GENE STRUCT EXPR, V1489, P405, DOI 10.1016/S0167-4781(99)00206-7; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; Parks CL, 1996, J BIOL CHEM, V271, P4417; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; PYRC JJ, 1992, BIOCHEMISTRY-US, V31, P4102, DOI 10.1021/bi00131a029; Song J, 1998, J BIOL CHEM, V273, P20603, DOI 10.1074/jbc.273.32.20603; Song J, 1999, BIOTECHNIQUES, V26, P1056, DOI 10.2144/99266bm11; Sun L, 1996, EMBO J, V15, P5358, DOI 10.1002/j.1460-2075.1996.tb00920.x; Takechi S, 1999, BIOCHEM BIOPH RES CO, V266, P405, DOI 10.1006/bbrc.1999.1836; VanderHeyden TC, 2000, MOL CELL ENDOCRINOL, V159, P89, DOI 10.1016/S0303-7207(99)00200-2; Young ET, 2000, BIOCHEMISTRY-US, V39, P567, DOI 10.1021/bi992049r	32	36	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30429	30434		10.1074/jbc.M103968200	http://dx.doi.org/10.1074/jbc.M103968200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11395515	hybrid			2022-12-25	WOS:000170558000108
J	Stebbins, EG; Mochly-Rosen, D				Stebbins, EG; Mochly-Rosen, D			Binding specificity for RACK1 resides in the V5 region of beta II protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC MYOCYTES; ANCHORING PROTEINS; IN-VIVO; HUMAN HEART; RAT; LOCALIZATION; EPSILON; ISOZYME; TRANSLOCATION; DOMAINS	Identification of selective anchoring proteins responsible for specialized localization of specific signaling proteins has led to the identification of new inhibitors of signal transduction, inhibitors of anchoring protein-ligand interactions. RACK1, the first receptor for activated C kinase identified in our lab, is a selective anchoring protein for beta II protein kinase C (beta IIPKC). We previously found that at least part of the RACK1-binding site resides in the C2 domain of beta IIPKC (Ron, D., Luo, J., and Mochly-Rosen, D. (1995) J. Biol. Chem. 270, 24180-24187). Here we show that the V5 domain also contains part of the RACK1-binding site in beta IIPKC. In neonatal rat cardiac myocytes, the beta IIPKC peptide (amino acids 645-650 in beta IIPKC) selectively inhibited phorbol 12-myristate 13-acetate (PMA)-induced translocation of beta IIPKC and not beta IIPKC. In addition, the beta IIV5-3 peptide inhibited cardiac myocyte hypertrophy in PMA-treated cells. Interestingly, beta IV5-3 (646-651 in beta IPKC), a selective translocation inhibitor of beta IPKC, also inhibited PMA-induced cardiac myocyte hypertrophy, demonstrating that both betaI- and beta IIPKC are essential for this cardiac function. Therefore, the beta IIV5 domain contains part of the RACK1-binding site in beta IIPKC; a peptide corresponding to this site is a selective inhibitor of beta IIPKC and, hence, enables the identification of beta IIPKC-selective functions.	Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA	Stanford University	Mochly-Rosen, D (corresponding author), Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA.			Mochly-Rosen, Daria/0000-0002-6691-8733	NHLBI NIH HHS [HL52141] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BORNER C, 1995, J BIOL CHEM, V270, P78, DOI 10.1074/jbc.270.1.78; Bowling N, 1999, CIRCULATION, V99, P384, DOI 10.1161/01.CIR.99.3.384; Buck E, 1999, SCIENCE, V283, P1332, DOI 10.1126/science.283.5406.1332; CARR DW, 1992, J BIOL CHEM, V267, P16816; Chalfant CE, 1996, MOL ENDOCRINOL, V10, P1273, DOI 10.1210/me.10.10.1273; Chen YB, 1997, P NATL ACAD SCI USA, V94, P2711, DOI 10.1073/pnas.94.6.2711; CHOI KY, 1994, CELL, V78, P499; Csukai M, 1997, J BIOL CHEM, V272, P29200, DOI 10.1074/jbc.272.46.29200; DISATNIK MH, 1994, EXP CELL RES, V210, P287, DOI 10.1006/excr.1994.1041; Dorn GW, 1999, P NATL ACAD SCI USA, V96, P12798, DOI 10.1073/pnas.96.22.12798; Edwards AS, 1997, J BIOL CHEM, V272, P18382, DOI 10.1074/jbc.272.29.18382; Gokmen-Polar Y, 1998, J BIOL CHEM, V273, P20261, DOI 10.1074/jbc.273.32.20261; Gray MO, 1997, J BIOL CHEM, V272, P30945, DOI 10.1074/jbc.272.49.30945; GU X, 1994, CIRC RES, V75, P926, DOI 10.1161/01.RES.75.5.926; Herberg FW, 2000, J MOL BIOL, V298, P329, DOI 10.1006/jmbi.2000.3662; Hunter JJ, 1999, NEW ENGL J MED, V341, P1276, DOI 10.1056/NEJM199910213411706; Johnson JA, 1996, CIRC RES, V79, P1086, DOI 10.1161/01.RES.79.6.1086; Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962; KARIYA K, 1991, J BIOL CHEM, V266, P10023; Keranen LM, 1997, J BIOL CHEM, V272, P25959, DOI 10.1074/jbc.272.41.25959; Luria A, 2000, BIOL REPROD, V62, P1564, DOI 10.1095/biolreprod62.6.1564; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Mochly-Rosen D, 2000, CIRC RES, V86, P1173; Mochly-Rosen D, 1998, FASEB J, V12, P35; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MOCHLYROSEN D, 1987, J BIOL CHEM, V262, P2291; MOCHLYROSEN D, 1992, BIOCHEMISTRY-US, V31, P8120, DOI 10.1021/bi00150a003; Murray NR, 1998, J BIOL CHEM, V273, P11514, DOI 10.1074/jbc.273.19.11514; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; ONO Y, 1987, SCIENCE, V236, P1116, DOI 10.1126/science.3576226; ONO Y, 1986, FEBS LETT, V206, P347, DOI 10.1016/0014-5793(86)81010-9; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Ron D, 1999, J BIOL CHEM, V274, P27039, DOI 10.1074/jbc.274.38.27039; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; SHUBEITA HE, 1992, P NATL ACAD SCI USA, V89, P1305, DOI 10.1073/pnas.89.4.1305; SIMPSON P, 1982, CIRC RES, V51, P787, DOI 10.1161/01.RES.51.6.787; Simpson PC, 1999, CIRCULATION, V99, P334, DOI 10.1161/01.CIR.99.3.334; Souroujon MC, 1998, NAT BIOTECHNOL, V16, P919, DOI 10.1038/nbt1098-919; Wakasaki H, 1997, P NATL ACAD SCI USA, V94, P9320, DOI 10.1073/pnas.94.17.9320; WALKER SD, 1995, P NATL ACAD SCI USA, V92, P9156, DOI 10.1073/pnas.92.20.9156; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Zhang ZH, 1997, CIRC RES, V80, P720, DOI 10.1161/01.RES.80.5.720	45	144	152	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29644	29650		10.1074/jbc.M101044200	http://dx.doi.org/10.1074/jbc.M101044200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11387319	hybrid			2022-12-25	WOS:000170558000008
J	Stewart, GS; Last, JIK; Stankovic, T; Haites, N; Kidd, AMJ; Byrd, PJ; Taylor, AMR				Stewart, GS; Last, JIK; Stankovic, T; Haites, N; Kidd, AMJ; Byrd, PJ; Taylor, AMR			Residual ataxia telangiectasia mutated protein function in cells from ataxia telangiectasia patients, with 5762ins137 and 7271T -> G mutations, showing a less severe phenotype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIJMEGEN BREAKAGE SYNDROME; DNA-DAMAGE RESPONSE; ATM-DEPENDENT PHOSPHORYLATION; CYCLE CHECKPOINT PATHWAY; CENTRAL-NERVOUS-SYSTEM; ABL TYROSINE KINASE; IONIZING-RADIATION; C-ABL; INDUCED APOPTOSIS; P53	We have assessed several ataxia Telangiectasia mutated (ATM)-dependent functions in cells derived from ataxia telangiectasia patients, carrying either an ATM 5762ins137 splice site or a 7271T -->G missense mutation, with a less severe phenotype compared with the classical disorder. ATM kinase in vitro, from 5762ins137 cells, showed the same specific activity as ATM in normal cells, but the protein was present at low levels. In contrast, mutant ATM kinase activity in the 7271T -->G cells was only about 6% that of the activity in normal cells, although the level of mutant protein expressed was similar to normal cells. Phosphorylation of the DNA double strand break repair proteins Nbs1 and hMre11, following DNA damage, was observed in normal and 7271T -->G cells but was almost absent in both 5762ins137 and classical ataxia telangiectasia cells. The kinetics of p53 response was intermediate between normal and classical ataxia telangiectasia cells in both the 7271T -->G and 5762ins137 cells, but interestingly, c-Jun kinase activation following DNA damage was equally deficient in cell lines derived from all the ataxia telangiectasia patients. Our results indicate that levels of ATM kinase activity, but not induction of p53 or e-Jun kinase activity, in these cells correlate with the degree of neurological disorder in the patients.	Univ Birmingham, Inst Canc Studies, CRC, Birmingham B15 2TT, W Midlands, England; Grampian Univ Hosp, Dept Med Genet, Aberdeen AB25 2ZD, Scotland	University of Birmingham; University of Aberdeen	Taylor, AMR (corresponding author), Univ Birmingham, Inst Canc Studies, CRC, Vincent Dr, Birmingham B15 2TT, W Midlands, England.			Stewart, Grant/0000-0002-0960-3241; Stankovic, Tatjana/0000-0002-3780-274X				ARTUSO M, 1995, ONCOGENE, V11, P1427; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barnes DE, 1998, CURR BIOL, V8, P1395, DOI 10.1016/S0960-9822(98)00021-9; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Becker-Catania SG, 2000, MOL GENET METAB, V70, P122, DOI 10.1006/mgme.2000.2998; Borghesani PR, 2000, P NATL ACAD SCI USA, V97, P3336, DOI 10.1073/pnas.050584897; CANMAN CE, 1994, CANCER RES, V54, P5054; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Chong MJ, 2000, P NATL ACAD SCI USA, V97, P889, DOI 10.1073/pnas.97.2.889; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Dolganov GM, 1996, MOL CELL BIOL, V16, P4832; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dong ZW, 1999, J BIOL CHEM, V274, P19513, DOI 10.1074/jbc.274.28.19513; Gao YJ, 2000, NATURE, V404, P897, DOI 10.1038/35009138; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; Gilad S, 1998, AM J HUM GENET, V62, P551, DOI 10.1086/301755; Gilad S, 1996, HUM MOL GENET, V5, P433, DOI 10.1093/hmg/5.4.433; Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KHANNA KK, 1993, ONCOGENE, V8, P3307; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lee Y, 2000, GENE DEV, V14, P2576, DOI 10.1101/gad.837100; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Lim DS, 1998, P NATL ACAD SCI USA, V95, P10146, DOI 10.1073/pnas.95.17.10146; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; McConville CM, 1996, AM J HUM GENET, V59, P320; Nacht M, 1996, GENE DEV, V10, P2055, DOI 10.1101/gad.10.16.2055; NEWMAN LS, 1995, CELL, V82, P773, DOI 10.1016/0092-8674(95)90474-3; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; SHAFMAN TD, 1995, CANCER RES, V55, P3242; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Stankovic T, 1998, AM J HUM GENET, V62, P334, DOI 10.1086/301706; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Vanasse GJ, 1999, BLOOD, V94, P3997, DOI 10.1182/blood.V94.12.3997.424k44_3997_4010; Wang Y, 2000, GENE DEV, V14, P927; Westphal CH, 1997, NAT GENET, V16, P397, DOI 10.1038/ng0897-397; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083	51	76	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30133	30141		10.1074/jbc.M103160200	http://dx.doi.org/10.1074/jbc.M103160200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11382771	hybrid			2022-12-25	WOS:000170558000072
J	Allen-Jennings, AE; Hartman, MG; Kociba, GJ; Hai, T				Allen-Jennings, AE; Hartman, MG; Kociba, GJ; Hai, T			The roles of ATF3 in glucose homeostasis - A transgenic mouse model with liver dysfunction and defects in endocrine pancreas	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHINESE-HAMSTER CELLS; TRANSCRIPTION FACTOR; FREE-RADICALS; N-ACETYLCYSTEINE; OXIDATIVE STRESS; CHOROID-PLEXUS; INSULIN GENE; NEWBORN MICE; BETA-CELLS; S-PHASE	Activating transcription factor 3 (ATF3) is a member of the ATF/cAMP-response element-binding protein family of transcription factors. It is a transcriptional repressor, and the expression of its corresponding gene is induced by stress signals in a variety of tissues, including the liver. In this report, we demonstrate that ATF3 is induced in the pancreas by partial pancreatectomy, streptozotocin treatment, and ischemia coupled with reperfusion. Furthermore, ATF3 is induced in cultured islet cells by oxidative stress. Interestingly, transgenic mice expressing ATF3 in the liver and pancreas under the control of the transthyretin promoter have defects in glucose homeostasis and perinatal lethality. We present evidence that expression of ATF3 in the liver represses the expression of genes encoding gluconeogenic enzymes. Furthermore, expression of ATF3 in the pancreas leads to abnormal endocrine pancreas and reduced numbers of hormone-producing cells. Analyses of embryos indicated that the ATF3 transgene is expressed in the ductal epithelium in the developing pancreas, and the transgenic pancreas has fewer mitotic cells than the non-transgenic counterpart, providing a potential explanation for the reduction of endocrine cells. Because ATF3 is a stress-inducible gene, these mice may represent a model to investigate the molecular mechanisms for some stress-associated diseases.	Ohio State Univ, Neurobiotechnol Ctr, Columbus, OH 43210 USA; Ohio State Univ, Ohio State Biochem Program, Columbus, OH 43210 USA; Ohio State Univ, Mol Cellular & Dev Biol Program, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Hai, T (corresponding author), Ohio State Univ, Dept Mol & Cellular Biochem, Rm 148,Rightmire Hall,1060 Carmack Rd, Columbus, OH 43210 USA.	hai.2@osu.edu	Hai, Tsonwin/H-4480-2011; Hai, Tsonwin/E-3185-2011	Hai, Tsonwin/0000-0003-4510-0315; Hai, Tsonwin/0000-0003-4510-0315	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064938] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008690] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK064938] Funding Source: Medline; NIEHS NIH HHS [ES08690] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANDERSON T, 1974, J CLIN INVEST, V54, P672, DOI 10.1172/JCI107805; ARUOMA OI, 1989, FREE RADICAL BIO MED, V6, P593, DOI 10.1016/0891-5849(89)90066-X; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes PJ, 1999, NATURE, V402, pB31, DOI 10.1038/35037026; BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; Bonner-Weir S, 2000, J MOL ENDOCRINOL, V24, P297, DOI 10.1677/jme.0.0240297; Bouwens L, 1997, DIABETOLOGIA, V40, P398, DOI 10.1007/s001250050693; BOUWENS L, 1994, DIABETES, V43, P1279, DOI 10.2337/diabetes.43.11.1279; Bouwens L, 1996, VIRCHOWS ARCH, V427, P553; BRAGANZA JM, 1989, FREE RADICALS CHEM P, P357; Brindle PK, 1992, CURR OPIN GENET DEV, V2, P199, DOI 10.1016/S0959-437X(05)80274-6; BROCKENBROUGH JS, 1988, DIABETES, V37, P232, DOI 10.2337/diabetes.37.2.232; BURGUNDER JM, 1989, EUR J CLIN PHARMACOL, V36, P127, DOI 10.1007/BF00609183; CHEN BPC, 1994, J BIOL CHEM, V269, P15819; Drysdale BE, 1996, MOL IMMUNOL, V33, P989, DOI 10.1016/S0161-5890(96)00043-0; Edlund H, 1998, DIABETES, V47, P1817, DOI 10.2337/diabetes.47.12.1817; ELMAGHRABI MR, 1991, J BIOL CHEM, V266, P2115; ERIKSSON U, 1982, BIOL NEONATE, V42, P239; FARBER JM, 1992, MOL CELL BIOL, V12, P1535, DOI 10.1128/MCB.12.4.1535; FREEMAN BA, 1982, LAB INVEST, V47, P412; GIRARD J, 1992, PHYSIOL REV, V72, P507, DOI 10.1152/physrev.1992.72.2.507; GRANNER D, 1991, RECENT PROG HORM RES, V47, P319; GURLEY LR, 1978, EUR J BIOCHEM, V84, P1, DOI 10.1111/j.1432-1033.1978.tb12135.x; GUZ Y, 1995, DEVELOPMENT, V121, P11; Habener JF, 1998, P ASSOC AM PHYSICIAN, V110, P12; Hai T, 1999, GENE EXPRESSION, V7, P321; HAI T, 2001, IN PRESS GENE; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HSU JC, 1991, P NATL ACAD SCI USA, V88, P3511, DOI 10.1073/pnas.88.9.3511; Ishiguro T, 1996, CANCER RES, V56, P875; JACOBSSON B, 1989, J HISTOCHEM CYTOCHEM, V37, P31, DOI 10.1177/37.1.2642294; Jensen J, 1996, J BIOL CHEM, V271, P18749, DOI 10.1074/jbc.271.31.18749; Jonas JC, 1999, J BIOL CHEM, V274, P14112, DOI 10.1074/jbc.274.20.14112; Kakkar R, 1998, CLIN SCI, V94, P623, DOI 10.1042/cs0940623; Kaufman M.H., 1992, ATLAS MOUSE DEV; KLONER RA, 1989, CIRCULATION, V80, P1115, DOI 10.1161/01.CIR.80.5.1115; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LAKE RS, 1972, BIOCHEMISTRY-US, V11, P4817, DOI 10.1021/bi00775a027; Leahy Jack L., 1996, P103; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT; Nizielski SE, 1996, J NUTR, V126, P2697; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; Oster A, 1998, J HISTOCHEM CYTOCHEM, V46, P707, DOI 10.1177/002215549804600602; PARKS DA, 1983, SURGERY, V94, P428; PICTET R, 1972, HDB PHYSL ENDOCRINOL, V7, P25; PICTET RL, 1972, DEV BIOL, V29, P436, DOI 10.1016/0012-1606(72)90083-8; Sander M, 1997, J MOL MED, V75, P327, DOI 10.1007/s001090050118; SANFEY H, 1984, ANN SURG, V200, P405, DOI 10.1097/00000658-198410000-00003; SASSONECORSI P, 1994, EMBO J, V13, P4717, DOI 10.1002/j.1460-2075.1994.tb06797.x; SCHMID E, 1987, EUR J BIOCHEM, V165, P499, DOI 10.1111/j.1432-1033.1987.tb11467.x; SLACK JMW, 1995, DEVELOPMENT, V121, P1569; SWENNE I, 1982, DIABETOLOGIA, V23, P525; Timchenko NA, 1997, MOL CELL BIOL, V17, P7353, DOI 10.1128/MCB.17.12.7353; Timchenko NA, 1999, MOL CELL BIOL, V19, P2936; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; Weir GC, 1997, ACTA DIABETOL, V34, P177, DOI 10.1007/s005920050071; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245; Xu B, 1999, FREE RADICAL BIO MED, V27, P830, DOI 10.1016/S0891-5849(99)00130-6; YAN C, 1990, EMBO J, V9, P869, DOI 10.1002/j.1460-2075.1990.tb08184.x; Ye HG, 1999, MOL CELL BIOL, V19, P8570; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	61	95	98	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29507	29514		10.1074/jbc.M100986200	http://dx.doi.org/10.1074/jbc.M100986200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11371557	hybrid			2022-12-25	WOS:000170346000114
J	Bagheri-Yarmand, R; Mandal, M; Taludker, AH; Wang, RA; Vadlamudi, RK; Kung, HJ; Kumar, R				Bagheri-Yarmand, R; Mandal, M; Taludker, AH; Wang, RA; Vadlamudi, RK; Kung, HJ; Kumar, R			Etk/Bmx tyrosine kinase activates Pak1 and regulates tumorigenicity of breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P21-ACTIVATED KINASE; SIGNAL-TRANSDUCTION; FAMILY; DOMAIN; TRANSFORMATION; ORGANIZATION; EXPRESSION; INHIBITION; HOMOLOGY; CDC42	Etk/Bmx, a member of the Tee family of nonreceptor protein-tyrosine kinases, is characterized by an N-terminal pleckstrin homology domain and has been shown to be a downstream effector of phosphatidylinositol 3-kinase. P21-activated kinase 1 (Pak1), another well characterized effector of phosphatidylinositol. 3-kinase, has been implicated in the progression of breast cancer cells. In this study, we characterized the role of Etk in mammary development and tumorigenesis and explored the functional interactions between Etk and Pak1. We report that Etk expression is developmentally regulated in the mammary gland. Using transient transfection, coimmunoprecipitation and glutathione S-transferase-pull down assays, we showed that Etk directly associates with Pak1 via its N-terminal pleckstrin homology domain and also phosphorylates Pak1 on tyrosine residues. The expression of wild-type Etk in a non-invasive human breast cancer MCF-7 cells significantly increased proliferation and anchorage-independent growth of epithelial cancer cells. Conversely, expression of kinase-inactive mutant Etk-KQ suppressed the proliferation, anchorage-independent growth, and tumorigenicity of human breast cancer MDA-MB435 cells. These results indicate that Pak1 is a target of Etk and that Etk controls the proliferation as well as the anchorage-independent and tumorigenic growth of mammary epithelial cancer cells.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Calif Davis, Ctr Canc, Sacramento, CA 95817 USA	University of Texas System; UTMD Anderson Cancer Center; University of California System; University of California Davis	Kumar, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Kung, Hsing-Jien/C-7651-2013; Mandal, Mahitosh/GMW-6195-2022; Wang, Brian/HGA-9535-2022	Mandal, Mahitosh/0000-0003-3861-3323; Bagheri-Yarmand, Rozita/0000-0001-5139-6381	NCI NIH HHS [CA80066, CA65746] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080066, U01CA065746, R01CA065746] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam L, 2000, J BIOL CHEM, V275, P12041, DOI 10.1074/jbc.275.16.12041; Dharmawardhane S, 1997, J CELL BIOL, V138, P1265, DOI 10.1083/jcb.138.6.1265; Ekman N, 1997, CIRCULATION, V96, P1729, DOI 10.1161/01.CIR.96.6.1729; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Hamazaki Y, 1998, ONCOGENE, V16, P2773, DOI 10.1038/sj.onc.1201799; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; Howe AK, 2000, NAT CELL BIOL, V2, P593, DOI 10.1038/35023536; Li ZM, 1997, P NATL ACAD SCI USA, V94, P13820, DOI 10.1073/pnas.94.25.13820; Mandal M, 2001, J BIOL CHEM, V276, P9699, DOI 10.1074/jbc.M008514200; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Mao JH, 1998, EMBO J, V17, P5638, DOI 10.1093/emboj/17.19.5638; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; Nisitani S, 2000, P NATL ACAD SCI USA, V97, P2737, DOI 10.1073/pnas.050583597; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; Qiu Y, 2000, ONCOGENE, V19, P5651, DOI 10.1038/sj.onc.1203958; Rawlings D J, 1995, Semin Immunol, V7, P237, DOI 10.1006/smim.1995.0028; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Satterthwaite AB, 2000, P NATL ACAD SCI USA, V97, P6687, DOI 10.1073/pnas.110146697; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; Tsai YT, 2000, MOL CELL BIOL, V20, P2043, DOI 10.1128/MCB.20.6.2043-2054.2000; Vadlamudi RK, 2000, J BIOL CHEM, V275, P36238, DOI 10.1074/jbc.M002138200; Xue LY, 1999, ONCOGENE, V18, P3391, DOI 10.1038/sj.onc.1202687; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	26	100	111	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29403	29409		10.1074/jbc.M103129200	http://dx.doi.org/10.1074/jbc.M103129200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11382770	hybrid			2022-12-25	WOS:000170346000102
J	Fujiwara, K; Takeuchi, S; Okamura-Ikeda, K; Motokawa, Y				Fujiwara, K; Takeuchi, S; Okamura-Ikeda, K; Motokawa, Y			Purification, characterization, and cDNA cloning of lipoate-activating enzyme from bovine liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCINE CLEAVAGE SYSTEM; H-PROTEIN; ESCHERICHIA-COLI; ACID; DEHYDROGENASE; LIPOYLATION; LIPOYLTRANSFERASE; IDENTIFICATION; EXPRESSION; COMPLEXES	In mammals, lipoate-activating enzyme (LAE) catalyzes the activation of lipoate to lipoyl-nucleoside monophosphate. The lipoyl moiety is then transferred to the specific lysine residue of lipoate-dependent enzymes by the action of lipoyltransferase. We purified LAE from bovine liver mitochondria to apparent homogeneity. LAE activated lipoate with GTP at a 1000-fold higher rate than with ATP. The reaction absolutely required lipoate, GTP, and Mg2+ ion, and the reaction product was lipoyl-GMP. LAE activated both (R)- and (S)-lipoate to the respective lipoyl-GMP, although a preference for (R)-lipoate was observed. Similarly, lipoyltransferase equally transferred both the (R)- and (S)-lipoyl moieties from the respectively activated lipoates to apoH-protein. Interestingly, however, only H-protein carrying (R)-lipoate was active in the glycine cleavage reaction. cDNA clones encoding a precursor LAE with a mitochondrial presequence were isolated. The predicted amino acid sequence of LAE is identical with that of xenobiotic-metabolizing/medium-chain fatty acid:CoA ligase-Ill, but an amino acid substitution due to a single nucleotide polymorphism was found. These results indicate that the medium-chain acyl-CoA synthetase in mitochondria has a novel function, the activation of lipoate with GTP.	Univ Tokushima, Inst Enzyme Res, Tokushima 7708503, Japan	Tokushima University	Motokawa, Y (corresponding author), Univ Tokushima, Inst Enzyme Res, Tokushima 7708503, Japan.							BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; FUJIWARA K, 1992, J BIOL CHEM, V267, P20011; FUJIWARA K, 1994, J BIOL CHEM, V269, P16605; Fujiwara K, 1997, J BIOL CHEM, V272, P31974, DOI 10.1074/jbc.272.51.31974; Fujiwara K, 1996, J BIOL CHEM, V271, P12932, DOI 10.1074/jbc.271.22.12932; FUJIWARA K, 1986, J BIOL CHEM, V261, P8836; FUJIWARA K, 1990, J BIOL CHEM, V265, P17463; KISHORE NS, 1991, J BIOL CHEM, V266, P8835; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORRIS TW, 1994, J BIOL CHEM, V269, P16091; Okamura-Ikeda K, 1999, EUR J BIOCHEM, V264, P446, DOI 10.1046/j.1432-1327.1999.00637.x; PERHAM RN, 1991, BIOCHEMISTRY-US, V30, P8501, DOI 10.1021/bi00099a001; REED LJ, 1990, J BIOL CHEM, V265, P8971; REED LJ, 1958, J BIOL CHEM, V232, P123; Sambrook J., 2002, MOL CLONING LAB MANU; SMITH CM, 1974, J BIOL CHEM, V249, P1497; Stuhlsatz-Krouper SM, 1998, J BIOL CHEM, V273, P28642, DOI 10.1074/jbc.273.44.28642; TSUNODA JN, 1967, ARCH BIOCHEM BIOPHYS, V118, P395, DOI 10.1016/0003-9861(67)90366-9; Vessey D A, 1995, J Biochem Toxicol, V10, P329, DOI 10.1002/jbt.2570100608; Vessey DA, 2000, J BIOCHEM MOL TOXIC, V14, P162, DOI 10.1002/(SICI)1099-0461(2000)14:3<162::AID-JBT6>3.3.CO;2-#; Vessey DA, 2000, J BIOCHEM MOL TOXIC, V14, P11, DOI 10.1002/(SICI)1099-0461(2000)14:1<11::AID-JBT2>3.3.CO;2-5	22	50	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					28819	28823		10.1074/jbc.M101748200	http://dx.doi.org/10.1074/jbc.M101748200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11382754	hybrid			2022-12-25	WOS:000170346000025
J	Wimmer, C; Hohl, TM; Hughes, CA; Muller, SA; Sollner, TH; Engel, A; Rothman, JE				Wimmer, C; Hohl, TM; Hughes, CA; Muller, SA; Sollner, TH; Engel, A; Rothman, JE			Molecular mass, stoichiometry, and assembly of 20 S particles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE FUSION PROTEIN; NSF-ATTACHMENT PROTEINS; TRANSMISSION ELECTRON-MICROSCOPY; INTEGRAL MEMBRANE-PROTEIN; OLIGOMERIC MATRIX PROTEIN; ALPHA-HELICAL BUNDLE; SNARE COMPLEX; CRYSTAL-STRUCTURE; VESICULAR TRANSPORT; IN-VITRO	N-Ethylmaleimide-sensitive factor (NSF), soluble NSF attachment proteins (SNAPs), and SNAP receptor (neuronal SNARE) complexes form 20 S particles with a mass of 788 +/- 122 kDa as judged by scanning transmission electron microscopy. A single NSF hexamer and three alpha SNAP monomers reside within a 20 S particle as determined by quantitative amino acid analysis. In order to study the binding of aSNAP and NSF in solution, to define their binding domains, and to specify the role of oligomerization in their interaction, we fused domains of aSNAP and NSF to oligomerization modules derived from thrombospondin-1, a trimer, and cartilage oligomeric matrix protein, a pentamer, respectively. Binding studies with these fusion proteins reproduced the interaction of aSNAP and NSF N domains in the absence of the hexamerization domain of NSF (D2). Trimeric aSNAP (or its C-terminal half) is sufficient to recruit NSF even in the absence of SNARE complexes. Furthermore, pentameric NSF N domains are able to bind aSNAP in complex with SNARES, whereas monomeric N domains do not. Our results demonstrate that the oligomerization of both NSF N domains and aSNAP provides a critical driving force for their interaction and the assembly of 20 S particles.	Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Univ Basel, Bioctr, Maurice E Muller Inst High Resolut Electron M, CH-4056 Basel, Switzerland	Memorial Sloan Kettering Cancer Center; University of Basel	Wimmer, C (corresponding author), Basel Inst Immunol, Grenzacherstr 487, CH-4005 Basel, Switzerland.	wimmer@bii.ch		Hohl, Tobias/0000-0002-9097-5412				Barnard RJO, 1997, J CELL BIOL, V139, P875, DOI 10.1083/jcb.139.4.875; BARNSTABLE CJ, 1985, DEV BRAIN RES, V20, P286, DOI 10.1016/0165-3806(85)90116-6; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; CLARY DO, 1990, J BIOL CHEM, V265, P10109; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; EFIMOV VP, 1994, FEBS LETT, V341, P54, DOI 10.1016/0014-5793(94)80239-4; Efimov VP, 1996, PROTEINS, V24, P259, DOI 10.1002/(SICI)1097-0134(199602)24:2<259::AID-PROT13>3.0.CO;2-M; ENGEL A, 1978, ULTRAMICROSCOPY, V3, P273, DOI 10.1016/S0304-3991(78)80037-0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fasshauer D, 1999, J BIOL CHEM, V274, P15440, DOI 10.1074/jbc.274.22.15440; Fasshauer D, 1997, J BIOL CHEM, V272, P28036, DOI 10.1074/jbc.272.44.28036; Fleming KG, 1998, J BIOL CHEM, V273, P15675, DOI 10.1074/jbc.273.25.15675; Fukuda R, 2000, NATURE, V407, P198, DOI 10.1038/35025084; GRIFF IC, 1992, J BIOL CHEM, V267, P12106; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; Harlow E., 1988, ANTIBODIES LAB MANUA; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; Haynes LP, 1998, FEBS LETT, V436, P1, DOI 10.1016/S0014-5793(98)01088-6; HODGES RS, 1973, COLD SPRING HARB SYM, V37, P299, DOI 10.1101/SQB.1973.037.01.040; Hohl TM, 1998, MOL CELL, V2, P539, DOI 10.1016/S1097-2765(00)80153-7; Katz L, 1998, EMBO J, V17, P6200, DOI 10.1093/emboj/17.21.6200; Kondo H, 1997, NATURE, V388, P75, DOI 10.1038/40411; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lenzen CU, 1998, CELL, V94, P525, DOI 10.1016/S0092-8674(00)81593-7; Lin RC, 1997, NEURON, V19, P1087, DOI 10.1016/S0896-6273(00)80399-2; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Malashkevich VN, 1996, SCIENCE, V274, P761, DOI 10.1126/science.274.5288.761; May AP, 1999, NAT CELL BIOL, V1, P175, DOI 10.1038/11097; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; Muller JMM, 1999, J BIOL CHEM, V274, P10154, DOI 10.1074/jbc.274.15.10154; MULLER SA, 1992, ULTRAMICROSCOPY, V46, P317, DOI 10.1016/0304-3991(92)90022-C; NAGIEC EE, 1995, J BIOL CHEM, V270, P29182, DOI 10.1074/jbc.270.49.29182; Nickel W, 1999, P NATL ACAD SCI USA, V96, P12571, DOI 10.1073/pnas.96.22.12571; Orci L, 1997, CELL, V90, P335, DOI 10.1016/S0092-8674(00)80341-4; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; Parlati F, 2000, NATURE, V407, P194, DOI 10.1038/35025076; Parlati F, 1999, P NATL ACAD SCI USA, V96, P12565, DOI 10.1073/pnas.96.22.12565; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; Rabouille C, 1998, CELL, V92, P603, DOI 10.1016/S0092-8674(00)81128-9; Rice LM, 1999, MOL CELL, V4, P85, DOI 10.1016/S1097-2765(00)80190-2; Rossi G, 1997, J BIOL CHEM, V272, P16610, DOI 10.1074/jbc.272.26.16610; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SOTTILE J, 1991, BIOCHEMISTRY-US, V30, P6556, DOI 10.1021/bi00240a028; Stenbeck G, 1998, INT J BIOCHEM CELL B, V30, P573, DOI 10.1016/S1357-2725(97)00064-2; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; TAGAYA M, 1993, J BIOL CHEM, V268, P2662; Terskikh AV, 1997, P NATL ACAD SCI USA, V94, P1663, DOI 10.1073/pnas.94.5.1663; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; Yu RC, 1999, MOL CELL, V4, P97, DOI 10.1016/S1097-2765(00)80191-4; Yu RC, 1998, NAT STRUCT BIOL, V5, P803, DOI 10.1038/1843	63	35	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29091	29097		10.1074/jbc.M011292200	http://dx.doi.org/10.1074/jbc.M011292200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11395481	hybrid			2022-12-25	WOS:000170346000062
J	Coniglio, SJ; Jou, TS; Symons, M				Coniglio, SJ; Jou, TS; Symons, M			Rac1 protects epithelial cells against anoikis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; RHO-FAMILY PROTEINS; ANCHORAGE-INDEPENDENT GROWTH; RAS TRANSFORMATION; INDUCED APOPTOSIS; SMALL GTPASES; PHOSPHATIDYLINOSITOL 3-KINASE; ALPHA PROTEOLYSIS; KINASE ACTIVATION; DEPENDENT PATHWAY	Rho family members play a critical role in malignant transformation. Anchorage-independent growth and the ability to avoid apoptosis caused by loss of anchorage (anoikis) are important features of transformed cells. Here we show that constitutive activation of Rac1 inhibits anoikis in Madin-Darby canine kidney (MDCK) epithelial cells. Constitutively active Rac1-V12 decreases DNA fragmentation and caspase activity by 50% in MDCK cells kept in suspension. In addition, expression of Rac1-V12 in MDCK cells in suspension conditions causes an increase in the number of surviving cells. We also investigated the signaling pathways that are activated by Rac1 to stimulate cell survival. We show that expression of Rac1-V12 in MDCK cells in suspension stimulates a number of signaling cascades that have been implicated in the control of cell survival, including the p42/44 ERK, p38, protein kinase B, and nuclear factor kappaB pathways. Using specific chemical or protein inhibitors of these respective pathways, we show that Rac1-mediated cell survival strongly depends on phosphatidylinositol 3-kinase activity and that activation of ERK, p38, and NF-kappaB are largely dispensable for Rac1 survival signaling. In conclusion, these studies demonstrate that Rac1 can suppress apoptosis in epithelial cells in anchorage-independent conditions and suggest a potential role for Rac1-mediated survival signaling in cell transformation.	Picower Inst Med Res, Manhasset, NY 11030 USA; Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan; Natl Taiwan Univ, Coll Med, Grad Inst Clin Med, Taipei 100, Taiwan	Northwell Health; National Taiwan University; National Taiwan University Hospital; National Taiwan University	Symons, M (corresponding author), Picower Inst Med Res, 350 Community Dr, Manhasset, NY 11030 USA.	msymons@picower.edu		JOU, TZUU-SHUH/0000-0003-4341-5137				Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Barth AIM, 1997, J CELL BIOL, V136, P693, DOI 10.1083/jcb.136.3.693; Bazenet CE, 1998, P NATL ACAD SCI USA, V95, P3984, DOI 10.1073/pnas.95.7.3984; Boehm JE, 1999, J BIOL CHEM, V274, P28632, DOI 10.1074/jbc.274.40.28632; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Crawley JB, 1997, J BIOL CHEM, V272, P15023, DOI 10.1074/jbc.272.23.15023; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; D'Souza-Schorey C, 1998, MOL CELL BIOL, V18, P3936, DOI 10.1128/MCB.18.7.3936; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Esteve P, 1998, ONCOGENE, V17, P1855, DOI 10.1038/sj.onc.1202082; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 1999, CURR BIOL, V9, P1047, DOI 10.1016/S0960-9822(99)80455-2; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Genot EM, 2000, MOL CELL BIOL, V20, P5469, DOI 10.1128/MCB.20.15.5469-5478.2000; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Jol H, 2000, ONCOGENE, V19, P841, DOI 10.1038/sj.onc.1203392; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Joneson T, 1999, MOL CELL BIOL, V19, P5892; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Kantak SS, 1998, J BIOL CHEM, V273, P16953, DOI 10.1074/jbc.273.27.16953; Kawazoe N, 1999, ONCOGENE, V18, P2413, DOI 10.1038/sj.onc.1202555; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Lassus P, 2000, ONCOGENE, V19, P2377, DOI 10.1038/sj.onc.1203553; Le Gall M, 2000, MOL BIOL CELL, V11, P1103, DOI 10.1091/mbc.11.3.1103; Leng J, 1999, J BIOL CHEM, V274, P37855, DOI 10.1074/jbc.274.53.37855; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; Lores P, 1997, ONCOGENE, V15, P601, DOI 10.1038/sj.onc.1201378; Mayo MW, 2000, BBA-REV CANCER, V1470, pM55, DOI 10.1016/S0304-419X(00)00002-0; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Nishida K, 1999, ONCOGENE, V18, P407, DOI 10.1038/sj.onc.1202301; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; Rickert P, 2000, TRENDS CELL BIOL, V10, P466, DOI 10.1016/S0962-8924(00)01841-9; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Ruggieri R, 2001, MOL MED, V7, P293, DOI 10.1007/BF03402212; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Rytomaa M, 1999, CURR BIOL, V9, P1043, DOI 10.1016/S0960-9822(99)80454-0; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Stennicke HR, 2000, METHOD ENZYMOL, V322, P91; Subauste MC, 2000, J BIOL CHEM, V275, P9725, DOI 10.1074/jbc.275.13.9725; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VAN AL, 1997, GENE DEV, V11, P2295; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	61	63	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28113	28120		10.1074/jbc.M102299200	http://dx.doi.org/10.1074/jbc.M102299200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11369774	hybrid			2022-12-25	WOS:000170093400050
J	DeLuca, JG; Newton, CN; Himes, RH; Jordan, MA; Wilson, L				DeLuca, JG; Newton, CN; Himes, RH; Jordan, MA; Wilson, L			Purification and characterization of native conventional kinesin, HSET, and CENP-E from mitotic HeLa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE MOTOR PROTEIN; URCHIN EGG KINESIN; CHROMOSOME ALIGNMENT; KINETOCHORE MOTOR; END; MOTILITY; DROSOPHILA; MOVEMENT; SPINDLE; MITOSIS	We have developed a strategy for the purification of native microtubule motor proteins from mitotic HeLa cells and describe here the purification and characterization of human conventional kinesin and two human kinesin-related proteins, HSET and CENP-E. We found that the 120-kDa HeLa cell conventional kinesin is an active motor that induces microtubule gliding at similar to 30 mum/min at room temperature. This active form of HeLa cell kinesin does not contain light chains, although light chains were detected in other fractions. HSET, a member of the C-terminal kinesin subfamily, was also purified in native form for the first time, and the protein migrates as a single band at similar to 75 kDa. The purified HSET is an active motor that induces microtubule gliding at a rate of similar to5 mum/min, and microtubules glide for an average of 3 mum before ceasing movement. Finally, we Purified native CENP-E, a kinesin-related protein that has been implicated in chromosome congression during mitosis, and we found that this form of CENP-E does not induce microtubule gliding but is able to bind to microtubules.	Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Mat Res Lab, Santa Barbara, CA 93106 USA; Univ Kansas, Dept Mol Biosci, Lawrence, KS 66045 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of Kansas	Wilson, L (corresponding author), Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.	wilson@lifesci.ucsb.edu			NATIONAL CANCER INSTITUTE [R01CA057291] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS013560] Funding Source: NIH RePORTER; NCI NIH HHS [CA57291] Funding Source: Medline; NINDS NIH HHS [NS13560] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDO A, 1994, IMMUNOGENETICS, V39, P194; Barton NR, 1996, P NATL ACAD SCI USA, V93, P1735, DOI 10.1073/pnas.93.5.1735; BLOOM GS, 1995, PROTEIN PROFILE, V2, P1109; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANDRA R, 1993, J BIOL CHEM, V268, P9005; COHN SA, 1989, J BIOL CHEM, V264, P4290; COLE DG, 1993, NATURE, V366, P268, DOI 10.1038/366268a0; Desai A, 1999, CELL, V96, P69, DOI 10.1016/S0092-8674(00)80960-5; Endow SA, 1999, EUR J BIOCHEM, V262, P12, DOI 10.1046/j.1432-1327.1999.00339.x; ENDOW SA, 1994, EMBO J, V13, P2708, DOI 10.1002/j.1460-2075.1994.tb06561.x; Goldstein LSB, 1999, ANNU REV CELL DEV BI, V15, P141, DOI 10.1146/annurev.cellbio.15.1.141; GYOEVA FK, 1991, NATURE, V353, P445, DOI 10.1038/353445a0; HACKNEY DD, 1991, BIOCHEM BIOPH RES CO, V174, P810, DOI 10.1016/0006-291X(91)91490-4; HALL DH, 1991, J CELL BIOL, V115, P389; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; HOLLENBECK PJ, 1990, NATURE, V346, P864, DOI 10.1038/346864a0; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HOWARD J, 1993, METHOD CELL BIOL, V39, P105, DOI 10.1016/S0091-679X(08)60164-8; HUNT AJ, 1993, P NATL ACAD SCI USA, V90, P11653, DOI 10.1073/pnas.90.24.11653; HYMAN AA, 1991, J CELL SCI, P125; JORDAN MA, 1991, CANCER RES, V51, P2212; JORDAN MA, 1992, J CELL SCI, V102, P401; Kashina AS, 1996, NATURE, V379, P270, DOI 10.1038/379270a0; KURIYAMA R, 1995, J CELL BIOL, V129, P1049, DOI 10.1083/jcb.129.4.1049; LIAO H, 1994, SCIENCE, V265, P394, DOI 10.1126/science.8023161; LIPPINCOTTSCHWARTZ J, 1995, J CELL BIOL, V128, P293, DOI 10.1083/jcb.128.3.293; LIPPINCOTTSCHWARTZ J, 1995, BIOCHEM SOC T, V23, P544, DOI 10.1042/bst0230544; LOMBILLO VA, 1995, J CELL BIOL, V128, P107, DOI 10.1083/jcb.128.1.107; MUROFUSHI H, 1988, J BIOL CHEM, V263, P12744; PORTER ME, 1987, J BIOL CHEM, V262, P2794; RODIONOV VI, 1991, P NATL ACAD SCI USA, V88, P4956, DOI 10.1073/pnas.88.11.4956; SAXTON WM, 1991, CELL, V64, P1093, DOI 10.1016/0092-8674(91)90264-Y; SAXTON WM, 1988, P NATL ACAD SCI USA, V85, P1109, DOI 10.1073/pnas.85.4.1109; Schaar BT, 1997, J CELL BIOL, V139, P1373, DOI 10.1083/jcb.139.6.1373; SHIMIZU T, 1991, J CELL BIOL, V112, P1189, DOI 10.1083/jcb.112.6.1189; Song H, 1997, BIOTECHNIQUES, V22, P82, DOI 10.2144/97221bm18; Steinberg G, 1996, J BIOL CHEM, V271, P7516, DOI 10.1074/jbc.271.13.7516; THROWER DA, 1995, EMBO J, V14, P918, DOI 10.1002/j.1460-2075.1995.tb07073.x; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALE RD, 1989, CELL MOVEMENT KINESI, P287; Walczak CE, 1997, J CELL BIOL, V136, P859, DOI 10.1083/jcb.136.4.859; Walczak CE, 1996, CELL, V85, P943, DOI 10.1016/S0092-8674(00)81295-7; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0; Wood KW, 1997, CELL, V91, P357, DOI 10.1016/S0092-8674(00)80419-5; WRIGHT BD, 1993, J CELL BIOL, V123, P681, DOI 10.1083/jcb.123.3.681; Yao XB, 2000, NAT CELL BIOL, V2, P484, DOI 10.1038/35019518; Yao XB, 1997, J CELL BIOL, V139, P435, DOI 10.1083/jcb.139.2.435; YEN TJ, 1992, NATURE, V359, P536, DOI 10.1038/359536a0	48	39	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28014	28021		10.1074/jbc.M102801200	http://dx.doi.org/10.1074/jbc.M102801200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11382767	hybrid			2022-12-25	WOS:000170093400037
J	Toonkool, P; Regan, DG; Kuchel, PW; Morris, MB; Weiss, AS				Toonkool, P; Regan, DG; Kuchel, PW; Morris, MB; Weiss, AS			Thermodynamic and hydrodynamic properties of human tropoelastin - Analytical ultracentrifuge and pulsed field-gradient spin-echo NMR studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELF-ASSOCIATION; COACERVATION; SEDIMENTATION; DIFFUSION; WATER; PROTEINS; SYSTEM	Tropoelastin is the soluble precursor of elastin that bestows tissue elasticity in vertebrates. Tropoelastin is soluble at 20 degreesC in phosphate-buffered saline, pH 7.4, but at 37 degreesC equilibrium is established between soluble protein and insoluble coacervate. Sedimentation equilibrium studies performed before (20 degreesC) and after (37 degreesC) coacervation showed that the soluble component was strictly monomeric. Sedimentation velocity experiments revealed that at both temperatures soluble tropoelastin exists as two independently sedimenting monomeric species present in approximately equal concentrations. Species I had a frictional ratio at both temperatures of similar to2.2, suggesting a very highly expanded or asymmetric protein. Species 2 displayed a frictional ratio at 20 degreesC of 1.4 that increased to 1.7 at 37 degreesC, indicating a compact and symmetrical conformation. that expanded or became asymmetric at the higher temperature. The slow interconversion of the two monomeric species contrasts with the rapid and reversible process of coacervation suggesting both efficiently incorporate into the coacervate. A hydrated protein of equivalent molecular weight modeled as a sphere and a flexible chain was predicted to have a frictional ratio of 1.2 and 1.6, respectively. Tropoelastin appeared as a single species when studied by pulsed field-gradient spin-echo NMR, but computer modeling showed that the method was insensitive to the presence of two species of equal concentration having similar diffusion coefficients. Scintillation proximity assays using radiolabeled tropoelastin and sedimentation analysis showed that the coacervation. at 37 degreesC was a highly cooperative monomer-n-mer self-association. A critical concentration of 3.4 g/liter was obtained when the coacervate was modeled as a helical polymer formed from the monomers via oligomeric intermediates.	Univ Sydney, Dept Biochem G08, Sydney, NSW 2006, Australia; Univ Sydney, Fac Pharm, Sydney, NSW 2006, Australia	University of Sydney; University of Sydney	Weiss, AS (corresponding author), Univ Sydney, Dept Biochem G08, Sydney, NSW 2006, Australia.	a.weiss@biochem.usyd.edu.au	Weiss, Anthony S/GYV-0157-2022; Weiss, Anthony S/F-8103-2010; Morris, Michael/AAP-6590-2021	Weiss, Anthony S/0000-0002-8106-4836; Kongsaeree, Prachumporn/0000-0003-0273-2638; Morris, Michael/0000-0002-1286-4784; Kuchel, Philip/0000-0003-4100-7332				ANDREU JM, 1986, METHOD ENZYMOL, V130, P47; ATTRI AK, 1991, J BIOL CHEM, V266, P6815; BRESSAN GM, 1986, J ULTRA MOL STRUCT R, V94, P209, DOI 10.1016/0889-1605(86)90068-6; BRESSAN GM, 1983, J ULTRA MOL STRUCT R, V82, P335, DOI 10.1016/S0022-5320(83)80021-5; CALLAGHAN PT, 1983, MACROMOLECULES, V16, P968, DOI 10.1021/ma00240a028; CLAVERIE JM, 1975, BIOPOLYMERS, V14, P1685, DOI 10.1002/bip.1975.360140811; COOKE R, 1974, ANNU REV BIOPHYS BIO, V3, P95, DOI 10.1146/annurev.bb.03.060174.000523; COX BA, 1974, J BIOL CHEM, V249, P997; COX BA, 1973, BIOCHIM BIOPHYS ACTA, V317, P209, DOI 10.1016/0005-2795(73)90215-8; CREETH JM, 1965, BIOCHIM BIOPHYS ACTA, V102, P549, DOI 10.1016/0926-6585(65)90145-7; Harris, 1984, DIFFUSION LIQUIDS TH; JOHNSON ML, 1978, BIOCHEMISTRY-US, V17, P1448, DOI 10.1021/bi00601a014; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Kaibara K, 2000, BIOPOLYMERS, V53, P369, DOI 10.1002/(SICI)1097-0282(20000415)53:5<369::AID-BIP2>3.3.CO;2-X; KIRKWOOD JG, 1967, MACROMOLECULES, P67; KUMOSINSKI TF, 1985, METHOD ENZYMOL, V117, P154; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Mecham R.P., 1991, CELL BIOL EXTRACELLU, V2nd, P79; MILLS R, 1973, J PHYS CHEM-US, V77, P685, DOI 10.1021/j100624a025; MILTHORPE BK, 1975, BIOPHYS CHEM, V3, P169, DOI 10.1016/0301-4622(75)80007-X; MORRIS M, 1989, BIOCHEMISTRY-US, V28, P8561, DOI 10.1021/bi00447a044; Morris M B, 1994, Subcell Biochem, V23, P25; NARAYANAN AS, 1978, BIOCHEM J, V173, P857, DOI 10.1042/bj1730857; OOSAWA F, 1962, J MOL BIOL, V4, P10, DOI 10.1016/S0022-2836(62)80112-0; OOSAWA F, 1975, THERMODYNAMICS POLYM, P25; Parkinson EJ, 2000, BIOCHEMISTRY-US, V39, P12345, DOI 10.1021/bi0005658; Philo JS, 1997, BIOPHYS J, V72, P435, DOI 10.1016/S0006-3495(97)78684-3; Prosser IW, 1988, SELF ASSEMBLING ARCH, P1; RALSTON GB, 1976, BIOCHIM BIOPHYS ACTA, V455, P163, DOI 10.1016/0005-2736(76)90161-9; RALSTON GB, 1990, J CHEM EDUC, V67, P857, DOI 10.1021/ed067p857; RALSTON GB, 1992, ANAL ULTRACENTRIFUGA, P253; RISEMAN J, 1967, MACROMOLECULES, P96; Schein J, 1977, Adv Exp Med Biol, V79, P727; Sorland GH, 2000, J MAGN RESON, V142, P323, DOI 10.1006/jmre.1999.1941; Stafford WF, 1994, MODERN ANAL ULTRACEN, P119; STARCHER BC, 1973, BIOCHIM BIOPHYS ACTA, V310, P481, DOI 10.1016/0005-2795(73)90132-3; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; Tanford C, 1961, PHYSICAL CHEM MACROM, P526; Teller D C, 1973, Methods Enzymol, V27, P346; Torres AM, 1999, J MAGN RESON, V138, P135, DOI 10.1006/jmre.1998.1701; URRY D W, 1976, Critical Reviews in Biochemistry, V4, P1, DOI 10.3109/10409237609102557; URRY DW, 1978, PERSPECT BIOL MED, V21, P265; URRY DW, 1969, NATURE, V222, P795, DOI 10.1038/222795a0; URRY DW, 1988, J PROTEIN CHEM, V7, P1, DOI 10.1007/BF01025411; VANHOLDE KE, 1971, PHYSICAL BIOCH, P79; Vrhovski B, 1998, EUR J BIOCHEM, V258, P1, DOI 10.1046/j.1432-1327.1998.2580001.x; Vrhovski B, 1997, EUR J BIOCHEM, V250, P92, DOI 10.1111/j.1432-1033.1997.00092.x; Wu WJ, 1999, J BIOL CHEM, V274, P21719, DOI 10.1074/jbc.274.31.21719; [No title captured]	50	39	42	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28042	28050		10.1074/jbc.M103391200	http://dx.doi.org/10.1074/jbc.M103391200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11371569	hybrid			2022-12-25	WOS:000170093400041
J	Ettenberg, SA; Magnifico, A; Cuello, M; Nau, MM; Rubinstein, YR; Yarden, Y; Weissman, AM; Lipkowitz, S				Ettenberg, SA; Magnifico, A; Cuello, M; Nau, MM; Rubinstein, YR; Yarden, Y; Weissman, AM; Lipkowitz, S			Cbl-b-dependent coordinated degradation of the epidermal growth factor receptor signaling complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEIN LIGASES; PROTOONCOGENE C-CBL; RING FINGER; TYROSINE KINASE; NEGATIVE REGULATOR; HORMONE RECEPTOR; CSF-1 RECEPTOR; EGF RECEPTOR; FAMILY; PHOSPHORYLATION	Cbl proteins function as ubiquitin protein ligases for the activated epidermal growth factor receptor and, thus, negatively regulate its activity. Here we show that Cbl-b is ubiquitinated and degraded upon activation of the receptor. Epidermal growth factor (EGF)-induced Cbl-b degradation requires intact RING finger and tyrosine kinase binding domains and requires binding of the Cbl-b protein to the activated EGF receptor (EGFR), Degradation of both the EGFR and the Cbl-b protein is blocked by lysosomal and proteasomal inhibitors, Other components of the EGFR-signaling complex (i.e. Grb2 and Shc) are also degraded in an EGF-induced Cbl-b-dependent fashion. Our results suggest that the ubiquitin protein ligase function of Cbl-b is regulated by coordinated degradation of the Cbl-b protein along with its substrate. Furthermore, the data demonstrate that Cbl-b mediates degradation of multiple proteins in the EGFR-signaling complex.	NCI, Dept Genet, Med Branch, Natl Naval Med Ctr,NIH, Bethesda, MD 20889 USA; NCI, Lab Immune Cell Biol, Ctr Canc Res, NIH, Bethesda, MD 20889 USA; Uniformed Serv Univ Hlth Sci, Cell & Mol Biol Program, Bethesda, MD 20889 USA; Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Walter Reed National Military Medical Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Uniformed Services University of the Health Sciences - USA; Weizmann Institute of Science	Lipkowitz, S (corresponding author), NCI, Dept Genet, Med Branch, Natl Naval Med Ctr,NIH, Bldg 8,Rm 5101, Bethesda, MD 20889 USA.	lipkowitz@nih.gov	YARDEN, YOSEF/K-1467-2012					Andoniou CE, 2000, MOL CELL BIOL, V20, P851, DOI 10.1128/MCB.20.3.851-867.2000; Bachmaier K, 2000, NATURE, V403, P211, DOI 10.1038/35003228; Bao J, 2000, J BIOL CHEM, V275, P26178, DOI 10.1074/jbc.M002367200; BLAKE TJ, 1991, ONCOGENE, V6, P653; Broome MA, 1999, ONCOGENE, V18, P2908, DOI 10.1038/sj.onc.1202873; CARPENTER G, 1976, J CELL BIOL, V71, P159, DOI 10.1083/jcb.71.1.159; Chiang YPJ, 2000, NATURE, V403, P216, DOI 10.1038/35003235; Ettenberg S A, 1999, Mol Cell Biol Res Commun, V2, P111, DOI 10.1006/mcbr.1999.0157; Ettenberg SA, 1999, ONCOGENE, V18, P1855, DOI 10.1038/sj.onc.1202499; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; GalchevaGargova Z, 1995, ONCOGENE, V11, P2649; Govers R, 1999, EMBO J, V18, P28, DOI 10.1093/emboj/18.1.28; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hime GR, 1997, ONCOGENE, V14, P2709, DOI 10.1038/sj.onc.1201223; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; HOU D, 1994, J BIOL CHEM, V269, P14244; Hu G, 1999, MOL CELL BIOL, V19, P724; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; JONGEWARD GD, 1995, GENETICS, V139, P1553; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Keane MM, 1999, CANCER RES, V59, P734; Keane MM, 1999, ONCOGENE, V18, P3365, DOI 10.1038/sj.onc.1202753; KEANE MM, 1995, ONCOGENE, V10, P2367; Kim M, 1999, GENE, V239, P145, DOI 10.1016/S0378-1119(99)00356-X; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lill NL, 2000, J BIOL CHEM, V275, P367, DOI 10.1074/jbc.275.1.367; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; Miyake S, 1997, CRIT REV ONCOGENESIS, V8, P189, DOI 10.1615/CritRevOncog.v8.i2-3.30; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Naramura M, 1998, P NATL ACAD SCI USA, V95, P15547, DOI 10.1073/pnas.95.26.15547; Ollendorff V, 1998, INT J ONCOL, V13, P1159; Ota S, 2000, J BIOL CHEM, V275, P414, DOI 10.1074/jbc.275.1.414; Rotin D, 2000, J MEMBRANE BIOL, V176, P1; SCHINDL L, 1994, LASER THER, V4, P25; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Smit L, 1997, CRIT REV ONCOGENESIS, V8, P359, DOI 10.1615/CritRevOncog.v8.i4.50; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; Strous GJ, 1996, EMBO J, V15, P3806, DOI 10.1002/j.1460-2075.1996.tb00754.x; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; Thien CBF, 1998, IMMUNOL CELL BIOL, V76, P473, DOI 10.1046/j.1440-1711.1998.00768.x; van Kerkhof P, 2000, J BIOL CHEM, V275, P1575, DOI 10.1074/jbc.275.3.1575; Wang Y, 1999, J CELL BIOCHEM, V72, P119; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	60	121	126	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27677	27684		10.1074/jbc.M102641200	http://dx.doi.org/10.1074/jbc.M102641200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11375397	hybrid			2022-12-25	WOS:000169966900124
J	Takeuchi, H; Chen, JH; O'Reilly, DR; Turner, PC; Rees, HH				Takeuchi, H; Chen, JH; O'Reilly, DR; Turner, PC; Rees, HH			Regulation of ecdysteroid signaling: Cloning and characterization of ecdysone oxidase - A novel steroid oxidase from the cotton leafworm, Spodoptera littoralis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMOLYMPH 3-DEHYDROECDYSONE 3-BETA-REDUCTASE; RECEPTOR-LIKE PROTEIN; MANDUCA-SEXTA; 3-OXOECDYSTEROID REDUCTASES; GMC OXIDOREDUCTASES; PROTHORACIC GLANDS; MOLECULAR-CLONING; INACTIVATION; ENZYMES; BIOSYNTHESIS	One route of inactivation of ecdysteroids in insects involves ecdysone oxidase-catalyzed conversion into 3-dehydroecdysteroid followed by irreversible reduction by 3-dehydroecdysone 3 alpha -reductase to 3-epiecdysone. We have purified from Spodoptera littoralis the first ecdysone oxidase and subjected it to limited amino acid sequencing. A reverse-transcriptase polymerase chain reaction-based approach has been used to clone the cDNA (2.8 kilobases) encoding this 65-kDa protein. Northern blotting showed that the mRNA transcript was expressed in midgut during the prepupal stage of the last larval instar at a time corresponding to an ecdysteroid titer peak. Conceptual translation of the ecdysone oxidase cDNA and data base searching revealed that the enzyme is an FAD flavoprotein that belongs to the glucose-methanol-choline oxidoreductase superfamily. Ecdysone oxidase represents the only oxidase in eukaryotic animals known to catalyze oxygen-dependent oxidation of steroids; by contrast, oxidation of steroids in vertebrates occurs via NAD(P)(+)-linked dehydrogenases. The injection of RH-5992, an ecdysteroid agonist, induced the transcription of ecdysone oxidase, suggesting that ecdysone oxidase is an ecdysteroid-responsive gene. The gene encoding this enzyme, consisting of five exons, has also been isolated. Sequences similar to the binding motifs for Broad-Complex and FTZ-F1 have been found in the 5'-flanking region. Southern blotting indicated that ecdysone oxidase is encoded by a single-copy gene. We have determined the kinetic characteristics of this novel recombinant ecdysone oxidase produced using a baculovirus expression system.	Univ Liverpool, Sch Biol Sci, Cellular Regulat & Signaling Div, Liverpool L69 7ZB, Merseyside, England; Univ London Imperial Coll Sci Technol & Med, Dept Biol, London SW7 2AZ, England	University of Liverpool; Imperial College London	Rees, HH (corresponding author), Univ Liverpool, Sch Biol Sci, Cellular Regulat & Signaling Div, Life Sci Bldg,Crown St, Liverpool L69 7ZB, Merseyside, England.							AYER S, 1992, MOL CELL BIOL, V12, P661, DOI 10.1128/MCB.12.2.661; BLAIS C, 1984, H-S Z PHYSIOL CHEM, V365, P809, DOI 10.1515/bchm2.1984.365.2.809; BLAIS C, 1991, CR ACAD SCI III-VIE, V313, P359; CAVENER DR, 1992, J MOL BIOL, V223, P811, DOI 10.1016/0022-2836(92)90992-S; Chen JH, 1999, J BIOL CHEM, V274, P10551, DOI 10.1074/jbc.274.15.10551; Chen JH, 1996, EUR J BIOCHEM, V242, P394, DOI 10.1111/j.1432-1033.1996.0394r.x; CHEN JH, 1994, BIOCHEM J, V301, P89, DOI 10.1042/bj3010089; Chen JH, 1999, INSECT BIOCHEM MOLEC, V29, P899, DOI 10.1016/S0965-1748(99)00065-X; CHERBAS L, 1991, GENE DEV, V5, P120, DOI 10.1101/gad.5.1.120; CHERBAS L, 1993, INSECT BIOCHEM MOLEC, V23, P81, DOI 10.1016/0965-1748(93)90085-7; GOGOS JA, 1992, SCIENCE, V257, P1951, DOI 10.1126/science.1290524; Kiess M, 1998, EUR J BIOCHEM, V252, P90, DOI 10.1046/j.1432-1327.1998.2520090.x; Kiriishi S, 1990, EXPERIENTIA, V46, P57; KOOLMAN J, 1978, EUR J BIOCHEM, V89, P453, DOI 10.1111/j.1432-1033.1978.tb12548.x; KOOLMAN J, 1978, H-S Z PHYSIOL CHEM, V359, P1315, DOI 10.1515/bchm2.1978.359.2.1315; KOOLMAN J, 1975, H-S Z PHYSIOL CHEM, V356, P1131, DOI 10.1515/bchm2.1975.356.2.1131; Koolman J, 1989, ECDYSONE; Lafont R., 1984, P196; LAVORGNA G, 1991, SCIENCE, V252, P848, DOI 10.1126/science.1709303; LUO Y, 1991, MOL CELL BIOL, V11, P3660, DOI 10.1128/MCB.11.7.3660; MILNER NP, 1985, BIOCHEM J, V231, P369, DOI 10.1042/bj2310369; Murata T, 1996, MOL CELL BIOL, V16, P6509; NIGG HN, 1974, LIPIDS, V9, P971, DOI 10.1007/BF02533820; O'Reilly D.R., 1994, BACULOVIRUS EXPRESSI; OHTA T, 1991, GENE, V103, P93, DOI 10.1016/0378-1119(91)90397-T; REES HH, 1995, EUR J ENTOMOL, V92, P9; SAKURAI S, 1989, ARCH INSECT BIOCHEM, V10, P179, DOI 10.1002/arch.940100303; Sambrook J., 2002, MOL CLONING LAB MANU; Schramm G, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.22.e96; SOMMEMARTIN G, 1988, INSECT BIOCHEM, V18, P729, DOI 10.1016/0020-1790(88)90082-0; Steel C.G.H., 1989, P221; SUN GC, 1994, DEV BIOL, V162, P426, DOI 10.1006/dbio.1994.1099; Takeuchi H, 2000, BIOCHEM J, V349, P239, DOI 10.1042/0264-6021:3490239; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; VONKALM L, 1994, EMBO J, V13, P3505, DOI 10.1002/j.1460-2075.1994.tb06657.x; WARREN JT, 1988, P NATL ACAD SCI USA, V85, P958, DOI 10.1073/pnas.85.3.958; Watson R.D., 1989, P188; Webb TJ, 1996, INSECT BIOCHEM MOLEC, V26, P809, DOI 10.1016/S0965-1748(96)00030-6; WEBB TJ, 1995, BIOCHEM J, V312, P561, DOI 10.1042/bj3120561; Weirich G.F., 1989, P174; WEIRICH GF, 1989, ARCH INSECT BIOCHEM, V12, P201, DOI 10.1002/arch.940120402; WEIRICH GF, 1993, ARCH INSECT BIOCHEM, V23, P199, DOI 10.1002/arch.940230406; Williams DR, 1997, J BIOL CHEM, V272, P8427, DOI 10.1074/jbc.272.13.8686; WOODARD CT, 1994, CELL, V79, P607, DOI 10.1016/0092-8674(94)90546-0	44	23	27	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26819	26828		10.1074/jbc.M104291200	http://dx.doi.org/10.1074/jbc.M104291200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11373299	hybrid			2022-12-25	WOS:000169966900014
J	Hampson, L; El Hady, ESA; Moore, JV; Kitchener, H; Hampson, IN				Hampson, L; El Hady, ESA; Moore, JV; Kitchener, H; Hampson, IN			The HPV16 E6 and E7 proteins and the radiation resistance of cervical carcinoma	FASEB JOURNAL			English	Article						HPV; ERCC1; cervical carcinoma	HUMAN-PAPILLOMAVIRUS TYPE-16; NUCLEOTIDE EXCISION-REPAIR; CELL-LINES; IONIZING-RADIATION; TUMOR-CELLS; INTRINSIC RADIOSENSITIVITY; P53 FUNCTION; HPV-16 E6; EXPRESSION; CANCER	Using a murine transplantation model, we have investigated the function of the HPV16 E6 and E7 proteins in the development of radiation resistance in advanced cervical carcinoma. Constitutive high-level expression of the HPV16 E6 oncogene in HPV negative human C33A cervical carcinoma cells was shown to induce rapid onset and radiation resistance in transplanted tumors when compared with tumors derived from E7 or vector transfected cells. The radiation-resistant, E6 tumor phenotype was not due solely to increased hypoxia, because all E6 tumors were shown to be uniformly hypoxic, and artificial induction of hypoxia, in E7 and control tumors, failed to produce the same degree of radiobiological resistance. Differential screening of a 1.2-k human cancer cDNA array indicated that E6 tumors had up-regulated expression of the DNA nucleotide excision repair gene excision repair cross-complementation enzyme 1 (ERCC1). High-level expression of ERCC1 mRNA and protein was found to be restricted to radiation-resistant E6 tumors. In vitro maintenance of E6 and control vector-expressing cells under anoxic conditions showed that ERCC1 expression was induced preferentially in E6-expressing cells. These data indicate that the HPV16 E6 protein may influence the response to therapy of cervical carcinoma by inappropriate activation of DNA repair mechanisms.	Univ Manchester, St Marys Hosp, Acad Unit Obstet & Gynaecol, Manchester M13 0JH, Lancs, England; Christie Hosp, Paterson Inst Canc Res, Dept Laser Oncol, Manchester M20 4BX, Lancs, England	University of Manchester; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research	Hampson, IN (corresponding author), Univ Manchester, St Marys Hosp, Acad Unit Obstet & Gynaecol, Manchester M13 0JH, Lancs, England.	mdsisinh@fs1.scg.man.ac.uk	Hampson, Lynne/E-1583-2011	Abdel-Hady, EL-SAID/0000-0001-5010-1449; Hampson, Lynne/0000-0002-0656-0127				ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; Britten RA, 2000, INT J CANCER, V89, P453, DOI 10.1002/1097-0215(20000920)89:5<453::AID-IJC9>3.3.CO;2-5; Carlomagno F, 2000, INT J CANCER, V85, P845, DOI 10.1002/(SICI)1097-0215(20000315)85:6<845::AID-IJC18>3.3.CO;2-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROOK T, 1989, EMBO J, V8, P513, DOI 10.1002/j.1460-2075.1989.tb03405.x; DeWeese TL, 1997, INT J RADIAT ONCOL, V37, P145, DOI 10.1016/S0360-3016(96)00448-8; DOEBERITZ MV, 1988, CANCER RES, V48, P3780; DOWHANICK JJ, 1995, J VIROL, V69, P7791, DOI 10.1128/JVI.69.12.7791-7799.1995; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Ferry KV, 2000, BIOCHEM PHARMACOL, V60, P1305, DOI 10.1016/S0006-2952(00)00441-X; Herring CJ, 1998, BRIT J CANCER, V78, P1128, DOI 10.1038/bjc.1998.641; Huang H, 1996, INT J RADIAT BIOL, V70, P151, DOI 10.1080/095530096145148; Lawrence S, 2000, EMBED SYST PROGRAM, V13, P55; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; MONGE RM, 1993, RADIOTHER ONCOL, V28, P127, DOI 10.1016/0167-8140(93)90004-R; Murray D, 1996, MUTAT RES-DNA REPAIR, V364, P217, DOI 10.1016/S0921-8777(96)00036-5; Murray D, 1996, INT J RADIAT BIOL, V69, P319, DOI 10.1080/095530096145878; Mythily DV, 1999, J GEN VIROL, V80, P1707, DOI 10.1099/0022-1317-80-7-1707; Notterman D, 1998, ONCOGENE, V17, P2743, DOI 10.1038/sj.onc.1202210; Santin AD, 1998, CANCER-AM CANCER SOC, V83, P2346, DOI 10.1002/(SICI)1097-0142(19981201)83:11<2346::AID-CNCR14>3.0.CO;2-G; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; Song SY, 1998, P NATL ACAD SCI USA, V95, P2290, DOI 10.1073/pnas.95.5.2290; STEWART FA, 1989, INT J RADIAT ONCOL, V16, P1195, DOI 10.1016/0360-3016(89)90282-4; TSANG NM, 1995, ONCOGENE, V10, P2403; Tseng CJ, 1999, J CLIN ONCOL, V17, P1391, DOI 10.1200/JCO.1999.17.5.1391; UNGER ER, 1995, J INFECT DIS, V172, P1184, DOI 10.1093/infdis/172.5.1184; Vispe S, 1998, NUCLEIC ACIDS RES, V26, P2859, DOI 10.1093/nar/26.12.2859; Weeda G, 1997, CURR BIOL, V7, P427, DOI 10.1016/S0960-9822(06)00190-4; WEST CML, 1993, BRIT J CANCER, V68, P819, DOI 10.1038/bjc.1993.434; Yang LY, 2000, CLIN CANCER RES, V6, P773; Yu YJ, 1997, ONCOGENE, V14, P1661, DOI 10.1038/sj.onc.1201026; ZURHAUSEN H, 1996, BIOCHIM BIOPHYS ACTA, V1288, pPF55	35	53	57	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 27	2001	15	6					1445	+		10.1096/fj.00-0728fje	http://dx.doi.org/10.1096/fj.00-0728fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387252				2022-12-25	WOS:000173705800017
J	Pooga, M; Kut, C; Kihlmark, M; Hallbrink, M; Fernaeus, S; Raid, R; Land, T; Hallberg, E; Bartfai, T; Langel, U				Pooga, M; Kut, C; Kihlmark, M; Hallbrink, M; Fernaeus, S; Raid, R; Land, T; Hallberg, E; Bartfai, T; Langel, U			Cellular translocation of proteins by transportan	FASEB JOURNAL			English	Article						peptide-mediated transport; cell-penetrating peptides; drug delivery; transport vectors; protein transduction	GREEN FLUORESCENT PROTEIN; IN-VIVO; INTRACELLULAR DELIVERY; TRANSDUCTION; PEPTIDES; CELLS; REAGENTS; DNA	Proteins with molecular masses ranging from 30 kDa. (green fluorescent protein, GFP) to 150 kDa (monoclonal and polyclonal antibodies) were coupled to the cellular translocating peptide transportan. We studied the ability of the resulting protein-peptide constructs to penetrate into Bowes melanoma, BRL, and COS-7 cells. After 0.5-3 h incubation with recombinant GFP coupled to transportan, most of the GFP fluorescence was found in intracellular membranes of BRL and COS-7 cells, which suggests that transportan could internalize covalently linked proteins of about 30 kDa in a folded state. Transportan could internalize covalently coupled molecules of even larger size; that is, avidin and antibodies, (up to 150 kDa). The covalent bond between the transport peptide and its cargo is not obligatory because streptavidin was translocated into the cells within 15 min as a noncovalent complex with biotinylated transportan. Inside the cells, the delivered streptavidin was first located mainly in close proximity to the plasma membrane and was later distributed to the perinuclear region. Most of the internalized streptavidin was confined to vesicular structures, but a significant fraction of the protein was distributed in the cytoplasm. Our data suggest that transportan can deliver proteins and other hydrophilic macromolecules into intact mammalian cells, and this finding demonstrates good potential as powerful cellular delivery vector for scientific and therapeutic purposes.	Scripps Res Inst, Dept Neuropharmacol, Harold L Dorris Neurol Res Ctr, La Jolla, CA 92037 USA; Univ Stockholm, Arrhenius Lab, Dept Neurochem & Neurotoxicol, S-10691 Stockholm, Sweden; Estonian Bioctr, EE-51010 Tartu, Estonia; Sodertorns Hogskola Univ Coll, Sect Nat Sci, S-14104 Huddinge, Sweden; Univ Stockholm, Arrhenius Lab, Dept Biochem, S-10691 Stockholm, Sweden; Univ Tartu, Inst Zool & Hydrobiol, EE-51014 Tartu, Estonia	Scripps Research Institute; Stockholm University; Estonian Biocentre; Sodertorn University; Stockholm University; University of Tartu	Langel, U (corresponding author), Scripps Res Inst, Dept Neuropharmacol, Harold L Dorris Neurol Res Ctr, 10550 N Torrey Pines Rd,Mail SR-307, La Jolla, CA 92037 USA.	ulangel@scripps.edu	Pooga, Margus/A-8575-2011	Pooga, Margus/0000-0003-4532-4087; Hallberg, Einar/0000-0003-2092-457X				ADAM SA, 1989, NATURE, V337, P276, DOI 10.1038/337276a0; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; Kato D, 1998, FEBS LETT, V427, P203, DOI 10.1016/S0014-5793(98)00426-8; Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Niemeyer CM, 1999, NUCLEIC ACIDS RES, V27, P4553, DOI 10.1093/nar/27.23.4553; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; PEETERS JM, 1989, J IMMUNOL METHODS, V120, P133, DOI 10.1016/0022-1759(89)90298-6; Phelan A, 1998, NAT BIOTECHNOL, V16, P440, DOI 10.1038/nbt0598-440; Pooga M, 1998, FASEB J, V12, P67, DOI 10.1096/fasebj.12.1.67; Pooga M, 1998, NAT BIOTECHNOL, V16, P857, DOI 10.1038/nbt0998-857; Prochiantz A, 1996, CURR OPIN NEUROBIOL, V6, P629, DOI 10.1016/S0959-4388(96)80095-X; Rojas M, 1998, NAT BIOTECHNOL, V16, P370, DOI 10.1038/nbt0498-370; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Schwarze SR, 2000, TRENDS PHARMACOL SCI, V21, P45, DOI 10.1016/S0165-6147(99)01429-7; Soomets U, 2000, BBA-BIOMEMBRANES, V1467, P165, DOI 10.1016/S0005-2736(00)00216-9; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509	21	149	162	0	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR 27	2001	15	6					1451	+		10.1096/fj.00-0780fje	http://dx.doi.org/10.1096/fj.00-0780fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11387254				2022-12-25	WOS:000173705800015
J	Ullrich, O; Diestel, A; Bechmann, I; Homberg, M; Grune, T; Hass, R; Nitsch, R				Ullrich, O; Diestel, A; Bechmann, I; Homberg, M; Grune, T; Hass, R; Nitsch, R			Turnover of oxidatively damaged nuclear proteins in BV-2 microglial cells is linked to their activation state by poly(ADP-ribose)polymerase	FASEB JOURNAL			English	Article						oxidative stress; proteasome; protein degradation; tumor necrosis factor-alpha; antioxidative protection	ADHESION MOLECULE EXPRESSION; ADP-RIBOSE-POLYMERASE; OXIDIZED PROTEINS; INTERFERON-GAMMA; ASTROCYTES; PROTEASOME; 20S; DIFFERENTIATION; DEGRADATION; MODULATION	During neuroinflammation, activated microglial cells migrate to the sites of neuronal injury, phagocytose neighboring cells, and produce large amounts of oxygen free radicals, which might contribute to severe cell damage and death. It is interesting that microglial cells have withstood this cytotoxic action of free radicals, which indicates that there is an intracellular mechanism that apparently enables microglial cells to cope with such oxidative challenges. In this study, we investigated the capability of BV-2 murine microglial cells to cope with oxidatively damaged proteins by the proteasomal proteolytic system. To induce a highly activated state, we used the proinflammatory cytokine tumor necrosis factor-alpha, which acts as a priming signal for microglial superoxide radical production. We showed that activation of the nuclear enzyme poly(ADPribose)polymerase (PARP) enabled activated microglial cells to resist oxidative damage by an up-regulation of the nuclear proteasome. Activated microglial cells revealed an efficient recognition and degradation of oxidatively damaged proteins during an enhanced endogenous protein turnover. The impairment of PARP function by inhibitor or antisense experiments resulted in an accumulation of damaged proteins and subsequently cell death. In contrast, this was not the case in resting microglial cells. These findings demonstrate the crucial role of the PARP in microglial cell survival during activation and renders it a potential anti-inflammatory target.	Humboldt Univ, Fac Med Charite, Dept Cell & Neurobiol, Inst Anat, D-10098 Berlin, Germany; Humboldt Univ, Fac Med Charite, Neurosci Res Ctr, D-10098 Berlin, Germany; Hannover Med Sch, Oststadtkrankenhaus, Clin Obstet & Gynecol OE 6410, Dept Biochem & Tumor Biol, D-30659 Hannover, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Hannover Medical School	Ullrich, O (corresponding author), Humboldt Univ, Fac Med Charite, Inst Anat, Dept Cell & Neurobiol, Philippstr 12, D-10115 Berlin, Germany.	oliver.ullrich@charite.de	Nitsch, Robert/AAI-9129-2021; Hass, Ralf/F-3197-2012	Hass, Ralf/0000-0002-2481-7547; Gimsa, Ulrike/0000-0003-2248-5793; Grune, Tilman/0000-0003-4775-9973				AKIYAMA H, 1993, ACTA NEUROPATHOL, V85, P628, DOI 10.1007/BF00334673; Bechmann I, 1997, GLIA, V20, P145, DOI 10.1002/(SICI)1098-1136(199706)20:2<145::AID-GLIA6>3.0.CO;2-8; Bhatia M, 1996, CELL GROWTH DIFFER, V7, P91; Bruce-Keller AJ, 1999, J NEUROSCI RES, V58, P191, DOI 10.1002/(SICI)1097-4547(19991001)58:1<191::AID-JNR17>3.0.CO;2-E; CANTONI O, 1989, BIOCHIM BIOPHYS ACTA, V1014, P1, DOI 10.1016/0167-4889(89)90234-6; COLTON CA, 1987, FEBS LETT, V223, P284, DOI 10.1016/0014-5793(87)80305-8; DEMURCIA G, 1991, BIOESSAYS, V13, P455, DOI 10.1002/bies.950130905; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; EMIG S, 1995, J BIOL CHEM, V270, P13787, DOI 10.1074/jbc.270.23.13787; GRADWOHL G, 1990, P NATL ACAD SCI USA, V87, P2990, DOI 10.1073/pnas.87.8.2990; Grune T, 1997, BIOFACTORS, V6, P165, DOI 10.1002/biof.5520060210; GRUNE T, 1995, J BIOL CHEM, V270, P2344, DOI 10.1074/jbc.270.5.2344; Grune T, 1996, J BIOL CHEM, V271, P15504, DOI 10.1074/jbc.271.26.15504; Hailer NP, 1996, GLIA, V18, P319, DOI 10.1002/(SICI)1098-1136(199612)18:4<319::AID-GLIA6>3.0.CO;2-S; Hailer NP, 1997, HIPPOCAMPUS, V7, P341, DOI 10.1002/(SICI)1098-1063(1997)7:3<341::AID-HIPO8>3.0.CO;2-N; Heppner FL, 1998, GLIA, V22, P180, DOI 10.1002/(SICI)1098-1136(199802)22:2<180::AID-GLIA9>3.0.CO;2-B; HOUGH R, 1987, J BIOL CHEM, V262, P8303; HU SX, 1995, GLIA, V13, P45, DOI 10.1002/glia.440130106; Jeggo PA, 1998, CURR BIOL, V8, pR49, DOI 10.1016/S0960-9822(98)70032-6; JENTOFT N, 1979, J BIOL CHEM, V254, P4359; KIRSTEN E, 1991, EXP CELL RES, V194, P1, DOI 10.1016/0014-4827(91)90122-B; Kleczkowska HE, 1996, MUTAT RES-FUND MOL M, V358, P215, DOI 10.1016/S0027-5107(96)00123-6; KREUTZBERG GW, 1995, ARZNEIMITTEL-FORSCH, V45-1, P357; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; LEE SC, 1993, J IMMUNOL, V150, P594; Leist P, 1996, FREE RADICAL BIO MED, V21, P297, DOI 10.1016/0891-5849(96)00045-7; Lindenau J, 1998, GLIA, V24, P252, DOI 10.1002/(SICI)1098-1136(199810)24:2<252::AID-GLIA10>3.0.CO;2-Z; Lo EH, 1998, STROKE, V29, P830, DOI 10.1161/01.STR.29.4.830; Mayer-Kuckuk P, 1999, BIOCHEM BIOPH RES CO, V259, P576, DOI 10.1006/bbrc.1999.0824; MAZEN A, 1989, NUCLEIC ACIDS RES, V17, P4589; MESSMER UK, 1995, MOL PHARMACOL, V47, P757; NIETOSAMPEDRO M, 1985, BRAIN RES, V343, P320, DOI 10.1016/0006-8993(85)90750-4; NITSCH R, 1993, HIPPOCAMPUS, V3, P247; Noack H, 1998, GLIA, V23, P285, DOI 10.1002/(SICI)1098-1136(199808)23:4<285::AID-GLIA1>3.0.CO;2-2; Paris D, 2000, NEUROSCI LETT, V278, P5, DOI 10.1016/S0304-3940(99)00901-5; PERRY VH, 1993, GLIA, V7, P60, DOI 10.1002/glia.440070111; Reinheckel T, 2000, ARCH BIOCHEM BIOPHYS, V377, P65, DOI 10.1006/abbi.2000.1717; REZNICK AZ, 1994, METHOD ENZYMOL, V233, P357; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; Schubert P, 1998, ALZ DIS ASSOC DIS, V12, pS21; STEWARD O, 1993, EXP NEUROL, V124, P167, DOI 10.1006/exnr.1993.1187; Stohwasser R, 2000, GLIA, V29, P355, DOI 10.1002/(SICI)1098-1136(20000215)29:4<355::AID-GLIA6>3.0.CO;2-4; Sugaya K, 1997, NEUROREPORT, V8, P2241, DOI 10.1097/00001756-199707070-00030; Takahashi K, 1999, BRAIN RES, V829, P46, DOI 10.1016/S0006-8993(99)01335-9; TOMODA T, 1992, BIOCHIM BIOPHYS ACTA, V1135, P79, DOI 10.1016/0167-4889(92)90169-C; Ullrich O, 2000, FREE RADICAL BIO MED, V29, P995, DOI 10.1016/S0891-5849(00)00399-3; Ullrich O, 1999, ARCH BIOCHEM BIOPHYS, V362, P211, DOI 10.1006/abbi.1998.1031; Ullrich O, 1999, P NATL ACAD SCI USA, V96, P6223, DOI 10.1073/pnas.96.11.6223; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; ZIELASEK J, 1993, NEUROSCI LETT, V153, P136, DOI 10.1016/0304-3940(93)90306-6; ZWILLING S, 1995, EMBO J, V14, P1198, DOI 10.1002/j.1460-2075.1995.tb07103.x	51	102	103	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 27	2001	15	6					1460	+		10.1096/fj.00-0540fje	http://dx.doi.org/10.1096/fj.00-0540fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11292676				2022-12-25	WOS:000173705800009
